Models O +
to O +
predict O +
intestinal O +
absorption O +
of O +
therapeutic O +
peptides O +
and O +
proteins O -
. O +

Prediction O +
of O +
human O +
intestinal O +
absorption O +
is O +
a O +
major O +
goal O +
in O +
the O +
design O -
, O +
optimization O -
, O +
and O +
selection O +
of O +
drugs O +
intended O +
for O +
oral O +
delivery O -
, O +
in O +
particular O +
proteins O -
, O +
which O +
possess O +
intrinsic O +
poor O +
transport O +
across O +
intestinal O +
epithelium O -
. O +

There O +
are O +
various O +
techniques O +
currently O +
employed O +
to O +
evaluate O +
the O +
extension O +
of O +
protein O +
absorption O +
in O +
the O +
different O +
phases O +
of O +
drug O +
discovery O +
and O +
development O -
. O +

Screening O +
protocols O +
to O +
evaluate O +
protein O +
absorption O +
include O +
a O +
range O +
of O +
preclinical O +
methodologies O +
like O +
in O +
silico O -
, O +
in O +
vitro O -
, O +
in O +
situ O -
, O +
ex O +
vivo O +
and O +
in O +
vivo O -
. O +

It O +
is O +
the O +
careful O +
and O +
critical O +
use O +
of O +
these O +
techniques O +
that O +
can O +
help O +
to O +
identify O +
drug O +
candidates O -
, O +
which O +
most O +
probably O +
will O +
be O +
well O +
absorbed O +
from O +
the O +
human O +
intestinal O +
tract O -
. O +

It O +
is O +
well O +
recognized O +
that O +
the O +
human O +
intestinal O +
permeability O +
can O -
not O +
be O +
accurately O +
predicted O +
based O +
on O +
a O +
single O +
preclinical O +
method O -
. O +

However O -
, O +
the O +
present O +
social O +
and O +
scientific O +
concerns O +
about O +
the O +
animal O +
well O +
care O +
as O +
well O +
as O +
the O +
pharmaceutical O +
industries O +
need O +
for O +
rapid O -
, O +
cheap O +
and O +
reliable O +
models O +
predicting O +
bioavailability O +
give O +
reasons O +
for O +
using O +
methods O +
providing O +
an O +
appropriate O +
correlation O +
between O +
results O +
of O +
in O +
vivo O +
and O +
in O +
vitro O +
drug O +
absorption O -
. O +

The O +
aim O +
of O +
this O +
review O +
is O +
to O +
describe O +
and O +
compare O +
in O +
silico O -
, O +
in O +
vitro O -
, O +
in O +
situ O -
, O +
ex O +
vivo O +
and O +
in O +
vivo O +
methods O +
used O +
to O +
predict O +
human O +
intestinal O +
absorption O -
, O +
giving O +
a O +
special O +
attention O +
to O +
the O +
intestinal O +
absorption O +
of O +
therapeutic O +
peptides O +
and O +
proteins O -
. O +

Fish O +
consumption O +
during O +
child O +
bearing O +
age O -
: O +
a O +
quantitative O +
risk O -
- O -
benefit O +
analysis O +
on O +
neurodevelopment O -
. O +

The O +
fish O +
ingredient O +
N3-docosahexaenoic B-Chemical +
acid I-Chemical +
22:6 O +
n-3 O +
( O -
DHA B-Chemical -
) O +
stimulates O +
brain O +
development O -
. O +

On O +
the O +
other O +
hand O +
methylmercury B-Chemical +
( O -
MeHg B-Chemical -
) O +
in O +
fish O +
disturbs O +
the O +
developing O +
central O +
nervous O +
system O -
. O +

In O +
this O +
Context O +
the O +
IQ O +
score O +
in O +
children O +
is O +
considered O +
as O +
an O +
aggregate O +
measure O +
of O +
in O +
utero O +
brain O +
development O -
. O +

To O +
determine O +
the O +
effect O +
of O +
DHA B-Chemical +
exposure O +
on O +
prenatal O +
neurodevelopment O +
the O +
maternal O +
DHA B-Chemical +
intake O +
during O +
pregnancy O +
was O +
compared O +
with O +
its O +
epidemiologically O +
observed O +
effect O +
on O +
the O +
IQ O +
score O +
of O +
children O -
. O +

For O +
MeHg B-Chemical +
the O +
maternal O +
intake O +
was O +
converted O +
into O +
its O +
accumulation O +
in O +
the O +
maternal O +
body O -
. O +

The O +
maternal O +
body O +
burden O +
then O +
was O +
compared O +
with O +
its O +
epidemiologically O +
observed O +
relationship O +
with O +
the O +
IQ O +
score O -
. O +

Taking O +
the O +
MeHg B-Chemical +
and O +
DHA B-Chemical +
content O +
of O +
33 O +
fish O +
species O +
the O +
net O +
effect O +
of O +
these O +
compounds O +
on O +
the O +
IQ O +
score O +
was O +
quantified O -
. O +

For O +
most O +
fish O +
species O +
the O +
adverse O +
effect O +
of O +
MeHg B-Chemical +
on O +
the O +
IQ O +
score O +
exceeded O +
the O +
beneficial O +
effect O +
of O +
DHA B-Chemical -
. O +

In O +
the O +
case O +
of O +
long O -
- O -
living O +
predators O +
a O +
negative O +
effect O +
up O +
to O +
10 O +
points O +
on O +
the O +
IQ O +
score O +
was O +
found O -
. O +

The O +
results O +
of O +
this O +
study O +
indicate O +
that O +
food O +
interventions O +
aiming O +
at O +
the O +
beneficial O +
effects O +
of O +
fish O +
consumption O +
should O +
focus O +
on O +
fish O +
species O +
with O +
a O +
high O +
DHA B-Chemical +
content O -
, O +
while O +
avoiding O +
fish O +
species O +
with O +
a O +
high O +
MeHg B-Chemical +
content O -
. O +

Tissues O +
distribution O +
of O +
heavy O +
metals O +
and O +
erythrocytes O +
antioxidant O +
status O +
in O +
rats O +
exposed O +
to O +
Nigerian O +
bonny O +
light O +
crude O +
oil O -
. O +

The O +
harmful O +
effects O +
of O +
folkloric O +
uses O +
of O +
Nigerian O +
bonny O +
light O +
crude O +
oil O +
( O -
BLCO O -
) O +
in O +
ailments O +
management O +
may O +
outweigh O +
the O +
expected O +
beneficial O +
effects O -
. O +

We O +
investigated O +
the O +
levels O +
of O +
heavy O +
metal O +
concentrations O +
in O +
the O +
tissues O +
as O +
well O +
as O +
the O +
effect O +
of O +
BLCO O +
on O +
the O +
antioxidant O +
status O +
of O +
erythrocytes O +
of O +
rats O +
after O +
oral O +
exposure O +
to O +
0 O -
, O +
200 O +
and O +
800 O +
mg O -
/ O -
kg O +
BLCO O +
for O +
7 O +
days O -
. O +

Analysis O +
of O +
heavy O +
metal O +
concentrations O +
in O +
BLCO O +
showed O +
that O +
Zn B-Chemical +
> O +
Fe B-Chemical +
> O +
Pb B-Chemical +
> O +
Cu B-Chemical +
> O +
Ni B-Chemical -
. O +

The O +
trend O +
of O +
accumulation O +
of O +
the O +
metals O +
in O +
the O +
tissues O +
is O +
blood O -
- O -
Fe B-Chemical +
> O +
Pb B-Chemical +
> O -
Zn B-Chemical +
whereas O +
Cu B-Chemical +
and O +
Ni B-Chemical +
levels O +
were O +
not O +
affected O -
; O +
Liver O -
- O -
Ni B-Chemical +
> O +
Zn B-Chemical +
> O +
Fe B-Chemical +
> O +
Cu B-Chemical +
> O +
Pb B-Chemical +
and O +
Testes O -
- O -
Ni B-Chemical +
> O +
Cu B-Chemical +
> O +
Pb B-Chemical +
> O +
Zn B-Chemical +
> O +
Fe B-Chemical -
. O +

The O +
order O +
of O +
concentration O +
of O +
the O +
metals O +
in O +
the O +
tissues O +
is O +
as O +
follows O -
: O +
iron B-Chemical -
- O -
blood O +
> O +
liver O +
> O +
testes O -
; O +
zinc B-Chemical -
- O -
liver O +
> O +
blood O +
> O +
testes O -
; O +
lead O -
- O -
blood O +
> O +
liver O +
> O +
testes O -
; O +
copper B-Chemical -
- O -
testes O +
> O +
liver O +
> O +
blood O -
; O +
nickel B-Chemical -
- O -
liver O +
> O +
testes O +
> O +
blood O -
. O +

Activities O +
of O +
the O +
antioxidant O +
enzymes O +
of O +
erythrocytes O +
such O +
as O +
superoxide B-Chemical +
dismutase O -
, O +
catalase O -
, O +
glutathione B-Chemical +
S O -
- O -
transferase O +
and O +
glutathione B-Chemical +
peroxidase O +
increased O +
significantly O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
with O +
significant O +
elevation O +
in O +
hydrogen B-Chemical +
peroxide I-Chemical +
and O +
malondialdehyde B-Chemical +
levels O -
, O +
whereas O +
glutathione B-Chemical +
level O +
was O +
not O +
significantly O +
decreased O +
in O +
BLCO O -
- O -
treated O +
animals O -
. O +

Collectively O -
, O +
the O +
results O +
showed O +
that O +
BLCO O +
induces O +
oxidative O +
damage O +
to O +
erythrocytes O +
of O +
rats O -
. O +

Green O +
tea O +
extract O +
alleviates O +
arsenic B-Chemical -
- O -
induced O +
biochemical O +
toxicity O +
and O +
lipid O +
peroxidation O +
in O +
rats O -
. O +

The O +
present O +
work O +
was O +
undertaken O +
to O +
evaluate O +
the O +
protective O +
effect O +
of O +
an O +
aqueous O +
extract O +
of O +
green O +
tea O +
( O -
GT O -
, O +
Camellia O +
sinensis O -
) O +
leaves O +
against O +
arsenic B-Chemical +
( O -
NaAsO2 B-Chemical -
) O -
-induced O +
biochemical O +
toxicity O +
and O +
lipid O +
peroxidation O +
production O +
in O +
experimental O +
rats O -
. O +

The O +
treatment O +
with O +
arsenic B-Chemical +
exhibited O +
a O +
significant O +
increase O +
in O +
some O +
serum O +
hepatic O +
and O +
renal O +
biochemical O +
parameters O +
( O -
alanine B-Chemical +
aminotransferase O -
, O +
aspartate B-Chemical +
aminotransferase O -
, O +
alkaline O +
phosphatase O -
, O +
total O +
protein O -
, O +
albumin O -
, O +
bilirubin B-Chemical -
, O +
cholesterol B-Chemical -
, O +
urea B-Chemical +
and O +
creatinine B-Chemical -
) O -
. O +

But O +
the O +
co O -
- O -
administration O +
of O +
GT O +
has O +
increased O +
the O +
level O +
of O +
plasmatic O +
concentration O +
of O +
biochemical O +
parameters O -
. O +

Exposure O +
of O +
rats O +
to O +
arsenic B-Chemical +
caused O +
also O +
a O +
significant O +
increase O +
in O +
liver O -
, O +
kidney O +
and O +
testicular O +
thiobarbituric B-Chemical +
acid I-Chemical +
reactive O +
substances O +
compared O +
to O +
control O -
. O +

However O -
, O +
the O +
co O -
- O -
administration O +
of O +
GT O +
was O +
effective O +
in O +
reducing O +
its O +
level O -
. O +

To O +
conclude O -
, O +
our O +
data O +
suggest O +
that O +
arsenic B-Chemical +
exposure O +
enhanced O +
an O +
oxidative O +
stress O +
by O +
disturbing O +
the O +
tissue O +
antioxidant O +
defense O +
system O -
, O +
but O +
the O +
GT O +
co O -
- O -
administration O +
alleviates O +
the O +
toxicity O +
induced O +
by O +
arsenic B-Chemical +
exposure O -
. O +

Changes O +
in O +
carbohydrate B-Chemical +
metabolism O -
, O +
oxidative O +
stress O +
and O +
loss O +
of O +
cortisol B-Chemical +
secretion O +
in O +
adrenocortica O +
l O +
cells O +
of O +
Oreochromis O +
niloticus O +
exposed O +
in O +
vitro O +
to O +
endosulfan B-Chemical -
. O +

The O +
effects O +
of O +
endosulfan B-Chemical -
, O +
an O +
organochlorine B-Chemical +
pesticide O +
regularly O +
used O +
in O +
Niger O +
Delta O +
ecological O +
zone O -
, O +
were O +
examined O +
and O +
also O +
its O +
effects O +
on O +
various O +
biochemical O +
parameters O +
in O +
the O +
serum O +
of O +
Oreochromis O +
niloticus O -
, O +
a O +
dominant O +
fish O +
species O +
in O +
Nigeria O -
. O +

One O +
hundred O +
and O +
fifty O +
juveniles O +
of O +
O. O +
niloticus O +
were O +
used O +
for O +
the O +
toxicity O +
study O -
. O +

Lethal O +
concentration O +
of O +
50 O -
% O +
mortality O +
of O +
sample O +
( O -
LC50 O -
) O +
was O +
determined O +
using O +
semi O -
- O -
static O +
method O -
. O +

From O +
the O +
result O +
of O +
the O +
LC50 O +
determination O -
, O +
lower O +
concentrations O +
of O +
endosulfan B-Chemical +
were O +
prepared O +
for O +
sublethal O +
test O -
. O +

Five O +
fish O +
per O +
test O +
concentration O +
in O +
three O +
replicates O +
were O +
exposed O +
to O +
varying O +
concentrations O +
of O +
endosulfan B-Chemical -
. O +

Glucose B-Chemical +
level O +
and O +
the O +
enzyme O +
activities O +
were O +
measured O +
spectrophotometrically O +
at O +
the O +
end O +
of O +
28 O +
days O +
of O +
exposure O -
. O +

Glucose B-Chemical +
levels O +
and O +
glutathione B-Chemical -
- B-Chemical -
S O -
- O -
transferase O +
activities O +
were O +
significantly O +
( O -
p O +
< O +
0.05 O -
) O +
higher O +
than O +
the O +
control O +
and O +
the O +
concentrations O +
increased O +
with O +
increasing O +
concentration O +
of O +
the O +
toxicant O +
and O +
exposure O +
duration O -
. O +

Cortisol B-Chemical +
secretion O +
was O +
significantly O +
( O -
p O +
= O +
0.05 O -
) O +
lower O +
in O +
the O +
treated O +
fish O +
than O +
the O +
control O -
. O +

These O +
findings O +
indicated O +
that O +
endosulfan B-Chemical +
altered O +
all O +
the O +
investigated O +
parameters O -
, O +
which O +
is O +
an O +
indication O +
of O +
their O +
suitability O +
as O +
markers O +
for O +
fish O +
and O +
other O +
aquatic O +
organism O +
toxicity O +
study O -
. O +

Serratin B-Chemical +
a O +
new O +
metabolite O +
obtained O +
from O +
Serratia O +
marcescens O -
, O +
a O +
bacterium O +
isolated O +
from O +
the O +
microflora O +
associated O +
with O +
banana O +
plantations O -
. O +

When O +
cultures O +
of O +
Serratia O +
marcescens O -
, O +
an O +
enterobacteria O +
isolated O +
from O +
the O +
microflora O +
associated O +
with O +
banana O +
plantations O +
incubated O +
at O +
27 O -
° O -
C O +
in O +
a O +
yeast O -
- O -
calcium B-Chemical +
carbonate I-Chemical -
- O -
dextrose B-Chemical +
solid O +
medium O +
( O -
10 O +
g O +
of O +
yeast O +
extract O -
, O +
20 O +
g O +
dextrose B-Chemical -
, O +
15 O +
g O +
bacteriological O +
agar O -
, O +
20 O +
g O +
calcium B-Chemical +
carbonate I-Chemical +
and O +
1000 O +
mL O +
distilled O +
water O -
) O +
were O +
extracted O +
with O +
chloroform B-Chemical +
and O +
purified O +
by O +
column O +
chromatography O -
, O +
we O +
obtained O +
a O +
new O +
colourless O +
bacterial O +
metabolite O +
which O +
according O +
to O +
spectroscopic O +
data O +
proved O +
to O +
be O +
serratin B-Chemical -
. O +

Development O +
and O +
characterization O +
of O +
coated O -
- O -
microparticles O +
based O +
on O +
whey O +
protein O -
/ O -
alginate O +
using O +
the O +
Encapsulator O +
device O -
. O +

The O +
aim O +
of O +
this O +
study O +
is O +
to O +
prepare O +
whey O +
protein O +
( O -
WP O -
) O -
-based O +
microparticles O +
( O -
MP O -
) O +
using O +
the O +
Encapsulator O -
( O -
® O -
) O +
device O -
. O +

The O +
viscosity O +
dependence O +
of O +
the O +
extrusion O +
device O +
required O +
to O +
mix O +
WP O +
with O +
a O +
food O -
- O -
grade O +
and O +
less O +
viscous O +
polymer O -
. O +

Mixed O +
WP O -
/ O -
ALG O +
MP O +
were O +
obtained O +
with O +
the O +
optimized O +
WP O -
/ O -
alginate O +
( O -
ALG O -
) O +
ratio O +
( O -
62 O -
/ O -
38 O -
) O -
. O +

These O +
particles O +
were O +
further O +
coated O +
with O +
WP O +
or O +
ALG O +
using O +
non O -
- O -
traumatic O +
and O +
solvent O -
- O -
free O +
coating O +
process O +
developed O +
in O +
this O +
study O -
. O +

Size O +
and O +
morphology O +
of O +
coated O +
and O +
uncoated O +
MP O +
were O +
determined O -
. O +

Then O -
, O +
swelling O +
and O +
degradation O +
( O -
WP O +
release O -
) O +
of O +
formulations O +
were O +
investigated O +
in O +
pH O +
1.2 O +
and O +
7.5 O +
buffers O +
and O +
in O +
simulated O +
gastric O +
and O +
intestinal O +
fluids O +
( O -
SGF O -
, O +
SIF O -
) O +
and O +
compared O +
to O +
pure O +
ALG O +
and O +
pure O +
WP O +
particle O +
behaviours O -
. O +

At O +
pH O +
1.2 O -
, O +
pure O +
ALG O +
shrank O +
and O +
pure O +
WP O +
swelled O -
, O +
whereas O +
the O +
sizes O +
of O +
mixed O +
WP O -
/ O -
ALG O +
matrix O +
were O +
stable O -
. O +

In O +
SGF O -
, O +
WP O -
/ O -
ALG O +
MP O +
resisted O +
to O +
pepsin O +
degradation O +
compare O +
to O +
pure O +
WP O +
particles O +
due O +
to O +
ALG O +
shrinkage O +
which O +
limited O +
pepsin O +
diffusion O +
within O +
particles O -
. O +

Coating O +
addition O +
with O +
WP O +
or O +
ALG O +
slowed O +
down O +
pepsin O +
degradation O -
. O +

At O +
pH O +
7.5 O -
, O +
WP O -
/ O -
ALG O +
particles O +
were O +
rapidly O +
degraded O +
due O +
to O +
ALG O +
sensitivity O +
but O +
the O +
addition O +
of O +
a O +
WP O +
coating O +
limited O +
effectively O +
the O +
swelling O +
and O +
the O +
degradation O +
of O +
MP O -
. O +

In O +
SIF O -
, O +
pancreatin O +
accelerated O +
MP O +
degradation O +
but O +
ALG O -
- O -
coated O +
MP O +
exhibited O +
interesting O +
robustness O -
. O +

These O +
results O +
confirmed O +
the O +
interest O +
and O +
the O +
feasibility O +
to O +
produce O +
coated O +
WP O -
- O -
based O +
MP O +
which O +
could O +
be O +
a O +
potential O +
orally O +
controlled O +
release O +
drug O +
delivery O +
system O -
. O +

New O +
immunosuppressive O +
cyclomyrsinol B-Chemical +
diterpenes I-Chemical +
from O +
Euphorbia O +
kopetdaghi O +
Prokh O -
. O +

Aceton B-Chemical -
: O +
chloroform B-Chemical +
( O -
1:2 O -
) O +
extracts O +
of O +
the O +
aerial O +
parts O +
of O +
Euphorbia O +
kopetdaghi O +
Prokh O -
. O +

( O -
Euphorbiaceae O -
) O +
were O +
investigated O +
for O +
its O +
diterpenoids B-Chemical +
and O +
afforded O +
three O +
new O +
five O -
- O -
membered O +
ring O -
, O +
pentacyclic B-Chemical +
myrisinane I-Chemical +
polyester I-Chemical +
comprised O +
of O +
3,5,10-O B-Chemical -
- I-Chemical -
triacetyl-8-O I-Chemical -
- I-Chemical -
isobutanoyl-14-O I-Chemical -
- I-Chemical -
benzoylcyclomyrsinol I-Chemical +
( O -
1 O -
) O -
, O +
3,5,10,14-O B-Chemical -
- I-Chemical -
tetraacetyl-8-O- I-Chemical -
( I-Chemical -
2'-methyl I-Chemical +
butanoyl I-Chemical -
) I-Chemical -
-cyclomyrsinol I-Chemical +
( O -
2 O -
) O +
and O +
3,5,10,14-O B-Chemical -
- I-Chemical -
tetracetyl-8-O I-Chemical -
- I-Chemical -
isobutanoylcyclomyrsinol I-Chemical +
( O -
3 O -
) O -
. O +

The O +
structures O +
were O +
elucidated O +
based O +
on O +
( B-Chemical -
13 I-Chemical -
) I-Chemical -
C- I-Chemical +
and O +
( B-Chemical -
1 I-Chemical -
) I-Chemical -
H I-Chemical -
- O -
NMR O +
as O +
well O +
as O +
2D O -
- O -
NMR O -
, O +
IR O +
and O +
different O +
MS O +
spectra O +
and O +
the O +
immunomodulation O +
activity O +
for O +
compound O +
1 O +
was O +
evaluated O +
through O +
lymphocyte O +
proliferation O +
assay O -
, O +
IL-2 O +
assay O -
, O +
oxidative O +
burst O +
of O +
phagocytic O +
leukocytes O +
and O +
through O +
their O +
cytotoxicity O +
on O +
two O +
cell O +
lines O -
. O +

Compound O +
1 O +
showed O +
significant O +
suppressive O +
activity O +
against O +
phytohemagglutinin O -
- O -
activated O +
T O -
- O -
cell O +
proliferation O +
with O +
an O +
IC O -
( O -
50 O -
) O +
of O +
1.83 O +
µg O +
mL O -
( O -
-1 O -
) O -
, O +
IL-2 O +
suppressive O +
activity O +
with O +
an O +
IC O -
( O -
50 O -
) O +
of O +
19.0 O +
µg O +
mL O -
( O -
-1 O -
) O +
and O +
oxidative O +
burst O +
suppressive O +
activity O +
with O +
an O +
IC O -
( O -
50 O -
) O +
of O +
1.6 O +
µg O +
mL O -
( O -
-1 O -
) O +
and O +
ignorable O +
cytotoxic O +
effect O +
on O +
the O +
CC-1 O +
rat O +
hepatocyte O +
and O +
3T3-L1 O +
mouse O +
fibroblast O +
cell O -
- O -
lines O -
. O +

Molecular O +
crosstalk O +
between O +
a O +
chemical O +
and O +
a O +
biological O +
stressor O +
and O +
consequences O +
on O +
disease O +
manifestation O +
in O +
rainbow O +
trout O -
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
examine O +
the O +
molecular O +
and O +
organism O +
reaction O +
of O +
rainbow O +
trout O -
, O +
Oncorhynchus O +
mykiss O -
, O +
to O +
the O +
combined O +
impact O +
of O +
two O +
environmental O +
stressors O -
. O +

The O +
two O +
stressors O +
were O +
the O +
myxozoan O +
parasite O -
, O +
Tetracapsuloides O +
bryosalmonae O -
, O +
which O +
is O +
the O +
etiological O +
agent O +
of O +
proliferative O +
kidney O +
disease O +
( O -
PKD O -
) O +
and O +
a O +
natural O +
stressor O +
to O +
salmonid O +
populations O -
, O +
and O +
17β B-Chemical -
- I-Chemical -
estradiol I-Chemical +
( O -
E2 O -
) O +
as O +
prototype O +
of O +
estrogen B-Chemical -
- O -
active O +
chemical O +
stressors O +
in O +
the O +
aquatic O +
environment O -
. O +

Both O +
stressors O -
, O +
the O +
parasite O +
and O +
estrogenic O +
contaminants O -
, O +
co O -
- O -
exist O +
in O +
Swiss O +
rivers O +
and O +
are O +
discussed O +
as O +
factors O +
contributing O +
to O +
the O +
decline O +
of O +
Swiss O +
brown O +
trout O +
populations O +
over O +
the O +
last O +
decades O -
. O +

Using O +
a O +
microarray O +
approach O +
contrasting O +
parasite O -
- O -
infected O +
and O +
non O -
- O -
infected O +
rainbow O +
trout O +
at O +
low O +
or O +
high O +
estrogen B-Chemical +
levels O -
, O +
it O +
was O +
observed O +
that O +
molecular O +
response O +
patterns O +
under O +
joint O +
exposure O +
differed O +
from O +
those O +
to O +
the O +
single O +
stressors O -
. O +

More O +
specifically O -
, O +
three O +
major O +
response O +
patterns O +
were O +
present O -
: O +
( O -
i O -
) O +
expression O +
responses O +
of O +
gene O +
transcripts O +
to O +
one O +
stressor O +
are O +
weakened O +
by O +
the O +
presence O +
of O +
the O +
second O +
stressor O -
; O +
( O -
ii O -
) O +
expression O +
responses O +
of O +
gene O +
transcripts O +
to O +
one O +
stressor O +
are O +
enhanced O +
by O +
the O +
presence O +
of O +
the O +
second O +
stressor O -
; O +
( O -
iii O -
) O +
expression O +
responses O +
of O +
gene O +
transcripts O +
at O +
joint O +
treatment O +
are O +
dominated O +
by O +
one O +
of O +
the O +
two O +
stressors O -
. O +

Organism O -
- O -
level O +
responses O +
to O +
concurrent O +
E2 O +
and O +
parasite O +
treatment O +
- O +
assessed O +
through O +
measuring O +
parasite O +
loads O +
in O +
the O +
fish O +
host O +
and O +
cumulative O +
mortalities O +
of O +
trout O +
- O +
were O +
dominated O +
by O +
the O +
pathogen O -
, O +
with O +
no O +
modulating O +
influence O +
of O +
E2 O -
. O +

The O +
findings O +
reveal O +
function- O +
and O +
level O -
- O -
specific O +
responses O +
of O +
rainbow O +
trout O +
to O +
stressor O +
combinations O -
, O +
which O +
are O +
only O +
partly O +
predictable O +
from O +
the O +
response O +
to O +
the O +
single O +
stressors O -
. O +

Intraspecific O +
chemical O +
variability O +
of O +
essential O +
oil O +
from O +
leaves O +
of O +
Cupressus O +
atlantica O +
Gaussen O -
, O +
an O +
endemic O +
and O +
endangered O +
coniferous O +
species O +
in O +
Morocco O -
. O +

The O +
composition O +
of O +
essential O +
oils O +
isolated O +
from O +
leaves O +
of O +
11 O +
natural O +
populations O +
of O +
Cupressus O +
atlantica O -
, O +
an O +
endemic O +
and O +
endangered O +
coniferous O +
species O +
from O +
Morocco O -
, O +
was O +
investigated O +
by O +
GC O -
- O -
MS O -
. O +

In O +
total O -
, O +
42 O +
essential O +
oil O +
components O +
were O +
identified O -
, O +
accounting O +
for O +
73.1 O -
- O -
97.7 O -
% O +
of O +
the O +
total O +
oil O -
. O +

Monoterpene B-Chemical +
( O -
25.2 O -
- O -
84.9 O -
% O -
) O +
and O +
sesquiterpene B-Chemical +
hydrocarbons I-Chemical +
( O -
12.2 O -
- O -
46.8 O -
% O -
) O +
were O +
the O +
principal O +
subclasses O +
of O +
compounds O -
, O +
with O +
α B-Chemical -
- I-Chemical -
pinene I-Chemical +
( O -
15 O -
- O -
65.4 O -
% O -
) O -
, O +
germacrene B-Chemical +
D I-Chemical +
( O -
5.9 O -
- O -
30.5 O -
% O -
) O -
, O +
δ-3-carene B-Chemical +
( O -
2 O -
- O -
16.6 O -
% O -
) O +
and O +
γ B-Chemical -
- I-Chemical -
cadinene I-Chemical +
( O -
1.3 O -
- O -
9.8 O -
% O -
) O +
as O +
the O +
main O +
constituents O -
. O +

The O +
results O +
of O +
the O +
oil O +
composition O +
were O +
analysed O +
by O +
hierarchical O +
cluster O +
and O +
principal O +
component O +
analysis O +
that O +
established O +
three O +
main O +
groups O +
of O +
essential O +
oils O -
. O +

These O +
oils O +
were O +
differentiated O +
by O +
the O +
content O +
of O +
the O +
major O +
constituents O +
( O -
α B-Chemical -
- I-Chemical -
pinene I-Chemical -
, O +
germacrene B-Chemical +
D I-Chemical -
, O +
δ-3-carene B-Chemical +
and O +
γ B-Chemical -
- I-Chemical -
cadinene I-Chemical -
) O -
, O +
geographical O +
location O +
and O +
climatic O +
characteristics O -
. O +

Effects O +
of O +
Bixa O +
orellana O +
L. O +
seeds O +
on O +
hyperlipidemia O -
. O +

Bixa O +
orellana O +
L. O -
, O +
urucum O -
, O +
or O +
urucu O -
, O +
a O +
native O +
tropical O +
tree O +
of O +
Central O +
and O +
South O +
American O +
rain O +
forests O +
is O +
used O +
to O +
treat O +
various O +
diseases O +
in O +
popular O +
medicine O -
. O +

In O +
Ceará O -
, O +
Northeast O +
of O +
Brazil O -
, O +
the O +
seeds O +
of O +
urucum O +
have O +
been O +
used O +
for O +
the O +
treatment O +
of O +
high O +
lipid O +
blood O +
levels O -
. O +

The O +
present O +
study O +
investigated O +
the O +
effects O +
of O +
the O +
aqueous O +
extract O +
from O +
Bixa O +
orellana O +
seeds O +
( O -
AEBO O -
) O +
in O +
mice O +
with O +
hyperlipidemia O +
induced O +
by O +
tyloxapol B-Chemical -
, O +
fructose B-Chemical +
and O +
ethanol B-Chemical -
. O +

In O +
hyperlipidemia O +
induced O +
by O +
Triton B-Chemical +
WR1339 I-Chemical -
, O +
400 O +
and O +
800 O +
mg O -
/ O -
kg O +
AEBO O +
reduced O +
triglycerides B-Chemical +
( O -
TG O -
) O +
serum O +
levels O +
at O +
24 O +
h O +
and O +
48 O +
h. O +
In O +
the O +
study O +
of O +
hypertriglyceridemia O +
induced O +
by O +
fructose B-Chemical -
, O +
AEBO O +
in O +
doses O +
of O +
400 O +
mg O -
/ O -
kg O +
and O +
800 O +
mg O -
/ O -
kg O +
reduced O +
TG O +
levels O +
by O +
48.2 O -
% O +
and O +
48.7 O -
% O -
, O +
respectively O -
. O +

Finally O -
, O +
the O +
ethanol B-Chemical +
experimental O +
model O +
with O +
400 O +
mg O -
/ O -
kg O +
AEBO O +
promoted O +
a O +
reduction O +
of O +
33.6 O -
% O +
of O +
TG O +
levels O -
, O +
while O +
the O +
800 O +
mg O -
/ O -
kg O +
concentration O +
reduced O +
hypertriglyceridemia O +
in O +
62.2 O -
% O -
. O +

In O +
conclusion O -
, O +
the O +
aqueous O +
extract O +
of O +
the O +
seeds O +
of O +
Bixa O +
orellana O +
was O +
capable O +
of O +
reversing O +
the O +
hypertriglyceridemia O +
induced O +
by O +
Triton B-Chemical -
, O +
fructose B-Chemical +
and O +
ethanol B-Chemical -
, O +
demonstrating O +
a O +
hypolipidemic O +
effect O -
. O +

However O -
, O +
further O +
studies O +
are O +
necessary O +
to O +
discover O +
the O +
precise O +
mechanism O +
of O +
action O -
. O +

Sarmentosamide B-Chemical -
, O +
a O +
novel O +
hexadienamide B-Chemical +
from O +
Thai O +
soil O +
actinomycetes O -
. O +

A O +
new O +
hexadienamide O +
derivative O +
named O +
sarmentosamide B-Chemical +
( O -
1 O -
) O +
was O +
identified O +
from O +
the O +
culture O +
of O +
Streptomyces O +
sp. O +
SBI108 O +
isolated O +
from O +
Thai O +
soil O +
under O +
an O +
herb O -
. O +

The O +
structure O +
was O +
elucidated O +
on O +
the O +
basis O +
of O +
spectroscopic O +
data O -
, O +
and O +
the O +
absolute O +
configuration O +
was O +
determined O +
by O +
chemical O +
degradation O -
. O +

Electroporation O -
- O -
mediated O +
gene O +
transfer O +
directly O +
to O +
the O +
swine O +
heart O -
. O +

In O +
vivo O +
gene O +
transfer O +
to O +
the O +
ischemic O +
heart O +
via O +
electroporation O +
holds O +
promise O +
as O +
a O +
potential O +
therapeutic O +
approach O +
for O +
the O +
treatment O +
of O +
heart O +
disease O -
. O +

In O +
the O +
current O +
study O -
, O +
we O +
investigated O +
the O +
use O +
of O +
in O +
vivo O +
electroporation O +
for O +
gene O +
transfer O +
using O +
three O +
different O +
penetrating O +
electrodes O +
and O +
one O +
non O -
- O -
penetrating O +
electrode O -
. O +

The O +
hearts O +
of O +
adult O +
male O +
swine O +
were O +
exposed O +
through O +
a O +
sternotomy O -
. O +

Eight O +
electric O +
pulses O +
synchronized O +
to O +
the O +
rising O +
phase O +
of O +
the O +
R O +
wave O +
of O +
the O +
electrocardiogram O +
were O +
administered O +
at O +
varying O +
pulse O +
widths O +
and O +
field O +
strengths O +
following O +
an O +
injection O +
of O +
either O +
a O +
plasmid O +
encoding O +
luciferase O +
or O +
one O +
encoding O +
green O +
fluorescent O +
protein O -
. O +

Four O +
sites O +
on O +
the O +
anterior O +
wall O +
of O +
the O +
left O +
ventricle O +
were O +
treated O -
. O +

Animals O +
were O +
killed O +
48 O +
h O +
after O +
injection O +
and O +
electroporation O +
and O +
gene O +
expression O +
was O +
determined O -
. O +

Results O +
were O +
compared O +
with O +
sites O +
in O +
the O +
heart O +
that O +
received O +
plasmid O +
injection O +
but O +
no O +
electric O +
pulses O +
or O +
were O +
not O +
treated O -
. O +

Gene O +
expression O +
was O +
higher O +
in O +
all O +
electroporated O +
sites O +
when O +
compared O +
with O +
injection O +
only O +
sites O +
demonstrating O +
the O +
robustness O +
of O +
this O +
approach O -
. O +

Our O +
results O +
provide O +
evidence O +
that O +
in O +
vivo O +
electroporation O +
can O +
be O +
a O +
safe O +
and O +
effective O +
non O -
- O -
viral O +
method O +
for O +
delivering O +
genes O +
to O +
the O +
heart O -
, O +
in O +
vivo O -
. O +

Continuous O +
infusion O +
of O +
20-hydroxyecdysone B-Chemical +
increased O +
mass O +
of O +
triceps O +
brachii O +
in O +
C57BL O -
/ O -
6 O +
mice O -
. O +

Phytoecdysteroids B-Chemical +
have O +
been O +
attributed O +
with O +
numerous O +
pharmacological O +
properties O +
in O +
animals O -
, O +
including O +
increasing O +
muscle O +
mass O -
, O +
and O +
20-hydroxyecdysone B-Chemical +
( O -
20E O -
) O +
is O +
one O +
of O +
the O +
most O +
abundant O +
phytoecdysteroids B-Chemical +
produced O +
by O +
plants O -
. O +

In O +
this O +
study O -
, O +
the O +
physiological O +
and O +
gene O +
expression O +
effects O +
of O +
20E O +
were O +
analyzed O +
in O +
C57BL O -
/ O -
6 O +
mice O +
given O +
a O +
continuous O +
infusion O +
of O +
saline O +
or O +
20E O +
( O -
5 O +
mg O -
/ O -
kg O -
/ O -
day O -
) O +
for O +
5 O +
or O +
15 O +
days O +
using O +
subcutaneously O +
implanted O +
Alzet O -
® O +
osmotic O +
pumps O -
. O +

The O +
masses O +
of O +
the O +
total O +
body O -
, O +
muscle O +
groups O +
and O +
organs O +
were O +
determined O -
. O +

There O +
was O +
a O +
significant O +
increase O +
( O +
p O +
= O +
0.01 O -
) O +
in O +
the O +
mass O +
of O +
triceps O +
brachii O +
in O +
mice O +
treated O +
with O +
20E O +
for O +
5 O +
days O +
( O -
115 O +
± O +
8 O +
mg O -
) O +
compared O +
with O +
mice O +
treated O +
with O +
saline O +
for O +
5 O +
days O +
( O -
88 O +
± O +
3 O +
mg O -
) O -
, O +
however O -
, O +
there O +
were O +
no O +
differences O +
in O +
the O +
other O +
measured O +
parameters O -
. O +

To O +
determine O +
potential O +
mechanisms O +
of O +
20E O +
in O +
skeletal O +
muscle O -
, O +
Illumina O -
's O +
Mouse O +
Whole O +
Genome-6 O +
v2.0 O +
Expression O +
BeadChips O +
were O +
used O +
to O +
evaluate O +
changes O +
in O +
gene O +
expression O +
of O +
the O +
triceps O +
brachii O +
after O +
20E O +
infusion O -
. O +

Ingenuity O +
Pathways O +
Analysis O +
was O +
used O +
to O +
identify O +
genes O +
with O +
the O +
most O +
evidence O +
for O +
differential O +
expression O -
, O +
of O +
which O -
, O +
16 O +
genes O +
involved O +
in O +
the O +
skeletal O +
and O +
muscular O +
system O +
were O +
identified O -
. O +

Overall O -
, O +
the O +
data O +
suggest O +
that O +
20E O +
does O +
not O +
have O +
potent O +
anabolic O +
properties O -
, O +
however O -
, O +
a O +
muscle O -
- O -
specific O +
increase O +
was O +
observed O +
and O +
genes O +
were O +
identified O +
to O +
provide O +
an O +
explanation O +
for O +
the O +
muscle O +
accretion O -
. O +

Continuous O +
production O +
of O +
drug O +
nanoparticle O +
suspensions O +
via O +
wet O +
stirred O +
media O +
milling O -
: O +
a O +
fresh O +
look O +
at O +
the O +
Rehbinder O +
effect O -
. O +

Nanoparticles O +
of O +
BCS O +
Class O +
II O +
drugs O +
are O +
produced O +
in O +
wet O +
stirred O +
media O +
mills O +
operating O +
in O +
batch O +
or O +
recirculation O +
mode O +
with O +
the O +
goal O +
of O +
resolving O +
the O +
poor O +
water O -
- O -
solubility O +
issue O -
. O +

Scant O +
information O +
is O +
available O +
regarding O +
the O +
continuous O +
production O +
of O +
drug O +
nanoparticles O +
via O +
wet O +
media O +
milling O -
. O +

Griseofulvin B-Chemical +
and O +
Naproxen B-Chemical +
were O +
milled O +
in O +
both O +
recirculation O +
mode O +
and O +
multi O -
- O -
pass O +
continuous O +
mode O +
to O +
study O +
the O +
breakage O +
dynamics O +
and O +
to O +
determine O +
the O +
effects O +
of O +
suspension O +
flow O +
rate O -
. O +

The O +
evolution O +
of O +
the O +
median O +
particle O +
size O +
was O +
measured O +
and O +
described O +
by O +
an O +
empirical O +
breakage O +
model O -
. O +

We O +
found O +
that O +
these O +
two O +
operation O +
modes O +
could O +
produce O +
drug O +
nanosuspensions O +
with O +
similar O +
particle O +
size O +
distributions O +
( O -
PSDs O -
) O -
. O +

A O +
reduced O +
suspension O +
flow O +
rate O +
slowed O +
the O +
breakage O +
rate O +
and O +
led O +
to O +
a O +
wider O +
PSD O +
and O +
more O +
differentiation O +
between O +
the O +
two O +
operation O +
modes O -
. O +

The O +
latter O +
part O +
of O +
this O +
study O +
focused O +
on O +
the O +
roles O +
of O +
stabilizers O +
( O -
hydroxypropyl B-Chemical +
cellulose O +
and O +
sodium B-Chemical +
lauryl I-Chemical +
sulfate I-Chemical -
) O +
and O +
elucidation O +
of O +
the O +
so O -
- O -
called O +
Rehbinder O +
effect O +
( O -
reduction O +
in O +
particle O +
strength O +
due O +
to O +
adsorbed O +
stabilizers O +
such O +
as O +
polymers O +
and O +
surfactants O -
) O -
. O +

Milling O +
the O +
drugs O +
in O +
the O +
absence O +
of O +
the O +
stabilizers O +
produced O +
primary O +
nanoparticles O +
and O +
their O +
aggregates O -
, O +
while O +
milling O +
with O +
the O +
stabilizers O +
produced O +
smaller O +
primary O +
nanoparticles O +
with O +
minimal O +
aggregation O -
. O +

Using O +
laser O +
diffraction O -
, O +
BET O +
nitrogen B-Chemical +
adsorption O -
, O +
scanning O +
electron O +
microscopy O +
imaging O -
, O +
and O +
a O +
microhydrodynamic O +
analysis O +
of O +
milling O -
, O +
this O +
study O -
, O +
for O +
the O +
first O +
time O -
, O +
provides O +
sufficient O +
evidence O +
for O +
the O +
existence O +
of O +
the O +
Rehbinder O +
effect O +
during O +
the O +
milling O +
of O +
drugs O -
. O +

Not O +
only O +
do O +
the O +
polymers O +
and O +
surfactants O +
allow O +
proper O +
stabilization O +
of O +
the O +
nanoparticles O +
in O +
the O +
suspensions O -
, O +
but O +
they O +
also O +
do O +
facilitate O +
drug O +
particle O +
breakage O -
. O +

PTPN14 O +
interacts O +
with O +
and O +
negatively O +
regulates O +
the O +
oncogenic O +
function O +
of O +
YAP O -
. O +

The O +
Hippo O +
signaling O +
pathway O +
regulates O +
cellular O +
proliferation O +
and O +
survival O -
, O +
thus O +
exerting O +
profound O +
effects O +
on O +
normal O +
cell O +
fate O +
and O +
tumorigenesis O -
. O +

The O +
pivotal O +
effector O +
of O +
this O +
pathway O +
is O +
YAP O -
, O +
a O +
transcriptional O +
co O -
- O -
activator O +
amplified O +
in O +
mouse O +
and O +
human O +
cancers O +
where O +
it O +
promotes O +
epithelial O -
- O -
to O -
- O -
mesenchymal O +
transition O +
and O +
malignant O +
transformation O -
. O +

Here O -
, O +
we O +
report O +
a O +
novel O +
regulatory O +
mechanism O +
for O +
the O +
YAP O +
oncogenic O +
function O +
via O +
direct O +
interaction O +
with O +
non O -
- O -
receptor O +
tyrosine B-Chemical +
phosphatase O +
14 O +
( O -
PTPN14 O -
) O +
through O +
the O +
WW O +
domain O +
of O +
YAP O +
and O +
the O +
PPxY O +
domain O +
of O +
PTPN14 O -
. O +

We O +
also O +
found O +
that O +
YAP O +
is O +
a O +
direct O +
substrate O +
of O +
PTPN14 O -
. O +

In O +
addition O -
, O +
luciferase O +
reporter O +
assay O +
showed O +
that O +
the O +
inhibition O +
of O +
the O +
YAP O +
transcriptional O +
co O -
- O -
activator O +
function O +
by O +
PTPN14 O +
is O +
mediated O +
through O +
their O +
protein O +
interactions O +
and O +
may O +
result O +
from O +
an O +
increase O +
in O +
the O +
inactive O +
cytoplasmic O +
form O +
of O +
YAP O -
. O +

Last O -
, O +
knockdown O +
of O +
PTPN14 O +
induces O +
the O +
nuclear O +
retention O +
of O +
YAP O +
and O +
increases O +
the O +
YAP O -
- O -
dependent O +
cell O +
migration O -
. O +

In O +
summary O -
, O +
our O +
results O +
indicate O +
a O +
potential O +
regulatory O +
role O +
of O +
PTPN14 O +
on O +
YAP O +
and O +
demonstrate O +
a O +
novel O +
mechanism O +
in O +
YAP O +
regulation O -
. O +

The O +
autophagy O -
- O -
associated O +
factors O +
DRAM1 O +
and O +
p62 O +
regulate O +
cell O +
migration O +
and O +
invasion O +
in O +
glioblastoma O +
stem O +
cells O -
. O +

The O +
aggressiveness O +
of O +
glioblastoma O +
multiforme O +
( O -
GBM O -
) O +
is O +
defined O +
by O +
local O +
invasion O +
and O +
resistance O +
to O +
therapy O -
. O +

Within O +
established O +
GBM O -
, O +
a O +
subpopulation O +
of O +
tumor O -
- O -
initiating O +
cells O +
with O +
stem O -
- O -
like O +
properties O +
( O -
GBM O +
stem O +
cells O -
, O +
GSCs O -
) O +
is O +
believed O +
to O +
underlie O +
resistance O +
to O +
therapy O -
. O +

The O +
metabolic O +
pathway O +
autophagy O +
has O +
been O +
implicated O +
in O +
the O +
regulation O +
of O +
survival O +
in O +
GBM O -
. O +

However O -
, O +
the O +
status O +
of O +
autophagy O +
in O +
GBM O +
and O +
its O +
role O +
in O +
the O +
cancer O +
stem O +
cell O +
fraction O +
is O +
currently O +
unclear O -
. O +

We O +
found O +
that O +
a O +
number O +
of O +
autophagy O +
regulators O +
are O +
highly O +
expressed O +
in O +
GBM O +
tumors O +
carrying O +
a O +
mesenchymal O +
signature O -
, O +
which O +
defines O +
aggressiveness O +
and O +
invasion O -
, O +
and O +
are O +
associated O +
with O +
components O +
of O +
the O +
MAPK O +
pathway O -
. O +

This O +
autophagy O +
signature O +
included O +
the O +
autophagy O -
- O -
associated O +
genes O +
DRAM1 O +
and O +
SQSTM1 O -
, O +
which O +
encode O +
a O +
key O +
regulator O +
of O +
selective O +
autophagy O -
, O +
p62 O -
. O +

High O +
levels O +
of O +
DRAM1 O +
were O +
associated O +
with O +
shorter O +
overall O +
survival O +
in O +
GBM O +
patients O -
. O +

In O +
GSCs O -
, O +
DRAM1 O +
and O +
SQSTM1 O +
expression O +
correlated O +
with O +
activation O +
of O +
MAPK O +
and O +
expression O +
of O +
the O +
mesenchymal O +
marker O +
c O -
- O -
MET O -
. O +

DRAM1 O +
knockdown O +
decreased O +
p62 O +
localization O +
to O +
autophagosomes O +
and O +
its O +
autophagy O -
- O -
mediated O +
degradation O -
, O +
thus O +
suggesting O +
a O +
role O +
for O +
DRAM1 O +
in O +
p62-mediated O +
autophagy O -
. O +

In O +
contrast O -
, O +
autophagy O +
induced O +
by O +
starvation O +
or O +
inhibition O +
of O +
mTOR O -
/ O -
PI-3 O -
K O +
was O +
not O +
affected O +
by O +
either O +
DRAM1 O +
or O +
p62 O +
downregulation O -
. O +

Functionally O -
, O +
DRAM1 O +
and O +
p62 O +
regulate O +
cell O +
motility O +
and O +
invasion O +
in O +
GSCs O -
. O +

This O +
was O +
associated O +
with O +
alterations O +
of O +
energy O +
metabolism O -
, O +
in O +
particular O +
reduced O +
ATP B-Chemical +
and O +
lactate B-Chemical +
levels O -
. O +

Taken O +
together O -
, O +
these O +
findings O +
shed O +
new O +
light O +
on O +
the O +
role O +
of O +
autophagy O +
in O +
GBM O +
and O +
reveal O +
a O +
novel O +
function O +
of O +
the O +
autophagy O +
regulators O +
DRAM1 O +
and O +
p62 O +
in O +
control O +
of O +
migration O -
/ O -
invasion O +
in O +
cancer O +
stem O +
cells O -
. O +

Effect O +
of O +
water O +
extracts O +
from O +
edible O +
myrtaceae O +
plants O +
on O +
uptake O +
of O +
2- B-Chemical -
( I-Chemical -
n- I-Chemical -
( I-Chemical -
7-nitrobenz-2-oxa-1,3-diazol-4-yl I-Chemical -
) I-Chemical -
amino I-Chemical -
) I-Chemical -
-2-deoxyglucose I-Chemical +
in O +
TNF O -
- O -
α O -
- O -
treated O +
FL83B O +
mouse O +
hepatocytes O -
. O +

This O +
study O +
investigated O +
the O +
glucose B-Chemical +
uptake O +
activity O +
of O +
the O +
water O +
extracts O +
from O +
the O +
leaves O +
and O +
fruit O +
of O +
edible O +
Myrtaceae O +
plants O -
, O +
including O +
guava O +
( O -
Psidium O +
guajava O +
Linn O -
. O -
) O -
, O +
wax O +
apples O +
[ O -
Syzygium O +
samarangense O +
( O -
Blume O -
) O +
Merr O -
. O +

and O +
L.M. O +
Perry O -
] O -
, O +
Pu O -
- O -
Tau O +
[ O -
Syzygium O +
jambo O +
( O -
L. O -
) O +
Alston O -
] O -
, O +
and O +
Kan O -
- O -
Shi O +
Pu O -
- O -
Tau O +
( O -
Syzygium O +
cumini O +
Linn O -
. O -
) O +
in O +
FL83B O +
mouse O +
hepatocytes O -
. O +

The O +
fluorescent O +
dye O +
2- B-Chemical -
( I-Chemical -
n- I-Chemical -
( I-Chemical -
7-nitrobenz-2-oxa-1,3-diazol-4-yl I-Chemical -
) I-Chemical -
amino I-Chemical -
) I-Chemical -
-2-deoxyglucose I-Chemical +
was O +
used O +
to O +
estimate O +
the O +
uptake O +
ability O +
of O +
the O +
cells O -
. O +

Glucose B-Chemical +
uptake O +
test O +
showed O +
that O +
pink O +
wax O +
apple O +
fruit O +
extract O +
( O -
PWFE O -
) O +
exhibits O +
the O +
highest O +
glucose B-Chemical +
uptake O +
activity O -
, O +
at O +
an O +
increment O +
of O +
21 O -
% O +
in O +
the O +
insulin O -
- O -
resistant O +
FL83B O +
mouse O +
hepatocytes O +
as O +
compared O +
with O +
the O +
TNF O -
- O -
α O -
- O -
treated O +
control O +
group O -
. O +

Vescalagin B-Chemical +
was O +
isolated O +
using O +
column O +
chromatography O +
of O +
PWFE O -
. O +

This O +
compound O -
, O +
at O +
the O +
concentration O +
of O +
6.25 O +
µg O -
/ O -
mL O -
, O +
exhibits O +
the O +
same O +
glucose B-Chemical +
uptake O +
improvement O +
in O +
insulin O -
- O -
resistant O +
cells O +
as O +
PWFE O +
at O +
a O +
100-µg O -
/ O -
mL O +
dose O -
. O +

We O +
postulate O +
that O +
vescalagin B-Chemical +
is O +
an O +
active O +
component O +
in O +
PWFE O +
that O +
may O +
alleviate O +
the O +
insulin O +
resistance O +
in O +
mouse O +
hepatocytes O -
. O +

TRAPPC9-related O +
autosomal O +
recessive O +
intellectual O +
disability O -
: O +
report O +
of O +
a O +
new O +
mutation O +
and O +
clinical O +
phenotype O -
. O +

Intellectual O +
disability O +
( O -
ID O -
) O +
with O +
autosomal O +
recessive O +
( O -
AR O -
) O +
inheritance O +
is O +
believed O +
to O +
be O +
common O -
; O +
however O -
, O +
very O +
little O +
is O +
known O +
about O +
causative O +
genes O +
and O +
genotype O -
- O -
phenotype O +
correlations O -
. O +

The O +
broad O +
genetic O +
heterogeneity O +
of O +
AR O -
- O -
ID O -
, O +
and O +
its O +
usually O +
nonsyndromic O +
nature O +
make O +
it O +
difficult O +
to O +
pool O +
multiple O +
pedigrees O +
with O +
the O +
same O +
underlying O +
genetic O +
defect O +
to O +
achieve O +
consistent O +
nosology O -
. O +

Nearly O +
all O +
autosomal O +
genes O +
responsible O +
for O +
recessive O +
cognitive O +
disorders O +
have O +
been O +
identified O +
in O +
large O +
consanguineous O +
families O +
from O +
the O +
Middle O +
East O -
, O +
and O +
nonsense O +
mutations O +
in O +
TRAPPC9 O +
have O +
been O +
reported O +
in O +
a O +
total O +
of O +
5 O -
. O +

Although O +
several O +
recurrent O +
phenotypic O +
abnormalities O +
are O +
described O +
in O +
some O +
of O +
these O +
patients O -
, O +
the O +
associated O +
phenotype O +
is O +
usually O +
referred O +
to O +
as O +
nonsyndromic O -
. O +

By O +
means O +
of O +
single O -
- O -
nucleotide O +
polymorphism O -
- O -
array O +
first O +
and O +
then O +
by O +
exome O +
sequencing O -
, O +
we O +
identified O +
a O +
new O +
pathogenic O +
mutation O +
in O +
TRAPPC9 O +
in O +
two O +
Italian O +
sisters O +
born O +
to O +
healthy O +
and O +
apparently O +
nonconsanguineous O +
parents O -
. O +

It O +
consists O +
of O +
a O +
homozygous O +
splice O +
site O +
mutation O +
causing O +
exon O +
skipping O +
with O +
frameshift O +
and O +
premature O +
termination O -
, O +
as O +
confirmed O +
by O +
mRNA O +
sequencing O -
. O +

By O +
detailed O +
phenotypic O +
analysis O +
of O +
our O +
patients O -
, O +
and O +
by O +
critical O +
literature O +
review O -
, O +
we O +
found O +
that O +
homozygous O +
TRAPPC9 O +
loss O -
- O -
of O -
- O -
function O +
mutations O +
cause O +
a O +
distinctive O +
phenotype O -
, O +
characterized O +
by O +
peculiar O +
facial O +
appearance O -
, O +
obesity O -
, O +
hypotonia O +
( O -
all O +
signs O +
resembling O +
a O +
Prader O -
- O -
Willi O -
- O -
like O +
phenotype O -
) O -
, O +
moderate O -
- O -
to O -
- O -
severe O +
ID O -
, O +
and O +
consistent O +
brain O +
abnormalities O -
. O +

The O +
effect O +
of O +
process O +
parameters O +
on O +
audible O +
acoustic O +
emissions O +
from O +
high O -
- O -
shear O +
granulation O -
. O +

Product O +
quality O +
in O +
high O -
- O -
shear O +
granulation O +
is O +
easily O +
compromised O +
by O +
minor O +
changes O +
in O +
raw O +
material O +
properties O +
or O +
process O +
conditions O -
. O +

It O +
is O +
desired O +
to O +
develop O +
a O +
process O +
analytical O +
technology O +
( O -
PAT O -
) O +
that O +
can O +
monitor O +
the O +
process O +
in O +
real O -
- O -
time O +
and O +
provide O +
feedback O +
for O +
quality O +
control O -
. O +

In O +
this O +
work O -
, O +
the O +
application O +
of O +
audible O +
acoustic O +
emissions O +
( O -
AAEs O -
) O +
as O +
a O +
PAT O +
tool O +
was O +
investigated O -
. O +

A O +
condenser O +
microphone O +
was O +
placed O +
at O +
the O +
top O +
of O +
the O +
air O +
exhaust O +
on O +
a O +
PMA-10 O +
high O -
- O -
shear O +
granulator O +
to O +
collect O +
AAEs O +
for O +
a O +
design O +
of O +
experiment O +
( O -
DOE O -
) O +
varying O +
impeller O +
speed O -
, O +
total O +
binder O +
volume O +
and O +
spray O +
rate O -
. O +

The O +
results O +
showed O +
the O +
10 O +
Hz O +
total O +
power O +
spectral O +
densities O +
( O -
TPSDs O -
) O +
between O +
20 O +
and O +
250 O +
Hz O +
were O +
significantly O +
affected O +
by O +
the O +
changes O +
in O +
process O +
conditions O -
. O +

Impeller O +
speed O +
and O +
spray O +
rate O +
were O +
shown O +
to O +
have O +
statistically O +
significant O +
effects O +
on O +
granulation O +
wetting O -
, O +
and O +
impeller O +
speed O +
and O +
total O +
binder O +
volume O +
were O +
significant O +
in O +
terms O +
of O +
process O +
end O -
- O -
point O -
. O +

The O +
DOE O +
results O +
were O +
confirmed O +
by O +
a O +
multivariate O +
PLS O +
model O +
of O +
the O +
TPSDs O -
. O +

The O +
scores O +
plot O +
showed O +
separation O +
based O +
on O +
impeller O +
speed O +
in O +
the O +
first O +
component O +
and O +
spray O +
rate O +
in O +
the O +
second O +
component O -
. O +

The O +
findings O +
support O +
the O +
use O +
of O +
AAEs O +
to O +
monitor O +
changes O +
in O +
process O +
conditions O +
in O +
real O -
- O -
time O +
and O +
achieve O +
consistent O +
product O +
quality O -
. O +

Discovery O +
and O +
structural O +
characterization O +
of O +
a O +
phospholamban O -
- O -
binding O +
cyclic O +
peptide O +
and O +
design O +
of O +
novel O +
inhibitors O +
of O +
phospholamban O -
. O +

The O +
interplay O +
between O +
cardiac O +
sarcoplasmic O +
Ca B-Chemical -
( I-Chemical -
2+ I-Chemical -
) I-Chemical -
ATPase O +
and O +
phospholamban O +
is O +
a O +
key O +
regulating O +
factor O +
of O +
contraction O +
and O +
relaxation O +
in O +
the O +
cardiac O +
muscle O -
. O +

In O +
heart O +
failure O -
, O +
aberrations O +
in O +
the O +
inhibition O +
of O +
sarcoplasmic O +
Ca B-Chemical -
( I-Chemical -
2+ I-Chemical -
) I-Chemical -
ATPase O +
by O +
phospholamban O +
are O +
associated O +
with O +
anomalies O +
in O +
cardiac O +
functions O -
. O +

In O +
experimental O +
heart O +
failure O +
models O -
, O +
modulation O +
of O +
the O +
interaction O +
between O +
these O +
two O +
proteins O +
has O +
been O +
shown O +
to O +
be O +
a O +
potential O +
therapeutic O +
approach O -
. O +

The O +
aim O +
of O +
our O +
research O +
was O +
to O +
find O +
molecules O +
able O +
to O +
interfere O +
with O +
the O +
inhibitory O +
activity O +
of O +
phospholamban O +
on O +
sarcoplasmic O +
Ca B-Chemical -
( I-Chemical -
2+ I-Chemical -
) I-Chemical -
ATPase O -
. O +

For O +
this O +
purpose O -
, O +
a O +
portion O +
of O +
phospholamban O +
was O +
synthesized O +
and O +
used O +
as O +
target O +
for O +
a O +
phage O -
- O -
display O +
peptide O +
library O +
screening O -
. O +

The O +
cyclic O +
peptide O +
C O -
- O -
Y O -
- O -
W O -
- O -
E O -
- O -
L O -
- O -
E O -
- O -
W O -
- O -
L O -
- O -
P O -
- O -
C O -
- O -
A O +
was O +
found O +
to O +
bind O +
to O +
phospholamban O +
( O -
1 O -
- O -
36 O -
) O +
with O +
high O +
specificity O -
. O +

Its O +
functional O +
activity O +
was O +
tested O +
in O +
Ca B-Chemical -
( I-Chemical -
2+ I-Chemical -
) I-Chemical -
uptake O +
assays O +
utilizing O +
preparations O +
from O +
cardiac O +
sarcoplasmic O +
reticulum O -
. O +

By O +
synthesizing O +
and O +
testing O +
a O +
series O +
of O +
alanine B-Chemical +
point O -
- O -
mutated O +
cyclic O +
peptides O -
, O +
we O +
identified O +
which O +
amino B-Chemical +
acid I-Chemical +
was O +
important O +
for O +
the O +
inhibition O +
of O +
the O +
phospholamban O +
function O -
. O +

The O +
structures O +
of O +
active O +
and O +
inactive O +
alanine B-Chemical -
- O -
mutated O +
cyclic O +
peptides O -
, O +
and O +
of O +
phospholamban O +
( O -
1 O -
- O -
36 O -
) O -
, O +
were O +
determined O +
by O +
NMR O -
. O +

This O +
structure O -
- O -
activity O +
analysis O +
allowed O +
building O +
a O +
model O +
of O +
phospholamban O +
-cyclic O +
peptide O +
complex O -
. O +

Thereafter O -
, O +
a O +
simple O +
pharmacophore O +
was O +
defined O +
and O +
used O +
for O +
the O +
design O +
of O +
small O +
molecules O -
. O +

Finally O -
, O +
examples O +
of O +
such O +
molecules O +
were O +
synthesized O +
and O +
characterized O +
as O +
phospholamban O +
inhibitors O -
. O +

Organ O +
accumulation O +
in O +
mice O +
after O +
inhalation O +
of O +
single O +
or O +
mixed O +
essential O +
oil O +
compounds O -
. O +

Essential O +
oils O +
are O +
composed O +
of O +
multiple O +
components O -
. O +

It O +
is O +
thought O +
that O +
the O +
effect O +
of O +
essential O +
oils O +
is O +
due O +
to O +
specific O +
component O +
ratios O -
, O +
which O +
may O +
differ O +
from O +
the O +
original O +
ratio O +
when O +
the O +
essential O +
oil O +
is O +
absorbed O -
. O +

However O -
, O +
very O +
little O +
detailed O +
research O +
exists O +
in O +
this O +
area O -
. O +

We O +
studied O +
the O +
distribution O +
of O +
essential O +
oil O +
components O +
after O +
inhalation O +
of O +
single O +
and O +
mixed O +
components O +
in O +
mice O -
. O +

This O +
research O +
was O +
done O +
using O +
four O +
main O +
components O +
of O +
Alpinia O +
zerumbet O +
( O -
Pers O -
. O -
) O +

B. O +
L. O +
Burtt O -
. O +

and O +
R. O +
M. O +
Sm O -
. O +

: O +
α B-Chemical -
- I-Chemical -
pinene I-Chemical -
, O +
p B-Chemical -
- I-Chemical -
cymene I-Chemical -
, O +
1,8-cineole B-Chemical -
, O +
and O +
limonene B-Chemical -
. O +

After O +
inhalation O +
of O +
single O +
or O +
mixed O +
components O +
for O +
90 O +
min O -
, O +
component O +
levels O +
in O +
the O +
brain O +
and O +
liver O +
of O +
mice O +
were O +
measured O -
. O +

The O +
results O +
indicated O +
that O +
the O +
amount O +
of O +
α B-Chemical -
- I-Chemical -
pinene I-Chemical +
in O +
the O +
brain O +
and O +
liver O +
was O +
twofold O +
greater O +
after O +
mixed O -
- O -
component O +
inhalation O +
than O +
that O +
after O +
single O -
- O -
component O +
inhalation O -
. O +

In O +
a O +
comparison O +
of O +
the O +
components O +
of O +
the O +
mixed O +
inhalation O -
, O +
the O +
ratio O +
of O +
α B-Chemical -
- I-Chemical -
pinene I-Chemical +
increased O +
to O +
about O +
three O +
times O +
that O +
of O +
1,8-cineole B-Chemical -
. O +

It O +
is O +
thought O +
that O +
the O +
absorption O +
via O +
the O +
nasal O +
mucus O +
greatly O +
influences O +
this O +
phenomenon O -
. O +

The O +
results O +
of O +
this O +
investigation O +
of O +
the O +
bodily O +
distribution O +
of O +
essential O +
oil O +
volatile O +
components O +
may O +
provide O +
clues O +
for O +
elucidating O +
their O +
action O -
. O +

Mitochondrial O +
activation O +
by O +
inhibition O +
of O +
PDKII O +
suppresses O +
HIF1a O +
signaling O +
and O +
angiogenesis O +
in O +
cancer O -
. O +

Most O +
solid O +
tumors O +
are O +
characterized O +
by O +
a O +
metabolic O +
shift O +
from O +
glucose B-Chemical +
oxidation O +
to O +
glycolysis O -
, O +
in O +
part O +
due O +
to O +
actively O +
suppressed O +
mitochondrial O +
function O -
, O +
a O +
state O +
that O +
favors O +
resistance O +
to O +
apoptosis O -
. O +

Suppressed O +
mitochondrial O +
function O +
may O +
also O +
contribute O +
to O +
the O +
activation O +
of O +
hypoxia O -
- O -
inducible O +
factor O +
1α O +
( O -
HIF1α O -
) O +
and O +
angiogenesis O -
. O +

We O +
have O +
previously O +
shown O +
that O +
the O +
inhibitor O +
of O +
pyruvate B-Chemical +
dehydrogenase O +
kinase O +
( O -
PDK O -
) O +
dichloroacetate B-Chemical +
( O -
DCA B-Chemical -
) O +
activates O +
glucose B-Chemical +
oxidation O +
and O +
induces O +
apoptosis O +
in O +
cancer O +
cells O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

We O +
hypothesized O +
that O +
DCA B-Chemical +
will O +
also O +
reverse O +
the O +
' O -
pseudohypoxic O -
' O +
mitochondrial O +
signals O +
that O +
lead O +
to O +
HIF1α O +
activation O +
in O +
cancer O -
, O +
even O +
in O +
the O +
absence O +
of O +
hypoxia O +
and O +
inhibit O +
cancer O +
angiogenesis O -
. O +

We O +
show O +
that O +
inhibition O +
of O +
PDKII O +
inhibits O +
HIF1α O +
in O +
cancer O +
cells O +
using O +
several O +
techniques O -
, O +
including O +
HIF1α O +
luciferase O +
reporter O +
assays O -
. O +

Using O +
pharmacologic O +
and O +
molecular O +
approaches O +
that O +
suppress O +
the O +
prolyl B-Chemical -
- O -
hydroxylase O +
( O -
PHD O -
) O -
-mediated O +
inhibition O +
of O +
HIF1α O -
, O +
we O +
show O +
that O +
DCA B-Chemical +
inhibits O +
HIF1α O +
by O +
both O +
a O +
PHD O -
- O -
dependent O +
mechanism O +
( O -
that O +
involves O +
a O +
DCA B-Chemical -
- O -
induced O +
increase O +
in O +
the O +
production O +
of O +
mitochondria O -
- O -
derived O +
α B-Chemical -
- I-Chemical -
ketoglutarate I-Chemical -
) O +
and O +
a O +
PHD O -
- O -
independent O +
mechanism O -
, O +
involving O +
activation O +
of O +
p53 O +
via O +
mitochondrial O -
- O -
derived O +
H B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
O I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
, O +
as O +
well O +
as O +
activation O +
of O +
GSK3β O -
. O +

Effective O +
inhibition O +
of O +
HIF1α O +
is O +
shown O +
by O +
a O +
decrease O +
in O +
the O +
expression O +
of O +
several O +
HIF1α O +
regulated O +
gene O +
products O +
as O +
well O +
as O +
inhibition O +
of O +
angiogenesis O +
in O +
vitro O +
in O +
matrigel O +
assays O -
. O +

More O +
importantly O -
, O +
in O +
rat O +
xenotransplant O +
models O +
of O +
non O -
- O -
small O +
cell O +
lung O +
cancer O +
and O +
breast O +
cancer O -
, O +
we O +
show O +
effective O +
inhibition O +
of O +
angiogenesis O +
and O +
tumor O +
perfusion O +
in O +
vivo O -
, O +
assessed O +
by O +
contrast O -
- O -
enhanced O +
ultrasonography O -
, O +
nuclear O +
imaging O +
techniques O +
and O +
histology O -
. O +

This O +
work O +
suggests O +
that O +
mitochondria O -
- O -
targeting O +
metabolic O +
modulators O +
that O +
increase O +
pyruvate B-Chemical +
dehydrogenase O +
activity O -
, O +
in O +
addition O +
to O +
the O +
recently O +
described O +
pro O -
- O -
apoptotic O +
and O +
anti O -
- O -
proliferative O +
effects O -
, O +
suppress O +
angiogenesis O +
as O +
well O -
, O +
normalizing O +
the O +
pseudo O -
- O -
hypoxic O +
signals O +
that O +
lead O +
to O +
normoxic O +
HIF1α O +
activation O +
in O +
solid O +
tumors O -
. O +

Macrophage O +
cathepsin O +
K O +
promotes O +
prostate O +
tumor O +
progression O +
in O +
bone O -
. O +

Bone O +
marrow O +
macrophages O +
( O -
BMMs O -
) O +
share O +
common O +
progenitors O +
with O +
osteoclasts O +
and O +
are O +
critical O +
components O +
of O +
bone O -
- O -
tumor O +
microenvironment O -
; O +
however O -
, O +
their O +
function O +
in O +
prostate O +
tumor O +
growth O +
in O +
the O +
skeleton O +
has O +
not O +
been O +
explored O -
. O +

BMMs O +
are O +
the O +
major O +
source O +
of O +
inflammatory O +
factors O +
and O +
proteases O -
, O +
including O +
cysteine B-Chemical +
protease O +
cathepsin O +
K O +
( O -
CTSK O -
) O -
. O +

In O +
this O +
study O -
, O +
utilizing O +
mice O +
deficient O +
in O +
CTSK O -
, O +
we O +
demonstrate O +
the O +
critical O +
involvement O +
of O +
this O +
potent O +
collagenase O +
in O +
tumor O +
progression O +
in O +
bone O -
. O +

We O +
present O +
the O +
evidence O +
that O +
tumor O +
growth O +
and O +
progression O +
in O +
the O +
bone O +
are O +
impaired O +
in O +
the O +
absence O +
of O +
CTSK O -
. O +

Most O +
importantly O -
, O +
we O +
show O +
for O +
the O +
first O +
time O +
that O +
BMM O -
- O -
supplied O +
CTSK O +
may O +
be O +
involved O +
in O +
CCL2- O +
and O +
COX-2-driven O +
pathways O +
that O +
contribute O +
to O +
tumor O +
progression O +
in O +
bone O -
. O +

Together O -
, O +
our O +
data O +
unravel O +
novel O +
roles O +
for O +
CTSK O +
in O +
macrophage O -
- O -
regulated O +
processes O -
, O +
and O +
provide O +
evidence O +
for O +
close O +
interplay O +
between O +
inflammatory O -
, O +
osteolytic O +
and O +
tumor O +
cell O -
- O -
driven O +
events O +
in O +
the O +
bone O -
- O -
tumor O +
microenvironment O -
. O +

Silibinin B-Chemical +
triggers O +
apoptosis O +
and O +
cell O -
- O -
cycle O +
arrest O +
of O +
SGC7901 O +
cells O -
. O +

Silibinin B-Chemical -
, O +
a O +
flavonoid B-Chemical +
compound O -
, O +
has O +
shown O +
to O +
be O +
of O +
chemopreventive O +
potential O +
against O +
many O +
cancers O -
. O +

However O -
, O +
its O +
efficacy O +
against O +
gastric O +
cancer O +
has O +
not O +
been O +
well O +
elucidated O -
. O +

Here O -
, O +
we O +
assessed O +
the O +
activity O +
of O +
Silibinin B-Chemical +
on O +
apoptosis O +
and O +
cell O -
- O -
cycle O +
arrest O +
in O +
human O +
gastric O +
cells O +
culture O +
system O +
using O +
SGC-7901 O +
as O +
the O +
model O -
. O +

Silibinin B-Chemical +
treatment O +
could O +
inhibit O +
the O +
cell O +
growth O +
and O +
cause O +
a O +
prominent O +
G2 O +
phase O +
arrest O +
and O +
apoptosis O +
in O +
dose- O +
and O +
time O -
- O -
dependent O +
manner O -
. O +

In O +
mechanistic O +
studies O -
, O +
Silibinin B-Chemical +
decreased O +
the O +
protein O +
level O +
of O +
p34cdc2 O -
, O +
which O +
might O +
be O +
the O +
possible O +
molecular O +
mechanism O +
of O +
Silibinin B-Chemical +
efficacy O +
on O +
the O +
growth O +
inhibition O +
in O +
SGC-7901 O +
cells O -
. O +

In O +
addition O -
, O +
Silibinin B-Chemical +
caused O +
an O +
increase O +
in O +
p53 O +
and O +
p21 O +
protein O +
level O +
as O +
well O +
as O +
mRNA O +
levels O -
. O +

Interestingly O -
, O +
Silibinin B-Chemical -
- O -
induced O +
apoptosis O +
in O +
SGC-7901 O +
cells O +
was O +
independent O +
of O +
caspases O +
activation O -
. O +

These O +
results O +
indicated O +
that O +
Silibinin B-Chemical +
is O +
a O +
cell O -
- O -
cycle O +
regulator O +
and O +
apoptosis O +
inducer O +
in O +
human O +
gastric O +
carcinoma O +
SGC-7901 O +
cells O +
and O +
might O +
be O +
used O +
as O +
a O +
candidate O +
chemopreventive O +
agent O +
for O +
gastric O +
carcinoma O +
prevention O +
and O +
intervention O -
. O +

Copyright O +
© O +
2012 O +
John O +
Wiley O +
& O +
Sons O -
, O +
Ltd. O +

Acetylation O +
and O +
deacetylation O -
-- O -
novel O +
factors O +
in O +
muscle O +
wasting O -
. O +

We O +
review O +
recent O +
evidence O +
that O +
acetylation O +
and O +
deacetylation O +
of O +
cellular O +
proteins O -
, O +
including O +
transcription O +
factors O +
and O +
nuclear O +
cofactors O -
, O +
may O +
be O +
involved O +
in O +
the O +
regulation O +
of O +
muscle O +
mass O -
. O +

The O +
level O +
of O +
protein O +
acetylation O +
is O +
balanced O +
by O +
histone O +
acetyltransferases O +
( O -
HATs O -
) O +
and O +
histone O +
deacetylases O +
( O -
HDACs O -
) O +
and O +
studies O +
suggest O +
that O +
this O +
balance O +
is O +
perturbed O +
in O +
muscle O +
wasting O -
. O +

Hyperacetylation O +
of O +
transcription O +
factors O +
and O +
nuclear O +
cofactors O +
regulating O +
gene O +
transcription O +
in O +
muscle O +
wasting O +
may O +
influence O +
muscle O +
mass O -
. O +

In O +
addition O -
, O +
hyperacetylation O +
may O +
render O +
proteins O +
susceptible O +
to O +
degradation O +
by O +
different O +
mechanisms O -
, O +
including O +
intrinsic O +
ubiquitin O +
ligase O +
activity O +
exerted O +
by O +
HATs O +
and O +
by O +
dissociation O +
of O +
proteins O +
from O +
cellular O +
chaperones O -
. O +

In O +
recent O +
studies O -
, O +
inhibition O +
of O +
p300 O -
/ O -
HAT O +
expression O +
and O +
activity O +
and O +
stimulation O +
of O +
SIRT1-dependent O +
HDAC O +
activity O +
reduced O +
glucocorticoid O -
- O -
induced O +
catabolic O +
response O +
in O +
skeletal O +
muscle O -
, O +
providing O +
further O +
evidence O +
that O +
hyperacetylation O +
plays O +
a O +
role O +
in O +
muscle O +
wasting O -
. O +

It O +
should O +
be O +
noted O -
, O +
however O -
, O +
that O +
although O +
several O +
studies O +
advocate O +
a O +
role O +
of O +
hyperacetylation O +
in O +
muscle O +
wasting O -
, O +
apparently O +
contradictory O +
results O +
have O +
also O +
been O +
reported O -
. O +

For O +
example O -
, O +
muscle O +
atrophy O +
caused O +
by O +
denervation O +
or O +
immobilization O +
may O +
be O +
associated O +
with O +
reduced O -
, O +
rather O +
than O +
increased O -
, O +
protein O +
acetylation O -
. O +

In O +
addition O -
, O +
whereas O +
hyperacetylation O +
results O +
in O +
increased O +
degradation O +
of O +
certain O +
proteins O -
, O +
other O +
proteins O +
may O +
be O +
stabilized O +
by O +
increased O +
acetylation O -
. O +

Thus O -
, O +
the O +
role O +
of O +
acetylation O +
and O +
deacetylation O +
in O +
the O +
regulation O +
of O +
muscle O +
mass O +
may O +
be O +
both O +
condition- O +
and O +
protein O -
- O -
specific O -
. O +

The O +
influence O +
of O +
HATs O +
and O +
HDACs O +
on O +
the O +
regulation O +
of O +
muscle O +
mass O -
, O +
as O +
well O +
as O +
methods O +
to O +
modulate O +
protein O +
acetylation O -
, O +
is O +
an O +
important O +
area O +
for O +
continued O +
research O +
aimed O +
at O +
preventing O +
and O +
treating O +
muscle O +
wasting O -
. O +

Combining O +
GLP-1 O +
receptor O +
agonists O +
with O +
insulin O -
: O +
therapeutic O +
rationales O +
and O +
clinical O +
findings O -
. O +

Due O +
to O +
the O +
increasing O +
prevalence O +
of O +
type O +
2 O +
diabetes O +
mellitus O +
( O -
T2DM O -
) O -
, O +
the O +
emergent O +
trend O +
towards O +
diagnosis O +
in O +
younger O +
patients O +
and O +
the O +
progressive O +
nature O +
of O +
this O +
disease O -
, O +
many O +
more O +
patients O +
than O +
before O +
now O +
require O +
insulin O +
to O +
maintain O +
glycaemic O +
control O -
. O +

However O -
, O +
there O +
is O +
a O +
degree O +
of O +
inertia O +
among O +
physicians O +
and O +
patients O +
regarding O +
the O +
initiation O +
and O +
intensification O +
of O +
insulin O +
therapy O -
, O +
in O +
part O +
due O +
to O +
concerns O +
about O +
the O +
associated O +
weight O +
gain O +
and O +
increased O +
risk O +
of O +
hypoglycaemia O -
. O +

Glucagon O -
- O -
like O +
peptide-1 O +
receptor O +
agonists O +
( O -
GLP-1RAs O -
) O +
increase O +
insulin O +
release O +
and O +
suppress O +
glucagon O +
secretion O +
in O +
a O +
glucose B-Chemical -
- O -
dependent O +
manner O -
, O +
thus O +
conferring O +
glycaemic O +
control O +
with O +
a O +
low O +
incidence O +
of O +
hypoglycaemia O -
. O +

GLP-1RAs O +
also O +
promote O +
weight O +
loss O -
, O +
and O +
have O +
beneficial O +
effects O +
on O +
markers O +
of O +
β O +
cell O +
function O -
, O +
lipid O +
levels O -
, O +
blood O +
pressure O +
and O +
cardiovascular O +
risk O +
markers O -
. O +

However O -
, O +
the O +
durability O +
of O +
their O +
effectiveness O +
is O +
unknown O +
and O -
, O +
compared O +
with O +
insulin O -
, O +
the O +
antihyperglycaemic O +
efficacy O +
of O +
GLP-1RAs O +
is O +
limited O -
. O +

The O +
combination O +
of O +
a O +
GLP-1RA O +
and O +
insulin O +
might O +
thus O +
be O +
highly O +
effective O +
for O +
optimal O +
glucose B-Chemical +
control O -
, O +
ameliorating O +
the O +
adverse O +
effects O +
typically O +
associated O +
with O +
insulin O -
. O +

Data O +
from O +
clinical O +
studies O +
support O +
the O +
therapeutic O +
potential O +
of O +
GLP-1RA O -
- O -
insulin O +
combination O +
therapy O -
, O +
typically O +
showing O +
beneficial O +
effects O +
on O +
glycaemic O +
control O +
and O +
body O +
weight O -
, O +
with O +
a O +
low O +
incidence O +
of O +
hypoglycaemia O +
and O -
, O +
in O +
established O +
insulin O +
therapy O -
, O +
facilitating O +
reductions O +
in O +
insulin O +
dose O -
. O +

In O +
this O +
review O -
, O +
the O +
physiological O +
and O +
pharmacological O +
rationale O +
for O +
using O +
GLP-1RA O +
and O +
insulin O +
therapies O +
in O +
combination O +
is O +
discussed O -
, O +
and O +
data O +
from O +
clinical O +
studies O +
that O +
have O +
assessed O +
the O +
efficacy O +
and O +
safety O +
of O +
this O +
treatment O +
strategy O +
are O +
outlined O -
. O +

Group O +
III O +
and O +
subtype O +
4 O +
metabotropic O +
glutamate B-Chemical +
receptor O +
agonists O -
: O +
discovery O +
and O +
pathophysiological O +
applications O +
in O +
Parkinson O -
's O +
disease O -
. O +

Restoring O +
the O +
balance O +
between O +
excitatory O +
and O +
inhibitory O +
circuits O +
in O +
the O +
basal O +
ganglia O -
, O +
following O +
the O +
loss O +
of O +
dopaminergic O +
( O -
DA O -
) O +
neurons O +
of O +
the O +
substantia O +
nigra O +
pars O +
compacta O -
, O +
represents O +
a O +
major O +
challenge O +
to O +
treat O +
patients O +
affected O +
by O +
Parkinson O -
's O +
disease O +
( O -
PD O -
) O -
. O +

The O +
imbalanced O +
situation O +
in O +
favor O +
of O +
excitation O +
in O +
the O +
disease O +
state O +
may O +
also O +
accelerate O +
excitotoxic O +
processes O -
, O +
thereby O +
representing O +
a O +
potential O +
target O +
for O +
neuroprotective O +
therapies O -
. O +

Reducing O +
the O +
excitatory O +
action O +
of O +
glutamate B-Chemical -
, O +
the O +
major O +
excitatory O +
neurotransmitter O +
in O +
the O +
basal O +
ganglia O -
, O +
should O +
lead O +
to O +
symptomatic O +
improvement O +
for O +
PD O +
patients O +
and O +
may O +
promote O +
the O +
survival O +
of O +
DA O +
neurons O -
. O +

Recent O +
studies O +
have O +
focused O +
on O +
the O +
modulatory O +
action O +
of O +
metabotropic O +
glutamate B-Chemical +
( O -
mGlu O -
) O +
receptors O +
on O +
neurodegenerative O +
diseases O +
including O +
PD O -
. O +

Group O +
III O +
mGlu O +
receptors O -
, O +
including O +
subtypes O +
4 O -
, O +
7 O +
and O +
8 O -
, O +
are O +
largely O +
expressed O +
in O +
the O +
basal O +
ganglia O -
. O +

Recent O +
studies O +
highlight O +
the O +
use O +
of O +
selective O +
mGlu4 O +
receptor O +
positive O +
allosteric O +
modulators O +
( O -
PAMs O -
) O +
for O +
the O +
treatment O +
of O +
PD O -
. O +

Here O +
we O +
review O +
the O +
effects O +
of O +
newly O -
- O -
designed O +
group O -
- O -
III O +
orthosteric O +
agonists O +
on O +
neuroprotection O -
, O +
neurorestoration O +
and O +
reduction O +
of O +
l B-Chemical -
- I-Chemical -
DOPA I-Chemical +
induced O +
dyskinesia O +
in O +
animal O +
models O +
of O +
PD O -
. O +

The O +
combination O +
of O +
orthosteric O +
mGlu4 O +
receptor O +
selective O +
agonists O +
with O +
PAMs O +
may O +
open O +
new O +
avenues O +
for O +
the O +
symptomatic O +
treatment O +
of O +
PD O -
. O +

This O +
article O +
is O +
part O +
of O +
a O +
Special O +
Issue O +
entitled O +
' O -
Metabotropic O +
Glutamate B-Chemical +
Receptors O -
' O -
. O +

A O +
new O +
bromobenzyl B-Chemical +
methyl I-Chemical +
sulphoxide I-Chemical +
from O +
marine O +
red O +
alga O +
Symphyocladia O +
latiuscula O -
. O +

A O +
new O +
bromophenol B-Chemical -
, O +
2,3,6-tribromo-4,5-dihydroxybenzyl B-Chemical +
methyl I-Chemical +
sulphoxide I-Chemical -
, O +
was O +
isolated O +
from O +
the O +
EtOH B-Chemical +
extract O +
of O +
the O +
marine O +
alga O +
Symphyocladia O +
latiuscula O -
. O +

Its O +
structure O +
was O +
confirmed O +
by O +
spectroscopic O +
methods O +
( O -
1D- O +
and O +
2D O -
- O -
NMR O -
, O +
HR O -
- O -
ESI O -
- O -
MS O -
) O -
. O +

This O +
new O +
bromophenol B-Chemical +
showed O +
moderate O +
antifungal O +
activity O +
against O +
Candida O +
albicans O +
with O +
MIC O +
value O +
of O +
37.5 O +
µg O +
mL O -
( O -
-1 O -
) O -
. O +

Aromadendrine B-Chemical -
, O +
a O +
new O +
component O +
of O +
the O +
flavonoid B-Chemical +
pattern O +
of O +
Olea O +
europaea O +
L. O +
and O +
its O +
anti O -
- O -
inflammatory O +
activity O -
. O +

Leaves O +
of O +
Olea O +
europaea O -
, O +
cultivar O +
Nocellara O +
del O +
Belice O -
, O +
were O +
examined O +
with O +
respect O +
to O +
the O +
medium O -
- O -
polar O +
fraction O -
, O +
obtained O +
by O +
an O +
ethyl B-Chemical +
acetate I-Chemical +
extraction O +
of O +
the O +
whole O +
extract O -
. O +

In O +
the O +
medium O +
polar O +
fraction O -
, O +
we O +
isolated O +
the O +
two O +
hydroxy B-Chemical -
- I-Chemical -
phenyl I-Chemical -
- I-Chemical -
ethyl I-Chemical +
alcohols I-Chemical +
( O -
hydroxyl B-Chemical -
- I-Chemical -
tyrosol I-Chemical +
and O +
tyrosol B-Chemical -
) O +
that O +
are O +
the O +
main O +
component O +
of O +
olives O -
. O +

In O +
addition O -
, O +
we O +
isolated O +
a O +
flavonoidic B-Chemical +
compound O -
, O +
aromadendrine B-Chemical -
, O +
a O +
dihydroflavonol B-Chemical +
yet O +
known O +
but O +
quite O +
rare O +
in O +
nature O -
. O +

It O +
is O +
the O +
first O +
time O +
that O +
aromadendrine B-Chemical +
is O +
isolated O +
in O +
O. O +
europaea O +
and O +
we O +
studied O +
the O +
aromadendrine B-Chemical +
biological O +
activity O -
. O +

In O +
particular O -
, O +
the O +
ability O +
of O +
aromadendrine B-Chemical +
to O +
reduce O +
the O +
inflammation O +
induced O +
in O +
normal O +
keratinocytes O +
using O +
an O +
in O +
vitro O +
cell O +
model O +
was O +
evaluated O -
. O +

The O +
results O +
of O +
the O +
present O +
research O +
indicate O +
aromadendrine B-Chemical +
as O +
a O +
novel O +
component O +
in O +
O. O +
europaea O +
with O +
effective O +
activity O +
against O +
skin O +
inflammation O -
. O +

Ibuprofen B-Chemical +
ion O -
- O -
exchange O +
fiber O +
complex O -
: O +
improved O +
dissolution O +
and O +
gastric O +
tolerance O +
based O +
on O +
ion O +
exchange O -
. O +

The O +
purpose O +
of O +
the O +
present O +
study O +
is O +
to O +
develop O +
a O +
novel O +
method O +
to O +
improve O +
the O +
dissolution O +
of O +
water O -
- O -
insoluble O +
drug O +
ibuprofen B-Chemical +
and O +
the O +
gastric O +
tolerance O +
of O +
this O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
drug O +
which O +
has O +
potentially O +
serious O +
gastrointestinal O +
side O +
effects O -
. O +

This O +
method O +
is O +
based O +
on O +
ion O +
exchange O +
of O +
ion O -
- O -
exchange O +
fibers O -
. O +

Water O -
- O -
insoluble O +
drug O +
ibuprofen B-Chemical +
was O +
dispersed O +
in O +
deionized O +
water O -
, O +
and O +
then O +
the O +
ion O -
- O -
exchange O +
fibers O +
in O +
OH B-Chemical -
( I-Chemical -
- I-Chemical -
) I-Chemical +
type O +
was O +
immersed O +
in O +
it O -
. O +

Ibuprofen B-Chemical +
and O +
the O +
active O +
groups O +
of O +
the O +
ion O -
- O -
exchange O +
fibers O +
combined O +
into O +
ion O +
pairs O +
based O +
on O +
the O +
acid O -
- O -
base O +
reaction O -
. O +

This O +
drug O +
carrier O +
did O +
not O +
release O +
drugs O +
in O +
deionized O +
water O -
, O +
but O +
in O +
water O +
solution O +
containing O +
other O +
ions O +
it O +
would O +
release O +
the O +
drugs O +
into O +
the O +
solution O +
by O +
ion O +
exchange O -
. O +

Confirmed O +
by O +
the O +
X O -
- O -
ray O +
diffraction O +
and O +
the O +
scanning O +
electron O +
microscopy O -
, O +
the O +
ibuprofen B-Chemical +
combined O +
onto O +
the O +
ion O -
- O -
exchange O +
fibers O +
was O +
in O +
a O +
highly O +
molecular O +
level O +
dispersed O +
state O -
. O +

The O +
improved O +
dissolution O +
of O +
ibuprofen B-Chemical +
ion O -
- O -
exchange O +
fiber O +
complexes O +
is O +
likely O +
to O +
originate O +
from O +
this O +
ibuprofen B-Chemical -
's O +
highly O +
dispersed O +
state O -
. O +

Due O +
to O +
this O -
, O +
ibuprofen B-Chemical -
's O +
highly O +
dispersed O +
state O -
, O +
ibuprofen B-Chemical +
ion O -
- O -
exchange O +
fiber O +
complexes O +
significantly O +
decreases O +
the O +
gastrointestinal O +
side O +
effects O +
of O +
ibuprofen B-Chemical +
by O +
avoiding O +
the O +
solid O +
ibuprofen B-Chemical -
's O +
educing O -
. O +

The O +
present O +
study O +
showed O +
that O +
ibuprofen B-Chemical +
ion O -
- O -
exchange O +
fiber O +
complexes O +
have O +
the O +
two O -
- O -
fold O +
advantages O -
. O +

One O +
is O +
to O +
improve O +
the O +
dissolution O +
of O +
ibuprofen B-Chemical -
. O +

The O +
other O +
is O +
to O +
decrease O +
the O +
ibuprofen B-Chemical -
's O +
gastrointestinal O +
toxicity O -
. O +

A O +
modern O +
approach O +
for O +
controlled O +
transdermal O +
delivery O +
of O +
diflunisal B-Chemical -
: O +
optimization O +
and O +
in O +
vivo O +
evaluation O -
. O +

The O +
purpose O +
of O +
the O +
present O +
work O +
was O +
to O +
elaborate O +
an O +
optimized O +
transdermal O +
therapeutic O +
system O +
for O +
diflunisal B-Chemical -
. O +

Selection O +
of O +
suitable O +
ingredients O +
was O +
done O +
via O +
solubility O +
and O +
phase O +
behavior O +
studies O -
. O +

Composition O +
of O +
microemulsion O +
( O -
ME O -
) O +
systems O +
consisting O +
of O +
butyl B-Chemical +
lactate I-Chemical -
, O +
Brij B-Chemical -
( O -
® O -
) O +
97 O -
, O +
Transcutol B-Chemical -
( O -
® O -
) O +
and O +
water O +
was O +
optimized O +
using O +
augmented O +
simplex O +
lattice O +
mixture O +
design O -
. O +

The O +
independent O +
variables O +
selected O +
were O +
the O +
percentages O +
of O +
butyl B-Chemical +
lactate I-Chemical -
, O +
surfactant O +
mixture O +
and O +
water O -
. O +

The O +
dependent O +
variables O +
were O +
refractive O +
index O -
, O +
pH O -
, O +
conductivity O -
, O +
viscosity O -
, O +
drug O +
solubility O +
in O +
the O +
ME O +
formulation O +
and O +
the O +
ex O +
vivo O +
skin O +
permeation O +
flux O -
. O +

Mathematical O +
equations O +
and O +
response O +
surface O +
plots O +
were O +
used O +
to O +
relate O +
the O +
dependent O +
and O +
independent O +
variables O -
. O +

The O +
statistical O +
validity O +
of O +
the O +
polynomials O +
was O +
established O -
. O +

Optimized O +
formulation O +
factors O +
were O +
selected O +
by O +
desirability O +
approach O -
. O +

The O +
optimized O +
ME O +
formulation O +
was O +
converted O +
into O +
gel O +
using O +
Carbomer B-Chemical -
( O -
® O -
) O +
934 O -
. O +

The O +
microemulsion O +
based O +
gel O +
( O -
MBG O -
) O +
showed O +
better O +
spreadability O +
and O +
5.07-fold O +
increase O +
in O +
the O +
transdermal O +
flux O +
than O +
Carbomer B-Chemical -
( O -
® O -
) O +
934 O +
gel O -
. O +

The O +
in O +
vivo O +
antihyperalgesia O +
assay O +
performed O +
on O +
mice O +
showed O +
significant O +
reduction O +
of O +
the O +
licking O +
time O +
in O +
the O +
treated O +
group O +
compared O +
to O +
the O +
control O +
group O -
. O +

This O +
demonstrated O +
the O +
reliability O +
of O +
the O +
simplex O +
lattice O +
statistical O +
design O +
for O +
predicting O +
optimum O +
ME O +
formulation O -
. O +

The O +
developed O +
MBG O +
proved O +
its O +
in O +
vivo O +
efficiency O +
for O +
transdermal O +
delivery O +
of O +
diflunisal B-Chemical -
. O +

Nanostructural O +
difference O +
of O +
water O -
- O -
soluble O +
pectin O +
and O +
chelate O -
- O -
soluble O +
pectin O +
among O +
ripening O +
stages O +
and O +
cultivars O +
of O +
Chinese O +
cherry O -
. O +

Nanostructure O +
of O +
water O -
- O -
soluble O +
pectin O +
( O -
WSP O -
) O +
and O +
chelate O -
- O -
soluble O +
pectin O +
( O -
CSP O -
) O +
of O +
two O +
Chinese O +
cherry O +
( O -
Prunus O +
pseudocerasus O +
L. O -
) O +
cultivars O +
( O -
soft O +
cultivar O +
' O -
Caode O -
' O +
and O +
crisp O +
cultivar O +
' O -
Bende O -
' O -
) O +
with O +
two O +
different O +
ripening O +
stages O +
were O +
characterised O +
using O +
atomic O +
force O +
microscopy O -
. O +

Both O +
cultivars O +
shared O +
some O +
common O +
values O +
of O +
chain O +
widths O +
for O +
WSP O +
or O +
CSP O -
, O +
and O +
both O +
pectins O +
shared O +
several O +
values O +
of O +
chain O +
widths O +
including O +
37 O -
, O +
55 O +
and O +
61 O +
nm O -
. O +

The O +
results O +
indicate O +
that O +
different O +
cultivars O +
shared O +
similar O +
components O +
of O +
pectin O -
, O +
and O +
cultivar O +
textural O +
difference O +
might O +
be O +
related O +
to O +
the O +
interaction O +
between O +
pectin O +
and O +
other O +
cherry O +
components O +
or O +
the O +
dissociation O +
of O +
pectin O -
. O +

During O +
ripening O -
, O +
the O +
wide O +
WSP O +
and O +
CSP O +
gradually O +
dissociate O +
in O +
width O -
. O +

The O +
results O +
demonstrated O +
that O +
the O +
changes O +
of O +
WSP O +
and O +
CSP O +
of O +
Chinese O +
cherry O +
in O +
widths O +
were O +
a O +
dissociation O +
process O -
. O +

Cation O -
- O -
chloride B-Chemical +
cotransporters O +
NKCC1 O +
and O +
KCC2 O +
as O +
potential O +
targets O +
for O +
novel O +
antiepileptic O +
and O +
antiepileptogenic O +
treatments O -
. O +

In O +
cortical O +
and O +
hippocampal O +
neurons O -
, O +
cation O -
- O -
chloride B-Chemical +
cotransporters O +
( O -
CCCs O -
) O +
control O +
the O +
reversal O +
potential O +
( O -
EGABA O -
) O +
of O +
GABAA O +
receptor O -
- O -
mediated O +
current O +
and O +
voltage O +
responses O +
and O -
, O +
consequently O -
, O +
they O +
modulate O +
the O +
efficacy O +
of O +
GABAergic O +
inhibition O -
. O +

Two O +
members O +
of O +
the O +
CCC O +
family O -
, O +
KCC2 O +
( O -
the O +
major O +
neuron O -
- O -
specific O +
K O -
- O -
Cl O +
cotransporter O -
; O +
KCC O +
isoform O +
2 O -
) O +
and O +
NKCC1 O +
( O -
the O +
Na O -
- O -
K-2Cl O +
cotransporter O +
isoform O +
1 O +
which O +
is O +
expressed O +
in O +
both O +
neurons O +
and O +
glial O +
cells O -
) O +
have O +
attracted O +
much O +
interest O +
in O +
studies O +
on O +
GABAergic O +
signaling O +
under O +
both O +
normal O +
and O +
pathophysiological O +
conditions O -
, O +
such O +
as O +
epilepsy O -
. O +

There O +
is O +
tentative O +
evidence O +
that O +
loop O +
diuretic O +
compounds O +
such O +
as O +
furosemide O +
and O +
bumetanide O +
may O +
have O +
clinically O +
relevant O +
antiepileptic O +
actions O -
, O +
especially O +
when O +
administered O +
in O +
combination O +
with O +
conventional O +
GABA O -
- O -
mimetic O +
drugs O +
such O +
as O +
phenobarbital O -
. O +

Furosemide O +
is O +
a O +
non O -
- O -
selective O +
inhibitor O +
of O +
CCCs O +
while O +
at O +
low O +
concentrations O +
bumetanide O +
is O +
selective O +
for O +
NKCCs O -
. O +

Search O +
for O +
novel O +
antiepileptic O +
drugs O +
( O -
AEDs O -
) O +
is O +
highly O +
motivated O +
especially O +
for O +
the O +
treatment O +
of O +
neonatal O +
seizures O +
which O +
are O +
often O +
resistant O +
to O -
, O +
or O +
even O +
aggravated O +
by O +
conventional O +
AEDs O -
. O +

This O +
review O +
shows O +
that O +
the O +
antiepileptic O +
effects O +
of O +
loop O +
diuretics O +
described O +
in O +
the O +
pertinent O +
literature O +
are O +
based O +
on O +
widely O +
heterogeneous O +
mechanisms O +
ranging O +
from O +
actions O +
on O +
both O +
neuronal O +
NKCC1 O +
and O +
KCC2 O +
to O +
modulation O +
of O +
the O +
brain O +
extracellular O +
volume O +
fraction O -
. O +

A O +
promising O +
strategy O +
for O +
the O +
development O +
of O +
novel O +
CCC O -
- O -
blocking O +
AEDs O +
is O +
based O +
on O +
prodrugs O +
that O +
are O +
activated O +
following O +
their O +
passage O +
across O +
the O +
blood O -
- O -
brain O +
barrier O -
. O +

This O +
article O +
is O +
part O +
of O +
the O +
Special O +
Issue O +
entitled O +
' O -
New O +
Targets O +
and O +
Approaches O +
to O +
the O +
Treatment O +
of O +
Epilepsy O -
' O -
. O +

Isolation O +
and O +
structure O +
determination O +
of O +
new O +
siderophore O +
tsukubachelin B-Chemical +
B I-Chemical +
from O +
Streptomyces O +
sp. O +
TM-74 O -
. O +

The O +
new O +
siderophore O +
tsukubachelin B-Chemical +
B I-Chemical +
( O -
1 O -
) O +
was O +
isolated O +
from O +
the O +
iron B-Chemical -
- O -
deficient O +
culture O +
medium O +
of O +
the O +
newly O +
isolated O +
strain O +
Streptomyces O +
sp. O +
TM-74 O -
. O +

The O +
chemical O +
structure O +
of O +
tsukubachelin B-Chemical +
B I-Chemical +
( O -
1 O -
) O +
was O +
established O +
via O +
interpretation O +
of O +
2D O +
nuclear O +
magnetic O +
resonance O +
and O +
electrospray O +
ionization O -
- O -
mass O +
spectroscopic O +
data O -
. O +

The O +
structure O +
of O +
tsukubachelin B-Chemical +
B I-Chemical +
( O -
1 O -
) O +
comprises O +
6 O +
mol O +
of O +
amino B-Chemical +
acids I-Chemical -
, O +
including O +
2 O +
mol O +
of O +
serine B-Chemical +
and O +
1 O +
mol O +
each O +
of O +
ornithine B-Chemical -
, O +
N B-Chemical -
- I-Chemical -
α I-Chemical -
- I-Chemical -
methyl I-Chemical -
- I-Chemical -
N I-Chemical -
- I-Chemical -
δ I-Chemical -
- I-Chemical -
hydroxy I-Chemical -
- I-Chemical -
N I-Chemical -
- I-Chemical -
δ I-Chemical -
- I-Chemical -
formylornithine I-Chemical -
, O +
N B-Chemical -
- I-Chemical -
α I-Chemical -
- I-Chemical -
methyl I-Chemical -
- I-Chemical -
N I-Chemical -
- I-Chemical -
δ I-Chemical -
- I-Chemical -
hydroxyornithine I-Chemical -
, O +
and O +
cyclic B-Chemical +
N I-Chemical -
- I-Chemical -
hydroxyornithine I-Chemical -
. O +

Hierarchical O +
clustering O +
analysis O +
of O +
blood O +
plasma O +
lipidomics O +
profiles O +
from O +
mono- O +
and O +
dizygotic O +
twin O +
families O -
. O +

Twin O +
and O +
family O +
studies O +
are O +
typically O +
used O +
to O +
elucidate O +
the O +
relative O +
contribution O +
of O +
genetic O +
and O +
environmental O +
variation O +
to O +
phenotypic O +
variation O -
. O +

Here O -
, O +
we O +
apply O +
a O +
quantitative O +
genetic O +
method O +
based O +
on O +
hierarchical O +
clustering O -
, O +
to O +
blood O +
plasma O +
lipidomics O +
data O +
obtained O +
in O +
a O +
healthy O +
cohort O +
consisting O +
of O +
37 O +
monozygotic O +
and O +
28 O +
dizygotic O +
twin O +
pairs O -
, O +
and O +
52 O +
of O +
their O +
biological O +
nontwin O +
siblings O -
. O +

Such O +
data O +
are O +
informative O +
of O +
the O +
concentrations O +
of O +
a O +
wide O +
range O +
of O +
lipids O +
in O +
the O +
studied O +
blood O +
samples O -
. O +

An O +
important O +
advantage O +
of O +
hierarchical O +
clustering O +
is O +
that O +
it O +
can O +
be O +
applied O +
to O +
a O +
high O -
- O -
dimensional O +
' O -
omics O -
' O +
type O +
data O -
, O +
whereas O +
the O +
use O +
of O +
many O +
other O +
quantitative O +
genetic O +
methods O +
for O +
analysis O +
of O +
such O +
data O +
is O +
hampered O +
by O +
the O +
large O +
number O +
of O +
correlated O +
variables O -
. O +

For O +
this O +
study O +
we O +
combined O +
two O +
lipidomics O +
data O +
sets O -
, O +
originating O +
from O +
two O +
different O +
measurement O +
blocks O -
, O +
which O +
we O +
corrected O +
for O +
block O +
effects O +
by O +
' O -
quantile O +
equating O -
' O -
. O +

In O +
the O +
analysis O +
of O +
the O +
combined O +
data O -
, O +
average O +
similarities O +
of O +
lipidomics O +
profiles O +
were O +
highest O +
between O +
monozygotic O +
( O -
MZ O -
) O +
cotwins O -
, O +
and O +
became O +
progressively O +
lower O +
between O +
dizygotic O +
( O -
DZ O -
) O +
cotwins O -
, O +
among O +
sex O -
- O -
matched O +
nontwin O +
siblings O +
and O +
among O +
sex O -
- O -
matched O +
unrelated O +
participants O -
, O +
respectively O -
. O +

Our O +
results O +
suggest O +
that O +
( O -
1 O -
) O +
shared O +
genetic O +
background O -
, O +
shared O +
environment O -
, O +
and O +
similar O +
age O +
contribute O +
to O +
similarities O +
in O +
blood O +
plasma O +
lipidomics O +
profiles O +
among O +
individuals O -
; O +
and O +
( O -
2 O -
) O +
that O +
the O +
power O +
of O +
quantitative O +
genetic O +
analyses O +
is O +
enhanced O +
by O +
quantile O +
equating O +
and O +
combination O +
of O +
data O +
sets O +
obtained O +
in O +
different O +
measurement O +
blocks O -
. O +

Anti O -
- O -
diabetic O +
Activity O +
of O +
Swertiamarin B-Chemical +
is O +
due O +
to O +
an O +
Active O +
Metabolite O -
, O +
Gentianine B-Chemical -
, O +
that O +
Upregulates O +
PPAR O -
- O -
γ O +
Gene O +
Expression O +
in O +
3T3-L1 O +
cells O -
. O +

We O +
have O +
previously O +
shown O +
the O +
anti O -
- O -
diabetic O +
effects O +
of O +
swertiamarin B-Chemical -
; O +
however O -
, O +
pharmacokinetic O +
analysis O +
showed O +
that O +
swertiamarin B-Chemical +
had O +
a O +
plasma O +
half O -
- O -
life O +
of O +
1.3 O +
h. O +
Gentianine B-Chemical +
is O +
an O +
active O +
metabolite O +
of O +
swertiamarin B-Chemical +
that O +
possesses O +
a O +
pharmacophoric O +
moiety O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
explore O +
the O +
possibility O +
whether O +
the O +
anti O -
- O -
diabetic O +
effect O +
of O +
swertiamarin B-Chemical +
is O +
due O +
to O +
gentianine B-Chemical -
. O +

Swertiamarin B-Chemical +
treatment O +
had O +
no O +
significant O +
effect O +
on O +
adipogenesis O -
, O +
or O +
the O +
mRNA O +
expression O +
of O +
PPAR O -
- O -
γ O +
and O +
GLUT-4 O -
; O +
however O -
, O +
there O +
was O +
a O +
significant O +
increase O +
in O +
the O +
mRNA O +
expression O +
of O +
adiponectin O -
. O +

On O +
the O +
other O +
hand O -
, O +
treatment O +
with O +
gentianine B-Chemical +
significantly O +
increased O +
adipogenesis O -
, O +
which O +
was O +
associated O +
with O +
a O +
significant O +
increase O +
in O +
the O +
mRNA O +
expression O +
of O +
PPAR O -
- O -
γ O -
, O +
GLUT-4 O +
and O +
adiponectin O -
. O +

These O +
findings O +
suggest O -
, O +
for O +
the O +
first O +
time O -
, O +
that O +
the O +
anti O -
- O -
diabetic O +
effect O +
of O +
swertiamarin B-Chemical +
is O +
due O +
to O +
gentianine B-Chemical -
, O +
an O +
active O +
metabolite O +
of O +
swertiamarin B-Chemical -
. O +

Copyright O +
© O +
2012 O +
John O +
Wiley O +
& O +
Sons O -
, O +
Ltd. O +

Chronic O +
treatment O +
with O +
selective O +
I2-imidazoline O +
receptor O +
ligands O +
decreases O +
the O +
content O +
of O +
pro O -
- O -
apoptotic O +
markers O +
in O +
rat O +
brain O -
. O +

Selective O +
I O -
( O -
2 O -
) O -
-imidazoline O +
receptor O +
ligands O +
induce O +
neuroprotection O +
through O +
various O +
molecular O +
mechanisms O +
including O +
blockade O +
of O +
N B-Chemical -
- I-Chemical -
methyl I-Chemical -
- I-Chemical -
D I-Chemical -
- I-Chemical -
aspartate I-Chemical +
( O -
NMDA B-Chemical -
) O +
receptors O -
. O +

To O +
investigate O +
new O +
neuroprotective O +
mechanisms O +
associated O +
with O +
I O -
( O -
2 O -
) O -
-imidazoline O +
receptors O -
, O +
the O +
effects O +
of O +
selective O +
( O -
2-styryl-2-imidazoline B-Chemical +
( O -
LSL B-Chemical +
61122 I-Chemical -
) O -
, O +
2- B-Chemical -
( I-Chemical -
2-benzofuranyl I-Chemical -
) I-Chemical -
-2-imidazoline I-Chemical +
( O -
2-BFI B-Chemical -
) O -
, O +
2- B-Chemical -
( I-Chemical -
4,5-dihydroimidazol-2-yl I-Chemical -
) I-Chemical +
quinoline I-Chemical +
hydrochloride I-Chemical +
( O -
BU-224 B-Chemical -
) O -
) O +
and O +
non O -
- O -
selective O +
( O -
idazoxan B-Chemical -
) O +
I O -
( O -
2 O -
) O -
-drugs O +
on O +
canonical O +
apoptotic O +
pathways O +
were O +
assessed O +
in O +
rat O +
brain O +
cortex O -
. O +

The O +
acute O +
treatment O +
with O +
LSL B-Chemical +
61122 I-Chemical +
( O -
10 O +
mg O -
/ O -
kg O -
) O +
reduced O +
the O +
content O +
of O +
mitochondrial O +
( O -
pro O -
- O -
apoptotic O -
) O +
Bax O +
( O -
-33 O -
% O -
) O +
and O +
cytochrome O +
c O +
( O -
-31 O -
% O -
) O -
, O +
which O +
was O +
prevented O +
by O +
idazoxan B-Chemical -
, O +
an O +
I O -
( O -
2 O -
) O -
-receptor O +
antagonist O -
. O +

The O +
sustained O +
stimulation O +
of O +
I O -
( O -
2 O -
) O -
-imidazoline O +
receptors O +
with O +
selective O +
drugs O +
( O -
10 O +
mg O -
/ O -
kg O -
, O +
every O +
12 O +
h O +
for O +
seven O +
days O -
) O +
was O +
associated O +
with O +
down O -
- O -
regulation O +
of O +
key O +
components O +
of O +
the O +
extrinsic O +
( O -
Fas O +
receptor O -
: O +
-20 O -
% O -
; O +
Fas O +
associated O +
protein O +
with O +
death O +
domain O +
( O -
FADD O -
) O +
adaptor O -
: O +
-47 O -
- O -
54 O -
% O -
) O +
and/or O +
intrinsic O +
( O -
Bax O -
: O +
-20 O -
- O -
23 O -
% O -
; O +
cytochrome O +
c O -
: O +
-22 O -
- O -
28 O -
% O -
) O +
apoptotic O +
signalling O +
and/or O +
up O -
- O -
regulation O +
of O +
survival O +
anti O -
- O -
apoptotic O +
factors O +
( O -
p O -
- O -
Ser194 B-Chemical +
FADD O -
/ O -
FADD O +
ratio O -
: O +
+ O -
1.6 O -
- O -
2.5-fold O -
; O +
and/or O +
Bcl-2 O -
/ O -
Bax O +
ratio O -
: O +
+ O -
1.5-fold O -
) O -
, O +
which O +
in O +
the O +
long O -
- O -
term O +
could O +
dampen O +
cell O +
death O +
in O +
the O +
brain O -
. O +

Similar O +
chronic O +
treatments O +
with O +
LSL B-Chemical +
60101 I-Chemical +
( O -
the O +
imidazole B-Chemical +
analogue O +
of O +
2-BFI B-Chemical -
) O +
and O +
idazoxan B-Chemical +
( O -
a O +
mixed O +
I O -
( O -
2 O -
) O -
/ O -
α O -
( O -
2 O -
) O -
-ligand O -
) O +
did O +
not O +
induce O +
significant O +
alterations O +
of O +
pro- O +
or O +
anti O -
- O -
apoptotic O +
proteins O -
. O +

The O +
disclosed O +
anti O -
- O -
apoptotic O +
mechanisms O +
of O +
selective O +
I O -
( O -
2 O -
) O -
-imidazoline O +
drugs O +
may O +
work O +
in O +
concert O +
with O +
other O +
molecular O +
mechanisms O +
of O +
neuroprotection O +
( O -
e.g. O +
blockade O +
of O +
NMDA O +
receptors O -
) O +
that O +
are O +
engaged O +
by O +
I O -
( O -
2 O -
) O -
-ligands O -
. O +

Alleviation O +
of O +
high O +
salt O +
toxicity O -
- O -
induced O +
oxidative O +
damage O +
by O +
salicylic B-Chemical +
acid I-Chemical +
pretreatment O +
in O +
two O +
wheat O +
cultivars O -
. O +

Role O +
of O +
exogenous O +
salicylic B-Chemical +
acid I-Chemical +
( O -
SA O -
) O +
in O +
the O +
antioxidative O +
response O +
to O +
salt O +
toxicity O +
of O +
two O +
wheat O +
( O -
Triticum O +
aestivum O -
) O +
cultivars O +
( O -
Gerek-79 O +
and O +
Bezostaya O -
) O +
was O +
investigated O -
. O +

Hydroponic O +
growth O +
environment O +
of O +
10-day O +
wheat O +
seedlings O +
grown O +
under O +
normal O +
conditions O +
( O -
22 O -
/ O -
20 O -
° O -
C O -
) O +
was O +
adjusted O +
to O +
0.0 O -
, O +
0.25 O -
, O +
0.50 O +
and O +
0.75 O +
M O +
of O +
salt O +
( O -
NaCl B-Chemical -
) O -
, O +
and O +
then O +
freshly O +
prepared O +
SA O +
solutions O +
( O -
0.0 O -
, O +
0.01 O +
and O +
0.1 O +
mM O -
) O +
were O +
once O +
sprayed O +
on O +
leaves O +
of O +
the O +
same O +
seedlings O -
. O +

Activities O +
of O +
superoxide B-Chemical +
dismutase O +
( O -
SOD O -
) O -
, O +
peroxidase O +
( O -
POX O -
) O +
and O +
catalase O +
( O -
CAT O -
) O +
were O +
determined O +
in O +
fresh O +
leaves O +
obtained O +
from O +
15-day O +
seedlings O -
. O +

Treatment O +
with O +
SA O +
alone O +
increased O +
all O +
the O +
antioxidant O +
activities O +
in O +
Gerek-79 O -
. O +

However O -
, O +
the O +
same O +
treatments O +
with O +
SA O +
decreased O +
the O +
activities O +
of O +
CAT O +
and O +
SOD O +
in O +
Bezostaya O -
, O +
while O +
increased O +
that O +
of O +
POX O -
. O +

Salt O +
applications O +
alone O +
increased O +
the O +
activities O +
of O +
POX O +
and O +
SOD O -
, O +
while O +
decreased O +
that O +
of O +
CAT O +
in O +
Bezostaya O -
. O +

The O +
same O +
salt O +
applications O +
increased O +
the O +
POX O +
activity O -
, O +
while O +
decreased O +
the O +
activities O +
of O +
CAT O +
and O +
SOD O +
in O +
Gerek-79 O -
. O +

In O +
plants O +
under O +
saline O +
conditions O -
, O +
except O +
0.75 O +
M O +
NaCl B-Chemical -
, O +
treatments O +
with O +
SA O +
increased O +
the O +
activities O +
of O +
CAT O -
, O +
POX O +
and O +
SOD O +
in O +
both O +
the O +
varieties O +
compared O +
with O +
plants O +
applied O +
salt O +
alone O -
. O +

In O +
plants O +
applied O +
with O +
0.75 O +
M O +
NaCl B-Chemical -
, O +
however O -
, O +
treatments O +
with O +
SA O +
decreased O +
CAT O +
activity O -
. O +

Results O +
showed O +
that O +
salt O +
toxicity O +
caused O +
a O +
derangement O +
in O +
the O +
regulation O +
of O +
antioxidant O +
enzyme O +
activities O +
by O +
decreasing O +
CAT O +
activity O +
especially O +
in O +
both O +
the O +
varieties O -
, O +
but O +
treatments O +
with O +
SA O +
could O +
turn O +
back O +
the O +
derangement O +
in O +
the O +
antioxidative O +
enzymes O +
caused O +
by O +
salt O +
toxicity O -
. O +

SA O +
can O +
involve O +
in O +
increasing O +
salt O +
tolerance O +
by O +
regulating O +
the O +
activities O +
of O +
antioxidant O +
enzymes O +
in O +
wheat O +
cultivars O +
exposed O +
to O +
salt O +
toxicity O -
. O +

Melamine B-Chemical +
in O +
prenatal O +
and O +
postnatal O +
organs O +
in O +
rats O -
. O +

Melamine B-Chemical +
can O +
be O +
transferred O +
to O +
fetus O +
in O +
utero O +
through O +
placenta O +
and O +
to O +
infant O +
ex O +
utero O +
by O +
breast O +
feeding O -
. O +

In O +
this O +
study O -
, O +
we O +
characterized O +
the O +
pharmacokinetics O +
of O +
melamine B-Chemical +
in O +
prenatal O +
and O +
postnatal O +
organs O +
in O +
rats O -
. O +

Single O +
bolus O +
of O +
melamine B-Chemical +
was O +
administered O +
to O +
pregnant O +
rats O +
at O +
different O +
gestational O +
stages O +
and O +
to O +
infants O +
at O +
different O +
postnatal O +
stages O -
. O +

Distribution O +
of O +
melamine B-Chemical +
in O +
maternal O +
serum O +
was O +
about O +
30 O -
% O +
higher O +
in O +
late O +
pregnancy O +
than O +
that O +
in O +
early O +
pregnancy O -
; O +
and O +
it O +
was O +
2 O +
folds O +
higher O +
in O +
postnatal O +
serum O +
in O +
early O +
infants O +
in O +
young O +
adulthood O -
. O +

Distribution O +
of O +
melamine B-Chemical +
in O +
all O +
postnatal O +
organs O +
was O +
higher O +
than O +
that O +
in O +
prenatal O +
organs O -
. O +

Postnatal O +
kidneys O +
in O +
early O +
infants O +
had O +
the O +
highest O +
maximum O +
concentration O +
and O +
the O +
lowest O +
clearance O +
of O +
melamine B-Chemical +
than O +
the O +
other O +
postnatal O +
organs O -
. O +

It O +
may O +
relate O +
to O +
the O +
high O +
vulnerability O +
to O +
the O +
toxicity O +
of O +
melamine B-Chemical +
in O +
this O +
population O -
. O +

Allosteric O +
alpha-7 O +
nicotinic O +
receptor O +
modulation O +
and O +
P50 O +
sensory O +
gating O +
in O +
schizophrenia O -
: O +
a O +
proof O -
- O -
of O -
- O -
mechanism O +
study O -
. O +

In O +
this O +
multicenter O -
, O +
double O -
- O -
blind O -
, O +
placebo O -
- O -
controlled O -
, O +
randomized O -
, O +
four O +
way O +
cross O -
- O -
over O +
proof O -
- O -
of O -
- O -
mechanism O +
study O -
, O +
we O +
tested O +
the O +
effect O +
of O +
the O +
positive O +
allosteric O +
α7 O +
nicotinic O +
acetylcholine B-Chemical +
receptor O +
( O -
nAChR O -
) O +
modulator O +
JNJ-39393406 B-Chemical +
in O +
a O +
key O +
translational O +
assay O +
( O -
sensory O +
P50 O +
gating O -
) O +
in O +
39 O +
regularly O +
smoking O +
male O +
patients O +
with O +
schizophrenia O -
. O +

All O +
patients O +
were O +
clinically O +
stable O +
and O +
JNJ-39393406 B-Chemical +
was O +
administered O +
as O +
an O +
adjunct O +
treatment O +
to O +
antipsychotics O -
. O +

No O +
indication O +
was O +
found O +
that O +
JNJ-39393406 B-Chemical +
has O +
the O +
potential O +
to O +
reverse O +
basic O +
deficits O +
of O +
information O +
processing O +
in O +
schizophrenia O +
( O -
sensory O +
P50 O +
gating O -
) O +
or O +
has O +
a O +
significant O +
effect O +
on O +
other O +
tested O +
electrophysiological O +
markers O +
( O -
MMN O -
, O +
P300 O +
and O +
quantitative O +
resting O +
EEG O -
) O -
. O +

Sensitivity O +
analyses O +
including O +
severity O +
of O +
disease O -
, O +
baseline O +
P50 O +
gating O -
, O +
medication O +
and O +
gene O +
variants O +
of O +
the O +
CHRNA7 O +
gene O +
did O +
not O +
reveal O +
any O +
subgroups O +
with O +
consistent O +
significant O +
effects O -
. O +

It O +
is O +
discussed O +
that O +
potential O +
positive O +
effects O +
in O +
subgroups O +
not O +
present O +
or O +
not O +
large O +
enough O +
in O +
the O +
current O +
study O +
or O +
upon O +
chronic O +
dosing O +
are O +
possible O -
, O +
but O +
unlikely O +
to O +
be O +
developed O -
. O +

This O +
article O +
is O +
part O +
of O +
a O +
Special O +
Issue O +
entitled O +
' O -
Cognitive O +
Enhancers O -
' O -
. O +

Metastability O +
in O +
Pressure O -
- O -
Induced O +
Structural O +
Transformations O +
of O +
CdSe B-Chemical -
/ O -
ZnS B-Chemical +
Core O -
/ O -
Shell O +
Nanocrystals O -
. O +

The O +
kinetics O +
and O +
thermodynamics O +
of O +
structural O +
transformations O +
under O +
pressure O +
depend O +
strongly O +
on O +
particle O +
size O +
due O +
to O +
the O +
influence O +
of O +
surface O +
free O +
energy O -
. O +

By O +
suitable O +
design O +
of O +
surface O +
structure O -
, O +
composition O -
, O +
and O +
passivation O +
it O +
is O +
possible O -
, O +
in O +
principle O -
, O +
to O +
prepare O +
nanocrystals O +
in O +
structures O +
inaccessible O +
to O +
bulk O +
materials O -
. O +

However O -
, O +
few O +
realizations O +
of O +
such O +
extreme O +
size O -
- O -
dependent O +
behavior O +
exist O -
. O +

Here O -
, O +
we O +
show O +
with O +
molecular O +
dynamics O +
computer O +
simulation O +
that O +
in O +
a O +
model O +
of O +
CdSe B-Chemical -
/ O -
ZnS B-Chemical +
core O -
/ O -
shell O +
nanocrystals O +
the O +
core O +
high O -
- O -
pressure O +
structure O +
can O +
be O +
made O +
metastable O +
under O +
ambient O +
conditions O +
by O +
tuning O +
the O +
thickness O +
of O +
the O +
shell O -
. O +

In O +
nanocrystals O +
with O +
thick O +
shells O -
, O +
we O +
furthermore O +
observe O +
a O +
wurtzite B-Chemical +
to O +
NiAs B-Chemical +
transformation O -
, O +
which O +
does O +
not O +
occur O +
in O +
the O +
pure O +
bulk O +
materials O -
. O +

These O +
phenomena O +
are O +
linked O +
to O +
a O +
fundamental O +
change O +
in O +
the O +
atomistic O +
transformation O +
mechanism O +
from O +
heterogeneous O +
nucleation O +
at O +
the O +
surface O +
to O +
homogeneous O +
nucleation O +
in O +
the O +
crystal O +
core O -
. O +

Serotonergic O +
involvement O +
in O +
the O +
amelioration O +
of O +
behavioral O +
abnormalities O +
in O +
dopamine B-Chemical +
transporter O +
knockout O +
mice O +
by O +
nicotine B-Chemical -
. O +

Dopamine B-Chemical +
transporter O +
knockout O +
( O -
DAT O +
KO O -
) O +
mice O +
exhibit O +
elevated O +
extracellular O +
dopamine B-Chemical +
levels O +
in O +
brain O +
regions O +
that O +
include O +
the O +
striatum O +
and O +
the O +
nucleus O +
accumbens O -
, O +
but O +
not O +
the O +
prefrontal O +
cortex O -
. O +

DAT O +
KO O +
mice O +
model O +
some O +
aspects O +
of O +
psychiatric O +
disorders O -
, O +
including O +
schizophrenia O -
. O +

Smoking O +
is O +
more O +
common O +
in O +
patients O +
with O +
schizophrenia O -
, O +
suggesting O +
that O +
nicotine O +
might O +
ameliorate O +
aspects O +
of O +
the O +
behavioral O +
abnormalities O +
and/or O +
treatment O +
side O +
effects O +
seen O +
in O +
these O +
individuals O -
. O +

We O +
report O +
nicotine B-Chemical -
- O -
induced O +
normalization O +
of O +
effects O +
on O +
locomotion O +
and O +
prepulse O +
inhibition O +
of O +
acoustic O +
startle O +
( O -
PPI O -
) O +
in O +
DAT O +
KO O +
mice O +
that O +
require O +
intact O +
serotonin B-Chemical +
5-HT1A O +
systems O -
. O +

First O -
, O +
we O +
observed O +
that O +
the O +
marked O +
hyperactivity O +
displayed O +
by O +
DAT O +
KO O +
mice O +
was O +
reduced O +
by O +
administration O +
of O +
nicotine B-Chemical -
. O +

This O +
nicotine B-Chemical +
effect O +
was O +
blocked O +
by O +
pretreatment O +
with O +
the O +
non O -
- O -
specific O +
nicotinic O +
acetylcholine B-Chemical +
( O -
nACh O -
) O +
receptor O +
antagonist O +
mecamylamine B-Chemical -
, O +
or O +
the O +
5-HT1A O +
antagonist O +
WAY100635 B-Chemical -
. O +

Secondly O -
, O +
we O +
examined O +
the O +
effects O +
of O +
nicotine B-Chemical +
on O +
PPI O +
in O +
DAT O +
KO O +
mice O -
. O +

Treatment O +
with O +
nicotine B-Chemical +
significantly O +
ameliorated O +
the O +
PPI O +
deficits O +
observed O +
in O +
DAT O +
KO O +
mice O -
. O +

The O +
ameliorating O +
action O +
of O +
nicotine B-Chemical +
on O +
PPI O +
deficits O +
in O +
DAT O +
KO O +
mice O +
was O +
blocked O +
by O +
mecamylamine B-Chemical -
, O +
the O +
α₇ O +
nACh O +
receptor O +
antagonist O +
methyllycaconitine B-Chemical +
or O +
WAY100635 B-Chemical -
, O +
while O +
the O +
α₄β₂ O +
nACh O +
receptor O +
antagonist O +
dihydro B-Chemical -
- I-Chemical -
β I-Chemical -
- I-Chemical -
erythroidinehydrobromide I-Chemical +
( O -
DHβE B-Chemical -
) O +
produced O +
only O +
a O +
non O -
- O -
significant O +
trend O +
toward O +
attenuation O +
of O +
nicotine B-Chemical +
effects O -
. O +

Finally O -
, O +
we O +
observed O +
that O +
administration O +
of O +
the O +
5-HT1A O +
receptor O +
agonist O +
8-OH B-Chemical -
- I-Chemical -
DPAT I-Chemical +
also O +
ameliorated O +
the O +
deficit O +
in O +
PPI O +
observed O +
in O +
DAT O +
KO O +
mice O -
. O +

This O +
amelioration O +
was O +
antagonized O +
by O +
pretreatment O +
with O +
WAY100635 B-Chemical -
. O +

These O +
data O +
support O +
the O +
idea O +
that O +
nicotine B-Chemical +
might O +
ameliorate O +
some O +
of O +
the O +
cognitive O +
dysfunctions O +
found O +
in O +
schizophrenia O +
in O +
a O +
5-HT1A O -
- O -
dependent O +
fashion O -
. O +

This O +
article O +
is O +
part O +
of O +
a O +
Special O +
Issue O +
entitled O +
' O -
Cognitive O +
Enhancers O -
' O -
. O +

Disposition O +
of O +
diiosononyl B-Chemical +
phthalate I-Chemical +
and O +
its O +
effects O +
on O +
sexual O +
development O +
of O +
the O +
male O +
fetus O +
following O +
repeated O +
dosing O +
in O +
pregnant O +
rats O -
. O +

Pregnant O +
Sprague O -
- O -
Dawley O +
rats O +
received O +
50 O -
, O +
250 O -
, O +
and O +
500 O +
mg O -
/ O -
kg O -
/ O -
day O +
diisononyl B-Chemical +
phthalate I-Chemical +
( O -
DiNP B-Chemical -
) O +
from O +
GD O +
12 O +
to O +
19 O +
via O +
corn O +
oil O +
gavage O +
to O +
study O +
the O +
dose O +
response O +
for O +
effects O +
on O +
fetal O +
male O +
rat O +
sexual O +
development O +
as O +
well O +
as O +
metabolite O +
disposition O +
in O +
the O +
dam O +
and O +
fetus O -
. O +

Monoisononyl B-Chemical +
phthalate I-Chemical +
( O -
MiNP B-Chemical -
) O -
, O +
mono B-Chemical -
( I-Chemical -
carboxy I-Chemical -
- I-Chemical -
isooctyl I-Chemical -
) I-Chemical +
phthalate I-Chemical +
( O -
MCiOP B-Chemical -
) O -
, O +
mono B-Chemical -
( I-Chemical -
hydroxyl I-Chemical -
- I-Chemical -
isononyl I-Chemical -
) I-Chemical +
phthalate I-Chemical +
( O -
MHiNP B-Chemical -
) O -
, O +
mono B-Chemical -
( I-Chemical -
oxo I-Chemical -
- I-Chemical -
isononyl I-Chemical -
) I-Chemical +
phthalate I-Chemical +
( O -
MOiNP B-Chemical -
) O -
, O +
and O +
monoisononyl B-Chemical +
phthalate I-Chemical +
glucuronide I-Chemical +
( O -
MiNP B-Chemical -
- I-Chemical -
G I-Chemical -
) O +
were O +
found O +
in O +
all O +
measured O +
tissues O -
. O +

MCiOP B-Chemical +
was O +
the O +
major O +
metabolite O -
, O +
followed O +
in O +
decreasing O +
order O +
by O +
MiNP B-Chemical -
, O +
MHiNP B-Chemical -
, O +
MOiNP B-Chemical -
, O +
and O +
MiNP B-Chemical -
- I-Chemical -
G. I-Chemical +
Percentage O +
of O +
dose O +
absorbed O +
decreased O +
at O +
750 O +
mg O -
/ O -
kg O -
/ O -
day O -
. O +

Testosterone B-Chemical +
concentration O +
in O +
the O +
fetal O +
testes O +
was O +
reduced O +
at O +
250 O +
and O +
750 O +
mg O -
/ O -
kg O -
/ O -
day O -
. O +

Multinucleated O +
germ O +
cells O +
were O +
increased O +
in O +
the O +
testes O +
of O +
rats O +
at O +
250 O +
and O +
750 O +
mg O -
/ O -
kg O -
/ O -
day O -
. O +

The O +
no O +
observed O +
effect O +
level O +
( O -
NOEL O -
) O +
for O +
this O +
study O +
was O +
50 O +
mg O -
/ O -
kg O -
/ O -
day O +
based O +
on O +
increased O +
MNGs O +
and O +
reduced O +
testes O +
testosterone B-Chemical +
concentration O +
in O +
the O +
fetal O +
rat O -
. O +

Effects O +
of O +
clopidogrel B-Chemical +
and O +
clarithromycin B-Chemical +
on O +
the O +
disposition O +
of O +
sibutramine B-Chemical +
and O +
its O +
active O +
metabolites O +
M1 O +
and O +
M2 O +
in O +
relation O +
to O +
CYP2B6 O -
* O -
6 O +
polymorphism O -
. O +

Plasma O +
concentrations O +
of O +
sibutramine B-Chemical +
and O +
its O +
two O +
active O +
metabolites O +
after O +
single O +
oral O +
dose O +
of O +
sibutramine B-Chemical +
were O +
determined O +
in O +
Korean O +
healthy O +
male O +
subjects O +
with O +
different O +
CYP2B6 O +
genotypes O +
( O -
CYP2B6 O -
* O -
1 O -
/ O -
*1 O -
, O +
* O -
1 O -
/ O -
*6 O +
and O +
* O -
6 O -
/ O -
*6 O -
) O -
, O +
either O +
alone O +
or O +
after O +
four O -
- O -
day O +
pretreatment O +
with O +
clopidogrel B-Chemical +
or O +
clarithromycin B-Chemical -
. O +

The O +
pretreatment O +
with O +
clopidogrel B-Chemical +
and O +
clarithromycin B-Chemical +
raised O +
the O +
mean O +
area O +
under O +
the O +
concentration O -
- O -
time O +
curve O +
( O -
AUC O -
) O +
of O +
sibutramine B-Chemical +
by O +
163 O -
% O +
and O +
255 O -
% O -
, O +
respectively O -
. O +

Co O -
- O -
administration O +
of O +
clarithromycin B-Chemical -
, O +
combined O +
with O +
CYP2B6 O -
* O -
6 O -
/ O -
*6 O +
genotype O -
, O +
led O +
to O +
highest O +
concentration O +
of O +
sibutramine B-Chemical -
. O +

The O +
molar O +
sum O +
AUC O +
( O -
M1 O +
+ O +
M2 O -
) O +
was O +
raised O +
by O +
35 O -
% O +
in O +
the O +
clopidogrel B-Chemical +
phase O +
but O +
not O +
significantly O +
affected O +
by O +
clarithromycin B-Chemical +
or O +
CYP2B6 O +
genotype O -
. O +

The O +
CYP2B6 O -
* O -
6 O -
/ O -
*6 O +
subjects O +
in O +
the O +
clopidogrel B-Chemical +
phase O +
showed O +
the O +
highest O +
molar O +
AUC O +
( O -
M1 O +
+ O +
M2 O -
) O +
among O +
three O +
genotype O +
groups O +
throughout O +
the O +
three O +
phases O -
. O +

The O +
exposure O +
of O +
sibutramine B-Chemical +
and O +
its O +
metabolites O +
seemed O +
to O +
be O +
associated O +
with O +
the O +
CYP2B6 O +
genotype O -
. O +

The O +
treatment O +
of O +
clopidogrel B-Chemical +
significantly O +
altered O +
the O +
disposition O +
of O +
active O +
metabolites O +
as O +
well O +
as O +
sibutramine B-Chemical -
, O +
but O +
clarithromycin B-Chemical +
only O +
affects O +
the O +
disposition O +
of O +
sibutramine B-Chemical -
. O +

These O +
results O +
suggest O +
that O +
the O +
perturbation O +
of O +
CYP2B6 O +
activity O +
may O +
contribute O +
to O +
the O +
inter O -
- O -
individual O +
variation O +
of O +
sibutramine B-Chemical +
drug O +
responses O +
although O +
the O +
clinical O +
relevance O +
is O +
remained O +
to O +
be O +
established O -
. O +

Naringin B-Chemical +
induces O +
death O +
receptor O +
and O +
mitochondria O -
- O -
mediated O +
apoptosis O +
in O +
human O +
cervical O +
cancer O +
( O -
SiHa O -
) O +
cells O -
. O +

Cervical O +
cancer O +
is O +
the O +
second O +
most O +
common O +
female O +
cancer O +
worldwide O -
, O +
and O +
it O +
remains O +
a O +
challenge O +
to O +
manage O +
preinvasive O +
and O +
invasive O +
lesions O -
. O +

Fruit O -
- O -
based O +
cancer O +
prevention O +
entities O -
, O +
such O +
as O +
flavonoid B-Chemical +
and O +
their O +
derivatives O -
, O +
have O +
demonstrated O +
a O +
marked O +
ability O +
to O +
inhibit O +
preclinical O +
models O +
of O +
epithelial O +
cancer O +
cell O +
growth O +
and O +
tumor O +
formation O -
. O +

Here O -
, O +
we O +
extend O +
the O +
role O +
of O +
naringin B-Chemical -
- O -
mediated O +
chemoprevention O +
to O +
that O +
of O +
cervical O +
carcinogenesis O -
. O +

The O +
present O +
study O +
sought O +
to O +
investigate O +
the O +
therapeutic O +
potential O +
effect O +
of O +
naringin B-Chemical +
on O +
apoptosis O +
in O +
human O +
cervical O +
SiHa O +
cancer O +
cells O -
. O +

Viability O +
of O +
SiHa O +
cells O +
was O +
evaluated O +
by O +
the O +
MTT B-Chemical +
assay O -
, O +
apoptosis O +
and O +
mitochondrial O +
transmembrane O +
potential O +
by O +
flow O +
cytometry O -
, O +
and O +
pro O -
- O -
apoptotic O +
related O +
genes O +
by O +
Real O -
- O -
time O +
quantitative O +
PCR O -
. O +

Naringin B-Chemical +
showed O +
a O +
50 O -
% O +
inhibition O +
of O +
SiHa O +
human O +
cervical O +
cancer O +
cells O +
at O +
a O +
concentration O +
of O +
750μM. O +
SiHa O +
cells O +
exhibited O +
apoptotic O +
cell O +
death O -
, O +
intranucleosomal O +
DNA O +
fragmentation O -
, O +
morphological O +
changes O +
and O +
decline O +
in O +
the O +
mitochondrial O +
transmembrane O +
potential O -
. O +

In O +
addition O -
, O +
administration O +
of O +
naringin B-Chemical +
increased O +
the O +
expression O +
of O +
caspases O -
, O +
p53 O +
and O +
Bax O -
, O +
Fas O +
death O +
receptor O +
and O +
its O +
adaptor O +
protein O +
FADD O -
. O +

These O +
results O +
suggest O +
that O +
the O +
induction O +
of O +
apoptosis O +
by O +
naringin B-Chemical +
is O +
through O +
both O +
death O -
- O -
receptor O +
and O +
mitochondrial O +
pathways O -
. O +

Taken O +
together O -
, O +
our O +
results O +
suggest O +
that O +
naringin B-Chemical +
might O +
be O +
an O +
effective O +
agent O +
to O +
treat O +
human O +
cervical O +
cancer O -
. O +

Powering O +
the O +
future O +
of O +
molecular O +
artificial O +
photosynthesis O +
with O +
light O -
- O -
harvesting O +
metallosupramolecular O +
dye O +
assemblies O -
. O +

Chemical O +
ingenuity O +
will O +
play O +
a O +
significant O +
role O +
in O +
solving O +
the O +
greatest O +
challenge O +
currently O +
facing O +
society O -
: O +
providing O +
clean O +
and O +
carbon O +
neutral O +
energy O +
for O +
all O +
of O +
humanity O -
. O +

Molecular O +
artificial O +
photosynthesis O +
is O +
an O +
emerging O +
technology O +
based O +
on O +
principles O +
learned O +
from O +
Nature O +
where O +
individual O +
components O +
perform O +
the O +
essential O +
light O -
- O -
harvesting O -
, O +
charge O -
- O -
separation O -
, O +
and O +
water O +
splitting O +
functions O +
to O +
store O +
solar O +
energy O +
in O +
the O +
form O +
of O +
chemical O +
bonds O -
. O +

This O +
tutorial O +
review O +
focuses O +
specifically O +
on O +
the O +
application O +
of O +
metallosupramolecular O +
self O -
- O -
assembly O +
strategies O +
to O +
interface O +
solar O +
fuel O +
catalysts O +
with O +
photosensitizers O +
and O +
construct O +
light O -
- O -
harvesting O +
antennae O +
capable O +
of O +
achieving O +
panchromatic O +
absorption O +
and O +
directional O +
energy O +
concentration O -
. O +

Inhibitory O +
function O +
of O +
the O +
dorsomedial O +
hypothalamic O +
nucleus O +
on O +
the O +
hypothalamic O -
- O -
pituitary O -
- O -
adrenal O +
axis O +
response O +
to O +
an O +
emotional O +
stressor O +
but O +
not O +
immune O +
challenge O -
. O +

Accumulating O +
evidence O +
implicates O +
the O +
dorsomedial O +
hypothalamic O +
nucleus O +
( O -
DMH O -
) O +
in O +
the O +
regulation O +
of O +
autonomic O +
and O +
neuroendocrine O +
stress O +
responses O -
. O +

However O -
, O +
although O +
projections O +
from O +
the O +
DMH O +
to O +
the O +
paraventricular O +
hypothalamic O +
nucleus O +
( O -
PVN O -
) O -
, O +
which O +
is O +
the O +
critical O +
site O +
of O +
the O +
neuroendocrine O +
stress O +
axis O -
, O +
have O +
been O +
described O -
, O +
the O +
impact O +
of O +
DMH O +
neurones O +
in O +
the O +
modulation O +
of O +
hypothalamic O -
- O -
pituitary O -
- O -
adrenal O +
( O -
HPA O -
) O +
axis O +
activation O +
during O +
stress O +
is O +
not O +
fully O +
understood O -
. O +

The O +
present O +
study O +
aimed O +
to O +
investigate O +
the O +
role O +
of O +
the O +
DMH O +
in O +
HPA O +
axis O +
responses O +
to O +
different O +
types O +
of O +
stimuli O -
. O +

Male O +
Sprague O -
- O -
Dawley O +
rats O +
fitted O +
with O +
a O +
chronic O +
jugular O +
venous O +
catheter O +
were O +
exposed O +
to O +
either O +
an O +
emotional O +
stressor O +
( O -
elevated O +
platform O -
- O -
exposure O -
) O +
or O +
immune O +
challenge O +
( O -
systemic O +
interleukin-1β O +
administration O -
) O -
. O +

Bilateral O +
electrolytic O +
lesions O +
of O +
the O +
DMH O +
disinhibited O +
HPA O +
axis O +
responses O +
to O +
the O +
emotional O +
stressor O -
, O +
as O +
indicated O +
by O +
higher O +
plasma O +
adrenocorticotrophic O +
hormone O +
levels O +
during O +
and O +
after O +
elevated O +
platform O +
exposure O +
in O +
lesioned O +
animals O +
compared O +
to O +
sham O -
- O -
lesioned O +
controls O -
. O +

Moreover O -
, O +
DMH O -
- O -
lesioned O +
animals O +
showed O +
increased O +
neuronal O +
activation O +
in O +
the O +
PVN O -
, O +
as O +
indicated O +
by O +
a O +
higher O +
c O -
- O -
Fos O +
expression O +
after O +
elevated O -
- O -
platform O +
exposure O +
compared O +
to O +
controls O -
. O +

By O +
contrast O -
, O +
DMH O -
- O -
lesions O +
had O +
no O +
effects O +
on O +
HPA O +
axis O +
responses O +
to O +
immune O +
challenge O -
. O +

Taken O +
together O -
, O +
our O +
data O +
suggest O +
an O +
inhibitory O +
role O +
of O +
DMH O +
neurones O +
on O +
stress O -
- O -
induced O +
HPA O +
axis O +
activation O +
that O +
is O +
dependent O +
upon O +
the O +
nature O +
of O +
the O +
stimulus O +
being O +
important O +
in O +
response O +
to O +
an O +
emotional O +
stressor O +
but O +
not O +
to O +
immune O +
challenge O -
. O +

Genotoxic O +
damage O +
in O +
the O +
oral O +
mucosa O +
cells O +
of O +
subjects O +
carrying O +
restorative O +
dental O +
fillings O -
. O +

A O +
large O +
proportion O +
of O +
the O +
population O +
carries O +
restorative O +
dental O +
fillings O +
containing O +
either O +
classic O +
Hg B-Chemical -
- O -
based O +
amalgams B-Chemical +
and/or O +
the O +
more O +
frequently O +
used O +
methacrylates B-Chemical -
. O +

Both O +
Hg- B-Chemical +
and O +
resin O -
- O -
based O +
materials O +
have O +
been O +
shown O +
to O +
be O +
released O +
into O +
the O +
buccal O +
cavity O +
and O +
to O +
be O +
spread O +
systemically O -
. O +

In O +
addition O -
, O +
they O +
induce O +
toxic O +
and O +
genotoxic O +
alterations O +
in O +
experimental O +
test O +
systems O -
. O +

Using O +
the O +
comet O +
assay O -
, O +
we O +
previously O +
demonstrated O +
that O +
circulating O +
lymphocytes O +
of O +
subjects O +
with O +
dental O +
fillings O +
have O +
an O +
increased O +
DNA O +
damage O -
. O +

Here O -
, O +
we O +
analyzed O +
the O +
oral O +
mucosa O +
cells O +
of O +
63 O +
young O +
subjects O +
of O +
both O +
genders O -
, O +
by O +
using O +
both O +
the O +
comet O +
assay O +
and O +
the O +
micronucleus O +
( O -
MN O -
) O +
test O +
and O +
by O +
monitoring O +
cell O +
death O +
markers O -
. O +

The O +
results O +
obtained O +
show O +
that O +
both O +
amalgams B-Chemical +
and O +
resin O -
- O -
based O +
composite O +
fillings O +
can O +
induce O +
genotoxic O +
damage O +
in O +
human O +
oral O +
mucosa O +
cells O -
, O +
as O +
convincingly O +
and O +
dose O -
- O -
dependently O +
inferred O +
from O +
the O +
results O +
of O +
the O +
MN O +
test O +
and O -
, O +
more O +
marginally O -
, O +
from O +
comet O +
assay O +
data O -
. O +

Lifestyle O +
variables O -
, O +
also O +
including O +
alcohol B-Chemical +
intake O +
and O +
smoking O +
habits O -
, O +
did O +
not O +
affect O +
the O +
genotoxic O +
response O +
and O +
did O +
not O +
act O +
as O +
confounding O +
factors O -
. O +

Thus O -
, O +
we O +
provide O +
unequivocal O +
evidence O +
for O +
the O +
genotoxicity O +
of O +
both O +
amalgams B-Chemical +
and O +
resin O -
- O -
based O +
dental O +
fillings O +
in O +
humans O +
not O +
only O +
by O +
testing O +
circulating O +
lymphocytes O +
but O +
also O +
by O +
analyzing O +
oral O +
mucosa O +
cells O -
. O +

These O +
findings O +
are O +
of O +
particular O +
relevance O +
due O +
to O +
the O +
circumstance O +
that O +
subjects O +
with O +
restorative O +
materials O +
are O +
exposed O +
continuously O +
and O +
for O +
long O +
periods O +
of O +
time O -
. O +

Thiazolidinediones B-Chemical +
( O -
TZDs B-Chemical -
) O +
affect O +
osteoblast O +
viability O +
and O +
biomarkers O +
independently O +
of O +
the O +
TZD B-Chemical +
effects O +
on O +
aromatase O -
. O +

Thiazolidinediones B-Chemical +
( O -
TZDs B-Chemical -
) O +
are O +
insulin O +
sensitizers O +
used O +
for O +
treatment O +
of O +
diabetes O -
. O +

We O +
have O +
previously O +
reported O +
that O +
TZDs B-Chemical +
reduce O +
estrogen B-Chemical +
synthesis O +
by O +
inhibiting O +
aromatase O +
activity O +
in O +
human O +
granulosa O +
cells O +
( O -
HGC O -
) O -
. O +

Multiple O +
clinical O +
trials O +
demonstrated O +
that O +
TZDs B-Chemical +
increase O +
the O +
risk O +
of O +
fractures O +
in O +
postmenopausal O +
women O +
with O +
type O +
2 O +
diabetes O -
. O +

We O +
studied O +
mouse O +
osteoblasts O +
alone O +
or O +
in O +
a O +
co O -
- O -
culture O +
with O +
HGC O +
to O +
determine O +
whether O +
TZD B-Chemical +
inhibition O +
of O +
aromatase O +
plays O +
a O +
role O +
in O +
their O +
effects O +
on O +
bone O +
metabolism O -
. O +

Mouse O +
osteoblasts O +
were O +
cultured O +
with O +
and O +
without O +
HGC O -
, O +
and O +
incubated O +
in O +
a O +
medium O +
with O +
or O +
without O +
testosterone B-Chemical -
, O +
pioglitazone B-Chemical +
or O +
rosiglitazone B-Chemical -
. O +

Cell O +
growth O -
, O +
oleic O +
acid O +
uptake O -
, O +
alkaline O +
phosphatase O +
activity O -
, O +
and O +
osteocalcin O +
production O +
were O +
measured O -
. O +

TZDs B-Chemical +
inhibited O +
estradiol B-Chemical +
production O +
by O +
up O +
to O +
84 O -
% O +
in O +
HGC O -
/ O -
mouse O +
osteoblast O +
co O -
- O -
cultures O -
. O +

TZDs B-Chemical +
induced O +
mouse O +
osteoblast O +
death O +
and O +
increased O +
oleic B-Chemical +
acid I-Chemical +
uptake O -
. O +

TZDs B-Chemical +
also O +
inhibited O +
alkaline O +
phosphatase O +
activity O +
( O -
58 O -
- O -
75 O -
% O -
, O +
p<0.046 O -
) O +
and O +
osteocalcin O +
production O +
( O -
52 O -
- O -
75 O -
% O -
, O +
p<0.031 O -
) O -
. O +

For O +
all O +
the O +
parameters O -
, O +
there O +
were O +
no O +
significant O +
differences O +
between O +
the O +
osteoblast O +
cultures O +
alone O +
and O +
the O +
HCG O -
/ O -
osteoblast O +
co O -
- O -
cultures O -
. O +

TZD B-Chemical +
effects O +
on O +
osteoblast O +
viability O -
, O +
oleic O +
acid O +
uptake O -
, O +
alkaline O +
phosphatase O +
and O +
osteocalcin O +
production O +
are O +
independent O +
of O +
their O +
effects O +
on O +
aromatase O -
. O +

Sonochemical O +
synthesis O +
of O +
hierarchical O +
ZnO B-Chemical +
nanostructures O -
. O +

This O +
work O +
is O +
about O +
fabrication O +
of O +
ZnO B-Chemical +
nanostructures O +
( O -
ZnO B-Chemical -
- O -
NS O -
) O +
via O +
a O +
simple O +
sonochemical O +
method O -
. O +

The O +
chemicals O +
used O +
for O +
the O +
synthesis O +
of O +
various O +
shaped O +
ZnO B-Chemical +
are O +
Zn B-Chemical +
salt O -
, O +
sodium B-Chemical +
hydroxide I-Chemical +
and O +
ammonia B-Chemical +
solution I-Chemical +
without O +
other O +
structure O +
directing O +
agent O +
or O +
surfactant O +
needed O -
. O +

This O +
method O +
is O +
feasible O +
and O +
green O -
, O +
as O +
it O +
does O +
not O +
require O +
high O +
temperature O +
and/or O +
highly O +
toxic O +
chemicals O -
. O +

The O +
shape O +
of O +
the O +
ZnO B-Chemical -
- O -
NS O +
can O +
be O +
tuned O +
by O +
adjusting O +
the O +
ultrasound O +
energy O +
dissipated O +
via O +
varying O +
the O +
ultrasonication O +
time O +
from O +
5 O +
to O +
60 O +
min O -
. O +

It O +
was O +
found O +
that O +
uniform O +
ZnO B-Chemical +
nanorods O +
with O +
diameter O +
around O +
50 O +
nm O +
were O +
formed O +
after O +
15 O +
min O +
of O +
ultrasonication O +
while O +
flowerlike O +
ZnO B-Chemical -
- O -
NS O +
was O +
formed O +
after O +
30 O +
min O -
. O +

This O +
method O +
produces O +
high O +
quality O +
ZnO B-Chemical -
- O -
NS O +
with O +
controllable O +
shapes O -
, O +
uniformity O -
, O +
and O +
purity O -
. O +

The O +
development O +
of O +
better O +
photocatalysts O +
through O +
composition- O +
and O +
structure O -
- O -
engineering O -
. O +

Semiconductor O +
photocatalysts O +
that O +
can O +
effectively O +
utilize O +
solar O +
irradiation O +
hold O +
great O +
potential O +
for O +
harnessing O +
renewable O -
- O -
energy O +
sources O -
, O +
as O +
well O +
as O +
for O +
environmental O +
protection O +
and O +
-remediation O -
. O +

Exploring O +
advanced O +
photocatalysts O +
that O +
have O +
improved O +
performance O +
has O +
been O +
a O +
central O +
theme O +
in O +
photocatalysis O +
research O -
. O +

Herein O -
, O +
we O +
review O +
the O +
recent O +
developments O +
in O +
the O +
design- O +
and O +
fabrication O +
of O +
photocatalysts O +
with O +
an O +
emphasis O +
on O +
composition- O +
and O +
structural O +
control O +
over O +
multiple O +
length O +
scales O -
. O +

This O +
Focus O +
Review O +
will O +
be O +
of O +
value O +
for O +
researchers O +
in O +
the O +
area O +
of O +
photocatalysis O -
, O +
in O +
particular O -
, O +
in O +
the O +
aspects O +
of O +
material O +
design O +
that O +
lead O +
to O +
the O +
synthesis O +
of O +
better O +
photocatalysts O -
. O +

Multidrug O +
resistance O -
- O -
associated O +
proteins O +
are O +
involved O +
in O +
the O +
transport O +
of O +
the O +
glutathione B-Chemical +
conjugates O +
of O +
the O +
ultimate O +
carcinogen O +
of O +
benzo B-Chemical -
[ I-Chemical -
a I-Chemical -
] I-Chemical -
pyrene I-Chemical +
in O +
human O +
Caco-2 O +
cells O -
. O +

A O +
wide O +
variety O +
of O +
contaminants O +
are O +
ingested O +
through O +
food O -
, O +
among O +
them O +
the O +
pro O -
- O -
carcinogenic O +
polycyclic O +
aromatic O +
hydrocarbon O +
benzo B-Chemical -
[ I-Chemical -
a I-Chemical -
] I-Chemical -
pyrene I-Chemical +
( O -
BP O -
) O +
that O +
is O +
resorbed O +
and O +
partially O +
metabolized O +
in O +
the O +
enterocytes O +
of O +
the O +
small O +
intestine O -
. O +

Previous O +
in O +
vitro O +
studies O +
have O +
revealed O +
that O +
BP B-Chemical +
phenols I-Chemical +
are O +
excreted O +
as O +
Phase O +
II O +
metabolites O +
including O +
glucuronides O +
and O +
sulfates B-Chemical -
. O +

This O +
export O +
is O +
mediated O +
by O +
the O +
breast O +
cancer O +
resistance O +
protein O +
( O -
ABCG2 O -
) O -
. O +

The O +
ultimate O +
carcinogenic O +
Phase O +
I O +
BP O +
metabolite O +
anti O -
- O -
BP-7,8-dihydrodiol-9,10-epoxide B-Chemical +
( O -
BPDE B-Chemical -
) O +
can O +
be O +
detoxified O +
by O +
glutathione B-Chemical +
conjugate O +
formation O +
catalyzed O +
by O +
glutathione B-Chemical +
S O -
- O -
transferases O -
. O +

In O +
the O +
present O +
study O -
, O +
differentiated O +
human O +
intestinal O +
Caco-2 O +
cells O +
were O +
used O +
as O +
a O +
model O +
for O +
the O +
human O +
small O +
intestine O +
to O +
investigate O +
the O +
detoxification O +
of O +
BPDE B-Chemical +
and O +
excretion O +
of O +
stereoisomeric O +
glutathione B-Chemical +
conjugates O +
in O +
the O +
presence O +
of O +
an O +
inhibitor O +
of O +
the O +
glutathione B-Chemical -
- O -
cleaving O +
enzyme O +
γ O -
- O -
glutamyl O +
transpeptidase O +
at O +
the O +
cell O +
surface O -
. O +

The O +
results O +
indicate O +
that O +
the O +
glutathione B-Chemical +
conjugates O +
of O +
BPDE B-Chemical +
are O +
formed O +
and O +
excreted O +
mainly O +
to O +
the O +
apical O +
and O +
to O +
a O +
minor O +
extent O +
to O +
the O +
basolateral O +
side O +
of O +
polarized O +
Caco-2 O +
monolayers O -
. O +

Inhibition O +
studies O +
revealed O +
that O +
the O +
multidrug O +
resistance O -
- O -
associated O +
proteins O +
( O -
ABCCs O -
) O +
are O +
involved O +
in O +
the O +
transport O +
of O +
BPDE B-Chemical +
glutathione I-Chemical +
conjugates O -
. O +

Stable O +
ABCC1 O -
, O +
ABCC2 O +
and O +
ABCC3 O +
knockdown O +
cell O +
lines O +
were O +
generated O -
, O +
thus O +
making O +
it O +
possible O +
to O +
demonstrate O +
that O +
ABCC1 O +
mediates O +
the O +
basolateral O +
and O +
ABCC2 O +
the O +
apical O +
excretion O +
of O +
BPDE B-Chemical +
glutathione I-Chemical +
conjugates O -
. O +

In O +
conclusion O -
, O +
the O +
ultimate O +
carcinogen O +
BPDE B-Chemical +
is O +
detoxified O +
via O +
glutathione B-Chemical +
conjugation O +
and O +
subsequently O +
excreted O +
by O +
Caco-2 O +
cells O +
in O +
both O +
apical O +
and O +
basolateral O +
directions O -
. O +

This O +
finding O +
is O +
equivalent O +
to O +
a O +
transport O +
into O +
feces O +
as O +
well O +
as O +
blood O +
system O +
in O +
the O +
in O +
vivo O +
situation O -
. O +

The O +
influence O +
of O +
the O +
choice O +
of O +
digestion O +
enzyme O +
used O +
to O +
prepare O +
rat O +
hepatocytes O +
on O +
xenobiotic O +
uptake O +
and O +
efflux O -
. O +

Isolated O +
rat O +
hepatocytes O +
are O +
widely O +
used O +
to O +
assess O +
the O +
metabolism O +
and O +
toxicity O +
of O +
xenobiotics O -
. O +

The O +
choice O +
of O +
digestion O +
enzyme O +
used O +
to O +
prepare O +
the O +
cells O +
has O +
been O +
shown O +
previously O +
to O +
influence O +
their O +
metabolic O +
capability O -
. O +

This O +
study O +
investigates O +
the O +
effect O +
of O +
the O +
digestion O +
enzyme O +
( O -
collagenase O +
II O -
, O +
collagenase O +
A O -
/ O -
trypsin O +
inhibitor O -
, O +
or O +
collagenase O +
plus O +
dispase O -
) O +
on O +
the O +
uptake O +
of O +
xenobiotics O +
into O -
, O +
and O +
efflux O +
from O -
, O +
hepatocytes O -
. O +

The O +
choice O +
of O +
digestion O +
enzymes O +
used O +
in O +
this O +
study O +
does O +
not O +
affect O +
uptake O +
of O +
either O +
pravastatin B-Chemical +
( O -
an O +
organic O +
anion O +
probe O +
substrate O +
for O +
Oatp O +
transporter O -
) O +
or O +
metformin B-Chemical +
( O -
an O +
organic O +
cation O +
probe O +
substrate O +
for O +
Oct O +
transporter O -
) O -
. O +

With O +
regard O +
to O +
efflux O +
transporters O -
, O +
hepatocyte O +
differentiation O +
was O +
better O +
maintained O +
when O +
cells O +
were O +
isolated O +
using O +
collagenase O +
II O +
alone O -
. O +

Impact O +
of O +
lead O +
and O +
mercuric B-Chemical +
ions O +
on O +
the O +
interleukin-2-dependent O +
proliferation O +
and O +
survival O +
of O +
T O +
cells O -
. O +

Mercury B-Chemical +
and O +
lead O +
are O +
widespread O +
in O +
the O +
environment O -
, O +
causing O +
chronic O +
exposure O +
of O +
a O +
large O +
population O +
to O +
low O +
concentrations O +
of O +
these O +
metals O -
. O +

While O +
several O +
studies O +
demonstrated O +
that O +
low O +
levels O +
of O +
both O +
metals O +
affect O +
the O +
immune O +
system O -
, O +
little O +
is O +
known O +
about O +
underlying O +
molecular O +
mechanisms O -
. O +

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
impact O +
of O +
mercuric B-Chemical +
( O -
Hg B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical -
) O +
and O +
lead O +
( O -
Pb B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical -
) O +
ions O +
on O +
T O +
cells O -
. O +

Up O +
to O +
100 O +
μM O +
Pb B-Chemical -
( I-Chemical -
NO I-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
) I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
had O +
no O +
effect O +
on O +
cellular O +
viability O +
and O +
proliferation O -
. O +

In O +
contrast O -
, O +
HgCl B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
caused O +
a O +
concentration O -
- O -
dependent O +
decline O +
of O +
viable O +
leukocytes O +
and O +
especially O +
of O +
activated O +
T O +
cells O -
. O +

Additionally O -
, O +
Hg B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
induced O +
reactive O +
oxygen B-Chemical +
species O +
( O -
ROS O -
) O +
generation O +
accompanied O +
by O +
the O +
loss O +
of O +
mitochondrial O +
transmembrane O +
potential O -
, O +
measured O +
by O +
Dihydrorhodamine B-Chemical +
and O +
Rhodamine-123 B-Chemical -
, O +
respectively O -
. O +

The O +
antioxidant O +
N B-Chemical -
- I-Chemical -
acetylcysteine I-Chemical +
partially O +
reversed O +
the O +
toxic O +
effects O +
of O +
Hg B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical -
, O +
pointing O +
to O +
an O +
involvement O +
of O +
ROS O -
. O +

The O +
major O +
cytokine O +
controlling O +
T O -
- O -
cell O +
survival O +
and O +
proliferation O +
is O +
interleukin O +
( O -
IL O -
) O -
-2 O -
. O +

Hg B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
had O +
no O +
effect O +
on O +
the O +
secretion O +
of O +
IL-2 O -
, O +
but O +
on O +
IL-2 O +
mediated O +
signal O +
transduction O +
pathways O -
, O +
reducing O +
phosphorylation O +
of O +
the O +
downstream O +
kinases O +
ERK1 O -
/ O -
2 O +
and O +
AKT O -
. O +

Moreover O -
, O +
Hg B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
led O +
to O +
an O +
arrest O +
of O +
the O +
cells O +
in O +
the O +
S O +
phase O +
of O +
the O +
cell O +
cycle O -
. O +

Taken O +
together O -
, O +
these O +
data O +
fit O +
a O +
model O +
in O +
which O +
Hg B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
disrupts O +
mitochondria O -
, O +
and O +
the O +
resulting O +
release O +
of O +
ROS O +
inhibits O +
IL-2-dependent O +
signal O +
transduction O -
, O +
reducing O +
proliferation O +
and O +
survival O +
of O +
T O +
cells O -
. O +

Analysis O +
of O +
cytotoxic O +
T O +
lymphocyte O +
antigen-4 O +
( O -
CTLA-4 O -
) O +
promoter O +
-318C O -
/ O -
T O +
and O +
+ O -
49A O -
/ O -
G O +
gene O +
polymorphisms O +
in O +
Turkish O +
patients O +
with O +
familial O +
Mediterranean O +
fever O -
. O +

Either O +
the O +
role O +
of O +
the O +
adaptive O +
immune O +
system O +
or O +
the O +
interaction O +
between O +
innate O +
and O +
adaptive O +
immune O +
systems O +
in O +
familial O +
Mediterranean O +
fever O +
( O -
FMF O -
) O +
is O +
not O +
clear O +
so O +
far O -
. O +

So O -
, O +
we O +
planned O +
to O +
search O +
for O +
the O +
interaction O +
between O +
the O +
innate O +
and O +
adaptive O +
immune O +
systems O +
in O +
the O +
pathogenesis O +
of O +
FMF O +
by O +
investigating O +
polymorphism O +
for O +
CTLA-4 O +
gene O -
, O +
which O +
plays O +
a O +
role O +
in O +
controlling O +
antigen O +
presentation O +
to O +
T O +
cells O -
. O +

We O +
also O +
aimed O +
to O +
investigate O +
whether O +
there O +
is O +
an O +
association O +
between O +
-318C O -
/ O -
T O +
and O +
+ O -
49A O -
/ O -
G O +
polymorphisms O +
in O +
the O +
CTLA-4 O +
gene O +
and O +
the O +
main O +
clinical O +
features O +
of O +
the O +
disease O -
. O +

75 O +
FMF O +
patients O +
and O +
179 O +
controls O +
were O +
studied O -
. O +

Polymorphism O +
was O +
detected O +
by O +
the O +
PCR O -
- O -
RFLP O +
technique O -
. O +

The O +
CT O +
genotype O +
and O +
T O +
allele O +
frequencies O +
of O +
the O +
-318C O -
/ O -
T O +
polymorphism O +
and O +
the O +
haplotype O +
frequency O +
for O +
the O +
-318T O -
/ O -
+49A O +
in O +
the O +
CTLA-4 O +
gene O +
were O +
higher O +
in O +
the O +
FMF O +
( O -
21.3 O -
, O +
21.3 O -
, O +
and O +
10.7 O +
% O -
) O +
when O +
compared O +
with O +
the O +
controls O +
( O -
10.6 O -
, O +
10.6 O -
, O +
and O +
5.3 O +
% O -
; O +
P O +
= O +
0.029 O -
, O +
0.044 O -
, O +
and O +
0.029 O -
) O -
. O +

However O -
, O +
these O +
differences O +
did O +
not O +
reach O +
a O +
statistically O +
significant O +
level O +
after O +
the O +
Bonferroni O +
correction O -
. O +

A O +
significant O +
linkage O +
disequilibrium O +
was O +
found O +
between O +
the O +
-318C O -
/ O -
T O +
and O +
+ O -
49A O -
/ O -
G O +
polymorphisms O +
in O +
the O +
CTLA-4 O +
gene O +
( O -
D O -
' O +
= O +
0.997 O -
, O +
r O -
( O -
2 O -
) O +
= O +
0.027 O -
, O +
P O +
= O +
0.0002 O -
) O -
. O +

Genotype O +
and O +
carrier O +
frequencies O +
of O +
the O +
CTLA-4 O +
gene O +
+ O -
49A O -
/ O -
G O +
polymorphism O +
were O +
not O +
significantly O +
different O +
between O +
FMF O +
patients O +
and O +
healthy O +
controls O -
. O +

No O +
association O +
was O +
found O +
between O +
the O +
studied O +
polymorphisms O +
and O +
the O +
main O +
clinical O +
features O +
of O +
the O +
disease O -
. O +

Our O +
findings O +
suggest O +
that O +
although O +
not O +
statistically O +
significant O -
, O +
higher O +
frequencies O +
of O +
CTLA-4 O +
gene O +
-318CT O +
genotype O -
, O +
T O +
allele O -
, O +
and O +
-318T O -
/ O -
+49A O +
haplotype O +
in O +
FMF O +
patients O +
may O +
be O +
related O +
to O +
the O +
non O -
- O -
autoimmune O +
pathogenesis O +
of O +
FMF O -
. O +

Cost O -
- O -
effectiveness O +
of O +
hepatitis O +
B O +
vaccination O +
in O +
adults O +
with O +
diagnosed O +
diabetes O -
. O +

OBJECTIVE O +
To O +
examine O +
the O +
cost O -
- O -
effectiveness O +
of O +
a O +
hepatitis O +
B O +
vaccination O +
program O +
for O +
unvaccinated O +
adults O +
with O +
diagnosed O +
diabetes O +
in O +
the O +
U.S. O +
RESEARCH O +
DESIGN O +
AND O +
METHODS O +
We O +
used O +
a O +
cost O -
- O -
effectiveness O +
simulation O +
model O +
to O +
estimate O +
the O +
cost O -
- O -
effectiveness O +
of O +
vaccinating O +
adults O +
20 O -
- O -
59 O +
years O +
of O +
age O +
with O +
diagnosed O +
diabetes O +
not O +
previously O +
vaccinated O +
for O +
or O +
infected O +
by O +
hepatitis O +
B O +
virus O +
( O -
HBV O -
) O -
. O +

The O +
model O +
estimated O +
acute O +
and O +
chronic O +
HBV O +
infections O -
, O +
complications O -
, O +
quality O -
- O -
adjusted O +
life O -
- O -
years O +
( O -
QALYs O -
) O -
, O +
and O +
incremental O +
cost O -
- O -
effectiveness O +
ratios O -
. O +

Data O +
sources O +
included O +
surveillance O +
data O -
, O +
epidemiological O +
studies O -
, O +
and O +
vaccine O +
prices O -
. O +

RESULTS O +
With O +
a O +
10 O -
% O +
uptake O +
rate O -
, O +
the O +
intervention O +
will O +
vaccinate O +
528,047 O +
people O +
and O +
prevent O +
4,271 O +
acute O +
and O +
256 O +
chronic O +
hepatitis O +
B O +
infections O -
. O +

Net O +
health O +
care O +
costs O +
will O +
increase O +
by O +
$ O -
91.4 O +
million O -
, O +
and O +
1,218 O +
QALYs O +
will O +
be O +
gained O -
, O +
producing O +
a O +
cost O -
- O -
effectiveness O +
ratio O +
of O +
$ O -
75,094 O +
per O +
QALY O +
gained O -
. O +

Results O +
are O +
most O +
sensitive O +
to O +
age O -
, O +
the O +
discount O +
rate O -
, O +
the O +
hepatitis O +
B O +
incidence O +
ratio O +
for O +
people O +
with O +
diabetes O -
, O +
and O +
hepatitis O +
B O +
infection O +
rates O -
. O +

Cost O -
- O -
effectiveness O +
ratios O +
rise O +
with O +
age O +
at O +
vaccination O -
; O +
an O +
alternative O +
intervention O +
that O +
vaccinates O +
adults O +
with O +
diabetes O +
60 O +
years O +
of O +
age O +
or O +
older O +
had O +
a O +
cost O -
- O -
effectiveness O +
ratio O +
of O +
$ O -
2.7 O +
million O +
per O +
QALY O -
. O +

CONCLUSIONS O +
Hepatitis O +
B O +
vaccination O +
for O +
adults O +
with O +
diabetes O +
20 O -
- O -
59 O +
years O +
of O +
age O +
is O +
modestly O +
cost O -
- O -
effective O -
. O +

Vaccinating O +
older O +
adults O +
with O +
diabetes O +
is O +
not O +
cost O -
- O -
effective O -
. O +

The O +
study O +
did O +
not O +
consider O +
hepatitis O +
outbreak O +
investigation O +
costs O -
, O +
and O +
limited O +
information O +
exists O +
on O +
hepatitis O +
progression O +
among O +
older O +
adults O +
with O +
diabetes O -
. O +

Partly O +
based O +
on O +
these O +
results O -
, O +
the O +
Advisory O +
Committee O +
on O +
Immunization O +
Practices O +
recently O +
recommended O +
hepatitis O +
B O +
vaccination O +
for O +
people O +
20 O -
- O -
59 O +
years O +
of O +
age O +
with O +
diagnosed O +
diabetes O -
. O +

Evaluation O +
of O +
aggregating O +
brain O +
cell O +
cultures O +
for O +
the O +
detection O +
of O +
acute O +
organ O -
- O -
specific O +
toxicity O -
. O +

As O +
part O +
of O +
the O +
ACuteTox O +
project O +
aimed O +
at O +
the O +
development O +
of O +
non O -
- O -
animal O +
testing O +
strategies O +
for O +
predicting O +
human O +
acute O +
oral O +
toxicity O -
, O +
aggregating O +
brain O +
cell O +
cultures O +
( O -
AGGR O -
) O +
were O +
examined O +
for O +
their O +
capability O +
to O +
detect O +
organ O -
- O -
specific O +
toxicity O -
. O +

Previous O +
multicenter O +
evaluations O +
of O +
in O +
vitro O +
cytotoxicity O +
showed O +
that O +
some O +
20 O -
% O +
of O +
the O +
tested O +
chemicals O +
exhibited O +
significantly O +
lower O +
in O +
vitro O +
toxicity O +
as O +
expected O +
from O +
in O +
vivo O +
toxicity O +
data O -
. O +

This O +
was O +
supposed O +
to O +
be O +
due O +
to O +
toxicity O +
at O +
supracellular O +
( O -
organ O +
or O +
system O -
) O +
levels O -
. O +

To O +
examine O +
the O +
capability O +
of O +
AGGR O +
to O +
alert O +
for O +
potential O +
organ O -
- O -
specific O +
toxicants O -
, O +
concentration O -
- O -
response O +
studies O +
were O +
carried O +
out O +
in O +
AGGR O +
for O +
86 O +
chemicals O -
, O +
taking O +
as O +
endpoints O +
the O +
mRNA O +
expression O +
levels O +
of O +
four O +
selected O +
genes O -
. O +

The O +
lowest O +
observed O +
effect O +
concentration O +
( O -
LOEC O -
) O +
determined O +
for O +
each O +
chemical O +
was O +
compared O +
with O +
the O +
IC20 O +
reported O +
for O +
the O +
3T3 O -
/ O -
NRU O +
cytotoxicity O +
assay O -
. O +

A O +
LOEC O +
lower O +
than O +
IC20 O +
by O +
at O +
least O +
a O +
factor O +
of O +
5 O +
was O +
taken O +
to O +
alert O +
for O +
organ O -
- O -
specific O +
toxicity O -
. O +

The O +
results O +
showed O +
that O +
the O +
frequency O +
of O +
alerts O +
increased O +
with O +
the O +
level O +
of O +
toxicity O +
observed O +
in O +
AGGR O -
. O +

Among O +
the O +
chemicals O +
identified O +
as O +
alert O +
were O +
many O +
compounds O +
known O +
for O +
their O +
organ O -
- O -
specific O +
toxicity O -
. O +

These O +
findings O +
suggest O +
that O +
AGGR O +
are O +
suitable O +
for O +
the O +
detection O +
of O +
organ O -
- O -
specific O +
toxicity O +
and O +
that O +
they O +
could O -
, O +
in O +
conjunction O +
with O +
the O +
3T3 O -
/ O -
NRU O +
cytotoxicity O +
assay O -
, O +
improve O +
the O +
predictive O +
capacity O +
of O +
in O +
vitro O +
toxicity O +
testing O -
. O +

Silver B-Chemical +
nanoparticle O -
- O -
induced O +
cytotoxicity O +
in O +
rat O +
brain O +
endothelial O +
cell O +
culture O -
. O +

Silver B-Chemical +
nanoparticles O +
( O -
AgNPs O -
) O +
are O +
among O +
the O +
most O +
widely O +
commercialised O +
engineered O +
nanomaterials O -
, O +
because O +
of O +
their O +
antimicrobial O +
properties O -
. O +

They O +
are O +
already O +
commonly O +
used O +
in O +
medical O +
devices O -
, O +
household O +
products O +
and O +
industry O -
. O +

Concerns O +
have O +
been O +
raised O +
about O +
potential O +
adverse O +
health O +
effects O +
due O +
to O +
increasing O +
dispersion O +
of O +
AgNPs O +
in O +
the O +
environment O -
. O +

The O +
present O +
study O +
examined O +
the O +
cytotoxic O +
effects O +
of O +
spherical O -
, O +
citrate B-Chemical -
- O -
coated O +
AgNPs O +
( O -
10 O -
, O +
50 O +
and O +
100 O +
nm O -
) O +
in O +
rat O +
brain O +
endothelial O +
( O -
RBE4 O -
) O +
cells O +
and O +
investigated O +
whether O +
the O +
observed O +
effects O +
can O +
be O +
explained O +
by O +
the O +
intrinsic O +
toxicity O +
of O +
the O +
particles O +
or O +
the O +
silver B-Chemical +
ions O +
released O +
from O +
the O +
particles O -
. O +

The O +
results O +
indicated O +
that O +
exposure O +
of O +
RBE4 O +
cells O +
to O +
AgNPs O +
lead O +
to O +
significant O +
reduction O +
in O +
dye O +
uptake O +
as O +
measured O +
with O +
the O +
Neutral B-Chemical +
red I-Chemical +
( O -
NR O -
) O +
assay O -
. O +

The O +
effect O +
was O +
found O +
to O +
be O +
related O +
to O +
particle O +
size O -
, O +
surface O +
area O -
, O +
dose O +
and O +
exposure O +
time O -
. O +

In O +
contrast O -
, O +
silver B-Chemical +
ions O +
increased O +
NR O +
uptake O +
( O -
ca O -
. O +
10 O -
% O -
) O +
in O +
RBE4 O +
cells O +
after O +
1h O -
, O +
while O +
a O +
reduction O +
in O +
NR O +
uptake O +
was O +
observed O +
after O +
24h O +
exposure O +
at O +
high O +
concentrations O +
( O -
20 O -
- O -
30 O +
μM O -
) O -
. O +

Colony O +
formation O -
, O +
as O +
an O +
indicator O +
of O +
proliferation O +
ability O -
, O +
was O +
completely O +
inhibited O +
by O +
AgNPs O +
at O +
concentrations O +
higher O +
than O +
1 O +
μg O -
/ O -
ml O -
. O +

Silver B-Chemical +
ions O +
had O +
less O +
effect O +
on O +
the O +
colony O +
formation O +
of O +
RBE4 O +
cells O +
than O +
AgNPs O -
. O +

Green O +
tomato O +
extract O +
attenuates O +
high O -
- O -
fat O -
- O -
diet O -
- O -
induced O +
obesity O +
through O +
activation O +
of O +
the O +
AMPK O +
pathway O +
in O +
C57BL O -
/ O -
6 O +
mice O -
. O +

Obesity O +
is O +
a O +
risk O +
factor O +
for O +
numerous O +
metabolic O +
disorders O -
. O +

Recently O -
, O +
natural O +
compounds O +
that O +
may O +
be O +
beneficial O +
for O +
improving O +
obesity O +
have O +
received O +
increasing O +
attention O -
. O +

In O +
this O +
study O -
, O +
we O +
investigated O +
whether O +
red O +
and O +
green O +
tomato O +
extracts O +
attenuate O +
high O -
- O -
fat O -
- O -
diet O -
- O -
induced O +
obesity O +
in O +
C57BL O -
/ O -
6 O +
mice O -
. O +

The O +
mice O +
were O +
maintained O +
on O +
a O +
normal O +
diet O +
( O -
ND O -
) O +
or O +
high O -
- O -
fat O +
diet O +
( O -
HFD O -
) O +
for O +
4 O +
weeks O +
and O +
then O +
fed O +
ND O -
, O +
HFD O -
, O +
HFD O +
plus O +
2 O -
% O +
red O +
tomato O +
extract O +
( O -
RTE O -
) O +
or O +
HFD O +
plus O +
2 O -
% O +
green O +
tomato O +
extract O +
( O -
GTE O -
) O +
for O +
13 O +
weeks O -
. O +

The O +
weekly O +
food O +
intakes O +
among O +
the O +
groups O +
were O +
not O +
significantly O +
different O -
. O +

Body O +
weight O +
of O +
mice O +
fed O +
HFD O +
plus O +
GTE O +
was O +
significantly O +
decreased O +
to O +
the O +
level O +
of O +
mice O +
fed O +
ND O -
, O +
but O +
the O +
body O +
weight O +
was O +
only O +
slightly O +
reduced O +
in O +
mice O +
fed O +
HFD O +
plus O +
RTE O -
. O +

Epididymal O +
adipose O +
tissue O +
and O +
liver O +
weights O +
were O +
significantly O +
decreased O +
in O +
mice O +
fed O +
HFD O +
plus O +
GTE O +
compared O +
to O +
those O +
in O +
HFD O -
. O +

Serum O +
total O +
cholesterol B-Chemical +
and O +
low O -
- O -
density O +
lipoprotein O +
cholesterol B-Chemical +
levels O +
in O +
mice O +
fed O +
GTE O +
were O +
modestly O +
reduced O -
, O +
and O +
liver O +
total O +
cholesterol B-Chemical +
level O +
was O +
strongly O +
decreased O +
in O +
HFD O +
plus O +
GTE O -
- O -
fed O +
mice O +
compared O +
to O +
that O +
in O +
HFD O -
- O -
fed O +
mice O -
. O +

Adenosine B-Chemical -
- I-Chemical -
monophosphate I-Chemical -
- O -
activated O +
protein O +
kinase O +
( O -
AMPK O -
) O +
and O +
acetyl B-Chemical -
- I-Chemical -
CoA I-Chemical +
carboxylase O +
phosphorylation O +
in O +
liver O +
from O +
HFD O +
plus O +
GTE O -
- O -
fed O +
mice O +
was O +
significantly O +
elevated O -
, O +
and O +
HMG B-Chemical -
- I-Chemical -
CoA I-Chemical +
reductase O +
expression O +
was O +
also O +
significantly O +
decreased O -
. O +

GTE O +
strongly O +
decreased O +
the O +
expression O +
of O +
peroxisome O +
proliferator O -
- O -
activated O +
receptor O +
gamma O -
, O +
CCAAT O -
/ O -
enhancer O -
- O -
binding O +
protein O +
alpha O +
and O +
perilipin O +
in O +
the O +
adipose O +
tissue O +
of O +
mice O +
fed O +
HFD O +
plus O +
GTE O -
. O +

Our O +
results O +
indicate O +
that O +
the O +
antiobesity O +
effects O +
of O +
GTE O +
may O +
be O +
associated O +
with O +
activation O +
of O +
the O +
AMPK O +
pathway O -
. O +

Opportunities O +
for O +
functional O +
selectivity O +
in O +
GPCR O +
antibodies O -
. O +

Monoclonal O +
antibodies O +
( O -
mAbs O -
) O +
have O +
been O +
used O +
for O +
decades O +
as O +
tools O +
to O +
probe O +
the O +
biology O +
and O +
pharmacology O +
of O +
receptors O +
in O +
cells O +
and O +
tissues O -
. O +

They O +
are O +
also O +
increasingly O +
being O +
developed O +
for O +
clinical O +
purposes O +
against O +
a O +
broad O +
range O +
of O +
targets O -
, O +
albeit O +
to O +
a O +
lesser O +
extent O +
for O +
G O -
- O -
protein O -
- O -
coupled O +
receptors O +
( O -
GPCRs O -
) O +
relative O +
to O +
other O +
therapeutic O +
targets O -
. O +

Recent O +
pharmacological O -
, O +
structural O +
and O +
biophysical O +
data O +
have O +
provided O +
a O +
great O +
deal O +
of O +
new O +
insight O +
into O +
the O +
molecular O +
details O -
, O +
complexity O +
and O +
regulation O +
of O +
GPCR O +
function O -
. O +

Whereas O +
GPCRs O +
used O +
to O +
be O +
viewed O +
as O +
having O +
either O +
" O -
on O -
" O +
or O +
" O -
off O -
" O +
conformational O +
states O -
, O +
it O +
is O +
now O +
recognized O +
that O +
their O +
structures O +
may O +
be O +
finely O +
tuned O +
by O +
ligands O +
and O +
other O +
interacting O +
proteins O -
, O +
leading O +
to O +
the O +
selective O +
activation O +
of O +
specific O +
signaling O +
pathways O -
. O +

This O +
information O +
coupled O +
with O +
new O +
technologies O +
for O +
the O +
selection O +
of O +
mAbs O +
targeting O +
GPCRs O +
will O +
be O +
increasingly O +
deployed O +
for O +
the O +
development O +
of O +
highly O +
selective O +
mAbs O +
that O +
recognize O +
conformational O +
determinants O +
leading O +
to O +
novel O +
therapeutics O -
. O +

Nephrogenic O +
systemic O +
fibrosis O -
- O -
like O +
effects O +
of O +
magnetic O +
resonance O +
imaging O +
contrast O +
agents O +
in O +
rats O +
with O +
adenine B-Chemical -
- O -
induced O +
renal O +
failure O -
. O +

Nephrogenic O +
systemic O +
fibrosis O +
( O -
NSF O -
) O +
is O +
a O +
scleroderma O -
- O -
like O +
disease O +
associated O +
with O +
prior O +
administration O +
of O +
certain O +
gadolinium B-Chemical +
chelates O +
( O -
GCs O -
) O -
. O +

NSF O +
occurs O +
in O +
patients O +
with O +
severe O +
renal O +
failure O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
set O +
up O +
a O +
rat O +
model O +
of O +
GC O -
- O -
associated O +
NSF O +
to O +
elucidate O +
the O +
mechanism O +
of O +
this O +
devastating O +
disease O -
. O +

Firstly O -
, O +
after O +
characterization O +
of O +
the O +
model O -
, O +
male O +
Wistar O +
rats O +
received O +
a O +
0.75 O -
% O +
adenine B-Chemical -
- O -
enriched O +
diet O +
for O +
8 O -
, O +
14 O -
, O +
or O +
16 O +
days O +
to O +
obtain O +
various O +
degrees O +
of O +
renal O +
failure O -
. O +

Rats O +
received O +
five O +
consecutive O +
daily O +
iv O +
injections O +
of O +
saline O +
or O +
gadodiamide B-Chemical +
( O -
2.5 O +
mmol O -
/ O -
kg O -
/ O -
day O -
) O -
. O +

Secondly O -
, O +
the O +
safety O +
profile O +
and O +
in O +
vivo O +
propensity O +
to O +
dissociate O +
of O +
all O +
categories O +
of O +
marketed O +
GCs O +
( O -
gadoterate B-Chemical -
, O +
gadobutrol B-Chemical -
, O +
gadobenate B-Chemical -
, O +
gadopentetate B-Chemical -
, O +
and O +
gadodiamide B-Chemical -
) O +
were O +
compared O +
in O +
rats O +
receiving O +
adenine B-Chemical -
- O -
enriched O +
diet O +
for O +
16 O +
days O -
. O +

Serial O +
skin O +
biopsies O +
were O +
performed O +
for O +
blinded O +
histopathological O +
study O -
. O +

Total O +
Gd B-Chemical +
concentration O +
in O +
tissues O +
was O +
measured O +
by O +
Inductively O +
Coupled O +
Plasma O +
Mass O +
Spectrometry O -
. O +

Relaxometry O +
was O +
used O +
to O +
evaluate O +
the O +
presence O +
of O +
dissociated O +
Gd B-Chemical +
in O +
skin O +
and O +
bone O -
. O +

Gadodiamide B-Chemical -
- O -
induced O +
high O +
mortality O +
and O +
skin O +
lesions O +
( O -
dermal O +
fibrosis O -
, O +
calcification O -
, O +
and O +
inflammation O -
) O +
were O +
related O +
to O +
adenine B-Chemical +
diet O +
duration O -
. O +

No O +
skin O +
lesions O +
were O +
observed O +
with O +
other O +
molecules O -
. O +

Unlike O +
macrocyclic O +
GCs O -
, O +
gadodiamide B-Chemical -
, O +
gadopentetate B-Chemical -
, O +
and O +
gadobenate B-Chemical +
gradually O +
increased O +
the O +
r O -
( O -
1 O -
) O +
relaxivity O +
value O -
, O +
consistent O +
with O +
in O +
vivo O +
dissociation O +
and O +
release O +
of O +
soluble O +
Gd B-Chemical +
( O -
or O -
, O +
in O +
the O +
case O +
of O +
gadobenate B-Chemical -
, O +
the O +
consequence O +
of O +
protein O +
binding O -
) O -
. O +

Gadodiamide B-Chemical -
- O -
induced O +
cutaneous O +
and O +
systemic O +
toxicity O +
depended O +
on O +
baseline O +
renal O +
function O -
. O +

We O +
demonstrate O +
in O +
vivo O +
dissociation O +
of O +
linear O +
GCs O -
, O +
gadodiamide B-Chemical -
, O +
and O +
gadopentetate B-Chemical -
, O +
whereas O +
macrocyclic O +
agents O +
remained O +
stable O +
over O +
the O +
study O +
period O -
. O +

Effects O +
of O +
ozone B-Chemical +
and O +
particulate O +
matter O +
on O +
cardiac O +
mechanics O -
: O +
role O +
of O +
the O +
atrial O +
natriuretic O +
peptide O +
gene O -
. O +

A O +
positive O +
association O +
between O +
air O +
pollution O +
exposure O +
and O +
increased O +
human O +
risk O +
of O +
chronic O +
heart O +
disease O +
progression O +
is O +
well O +
established O -
. O +

In O +
the O +
current O +
study O -
, O +
we O +
test O +
two O +
hypotheses O -
: O +
( O -
1 O -
) O +
the O +
cardiac O +
compensatory O +
changes O +
in O +
response O +
to O +
air O +
pollution O +
are O +
dependent O +
on O +
its O +
composition O +
and O +
( O -
2 O -
) O +
specific O +
cardiac O +
adaptations O +
are O +
regulated O +
by O +
atrial O +
natriuretic O +
peptide O +
( O -
ANP O -
) O -
. O +

We O +
address O +
these O +
hypotheses O +
by O +
initially O +
examining O +
the O +
exposure O +
effects O +
of O +
ozone B-Chemical +
( O -
O B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
) O +
and/or O +
particulate O +
matter O +
( O -
PM O -
) O +
on O +
cardiac O +
function O +
in O +
C57Bl O -
/ O -
6J O +
( O -
B6 O -
) O +
mice O -
. O +

Subsequently O -
, O +
the O +
results O +
are O +
compared O +
with O +
cardiac O +
functional O +
changes O +
to O +
the O +
same O +
exposures O +
in O +
Nppa O +
( O -
the O +
precursor O +
gene O +
for O +
ANP O -
) O +
knockout O +
( O -
KO O -
) O +
mice O -
. O +

Separate O +
groups O +
of O +
mice O +
underwent O +
3 O +
consecutive O +
days O +
of O +
the O +
same O +
exposure O +
sequence O +
for O +
3h O +
each O +
consisting O +
of O +
the O +
following O -
: O +
( O -
1 O -
) O +
6h O +
of O +
filtered O +
air O +
( O -
FAFA O -
) O -
, O +
( O -
2 O -
) O +
O B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical +
then O +
FA O +
( O -
O B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
FA O -
) O -
, O +
( O -
3 O -
) O +
FA O +
then O +
carbon B-Chemical +
black I-Chemical +
( O -
FACB O -
) O -
, O +
or O +
( O -
4 O -
) O +
O B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical +
then O +
CB O -
. O +

Cardiac O +
function O +
was O +
assessed O +
using O +
a O +
conductance O +
catheter O +
to O +
generate O +
cardiac O +
pressure O -
- O -
volume O +
loops O +
8 O -
- O -
10h O +
following O +
each O +
exposure O +
sequence O -
. O +

As O +
compared O +
with O +
FAFA O -
, O +
each O +
sequence O +
led O +
to O +
a O +
substantial O +
drop O +
( O -
as O +
much O +
as O +
33 O -
% O -
) O +
in O +
stroke O +
volume O +
and O +
cardiac O +
output O -
. O +

However O -
, O +
these O +
losses O +
of O +
cardiac O +
function O +
occurred O +
by O +
different O +
compensatory O +
mechanisms O +
dependent O +
on O +
the O +
pollutant O +
composition O -
. O +

For O +
example O -
, O +
O B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
FA O +
exposure O +
led O +
to O +
reductions O +
in O +
both O +
end O -
- O -
systolic O +
and O +
end O -
- O -
diastolic O +
left O +
ventricular O +
( O -
LV O -
) O +
volumes O -
, O +
whereas O +
FACB O +
exposure O +
led O +
an O +
increase O +
in O +
end O -
- O -
diastolic O +
LV O +
volume O -
. O +

These O +
same O +
cardiac O +
compensatory O +
changes O +
were O +
largely O +
abolished O +
in O +
Nppa O +
KO O +
mice O +
following O +
O B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
FA O +
or O +
FACB O +
exposure O -
. O +

These O +
results O +
suggest O +
that O +
cardiac O +
functional O +
changes O +
in O +
response O +
to O +
air O +
pollution O +
exposure O +
are O +
strongly O +
dependent O +
on O +
the O +
pollutant O +
constituents O -
, O +
especially O +
related O +
to O +
O B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical +
and/or O +
PM O -
. O +

Furthermore O -
, O +
ANP O +
regulation O +
appears O +
to O +
be O +
crucial O +
to O +
these O +
cardiac O +
compensatory O +
mechanisms O +
induced O +
by O +
air O +
pollution O -
. O +

Solving O +
the O +
lost O +
in O +
translation O +
problem O -
: O +
improving O +
the O +
effectiveness O +
of O +
translational O +
research O -
. O +

Translational O +
research O +
frequently O +
fails O +
to O +
replicate O +
in O +
the O +
clinic O +
what O +
has O +
been O +
demonstrated O +
in O +
the O +
laboratory O -
. O +

This O +
has O +
been O +
true O +
for O +
neuroprotection O +
in O +
the O +
central O +
nervous O +
system O -
, O +
neuroprotection O +
in O +
glaucoma O -
, O +
as O +
well O +
as O +
many O +
other O +
areas O +
of O +
medicine O -
. O +

Two O +
fundamental O +
reasons O +
for O +
this O +
' O -
Lost O +
in O +
Translation O -
' O +
problem O +
are O +
the O +
' O -
Butterfly O +
Effect O -
' O +
( O -
chaotic O +
behavior O +
of O +
many O +
animal O +
models O -
) O +
and O +
the O +
' O -
Two O +
Cultures O -
' O +
problem O +
( O -
differences O +
between O +
the O +
methodologies O +
for O +
preclinical O +
and O +
clinical O +
research O -
) O -
. O +

We O +
propose O +
several O +
strategies O +
to O +
deal O +
with O +
these O +
issues O -
, O +
including O +
the O +
use O +
of O +
ensembles O +
of O +
animal O +
models O -
, O +
adding O +
intraocular O +
pressure O +
lowering O +
to O +
preclinical O +
neuroprotection O +
studies O -
, O +
changing O +
the O +
way O +
in O +
which O +
preclinical O +
research O +
is O +
done O -
, O +
and O +
increasing O +
interactions O +
between O +
the O +
preclinical O +
and O +
clinical O +
teams O -
. O +

The O +
involvement O +
of O +
Reelin O +
in O +
neurodevelopmental O +
disorders O -
. O +

Reelin O +
is O +
a O +
glycoprotein O +
that O +
serves O +
important O +
roles O +
both O +
during O +
development O +
( O -
regulation O +
of O +
neuronal O +
migration O +
and O +
brain O +
lamination O -
) O +
and O +
in O +
adulthood O +
( O -
maintenance O +
of O +
synaptic O +
function O -
) O -
. O +

A O +
number O +
of O +
neuropsychiatric O +
disorders O +
including O +
autism O -
, O +
schizophrenia O -
, O +
bipolar O +
disorder O -
, O +
major O +
depression O -
, O +
Alzheimer O -
's O +
disease O +
and O +
lissencephaly O +
share O +
a O +
common O +
feature O +
of O +
abnormal O +
Reelin O +
expression O +
in O +
the O +
brain O -
. O +

Altered O +
Reelin O +
expression O +
has O +
been O +
hypothesized O +
to O +
impair O +
neuronal O +
connectivity O +
and O +
synaptic O +
plasticity O -
, O +
leading O +
ultimately O +
to O +
the O +
cognitive O +
deficits O +
present O +
in O +
these O +
disorders O -
. O +

The O +
mechanisms O +
for O +
abnormal O +
Reelin O +
expression O +
in O +
some O +
of O +
these O +
disorders O +
are O +
currently O +
unknown O +
although O +
possible O +
explanations O +
include O +
early O +
developmental O +
insults O -
, O +
mutations O -
, O +
hypermethylation O +
of O +
the O +
promoter O +
for O +
the O +
Reelin O +
gene O +
( O -
RELN O -
) O -
, O +
miRNA O +
silencing O +
of O +
Reelin O +
mRNA O -
, O +
FMRP O +
underexpression O +
and O +
Reelin O +
processing O +
abnormalities O -
. O +

Increasing O +
Reelin O +
expression O +
through O +
pharmacological O +
therapies O +
may O +
help O +
ameliorate O +
symptoms O +
resulting O +
from O +
Reelin O +
deficits O -
. O +

This O +
article O +
is O +
part O +
of O +
the O +
Special O +
Issue O +
entitled O +
' O -
Neurodevelopmental O +
Disorders O -
' O -
. O +

Antidepressant O -
- O -
like O +
properties O +
of O +
three O +
new O +
α2-adrenoceptor O +
antagonists O -
. O +

Evidence O +
suggests O +
that O +
depression O +
is O +
associated O +
with O +
an O +
increase O +
in O +
the O +
high O -
- O -
affinity O +
conformation O +
of O +
the O +
α2-adrenoceptors O +
in O +
human O +
brain O -
. O +

Such O +
enhanced O +
α2-adrenoceptor O +
activity O +
could O +
explain O +
the O +
deficit O +
in O +
central O +
noradrenergic O +
transmission O +
described O +
in O +
the O +
aetiology O +
of O +
depression O -
. O +

Thus O -
, O +
administration O +
of O +
α2-adrenoceptor O +
antagonists O +
augments O +
noradrenaline B-Chemical +
levels O +
and O +
provides O +
an O +
effective O +
therapeutic O +
approach O +
for O +
the O +
treatment O +
of O +
depressive O +
disorders O -
. O +

In O +
previous O +
studies O -
, O +
we O +
have O +
characterized O +
three O +
new O +
synthesized O +
guanidine B-Chemical +
and O +
2-aminoimidazoline B-Chemical +
aromatic O +
derivatives O +
( O -
8b O -
, O +
17b O +
and O +
20b O -
) O +
as O +
α2-adrenoceptor O +
antagonists O +
that O +
are O +
able O +
to O +
increase O +
extracellular O +
concentration O +
of O +
noradrenaline B-Chemical +
in O +
rat O +
brain O -
. O +

The O +
purpose O +
of O +
the O +
present O +
study O +
was O +
to O +
evaluate O +
the O +
in O +
vivo O +
antidepressant O -
- O -
like O +
properties O +
of O +
these O +
three O +
new O +
α2-adrenoceptor O +
antagonists O -
. O +

For O +
that O +
aim O -
, O +
compounds O +
were O +
tested O +
on O +
the O +
tail O +
suspension O +
test O +
( O -
TST O -
) O +
and O +
forced O +
swim O +
test O +
( O -
FST O -
) O -
, O +
two O +
classically O +
widely O -
- O -
used O +
behavioural O +
paradigms O +
for O +
the O +
evaluation O +
of O +
antidepressant O -
- O -
like O +
activity O -
. O +

Compound O +
8b O +
significantly O +
reduced O +
the O +
immobility O +
time O +
at O +
10 O -
, O +
20 O +
and O +
40 O +
mg O -
/ O -
kg O +
doses O +
in O +
both O +
TST O +
and O +
FST O -
. O +

Compound O +
17b O +
reduced O +
the O +
immobility O +
time O +
at O +
40 O +
mg O -
/ O -
kg O +
in O +
both O +
TST O +
and O +
FST O -
. O +

Compound O +
20b O +
showed O +
a O +
significant O +
decrease O +
in O +
the O +
immobility O +
time O +
at O +
20 O +
mg O -
/ O -
kg O +
in O +
the O +
TST O -
. O +

As O +
drugs O +
of O +
reference O -
, O +
fluoxetine B-Chemical +
induced O +
a O +
significant O +
antidepressant O -
- O -
like O +
effect O +
in O +
both O +
TST O +
and O +
FST O -
, O +
while O +
mirtazapine B-Chemical +
induced O +
a O +
significant O +
antidepressant O -
- O -
like O +
effect O +
only O +
in O +
the O +
FST O -
. O +

Additionally O -
, O +
none O +
of O +
the O +
tested O +
compounds O +
increased O +
locomotor O +
activity O +
or O +
displayed O +
anxiolytic O -
- O -
like O +
properties O -
. O +

These O +
results O +
suggest O +
that O +
these O +
new O +
synthesized O +
α2-adrenoceptor O +
antagonists O +
may O +
be O +
useful O +
as O +
potential O +
antidepressant O +
drugs O -
. O +

Leptin O +
overexpression O +
in O +
VTA O +
trans O -
- O -
activates O +
the O +
hypothalamus O +
whereas O +
prolonged O +
leptin O +
action O +
in O +
either O +
region O +
cross O -
- O -
desensitizes O -
. O +

High O -
- O -
fat O +
feeding O +
or O +
CNS O +
leptin O +
overexpression O +
in O +
chow O -
- O -
fed O +
rats O +
results O +
in O +
a O +
region O -
- O -
specific O +
cellular O +
leptin O +
resistance O +
in O +
medial O +
basal O +
hypothalamic O +
regions O +
and O +
the O +
ventral O +
tegmental O +
area O +
( O -
VTA O -
) O -
. O +

The O +
present O +
investigation O +
examined O +
the O +
effects O +
of O +
targeted O +
chronic O +
leptin O +
overexpression O +
in O +
the O +
VTA O +
as O +
compared O +
with O +
the O +
medial O +
basal O +
hypothalamus O +
on O +
long O -
- O -
term O +
body O +
weight O +
homeostasis O -
. O +

The O +
study O +
also O +
examined O +
if O +
this O +
targeted O +
intervention O +
conserves O +
regional O +
leptin O +
sensitivity O +
or O +
results O +
in O +
localized O +
leptin O +
resistance O -
. O +

Cellular O +
leptin O +
resistance O +
was O +
assessed O +
by O +
leptin O -
- O -
stimulated O +
phosphorylation O +
of O +
signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
3 O +
( O -
STAT3 O -
) O -
. O +

Tyrosine B-Chemical +
hydroxylase O +
was O +
measured O +
in O +
hypothalamus O +
and O +
VTA O +
along O +
with O +
brown O +
adipose O +
tissue O +
uncoupling O +
protein O +
1 O -
. O +

Leptin O +
overexpression O +
in O +
VTA O +
tempered O +
HF O -
- O -
induced O +
obesity O -
, O +
but O +
to O +
a O +
slightly O +
lesser O +
extent O +
than O +
that O +
with O +
leptin O +
overexpression O +
in O +
the O +
hypothalamus O -
. O +

Moreover O -
, O +
the O +
overexpression O +
of O +
leptin O +
in O +
the O +
VTA O +
stimulated O +
cellular O +
STAT3 O +
phosphorylation O +
in O +
several O +
regions O +
of O +
the O +
medial O +
basal O +
hypothalamus O -
, O +
whereas O +
verexpression O +
in O +
the O +
hypothalamus O +
did O +
not O +
activate O +
STAT3 O +
signaling O +
in O +
the O +
VTA O -
. O +

This O +
unidirectional O +
trans O -
- O -
stimulation O +
did O +
not O +
appear O +
to O +
involve O +
migration O +
of O +
either O +
the O +
vector O +
or O +
the O +
gene O +
product O -
. O +

Long O -
- O -
term O +
leptin O +
overexpression O +
in O +
either O +
the O +
medial O +
basal O +
hypothalamus O +
or O +
VTA O +
caused O +
desensitization O +
of O +
leptin O +
signaling O +
in O +
the O +
treated O +
region O +
and O +
cross O -
- O -
desensitization O +
of O +
leptin O +
signaling O +
in O +
the O +
untreated O +
region O -
. O +

These O +
results O +
demonstrate O +
a O +
role O +
of O +
leptin O +
receptors O +
in O +
the O +
VTA O +
in O +
long O -
- O -
term O +
body O +
weight O +
regulation O -
, O +
but O +
the O +
trans O -
- O -
activation O +
of O +
the O +
hypothalamus O +
following O +
VTA O +
leptin O +
stimulation O +
suggests O +
that O +
an O +
integrative O +
response O +
involving O +
both O +
brain O +
regions O +
may O +
account O +
for O +
the O +
observed O +
physiological O +
outcomes O -
. O +

Experiences O +
of O +
microsurgical O +
reconstruction O +
for O +
variant O +
hepatic O +
artery O +
in O +
living O +
donor O +
liver O +
transplantation O -
. O +

There O +
is O +
an O +
emergent O +
need O +
for O +
improving O +
the O +
microsurgical O +
technique O +
of O +
variant O +
arterial O +
anastomosis O +
to O +
reduce O +
the O +
often O +
seen O +
surgery O -
- O -
related O +
complications O -
. O +

We O +
describe O +
in O +
this O +
article O +
our O +
experience O +
in O +
improving O +
this O +
technique O -
, O +
in O +
73 O +
living O +
donor O +
liver O +
grafts O +
( O -
64 O +
right O +
lobes O -
, O +
9 O +
left O +
lobes O -
) O +
in O +
patients O +
with O +
end O -
- O -
stage O +
liver O +
disease O +
during O +
living O +
donor O +
liver O +
transplantation O -
. O +

The O +
hepatic O +
arteries O +
were O +
evaluated O +
preoperatively O +
with O +
computed O +
tomography O +
and O +
magnetic O +
resonance O +
angiography O -
. O +

In O +
this O +
series O -
, O +
13 O +
grafts O +
( O -
17.80 O +
% O -
) O +
with O +
variant O +
hepatic O +
artery O +
were O +
conducted O +
arterioplasty O +
on O +
a O +
back O -
- O -
table O +
under O +
a O +
loupe O +
or O +
a O +
high O -
- O -
power O +
microscope O -
, O +
which O +
included O +
one O +
recipient O +
in O +
situ O +
interposition O +
vessel O +
graft O +
of O +
recipient O +
proper O +
hepatic O +
artery O +
for O +
artery O +
reconstruction O -
. O +

The O +
back O -
- O -
table O +
reconstruction O +
time O +
was O +
16 O +
± O +
5.6 O +
min O -
. O +

No O +
arterial O +
thrombosis O +
was O +
found O +
in O +
these O +
cases O +
during O +
the O +
6-month O +
postoperative O +
follow O -
- O -
up O -
. O +

On O +
the O +
basis O +
of O +
our O +
experience O -
, O +
we O +
suggest O +
that O +
back O -
- O -
table O +
microsurgical O +
plasty O +
for O +
graft O +
with O +
arterial O +
variation O +
should O +
be O +
applied O +
to O +
minimize O +
operative O +
difficulties O +
and O +
to O +
avoid O +
arterial O +
complications O +
in O +
living O +
donor O +
liver O +
transplantation O -
. O +

Purinergic O +
receptor O +
antagonist O +
a438079 O +
protects O +
against O +
acetaminophen B-Chemical -
- O -
induced O +
liver O +
injury O +
by O +
inhibiting O +
p450 O +
isoenzymes O -
, O +
not O +
by O +
inflammasome O +
activation O -
. O +

Acetaminophen B-Chemical +
( O -
APAP B-Chemical -
) O +
overdose O +
is O +
the O +
most O +
frequent O +
cause O +
of O +
acute O +
liver O +
failure O +
in O +
the O +
western O +
world O -
. O +

Controversy O +
exists O +
regarding O +
the O +
hypothesis O +
that O +
the O +
hepatocyte O +
injury O +
is O +
amplified O +
by O +
a O +
sterile O +
inflammatory O +
response O -
, O +
rather O +
than O +
being O +
the O +
result O +
of O +
intracellular O +
mechanisms O +
alone O -
. O +

A O +
recent O +
study O +
suggested O +
that O +
the O +
purinergic O +
receptor O +
antagonist O +
A438079 B-Chemical +
protects O +
against O +
APAP B-Chemical -
- O -
induced O +
liver O +
injury O +
by O +
preventing O +
the O +
activation O +
of O +
the O +
Nalp3 O +
inflammasome O +
in O +
Kupffer O +
cells O +
and O +
thereby O +
preventing O +
inflammatory O +
injury O -
. O +

To O +
test O +
the O +
hypothesis O +
that O +
A438079 B-Chemical +
actually O +
affects O +
the O +
intracellular O +
signaling O +
events O +
in O +
hepatocytes O -
, O +
C57Bl O -
/ O -
6 O +
mice O +
were O +
treated O +
with O +
APAP B-Chemical +
( O -
300 O +
mg O -
/ O -
kg O -
) O +
and O +
A438079 B-Chemical +
( O -
80 O +
mg O -
/ O -
kg O -
) O +
or O +
saline O +
and O +
GSH B-Chemical +
depletion O -
, O +
protein O +
adduct O +
formation O -
, O +
c O -
- O -
jun O -
- B-Chemical -
N O -
- O -
terminal O +
kinase O +
( O -
JNK O -
) O +
activation O -
, O +
oxidant O +
stress O -
, O +
and O +
liver O +
cell O +
necrosis O +
were O +
determined O +
between O +
0 O +
and O +
6 O +
h O +
after O +
APAP B-Chemical +
administration O -
. O +

APAP B-Chemical +
caused O +
rapid O +
GSH B-Chemical +
depletion O -
, O +
extensive O +
protein O +
adduct O +
formation O +
in O +
liver O +
homogenates O +
and O +
in O +
mitochondria O -
, O +
JNK O +
phosphorylation O +
and O +
mitochondrial O +
translocation O +
of O +
phospho O -
- O -
JNK O +
within O +
2 O +
h O -
, O +
oxidant O +
stress O -
, O +
and O +
extensive O +
centrilobular O +
necrosis O +
at O +
6 O +
h. O +
A438079 B-Chemical +
significantly O +
attenuated O +
GSH B-Chemical +
depletion O -
, O +
which O +
resulted O +
in O +
a O +
50 O -
% O +
reduction O +
of O +
total O +
liver O +
and O +
mitochondrial O +
protein O +
adducts O +
and O +
substantial O +
reduction O +
of O +
JNK O +
activation O -
, O +
mitochondrial O +
P O -
- O -
JNK O +
translocation O -
, O +
oxidant O +
stress O -
, O +
and O +
liver O +
injury O -
. O +

The O +
same O +
results O +
were O +
obtained O +
using O +
primary O +
mouse O +
hepatocytes O -
. O +

A438079 B-Chemical +
did O +
not O +
directly O +
affect O +
JNK O +
activation O +
induced O +
by O +
tert B-Chemical -
- I-Chemical -
butyl I-Chemical +
hydroperoxide I-Chemical +
and O +
GSH B-Chemical +
depletion O -
. O +

However O -
, O +
A438079 B-Chemical +
dose O -
- O -
dependently O +
inhibited O +
hepatic O +
P450 O +
enzyme O +
activity O -
. O +

Thus O -
, O +
the O +
protective O +
effect O +
of O +
A438079 B-Chemical +
against O +
APAP B-Chemical +
hepatotoxicity O +
in O +
vivo O +
can O +
be O +
explained O +
by O +
its O +
effect O +
on O +
metabolic O +
activation O +
and O +
cell O +
death O +
pathways O +
in O +
hepatocytes O +
without O +
involvement O +
of O +
the O +
Nalp3 O +
inflammasome O -
. O +

Aryl B-Chemical +
methylcarbamates I-Chemical -
: O +
Potency O +
and O +
selectivity O +
towards O +
wild O -
- O -
type O +
and O +
carbamate B-Chemical -
- O -
insensitive O +
( O -
G119S O -
) O +
Anopheles O +
gambiae O +
acetylcholinesterase O -
, O +
and O +
toxicity O +
to O +
G3 O +
strain O +
An O -
. O +

gambiae O -
. O +

New O +
carbamates B-Chemical +
that O +
are O +
highly O +
selective O +
for O +
inhibition O +
of O +
Anopheles O +
gambiae O +
acetylcholinesterase O +
( O -
AChE O -
) O +
over O +
the O +
human O +
enzyme O +
might O +
be O +
useful O +
in O +
continuing O +
efforts O +
to O +
limit O +
malaria O +
transmission O -
. O +

In O +
this O +
report O +
we O +
assessed O +
34 O +
synthesized O +
and O +
commercial O +
carbamates B-Chemical +
for O +
their O +
selectivity O +
to O +
inhibit O +
the O +
AChEs O +
found O +
in O +
carbamate B-Chemical -
- O -
susceptible O +
( O -
G3 O -
) O +
and O +
carbamate B-Chemical -
- O -
resistant O +
( O -
Akron O -
) O +
An O -
. O +

gambiae O -
, O +
relative O +
to O +
human O +
AChE. O +
Excellent O +
correspondence O +
is O +
seen O +
between O +
inhibition O +
potencies O +
measured O +
with O +
carbamate B-Chemical -
- O -
susceptible O +
mosquito O +
homogenate O +
and O +
purified O +
recombinant O +
wild O -
- O -
type O +
( O -
WT O -
) O +
An O -
. O +

gambiae O +
AChE O +
( O -
AgAChE O -
) O -
. O +

Similarly O -
, O +
excellent O +
correspondence O +
is O +
seen O +
between O +
inhibition O +
potencies O +
measured O +
with O +
carbamate B-Chemical -
- O -
resistant O +
mosquito O +
homogenate O +
and O +
purified O +
recombinant O +
G119S O +
AgAChE O -
, O +
consistent O +
with O +
our O +
earlier O +
finding O +
that O +
the O +
Akron O +
strain O +
carries O +
the O +
G119S O +
mutation O -
. O +

Although O +
high O +
( O -
100- O +
to O +
500-fold O -
) O +
WT O +
An O -
. O +

gambiae O +
vs O +
human O +
selectivity O +
is O +
observed O +
for O +
several O +
compounds O -
, O +
none O +
of O +
the O +
carbamates B-Chemical +
tested O +
potently O +
inhibits O +
the O +
G119S O +
mutant O +
enzyme O -
. O +

Finally O -
, O +
we O +
describe O +
a O +
predictive O +
model O +
for O +
WT O +
An O -
. O +

gambiae O +
tarsal O +
contact O +
toxicity O +
of O +
the O +
carbamates B-Chemical +
that O +
relies O +
on O +
inhibition O +
potency O -
, O +
molecular O +
volume O -
, O +
and O +
polar O +
surface O +
area O -
. O +

Single O +
molecule O +
sensing O +
with O +
solid O -
- O -
state O +
nanopores O -
: O +
novel O +
materials O -
, O +
methods O -
, O +
and O +
applications O -
. O +

This O +
tutorial O +
review O +
will O +
introduce O +
and O +
explore O +
the O +
fundamental O +
aspects O +
of O +
nanopore O +
( O -
bio O -
) O -
sensing O -
, O +
fabrication O -
, O +
modification O -
, O +
and O +
the O +
emerging O +
technologies O +
and O +
applications O +
that O +
both O +
intrigue O +
and O +
inspire O +
those O +
working O +
in O +
and O +
around O +
the O +
field O -
. O +

Although O +
nanopores O +
can O +
be O +
classified O +
into O +
two O +
categories O -
, O +
solid O -
- O -
state O +
and O +
biological O -
, O +
they O +
are O +
essentially O +
two O +
sides O +
of O +
the O +
same O +
coin O -
. O +

For O +
instance O -
, O +
both O +
garner O +
popularity O +
due O +
to O +
their O +
ability O +
to O +
confine O +
analytes O +
of O +
interest O +
to O +
a O +
nanoscale O +
volume O -
. O +

Due O +
to O +
the O +
vast O +
diversity O +
of O +
nanopore O +
platforms O +
and O +
applications O -
, O +
no O +
single O +
review O +
can O +
cover O +
the O +
entire O +
landscape O +
of O +
published O +
work O +
in O +
the O +
field O -
. O +

Therefore O -
, O +
in O +
this O +
article O +
focus O +
will O +
be O +
placed O +
on O +
recent O +
advancements O +
and O +
developments O +
taking O +
place O +
in O +
the O +
field O +
of O +
solid O -
- O -
state O +
nanopores O -
. O +

It O +
should O +
be O +
stated O +
that O +
the O +
intention O +
of O +
this O +
tutorial O +
review O +
is O +
not O +
to O +
cite O +
all O +
articles O +
relating O +
to O +
solid O -
- O -
state O +
nanopores O -
, O +
but O +
rather O +
to O +
highlight O +
recent O -
, O +
select O +
developments O +
that O +
will O +
hopefully O +
benefit O +
the O +
new O +
and O +
seasoned O +
scientist O +
alike O -
. O +

Initially O +
we O +
begin O +
with O +
the O +
fundamentals O +
of O +
solid O -
- O -
state O +
nanopore O +
sensing O -
. O +

Then O +
the O +
spotlight O +
is O +
shone O +
on O +
the O +
sophisticated O +
fabrication O +
methods O +
that O +
have O +
their O +
origins O +
in O +
the O +
semiconductor O +
industry O -
. O +

One O +
inherent O +
advantage O +
of O +
solid O -
- O -
state O +
nanopores O +
is O +
in O +
the O +
ease O +
of O +
functionalizing O +
the O +
surface O +
with O +
a O +
range O +
of O +
molecules O +
carrying O +
functional O +
groups O -
. O +

Therefore O -
, O +
an O +
entire O +
section O +
is O +
devoted O +
to O +
highlighting O +
various O +
chemical O +
and O +
bio O -
- O -
molecular O +
modifications O +
and O +
explores O +
how O +
these O +
permit O +
the O +
development O +
of O +
novel O +
sensors O +
with O +
specific O +
targets O +
and O +
functions O -
. O +

The O +
review O +
is O +
completed O +
with O +
a O +
discussion O +
on O +
novel O +
detection O +
strategies O +
using O +
nanopores O -
. O +

Although O +
the O +
most O +
popular O +
mode O +
of O +
nanopore O +
sensing O +
is O +
based O +
upon O +
what O +
has O +
come O +
to O +
be O +
known O +
as O +
ionic O -
- O -
current O +
blockade O +
sensing O -
, O +
there O +
is O +
a O +
vast O -
, O +
growing O +
literature O +
based O +
around O +
exploring O +
alternative O +
detection O +
techniques O +
to O +
further O +
expand O +
on O +
the O +
versatility O +
of O +
the O +
sensors O -
. O +

Such O +
techniques O +
include O +
optical O -
, O +
electronic O -
, O +
and O +
force O +
based O +
methods O -
. O +

It O +
is O +
perhaps O +
fair O +
to O +
say O +
that O +
these O +
new O +
frontiers O +
have O +
caused O +
further O +
excitement O +
within O +
the O +
sensing O +
community O -
. O +

Wogonoside B-Chemical +
induces O +
autophagy O +
in O +
MDA O -
- O -
MB-231 O +
cells O +
by O +
regulating O +
MAPK O -
- O -
mTOR O +
pathway O -
. O +

Previous O +
studies O +
have O +
demonstrated O +
that O +
wogonoside B-Chemical -
, O +
a O +
bioactive O +
flavonoid B-Chemical +
extracted O +
from O +
the O +
root O +
of O +
Scutellaria O +
baicalensis O +
Gerogi O -
, O +
has O +
anti O -
- O -
inflammatory O +
and O +
anti O -
- O -
angiogenic O +
activities O -
. O +

In O +
this O +
study O -
, O +
we O +
evaluated O +
wogonoside B-Chemical -
- O -
induced O +
autophagy O +
on O +
human O +
breast O +
MDA O -
- O -
MB-231 O +
cells O -
. O +

We O +
report O +
that O +
wogonoside B-Chemical +
triggered O +
the O +
formation O +
of O +
microtubule O -
- O -
associated O +
protein O -
- O -
light O +
chain O +
3 O +
( O -
MAP O -
- O -
LC3 O -
) O +
positive O +
autophagosomes O +
and O +
the O +
accumulation O +
of O +
acidic O +
vesicular O +
and O +
autolysosomes O +
in O +
MDA O -
- O -
MB-231 O +
cells O -
. O +

In O +
addition O -
, O +
cells O +
treated O +
by O +
wogonoside B-Chemical +
developed O +
autophagosome O -
- O -
like O +
characteristics O -
, O +
including O +
single O +
and O +
double O +
membrane O +
vacuoles O +
containing O +
intact O +
and O +
degraded O +
cellular O +
debris O -
. O +

The O +
results O +
showed O +
that O +
wogonoside B-Chemical +
promotes O +
the O +
expression O +
of O +
LC3-II O +
and O +
Beclin-1 O -
. O +

Furthermore O -
, O +
wogonoside B-Chemical +
inhibited O +
cell O +
growth O +
of O +
MDA O -
- O -
MB-231 O +
cells O +
in O +
a O +
concentration- O +
and O +
time O -
- O -
dependent O +
manner O -
, O +
which O +
was O +
associated O +
with O +
wogonoside B-Chemical -
- O -
induced O +
autophagy O -
. O +

Wogonoside B-Chemical +
also O +
suppressed O +
the O +
activation O +
of O +
mammalian O +
target O +
of O +
rapamycin B-Chemical +
( O -
mTOR O -
) O +
and O +
p70-S6 O +
kinase O +
( O -
p70S6 O -
K O -
) O +
by O +
regulating O +
the O +
expression O +
of O +
the O +
extracellular O +
signal O -
- O -
regulated O +
kinase O +
( O -
ERK1 O -
/ O -
2 O -
) O +
and O +
p38 O +
involved O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O -
MAPK O -
) O +
signaling O +
pathway O -
. O +

Taken O +
together O -
, O +
these O +
results O +
suggest O +
that O +
wogonoside B-Chemical +
partially O +
inhibits O +
MDA O -
- O -
MB-231 O +
cell O +
growth O +
by O +
inducing O +
autophagy O +
through O +
the O +
MAPK O -
- O -
mTOR O +
pathway O +
and O +
may O +
be O +
a O +
promising O +
anti O -
- O -
tumor O +
agent O -
. O +

Water O +
extracts O +
of O +
tree O +
Hypericum O +
sps O -
. O +

protect O +
DNA O +
from O +
oxidative O +
and O +
alkylating O +
damage O +
and O +
enhance O +
DNA O +
repair O +
in O +
colon O +
cells O -
. O +

Diet O +
may O +
induce O +
colon O +
carcinogenesis O +
through O +
oxidative O +
or O +
alkylating O +
DNA O +
damage O -
. O +

However O -
, O +
diet O +
may O +
also O +
contain O +
anticarcinogenic O +
compounds O +
that O +
contribute O +
to O +
cancer O +
prevention O -
. O +

DNA O +
damage O +
prevention O +
and/or O +
induction O +
of O +
repair O +
are O +
two O +
important O +
mechanisms O +
involved O +
in O +
cancer O +
chemoprevention O +
by O +
dietary O +
compounds O -
. O +

Hypericum O +
sps O -
. O +
are O +
widely O +
used O +
in O +
traditional O +
medicine O +
to O +
prepare O +
infusions O +
due O +
to O +
their O +
beneficial O +
digestive O +
and O +
neurologic O +
effects O -
. O +

In O +
this O +
study O -
, O +
we O +
investigated O +
the O +
potential O +
of O +
water O +
extracts O +
from O +
three O +
Hypericum O +
sps O -
. O +

and O +
some O +
of O +
their O +
main O +
phenolic B-Chemical +
compounds O +
to O +
prevent O +
and O +
repair O +
oxidative O +
and O +
alkylating O +
DNA O +
damage O +
in O +
colon O +
cells O -
. O +

The O +
results O +
showed O +
that O +
water O +
extracts O +
of O +
Hypericum O +
perforatum O -
, O +
Hypericum O +
androsaemum O -
, O +
Hypericum O +
undulatum O -
, O +
quercetin B-Chemical +
and O +
rutin B-Chemical +
have O +
protective O +
effect O +
against O +
oxidative O +
DNA O +
damage O +
in O +
HT29 O +
cells O -
. O +

Protective O +
effect O +
was O +
also O +
observed O +
against O +
alkylating O +
DNA O +
damage O +
induced O +
by O +
methyl B-Chemical -
- I-Chemical -
methanesulfonate I-Chemical -
, O +
except O +
for O +
H. O +
androsaemum O -
. O +

With O +
regard O +
to O +
alkylating O +
damage O +
repair O +
H. O +
perforatum O -
, O +
H. O +
androsaemum O +
and O +
chlorogenic B-Chemical +
acid I-Chemical +
increased O +
repair O +
of O +
alkylating O +
DNA O +
damage O +
by O +
base O +
excision O +
repair O +
pathway O -
. O +

No O +
effect O +
was O +
observed O +
on O +
nucleotide B-Chemical +
excision O +
repair O +
pathway O -
. O +

Antigenotoxic O +
effects O +
of O +
Hypericum O +
sps O -
. O +

may O +
contribute O +
to O +
colon O +
cancer O +
prevention O +
and O +
the O +
high O +
amount O +
of O +
phenolic B-Chemical +
compounds O +
present O +
in O +
Hypericum O +
sps O -
. O +

play O +
an O +
important O +
role O +
in O +
DNA O +
protective O +
effects O -
. O +

Lattice O +
Microbes O -
: O +
high O -
- O -
performance O +
stochastic O +
simulation O +
method O +
for O +
the O +
reaction O -
- O -
diffusion O +
master O +
equation O -
. O +

Spatial O +
stochastic O +
simulation O +
is O +
a O +
valuable O +
technique O +
for O +
studying O +
reactions O +
in O +
biological O +
systems O -
. O +

With O +
the O +
availability O +
of O +
high O -
- O -
performance O +
computing O +
( O -
HPC O -
) O -
, O +
the O +
method O +
is O +
poised O +
to O +
allow O +
integration O +
of O +
data O +
from O +
structural O -
, O +
single O -
- O -
molecule O +
and O +
biochemical O +
studies O +
into O +
coherent O +
computational O +
models O +
of O +
cells O -
. O +

Here O -
, O +
we O +
introduce O +
the O +
Lattice O +
Microbes O +
software O +
package O +
for O +
simulating O +
such O +
cell O +
models O +
on O +
HPC O +
systems O -
. O +

The O +
software O +
performs O +
either O +
well O -
- O -
stirred O +
or O +
spatially O +
resolved O +
stochastic O +
simulations O +
with O +
approximated O +
cytoplasmic O +
crowding O +
in O +
a O +
fast O +
and O +
efficient O +
manner O -
. O +

Our O +
new O +
algorithm O +
efficiently O +
samples O +
the O +
reaction O -
- O -
diffusion O +
master O +
equation O +
using O +
NVIDIA O +
graphics O +
processing O +
units O +
and O +
is O +
shown O +
to O +
be O +
two O +
orders O +
of O +
magnitude O +
faster O +
than O +
exact O +
sampling O +
for O +
large O +
systems O +
while O +
maintaining O +
an O +
accuracy O +
of O +
! O +

0.1 O -
% O -
. O +

Display O +
of O +
cell O +
models O +
and O +
animation O +
of O +
reaction O +
trajectories O +
involving O +
millions O +
of O +
molecules O +
is O +
facilitated O +
using O +
a O +
plug O -
- O -
in O +
to O +
the O +
popular O +
VMD O +
visualization O +
platform O -
. O +

The O +
Lattice O +
Microbes O +
software O +
is O +
open O +
source O +
and O +
available O +
for O +
download O +
at O +
http://www.scs.illinois.edu/schulten/lm O +

Toxicological O +
and O +
mutagenic O +
analysis O +
of O +
Artemisia O +
dracunculus O +
( O -
tarragon O -
) O +
extract O -
. O +

Mutagenicity O +
and O +
liver O +
toxicity O +
of O +
the O +
herb O +
tarragon O +
( O -
Artemisia O +
dracunculus O -
) O +
were O +
evaluated O +
using O +
single O +
cell O +
gel O +
( O -
comet O -
) O +
electrophoresis O -
. O +

Ten O +
microlitres O +
aliquots O +
of O +
peripheral O +
venous O +
human O +
blood O +
were O +
incubated O +
with O +
tarragon O +
extract O -
, O +
saline O -
, O +
or O +
the O +
mutagen O +
sodium B-Chemical +
dichromate I-Chemical -
. O +

Cell O +
suspensions O +
dispersed O +
in O +
low O -
- O -
melting O +
agarose O +
were O +
electrophoresed O +
in O +
ethidium B-Chemical +
bromide I-Chemical -
. O +

The O +
resulting O +
DNA O +
migration O +
trails O +
were O +
obtained O +
using O +
fluorescent O +
microscopy O +
at O +
400 O -
× O +
magnification O -
, O +
and O +
graded O +
according O +
to O +
the O +
mutagenicity O +
index O +
( O -
MI O -
) O +
for O +
each O +
cell O +
incubation O +
condition O -
. O +

The O +
in O +
vivo O +
liver O +
toxicity O +
of O +
Artemisia O +
dracunculus O +
was O +
assessed O +
in O +
the O +
blood O +
of O +
mice O +
treated O +
orally O +
with O +
the O +
extract O +
of O +
the O +
herb O -
, O +
using O +
alanine B-Chemical +
aminotransferase O +
( O -
ALT O -
) O +
and O +
aspartate B-Chemical +
aminotransferase O +
( O -
AST O -
) O +
as O +
liver O +
function O +
indicators O -
. O +

Liver O +
morphology O +
was O +
assessed O +
using O +
hematoxylin B-Chemical +
and O +
eosin B-Chemical +
( O -
HE O -
) O +
staining O +
of O +
liver O +
tissue O -
. O +

The O +
present O +
study O +
demonstrated O +
a O +
direct O +
correlation O +
between O +
tarragon O +
extract O +
dosage O +
and O +
three O +
major O +
outcome O +
variables O -
: O +
MI O -
; O +
serum O +
liver O +
enzyme O +
activity O -
; O +
and O +
liver O +
histopathology O -
. O +

These O +
outcomes O +
are O +
possibly O +
due O +
to O +
the O +
presence O +
in O +
tarragon O +
of O +
methylchavicol B-Chemical +
and O +
other O +
genotoxic O +
compounds O -
. O +

These O +
findings O +
provide O +
a O +
preliminary O +
guide O +
for O +
risk O +
assessment O +
of O +
tarragon O +
in O +
diet O +
and O +
in O +
possible O +
therapeutic O +
applications O -
. O +

Phenolics B-Chemical +
profiles O +
of O +
olive O +
fruits O +
( O -
Olea O +
europaea O +
L. O -
) O +
and O +
oils O +
from O +
Ayvalık O -
, O +
Domat O +
and O +
Gemlik O +
varieties O +
at O +
different O +
ripening O +
stages O -
. O +

Phenolic B-Chemical +
compounds O +
in O +
olive O +
fruit O +
and O +
oils O +
obtained O +
from O +
Ayvalık O -
, O +
Domat O +
and O +
Gemlik O +
olive O +
varieties O +
collected O +
at O +
different O +
ripening O +
periods O +
were O +
evaluated O +
by O +
High O +
Performance O +
Liquid O +
Chromatography O +
( O -
HPLC O -
) O -
. O +

Gallic B-Chemical +
acid I-Chemical +
and O +
p B-Chemical -
- I-Chemical -
cumaric I-Chemical +
acid I-Chemical +
were O +
identified O +
for O +
Ayvalık O +
and O +
Domat O +
at O +
each O +
period O +
of O +
ripening O -
, O +
respectively O -
. O +

In O +
addition O -
, O +
gallic B-Chemical +
acid I-Chemical -
, O +
p B-Chemical -
- I-Chemical -
cumaric I-Chemical +
acid I-Chemical -
, O +
sinapinic B-Chemical +
and I-Chemical +
apigenin I-Chemical +
acids I-Chemical +
were O +
detected O +
in O +
Gemlik O +
olive O +
fruit O -
. O +

Hydroxytyrosol B-Chemical -
, O +
rutin B-Chemical -
, O +
oleoropein B-Chemical -
, O +
luteolin B-Chemical -
, O +
tyrosol B-Chemical -
, O +
vanilic B-Chemical +
acid I-Chemical +
and O +
gallic B-Chemical +
acid I-Chemical +
in O +
Ayvalık O +
olive O +
fruit O +
in O +
all O +
ripening O +
periods O +
were O +
determined O -
. O +

The O +
tyrasol B-Chemical +
contents O +
varied O +
between O +
0.18 O +
to O +
1.57mg O -
/ O -
kg O -
. O +

Luteolin B-Chemical +
contents O +
of O +
olive O +
oils O +
ranged O +
at O +
the O +
levels O +
between O +
0.12 O +
to O +
2.28mg O -
/ O -
kg O -
. O +

In O +
contrast O -
, O +
oils O +
had O +
the O +
lowest O +
syringic B-Chemical -
, I-Chemical +
p I-Chemical -
- I-Chemical -
cumaric I-Chemical -
, I-Chemical +
chlorogenic I-Chemical +
and I-Chemical +
ferulic I-Chemical +
acids I-Chemical -
. O +

Vanillic B-Chemical +
acid I-Chemical +
contents O +
of O +
oils O +
ranged O +
between O +
0.08 O +
to O +
2.38mg O -
/ O -
kg O -
. O +

Optimization O +
of O +
frozen O +
sour O +
cherries O +
vacuum O +
drying O +
process O -
. O +

The O +
objective O +
of O +
this O +
research O +
was O +
to O +
optimize O +
the O +
vacuum O -
- O -
drying O +
of O +
frozen O +
sour O +
cherries O +
in O +
order O +
to O +
preserve O +
health O -
- O -
beneficial O +
phytochemicals O -
, O +
as O +
well O +
as O +
textural O +
characteristics O -
. O +

Investigated O +
range O +
of O +
temperature O +
was O +
46 O -
- O -
74 O -
° O -
C O +
and O -
, O +
of O +
pressure O -
, O +
17 O -
- O -
583 O -
mbar O -
, O +
in O +
a O +
new O +
design O +
of O +
vacuum O -
- O -
dryer O +
equipment O -
. O +

The O +
total O +
solids O -
, O +
a O -
( O -
w O -
) O +
value O -
, O +
total O +
phenolics B-Chemical -
, O +
vitamin B-Chemical +
C I-Chemical -
, O +
antioxidant O +
activity O -
, O +
anthocyanin B-Chemical +
content O -
, O +
total O +
colour O +
change O +
and O +
firmness O +
were O +
used O +
as O +
quality O +
indicators O +
of O +
dried O +
sour O +
cherry O -
. O +

Within O +
the O +
experimental O +
range O +
of O +
studied O +
variables O -
, O +
the O +
optimum O +
conditions O +
of O +
54.03 O -
° O -
C O +
and O +
148.16 O -
mbar O +
were O +
established O +
for O +
vacuum O +
drying O +
of O +
sour O +
cherry O -
. O +

Separate O +
validation O +
experiments O +
were O +
conducted O -
, O +
under O +
optimum O +
conditions O -
, O +
to O +
verify O +
predictions O +
and O +
adequacy O +
of O +
the O +
second O -
- O -
order O +
polynomial O +
models O -
. O +

Under O +
these O +
optimal O +
conditions O -
, O +
the O +
predicted O +
amount O +
of O +
total O +
phenolics B-Chemical +
was O +
744 O -
mg O +
CAE O -
/ O -
100 O +
dw O -
, O +
vitamin B-Chemical +
C I-Chemical +
1.44mg O -
/ O -
100 O -
g O +
per O +
dry O +
weight O +
( O -
g O +
dw O -
) O -
, O +
anthocyanin B-Chemical +
content O +
125mg O -
/ O -
100 O -
g O +
dw O -
, O +
IC O -
( O -
50 O -
) O +
3.23mg O -
/ O -
ml O -
, O +
total O +
solids O +
70.72 O -
% O -
, O +
a O -
( O -
w O -
) O +
value O +
0.646 O -
, O +
total O +
colour O +
change O +
52.61 O +
and O +
firmness O +
3395.4 O -
g O -
. O +

The O +
investigated O +
parameters O +
had O +
a O +
significant O +
effect O +
on O +
the O +
quality O +
of O +
the O +
dried O +
sour O +
cherries O -
. O +

Occurrence O +
of O +
ochratoxin B-Chemical +
A I-Chemical +
in O +
cocoa O +
by O -
- O -
products O +
and O +
determination O +
of O +
its O +
reduction O +
during O +
chocolate O +
manufacture O -
. O +

This O +
work O +
reports O +
an O +
investigation O +
carried O +
out O +
to O +
assess O +
the O +
natural O +
occurrence O +
of O +
ochratoxin B-Chemical +
A I-Chemical +
in O +
168 O +
samples O +
from O +
different O +
fractions O +
obtained O +
during O +
the O +
technological O +
processing O +
of O +
cocoa O +
( O -
shell O -
, O +
nibs O -
, O +
liquor O -
, O +
butter O -
, O +
cake O +
and O +
cocoa O +
powder O -
) O +
and O +
the O +
reduction O +
of O +
ochratoxin B-Chemical +
A I-Chemical +
during O +
chocolate O +
manufacture O -
. O +

Ochratoxin B-Chemical +
A I-Chemical +
analyses O +
were O +
performed O +
with O +
immunoaffinity O +
columns O +
and O +
detection O +
by O +
high O +
performance O +
liquid O +
chromatography O -
. O +

Concerning O +
the O +
natural O +
ochratoxin B-Chemical +
A I-Chemical +
contamination O +
in O +
cocoa O +
by O -
- O -
products O -
, O +
the O +
highest O +
levels O +
of O +
ochratoxin B-Chemical +
A I-Chemical +
were O +
found O +
in O +
the O +
shell O -
, O +
cocoa O +
powder O +
and O +
cocoa O +
cake O -
. O +

The O +
cocoa O +
butter O +
was O +
the O +
least O +
contaminated O -
, O +
showing O +
that O +
ochratoxin B-Chemical +
A I-Chemical +
seems O +
to O +
remain O +
in O +
the O +
defatted O +
cocoa O +
solids O -
. O +

Under O +
the O +
technological O +
conditions O +
applied O +
during O +
the O +
manufacture O +
of O +
chocolate O +
in O +
this O +
study O +
and O +
the O +
level O +
of O +
contamination O +
present O +
in O +
the O +
cocoa O +
beans O -
, O +
this O +
experiment O +
demonstrated O +
that O +
93.6 O -
% O +
of O +
ochratoxin B-Chemical +
A I-Chemical +
present O +
in O +
the O +
beans O +
was O +
reduced O +
during O +
the O +
chocolate O +
producing O -
. O +

Diuretic O +
effects O +
of O +
cannabinoids O -
. O +

In O +
vivo O +
effects O +
of O +
cannabinoid O +
( O -
CB O -
) O +
agonists O +
are O +
often O +
assessed O +
using O +
four O +
well O -
- O -
established O +
measures O -
: O +
locomotor O +
activity O -
, O +
hypothermia O -
, O +
cataleptic O -
- O -
like O +
effects O -
, O +
and O +
analgesia O -
. O +

The O +
present O +
studies O +
demonstrate O +
that O +
doses O +
of O +
CB O +
agonists O +
that O +
produce O +
these O +
effects O +
also O +
reliably O +
increase O +
diuresis O -
. O +

Diuretic O +
effects O +
of O +
several O +
CB O +
agonists O +
were O +
measured O +
in O +
female O +
rats O +
over O +
2 O +
hours O +
immediately O +
after O +
drug O +
injection O -
, O +
and O +
results O +
were O +
compared O +
with O +
hypothermic O +
effects O -
. O +

Direct O -
- O -
acting O +
CB1 O +
agonists O -
, O +
including O +
Δ B-Chemical -
( I-Chemical -
9 I-Chemical -
) I-Chemical -
-tetrahydrocannabinol I-Chemical -
, O +
WIN B-Chemical +
55,212 I-Chemical +
[ O -
R- B-Chemical -
( I-Chemical -
1 I-Chemical -
) I-Chemical -
- I-Chemical -
[ I-Chemical -
2,3-dihydro-5-methyl-3- I-Chemical -
[ I-Chemical -
( I-Chemical -
morpholinyl I-Chemical -
) I-Chemical -
methyl I-Chemical -
] I-Chemical -
pyrrolo I-Chemical -
[ I-Chemical -
1,2,3-de I-Chemical -
] I-Chemical -
-1,4-benzoxazinyl I-Chemical -
] I-Chemical -
- I-Chemical -
( I-Chemical -
1-naphthalenyl I-Chemical -
) I-Chemical -
methanone I-Chemical +
mesylate I-Chemical -
] O -
, O +
AM2389 B-Chemical +
[ O -
9β B-Chemical -
- I-Chemical -
hydroxy-3- I-Chemical -
( I-Chemical -
1-hexyl I-Chemical -
- I-Chemical -
cyclobut-1-yl I-Chemical -
) I-Chemical -
-hexahydrocannabinol I-Chemical -
] O -
, O +
and O +
AM4054 B-Chemical +
[ O -
9β- B-Chemical -
( I-Chemical -
hydroxymethyl I-Chemical -
) I-Chemical -
-3- I-Chemical -
( I-Chemical -
1-adamantyl I-Chemical -
) I-Chemical -
-hexahydrocannabinol I-Chemical -
] O -
, O +
produced O +
dose O -
- O -
dependent O +
increases O +
in O +
diuresis O +
and O +
decreases O +
in O +
colonic O +
temperature O -
, O +
with O +
slightly O +
lower O +
ED O -
( O -
50 O -
) O +
values O +
for O +
diuresis O +
than O +
for O +
hypothermia O -
. O +

The O +
highest O +
doses O +
of O +
cannabinoid O +
drugs O +
yielded O -
, O +
on O +
average O -
, O +
26 O -
- O -
32 O +
g O -
/ O -
kg O +
urine O -
; O +
comparable O +
effects O +
were O +
obtained O +
with O +
10 O +
mg O -
/ O -
kg O +
furosemide B-Chemical +
and O +
3.0 O +
mg O -
/ O -
kg O +
trans- B-Chemical -
( I-Chemical -
- I-Chemical -
) I-Chemical -
-3,4-dichloro I-Chemical -
- I-Chemical -
N I-Chemical -
- I-Chemical -
methyl I-Chemical -
- I-Chemical -
N- I-Chemical -
[ I-Chemical -
2- I-Chemical -
( I-Chemical -
1-pyrrolidinyl I-Chemical -
) I-Chemical -
cyclohexyl I-Chemical -
] I-Chemical -
benzeneacetamide I-Chemical +
( O -
U50 B-Chemical -
- I-Chemical -
488 I-Chemical -
) O -
. O +

Methanandamide B-Chemical +
( O -
10.0 O +
mg O -
/ O -
kg O -
) O +
had O +
lesser O +
effect O +
than O +
other O +
CB O +
agonists O -
, O +
and O +
the O +
CB2 O +
agonist O +
AM1241 B-Chemical +
[ O -
1- B-Chemical -
( I-Chemical -
methylpiperidin-2-ylmethyl I-Chemical -
) I-Chemical -
-3- I-Chemical -
( I-Chemical -
2-iodo-5-nitrobenzoyl I-Chemical -
) I-Chemical -
indole I-Chemical -
] O -
, O +
the O +
anandamide B-Chemical +
transport O +
inhibitor O +
AM404 B-Chemical -
, O +
and O +
the O +
CB O +
antagonist O +
rimonabant B-Chemical +
did O +
not O +
have O +
diuretic O +
effects O -
. O +

In O +
further O +
studies O -
, O +
the O +
diuretic O +
effects O +
of O +
the O +
CB1 O +
agonist O +
AM4054 B-Chemical +
were O +
similar O +
in O +
male O +
and O +
female O +
rats O -
, O +
displayed O +
a O +
relatively O +
rapid O +
onset O +
to O +
action O -
, O +
and O +
were O +
dose O -
- O -
dependently O +
antagonized O +
by O +
30 O +
minutes O +
pretreatment O +
with O +
rimonabant B-Chemical -
, O +
but O +
not O +
by O +
the O +
vanilloid B-Chemical +
receptor O +
type O +
I O +
antagonist O +
capsazepine B-Chemical -
, O +
nor O +
were O +
the O +
effects O +
of O +
WIN B-Chemical +
55,212 I-Chemical +
antagonized O +
by O +
the O +
CB2 O +
antagonist O +
AM630 B-Chemical +
[ O -
( B-Chemical -
6-iodo-2-methyl-1- I-Chemical -
[ I-Chemical -
2- I-Chemical -
( I-Chemical -
4-morpholinyl I-Chemical -
) I-Chemical -
ethyl I-Chemical -
] I-Chemical -
-1H I-Chemical -
- I-Chemical -
indol-3-yl I-Chemical -
] I-Chemical -
( I-Chemical -
4-methoxyphenyl I-Chemical -
) I-Chemical +
methanone I-Chemical -
) I-Chemical -
] O -
. O +

These O +
data O +
indicate O +
that O +
cannabinoids O +
have O +
robust O +
diuretic O +
effects O +
in O +
rats O +
that O +
are O +
mediated O +
via O +
CB1 O +
receptor O +
mechanisms O -
. O +

The O +
PNarec O +
method O +
for O +
detection O +
of O +
ancient O +
recombinations O +
through O +
phylogenetic O +
network O +
analysis O -
. O +

Recombinations O +
are O +
known O +
to O +
disrupt O +
bifurcating O +
tree O +
structure O +
of O +
gene O +
genealogies O -
. O +

Although O +
recently O +
occurred O +
recombinations O +
are O +
easily O +
detectable O +
by O +
using O +
conventional O +
methods O -
, O +
recombinations O +
may O +
have O +
occurred O +
at O +
any O +
time O -
. O +

We O +
devised O +
a O +
new O +
method O +
for O +
detecting O +
ancient O +
recombinations O +
through O +
phylogenetic O +
network O +
analysis O -
, O +
and O +
detected O +
five O +
ancient O +
recombinations O +
in O +
gibbon O +
ABO O +
blood O +
group O +
genes O +
[ O -
Kitano O +
et O +
al. O -
, O +
2009 O -
. O +

Mol O -
. O +

Phylogenet O -
. O +

Evol O -
. O -
, O +
51 O -
, O +
465 O -
- O -
471 O -
] O -
. O +

We O +
present O +
applications O +
of O +
this O +
method O -
, O +
now O +
named O +
as O +
" O -
PNarec O -
" O -
, O +
to O +
various O +
virus O +
sequences O +
as O +
well O +
as O +
HLA O +
genes O -
. O +

Association O +
analysis O +
between O +
K O +
and O +
-116A O +
variants O +
of O +
butyrylcholinesterase O +
and O +
Alzheimer O -
's O +
disease O +
in O +
a O +
Brazilian O +
population O -
. O +

In O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O +
a O +
reduction O +
in O +
acetylcholinesterase O +
( O -
AChE O -
) O +
and O +
an O +
increase O +
in O +
butyrylcholinesterase O +
( O -
BChE O -
) O +
activity O +
are O +
observed O -
. O +

K O +
variant O +
( O -
539 O -
T O -
) O +
is O +
the O +
most O +
common O +
variant O +
of O +
the O +
BCHE O +
gene O +
and O -
, O +
although O +
controversial O -
, O +
several O +
studies O +
reported O +
association O +
between O +
K O +
variant O +
and O +
AD O -
. O +

Previous O +
results O +
showed O +
that O +
the O +
K O +
variant O +
alone O +
is O +
not O +
capable O +
of O +
diminishing O +
BChE O +
activity O -
, O +
depending O +
on O +
the O +
presence O +
of O +
the O +
-116A O +
variant O -
. O +

Considering O +
that O -
, O +
we O +
conducted O +
a O +
case O -
- O -
control O +
association O +
study O +
using O +
a O +
clinically O +
well O +
defined O +
group O +
of O +
AD O +
patients O +
( O -
n=82 O -
) O +
and O +
age O +
and O +
sex O +
matched O +
control O +
subjects O +
( O -
EC O -
; O +
n=78 O -
) O +
in O +
order O +
to O +
test O +
the O +
association O +
with O +
these O +
variations O +
of O +
BCHE O +
gene O +
in O +
a O +
Brazilian O +
population O -
. O +

The O +
allele O -
, O +
genotype O +
and O +
haplotype O +
frequencies O +
of O +
the O +
K O +
and O +
the O +
-116A O +
variants O +
of O +
BCHE O +
gene O +
were O +
not O +
significantly O +
different O +
between O +
cases O +
and O +
controls O -
. O +

Although O +
not O +
reaching O +
statistical O +
significance O -
, O +
the O +
results O +
suggested O +
that O +
the O +
presence O +
of O +
-116A O +
variant O +
may O +
have O +
a O +
protective O +
effect O +
against O +
AD O -
. O +

The O +
association O +
of O +
the O +
K O +
variant O +
with O +
AD O +
in O +
a O +
controversial O +
manner O +
in O +
different O +
surveys O +
is O +
probably O +
caused O +
by O +
its O +
linkage O +
disequilibrium O +
with O +
-116A O +
that O -
, O +
by O +
reducing O +
BChE O +
activity O -
, O +
potentially O +
increases O +
cholinergic O +
transmission O +
in O +
comparison O +
with O +
usual O +
genotypes O -
. O +

Methamphetamine B-Chemical +
regulation O +
of O +
sulfotransferase O +
1A1 O +
and O +
2A1 O +
expression O +
in O +
rat O +
brain O +
sections O -
. O +

Sulfotransferase O +
catalyzed O +
sulfation O +
regulates O +
the O +
biological O +
activities O +
of O +
various O +
neurotransmitters O -
/ O -
hormones O +
and O +
detoxifies O +
xenobiotics O -
. O +

Rat O +
sulfotransferase O +
rSULT1A1 O +
catalyzes O +
the O +
sulfation O +
of O +
neurotransmitters O +
and O +
xenobiotic O +
phenolic B-Chemical +
compounds O -
. O +

rSULT2A1 O +
catalyzes O +
the O +
sulfation O +
of O +
hydroxysteroids B-Chemical +
and O +
xenobiotic O +
alcoholic B-Chemical +
compounds O -
. O +

In O +
this O +
work O -
, O +
Western O +
blot O +
and O +
real O -
- O -
time O +
RT O -
- O -
PCR O +
were O +
used O +
to O +
investigate O +
the O +
effect O +
of O +
methamphetamine B-Chemical +
on O +
rSULT1A1 O +
and O +
rSULT2A1 O +
protein O +
and O +
mRNA O +
expression O +
in O +
rat O +
cerebellum O -
, O +
frontal O +
cortex O -
, O +
hippocampus O -
, O +
and O +
striatum O -
. O +

After O +
1-day O +
treatment O -
, O +
significant O +
induction O +
of O +
rSULT1A1 O +
was O +
observed O +
only O +
in O +
the O +
cerebellum O -
; O +
rSULT2A1 O +
was O +
induced O +
significantly O +
in O +
the O +
cerebellum O -
, O +
frontal O +
cortex O -
, O +
and O +
hippocampus O -
. O +

After O +
7 O +
days O +
of O +
exposure O -
, O +
rSULT1A1 O +
was O +
induced O +
in O +
the O +
cerebellum O -
, O +
frontal O +
cortex O -
, O +
and O +
hippocampus O -
, O +
while O +
rSULT2A1 O +
was O +
induced O +
significantly O +
in O +
all O +
four O +
regions O -
. O +

Western O +
blot O +
results O +
agreed O +
with O +
the O +
real O -
- O -
time O +
RT O -
- O -
PCR O +
results O -
, O +
suggesting O +
that O +
the O +
induction O +
occurred O +
at O +
the O +
gene O +
transcriptional O +
level O -
. O +

Results O +
indicate O +
that O +
rSULT1A1 O +
and O +
rSULT2A1 O +
are O +
expressed O +
in O +
rat O +
frontal O +
cortex O -
, O +
cerebellum O -
, O +
striatum O -
, O +
and O +
hippocampus O -
. O +

rSULT1A1 O +
and O +
rSULT2A1are O +
inducible O +
by O +
methamphetamine B-Chemical +
in O +
rat O +
brain O +
sections O +
in O +
a O +
time O +
dependable O +
manner O -
. O +

rSULT2A1 O +
is O +
more O +
inducible O +
than O +
rSULT1A1 O +
by O +
methamphetamine B-Chemical +
in O +
rat O +
brain O +
sections O -
. O +

Induction O +
activity O +
of O +
methamphetamine B-Chemical +
is O +
in O +
the O +
order O +
of O +
cerebellum O -
> O -
frontal O +
cortex O -
, O +
hippocampus O -
> O -
striatum O -
. O +

These O +
results O +
suggest O +
that O +
the O +
physiological O +
functions O +
of O +
rSULT1A1 O +
and O +
rSULT2A1 O +
in O +
different O +
brain O +
regions O +
can O +
be O +
affected O +
by O +
methamphetamine B-Chemical -
. O +

Nanostructured O +
superhydrophobic O +
substrates O +
trigger O +
the O +
development O +
of O +
3D O +
neuronal O +
networks O -
. O +

The O +
generation O +
of O +
3D O +
networks O +
of O +
primary O +
neurons O +
is O +
a O +
big O +
challenge O +
in O +
neuroscience O -
. O +

Here O -
, O +
a O +
novel O +
method O +
is O +
presented O +
for O +
a O +
3D O +
neuronal O +
culture O +
on O +
superhydrophobic O +
( O -
SH O -
) O +
substrates O -
. O +

How O +
nano O -
- O -
patterned O +
SH O +
devices O +
stimulate O +
neurons O +
to O +
build O +
3D O +
networks O +
is O +
investigated O -
. O +

Scanning O +
electron O +
microscopy O +
and O +
confocal O +
imaging O +
show O +
that O +
soon O +
after O +
plating O +
neurites O +
adhere O +
to O +
the O +
nanopatterned O +
pillar O +
sidewalls O +
and O +
they O +
are O +
subsequently O +
pulled O +
between O +
pillars O +
in O +
a O +
suspended O +
position O -
. O +

These O +
neurons O +
display O +
an O +
enhanced O +
survival O +
rate O +
compared O +
to O +
standard O +
cultures O +
and O +
develop O +
mature O +
networks O +
with O +
physiological O +
excitability O -
. O +

These O +
findings O +
underline O +
the O +
importance O +
of O +
using O +
nanostructured O +
SH O +
surfaces O +
for O +
directing O +
3D O +
neuronal O +
growth O -
, O +
as O +
well O +
as O +
for O +
the O +
design O +
of O +
biomaterials O +
for O +
neuronal O +
regeneration O -
. O +

The O +
GARD O +
assay O +
for O +
assessment O +
of O +
chemical O +
skin O +
sensitizers O -
. O +

Allergic O +
contact O +
dermatitis O +
is O +
a O +
skin O +
disease O +
caused O +
by O +
an O +
immunologic O +
reaction O +
to O +
low O +
molecular O +
weight O +
compounds O -
, O +
so O +
called O +
haptens O -
. O +

These O +
substances O +
are O +
commonly O +
present O +
in O +
products O +
used O +
by O +
humans O +
in O +
daily O +
life O -
, O +
such O +
as O +
in O +
cosmetics O +
and O +
fragrances O -
, O +
as O +
well O +
as O +
within O +
chemical O +
industry O +
and O +
in O +
pharmaceuticals O -
. O +

The O +
frequent O +
usage O +
of O +
these O +
compounds O +
in O +
different O +
applications O +
has O +
led O +
to O +
increasing O +
incidences O +
of O +
allergic O +
contact O +
dermatitis O -
, O +
which O +
has O +
become O +
a O +
substantial O +
economic O +
burden O +
for O +
society O -
. O +

As O +
a O +
consequence O -
, O +
chemicals O +
are O +
routinely O +
tested O +
for O +
their O +
ability O +
to O +
induce O +
skin O +
sensitization O -
, O +
using O +
animal O +
models O +
such O +
as O +
the O +
murine O +
Local O +
Lymph O +
Node O +
Assay O -
. O +

However O -
, O +
recent O +
legislations O +
regulate O +
the O +
use O +
of O +
animal O +
models O +
within O +
chemical O +
testing O -
. O +

Thus O -
, O +
there O +
is O +
an O +
urgent O +
need O +
for O +
in O +
vitro O +
alternatives O +
to O +
replace O +
these O +
assays O +
for O +
safety O +
assessment O +
of O +
chemicals O -
. O +

Recently O -
, O +
we O +
identified O +
a O +
signature O +
of O +
predictive O +
genes O -
, O +
which O +
are O +
differentially O +
regulated O +
in O +
the O +
human O +
myeloid O +
cell O -
- O -
line O +
MUTZ-3 O +
when O +
stimulated O +
with O +
sensitizing O +
compounds O +
compared O +
to O +
non O -
- O -
sensitizing O +
compounds O -
. O +

Based O +
on O +
these O +
findings O -
, O +
we O +
have O +
formulated O +
a O +
test O +
strategy O +
for O +
assessment O +
of O +
sensitizing O +
compounds O -
, O +
called O +
Genomic O +
Allergen O +
Rapid O +
Detection O -
, O +
GARD O -
. O +

In O +
this O +
paper O -
, O +
we O +
present O +
a O +
detailed O +
method O +
description O +
of O +
how O +
the O +
assay O +
should O +
be O +
performed O -
. O +

Rational O +
design O +
of O +
apoptosis O +
signal O -
- O -
regulating O +
kinase O +
1 O +
inhibitors O -
: O +
discovering O +
novel O +
structural O +
scaffold O -
. O +

Increased O +
activity O +
of O +
apoptosis O +
signal O -
- O -
regulating O +
kinase O +
1 O +
( O -
ASK1 O -
) O +
is O +
associated O +
with O +
a O +
number O +
of O +
human O +
disorders O +
and O +
the O +
inhibitors O +
of O +
ASK1 O +
may O +
become O +
important O +
compounds O +
for O +
pharmaceutical O +
application O -
. O +

Here O +
we O +
report O +
novel O +
ASK1 O +
inhibitor O +
scaffold O -
, O +
namely O +
5- B-Chemical -
( I-Chemical -
5-Phenyl I-Chemical -
- I-Chemical -
furan-2-ylmethylene I-Chemical -
) I-Chemical -
-2-thioxo I-Chemical -
- I-Chemical -
thiazolidin-4-one I-Chemical -
, O +
that O +
has O +
been O +
identified O +
using O +
virtual O +
screening O +
and O +
biochemical O +
tests O -
. O +

A O +
series O +
of O +
derivatives O +
has O +
been O +
synthesized O +
and O +
evaluated O +
in O +
vitro O +
towards O +
human O +
protein O +
kinase O +
ASK1 O -
. O +

It O +
was O +
revealed O +
that O +
the O +
most O +
active O +
compounds O +
4- B-Chemical -
( I-Chemical -
( I-Chemical -
5Z I-Chemical -
) I-Chemical -
-5- I-Chemical -
{ I-Chemical -
[ I-Chemical -
5- I-Chemical -
( I-Chemical -
4-bromophenyl I-Chemical -
) I-Chemical -
-2-furyl I-Chemical -
] I-Chemical -
methylene I-Chemical -
} I-Chemical -
-4-oxo-2-thioxo-1,3-thiazolidin-3-yl I-Chemical -
) I-Chemical -
butanoic I-Chemical +
acid I-Chemical +
and O +
6- B-Chemical -
( I-Chemical -
( I-Chemical -
5Z I-Chemical -
) I-Chemical -
-5- I-Chemical -
{ I-Chemical -
[ I-Chemical -
5- I-Chemical -
( I-Chemical -
4-bromophenyl I-Chemical -
) I-Chemical -
-2-furyl I-Chemical -
] I-Chemical -
methylene I-Chemical -
} I-Chemical -
-4-oxo-2-thioxo-1,3-thiazolidin-3-yl I-Chemical -
) I-Chemical -
hexanoic I-Chemical +
acid I-Chemical +
inhibit O +
ASK1 O +
with O +
IC50 O +
of O +
0.2 O +
μM. O +
Structure O -
- O -
activity O +
relationships O +
of O +
33 O +
derivatives O +
of O +
5- B-Chemical -
( I-Chemical -
5-Phenyl I-Chemical -
- I-Chemical -
furan-2-ylmethylene I-Chemical -
) I-Chemical -
-2-thioxo I-Chemical -
- I-Chemical -
thiazolidin-4-one I-Chemical +
have O +
been O +
studied O +
and O +
binding O +
mode O +
of O +
this O +
chemical O +
class O +
has O +
been O +
predicted O -
. O +

Identification O +
and O +
characterization O +
of O +
novel O +
catalytic O +
bioscavengers O +
of O +
organophosphorus B-Chemical +
nerve O +
agents O -
. O +

In O +
an O +
effort O +
to O +
discover O +
novel O +
catalytic O +
bioscavengers O +
of O +
organophosphorus B-Chemical +
( O -
OP O -
) O +
nerve O +
agents O -
, O +
cell O +
lysates O +
from O +
a O +
diverse O +
set O +
of O +
bacterial O +
strains O +
were O +
screened O +
for O +
their O +
capacity O +
to O +
hydrolyze O +
the O +
OP O +
nerve O +
agents O +
VX O -
, O +
VR O -
, O +
and O +
soman B-Chemical +
( O -
GD O -
) O -
. O +

The O +
library O +
of O +
bacterial O +
strains O +
was O +
identified O +
using O +
both O +
random O +
and O +
rational O +
approaches O -
. O +

Specifically O -
, O +
two O +
representative O +
strains O +
from O +
eight O +
categories O +
of O +
extremophiles O +
were O +
chosen O +
at O +
random O -
. O +

For O +
the O +
rational O +
approach O -
, O +
the O +
protein O +
sequence O +
of O +
organophosphorus B-Chemical +
hydrolase O +
( O -
OPH O -
) O +
from O +
Brevundimonas O +
diminuta O +
was O +
searched O +
against O +
a O +
non O -
- O -
redundant O +
protein O +
database O +
using O +
the O +
Basic O +
Local O +
Alignment O +
Search O +
Tool O +
to O +
find O +
regions O +
of O +
local O +
similarity O +
between O +
sequences O -
. O +

Over O +
15 O +
protein O +
sequences O +
with O +
significant O +
sequence O +
similarity O +
to O +
OPH O +
were O +
identified O +
from O +
a O +
variety O +
of O +
bacterial O +
strains O -
. O +

Some O +
of O +
these O +
matches O +
were O +
based O +
on O +
predicted O +
protein O +
structures O +
derived O +
from O +
bacterial O +
genome O +
sequences O +
rather O +
than O +
from O +
bona O +
fide O +
proteins O +
isolated O +
from O +
bacteria O -
. O +

Of O +
the O +
25 O +
strains O +
selected O +
for O +
nerve O +
agent O +
testing O -
, O +
three O +
bacterial O +
strains O +
had O +
measurable O +
levels O +
of O +
OP O +
hydrolase O +
activity O -
. O +

These O +
strains O +
are O +
Ammoniphilus O +
oxalaticus O -
, O +
Haloarcula O +
sp. O -
, O +
and O +
Micromonospora O +
aurantiaca O -
. O +

Lysates O +
from O +
A. O +
oxalaticus O +
had O +
detectable O +
hydrolysis O +
of O +
VR O -
; O +
Haloarcula O +
sp. O +
had O +
appreciable O +
hydrolysis O +
of O +
VX O +
and O +
VR O -
, O +
whereas O +
lysates O +
from O +
M. O +
aurantiaca O +
had O +
detectable O +
hydrolysis O +
of O +
VR O +
and O +
GD O -
. O +

Establishment O +
of O +
an O +
in O +
vitro O +
photoallergy O +
test O +
using O +
NCTC2544 O +
cells O +
and O +
IL-18 O +
production O -
. O +

Differentiation O +
between O +
photoallergenic O +
and O +
phototoxic O +
reactions O +
induced O +
by O +
low O +
molecular O +
weight O +
compounds O +
represents O +
a O +
current O +
problem O -
. O +

The O +
use O +
of O +
keratinocytes O +
as O +
a O +
potential O +
tool O +
for O +
the O +
detection O +
of O +
photoallergens O +
as O +
opposed O +
to O +
photoirritants O +
is O +
considered O +
an O +
interesting O +
strategy O +
for O +
developing O +
in O +
vitro O +
methods O -
. O +

We O +
have O +
previously O +
demonstrated O +
the O +
possibility O +
to O +
use O +
the O +
human O +
keratinocyte O +
cell O +
line O +
NCTC2455 O +
and O +
the O +
production O +
of O +
interleukin-18 O +
( O -
IL-18 O -
) O +
to O +
screen O +
low O +
molecular O +
weight O +
sensitizers O -
. O +

The O +
purpose O +
of O +
this O +
work O +
was O +
to O +
explore O +
the O +
possibility O +
to O +
use O +
the O +
NCTC2544 O +
assay O +
to O +
identify O +
photoallergens O +
and O +
discriminate O +
from O +
phototoxic O +
chemicals O -
. O +

First O -
, O +
we O +
identified O +
suitable O +
condition O +
of O +
UV O -
- O -
irradiation O +
( O -
3.5 O +
J O -
/ O -
cm O -
( O -
2 O -
) O -
) O +
by O +
investigating O +
the O +
effect O +
of O +
UVA O +
irradiation O +
on O +
intracellular O +
IL-18 O +
on O +
untreated O +
or O +
chloropromazine B-Chemical +
( O -
a O +
representative O +
phototoxic O +
compound O -
) O -
-treated O +
NCTC2544 O +
cells O -
. O +

Then O -
, O +
the O +
effect O +
of O +
UVA O -
- O -
irradiation O +
over O +
NCTC2544 O +
cells O +
treated O +
with O +
increasing O +
concentrations O +
of O +
15 O +
compounds O +
including O +
photoallergens O +
( O -
benzophenone B-Chemical -
, O +
4-ter B-Chemical -
- I-Chemical -
butyl-4-methoxy I-Chemical -
- I-Chemical -
dibenzoylmethane I-Chemical -
, I-Chemical +
2-ethylexyl I-Chemical -
- I-Chemical -
p I-Chemical -
- I-Chemical -
methoxycinnamate I-Chemical -
, O +
ketoprofen B-Chemical -
, O +
6-methylcumarin B-Chemical -
) O -
; O +
photoirritant O +
and O +
photoallergen O +
( O -
4-aminobenzoic B-Chemical +
acid I-Chemical -
, O +
chlorpromazine B-Chemical -
, O +
promethazine B-Chemical -
) O -
; O +
photoirritants O +
( O -
acridine B-Chemical -
, O +
ibuprofen B-Chemical -
, O +
8-methoxypsoralen B-Chemical -
, O +
retinoic B-Chemical +
acid I-Chemical -
) O -
; O +
and O +
negative O +
compounds O +
( O -
lactic B-Chemical +
acid I-Chemical -
, O +
SDS B-Chemical +
and O +
p B-Chemical -
- I-Chemical -
phenilendiamine I-Chemical -
) O +
was O +
investigated O -
. O +

Twenty O -
- O -
four O +
hours O +
after O +
exposure O -
, O +
cytotoxicity O +
was O +
evaluated O +
by O +
the O +
MTT B-Chemical +
assay O +
or O +
LDH O +
leakage O -
, O +
while O +
ELISA O +
was O +
used O +
to O +
measure O +
the O +
production O +
of O +
IL-18 O -
. O +

At O +
the O +
maximal O +
concentration O +
assayed O +
with O +
non O -
- O -
cytotoxic O +
effects O +
( O -
CV80 O +
under O +
irradiated O +
condition O -
) O -
, O +
all O +
tested O +
photoallergens O +
induced O +
a O +
significant O +
and O +
a O +
dose O -
- O -
dependent O +
increase O +
of O +
intracellular O +
IL-18 O +
following O +
UVA O +
irratiation O -
, O +
whereas O +
photoirritants O +
failed O -
. O +

We O +
suggest O +
that O +
this O +
system O +
may O +
be O +
useful O +
for O +
the O +
in O +
vitro O +
evaluation O +
of O +
the O +
photoallergic O +
potential O +
of O +
chemicals O -
. O +

Differing O +
effects O +
of O +
PTH O +
1 O -
- O -
34 O -
, O +
PTH O +
1 O -
- O -
84 O -
, O +
and O +
zoledronic B-Chemical +
acid I-Chemical +
on O +
bone O +
microarchitecture O +
and O +
estimated O +
strength O +
in O +
postmenopausal O +
women O +
with O +
osteoporosis O -
: O +
an O +
18-month O +
open O -
- O -
labeled O +
observational O +
study O +
using O +
HR O -
- O -
pQCT O -
. O +

Whereas O +
the O +
beneficial O +
effects O +
of O +
intermittent O +
treatment O +
with O +
parathyroid O +
hormone O +
( O -
PTH O -
) O +
( O -
intact O +
PTH O +
1 O -
- O -
84 O +
or O +
fragment O +
PTH O +
1 O -
- O -
34 O -
, O +
teriparatide O -
) O +
on O +
vertebral O +
strength O +
is O +
well O +
documented O -
, O +
treatment O +
may O +
not O +
be O +
equally O +
effective O +
in O +
the O +
peripheral O +
skeleton O -
. O +

We O +
used O +
high O -
- O -
resolution O +
peripheral O +
quantitative O +
computed O +
tomography O +
( O -
HR O -
- O -
pQCT O -
) O +
to O +
detail O +
effects O +
on O +
compartmental O +
geometry O -
, O +
density O -
, O +
and O +
microarchitecture O +
as O +
well O +
as O +
finite O +
element O +
( O -
FE O -
) O +
estimated O +
integral O +
strength O +
at O +
the O +
distal O +
radius O +
and O +
tibia O +
in O +
postmenopausal O +
osteoporotic O +
women O +
treated O +
with O +
PTH O +
1 O -
- O -
34 O +
( O -
20 O +
µg O +
sc O +
daily O -
, O +
n O +
= O +
18 O -
) O +
or O +
PTH O +
1 O -
- O -
84 O +
( O -
100 O +
µg O +
sc O +
daily O -
, O +
n O +
= O +
20 O -
) O +
for O +
18 O +
months O +
in O +
an O +
open O -
- O -
label O -
, O +
nonrandomized O +
study O -
. O +

A O +
group O +
of O +
postmenopausal O +
osteoporotic O +
women O +
receiving O +
zoledronic B-Chemical +
acid I-Chemical +
( O -
5 O +
mg O +
infusion O +
once O +
yearly O -
, O +
n O +
= O +
33 O -
) O +
was O +
also O +
included O -
. O +

Anabolic O +
therapy O +
increased O +
cortical O +
porosity O +
in O +
radius O +
( O -
PTH O +
1 O -
- O -
34 O +
32 O +
± O +
37 O -
% O -
, O +
PTH O +
1 O -
- O -
84 O +
39 O +
± O +
32 O -
% O -
, O +
both O +
p O +
< O +
0.001 O -
) O +
and O +
tibia O +
( O -
PTH O +
1 O -
- O -
34 O +
13 O +
± O +
27 O -
% O -
, O +
PTH O +
1 O -
- O -
84 O +
15 O +
± O +
22 O -
% O -
, O +
both O +
p O +
< O +
0.001 O -
) O +
with O +
corresponding O +
declines O +
in O +
cortical O +
density O -
. O +

With O +
PTH O +
1 O -
- O -
34 O -
, O +
increases O +
in O +
cortical O +
thickness O +
in O +
radius O +
( O -
2.0 O +
± O +
3.8 O -
% O -
, O +
p O +
< O +
0.05 O -
) O +
and O +
tibia O +
( O -
3.8 O +
± O +
10.4 O -
% O -
, O +
p O +
< O +
0.01 O -
) O +
were O +
found O -
. O +

Trabecular O +
number O +
increased O +
in O +
tibia O +
with O +
both O +
PTH O +
1 O -
- O -
34 O +
( O -
4.2 O +
± O +
7.1 O -
% O -
, O +
p O +
< O +
0.05 O -
) O +
and O +
PTH O +
1 O -
- O -
84 O +
( O -
5.3 O +
± O +
8.3 O -
% O -
, O +
p O +
< O +
0.01 O -
) O -
. O +

Zoledronic B-Chemical +
acid I-Chemical +
did O +
not O +
impact O +
cortical O +
porosity O +
at O +
either O +
site O +
but O +
increased O +
cortical O +
thickness O +
( O -
3.0 O +
± O +
3.5 O -
% O -
, O +
p O +
< O +
0.01 O -
) O -
, O +
total O +
( O -
2.7 O +
± O +
2.5 O -
% O -
, O +
p O +
< O +
0.001 O -
) O +
and O +
cortical O +
density O +
( O -
1.5 O +
± O +
2.0 O -
% O -
, O +
p O +
< O +
0.01 O -
) O +
in O +
tibia O +
as O +
well O +
as O +
trabecular O +
volume O +
fraction O +
in O +
radius O +
( O -
2.5 O +
± O +
5.1 O -
% O -
, O +
p O +
< O +
0.05 O -
) O +
and O +
tibia O +
( O -
2.2 O +
± O +
2.2 O -
% O -
, O +
p O +
< O +
0.01 O -
) O -
. O +

FE O +
estimated O +
bone O +
strength O +
was O +
preserved O -
, O +
but O +
not O +
increased O -
, O +
with O +
PTH O +
1 O -
- O -
34 O +
and O +
zoledronic B-Chemical +
acid I-Chemical +
at O +
both O +
sites O -
, O +
whereas O +
it O +
decreased O +
with O +
PTH O +
1 O -
- O -
84 O +
in O +
radius O +
( O -
-2.8 O +
± O +
5.8 O -
% O -
, O +
p O +
< O +
0.05 O -
) O +
and O +
tibia O +
( O -
-3.9 O +
± O +
4.8 O -
% O -
, O +
p O +
< O +
0.001 O -
) O -
. O +

Conclusively O -
, O +
divergent O +
treatment O -
- O -
specific O +
effects O +
in O +
cortical O +
and O +
trabecular O +
bone O +
were O +
observed O +
with O +
anabolic O +
and O +
zoledronic B-Chemical +
acid I-Chemical +
therapy O -
. O +

The O +
finding O +
of O +
decreased O +
estimated O +
strength O +
with O +
PTH O +
1 O -
- O -
84 O +
treatment O +
was O +
surprising O +
and O +
warrants O +
confirmation O -
. O +

Deletion O +
of O +
CD74 O -
, O +
a O +
putative O +
MIF O +
receptor O -
, O +
in O +
mice O +
enhances O +
osteoclastogenesis O +
and O +
decreases O +
bone O +
mass O -
. O +

CD74 O +
is O +
a O +
type O +
II O +
transmembrane O +
protein O +
that O +
can O +
act O +
as O +
a O +
receptor O +
for O +
macrophage O +
migration O +
inhibitory O +
factor O +
( O -
MIF O -
) O +
and O +
plays O +
a O +
role O +
in O +
MIF O -
- O -
regulated O +
responses O -
. O +

We O +
reported O +
that O +
MIF O +
inhibited O +
osteoclast O +
formation O +
and O +
MIF O +
knockout O +
( O -
KO O -
) O +
mice O +
had O +
decreased O +
bone O +
mass O -
. O +

We O +
therefore O +
examined O +
if O +
CD74 O +
was O +
involved O +
in O +
the O +
ability O +
of O +
MIF O +
to O +
alter O +
osteoclastogenesis O +
in O +
cultured O +
bone O +
marrow O +
( O -
BM O -
) O +
from O +
wild O -
- O -
type O +
( O -
WT O -
) O +
and O +
CD74-deficient O +
( O -
KO O -
) O +
male O +
mice O -
. O +

We O +
also O +
measured O +
the O +
bone O +
phenotype O +
of O +
CD74 O +
KO O +
male O +
mice O -
. O +

Bone O +
mass O +
in O +
the O +
femur O +
of O +
8-week O -
- O -
old O +
mice O +
was O +
measured O +
by O +
micro O -
- O -
computed O +
tomography O +
and O +
histomorphometry O -
. O +

Bone O +
marrow O +
cells O +
from O +
CD74 O +
KO O +
mice O +
formed O +
15 O -
% O +
more O +
osteoclast O -
- O -
like O +
cells O +
( O -
OCLs O -
) O +
with O +
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O -
M O -
- O -
CSF O -
) O +
and O +
receptor O +
activator O +
of O +
NF O -
- O -
κB O +
ligand O +
( O -
RANKL O -
) O +
( O -
both O +
at O +
30 O +
ng O -
/ O -
mL O -
) O +
compared O +
to O +
WT O -
. O +

Addition O +
of O +
MIF O +
to O +
WT O +
cultures O +
inhibited O +
OCL O +
formation O +
by O +
16 O -
% O +
but O +
had O +
no O +
effect O +
on O +
CD74KO O +
cultures O -
. O +

The O +
number O +
of O +
colony O +
forming O +
unit O +
granulocyte O -
- O -
macrophage O +
( O -
CFU O -
- O -
GM O -
) O +
in O +
the O +
bone O +
marrow O +
of O +
CD74 O +
KO O +
mice O +
was O +
26 O -
% O +
greater O +
than O +
in O +
WT O +
controls O -
. O +

Trabecular O +
bone O +
volume O +
( O -
TBV O -
) O +
in O +
the O +
femurs O +
of O +
CD74 O +
KO O +
male O +
mice O +
was O +
decreased O +
by O +
26 O -
% O +
compared O +
to O +
WT O -
. O +

In O +
addition O -
, O +
cortical O +
area O +
and O +
thickness O +
were O +
decreased O +
by O +
14 O -
% O +
and O +
11 O -
% O -
, O +
respectively O -
. O +

Histomorphometric O +
analysis O +
demonstrated O +
that O +
tartrate B-Chemical -
- O -
resistant O +
acid O +
phosphatase O +
( O -
TRAP O -
) O -
( O -
+ O -
) O +
osteoclast O +
number O +
and O +
area O +
were O +
significantly O +
increased O +
in O +
CD74 O +
KO O +
by O +
35 O -
% O +
and O +
43 O -
% O -
, O +
respectively O +
compared O +
to O +
WT O -
. O +

Finally O -
, O +
we O +
examined O +
the O +
effect O +
of O +
MIF O +
on O +
RANKL O -
- O -
induced O -
- O -
signaling O +
pathways O +
in O +
bone O +
marrow O +
macrophage O +
( O -
BMM O -
) O +
cultures O -
. O +

MIF O +
treatment O +
decreased O +
RANKL O -
- O -
induced O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O -
, O +
cytoplasmic O +
1 O +
( O -
NFATc1 O -
) O +
and O +
c O -
- O -
Fos O +
protein O +
in O +
BMM O +
cultures O +
by O +
70 O -
% O +
and O +
41 O -
% O -
, O +
respectively O -
. O +

Our O +
data O +
demonstrate O +
that O +
CD74 O +
is O +
required O +
for O +
MIF O +
to O +
affect O +
in O +
vitro O +
osteoclastogenesis O -
. O +

Further O -
, O +
the O +
bone O +
phenotype O +
of O +
CD74 O +
KO O +
mice O +
is O +
similar O +
to O +
that O +
of O +
MIF O +
KO O +
mice O -
. O +

MIF O +
treatment O +
of O +
WT O +
cultures O +
suppressed O +
RANKL O -
- O -
induced O +
activator O +
protein O +
1 O +
( O -
AP-1 O -
) O +
expression O -
, O +
which O +
resulted O +
in O +
decreased O +
osteoclast O +
differentiation O +
in O +
vitro O -
. O +

We O +
propose O +
that O +
CD74 O +
plays O +
a O +
critical O +
role O +
in O +
the O +
MIF O +
inhibition O +
of O +
osteoclastogenesis O -
. O +

Hierarchical O +
rutile O +
TiO2 B-Chemical +
flower O +
cluster O -
- O -
based O +
high O +
efficiency O +
dye O -
- O -
sensitized O +
solar O +
cells O +
via O +
direct O +
hydrothermal O +
growth O +
on O +
conducting O +
substrates O -
. O +

Dye O -
- O -
sensitized O +
solar O +
cells O +
( O -
DSSCs O -
) O +
based O +
on O +
hierarchical O +
rutile O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
flower O +
clusters O +
prepared O +
by O +
a O +
facile O -
, O +
one O -
- O -
pot O +
hydrothermal O +
process O +
exhibit O +
a O +
high O +
efficiency O -
. O +

Complex O +
yet O +
appealing O +
rutile O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
flower O +
films O +
are O -
, O +
for O +
the O +
first O +
time O -
, O +
directly O +
hydrothermally O +
grown O +
on O +
a O +
transparent O +
conducting O +
fluorine B-Chemical -
- I-Chemical -
doped I-Chemical +
tin I-Chemical +
oxide I-Chemical +
( O -
FTO B-Chemical -
) O +
substrate O -
. O +

The O +
thickness O +
and O +
density O +
of O +
as O -
- O -
grown O +
flower O +
clusters O +
can O +
be O +
readily O +
tuned O +
by O +
tailoring O +
growth O +
parameters O -
, O +
such O +
as O +
growth O +
time O -
, O +
the O +
addition O +
of O +
cations O +
of O +
different O +
valence O +
and O +
size O -
, O +
initial O +
concentrations O +
of O +
precursor O +
and O +
cation O -
, O +
growth O +
temperature O -
, O +
and O +
acidity O -
. O +

Notably O -
, O +
the O +
small O +
lattice O +
mismatch O +
between O +
the O +
FTO B-Chemical +
substrate O +
and O +
rutile O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
renders O +
the O +
epitaxial O +
growth O +
of O +
a O +
compact O +
rutile O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
layer O +
on O +
the O +
FTO B-Chemical +
glass O -
. O +

Intriguingly O -
, O +
these O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
flower O +
clusters O +
can O +
then O +
be O +
exploited O +
as O +
photoanodes O +
to O +
produce O +
DSSCs O -
, O +
yielding O +
a O +
power O +
conversion O +
efficiency O +
of O +
2.94 O -
% O +
despite O +
their O +
rutile O +
nature O -
, O +
which O +
is O +
further O +
increased O +
to O +
4.07 O -
% O +
upon O +
the O +
TiCl B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical +
treatment O -
. O +

INO-8875 B-Chemical -
, O +
a O +
highly O +
selective O +
A1 O +
adenosine B-Chemical +
receptor O +
agonist O -
: O +
evaluation O +
of O +
chronotropic O -
, O +
dromotropic O -
, O +
and O +
hemodynamic O +
effects O +
in O +
rats O -
. O +

Selective O +
pharmacological O +
activation O +
of O +
the O +
adenosine B-Chemical +
1 O +
receptor O +
( O -
A O -
( O -
1 O -
) O -
R O -
) O +
is O +
a O +
promising O +
new O +
approach O +
to O +
achieve O +
a O +
potent O +
block O +
of O +
atrioventricular O +
( O -
A O -
- O -
V O -
) O -
-nodal O +
conduction O +
without O +
significant O +
cardiovascular O +
side O +
effects O -
. O +

The O +
purpose O +
of O +
the O +
present O +
study O +
was O +
to O +
evaluate O +
the O +
cardiovascular O +
profile O +
of O +
INO-8875 B-Chemical -
, O +
a O +
highly O +
selective O +
A O -
( O -
1 O -
) O -
R O +
agonist O -
, O +
and O +
to O +
compare O +
its O +
properties O +
with O +
N- B-Chemical -
[ I-Chemical -
3 I-Chemical -
( I-Chemical -
R I-Chemical -
) I-Chemical -
-tetrahydrofuranyl I-Chemical -
] I-Chemical -
-6-aminopurine I-Chemical +
riboside I-Chemical +
( O -
CVT-510 B-Chemical -
) O -
, O +
which O +
has O +
already O +
been O +
shown O +
to O +
induce O +
negative O +
dromotropic O +
effects O +
with O +
minimal O +
cardiovascular O +
side O +
effects O +
in O +
animals O +
and O +
in O +
clinical O +
studies O -
. O +

Dose O -
- O -
response O +
experiments O +
in O +
the O +
isolated O +
hearts O +
of O +
rats O +
were O +
used O +
to O +
evaluate O +
the O +
functional O +
selectivity O +
of O +
INO-8875 B-Chemical +
for O +
the O +
slowing O +
of O +
A O -
- O -
V O -
- O -
nodal O +
conduction O -
. O +

Ventilated O +
adult O +
rats O +
were O +
used O +
to O +
study O +
the O +
effects O +
of O +
INO-8875 B-Chemical -
, O +
in O +
vivo O -
, O +
on O +
arterial O +
blood O +
pressure O +
as O +
well O +
as O +
on O +
supraventricular O +
electrophysiology O -
. O +

Ex O +
vivo O -
, O +
INO-8875 B-Chemical +
( O -
100 O +
nM O +
to O +
3 O +
μM O -
) O +
progressively O +
prolonged O +
A O -
- O -
V O -
- O -
nodal O +
conduction O +
without O +
reducing O +
left O +
ventricular O +
function O +
or O +
coronary O +
resistance O -
. O +

In O +
vivo O -
, O +
INO-8875 B-Chemical +
up O +
to O +
a O +
dose O +
of O +
50 O +
μg O -
/ O -
kg O +
did O +
not O +
reduce O +
the O +
carotid O +
arterial O +
blood O +
pressure O +
( O -
n O +
= O +
4 O -
) O -
. O +

INO-8875 B-Chemical +
( O -
1 O -
- O -
50 O +
μg O -
/ O -
kg O -
) O +
and O +
CVT-510 B-Chemical +
( O -
20 O +
and O +
50 O +
μg O -
/ O -
kg O -
) O +
both O +
induced O +
a O +
dose O -
- O -
dependent O +
decrease O +
in O +
heart O +
rate O +
and O +
atrial O +
refractoriness O -
, O +
as O +
well O +
as O +
slowing O +
of O +
A O -
- O -
V O -
- O -
nodal O +
conduction O -
. O +

However O -
, O +
compared O +
with O +
CVT-510 B-Chemical -
, O +
the O +
activity O +
of O +
INO-8875 B-Chemical +
was O +
more O +
pronounced O +
in O +
A O -
- O -
V O -
- O -
nodal O +
function O -
. O +

INO-8875 B-Chemical +
exhibited O +
a O +
greater O +
duration O +
of O +
action O -
, O +
lasting O +
up O +
to O +
2.5 O +
hours O +
post O +
dosing O -
, O +
whereas O +
the O +
effects O +
of O +
CVT-510 B-Chemical +
dissipated O +
over O +
1 O +
hour O -
. O +

INO-8875 B-Chemical +
demonstrates O +
functional O +
properties O +
of O +
a O +
highly O +
selective O +
A O -
( O -
1 O -
) O -
R O +
agonist O -
. O +

INO-8875 B-Chemical +
exhibits O +
an O +
increased O +
dromotropic O +
effect O +
and O +
greater O +
duration O +
of O +
action O +
compared O +
with O +
CVT-510 B-Chemical -
. O +

Exposures O +
to O +
1,3-dimethylamylamine B-Chemical -
- O -
containing O +
products O +
reported O +
to O +
Texas O +
poison O +
centers O -
. O +

1,3-Dimethylamylamine B-Chemical +
( O -
DMAA B-Chemical -
) O +
is O +
an O +
ingredient O +
in O +
a O +
number O +
of O +
weight O +
loss O +
and O +
exercise O +
performance O +
enhancing O +
products O -
. O +

However O -
, O +
information O +
on O +
the O +
safety O +
of O +
DMAA B-Chemical -
- O -
containing O +
products O +
is O +
limited O -
. O +

Exposures O +
to O +
DMAA B-Chemical -
- O -
containing O +
products O +
reported O +
to O +
Texas O +
poison O +
centers O +
during O +
2010 O -
- O -
2011 O +
were O +
identified O +
and O +
selected O +
factors O +
were O +
examined O -
. O +

A O +
total O +
of O +
56 O +
exposures O +
were O +
found O -
, O +
of O +
which O +
75.0 O -
% O +
were O +
reported O +
during O +
2011 O -
. O +

OxyElite O +
Pro O -
™ O +
was O +
the O +
reported O +
product O +
in O +
80.4 O -
% O +
of O +
the O +
exposures O -
. O +

The O +
patients O +
were O +
51.8 O -
% O +
male O +
and O +
55.4 O -
% O +
age O +
≤5 O +
years O -
. O +

The O +
patient O +
was O +
managed O +
on O +
site O +
( O -
such O +
as O +
at O +
home O -
) O +
in O +
57.1 O -
% O +
of O +
the O +
cases O -
, O +
and O +
the O +
exposure O +
was O +
known O +
or O +
expected O +
to O +
result O +
in O +
an O +
outcome O +
that O +
was O +
classified O +
as O +
not O +
serious O +
in O +
80.4 O -
% O -
. O +

The O +
most O +
frequently O +
reported O +
clinical O +
effects O +
were O +
tachycardia O +
( O -
28.6 O -
% O -
) O -
, O +
nausea O +
( O -
16.1 O -
% O -
) O -
, O +
and O +
vomiting O +
( O -
12.5 O -
% O -
) O -
. O +

The O +
most O +
common O +
treatments O +
were O +
dilution O +
( O -
41.1 O -
% O -
) O -
, O +
food O +
( O -
19.6 O -
% O -
) O -
, O +
and O +
activated O +
charcoal B-Chemical +
( O -
14.3 O -
% O -
) O -
. O +

It O +
should O +
be O +
noted O +
that O +
the O +
adverse O +
clinical O +
effects O +
may O +
be O +
due O +
to O +
other O +
ingredients O +
in O +
the O +
DMAA B-Chemical -
- O -
containing O +
products O -
, O +
such O +
as O +
caffeine B-Chemical -
. O +

Emergency O +
do O +
not O +
consume O -
/ O -
do O +
not O +
use O +
concentrations O +
for O +
blended O +
phosphates B-Chemical +
in O +
drinking O +
water O -
. O +

The O +
U.S. O +
Congress O +
[ O -
PL O +
107 O -
- O -
188 O -
] O +
amended O +
the O +
Safe O +
Drinking O +
Water O +
Act O +
and O +
required O +
each O +
community O +
water O +
system O +
serving O +
more O +
than O +
3,000 O +
people O +
to O +
conduct O +
vulnerability O +
assessments O -
. O +

These O +
assessments O +
address O +
potential O +
circumstances O +
that O +
could O +
compromise O +
the O +
safety O +
and O +
reliability O +
of O +
municipal O +
water O -
. O +

The O +
present O +
evaluation O +
concerns O +
the O +
concentrations O +
of O +
the O +
blended O +
phosphates B-Chemical +
( O -
also O +
known O +
as O +
polyphosphates B-Chemical -
, O +
condensed O +
complex O +
phosphates B-Chemical -
, O +
polyphosphate O +
glassy O +
balls O -
, O +
and O +
pyrophosphates B-Chemical -
) O +
intended O +
to O +
aid O +
regulatory O +
agencies O +
in O +
decisions O +
to O +
avoid O +
contact O +
with O +
affected O +
water O -
. O +

Polyphosphates B-Chemical +
are O +
direct O +
food O +
additives O +
and O +
they O +
are O +
used O +
to O +
treat O +
municipal O +
drinking O +
water O -
, O +
but O +
depending O +
upon O +
the O +
concentration O +
and O +
duration O +
of O +
exposure O +
these O +
substances O +
can O +
induce O +
chemical O +
burns O -
. O +

Ingested O +
polyphosphates B-Chemical +
are O +
degraded O +
by O +
phosphatase O +
enzymes O +
to O +
monophosphates B-Chemical -
, O +
substances O +
that O +
are O +
over O -
- O -
the O -
- O -
counter O +
bowel O +
purgatives O -
. O +

High O +
oral O +
doses O +
of O +
the O +
monophosphates B-Chemical +
can O +
induce O +
transient O +
hyperphosphatemia O +
in O +
older O +
and O +
susceptible O +
young O +
people O -
, O +
which O +
can O +
lead O +
to O +
acute O +
phosphate B-Chemical +
nephropathy O -
. O +

In O +
some O +
patients O -
, O +
the O +
condition O +
is O +
fatal O -
. O +

Based O +
on O +
the O +
acute O +
diarrhea O +
after O +
the O +
ingestion O +
of O +
a O +
single O +
oral O +
dose O +
of O +
monobasic O +
( O -
NaH2PO B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
) O +
and O +
dibasic O +
( O -
Na2HPO B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
) O +
monophosphates B-Chemical +
in O +
adults O -
, O +
a O +
do O +
not O +
consume O +
concentration O +
of O +
600 O +
mg O +
PO B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
/ O -
L O +
can O +
be O +
derived O -
. O +

Based O +
on O +
mild O +
local O +
irritation O +
after O +
topical O +
application O +
of O +
1.0 O -
% O +
sodium B-Chemical +
metaphosphate I-Chemical +
[ O -
( B-Chemical -
NaPO I-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
) I-Chemical -
6 I-Chemical +
• I-Chemical +
H2O I-Chemical -
] O +
to O +
intact O +
skin O +
of O +
sensitive O +
volunteers O -
, O +
a O +
do O +
not O +
use O +
concentration O +
of O +
8,000 O +
mg O +
PO4 B-Chemical -
/ O -
L O +
can O +
be O +
assigned O -
. O +

Given O +
the O +
lack O +
of O +
eye O +
irritation O +
in O +
rabbits O +
after O +
direct O +
instillation O +
of O +
0.2 O -
% O +
( B-Chemical -
NaPO I-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
) I-Chemical -
6 I-Chemical +
• I-Chemical +
H2O I-Chemical -
, O +
an O +
acute O +
ocular O +
contact O +
limit O +
of O +
50 O +
mg O +
PO4 B-Chemical -
/ O -
L O +
serves O +
as O +
the O +
overall O +
do O +
not O +
use O +
level O -
. O +

Anti O -
- O -
tumor O +
necrosis O +
factor O +
treatment O +
in O +
cherubism O -
-- O -
clinical O -
, O +
radiological O +
and O +
histological O +
findings O +
in O +
two O +
children O -
. O +

Cherubism O +
is O +
a O +
rare O +
and O +
disfiguring O +
genetic O +
disorder O +
with O +
excessive O +
bone O +
resorption O +
and O +
multilocular O +
lesions O +
in O +
the O +
mandible O +
and/or O +
maxilla O -
. O +

The O +
disease O -
- O -
causing O +
gain O -
- O -
of O -
- O -
function O +
mutations O +
in O +
the O +
SH3-binding O +
protein O +
2 O +
( O -
SH3BP2 O -
) O +
gene O +
result O +
in O +
increased O +
myeloid O +
cell O +
responses O +
to O +
macrophage O +
colony O +
stimulating O +
factor O +
and O +
RANK O +
ligand O -
, O +
formation O +
of O +
hyperactive O +
osteoclasts O +
( O -
giant O +
cells O -
) O -
, O +
and O +
hyper O -
- O -
reactive O +
macrophages O +
that O +
produce O +
excessive O +
amounts O +
of O +
the O +
inflammatory O +
cytokine O +
tumor O +
necrosis O +
factor O +
α O +
( O -
TNF O -
- O -
α O -
) O -
. O +

Recent O +
findings O +
in O +
the O +
cherubism O +
mouse O +
model O +
suggest O +
that O +
TNF O -
- O -
α O +
plays O +
a O +
major O +
role O +
in O +
disease O +
pathogenesis O +
and O +
that O +
removal O +
of O +
TNF O -
- O -
α O +
prevents O +
development O +
of O +
the O +
bone O +
phenotype O -
. O +

We O +
treated O +
two O +
children O +
with O +
cherubism O +
with O +
the O +
TNF O -
- O -
α O +
antagonist O +
adalimumab O +
for O +
approximately O +
2.5 O +
years O +
and O +
collected O +
extensive O +
clinical O -
, O +
radiological O +
and O +
histological O +
follow O -
- O -
up O +
data O +
during O +
the O +
treatment O -
. O +

Histologically O +
the O +
treatment O +
resulted O +
in O +
a O +
significant O +
reduction O +
in O +
the O +
number O +
of O +
multinucleated O +
giant O +
cells O +
and O +
TNF O -
- O -
α O +
staining O +
positivity O +
in O +
both O +
patients O -
. O +

As O +
evaluated O +
by O +
computed O +
tomography O +
and O +
magnetic O +
resonance O +
imaging O -
, O +
the O +
lesions O +
in O +
Patient O +
1 O +
showed O +
either O +
moderate O +
enlargement O +
( O -
mandibular O +
symphysis O -
) O +
or O +
remained O +
stable O +
( O -
mandibular O +
rami O +
and O +
body O -
, O +
the O +
maxilla O -
) O -
. O +

In O +
Patient O +
2 O -
, O +
the O +
lesions O +
in O +
mandibular O +
symphysis O +
showed O +
enlargement O +
during O +
the O +
first O +
8 O +
months O +
of O +
treatment O -
, O +
and O +
thereafter O +
the O +
lesions O +
remained O +
unchanged O -
. O +

Bone O +
formation O +
and O +
resorption O +
markers O +
remained O +
unaffected O -
. O +

The O +
treatment O +
was O +
well O +
tolerated O -
. O +

Based O +
on O +
our O +
findings O -
, O +
TNF O -
- O -
α O +
antagonist O +
may O +
decrease O +
the O +
formation O +
of O +
pathogenic O +
giant O +
cells O -
, O +
but O +
does O +
not O +
result O +
in O +
lesion O +
regression O +
or O +
prevent O +
lesion O +
expansion O +
in O +
active O +
cherubism O -
. O +

TNF O -
- O -
α O +
modulator O +
treatment O +
thus O +
does O +
not O +
appear O +
to O +
provide O +
sufficient O +
amelioration O +
for O +
patients O +
suffering O +
from O +
cherubism O -
. O +

Design O -
, O +
synthesis O -
, O +
and O +
in O +
vitro O +
evaluation O +
of O +
new O +
amphiphilic O +
cyclodextrin O -
- O -
based O +
nanoparticles O +
for O +
the O +
incorporation O +
and O +
controlled O +
release O +
of O +
acyclovir B-Chemical -
. O +

Acyclovir B-Chemical +
possesses O +
low O +
solubility O +
in O +
water O +
and O +
in O +
lipid O +
bilayers O -
, O +
so O +
that O +
its O +
dosage O +
forms O +
do O +
not O +
allow O +
suitable O +
drug O +
levels O +
at O +
target O +
sites O +
following O +
oral O -
, O +
local O -
, O +
or O +
parenteral O +
administration O -
. O +

In O +
order O +
to O +
improve O +
this O +
lack O +
of O +
solubility O -
, O +
new O +
cyclodextrin O -
- O -
based O +
amphiphilic O +
derivatives O +
have O +
been O +
designed O +
to O +
form O +
nanoparticles O -
, O +
allowing O +
the O +
efficient O +
encapsulation O +
of O +
this O +
hydrophobic O +
antiviral O +
agent O -
. O +

The O +
present O +
work O +
first O +
describes O +
the O +
synthesis O +
and O +
characterization O +
of O +
five O +
new O +
O-2,O-3 B-Chemical +
permethylated I-Chemical +
O-6 I-Chemical +
alkylthio- I-Chemical +
and I-Chemical +
perfluoroalkyl I-Chemical -
- I-Chemical -
propanethio I-Chemical -
- I-Chemical -
amphiphilic I-Chemical +
β I-Chemical -
- I-Chemical -
cyclodextrins I-Chemical -
. O +

These O +
derivatives O +
have O +
been O +
obtained O +
with O +
good O +
overall O +
yields O -
. O +

The O +
capacity O +
of O +
these O +
molecules O +
to O +
form O +
nanoparticles O +
in O +
water O +
and O +
to O +
encapsulate O +
acyclovir B-Chemical +
has O +
then O +
been O +
studied O -
. O +

The O +
nanoparticles O +
prepared O +
from O +
the O +
new O +
β B-Chemical -
- I-Chemical -
cyclodextrin I-Chemical +
derivatives O +
have O +
been O +
characterized O +
by O +
dynamic O +
light O +
scattering O +
and O +
have O +
an O +
average O +
size O +
of O +
120 O -
nm O +
for O +
the O +
fluorinated O +
derivatives O +
and O +
220 O -
nm O +
for O +
the O +
hydrogenated O +
analogs O -
. O +

They O +
all O +
allowed O +
high O +
loading O +
and O +
sustained O +
release O +
of O +
acyclovir B-Chemical -
. O +

The O +
arginine B-Chemical +
and O +
GHRP-2 O +
tests O +
as O +
alternatives O +
to O +
the O +
insulin O +
tolerance O +
test O +
for O +
the O +
diagnosis O +
of O +
adult O +
GH O +
deficiency O +
in O +
Japanese O +
patients O -
: O +
a O +
comparison O -
. O +

The O +
arginine B-Chemical +
+ O +
GHRH O +
test O +
has O +
been O +
established O +
as O +
an O +
alternative O +
to O +
the O +
insulin O +
tolerance O +
test O +
( O -
ITT O -
) O +
for O +
the O +
diagnosis O +
of O +
adult O +
GH O +
deficiency O +
( O -
AGHD O -
) O -
. O +

However O -
, O +
the O +
glucagon O -
, O +
arginine B-Chemical -
, O +
and O +
GH O +
releasing O +
peptide-2 O +
( O -
GHRP-2 O -
) O +
test O +
are O +
recommended O +
as O +
alternatives O +
in O +
Japan O -
. O +

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
evaluate O +
the O +
arginine B-Chemical +
and O +
GHRP-2 O +
tests O +
as O +
alternatives O +
to O +
the O +
ITT O +
for O +
the O +
diagnosis O +
of O +
AGHD O +
in O +
a O +
Japanese O +
population O -
. O +

Three O +
stimulation O +
tests O +
( O -
ITT O -
, O +
arginine B-Chemical +
test O -
, O +
and O +
GHRP-2 O +
test O -
) O +
were O +
conducted O +
in O +
71 O +
pre O -
- O -
operative O +
adult O +
patients O +
with O +
pituitary O +
tumors O +
( O -
age O -
, O +
18 O -
- O -
65 O +
years O -
) O -
. O +

The O +
peak O +
GH O +
responses O +
to O +
each O +
test O +
were O +
examined O -
. O +

The O +
peak O +
GH O +
responses O +
were O +
significantly O +
lower O +
with O +
the O +
ARG B-Chemical +
test O +
( O -
median O +
4.43 O +
μg O -
/ O -
L O -
) O +
( O -
p O +
< O +
0.0001 O -
) O +
than O +
with O +
the O +
ITT O +
( O -
median O +
9.38 O +
μg O -
/ O -
L O -
) O -
, O +
and O +
the O +
peak O +
GH O +
responses O +
with O +
the O +
GHRP-2 O +
test O +
( O -
median O +
28.88 O +
μg O -
/ O -
L O -
) O +
were O +
higher O +
( O -
p O +
< O +
0.0001 O -
) O -
. O +

However O -
, O +
among O +
the O +
AGHD O +
patients O -
, O +
there O +
was O +
no O +
significant O +
difference O +
between O +
the O +
peak O +
GH O +
responses O +
to O +
the O +
ARG B-Chemical +
test O +
and O +
the O +
ITT O -
. O +

The O +
sensitivities O +
and O +
specificities O +
of O +
the O +
ARG B-Chemical +
/ O +
GHRP-2 O +
tests O +
compared O +
to O +
the O +
ITT O +
for O +
the O +
diagnosis O +
of O +
severe O +
AGHD O +
( O -
peak O +
GH O +
responses O +
to O +
ITT O +
≤ O +
1.8 O +
μg O -
/ O -
L O -
) O +
were O +
93.8 O -
% O +
/ O +
81.3 O -
% O +
and O +
85.5 O -
% O +
/ O +
94.5 O -
% O -
, O +
respectively O -
. O +

The O +
arginine B-Chemical +
and O +
GHRP-2 O +
stimulation O +
tests O +
are O +
acceptable O +
alternatives O +
to O +
the O +
ITT O +
for O +
the O +
diagnosis O +
of O +
AGHD O +
in O +
Japanese O +
patients O -
. O +

The O +
method O +
and O +
criterion O +
for O +
the O +
diagnosis O +
of O +
AGHD O +
should O +
be O +
reconsidered O +
and O +
adjusted O +
to O +
each O +
population O -
. O +

H B-Chemical -
- O -
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
@MnO O -
( B-Chemical -
2 I-Chemical -
) I-Chemical +
/ O -
/ O -
H B-Chemical -
- O -
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
@C O +
core O -
- O -
shell O +
nanowires O +
for O +
high O +
performance O +
and O +
flexible O +
asymmetric O +
supercapacitors O -
. O +

A O +
flexible O +
solid O -
- O -
state O +
asymmetric O +
supercapacitor O +
device O +
with O +
H O -
- O -
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
@MnO O -
( B-Chemical -
2 I-Chemical -
) I-Chemical +
core O -
- O -
shell O +
NWs O +
as O +
the O +
positive O +
electrode O +
and O +
H O -
- O -
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
@C B-Chemical +
core O -
- O -
shell O +
NWs O +
as O +
the O +
negative O +
electrode O +
is O +
developed O -
. O +

This O +
device O +
operates O +
in O +
a O +
1.8 O +
V O +
voltage O +
window O +
and O +
is O +
able O +
to O +
deliver O +
a O +
high O +
specific O +
capacitance O +
of O +
139.6 O +
F O +
g O -
( O -
-1 O -
) O +
and O +
maximum O +
volumetric O +
energy O +
density O +
of O +
0.30 O +
mWh O +
cm O -
( O -
-3 O -
) O +
with O +
excellent O +
cycling O +
performance O +
and O +
good O +
flexibility O -
. O +

Sub O -
- O -
lethal O +
effects O +
of O +
titanium B-Chemical +
dioxide I-Chemical +
nanoparticles O +
on O +
the O +
physiology O +
and O +
reproduction O +
of O +
zebrafish O -
. O +

There O +
are O +
limited O +
data O +
on O +
the O +
sub O -
- O -
lethal O +
physiological O +
effects O +
of O +
titanium B-Chemical +
dioxide I-Chemical +
nanoparticles O +
( O -
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
NPs O -
) O +
in O +
adult O +
fishes O -
, O +
and O +
the O +
consequences O +
of O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
NP O +
exposure O +
on O +
reproductive O +
success O +
are O +
also O +
unclear O -
. O +

This O +
study O +
aimed O +
to O +
examine O +
the O +
sub O -
- O -
lethal O +
effects O +
of O +
a O +
14-d O +
aqueous O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
( O -
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
NP O -
, O +
0.1 O +
or O +
1.0 O +
mg O +
l O -
( O -
-1 O -
) O -
; O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
bulk O -
, O +
1.0 O +
mg O +
l O -
( O -
-1 O -
) O -
) O +
exposure O +
on O +
the O +
physiology O +
and O +
reproductive O +
health O +
of O +
zebrafish O -
. O +

After O +
the O +
14-d O +
exposure O -
, O +
fish O +
were O +
examined O +
for O +
haematology O -
, O +
whole O +
body O +
electrolyte O +
and O +
trace O +
metal O +
profiles O -
, O +
biochemistry O -
, O +
and O +
histopathology O -
. O +

Then O -
, O +
during O +
a O +
21-d O +
post O +
exposure O +
recovery O +
period O -
, O +
effects O +
of O +
the O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
exposure O +
on O +
reproductive O +
success O +
were O +
evaluated O -
. O +

Whole O +
body O +
Ti B-Chemical +
concentrations O +
increased O +
significantly O +
in O +
fish O +
exposed O +
to O +
both O +
the O +
1.0 O +
mg O +
l O -
( O -
-1 O -
) O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
NP O +
and O +
bulk O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
compared O +
to O +
controls O -
, O +
but O +
concentrations O +
returned O +
to O +
control O +
levels O +
by O +
the O +
end O +
of O +
the O +
recovery O +
period O -
. O +

No O +
change O +
in O +
erythrocyte O +
counts O +
were O +
observed O -
, O +
but O +
there O +
was O +
a O +
two O -
- O -
fold O +
decline O +
in O +
leukocyte O +
counts O +
in O +
all O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
treatment O +
groups O +
relative O +
to O +
time O -
- O -
matched O +
controls O -
. O +

Whole O +
body O +
electrolyte O +
and O +
trace O +
metal O +
profiles O +
were O +
not O +
affected O +
by O +
exposure O +
to O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
, O +
and O +
there O +
were O +
no O +
changes O +
in O +
Na B-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical -
K B-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical -
-ATPase O +
activity O +
in O +
brain O -
, O +
gill O +
or O +
liver O +
tissues O -
. O +

Total O +
glutathione B-Chemical +
( O -
GSH B-Chemical -
) O +
levels O +
in O +
brain O -
, O +
gill O +
and O +
liver O +
tissues O +
were O +
higher O +
in O +
fish O +
exposed O +
to O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
NP O +
( O -
both O +
0.1 O +
and O +
1.0 O +
mg O +
l O -
( O -
-1 O -
) O -
) O +
compared O +
to O +
bulk O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
and O +
control O +
fish O -
. O +

Histological O +
examination O +
of O +
gill O -
, O +
liver O -
, O +
brain O +
and O +
gonad O +
tissues O +
showed O +
little O +
evidence O +
of O +
treatment O -
- O -
related O +
morphological O +
change O -
. O +

At O +
the O +
end O +
of O +
the O +
14-d O +
exposure O +
adult O +
zebrafish O +
were O +
able O +
to O +
reproduce O -
; O +
however O -
, O +
the O +
cumulative O +
number O +
of O +
viable O +
embryos O +
produced O +
was O +
lower O +
in O +
fish O +
exposed O +
to O +
1.0 O +
mg O +
l O -
( O -
-1 O -
) O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
( O -
both O +
NP O +
and O +
bulk O -
) O +
by O +
the O +
end O +
of O +
the O +
21-d O +
recovery O +
period O -
. O +

Overall O -
, O +
this O +
study O +
showed O +
limited O +
toxicity O +
of O +
bulk O +
or O +
nano O +
scale O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
during O +
the O +
exposure O -
; O +
however O +
reproduction O +
was O +
affected O +
in O +
both O +
bulk O +
and O +
NP O +
1.0 O +
mg O +
l O -
( O -
-1 O -
) O +
groups O -
. O +

Toxic O +
effects O +
of O +
microcystin B-Chemical -
- I-Chemical -
LR I-Chemical +
on O +
the O +
reproductive O +
system O +
of O +
male O +
Rana O +
nigromaculata O +
in O +
vitro O -
. O +

This O +
study O +
aims O +
to O +
demonstrate O +
that O +
microcystin B-Chemical -
- I-Chemical -
LR I-Chemical +
( O -
MC B-Chemical -
- I-Chemical -
LR I-Chemical -
) O +
has O +
toxic O +
effects O +
on O +
the O +
reproductive O +
system O +
of O +
male O +
Rana O +
nigromaculata O +
in O +
vitro O -
. O +

R. O +
nigromaculata O +
were O +
treated O +
with O +
0 O -
, O +
0.1 O -
, O +
1 O -
, O +
10 O -
, O +
and O +
100 O +
nmol O -
/ O -
L O +
of O +
MC O -
- O -
LR O +
for O +
6 O +
h. O +
Results O +
show O +
that O +
exposure O +
to O +
1 O +
nmol O -
/ O -
L O +
to O +
100 O +
nmol O -
/ O -
L O +
of O +
MC B-Chemical -
- I-Chemical -
LR I-Chemical +
decreased O +
sperm O +
motility O +
and O +
number O +
of O +
sperm O +
cells O +
and O +
increased O +
the O +
sperm O +
abnormality O +
rate O -
, O +
whose O +
values O +
were O +
significantly O +
different O +
from O +
those O +
of O +
the O +
control O +
( O -
P<0.01 O -
) O -
. O +

Moreover O -
, O +
the O +
same O +
dosage O +
of O +
MC B-Chemical -
- I-Chemical -
LR I-Chemical +
increased O +
reactive O +
oxygen B-Chemical +
species O +
production O +
and O +
malondialdehyde B-Chemical +
content O -
. O +

At O +
the O +
same O +
time O -
, O +
antioxidant O +
enzyme O +
( O -
catalase O +
and O +
glutathione B-Chemical +
S O -
- O -
transferase O -
) O +
activity O +
and O +
glutathione B-Chemical +
reduced O +
content O +
rapidly O +
increased O -
, O +
whereas O +
antioxidant O +
enzyme O +
superoxide B-Chemical +
dismutase O +
activity O +
significantly O +
decreased O -
. O +

These O +
results O +
imply O +
that O +
the O +
defense O +
system O +
of O +
the O +
testes O +
quickly O +
responds O +
to O +
oxidative O +
stress O -
. O +

Ultrastructural O +
observation O +
shows O +
distention O +
of O +
the O +
mitochondria O -
, O +
endoplasmic O +
reticulum O -
, O +
and O +
Golgi O +
apparatus O +
and O +
changes O +
in O +
the O +
mitochondrial O +
matrix O +
color O -
, O +
cristae O +
number O -
, O +
and O +
morphology O -
. O +

Moreover O -
, O +
using O +
real O -
- O -
time O +
PCR O -
, O +
increased O +
relative O +
expressions O +
of O +
P450 O +
aromatase O +
and O +
SF-1 O +
genes O +
were O +
observed O -
. O +

The O +
results O +
demonstrate O +
for O +
the O +
first O +
time O +
that O +
MC B-Chemical -
- I-Chemical -
LR I-Chemical +
could O +
induce O +
toxicity O +
in O +
the O +
male O +
reproductive O +
system O +
of O +
R. O +
nigromaculata O -
. O +

The O +
findings O +
in O +
this O +
research O +
will O +
provide O +
more O +
insights O +
into O +
the O +
relationships O +
between O +
aquatic O +
microcystins B-Chemical +
and O +
amphibians O -
. O +

Ultrasound O -
- O -
promoted O +
coating O +
of O +
silk O +
yarn O +
with O +
different O +
morphology O +
of O +
magnesium B-Chemical +
hydroxide I-Chemical +
nanostructures O -
. O +

The O +
growth O +
of O +
magnesium B-Chemical +
hydroxide I-Chemical +
nanostructures O +
on O +
silk O +
yarn O +
was O +
achieved O +
by O +
sequential O +
dipping O +
steps O +
in O +
alternating O +
bath O +
of O +
magnesium B-Chemical +
nitrate I-Chemical +
and O +
potassium B-Chemical +
hydroxide I-Chemical +
under O +
ultrasound O +
irradiation O -
. O +

The O +
effects O +
of O +
ultrasound O +
irradiation O -
, O +
concentration O -
, O +
pH O +
and O +
sequential O +
dipping O +
steps O +
on O +
growth O +
of O +
the O +
Mg B-Chemical -
( I-Chemical -
OH I-Chemical -
) I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
nanostructures O +
have O +
been O +
studied O -
. O +

Morphology O +
of O +
the O +
nanostructures O -
, O +
depending O +
on O +
pH O +
and O +
with O +
decreasing O +
pH O +
from O +
13 O +
to O +
8 O -
, O +
changed O +
from O +
nanoparticle O +
to O +
nanoneedle O -
. O +

Results O +
show O +
a O +
decrease O +
in O +
the O +
particles O +
size O +
as O +
the O +
concentration O +
and O +
sequential O +
dipping O +
steps O +
increased O -
. O +

The O +
physicochemical O +
properties O +
of O +
the O +
nanostructures O +
were O +
determined O +
by O +
powder O +
X O -
- O -
ray O +
diffraction O +
( O -
XRD O -
) O -
, O +
scanning O +
electron O +
microscopy O +
( O -
SEM O -
) O +
and O +
wavelength O +
dispersive O +
X O -
- O -
ray O +
( O -
WDX O -
) O -
. O +

Effect O +
of O +
amorphization O +
method O +
on O +
telmisartan B-Chemical +
solubility O +
and O +
the O +
tableting O +
process O -
. O +

Telmisartan B-Chemical +
( O -
TLM B-Chemical -
) O -
, O +
a O +
poorly O +
water O -
- O -
soluble O +
angiotensin O +
II O +
receptor O +
antagonist O +
in O +
crystalline O +
form O -
, O +
was O +
transformed O +
into O +
the O +
amorphous O +
state O +
by O +
the O +
melt O +
quench O +
technique O -
, O +
as O +
well O +
as O +
a O +
cryogenic O +
grinding O +
method O -
, O +
in O +
order O +
to O +
improve O +
its O +
physiochemical O +
properties O -
. O +

The O +
chemical O +
stability O +
of O +
TLM B-Chemical -
, O +
that O +
is O -
, O +
the O +
tendency O +
of O +
the O +
material O +
to O +
resist O +
change O +
or O +
decomposition O +
due O +
to O +
internal O +
reaction O -
, O +
or O +
due O +
to O +
the O +
effects O +
of O +
air O -
, O +
heat O -
, O +
light O -
, O +
pressure O -
, O +
etc O -
. O -
, O +
during O +
formation O +
of O +
the O +
amorphous O +
phase O +
was O +
assessed O +
by O +
monitoring O +
high O +
performance O +
liquid O +
chromatography O -
. O +

The O +
existence O +
of O +
the O +
amorphous O +
state O +
was O +
confirmed O +
by O +
differential O +
scanning O +
calorimetry O +
and O +
X O -
- O -
ray O +
powder O +
diffraction O -
. O +

The O +
glass O +
transition O +
occurred O +
at O +
T O -
( O -
g O -
) O -
=401 O -
K O -
. O +

In O +
the O +
next O +
stage O -
, O +
the O +
solubility O +
of O +
TLM B-Chemical +
in O +
0.1 O -
M O +
HCl B-Chemical -
, O +
phosphate O +
buffer O -
, O +
pH=6.8 O -
, O +
and O +
water O +
( O -
25 O -
° O -
C O +
and O +
37 O -
° O -
C O -
) O +
was O +
determined O -
. O +

Both O +
amorphous O +
forms O +
of O +
TLM B-Chemical +
( O -
vitrified O +
and O +
cryogrinded O -
) O +
had O +
a O +
higher O +
solubility O +
( O -
μg O -
/ O -
ml O -
) O +
than O +
their O +
crystalline O +
counterpart O -
. O +

An O +
important O +
and O +
interesting O +
problem O +
of O +
the O +
study O +
was O +
to O +
evaluate O +
how O +
the O +
tableting O +
process O +
was O +
affected O +
by O +
the O +
choice O +
of O +
either O +
a O +
crystalline O +
or O +
an O +
amorphous O +
form O +
of O +
TLM B-Chemical -
. O +

Eight O +
different O +
tablet O +
formulations O +
were O +
evaluated O +
using O +
both O +
the O +
crystalline O +
and O +
the O +
amorphous O +
form O +
of O +
TLM B-Chemical -
. O +

Measurements O +
of O +
the O +
physical O +
properties O +
and O +
dissolution O +
tests O +
of O +
G4 O +
formulations O +
tablets O +
with O +
telmisartan B-Chemical +
in O +
crystalline O +
and O +
amorphous O +
form O +
after O +
different O +
storage O +
periods O +
were O +
also O +
performed O -
. O +

Binding O +
of O +
Gq O +
protein O +
stabilizes O +
the O +
activated O +
state O +
of O +
the O +
muscarinic O +
receptor O +
type O +
1 O -
. O +

Activation O +
of O +
G O +
protein O +
coupled O +
receptors O +
( O -
GPCRs O -
) O +
induces O +
various O +
cellular O +
responses O +
through O +
interactions O +
with O +
G O +
proteins O -
. O +

The O +
key O +
trigger O +
of O +
GPCR O +
activation O +
is O +
agonist O +
binding O -
. O +

It O +
is O +
reportedly O +
known O +
that O +
the O +
agonist O -
- O -
bound O +
active O +
conformation O +
of O +
the O +
GPCRs O -
, O +
such O +
as O +
the O +
muscarinic O +
acetylcholine O +
receptor O +
type O +
1 O +
( O -
M O -
( O -
1 O -
) O -
R O -
) O -
, O +
can O +
be O +
affected O +
by O +
the O +
coupling O +
of O +
G O +
proteins O +
and O +
by O +
depolarization O +
of O +
the O +
membrane O +
potential O -
. O +

Here O +
we O +
aimed O +
at O +
investigating O +
their O +
effects O +
on O +
the O +
structural O +
rearrangements O +
of O +
the O +
M O -
( O -
1 O -
) O -
Rs O +
between O +
the O +
active O +
and O +
quiescent O +
states O -
, O +
using O +
the O +
fluorescence O +
resonance O +
energy O +
transfer O +
( O -
FRET O -
) O +
technique O -
. O +

For O +
this O +
purpose O -
, O +
fluorescent O +
M O -
( O -
1 O -
) O -
R O +
constructs O +
that O +
maintained O +
intact O +
activation O +
of O +
the O +
Gq O +
pathway O +
and O +
interaction O +
with O +
Gq O +
were O +
used O -
. O +

We O +
captured O +
the O +
agonist O -
- O -
induced O +
conformational O +
changes O +
of O +
the O +
M O -
( O -
1 O -
) O -
R O +
as O +
the O +
FRET O +
decreases O +
and O +
found O +
that O +
the O +
FRET O +
decreases O +
were O +
enhanced O +
by O +
co O -
- O -
expression O +
of O +
the O +
Gq O +
subunits O -
. O +

In O +
addition O -
, O +
co O -
- O -
expression O +
of O +
the O +
Gq O +
subunits O +
decelerated O +
the O +
recovery O +
of O +
the O +
declined O +
FRET O +
upon O +
removal O +
of O +
the O +
agonists O -
, O +
which O +
was O +
slower O +
than O +
the O +
dissociation O +
of O +
the O +
Gq O +
subunits O +
from O +
the O +
receptor O -
. O +

These O +
results O +
suggested O +
that O +
Gq O +
binding O +
stabilizes O +
the O +
agonist O -
- O -
induced O +
activated O +
conformation O +
of O +
the O +
M O -
( O -
1 O -
) O -
R. O +
We O +
also O +
found O +
that O +
depolarization O +
of O +
the O +
membrane O +
potential O +
slightly O +
but O +
significantly O +
enhanced O +
the O +
agonist O -
- O -
induced O +
FRET O +
decrease O -
, O +
by O +
accelerating O +
the O +
agonist O -
- O -
induced O +
conformational O +
changes O -
. O +

Thus O -
, O +
structural O +
rearrangement O +
analyses O +
by O +
FRET O +
revealed O +
that O +
Gq O +
coupling O +
stabilizes O +
the O +
active O +
conformation O +
of O +
the O +
M O -
( O -
1 O -
) O -
R O +
and O +
also O +
suggested O +
that O +
depolarization O +
accelerates O +
the O +
transition O +
from O +
quiescent O +
to O +
activation O +
conformation O -
. O +

What O +
is O +
behind O +
the O +
non O -
- O -
antibiotic O +
properties O +
of O +
minocycline B-Chemical -
? O +

Minocycline B-Chemical +
is O +
a O +
second O -
- O -
generation O -
, O +
semi O -
- O -
synthetic O +
tetracycline B-Chemical +
that O +
has O +
been O +
in O +
use O +
in O +
therapy O +
for O +
over O +
30 O +
years O +
for O +
its O +
antibiotic O +
properties O +
against O +
both O +
Gram O -
- O -
positive O +
and O +
Gram O -
- O -
negative O +
bacteria O -
. O +

It O +
displays O +
antibiotic O +
activity O +
due O +
to O +
its O +
ability O +
to O +
bind O +
to O +
the O +
30S O +
ribosomal O +
subunit O +
of O +
bacteria O +
and O +
thus O +
inhibit O +
protein O +
synthesis O -
. O +

More O +
recently O -
, O +
it O +
has O +
been O +
described O +
to O +
exert O +
a O +
variety O +
of O +
biological O +
actions O +
beyond O +
its O +
antimicrobial O +
activity O -
, O +
including O +
anti O -
- O -
inflammatory O +
and O +
anti O -
- O -
apoptotic O +
activities O -
, O +
inhibition O +
of O +
proteolysis O -
, O +
as O +
well O +
as O +
suppression O +
of O +
angiogenesis O +
and O +
tumor O +
metastasis O -
, O +
which O +
have O +
been O +
confirmed O +
in O +
different O +
experimental O +
models O +
of O +
non O -
- O -
infectious O +
diseases O -
. O +

There O +
are O +
also O +
many O +
studies O +
that O +
have O +
focused O +
on O +
the O +
mechanisms O +
involved O +
in O +
these O +
non O -
- O -
antibiotic O +
properties O +
of O +
minocycline B-Chemical -
, O +
including O +
anti O -
- O -
oxidant O +
activity O -
, O +
inhibition O +
of O +
several O +
enzyme O +
activities O -
, O +
inhibition O +
of O +
apoptosis O +
and O +
regulation O +
of O +
immune O +
cell O +
activation O +
and O +
proliferation O -
. O +

This O +
review O +
summarizes O +
the O +
current O +
findings O +
in O +
this O +
topic O -
, O +
mainly O +
focusing O +
on O +
the O +
mechanisms O +
underlying O +
the O +
immunomodulatory O +
and O +
anti O -
- O -
inflammatory O +
activities O +
of O +
minocycline B-Chemical -
. O +

Target O +
promiscuity O +
and O +
physicochemical O +
properties O +
contribute O +
to O +
pharmacologically O +
induced O +
ER O -
- O -
stress O -
. O +

In O +
vivo O +
toxicity O +
of O +
drug O +
candidates O +
remains O +
a O +
major O +
problem O +
in O +
the O +
pharmaceutical O +
industry O -
, O +
and O +
is O +
a O +
significant O +
cause O +
of O +
late O +
stage O +
attrition O -
. O +

As O +
a O +
consequence O +
predictive O +
in O +
vitro O +
assays O +
are O +
developed O +
and O +
put O +
in O +
place O +
early O +
in O +
the O +
discovery O +
pipeline O +
to O +
aid O +
compound O +
selection O -
. O +

Endoplasmic O +
reticulum O +
stress O +
( O -
ER O -
- O -
stress O -
) O +
has O +
been O +
implicated O +
in O +
many O +
disease O +
states O -
, O +
as O +
well O +
as O +
compound O -
- O -
induced O +
organ O +
toxicities O -
. O +

We O +
explored O +
the O +
role O +
of O +
ER O -
- O -
stress O +
as O +
a O +
general O +
mechanism O +
of O +
toxicity O +
by O +
utilizing O +
a O +
high O -
- O -
throughput O +
in O +
vitro O +
assay O +
to O +
screen O +
316 O +
chemically O +
diverse O +
Pfizer O +
proprietary O +
compounds O +
with O +
known O +
in O +
vivo O +
toxicity O +
outcome O +
for O +
nuclear O +
accumulation O +
of O +
spliced O +
x O -
- O -
box O +
binding O +
protein O +
1 O +
( O -
XBP1s O -
) O -
, O +
a O +
key O +
transcription O +
factor O +
of O +
the O +
unfolded O +
protein O +
response O +
( O -
UPR O -
) O -
. O +

We O +
examined O +
the O +
correlation O +
between O +
physicochemical O +
properties O -
, O +
such O +
as O +
molecular O +
weight O -
, O +
pKA O -
, O +
lipophilicity O -
, O +
topological O +
polar O +
surface O +
area O -
, O +
and O +
passive O +
permeability O -
, O +
as O +
well O +
as O +
target O +
promiscuity O -
, O +
between O +
XBP1s O +
hits O +
and O +
non O -
- O -
hits O +
and O +
found O +
that O +
lipophilicity O -
, O +
target O +
promiscuity O +
and O +
low O +
passive O +
permeability O +
significantly O +
contributed O +
to O +
ER O -
- O -
stress O -
. O +

In O +
addition O -
, O +
we O +
have O +
shown O +
that O +
compounds O +
which O +
cause O +
ER O -
- O -
stress O +
in O +
the O +
form O +
of O +
XBP1s O +
activation O +
at O +
concentrations O +
below O +
40 O +
μM O +
have O +
a O +
more O +
than O +
four O +
times O +
greater O +
chance O +
of O +
causing O +
in O +
vivo O +
toxicity O +
at O +
10 O +
μM O +
plasma O +
exposure O -
. O +

Chemical O +
cholecystokinin O +
receptor O +
activation O +
protects O +
against O +
obesity O -
- O -
diabetes O +
in O +
high O +
fat O +
fed O +
mice O +
and O +
has O +
sustainable O +
beneficial O +
effects O +
in O +
genetic O +
ob O -
/ O -
ob O +
mice O -
. O +

The O +
current O +
study O +
has O +
determined O +
the O +
ability O +
of O +
( O -
pGlu O -
- O -
Gln O -
) O -
-CCK-8 O +
to O +
counter O +
the O +
development O +
of O +
diet O -
- O -
induced O +
obesity O -
- O -
diabetes O +
and O +
examined O +
persistence O +
of O +
beneficial O +
metabolic O +
effects O +
in O +
high O +
fat O +
and O +
ob O -
/ O -
ob O +
mice O -
, O +
respectively O -
. O +

Twice O +
daily O +
injection O +
of O +
( O -
pGlu O -
- O -
Gln O -
) O -
-CCK-8 O +
in O +
normal O +
mice O +
transferred O +
to O +
a O +
high O +
fat O +
diet O +
reduced O +
energy O +
intake O +
( O -
p O +
< O +
0.001 O -
) O -
, O +
body O +
weight O +
( O -
p O +
< O +
0.01 O -
) O -
, O +
circulating O +
insulin O +
and O +
LDL O -
- O -
cholesterol B-Chemical +
( O -
p O +
< O +
0.001 O -
) O +
and O +
improved O +
insulin O +
sensitivity O +
( O -
p O +
< O +
0.001 O -
) O +
as O +
well O +
as O +
oral O +
and O +
intraperitoneal O +
( O -
p O +
< O +
0.001 O -
) O +
glucose B-Chemical +
tolerance O -
. O +

Energy O +
intake O -
, O +
body O +
weight O -
, O +
circulating O +
insulin O +
and O +
glucose B-Chemical +
tolerance O +
of O +
( O -
pGlu O -
- O -
Gln O -
) O -
-CCK-8 O +
mice O +
were O +
similar O +
to O +
lean O +
controls O -
. O +

In O +
addition O -
, O +
( O -
pGlu O -
- O -
Gln O -
) O -
-CCK-8 O +
prevented O +
the O +
effect O +
of O +
high O +
fat O +
feeding O +
on O +
triacylglycerol B-Chemical +
accumulation O +
in O +
liver O +
and O +
muscle O -
. O +

Interestingly O -
, O +
( O -
pGlu O -
- O -
Gln O -
) O -
-CCK-8 O +
significantly O +
( O -
p O +
< O +
0.001 O -
) O +
elevated O +
pancreatic O +
glucagon O +
content O -
. O +

Histological O +
examination O +
of O +
the O +
pancreata O +
of O +
( O -
pGlu O -
- O -
Gln O -
) O -
-CCK-8 O +
mice O +
revealed O +
no O +
changes O +
in O +
islet O +
number O +
or O +
size O -
, O +
but O +
there O +
was O +
increased O +
turnover O +
of O +
beta O -
- O -
cells O +
with O +
significantly O +
( O -
p O +
< O +
0.001 O -
) O +
increased O +
numbers O +
of O +
peripherally O +
located O +
alpha O -
- O -
cells O -
, O +
co O -
- O -
expressing O +
both O +
glucagon O +
and O +
GLP-1 O -
. O +

Beneficial O +
metabolic O +
effects O +
were O +
observed O +
similarly O +
in O +
ob O -
/ O -
ob O +
mice O +
treated O +
twice O +
daily O +
with O +
( O -
pGlu O -
- O -
Gln O -
) O -
-CCK-8 O +
for O +
18 O +
days O -
, O +
including O +
significantly O +
reduced O +
energy O +
intake O +
( O -
p O +
< O +
0.05 O -
) O -
, O +
body O +
weight O +
( O -
p O +
< O +
0.05 O +
to O +
p O +
< O +
0.01 O -
) O -
, O +
circulating O +
glucose B-Chemical +
( O -
p O +
< O +
0.05 O +
to O +
p O +
< O +
0.01 O -
) O +
and O +
insulin O +
( O -
p O +
< O +
0.05 O +
to O +
p O +
< O +
0.001 O -
) O +
and O +
improved O +
glucose B-Chemical +
tolerance O +
( O -
p O +
< O +
0.05 O -
) O +
and O +
insulin O +
sensitivity O +
( O -
p O +
< O +
0.001 O -
) O -
. O +

Notably O -
, O +
these O +
beneficial O +
effects O +
were O +
still O +
evident O +
18 O +
days O +
following O +
cessation O +
of O +
treatment O -
. O +

These O +
studies O +
emphasize O +
the O +
potential O +
of O +
( O -
pGlu O -
- O -
Gln O -
) O -
-CCK-8 O +
for O +
the O +
treatment O +
of O +
obesity O -
- O -
diabetes O -
. O +

Effects O +
of O +
DMSA B-Chemical -
- O -
coated O +
Fe3O4 B-Chemical +
nanoparticles O +
on O +
the O +
transcription O +
of O +
genes O +
related O +
to O +
iron B-Chemical +
and O +
osmosis O +
homeostasis O -
. O +

In O +
this O +
article O -
, O +
we O +
checked O +
the O +
effect O +
of O +
2,3-dimercaptosuccinic B-Chemical +
acid I-Chemical -
- O -
coated O +
Fe B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
O I-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical +
nanoparticles O +
on O +
gene O +
expression O +
of O +
mouse O +
macrophage O +
RAW264.7 O +
cells O +
and O +
found O +
that O +
the O +
transcription O +
of O +
several O +
important O +
genes O +
related O +
to O +
intracellular O +
iron B-Chemical +
homeostasis O +
were O +
significantly O +
changed O -
. O +

We O +
thus O +
speculated O +
that O +
the O +
cellular O +
iron B-Chemical +
homeostasis O +
might O +
be O +
disturbed O +
by O +
this O +
nanoparticle O +
through O +
releasing O +
iron B-Chemical +
ion O +
in O +
cells O -
. O +

To O +
verify O +
this O +
speculation O -
, O +
we O +
first O +
confirmed O +
the O +
transcriptional O +
changes O +
of O +
several O +
key O +
iron B-Chemical +
homeostasis- O +
related O +
genes O -
, O +
such O +
as O +
Tfrc O -
, O +
Trf O -
, O +
and O +
Lcn2 O -
, O +
using O +
quantitative O +
PCR O -
, O +
and O +
found O +
that O +
an O +
iron B-Chemical +
ion O +
chelator O -
, O +
desferrioxamine B-Chemical -
, O +
could O +
alleviate O +
the O +
transcriptional O +
alterations O +
of O +
two O +
typical O +
genes O -
, O +
Tfrc O +
and O +
Lcn2 O -
. O +

Then O -
, O +
we O +
designed O +
and O +
validated O +
a O +
method O +
based O +
on O +
centrifugation O +
for O +
assaying O +
intracellular O +
irons B-Chemical +
in O +
ion O +
and O +
nanoparticle O +
state O -
. O +

After O +
extensive O +
measures O +
of O +
intracellular O +
iron B-Chemical +
in O +
two O +
forms O +
and O +
total O +
iron B-Chemical -
, O +
we O +
found O +
that O +
the O +
intracellular O +
iron B-Chemical +
ion O +
significantly O +
increased O +
with O +
intracellular O +
total O +
iron B-Chemical +
and O +
nanoparticle O +
iron B-Chemical -
, O +
demonstrating O +
degradation O +
of O +
this O +
nanoparticle O +
into O +
iron B-Chemical +
ion O +
in O +
cells O -
. O +

We O +
next O +
mimicked O +
the O +
intralysosomal O +
environment O +
in O +
vitro O +
and O +
verified O +
that O +
the O +
internalized O +
iron O +
nanoparticle O +
could O +
release O +
iron B-Chemical +
ion O +
in O +
lysosome O -
. O +

We O +
found O +
that O +
as O +
another O +
important O +
compensatory O +
response O +
to O +
intracellular O +
overload O +
of O +
iron B-Chemical +
ion O -
, O +
cells O +
significantly O +
downregulated O +
the O +
expressions O +
of O +
genes O +
belonging O +
to O +
solute O +
carrier O +
family O +
which O +
are O +
responsible O +
for O +
transferring O +
many O +
organic O +
solutes O +
into O +
cells O -
, O +
such O +
as O +
Slc5a3 O +
and O +
Slc44a1 O -
, O +
in O +
order O +
to O +
prevent O +
more O +
organic O +
solutes O +
into O +
cells O +
and O +
thus O +
lower O +
the O +
intracellular O +
osmosis O -
. O +

Based O +
on O +
these O +
findings O -
, O +
we O +
profiled O +
a O +
map O +
of O +
gene O +
effects O +
after O +
cells O +
were O +
treated O +
with O +
this O +
iron B-Chemical +
nanoparticle O +
and O +
concluded O +
that O +
the O +
iron B-Chemical +
nanoparticles O +
might O +
be O +
more O +
detrimental O +
to O +
cell O +
than O +
iron B-Chemical +
ion O +
due O +
to O +
its O +
intracellular O +
internalization O +
fashion O -
, O +
nonspecific O +
endocytosis O -
. O +

Developmental O +
consequences O +
of O +
the O +
ColQ O -
/ O -
MuSK O +
interactions O -
. O +

CollagenQ O +
( O -
ColQ O -
) O +
is O +
a O +
specific O +
collagen O +
that O +
anchors O +
acetylcholinesterase O +
( O -
AChE O -
) O +
in O +
the O +
synaptic O +
basal O +
lamina O +
of O +
the O +
neuromuscular O +
junction O +
( O -
NMJ O -
) O -
. O +

Over O +
30 O +
mutations O +
in O +
the O +
COLQ O +
gene O +
have O +
been O +
identified O +
that O +
are O +
responsible O +
for O +
a O +
congenital O +
myasthenic O +
syndrome O +
with O +
AChE O +
deficiency O -
, O +
highlighting O +
the O +
importance O +
of O +
this O +
collagen O +
in O +
the O +
physiology O +
of O +
the O +
NMJ O -
. O +

The O +
anchoring O +
of O +
AChE O +
at O +
the O +
synapse O +
requires O +
the O +
interaction O +
of O +
ColQ O +
with O +
MuSK O +
( O -
Muscle O -
- O -
Specific O +
Kinase O -
) O -
, O +
a O +
tyrosine B-Chemical +
kinase O +
expressed O +
on O +
the O +
muscle O +
membrane O +
that O +
is O +
necessary O +
for O +
the O +
formation O +
and O +
the O +
maintenance O +
of O +
the O +
NMJ O -
. O +

MuSK O +
forms O +
with O +
its O +
co O -
- O -
receptor O +
LRP4 O -
, O +
a O +
member O +
of O +
the O +
Low O -
- O -
density O +
Related O +
Protein O +
family O -
, O +
a O +
receptor O +
complex O +
for O +
agrin O +
and O +
Wnts O -
, O +
representing O +
the O +
core O +
system O +
from O +
which O +
the O +
postsynaptic O +
domain O +
is O +
built O -
, O +
the O +
growth O +
cone O +
attracted O +
and O +
the O +
presynaptic O +
element O +
instructed O +
for O +
some O +
aspects O +
of O +
its O +
differentiation O -
. O +

Therefore O -
, O +
the O +
discovery O +
that O +
ColQ O +
binds O +
to O +
MuSK O +
prompted O +
us O +
to O +
study O +
a O +
possible O +
regulatory O +
function O +
of O +
ColQ O +
during O +
NMJ O +
development O -
. O +

In O +
this O +
review O -
, O +
after O +
a O +
brief O +
survey O +
on O +
ColQ O -
, O +
we O +
summarize O +
our O +
recent O +
data O +
demonstrating O +
that O +
ColQ O -
, O +
in O +
addition O +
to O +
its O +
anchoring O +
role O -
, O +
exerts O +
signaling O +
functions O +
and O +
controls O +
some O +
aspects O +
of O +
postsynaptic O +
differentiation O +
such O +
as O +
the O +
clustering O +
of O +
acetylcholine O +
receptors O -
. O +

Our O +
results O +
also O +
strengthen O +
the O +
hypothesis O +
that O +
the O +
defects O +
observed O +
in O +
synaptic O +
congenital O +
myasthenic O +
syndromes O +
might O +
be O +
linked O -
, O +
at O +
least O +
in O +
part O -
, O +
to O +
alterations O +
of O +
ColQ O +
signaling O +
functions O +
and O +
not O +
only O +
to O +
AChE O +
deficiency O -
. O +

Finally O -
, O +
we O +
discuss O +
future O +
research O +
directions O +
to O +
understand O +
how O +
ColQ O +
may O +
modulate O +
the O +
action O +
of O +
the O +
other O +
ligands O +
of O +
the O +
MuSK O -
/ O -
LRP4 O +
complex O +
and O +
cooperate O +
with O +
them O +
to O +
coordinate O +
the O +
different O +
steps O +
of O +
NMJ O +
formation O +
and O +
maintenance O -
. O +

Enhanced O +
charge O +
carrier O +
mobility O +
in O +
two O -
- O -
dimensional O +
high O +
dielectric O +
molybdenum B-Chemical +
oxide I-Chemical -
. O +

We O +
demonstrate O +
that O +
the O +
energy O +
bandgap O +
of O +
layered O -
, O +
high O -
- O -
dielectric O +
α B-Chemical -
- I-Chemical -
MoO I-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical +
can O +
be O +
reduced O +
to O +
values O +
viable O +
for O +
the O +
fabrication O +
of O +
2D O +
electronic O +
devices O -
. O +

This O +
is O +
achieved O +
through O +
embedding O +
Coulomb O +
charges O +
within O +
the O +
high O +
dielectric O +
media O -
, O +
advantageously O +
limiting O +
charge O +
scattering O -
. O +

As O +
a O +
result O -
, O +
devices O +
with O +
α B-Chemical -
- I-Chemical -
MoO I-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical +
of O +
∼11 O +
nm O +
thickness O +
and O +
carrier O +
mobilities O +
larger O +
than O +
1100 O +
cm O -
( O -
2 O -
) O +
V O -
( O -
-1 O -
) O +
s O -
( O -
-1 O -
) O +
are O +
obtained O -
. O +

Adsorption O +
of O +
multimeric O +
T O +
cell O +
antigens O +
on O +
carbon B-Chemical +
nanotubes O -
: O +
effect O +
on O +
protein O +
structure O +
and O +
antigen O -
- O -
specific O +
T O +
cell O +
stimulation O -
. O +

Antigen O -
- O -
specific O +
activation O +
of O +
cytotoxic O +
T O +
cells O +
can O +
be O +
enhanced O +
up O +
to O +
three O -
- O -
fold O +
more O +
than O +
soluble O +
controls O +
when O +
using O +
functionalized O +
bundled O +
carbon B-Chemical +
nanotube O +
substrates O +
( O -
( O -
b O -
) O +
CNTs O -
) O -
. O +

To O +
overcome O +
the O +
denaturing O +
effects O +
of O +
direct O +
adsorption O +
on O +
( O -
b O -
) O +
CNTs O -
, O +
a O +
simple O +
but O +
robust O +
method O +
is O +
demonstrated O +
to O +
stabilize O +
the O +
T O +
cell O +
stimulus O +
on O +
carbon B-Chemical +
nanotube O +
substrates O +
through O +
non O -
- O -
covalent O +
attachment O +
of O +
the O +
linker O +
neutravidin O -
. O +

Combination O +
lopinavir B-Chemical +
and O +
ritonavir B-Chemical +
alter O +
exogenous O +
and O +
endogenous O +
bile B-Chemical +
acid I-Chemical +
disposition O +
in O +
sandwich O -
- O -
cultured O +
rat O +
hepatocytes O -
. O +

Inhibition O +
of O +
the O +
bile B-Chemical +
salt I-Chemical +
export O +
pump O +
( O -
BSEP O -
) O +
can O +
cause O +
intracellular O +
accumulation O +
of O +
bile B-Chemical +
acids I-Chemical +
and O +
is O +
a O +
risk O +
factor O +
for O +
drug O -
- O -
induced O +
liver O +
injury O +
in O +
humans O -
. O +

Antiretroviral O +
protease O +
inhibitors O +
lopinavir B-Chemical +
( O -
LPV B-Chemical -
) O +
and O +
ritonavir B-Chemical +
( O -
RTV B-Chemical -
) O +
are O +
reported O +
BSEP O +
inhibitors O -
. O +

However O -
, O +
the O +
consequences O +
of O +
LPV B-Chemical +
and O +
RTV B-Chemical -
, O +
alone O +
and O +
combined O +
( O -
LPV B-Chemical -
/ O -
r O -
) O -
, O +
on O +
hepatocyte O +
viability O -
, O +
bile B-Chemical +
acid I-Chemical +
transport O -
, O +
and O +
endogenous O +
bile B-Chemical +
acid I-Chemical +
disposition O +
in O +
rat O +
hepatocytes O +
have O +
not O +
been O +
examined O -
. O +

The O +
effect O +
of O +
LPV B-Chemical -
, O +
RTV B-Chemical -
, O +
and O +
LPV B-Chemical -
/ O -
r O +
on O +
cellular O +
viability O +
and O +
the O +
disposition O +
of O +
[ B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
H I-Chemical -
] I-Chemical -
taurocholic I-Chemical +
acid I-Chemical +
( O -
TCA B-Chemical -
) O +
and O +
[ B-Chemical -
( I-Chemical -
14 I-Chemical -
) I-Chemical -
C I-Chemical -
] I-Chemical -
chenodeoxycholic I-Chemical +
acid I-Chemical +
( O -
CDCA B-Chemical -
) O +
was O +
determined O +
in O +
sandwich O -
- O -
cultured O +
rat O +
hepatocytes O +
( O -
SCRH O -
) O +
and O +
suspended O +
rat O +
hepatocytes O -
. O +

Lactate B-Chemical +
dehydrogenase O +
and O +
ATP B-Chemical +
assays O +
revealed O +
a O +
concentration O -
- O -
dependent O +
effect O +
of O +
LPV B-Chemical +
and O +
RTV B-Chemical +
on O +
cellular O +
viability O -
. O +

LPV B-Chemical +
( O -
5 O +
µM O -
) O -
, O +
alone O +
and O +
combined O +
with O +
5 O +
µM O +
RTV B-Chemical -
, O +
significantly O +
decreased O +
[ B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
H I-Chemical -
] I-Chemical -
TCA I-Chemical +
accumulation O +
in O +
cells O +
+ O +
bile O +
of O +
SCRHs O +
compared O +
with O +
control O -
. O +

LPV B-Chemical -
/ O -
r O +
significantly O +
increased O +
[ B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
H I-Chemical -
] I-Chemical -
TCA I-Chemical +
cellular O +
accumulation O +
( O -
7.7 O +
± O +
0.1 O +
pmol O -
/ O -
mg O +
of O +
protein O -
) O +
compared O +
with O +
vehicle O +
and O +
5 O +
µM O +
LPV B-Chemical +
alone O +
( O -
5.1 O +
± O +
0.7 O +
and O +
5.0 O +
± O +
0.5 O +
pmol O -
/ O -
mg O +
of O +
protein O -
) O -
. O +

The O +
[ B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
H I-Chemical -
] I-Chemical -
TCA I-Chemical +
biliary O +
clearance O +
was O +
reduced O +
significantly O +
by O +
LPV B-Chemical +
and O +
RTV B-Chemical +
and O +
further O +
reduced O +
by O +
LPV B-Chemical -
/ O -
r O -
. O +

LPV B-Chemical +
and O +
RTV B-Chemical +
did O +
not O +
affect O +
the O +
initial O +
uptake O +
rates O +
of O +
[ B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
H I-Chemical -
] I-Chemical -
TCA I-Chemical +
or O +
[ B-Chemical -
( I-Chemical -
14 I-Chemical -
) I-Chemical -
C I-Chemical -
] I-Chemical -
CDCA I-Chemical +
in O +
suspended O +
rat O +
hepatocytes O -
. O +

LPV B-Chemical +
( O -
50 O +
µM O -
) O -
, O +
RTV B-Chemical +
( O -
5 O +
µM O -
) O -
, O +
and O +
LPV B-Chemical -
/ O -
r O +
( O -
5 O +
and O +
50 O +
µM O -
/ O -
5 O +
µM O -
) O +
significantly O +
decreased O +
the O +
accumulation O +
of O +
total O +
measured O +
endogenous O +
bile B-Chemical +
acids I-Chemical +
( O -
TCA B-Chemical -
, O +
glycocholic B-Chemical +
acid I-Chemical -
, O +
taurochenodeoxycholic B-Chemical +
acid I-Chemical -
, O +
glycochenodeoxycholic B-Chemical +
acid I-Chemical -
, O +
and O +
α B-Chemical -
/ I-Chemical -
β I-Chemical -
- I-Chemical -
tauromuricholic I-Chemical +
acid I-Chemical -
) O +
in O +
SCRH O -
. O +

Quantification O +
of O +
endogenous O +
bile B-Chemical +
acids I-Chemical +
in O +
SCRH O +
may O +
reveal O +
important O +
adaptive O +
responses O +
associated O +
with O +
exposure O +
to O +
known O +
BSEP O +
inhibitors O -
. O +

Phosphoinositide O -
- O -
dependent O +
kinase-1 O +
and O +
protein O +
kinase O +
Cδ O +
contribute O +
to O +
endothelin-1 O +
constriction O +
and O +
elevated O +
blood O +
pressure O +
in O +
intermittent O +
hypoxia O -
. O +

Obstructive O +
sleep O +
apnea O +
( O -
OSA O -
) O +
is O +
associated O +
with O +
cardiovascular O +
complications O +
including O +
hypertension O -
. O +

Previous O +
findings O +
from O +
our O +
laboratory O +
indicate O +
that O +
exposure O +
to O +
intermittent O +
hypoxia O +
( O -
IH O -
) O -
, O +
to O +
mimic O +
sleep O +
apnea O -
, O +
increases O +
blood O +
pressure O +
in O +
rats O -
. O +

IH O +
also O +
increases O +
endothelin-1 O +
( O -
ET-1 O -
) O +
constrictor O +
sensitivity O +
in O +
a O +
protein O +
kinase O +
C O +
( O -
PKC O -
) O +
δ O -
- O -
dependent O +
manner O +
in O +
mesenteric O +
arteries O -
. O +

Because O +
phosphoinositide O -
- O -
dependent O +
kinase-1 O +
( O -
PDK-1 O -
) O +
regulates O +
PKCδ O +
activity O -
, O +
we O +
hypothesized O +
that O +
PDK-1 O +
contributes O +
to O +
the O +
augmented O +
ET-1 O +
constrictor O +
sensitivity O +
and O +
elevated O +
blood O +
pressure O +
following O +
IH O -
. O +

Male O +
Sprague O -
- O -
Dawley O +
rats O +
were O +
exposed O +
to O +
either O +
sham O +
or O +
IH O +
( O -
cycles O +
between O +
21 O -
% O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
/ O -
0 O -
% O +
CO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
and O +
5 O -
% O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
/ O -
5 O -
% O +
CO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
) O +
conditions O +
for O +
7 O +
h O -
/ O -
day O +
for O +
14 O +
or O +
21 O +
days O -
. O +

The O +
contribution O +
of O +
PKCδ O +
and O +
PDK-1 O +
to O +
ET-1-mediated O +
vasoconstriction O +
was O +
assessed O +
in O +
mesenteric O +
arteries O +
using O +
pharmacological O +
inhibitors O -
. O +

Constrictor O +
sensitivity O +
to O +
ET-1 O +
was O +
enhanced O +
in O +
arteries O +
from O +
IH O -
- O -
exposed O +
rats O -
. O +

Inhibition O +
of O +
PKCδ O +
or O +
PDK-1 O +
blunted O +
ET-1 O +
constriction O +
in O +
arteries O +
from O +
IH O +
but O +
not O +
sham O +
group O +
rats O -
. O +

Western O +
analysis O +
revealed O +
similar O +
levels O +
of O +
total O +
and O +
phosphorylated O +
PDK-1 O +
in O +
arteries O +
from O +
sham O +
and O +
IH O +
group O +
rats O +
but O +
decreased O +
protein O -
- O -
protein O +
interaction O +
between O +
PKCδ O +
and O +
PDK-1 O +
in O +
arteries O +
from O +
IH- O +
compared O +
with O +
sham O -
- O -
exposed O +
rats O -
. O +

Blood O +
pressure O +
was O +
increased O +
in O +
rats O +
exposed O +
to O +
IH O -
, O +
and O +
treatment O +
with O +
the O +
PDK-1 O +
inhibitor O +
OSU-03012 B-Chemical +
[ O -
2-amino B-Chemical -
- I-Chemical -
N- I-Chemical -
{ I-Chemical -
4- I-Chemical -
[ I-Chemical -
5- I-Chemical -
( I-Chemical -
2-phenanthrenyl I-Chemical -
) I-Chemical -
-3- I-Chemical -
( I-Chemical -
trifluoromethyl I-Chemical -
) I-Chemical -
-1H I-Chemical -
- I-Chemical -
pyrazol-1-yl I-Chemical -
] I-Chemical -
-phenyl I-Chemical -
} I-Chemical -
-acetamide I-Chemical -
] O +
( O -
33 O +
mg O -
/ O -
day O -
) O +
lowered O +
blood O +
pressure O +
in O +
IH O +
but O +
not O +
sham O +
group O +
rats O -
. O +

Our O +
results O +
suggest O +
that O +
exposure O +
to O +
IH O +
unmasks O +
a O +
role O +
for O +
PDK-1 O +
in O +
regulating O +
ET-1 O +
constrictor O +
sensitivity O +
and O +
blood O +
pressure O +
that O +
is O +
not O +
present O +
under O +
normal O +
conditions O -
. O +

These O +
novel O +
findings O +
suggest O +
that O +
PDK-1 O +
may O +
be O +
a O +
uniquely O +
effective O +
antihypertensive O +
therapy O +
for O +
OSA O +
patients O -
. O +

Mouse O +
liver O +
protein O +
sulfhydryl B-Chemical +
depletion O +
after O +
acetaminophen B-Chemical +
exposure O -
. O +

Acetaminophen B-Chemical +
( O -
APAP B-Chemical -
) O -
-induced O +
liver O +
injury O +
is O +
the O +
leading O +
cause O +
of O +
acute O +
liver O +
failure O +
in O +
many O +
countries O -
. O +

This O +
study O +
determined O +
the O +
extent O +
of O +
liver O +
protein O +
sulfhydryl B-Chemical +
depletion O +
not O +
only O +
in O +
whole O +
liver O +
homogenate O +
but O +
also O +
in O +
the O +
zonal O +
pattern O +
of O +
sulfhydryl B-Chemical +
depletion O +
within O +
the O +
liver O +
lobule O -
. O +

A O +
single O +
oral O +
gavage O +
dose O +
of O +
150 O +
or O +
300 O +
mg O -
/ O -
kg O +
APAP B-Chemical +
in O +
B6C3F1 O +
mice O +
produced O +
increased O +
serum O +
alanine B-Chemical +
aminotransferase O +
levels O -
, O +
liver O +
necrosis O -
, O +
and O +
glutathione B-Chemical +
depletion O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O +

Free O +
protein O +
sulfhydryls B-Chemical +
were O +
measured O +
in O +
liver O +
protein O +
homogenates O +
by O +
labeling O +
with O +
maleimide B-Chemical +
linked O +
to O +
a O +
near O +
infrared O +
fluorescent O +
dye O +
followed O +
by O +
SDS B-Chemical -
- O -
polyacrylamide B-Chemical +
gel O +
electrophoresis O -
. O +

Global O +
protein O +
sulfhydryl B-Chemical +
levels O +
were O +
decreased O +
significantly O +
( O -
48.4 O -
% O -
) O +
starting O +
at O +
1 O +
hour O +
after O +
the O +
APAP B-Chemical +
dose O +
and O +
maintained O +
at O +
this O +
reduced O +
level O +
through O +
24 O +
hours O -
. O +

To O +
visualize O +
the O +
specific O +
hepatocytes O +
that O +
had O +
reduced O +
protein O +
sulfhydryl B-Chemical +
levels O -
, O +
frozen O +
liver O +
sections O +
were O +
labeled O +
with O +
maleimide B-Chemical +
linked O +
to O +
horseradish O +
peroxidase O -
. O +

The O +
centrilobular O +
areas O +
exhibited O +
dramatic O +
decreases O +
in O +
free O +
protein O +
sulfhydryls B-Chemical +
while O +
the O +
periportal O +
regions O +
were O +
essentially O +
spared O -
. O +

These O +
protein O +
sulfhydryl B-Chemical -
- O -
depleted O +
regions O +
correlated O +
with O +
areas O +
exhibiting O +
histopathologic O +
injury O +
and O +
APAP B-Chemical +
binding O +
to O +
protein O -
. O +

The O +
majority O +
of O +
protein O +
sulfhydryl B-Chemical +
depletion O +
was O +
due O +
to O +
reversible O +
oxidation O +
since O +
the O +
global- O +
and O +
lobule O -
- O -
specific O +
effects O +
were O +
essentially O +
reversed O +
when O +
the O +
samples O +
were O +
reduced O +
with O +
tris B-Chemical -
( I-Chemical -
2-carboxyethy I-Chemical -
) I-Chemical -
phosphine I-Chemical +
before O +
maleimide B-Chemical +
labeling O -
. O +

These O +
temporal O +
and O +
zonal O +
pattern O +
changes O +
in O +
protein O +
sulfhydryl B-Chemical +
oxidation O +
shed O +
new O +
light O +
on O +
the O +
importance O +
that O +
changes O +
in O +
protein O +
redox O +
status O +
might O +
play O +
in O +
the O +
pathogenesis O +
of O +
APAP B-Chemical +
hepatotoxicity O -
. O +

Dietary O +
exposure O +
to O +
inorganic O +
arsenic B-Chemical +
of O +
the O +
Hong O +
Kong O +
population O -
: O +
results O +
of O +
the O +
first O +
Hong O +
Kong O +
total O +
diet O +
study O -
. O +

Inorganic O +
arsenic B-Chemical -
, O +
a O +
human O +
carcinogen O -
, O +
can O +
be O +
found O +
in O +
the O +
environment O +
and O +
food O -
. O +

In O +
the O +
first O +
Hong O +
Kong O +
Total O +
Diet O +
Study O -
, O +
the O +
dietary O +
exposure O +
of O +
the O +
Hong O +
Kong O +
people O -
, O +
including O +
various O +
age O -
- O -
gender O +
subgroups O -
, O +
to O +
inorganic O +
arsenic B-Chemical +
was O +
estimated O +
for O +
assessing O +
the O +
associated O +
health O +
risk O -
. O +

Food O +
samples O -
, O +
which O +
represented O +
the O +
Hong O +
Kong O +
people O -
's O +
diet O -
, O +
were O +
collected O +
and O +
prepared O +
" O -
as O +
consumed O -
" O +
for O +
analysis O -
. O +

Concentrations O +
of O +
inorganic O +
arsenic B-Chemical -
, O +
as O +
sum O +
of O +
arsenite B-Chemical +
( O -
As B-Chemical -
( I-Chemical -
III I-Chemical -
) I-Chemical -
) O +
and O +
arsenate B-Chemical +
( O -
As B-Chemical -
( I-Chemical -
V I-Chemical -
) I-Chemical -
) O +
were O +
determined O +
in O +
600 O +
composite O +
samples O +
by O +
using O +
inductively O +
coupled O +
plasma O +
mass O +
spectrometry O -
. O +

The O +
dietary O +
exposures O +
were O +
estimated O +
by O +
combining O +
the O +
analytical O +
results O +
with O +
the O +
local O +
food O +
consumption O +
data O +
of O +
the O +
adult O +
population O -
. O +

The O +
mean O +
and O +
95th O +
percentile O +
of O +
inorganic O +
arsenic B-Chemical +
exposures O +
of O +
the O +
Hong O +
Kong O +
people O +
were O +
0.22 O +
and O +
0.38μg O -
/ O -
kg O +
body O +
weight O +
( O -
bw O -
) O -
/ O -
day O -
, O +
respectively O -
. O +

Among O +
the O +
12 O +
age O -
- O -
gender O +
subgroups O -
, O +
the O +
respective O +
exposures O +
ranged O +
from O +
0.19 O +
to O +
0.26μg O -
/ O -
kg O +
bw O -
/ O -
day O +
and O +
from O +
0.33 O +
to O +
0.46μg O -
/ O -
kg O +
bw O -
/ O -
day O -
. O +

The O +
main O +
food O +
category O +
that O +
contributed O +
inorganic O +
arsenic B-Chemical +
was O +
" O -
cereals O +
and O +
their O +
products O -
" O +
( O -
53.5 O -
% O +
of O +
the O +
total O +
exposure O -
) O -
, O +
particularly O +
rice O -
. O +

Having O +
considered O +
the O +
carcinogenic O +
risk O +
of O +
inorganic O +
arsenic B-Chemical +
to O +
humans O -
, O +
it O +
is O +
suggested O +
that O +
efforts O +
should O +
be O +
made O +
to O +
reduce O +
the O +
inorganic O +
arsenic B-Chemical +
exposure O +
of O +
the O +
Hong O +
Kong O +
population O -
. O +

Reelin O +
supplementation O +
recovers O +
sensorimotor O +
gating O -
, O +
synaptic O +
plasticity O +
and O +
associative O +
learning O +
deficits O +
in O +
the O +
heterozygous O +
reeler O +
mouse O -
. O +

The O +
lipoprotein O +
receptor O +
ligand O +
Reelin O +
is O +
important O +
for O +
the O +
processes O +
of O +
normal O +
synaptic O +
plasticity O -
, O +
dendritic O +
morphogenesis O -
, O +
and O +
learning O +
and O +
memory O -
. O +

Heterozygous O +
reeler O +
mice O +
( O -
HRM O -
) O +
show O +
many O +
neuroanatomical O -
, O +
biochemical O -
, O +
and O +
behavioral O +
features O +
that O +
are O +
associated O +
with O +
schizophrenia O -
. O +

HRM O +
show O +
subtle O +
morphological O +
defects O +
including O +
reductions O +
in O +
dendritic O +
spine O +
density O -
, O +
altered O +
synaptic O +
plasticity O +
and O +
behavioral O +
deficits O +
in O +
associative O +
learning O +
and O +
memory O +
and O +
pre O -
- O -
pulse O +
inhibition O -
. O +

The O +
present O +
studies O +
test O +
the O +
hypothesis O +
that O +
in O +
vivo O +
elevation O +
of O +
Reelin O +
levels O +
can O +
rescue O +
synaptic O +
and O +
behavioral O +
phenotypes O +
associated O +
with O +
HRM O -
. O +

We O +
demonstrate O +
that O +
a O +
single O +
in O +
vivo O +
injection O +
of O +
Reelin O +
increases O +
GAD67 O +
expression O +
and O +
alters O +
dendritic O +
spine O +
morphology O -
. O +

In O +
parallel O +
we O +
observed O +
enhancement O +
of O +
hippocampal O +
synaptic O +
function O +
and O +
associative O +
learning O +
and O +
memory O -
. O +

Reelin O +
supplementation O +
also O +
increases O +
pre O -
- O -
pulse O +
inhibition O -
. O +

These O +
results O +
suggest O +
that O +
characteristics O +
of O +
HRM O -
, O +
similar O +
to O +
those O +
observed O +
in O +
schizophrenia O -
, O +
are O +
sensitive O +
to O +
Reelin O +
levels O +
and O +
can O +
be O +
modified O +
with O +
Reelin O +
supplementation O +
in O +
male O +
and O +
female O +
adults O -
. O +

Identification O +
of O +
two O -
- O -
component O +
system O +
AfsQ1 O -
/ O -
Q2 O +
regulon O +
and O +
its O +
cross O -
- O -
regulation O +
with O +
GlnR O +
in O +
Streptomyces O +
coelicolor O -
. O +

The O +
two O -
- O -
component O +
system O +
AfsQ1 O -
/ O -
Q2 O +
of O +
Streptomyces O +
coelicolor O +
was O +
identified O +
in O +
our O +
previous O +
work O +
as O +
a O +
pleiotropic O +
regulator O +
for O +
antibiotic O +
biosynthesis O +
and O +
morphological O +
differentiation O +
under O +
the O +
condition O +
of O +
a O +
minimal O +
medium O +
supplemented O +
with O +
75 O +
mM O +
glutamate B-Chemical -
. O +

In O +
this O +
work O -
, O +
we O +
report O +
the O +
dissection O +
of O +
the O +
mechanism O +
underlying O +
the O +
function O +
of O +
AfsQ1 O -
/ O -
Q2 O +
on O +
antibiotic O +
production O +
and O +
also O +
the O +
identification O +
of O +
the O +
AfsQ1 O -
/ O -
Q2 O +
regulon O -
. O +

The O +
results O +
showed O +
that O +
AfsQ1 O -
/ O -
Q2 O +
stimulated O +
antibiotic O +
ACT O -
, O +
RED O +
and O +
CDA O +
production O +
directly O +
through O +
the O +
pathway O -
- O -
specific O +
activator O +
genes O +
actII O -
- O -
ORF4 O -
, O +
redZ O +
and O +
cdaR O +
respectively O -
. O +

In O +
addition O -
, O +
expression O +
of O +
sigQ O +
that O +
encodes O +
a O +
sigma O +
factor O +
and O +
is O +
divergently O +
transcribed O +
from O +
afsQ1 O +
was O +
also O +
subject O +
to O +
direct O +
regulation O +
by O +
AfsQ1 O -
/ O -
Q2 O -
. O +

The O +
precise O +
AfsQ1 O +
binding O +
sites O +
in O +
the O +
upstream O +
regions O +
of O +
these O +
target O +
genes O +
were O +
determined O +
by O +
DNase O +
I O +
footprinting O +
assays O +
coupled O +
with O +
site O -
- O -
directed O +
DNA O +
mutagenesis O -
. O +

By O +
computational O +
prediction O +
and O +
functional O +
analysis O -
, O +
at O +
least O +
17 O +
new O +
AfsQ1 O +
targets O +
were O +
identified O -
, O +
including O +
pstS O +
gene O +
encoding O +
a O +
high O -
- O -
affinity O +
phosphate B-Chemical -
- O -
binding O +
protein O +
and O +
two O +
developmental O +
genes O +
whiD O -
, O +
bldM. O +
For O +
the O +
AfsQ1 O -
/ O -
Q2 O +
regulon O -
, O +
an O +
AfsQ1 O +
binding O +
motif O +
comprising O +
the O +
sequence O +
GTnAC O -
- O -
n O -
( O -
6 O -
) O +
-GTnAC O +
has O +
been O +
defined O -
. O +

Interestingly O -
, O +
we O +
found O +
from O +
electrophoretic O +
mobility O +
shift O +
assays O +
and O +
transcriptional O +
analysis O +
that O +
AfsQ1 O -
/ O -
Q2 O +
can O +
also O +
function O +
as O +
a O +
repressor O +
for O +
nitrogen B-Chemical +
assimilation O -
, O +
and O +
AfsQ1 O +
can O +
compete O +
with O +
GlnR O +
for O +
the O +
promoter O +
regions O +
of O +
glnA O +
and O +
nirB O -
, O +
suggesting O +
the O +
cross O -
- O -
regulation O +
between O +
AfsQ1 O -
/ O -
Q2 O +
and O +
GlnR O +
in O +
nitrogen B-Chemical +
metabolism O -
. O +

These O +
findings O +
suggested O +
that O +
AfsQ1 O -
/ O -
Q2 O +
is O +
important O +
not O +
only O +
for O +
antibiotic O +
biosynthesis O +
but O +
also O +
in O +
maintaining O +
the O +
metabolic O +
homeostasis O +
of O +
nutrient O +
utilization O +
under O +
the O +
stress O +
of O +
high O +
concentration O +
of O +
glutamate B-Chemical +
in O +
S. O +
coelicolor O -
. O +

Synthesis O +
and O +
chiral O +
recognition O +
of O +
nickel B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical +
macrocyclic O +
complex O +
with O +
( B-Chemical -
R I-Chemical -
) I-Chemical -
-naphthylethyleneamine I-Chemical +
pendant O +
groups O +
and O +
its O +
self O -
- O -
assembled O +
framework O -
. O +

A O +
novel O +
nickel B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical +
hexaaza I-Chemical +
macrocyclic O +
complex O -
, O +
[ B-Chemical -
Ni I-Chemical -
( I-Chemical -
L I-Chemical -
( I-Chemical -
R I-Chemical -
, I-Chemical -
R I-Chemical -
) I-Chemical -
) I-Chemical -
] I-Chemical -
( I-Chemical -
ClO I-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
) I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
( O -
1 O -
) O -
, O +
containing O +
chiral O +
pendant O +
groups O +
was O +
synthesized O +
by O +
an O +
efficient O +
one O -
- O -
pot O +
template O +
condensation O +
and O +
characterized O +
( O -
L O -
( O -
R O -
, O -
R O -
) O +
═ O -
1,8-di B-Chemical -
( I-Chemical -
( I-Chemical -
R I-Chemical -
) I-Chemical -
-α I-Chemical -
- I-Chemical -
methylnaphthyl I-Chemical -
) I-Chemical -
-1,3,6,8,10,13-hexaazacyclotetradecane I-Chemical -
) O -
. O +

The O +
crystal O +
structure O +
of O +
compound O +
1 O +
was O +
determined O +
by O +
single O -
- O -
crystal O +
X O -
- O -
ray O +
analysis O -
. O +

The O +
complex O +
was O +
found O +
to O +
have O +
a O +
square O -
- O -
planar O +
coordination O +
environment O +
for O +
the O +
nickel B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical +
ion O -
. O +

Open O +
framework O +
[ B-Chemical -
Ni I-Chemical -
( I-Chemical -
L I-Chemical -
( I-Chemical -
R I-Chemical -
, I-Chemical -
R I-Chemical -
) I-Chemical -
) I-Chemical -
] I-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical +
[ I-Chemical -
C I-Chemical -
( I-Chemical -
6 I-Chemical -
) I-Chemical -
H I-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
( I-Chemical -
COO I-Chemical -
) I-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
] I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
( O -
2 O -
) O +
was O +
constructed O +
from O +
the O +
self O -
- O -
assembly O +
of O +
compound O +
1 O +
with O +
deprotonated O +
1,3,5-benzenetricarboxylic B-Chemical +
acid I-Chemical -
, O +
BTC B-Chemical -
( I-Chemical -
3- I-Chemical -
) I-Chemical -
. O +

Chiral O +
discrimination O +
of O +
rac-1,1'-bi-2-naphthol B-Chemical +
and O +
rac-2,2,2-trifluoro-1- B-Chemical -
( I-Chemical -
9-anthryl I-Chemical -
) I-Chemical -
ethanol I-Chemical +
was O +
performed O +
to O +
determine O +
the O +
chiral O +
recognition O +
ability O +
of O +
the O +
chiral O +
complex O +
( O -
1 O -
) O +
and O +
its O +
self O -
- O -
assembled O +
framework O +
( O -
2 O -
) O -
. O +

Binaphthol B-Chemical +
showed O +
a O +
good O +
chiral O +
discrimination O +
on O +
the O +
framework O +
( O -
2 O -
) O -
. O +

The O +
optimum O +
experimental O +
conditions O +
for O +
the O +
chiral O +
discrimination O +
were O +
examined O +
by O +
changing O +
the O +
weight O +
ratio O +
between O +
the O +
macrocyclic O +
complex O +
1 O +
or O +
self O -
- O -
assembled O +
framework O +
2 O +
and O +
racemates O -
. O +

The O +
detailed O +
synthetic O +
procedures O -
, O +
spectroscopic O +
data O +
including O +
single O -
- O -
crystal O +
X O -
- O -
ray O +
analysis O -
, O +
and O +
the O +
results O +
of O +
the O +
chiral O +
recognition O +
for O +
the O +
compounds O +
are O +
described O -
. O +

Sclerostin O +
antibody O +
treatment O +
improves O +
bone O +
mass O -
, O +
bone O +
strength O -
, O +
and O +
bone O +
defect O +
regeneration O +
in O +
rats O +
with O +
type O +
2 O +
diabetes O +
mellitus O -
. O +

Type O +
2 O +
diabetes O +
mellitus O +
results O +
in O +
increased O +
risk O +
of O +
fracture O +
and O +
delayed O +
fracture O +
healing O -
. O +

ZDF O +
fa O -
/ O -
fa O +
rats O +
are O +
an O +
established O +
model O +
of O +
type O +
2 O +
diabetes O +
mellitus O +
with O +
low O +
bone O +
mass O +
and O +
delayed O +
bone O +
healing O -
. O +

We O +
tested O +
whether O +
a O +
sclerostin O -
- O -
neutralizing O +
antibody O +
( O -
Scl O -
- O -
AbVI O -
) O +
would O +
reverse O +
the O +
skeletal O +
deficits O +
of O +
diabetic O +
ZDF O +
rats O -
. O +

Femoral O +
defects O +
of O +
3 O +
mm O +
were O +
created O +
in O +
11-week O -
- O -
old O +
diabetic O +
ZDF O +
fa O -
/ O -
fa O +
and O +
nondiabetic O +
ZDF O +
+ O -
/+ O +
rats O +
and O +
stabilized O +
by O +
an O +
internal O +
plate O -
. O +

Saline O +
or O +
25 O +
mg O -
/ O -
kg O +
Scl O -
- O -
AbVI O +
was O +
administered O +
subcutaneously O +
( O -
s.c O -
. O -
) O +
twice O +
weekly O +
for O +
12 O +
weeks O +
( O -
n O +
= O +
9 O -
- O -
10 O -
/ O -
group O -
) O -
. O +

Bone O +
mass O +
and O +
strength O +
were O +
assessed O +
using O +
pQCT O -
, O +
micro O -
- O -
computed O +
tomography O +
( O -
µCT O -
) O -
, O +
and O +
biomechanical O +
testing O -
. O +

Bone O +
histomorphometry O +
was O +
used O +
to O +
assess O +
bone O +
formation O -
, O +
and O +
the O +
filling O +
of O +
the O +
bone O +
defect O +
was O +
analyzed O +
by O +
µCT O -
. O +

Diabetic O +
rats O +
displayed O +
lower O +
spinal O +
and O +
femoral O +
bone O +
mass O +
compared O +
to O +
nondiabetic O +
rats O -
, O +
and O +
Scl O -
- O -
AbVI O +
treatment O +
significantly O +
enhanced O +
bone O +
mass O +
of O +
the O +
femur O +
and O +
the O +
spine O +
of O +
diabetic O +
rats O +
( O -
p O +
< O +
0.0001 O -
) O -
. O +

Scl O -
- O -
AbVI O +
also O +
reversed O +
the O +
deficit O +
in O +
bone O +
strength O +
in O +
the O +
diabetic O +
rats O -
, O +
with O +
65 O -
% O +
and O +
89 O -
% O +
increases O +
in O +
maximum O +
load O +
at O +
the O +
femoral O +
shaft O +
and O +
neck O -
, O +
respectively O +
( O -
p O +
< O +
0.0001 O -
) O -
. O +

The O +
lower O +
bone O +
mass O +
in O +
diabetic O +
rats O +
was O +
associated O +
with O +
a O +
65 O -
% O +
decrease O +
in O +
vertebral O +
bone O +
formation O +
rate O -
, O +
which O +
Scl O -
- O -
AbVI O +
increased O +
by O +
sixfold O -
, O +
consistent O +
with O +
a O +
pronounced O +
anabolic O +
effect O -
. O +

Nondiabetic O +
rats O +
filled O +
57 O -
% O +
of O +
the O +
femoral O +
defect O -
, O +
whereas O +
diabetic O +
rats O +
filled O +
only O +
21 O -
% O +
( O -
p O +
< O +
0.05 O -
) O -
. O +

Scl O -
- O -
AbVI O +
treatment O +
increased O +
defect O +
regeneration O +
by O +
47 O -
% O +
and O +
74 O -
% O -
, O +
respectively O +
( O -
p O +
< O +
0.05 O -
) O -
. O +

Sclerostin O +
antibody O +
treatment O +
reverses O +
the O +
adverse O +
effects O +
of O +
type O +
2 O +
diabetes O +
mellitus O +
on O +
bone O +
mass O +
and O +
strength O -
, O +
and O +
improves O +
bone O +
defect O +
regeneration O +
in O +
rats O -
. O +

SPIDIA O -
- O -
RNA O -
: O +
first O +
external O +
quality O +
assessment O +
for O +
the O +
pre O -
- O -
analytical O +
phase O +
of O +
blood O +
samples O +
used O +
for O +
RNA O +
based O +
analyses O -
. O +

The O +
diagnostic O +
use O +
of O +
in O +
vitro O +
molecular O +
assays O +
can O +
be O +
limited O +
by O +
the O +
lack O +
of O +
guidelines O +
for O +
collection O -
, O +
handling O -
, O +
stabilization O +
and O +
storage O +
of O +
patient O +
specimens O -
. O +

One O +
of O +
the O +
major O +
goals O +
of O +
the O +
EC O +
funded O +
project O +
SPIDIA O +
( O -
www.spidia.eu O -
) O +
is O +
to O +
develop O +
evidence O -
- O -
based O +
quality O +
guidelines O +
for O +
the O +
pre O -
- O -
analytical O +
phase O +
of O +
blood O +
samples O +
used O +
for O +
molecular O +
testing O +
which O +
requires O +
intracellular O +
RNA O +
analytes O -
. O +

To O +
this O +
end O -
, O +
a O +
survey O +
and O +
a O +
pan O -
- O -
European O +
external O +
quality O +
assessment O +
( O -
EQA O -
) O +
were O +
implemented O -
. O +

This O +
report O +
is O +
the O +
summary O +
of O +
the O +
results O +
of O +
that O +
trial O -
. O +

With O +
the O +
European O +
Federation O +
of O +
Laboratory O +
Medicine O +
( O -
EFLM O -
) O +
support O -
, O +
124 O +
applications O +
for O +
participation O +
in O +
the O +
trial O +
were O +
received O +
from O +
27 O +
different O +
European O +
countries O -
, O +
and O +
102 O +
laboratories O +
actually O +
participated O +
in O +
the O +
trial O -
. O +

Each O +
participating O +
laboratory O +
described O +
their O +
respective O +
laboratory O +
policies O +
and O +
practices O +
as O +
well O +
as O +
blood O +
collection O +
tubes O +
typically O +
used O +
in O +
performing O +
this O +
type O +
of O +
testing O -
. O +

The O +
participating O +
laboratories O +
received O +
two O +
identical O +
blood O +
specimens O -
: O +
in O +
an O +
EDTA B-Chemical +
tubes O +
( O -
unstabilized O +
blood O -
; O +
n=67 O -
) O +
or O +
in O +
tubes O +
designed O +
specifically O +
for O +
the O +
stabilization O +
of O +
intracellular O +
RNA O +
in O +
blood O +
( O -
PAXgene O -
® O +
Blood O +
RNA O +
tubes O -
; O +
n=35 O -
) O -
. O +

Laboratories O +
were O +
requested O +
to O +
perform O +
RNA O +
extraction O +
according O +
to O +
the O +
laboratory O -
's O +
own O +
procedure O +
as O +
soon O +
as O +
possible O +
upon O +
receipt O +
of O +
the O +
tubes O +
for O +
one O +
tube O +
and O +
24h O +
after O +
the O +
first O +
extraction O +
for O +
the O +
second O +
tube O -
. O +

Participants O +
( O -
n=93 O -
) O +
returned O +
the O +
two O +
extracted O +
RNAs O +
to O +
SPIDIA O +
facility O +
for O +
analysis O -
, O +
and O +
provided O +
details O +
about O +
the O +
reagents O +
and O +
protocols O +
they O +
used O +
for O +
the O +
extraction O -
. O +

At O +
the O +
SPIDIA O +
facility O +
responsible O +
for O +
coordinating O +
the O +
study O -
, O +
the O +
survey O +
data O +
were O +
classified O -
, O +
and O +
the O +
extracted O +
RNA O +
samples O +
were O +
evaluated O +
for O +
purity O -
, O +
yield O -
, O +
integrity O -
, O +
stability O -
, O +
and O +
the O +
presence O +
of O +
interfering O +
substances O +
affecting O +
RT O -
- O -
qPCR O +
assays O -
. O +

All O +
participants O +
received O +
a O +
report O +
comparing O +
the O +
performance O +
of O +
the O +
RNA O +
they O +
submitted O +
to O +
that O +
of O +
the O +
other O +
participants O -
. O +

All O +
the O +
results O +
obtained O +
by O +
participants O +
for O +
each O +
RNA O +
quality O +
parameter O +
were O +
classified O +
as O +
" O -
in O +
control O -
" O -
, O +
" O -
warning O -
" O -
, O +
" O -
out O +
of O +
control O -
" O +
and O +
" O -
missing O -
" O +
by O +
consensus O +
mean O +
analysis O -
. O +

From O +
the O +
survey O +
data O -
, O +
the O +
most O +
variable O +
parameters O +
were O +
the O +
volume O +
of O +
blood O +
collected O +
and O +
the O +
time O +
and O +
storage O +
temperature O +
between O +
blood O +
collection O +
and O +
RNA O +
extraction O -
. O +

Analyzing O +
the O +
results O +
of O +
quality O +
testing O +
of O +
submitted O +
RNA O +
samples O +
we O +
observed O +
a O +
data O +
distribution O +
of O +
purity O -
, O +
yield O -
, O +
and O +
presence O +
of O +
assay O +
interference O +
in O +
agreement O +
with O +
expected O +
values O -
. O +

The O +
RNA O +
Integrity O +
Number O +
( O -
RIN O -
) O +
values O +
distribution O +
was O -
, O +
on O +
the O +
other O +
hand O -
, O +
much O +
wider O +
than O +
the O +
optimal O +
expected O +
value O -
, O +
which O +
led O +
to O +
an O +
" O -
in O +
control O -
" O +
classification O -
, O +
even O +
for O +
partly O +
degraded O +
RNA O +
samples O -
. O +

On O +
the O +
other O +
hand O -
, O +
RIN O +
values O +
below O +
5 O +
significantly O +
correlated O +
with O +
a O +
reduction O +
of O +
GAPDH O +
expression O +
levels O -
. O +

Furthermore O -
, O +
the O +
distribution O +
of O +
the O +
values O +
of O +
the O +
four O +
transcripts O +
investigated O +
( O -
c O -
- O -
fos O -
, O +
IL-1β O -
, O +
IL-8 O -
, O +
and O +
GAPDH O -
) O +
was O +
wide O +
and O +
the O +
RNA O +
instability O +
between O +
samples O +
separated O +
by O +
24h O +
were O +
similar O -
. O +

Assuming O +
the O +
presence O +
of O +
at O +
least O +
two O +
quality O +
parameters O +
" O -
out O +
of O +
control O -
" O +
as O +
an O +
indication O +
of O +
a O +
critical O +
performance O +
of O +
the O +
laboratory O -
, O +
33 O -
% O +
of O +
the O +
laboratories O +
were O +
included O +
in O +
this O +
group O -
. O +

The O +
results O +
of O +
this O +
study O +
will O +
be O +
the O +
basis O +
for O +
implementing O +
a O +
second O +
pan O -
- O -
European O +
EQA O +
and O +
the O +
results O +
of O +
both O +
EQAs O +
will O +
be O +
pooled O +
and O +
will O +
provide O +
the O +
basis O +
for O +
the O +
implementation O +
of O +
evidence O -
- O -
based O +
guidelines O +
for O +
the O +
pre O -
- O -
analytical O +
phase O +
of O +
RNA O +
analysis O +
of O +
blood O +
samples O -
. O +

Reversal O +
of O +
efflux O +
mediated O +
antifungal O +
resistance O +
underlies O +
synergistic O +
activity O +
of O +
two O +
monoterpenes B-Chemical +
with O +
fluconazole B-Chemical -
. O +

Thymol B-Chemical +
( O -
THY B-Chemical -
) O +
and O +
carvacrol B-Chemical +
( O -
CARV B-Chemical -
) O -
, O +
the O +
principal O +
chemical O +
components O +
of O +
thyme O +
oil O +
have O +
long O +
been O +
known O +
for O +
their O +
wide O +
use O +
in O +
medicine O +
due O +
to O +
antimicrobial O +
and O +
disinfectant O +
properties O -
. O +

This O +
study O -
, O +
however O -
, O +
draws O +
attention O +
to O +
a O +
possible O +
synergistic O +
antifungal O +
effect O +
of O +
these O +
monoterpenes B-Chemical +
with O +
azole B-Chemical +
antimycotic O -
- O -
fluconazole B-Chemical -
. O +

Resistance O +
to O +
azoles B-Chemical +
in O +
Candida O +
albicans O +
involves O +
over O -
- O -
expression O +
of O +
efflux O -
- O -
pump O +
genes O +
MDR1 O -
, O +
CDR1 O -
, O +
CDR2 O +
or O +
mutations O +
and O +
over O -
- O -
expression O +
of O +
target O +
gene O +
ERG11 O -
. O +

The O +
inhibition O +
of O +
drug O +
efflux O +
pumps O +
is O +
considered O +
a O +
feasible O +
strategy O +
to O +
overcome O +
clinical O +
antifungal O +
resistance O -
. O +

To O +
put O +
forward O +
this O +
approach O -
, O +
we O +
investigated O +
the O +
combination O +
effects O +
of O +
these O +
monoterpenes B-Chemical +
and O +
FLC B-Chemical +
against O +
38 O +
clinically O +
obtained O +
FLC B-Chemical -
- O -
sensitive O -
, O +
and O +
eleven O +
FLC B-Chemical -
- O -
resistant O +
Candida O +
isolates O -
. O +

Synergism O +
was O +
observed O +
with O +
combinations O +
of O +
THY B-Chemical -
- O -
FLC B-Chemical +
and O +
CARV B-Chemical -
- O -
FLC B-Chemical +
evaluated O +
by O +
checkerboard O +
microdilution O +
method O +
and O +
nature O +
of O +
the O +
interactions O +
was O +
calculated O +
by O +
FICI O -
. O +

In O +
addition O -
, O +
antifungal O +
activity O +
was O +
assessed O +
using O +
agar O -
- O -
diffusion O +
and O +
time O -
- O -
kill O +
curves O -
. O +

The O +
drug O +
efflux O +
activity O +
was O +
determined O +
using O +
two O +
dyes O -
, O +
Rhodamine6 B-Chemical -
G I-Chemical +
( O -
R6 B-Chemical -
G I-Chemical -
) O +
and O +
fluorescent O +
Hoechst B-Chemical +
33342 I-Chemical -
. O +

No O +
significant O +
differences O +
were O +
observed O +
in O +
dye O +
uptakes O +
between O +
FLC O -
- O -
susceptible O +
and O +
resistant O +
isolates O -
, O +
incubated O +
in O +
glucose B-Chemical +
free O +
buffer O -
. O +

However O -
, O +
a O +
significantly O +
higher O +
efflux O +
was O +
recorded O +
in O +
FLC B-Chemical -
- O -
resistant O +
isolates O +
when O +
glucose B-Chemical +
was O +
added O -
. O +

Both O +
monoterpenes B-Chemical +
inhibited O +
efflux O +
by O +
70 O -
- O -
90 O -
% O -
, O +
showing O +
their O +
high O +
potency O +
to O +
block O +
drug O +
transporter O +
pumps O -
. O +

Significant O +
differences O -
, O +
in O +
the O +
expression O +
levels O +
of O +
CDR1 O +
and O +
MDR1 O -
, O +
induced O +
by O +
monoterpenes B-Chemical +
revealed O +
reversal O +
of O +
FLC B-Chemical -
- O -
resistance O -
. O +

The O +
selectively O +
fungicidal O +
characteristics O +
and O +
ability O +
to O +
restore O +
FLC B-Chemical +
susceptibility O +
in O +
resistant O +
isolates O +
signify O +
a O +
promising O +
candidature O +
of O +
THY B-Chemical +
and O +
CARV B-Chemical +
as O +
antifungal O +
agents O +
in O +
combinational O +
treatments O +
for O +
candidiasis O -
. O +

Adaptive O +
radiation O -
- O -
induced O +
epigenetic O +
alterations O +
mitigated O +
by O +
antioxidants O -
. O +

Humans O +
are O +
exposed O +
to O +
low O -
- O -
dose O +
ionizing O +
radiation O +
( O -
LDIR O -
) O +
from O +
a O +
number O +
of O +
environmental O +
and O +
medical O +
sources O -
. O +

In O +
addition O +
to O +
inducing O +
genetic O +
mutations O -
, O +
there O +
is O +
concern O +
that O +
LDIR O +
may O +
also O +
alter O +
the O +
epigenome O -
. O +

Such O +
heritable O +
effects O +
early O +
in O +
life O +
can O +
either O +
be O +
positively O +
adaptive O +
or O +
result O +
in O +
the O +
enhanced O +
formation O +
of O +
diseases O -
, O +
including O +
cancer O -
, O +
diabetes O -
, O +
and O +
obesity O -
. O +

Herein O -
, O +
we O +
show O +
that O +
LDIR O +
significantly O +
increased O +
DNA O +
methylation O +
at O +
the O +
viable O +
yellow O +
agouti O +
( O -
A O -
( O -
vy O -
) O -
) O +
locus O +
in O +
a O +
sex O -
- O -
specific O +
manner O +
( O -
P=0.004 O -
) O -
. O +

Average O +
DNA O +
methylation O +
was O +
significantly O +
increased O +
in O +
male O +
offspring O +
exposed O +
to O +
doses O +
between O +
0.7 O +
and O +
7.6 O +
cGy O -
, O +
with O +
maximum O +
effects O +
at O +
1.4 O +
and O +
3.0 O +
cGy O +
( O -
P<0.01 O -
) O -
. O +

Offspring O +
coat O +
color O +
was O +
concomitantly O +
shifted O +
toward O +
pseudoagouti O +
( O -
P<0.01 O -
) O -
. O +

Maternal O +
dietary O +
antioxidant O +
supplementation O +
mitigated O +
both O +
the O +
DNA O +
methylation O +
changes O +
and O +
coat O +
color O +
shift O +
in O +
the O +
irradiated O +
offspring O -
. O +

Thus O -
, O +
LDIR O +
exposure O +
during O +
gestation O +
elicits O +
epigenetic O +
alterations O +
that O +
lead O +
to O +
positive O +
adaptive O +
phenotypic O +
changes O +
that O +
are O +
negated O +
with O +
antioxidants O -
, O +
indicating O +
they O +
are O +
mediated O +
in O +
part O +
by O +
oxidative O +
stress O -
. O +

These O +
findings O +
provide O +
evidence O +
that O +
in O +
the O +
isogenic O +
A O -
( O -
vy O -
) O +
mouse O +
model O -
, O +
epigenetic O +
alterations O +
resulting O +
from O +
LDIR O +
play O +
a O +
role O +
in O +
radiation O +
hormesis O -
, O +
bringing O +
into O +
question O +
the O +
assumption O +
that O +
every O +
dose O +
of O +
radiation O +
is O +
harmful O -
. O +

Inhibitory O +
effect O +
of O +
aqueous O +
spinach O +
extract O +
on O +
degranulation O +
of O +
RBL-2H3 O +
cells O -
. O +

The O +
inhibitory O +
effect O +
of O +
an O +
aqueous O +
extract O +
from O +
spinach O +
on O +
degranulation O +
of O +
RBL-2H3 O +
cells O +
is O +
herein O +
reported O -
. O +

The O +
extract O +
significantly O +
suppressed O +
antigen O -
- O -
induced O +
degranulation O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
without O +
affecting O +
cell O +
viability O -
. O +

Active O +
substances O +
in O +
the O +
extract O +
were O +
heat O -
- O -
stable O +
and O +
trypsin O -
- O -
resistant O +
with O +
molecular O +
weights O +
ranging O +
from O +
500 O +
Da O +
to O +
14 O +
kDa O -
. O +

The O +
extract O +
inhibited O +
elevation O +
of O +
the O +
intracellular O +
Ca B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
concentration O +
caused O +
by O +
stimulation O +
by O +
antigen O -
, O +
while O +
not O +
suppressing O +
degranulation O +
induced O +
by O +
a O +
calcium B-Chemical +
ionophore O +
A23187 B-Chemical -
. O +

Immunoblot O +
analysis O +
revealed O +
that O +
the O +
inhibitory O +
effect O +
results O +
from O +
downregulation O +
of O +
phosphorylation O +
of O +
both O +
Syk O +
kinase O +
and O +
phosphatidylinositol B-Chemical +
3-kinase O +
in O +
the O +
signalling O +
pathways O +
involved O +
in O +
degranulation O +
caused O +
by O +
the O +
antigen O -
- O -
antibody O +
interaction O -
. O +

Taken O +
together O -
, O +
these O +
findings O +
suggest O +
that O +
aqueous O +
spinach O +
extract O +
has O +
an O +
anti O -
- O -
allergic O +
activity O +
that O +
controls O +
degranulation O -
. O +

Anthraquinone B-Chemical +
profile O -
, O +
antioxidant O +
and O +
antimicrobial O +
activity O +
of O +
bark O +
extracts O +
of O +
Rhamnus O +
alaternus O -
, O +
R. O +
fallax O -
, O +
R. O +
intermedia O +
and O +
R. O +
pumila O -
. O +

The O +
quantity O +
of O +
phenols B-Chemical -
, O +
as O +
well O +
as O +
antioxidant O +
and O +
antimicrobial O +
activities O -
, O +
were O +
investigated O +
in O +
bark O +
of O +
Rhamnus O +
alaternus O +
L. O -
, O +
R. O +
fallax O +
Boiss O -
. O +

, O +
R. O +
intermedia O +
Steud O -
. O +

et O +
Hochst O -
. O -
, O +
and O +
R. O +
pumila O +
Turra O +
from O +
natural O +
stands O +
in O +
Croatia O -
. O +

The O +
most O +
abundant O +
anthraquinones B-Chemical +
in O +
the O +
investigated O +
extracts O +
were O +
chrysophanol B-Chemical +
in O +
R. O +
alaternus O +
( O -
3.14 O +
mg O -
/ O -
g O -
) O -
, O +
emodin B-Chemical +
in O +
R. O +
pumila O +
( O -
0.339 O +
mg O -
/ O -
g O -
) O -
, O +
and O +
physcion B-Chemical +
in O +
R. O +
fallax O +
( O -
2.70 O +
mg O -
/ O -
g O -
) O +
and O +
R. O +
intermedia O +
( O -
0.285 O +
mg O -
/ O -
g O -
) O -
. O +

The O +
species O +
exhibiting O +
the O +
highest O +
antioxidant O +
activity O +
were O +
R. O +
fallax O +
and O +
R. O +
pumila O -
. O +

A O +
positive O +
correlation O +
was O +
observed O +
between O +
total O +
phenolic B-Chemical +
and O +
flavonoid B-Chemical +
levels O +
of O +
the O +
extracts O +
and O +
antioxidant O +
activity O +
in O +
some O +
of O +
the O +
assays O -
. O +

All O +
species O +
showed O +
antimicrobial O +
activity O +
against O +
Staphylococcus O +
aureus O -
, O +
Pseudomonas O +
aeruginosa O -
, O +
Escherichia O +
coli O -
, O +
Candida O +
albicans O -
, O +
Aspergillus O +
niger O +
and O +
Microsporum O +
gypseum O +
with O +
minimal O +
inhibitory O +
concentrations O +
equal O +
to O +
or O +
below O +
2.500 O +
mg O -
/ O -
mL. O +
The O +
results O +
indicate O +
that O +
the O +
investigated O +
Rhamnus O +
species O +
are O +
a O +
source O +
of O +
anthraquinones B-Chemical +
and O +
other O +
phenols B-Chemical -
, O +
which O +
act O +
as O +
multifunctional O +
antioxidants O +
with O +
antimicrobial O +
activity O -
. O +

Syzygium O +
aqueum O +
leaf O +
extract O +
and O +
its O +
bioactive O +
compounds O +
enhances O +
pre O -
- O -
adipocyte O +
differentiation O +
and O +
2-NBDG B-Chemical +
uptake O +
in O +
3T3-L1 O +
cells O -
. O +

The O +
insulin O -
- O -
like O +
and/or O +
insulin O -
- O -
sensitising O +
effects O +
of O +
Syzygium O +
aqueum O +
leaf O +
extract O +
and O +
its O +
six O +
bioactive O +
compounds O -
; O +
4-hydroxybenzaldehyde B-Chemical -
, O +
myricetin-3-O B-Chemical -
- I-Chemical -
rhamnoside I-Chemical -
, O +
europetin-3-O B-Chemical -
- I-Chemical -
rhamnoside I-Chemical -
, O +
phloretin B-Chemical -
, O +
myrigalone B-Chemical -
- I-Chemical -
G I-Chemical +
and O +
myrigalone B-Chemical -
- I-Chemical -
B I-Chemical +
were O +
investigated O +
in O +
3T3-L1 O +
adipocytes O -
. O +

We O +
observed O +
that O -
, O +
S. O +
aqueum O +
leaf O +
extract O +
( O -
0.04 O -
- O -
5 O +
μg O -
/ O -
ml O -
) O +
and O +
its O +
six O +
bioactive O +
compounds O +
( O -
0.08 O -
- O -
10 O +
μM O -
) O +
at O +
non O -
- O -
cytotoxic O +
concentrations O +
were O +
effectively O +
enhance O +
adipogenesis O -
, O +
stimulate O +
glucose B-Chemical +
uptake O +
and O +
increase O +
adiponectin O +
secretion O +
in O +
3T3-L1 O +
adipocytes O -
. O +

Clearly O -
, O +
the O +
compounds O +
myricetin-3-O B-Chemical -
- I-Chemical -
rhamnoside I-Chemical +
and O +
europetin-3-O B-Chemical -
- I-Chemical -
rhamnoside I-Chemical +
showed O +
insulin O -
- O -
like O +
and O +
insulin O -
- O -
sensitising O +
effects O +
on O +
adipocytes O +
from O +
a O +
concentration O +
of O +
0.08 O +
μM. O +
These O +
compounds O +
were O +
far O +
better O +
than O +
rosiglitazone B-Chemical +
and O +
the O +
other O +
isolated O +
compounds O +
in O +
enhancing O +
adipogenesis O -
, O +
stimulating O +
2-NBDG B-Chemical +
uptake O +
and O +
increasing O +
adiponectin O +
secretion O +
at O +
all O +
the O +
concentrations O +
tested O -
. O +

These O +
suggest O +
the O +
antidiabetic O +
potential O +
of O +
S. O +
aqueum O +
leaf O +
extract O +
and O +
its O +
six O +
bioactive O +
compounds O -
. O +

However O -
, O +
further O +
molecular O +
interaction O +
studies O +
to O +
explain O +
the O +
mechanisms O +
of O +
action O +
are O +
highly O +
warranted O -
. O +

An O +
improved O +
mass O +
spectrometric O +
method O +
for O +
identification O +
and O +
quantification O +
of O +
phenolic B-Chemical +
compounds O +
in O +
apple O +
fruits O -
. O +

Thirty O -
- O -
nine O +
phenolic B-Chemical +
compounds O +
were O +
analysed O +
using O +
ultra O +
high O +
performance O +
liquid O +
chromatography O +
( O -
UHPLC O -
) O +
coupled O +
with O +
diode O +
array O +
and O +
accurate O +
mass O +
spectrometry O +
detection O +
using O +
electrospray O +
ionisation O +
( O -
DAD O -
/ O -
ESI O -
- O -
am O -
- O -
MS O -
) O -
. O +

Instrumental O +
parameters O +
such O +
as O +
scan O +
speed O -
, O +
resolution O -
, O +
and O +
mass O +
accuracy O +
were O +
optimised O +
to O +
establish O +
accurate O +
mass O +
measurements O -
. O +

The O +
method O +
was O +
fully O +
validated O +
in O +
terms O +
of O +
model O +
deviation O +
( O -
r O -
( O -
2 O -
) O -
>0.9990 O -
) O -
, O +
range O +
( O -
typically O +
10 O -
- O -
3500 O +
ngg O -
( O -
-1 O -
) O -
) O -
, O +
intra O -
/ O -
inter O -
- O -
day O +
precision O +
( O -
< O -
6 O -
% O +
and O +
< O -
8 O -
% O -
, O +
respectively O -
) O +
and O +
accuracy O +
( O -
typically O +
100 O +
± O +
10 O -
% O -
) O -
. O +

The O +
mass O +
accuracy O +
of O +
each O +
selected O +
phenolic B-Chemical +
compound O +
was O +
below O +
1.5 O +
ppm O -
. O +

The O +
results O +
confirmed O +
that O +
the O +
UHPLC O -
- O -
DAD O -
/ O -
ESI O -
- O -
am O -
- O -
MS O +
method O +
developed O +
here O +
was O +
convenient O +
and O +
reliable O +
for O +
the O +
determination O +
of O +
phenolic B-Chemical +
compounds O +
in O +
apple O +
extracts O -
. O +

Identification O +
of O +
active O +
compounds O +
in O +
vegetal O +
extracts O +
based O +
on O +
correlation O +
between O +
activity O +
and O +
HPLC O -
- O -
MS O +
data O -
. O +

We O +
propose O +
a O +
method O +
identifying O +
candidates O +
for O +
active O +
compounds O +
in O +
vegetal O +
extracts O -
. O +

From O +
a O +
collection O +
of O +
samples O -
, O +
the O +
method O +
requires O -
, O +
for O +
each O +
sample O -
, O +
a O +
HPLC O -
- O -
MS O +
analysis O +
and O +
a O +
measurement O +
of O +
the O +
activity O -
. O +

By O +
applying O +
a O +
correlation O +
analysis O +
between O +
the O +
activity O +
and O +
the O +
chromatographic O +
area O +
for O +
each O +
interval O +
of O +
elution O +
time O +
and O +
m O -
/ O -
z O +
ratio O -
, O +
the O +
peaks O +
corresponding O +
to O +
candidates O +
for O +
active O +
compounds O +
can O +
be O +
identified O -
. O +

Additionally O -
, O +
when O +
peaks O +
are O +
identified O -
, O +
a O +
model O +
can O +
be O +
estimated O +
to O +
predict O +
the O +
activity O +
in O +
new O +
samples O -
. O +

Both O +
methods O +
are O +
evaluated O +
in O +
one O +
experiment O +
involving O +
the O +
phenolic O +
extract O +
( O -
PE O -
) O +
from O +
22 O +
samples O +
of O +
extra O +
virgin O +
olive O +
oil O +
( O -
EVOO O -
) O +
where O +
the O +
activity O +
is O +
a O +
cytotoxicity O +
index O +
against O +
JIMT-1 O +
breast O +
cancer O +
cells O -
. O +

In O +
this O +
experiment O -
, O +
the O +
samples O +
were O +
separated O +
into O +
two O +
disjunct O +
partitions O -
: O +
one O +
was O +
used O +
for O +
training O +
( O -
identification O +
of O +
candidates O +
and O +
estimation O +
of O +
prediction O +
model O -
) O -
, O +
while O +
the O +
other O +
was O +
used O +
for O +
validation O +
( O -
by O +
comparing O +
the O +
predicted O +
and O +
the O +
measured O +
activities O -
) O -
. O +

Three O +
compounds O +
were O +
identified O +
as O +
candidates O +
to O +
be O +
responsible O +
for O +
the O +
cytotoxicity O +
of O +
the O +
EVOO O -
- O -
PE O +
against O +
JIMT-1 O +
cells O -
. O +

The O +
prediction O +
model O +
provided O +
an O +
accurate O +
estimation O +
of O +
the O +
activity O -
. O +

Phillyrin B-Chemical +
attenuates O +
high O +
glucose B-Chemical -
- O -
induced O +
lipid O +
accumulation O +
in O +
human O +
HepG2 O +
hepatocytes O +
through O +
the O +
activation O +
of O +
LKB1 O -
/ O -
AMP B-Chemical -
- O -
activated O +
protein O +
kinase O -
- O -
dependent O +
signalling O -
. O +

Phillyrin B-Chemical -
, O +
an O +
active O +
constituent O +
found O +
in O +
many O +
medicinal O +
plants O +
and O +
certain O +
functional O +
foods O -
, O +
has O +
anti O -
- O -
obesity O +
activity O +
in O +
vivo O -
. O +

The O +
aim O +
of O +
our O +
study O +
was O +
to O +
provide O +
new O +
data O +
on O +
the O +
molecular O +
mechanism O -
( O -
s O -
) O +
underlying O +
the O +
role O +
of O +
phillyrin B-Chemical +
in O +
the O +
prevention O +
of O +
high O +
glucose B-Chemical -
- O -
induced O +
lipid O +
accumulation O +
in O +
human O +
HepG2 O +
hepatocytes O -
. O +

We O +
found O +
that O +
phillyrin B-Chemical +
suppressed O +
high O +
glucose B-Chemical -
- O -
induced O +
lipid O +
accumulation O +
in O +
HepG2 O +
cells O -
. O +

Phillyrin B-Chemical +
strongly O +
inhibited O +
high O +
glucose B-Chemical -
- O -
induced O +
fatty B-Chemical +
acid I-Chemical +
synthase O +
( O -
FAS O -
) O +
expression O +
by O +
modulating O +
sterol B-Chemical +
regulatory O +
element O -
- O -
binding O +
protein-1c O +
( O -
SREBP-1c O -
) O +
activation O -
. O +

Moreover O -
, O +
use O +
of O +
the O +
pharmacological O +
AMP B-Chemical -
- O -
activated O +
protein O +
kinase O +
( O -
AMPK O -
) O +
inhibitor O +
compound B-Chemical +
C I-Chemical +
revealed O +
that O +
AMPK O +
is O +
essential O +
for O +
suppressing O +
SREBP-1c O +
expression O +
in O +
phillyrin B-Chemical -
- O -
treated O +
cells O -
. O +

Finally O -
, O +
we O +
found O +
that O +
liver O +
kinase O +
B1 O +
( O -
LKB1 O -
) O +
phosphorylation O +
is O +
required O +
for O +
the O +
phillyrin B-Chemical -
- O -
enhanced O +
activation O +
of O +
AMPK O +
in O +
HepG2 O +
hepatocytes O -
. O +

These O +
results O +
indicate O +
that O +
phillyrin B-Chemical +
prevents O +
lipid O +
accumulation O +
in O +
HepG2 O +
cells O +
by O +
blocking O +
the O +
expression O +
of O +
SREBP-1c O +
and O +
FAS O +
through O +
LKB1 O -
/ O -
AMPK O +
activation O -
, O +
suggesting O +
that O +
phillyrin B-Chemical +
is O +
a O +
novel O +
AMPK O +
activator O +
with O +
a O +
role O +
in O +
the O +
prevention O +
and O +
treatment O +
of O +
obesity O -
. O +

Physicochemical O +
parameters O +
that O +
influence O +
carotenoids O +
bioaccessibility O +
from O +
a O +
tomato O +
juice O -
. O +

In O +
vitro O +
digestion O +
models O +
have O +
been O +
developed O +
to O +
estimate O +
carotenoid O +
bioavailability O +
but O +
most O +
do O +
not O +
consider O +
that O +
their O +
diffusion O +
from O +
fruit O +
matrix O +
to O +
the O +
lipid O +
phase O +
of O +
the O +
bolus O +
could O +
be O +
a O +
limiting O +
step O -
. O +

Therefore O +
we O +
designed O +
a O +
model O +
in O +
which O +
tomato O +
juice O +
is O +
mixed O +
with O +
oil O +
or O +
oil O -
/ O -
water O +
emulsions O -
, O +
and O +
the O +
carotenoids O +
diffusing O +
to O +
oil O +
are O +
measured O +
by O +
spectrometry O -
. O +

Temperature O -
, O +
pH O +
and O +
tomato O +
juice O -
/ O -
peanut O +
oil O +
ratio O +
were O +
evaluated O +
for O +
their O +
influence O +
on O +
carotenoid O +
diffusion O -
. O +

When O +
oil O -
/ O -
tomato O +
ratio O +
was O +
between O +
0.11 O +
and O +
1 O -
, O +
extraction O +
of O +
lycopene B-Chemical +
was O +
limited O +
by O +
the O +
saturation O +
of O +
the O +
oil O +
phase O -
. O +

With O +
a O +
large O +
excess O +
of O +
oil O -
, O +
diffusion O +
was O +
also O +
limited O -
, O +
as O +
only O +
31 O +
± O +
1 O -
% O +
of O +
lycopene B-Chemical +
could O +
be O +
extracted O +
from O +
the O +
juice O -
. O +

Diffusion O +
did O +
not O +
vary O +
significantly O +
with O +
pH O +
but O +
doubled O +
when O +
temperature O +
rose O +
from O +
10 O -
° O -
C O +
to O +
37 O -
° O -
C O -
. O +

When O +
the O +
juice O +
was O +
mixed O +
in O +
an O +
emulsion O +
stabilised O +
with O +
bovine O +
serum O +
albumin O +
or O +
phospholipids O +
the O +
maximum O +
extraction O +
decreased O +
to O +
14.5 O +
± O +
0.2 O -
% O +
and O +
18.5 O +
± O +
1.5 O -
% O +
respectively O -
, O +
indicating O +
that O +
in O +
addition O +
to O +
the O +
saturation O +
of O +
the O +
oil O +
phase O +
at O +
low O +
oil O -
/ O -
tomato O +
ratio O +
and O +
in O +
addition O +
to O +
intrinsic O +
properties O +
of O +
the O +
tomato O +
juice O +
in O +
non O -
- O -
saturating O +
conditions O -
, O +
lycopene B-Chemical +
diffusion O +
was O +
limited O +
by O +
the O +
structure O +
of O +
the O +
interface O +
in O +
emulsions O -
. O +

Effect O +
of O +
heat O +
treatments O +
on O +
the O +
essential O +
oils O +
of O +
kumquat O +
( O -
Fortunella O +
margarita O +
Swingle O -
) O -
. O +

Kumquats O +
( O -
Fortunella O +
margarita O +
Swingle O -
) O +
cultivated O +
in O +
Taiwan O +
are O +
eaten O +
raw O +
or O +
made O +
into O +
candied O +
fruit O +
or O +
fruit O +
tea O -
. O +

For O +
the O +
experiments O +
described O +
in O +
this O +
paper O -
, O +
essential O +
oils O +
were O +
obtained O +
from O +
kumquat O +
peels O +
or O +
whole O +
fruit O +
by O +
cold O +
pressing O -
, O +
steam O +
distillation O +
or O +
heating O +
in O +
water O +
at O +
90 O -
° O -
C O +
for O +
15 O +
min O +
followed O +
by O +
steam O +
distillation O -
. O +

The O +
volatile O +
components O +
contained O +
in O +
the O +
essential O +
oils O +
were O +
identified O +
by O +
direct O +
injection O +
( O -
DI O -
) O +
or O +
headspace O -
- O -
solid O +
phase O +
microextraction O +
( O -
HS O -
- O -
SPME O -
) O +
coupled O +
with O +
gas O +
chromatography O +
( O -
GC O -
) O -
. O +

A O +
total O +
of O +
43 O +
compounds O +
were O +
identified O -
, O +
of O +
which O +
37 O +
were O +
verified O +
by O +
DI O -
/ O -
GC O +
and O +
31 O +
by O +
HS O -
- O -
SPME O -
/ O -
GC O -
. O +

Hot O +
water O +
heating O +
increased O +
the O +
yields O +
of O +
essential O +
oils O +
from O +
both O +
peels O +
and O +
whole O +
fruit O -
. O +

The O +
principal O +
constituents O +
of O +
the O +
oils O +
were O +
similar O +
except O +
for O +
the O +
minor O +
compounds O -
, O +
including O +
linalool B-Chemical -
, O +
terpinen-4-ol B-Chemical +
and O +
α B-Chemical -
- I-Chemical -
terpineol I-Chemical -
, O +
the O +
levels O +
of O +
which O +
increased O +
after O +
steam O +
distillation O -
. O +

The O +
whole O +
fruit O +
also O +
contained O +
higher O +
levels O +
of O +
terpene B-Chemical +
alcohols I-Chemical -
. O +

Salicylic B-Chemical +
acid I-Chemical -
- O -
induced O +
elicitation O +
of O +
folates O +
in O +
coriander O +
( O -
Coriandrum O +
sativum O +
L. O -
) O +
improves O +
bioaccessibility O +
and O +
reduces O +
pro O -
- O -
oxidant O +
status O -
. O +

Foliage O +
of O +
Coriandrum O +
sativum O +
is O +
a O +
rich O +
source O +
of O +
natural O +
folates O +
amenable O +
for O +
enhancement O +
through O +
salicylic B-Chemical +
acid I-Chemical -
- O -
mediated O +
elicitation O -
, O +
thereby O +
holding O +
a O +
great O +
promise O +
for O +
natural O -
- O -
mode O +
alleviation O +
of O +
this O +
vitamin B-Chemical +
( I-Chemical -
B I-Chemical -
( I-Chemical -
9 I-Chemical -
) I-Chemical -
) I-Chemical +
deficiency O -
. O +

In O +
the O +
present O +
study O +
we O +
report O +
salicylic B-Chemical +
acid I-Chemical -
- O -
mediated O +
differential O +
elicitation O +
of O +
different O +
forms O +
of O +
folates B-Chemical +
- O +
5-methyltetrahydrofolate B-Chemical -
, O +
5-formyltetrahydrofolate B-Chemical +
and O +
10-formyltetrahydrofolate B-Chemical +
- O +
their O +
stabilities O +
during O +
microwave O -
- O -
drying O +
and O +
bioaccessibilities O +
from O +
fresh O +
and O +
dried O +
foliage O -
. O +

The O +
first O +
two O +
compounds O +
nearly O +
doubled O +
and O +
the O +
third O +
increased O +
sixfold O +
post O -
- O -
elicitation O -
, O +
with O +
all O +
three O +
showing O +
concomitant O +
increase O +
in O +
bioaccessibilities O -
. O +

Although O +
a O +
slight O +
decrease O +
in O +
bioaccessibility O +
was O +
observed O +
in O +
dried O +
foliage O -
, O +
over O +
twofold O +
increase O +
of O +
each O +
form O +
of O +
folate O +
upon O +
elicitation O +
would O +
deliver O +
much O +
higher O +
levels O +
of O +
natural O +
folates O +
from O +
this O +
traditional O +
culinary O +
foliage O -
, O +
which O +
is O +
widely O +
used O +
in O +
many O +
cuisines O -
. O +

Elicitor O -
- O -
mediated O +
folate O +
enhancement O +
also O +
imparted O +
reduction O +
of O +
oxidative O +
status O +
and O +
the O +
enhancement O +
of O +
antioxidant O +
enzyme O +
activities O +
in O +
coriander O +
foliage O -
. O +

Short O -
- O -
term O +
comparative O +
study O +
of O +
the O +
influence O +
of O +
fried O +
edible O +
oils O +
intake O +
on O +
the O +
metabolism O +
of O +
essential O +
fatty B-Chemical +
acids I-Chemical +
in O +
obese O +
individuals O -
. O +

The O +
effect O +
of O +
breakfast O +
intake O +
of O +
fried O +
oils O +
containing O +
natural O +
antioxidants O +
or O +
a O +
synthetic O +
autooxidation O +
inhibitor O +
on O +
the O +
metabolism O +
of O +
essential O +
fatty B-Chemical +
acids I-Chemical +
focused O +
on O +
obese O +
individuals O -
. O +

Serum O +
levels O +
of O +
eicosanoids B-Chemical +
were O +
compared O +
in O +
individuals O +
before O +
and O +
after O +
intake O +
of O +
different O +
breakfasts O -
. O +

Univariate O +
descriptive O +
analysis O +
was O +
used O +
to O +
characterise O +
the O +
cohort O +
selected O +
for O +
this O +
study O +
and O +
multivariate O +
analysis O +
to O +
reveal O +
statistical O +
differences O +
of O +
normalised O +
eicosanoids B-Chemical +
concentrations O +
( O -
determined O +
by O +
solid O -
- O -
phase O +
extraction O +
coupled O +
to O +
LC O -
- O -
MS O -
/ O -
MS O -
) O +
depending O +
on O +
the O +
edible O +
oil O +
used O +
for O +
breakfast O +
preparation O -
. O +

The O +
results O +
showed O +
that O +
the O +
intake O +
of O +
breakfast O +
prepared O +
with O +
pure O +
sunflower O +
oil O +
subjected O +
to O +
deep O +
frying O +
causes O +
an O +
effect O +
over O +
the O +
eicosanoids B-Chemical +
profile O +
that O +
enables O +
discrimination O +
versus O +
the O +
rest O +
of O +
individuals O -
. O +

The O +
effect O +
was O +
a O +
significant O +
increase O +
in O +
the O +
concentration O +
of O +
hydroxyoctadecadienoic B-Chemical +
acid I-Chemical +
( O -
HODE B-Chemical -
) O +
metabolites O -
, O +
indicative O +
markers O +
of O +
the O +
intake O +
of O +
fried O +
oils O -
. O +

The O +
concentration O +
of O +
HODE B-Chemical +
metabolites O +
was O +
lower O +
when O +
the O +
oil O +
contained O +
either O +
natural O +
antioxidants O +
from O +
olive O -
- O -
oil O +
pomace O +
or O +
a O +
synthetic O +
autooxidation O +
inhibitor O +
as O +
dimethylsiloxane B-Chemical -
. O +

The O +
comparison O +
of O +
the O +
effect O +
of O +
fried O +
sunflower O +
oils O +
with O +
fried O +
extra O +
virgin O +
olive O +
oil O +
shows O +
the O +
benefits O +
associated O +
to O +
the O +
consumption O +
of O +
the O +
latter O -
. O +

Comprehensive O +
analysis O +
of O +
Phyteuma O +
orbiculare O +
L. O -
, O +
a O +
wild O +
Alpine O +
food O +
plant O -
. O +

Plants O +
which O +
have O +
been O +
traditionally O +
eaten O +
by O +
the O +
alpine O +
population O +
may O +
provide O +
new O +
opportunities O +
for O +
agricultural O +
development O +
in O +
mountain O +
regions O -
. O +

In O +
this O +
context O +
we O +
have O +
investigated O +
the O +
chemical O +
composition O +
of O +
Phyteuma O +
orbiculare O +
( O -
Campanulaceae O -
) O -
, O +
a O +
perennial O +
herb O +
whose O +
leaves O +
have O +
been O +
eaten O +
as O +
salad O +
by O +
rural O +
populations O +
in O +
Valais O +
( O -
Switzerland O -
) O -
. O +

Extracts O +
of O +
different O +
polarities O +
were O +
subjected O +
to O +
comprehensive O +
metabolite O +
profiling O +
using O +
a O +
dereplication O +
platform O +
combining O +
HPLC O -
- O -
PDA O -
- O -
MS O -
, O +
and O +
offline O +
NMR O +
analysis O -
. O +

Twenty O -
- O -
three O +
compounds O -
, O +
including O +
various O +
phenolic B-Chemical +
glycosides I-Chemical -
, O +
a O +
new O +
dimeric O +
phenylpropanoid B-Chemical +
glucoside I-Chemical -
, O +
saponins B-Chemical -
, O +
and O +
fatty B-Chemical +
acids I-Chemical +
were O +
identified O +
online O -
, O +
or O +
after O +
targeted O +
isolation O -
. O +

Selected O +
phenolic O +
constituents O +
were O +
quantitatively O +
assessed O +
by O +
HPLC O -
- O -
PDA O +
analysis O -
. O +

In O +
addition O -
, O +
substances O +
relevant O +
for O +
nutrition O -
, O +
such O +
as O +
β B-Chemical -
- I-Chemical -
carotene I-Chemical -
, O +
fatty B-Chemical +
acids I-Chemical -
, O +
ascorbic B-Chemical +
acid I-Chemical +
and O +
minerals O +
were O +
quantified O +
in O +
leaves O +
and O +
flowers O -
. O +

The O +
antioxidant O +
capacity O +
was O +
determined O +
with O +
an O +
ORAC O +
assay O -
, O +
and O +
total O +
phenolic B-Chemical +
compounds O +
were O +
quantified O -
. O +

Finally O -
, O +
the O +
phytochemical O +
profile O +
was O +
compared O +
to O +
that O +
of O +
the O +
related O +
species O +
P. O +
spicatum O -
, O +
P. O +
hemisphaericum O +
and O +
P. O +
ovatum O -
. O +

Neferine B-Chemical +
induces O +
reactive O +
oxygen B-Chemical +
species O +
mediated O +
intrinsic O +
pathway O +
of O +
apoptosis O +
in O +
HepG2 O +
cells O -
. O +

Evidence O +
has O +
accumulated O +
concerning O +
the O +
medicinal O +
application O +
of O +
Nelumbo O +
nucifera O +
in O +
the O +
treatment O +
of O +
various O +
diseases O -
. O +

Neferine B-Chemical -
, O +
an O +
alkaloid O +
from O +
N. O +
nucifera O +
was O +
found O +
to O +
exert O +
cytotoxicity O +
on O +
liver O +
cancer O +
cells O +
HepG2 O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O +

We O +
evaluated O +
its O +
anticancer O +
potential O +
by O +
studying O +
its O +
effect O +
on O +
mitochondrial O +
membrane O +
potential O -
, O +
intracellular O +
calcium B-Chemical +
levels O +
[ O -
Ca B-Chemical -
( I-Chemical -
2+ I-Chemical -
) I-Chemical -
] O -
( O -
i O -
) O -
, O +
cell O +
membrane O +
integrity O -
, O +
apoptotic O +
body O +
formation O +
and O +
DNA O +
fragmentation O +
in O +
cultured O +
HepG2 O +
cells O -
. O +

The O +
reactive O +
oxygen B-Chemical +
species O +
level O +
has O +
been O +
increased O +
upon O +
neferine B-Chemical +
treatment O +
with O +
concomitant O +
decrease O +
in O +
reduced O +
glutathione B-Chemical -
. O +

Our O +
data O +
further O +
indicate O +
reduction O +
of O +
ΔψM O +
and O +
increased O +
[ O -
Ca B-Chemical -
( I-Chemical -
2+ I-Chemical -
) I-Chemical -
] O -
( O -
i O -
) O +
during O +
apoptosis O +
induction O +
by O +
neferine B-Chemical +
with O +
increased O +
expression O +
of O +
apoptotic O +
proteins O +
such O +
as O +
Bax O -
, O +
Bad O -
, O +
cleaved O +
forms O +
of O +
caspase O +
3 O -
, O +
caspase O +
9 O +
and O +
PARP O -
, O +
with O +
the O +
downregulation O +
of O +
anti O -
- O -
apoptotic O +
protein O +
Bcl2 O +
in O +
HepG2 O +
cells O -
. O +

Moreover O -
, O +
the O +
expressions O +
of O +
tumour O +
suppressor O +
proteins O +
p53 O +
and O +
PTEN O +
were O +
upregulated O +
along O +
with O +
the O +
downregulation O +
of O +
P O -
- O -
Akt O -
. O +

In O +
addition O -
, O +
expression O +
levels O +
of O +
TNF O -
- O -
α O -
, O +
p38 O +
and O +
ERK1 O -
/ O -
2 O +
MAP O +
kinases O +
were O +
increased O +
upon O +
neferine B-Chemical +
treatment O -
. O +

These O +
results O +
imply O +
that O +
mitochondrial O -
- O -
mediated O +
ROS O +
generation O +
induced O +
by O +
neferine B-Chemical +
leads O +
to O +
caspase O -
- O -
dependent O +
apoptosis O +
in O +
HepG2 O +
cells O -
. O +

A O +
sensitive O +
enzyme O -
- O -
linked O +
immunosorbent O +
assay O +
for O +
the O +
determination O +
of O +
fish O +
protein O +
in O +
processed O +
foods O -
. O +

Fish O +
is O +
one O +
of O +
the O +
most O +
common O +
causes O +
of O +
food O +
allergy O +
and O +
its O +
major O +
allergen O +
is O +
parvalbumin O -
, O +
a O +
12 O +
kDa O +
muscular O +
protein O -
. O +

In O +
this O +
study O -
, O +
a O +
sandwich O +
enzyme O -
- O -
linked O +
immunosorbent O +
assay O +
( O -
ELISA O -
) O +
for O +
the O +
determination O +
of O +
fish O +
protein O +
in O +
processed O +
foods O +
was O +
developed O +
using O +
a O +
polyclonal O +
antibody O +
raised O +
against O +
Pacific O +
mackerel O +
parvalbumin O -
. O +

The O +
developed O +
sandwich O +
ELISA O +
showed O +
22.6 O -
- O -
99.0 O -
% O +
reactivity O +
( O -
based O +
on O +
the O +
reactivity O +
to O +
Pacific O +
mackerel O +
parvalbumin O -
) O +
to O +
parvalbumins O +
from O +
various O +
species O +
of O +
fish O -
. O +

The O +
limits O +
of O +
detection O +
and O +
quantitation O +
were O +
estimated O +
to O +
be O +
0.23 O +
and O +
0.70 O +
μg O +
protein O +
per O +
g O +
of O +
food O -
, O +
respectively O -
. O +

When O +
the O +
sandwich O +
ELISA O +
was O +
subjected O +
to O +
inter O -
- O -
laboratory O +
validation O -
, O +
spiked O +
fish O +
protein O +
was O +
recovered O +
from O +
five O +
model O +
processed O +
foods O +
in O +
the O +
range O +
of O +
69.4 O -
- O -
84.8 O -
% O +
and O +
the O +
repeatability O +
and O +
reproducibility O +
relative O +
standard O +
deviations O +
were O +
satisfactorily O +
low O +
( O -
≤ O +
10.5 O -
% O -
) O -
. O +

Thus O -
, O +
the O +
sandwich O +
ELISA O +
was O +
judged O +
to O +
be O +
a O +
useful O +
tool O +
to O +
determine O +
fish O +
protein O +
in O +
processed O +
foods O -
. O +

Batch O +
and O +
continuous O +
synthesis O +
of O +
lactulose B-Chemical +
from O +
whey O +
lactose B-Chemical +
by O +
immobilized O +
β O -
- O -
galactosidase O -
. O +

In O +
this O +
study O -
, O +
lactulose B-Chemical +
synthesis O +
from O +
whey O +
lactose B-Chemical +
was O +
investigated O +
in O +
batch O +
and O +
continuous O +
systems O +
using O +
immobilized O +
β O -
- O -
galactosidase O -
. O +

In O +
the O +
batch O +
system O -
, O +
the O +
optimal O +
concentration O +
of O +
fructose B-Chemical +
for O +
lactulose B-Chemical +
synthesis O +
was O +
20 O -
% O -
, O +
and O +
the O +
effect O +
of O +
galactose B-Chemical -
, O +
glucose B-Chemical +
and O +
fructose B-Chemical +
on O +
β O -
- O -
galactosidase O +
activity O +
was O +
determined O +
for O +
hydrolysis O +
of O +
whey O +
lactose B-Chemical +
and O +
the O +
transgalactosylation O +
reaction O +
for O +
lactulose B-Chemical +
synthesis O -
. O +

Galactose B-Chemical +
and O +
fructose B-Chemical +
were O +
competitive O +
inhibitors O -
, O +
and O +
glucose B-Chemical +
acted O +
as O +
a O +
noncompetitive O +
inhibitor O -
. O +

The O +
inhibitory O +
effects O +
of O +
galactose B-Chemical +
and O +
glucose B-Chemical +
were O +
stronger O +
in O +
the O +
transgalactosylation O +
reaction O +
than O +
they O +
were O +
in O +
the O +
hydrolysis O +
reaction O -
. O +

In O +
addition O -
, O +
when O +
immobilized O +
β O -
- O -
galactosidase O +
was O +
reused O +
for O +
lactulose B-Chemical +
synthesis O -
, O +
its O +
catalytic O +
activity O +
was O +
retained O +
to O +
the O +
extent O +
of O +
52.9 O -
% O +
after O +
10 O +
reuses O -
. O +

Lactulose B-Chemical +
was O +
synthesized O +
continuously O +
in O +
a O +
packed O -
- O -
bed O +
reactor O -
. O +

We O +
synthesized O +
19.1g O -
/ O -
l O +
lactulose B-Chemical +
during O +
the O +
continuous O +
flow O +
reaction O +
at O +
a O +
flow O +
rate O +
of O +
0.5 O +
ml O -
/ O -
min O -
. O +

Gangliosides O +
and O +
sialic B-Chemical +
acid I-Chemical +
effects O +
upon O +
newborn O +
pathogenic O +
bacteria O +
adhesion O -
: O +
an O +
in O +
vitro O +
study O -
. O +

The O +
effect O +
of O +
the O +
main O +
gangliosides O +
( O -
GM O -
( O -
1 O -
) O -
, O +
GM O -
( O -
3 O -
) O -
, O +
GD O -
( O -
3 O -
) O -
) O +
and O +
free O +
sialic B-Chemical +
acid I-Chemical +
( O -
Neu5Ac B-Chemical -
) O +
upon O +
the O +
adhesion O +
of O +
pathogenic O +
bacteria O +
implicated O +
in O +
infant O +
diarrhoea O +
is O +
assessed O +
in O +
vitro O +
using O +
the O +
Caco-2 O +
cell O +
line O -
. O +

Concentrations O +
of O +
the O +
bioactive O +
compounds O +
found O +
in O +
the O +
bioaccessible O +
( O -
soluble O -
) O +
fraction O +
of O +
infant O +
formula O +
and O +
human O +
milk O +
are O +
employed O -
. O +

Bacterial O +
adhesion O +
behaviour O +
included O +
enterotoxigenic O +
Escherichia O +
coli O +
( O -
ETEC O -
) O -
, O +
enteropathogenic O +
E.coli O +
( O -
EPEC O -
) O -
, O +
Listeria O +
monocytogenes O -
, O +
Salmonella O +
entericaserovartyphi O -
, O +
Shigella O +
sonnei O -
, O +
Campylobacter O +
jejuni O +
and O +
Helicobacter O +
pylori O -
. O +

Three O +
different O +
approaches O +
were O +
assayed O -
: O +
pre O -
- O -
incubation O +
of O +
bacteria O +
and O +
compounds O +
before O +
addition O +
to O +
cells O +
( O -
competition O -
) O -
; O +
pre O -
- O -
incubation O +
of O +
the O +
cells O +
with O +
compounds O +
( O -
exclusion O -
) O -
; O +
and O +
pre O -
- O -
incubation O +
of O +
cells O +
with O +
bacteria O +
( O -
displacement O -
) O -
. O +

Furthermore O -
, O +
the O +
spatial O +
localization O +
of O +
the O +
most O +
abundant O +
gangliosides O -
, O +
GM O -
( O -
3 O -
) O +
and O +
GD O -
( O -
3 O -
) O -
, O +
in O +
Caco-2 O +
cells O +
has O +
been O +
determined O +
using O +
confocal O +
microscopy O -
. O +

Results O +
show O +
that O +
GM O -
( O -
3 O -
) O -
, O +
GD O -
( O -
3 O -
) O -
, O +
GM O -
( O -
1 O -
) O +
and O +
Neu5Ac B-Chemical +
at O +
the O +
assayed O +
concentrations O +
are O +
able O +
to O +
interfere O +
with O +
the O +
adhesion O +
of O +
several O +
pathogenic O +
bacteria O +
involved O +
in O +
neonatal O +
diseases O -
- O -
the O +
greatest O +
effect O +
corresponding O +
to O +
Neu5Ac B-Chemical -
, O +
followed O +
by O +
GD O -
( O -
3 O -
) O -
, O +
GM O -
( O -
1 O -
) O +
and O +
GM O -
( O -
3 O -
) O -
. O +

Gangliosides O +
GM O -
( O -
3 O -
) O +
and O +
GD O -
( O -
3 O -
) O +
are O +
located O +
in O +
the O +
apical O +
and O +
basolateral O +
membranes O +
of O +
the O +
Caco-2 O +
cells O -
. O +

A O +
simple O +
GC O -
- O -
MS O +
method O +
for O +
the O +
screening O +
of O +
betulinic B-Chemical -
, I-Chemical +
corosolic I-Chemical -
, I-Chemical +
maslinic I-Chemical -
, I-Chemical +
oleanolic I-Chemical +
and I-Chemical +
ursolic I-Chemical +
acid I-Chemical +
contents O +
in O +
commercial O +
botanicals O +
used O +
as O +
food O +
supplement O +
ingredients O -
. O +

The O +
occurrence O +
of O +
triterpene B-Chemical +
pentacyclic I-Chemical +
acids I-Chemical +
in O +
plants O +
is O +
extensive O -
, O +
but O +
little O +
is O +
known O +
about O +
their O +
availability O +
in O +
commercial O +
extracts O -
. O +

A O +
simple O +
GC O -
- O -
MS O +
method O +
for O +
the O +
simultaneous O +
determination O +
of O +
betulinic B-Chemical -
, I-Chemical +
corosolic I-Chemical -
, I-Chemical +
maslinic I-Chemical -
, I-Chemical +
oleanolic I-Chemical +
and I-Chemical +
ursolic I-Chemical +
acids I-Chemical +
was O +
developed O +
and O +
applied O +
to O +
38 O +
different O +
commercial O +
plant O +
extracts O +
sold O +
as O +
ingredients O +
for O +
dietary O +
supplements O -
. O +

A O +
suitable O +
protocol O +
was O +
set O +
up O +
to O +
perform O +
routine O +
control O +
of O +
a O +
diverse O +
array O +
of O +
samples O +
with O +
different O +
botanical O -
, O +
chemical O +
and O +
physical O +
characteristics O -
. O +

Remarkable O +
quantities O +
of O +
corosolic B-Chemical +
acid I-Chemical +
were O +
found O +
in O +
dried O +
extracts O +
from O +
aerial O +
parts O +
of O +
Lagerstroemia O +
speciosa O +
and O +
Ortosiphon O +
stamineus O +
( O -
14233 O +
and O +
1132 O +
mg O -
/ O -
kg O -
, O +
respectively O -
) O -
, O +
while O +
oleanolic B-Chemical +
acid I-Chemical +
was O +
abundant O +
in O +
O. O +
stamineus O +
and O +
Crataegus O +
monogyna O +
flowers O +
( O -
2774 O +
and O +
2339 O +
mg O -
/ O -
kg O -
) O -
; O +
ursolic B-Chemical +
was O +
identified O +
in O +
O. O +
stamineus O -
, O +
C. O +
monogyna O -
, O +
L. O +
speciosa O +
and O +
Arctostaphylos O +
uva O -
- O -
ursi O +
leaves O +
( O -
7773 O -
, O +
4165 O -
, O +
2108 O +
and O +
1034 O +
mg O -
/ O -
kg O -
) O -
. O +

Only O +
L. O +
speciosa O +
was O +
rich O +
in O +
maslinic B-Chemical +
acid I-Chemical +
( O -
4958 O +
mg O -
/ O -
kg O -
) O -
, O +
while O +
minor O +
amounts O +
of O +
betulinic B-Chemical +
acid I-Chemical +
( O -
257 O +
and O +
80 O +
mg O -
/ O -
kg O -
) O +
were O +
detected O +
in O +
L. O +
speciosa O +
and O +
C. O +
monogyna O +
extracts O -
. O +

Lower O +
quantities O +
of O +
triterpenic B-Chemical +
acids I-Chemical +
were O +
identified O +
in O +
dried O +
extracts O +
of O +
Harpagophyton O +
procumbens O +
root O -
, O +
propolis O -
, O +
Punica O +
granatum O +
root O -
, O +
Styrax O +
benzoin O -
, O +
Vaccinium O +
myrtillus O +
fruits O +
and O +
Vitis O +
vinifera O +
seeds O -
. O +

Decoctions O +
and O +
fluid O +
extracts O +
lacked O +
or O +
contained O +
very O +
low O +
amounts O +
of O +
triterpenic B-Chemical +
acids I-Chemical -
. O +

Results O +
are O +
discussed O +
in O +
terms O +
of O +
quality O +
and O +
safety O +
of O +
these O +
ingredients O -
. O +

The O +
importance O +
of O +
amylose O +
and O +
amylopectin O +
fine O +
structures O +
for O +
starch O +
digestibility O +
in O +
cooked O +
rice O +
grains O -
. O +

Statistically O +
and O +
causally O +
meaningful O +
relationships O +
are O +
established O +
between O +
starch O +
molecular O +
structures O +
( O -
obtained O +
by O +
size O -
- O -
exclusion O +
chromatography O -
, O +
proton O +
NMR O +
and O +
multiple O -
- O -
angle O +
laser O +
light O +
scattering O -
) O +
and O +
digestibility O +
of O +
cooked O +
rice O +
grains O +
( O -
measured O +
by O +
in O +
vitro O +
digestion O -
) O -
. O +

Significant O +
correlations O +
are O +
observed O +
between O +
starch O +
digestion O +
rate O +
and O +
molecular O +
structural O +
characteristics O -
, O +
including O +
fine O +
structures O +
of O +
the O +
distributions O +
of O +
branch O +
( O -
chain O -
) O +
lengths O +
in O +
both O +
amylose O +
and O +
amylopectin O -
. O +

The O +
in O +
vitro O +
digestion O +
rate O +
tends O +
to O +
increase O +
with O +
longer O +
amylose O +
branches O +
and O +
smaller O +
ratios O +
of O +
long O +
amylopectin O +
and O +
long O +
amylose O +
branches O +
to O +
short O +
amylopectin O +
branches O -
, O +
although O +
the O +
statistical O +
analyses O +
show O +
that O +
further O +
data O +
are O +
needed O +
to O +
establish O +
this O +
unambiguously O -
. O +

These O +
new O +
relationships O +
between O +
fine O +
starch O +
structural O +
features O +
and O +
digestibility O +
of O +
cooked O +
rice O +
grains O +
are O +
mechanistically O +
reasonable O -
, O +
but O +
suggestive O +
rather O +
than O +
statistically O +
definitive O -
. O +

Immunoreactivity O +
of O +
hen O +
egg O +
allergens O -
: O +
influence O +
on O +
in O +
vitro O +
gastrointestinal O +
digestion O +
of O +
the O +
presence O +
of O +
other O +
egg O +
white O +
proteins O +
and O +
of O +
egg O +
yolk O -
. O +

Hen O +
egg O +
white O +
comprises O +
of O +
a O +
complex O +
mixture O +
of O +
proteins O -
, O +
which O +
greatly O +
differ O +
in O +
their O +
physicochemical O +
characteristics O +
and O +
relative O +
abundance O -
. O +

We O +
aimed O +
to O +
identify O +
potential O +
undiscovered O +
egg O +
allergens O +
within O +
the O +
egg O +
white O +
proteome O +
and O +
investigated O +
the O +
existence O +
of O +
matrix O +
effects O +
on O +
the O +
proteolytic O +
stability O +
and O +
resultant O +
IgE O -
- O -
binding O +
of O +
the O +
allergenic O +
proteins O -
. O +

In O +
addition O +
to O +
the O +
main O +
egg O +
allergens O -
: O +
ovalbumin O +
( O -
OVA O -
) O -
, O +
ovomucoid O +
( O -
OM O -
) O +
and O +
lysozyme O +
( O -
LYS O -
) O -
, O +
two O +
minor O +
egg O +
white O +
proteins O -
, O +
tentatively O +
identified O +
as O +
ovoinhibitor O +
and O +
clusterin O -
, O +
were O +
found O +
to O +
react O +
with O +
serum O +
IgE O +
from O +
egg O -
- O -
allergic O +
patients O -
. O +

Egg O +
white O +
exhibited O +
residual O +
immunoreactivity O +
after O +
gastrointestinal O +
digestion O +
due O +
to O +
the O +
presence O +
of O +
intact O +
OVA O +
and O +
LYS O -
, O +
as O +
well O +
as O +
of O +
several O +
IgE O -
- O -
binding O +
peptides O +
derived O +
from O +
OVA O -
. O +

The O +
presence O +
of O +
egg O +
yolk O +
slightly O +
increased O +
the O +
susceptibility O +
to O +
hydrolysis O +
of O +
egg O +
white O +
proteins O +
and O +
abrogated O +
bile B-Chemical +
salt I-Chemical -
- O -
induced O +
precipitation O +
of O +
LYS O +
in O +
the O +
duodenal O +
medium O -
. O +

However O -
, O +
the O +
resultant O +
immunoreactivity O +
against O +
IgE O +
of O +
egg O +
white O +
proteins O +
after O +
in O +
vitro O +
digestion O +
was O +
not O +
significantly O +
modified O +
by O +
the O +
presence O +
of O +
yolk O +
components O -
. O +

Comparison O +
the O +
neuropreotective O +
effect O +
of O +
Cortex O +
Phellodendri O +
chinensis O +
and O +
Cortex O +
Phellodendri O +
amurensis O +
against O +
beta O -
- O -
amyloid O -
- O -
induced O +
neurotoxicity O +
in O +
PC12 O +
cells O -
. O +

Cortex O +
Phellodendron O +
chinensis O +
( O -
CPC O -
) O +
and O +
Cortex O +
Phellodendron O +
amurensis O +
( O -
CPA O -
) O +
derived O +
from O +
the O +
dried O +
bark O +
of O +
Phellodendron O +
chinense O +
Schneid O -
. O +
or O +
Phellodendron O +
amurense O +
Rupr O -
. O -
, O +
respectively O -
, O +
are O +
used O +
interchangeably O +
in O +
clinical O +
practice O +
under O +
the O +
name O +
" O -
Huang O +
Bai O -
" O +
for O +
centuries O +
in O +
Chinese O +
medicine O +
for O +
the O +
treatment O +
of O +
various O +
inflammatory O +
conditions O -
. O +

Previous O +
study O +
in O +
our O +
laboratory O +
demonstrated O +
that O +
CPC O +
and O +
CPA O +
had O +
different O +
anti O -
- O -
diarrheal O -
, O +
anti O -
- O -
bacterial O +
and O +
anti O -
- O -
inflammatory O +
effects O -
. O +

In O +
this O +
present O +
study O -
, O +
we O +
aimed O +
to O +
compare O +
the O +
protective O +
effect O +
of O +
ethanol B-Chemical +
extract O +
of O +
Cortex O +
Phellodendri O +
chinensis O +
( O -
ECPC O -
) O +
and O +
Cortex O +
Phellodendri O +
Amurensis O +
( O -
ECPA O -
) O +
against O +
beta O -
- O -
amyloid O +
( O -
Aβ O -
) O -
-induced O +
neurotoxicity O +
in O +
PC12 O +
cells O -
, O +
a O +
typical O +
model O +
of O +
Alzheimer O -
's O +
disease O -
. O +

The O +
results O +
showed O +
that O +
ECPC O +
and O +
ECPA O +
contain O +
four O +
common O +
chemical O +
markers O +
such O +
as O +
berberine B-Chemical -
, O +
but O +
palmatine B-Chemical +
and O +
jatrorrhizin B-Chemical +
were O +
not O +
found O +
in O +
CPC O +
in O +
contrast O +
to O +
the O +
presence O +
in O +
CPA O -
. O +

In O +
addition O -
, O +
both O +
ECPC O +
and O +
ECPA O +
can O +
significantly O +
increase O +
the O +
cell O +
viability O +
in O +
Aβ O -
- O -
treated O +
PC12 O +
cells O -
. O +

Moreover O -
, O +
ECPC O +
and O +
ECPA O +
can O +
markedly O +
elevate O +
the O +
ratio O +
of O +
the O +
protein O +
and O +
mRNA O +
levels O +
of O +
Bcl-2 O -
/ O -
Bax O -
, O +
while O +
remarkably O +
decrease O +
the O +
release O +
of O +
cytochrome O +
c O -
, O +
and O +
the O +
protein O +
and O +
mRNA O +
expression O +
of O +
caspase-3 O -
. O +

Interestingly O -
, O +
ECPA O +
has O +
better O +
protective O +
effect O +
than O +
ECPC O +
against O +
Aβ O -
- O -
induced O +
neurotoxicity O +
in O +
PC12 O +
cells O -
. O +

These O +
results O +
indicate O +
that O +
both O +
ECPC O +
and O +
ECPA O +
have O +
potential O +
protective O +
effect O +
against O +
Aβ O -
- O -
induced O +
neurotoxicity O +
in O +
PC12 O +
cells O -
, O +
and O +
ECPA O +
is O +
more O +
potential O +
of O +
the O +
two O +
species O +
to O +
be O +
used O +
in O +
traditional O +
medicine O +
as O +
a O +
neuroprotective O +
agent O +
for O +
the O +
treatment O +
of O +
AD O -
. O +

The O +
neuroprotective O +
effect O +
of O +
the O +
two O +
species O +
may O +
be O +
mediated O -
, O +
at O +
least O +
in O +
part O -
, O +
via O +
suppressing O +
of O +
the O +
cellular O +
apoptosis O -
. O +

β B-Chemical -
- I-Chemical -
Asarone I-Chemical -
, O +
an O +
active O +
principle O +
of O +
Acorus O +
calamus O +
rhizome O -
, O +
inhibits O +
morphogenesis O -
, O +
biofilm O +
formation O +
and O +
ergosterol B-Chemical +
biosynthesis O +
in O +
Candida O +
albicans O -
. O +

Anti O -
- O -
Candida O +
potential O +
of O +
Acorus O +
calamus O +
rhizome O +
and O +
its O +
active O +
principle O -
, O +
β B-Chemical -
- I-Chemical -
asarone I-Chemical -
, O +
was O +
evaluated O +
against O +
the O +
human O +
fungal O +
pathogen O -
, O +
Candida O +
albicans O -
. O +

β B-Chemical -
- I-Chemical -
Asarone I-Chemical +
exhibited O +
promising O +
growth O +
inhibitory O +
activity O +
at O +
0.5mg O -
/ O -
ml O +
and O +
it O +
was O +
fungicidal O +
at O +
8 O +
mg O -
/ O -
ml O -
. O +

Time O +
dependant O +
kill O +
curve O +
assay O +
showed O +
that O +
MFC O +
of O +
β B-Chemical -
- I-Chemical -
asarone I-Chemical +
was O +
highly O +
toxic O +
to O +
C. O +
albicans O -
, O +
killing O +
99.9 O -
% O +
inoculum O +
within O +
120 O +
min O +
of O +
exposure O -
. O +

β B-Chemical -
- I-Chemical -
Asarone I-Chemical +
caused O +
significant O +
inhibition O +
of O +
C. O +
albicans O +
morphogenesis O +
and O +
biofilm O +
development O +
at O +
sub O -
- O -
inhibitory O +
concentrations O -
. O +

Our O +
data O +
indicate O +
that O +
the O +
growth O +
inhibitory O +
activity O +
of O +
β B-Chemical -
- I-Chemical -
asarone I-Chemical +
might O +
be O +
through O +
inhibition O +
of O +
ergosterol B-Chemical +
biosynthesis O -
. O +

Hemolytic O +
assay O +
showed O +
that O +
β B-Chemical -
- I-Chemical -
asarone I-Chemical +
is O +
non O -
- O -
toxic O -
, O +
even O +
at O +
concentrations O +
approaching O +
MIC O +
value O -
. O +

Our O +
results O +
suggest O +
that O +
β B-Chemical -
- I-Chemical -
asarone I-Chemical +
may O +
be O +
safe O +
as O +
a O +
topical O +
antifungal O +
agent O -
. O +

Testing O +
of O +
novel O +
brain O -
- O -
penetrating O +
oxime B-Chemical +
reactivators O +
of O +
acetylcholinesterase O +
inhibited O +
by O +
nerve O +
agent O +
surrogates O -
. O +

A O +
critical O +
need O +
for O +
combating O +
the O +
effects O +
of O +
organophosphate B-Chemical +
( O -
OP O -
) O +
anticholinesterases O -
, O +
such O +
as O +
nerve O +
agents O -
, O +
is O +
the O +
current O +
lack O +
of O +
an O +
effective O +
oxime B-Chemical +
reactivator O +
which O +
can O +
penetrate O +
the O +
blood O -
- O -
brain O +
barrier O +
( O -
BBB O -
) O -
, O +
and O +
therefore O +
reactivate O +
inhibited O +
acetylcholinesterase O +
( O -
AChE O -
) O +
in O +
the O +
brain O -
. O +

Our O +
laboratories O +
have O +
synthesized O +
and O +
have O +
initiated O +
testing O +
of O +
novel O +
phenoxyalkyl B-Chemical +
pyridinium I-Chemical +
oximes I-Chemical +
( O -
patent O +
pending O -
) O +
that O +
are O +
more O +
lipophilic O +
than O +
currently O +
approved O +
oximes B-Chemical -
. O +

This O +
is O +
a O +
preliminary O +
report O +
on O +
these O +
novel O +
oximes B-Chemical +
which O +
have O +
been O +
tested O +
in O +
vitro O +
in O +
rat O +
brain O +
homogenates O +
with O +
highly O +
relevant O +
surrogates O +
for O +
sarin B-Chemical +
( O -
phthalimidyl B-Chemical +
isopropyl I-Chemical +
methylphosphonate I-Chemical -
; O +
PIMP B-Chemical -
) O +
and O +
VX O +
( O -
nitrophenyl B-Chemical +
ethyl I-Chemical +
methylphosphonate I-Chemical -
; O +
NEMP B-Chemical -
) O -
. O +

The O +
oximes B-Chemical +
demonstrated O +
a O +
range O +
of O +
14 O -
- O -
76 O -
% O +
reactivation O +
of O +
rat O +
brain O +
AChE O +
in O +
vitro O -
. O +

An O +
in O +
vivo O +
testing O +
paradigm O +
was O +
developed O +
in O +
which O +
the O +
novel O +
oxime B-Chemical +
was O +
administered O +
at O +
the O +
time O +
of O +
maximal O +
brain O +
AChE O +
inhibition O +
( O -
about O +
80 O -
% O -
) O +
( O -
1h O -
) O +
elicited O +
by O +
nitrophenyl B-Chemical +
isopropyl I-Chemical +
methylphosphonate I-Chemical +
( O -
NIMP B-Chemical -
; O +
sarin B-Chemical +
surrogate O -
) O -
. O +

This O +
paradigm O -
, O +
with O +
delayed O +
administration O +
of O +
oxime B-Chemical +
to O +
a O +
time O +
when O +
brain O +
AChE O +
was O +
starting O +
to O +
recover O -
, O +
was O +
designed O +
to O +
minimize O +
reactivation O -
/ O -
reinhibition O +
of O +
peripheral O +
AChE O +
during O +
the O +
reactivation O +
period O +
which O +
would O +
decrease O +
the O +
availability O +
of O +
the O +
surrogate O +
for O +
entry O +
into O +
the O +
brain O -
; O +
this O +
paradigm O +
will O +
allow O +
proof O +
of O +
concept O +
of O +
BBB O +
penetrability O -
. O +

The O +
initial O +
studies O +
of O +
these O +
oximes B-Chemical +
in O +
vivo O +
with O +
the O +
sarin B-Chemical +
surrogate O +
NIMP B-Chemical +
have O +
indicated O +
reactivation O +
of O +
up O +
to O +
about O +
25 O -
% O +
at O +
30min O +
after O +
oxime B-Chemical +
administration O +
and O +
substantial O +
attenuation O +
of O +
seizure O +
behavior O +
from O +
some O +
of O +
the O +
oximes B-Chemical -
. O +

Therefore O +
these O +
novel O +
oximes B-Chemical +
have O +
considerable O +
potential O +
as O +
brain O -
- O -
protecting O +
therapeutics O +
for O +
anticholinesterases O -
. O +

Absolute O +
quantitation O +
of O +
stevioside B-Chemical +
and O +
rebaudioside B-Chemical +
A I-Chemical +
in O +
commercial O +
standards O +
by O +
quantitative O +
NMR O -
. O +

The O +
extract O +
prepared O +
from O +
the O +
leaves O +
of O +
Stevia O +
rebaudiana O +
BERTONI O +
( O -
Asteraceae O -
) O +
contains O +
sweet O +
steviol B-Chemical +
glycosides I-Chemical -
, O +
mainly O +
stevioside B-Chemical +
and O +
rebaudioside B-Chemical +
A. I-Chemical +
Highly O +
purified O +
stevia O +
extracts O +
have O +
become O +
popular O +
worldwide O +
as O +
a O +
natural O -
, O +
low O -
- O -
calorie O +
sweetener O -
. O +

They O +
contain O +
various O +
types O +
of O +
steviol B-Chemical +
glycosides I-Chemical -
, O +
and O +
their O +
main O +
components O +
are O +
stevioside B-Chemical +
and O +
rebaudioside B-Chemical +
A. I-Chemical +
The O +
content O +
of O +
each O +
steviol B-Chemical +
glycoside I-Chemical +
is O +
quantified O +
by O +
comparing O +
the O +
ratios O +
of O +
the O +
molecular O +
weights O +
and O +
the O +
chromatographic O +
peak O +
areas O +
of O +
the O +
samples O +
to O +
those O +
of O +
stevioside B-Chemical +
or O +
rebaudioside B-Chemical +
A I-Chemical +
standards O +
of O +
the O +
Food O +
and O +
Agriculture O +
Organization O +
of O +
the O +
United O +
Nations O +
( O -
FAO O -
) O -
/ O -
World O +
Health O +
Organization O +
( O -
WHO O -
) O +
Joint O +
Expert O +
Committee O +
on O +
Food O +
Additives O +
( O -
JECFA O -
) O +
and O +
other O +
specifications O -
. O +

However O -
, O +
various O +
commercial O +
standard O +
reagents O +
of O +
stevioside B-Chemical +
and O +
rebaudioside B-Chemical +
A I-Chemical +
are O +
available O -
. O +

Their O +
purities O +
are O +
different O +
and O +
their O +
exact O +
purities O +
are O +
not O +
indicated O -
. O +

Therefore O -
, O +
the O +
measured O +
values O +
of O +
stevioside B-Chemical +
and O +
rebaudioside B-Chemical +
A I-Chemical +
contained O +
in O +
a O +
sample O +
vary O +
according O +
to O +
the O +
standard O +
used O +
for O +
the O +
quantification O -
. O +

In O +
this O +
study O -
, O +
we O +
utilized O +
an O +
accurate O +
method O -
, O +
quantitative O +
NMR O +
( O -
qNMR O -
) O -
, O +
for O +
determining O +
the O +
contents O +
of O +
stevioside B-Chemical +
and O +
rebaudioside B-Chemical +
A I-Chemical +
in O +
standards O -
, O +
with O +
traceability O +
to O +
the O +
International O +
System O +
of O +
Units O +
( O -
SI O +
units O -
) O -
. O +

The O +
purities O +
of O +
several O +
commercial O +
standards O +
were O +
determined O +
to O +
confirm O +
their O +
actual O +
values O -
. O +

2-Amino-4-arylthiazole B-Chemical +
compounds O +
as O +
TRPA1 O +
antagonists O +
( O -
WO O +
2012085662 O -
) O -
: O +
a O +
patent O +
evaluation O -
. O +

The O +
patent O +
claims O +
2-amino-4-arylthiazole B-Chemical +
derivative O +
compounds O +
as O +
inhibitors O +
of O +
the O +
TRPA1 O +
( O -
transient O +
receptor O +
potential O +
ankyrin O -
, O +
member O +
1 O -
) O +
receptor O -
. O +

These O +
compounds O +
are O +
potent O +
antagonists O +
on O +
the O +
basis O +
of O +
the O +
results O +
of O +
in O +
vitro O +
assays O -
, O +
and O +
are O +
expected O +
to O +
be O +
useful O +
for O +
treating O +
conditions O +
and O +
disorders O +
associated O +
with O +
TRPA1 O +
function O +
such O +
as O +
pain O -
, O +
chronic O +
pain O -
, O +
neuropathic O +
pain O -
, O +
rheumatoid O +
arthritic O +
pain O -
, O +
osteoarthritic O +
pain O -
, O +
diabetic O +
neuropathy O +
and O +
inflammatory O +
disorders O -
. O +

Bioactive O +
constituents O +
of O +
Salvia O +
chrysophylla O +
Stapf O -
. O +

The O +
dichloromethane B-Chemical +
extract O +
of O +
the O +
aerial O +
parts O +
of O +
Salvia O +
chrysophylla O +
Stapf O +
( O -
Lamiaceae O -
) O -
, O +
which O +
is O +
an O +
endemic O +
species O +
to O +
south O -
- O -
western O +
Anatolia O -
, O +
was O +
studied O +
for O +
non O -
- O -
volatile O +
secondary O +
metabolites O +
for O +
the O +
first O +
time O +
in O +
this O +
study O -
. O +

Structures O +
of O +
the O +
isolated O +
compounds O +
were O +
elucidated O +
as O +
sclareol B-Chemical -
, O +
β B-Chemical -
- I-Chemical -
sitosterol I-Chemical -
, O +
salvigenin B-Chemical -
, O +
oleanolic B-Chemical +
acid I-Chemical +
and O +
ursolic B-Chemical +
acid I-Chemical -
. O +

The O +
lipid O +
peroxidation O +
inhibitory O +
activity O +
and O +
the O +
DPPH B-Chemical +
free O +
radical O +
scavenging O +
activity O +
of O +
the O +
pure O +
isolates O +
were O +
investigated O +
to O +
establish O +
their O +
antioxidant O +
potential O -
. O +

Their O +
anticholinesterase O +
activity O +
was O +
carried O +
out O +
by O +
the O +
Ellman O +
assay O +
against O +
both O +
enzymes O -
, O +
acetylcholinesterase O +
( O -
AChE O -
) O +
and O +
butyrylcholinesterase O -
, O +
and O +
diterpene O +
sclareol B-Chemical +
exhibited O +
fairly O +
good O +
activity O +
against O +
both O +
the O +
enzymes O +
while O +
the O +
two O +
triterpenoids O +
oleanolic B-Chemical +
and I-Chemical +
ursolic I-Chemical +
acids I-Chemical +
exhibited O +
selective O +
activity O +
against O +
AChE. O +

Protective O +
effect O +
of O +
cinnamon O +
polyphenols B-Chemical +
against O +
STZ B-Chemical -
- O -
diabetic O +
mice O +
fed O +
high O -
- O -
sugar O -
, O +
high O -
- O -
fat O +
diet O +
and O +
its O +
underlying O +
mechanism O -
. O +

This O +
study O +
was O +
designed O +
to O +
investigate O +
the O +
potential O +
effects O +
of O +
14days O -
' O +
intragastrically O +
given O +
of O +
cinnamon O +
polyphenols B-Chemical +
( O -
CPS O -
) O +
in O +
treating O +
diabetic O +
mice O +
induced O +
by O +
intraperitoneal O +
injection O +
of O +
streptozotocin B-Chemical +
( O -
150mgkg O -
( O -
-1 O -
) O -
) O +
and O +
fed O +
high O -
- O -
sugar B-Chemical -
, O +
high O -
- O -
fat O +
diet O -
. O +

The O +
diabetic O +
mice O +
model O +
was O +
successfully O +
established O +
through O +
determining O +
on O +
fasting O +
blood O -
- O -
glucose B-Chemical +
( O -
FBG O -
) O +
test O -
. O +

As O +
revealed O +
by O +
glucose B-Chemical +
oxidase O +
( O -
GOD O -
) O +
and O +
radioimmunoassay O +
( O -
RIA O -
) O -
, O +
both O +
dimethyldiguanide B-Chemical +
( O -
DC O -
, O +
0.6gkg O -
( O -
-1 O -
) O -
d O -
( O -
-1 O -
) O -
) O +
and O +
CPS O +
( O -
0.3 O -
, O +
0.6 O -
, O +
1.2gkg O -
( O -
-1 O -
) O -
d O -
( O -
-1 O -
) O -
) O +
treatments O +
significantly O +
resulted O +
in O +
down O -
- O -
regulation O +
of O +
blood O +
glucose B-Chemical +
and O +
insulin O +
levels O +
in O +
serum O -
, O +
while O +
the O +
levels O +
of O +
oxidative O +
stress O +
markers O +
were O +
markedly O +
lowered O +
through O +
ELISA O +
assay O -
. O +

Meanwhile O -
, O +
the O +
pathological O +
damage O +
in O +
islet O +
with O +
pancreatic O +
beta O +
cells O +
was O +
ameliorated O +
by O +
treatment O +
of O +
CPS O +
at O +
different O +
doses O -
, O +
as O +
shown O +
in O +
HE O +
stain O -
. O +

At O +
the O +
same O +
time O -
, O +
the O +
treatments O +
also O +
caused O +
notable O +
reduction O +
of O +
iNOS O -
, O +
NF O -
- O -
κB O +
expressions O +
showing O +
in O +
Western O +
blot O +
analysis O -
. O +

These O +
findings O +
demonstrate O +
that O +
cinnamon O +
polyphenols B-Chemical +
can O +
exert O +
the O +
hypoglycemic O +
and O +
hypolipidemic O +
effects O +
through O +
the O +
mechanisms O +
that O +
may O +
be O +
associated O +
with O +
repairing O +
pancreatic O +
beta O +
cells O +
in O +
diabetic O +
mice O +
and O +
improving O +
its O +
anti O -
- O -
oxidative O +
capacity O -
, O +
as O +
well O +
as O +
attenuating O +
cytotoxicity O +
via O +
inhibition O +
of O +
iNOS O -
, O +
NF O -
- O -
κB O +
activation O -
. O +

Postexposure O +
application O +
of O +
Fas O +
receptor O +
small O -
- O -
interfering O +
RNA O +
to O +
suppress O +
sulfur B-Chemical +
mustard O -
- O -
induced O +
apoptosis O +
in O +
human O +
airway O +
epithelial O +
cells O -
: O +
implication O +
for O +
a O +
therapeutic O +
approach O -
. O +

Sulfur B-Chemical +
mustard O +
( O -
SM O -
) O +
is O +
a O +
vesicant O +
chemical O +
warfare O +
and O +
terrorism O +
agent O -
. O +

Besides O +
skin O +
and O +
eye O +
injury O -
, O +
respiratory O +
damage O +
has O +
been O +
mainly O +
responsible O +
for O +
morbidity O +
and O +
mortality O +
after O +
SM O +
exposure O -
. O +

Previously O -
, O +
it O +
was O +
shown O +
that O +
suppressing O +
the O +
death O +
receptor O +
( O -
DR O -
) O +
response O +
by O +
the O +
dominant O -
- O -
negative O +
Fas O -
- O -
associated O +
death O +
domain O +
protein O +
prior O +
to O +
SM O +
exposure O +
blocked O +
apoptosis O +
and O +
microvesication O +
in O +
skin O -
. O +

Here O -
, O +
we O +
studied O +
whether O +
antagonizing O +
the O +
Fas O +
receptor O +
( O -
FasR O -
) O +
pathway O +
by O +
small O -
- O -
interfering O +
RNA O +
( O -
siRNA O -
) O +
applied O +
after O +
SM O +
exposure O +
would O +
prevent O +
apoptosis O +
and O -
, O +
thus O -
, O +
airway O +
injury O -
. O +

Normal O +
human O +
bronchial O -
/ O -
tracheal O +
epithelial O +
( O -
NHBE O -
) O +
cells O +
were O +
used O +
as O +
an O +
in O +
vitro O +
model O +
with O +
FasR O +
siRNA O -
, O +
FasR O +
agonistic O +
antibody O +
CH11 O -
, O +
and O +
FasR O +
antagonistic O +
antibody O +
ZB4 O +
as O +
investigative O +
tools O -
. O +

In O +
NHBE O +
cells O -
, O +
both O +
SM O +
( O -
300 O +
µM O -
) O +
and O +
CH11 O +
( O -
100 O +
ng O -
/ O -
ml O -
) O +
induced O +
caspase-3 O +
activation O -
, O +
which O +
was O +
inhibited O +
by O +
FasR O +
siRNA O +
and O +
ZB4 O -
, O +
indicating O +
that O +
SM O -
- O -
induced O +
apoptosis O +
was O +
via O +
the O +
Fas O +
response O -
. O +

FasR O +
siRNA O +
inhibited O +
SM O -
- O -
induced O +
caspase-3 O +
activation O +
when O +
added O +
to O +
NHBE O +
cultures O +
up O +
to O +
8 O +
hours O +
after O +
SM O -
. O +

Results O +
using O +
annexin O +
V O -
/ O -
propidium B-Chemical +
iodide I-Chemical -
- O -
stained O +
cells O +
showed O +
that O +
both O +
apoptosis O +
and O +
necrosis O +
were O +
involved O +
in O +
cell O +
death O +
due O +
to O +
SM O -
; O +
FasR O +
siRNA O +
decreased O +
both O +
apoptotic O +
and O +
necrotic O +
cell O +
populations O -
. O +

Bronchoalveolar O +
lavage O +
fluid O +
( O -
BALF O -
) O +
of O +
rats O +
exposed O +
to O +
SM O +
( O -
1 O +
mg O -
/ O -
kg O -
, O +
50 O +
minutes O -
) O +
revealed O +
a O +
significant O +
( O -
P O +
< O +
0.05 O -
) O +
increase O +
in O +
soluble O +
Fas O +
ligand O +
and O +
active O +
caspase-3 O +
in O +
BALF O +
cells O -
. O +

These O +
findings O +
suggest O +
an O +
intervention O +
of O +
Fas O -
- O -
mediated O +
apoptosis O +
as O +
a O +
postexposure O +
therapeutic O +
strategy O +
with O +
a O +
therapeutic O +
window O +
for O +
SM O +
inhalation O +
injury O +
and O +
possibly O +
other O +
respiratory O +
diseases O +
involving O +
the O +
Fas O +
response O -
. O +

Investigating O +
the O +
roles O +
of O +
different O +
monoamine B-Chemical +
transmitters O +
and O +
impulse O +
control O +
using O +
the O +
5-choice O +
serial O +
reaction O +
time O +
task O -
. O +

Previous O +
studies O +
have O +
shown O +
that O +
drugs O +
which O +
block O +
the O +
reuptake O +
of O +
catecholamine B-Chemical +
neurotransmitters O +
improve O +
impulse O +
control O +
in O +
diseases O +
such O +
as O +
attention O +
deficit O +
hyperactivity O +
disorder O +
( O -
ADHD O -
) O -
. O +

Serotonin B-Chemical -
- O -
specific O +
reuptake O +
inhibitors O +
( O -
SSRI O -
) O +
lack O +
efficacy O +
in O +
ADHD O +
and O +
have O +
been O +
linked O +
to O +
increased O +
suicide O +
risk O -
. O +

The O +
present O +
study O +
investigated O +
drugs O +
with O +
affinity O +
for O +
one O +
or O +
more O +
of O +
the O +
monoamine B-Chemical +
reuptake O +
transporters O +
using O +
the O +
5-choice O +
serial O +
reaction O +
time O +
task O -
, O +
a O +
model O +
of O +
attention O +
and O +
impulsivity O +
in O +
rodents O -
. O +

We O +
also O +
tested O +
the O +
effects O +
of O +
the O +
alpha O -
( O -
2 O -
) O -
-adreoceptor O +
antagonist O -
, O +
idazoxan B-Chemical +
and O +
novel O +
antidepressant O -
, O +
agomelatine B-Chemical -
, O +
which O +
both O +
increase O +
cortical O +
noradrenaline B-Chemical +
concentrations O +
through O +
non O -
- O -
reuptake O +
mechanisms O -
. O +

Improvements O +
in O +
impulse O +
control O +
were O +
observed O +
with O +
venlafaxine B-Chemical -
, O +
a O +
serotonin B-Chemical +
and O +
noradrenaline B-Chemical +
re O -
- O -
uptake O +
inhibitor O +
( O -
SNRI O -
) O +
but O +
not O +
bupropion B-Chemical +
( O -
dopamine B-Chemical +
and O +
noradrenaline B-Chemical +
re O -
- O -
uptake O +
inhibitor O -
) O -
. O +

Sibutramine B-Chemical +
( O -
SNRI O -
) O +
reduced O +
premature O +
responses O +
by O +
~50 O -
% O +
at O +
the O +
highest O +
dose O +
tested O +
but O +
this O +
was O +
not O +
significant O -
. O +

All O +
three O +
of O +
the O +
SSRIs O +
tested O +
reduced O +
premature O +
responding O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
, O +
although O +
also O +
slowed O +
response O +
and O +
collection O +
latencies O -
. O +

Neither O +
idazoxan B-Chemical +
nor O +
agomelatine B-Chemical +
significantly O +
reduced O +
premature O +
responding O -
, O +
suggesting O +
a O +
lack O +
of O +
efficacy O +
at O +
the O +
doses O +
tested O -
. O +

None O +
of O +
the O +
drugs O +
tested O +
improved O +
attention O +
in O +
this O +
task O +
but O +
sibutramine B-Chemical +
( O -
SNRI O -
) O -
, O +
fluoxetine B-Chemical +
( O -
SSRI O -
) O +
and O +
paroxetine B-Chemical +
( O -
SSRI O -
) O +
all O +
increased O +
omissions O +
at O +
the O +
highest O +
dose O +
tested O -
. O +

These O +
data O +
suggest O +
that O +
the O +
SNRIs O +
and O +
SSRIs O +
reduce O +
premature O +
responding O +
but O +
tend O +
to O +
be O +
less O +
specific O +
than O +
noradrenaline B-Chemical +
specific O +
reuptake O +
inhibitors O +
in O +
this O +
model O -
. O +

SSRIs O +
did O +
not O +
induce O +
any O +
specific O +
impairment O +
in O +
impulse O +
control O +
in O +
this O +
model O -
. O +

Interactions O +
between O +
chemical O +
and O +
climate O +
stressors O -
: O +
a O +
role O +
for O +
mechanistic O +
toxicology O +
in O +
assessing O +
climate O +
change O +
risks O -
. O +

Incorporation O +
of O +
global O +
climate O +
change O +
( O -
GCC O -
) O +
effects O +
into O +
assessments O +
of O +
chemical O +
risk O +
and O +
injury O +
requires O +
integrated O +
examinations O +
of O +
chemical O +
and O +
nonchemical O +
stressors O -
. O +

Environmental O +
variables O +
altered O +
by O +
GCC O +
( O -
temperature O -
, O +
precipitation O -
, O +
salinity O -
, O +
pH O -
) O +
can O +
influence O +
the O +
toxicokinetics O +
of O +
chemical O +
absorption O -
, O +
distribution O -
, O +
metabolism O -
, O +
and O +
excretion O +
as O +
well O +
as O +
toxicodynamic O +
interactions O +
between O +
chemicals O +
and O +
target O +
molecules O -
. O +

In O +
addition O -
, O +
GCC O +
challenges O +
processes O +
critical O +
for O +
coping O +
with O +
the O +
external O +
environment O +
( O -
water O +
balance O -
, O +
thermoregulation O -
, O +
nutrition O -
, O +
and O +
the O +
immune O -
, O +
endocrine O -
, O +
and O +
neurological O +
systems O -
) O -
, O +
leaving O +
organisms O +
sensitive O +
to O +
even O +
slight O +
perturbations O +
by O +
chemicals O +
when O +
pushed O +
to O +
the O +
limits O +
of O +
their O +
physiological O +
tolerance O +
range O -
. O +

In O +
simplest O +
terms O -
, O +
GCC O +
can O +
make O +
organisms O +
more O +
sensitive O +
to O +
chemical O +
stressors O -
, O +
while O +
alternatively O -
, O +
exposure O +
to O +
chemicals O +
can O +
make O +
organisms O +
more O +
sensitive O +
to O +
GCC O +
stressors O -
. O +

One O +
challenge O +
is O +
to O +
identify O +
potential O +
interactions O +
between O +
nonchemical O +
and O +
chemical O +
stressors O +
affecting O +
key O +
physiological O +
processes O +
in O +
an O +
organism O -
. O +

We O +
employed O +
adverse O +
outcome O +
pathways O -
, O +
constructs O +
depicting O +
linkages O +
between O +
mechanism O -
- O -
based O +
molecular O +
initiating O +
events O +
and O +
impacts O +
on O +
individuals O +
or O +
populations O -
, O +
to O +
assess O +
how O +
chemical- O +
and O +
climate O -
- O -
specific O +
variables O +
interact O +
to O +
lead O +
to O +
adverse O +
outcomes O -
. O +

Case O +
examples O +
are O +
presented O +
for O +
prospective O +
scenarios O -
, O +
hypothesizing O +
potential O +
chemical O -
- O -
GCC O +
interactions O -
, O +
and O +
retrospective O +
scenarios O -
, O +
proposing O +
mechanisms O +
for O +
demonstrated O +
chemical O -
- O -
climate O +
interactions O +
in O +
natural O +
populations O -
. O +

Understanding O +
GCC O +
interactions O +
along O +
adverse O +
outcome O +
pathways O +
facilitates O +
extrapolation O +
between O +
species O +
or O +
other O +
levels O +
of O +
organization O -
, O +
development O +
of O +
hypotheses O +
and O +
focal O +
areas O +
for O +
further O +
research O -
, O +
and O +
improved O +
inputs O +
for O +
risk O +
and O +
resource O +
injury O +
assessments O -
. O +

How O +
is O +
( B-Chemical -
68 I-Chemical -
) I-Chemical -
Ga I-Chemical +
labeling O +
of O +
macrocyclic O +
chelators O +
influenced O +
by O +
metal O +
ion O +
contaminants O +
in O +
( B-Chemical -
68 I-Chemical -
) I-Chemical -
Ge I-Chemical -
/ O -
( B-Chemical -
68 I-Chemical -
) I-Chemical -
Ga I-Chemical +
generator O +
eluates O -
? O +

To O +
assess O +
the O +
influence O +
of O +
Zn B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
, O +
Cu B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
, O +
Fe B-Chemical -
( I-Chemical -
3 I-Chemical -
+ I-Chemical -
) I-Chemical +
, O +
Al B-Chemical -
( I-Chemical -
3 I-Chemical -
+ I-Chemical -
) I-Chemical +
, O +
Ti B-Chemical -
( I-Chemical -
IV I-Chemical -
) I-Chemical +
, O +
and O +
Sn B-Chemical -
( I-Chemical -
IV I-Chemical -
) I-Chemical +
on O +
incorporation O +
of O +
( B-Chemical -
68 I-Chemical -
) I-Chemical +
Ga I-Chemical -
( I-Chemical -
3 I-Chemical -
+ I-Chemical -
) I-Chemical +
into O +
pendant O -
- O -
arm O +
macrocyclic O +
chelators O -
, O +
the O +
( B-Chemical -
68 I-Chemical -
) I-Chemical +
Ga I-Chemical +
labeling O +
of O +
1,4,7-triazacyclononane-1,4,7-triacetic B-Chemical +
acid I-Chemical +
( O -
NOTA B-Chemical -
) O -
, O +
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic B-Chemical +
acid I-Chemical +
( O -
DOTA B-Chemical -
) O -
, O +
1,4,7-triazacyclononane-1,4,7-tris B-Chemical -
[ I-Chemical -
methyl I-Chemical -
( I-Chemical -
2-carboxyethyl I-Chemical -
) I-Chemical -
phosphinic I-Chemical +
acid I-Chemical -
] I-Chemical -
) I-Chemical +
( O -
TRAP B-Chemical -
) O -
, O +
and O +
1,4,7-triazacyclononane-1- B-Chemical -
[ I-Chemical -
methyl I-Chemical -
( I-Chemical -
2-carboxyethyl I-Chemical -
) I-Chemical -
phosphinic I-Chemical +
acid I-Chemical -
] I-Chemical -
-4,7-bis I-Chemical -
[ I-Chemical -
methyl I-Chemical -
( I-Chemical -
2-hydroxymethyl I-Chemical -
) I-Chemical -
phosphinic I-Chemical +
acid I-Chemical -
] I-Chemical +
( O -
NOPO B-Chemical -
) O -
, O +
as O +
well O +
as O +
their O +
peptide O +
conjugates O -
, O +
was O +
investigated O +
in O +
the O +
presence O +
of O +
varying O +
concentrations O +
of O +
these O +
metal O +
ions O -
. O +

The O +
( B-Chemical -
68 I-Chemical -
) I-Chemical +
Ga I-Chemical +
labeling O +
yield O +
for O +
carboxylate B-Chemical -
- O -
type O +
chelators O +
NOTA B-Chemical +
and O +
DOTA B-Chemical +
is O +
decreased O +
at O +
lower O +
metal O +
ion O +
contaminant O +
concentrations O +
compared O +
with O +
phosphinate B-Chemical -
- O -
type O +
chelators O +
TRAP B-Chemical +
and O +
NOPO B-Chemical -
. O +

The O +
latter O +
are O +
able O +
to O +
rapidly O +
exchange O +
coordinated O +
Zn B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical +
with O +
( B-Chemical -
68 I-Chemical -
) I-Chemical +
Ga I-Chemical -
( I-Chemical -
3 I-Chemical -
+ I-Chemical -
) I-Chemical +
, O +
as O +
confirmed O +
by O +
mass O +
spectrometry O +
and O +
( B-Chemical -
31 I-Chemical -
) I-Chemical +
P I-Chemical +
NMR O +
spectroscopy O -
. O +

( B-Chemical -
68 I-Chemical -
) I-Chemical +
Ga I-Chemical +
labeling O +
of O +
Zn B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical +
complexes O +
of O +
TRAP B-Chemical +
and O +
NOPO B-Chemical +
proceeds O +
as O +
efficient O +
as O +
labeling O +
of O +
neat O +
NOTA B-Chemical -
; O +
this O +
applies O +
also O +
to O +
the O +
corresponding O +
peptide O +
conjugates O +
of O +
these O +
chelators O -
. O +

This O +
behavior O +
results O +
in O +
substantially O +
improved O +
selectivity O +
for O +
Ga B-Chemical -
( I-Chemical -
3 I-Chemical -
+ I-Chemical -
) I-Chemical +
and O -
, O +
therefore O -
, O +
in O +
more O +
robust O +
and O +
reliable O +
( B-Chemical -
68 I-Chemical -
) I-Chemical +
Ga I-Chemical +
labeling O +
procedures O -
. O +

In O +
addition O -
, O +
none O +
of O +
the O +
investigated O +
chelators O +
binds O +
( B-Chemical -
68 I-Chemical -
) I-Chemical +
Ge I-Chemical -
, O +
rendering O +
post O -
- O -
labeling O +
purification O +
protocols O -
, O +
for O +
example O -
, O +
solid O -
- O -
phase O +
extraction O -
, O +
a O +
reliable O +
means O +
of O +
removal O +
of O +
( B-Chemical -
68 I-Chemical -
) I-Chemical +
Ge I-Chemical +
contamination O +
from O +
( B-Chemical -
68 I-Chemical -
) I-Chemical +
Ga I-Chemical +
radiopharmaceuticals O -
. O +

Influence O +
of O +
global O +
climate O +
change O +
on O +
chemical O +
fate O +
and O +
bioaccumulation O -
: O +
the O +
role O +
of O +
multimedia O +
models O -
. O +

Multimedia O +
environmental O +
fate O +
models O +
are O +
valuable O +
tools O +
for O +
investigating O +
potential O +
changes O +
associated O +
with O +
global O +
climate O +
change O -
, O +
particularly O +
because O +
thermodynamic O +
forcing O +
on O +
partitioning O +
behavior O +
as O +
well O +
as O +
diffusive O +
and O +
nondiffusive O +
exchange O +
processes O +
are O +
implicitly O +
considered O -
. O +

Similarly O -
, O +
food O -
- O -
web O +
bioaccumulation O +
models O +
are O +
capable O +
of O +
integrating O +
the O +
net O +
effect O +
of O +
changes O +
associated O +
with O +
factors O +
such O +
as O +
temperature O -
, O +
growth O +
rates O -
, O +
feeding O +
preferences O -
, O +
and O +
partitioning O +
behavior O +
on O +
bioaccumulation O +
potential O -
. O +

For O +
the O +
climate O +
change O +
scenarios O +
considered O +
in O +
the O +
present O +
study O -
, O +
such O +
tools O +
indicate O +
that O +
alterations O +
to O +
exposure O +
concentrations O +
are O +
typically O +
within O +
a O +
factor O +
of O +
2 O +
of O +
the O +
baseline O +
output O -
. O +

Based O +
on O +
an O +
appreciation O +
for O +
the O +
uncertainty O +
in O +
model O +
parameters O +
and O +
baseline O +
output O -
, O +
the O +
authors O +
recommend O +
caution O +
when O +
interpreting O +
or O +
speculating O +
on O +
the O +
relative O +
importance O +
of O +
global O +
climate O +
change O +
with O +
respect O +
to O +
how O +
changes O +
caused O +
by O +
it O +
will O +
influence O +
chemical O +
fate O +
and O +
bioavailability O -
. O +

High O -
- O -
dose O +
sodium B-Chemical +
selenite I-Chemical +
toxicity O +
can O -
not O +
be O +
prevented O +
by O +
the O +
co O -
- O -
administration O +
of O +
pharmacological O +
levels O +
of O +
epigallocatechin-3-gallate B-Chemical +
which O +
in O +
turn O +
aggravates O +
the O +
toxicity O -
. O +

Selenium B-Chemical -
, O +
an O +
essential O +
trace O +
element O -
, O +
can O +
also O +
be O +
toxic O +
at O +
higher O +
levels O +
of O +
exposure O -
. O +

Several O +
lines O +
of O +
evidence O +
show O +
epigallocatechin-3-gallate B-Chemical +
( O -
EGCG B-Chemical -
) O -
, O +
a O +
predominant O +
component O +
of O +
green O +
tea O +
catechins B-Chemical +
with O +
numerous O +
health O +
benefits O -
, O +
can O +
ameliorate O +
the O +
toxicity O +
of O +
many O +
agents O -
. O +

A O +
proof O -
- O -
in O -
- O -
principle O +
experiment O +
was O +
conducted O +
to O +
determine O +
if O +
EGCG B-Chemical +
would O +
ameliorate O +
sodium B-Chemical +
selenite I-Chemical -
- O -
induced O +
growth O +
suppression O -
. O +

Mice O +
were O +
intraperitioneally O +
injected O +
with O +
selenite B-Chemical +
once O +
daily O +
for O +
five O +
days O +
at O +
a O +
dose O +
of O +
3 O +
mg O +
Se B-Chemical -
/ O -
kg O -
, O +
which O +
fully O +
suppressed O +
animal O +
growth O +
but O +
did O +
not O +
cause O +
death O -
. O +

Surprisingly O +
the O +
co O -
- O -
administration O +
of O +
the O +
selenite B-Chemical +
and O +
nontoxic O +
doses O +
of O +
EGCG B-Chemical +
( O -
10 O -
, O +
20 O +
and O +
40 O +
mg O -
/ O -
kg O -
, O +
intraperitioneally O -
) O +
resulted O +
in O +
the O +
mortality O +
of O +
treated O +
mice O +
in O +
a O +
dose O +
and O +
time O -
- O -
dependent O +
manner O +
( O -
33.3 O -
% O -
, O +
100 O -
% O +
and O +
100 O -
% O -
, O +
respectively O -
) O -
. O +

EGCG B-Chemical -
- O -
selenite B-Chemical +
induced O +
lethality O +
did O +
not O +
result O +
from O +
enhanced O +
selenium B-Chemical +
accumulation O +
but O +
appeared O +
to O +
involve O +
the O +
suppression O +
of O +
a O +
selenite B-Chemical -
- O -
induced O +
adaptive O +
response O +
as O +
evidenced O +
by O +
hepatic O +
glutathione B-Chemical +
S O -
- O -
transferase O +
activity O -
. O +

While O +
EGCG B-Chemical +
has O +
been O +
reported O +
to O +
ameliorate O +
the O +
toxicity O +
of O +
some O +
agents O -
, O +
the O +
induction O +
of O +
mortality O +
by O +
combined O +
treatment O +
with O +
pharmacological O +
doses O +
of O +
selenium B-Chemical +
and O +
EGCG B-Chemical +
is O +
a O +
previously O +
unrecognized O +
synergism O +
that O +
must O +
be O +
considered O +
not O +
only O +
in O +
the O +
remediation O +
of O +
high O +
environmental O +
selenium B-Chemical +
exposures O +
but O +
also O +
in O +
the O +
development O +
of O +
pharmaceuticals O +
and O +
nutriceuticals O -
. O +

Chinese O +
medicine O +
formula O +
" O -
Weikang O +
Keli O -
" O +
induces O +
autophagic O +
cell O +
death O +
on O +
human O +
gastric O +
cancer O +
cell O +
line O +
SGC-7901 O -
. O +

Weikang O +
Keli O +
( O -
constitutes O +
of O +
Root O +
of O +
Codonopsis O +
pilosula O -
, O +
Rhizoma O +
Atractylodis O +
Macrocephalae O -
, O +
Rhizoma O +
Curcumae O +
Aeruginosae O -
, O +
Rhizoma O +
Pinelliae O -
, O +
Actinidia O +
chinensis O +
Planch O -
, O +
and O +
Rhodiola O +
rosea O -
) O +
is O +
a O +
well O +
known O +
Chinese O +
herbal O +
formula O +
for O +
gastric O +
cancer O +
therapy O +
in O +
clinical O +
treatment O -
. O +

However O -
, O +
the O +
detailed O +
molecular O +
mechanisms O +
involved O +
are O +
still O +
not O +
fully O +
understood O -
. O +

In O +
this O +
study O -
, O +
we O +
found O +
that O +
Weikang O +
Keli O +
could O +
induce O +
patterns O +
of O +
autophagy O +
in O +
SGC-7901 O +
cells O -
, O +
including O +
intracellular O +
vacuole O +
formation O -
, O +
microtubule O -
- O -
associated O +
protein O +
1 O +
light O +
chain O +
3 O +
( O -
LC3 O -
) O +
conversion O -
. O +

Hoechst B-Chemical +
33258 I-Chemical +
staining O +
and O +
Western O +
blot O +
analysis O +
of O +
apoptosis O -
- O -
related O +
proteins O +
showed O +
that O +
WK O +
induced O +
SGC-7901 O +
cell O +
death O +
was O +
not O +
through O +
apoptosis O -
. O +

In O +
vivo O +
study O +
also O +
revealed O +
that O +
i.g O -
. O +

administration O +
of O +
Weikang O +
Keli O +
once O +
a O +
day O +
for O +
25 O +
days O +
could O +
significantly O +
reduce O +
tumor O +
volumes O +
by O +
about O +
50 O -
% O -
. O +

Collectively O -
, O +
the O +
current O +
data O +
indicated O +
that O +
Weikang O +
Keli O +
induced O +
gastric O +
cancer O +
cell O +
death O +
by O +
autophagy O +
effects O -
. O +

Relieving O +
visceral O +
hyperalgesia O +
effect O +
of O +
Kangtai O +
capsule O +
and O +
its O +
potential O +
mechanisms O +
via O +
modulating O +
the O +
5-HT B-Chemical +
and O +
NO B-Chemical +
level O +
in O +
vivo O -
. O +

Kangtai O +
capsule O +
( O -
KT O -
) O +
is O +
one O +
type O +
of O +
traditional O +
Chinese O +
medicine O +
preparation O +
derived O +
from O +
the O +
proved O +
recipe O -
, O +
which O +
was O +
frequently O +
applied O +
as O +
an O +
effective O +
clinical O +
treatment O +
of O +
IBS O -
. O +

However O -
, O +
there O +
still O +
lack O +
the O +
reasonable O +
and O +
all O -
- O -
round O +
analytical O +
approach O +
and O +
the O +
scientific O +
studies O +
on O +
its O +
underlying O +
mechanisms O -
. O +

Therefore O -
, O +
our O +
study O +
aimed O +
to O +
develop O +
the O +
novel O +
method O +
for O +
evaluating O +
its O +
quality O +
as O +
well O +
as O +
to O +
interpret O +
the O +
potential O +
mechanisms O -
. O +

In O +
our O +
study O -
, O +
high O +
performance O +
liquid O +
chromatography O +
( O -
HPLC O -
) O +
fingerprint O +
was O +
applied O +
to O +
provide O +
a O +
chemical O +
profile O +
of O +
KT O -
. O +

The O +
neonatal O +
maternal O +
separation O +
( O -
NMS O -
) O +
on O +
Sprague O -
- O -
Dawley O +
pups O +
was O +
employed O +
to O +
evaluate O +
the O +
therapeutic O +
effect O +
of O +
KT O +
by O +
virtue O +
of O +
various O +
parameters O +
including O +
visceral O +
hyperalgesia O -
, O +
serum O +
nitric B-Chemical +
oxide I-Chemical +
( O -
NO B-Chemical -
) O +
level O -
, O +
and O +
tissue O +
5-hydroxytryptamine B-Chemical +
( O -
5-HT B-Chemical -
) O +
level O -
. O +

Consequently O -
, O +
a O +
chromatographic O +
condition O -
, O +
which O +
was O +
carried O +
at O +
30 O -
° O -
C O +
with O +
a O +
flow O +
rate O +
of O +
0.5 O +
ml O -
/ O -
min O +
on O +
AQUA O +
3μ O +
C18 O +
column O +
with O +
mobile O +
phase O +
of O +
acetonitrile B-Chemical +
and O +
water O -
- O -
phosphoric B-Chemical +
acid I-Chemical +
( O -
100:0.1 O -
, O +
v O -
/ O -
v O -
) O -
, O +
was O +
established O +
to O +
give O +
a O +
common O +
fingerprint O +
chromatography O +
under O +
254 O +
nm O +
with O +
a O +
similarity O +
index O +
of O +
0.963 O +
within O +
ten O +
batches O +
of O +
KT O +
samples O -
. O +

On O +
the O +
NMS O +
model O -
, O +
KT O +
markedly O +
elevated O +
the O +
pain O +
threshold O +
of O +
NMS O +
rats O -
. O +

Furthermore O -
, O +
KT O +
at O +
three O +
doses O +
significantly O +
decreased O +
5-HT B-Chemical +
content O +
from O +
distal O +
colon O +
of O +
visceral O +
hyperalgesia O +
rats O +
induced O +
by O +
NMS O -
, O +
while O +
the O +
significant O +
decrease O +
of O +
5-HT B-Chemical +
content O +
in O +
serum O +
was O +
only O +
observed O +
in O +
the O +
group O +
with O +
KT O +
at O +
high O +
dose O -
. O +

However O -
, O +
compared O +
with O +
that O +
in O +
NMS O +
rats O +
without O +
KT O -
, O +
there O +
was O +
no O +
apparent O +
difference O +
of O +
5-HT B-Chemical +
level O +
from O +
brain O +
issue O +
in O +
the O +
rats O +
with O +
various O +
doses O -
. O +

Besides O -
, O +
KT O +
could O +
substantially O +
elevate O +
the O +
concentration O +
of O +
NO B-Chemical +
in O +
the O +
serum O -
. O +

The O +
results O +
showed O +
our O +
study O +
developed O +
the O +
simple O -
, O +
rapid O -
, O +
accurate O -
, O +
reproducible O +
qualitative O +
and O +
quantitative O +
analysis O +
by O +
HPLC O +
fingerprint O +
for O +
the O +
quality O +
control O +
for O +
KT O -
. O +

Data O +
from O +
the O +
pharmacological O +
investigation O +
suggested O +
that O +
the O +
curative O +
effect O +
of O +
KT O +
to O +
the O +
visceral O +
hypersensitivity O +
may O +
be O +
concerned O +
with O +
the O +
level O +
of O +
5-HT B-Chemical +
and O +
NO B-Chemical +
in O +
vivo O -
, O +
promising O +
its O +
potential O +
in O +
irritable O +
bowel O +
syndrome O +
treatment O -
. O +

Effects O +
of O +
phospholipase O +
A2 O +
and O +
metalloprotease O +
fractions O +
of O +
Russell O -
's O +
viper O +
venom O +
on O +
cytokines O +
and O +
renal O +
hemodynamics O +
in O +
dogs O -
. O +

Several O +
enzymes O +
in O +
Russell O -
's O +
viper O +
( O -
Daboia O +
siamensis O -
) O +
venom O +
are O +
involved O +
in O +
the O +
venom O +
effects O +
and O +
renal O +
injury O -
. O +

The O +
effects O +
of O +
fractional O +
components O +
of O +
Russell O -
's O +
viper O +
venom O -
, O +
phospholipase O +
A O -
( O -
2 O -
) O +
and O +
metalloprotease O +
fractions O -
, O +
were O +
examined O +
in O +
two O +
groups O +
of O +
four O +
experimental O +
dogs O +
each O -
. O +

Animals O +
received O +
an O +
intravenous O +
injection O +
of O +
140 O +
μg O -
/ O -
kg O +
of O +
each O +
venom O +
fraction O -
. O +

The O +
inflammatory O +
effects O +
and O +
renal O +
hemodynamic O +
changes O +
were O +
assessed O -
. O +

Plasma O +
concentrations O +
of O +
interleukin-6 O +
( O -
IL-6 O -
) O -
, O +
tumor O +
necrosis O +
factor O -
- O -
α O +
( O -
TNF O -
- O -
α O -
) O +
and O +
PGE2 B-Chemical +
were O +
elevated O +
by O +
both O +
phospholipase O +
A O -
( O -
2 O -
) O +
( O -
PLA O -
( O -
2 O -
) O -
) O +
and O +
metalloprotease O +
( O -
MP O -
) O +
fractions O -
. O +

The O +
plasma O +
level O +
of O +
nitric B-Chemical +
oxide I-Chemical +
was O +
increased O +
after O +
PLA O -
( O -
2 O -
) O +
fraction O +
injection O +
but O +
not O +
with O +
MP O +
fraction O +
injection O -
. O +

Leukocytosis O +
with O +
increase O +
in O +
lymphocytes O -
, O +
monocytes O +
and O +
granulocytes O +
was O +
observed O +
after O +
both O +
PLA O -
( O -
2 O -
) O +
and O +
MP O +
injections O -
. O +

Results O +
from O +
this O +
study O +
suggested O +
that O +
both O +
PLA O -
( O -
2 O -
) O +
and O +
MP O +
were O +
inflammatory O -
. O +

Increased O +
red O +
blood O +
cell O +
count O -
, O +
hematocrit O +
and O +
hemoglobin O +
concentration O +
were O +
observed O +
in O +
animals O +
injected O +
with O +
PLA O -
( O -
2 O -
) O +
fraction O -
, O +
but O +
not O +
with O +
MP O +
fraction O -
. O +

Hemodynamically O -
, O +
PLA O -
( O -
2 O -
) O +
fraction O +
induced O +
marked O +
decrease O +
in O +
mean O +
arterial O +
pressure O +
with O +
decreased O +
renal O +
vascular O +
resistance O +
initially O +
followed O +
later O +
by O +
increased O +
renal O +
vascular O +
resistance O -
. O +

MP O +
fraction O +
caused O +
less O +
decrease O +
of O +
mean O +
arterial O +
pressure O +
but O +
increased O +
renal O +
vascular O +
resistance O +
throughout O +
the O +
experiment O -
. O +

Both O +
enzymes O +
decreased O +
renal O +
blood O +
flow O -
, O +
glomerular O +
filtration O +
rate O +
and O +
urine O +
flow O -
. O +

The O +
findings O +
indicate O +
vasodilating O +
effect O +
of O +
PLA O -
( O -
2 O -
) O +
fraction O +
and O +
vasoconstricting O +
effect O +
and O +
decreased O +
cardiac O +
function O +
of O +
MP O +
fraction O -
. O +

Heteromtoxin O +
( O -
HmTx O -
) O -
, O +
a O +
novel O +
heterodimeric O +
phospholipase O +
A O -
( O -
2 O -
) O +
from O +
Heterometrus O +
laoticus O +
scorpion O +
venom O -
. O +

Heteromtoxin O +
( O -
HmTx O -
) O +
is O +
a O +
group O +
III O +
phospholipase O +
A O -
( O -
2 O -
) O +
produced O +
in O +
Heterometrus O +
laoticus O -
, O +
in O +
Thailand O -
. O +

In O +
this O +
study O -
, O +
HmTx O +
was O +
purified O +
from O +
venom O +
by O +
separation O +
chromatography O -
, O +
and O +
the O +
PLA O -
( O -
2 O -
) O +
activity O +
of O +
the O +
fractions O +
was O +
determined O +
by O +
lecithin O +
agar O +
assay O -
. O +

The O +
enzyme O +
is O +
an O +
acidic O +
protein O +
with O +
a O +
pI O +
of O +
5.6 O +
and O +
an O +
apparent O +
molecular O +
weight O +
of O +
14018.4 O +
Da O -
. O +

The O +
nucleotide B-Chemical +
sequence O +
of O +
HmTx O +
contains O +
649 O +
bp O -
, O +
and O +
the O +
mature O +
protein O +
is O +
predicted O +
to O +
have O +
131 O +
amino B-Chemical +
acid I-Chemical +
residues-104 O +
of O +
which O +
make O +
up O +
the O +
large O +
subunit O -
, O +
and O +
27 O +
of O +
which O +
make O +
up O +
the O +
small O +
subunit O -
. O +

The O +
subunit O +
structure O +
of O +
HmTx O +
is O +
highly O +
similar O +
to O +
that O +
of O +
the O +
other O +
toxin O -
, O +
Pandinus O +
imperator O +
imperatoxin O +
I O +
( O -
IpTx O -
( O -
i O -
) O -
) O +
and O +
to O +
Mesobuthus O +
tamulus O +
phospholipase O +
A O -
( O -
2 O -
) O +
( O -
MtPLA O -
( O -
2 O -
) O -
) O -
. O +

The O +
3D O -
- O -
structure O +
of O +
HmTx O +
consists O +
of O +
three O +
conserved O +
alpha O -
- O -
helices O -
: O +
h1 O +
( O -
Lys24-His34 B-Chemical -
) O -
, O +
h2 O +
( O -
Cys59-Asp71 B-Chemical -
) O -
, O +
and O +
h3 O +
( O -
Ala80-Phe89 B-Chemical -
) O -
. O +

The O +
beta O -
- O -
sheet O +
consisted O +
of O +
a O +
single O +
stranded O +
anti O -
- O -
parallel O +
beta O -
- O -
sheet O +
( O -
b1.1 O +
at O +
Glu43-Lys45 B-Chemical +
and O +
b1.2 O +
at O +
Lys48-Asn50 B-Chemical -
) O +
that O +
was O +
highly O +
similar O +
to O +
the O +
conserved O +
sequences O +
( O -
-CGXG- O -
, O +
-CCXXHDXC- O +
and O +
CXCEXXXXXC- O -
) O +
of O +
Apis O +
mellifera O +
( O -
bee O -
) O +
phospholipases O -
. O +

A O +
non O -
- O -
catalytic O +
function O +
of O +
Rev1 O +
in O +
translesion O +
DNA O +
synthesis O +
and O +
mutagenesis O +
is O +
mediated O +
by O +
its O +
stable O +
interaction O +
with O +
Rad5 O -
. O +

DNA O +
damage O +
tolerance O +
consisting O +
of O +
template O +
switching O +
and O +
translesion O +
synthesis O +
is O +
a O +
major O +
cellular O +
mechanism O +
in O +
response O +
to O +
unrepaired O +
DNA O +
lesions O +
during O +
replication O -
. O +

The O +
Rev1 O +
pathway O +
constitutes O +
the O +
major O +
mechanism O +
of O +
translesion O +
synthesis O +
and O +
base O +
damage O -
- O -
induced O +
mutagenesis O +
in O +
model O +
cell O +
systems O -
. O +

Rev1 O +
is O +
a O +
dCMP B-Chemical +
transferase O -
, O +
but O +
additionally O +
plays O +
non O -
- O -
catalytic O +
functions O +
in O +
translesion O +
synthesis O -
. O +

Using O +
the O +
yeast O +
model O +
system O -
, O +
we O +
attempted O +
to O +
gain O +
further O +
insights O +
into O +
the O +
non O -
- O -
catalytic O +
functions O +
of O +
Rev1 O -
. O +

Rev1 O +
stably O +
interacts O +
with O +
Rad5 O +
( O -
a O +
central O +
component O +
of O +
the O +
template O +
switching O +
pathway O -
) O +
via O +
the O +
C O -
- O -
terminal O +
region O +
of O +
Rev1 O +
and O +
the O +
N O -
- O -
terminal O +
region O +
of O +
Rad5 O -
. O +

Supporting O +
functional O +
significance O +
of O +
this O +
interaction O -
, O +
both O +
the O +
Rev1 O +
pathway O +
and O +
Rad5 O +
are O +
required O +
for O +
translesion O +
synthesis O +
and O +
mutagenesis O +
of O +
1,N B-Chemical -
( I-Chemical -
6 I-Chemical -
) I-Chemical -
-ethenoadenine I-Chemical -
. O +

Furthermore O -
, O +
disrupting O +
the O +
Rev1-Rad5 O +
interaction O +
by O +
mutating O +
Rev1 O +
did O +
not O +
affect O +
its O +
dCMP B-Chemical +
transferase O -
, O +
but O +
led O +
to O +
inactivation O +
of O +
the O +
Rev1 O +
non O -
- O -
catalytic O +
function O +
in O +
translesion O +
synthesis O +
of O +
UV O -
- O -
induced O +
DNA O +
damage O -
. O +

Deletion O +
analysis O +
revealed O +
that O +
the O +
C O -
- O -
terminal O +
21-amino O +
acid B-Chemical +
sequence O +
of O +
Rev1 O +
is O +
uniquely O +
required O +
for O +
its O +
interaction O +
with O +
Rad5 O +
and O +
is O +
essential O +
for O +
its O +
non O -
- O -
catalytic O +
function O -
. O +

Deletion O +
analysis O +
additionally O +
implicated O +
a O +
C O -
- O -
terminal O +
region O +
of O +
Rev1 O +
in O +
its O +
negative O +
regulation O -
. O +

These O +
results O +
show O +
that O +
a O +
non O -
- O -
catalytic O +
function O +
of O +
Rev1 O +
in O +
translesion O +
synthesis O +
and O +
mutagenesis O +
is O +
mediated O +
by O +
its O +
interaction O +
with O +
Rad5 O -
. O +

TNF O -
- O -
α O -
- O -
induced O +
CXCL8 O +
production O +
by O +
A549 O +
cells O -
: O +
involvement O +
of O +
the O +
non O -
- O -
neuronal O +
cholinergic O +
system O -
. O +

It O +
was O +
recently O +
suggested O +
that O +
the O +
non O -
- O -
neuronal O +
cholinergic O +
system O +
has O +
a O +
regulatory O +
role O +
in O +
pulmonary O +
inflammation O -
. O +

We O +
investigated O +
this O +
system O -
's O +
involvement O +
in O +
the O +
control O +
of O +
cytokine O +
production O +
by O +
the O +
A549 O +
human O +
alveolar O +
epithelial O +
cell O +
line O -
. O +

CXCL8 O +
and O +
acetylcholine B-Chemical +
( O -
ACh B-Chemical -
) O +
concentrations O +
were O +
measured O +
using O +
ELISA O +
and O +
LC O -
- O -
MS O -
/ O -
MS O -
, O +
respectively O -
. O +

The O +
mRNA O +
expression O +
of O +
muscarinic O +
receptor O +
( O -
MR O -
) O +
subtypes O +
was O +
determined O +
using O +
RT O -
- O -
PCR O -
. O +

In O +
A549 O +
cells O -
, O +
TNF O -
- O -
α O +
increased O +
the O +
release O +
of O +
CXCL8 O +
and O +
ACh B-Chemical +
and O +
the O +
expression O +
of O +
the O +
subtype O +
3 O +
MR O +
( O -
M3R O -
) O -
. O +

Furthermore O -
, O +
TNF O -
- O -
α O -
- O -
induced O +
CXCL8 O +
secretion O +
was O +
( O -
i O -
) O +
inhibited O +
by O +
the O +
MR O +
antagonist O +
tiotropium B-Chemical +
and O +
the O +
M3R O +
antagonist O +
4-DAMP B-Chemical +
and O +
( O -
ii O -
) O +
enhanced O +
by O +
the O +
M1 O -
/ O -
M3R O +
agonist O +
pilocarpine B-Chemical +
and O +
the O +
cholinesterase O +
inhibitor O +
physostigmine B-Chemical -
. O +

Taken O +
as O +
a O +
whole O -
, O +
these O +
results O +
suggest O +
that O +
ACh B-Chemical +
release O +
by O +
A549 O +
cells O +
enhances O +
TNF O -
- O -
α O -
- O -
induced O +
CXCL8 O +
secretion O +
through O +
activation O +
of O +
the O +
M3R O -
. O +

Western O +
blot O +
analysis O +
revealed O +
that O +
pilocarpine B-Chemical +
and O +
physostigmine B-Chemical +
enhanced O +
the O +
TNF O -
- O -
α O -
- O -
induced O +
phosphorylation O +
of O +
ERK1 O -
/ O -
2 O +
and O +
p38 O +
MAPK O +
and O +
the O +
degradation O +
of O +
IκBα O -
. O +

Inhibition O +
of O +
these O +
pathways O +
with O +
specific O +
inhibitors O +
abrogated O +
the O +
pilocarpine B-Chemical -
- O -
induced O +
CXCL8 O +
release O -
. O +

Our O +
results O +
suggest O +
that O +
the O +
TNF O -
- O -
α O -
- O -
induced O +
secretion O +
of O +
CXCL8 O +
in O +
A549 O +
cells O +
is O +
regulated O +
by O +
the O +
release O +
of O +
ACh B-Chemical -
, O +
the O +
latter O -
's O +
binding O +
to O +
the O +
M3R O +
and O +
the O +
downstream O +
activation O +
of O +
NF O -
- O -
κB O +
and O +
the O +
ERK1 O -
/ O -
2 O +
and O +
p38 O +
MAPK O +
signaling O +
pathways O -
. O +

Our O +
findings O +
suggest O +
that O +
MR O +
antagonists O +
may O +
have O +
anti O -
- O -
inflammatory O +
effects O +
by O +
preventing O +
pro O -
- O -
inflammatory O +
events O +
driven O +
by O +
endogenous O -
, O +
non O -
- O -
neuronal O +
ACh B-Chemical -
. O +

Inhibition O +
of O +
vitellogenin O +
gene O +
induction O +
by O +
2,3,7,8-tetrachlorodibenzo B-Chemical -
- I-Chemical -
p I-Chemical -
- I-Chemical -
dioxin I-Chemical +
is O +
mediated O +
by O +
aryl B-Chemical +
hydrocarbon I-Chemical +
receptor O +
2 O +
( O -
AHR2 O -
) O +
in O +
zebrafish O +
( O -
Danio O +
rerio O -
) O -
. O +

Vitellogenins O +
are O +
hepatically O +
derived O +
yolk O -
- O -
protein O +
precursors O +
required O +
for O +
oogenesis O +
in O +
all O +
oviparous O +
teleosts O -
. O +

Altered O +
gene O -
- O -
regulation O +
of O +
vitellogenesis O +
by O +
environmental O +
contaminants O +
can O +
have O +
profound O +
effects O +
on O +
reproductive O +
success O -
, O +
and O +
ultimately O +
population O +
sustainability O -
. O +

To O +
better O +
understand O +
chemical O +
effects O +
on O +
vitellogenin O +
gene O +
regulation O -
, O +
we O +
tested O +
the O +
hypothesis O +
that O +
activation O +
of O +
the O +
aryl B-Chemical +
hydrocarbon I-Chemical +
receptor O +
2 O +
( O -
AHR2 O -
) O +
by O +
dioxin B-Chemical +
inhibits O +
the O +
estrogen B-Chemical +
receptor O +
pathway O +
regulation O +
of O +
3 O +
vitellogenin O +
genes O +
( O -
vtg1 O -
- O -
3 O -
) O +
in O +
vivo O -
, O +
using O +
zebrafish O +
( O -
Danio O +
rerio O -
) O +
as O +
a O +
model O +
teleost O -
. O +

Using O +
an O +
embryo O -
- O -
larval O +
bioassay O -
, O +
embryos O +
were O +
either O +
treated O +
with O +
1000 O +
pptr O +
( O -
parts O -
- O -
per O -
- O -
trillion O -
, O +
pg O -
/ O -
mL O -
) O +
17α B-Chemical -
- I-Chemical -
ethynylestradiol I-Chemical +
( O -
EE2 B-Chemical -
) O +
alone O +
from O +
6h O +
post O +
fertilization O +
( O -
hpf O -
) O +
to O +
4 O +
days O +
post O +
fertilization O +
( O -
dpf O -
) O -
, O +
or O +
pre O -
- O -
treated O +
with O +
dioxin O +
( O -
4 O -
- O -
5 O +
hpf O -
) O +
prior O +
to O +
EE2 B-Chemical -
. O +

Pre O -
- O -
treatment O +
with O +
400 O +
pptr O +
2,3,7,8-tetrachlorodibenzo B-Chemical -
- I-Chemical -
p I-Chemical -
- I-Chemical -
dioxin I-Chemical +
( O -
2,3,7,8-TCDD B-Chemical -
) O +
or O +
1,2,3,7,8-pentachlorodibenzo B-Chemical -
- I-Chemical -
p I-Chemical -
- I-Chemical -
dioxin I-Chemical +
inhibited O +
the O +
EE2 B-Chemical +
induction O +
of O +
vtg1 O -
, O +
vtg2 O +
and O +
vtg3 O +
by O +
> O -
95 O -
% O +
( O -
p≤0.05 O -
) O -
. O +

In O +
comparison O -
, O +
a O +
splice O -
- O -
blocking O +
AHR2 O +
morpholino O +
used O +
to O +
down O -
- O -
regulate O +
ahr2 O +
expression O +
significantly O +
reduced O +
the O +
inhibition O +
of O +
vtg1 O -
, O +
vtg2 O +
and O +
vtg3 O +
by O +
400 O +
pptr O +
2,3,7,8-TCDD B-Chemical +
( O -
20.7 O -
- O -
27.4 O -
% O +
rescue O -
) O -
. O +

These O +
studies O +
demonstrate O +
that O +
2,3,7,8-TCDD B-Chemical +
directly O +
inhibits O +
the O +
vitellogenin O +
pathway O +
in O +
vivo O +
through O +
activation O +
of O +
the O +
AHR2 O -
. O +

This O +
work O +
provides O +
evidence O +
for O +
AHR2 O +
dependent O +
cross O -
- O -
talk O +
inhibition O +
of O +
vitellogenin O +
genes O +
and O +
offers O +
insight O +
into O +
anti O -
- O -
estrogenic O +
reproductive O +
effects O +
observed O +
in O +
oviparous O +
species O +
exposed O +
to O +
AHR O +
agonist O +
contaminants O -
. O +

Gene O +
transcription O +
and O +
biomarker O +
responses O +
in O +
the O +
clam O +
Ruditapes O +
philippinarum O +
after O +
exposure O +
to O +
ibuprofen B-Chemical -
. O +

Pharmaceuticals O +
are O +
a O +
class O +
of O +
emerging O +
environmental O +
contaminants O +
that O +
continuously O +
enter O +
aquatic O +
environments O -
. O +

Presently O -
, O +
little O +
information O +
is O +
available O +
about O +
the O +
effects O +
of O +
these O +
substances O +
on O +
non O -
- O -
target O +
organisms O -
, O +
such O +
as O +
bivalves O -
. O +

We O +
investigated O +
the O +
effects O +
of O +
ibuprofen B-Chemical +
( O -
IBU B-Chemical -
) O +
on O +
the O +
clam O +
Ruditapes O +
philippinarum O -
. O +

Clams O +
were O +
exposed O +
for O +
1 O -
, O +
3 O -
, O +
5 O +
and O +
7 O +
days O +
to O +
0 O -
, O +
100 O +
and O +
1000 O +
μgIBU O -
/ O -
L O -
, O +
and O +
established O +
biomarker O +
responses O +
( O -
haemolymph O +
lysozyme O -
, O +
gill O +
acetylcholinesterase O +
and O +
digestive O +
gland O +
superoxide B-Chemical +
dismutase O +
activities O -
) O +
as O +
well O +
as O +
digestive O +
gland O +
transcriptome O +
were O +
evaluated O -
. O +

A O +
two O -
- O -
way O +
ANOVA O +
revealed O +
significant O +
effects O +
of O +
both O +
" O -
IBU B-Chemical +
concentration O -
" O +
and O +
" O -
exposure O +
duration O -
" O +
on O +
biomarker O +
responses O -
. O +

Overall O -
, O +
the O +
enzyme O +
activities O +
were O +
generally O +
lower O +
in O +
IBU B-Chemical -
- O -
exposed O +
clams O +
than O +
in O +
controls O -
. O +

Although O +
limited O +
knowledge O +
of O +
the O +
mollusc O +
transcriptome O +
makes O +
it O +
difficult O +
to O +
interpret O +
the O +
effects O +
of O +
IBU B-Chemical +
on O +
clams O -
, O +
the O +
gene O +
transcription O +
analysis O +
using O +
DNA O +
microarrays O +
enabled O +
the O +
identification O +
of O +
the O +
putative O +
molecular O +
mode O +
of O +
action O +
of O +
the O +
IBU B-Chemical -
. O +

The O +
functional O +
analysis O +
of O +
differentially O +
transcribed O +
genes O +
suggests O +
that O +
IBU B-Chemical +
can O +
interfere O +
with O +
various O +
signalling O +
pathways O +
in O +
clams O -
, O +
such O +
as O +
arachidonic B-Chemical +
acid I-Chemical +
metabolism O -
, O +
apoptosis O -
, O +
peroxisomal O +
proliferator O -
- O -
activated O +
receptors O -
, O +
and O +
nuclear O +
factor O -
- O -
kappa O +
B. O +
In O +
addition O -
, O +
several O +
genes O +
involved O +
in O +
the O +
metabolism O +
of O +
xenobiotics O +
( O -
e.g. O -
, O +
glutathione B-Chemical +
S O -
- O -
transferase O -
, O +
sulfotransferase O -
, O +
cytochrome O +
P450 O -
) O +
were O +
also O +
found O +
to O +
be O +
significantly O +
affected O +
by O +
IBU B-Chemical +
exposure O -
. O +

In O +
summary O -
, O +
the O +
integrated O +
approach O +
of O +
gene O +
transcription O +
analysis O +
and O +
biomarker O +
responses O +
facilitated O +
the O +
elucidation O +
of O +
the O +
putative O +
mechanisms O +
of O +
action O +
of O +
IBU B-Chemical +
in O +
non O -
- O -
target O +
species O -
. O +

Thyroid O +
disruption O +
in O +
the O +
lizard O +
Podarcis O +
bocagei O +
exposed O +
to O +
a O +
mixture O +
of O +
herbicides O -
: O +
a O +
field O +
study O -
. O +

Pesticide O +
exposure O +
has O +
been O +
related O +
with O +
thyroid O +
disrupting O +
effects O +
in O +
different O +
vertebrate O +
species O -
. O +

However O -
, O +
very O +
little O +
is O +
known O +
about O +
the O +
effects O +
of O +
these O +
compounds O +
in O +
reptiles O -
. O +

In O +
the O +
Mediterranean O +
area O -
, O +
lacertid O +
lizards O +
are O +
the O +
most O +
abundant O +
vertebrate O +
group O +
in O +
agroecosystems O -
, O +
and O +
have O +
been O +
identified O +
as O +
potential O +
model O +
species O +
for O +
reptile O +
ecotoxicology O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
understand O +
if O +
the O +
herbicides O +
applied O +
in O +
corn O +
fields O +
have O +
thyroid O +
disruptive O +
effects O +
in O +
the O +
lizard O +
Podarcis O +
bocagei O -
. O +

Adult O +
male O +
lizards O +
were O +
captured O +
in O +
north O -
- O -
western O +
Portugal O +
in O +
corn O +
fields O +
treated O +
with O +
herbicides O +
( O -
exposed O +
sites O -
) O -
, O +
and O +
in O +
organic O +
agricultural O +
fields O +
( O -
reference O +
sites O -
) O -
. O +

Thyroid O +
and O +
male O +
gonad O +
morphology O +
and O +
functionality O -
, O +
and O +
testosterone B-Chemical +
levels O +
were O +
investigated O +
through O +
histological O -
, O +
immunohistochemical O +
and O +
biochemical O +
techniques O -
. O +

Lizards O +
from O +
exposed O +
locations O +
displayed O +
thyroid O +
follicular O +
lumens O +
with O +
more O +
reabsorption O +
vacuoles O +
and O +
significantly O +
larger O +
follicular O +
area O +
than O +
those O +
from O +
reference O +
fields O -
. O +

Furthermore O -
, O +
testes O +
of O +
lizards O +
from O +
exposed O +
locations O +
had O +
significantly O +
larger O +
seminiferous O +
tubule O +
diameters O -
, O +
significantly O +
higher O +
number O +
of O +
spermatogenic O +
layers O +
and O +
displayed O +
an O +
up O -
- O -
regulation O +
of O +
thyroid O +
hormone O +
receptors O +
when O +
compared O +
with O +
lizards O +
from O +
reference O +
areas O -
. O +

These O +
findings O +
strongly O +
suggest O +
that O +
the O +
complex O +
mixture O +
of O +
herbicides O +
that O +
lizards O +
are O +
exposed O +
to O +
in O +
agricultural O +
areas O +
have O +
thyroid O +
disrupting O +
effects O +
which O +
ultimately O +
affect O +
the O +
male O +
reproductive O +
system O -
. O +

Alachlor B-Chemical -
, O +
which O +
has O +
demonstrated O +
thyroid O +
effects O +
in O +
mammals O -
, O +
may O +
be O +
largely O +
responsible O +
for O +
the O +
observed O +
effects O -
. O +

Effects O +
of O +
pyrene B-Chemical +
exposure O +
and O +
temperature O +
on O +
early O +
development O +
of O +
two O +
co O -
- O -
existing O +
Arctic O +
copepods O -
. O +

Oil O +
exploration O +
is O +
expected O +
to O +
increase O +
in O +
the O +
near O +
future O +
in O +
Western O +
Greenland O -
. O +

At O +
present O -
, O +
effects O +
of O +
exposure O +
to O +
oil O +
compounds O +
on O +
early O +
life O -
- O -
stages O +
of O +
the O +
ecologically O +
important O +
Calanus O +
spp O -
. O +
are O +
unknown O -
. O +

We O +
investigated O +
the O +
effects O +
of O +
the O +
oil O +
compound O +
pyrene B-Chemical -
, O +
on O +
egg O +
hatching O +
and O +
naupliar O +
development O +
of O +
the O +
calanoid O +
copepods O +
Calanus O +
glacialis O +
and O +
C. O +
finmarchicus O -
, O +
two O +
key O +
species O +
in O +
the O +
Disko O +
Bay O -
, O +
Western O +
Greenland O -
. O +

At O +
low O +
temperature O +
the O +
nauplii O +
of O +
C. O +
glacialis O +
experienced O +
reduced O +
growth O +
when O +
exposed O +
to O +
pyrene B-Chemical -
, O +
and O +
survival O +
in O +
both O +
species O +
decreased O -
. O +

Naupliar O +
mortality O +
increased O +
with O +
temperature O +
at O +
high O +
pyrene B-Chemical +
concentration O +
in O +
C. O +
finmarchicus O -
. O +

Both O +
Calanus O +
species O +
were O +
affected O +
by O +
pyrene B-Chemical +
exposure O +
but O +
C. O +
finmarchicus O +
was O +
more O +
sensitive O +
compared O +
to O +
C. O +
glacialis O -
. O +

Lowered O +
growth O +
rate O +
and O +
increased O +
mortality O +
of O +
the O +
naupliar O +
stages O +
entail O +
reduced O +
recruitment O +
to O +
copepod O +
populations O -
. O +

Exposure O +
to O +
pyrene B-Chemical +
from O +
an O +
oil O +
spill O +
may O +
reduce O +
the O +
standing O +
stock O +
of O +
Calanus O -
, O +
which O +
can O +
lead O +
to O +
less O +
energy O +
available O +
to O +
higher O +
trophic O +
levels O +
in O +
the O +
Arctic O +
marine O +
food O +
web O -
. O +

A O +
perspective O +
on O +
the O +
contribution O +
of O +
metabolites O +
to O +
drug O -
- O -
drug O +
interaction O +
potential O -
: O +
the O +
need O +
to O +
consider O +
both O +
circulating O +
levels O +
and O +
inhibition O +
potency O -
. O +

The O +
2012 O +
drug O -
- O -
drug O +
interaction O +
( O -
DDI O -
) O +
guidance O +
from O +
the O +
European O +
Medicines O +
Agency O +
( O -
EMA O -
) O +
and O +
the O +
draft O +
DDI O +
guidance O +
from O +
the O +
Food O +
and O +
Drug O +
Administration O +
( O -
FDA O -
) O +
have O +
proposed O +
that O +
metabolites O +
present O +
at O +
> O -
25 O -
% O +
of O +
the O +
parent O +
area O +
under O +
the O +
time O -
- O -
concentration O +
curve O +
( O -
AUC O -
) O +
( O -
EMA O +
and O +
FDA O -
) O +
and O +
> O -
10 O -
% O +
of O +
the O +
total O +
drug O -
- O -
related O +
exposure O +
( O -
EMA O -
) O +
should O +
be O +
investigated O +
in O +
vitro O +
for O +
their O +
DDI O +
potential O -
. O +

This O +
commentary O +
attempts O +
to O +
rationalize O +
the O +
clinically O +
relevant O +
levels O +
of O +
metabolite O -
( O -
s O -
) O +
that O +
contribute O +
to O +
DDI O +
by O +
considering O +
not O +
only O +
the O +
abundance O +
but O +
also O +
inhibition O +
potency O -
, O +
physicochemical O +
properties O -
, O +
and O +
structural O +
alerts O +
of O +
the O +
metabolite O -
. O +

A O +
decision O +
tree O +
is O +
proposed O +
for O +
levels O +
of O +
metabolites O +
that O +
could O +
trigger O +
in O +
vitro O +
DDI O +
assessment O -
. O +

When O +
the O +
parent O +
is O +
an O +
inhibitor O +
of O +
cytochrome O +
P450s O +
( O -
P450s O -
) O -
, O +
clinical O +
DDI O +
studies O +
will O +
assess O +
the O +
in O +
vivo O +
DDI O +
effect O +
of O +
the O +
combination O +
of O +
parent O +
and O +
metabolite O -
( O -
s O -
) O -
. O +

When O +
the O +
parent O +
is O +
not O +
a O +
P450 O +
inhibitor O -
, O +
it O +
is O +
important O +
to O +
assess O +
the O +
inhibition O +
potential O +
of O +
abundant O +
metabolites O +
in O +
vitro O -
. O +

The O +
proposal O +
is O +
to O +
apply O +
a O +
default O +
cutoff O +
value O +
of O +
metabolite O +
level O +
which O +
is O +
100 O -
% O +
of O +
the O +
parent O +
AUC O -
. O +

It O +
is O +
important O +
to O +
note O +
that O +
exceptions O +
can O +
occur O -
, O +
and O +
different O +
metabolite O +
levels O +
may O +
be O +
considered O +
depending O +
on O +
the O +
physiochemical O +
properties O +
of O +
metabolites O +
( O -
e.g. O -
, O +
increased O +
lipophilicity O -
) O +
and O +
whether O +
the O +
metabolite O +
contains O +
structural O +
alerts O +
for O +
DDI O +
( O -
e.g. O -
, O +
mechanism O -
- O -
based O +
inhibition O -
) O -
. O +

A O +
key O +
objective O +
of O +
this O +
commentary O +
is O +
to O +
stimulate O +
discussions O +
among O +
the O +
scientific O +
community O +
on O +
this O +
important O +
topic O -
, O +
so O +
that O +
appropriate O +
in O +
vitro O +
metabolism O +
studies O +
are O +
conducted O +
on O +
metabolites O -
, O +
to O +
ensure O +
the O +
safety O +
of O +
drugs O +
in O +
development O +
balanced O +
with O +
the O +
desire O +
to O +
avoid O +
creating O +
unnecessary O +
studies O +
that O +
will O +
add O +
little O +
to O +
no O +
value O +
in O +
ensuring O +
patient O +
safety O -
. O +

Male O +
mating O +
behaviour O +
in O +
relation O +
to O +
female O +
sexual O +
swellings O -
, O +
socio O -
- O -
sexual O +
behaviour O +
and O +
hormonal O +
changes O +
in O +
wild O +
Barbary O +
macaques O -
. O +

In O +
many O +
cercopithecine O +
primates O +
females O +
display O +
probabilistic O +
cues O +
of O +
fertility O +
to O +
indicate O +
the O +
periovulatory O +
period O +
to O +
males O -
. O +

These O +
cues O +
may O +
include O +
female O +
behaviour O -
, O +
acoustic O +
signals O -
, O +
and O +
morphological O +
signs O +
such O +
as O +
the O +
anogenital O +
swelling O -
. O +

However O -
, O +
the O +
extent O +
to O +
which O +
males O +
can O +
utilise O +
this O +
information O +
varies O +
between O +
species O -
. O +

We O +
describe O +
male O +
sexual O +
behaviour O +
in O +
relation O +
to O +
changes O +
in O +
anogenital O +
swelling O +
size O -
, O +
timing O +
of O +
ovulation O +
and O +
female O +
socio O -
- O -
sexual O +
behaviour O +
in O +
wild O +
Barbary O +
macaques O +
( O -
Macaca O +
sylvanus O -
) O -
. O +

We O +
further O +
compare O +
male O +
sexual O +
behaviour O +
during O +
conception O +
and O +
post O -
- O -
conception O +
cycles O +
to O +
evaluate O +
if O +
males O +
differentiate O +
between O +
these O +
qualitatively O +
different O +
cycle O +
types O -
. O +

Our O +
results O +
show O +
that O +
during O +
conception O +
cycles O +
male O +
mating O +
behaviour O +
was O +
concentrated O +
around O +
the O +
fertile O +
phase O +
implying O +
that O +
males O +
inferred O +
information O +
from O +
more O +
than O +
swelling O +
size O +
alone O -
. O +

Male O +
mating O +
frequency O +
increased O +
in O +
line O +
with O +
female O +
socio O -
- O -
sexual O +
behaviour O -
, O +
namely O +
female O +
presenting O +
and O +
the O +
frequency O +
of O +
copulations O +
with O +
copulation O +
calls O -
. O +

Most O +
strikingly O +
our O +
results O +
show O +
that O +
males O +
invested O +
equally O +
in O +
mating O +
during O +
fertile O +
and O +
non O -
- O -
fertile O -
, O +
i.e. O +
post O -
- O -
conception O -
, O +
maximum O +
swelling O +
phases O -
. O +

Whether O +
post O -
- O -
conception O +
swellings O +
were O +
merely O +
a O +
result O +
of O +
changes O +
in O +
hormone O +
concentrations O +
during O +
pregnancy O +
or O +
part O +
of O +
a O +
female O +
reproductive O +
strategy O +
remains O +
elusive O -
. O +

In O +
sum O -
, O +
this O +
study O +
adds O +
to O +
the O +
body O +
of O +
research O +
on O +
the O +
evolution O +
of O +
female O +
sexual O +
signals O +
and O +
how O +
males O +
may O +
infer O +
information O +
from O +
these O +
cues O -
. O +

Metabolically O +
competent O +
human O +
skin O +
models O -
: O +
activation O +
and O +
genotoxicity O +
of O +
benzo B-Chemical -
[ I-Chemical -
a I-Chemical -
] I-Chemical -
pyrene I-Chemical -
. O +

The O +
polycyclic B-Chemical +
aromatic I-Chemical +
hydrocarbon I-Chemical +
( O -
PAH B-Chemical -
) O +
benzo B-Chemical -
[ I-Chemical -
a I-Chemical -
] I-Chemical -
pyrene I-Chemical +
( O -
BP O -
) O +
is O +
metabolized O +
into O +
a O +
complex O +
pattern O +
of O +
BP O +
derivatives O -
, O +
among O +
which O +
the O +
ultimate O +
carcinogen O +
( B-Chemical -
+ I-Chemical -
) I-Chemical -
-anti I-Chemical -
- I-Chemical -
BP-7,8-diol-9,10-epoxide I-Chemical +
( O -
BPDE B-Chemical -
) O +
is O +
formed O +
to O +
certain O +
extents O -
. O +

Skin O +
is O +
frequently O +
in O +
contact O +
with O +
PAHs B-Chemical +
and O +
data O +
on O +
the O +
metabolic O +
capacity O +
of O +
skin O +
tissue O +
toward O +
these O +
compounds O +
are O +
inconclusive O -
. O +

We O +
compared O +
BP O +
metabolism O +
in O +
excised O +
human O +
skin O -
, O +
commercially O +
available O +
in O +
vitro O +
3D O +
skin O +
models O +
and O +
primary O +
2D O +
skin O +
cell O +
cultures O -
, O +
and O +
analyzed O +
the O +
metabolically O +
catalyzed O +
occurrence O +
of O +
seven O +
different O +
BP O +
follow O -
- O -
up O +
products O +
by O +
means O +
of O +
liquid O +
chromatography O +
coupled O +
to O +
tandem O +
mass O +
spectrometry O +
( O -
LC O -
- O -
MS O -
/ O -
MS O -
) O -
. O +

All O +
models O +
investigated O +
were O +
competent O +
to O +
metabolize O +
BP O -
, O +
and O +
the O +
metabolic O +
profiles O +
generated O +
by O +
ex O +
vivo O +
human O +
skin O +
and O +
skin O +
models O +
were O +
remarkably O +
similar O -
. O +

Furthermore O -
, O +
the O +
genotoxicity O +
of O +
BP O +
and O +
its O +
derivatives O +
was O +
monitored O +
in O +
these O +
models O +
via O +
comet O +
assays O -
. O +

In O +
a O +
full O -
- O -
thickness O +
skin O -
, O +
equivalent O +
BP O -
- O -
mediated O +
genotoxic O +
stress O +
was O +
generated O +
via O +
keratinocytes O -
. O +

Cultured O +
primary O +
keratinocytes O +
revealed O +
a O +
level O +
of O +
genotoxicity O +
comparable O +
with O +
that O +
of O +
direct O +
exposure O +
to O +
50 O -
- O -
100 O +
nM O +
of O +
BPDE B-Chemical -
. O +

Our O +
data O +
demonstrate O +
that O +
the O +
metabolic O +
capacity O +
of O +
human O +
skin O +
ex O +
vivo O -
, O +
as O +
well O +
as O +
organotypic O +
human O +
3D O +
skin O +
models O +
toward O +
BP O -
, O +
is O +
sufficient O +
to O +
cause O +
significant O +
genotoxic O +
stress O +
and O +
thus O +
cutaneous O +
bioactivation O +
may O +
potentially O +
contribute O +
to O +
mutations O +
that O +
ultimately O +
lead O +
to O +
skin O +
cancer O -
. O +

Response O +
to O +
variable O +
light O +
intensity O +
in O +
photoacclimated O +
algae O +
and O +
cyanobacteria O +
exposed O +
to O +
atrazine B-Chemical -
. O +

Atrazine B-Chemical +
is O +
frequently O +
detected O +
in O +
freshwater O +
ecosystems O +
exposed O +
to O +
agricultural O +
waste O +
waters O +
and O +
runoffs O +
worldwide O +
and O +
it O +
can O +
affect O +
non O -
- O -
target O +
organisms O +
( O -
mainly O +
photoautotrophic O -
) O +
and O +
modify O +
community O +
structure O -
. O +

Meanwhile O -
, O +
light O +
environment O +
is O +
known O +
to O +
vary O +
between O +
aquatic O +
ecosystems O -
, O +
but O +
also O +
before O +
and O +
during O +
the O +
exposure O +
to O +
atrazine B-Chemical +
and O +
these O +
variations O +
may O +
modify O +
the O +
sensitivity O +
to O +
atrazine B-Chemical +
of O +
photoautotroph O +
organisms O -
. O +

In O +
this O +
study O -
, O +
10 O +
species O +
of O +
phytoplankton O +
( O -
chlorophytes O -
, O +
baccilariophytes O +
and O +
cyanophytes O -
) O +
acclimated O +
to O +
low O +
or O +
high O +
light O +
intensities O +
were O +
exposed O +
to O +
atrazine B-Chemical +
and O +
light O +
of O +
different O +
intensities O +
to O +
compare O +
their O +
combined O +
effect O -
. O +

Our O +
data O +
showed O +
that O +
chlorophytes O +
and O +
baccilariophytes O +
were O +
more O +
resistant O +
to O +
atrazine B-Chemical +
compared O +
to O +
cyanophytes O +
for O +
all O +
light O +
conditions O -
. O +

Atrazine B-Chemical +
was O +
found O +
to O +
inhibit O +
Φ' O -
( O -
M O -
) O -
, O +
Ψ O -
( O -
0 O -
) O -
, O +
P O -
( O -
M O -
) O +
and O +
non O -
- O -
photochemical O +
quenching O +
for O +
all O +
species O +
indicating O +
an O +
effect O +
on O +
electron O +
transport O -
, O +
primary O +
production O +
and O +
photoregulation O +
processes O -
. O +

These O +
data O +
also O +
indicate O +
a O +
higher O +
sensitivity O +
of O +
Ψ O -
( O -
0 O -
) O +
( O -
average O +
Ψ O -
( O -
0 O -
) O -
-EC O -
( O -
50 O -
) O +
of O +
91 O +
± O +
11 O +
nM O +
or O +
19.6 O +
± O +
0.9 O +
μgL O -
( O -
-1 O -
) O -
) O +
compared O +
to O +
Φ' O -
( O -
M O -
) O +
( O -
average O +
Φ' O -
( O -
M O -
) O -
-EC O -
( O -
50 O -
) O +
of O +
217 O +
± O +
19 O +
nM O +
or O +
46.8 O +
± O +
4.1 O +
μgL O -
( O -
-1 O -
) O -
) O +
and O +
suggest O +
that O +
photoregulation O +
processes O +
activated O +
in O +
presence O +
of O +
light O +
decrease O +
the O +
effect O +
of O +
atrazine B-Chemical -
. O +

We O +
also O +
showed O +
that O +
increasing O +
light O +
intensity O +
decreased O +
Φ' O -
( O -
M O -
) O -
-EC O -
( O -
50 O -
) O +
in O +
both O +
low O +
( O -
except O +
baccilariophytes O -
) O +
and O +
high O +
light O +
acclimated O +
conditions O -
. O +

Despite O +
this O +
similarity O -
, O +
most O +
species O +
acclimated O +
to O +
high O +
light O +
were O +
found O +
to O +
have O +
higher O +
or O +
similar O +
Φ' O -
( O -
M O -
) O -
-EC O -
( O -
50 O -
) O +
compared O +
to O +
low O +
light O +
acclimated O +
cells O +
and O +
thus O -
, O +
were O +
less O +
sensitive O +
to O +
atrazine B-Chemical +
in O +
low O +
light O +
and O +
high O +
light O +
environments O -
. O +

We O +
concluded O +
that O +
an O +
increase O +
in O +
the O +
plastoquinone B-Chemical +
pool O +
induced O +
by O +
acclimation O +
to O +
high O +
light O +
decreased O +
the O +
sensitivity O +
to O +
atrazine B-Chemical +
in O +
phytoplankton O +
and O +
we O +
hypothesized O +
that O +
the O +
effect O +
observed O +
was O +
the O +
result O +
of O +
a O +
dilution O +
of O +
atrazine B-Chemical +
toxicity O +
through O +
increased O +
binding O +
site O +
availability O +
( O -
quinones B-Chemical -
) O +
combined O +
with O +
increased O +
photoregulation O +
processes O +
capacity O -
. O +

RBFOX2 O +
is O +
an O +
important O +
regulator O +
of O +
mesenchymal O +
tissue O -
- O -
specific O +
splicing O +
in O +
both O +
normal O +
and O +
cancer O +
tissues O -
. O +

Alternative O +
splicing O +
provides O +
a O +
critical O +
and O +
flexible O +
layer O +
of O +
regulation O +
intervening O +
in O +
many O +
biological O +
processes O +
to O +
regulate O +
the O +
diversity O +
of O +
proteins O +
and O +
impact O +
cell O +
phenotype O -
. O +

To O +
identify O +
alternative O +
splicing O +
differences O +
that O +
distinguish O +
epithelial O +
from O +
mesenchymal O +
tissues O -
, O +
we O +
have O +
investigated O +
hundreds O +
of O +
cassette O +
exons O +
using O +
a O +
high O -
- O -
throughput O +
reverse O +
transcription O -
- O -
PCR O +
( O -
RT O -
- O -
PCR O -
) O +
platform O -
. O +

Extensive O +
changes O +
in O +
splicing O +
were O +
noted O +
between O +
epithelial O +
and O +
mesenchymal O +
tissues O +
in O +
both O +
human O +
colon O +
and O +
ovarian O +
tissues O -
, O +
with O +
many O +
changes O +
from O +
mostly O +
one O +
splice O +
variant O +
to O +
predominantly O +
the O +
other O -
. O +

Remarkably O -
, O +
many O +
of O +
the O +
splicing O +
differences O +
that O +
distinguish O +
normal O +
mesenchymal O +
from O +
normal O +
epithelial O +
tissues O +
matched O +
those O +
that O +
differentiate O +
normal O +
ovarian O +
tissues O +
from O +
ovarian O +
cancer O -
. O +

Furthermore O -
, O +
because O +
splicing O +
profiling O +
could O +
classify O +
cancer O +
cell O +
lines O +
according O +
to O +
their O +
epithelial O -
/ O -
mesenchymal O +
characteristics O -
, O +
we O +
used O +
these O +
cancer O +
cell O +
lines O +
to O +
identify O +
regulators O +
for O +
these O +
specific O +
splicing O +
signatures O -
. O +

By O +
knocking O +
down O +
78 O +
potential O +
splicing O +
factors O +
in O +
five O +
cell O +
lines O -
, O +
we O +
provide O +
an O +
extensive O +
view O +
of O +
the O +
complex O +
regulatory O +
landscape O +
associated O +
with O +
the O +
epithelial O +
and O +
mesenchymal O +
states O -
, O +
thus O +
revealing O +
that O +
RBFOX2 O +
is O +
an O +
important O +
driver O +
of O +
mesenchymal O +
tissue O -
- O -
specific O +
splicing O -
. O +

Design O -
, O +
synthesis O +
and O +
anticancer O +
activity O +
of O +
N B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
,N I-Chemical -
( I-Chemical -
11 I-Chemical -
) I-Chemical -
-bis I-Chemical -
( I-Chemical -
2-hydroxyethyl I-Chemical -
) I-Chemical -
-14-aryl-14H I-Chemical -
- I-Chemical -
dibenzo I-Chemical -
[ I-Chemical -
a I-Chemical -
, I-Chemical -
j I-Chemical -
] I-Chemical -
xanthenes-3,11-dicarboxamide I-Chemical -
. O +

A O +
series O +
of O +
novel O +
N B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
,N I-Chemical -
( I-Chemical -
11 I-Chemical -
) I-Chemical -
-bis I-Chemical -
( I-Chemical -
2-hydroxyethyl I-Chemical -
) I-Chemical -
-14-aryl-14H I-Chemical -
- I-Chemical -
dibenzo I-Chemical -
[ I-Chemical -
a I-Chemical -
, I-Chemical -
j I-Chemical -
] I-Chemical -
xanthenes-3,11-dicarboxamide I-Chemical -
, O +
three O +
N B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
,N I-Chemical -
( I-Chemical -
11 I-Chemical -
) I-Chemical -
-bis I-Chemical -
( I-Chemical -
2-hydroxyethyl I-Chemical -
) I-Chemical -
-14-aryl-14H I-Chemical -
- I-Chemical -
dibenzo I-Chemical -
[ I-Chemical -
a I-Chemical -
, I-Chemical -
j I-Chemical -
] I-Chemical -
xanthene-3,11-dimethanamine I-Chemical +
derivatives O +
and O +
their O +
intermediates O +
14-aryl-14H B-Chemical -
- I-Chemical -
dibenzo I-Chemical -
[ I-Chemical -
a I-Chemical -
, I-Chemical -
j I-Chemical -
] I-Chemical -
xanthenes-3,11-dicarboxylic I-Chemical +
acid I-Chemical -
, O +
were O +
synthesized O -
, O +
and O +
the O +
structures O +
of O +
which O +
were O +
characterized O +
by O +
( B-Chemical -
1 I-Chemical -
) I-Chemical -
H I-Chemical -
- O -
NMR O -
, O +
( B-Chemical -
13 I-Chemical -
) I-Chemical -
C I-Chemical -
- O -
NMR O -
, O +
high O +
resolution O +
( O -
HR O -
) O -
-MS O -
, O +
and O +
IR O +
spectra O -
. O +

The O +
antitumor O +
activities O +
of O +
these O +
molecules O +
were O +
evaluated O +
on O +
five O +
cancer O +
cell O +
lines O -
. O +

The O +
results O +
of O +
in O +
vitro O +
assay O +
against O +
human O +
hepatocellular O +
carcinoma O +
cell O +
lines O +
( O -
SK O -
- O -
HEP-1 O +
and O +
HepG2 O +
and O +
SMMC-7721 O +
cells O -
) O -
, O +
acute O +
promyelocytic O +
leukemia O +
NB4 O +
cells O +
and O +
uterine O +
cervix O +
cancer O +
HeLa O +
cells O -
, O +
show O +
several O +
compounds O +
to O +
be O +
endowed O +
with O +
cytotoxicity O +
in O +
micromolar O +
to O +
submicromolar O +
range O -
. O +

The O +
carboxamide B-Chemical +
derivatives O +
6c O +
and O +
6e O +
exhibitted O +
good O +
inhibition O +
on O +
NB4 O +
cancer O +
cells O -
, O +
and O +
the O +
IC O -
( O -
50 O -
) O +
values O +
of O +
which O +
were O +
0.82 O +
µM O +
and O +
0.96 O +
µM O -
, O +
respectively O -
, O +
much O +
lower O +
than O +
5.01 O +
µM O +
of O +
the O +
positive O +
control O +
As B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
O I-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
. O +

Flow O +
cytometric O +
analysis O +
results O +
revealed O +
that O +
compounds O +
6e O +
and O +
6f O +
may O +
induce O +
tumor O +
cell O +
apoptosis O -
. O +

Membrane O +
domains O +
and O +
the O +
" O -
lipid O +
raft O -
" O +
concept O -
. O +

The O +
bulk O +
structure O +
of O +
biological O +
membranes O +
consists O +
of O +
a O +
bilayer O +
of O +
amphipathic O +
lipids O -
. O +

According O +
to O +
the O +
fluid O +
mosaic O +
model O +
proposed O +
by O +
Singer O +
and O +
Nicholson O -
, O +
the O +
glycerophospholipid B-Chemical +
bilayer O +
is O +
a O +
two O -
- O -
dimensional O +
fluid O +
construct O +
that O +
allows O +
the O +
lateral O +
movement O +
of O +
membrane O +
components O -
. O +

Different O +
types O +
of O +
lateral O +
interactions O +
among O +
membrane O +
components O +
can O +
take O +
place O -
, O +
giving O +
rise O +
to O +
multiple O +
levels O +
of O +
lateral O +
order O +
that O +
lead O +
to O +
highly O +
organized O +
structures O -
. O +

Early O +
observations O +
suggested O +
that O +
some O +
of O +
the O +
lipid O +
components O +
of O +
biological O +
membranes O +
may O +
play O +
active O +
roles O +
in O +
the O +
creation O +
of O +
these O +
levels O +
of O +
order O -
. O +

In O +
the O +
late O +
1980s O -
, O +
a O +
diverse O +
series O +
of O +
experimental O +
findings O +
collectively O +
gave O +
rise O +
to O +
the O +
lipid O +
raft O +
hypothesis O -
. O +

Lipid O +
rafts O +
were O +
originally O +
defined O +
as O +
membrane O +
domains O -
, O +
i.e. O -
, O +
ordered O +
structures O +
created O +
as O +
a O +
consequence O +
of O +
the O +
lateral O +
segregation O +
of O +
sphingolipids B-Chemical +
and O +
differing O +
from O +
the O +
surrounding O +
membrane O +
in O +
their O +
molecular O +
composition O +
and O +
properties O -
. O +

This O +
definition O +
was O +
subsequently O +
modified O +
to O +
introduce O +
the O +
notion O +
that O +
lipid O +
rafts O +
correspond O +
to O +
membrane O +
areas O +
stabilized O +
by O +
the O +
presence O +
of O +
cholesterol B-Chemical +
within O +
a O +
liquid O -
- O -
ordered O +
phase O -
. O +

During O +
the O +
past O +
two O +
decades O -
, O +
the O +
concept O +
of O +
lipid O +
rafts O +
has O +
become O +
extremely O +
popular O +
among O +
cell O +
biologists O -
, O +
and O +
these O +
structures O +
have O +
been O +
suggested O +
to O +
be O +
involved O +
in O +
a O +
great O +
variety O +
of O +
cellular O +
functions O +
and O +
biological O +
events O -
. O +

During O +
the O +
same O +
period O -
, O +
however O -
, O +
some O +
groups O +
presented O +
experimental O +
evidence O +
that O +
appeared O +
to O +
contradict O +
the O +
basic O +
tenets O +
that O +
underlie O +
the O +
lipid O +
raft O +
concept O -
. O +

The O +
concept O +
is O +
currently O +
being O +
re O -
- O -
defined O -
, O +
with O +
greater O +
consistency O +
regarding O +
the O +
true O +
nature O +
and O +
role O +
of O +
lipid O +
rafts O -
. O +

In O +
this O +
article O +
we O +
will O +
review O +
the O +
concepts O -
, O +
criticisms O -
, O +
and O +
the O +
novel O +
confirmatory O +
findings O +
relating O +
to O +
the O +
lipid O +
raft O +
hypothesis O -
. O +

The O +
onset O +
of O +
antineutrophil O +
cytoplasmic O +
antibody O -
- O -
associated O +
vasculitis O +
immediately O +
after O +
methimazole B-Chemical +
was O +
switched O +
to O +
propylthiouracil B-Chemical +
in O +
a O +
woman O +
with O +
Graves O -
' O +
disease O +
who O +
wished O +
to O +
become O +
pregnant O -
. O +

Propylthiouracil B-Chemical +
( O -
PTU B-Chemical -
) O +
is O +
recommended O +
as O +
a O +
first O -
- O -
line O +
antithyroid O +
drug O +
( O -
ATD O -
) O +
during O +
first O +
trimester O +
organogenesis O +
in O +
pregnancy O +
because O +
recent O +
evidence O +
suggests O +
that O +
methimazole B-Chemical +
( O -
MMI B-Chemical -
) O +
may O +
be O +
associated O +
with O +
congenital O +
anomalies O -
. O +

However O -
, O +
PTU B-Chemical +
more O +
commonly O +
causes O +
myeloperoxidase O +
( O -
MPO O -
) O -
-antineutrophil O +
cytoplasmic O +
antibody O +
( O -
ANCA O -
) O -
-associated O +
vasculitis O -
, O +
which O +
usually O +
occurs O +
during O +
prolonged O +
treatment O -
, O +
compared O +
with O +
MMI B-Chemical -
. O +

We O +
report O +
a O +
case O +
of O +
MPO O -
- O -
ANCA O -
- O -
associated O +
vasculitis O +
in O +
a O +
35-year O -
- O -
old O +
woman O +
with O +
Graves'disease O -
. O +

Although O +
her O +
thyroid O +
function O +
could O +
be O +
maintained O +
euthyroid O +
by O +
MMI O -
, O +
her O +
ATD O +
was O +
switched O +
to O +
PTU B-Chemical +
because O +
she O +
wished O +
to O +
become O +
pregnant O -
. O +

The O +
patient O +
presented O +
with O +
flu O -
- O -
like O +
symptoms O +
8 O +
days O +
after O +
starting O +
PTU B-Chemical +
and O +
developed O +
hemoptysis O +
and O +
dyspnea O +
at O +
22 O +
days O -
. O +

Her O +
MPO O -
- O -
ANCA O +
titer O +
was O +
21 O +
ELISA O +
units O +
( O -
EUs O -
) O +
before O +
PTU B-Chemical +
treatment O +
but O +
increased O +
to O +
259 O +
EUs O +
at O +
22 O +
days O +
after O +
PTU B-Chemical +
treatment O -
. O +

Her O +
clinical O +
condition O +
improved O +
with O +
the O +
discontinuation O +
of O +
PTU B-Chemical +
and O +
with O +
immunosuppressive O +
therapy O -
. O +

This O +
case O +
indicated O +
that O +
MPO O -
- O -
ANCA O +
vasculitis O +
occurred O +
within O +
several O +
weeks O +
after O +
the O +
initiation O +
of O +
PTU B-Chemical +
and O +
that O +
this O +
side O +
effect O +
could O +
be O +
caused O +
by O +
the O +
change O +
from O +
MMI B-Chemical +
to O +
PTU B-Chemical -
. O +

Thus O -
, O +
our O +
clinical O +
observation O +
suggests O +
that O +
patients O +
treated O +
with O +
PTU B-Chemical +
should O +
be O +
carefully O +
monitored O +
for O +
MPO O -
- O -
ANCA O +
titers O +
and O +
variable O +
manifestations O +
of O +
MPO O -
- O -
ANCA O -
- O -
associated O +
vasculitis O +
regardless O +
of O +
the O +
period O +
of O +
administration O -
. O +

Effects O +
of O +
antipsychotics O +
on O +
the O +
BDNF O +
in O +
schizophrenia O -
. O +

Brain O -
- O -
derived O +
neurotropic O +
factor O +
( O -
BDNF O -
) O +
is O +
involved O +
in O +
the O +
development O +
of O +
the O +
brain O -
, O +
and O +
likely O +
influences O +
the O +
neuroplasticity O +
in O +
schizophrenia O -
. O +

BDNF O +
is O +
also O +
believed O +
to O +
interact O +
with O +
other O +
neurotransmitter O +
systems O +
implicated O +
in O +
schizophrenia O -
, O +
such O +
as O +
dopamine B-Chemical -
, O +
glutamate B-Chemical -
, O +
serotonin B-Chemical +
and O +
GABA B-Chemical -
. O +

Therefore O -
, O +
BDNF O +
is O +
a O +
candidate O +
gene O +
for O +
schizophrenia O -
. O +

In O +
past O +
decades O -
, O +
the O +
blood O +
( O -
serum O +
or O +
plasma O -
) O +

BDNF O +
protein O +
levels O +
and O +
BDNF O +
gene O +
alleles O +
and O +
genotypes O +
to O +
the O +
clinical O +
features O +
of O +
schizophrenia O -
, O +
such O +
as O +
age O +
of O +
onset O -
, O +
clinical O +
subtypes O -
, O +
symptom O +
severity O -
, O +
and O +
drug O +
response O -
, O +
have O +
been O +
evaluated O +
among O +
different O +
populations O -
. O +

However O -
, O +
the O +
results O +
are O +
still O +
inconsistent O -
. O +

Further O -
, O +
different O +
drugs O +
have O +
been O +
reported O +
to O +
have O +
different O +
effects O +
on O +
BDNF O +
protein O +
levels O -
. O +

A O +
cross O -
- O -
sectional O +
survey O +
revealed O +
that O +
serum O +
BDNF O +
levels O +
in O +
chronic O +
schizophrenic O +
patients O +
treated O +
with O +
clozapine B-Chemical +
exceeded O +
those O +
of O +
patients O +
treated O +
with O +
risperidone B-Chemical +
or O +
with O +
typical O +
antipsychotics O -
. O +

In O +
recent O +
times O -
, O +
BDNF O +
epigenetic O +
studies O +
have O +
also O +
been O +
conducted O +
in O +
clinical O +
studies O +
of O +
schizophrenia O +
to O +
address O +
the O +
question O +
of O +
why O +
patients O +
with O +
the O +
same O +
gene O +
genotype O +
and O +
alleles O +
have O +
different O +
clinical O +
presentations O -
. O +

In O +
addition O -
, O +
the O +
effects O +
of O +
different O +
antipsychotic O +
drugs O +
on O +
gene O +
methylation O +
and O +
protein O +
acetylation O +
have O +
also O +
been O +
reported O -
. O +

In O +
conclusion O -
, O +
more O +
data O +
are O +
needed O +
regarding O +
BDNF O +
in O +
the O +
brain O +
and O +
in O +
peripheral O +
blood O -
, O +
including O +
protein O +
levels O -
, O +
single O +
nucleotide O +
polymorphisms O -
, O +
epigenetic O +
regulation O -
, O +
and O +
clinical O +
data O +
in O +
order O +
to O +
understand O +
the O +
role O +
of O +
BDNF O +
in O +
schizophrenia O -
. O +

Facilitative O +
effect O +
of O +
serotonin B-Chemical -
( O -
1A O -
) O +
receptor O +
agonists O +
on O +
cognition O +
in O +
patients O +
with O +
schizophrenia O -
. O +

Disturbances O +
of O +
cognitive O +
function O +
are O +
considered O +
to O +
largely O +
affect O +
the O +
outcome O +
in O +
patients O +
with O +
schizophrenia O -
. O +

There O +
is O +
much O +
attention O +
to O +
the O +
role O +
of O +
psychotropic O +
compounds O +
acting O +
on O +
serotonin B-Chemical +
( O -
5-HT B-Chemical -
) O +
receptors O +
in O +
ameliorating O +
cognitive O +
deficits O +
of O +
the O +
disease O -
. O +

Among O +
the O +
5-HT B-Chemical +
receptor O +
subtypes O -
, O +
the O +
5-HT B-Chemical -
( O -
1A O -
) O +
receptor O +
is O +
attracting O +
particular O +
interests O +
as O +
a O +
potential O +
target O +
for O +
enhancing O +
cognition O -
, O +
based O +
on O +
preclinical O +
and O +
clinical O +
evidence O -
. O +

The O +
neural O +
network O +
underlying O +
the O +
ability O +
of O +
5-HT B-Chemical -
( O -
1A O -
) O +
agonists O +
to O +
treat O +
cognitive O +
impairments O +
of O +
schizophrenia O +
likely O +
includes O +
dopamine B-Chemical -
, O +
glutamate B-Chemical -
, O +
and O +
gamma B-Chemical -
- I-Chemical -
aminobutyric I-Chemical +
acid I-Chemical +
neurons O -
. O +

Recent O +
advances O +
of O +
electrophysiological O +
measures O -
, O +
such O +
as O +
event O -
- O -
related O +
potentials O -
, O +
have O +
provided O +
insights O +
into O +
facilitative O +
effects O +
on O +
cognition O +
of O +
some O +
atypical O +
antipsychotic O +
drugs O +
or O +
related O +
compounds O +
acting O +
directly O +
or O +
indirectly O +
on O +
5-HT B-Chemical -
( O -
1A O -
) O +
receptors O -
. O +

These O +
considerations O +
are O +
expected O +
to O +
promote O +
the O +
development O +
of O +
novel O +
therapeutics O +
for O +
the O +
betterment O +
of O +
functional O +
outcome O +
in O +
people O +
suffering O +
from O +
schizophrenia O -
. O +

Neurobiological O +
basis O +
of O +
dyskinetic O +
effects O +
induced O +
by O +
antipsychotics O -
: O +
the O +
contribution O +
of O +
animal O +
models O -
. O +

Tardive O +
dyskinesia O +
( O -
TD O -
) O +
is O +
a O +
movement O +
disorder O +
characterized O +
by O +
abnormal O +
involuntary O +
facial O +
movements O +
induced O +
by O +
chronic O +
therapy O +
with O +
classical O +
antipsychotic O +
medications O -
. O +

Currently O -
, O +
there O +
is O +
no O +
satisfactory O +
pharmacotherapy O +
for O +
TD O -
, O +
which O +
represents O +
a O +
major O +
limitation O +
to O +
therapy O +
with O +
classical O +
antipsychotics O -
. O +

In O +
order O +
to O +
develop O +
or O +
optimize O +
therapies O +
for O +
TD O -
, O +
and O +
to O +
develop O +
new O +
APDs O +
with O +
lower O +
indices O +
of O +
motor O +
side O +
effects O -
, O +
the O +
pathology O +
underlying O +
TD O +
must O +
first O +
be O +
understood O -
. O +

The O +
use O +
of O +
animal O +
models O +
has O +
been O +
used O +
to O +
further O +
this O +
objective O -
. O +

Here O -
, O +
we O +
review O +
different O +
preparations O +
that O +
have O +
been O +
used O +
to O +
model O +
TD O +
and O +
discuss O +
the O +
contribution O +
of O +
neuroimaging O +
studies O +
conducted O +
in O +
these O +
models O -
. O +

Studies O +
in O +
animal O +
models O +
have O +
lead O +
to O +
several O +
hypotheses O +
of O +
TD O +
pathology O -
, O +
although O +
none O +
has O +
yet O +
emerged O +
as O +
the O +
ultimate O +
underlying O +
cause O +
of O +
this O +
syndrome O -
. O +

We O +
discuss O +
alterations O +
in O +
functional O +
indices O -
, O +
neuron O +
and O +
synapse O +
morphology O +
and O +
changes O +
in O +
specific O +
neurotransmitter O +
systems O +
that O +
have O +
been O +
described O +
in O +
animal O +
models O +
of O +
TD O -
, O +
and O +
outline O +
how O +
these O +
findings O +
have O +
contributed O +
to O +
our O +
understanding O +
of O +
antipsychotic O -
- O -
induced O +
dyskinesias O -
. O +

We O +
conclude O +
that O +
several O +
non O -
- O -
mutually O +
exclusive O +
theories O +
of O +
TD O +
are O +
supported O +
by O +
animal O +
studies O -
, O +
including O +
increases O +
in O +
oxidative O +
stress O +
leading O +
to O +
structural O +
and O +
functional O +
changes O +
in O +
specific O +
neurotransmitter O +
systems O -
. O +

Elucidating O +
the O +
mechanisms O +
underlying O +
TD O +
neuropathology O +
partly O +
through O +
the O +
use O +
of O +
animal O +
models O +
will O +
lead O +
to O +
the O +
development O +
of O +
APDs O +
with O +
superior O +
side O +
effect O +
profiles O +
or O +
more O +
effective O +
therapies O +
for O +
TD O -
. O +

Abnormal O +
striatal O +
dopamine B-Chemical +
transmission O +
in O +
schizophrenia O -
. O +

Despite O +
numerous O +
revisions O +
and O +
reformulations O -
, O +
dopamine B-Chemical +
( O -
DA O -
) O +
hypothesis O +
of O +
schizophrenia O +
remains O +
a O +
pivotal O +
neurochemical O +
hypothesis O +
of O +
this O +
illness O -
. O +

The O +
aim O +
of O +
this O +
review O +
is O +
to O +
expose O +
and O +
discuss O +
findings O +
from O +
positron O +
emission O +
tomography O +
( O -
PET O -
) O +
or O +
single O -
- O -
photon- O +
emission O +
computed O +
tomography O +
( O -
SPECT O -
) O +
studies O +
investigating O +
DA O +
function O +
in O +
the O +
striatum O +
of O +
medicated O -
, O +
drug O -
- O -
naive O +
or O +
drug O -
- O -
free O +
patients O +
with O +
schizophrenia O +
and O +
in O +
individuals O +
at O +
risk O +
compared O +
with O +
healthy O +
volunteers O -
. O +

DA O +
function O +
was O +
studied O +
at O +
several O +
levels O -
: O +
i O -
) O +
at O +
a O +
presynaptic O +
level O +
where O +
neuroimaging O +
studies O +
investigating O +
DOPA B-Chemical +
uptake O +
capacity O +
clearly O +
show O +
an O +
increase O +
of O +
DA O +
synthesis O +
in O +
patients O +
with O +
schizophrenia O -
; O +
ii O -
) O +
at O +
a O +
synaptic O +
level O +
where O +
neuroimaging O +
studies O +
investigating O +
dopamine B-Chemical +
transporter O +
availability O +
( O -
DAT O -
) O +
does O +
not O +
bring O +
any O +
evidence O +
of O +
dysfunction O -
; O +
iii O -
) O +
and O +
finally O -
, O +
neuroimaging O +
studies O +
investigating O +
DA O +
receptor O +
density O +
show O +
a O +
mild O +
increase O +
of O +
D2 O +
receptor O +
density O +
in O +
basic O +
condition O +
and O -
, O +
an O +
hyperreactivity O +
of O +
DA O +
system O +
in O +
dynamic O +
condition O -
. O +

These O +
results O +
are O +
discussed O +
regarding O +
laterality O -
, O +
sub O -
- O -
regions O +
of O +
striatum O +
and O +
implications O +
for O +
the O +
at O -
- O -
risk O +
population O -
. O +

Striatal O +
DA O +
abnormalities O +
are O +
now O +
clearly O +
demonstrated O +
in O +
patients O +
with O +
schizophrenia O +
and O +
at O +
risk O +
population O +
and O +
could O +
constitute O +
an O +
endophenotype O +
of O +
schizophrenia O -
. O +

Subtle O +
sub O -
- O -
clinical O +
striatal O +
DA O +
abnormalities O +
in O +
at O +
risk O +
population O +
could O +
be O +
a O +
biomarker O +
of O +
transition O +
from O +
a O +
vulnerability O +
state O +
to O +
the O +
expression O +
of O +
frank O +
psychosis O -
. O +

Proton O +
magnetic O +
resonance O +
spectroscopy O +
changes O +
after O +
antipsychotic O +
treatment O -
. O +

Proton O +
magnetic O +
resonance O +
spectroscopy O +
( O -
( B-Chemical -
1 I-Chemical -
) I-Chemical -
H I-Chemical +
MRS O -
) O +
enables O +
the O +
observation O +
of O +
brain O +
function O +
in O +
vivo O -
. O +

Several O +
brain O +
metabolites O +
can O +
be O +
measured O +
by O +
the O +
means O +
of O +
( O -
1 O -
) O -
H O +
MRS O -
: O +
N B-Chemical -
- I-Chemical -
acetylaspartate I-Chemical +
( O -
NAA B-Chemical -
) O -
, O +
choline B-Chemical +
containing O +
compounds O +
( O -
Cho O -
) O -
, O +
myo B-Chemical -
- I-Chemical -
inositol I-Chemical +
( O -
mI O -
) O +
and O +
glutamate B-Chemical +
( O -
Glu B-Chemical -
) O -
, O +
glutamine B-Chemical +
( O -
Gln B-Chemical -
) O +
and O +
GABA B-Chemical +
( O -
together O +
as O +
Glx O +
complex O +
or O +
separately O -
) O -
. O +

( B-Chemical -
1 I-Chemical -
) I-Chemical -
H I-Chemical +
MRS O +
measures O +
have O +
been O +
found O +
to O +
be O +
abnormal O +
in O +
psychotic O +
disorders O +
such O +
as O +
schizophrenia O -
. O +

Here O +
we O +
specifically O +
review O +
the O +
influence O +
exerted O +
by O +
antipsychotic O +
drugs O +
on O +
brain O +
metabolism O -
, O +
as O +
detected O +
by O +
( B-Chemical -
1 I-Chemical -
) I-Chemical -
H I-Chemical +
MRS O -
. O +

We O +
systematically O +
reviewed O +
the O +
available O +
literature O +
and O +
uncovered O +
27 O +
studies O -
, O +
16 O +
before O -
- O -
after O +
treatment O +
and O +
11 O +
cross O -
- O -
sectional O -
. O +

Most O +
of O +
them O +
addressed O +
the O +
effects O +
of O +
antipsychotics O +
in O +
schizophrenia O +
and O +
mainly O +
focusing O +
on O +
NAA B-Chemical +
alterations O -
. O +

Follow O +
up O +
studies O +
indicated O +
antipsychotic O +
drugs O +
may O +
act O +
by O +
increasing O +
NAA B-Chemical +
levels O +
in O +
selected O +
brain O +
areas O +
( O -
the O +
frontal O +
lobe O +
and O +
thalamus O -
) O -
, O +
especially O +
during O +
the O +
short O -
- O -
time O +
observation O -
. O +

This O +
phenomenon O +
seems O +
to O +
vanish O +
after O +
longer O +
observation O -
. O +

Other O +
studies O +
indicated O +
that O +
glutamate B-Chemical +
measures O +
are O +
decreasing O +
along O +
with O +
the O +
duration O +
of O +
the O +
disease O -
, O +
suggesting O +
both O +
a O +
neurodegenerative O +
process O +
present O +
in O +
schizophrenic O +
brain O +
as O +
well O +
as O +
an O +
influence O +
of O +
antipsychotics O -
. O +

The O +
above O +
results O +
were O +
reviewed O +
according O +
to O +
the O +
most O +
recent O +
theories O +
in O +
the O +
field O +
accounting O +
for O +
the O +
impact O +
of O +
antipsychotics O +
( B-Chemical -
1 I-Chemical -
) I-Chemical -
HMRS I-Chemical +
measures O -
. O +

The O +
next O +
frontier O +
in O +
composite O +
tissue O +
allotransplantation O -
. O +

Solid O +
organ O +
transplantations O +
became O +
a O +
clinical O +
option O +
in O +
the O +
1950s O -
. O +

The O +
hand O +
allograft O +
was O +
the O +
pioneer O +
of O +
composite O +
tissue O +
allotransplantation O +
( O -
CTA O -
) O -
, O +
successfully O +
started O +
near O +
the O +
end O +
of O +
the O +
last O +
century O +
despite O +
arguments O +
over O +
the O +
practicality O +
and O +
methods O -
. O +

Since O +
then O -
, O +
CTA O +
such O +
as O +
hand O +
and O +
face O +
has O +
continued O +
to O +
progress O +
from O +
the O +
theoretical O +
to O +
clinical O +
reality O -
. O +

The O +
treatment O +
principles O -
, O +
drug O +
combinations O -
, O +
and O +
mechanisms O +
of O +
the O +
immunosuppression O +
medications O +
on O +
which O +
contemporary O +
transplant O +
surgeries O +
have O +
been O +
based O +
continue O +
to O +
develop O +
as O +
researchers O +
and O +
physicians O +
gain O +
more O +
experience O +
in O +
the O +
CTA O +
field O -
. O +

It O +
could O +
be O +
argued O +
that O +
the O +
ethical O +
issues O +
associated O +
with O +
CTA O +
have O +
prevented O +
evolution O +
of O +
the O +
field O +
rather O +
than O +
surgical O +
or O +
technical O +
skill O -
. O +

This O +
is O +
particularly O +
true O +
for O +
allo O -
- O -
head O +
and O +
body O +
reconstruction O +
( O -
AHBR O -
) O -
. O +

How O +
can O +
leaders O +
in O +
the O +
field O +
of O +
CTA O +
develop O +
a O +
model O +
that O +
would O +
satisfy O +
ethical O +
concerns O -
? O +

Bolstered O +
by O +
recent O +
successes O +
in O +
the O +
field O -
, O +
is O +
it O +
time O +
to O +
traverse O +
the O +
next O +
frontier O -
? O +

Can O +
AHBR O +
ever O +
be O +
a O +
feasible O +
option O +
in O +
the O +
clinical O +
setting O -
? O +

The O +
reader O +
will O +
be O +
provided O +
with O +
a O +
brief O +
history O +
of O +
CTA O +
from O +
theory O +
to O +
research O +
to O +
clinical O +
practice O -
. O +

A O +
concise O +
description O +
of O +
AHBR O +
as O +
it O +
pertains O +
to O +
the O +
critical O +
procedure O +
( O -
i.e. O -
, O +
surgery O +
design O -
) O +
will O +
also O +
be O +
discussed O -
. O +

Behavioural O +
and O +
EEG O +
effects O +
of O +
chronic O +
rapamycin B-Chemical +
treatment O +
in O +
a O +
mouse O +
model O +
of O +
Tuberous O +
Sclerosis O +
Complex O -
. O +

Tuberous O +
Sclerosis O +
Complex O +
( O -
TSC O -
) O +
is O +
a O +
multisystem O +
genetic O +
disorder O +
caused O +
by O +
mutation O +
in O +
either O +
Tsc1 O +
or O +
Tsc2 O +
genes O +
that O +
leads O +
to O +
the O +
hyper O +
activation O +
of O +
the O +
mTOR O +
pathway O -
, O +
a O +
key O +
signalling O +
pathway O +
for O +
synaptic O +
plasticity O -
. O +

TSC O +
is O +
characterized O +
by O +
benign O +
tumors O +
arising O +
in O +
different O +
organs O +
and O +
severe O +
neuropsychiatric O +
symptoms O -
, O +
such O +
as O +
epilepsy O -
, O +
intellectual O +
disability O -
, O +
autism O -
, O +
anxiety O +
and O +
depressive O +
behaviour O -
. O +

Rapamycin B-Chemical +
is O +
a O +
potent O +
inhibitor O +
of O +
mTOR O +
and O +
its O +
efficacy O +
in O +
treating O +
epilepsy O +
and O +
neurological O +
symptoms O +
remains O +
elusive O -
. O +

In O +
a O +
mouse O +
model O +
in O +
which O +
Tsc1 O +
has O +
been O +
deleted O +
in O +
embryonic O +
telencephalic O +
neural O +
stem O +
cells O -
, O +
we O +
analyzed O +
anxiety- O +
and O +
depression O -
- O -
like O +
behaviour O +
by O +
elevated O -
- O -
plus O +
maze O +
( O -
EPM O -
) O -
, O +
open O -
- O -
field O +
test O +
( O -
OFT O -
) O -
, O +
forced O -
- O -
swim O +
test O +
( O -
FST O -
) O +
and O +
tail O -
- O -
suspension O +
test O +
( O -
TST O -
) O -
, O +
after O +
chronic O +
administration O +
of O +
rapamycin B-Chemical -
. O +

In O +
addition O -
, O +
spectral O +
analysis O +
of O +
background O +
EEG O +
was O +
performed O -
. O +

Rapamycin B-Chemical -
- O -
treated O +
mutant O +
mice O +
displayed O +
a O +
reduction O +
in O +
anxiety- O +
and O +
depression O -
- O -
like O +
phenotype O -
, O +
as O +
shown O +
by O +
the O +
EPM O -
/ O -
OFT O +
and O +
FST O -
, O +
respectively O -
. O +

These O +
results O +
were O +
inline O +
with O +
EEG O +
power O +
spectra O +
outcomes O -
. O +

The O +
same O +
effects O +
of O +
rapamycin B-Chemical +
were O +
observed O +
in O +
wild O -
- O -
type O +
mice O -
. O +

Notably O -
, O +
in O +
heterozygous O +
animals O +
we O +
did O +
not O +
observe O +
any O +
EEG O +
and/or O +
behavioural O +
variation O +
after O +
rapamycin B-Chemical +
treatment O -
. O +

Together O +
these O +
results O +
suggest O +
that O +
both O +
TSC1 O +
deletion O +
and O +
chronic O +
rapamycin B-Chemical +
treatment O +
might O +
have O +
a O +
role O +
in O +
modulating O +
behaviour O +
and O +
brain O +
activity O -
, O +
and O +
point O +
out O +
to O +
the O +
potential O +
usefulness O +
of O +
background O +
EEG O +
analysis O +
in O +
tracking O +
brain O +
dysfunction O +
in O +
parallel O +
with O +
behavioural O +
testing O -
. O +

Novel O +
antitussive O +
strategies O -
. O +

Acute O +
and O +
chronic O +
cough O +
represent O +
one O +
of O +
the O +
most O +
common O +
symptoms O +
of O +
medical O +
importance O +
but O +
effective O +
pharmacotherapy O +
is O -
, O +
to O +
all O +
intents O +
and O +
purposes O -
, O +
absent O -
. O +

Numerous O +
initiatives O +
targeting O +
the O +
recently O +
discovered O +
tussive O +
pathways O +
are O +
in O +
progress O -
. O +

Here O -
, O +
we O +
review O +
the O +
current O +
antitussive O +
armamentarium O +
and O +
provide O +
an O +
update O +
on O +
the O +
novel O +
strategies O +
and O +
compounds O +
in O +
development O -
. O +

A O +
method O +
for O +
assessing O +
the O +
potential O +
for O +
confounding O +
applied O +
to O +
ionic O +
strength O +
in O +
central O +
Appalachian O +
streams O -
. O +

Causal O +
relationships O +
derived O +
from O +
field O +
data O +
are O +
potentially O +
confounded O +
by O +
variables O +
that O +
are O +
correlated O +
with O +
both O +
the O +
cause O +
and O +
its O +
effect O -
. O +

The O +
present O +
study O +
presents O +
a O +
method O +
for O +
assessing O +
the O +
potential O +
for O +
confounding O +
and O +
applies O +
it O +
to O +
the O +
relationship O +
between O +
ionic O +
strength O +
and O +
impairment O +
of O +
benthic O +
invertebrate O +
assemblages O +
in O +
central O +
Appalachian O +
streams O -
. O +

The O +
method O +
weighs O +
all O +
available O +
evidence O +
for O +
and O +
against O +
confounding O +
by O +
each O +
potential O +
confounder O -
. O +

It O +
identifies O +
10 O +
types O +
of O +
evidence O +
for O +
confounding O -
, O +
presents O +
a O +
qualitative O +
scoring O +
system O -
, O +
and O +
provides O +
rules O +
for O +
applying O +
the O +
scores O -
. O +

Twelve O +
potential O +
confounders O +
were O +
evaluated O -
: O +
habitat O -
, O +
organic O +
enrichment O -
, O +
nutrients O -
, O +
deposited O +
sediments O -
, O +
pH O -
, O +
selenium B-Chemical -
, O +
temperature O -
, O +
lack O +
of O +
headwaters O -
, O +
catchment O +
area O -
, O +
settling O +
ponds O -
, O +
dissolved O +
oxygen B-Chemical -
, O +
and O +
metals O -
. O +

One O +
potential O +
confounder O -
, O +
low O +
pH O -
, O +
was O +
found O +
to O +
be O +
biologically O +
significant O +
and O +
eliminated O +
by O +
removing O +
sites O +
with O +
pH O +
< O +
6 O -
. O +

Other O +
potential O +
confounders O +
were O +
eliminated O +
based O +
on O +
the O +
weight O +
of O +
evidence O -
. O +

This O +
method O +
was O +
found O +
to O +
be O +
useful O +
and O +
defensible O -
. O +

It O +
could O +
be O +
applied O +
to O +
other O +
environmental O +
assessments O +
that O +
use O +
field O +
data O +
to O +
develop O +
causal O +
relationships O -
, O +
including O +
contaminated O +
site O +
remediation O +
or O +
management O +
of O +
natural O +
resources O -
. O +

Substituent O +
variation O +
drives O +
metal O -
/ O -
monolayer O -
/ O -
semiconductor O +
junctions O +
from O +
strongly O +
rectifying O +
to O +
ohmic O +
behavior O -
. O +

An O +
eight O -
- O -
orders O +
of O +
magnitude O +
enhancement O +
in O +
current O +
across O +
Hg B-Chemical -
/ O -
X O -
- O -
styrene B-Chemical -
- O -
Si B-Chemical +
junctions O +
is O +
caused O +
by O +
merely O +
altering O +
a O +
substituent O -
, O +
X. O +
Interface O +
states O +
are O +
passivated O +
and O -
, O +
depending O +
on O +
X O -
, O +
the O +
Si B-Chemical +
Schottky O +
junction O +
encompasses O +
the O +
full O +
range O +
from O +
Ohmic O +
to O +
strongly O +
rectifying O -
. O +

This O +
powerful O +
electrostatic O +
molecular O +
effect O +
has O +
immediate O +
implications O +
for O +
interface O +
band O +
alignment O +
and O +
sensing O -
. O +

Influence O +
of O +
silver B-Chemical +
doping O +
on O +
electron O +
transport O +
in O +
thin O +
films O +
of O +
PbSe B-Chemical +
nanocrystals O -
. O +

Field O -
- O -
effect O +
transistors O +
are O +
fabricated O +
from O +
thin O +
films O +
of O +
Ag B-Chemical -
- I-Chemical -
doped I-Chemical +
PbSe I-Chemical +
nanocrystals O +
to O +
analyze O +
the O +
influence O +
of O +
electronically O +
active O +
impurities O +
on O +
electrical O +
transport O +
in O +
this O +
important O +
material O +
for O +
nanocrystal O +
applications O -
. O +

Data O +
is O +
collected O +
as O +
a O +
function O +
of O +
nanocrystal O +
size O -
, O +
dopant O +
concentration O -
, O +
and O +
temperature O -
. O +

Changes O +
in O +
the O +
Fermi O +
level O +
and O +
transport O +
parameters O +
indicate O +
that O +
Ag B-Chemical +
is O +
acting O +
as O +
a O +
p O -
- O -
type O +
dopant O +
( O -
acceptor O -
) O -
. O +

New O +
horizons O +
for O +
diagnostics O +
and O +
therapeutic O +
applications O +
of O +
graphene B-Chemical +
and O +
graphene B-Chemical +
oxide I-Chemical -
. O +

Graphene B-Chemical -
, O +
a O +
one O -
- O -
atom O -
- O -
thick O +
two O -
- O -
dimensional O +
( O -
2D O -
) O +
layer O +
of O +
sp O -
( O -
2 O -
) O +
-bonded O +
carbon B-Chemical -
, O +
has O +
received O +
worldwide O +
attention O +
owing O +
to O +
its O +
extraordinary O +
physical O +
and O +
chemical O +
properties O -
. O +

Recently O -
, O +
great O +
efforts O +
have O +
been O +
devoted O +
to O +
explore O +
potential O +
applications O +
of O +
graphene B-Chemical +
and O +
its O +
oxide O +
in O +
life O +
science O -
, O +
especially O +
in O +
disease O -
- O -
related O +
diagnostics O -
, O +
near O -
- O -
Infrared O +
( O -
NIR O -
) O +
phototherapy O +
and O +
imaging O -
. O +

Here O +
we O +
will O +
introduce O +
recent O +
advances O +
and O +
new O +
horizons O +
in O +
this O +
area O -
, O +
and O +
focus O +
on O +
the O +
rising O +
progress O +
on O +
NIR O +
photothermal O +
therapy O +
for O +
cancer O +
and O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O -
, O +
human O +
telomerase O +
detection O -
, O +
stem O +
cell O +
proliferation O +
and O +
differentiation O +
on O +
graphene B-Chemical +
substrate O -
, O +
diagnosis O +
of O +
cancer O +
cell O +
and O +
related O +
biomarkers O -
, O +
drug O -
/ O -
nucleotide B-Chemical -
/ O -
peptide O +
delivery O +
and O +
cell O +
imaging O -
, O +
which O +
have O +
not O +
been O +
comprehensively O +
reviewed O -
. O +

We O +
hope O +
to O +
provide O +
an O +
outlook O +
to O +
the O +
applications O +
of O +
graphene B-Chemical +
and O +
its O +
oxide O -
, O +
especially O +
on O +
the O +
new O +
horizons O +
in O +
this O +
field O -
, O +
and O +
inspire O +
broader O +
interests O +
across O +
various O +
disciplines O -
. O +

SchistoDB O -
: O +
an O +
updated O +
genome O +
resource O +
for O +
the O +
three O +
key O +
schistosomes O +
of O +
humans O -
. O +

The O +
new O +
release O +
of O +
SchistoDB O +
( O -
http://SchistoDB.net O -
) O +
provides O +
a O +
rich O +
resource O +
of O +
genomic O +
data O +
for O +
key O +
blood O +
flukes O +
( O -
genus O +
Schistosoma O -
) O +
which O +
cause O +
disease O +
in O +
hundreds O +
of O +
millions O +
of O +
people O +
worldwide O -
. O +

SchistoDB O +
integrates O +
whole O -
- O -
genome O +
sequence O +
and O +
annotation O +
of O +
three O +
species O +
of O +
the O +
genus O +
and O +
provides O +
enhanced O +
bioinformatics O +
analyses O +
and O +
data O -
- O -
mining O +
tools O -
. O +

A O +
simple O -
, O +
yet O +
comprehensive O +
web O +
interface O +
provided O +
through O +
the O +
Strategies O +
Web O +
Development O +
Kit O +
is O +
available O +
for O +
the O +
mining O +
and O +
visualization O +
of O +
the O +
data O -
. O +

Genomic O +
scale O +
data O +
can O +
be O +
queried O +
based O +
on O +
BLAST O +
searches O -
, O +
annotation O +
keywords O +
and O +
gene O +
ID O +
searches O -
, O +
gene O +
ontology O +
terms O -
, O +
sequence O +
motifs O -
, O +
protein O +
characteristics O +
and O +
phylogenetic O +
relationships O -
. O +

Search O +
strategies O +
can O +
be O +
saved O +
within O +
a O +
user O -
's O +
profile O +
for O +
future O +
retrieval O +
and O +
may O +
also O +
be O +
shared O +
with O +
other O +
researchers O +
using O +
a O +
unique O +
web O +
address O -
. O +

Genetic O +
requirements O +
for O +
Moraxella O +
catarrhalis O +
growth O +
under O +
iron B-Chemical -
- O -
limiting O +
conditions O -
. O +

Iron B-Chemical +
sequestration O +
by O +
the O +
human O +
host O +
is O +
a O +
first O +
line O +
defence O +
against O +
respiratory O +
pathogens O +
like O +
Moraxella O +
catarrhalis O -
, O +
which O +
consequently O +
experiences O +
a O +
period O +
of O +
iron B-Chemical +
starvation O +
during O +
colonization O -
. O +

We O +
determined O +
the O +
genetic O +
requirements O +
for O +
M. O +
catarrhalis O +
BBH18 O +
growth O +
during O +
iron B-Chemical +
starvation O +
using O +
the O +
high O -
- O -
throughput O +
genome O -
- O -
wide O +
screening O +
technology O +
genomic O +
array O +
footprinting O +
( O -
GAF O -
) O -
. O +

By O +
subjecting O +
a O +
large O +
random O +
transposon O +
mutant O +
library O +
to O +
growth O +
under O +
iron B-Chemical -
- O -
limiting O +
conditions O -
, O +
mutants O +
of O +
the O +
MCR_0996-rhlB O -
- O -
yggW O +
operon O -
, O +
rnd O -
, O +
and O +
MCR_0457 O +
were O +
negatively O +
selected O -
. O +

Growth O +
experiments O +
using O +
directed O +
mutants O +
confirmed O +
the O +
GAF O +
phenotypes O +
with O +
ΔyggW O +
( O -
putative O +
haem O -
- O -
shuttling O +
protein O -
) O +
and O +
ΔMCR_0457 O +
( O -
hypothetical O +
protein O -
) O +
most O +
severely O +
attenuated O +
during O +
iron B-Chemical +
starvation O -
, O +
phenotypes O +
which O +
were O +
restored O +
upon O +
genetic O +
complementation O +
of O +
the O +
deleted O +
genes O -
. O +

Deletion O +
of O +
yggW O +
resulted O +
in O +
similar O +
attenuated O +
phenotypes O +
in O +
three O +
additional O +
strains O -
. O +

Transcriptional O +
profiles O +
of O +
ΔyggW O +
and O +
ΔMCR_0457 O +
were O +
highly O +
altered O +
with O +
393 O +
and O +
192 O +
differentially O +
expressed O +
genes O +
respectively O -
. O +

In O +
all O +
five O +
mutants O -
, O +
expression O +
of O +
nitrate B-Chemical +
reductase O +
genes O +
was O +
increased O +
and O +
of O +
nitrite B-Chemical +
reductase O +
decreased O -
, O +
suggesting O +
an O +
impaired O +
aerobic O +
respiration O -
. O +

Alteration O +
of O +
iron B-Chemical +
metabolism O +
may O +
affect O +
nasopharyngeal O +
colonization O +
as O +
adherence O +
of O +
all O +
mutants O +
to O +
respiratory O +
tract O +
epithelial O +
cells O +
was O +
attenuated O -
. O +

In O +
conclusion O -
, O +
we O +
elucidated O +
the O +
genetic O +
requirements O +
for O +
M. O +
catarrhalis O +
growth O +
during O +
iron B-Chemical +
starvation O +
and O +
characterized O +
the O +
roles O +
of O +
the O +
identified O +
genes O +
in O +
bacterial O +
growth O +
and O +
host O +
interaction O -
. O +

Synaptic O +
plasticity O +
in O +
the O +
hippocampus O +
shows O +
resistance O +
to O +
acute O +
ethanol B-Chemical +
exposure O +
in O +
transgenic O +
mice O +
with O +
astrocyte O -
- O -
targeted O +
enhanced O +
CCL2 O +
expression O -
. O +

It O +
has O +
been O +
shown O +
that O +
ethanol O +
exposure O +
can O +
activate O +
astrocytes O +
and O +
microglia O +
resulting O +
in O +
the O +
production O +
of O +
neuroimmune O +
factors O -
, O +
including O +
the O +
chemokine O +
CCL2 O -
. O +

The O +
role O +
of O +
these O +
neuroimmune O +
factors O +
in O +
the O +
effects O +
of O +
ethanol B-Chemical +
on O +
the O +
central O +
nervous O +
system O +
has O +
yet O +
to O +
be O +
elucidated O -
. O +

To O +
address O +
this O +
question O -
, O +
we O +
investigated O +
the O +
effects O +
of O +
ethanol B-Chemical +
on O +
synaptic O +
transmission O +
and O +
plasticity O +
in O +
the O +
hippocampus O +
from O +
mice O +
that O +
express O +
elevated O +
levels O +
of O +
CCL2 O +
in O +
the O +
brain O +
and O +
their O +
non O -
- O -
transgenic O +
littermate O +
controls O -
. O +

The O +
brains O +
of O +
the O +
transgenic O +
mice O +
simulate O +
one O +
aspect O +
of O +
the O +
alcoholic O +
brain O -
, O +
chronically O +
increased O +
levels O +
of O +
CCL2 O -
. O +

We O +
used O +
extracellular O +
field O +
potential O +
recordings O +
in O +
acutely O +
isolated O +
hippocampal O +
slices O +
to O +
identify O +
neuroadaptive O +
changes O +
produced O +
by O +
elevated O +
levels O +
of O +
CCL2 O +
and O +
how O +
these O +
neuroadaptive O +
changes O +
affect O +
the O +
actions O +
of O +
acute O +
ethanol B-Chemical -
. O +

Results O +
showed O +
that O +
synaptic O +
transmission O +
and O +
the O +
effects O +
of O +
ethanol B-Chemical +
on O +
synaptic O +
transmission O +
were O +
similar O +
in O +
the O +
CCL2-transgenic O +
and O +
non O -
- O -
transgenic O +
hippocampus O -
. O +

However O -
, O +
long O -
- O -
term O +
potentiation O +
( O -
LTP O -
) O -
, O +
a O +
cellular O +
mechanism O +
thought O +
to O +
underlie O +
learning O +
and O +
memory O -
, O +
in O +
the O +
CCL2-transgenic O +
hippocampus O +
was O +
resistant O +
to O +
the O +
ethanol B-Chemical -
- O -
induced O +
depression O +
of O +
LTP O +
observed O +
in O +
the O +
non O -
- O -
transgenic O +
hippocampus O -
. O +

Consistent O +
with O +
these O +
results O -
, O +
ethanol B-Chemical +
pretreatment O +
significantly O +
impaired O +
cued O +
and O +
contextual O +
fear O +
conditioning O +
in O +
non O -
- O -
transgenic O +
mice O -
, O +
but O +
had O +
no O +
effect O +
in O +
CCL2-transgenic O +
mice O -
. O +

These O +
data O +
show O +
that O +
chronically O +
elevated O +
levels O +
of O +
CCL2 O +
in O +
the O +
hippocampus O +
produce O +
neuroadaptive O +
changes O +
that O +
block O +
the O +
depressing O +
effects O +
of O +
ethanol B-Chemical +
on O +
hippocampal O +
synaptic O +
plasticity O +
and O +
support O +
the O +
hypothesis O +
that O +
CCL2 O +
may O +
provide O +
a O +
neuroprotective O +
effect O +
against O +
the O +
devastating O +
actions O +
of O +
ethanol B-Chemical +
on O +
hippocampal O +
function O -
. O +

Supra O -
- O -
normal O +
stimulation O +
of O +
dopamine B-Chemical +
D1 O +
receptors O +
in O +
the O +
prelimbic O +
cortex O +
blocks O +
behavioral O +
expression O +
of O +
both O +
aversive O +
and O +
rewarding O +
associative O +
memories O +
through O +
a O +
cyclic B-Chemical -
- I-Chemical -
AMP I-Chemical -
- O -
dependent O +
signaling O +
pathway O -
. O +

Dopamine B-Chemical +
( O -
DA O -
) O +
receptor O +
transmission O +
through O +
either O +
D O -
( O -
1 O -
) O +
or O +
D O -
( O -
2 O -
) O -
-like O +
subtypes O +
is O +
involved O +
critically O +
in O +
the O +
processing O +
of O +
emotional O +
information O +
within O +
the O +
medial O +
prefrontal O +
cortex O +
( O -
mPFC O -
) O -
. O +

However O +
the O +
functional O +
role O +
of O +
specific O +
DA O +
D O -
( O -
1 O -
) O -
-like O +
receptor O +
transmission O +
in O +
the O +
expression O +
of O +
emotionally O +
salient O +
associative O +
memories O +
( O -
either O +
aversive O +
or O +
rewarding O -
) O +
is O +
not O +
currently O +
understood O -
. O +

Here O +
we O +
demonstrate O +
that O +
specific O +
activation O +
of O +
DA O +
D O -
( O -
1 O -
) O +
receptors O +
in O +
the O +
prelimbic O +
( O -
PLC O -
) O +
division O +
of O +
the O +
mPFC O +
causes O +
a O +
transient O +
block O +
in O +
the O +
behavioral O +
expression O +
of O +
both O +
aversive O +
and O +
rewarding O +
associative O +
memories O -
. O +

We O +
report O +
that O +
intra O -
- O -
PLC O +
microinfusions O +
of O +
a O +
selective O +
D O -
( O -
1 O -
) O +
receptor O +
agonist O +
block O +
the O +
spontaneous O +
expression O +
of O +
an O +
associative O +
olfactory O +
fear O +
memory O -
, O +
without O +
altering O +
the O +
stability O +
of O +
the O +
original O +
memory O +
trace O -
. O +

Furthermore O -
, O +
using O +
an O +
unbiased O +
place O +
conditioning O +
procedure O +
( O -
CPP O -
) O -
, O +
intra O -
- O -
PLC O +
D O -
( O -
1 O -
) O +
receptor O +
activation O +
blocks O +
the O +
spontaneous O +
expression O +
of O +
an O +
associative O +
morphine B-Chemical +
( O -
5 O +
mg O -
/ O -
kg O -
; O +
i.p O -
. O -
) O +
reward O +
memory O -
, O +
while O +
leaving O +
morphine B-Chemical -
- O -
primed O +
memory O +
expression O +
intact O -
. O +

Interestingly O -
, O +
both O +
intra O -
- O -
PLC O +
D O -
( O -
1 O -
) O -
-receptor O +
mediated O +
block O +
of O +
either O +
fear O -
- O -
related O +
or O +
reward O -
- O -
related O +
associative O +
memories O +
were O +
dependent O +
upon O +
downstream O +
cyclic B-Chemical -
- I-Chemical -
AMP I-Chemical +
( O -
cAMP B-Chemical -
) O +
signaling O +
as O +
both O +
effects O +
were O +
rescued O +
by O +
co O -
- O -
administration O +
of O +
a O +
cAMP B-Chemical +
signaling O +
inhibitor O -
. O +

The O +
blockade O +
of O +
both O +
rewarding O +
and O +
aversive O +
associative O +
memories O +
is O +
mediated O +
through O +
a O +
D O -
( O -
1 O -
) O -
-specific O +
signaling O +
pathway O -
, O +
as O +
neither O +
forms O +
of O +
spontaneous O +
memory O +
expression O +
were O +
blocked O +
by O +
intra O -
- O -
PLC O +
microinfusions O +
of O +
a O +
D O -
( O -
2 O -
) O -
-like O +
receptor O +
agonist O -
. O +

Our O +
results O +
demonstrate O +
that O +
the O +
spontaneous O +
expression O +
of O +
either O +
rewarding O +
or O +
aversive O +
emotionally O +
salient O +
memories O +
shares O +
a O +
common O -
, O +
D O -
( O -
1 O -
) O -
-receptor O +
mediated O +
substrate O +
within O +
the O +
mPFC O -
. O +

Glucose B-Chemical +
attenuates O +
impairments O +
in O +
memory O +
and O +
CREB O +
activation O +
produced O +
by O +
an O +
α4β2 O +
but O +
not O +
an O +
α7 O +
nicotinic O +
receptor O +
antagonist O -
. O +

Glucose B-Chemical +
improves O +
memory O +
for O +
a O +
variety O +
of O +
tasks O +
when O +
administered O +
to O +
rats O +
and O +
mice O +
near O +
the O +
time O +
of O +
training O -
. O +

Prior O +
work O +
indicates O +
glucose B-Chemical +
may O +
enhance O +
memory O +
by O +
increasing O +
the O +
synthesis O +
and O +
release O +
of O +
the O +
neurotransmitter O +
acetylcholine B-Chemical +
in O +
the O +
brain O -
. O +

To O +
investigate O +
if O +
specific O +
acetylcholine B-Chemical +
receptor O +
subtypes O +
may O +
mediate O +
some O +
of O +
the O +
memory O -
- O -
enhancing O +
actions O +
of O +
glucose B-Chemical -
, O +
we O +
examined O +
the O +
effects O +
of O +
subtype O -
- O -
specific O +
nicotinic O +
acetylcholine B-Chemical +
receptor O +
antagonists O +
on O +
memory O +
in O +
Fischer-344 O +
rats O +
and O +
also O +
examined O +
the O +
ability O +
of O +
glucose B-Chemical +
to O +
reverse O +
drug O -
- O -
induced O +
impairments O -
. O +

Pre O -
- O -
training O +
peripheral O +
injections O +
of O +
methyllycaconitine B-Chemical +
( O -
MLA B-Chemical -
) O +
or O +
dihydro B-Chemical -
- I-Chemical -
beta I-Chemical -
- I-Chemical -
erythroidine I-Chemical +
( O -
DHβE B-Chemical -
) O -
, O +
which O +
are O +
specific O +
α7 O +
and O +
α4β2 O +
nicotinic O +
receptor O +
antagonists O -
, O +
respectively O -
, O +
dose O -
- O -
dependently O +
impaired O +
retention O +
latencies O +
in O +
an O +
inhibitory O +
avoidance O +
task O +
when O +
tested O +
7-days O +
but O +
not O +
1 O +
h O +
after O +
training O -
. O +

Immediate O +
post O -
- O -
training O +
glucose B-Chemical +
injections O +
attenuated O +
the O +
impairments O -
, O +
but O +
were O +
more O +
effective O +
in O +
attenuating O +
the O +
DHβE B-Chemical -
- O -
induced O +
impairments O -
. O +

Likewise O -
, O +
peripheral O +
or O +
direct O +
intrahippocampal O +
injections O +
of O +
MLA B-Chemical +
or O +
DHβE B-Chemical +
dose O -
- O -
dependently O +
impaired O +
spatial O +
working O +
memory O +
scores O +
on O +
a O +
spontaneous O +
alternation O +
task O -
. O +

Concurrent O +
administration O +
of O +
glucose B-Chemical +
reversed O +
DHβE- B-Chemical +
but O +
not O +
MLA B-Chemical -
- O -
induced O +
impairments O -
. O +

CREB O +
phosphorylation O +
downstream O +
of O +
cholinergic O +
signaling O +
was O +
assessed O +
30 O +
min O +
after O +
spontaneous O +
alternation O +
testing O +
and O +
intrahippocampal O +
drug O +
infusions O -
. O +

Both O +
MLA B-Chemical +
and O +
DHβE B-Chemical +
impaired O +
hippocampal O +
CREB O +
phosphorylation O -
; O +
glucose B-Chemical +
reversed O +
DHβE- B-Chemical +
but O +
not O +
MLA B-Chemical -
- O -
induced O +
deficits O -
. O +

The O +
effectiveness O +
of O +
glucose B-Chemical +
in O +
reversing O +
DHβE- B-Chemical +
but O +
not O +
MLA B-Chemical -
- O -
induced O +
impairments O +
in O +
behavioral O +
performance O +
and O +
CREB O +
phosphorylation O +
suggests O +
that O +
activation O +
of O +
α7 O +
receptors O +
may O +
play O +
an O +
important O +
role O +
in O +
memory O +
enhancement O +
by O +
glucose B-Chemical -
. O +

Enantioselective O +
synthesis O +
of O +
derivatives O +
and O +
structure O -
- O -
activity O +
relationship O +
study O +
in O +
the O +
development O +
of O +
NA255 B-Chemical +
as O +
a O +
novel O +
host O -
- O -
targeting O +
anti O -
- O -
HCV O +
agent O -
. O +

Hepatitis O +
C O +
virus O +
( O -
HCV O -
) O +
infection O +
represents O +
a O +
serious O +
health O -
- O -
care O +
problem O -
. O +

Previously O +
we O +
reported O +
the O +
identification O +
of O +
NA255 B-Chemical +
from O +
our O +
natural O +
products O +
library O +
using O +
a O +
HCV O +
sub O -
- O -
genomic O +
replicon O +
cell O +
culture O +
system O -
. O +

Herein O -
, O +
we O +
report O +
how O +
the O +
absolute O +
stereochemistry O +
of O +
NA255 B-Chemical +
was O +
determined O +
and O +
an O +
enantioselective O +
synthetic O +
method O +
for O +
NA255 B-Chemical +
derivatives O +
was O +
developed O -
. O +

The O +
structure O -
- O -
activity O +
relationship O +
of O +
the O +
NA255 B-Chemical +
derivatives O +
and O +
rat O +
pharmacokinetic O +
profiles O +
of O +
the O +
representative O +
compounds O +
are O +
disclosed O -
. O +

Reproductive O +
and O +
developmental O +
toxicity O +
screening O +
test O +
of O +
3-cyanopyridine B-Chemical +
in O +
rats O -
. O +

Crl O -
: O -
CD O -
( O -
SD O -
) O -
rats O +
were O +
given O +
3-cyanopyridine B-Chemical +
by O +
gavage O +
at O +
0 O -
, O +
5 O -
, O +
30 O +
or O +
180 O +
mg O -
/ O -
kg O -
/ O -
day O -
. O +

Males O +
were O +
dosed O +
for O +
42 O +
days O +
beginning O +
14 O +
days O +
before O +
mating O -
, O +
and O +
females O +
for O +
40 O -
- O -
53 O +
days O +
beginning O +
14 O +
days O +
before O +
mating O +
to O +
day O +
3 O +
of O +
lactation O -
, O +
including O +
throughout O +
the O +
mating O +
and O +
gestation O +
periods O -
. O +

General O +
toxicity O -
, O +
mainly O +
liver O +
damage O -
, O +
was O +
observed O +
in O +
males O +
at O +
≥30 O +
mg O -
/ O -
kg O -
/ O -
day O +
and O +
in O +
females O +
at O +
≥5 O +
mg O -
/ O -
kg O -
/ O -
day O -
. O +

Sertoli O +
cell O +
vacuolation O +
was O +
observed O +
at O +
180 O +
mg O -
/ O -
kg O -
/ O -
day O -
, O +
and O +
spermatocyte O +
damages O +
were O +
observed O +
at O +
≥30 O +
mg O -
/ O -
kg O -
/ O -
day O -
. O +

Effects O +
on O +
estrous O +
cycles O -
, O +
corpora O +
lutea O +
and O +
implantations O -
, O +
and O +
unsuccessfully O +
mated O +
females O -
, O +
despite O +
additional O +
mating O -
, O +
were O +
observed O +
at O +
180 O +
mg O -
/ O -
kg O -
/ O -
day O -
. O +

Delayed O +
initiation O +
of O +
delivery O -
, O +
dystocia O -
, O +
and O +
deaths O +
or O +
moribundities O +
of O +
pregnant O +
females O +
were O +
observed O +
at O +
180 O +
mg O -
/ O -
kg O -
/ O -
day O -
, O +
and O +
only O +
two O +
pregnant O +
rats O +
delivered O +
live O +
pups O +
at O +
that O +
dose O -
. O +

The O +
NOAEL O +
for O +
reproductive O -
/ O -
developmental O +
toxicity O +
was O +
concluded O +
to O +
be O +
30 O +
mg O -
/ O -
kg O -
/ O -
day O -
. O +

Three O -
- O -
month O +
subchronic O +
intramuscular O +
toxicity O +
study O +
of O +
rotigotine B-Chemical -
- O -
loaded O +
microspheres O +
in O +
Cynomolgus O +
monkeys O -
. O +

Continuous O +
dopaminergic O +
stimulation O +
( O -
CDS O -
) O +
is O +
an O +
important O +
drug O +
development O +
strategy O +
in O +
the O +
treatment O +
of O +
Parkinson O -
's O +
disease O +
( O -
PD O -
) O -
. O +

Rotigotine B-Chemical +
is O +
a O +
non O -
- O -
ergoline B-Chemical +
D O -
( O -
3 O -
) O -
/ O -
D O -
( O -
2 O -
) O -
/ O -
D O -
( O -
1 O -
) O +
dopamine B-Chemical +
receptor O +
agonist O +
for O +
treating O +
PD O -
. O +

As O +
a O +
new O +
treatment O +
option O +
for O +
CDS O -
, O +
rotigotine B-Chemical -
- O -
loaded O +
microspheres O +
( O -
RoMS O -
) O -
, O +
long O -
- O -
acting O +
sustained O -
- O -
release O +
microspheres O +
with O +
poly B-Chemical -
( I-Chemical -
lactide I-Chemical -
- I-Chemical -
co I-Chemical -
- I-Chemical -
glycolide I-Chemical -
) I-Chemical +
as O +
drug O +
carrier O -
, O +
are O +
now O +
being O +
evaluated O +
in O +
clinical O +
trial O -
. O +

In O +
the O +
present O +
study O -
, O +
the O +
subchronic O +
toxicity O +
in O +
Cynomolgus O +
monkeys O +
has O +
been O +
characterized O +
via O +
intramuscular O +
administration O +
with O +
RoMS O +
at O +
0 O -
, O +
10 O -
, O +
40 O +
and O +
160 O +
mg O -
/ O -
kg O -
, O +
weekly O +
for O +
3 O +
months O +
with O +
a O +
1-month O +
recovery O +
period O -
. O +

The O +
NOAEL O +
was O +
10 O +
mg O -
/ O -
kg O -
/ O -
week O -
. O +

One O +
male O +
at O +
160 O +
mg O -
/ O -
kg O +
died O +
from O +
an O +
extensive O +
pulmonary O +
embolism O -
. O +

The O +
major O +
toxicological O +
effects O +
were O +
associated O +
with O +
dopamine B-Chemical +
agonist O -
- O -
related O +
pharmacodynamic O +
properties O +
of O +
rotigotine B-Chemical +
( O -
e.g. O -
, O +
hyperactivity O +
and O +
stereotype O -
, O +
decreased O +
serum O +
prolactin O +
level O -
) O +
and O +
foreign O +
body O +
removal O +
reaction O +
induced O +
by O +
poly B-Chemical -
( I-Chemical -
lactide I-Chemical -
- I-Chemical -
co I-Chemical -
- I-Chemical -
glycolide I-Chemical -
) I-Chemical +
and O +
carboxymethycellulose O +
sodium B-Chemical +
( O -
e.g. O -
, O +
increased O +
mononuclear O +
cells O +
and O +
neutrophils O -
, O +
thymus O +
atrophy O +
and O +
vacuolar O +
degeneration O +
of O +
adrenal O +
cortex O -
, O +
foreign O +
body O +
granuloma O +
with O +
foam O +
cells O +
accumulation O +
at O +
injection O +
sites O +
and O +
foam O +
cells O +
accumulation O +
in O +
spleen O +
and O +
multiple O +
lymph O +
sinuses O -
) O -
. O +

At O +
the O +
end O +
of O +
recovery O +
period O -
, O +
above O +
findings O +
recovered O +
to O +
a O +
normal O +
level O +
or O +
to O +
a O +
certain O +
degree O +
except O +
vacuolar O +
degeneration O +
of O +
adrenal O +
gland O -
. O +

RoMS O +
has O +
exhibited O +
high O +
safety O +
on O +
monkeys O -
. O +

In O +
vitro O +
combined O +
cytotoxic O +
effects O +
of O +
pesticide O +
cocktails O +
simultaneously O +
found O +
in O +
the O +
French O +
diet O -
. O +

Although O +
human O +
populations O +
may O +
be O +
constantly O +
exposed O +
to O +
complex O +
pesticide O +
mixtures O +
through O +
their O +
diet O -
, O +
the O +
human O +
health O +
risk O +
of O +
pesticide O +
exposure O +
is O +
currently O +
assessed O +
on O +
the O +
basis O +
of O +
toxicity O +
data O +
on O +
individual O +
compounds O -
. O +

To O +
investigate O +
the O +
combined O +
toxic O +
effects O +
of O +
pesticide O +
cocktails O +
previously O +
identified O +
in O +
the O +
French O +
diet O -
, O +
we O +
first O +
studied O +
the O +
cytotoxicity O +
induced O +
by O +
seven O +
cocktails O +
composed O +
of O +
two O +
to O +
six O +
pesticides O +
on O +
human O +
hepatic O +
( O -
HepG2 O -
) O +
and O +
colon O +
( O -
Caco-2 O -
) O +
cell O +
lines O +
using O +
the O +
MTT B-Chemical +
and O +
neutral B-Chemical +
red I-Chemical +
uptake O +
assays O -
. O +

Secondly O -
, O +
we O +
challenged O +
to O +
assess O +
the O +
combined O +
effects O +
of O +
the O +
two O +
most O +
cytotoxic O +
cocktails O +
by O +
comparing O +
the O +
measured O +
effects O +
of O +
the O +
mixtures O +
with O +
the O +
predictions O +
based O +
on O +
additive O +
effects O +
on O +
two O +
concepts O -
- O -
independent O +
action O +
( O -
IA O -
) O +
and O +
concentration O +
addition O +
( O -
CA O -
) O -
. O +

For O +
the O +
cocktail O +
composed O +
of O +
dichlorodiphenyltrichloroethane B-Chemical +
( O -
DDT B-Chemical -
) O +
and O +
dieldrin B-Chemical -
, O +
the O +
cytotoxicity O +
of O +
the O +
equimolar O +
cocktail O +
proved O +
greater O +
than O +
the O +
additive O +
effect O +
estimated O +
by O +
the O +
two O +
concepts O -
. O +

Furthermore O -
, O +
apoptosis O +
induction O +
was O +
higher O +
in O +
equimolar O +
cocktail O +
than O +
predicted O +
by O +
summing O +
the O +
effects O +
of O +
DDT B-Chemical +
and O +
dieldrin B-Chemical -
. O +

Thus O -
, O +
some O +
supra O -
- O -
additive O +
toxicity O +
was O +
found O +
in O +
the O +
DDT B-Chemical -
- O -
dieldrin B-Chemical +
cocktail O -
. O +

Nevertheless O -
, O +
if O +
IA O +
and O +
CA O +
models O +
could O +
reveal O +
combined O +
effects O +
of O +
pesticide O +
cocktails O -
, O +
an O +
accurate O +
evaluation O +
remains O +
challenging O -
. O +

Identification O -
, O +
characterization O -
, O +
and O +
isolation O +
of O +
a O +
common O +
progenitor O +
for O +
osteoclasts O -
, O +
macrophages O -
, O +
and O +
dendritic O +
cells O +
from O +
murine O +
bone O +
marrow O +
and O +
periphery O -
. O +

Osteoclasts O +
are O +
specialized O +
bone O -
- O -
resorbing O +
cells O +
that O +
derive O +
from O +
monocyte O +
precursors O -
. O +

We O +
have O +
identified O +
three O +
populations O +
of O +
cells O +
with O +
high O +
osteoclastogenic O +
potential O +
in O +
murine O +
bone O +
marrow O -
, O +
which O +
expressed O +
the O +
phenotype O +
B220 O -
( O -
- O -
) O +
CD3 O -
( O -
- O -
) O +
CD11b O -
( O -
- O -
/ O -
low O -
) O +
CD115 O -
( O -
+ O -
) O +
and O +
either O +
CD117 O -
( O -
hi O -
) O +
, O +
CD117 O -
( O -
intermediate O -
) O +
, O +
or O +
CD117 O -
( O -
low O -
) O +
. O +

We O +
have O +
evaluated O +
these O +
populations O +
for O +
their O +
ability O +
to O +
also O +
generate O +
macrophages O +
and O +
dendritic O +
cells O -
. O +

At O +
a O +
single O -
- O -
cell O +
level O -
, O +
the O +
population O +
expressing O +
higher O +
CD117 O +
levels O +
was O +
able O +
to O +
generate O +
bone O -
- O -
resorbing O +
osteoclasts O -
, O +
phagocytic O +
macrophages O -
, O +
and O +
antigen O -
- O -
presenting O +
dendritic O +
cells O +
in O +
vitro O +
with O +
efficiencies O +
of O +
more O +
than O +
90 O -
% O -
, O +
indicating O +
that O +
there O +
exists O +
a O +
common O +
developmental O +
pathway O +
for O +
these O +
cell O +
types O -
. O +

Cells O +
with O +
osteoclastogenic O +
potential O +
also O +
exist O +
in O +
blood O +
and O +
peripheral O +
hematopoietic O +
organs O -
. O +

Their O +
functional O +
meaning O +
and/or O +
their O +
relationship O +
with O +
bone O +
marrow O +
progenitors O +
is O +
not O +
well O +
established O -
. O +

Hence O -
, O +
we O +
characterized O +
murine O +
peripheral O +
cell O +
populations O +
for O +
their O +
ability O +
to O +
form O +
osteoclasts O -
, O +
macrophages O -
, O +
and O +
dendritic O +
cells O +
in O +
vitro O -
. O +

The O +
spleen O +
and O +
peripheral O +
blood O +
monocyte O +
progenitors O +
share O +
phenotypic O +
markers O +
with O +
bone O +
marrow O +
progenitors O +
but O +
differ O +
in O +
their O +
expression O +
of O +
CD11b O -
, O +
which O +
was O +
low O +
in O +
bone O +
marrow O +
but O +
high O +
in O +
periphery O -
. O +

We O +
propose O +
that O +
circulating O +
monocyte O +
progenitors O +
are O +
derived O +
from O +
a O +
common O +
bone O +
marrow O +
osteoclasts O -
/ O -
macrophage O -
/ O -
dendritic O +
cell O +
progenitor O +
( O -
OcMDC O -
) O -
, O +
which O +
we O +
have O +
now O +
characterized O +
at O +
a O +
clonal O +
level O -
. O +

However O -
, O +
the O +
lineage O +
relationship O +
between O +
the O +
bone O +
marrow O +
and O +
peripheral O +
monocyte O +
progenitors O +
has O +
yet O +
to O +
be O +
defined O -
. O +

© O +
2013 O +
American O +
Society O +
for O +
Bone O +
and O +
Mineral O +
Research O -
. O +

Fabrication O +
of O +
3-dimensional O +
cellular O +
constructs O +
via O +
microstereolithography O +
using O +
a O +
simple O -
, O +
three O -
- O -
component O -
, O +
poly B-Chemical -
( I-Chemical -
ethylene I-Chemical +
glycol I-Chemical -
) I-Chemical +
acrylate I-Chemical -
- O -
based O +
system O -
. O +

A O +
novel O +
method O +
for O +
the O +
production O +
of O +
inhibitor- O +
and O +
solvent O -
- O -
free O +
resins O +
suitable O +
for O +
three O -
- O -
dimensional O +
( O -
3D O -
) O +
microstereolithography O +
is O +
reported O -
. O +

Using O +
an O +
exemplar O +
poly B-Chemical -
( I-Chemical -
ethylene I-Chemical +
glycol I-Chemical -
) I-Chemical -
-based O +
resin O -
, O +
the O +
control O +
of O +
features O +
in O +
the O +
X O -
, O +
Y O -
, O +
and O +
Z O +
planes O +
is O +
demonstrated O +
such O +
that O +
complex O +
structures O +
can O +
be O +
manufactured O -
. O +

Human O +
mesenchymal O +
stem O +
cells O +
cultured O +
on O +
the O +
manufactured O +
scaffolds O +
remained O +
viable O +
during O +
the O +
7 O +
day O +
assessment O +
period O -
, O +
with O +
proliferation O +
rates O +
comparable O +
to O +
those O +
observed O +
on O +
tissue O +
culture O +
polystyrene B-Chemical -
. O +

These O +
data O +
suggest O +
that O +
this O +
novel O -
, O +
yet O +
simple O -
, O +
method O +
is O +
suitable O +
for O +
the O +
production O +
of O +
3D O +
scaffolds O +
for O +
tissue O +
engineering O +
and O +
regenerative O +
medicine O +
applications O -
. O +

8,8-dialkyldihydroberberines B-Chemical +
with O +
potent O +
antiprotozoal O +
activity O -
. O +

Semisynthetic O +
8,8-dialkyldihydroberberines B-Chemical +
( O -
8,8-DDBs B-Chemical -
) O +
were O +
found O +
to O +
possess O +
mid- O +
to O +
low O -
- O -
nanomolar O +
potency O +
against O +
Plasmodium O +
falciparum O +
blood O -
- O -
stage O +
parasites O -
, O +
Leishmania O +
donovani O +
intracellular O +
amastigotes O -
, O +
and O +
Trypanosoma O +
brucei O +
brucei O +
bloodstream O +
forms O -
. O +

For O +
example O -
, O +
8,8-diethyldihydroberberine B-Chemical +
chloride I-Chemical +
( O -
5b O -
) O +
exhibited O +
in O +
vitro O +
IC50 O +
values O +
of O +
77 O -
, O +
100 O -
, O +
and O +
5.3 O +
nM O +
against O +
these O +
three O +
parasites O -
, O +
respectively O -
. O +

In O +
turn O -
, O +
two O +
8,8-dialkylcanadines B-Chemical -
, O +
obtained O +
by O +
reduction O +
of O +
the O +
corresponding O +
8,8-DDBs B-Chemical -
, O +
were O +
much O +
less O +
potent O +
against O +
these O +
parasites O +
in O +
vitro O -
. O +

While O +
the O +
natural O +
product O +
berberine O +
is O +
a O +
weak O +
DNA O +
binder O -
, O +
the O +
8,8-DDBs B-Chemical +
displayed O +
no O +
affinity O +
for O +
DNA O -
, O +
as O +
assessed O +
by O +
changes O +
in O +
the O +
melting O +
temperature O +
of O +
poly B-Chemical -
( I-Chemical -
dA·dT I-Chemical -
) I-Chemical +
DNA O -
. O +

Selected O +
8,8-DDBs B-Chemical +
showed O +
efficacy O +
in O +
mouse O +
models O +
of O +
visceral O +
leishmaniasis O +
and O +
African O +
trypanosomiasis O -
, O +
with O +
8,8-dimethyldihydroberberine B-Chemical +
chloride I-Chemical +
( O -
5a O -
) O +
reducing O +
liver O +
parasitemia O +
by O +
46 O -
% O +
in O +
L. O +
donovani O -
- O -
infected O +
BALB O -
/ O -
c O +
mice O +
when O +
given O +
at O +
an O +
intraperitoneal O +
dose O +
of O +
10 O +
mg O -
/ O -
kg O -
/ O -
day O +
for O +
five O +
days O -
. O +

The O +
8,8-DDBs O +
may O +
thus O +
serve O +
as O +
leads O +
for O +
discovering O +
new O +
antimalarial O -
, O +
antileishmanial O -
, O +
and O +
antitrypanosomal O +
drug O +
candidates O -
. O +

Stiripentol B-Chemical +
is O +
anticonvulsant O +
by O +
potentiating O +
GABAergic O +
transmission O +
in O +
a O +
model O +
of O +
benzodiazepine B-Chemical -
- O -
refractory O +
status O +
epilepticus O -
. O +

Benzodiazepines B-Chemical +
( O -
BZDs B-Chemical -
) O +
are O +
first O -
- O -
line O +
therapy O +
for O +
treatment O +
of O +
status O +
epilepticus O +
( O -
SE O -
) O -
. O +

However O -
, O +
BZD B-Chemical +
treatment O +
is O +
negatively O +
affected O +
by O +
seizure O +
duration O +
due O +
to O +
decreases O +
in O +
BZD B-Chemical -
- O -
sensitive O +
GABA O -
( O -
A O -
) O +
receptors O +
during O +
prolonged O +
SE O -
. O +

Stiripentol B-Chemical +
( O -
STP B-Chemical -
) O +
is O +
an O +
anticonvulsant O +
that O +
is O +
used O +
as O +
add O -
- O -
on O +
treatment O +
for O +
Dravet O +
Syndrome O -
. O +

Recent O +
studies O +
have O +
shown O +
that O +
STP B-Chemical +
is O +
a O +
positive O +
allosteric O +
modulator O +
of O +
the O +
GABA O -
( O -
A O -
) O +
receptor O -
. O +

The O +
subunit O +
selectivity O +
of O +
STP B-Chemical +
at O +
this O +
receptor O +
suggests O +
that O +
it O +
would O +
be O +
anticonvulsant O +
in O +
both O +
brief O +
as O +
well O +
as O +
prolonged O +
SE O -
. O +

We O +
tested O +
this O +
possibility O +
by O +
comparing O +
the O +
ability O +
of O +
STP B-Chemical +
and O +
diazepam B-Chemical +
( O -
DZP B-Chemical -
) O -
, O +
a O +
commonly O +
used O +
BZD B-Chemical -
, O +
to O +
terminate O +
behavioral O +
convulsions O +
in O +
a O +
rodent O +
model O +
of O +
pharmacoresistant O +
SE O -
. O +

We O +
found O +
that O +
STP B-Chemical +
was O +
anticonvulsant O +
in O +
this O +
model O +
and O +
remained O +
effective O +
during O +
prolonged O +
SE O -
, O +
unlike O +
DZP B-Chemical +
which O +
exhibited O +
a O +
14 O +
fold O +
increase O +
in O +
its O +
ED O -
( O -
50 O -
) O -
. O +

Whole O +
cell O +
recording O +
from O +
hippocampal O +
slices O +
from O +
these O +
animals O +
revealed O +
that O +
STP B-Chemical +
potentiated O +
GABAergic O +
IPSCs O -
, O +
as O +
well O +
as O +
tonic O +
GABAergic O +
current O +
by O +
acting O +
at O +
a O +
site O +
on O +
the O +
GABA O -
( O -
A O -
) O +
receptor O +
separate O +
from O +
the O +
BDZ B-Chemical +
binding O +
site O -
. O +

Potentiation O +
of O +
GABAergic O +
currents O +
by O +
STP B-Chemical +
remained O +
intact O +
during O +
prolonged O +
SE O -
, O +
while O +
potentiation O +
by O +
DZP B-Chemical +
was O +
lost O -
. O +

Both O +
IPSC O +
potentiation O +
and O +
anticonvulsant O +
activity O +
of O +
STP B-Chemical +
were O +
greater O +
in O +
younger O +
animals O +
than O +
in O +
adults O -
. O +

These O +
findings O +
suggest O +
that O +
at O +
doses O +
that O +
yield O +
therapeutically O +
relevant O +
concentrations O -
, O +
STP B-Chemical +
is O +
anticonvulsant O +
by O +
potentiating O +
GABAergic O +
inhibition O +
and O +
that O +
the O +
subunit O +
selectivity O +
profile O +
of O +
STP B-Chemical +
enables O +
it O +
to O +
remain O +
effective O +
despite O +
GABA O -
( O -
A O -
) O +
receptor O +
subunit O +
changes O +
during O +
prolonged O +
SE O -
. O +

Regulation O +
of O +
serotonin B-Chemical +
( O -
5-HT B-Chemical -
) O +
function O +
by O +
a O +
VGLUT1 O +
dependent O +
glutamate B-Chemical +
pathway O -
. O +

Unraveling O +
the O +
mechanisms O +
of O +
5-HT B-Chemical +
neuron O +
control O +
might O +
provide O +
new O +
insights O +
into O +
depression O +
pathophysiology O -
. O +

In O +
addition O +
to O +
the O +
inhibitory O +
5-HT1A O +
autoreceptors O -
, O +
cortico O -
- O -
raphe O +
glutamatergic O +
descending O +
pathways O +
are O +
suggested O +
to O +
modulate O +
5-HT B-Chemical +
activity O +
in O +
the O +
DRN O -
. O +

Here O +
we O +
studied O +
how O +
decreased O +
VGLUT1 O +
levels O +
in O +
the O +
brain O +
stem O +
affect O +
glutamate B-Chemical +
regulation O +
of O +
5-HT B-Chemical +
function O -
. O +

VGLUT1+ O -
/ O -
- O +
mice O +
( O -
C57BL O -
/ O -
6 O -
) O +
and O +
wild O +
type O +
( O -
WT O -
) O +
littermates O +
were O +
used O -
. O +

VGLUT1 O +
expression O +
in O +
the O +
DRN O -
, O +
5-HT B-Chemical +
turnover O +
and O +
immuno O +
histochemical O +
analysis O +
of O +
neuronal O +
activity O +
in O +
different O +
areas O +
was O +
studied O -
. O +

Moreover O -
, O +
the O +
functionality O +
of O +
the O +
inhibitory O +
5-HT1A O +
autoreceptor O +
was O +
assessed O +
using O +
electrophysiological O -
, O +
biochemical O +
and O +
pharmacological O +
approaches O -
. O +

VGLUT1 O +
immunoreactivity O +
was O +
markedly O +
lower O +
in O +
the O +
DRN O +
of O +
the O +
VGLUT1+ O -
/ O -
- O +
mice O +
and O +
specifically O -
, O +
in O +
the O +
surroundings O +
of O +
GABA B-Chemical +
and O +
5-HT B-Chemical +
cell O +
bodies O -
. O +

These O +
mice O +
showed O +
decreased O +
induced O +
neuronal O +
activity O +
in O +
5-HT B-Chemical +
cells O +
bodies O +
and O +
in O +
different O +
forebrain O +
areas O -
, O +
as O +
well O +
as O +
decreased O +
hippocampal O +
cell O +
proliferation O +
and O +
5-HT B-Chemical +
turnover O -
. O +

Further O -
, O +
5-HT1A O +
autoreceptor O +
desensitization O +
was O +
evidenced O +
by O +
electrophysiological O +
studies O -
, O +
GTP B-Chemical -
- I-Chemical -
γ I-Chemical -
- I-Chemical -
S I-Chemical +
coupling O +
to O +
5-HT1A O +
autoreceptor O +
and O +
a O +
lower O +
hypothermic O +
response O +
to O +
5-HT1A O +
activation O -
. O +

This O +
study O +
shows O +
first O +
time O +
that O +
VGLUT1 O +
dependent O +
glutamate B-Chemical +
innervation O +
of O +
the O +
DRN O +
could O +
modulate O +
5-HT B-Chemical +
function O -
. O +

Solid O -
- O -
state O +
NMR O +
studies O +
of O +
micelle O -
- O -
templated O +
mesoporous O +
solids O -
. O +

In O +
this O +
tutorial O +
review O +
we O +
intend O +
to O +
give O +
an O +
overview O +
of O +
the O +
potential O +
of O +
NMR O +
spectroscopy O -
, O +
and O +
in O +
particular O +
solid O -
- O -
state O +
NMR O -
, O +
in O +
characterising O +
micelle O -
- O -
templated O +
mesoporous O +
materials O -
. O +

Different O +
topics O +
are O +
covered O +
including O +
the O +
study O +
of O +
formation O +
mechanisms O -
, O +
the O +
characterisation O +
of O +
structures O -
, O +
textures O -
, O +
surfaces O +
and O +
interfaces O -
, O +
functionalisation O -
, O +
dynamic O +
properties O +
and O +
structure O -
- O -
reactivity O +
correlations O -
. O +

Some O +
selected O +
examples O +
illustrate O +
the O +
variety O +
of O +
information O +
provided O +
by O +
this O +
spectroscopy O -
. O +

Particular O +
attention O +
is O +
paid O +
to O +
recent O +
technological O +
and/or O +
methodological O +
developments O -
. O +

Metabolism O +
and O +
pharmacokinetics O +
of O +
3-n B-Chemical -
- I-Chemical -
butylphthalide I-Chemical +
( O -
NBP B-Chemical -
) O +
in O +
humans O -
: O +
the O +
role O +
of O +
cytochrome O +
P450s O +
and O +
alcohol B-Chemical +
dehydrogenase O +
in O +
biotransformation O -
. O +

3-n B-Chemical -
- I-Chemical -
Butylphthalide I-Chemical +
( O -
NBP B-Chemical -
) O +
is O +
a O +
cardiovascular O +
drug O +
currently O +
used O +
for O +
the O +
treatment O +
of O +
cerebral O +
ischemia O -
. O +

The O +
present O +
study O +
aims O +
to O +
investigate O +
the O +
metabolism O -
, O +
pharmacokinetics O -
, O +
and O +
excretion O +
of O +
NBP B-Chemical +
in O +
humans O +
and O +
identify O +
the O +
enzymes O +
responsible O +
for O +
the O +
formation O +
of O +
major O +
metabolites O -
. O +

NBP B-Chemical +
underwent O +
extensive O +
metabolism O +
after O +
an O +
oral O +
administration O +
of O +
200 O +
mg O +
NBP B-Chemical +
and O +
23 O +
metabolites O +
were O +
identified O +
in O +
human O +
plasma O +
and O +
urine O -
. O +

Principal O +
metabolic O +
pathways O +
included O +
hydroxylation O +
on O +
alkyl B-Chemical +
side O +
chain O -
, O +
particularly O +
at O +
3- B-Chemical -
, I-Chemical +
ω-1- I-Chemical -
, I-Chemical +
and I-Chemical +
ω I-Chemical -
- I-Chemical -
carbons I-Chemical -
, O +
and O +
further O +
oxidation O +
and O +
conjugation O -
. O +

Approximately O +
81.6 O -
% O +
of O +
the O +
dose O +
was O +
recovered O +
in O +
urine O -
, O +
mainly O +
as O +
NBP-11-oic B-Chemical +
acid I-Chemical +
( O -
M5 O -
- O -
2 O -
) O +
and O +
glucuronide O +
conjugates O +
of O +
M5 O -
- O -
2 O +
and O +
mono O -
- O -
hydroxylated O +
products O -
. O +

10-Keto B-Chemical -
- I-Chemical -
NBP I-Chemical +
( O -
M2 O -
) O -
, O +
3-hydroxy B-Chemical -
- I-Chemical -
NBP I-Chemical +
( O -
M3 O -
- O -
1 O -
) O -
, O +
10-hydroxy B-Chemical -
- I-Chemical -
NBP I-Chemical +
( O -
M3 O -
- O -
2 O -
) O -
, O +
and O +
M5 O -
- O -
2 O +
were O +
the O +
major O +
circulating O +
metabolites O -
, O +
wherein O +
the O +
areas O +
under O +
the O +
curve O +
values O +
were O +
1.6- O -
, O +
2.9- O -
, O +
10.3- O -
, O +
and O +
4.1-fold O +
higher O +
than O +
that O +
of O +
NBP B-Chemical -
. O +

Reference O +
standards O +
of O +
these O +
four O +
metabolites O +
were O +
obtained O +
through O +
microbial O +
biotransformation O +
by O +
Cunninghamella O +
blakesleana O -
. O +

In O +
vitro O +
phenotyping O +
studies O +
demonstrated O +
that O +
multiple O +
cytochrome O +
P450 O +
( O -
P450 O -
) O +
isoforms O -
, O +
especially O +
CYP3A4 O -
, O +
2E1 O -
, O +
and O +
1A2 O -
, O +
were O +
involved O +
in O +
the O +
formation O +
of O +
M3 O -
- O -
1 O -
, O +
M3 O -
- O -
2 O -
, O +
and O +
11-hydroxy B-Chemical -
- I-Chemical -
NBP I-Chemical -
. O +

Using O +
M3 O -
- O -
2 O +
and O +
11-hydroxy B-Chemical -
- I-Chemical -
NBP I-Chemical +
as O +
substrates O -
, O +
human O +
subcellular O +
fractions O +
experiments O +
revealed O +
that O +
P450 O -
, O +
alcohol B-Chemical +
dehydrogenase O -
, O +
and O +
aldehyde B-Chemical +
dehydrogenase O +
catalyzed O +
the O +
generation O +
of O +
M2 O +
and O +
M5 O -
- O -
2 O -
. O +

Formation O +
of O +
M5 O -
- O -
2 O +
was O +
much O +
faster O +
than O +
that O +
of O +
M2 O -
, O +
and O +
M5 O -
- O -
2 O +
can O +
undergo O +
β O -
- O -
oxidation O +
to O +
yield O +
phthalide-3-acetic B-Chemical +
acid I-Chemical +
in O +
rat O +
liver O +
homogenate O -
. O +

Overall O -
, O +
our O +
study O +
demonstrated O +
that O +
NBP B-Chemical +
was O +
well O +
absorbed O +
and O +
extensively O +
metabolized O +
by O +
multiple O +
enzymes O +
to O +
various O +
metabolites O +
prior O +
to O +
urinary O +
excretion O -
. O +

Pharmacokinetics O -
, O +
metabolism O -
, O +
and O +
excretion O +
of O +
the O +
antidiabetic O +
agent O +
ertugliflozin B-Chemical +
( O -
PF-04971729 B-Chemical -
) O +
in O +
healthy O +
male O +
subjects O -
. O +

The O +
disposition O +
of O +
ertugliflozin B-Chemical +
( O -
PF-04971729 B-Chemical -
) O -
, O +
an O +
orally O +
active O +
selective O +
inhibitor O +
of O +
the O +
sodium B-Chemical -
- O -
dependent O +
glucose B-Chemical +
cotransporter O +
2 O -
, O +
was O +
studied O +
after O +
a O +
single O +
25-mg O +
oral O +
dose O +
of O +
[ B-Chemical -
( I-Chemical -
14 I-Chemical -
) I-Chemical -
C I-Chemical -
] I-Chemical -
-ertugliflozin I-Chemical +
to O +
healthy O +
human O +
subjects O -
. O +

Mass O +
balance O +
was O +
achieved O +
with O +
approximately O +
91 O -
% O +
of O +
the O +
administered O +
dose O +
recovered O +
in O +
urine O +
and O +
feces O -
. O +

The O +
total O +
administered O +
radioactivity O +
excreted O +
in O +
feces O +
and O +
urine O +
was O +
40.9 O -
% O +
and O +
50.2 O -
% O -
, O +
respectively O -
. O +

The O +
absorption O +
of O +
ertugliflozin B-Chemical +
in O +
humans O +
was O +
rapid O +
with O +
a O +
T O -
( O -
max O -
) O +
at O +
∼1.0 O +
hour O -
. O +

Of O +
the O +
total O +
radioactivity O +
excreted O +
in O +
feces O +
and O +
urine O -
, O +
unchanged O +
ertugliflozin B-Chemical +
collectively O +
accounted O +
for O +
∼35.3 O -
% O +
of O +
the O +
dose O -
, O +
suggestive O +
of O +
moderate O +
metabolic O +
elimination O +
in O +
humans O -
. O +

The O +
principal O +
biotransformation O +
pathway O +
involved O +
glucuronidation O +
of O +
the O +
glycoside O +
hydroxyl B-Chemical +
groups O +
to O +
yield O +
three O +
regioisomeric O +
metabolites O -
, O +
M4a O -
, O +
M4b O -
, O +
and O +
M4c O +
( O -
∼39.3 O -
% O +
of O +
the O +
dose O +
in O +
urine O -
) O -
, O +
of O +
which O +
M4c O +
was O +
the O +
major O +
regioisomer O +
( O -
∼31.7 O -
% O +
of O +
the O +
dose O -
) O -
. O +

The O +
structure O +
of O +
M4a O +
and O +
M4c O +
were O +
confirmed O +
to O +
be O +
ertugliflozin B-Chemical +
-4-O I-Chemical -
- I-Chemical -
β- I-Chemical +
and I-Chemical +
-3-O I-Chemical -
- I-Chemical -
β I-Chemical -
- I-Chemical -
glucuronide I-Chemical -
, O +
respectively O -
, O +
via O +
comparison O +
of O +
the O +
HPLC O +
retention O +
time O +
and O +
mass O +
spectra O +
with O +
authentic O +
standards O -
. O +

A O +
minor O +
metabolic O +
fate O +
involved O +
oxidation O +
by O +
cytochrome O +
P450 O +
to O +
yield O +
monohydroxylated O +
metabolites O +
M1 O +
and O +
M3 O +
and O +
des B-Chemical -
- I-Chemical -
ethyl I-Chemical +
ertugliflozin I-Chemical +
( O -
M2 O -
) O -
, O +
which O +
accounted O +
for O +
∼5.2 O -
% O +
of O +
the O +
dose O +
in O +
excreta O -
. O +

In O +
plasma O -
, O +
unchanged O +
ertugliflozin B-Chemical +
and O +
the O +
corresponding O +
4-O O -
- O -
β- O +
( O -
M4a O -
) O +
and O +
3-O O -
- O -
β- O +
( O -
M4c O -
) O +
glucuronides O +
were O +
the O +
principal O +
components O -
, O +
which O +
accounted O +
for O +
49.9 O -
, O +
12.2 O -
, O +
and O +
24.1 O -
% O +
of O +
the O +
circulating O +
radioactivity O -
. O +

Overall O -
, O +
these O +
data O +
suggest O +
that O +
ertugliflozin O +
is O +
well O +
absorbed O +
in O +
humans O -
, O +
and O +
eliminated O +
largely O +
via O +
glucuronidation O -
. O +

The O +
role O +
of O +
cytochrome O +
P450-dependent O +
metabolism O +
in O +
the O +
regulation O +
of O +
mouse O +
hepatic O +
growth O +
hormone O +
signaling O +
components O +
and O +
target O +
genes O +
by O +
3-methylcholanthrene B-Chemical -
. O +

3-Methylcholanthrene B-Chemical +
( O -
MC O -
) O +
is O +
a O +
readily O +
metabolized O +
aryl B-Chemical +
hydrocarbon I-Chemical +
receptor O +
( O -
AHR O -
) O +
agonist O -
. O +

MC O +
disrupts O +
expression O +
of O +
mouse O +
hepatic O +
growth O +
hormone O +
( O -
GH O -
) O +
signaling O +
components O +
and O +
suppresses O +
cytochrome O +
P450 O +
2D9 O +
( O -
Cyp2d9 O -
) O -
, O +
a O +
male O -
- O -
specific O +
gene O +
controlled O +
by O +
pulsatile O +
GH O +
via O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
5b O +
( O -
STAT5b O -
) O -
. O +

To O +
determine O +
if O +
these O +
effects O +
of O +
MC O +
depend O +
on O +
hepatic O +
microsomal O +
P450-mediated O +
activity O -
, O +
we O +
examined O +
biologic O +
responses O +
to O +
MC O +
treatment O +
in O +
liver O +
Cpr O -
- O -
null O +
( O -
LCN O -
) O +
mice O +
with O +
hepatocyte O -
- O -
specific O +
conditional O +
deletion O +
of O +
NADPH B-Chemical -
- O -
cytochrome O +
P450 O +
oxidoreductase O +
( O -
POR O -
) O -
. O +

MC O +
caused O +
mild O +
induction O +
of O +
Por O +
and O +
a O +
hepatic O +
inflammatory O +
marker O +
in O +
wild O -
- O -
type O +
mice O -
, O +
whereas O +
MC O +
caused O +
strong O +
induction O +
of O +
AHR O +
target O +
genes O -
, O +
Cyp1a1 O -
, O +
Cyp1a2 O -
, O +
and O +
Cyp1b1 O +
in O +
wild O -
- O -
type O +
and O +
LCN O +
mice O -
. O +

Two O +
mouse O +
hepatic O +
STAT5b O +
target O +
genes O -
, O +
Cyp2d9 O +
and O +
major O +
urinary O +
protein O +
2 O +
( O -
Mup2 O -
) O -
, O +
were O +
suppressed O +
by O +
MC O +
in O +
wild O -
- O -
type O +
mice O -
, O +
and O +
the O +
CYP2D9 O +
mRNA O +
response O +
was O +
maintained O +
in O +
LCN O +
mice O -
. O +

In O +
wild O -
- O -
type O +
mice O +
only O -
, O +
MC O +
decreased O +
hepatic O +
GH O +
receptor O +
( O -
GHR O -
) O +
mRNA O +
but O +
increased O +
GHR O +
protein O +
levels O -
. O +

There O +
was O +
an O +
apparent O +
impairment O +
of O +
STAT5 O +
phosphorylation O +
by O +
MC O +
in O +
wild O -
- O -
type O +
and O +
LCN O +
mice O -
, O +
but O +
large O +
interanimal O +
variation O +
prevented O +
achievement O +
of O +
statistical O +
significance O -
. O +

In O +
vehicle O -
- O -
treated O +
mice O -
, O +
basal O +
levels O +
of O +
MUP2 O +
mRNA O -
, O +
GHR O +
mRNA O -
, O +
GHR O +
protein O -
, O +
and O +
the O +
activation O +
status O +
of O +
extracellular O +
signal O -
- O -
regulated O +
kinase O +
2 O +
and O +
Akt O +
were O +
influenced O +
by O +
hepatic O +
Por O +
genetic O +
status O -
. O +

These O +
results O +
indicate O +
that O +
the O +
effects O +
of O +
MC O +
on O +
hepatic O +
GH O +
signaling O +
components O +
and O +
target O +
genes O +
are O +
complex O -
, O +
involving O +
aspects O +
that O +
are O +
both O +
dependent O +
and O +
independent O +
of O +
hepatic O +
microsomal O +
P450-mediated O +
activity O -
. O +

High O +
electrochemical O +
performance O +
based O +
on O +
ultrathin O +
porous O +
CuO B-Chemical +
nanobelts O +
grown O +
on O +
Cu B-Chemical +
substrate O +
as O +
integrated O +
electrode O -
. O +

A O +
facile O +
and O +
low O -
- O -
cost O +
approach O +
has O +
been O +
developed O +
to O +
fabricate O +
porous O +
CuO B-Chemical +
nanobelts O +
directly O +
grown O +
on O +
a O +
Cu B-Chemical +
substrate O -
. O +

The O +
as O -
- O -
prepared O +
CuO B-Chemical +
samples O +
can O +
be O +
directly O +
used O +
as O +
integrated O +
electrodes O +
for O +
lithium B-Chemical -
- O -
ion O +
batteries O +
and O +
pseudo O -
- O -
supercapacitors O +
without O +
the O +
addition O +
of O +
other O +
ancillary O +
materials O +
such O +
as O +
carbon B-Chemical +
black I-Chemical +
or O +
a O +
binder O +
to O +
enhance O +
electrode O +
conductivity O +
and O +
cycling O +
stability O -
. O +

The O +
unique O +
nanostructural O +
features O +
endow O +
them O +
with O +
excellent O +
electrochemical O +
performance O +
as O +
demonstrated O +
by O +
high O +
capacities O +
of O +
640 O +
mA O +
h O +
g O -
( O -
-1 O -
) O +
after O +
100 O +
cycles O +
at O +
0.2 O +
C O +
rate O +
and O +
an O +
excellent O +
specific O +
capacitance O +
of O +
340 O +
F O +
g O -
( O -
-1 O -
) O -
, O +
which O +
corresponds O +
to O +
the O +
energy O +
density O +
of O +
45 O +
W O +
h O +
kg O -
( O -
-1 O -
) O -
. O +

The O +
cyclability O +
of O +
the O +
electrode O +
demonstrates O +
only O +
a O +
10 O -
- O -
15 O -
% O +
loss O +
in O +
capacitance O +
over O +
5000 O +
cycles O -
. O +

Xenobiotic O +
receptor O +
humanized O +
mice O +
and O +
their O +
utility O -
. O +

The O +
nuclear O +
receptors O +
pregnane O +
X O +
receptor O -
, O +
constitutive O +
androstane B-Chemical +
receptor O -
, O +
and O +
peroxisome O +
proliferator O -
- O -
activated O +
receptor O +
alpha O +
have O +
important O +
endogenous O +
functions O +
and O +
are O +
also O +
involved O +
in O +
the O +
induction O +
of O +
drug O -
- O -
metabolizing O +
enzymes O +
and O +
transporters O +
in O +
response O +
to O +
exogenous O +
xenobiotics O -
. O +

Though O +
not O +
belonging O +
to O +
the O +
same O +
protein O +
family O -
, O +
the O +
Per O -
- O -
Sim O -
- O -
ARNT O +
domain O +
receptor O +
aryl B-Chemical +
hydrocarbon I-Chemical +
receptor O +
functionally O +
overlaps O +
with O +
the O +
three O +
nuclear O +
receptors O +
in O +
many O +
aspects O +
and O +
is O +
therefore O +
included O +
in O +
this O +
review O -
. O +

Significant O +
species O +
differences O +
in O +
ligand O +
affinity O +
and O +
biological O +
responses O +
as O +
a O +
result O +
of O +
activation O +
of O +
these O +
receptors O +
have O +
been O +
described O -
. O +

Several O +
xenobiotic O +
receptor O +
humanized O +
mice O +
have O +
been O +
created O +
to O +
overcome O +
these O +
species O +
differences O +
and O +
to O +
provide O +
in O +
vivo O +
models O +
that O +
are O +
more O +
predictive O +
for O +
human O +
responses O -
. O +

This O +
review O +
provides O +
an O +
overview O +
of O +
the O +
different O +
xenobiotic O +
receptor O +
humanized O +
mouse O +
models O +
described O +
to O +
date O +
and O +
will O +
summarize O +
how O +
these O +
models O +
can O +
be O +
applied O +
in O +
basic O +
research O +
and O +
improve O +
drug O +
discovery O +
and O +
development O -
. O +

Some O +
of O +
the O +
key O +
applications O +
in O +
the O +
evaluation O +
of O +
drug O +
induction O -
, O +
drug O -
- O -
drug O +
interactions O -
, O +
nongenotoxic O +
carcinogenicity O -
, O +
other O +
toxicity O -
, O +
or O +
efficacy O +
studies O +
are O +
described O -
. O +

We O +
also O +
discuss O +
relevant O +
considerations O +
in O +
the O +
interpretation O +
of O +
such O +
data O +
and O +
potential O +
future O +
directions O +
for O +
the O +
use O +
of O +
xenobiotic O +
receptor O +
humanized O +
mice O -
. O +

The O +
relationship O +
between O +
carotid O +
intima O -
- O -
media O +
thickness O +
and O +
endogenous O +
androgens B-Chemical +
in O +
young O +
women O +
with O +
polycystic O +
ovary O +
syndrome O +
in O +
Taiwan O -
. O +

Polycystic O +
ovary O +
syndrome O +
( O -
PCOS O -
) O +
is O +
a O +
common O +
and O +
complex O +
female O +
endocrinopathy O +
that O +
is O +
associated O +
with O +
multiple O +
vascular O +
risk O +
factors O -
. O +

Our O +
objective O +
was O +
to O +
investigate O +
the O +
relationship O +
between O +
carotid O +
intima O -
- O -
media O +
thickness O +
( O -
CIMT O -
) O +
and O +
endogenous O +
androgens B-Chemical +
in O +
young O +
Taiwanese O -
- O -
Chinese O +
women O +
with O +
PCOS O -
. O +

We O +
measured O +
CIMT O +
with O +
B O -
- O -
mode O +
ultrasound O +
in O +
42 O +
young O +
PCOS O +
patients O +
and O +
43 O +
controls O -
. O +

Atherosclerosis O -
- O -
associated O +
profiles O +
and O +
endocrinological O +
parameters O +
were O +
also O +
measured O -
. O +

The O +
results O +
showed O +
that O +
although O +
Taiwanese O -
- O -
Chinese O +
PCOS O +
patients O +
tend O +
to O +
possess O +
more O +
risk O +
factors O +
for O +
atherosclerosis O +
than O +
controls O -
, O +
there O +
was O +
no O +
evidence O +
to O +
support O +
that O +
they O +
have O +
a O +
greater O +
CIMT O +
at O +
this O +
age O -
. O +

Furthermore O -
, O +
androstenedione B-Chemical +
appears O +
to O +
be O +
inversely O +
associated O +
with O +
CIMT O -
. O +

Histopathological O +
effects O +
of O +
waterborne O +
copper B-Chemical +
nanoparticles O +
and O +
copper B-Chemical +
sulphate I-Chemical +
on O +
the O +
organs O +
of O +
rainbow O +
trout O +
( O -
Oncorhynchus O +
mykiss O -
) O -
. O +

It O +
is O +
unclear O +
whether O +
copper B-Chemical +
nanoparticles O +
are O +
more O +
toxic O +
than O +
traditional O +
forms O +
of O +
dissolved O +
copper B-Chemical -
. O +

This O +
study O +
aimed O +
to O +
describe O +
the O +
pathologies O +
in O +
gill O -
, O +
gut O -
, O +
liver O -
, O +
kidney O -
, O +
brain O +
and O +
muscle O +
of O +
juvenile O +
rainbow O +
trout O -
, O +
Oncorhynchus O +
mykiss O -
, O +
exposed O +
in O +
triplicate O +
to O +
either O +
a O +
control O +
( O -
no O +
added O +
Cu B-Chemical -
) O -
, O +
20 O +
or O +
100 O +
μg O +
l O -
( O -
-1 O -
) O +
of O +
either O +
dissolved O +
Cu B-Chemical +
( O -
as O +
CuSO B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
) O +
or O +
Cu B-Chemical -
- O -
NPs O +
( O -
mean O +
primary O +
particle O +
size O +
of O +
87 O +
± O +
27 O +
nm O -
) O +
in O +
a O +
semi O -
- O -
static O +
waterborne O +
exposure O +
regime O -
. O +

Fish O +
were O +
sampled O +
at O +
days O +
0 O -
, O +
4 O -
, O +
and O +
10 O +
for O +
histology O -
. O +

All O +
treatments O +
caused O +
organ O +
injuries O -
, O +
and O +
the O +
kinds O +
of O +
pathologies O +
observed O +
with O +
Cu B-Chemical -
- O -
NPs O +
were O +
broadly O +
of O +
the O +
same O +
type O +
as O +
CuSO B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical +
including O -
: O +
hyperplasia O -
, O +
aneurisms O -
, O +
and O +
necrosis O +
in O +
the O +
secondary O +
lamellae O +
of O +
the O +
gills O -
; O +
swelling O +
of O +
goblet O +
cells O -
, O +
necrosis O +
in O +
the O +
mucosa O +
layer O +
and O +
vacuole O +
formation O +
in O +
the O +
gut O -
; O +
hepatitis O -
- O -
like O +
injury O +
and O +
cells O +
with O +
pyknotic O +
nuclei O +
in O +
the O +
liver O -
; O +
damage O +
to O +
the O +
epithelium O +
of O +
some O +
renal O +
tubules O +
and O +
increased O +
Bowman O -
's O +
space O +
in O +
the O +
kidney O -
. O +

In O +
the O +
brain O -
, O +
some O +
mild O +
changes O +
were O +
observed O +
in O +
the O +
nerve O +
cell O +
bodies O +
in O +
the O +
telencephalon O -
, O +
alteration O +
in O +
the O +
thickness O +
of O +
the O +
mesencephalon O +
layers O -
, O +
and O +
enlargement O +
of O +
blood O +
vessel O +
on O +
the O +
ventral O +
surface O +
of O +
the O +
cerebellum O -
. O +

Changes O +
in O +
the O +
proportional O +
area O +
of O +
muscle O +
fibres O +
were O +
observed O +
in O +
skeletal O +
muscle O -
. O +

Overall O +
the O +
data O +
showed O +
that O +
pathology O +
from O +
CuSO B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical +
and O +
Cu B-Chemical -
- O -
NPs O +
were O +
of O +
similar O +
types O -
, O +
but O +
there O +
were O +
some O +
material O -
- O -
type O +
effects O +
in O +
the O +
severity O +
or O +
incidence O +
of O +
injuries O +
with O +
Cu B-Chemical -
- O -
NPs O +
causing O +
more O +
injury O +
in O +
the O +
intestine O -
, O +
liver O +
and O +
brain O +
than O +
the O +
equivalent O +
concentration O +
of O +
CuSO B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical +
by O +
the O +
end O +
of O +
the O +
experiment O -
, O +
but O +
in O +
the O +
gill O +
and O +
muscle O +
CuSO B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical +
caused O +
more O +
pathology O -
. O +

Pharmacological O +
and O +
behavioral O +
characterization O +
of O +
the O +
novel O +
CRF O -
( O -
1 O -
) O +
antagonist O +
BMS-763534 B-Chemical -
. O +

BMS-763534 B-Chemical +
is O +
a O +
potent O +
( O -
CRF O -
( O -
1 O -
) O +
IC O -
( O -
50 O -
) O +
= O +
0.4 O +
nM O -
) O +
and O +
selective O +
( O -
> O -
1000-fold O +
selectivity O +
vs. O +
all O +
other O +
sites O +
tested O -
) O +
CRF O -
( O -
1 O -
) O +
receptor O +
antagonist O +
( O -
pA2 O +
= O +
9.47 O +
vs. O +
CRF O -
( O -
1 O -
) O -
-mediated O +
cAMP B-Chemical +
production O +
in O +
Y79 O +
cells O -
) O -
. O +

BMS-763534 B-Chemical +
accelerated O +
the O +
dissociation O +
of O +
( B-Chemical -
125 I-Chemical -
) I-Chemical -
I I-Chemical -
- O -
o O -
- O -
CRF O +
from O +
rat O +
frontal O +
cortex O +
membrane O +
CRF O -
( O -
1 O -
) O +
receptors O +
consistent O +
with O +
a O +
negative O +
allosteric O +
modulation O +
of O +
CRF O +
binding O -
. O +

BMS-763534 B-Chemical +
produced O +
dose O -
- O -
dependent O +
increases O +
in O +
CRF O -
( O -
1 O -
) O +
receptor O +
occupancy O +
and O +
anxiolytic O +
efficacy O -
; O +
lowest O +
effective O +
anxiolytic O +
dose O +
= O +
0.56 O +
mg O -
/ O -
kg O -
, O +
PO O -
, O +
which O +
was O +
associated O +
with O +
71 O +
± O +
5 O -
% O +
CRF O -
( O -
1 O -
) O +
receptor O +
occupancy O +
of O +
frontoparietal O +
CRF O -
( O -
1 O -
) O +
receptors O -
. O +

Sedative O -
/ O -
ataxic O +
effects O +
of O +
BMS-763534 B-Chemical +
were O +
only O +
observed O +
at O +
high O +
dose O +
multiples O +
( O -
54 O -
- O -
179 O -
× O -
) O +
relative O +
to O +
the O +
lowest O +
dose O +
required O +
for O +
anxiolytic O +
efficacy O -
. O +

At O +
doses O +
of O +
5- O +
to O +
18-fold O +
higher O +
than O +
the O +
lowest O +
efficacious O +
dose O +
in O +
the O +
anxiety O +
assay O -
, O +
BMS-763534 B-Chemical +
shared O +
subjective O +
effects O +
with O +
the O +
benzodiazepine O +
chlordiazepoxide B-Chemical -
. O +

Interestingly O +
BMS-790318 B-Chemical -
, O +
the O +
O O -
- O -
demethylated O +
metabolite O +
of O +
BMS-763534 B-Chemical -
, O +
showed O +
weak O +
affinity O +
for O +
the O +
TBOB B-Chemical +
site O +
of O +
the O +
GABA B-Chemical -
( O -
A O -
) O +
receptor O +
( O -
67 O -
% O +
inhibition O +
at O +
10 O +
μM O -
) O +
and O +
augmented O +
GABA B-Chemical +
evoked O +
currents O +
( O -
EC O -
( O -
50 O -
) O +
= O +
1.6 O +
μM O -
) O -
. O +

Thus O -
, O +
the O +
unanticipated O +
signal O +
in O +
the O +
drug O +
discrimination O +
assay O +
may O +
have O +
resulted O +
from O +
an O +
interaction O +
of O +
the O +
metabolite O +
BMS-790318 B-Chemical +
with O +
the O +
TBOB B-Chemical +
site O +
on O +
the O +
GABA B-Chemical -
( O -
A O -
) O +
channel O +
where O +
it O +
appears O +
to O +
behave O +
as O +
an O +
allosteric O +
potentiator O +
of O +
GABA B-Chemical +
evoked O +
currents O -
. O +

Ginkgo O +
biloba O +
extract O +
attenuates O +
hippocampal O +
neuronal O +
loss O +
and O +
cognitive O +
dysfunction O +
resulting O +
from O +
trimethyltin B-Chemical +
in O +
mice O -
. O +

The O +
present O +
study O +
was O +
an O +
attempt O +
to O +
investigate O +
the O +
neuromodulatory O +
potential O +
of O +
Ginkgo O +
biloba O +
extract O +
( O -
GBE O -
) O +
against O +
hippocamapal O +
structural O +
and O +
functional O +
damages O +
induced O +
by O +
trimethyltin B-Chemical +
( O -
TMT B-Chemical -
) O +
a O +
potent O +
neurotoxicant O -
. O +

Male O +
Balb O -
/ O -
C O +
mice O +
were O +
administered O +
with O +
Ginkgo O +
biloba O +
extract O +
for O +
14 O +
days O +
at O +
a O +
dose O +
of O +
70 O +
mg O -
/ O -
kg O +
body O +
weight O +
interperitoneally O +
and O +
on O +
11-day O +
of O +
treatment O +
animals O +
were O +
exposed O +
to O +
Trimethyltin B-Chemical +
( O -
2.5 O +
mg O -
/ O -
kg O +
b.w O -
) O +
single O +
intraperitoneal O +
injection O -
. O +

The O +
co O -
- O -
administered O +
of O +
TMT B-Chemical +
with O +
GBE O +
showed O +
marked O +
improvement O +
in O +
memory O +
and O +
aggressive O +
behavior O -
. O +

Which O +
were O +
in O +
turn O +
reflected O +
in O +
the O +
levels O +
of O +
serotonin B-Chemical +
and O +
acetylcholine B-Chemical +
esterase O -
. O +

The O +
conjunctive O +
treatment O +
also O +
showed O +
significant O +
decrease O +
in O +
oxidative O +
stress O +
as O +
assessed O +
by O +
MDA B-Chemical +
levels O +
and O +
the O +
antioxidant O +
enzymes O +
( O -
GSH B-Chemical -
, O +
GSSH B-Chemical -
, O +
GPX O -
, O +
total O +
glutathione B-Chemical -
, O +
Catalase O +
and O +
Superoxide B-Chemical +
dismutase O -
) O +
which O +
were O +
depressed O +
by O +
TMT B-Chemical +
treatment O +
was O +
significantly O +
improved O +
by O +
GBE O -
. O +

Correspondingly O -
, O +
induction O +
of O +
Bcl-2 O +
mitochondrial O +
apoptotic O +
pathway O +
by O +
trimethyltin B-Chemical +
was O +
down O +
regulated O +
by O +
Ginkgo O +
biloba O +
treatment O -
. O +

The O +
structural O +
analysis O +
of O +
dentate O +
gyrus O +
revealed O +
improvement O +
in O +
degenerating O +
neurons O +
by O +
treatment O +
with O +
GBE O -
. O +

Therefore O -
, O +
it O +
is O +
suggested O +
that O +
prophylactic O +
treatment O +
of O +
Ginkgo O +
biloba O +
extract O +
protects O +
against O +
the O +
trimethyltin B-Chemical +
induced O +
neurodegenration O +
by O +
multiple O +
mechanism O +
involved O +
in O +
its O +
antioxidant O +
effects O +
and O +
may O +
be O +
useful O +
in O +
developing O +
therapies O +
against O +
neurodegenration O -
. O +

Solubility O -
- O -
pH O +
profiles O +
of O +
some O +
acidic O -
, O +
basic O +
and O +
amphoteric O +
drugs O -
. O +

The O +
solubility O +
vs. O +
pH O +
profiles O +
of O +
five O +
ionizable O +
drugs O +
of O +
different O +
nature O +
( O -
a O +
monoprotic O +
acid O -
, O +
a O +
monoprotic O +
base O -
, O +
a O +
diprotic O +
base O +
and O +
two O +
amphoteric O +
compounds O +
showing O +
a O +
zwitterionic O +
species O +
each O +
one O -
) O +
have O +
been O +
determined O +
through O +
two O +
different O +
methodologies O -
: O +
the O +
classical O +
shake O -
- O -
flask O +
( O -
S O -
- O -
F O -
) O +
and O +
the O +
potentiometric O +
Cheqsol O +
methods O +
using O +
in O +
both O +
instances O +
the O +
appropriate O +
Henderson O -
- O -
Hasselbalch O +
( O -
H O -
- O -
H O -
) O +
or O +
derived O +
relationships O -
. O +

The O +
results O +
obtained O +
independently O +
from O +
both O +
approaches O +
are O +
consistent O -
. O +

A O +
critical O +
revision O +
about O +
the O +
influence O +
of O +
the O +
electrolyte O +
used O +
as O +
buffering O +
agent O +
in O +
the O +
S O -
- O -
F O +
method O +
on O +
the O +
obtained O +
solubility O +
values O +
is O +
also O +
performed O -
. O +

Thus O -
, O +
some O +
deviations O +
of O +
the O +
experimental O +
points O +
with O +
respect O +
the O +
H O -
- O -
H O +
profiles O +
can O +
be O +
attributed O +
to O +
specific O +
interactions O +
between O +
the O +
buffering O +
electrolyte O +
and O +
the O +
drug O +
due O +
to O +
the O +
hydrotrophic O +
character O +
of O +
citric B-Chemical +
and I-Chemical +
lactic I-Chemical +
acids I-Chemical -
. O +

In O +
other O +
cases O -
, O +
the O +
observed O +
deviations O +
are O +
independent O +
of O +
the O +
buffers O +
used O +
since O +
they O +
are O +
caused O +
by O +
the O +
formation O +
of O +
new O +
species O +
such O +
as O +
drug O +
aggregates O +
( O -
cefadroxil B-Chemical -
) O +
or O +
the O +
precipitation O +
of O +
a O +
salt O +
from O +
a O +
cationic O +
species O +
of O +
the O +
analyzed O +
compound O +
( O -
quetiapine B-Chemical -
) O -
. O +

APLF O +
promotes O +
the O +
assembly O +
and O +
activity O +
of O +
non O -
- O -
homologous O +
end O +
joining O +
protein O +
complexes O -
. O +

Non O -
- O -
homologous O +
end O +
joining O +
( O -
NHEJ O -
) O +
is O +
critical O +
for O +
the O +
maintenance O +
of O +
genetic O +
integrity O +
and O +
DNA O +
double O -
- O -
strand O +
break O +
( O -
DSB O -
) O +
repair O -
. O +

NHEJ O +
is O +
regulated O +
by O +
a O +
series O +
of O +
interactions O +
between O +
core O +
components O +
of O +
the O +
pathway O -
, O +
including O +
Ku O +
heterodimer O -
, O +
XLF O -
/ O -
Cernunnos O -
, O +
and O +
XRCC4 O -
/ O -
DNA O +
Ligase O +
4 O +
( O -
Lig4 O -
) O -
. O +

However O -
, O +
the O +
mechanisms O +
by O +
which O +
these O +
proteins O +
assemble O +
into O +
functional O +
protein O -
- O -
DNA O +
complexes O +
are O +
not O +
fully O +
understood O -
. O +

Here O -
, O +
we O +
show O +
that O +
the O +
von O +
Willebrand O +
( O -
vWA O -
) O +
domain O +
of O +
Ku80 O +
fulfills O +
a O +
critical O +
role O +
in O +
this O +
process O +
by O +
recruiting O +
Aprataxin O -
- O -
and O -
- O -
PNK O -
- O -
Like O +
Factor O +
( O -
APLF O -
) O +
into O +
Ku O -
- O -
DNA O +
complexes O -
. O +

APLF O -
, O +
in O +
turn O -
, O +
functions O +
as O +
a O +
scaffold O +
protein O +
and O +
promotes O +
the O +
recruitment O +
and/or O +
retention O +
of O +
XRCC4-Lig4 O +
and O +
XLF O -
, O +
thereby O +
assembling O +
multi O -
- O -
protein O +
Ku O +
complexes O +
capable O +
of O +
efficient O +
DNA O +
ligation O +
in O +
vitro O +
and O +
in O +
cells O -
. O +

Disruption O +
of O +
the O +
interactions O +
between O +
APLF O +
and O +
either O +
Ku80 O +
or O +
XRCC4-Lig4 O +
disrupts O +
the O +
assembly O +
and O +
activity O +
of O +
Ku O +
complexes O -
, O +
and O +
confers O +
cellular O +
hypersensitivity O +
and O +
reduced O +
rates O +
of O +
chromosomal O +
DSB O +
repair O +
in O +
avian O +
and O +
human O +
cells O -
, O +
respectively O -
. O +

Collectively O -
, O +
these O +
data O +
identify O +
a O +
role O +
for O +
the O +
vWA O +
domain O +
of O +
Ku80 O +
and O +
a O +
molecular O +
mechanism O +
by O +
which O +
DNA O +
ligase O +
proficient O +
complexes O +
are O +
assembled O +
during O +
NHEJ O +
in O +
mammalian O +
cells O -
, O +
and O +
reveal O +
APLF O +
to O +
be O +
a O +
structural O +
component O +
of O +
this O +
critical O +
DSB O +
repair O +
pathway O -
. O +

Human O +
embryonic O +
stem O +
cell O -
- O -
derived O +
test O +
systems O +
for O +
developmental O +
neurotoxicity O -
: O +
a O +
transcriptomics O +
approach O -
. O +

Developmental O +
neurotoxicity O +
( O -
DNT O -
) O +
and O +
many O +
forms O +
of O +
reproductive O +
toxicity O +
( O -
RT O -
) O +
often O +
manifest O +
themselves O +
in O +
functional O +
deficits O +
that O +
are O +
not O +
necessarily O +
based O +
on O +
cell O +
death O -
, O +
but O +
rather O +
on O +
minor O +
changes O +
relating O +
to O +
cell O +
differentiation O +
or O +
communication O -
. O +

The O +
fields O +
of O +
DNT O -
/ O -
RT O +
would O +
greatly O +
benefit O +
from O +
in O +
vitro O +
tests O +
that O +
allow O +
the O +
identification O +
of O +
toxicant O -
- O -
induced O +
changes O +
of O +
the O +
cellular O +
proteostasis O -
, O +
or O +
of O +
its O +
underlying O +
transcriptome O +
network O -
. O +

Therefore O -
, O +
the O +
' O -
human O +
embryonic O +
stem O +
cell O +
( O -
hESC O -
) O -
-derived O +
novel O +
alternative O +
test O +
systems O +
( O -
ESNATS O -
) O -
' O +
European O +
commission O +
research O +
project O +
established O +
RT O +
tests O +
based O +
on O +
defined O +
differentiation O +
protocols O +
of O +
hESC O +
and O +
their O +
progeny O -
. O +

Valproic B-Chemical +
acid I-Chemical +
( O -
VPA B-Chemical -
) O +
and O +
methylmercury B-Chemical +
( O -
MeHg B-Chemical -
) O +
were O +
used O +
as O +
positive O +
control O +
compounds O +
to O +
address O +
the O +
following O +
fundamental O +
questions O -
: O +
( O -
1 O -
) O +
Does O +
transcriptome O +
analysis O +
allow O +
discrimination O +
of O +
the O +
two O +
compounds O -
? O +

( O -
2 O -
) O +
How O +
does O +
analysis O +
of O +
enriched O +
transcription O +
factor O +
binding O +
sites O +
( O -
TFBS O -
) O +
and O +
of O +
individual O +
probe O +
sets O +
( O -
PS O -
) O +
distinguish O +
between O +
test O +
systems O -
? O +

( O -
3 O -
) O +
Can O +
batch O +
effects O +
be O +
controlled O -
? O +

( O -
4 O -
) O +
How O +
many O +
DNA O +
microarrays O +
are O +
needed O -
? O +

( O -
5 O -
) O +
Is O +
the O +
highest O +
non O -
- O -
cytotoxic O +
concentration O +
optimal O +
and O +
relevant O +
for O +
the O +
study O +
of O +
transcriptome O +
changes O -
? O +

VPA O +
triggered O +
vast O +
transcriptional O +
changes O -
, O +
whereas O +
MeHg B-Chemical +
altered O +
fewer O +
transcripts O -
. O +

To O +
attenuate O +
batch O +
effects O -
, O +
analysis O +
has O +
been O +
focused O +
on O +
the O +
500 O +
PS O +
with O +
highest O +
variability O -
. O +

The O +
test O +
systems O +
differed O +
significantly O +
in O +
their O +
responses O +
( O -
< O -
20 O +
% O +
overlap O -
) O -
. O +

Moreover O -
, O +
within O +
one O +
test O +
system O -
, O +
little O +
overlap O +
between O +
the O +
PS O +
changed O +
by O +
the O +
two O +
compounds O +
has O +
been O +
observed O -
. O +

However O -
, O +
using O +
TFBS O +
enrichment O -
, O +
a O +
relatively O +
large O +
' O -
common O +
response O -
' O +
to O +
VPA B-Chemical +
and O +
MeHg B-Chemical +
could O +
be O +
distinguished O +
from O +
' O -
compound O -
- O -
specific O -
' O +
responses O -
. O +

In O +
conclusion O -
, O +
the O +
ESNATS O +
assay O +
battery O +
allows O +
classification O +
of O +
human O +
DNT O -
/ O -
RT O +
toxicants O +
on O +
the O +
basis O +
of O +
their O +
transcriptome O +
profiles O -
. O +

Therapy O +
of O +
adrenal O +
insufficiency O -
: O +
an O +
update O -
. O +

Adrenal O +
insufficiency O +
may O +
be O +
caused O +
by O +
the O +
destruction O +
or O +
altered O +
function O +
of O +
the O +
adrenal O +
gland O +
with O +
a O +
primary O +
deficit O +
in O +
cortisol B-Chemical +
secretion O +
( O -
primary O +
adrenal O +
insufficiency O -
) O +
or O +
by O +
hypothalamic O -
- O -
pituitary O +
pathologies O +
determining O +
a O +
deficit O +
of O +
ACTH O +
( O -
secondary O +
adrenal O +
insufficiency O -
) O -
. O +

The O +
clinical O +
picture O +
is O +
determined O +
by O +
the O +
glucocorticoid O +
deficit O -
, O +
which O +
may O +
in O +
some O +
conditions O +
be O +
accompanied O +
by O +
a O +
deficit O +
of O +
mineralcorticoids O +
and O +
adrenal O +
androgens B-Chemical -
. O +

The O +
substitutive O +
treatment O +
is O +
aimed O +
at O +
reducing O +
the O +
signs O +
and O +
symptoms O +
of O +
the O +
disease O +
as O +
well O +
as O +
at O +
preventing O +
the O +
development O +
of O +
an O +
addisonian O +
crisis O -
, O +
a O +
clinical O +
emergency O +
characterized O +
by O +
hypovolemic O +
shock O -
. O +

The O +
oral O +
substitutive O +
treatment O +
should O +
attempt O +
at O +
mimicking O +
the O +
normal O +
circadian O +
profile O +
of O +
cortisol B-Chemical +
secretion O -
, O +
by O +
using O +
the O +
lower O +
possible O +
doses O +
able O +
to O +
guarantee O +
an O +
adequate O +
quality O +
of O +
life O +
to O +
patients O -
. O +

The O +
currently O +
available O +
hydrocortisone B-Chemical +
or O +
cortisone B-Chemical +
acetate I-Chemical +
preparations O +
do O +
not O +
allow O +
an O +
accurate O +
reproduction O +
of O +
the O +
physiological O +
secretion O +
pattern O +
of O +
cortisol B-Chemical -
. O +

A O +
novel O +
dual O -
- O -
release O +
formulation O +
of O +
hydrocortisone B-Chemical -
, O +
recently O +
approved O +
by O +
EMEA O -
, O +
represents O +
an O +
advancement O +
in O +
the O +
optimization O +
of O +
the O +
clinical O +
management O +
of O +
patients O +
with O +
adrenal O +
insufficiency O -
. O +

Future O +
clinical O +
trials O +
of O +
immunomodulation O +
or O +
immunoprevention O +
will O +
test O +
the O +
possibility O +
to O +
delay O +
( O -
or O +
prevent O -
) O +
the O +
autoimmune O +
destruction O +
of O +
the O +
adrenal O +
gland O +
in O +
autoimmune O +
Addison O -
's O +
disease O -
. O +

DDBJ O +
new O +
system O +
and O +
service O +
refactoring O -
. O +

The O +
DNA O +
data O +
bank O +
of O +
Japan O +
( O -
DDBJ O -
, O +
http://www.ddbj.nig.ac.jp O -
) O +
maintains O +
a O +
primary O +
nucleotide O +
sequence O +
database O +
and O +
provides O +
analytical O +
resources O +
for O +
biological O +
information O +
to O +
researchers O -
. O +

This O +
database O +
content O +
is O +
exchanged O +
with O +
the O +
US O +
National O +
Center O +
for O +
Biotechnology O +
Information O +
( O -
NCBI O -
) O +
and O +
the O +
European O +
Bioinformatics O +
Institute O +
( O -
EBI O -
) O +
within O +
the O +
framework O +
of O +
the O +
International O +
Nucleotide O +
Sequence O +
Database O +
Collaboration O +
( O -
INSDC O -
) O -
. O +

Resources O +
provided O +
by O +
the O +
DDBJ O +
include O +
traditional O +
nucleotide O +
sequence O +
data O +
released O +
in O +
the O +
form O +
of O +
27 O +
316 O +
452 O +
entries O +
or O +
16 O +
876 O +
791 O +
557 O +
base O +
pairs O +
( O -
as O +
of O +
June O +
2012 O -
) O -
, O +
and O +
raw O +
reads O +
of O +
new O +
generation O +
sequencers O +
in O +
the O +
sequence O +
read O +
archive O +
( O -
SRA O -
) O -
. O +

A O +
Japanese O +
researcher O +
published O +
his O +
own O +
genome O +
sequence O +
via O +
DDBJ O -
- O -
SRA O +
on O +
31 O +
July O +
2012 O -
. O +

To O +
cope O +
with O +
the O +
ongoing O +
genomic O +
data O +
deluge O -
, O +
in O +
March O +
2012 O -
, O +
our O +
computer O +
previous O +
system O +
was O +
totally O +
replaced O +
by O +
a O +
commodity O +
cluster O -
- O -
based O +
system O +
that O +
boasts O +
122.5 O +
TFlops O +
of O +
CPU O +
capacity O +
and O +
5 O +
PB O +
of O +
storage O +
space O -
. O +

During O +
this O +
upgrade O -
, O +
it O +
was O +
considered O +
crucial O +
to O +
replace O +
and O +
refactor O +
substantial O +
portions O +
of O +
the O +
DDBJ O +
software O +
systems O +
as O +
well O -
. O +

As O +
a O +
result O +
of O +
the O +
replacement O +
process O -
, O +
which O +
took O +
more O +
than O +
2 O +
years O +
to O +
perform O -
, O +
we O +
have O +
achieved O +
significant O +
improvements O +
in O +
system O +
performance O -
. O +

Genomic O +
deletions O +
and O +
point O +
mutations O +
induced O +
in O +
Saccharomyces O +
cerevisiae O +
by O +
the O +
trinucleotide O +
repeats O +
( O -
GAA·TTC O -
) O +
associated O +
with O +
Friedreich O -
's O +
ataxia O -
. O +

Expansion O +
of O +
certain O +
trinucleotide O +
repeats O +
causes O +
several O +
types O +
of O +
human O +
diseases O -
, O +
and O +
such O +
tracts O +
are O +
associated O +
with O +
the O +
formation O +
of O +
deletions O +
and O +
other O +
types O +
of O +
genetic O +
rearrangements O +
in O +
Escherichia O +
coli O -
, O +
yeast O -
, O +
and O +
mammalian O +
cells O -
. O +

Below O -
, O +
we O +
show O +
that O +
long O +
( O -
230 O +
repeats O -
) O +
tracts O +
of O +
the O +
trinucleotide O +
associated O +
with O +
Friedreich O -
's O +
ataxia O +
( O -
GAA·TTC O -
) O +
stimulate O +
both O +
large O +
( O -
> O -
50 O +
bp O -
) O +
deletions O +
and O +
point O +
mutations O +
in O +
a O +
reporter O +
gene O +
located O +
more O +
than O +
1 O +
kb O +
from O +
the O +
repetitive O +
tract O -
. O +

Sequence O +
analysis O +
of O +
deletion O +
breakpoints O +
indicates O +
that O +
the O +
deletions O +
reflect O +
non O -
- O -
homologous O +
end O +
joining O +
of O +
double O -
- O -
stranded O +
DNA O +
breaks O +
( O -
DSBs O -
) O +
initiated O +
in O +
the O +
tract O -
. O +

The O +
tract O -
- O -
induced O +
point O +
mutations O +
appear O +
to O +
reflect O +
a O +
different O +
mechanism O +
involving O +
single O -
- O -
strand O +
annealing O +
of O +
DNA O +
molecules O +
generated O +
by O +
DSBs O +
within O +
the O +
tract O -
, O +
followed O +
by O +
filling O -
- O -
in O +
of O +
single O -
- O -
stranded O +
gaps O +
by O +
the O +
error O -
- O -
prone O +
DNA O +
polymerase O +
zeta O -
. O +

An O +
artificial O +
neural O +
network O +
approach O +
to O +
improving O +
the O +
correlation O +
between O +
protein O +
energetics O +
and O +
the O +
backbone O +
structure O -
. O +

Computational O +
approaches O +
to O +
modeling O +
protein O +
structures O +
have O +
made O +
significant O +
advances O +
over O +
the O +
past O +
decade O -
. O +

However O -
, O +
the O +
current O +
limitation O +
in O +
modeling O +
protein O +
structures O +
is O +
to O +
produce O +
protein O +
structures O +
consistently O +
below O +
the O +
limit O +
of O +
6 O +
Å O +
compared O +
to O +
their O +
native O +
structure O -
. O +

Therefore O -
, O +
improvement O +
of O +
protein O +
structures O +
consistently O +
below O +
the O +
6 O +
Å O +
limit O +
using O +
simulation O +
of O +
biophysical O +
forces O +
is O +
of O +
significant O +
interest O -
. O +

Current O +
protein O +
force O +
fields O +
such O +
as O +
those O +
implemented O +
in O +
CHARMM O -
, O +
AMBER O -
, O +
and O +
NAMD O +
have O +
been O +
deemed O +
complete O -
, O +
yet O +
their O +
use O +
in O +
ab O +
initio O +
approaches O +
to O +
protein O +
structure O +
determination O +
has O +
been O +
unsuccessful O -
. O +

Here O -
, O +
we O +
introduce O +
a O +
new O +
approach O +
in O +
evaluation O +
of O +
protein O +
structures O +
based O +
on O +
analysis O +
of O +
energy O +
profiles O +
produced O +
by O +
the O +
SCOPE O +
software O +
package O -
. O +

The O +
latest O +
version O +
of O +
SCOPE O +
produces O +
a O +
hydrogen B-Chemical +
bond O +
profile O +
that O +
is O +
substantially O +
more O +
informative O +
than O +
a O +
single O +
hydrogen B-Chemical +
bond O +
energy O +
value O -
. O +

We O +
demonstrate O +
how O +
analysis O +
of O +
SCOPE O -
's O +
energy O +
profile O +
by O +
an O +
artificial O +
neural O +
network O +
shows O +
a O +
significant O +
improvement O +
compared O +
to O +
the O +
traditional O +
force O -
- O -
based O +
approaches O +
to O +
evaluation O +
of O +
structures O -
. O +

The O +
artificial O +
neural O +
network O +
based O +
analysis O +
of O +
SCOPE O -
's O +
energy O +
profile O +
showed O +
identification O +
of O +
structures O +
to O +
within O +
the O +
range O +
of O +
1.5 O -
- O -
3.0 O +
Å O +
of O +
the O +
native O +
structure O -
. O +

These O +
results O +
have O +
been O +
obtained O +
by O +
testing O +
structures O +
in O +
the O +
same O +
Homology O -
, O +
Topology O -
, O +
Architecture O -
, O +
or O +
Class O +
of O +
the O +
CATH O +
family O -
. O +

Evaluation O +
of O +
romidepsin B-Chemical +
for O +
clinical O +
activity O +
and O +
radioactive B-Chemical +
iodine I-Chemical +
reuptake O +
in O +
radioactive B-Chemical +
iodine I-Chemical -
- O -
refractory O +
thyroid O +
carcinoma O -
. O +

Background O -
: O +
Historically O -
, O +
systemic O +
therapy O +
for O +
radioactive B-Chemical +
iodine I-Chemical +
( O -
RAI B-Chemical -
) O -
-refractory O +
thyroid O +
cancer O +
has O +
been O +
understudied O -
. O +

Available O +
drugs O +
have O +
modest O +
efficacy O -
. O +

Romidepsin B-Chemical +
is O +
a O +
histone O +
deacetylase O +
inhibitor O +
with O +
potent O +
antitumor O +
effects O +
both O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

In O +
thyroid O +
cancer O +
cell O +
lines O -
, O +
romidepsin O +
increases O +
expression O +
of O +
both O +
thyroglobulin O +
and O +
the O +
sodium B-Chemical +
iodide I-Chemical +
symporter O +
messenger O +
RNAs O -
, O +
suggesting O +
the O +
possibility O +
of O +
improved O +
iodine B-Chemical +
concentrating O +
ability O +
of O +
RAI B-Chemical -
- O -
resistant O +
tumors O -
. O +

Methods O -
: O +
This O +
was O +
a O +
single O -
- O -
institution O +
Simon O +
2-stage O +
phase O +
II O +
clinical O +
study O -
. O +

Eligible O +
patients O +
had O +
progressive O -
, O +
RAI B-Chemical -
- O -
refractory O -
, O +
recurrent O -
/ O -
metastatic O -
, O +
nonmedullary O -
, O +
nonanaplastic O +
thyroid O +
cancer O -
. O +

Response O +
Evaluation O +
Criteria O +
in O +
Solid O +
Tumors O +
( O -
RECIST O -
) O +
1.0 O +
measurable O +
disease O +
and O +
adequate O +
organ O -
/ O -
marrow O +
function O +
were O +
required O -
. O +

Romidepsin B-Chemical +
13 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
was O +
administered O +
intravenously O +
on O +
days O +
1 O -
, O +
8 O -
, O +
and O +
15 O -
, O +
in O +
cycles O +
of O +
28 O +
days O -
. O +

The O +
primary O +
endpoint O +
was O +
the O +
response O +
rate O +
by O +
RECIST O -
; O +
change O +
in O +
RAI B-Chemical +
avidity O +
was O +
a O +
secondary O +
endpoint O -
. O +

The O +
study O +
closed O +
after O +
the O +
first O +
stage O +
due O +
to O +
the O +
lack O +
of O +
response O -
. O +

Results O -
: O +
Twenty O +
patients O +
were O +
enrolled O -
: O +
female O -
, O +
50 O -
% O -
; O +
median O +
age O -
, O +
64 O +
years O -
; O +
histology O -
, O +
8 O +
papillary O -
/ O -
1 O +
follicular O -
/ O -
11 O +
Hürthle O -
. O +

Grade O +
4 O -
- O -
5 O +
adverse O +
events O +
( O -
AEs O -
) O +
possibly O +
related O +
to O +
the O +
drug O -
: O +
grade O +
5 O -
, O +
1 O +
sudden O +
death O -
; O +
grade O +
4 O -
, O +
1 O +
pulmonary O +
embolus O -
. O +

Twelve O +
of O +
20 O +
subjects O +
had O +
a O +
reported O +
adverse O +
event O -
. O +

No O +
RECIST O +
major O +
responses O +
have O +
been O +
seen O -
. O +

Response O +
per O +
protocol O -
: O +
stable O +
disease O -
, O +
13 O -
; O +
disease O +
progression O -
, O +
7 O -
. O +

Restoration O +
of O +
RAI B-Chemical +
avidity O +
was O +
documented O +
in O +
two O +
patients O -
. O +

Median O +
overall O +
survival O +
and O +
time O +
on O +
study O +
was O +
33.2 O +
( O -
1 O -
- O -
71 O -
+ O -
) O +
and O +
1.7 O +
( O -
0.46 O -
- O -
12 O -
) O +
months O -
, O +
respectively O -
. O +

Conclusions O +

: O +
We O +
observed O +
preliminary O +
signs O +
of O +
in O +
vivo O +
reversal O +
of O +
RAI B-Chemical +
resistance O +
after O +
treatment O +
with O +
romidepsin B-Chemical -
. O +

However O -
, O +
no O +
major O +
responses O +
were O +
observed O +
and O +
accrual O +
was O +
poor O +
after O +
the O +
grade O +
5 O +
AE O -
. O +

Quantification O +
of O +
silanol B-Chemical +
sites O +
for O +
the O +
most O +
common O +
mesoporous O +
ordered O +
silicas B-Chemical +
and O +
organosilicas B-Chemical -
: O +
total O +
versus O +
accessible O +
silanols B-Chemical -
. O +

IR O +
and O +
NMR O +
spectroscopy O +
were O +
used O +
to O +
determine O +
the O +
silanol B-Chemical +
content O +
in O +
the O +
most O +
common O +
mesoporous O +
ordered O +
silicas B-Chemical -
: O +
MCM-41 B-Chemical -
, O +
MCM-48 B-Chemical -
, O +
SBA-15 B-Chemical +
and O +
SBA-16 B-Chemical -
. O +

In O +
addition O -
, O +
a O +
spray O +
dried O +
MCM-41 B-Chemical +
and O +
an O +
ethene B-Chemical +
bridged O +
PMO B-Chemical +
are O +
investigated O -
. O +

The O +
results O +
are O +
compared O +
with O +
a O +
commercial O +
chromatographic O +
silica B-Chemical +
( O -
Nucleosil B-Chemical -
) O -
. O +

The O +
complete O +
distribution O +
of O +
surface O +
and O +
bulk O +
silanols B-Chemical -
, O +
and O +
of O +
isolated O -
, O +
geminal B-Chemical +
and I-Chemical +
vicinal I-Chemical +
silanols I-Chemical +
for O +
all O +
these O +
materials O +
is O +
presented O -
. O +

A O +
distinction O +
is O +
made O +
between O +
the O +
total O +
silanol B-Chemical +
number O +
and O +
the O +
reachable O +
or O +
surface O +
silanol B-Chemical +
content O -
. O +

The O +
latter O +
is O +
determined O +
by O +
controlled O +
reactions O +
with O +
simple O +
silanes B-Chemical -
. O +

All O +
mesoporous O +
ordered O +
silicas B-Chemical -
, O +
and O +
especially O +
the O +
thick O +
walled O +
SBA O -
- O -
type O +
materials O +
and O +
the O +
PMO B-Chemical +
contain O +
a O +
surprisingly O +
high O +
amount O +
of O +
total O +
silanol B-Chemical +
sites O -
, O +
albeit O +
that O +
up O +
to O +
90 O -
% O +
of O +
these O +
silanols B-Chemical +
are O +
buried O +
inside O +
the O +
walls O +
and O +
are O +
not O +
reachable O +
for O +
small O +
silanes B-Chemical -
. I-Chemical +

Mechanism O +
of O +
the O +
antiproliferative O +
activity O +
of O +
some O +
naphthalene B-Chemical +
diimide I-Chemical +
G O -
- O -
quadruplex O +
ligands O -
. O +

G O -
- O -
quadruplexes O +
are O +
higher O -
- O -
order O +
nucleic O +
acid O +
structures O +
that O +
can O +
form O +
in O +
G O -
- O -
rich O +
telomeres O +
and O +
promoter O +
regions O +
of O +
oncogenes O -
. O +

Telomeric O +
quadruplex O +
stabilization O +
by O +
small O +
molecules O +
can O +
lead O +
to O +
telomere O +
uncapping O -
, O +
followed O +
by O +
DNA O +
damage O +
response O +
and O +
senescence O -
, O +
as O +
well O +
as O +
chromosomal O +
fusions O +
leading O +
to O +
deregulation O +
of O +
mitosis O -
, O +
followed O +
by O +
apoptosis O +
and O +
downregulation O +
of O +
oncogene O +
expression O -
. O +

We O +
report O +
here O +
on O +
investigations O +
into O +
the O +
mechanism O +
of O +
action O +
of O +
tetra O -
- O -
substituted O +
naphthalene B-Chemical +
diimide I-Chemical +
ligands O +
on O +
the O +
basis O +
of O +
cell O +
biologic O +
data O +
together O +
with O +
a O +
National O +
Cancer O +
Institute O +
COMPARE O +
study O -
. O +

We O +
conclude O +
that O +
four O +
principal O +
mechanisms O +
of O +
action O +
are O +
implicated O +
for O +
these O +
compounds O -
: O +
1 O -
) O +
telomere O +
uncapping O +
with O +
subsequent O +
DNA O +
damage O +
response O +
and O +
senescence O -
; O +
2 O -
) O +
inhibition O +
of O +
transcription O -
/ O -
translation O +
of O +
oncogenes O -
; O +
3 O -
) O +
genomic O +
instability O +
through O +
telomeric O +
DNA O +
end O +
fusions O -
, O +
resulting O +
in O +
mitotic O +
catastrophe O +
and O +
apoptosis O -
; O +
and O +
4 O -
) O +
induction O +
of O +
chromosomal O +
instability O +
by O +
telomere O +
aggregate O +
formation O -
. O +

Mangiferin B-Chemical +
- O +
a O +
bioactive O +
xanthonoid B-Chemical -
, O +
not O +
only O +
from O +
mango O +
and O +
not O +
just O +
antioxidant O -
. O +

Mangiferin B-Chemical +
is O +
a O +
plant O +
natural O +
polyphenol B-Chemical +
of O +
C B-Chemical -
- I-Chemical -
glycosylxanthone I-Chemical +
structure O +
and O +
various O +
pharmacological O +
activities O -
. O +

It O +
can O +
be O +
found O +
in O +
many O +
plant O +
species O -
, O +
among O +
which O +
the O +
mango O +
tree O +
( O -
Mangifera O +
indica O -
) O +
is O +
one O +
of O +
the O +
primary O +
sources O -
. O +

Mangiferin B-Chemical +
is O +
also O +
present O +
in O +
some O +
medicinal O +
herbs O -
, O +
influencing O +
their O +
therapeutic O +
and O +
preventive O +
properties O -
, O +
and O +
in O +
honeybush O +
( O -
Cyclopia O +
sp. O -
) O -
, O +
a O +
popular O +
South O +
African O +
herbal O +
tea O -
. O +

Mangiferin B-Chemical +
dissolves O +
well O +
in O +
water O -
, O +
so O +
it O +
can O +
be O +
easily O +
extracted O +
into O +
infusions O +
and O +
decoctions O -
. O +

In O +
the O +
mangiferin B-Chemical +
molecule O -
, O +
four O +
aromatic B-Chemical +
hydroxyl I-Chemical +
groups O +
determine O +
its O +
strong O +
antiradical O +
and O +
antioxidant O +
properties O -
. O +

Mangiferin B-Chemical +
is O +
also O +
an O +
efficient O +
iron B-Chemical +
chelator O -
, O +
therefore O +
preventing O +
the O +
generation O +
of O +
hydroxyl B-Chemical +
radical O +
in O +
Fenton O -
- O -
type O +
reactions O -
. O +

Numerous O +
published O +
in O +
vitro O +
and O +
in O +
vivo O +
pharmacological O +
studies O -
, O +
demonstrated O +
many O +
other O +
activities O +
of O +
mangiferin B-Chemical -
: O +
analgesic O -
, O +
antidiabetic O -
, O +
antisclerotic O -
, O +
atimicrobial O +
and O +
antiviral O -
, O +
cardio- O -
, O +
hepato- O -
, O +
and O +
neuroprotective O -
, O +
antiinflammatory O -
, O +
antiallergic O -
, O +
MAO O +
inhibiting O +
and O +
memory O +
improving O -
, O +
as O +
well O +
as O +
radioprotective O +
against O +
X O -
- O -
ray O -
, O +
gamma O -
, O +
and O +
UV O +
radiation O -
. O +

Several O +
studies O +
indicated O +
also O +
its O +
ability O +
to O +
inhibit O +
cancerogenesis O +
and O +
cancer O +
cells O +
growth O +
by O +
apoptosis O +
induction O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

It O +
is O +
also O +
used O +
in O +
cosmetics O -
, O +
due O +
to O +
antioxidant O +
and O +
UV O -
- O -
protecting O +
properties O -
. O +

Phenolic B-Chemical +
compounds O +
as O +
antioxidants O -
: O +
carbonic O +
anhydrase O +
isoenzymes O +
inhibitors O -
. O +

Antioxidant O +
compounds O +
can O +
scavenge O +
free O +
radicals O +
and O +
increase O +
shelf O +
life O +
by O +
retarding O +
the O +
process O +
of O +
lipid O +
peroxidation O -
, O +
which O +
is O +
one O +
of O +
the O +
major O +
reasons O +
for O +
deterioration O +
of O +
food O -
, O +
medicine O +
and O +
pharmaceutical O +
products O +
during O +
processing O +
and O +
storage O -
. O +

An O +
antioxidant O +
molecule O +
has O +
been O +
defined O +
as O +
any O +
substance O +
when O +
found O +
in O +
low O +
concentrations O +
compared O +
to O +
that O +
of O +
an O +
oxidizable O +
substrate O +
significantly O +
delays O +
or O +
inhibits O +
the O +
oxidation O -
. O +

The O +
major O +
antioxidant O +
compounds O +
are O +
especially O +
phenolics B-Chemical +
and O +
flavonoids B-Chemical -
, O +
which O +
are O +
responsible O +
for O +
their O +
health O +
benefits O -
. O +

Carbonic O +
anhydrase O +
( O -
EC O +
4.2.1.1 O -
. O -
, O +
CA O -
) O +
is O +
a O +
pH O +
regulatory O -
/ O -
metabolic O +
enzyme O +
in O +
all O +
life O +
kingdoms O -
, O +
being O +
found O +
in O +
organisms O +
all O +
over O +
the O +
phylogenetic O +
tree O -
. O +

It O +
catalyzes O +
the O +
hydration O +
of O +
carbon B-Chemical +
dioxide I-Chemical +
( O -
CO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
) O +
to O +
bicarbonate B-Chemical +
( O -
HCO B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical +
- I-Chemical -
) O +
and O +
the O +
corresponding O +
dehydration O +
of O +
HCO B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical +
-in I-Chemical +
acidic O +
medium O +
with O +
regeneration O +
of O +
CO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
. O +

Also O -
, O +
CA O +
isoforms O +
are O +
found O +
in O +
a O +
variety O +
of O +
tissues O +
where O +
they O +
participate O +
in O +
several O +
important O +
biological O +
processes O +
such O +
as O +
acid O -
- O -
base O +
balance O -
, O +
respiration O -
, O +
carbon B-Chemical +
dioxide I-Chemical +
and O +
ion O +
transport O -
, O +
bone O +
resorption O -
, O +
ureagenesis O -
, O +
gluconeogenesis O -
, O +
lipogenesis O +
and O +
electrolyte O +
secretion O -
. O +

On O +
the O +
other O +
hand O -
, O +
the O +
phenyl B-Chemical +
moiety O +
of O +
phenol B-Chemical +
was O +
found O +
to O +
lay O +
in O +
the O +
hydrophobic O +
part O +
of O +
the O +
CA O +
active O +
site O -
, O +
where O +
CO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
, O +
the O +
physiologic O +
substrate O +
of O +
the O +
CAs O -
, O +
binds O +
in O +
the O +
precatalytic O +
complex O -
, O +
explaining O +
thus O +
the O +
behavior O +
of O +
phenol B-Chemical +
as O +
a O +
unique O +
CO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
competitive O +
inhibitor O -
. O +

This O +
review O +
consists O +
of O +
two O +
main O +
sections O -
. O +

The O +
first O +
section O +
is O +
devoted O +
to O +
main O +
phenolic B-Chemical +
antioxidant O +
compounds O +
in O +
the O +
foodstuffs O +
and O +
beverages O -
. O +

The O +
second O +
general O +
section O +
is O +
about O +
some O +
definitions O +
of O +
CA O +
inhibitory O +
effects O +
of O +
the O +
main O +
phenolic B-Chemical +
compounds O +
used O +
for O +
antioxidant O +
activity O -
. O +

The O +
phenolic B-Chemical +
compounds O +
and O +
acids O +
had O +
marked O +
especially O +
CA O +
I O +
and O +
CA O +
II O +
inhibitory O +
effects O +
and O +
might O +
be O +
used O +
as O +
leads O +
for O +
generating O +
CA O +
isoenzyme O +
inhibitors O -
. O +

This O +
class O +
of O +
compounds O +
may O +
lead O +
to O +
isoform O -
- O -
selective O +
inhibitors O +
targeting O +
just O +
one O +
or O +
few O +
of O +
the O +
medicinally O +
relevant O +
CAs O -
. O +

In O +
addition O -
, O +
there O +
are O +
given O +
some O +
chemical O +
and O +
kinetic O +
basis O +
and O +
technical O +
details O +
related O +
to O +
phenolic B-Chemical +
antioxidant O +
compounds O +
and O +
carbonic O +
anhydrase O +
isoenzymes O -
. O +

Recent O +
studies O +
of O +
antioxidant O +
quinoline B-Chemical +
derivatives O -
. O +

Quinoline B-Chemical +
derivatives O +
constitute O +
an O +
important O +
class O +
of O +
compounds O +
for O +
new O +
drug O +
development O -
. O +

As O +
a O +
large O +
number O +
of O +
experimental O +
and O +
theoretical O +
studies O +
have O +
shown O +
that O +
the O +
quinoline B-Chemical +
ring O +
system O +
is O +
an O +
important O +
structural O +
unit O +
widely O +
existing O +
in O +
alkaloids O -
, O +
therapeutics O +
and O +
synthetic O +
analogues O +
with O +
exciting O +
biological O +
activities O -
. O +

The O +
present O +
review O +
provides O +
recent O +
antioxidant O +
activities O +
covering O +
in O +
vivo O +
and O +
in O +
vitro O +
studies O +
of O +
natural O +
and O +
synthetic O +
analogues O -
, O +
as O +
well O +
as O +
the O +
proposed O +
mechanisms O +
of O +
action O +
and O +
structure O -
- O -
activity O +
relationships O -
. O +

Supramolecular O +
hydrogels O +
with O +
reverse O +
thermal O +
gelation O +
properties O +
from O +
( B-Chemical -
oligo I-Chemical -
) I-Chemical -
tyrosine I-Chemical +
containing O +
block O +
copolymers O -
. O +

Novel O +
block O +
copolymers O +
comprising O +
poly B-Chemical -
( I-Chemical -
ethylene I-Chemical +
glycol I-Chemical -
) I-Chemical +
( O -
PEG B-Chemical -
) O +
and O +
an O +
oligo B-Chemical -
( I-Chemical -
tyrosine I-Chemical -
) I-Chemical +
block O +
were O +
synthesized O +
in O +
different O +
compositions O +
by O +
N B-Chemical -
- I-Chemical -
carboxyanhydride I-Chemical +
( O -
NCA B-Chemical -
) O +
polymerization O -
. O +

It O +
was O +
shown O +
that O +
PEG2000-Tyr B-Chemical -
( I-Chemical -
6 I-Chemical -
) I-Chemical +
undergoes O +
thermoresponsive O +
hydrogelation O +
at O +
a O +
low O +
concentration O +
range O +
of O +
0.25 O -
- O -
3.0 O +
wt O +
% O +
within O +
a O +
temperature O +
range O +
of O +
25 O -
- O -
50 O +
° O -
C O -
. O +

Cryogenic O +
transmission O +
electron O +
microscopy O +
( O -
Cryo O -
- O -
TEM O -
) O +
revealed O +
a O +
continuous O +
network O +
of O +
fibers O +
throughout O +
the O +
hydrogel O +
sample O -
, O +
even O +
at O +
concentrations O +
as O +
low O +
as O +
0.25 O +
wt O +
% O -
. O +

Circular O +
dichroism O +
( O -
CD O -
) O +
results O +
suggest O +
that O +
better O +
packing O +
of O +
the O +
β O -
- O -
sheet O +
tyrosine B-Chemical +
block O +
at O +
increasing O +
temperature O +
induces O +
the O +
reverse O +
thermogelation O -
. O +

A O +
preliminary O +
assessment O +
of O +
the O +
potential O +
of O +
the O +
hydrogel O +
for O +
in O +
vitro O +
application O +
confirmed O +
the O +
hydrogel O +
is O +
not O +
cytotoxic O -
, O +
is O +
biodegradable O -
, O +
and O +
produced O +
a O +
sustained O +
release O +
of O +
a O +
small O -
- O -
molecule O +
drug O -
. O +

Green O +
asymmetric O +
synthesis O -
: O +
β B-Chemical -
- I-Chemical -
amino I-Chemical +
alcohol I-Chemical -
- O -
catalyzed O +
direct O +
asymmetric O +
aldol B-Chemical +
reactions O +
in O +
aqueous O +
micelles O -
. O +

The O +
ability O +
of O +
chiral B-Chemical +
β I-Chemical -
- I-Chemical -
amino I-Chemical +
alcohols I-Chemical +
to O +
catalyze O +
the O +
direct O +
asymmetric O +
aldol B-Chemical +
reaction O +
was O +
evaluated O +
for O +
the O +
first O +
time O +
in O +
aqueous O +
micellar O +
media O -
. O +

A O +
family O +
of O +
cheap O +
and O +
easily O +
accessible O +
β B-Chemical -
- I-Chemical -
amino I-Chemical +
alcohols I-Chemical -
, O +
obtained O +
in O +
one O +
step O +
from O +
naturally O +
occurring O +
amino B-Chemical +
acids I-Chemical -
, O +
was O +
shown O +
to O +
successfully O +
catalyze O +
the O +
asymmetric O +
aldol B-Chemical +
reaction O +
between O +
a O +
series O +
of O +
ketones B-Chemical +
and O +
aromatic B-Chemical +
aldehydes I-Chemical -
. O +

These O +
aldol B-Chemical +
reactions O +
furnished O +
the O +
corresponding O +
β B-Chemical -
- I-Chemical -
hydroxy I-Chemical +
ketones I-Chemical +
with O +
up O +
to O +
93 O -
% O +
isolated O +
yield O +
and O +
89 O -
% O +
ee O -
. O +

( B-Chemical -
S I-Chemical -
) I-Chemical -
-2-phenylglycinol I-Chemical +
and O +
Triton B-Chemical +
X-100 I-Chemical +
proved O +
to O +
be O +
the O +
best O +
organocatalyst O +
and O +
surfactant O -
, O +
respectively O -
. O +

Allen O +
Brain O +
Atlas O -
: O +
an O +
integrated O +
spatio O -
- O -
temporal O +
portal O +
for O +
exploring O +
the O +
central O +
nervous O +
system O -
. O +

The O +
Allen O +
Brain O +
Atlas O +
( O -
http://www.brain-map.org O -
) O +
provides O +
a O +
unique O +
online O +
public O +
resource O +
integrating O +
extensive O +
gene O +
expression O +
data O -
, O +
connectivity O +
data O +
and O +
neuroanatomical O +
information O +
with O +
powerful O +
search O +
and O +
viewing O +
tools O +
for O +
the O +
adult O +
and O +
developing O +
brain O +
in O +
mouse O -
, O +
human O +
and O +
non O -
- O -
human O +
primate O -
. O +

Here O -
, O +
we O +
review O +
the O +
resources O +
available O +
at O +
the O +
Allen O +
Brain O +
Atlas O -
, O +
describing O +
each O +
product O +
and O +
data O +
type O +
[ O -
such O +
as O +
in O +
situ O +
hybridization O +
( O -
ISH O -
) O +
and O +
supporting O +
histology O -
, O +
microarray O -
, O +
RNA O +
sequencing O -
, O +
reference O +
atlases O -
, O +
projection O +
mapping O +
and O +
magnetic O +
resonance O +
imaging O -
] O -
. O +

In O +
addition O -
, O +
standardized O +
and O +
unique O +
features O +
in O +
the O +
web O +
applications O +
are O +
described O +
that O +
enable O +
users O +
to O +
search O +
and O +
mine O +
the O +
various O +
data O +
sets O -
. O +

Features O +
include O +
both O +
simple O +
and O +
sophisticated O +
methods O +
for O +
gene O +
searches O -
, O +
colorimetric O +
and O +
fluorescent O +
ISH O +
image O +
viewers O -
, O +
graphical O +
displays O +
of O +
ISH O -
, O +
microarray O +
and O +
RNA O +
sequencing O +
data O -
, O +
Brain O +
Explorer O +
software O +
for O +
3D O +
navigation O +
of O +
anatomy O +
and O +
gene O +
expression O -
, O +
and O +
an O +
interactive O +
reference O +
atlas O +
viewer O -
. O +

In O +
addition O -
, O +
cross O +
data O +
set O +
searches O +
enable O +
users O +
to O +
query O +
multiple O +
Allen O +
Brain O +
Atlas O +
data O +
sets O +
simultaneously O -
. O +

All O +
of O +
the O +
Allen O +
Brain O +
Atlas O +
resources O +
can O +
be O +
accessed O +
through O +
the O +
Allen O +
Brain O +
Atlas O +
data O +
portal O -
. O +

Arcuate O +
nucleus O +
homeostatic O +
systems O +
are O +
not O +
altered O +
immediately O +
prior O +
to O +
the O +
scheduled O +
consumption O +
of O +
large O -
, O +
binge O -
- O -
type O +
meals O +
of O +
palatable O +
solid O +
or O +
liquid O +
diet O +
in O +
rats O +
and O +
Mice O -
. O +

Meal O +
feeding O +
is O +
a O +
critical O +
issue O +
in O +
the O +
over O -
- O -
consumption O +
of O +
calories O +
leading O +
to O +
human O +
obesity O -
. O +

To O +
investigate O +
the O +
mechanisms O +
involved O +
in O +
the O +
regulation O +
of O +
meal O +
feeding O +
in O +
rodents O -
, O +
we O +
studied O +
a O +
scheduled O +
feeding O +
regime O +
that O +
induces O +
substantial O +
food O +
intake O +
over O +
short O +
periods O +
of O +
time O -
. O +

Male O +
Sprague O -
- O -
Dawley O +
rats O +
and O +
C57BL6 O +
mice O +
were O +
fed O +
one O +
of O +
four O +
palatable O +
diets O +
[ O -
45 O -
% O +
fat O +
pellet O -
, O +
60 O -
% O +
fat O +
pellet O +
or O +
standard O +
pellet O +
supplemented O +
with O +
Ensure O +
( O -
EN O -
; O +
Abbott O +
Laboratories O -
, O +
Maidenhead O -
, O +
UK O -
) O +
or O +
12.5 O -
% O +
sucrose O +
( O -
SUC O -
) O -
] O +
either O +
ad O +
lib O -
. O +
or O +
with O +
daily O +
2-h O +
scheduled O +
access O +
and O +
standard O +
pellet O +
available O +
for O +
22 O +
h. O +
Energy O +
balance O +
gene O +
expression O +
in O +
the O +
hypothalamic O +
arcuate O +
nucleus O +
( O -
ARC O -
) O +
and O +
nucleus O +
accumbens O +
( O -
NAcc O -
) O +
reward O +
gene O +
expression O +
were O +
assessed O +
by O +
in O +
situ O +
hybridisation O -
. O +

Rats O +
fed O +
ad O +
lib O -
. O +

on O +
45 O -
% O +
or O +
60 O -
% O +
fat O +
diet O +
were O +
heavier O +
and O +
fatter O +
than O +
controls O -
, O +
and O +
had O +
reduced O +
neuropeptide O +
Y O +
( O -
NPY O -
) O +
gene O +
expression O +
in O +
the O +
ARC O -
. O +

Mice O +
fed O +
ad O +
lib O -
. O +

on O +
any O +
of O +
the O +
palatable O +
diets O +
were O +
heavier O -
, O +
fatter O +
and O +
had O +
higher O +
blood O +
leptin O +
than O +
controls O -
, O +
and O +
had O +
reduced O +
NPY O +
and O +
increased O +
cocaine- B-Chemical +
and O -
- O -
amphetamine B-Chemical -
- O -
regulated O +
transcript O +
mRNA O +
in O +
the O +
ARC O -
. O +

Schedule O -
- O -
fed O +
rats O +
and O +
mice O +
quickly O +
adapted O +
their O +
feeding O +
behaviour O +
to O +
2-h O +
access O +
on O +
palatable O +
food O -
. O +

Three O +
schedule O -
- O -
fed O +
groups O +
binged O -
: O +
the O +
percentage O +
of O +
daily O +
calories O +
consumed O +
in O +
2 O +
h O +
on O +
45 O -
% O +
fat O +
diet O -
, O +
60 O -
% O +
fat O +
diet O +
or O +
EN O -
, O +
respectively O -
, O +
was O +
55 O -
% O -
, O +
63 O -
% O +
and O +
49 O -
% O +
in O +
rats O -
, O +
and O +
86 O -
% O -
, O +
86 O -
% O +
and O +
45 O -
% O +
in O +
mice O -
. O +

However O -
, O +
changed O +
feeding O +
behaviour O +
was O +
not O +
reflected O +
in O +
an O +
induction O +
of O +
orexigenic O +
neuropeptide O +
or O +
suppression O +
of O +
anorexigenic O +
neuropeptide O +
gene O +
expression O +
in O +
the O +
ARC O -
, O +
in O +
the O +
2-h O +
period O +
prior O +
to O +
scheduled O +
feeding O -
. O +

The O +
mechanisms O +
underlying O +
large O +
meal O -
/ O -
binge O -
- O -
type O +
eating O +
may O +
be O +
regulated O +
by O +
nonhomeostatic O +
processes O +
involving O +
other O +
genes O +
in O +
the O +
hypothalamus O +
or O +
other O +
brain O +
areas O -
. O +

However O -
, O +
assessment O +
of O +
opioid O +
and O +
dopamine B-Chemical +
receptor O +
gene O +
expression O +
in O +
the O +
NAcc O +
did O +
not O +
reveal O +
evidence O +
of O +
the O +
involvement O +
of O +
these O +
genes O +
in O +
driving O +
large O +
meals O -
, O +
at O +
least O +
at O +
the O +
investigated O +
time O +
point O -
. O +

A O +
potential O +
practical O +
approach O +
to O +
reduce O +
Ara O +
h O +
6 O +
allergenicity O +
by O +
gamma O +
irradiation O -
. O +

Peanut O +
allergen O +
Ara O +
h O +
6 O +
was O +
isolated O +
and O +
irradiated O +
at O +
1 O -
, O +
3 O -
, O +
5 O -
, O +
or O +
10 O +
kGy O -
, O +
and O +
a O +
whole O +
peanut O +
protein O +
extract O +
( O -
WPPE O -
) O +
was O +
also O +
treated O +
by O +
irradiation O -
. O +

Alteration O +
in O +
structure O +
of O +
Ara O +
h O +
6 O +
was O +
characterised O +
by O +
circular O +
dichroism O +
( O -
CD O -
) O +
spectroscopy O -
, O +
ultraviolet O +
( O -
UV O -
) O +
absorption O +
spectroscopy O -
, O +
fluorescence O +
spectroscopy O +
and O +
SDS B-Chemical -
- O -
PAGE O -
, O +
and O +
antigenicity O +
was O +
evaluated O +
by O +
immunoblotting O +
and O +
indirect O +
ELISA O +
with O +
anti O -
- O -
Ara O +
h O +
6 O +
polyclonal O +
antibody O -
. O +

Irradiation O +
induced O +
significant O +
changes O +
in O +
the O +
secondary O +
and O +
tertiary O +
structures O +
of O +
Ara O +
h O +
6 O -
, O +
and O +
the O +
antigenicity O +
of O +
both O +
purified O +
Ara O +
h O +
6 O +
and O +
WPPE O +
were O +
reduced O +
upon O +
increasing O +
the O +
irradiation O +
doses O -
. O +

Moreover O -
, O +
a O +
good O +
correlation O +
between O +
the O +
loss O +
in O +
α O -
- O -
helix O +
and O +
IgG O +
binding O +
to O +
Ara O +
h O +
6 O +
was O +
observed O -
. O +

This O +
indicated O +
that O +
irradiation O +
might O +
be O +
an O +
efficient O +
approach O +
to O +
reduce O +
or O +
eliminate O +
peanut O +
allergenicity O -
. O +

Analysis O +
of O +
total O +
polyphenols B-Chemical +
in O +
wines O +
by O +
FIA O +
with O +
highly O +
stable O +
amperometric O +
detection O +
using O +
carbon B-Chemical +
nanotube O -
- O -
modified O +
electrodes O -
. O +

The O +
use O +
of O +
glassy O +
carbon B-Chemical +
electrodes O +
( O -
GCEs O -
) O +
modified O +
with O +
multi O -
- O -
walled O +
carbon B-Chemical +
nanotube O +
( O -
CNT O -
) O +
films O +
for O +
the O +
continuous O +
monitoring O +
of O +
polyphenols B-Chemical +
in O +
flow O +
systems O +
has O +
been O +
examined O -
. O +

The O +
performance O +
of O +
these O +
modified O +
electrodes O +
was O +
evaluated O +
and O +
compared O +
to O +
bare O +
GCE O +
by O +
cyclic O +
voltammetry O +
experiments O +
and O +
by O +
flow O +
injection O +
analysis O +
( O -
FIA O -
) O +
with O +
amperometric O +
detection O +
monitoring O +
the O +
response O +
of O +
gallic B-Chemical -
, I-Chemical +
caffeic I-Chemical -
, I-Chemical +
ferulic I-Chemical +
and I-Chemical +
p I-Chemical -
- I-Chemical -
coumaric I-Chemical +
acids I-Chemical +
in O +
0.050 O +
M O +
acetate B-Chemical +
buffer O +
pH O +
4.5 O +
containing O +
100 O +
mM O +
NaCl B-Chemical -
. O +

The O +
GCE O +
modified O +
with O +
CNT O +
dispersions O +
in O +
polyethyleneimine B-Chemical +
( O -
PEI B-Chemical -
) O +
provided O +
lower O +
overpotentials O -
, O +
higher O +
sensitivity O +
and O +
much O +
higher O +
signal O +
stability O +
under O +
a O +
dynamic O +
regime O +
than O +
bare O +
GCEs O -
. O +

These O +
properties O +
allowed O +
the O +
estimation O +
of O +
the O +
total O +
polyphenol B-Chemical +
content O +
in O +
red O +
and O +
white O +
wines O +
with O +
a O +
remarkable O +
long O -
- O -
term O +
stability O +
in O +
the O +
measurements O +
despite O +
the O +
presence O +
of O +
potential O +
fouling O +
substances O +
in O +
the O +
wine O +
matrix O -
. O +

In O +
addition O -
, O +
the O +
versatility O +
of O +
the O +
electrochemical O +
methodology O +
allowed O +
the O +
selective O +
estimation O +
of O +
the O +
easily O +
oxidisable O +
polyphenol B-Chemical +
fraction O +
as O +
well O +
as O +
the O +
total O +
polyphenol B-Chemical +
content O +
just O +
by O +
tuning O +
the O +
detection O +
potential O +
at O +
+ O -
0.30 O +
or O +
0.70 O +
V O -
, O +
respectively O -
. O +

The O +
significance O +
of O +
the O +
electrochemical O +
results O +
was O +
demonstrated O +
through O +
correlation O +
studies O +
with O +
the O +
results O +
obtained O +
with O +
conventional O +
spectrophotometric O +
assays O +
for O +
polyphenols B-Chemical +
( O -
Folin O -
- O -
Ciocalteu O -
, O +
absorbance O +
at O +
280 O +
nm O +
index O +
and O +
colour O +
intensity O +
index O -
) O -
. O +

Use O +
of O +
an O +
electrodialytic O +
reactor O +
for O +
the O +
simultaneous O +
β O -
- O -
lactoglobulin O +
enzymatic O +
hydrolysis O +
and O +
fractionation O +
of O +
generated O +
bioactive O +
peptides O -
. O +

The O +
enzymatic O +
hydrolysis O +
of O +
β O -
- O -
lactoglobulin O +
and O +
the O +
fractionation O +
of O +
peptides O +
were O +
performed O +
in O +
one O +
step O +
in O +
an O +
electrodialysis O +
cell O +
with O +
ultrafiltration O +
membranes O +
stacked O -
. O +

After O +
240 O +
min O +
of O +
treatment O -
, O +
15 O +
anionic O +
and O +
4 O +
cationic O +
peptides O +
were O +
detected O +
in O +
the O +
anionic O +
and O +
cationic O +
peptide O +
recovery O +
compartments O -
. O +

Amongst O +
these O +
15 O +
anionic O +
peptides O -
, O +
2 O +
hypocholesterolemic O -
, O +
3 O +
antihypertensive O +
and O +
1 O +
antibacterial O +
peptides O +
were O +
recovered O +
and O +
concentrated O +
with O +
migration O +
rates O +
ranging O +
from O +
5.5 O -
% O +
and O +
81.7 O -
% O -
. O +

Amongst O +
the O +
4 O +
cationic O +
peptides O -
, O +
the O +
peptide O +
sequence O +
ALPMHIR O -
, O +
identified O +
as O +
lactokinin B-Chemical +
and O +
known O +
to O +
exert O +
an O +
important O +
antihypertensive O +
effect O -
, O +
was O +
recovered O +
with O +
an O +
estimated O +
66 O -
% O +
migration O +
rate O -
. O +

To O +
our O +
knowledge O -
, O +
it O +
was O +
the O +
first O +
attempt O +
to O +
perform O +
hydrolysis O +
under O +
an O +
electric O +
field O +
and O +
to O +
simultaneously O +
separate O +
anionic O +
and O +
cationic O +
peptides O +
produced O -
. O +

The O +
heat O +
treatment O +
and O +
the O +
gelation O +
are O +
strong O +
determinants O +
of O +
the O +
kinetics O +
of O +
milk O +
proteins O +
digestion O +
and O +
of O +
the O +
peripheral O +
availability O +
of O +
amino B-Chemical +
acids I-Chemical -
. O +

This O +
study O +
aimed O +
to O +
determine O +
the O +
kinetics O +
of O +
milk O +
protein O +
digestion O +
and O +
amino B-Chemical +
acid I-Chemical +
absorption O +
after O +
ingestion O +
of O +
four O +
dairy O +
matrices O +
by O +
six O +
minipigs O -
: O +
unheated O +
or O +
heated O +
skim O +
milk O +
and O +
corresponding O +
rennet O +
gels O -
. O +

Digestive O +
contents O +
and O +
plasma O +
samples O +
were O +
collected O +
over O +
a O +
7 O +
h O -
- O -
period O +
after O +
meal O +
ingestion O -
. O +

Gelation O +
of O +
milk O +
slowed O +
down O +
the O +
outflow O +
of O +
the O +
meal O +
from O +
the O +
stomach O +
and O +
the O +
subsequent O +
absorption O +
of O +
amino B-Chemical +
acids I-Chemical -
, O +
and O +
decreased O +
their O +
bioavailability O +
in O +
peripheral O +
blood O -
. O +

The O +
gelled O +
rennet O +
matrices O +
also O +
led O +
to O +
low O +
levels O +
of O +
milk O +
proteins O +
at O +
the O +
duodenum O -
. O +

Caseins O +
and O +
β O -
- O -
lactoglobulin O -
, O +
respectively O -
, O +
were O +
sensitive O +
and O +
resistant O +
to O +
hydrolysis O +
in O +
the O +
stomach O +
with O +
the O +
unheated O +
matrices O -
, O +
but O +
showed O +
similar O +
digestion O +
with O +
the O +
heated O +
matrices O -
, O +
with O +
a O +
heat O -
- O -
induced O +
susceptibility O +
to O +
hydrolysis O +
for O +
β O -
- O -
lactoglobulin O -
. O +

These O +
results O +
suggest O +
a O +
significant O +
influence O +
of O +
the O +
meal O +
microstructure O +
( O -
resulting O +
from O +
heat O +
treatment O -
) O +
and O +
macrostructure O +
( O -
resulting O +
from O +
gelation O +
process O -
) O +
on O +
the O +
different O +
steps O +
of O +
milk O +
proteins O +
digestion O -
. O +

The O +
presence O +
of O +
D B-Chemical -
- I-Chemical -
fagomine I-Chemical +
in O +
the O +
human O +
diet O +
from O +
buckwheat O -
- O -
based O +
foodstuffs O -
. O +

Buckwheat O +
( O -
Fagopyrum O +
esculentum O +
Moench O -
) O +
groats O +
contain O +
the O +
iminosugar O +
D B-Chemical -
- I-Chemical -
fagomine I-Chemical +
as O +
a O +
minor O +
component O +
that O +
might O +
contribute O +
to O +
the O +
alleged O +
health O +
benefits O +
of O +
this O +
pseudo O -
- O -
cereal O -
. O +

This O +
study O +
presents O +
analysis O +
of O +
D B-Chemical -
- I-Chemical -
fagomine I-Chemical +
in O +
buckwheat O -
- O -
based O +
foodstuffs O +
by O +
liquid O +
chromatography O +
coupled O +
to O +
mass O +
spectrometry O +
and O +
an O +
estimation O +
of O +
its O +
presence O +
in O +
the O +
human O +
diet O +
based O +
on O +
a O +
published O +
population O -
- O -
based O +
cross O -
- O -
sectional O +
nutrition O +
survey O -
. O +

D B-Chemical -
- I-Chemical -
fagomine I-Chemical +
is O +
present O +
in O +
common O +
buckwheat O -
- O -
based O +
foodstuffs O +
in O +
amounts O +
ranging O +
from O +
1 O +
to O +
25 O +
mg O -
/ O -
kg O +
or O +
mg O -
/ O -
L O -
, O +
it O +
is O +
stable O +
during O +
boiling O -
, O +
baking O -
, O +
frying O +
and O +
fermentation O -
, O +
and O +
it O +
is O +
biosynthesised O +
upon O +
sprouting O -
. O +

The O +
estimated O +
total O +
intake O +
of O +
D B-Chemical -
- I-Chemical -
fagomine I-Chemical +
resulting O +
from O +
a O +
diet O +
that O +
includes O +
such O +
foodstuffs O +
would O +
be O +
between O +
3 O +
and O +
17 O +
mg O +
per O +
day O +
( O -
mean O +
for O +
both O +
genders O -
; O +
range O +
from O +
P5 O +
to O +
P95 O -
) O -
. O +

A O +
diet O +
rich O +
in O +
buckwheat O +
products O +
would O +
provide O +
a O +
daily O +
amount O +
of O +
D B-Chemical -
- I-Chemical -
fagomine I-Chemical +
that O +
may O +
in O +
part O +
explain O +
the O +
beneficial O +
properties O +
traditionally O +
attributed O +
to O +
buckwheat O +
consumption O -
. O +

The O +
in O +
vivo O +
antioxidant O +
and O +
antifibrotic O +
properties O +
of O +
green O +
tea O +
( O -
Camellia O +
sinensis O -
, O +
Theaceae O -
) O -
. O +

The O +
in O +
vivo O +
antioxidant O +
and O +
antifibrotic O +
properties O +
of O +
green O +
tea O +
( O -
Camellia O +
sinensis O -
, O +
Theaceae O -
) O +
were O +
investigated O +
with O +
a O +
study O +
of O +
carbon B-Chemical +
tetrachloride I-Chemical +
( O -
CCl B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
) O -
-induced O +
oxidative O +
stress O +
and O +
hepatic O +
fibrosis O +
in O +
male O +
ICR O +
mice O -
. O +

Oral O +
administration O +
of O +
green O +
tea O +
extract O +
at O +
doses O +
of O +
125 O -
, O +
625 O +
and O +
1250 O +
mg O -
/ O -
kg O +
for O +
8 O +
weeks O +
significantly O +
reduced O +
( O -
p<0.05 O -
) O +
the O +
levels O +
of O +
thiobarbituric B-Chemical +
acid I-Chemical -
- O -
reactive O +
substances O +
( O -
TBARS O -
) O +
and O +
protein O +
carbonyls B-Chemical +
in O +
the O +
liver O +
by O +
at O +
least O +
28 O -
% O +
compared O +
with O +
that O +
was O +
induced O +
by O +
CCl B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical +
( O -
1 O +
mL O -
/ O -
kg O -
) O +
in O +
mice O -
. O +

Moreover O -
, O +
green O +
tea O +
extract O +
administration O +
significantly O +
increased O +
( O -
p<0.05 O -
) O +
the O +
activities O +
of O +
catalase O -
, O +
glutathione B-Chemical +
peroxidase O +
( O -
GSH B-Chemical -
- O -
Px O -
) O +
and O +
glutathione B-Chemical +
reductase O +
( O -
GSH B-Chemical -
- O -
Rd O -
) O +
in O +
the O +
liver O -
. O +

Our O +
study O +
found O +
that O +
oral O +
administration O +
of O +
green O +
tea O +
extract O +
prevented O +
CCl B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
-induced O +
hepatic O +
fibrosis O -
, O +
as O +
evidenced O +
by O +
a O +
decreased O +
hydroxyproline B-Chemical +
level O +
in O +
the O +
liver O +
and O +
a O +
reduced O +
incidence O +
of O +
hepatic O +
fibrosis O +
by O +
histological O +
observations O -
. O +

These O +
results O +
indicate O +
that O +
green O +
tea O +
exhibits O +
potent O +
protective O +
effects O +
against O +
CCl B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
-induced O +
oxidative O +
stress O +
and O +
hepatic O +
fibrosis O +
in O +
mice O +
by O +
inhibiting O +
oxidative O +
damage O +
and O +
increasing O +
antioxidant O +
enzyme O +
activities O -
. O +

Whey O +
protein O +
hydrolysate O +
enhances O +
the O +
exercise O -
- O -
induced O +
heat O +
shock O +
protein O +
( O -
HSP70 O -
) O +
response O +
in O +
rats O -
. O +

Whey O +
protein O +
has O +
been O +
suggested O +
to O +
be O +
potential O +
protective O +
agent O +
against O +
various O +
forms O +
of O +
stress O -
. O +

The O +
heat O +
shock O +
protein O +
HSP70 O +
confers O +
greater O +
cellular O +
tolerance O +
against O +
stressors O -
. O +

The O +
present O +
study O +
evaluated O +
the O +
effects O +
of O +
whey O +
protein O +
intake O +
on O +
HSP70 O +
expression O -
. O +

Forty O -
- O -
eight O +
male O +
Wistar O +
rats O +
were O +
divided O +
into O +
sedentary O +
and O +
exercised O +
groups O -
, O +
and O +
each O +
group O +
was O +
fed O +
as O +
a O +
protein O +
source O +
casein O +
( O -
CAS O -
) O -
, O +
whey O +
protein O +
( O -
WP O -
) O +
or O +
whey O +
protein O +
hydrolysate O +
( O -
WPH O -
) O +
for O +
3weeks O -
. O +

Exercise O +
on O +
a O +
treadmill O +
was O +
used O +
as O +
the O +
source O +
of O +
stress O +
in O +
the O +
animals O +
from O +
the O +
exercised O +
group O -
. O +

The O +
results O +
showed O +
a O +
larger O +
increase O +
in O +
HSP70 O +
expression O +
in O +
the O +
soleus O -
, O +
gastrocnemius O +
and O +
lung O +
of O +
the O +
WPH O -
- O -
fed O +
rats O +
than O +
WP O +
or O +
casein O -
- O -
fed O +
rats O -
. O +

HSP70 O +
expression O +
in O +
the O +
sedentary O +
rats O +
was O +
very O +
low O -
, O +
independent O +
of O +
the O +
diet O +
or O +
tissue O -
. O +

Protein O +
carbonyls B-Chemical +
were O +
lower O +
in O +
the O +
group O +
that O +
consumed O +
WPH O -
. O +

These O +
data O +
suggest O +
that O +
the O +
consumption O +
of O +
WPH O +
enhances O +
HSP70 O +
expression O -
. O +

A O +
new O +
QSAR O +
model O -
, O +
for O +
angiotensin B-Chemical +
I I-Chemical -
- O -
converting O +
enzyme O +
inhibitory O +
oligopeptides O -
. O +

A O +
new O +
quantitative O +
structure O +
activity O +
relationship O +
( O -
QSAR O -
) O +
model O +
is O +
established O +
for O +
oligopeptides O +
that O +
inhibit O +
angiotensin B-Chemical +
I I-Chemical -
- O -
converting O +
enzyme O +
( O -
ACE O -
) O -
. O +

Information O +
concerning O +
the O +
C O -
- O -
terminal O +
pentapeptide O +
is O +
considered O +
to O +
describe O +
the O +
peptide O +
structure O +
in O +
the O +
model O -
. O +

A O +
database O +
is O +
constructed O -
, O +
with O +
263 O +
ACE O +
inhibitory O +
peptides O +
and O +
38 O +
physicochemical O +
descriptors O -
, O +
abstracted O +
from O +
the O +
published O +
literature O -
. O +

The O +
model O +
is O +
generated O +
through O +
a O +
generalised O +
linear O +
model O -
, O +
with O +
a O +
gamma O +
distribution O +
that O +
yields O +
a O +
coefficient O +
of O +
determination O +
of O +
94.4 O -
% O -
. O +

The O +
whole O +
C O -
- O -
terminal O +
pentapeptide O +
information O +
is O +
a O +
determinant O +
for O +
modelling O +
the O +
ACE O +
inhibition O +
activity O +
of O +
oligopeptides O -
. O +

Starting O +
from O +
the O +
C O -
- O -
terminus O -
, O +
the O +
C-1 O +
position O +
is O +
the O +
most O +
relevant O +
position O +
in O +
the O +
model O -
; O +
this O +
is O +
followed O +
by O +
position O +
C-4 O -
. O +

In O +
C-1 O -
, O +
there O +
is O +
a O +
preference O +
for O +
aliphatic O +
and O +
tiny O +
residues O -
. O +

However O -
, O +
in O +
the O +
C-4 O +
position O -
, O +
the O +
model O +
indicates O +
a O +
clear O +
preference O +
for O +
bulky O +
hydrophobic O +
amino B-Chemical +
acids I-Chemical +
and O +
for O +
sulphur B-Chemical -
- O -
containing O +
amino B-Chemical +
acids I-Chemical -
. O +

Due O +
to O +
its O +
good O +
predictive O +
capability O -
, O +
this O +
model O +
could O +
be O +
used O +
as O +
a O +
tool O +
for O +
identifying O +
and O +
prioritizing O +
the O +
potential O +
ACE O +
inhibitory O +
peptides O +
present O +
in O +
a O +
complex O +
matrix O -
. O +

Total O +
polyphenols B-Chemical -
, O +
catechin B-Chemical +
profiles O +
and O +
antioxidant O +
activity O +
of O +
tea O +
products O +
from O +
purple O +
leaf O +
coloured O +
tea O +
cultivars O -
. O +

Black O +
( O -
aerated O -
) O +
and O +
green O +
( O -
unaerated O -
) O +
tea O +
products O -
, O +
processed O +
from O +
10 O +
green O +
and O +
18 O +
purple O +
leaf O +
coloured O +
cultivars O +
of O +
Kenyan O +
origin O -
, O +
and O +
two O +
tea O +
products O -
, O +
from O +
the O +
Japanese O +
cultivars O -
, O +
Yabukita O +
and O +
Yutakamidori O -
, O +
were O +
assayed O +
for O +
total O +
polyphenols B-Chemical +
( O -
TP O -
) O +
content O -
, O +
individual O +
catechin B-Chemical +
profiles O +
and O +
in O +
vitro O +
antioxidant O +
capacity O +
( O -
AA O -
) O -
. O +

In O +
addition O -
, O +
the O +
phenolic B-Chemical +
content O +
of O +
the O +
tea O +
products O +
was O +
determined O +
using O +
the O +
Folin B-Chemical -
- I-Chemical -
Ciocalteu I-Chemical +
phenol I-Chemical +
reagent O -
. O +

Catechin B-Chemical +
fractions O +
were O +
identified O +
using O +
reverse O +
phase O +
high O +
performance O +
liquid O +
chromatography O +
( O -
HPLC O -
) O +
with O +
a O +
binary O +
gradient O +
elution O +
system O -
. O +

The O +
AA% O +
of O +
the O +
tea O +
products O +
was O +
determined O +
using O +
a O +
2,2'-diphenyl B-Chemical +
picrylhydrazyl I-Chemical +
( O -
DPPH B-Chemical -
) O +
radical O +
assay O +
method O -
. O +

The O +
results O +
showed O +
that O +
TPs O -
, O +
catechin B-Chemical +
profiles O +
and O +
antioxidant O +
activities O +
were O +
significantly O +
( O -
p≤0.05 O -
) O +
higher O +
in O +
unaerated O +
than O +
in O +
aerated O +
teas O -
. O +

Tea O +
products O +
from O +
the O +
purple O +
leaf O +
coloured O +
tea O +
cultivars O +
had O +
levels O +
of O +
TPs O -
, O +
total O +
catechin B-Chemical +
( O -
TC O -
) O +
and O +
antioxidant O +
activities O +
similar O +
to O +
those O +
from O +
the O +
green O +
leaf O +
coloured O +
cultivars O -
, O +
except O +
for O +
teas O +
from O +
the O +
Japanese O +
cultivars O +
that O +
were O +
very O +
low O +
in O +
the O +
assayed O +
parameters O -
. O +

Caffeine B-Chemical +
content O +
was O +
significantly O +
( O -
p≤0.05 O -
) O +
lower O +
in O +
products O +
from O +
the O +
purple O +
leaf O +
coloured O +
cultivars O +
than O +
in O +
those O +
from O +
the O +
green O +
leaf O +
coloured O +
tea O +
cultivars O -
. O +

Antioxidant O +
activity O +
( O -
% O -
) O +
was O +
higher O +
in O +
tea O +
products O +
from O +
the O +
Kenyan O +
germplasm O +
than O +
in O +
those O +
from O +
the O +
Japanese O +
cultivars O -
. O +

Antioxidant O +
potency O +
of O +
tea O +
products O +
was O +
significantly O +
( O -
r=0.789 O -
( O -
∗∗ O -
) O -
, O +
p≤0.01 O -
) O +
influenced O +
by O +
the O +
total O +
anthocyanin B-Chemical +
content O +
of O +
the O +
purple O +
leaf O +
coloured O +
cultivars O -
. O +

Cyanidin-3-O B-Chemical -
- I-Chemical -
glucoside I-Chemical +
was O +
the O +
anthocyanin B-Chemical +
most O +
highly O +
correlated O +
with O +
AA% O +
( O -
r=0.843 O -
( O -
∗∗ O -
) O -
, O +
p≤0.01 O +
in O +
unaerated O +
tea O -
) O -
. O +

Total O +
catechins B-Chemical +
in O +
the O +
unaerated O +
products O +
from O +
the O +
green O +
leaf O +
coloured O +
tea O +
cultivars O +
were O +
also O +
significantly O +
correlated O +
with O +
antioxidant O +
capacity O +
( O -
r=0.818 O -
( O -
∗∗ O -
) O -
, O +
p≤0.01 O -
) O -
. O +

Results O +
from O +
this O +
study O +
suggest O +
that O +
the O +
antioxidant O +
potency O +
of O +
teas O +
is O +
dependent O +
on O +
the O +
predominant O +
flavonoid B-Chemical +
compound O -
, O +
the O +
type O +
of O +
tea O +
cultivar O +
and O +
the O +
processing O +
method O -
. O +

Simple O +
multiresidue O +
extraction O +
method O +
for O +
the O +
determination O +
of O +
fungicides O +
and O +
plant O +
growth O +
regulator O +
in O +
bean O +
sprouts O +
using O +
low O +
temperature O +
partitioning O +
and O +
tandem O +
mass O +
spectrometry O -
. O +

A O +
simple O +
multiresidue O +
analytical O +
method O +
is O +
developed O +
for O +
the O +
simultaneous O +
determination O +
of O +
carbendazim B-Chemical +
( O -
CB O -
) O -
, O +
thiabendazole B-Chemical +
( O -
TB O -
) O -
, O +
and O +
6-benzyl B-Chemical +
aminopurine I-Chemical +
( O -
6-BA B-Chemical -
) O +
in O +
bean O +
sprouts O -
. O +

The O +
samples O +
were O +
extracted O +
with O +
acetonitrile B-Chemical +
followed O +
by O +
partitioning O +
at O +
-80 O -
° O -
C O +
for O +
5 O -
- O -
10 O +
min O -
. O +

A O +
YMC O +
C O -
( O -
8 O -
) O +
column O +
was O +
used O +
to O +
separate O +
the O +
analytes O +
before O +
being O +
qualitatively O +
and O +
quantitatively O +
determined O +
by O +
liquid O +
chromatography O -
- O -
electrospray O +
ionization O +
tandem O +
mass O +
spectrometry O +
( O -
LC O -
- O -
ESI O -
- O -
MS O -
/ O -
MS O -
) O +
in O +
positive O +
ion O +
mode O +
using O +
multiple O +
reaction O +
monitoring O +
( O -
MRM O -
) O -
. O +

The O +
matrix O -
- O -
matched O +
calibration O +
curves O +
showed O +
good O +
linearity O +
in O +
the O +
range O +
0.01 O -
- O -
1.0 O +
mg O -
/ O -
kg O +
with O +
correlation O +
coefficients O +
in O +
excess O +
of O +
0.998 O -
. O +

The O +
mean O +
recoveries O +
were O +
in O +
the O +
range O +
of O +
80.4 O -
- O -
96.3 O -
% O +
at O +
0.1 O +
and O +
0.5 O +
spiked O +
levels O -
, O +
and O +
the O +
relative O +
standard O +
deviations O +
( O -
RSDs O -
) O +
were O +
in O +
the O +
range O +
of O +
0.5 O -
- O -
7.6 O -
% O -
. O +

The O +
limits O +
of O +
quantifications O +
( O -
LOQ O -
) O +
were O +
in O +
the O +
range O +
of O +
0.005 O -
- O -
0.01 O +
mg O -
/ O -
kg O -
. O +

The O +
method O +
was O +
successfully O +
applied O +
to O +
90 O +
samples O +
( O -
among O +
which O +
45 O +
were O +
organic O -
) O +
collected O +
from O +
a O +
commercial O +
bean O +
sprout O +
production O +
house O +
throughout O +
the O +
city O -
. O +

Except O +
for O +
6-BA B-Chemical -
, O +
the O +
rest O +
of O +
the O +
analytes O +
had O +
values O +
lower O +
than O +
their O +
LOQs O -
. O +

In O +
sum O -
, O +
carbendazim B-Chemical -
, O +
thiabendazole B-Chemical -
, O +
and O +
6-BA B-Chemical +
were O +
extracted O +
in O +
a O +
single O +
step O -
, O +
and O +
no O +
steps O +
for O +
clean O -
- O -
up O +
or O +
concentration O +
of O +
the O +
extracts O +
were O +
needed O -
. O +

The O +
current O +
method O +
can O +
be O +
used O +
for O +
sensitive O +
and O +
accurate O +
determination O +
and O +
confirmation O +
of O +
residues O +
in O +
bean O +
sprout O +
samples O -
. O +

Screening O +
of O +
whey O +
protein O +
isolate O +
hydrolysates O +
for O +
their O +
dual O +
functionality O -
: O +
influence O +
of O +
heat O +
pre O -
- O -
treatment O +
and O +
enzyme O +
specificity O -
. O +

Heat O +
pre O -
- O -
treated O +
and O +
non O +
heat O +
pre O -
- O -
treated O +
whey O +
protein O +
isolate O +
( O -
WPI O -
) O +
were O +
hydrolysed O +
using O +
α O -
- O -
chymotrypsin O +
( O -
chymotrypsin O -
) O -
, O +
pepsin O +
and O +
trypsin O -
. O +

The O +
in O +
vitro O +
antioxidant O +
activity O -
, O +
ACE O -
- O -
inhibition O +
activity O +
and O +
surface O +
hydrophobicities O +
of O +
the O +
hydrolysates O +
were O +
measured O +
in O +
order O +
to O +
determine O +
if O +
peptides O +
with O +
dual O +
functionalities O +
were O +
present O -
. O +

Dual O +
functional O +
peptides O +
have O +
both O +
biological O +
( O -
e.g. O +
antioxidant O -
, O +
ACE O -
- O -
inhibition O -
, O +
opioid O +
activities O -
) O +
and O +
technological O +
( O -
e.g. O +
nanoemulsification O +
abilities O -
) O +
functions O +
in O +
food O +
systems O -
. O +

Heat O +
pre O -
- O -
treatment O +
marginally O +
enhanced O +
the O +
hydrolysis O +
of O +
WPI O +
by O +
pepsin O +
and O +
trypsin O +
but O +
had O +
no O +
effect O +
on O +
WPI O +
hydrolysis O +
with O +
chymotrypsin O -
. O +

With O +
the O +
exception O +
of O +
the O +
hydrolysis O +
by O +
trypsin O -
, O +
heat O +
pre O -
- O -
treatment O +
did O +
not O +
affect O +
the O +
peptide O +
profile O +
of O +
the O +
hydrolysates O +
as O +
analysed O +
using O +
size O +
exclusion O +
chromatography O -
, O +
or O +
the O +
antioxidant O +
activity O +
( O -
P>0.05 O -
) O -
. O +

Heat O +
pre O -
- O -
treatment O +
significantly O +
affected O +
the O +
ACE O -
- O -
inhibition O +
activities O +
and O +
the O +
surface O +
hydrophobicities O +
of O +
the O +
hydrolysates O +
( O -
P<0.05 O -
) O -
, O +
which O +
was O +
a O +
function O +
of O +
the O +
specificity O +
of O +
the O +
hydrolysing O +
enzyme O -
. O +

Extended O +
hydrolysis O +
( O -
up O +
to O +
24 O +
h O -
) O +
had O +
no O +
significant O +
effect O +
on O +
the O +
DH O +
and O +
the O +
molecular O +
weight O +
profiles O +
( O -
P>0.05 O -
) O +
but O +
in O +
some O +
instances O +
caused O +
a O +
reduction O +
in O +
the O +
antioxidant O +
activity O +
of O +
WPI O +
hydrolysates O -
. O +

The O +
chymotrypsin O +
hydrolysate O +
showed O +
a O +
broad O +
MW O +
size O +
range O -
, O +
and O +
was O +
followed O +
by O +
pepsin O +
and O +
then O +
trypsin O -
. O +

The O +
bioactivities O +
of O +
the O +
hydrolysates O +
generally O +
decreased O +
in O +
the O +
order O -
; O +
chymotrypsin O -
> O -
trypsin O -
> O -
pepsin O -
. O +

This O +
study O +
showed O +
that O +
by O +
manipulating O +
protein O +
conformation O +
with O +
pre O -
- O -
hydrolysis O +
heat O +
treatment O -
, O +
combined O +
with O +
careful O +
enzyme O +
selection O -
, O +
peptides O +
with O +
dual O +
functionalities O +
can O +
be O +
produced O +
from O +
WPI O +
for O +
use O +
as O +
functional O +
ingredients O +
in O +
the O +
manufacture O +
of O +
functional O +
foods O -
. O +

Purification O -
, O +
physicochemical O +
characterisation O +
and O +
anticancer O +
activity O +
of O +
a O +
polysaccharide O +
from O +
Cyclocarya O +
paliurus O +
leaves O -
. O +

A O +
Cyclocarya O +
paliurus O +
( O -
Batal O -
. O -
) O +

Iljinskaja O +
polysaccharide O +
( O -
CPP O -
) O +
was O +
isolated O +
and O +
purified O +
by O +
hot O +
water O +
extraction O -
, O +
ethanol B-Chemical +
precipitation O -
, O +
deproteinisation O +
and O +
anion O -
- O -
exchange O +
chromatography O -
. O +

Its O +
physicochemical O +
properties O +
were O +
characterised O +
by O +
gel O +
permeation O +
chromatography O +
( O -
GPC O -
) O -
, O +
gas O +
chromatography O -
- O -
mass O +
spectrometry O +
( O -
GC O -
- O -
MS O -
) O -
, O +
thermal O +
gravimetric O +
analysis O +
( O -
TGA O -
) O -
, O +
Fourier O +
transform O +
infrared O +
spectrometry O +
( O -
FTIR O -
) O -
, O +
UV O -
- O -
visible O +
spectrophotometry O -
, O +
dynamic O +
light O +
scattering O +
( O -
DLS O -
) O +
and O +
viscometry O +
analysis O -
. O +

The O +
anticancer O +
effect O +
of O +
CPP O +
in O +
human O +
gastric O +
cancer O +
HeLa O +
cells O +
was O +
also O +
evaluated O +
by O +
3- B-Chemical -
( I-Chemical -
4,5-dimethylthiazol-2-yl I-Chemical -
) I-Chemical -
-2,5-diphenyltetrazolium I-Chemical +
bromide I-Chemical +
( O -
MTT B-Chemical -
) O +
assay O -
. O +

The O +
results O +
showed O +
that O +
the O +
molecular O +
weight O +
of O +
CPP O +
was O +
900 O +
kDa O -
, O +
and O +
it O +
contained O +
64.8 O -
% O +
total O +
sugar O -
, O +
23.5 O -
% O +
uronic B-Chemical +
acid I-Chemical -
, O +
9.26 O -
% O +
protein O -
, O +
and O +
six O +
kinds O +
of O +
monosaccharides B-Chemical -
, O +
including O +
glucose B-Chemical -
, O +
rhamnose B-Chemical -
, O +
arabinose B-Chemical -
, O +
xylose B-Chemical -
, O +
mannose B-Chemical +
and O +
galactose B-Chemical -
, O +
with O +
molar O +
percentages O +
of O +
32.7 O -
% O -
, O +
9.33 O -
% O -
, O +
30.6 O -
% O -
, O +
3.48 O -
% O -
, O +
10.4 O -
% O -
, O +
and O +
13.5 O -
% O -
, O +
respectively O -
. O +

Furthermore O -
, O +
the O +
results O +
showed O +
that O +
CPP O +
exhibited O +
a O +
strong O +
inhibition O +
effect O +
on O +
the O +
growth O +
of O +
human O +
gastric O +
cancer O +
HeLa O +
cells O -
. O +

Field O +
application O +
of O +
farm O -
- O -
food O +
safety O +
risk O +
assessment O +
( O -
FRAMp O -
) O +
tool O +
for O +
small O +
and O +
medium O +
fresh O +
produce O +
farms O -
. O +

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
develop O +
a O +
farm O +
food O +
safety O -
- O -
risk O +
assessment O +
tool O +
( O -
FRAMp O -
) O +
which O +
serves O +
as O +
a O +
self O -
- O -
assessment O +
and O +
educational O +
tool O +
for O +
fresh O +
produce O +
farms O -
. O +

FRAMp O +
was O +
developed O +
in O +
Microsoft O -
® O +
Excel O +
spreadsheet O +
software O +
using O +
standard O +
mathematical O +
and O +
logical O +
functions O +
and O +
utilised O +
a O +
qualitative O +
risk O +
assessment O +
approach O +
for O +
farmers O +
to O +
evaluate O +
their O +
food O +
safety O +
practices O -
. O +

The O +
FRAMp O +
tool O +
has O +
since O +
been O +
tested O +
on O +
12 O +
fresh O +
produce O +
farms O +
throughout O +
UK O -
. O +

All O +
the O +
farms O +
determined O +
that O +
FRAMp O +
was O +
interesting O +
but O +
17 O -
% O +
found O +
it O +
too O +
long O +
while O +
25 O -
% O +
of O +
the O +
farms O +
felt O +
the O +
tool O +
was O +
too O +
complicated O -
. O +

The O +
instructions O +
on O +
FRAMp O +
usage O +
were O +
revised O +
and O +
farmers O +
were O +
given O +
the O +
options O +
to O +
skip O +
and O +
select O +
specific O +
steps O +
in O +
the O +
farm O +
risk O +
assessment O -
. O +

The O +
end O +
users O +
( O -
farmers O -
/ O -
farm O +
managers O -
) O +
determined O +
that O +
developing O +
their O +
own O +
action O +
plans O +
and O +
using O +
it O +
as O +
proof O +
of O +
assessment O +
for O +
future O +
third O -
- O -
party O +
audits O +
were O +
most O +
useful O +
to O +
them O -
. O +

FRAMp O +
tool O +
can O +
be O +
described O +
as O +
an O +
illustrative O +
risk O +
ranking O +
tool O +
to O +
facilitate O +
farms O +
to O +
identify O +
potential O +
risk O +
factors O +
during O +
their O +
crop O +
production O -
. O +

Synthesis O +
and O +
antiplasmodial O +
evaluation O +
of O +
novel O +
( B-Chemical -
4-aminobutyloxy I-Chemical -
) I-Chemical -
quinolines I-Chemical -
. O +

A O +
variety O +
of O +
5- B-Chemical -
, I-Chemical +
6- I-Chemical +
and I-Chemical +
8- I-Chemical -
( I-Chemical -
4-aminobutyloxy I-Chemical -
) I-Chemical -
quinolines I-Chemical +
as O +
novel O +
oxygen B-Chemical +
analogues O +
of O +
known O +
4- B-Chemical +
and I-Chemical +
8- I-Chemical -
( I-Chemical -
4-aminobutylamino I-Chemical -
) I-Chemical -
quinoline I-Chemical +
antimalarial O +
drugs O +
was O +
generated O +
from O +
hydroxyquinolines B-Chemical +
through O +
a O +
three O -
- O -
step O +
approach O +
with O +
a O +
rhodium B-Chemical -
- O -
catalyzed O +
hydroformylation O +
as O +
the O +
key O +
step O -
. O +

Antiplasmodial O +
assays O +
of O +
these O +
new O +
quinolines B-Chemical +
revealed O +
micromolar O +
potency O +
for O +
all O +
representatives O +
against O +
a O +
chloroquine B-Chemical -
- O -
sensitive O +
strain O +
of O +
Plasmodium O +
falciparum O -
, O +
and O +
three O +
compounds O +
showed O +
submicromolar O +
activity O +
against O +
a O +
chloroquine B-Chemical -
- O -
resistant O +
strain O +
of O +
P. O +
falciparum O +
with O +
IC O -
( O -
50 O -
) O -
-values O +
ranging O +
between O +
150 O +
and O +
680 O +
nM. O +

Reproductive O +
experience O +
modifies O +
the O +
effects O +
of O +
estradiol B-Chemical +
on O +
learning O +
and O +
memory O +
bias O +
in O +
female O +
rats O -
. O +

Previous O +
studies O +
have O +
shown O +
that O +
estrogen B-Chemical +
affects O +
whether O +
a O +
hippocampus O -
- O -
mediated O +
place O +
( O -
allocentric O -
) O +
or O +
a O +
striatum O -
- O -
mediated O +
response O +
( O -
egocentric O -
) O +
memory O +
system O +
is O +
employed O +
by O +
female O +
rats O +
when O +
searching O +
for O +
a O +
food O +
reward O +
in O +
a O +
maze O -
. O +

Because O +
it O +
has O +
been O +
suggested O +
that O +
reproductive O +
experience O +
alters O +
some O +
of O +
the O +
responses O +
to O +
E O +
in O +
the O +
brain O -
, O +
two O +
experiments O +
were O +
carried O +
out O +
to O +
investigate O +
whether O +
reproductive O +
experience O +
would O +
also O +
alter O +
the O +
effect O +
of O +
E O +
on O +
place O +
and O +
response O +
learning O -
. O +

In O +
experiment O +
1 O -
, O +
152 O +
ovariectomized O +
nulliparous O +
( O -
n=77 O -
; O +
no O +
reproductive O +
experience O -
) O +
and O +
primiparous O +
( O -
n=74 O -
; O +
having O +
had O +
and O +
raised O +
one O +
litter O +
of O +
pups O -
) O +

Wistar O +
rats O +
were O +
trained O +
on O +
an O +
ambiguous O +
t O -
- O -
maze O +
task O +
and O +
tested O +
for O +
memory O +
system O +
bias O -
. O +

In O +
experiment O +
2 O -
, O +
35 O +
ovariectomized O +
nulliparous O +
( O -
n=16 O -
) O +
and O +
primiparous O +
( O -
n=19 O -
) O +
Wistar O +
rats O +
were O +
trained O +
on O +
place O +
and O +
response O +
plus O -
- O -
maze O +
tasks O -
. O +

All O +
rats O +
were O +
exposed O +
to O +
no O -
, O +
chronic O +
low O +
or O +
chronic O +
low O +
with O +
pulsatile O +
high O +
17β B-Chemical -
- I-Chemical -
estradiol I-Chemical +
( O -
E2 O -
) O +
replacement O -
. O +

Congruent O +
with O +
previous O +
findings O -
, O +
low O +
E2 O +
nulliparous O +
rats O +
showed O +
predominant O +
use O +
of O +
response O +
memory O +
and O +
faster O +
response O +
learning O -
, O +
whereas O +
high O +
E2 O +
nulliparous O +
rats O +
showed O +
a O +
trend O +
towards O +
predominant O +
place O +
memory O +
use O -
. O +

Interestingly O -
, O +
the O +
facilitatory O +
effect O +
of O +
low O +
E2 O +
on O +
response O +
task O +
learning O +
and O +
memory O +
seen O +
in O +
nulliparous O +
rats O +
was O +
not O +
observed O +
in O +
low O +
E2 O +
primiparous O +
rats O +
in O +
either O +
experiment O -
. O +

In O +
conclusion O -
, O +
E2 O +
levels O +
do O +
dictate O +
the O +
rate O +
at O +
which O +
female O +
rats O +
learn O +
a O +
response O +
task O +
and O +
utilize O +
response O +
memory O -
, O +
but O +
only O +
in O +
those O +
with O +
no O +
reproductive O +
experience O -
. O +

Ubiquitin O -
- O -
dependent O +
regulation O +
of O +
phospho B-Chemical -
- O -
AKT O +
dynamics O +
by O +
the O +
ubiquitin O +
E3 O +
ligase O -
, O +
NEDD4 O -
- O -
1 O -
, O +
in O +
the O +
insulin O -
- O -
like O +
growth O +
factor-1 O +
response O -
. O +

AKT O +
is O +
a O +
critical O +
effector O +
kinase O +
downstream O +
of O +
the O +
PI3 O -
K O +
pathway O +
that O +
regulates O +
a O +
plethora O +
of O +
cellular O +
processes O +
including O +
cell O +
growth O -
, O +
death O -
, O +
differentiation O -
, O +
and O +
migration O -
. O +

Mechanisms O +
underlying O +
activated O +
phospho B-Chemical -
- O -
AKT O +
( O -
pAKT O -
) O +
translocation O +
to O +
its O +
action O +
sites O +
remain O +
unclear O -
. O +

Here O +
we O +
show O +
that O +
NEDD4 O -
- O -
1 O +
is O +
a O +
novel O +
E3 O +
ligase O +
that O +
specifically O +
regulates O +
ubiquitin O -
- O -
dependent O +
trafficking O +
of O +
pAKT O +
in O +
insulin O -
- O -
like O +
growth O +
factor O +
( O -
IGF O -
) O -
-1 O +
signaling O -
. O +

NEDD4 O -
- O -
1 O +
physically O +
interacts O +
with O +
AKT O +
and O +
promotes O +
HECT O +
domain O -
- O -
dependent O +
ubiquitination O +
of O +
exogenous O +
and O +
endogenous O +
AKT O -
. O +

NEDD4 O -
- O -
1 O +
catalyzes O +
K63-type O +
polyubiquitin O +
chain O +
formation O +
on O +
AKT O +
in O +
vitro O -
. O +

Plasma O +
membrane O +
binding O +
is O +
the O +
key O +
step O +
for O +
AKT O +
ubiquitination O +
by O +
NEDD4 O -
- O -
1 O +
in O +
vivo O -
. O +

Ubiquitinated O +
pAKT O +
translocates O +
to O +
perinuclear O +
regions O -
, O +
where O +
it O +
is O +
released O +
into O +
the O +
cytoplasm O -
, O +
imported O +
into O +
the O +
nucleus O -
, O +
or O +
coupled O +
with O +
proteasomal O +
degradation O -
. O +

IGF-1 O +
signaling O +
specifically O +
stimulates O +
NEDD4 O -
- O -
1-mediated O +
ubiquitination O +
of O +
pAKT O -
, O +
without O +
altering O +
total O +
AKT O +
ubiquitination O -
. O +

A O +
cancer O -
- O -
derived O +
plasma O +
membrane O -
- O -
philic O +
mutant O +
AKT O -
( O -
E17 O -
K O -
) O +
is O +
more O +
effectively O +
ubiquitinated O +
by O +
NEDD4 O -
- O -
1 O +
and O +
more O +
efficiently O +
trafficked O +
into O +
the O +
nucleus O +
compared O +
with O +
wild O +
type O +
AKT O -
. O +

This O +
study O +
reveals O +
a O +
novel O +
mechanism O +
by O +
which O +
a O +
specific O +
E3 O +
ligase O +
is O +
required O +
for O +
ubiquitin O -
- O -
dependent O +
control O +
of O +
pAKT O +
dynamics O +
in O +
a O +
ligand O -
- O -
specific O +
manner O -
. O +

Identification O +
of O +
transporters O +
associated O +
with O +
Etoposide B-Chemical +
sensitivity O +
of O +
stomach O +
cancer O +
cell O +
lines O +
and O +
methotrexate B-Chemical +
sensitivity O +
of O +
breast O +
cancer O +
cell O +
lines O +
by O +
quantitative O +
targeted O +
absolute O +
proteomics O -
. O +

Membrane O +
transporter O +
proteins O +
may O +
influence O +
the O +
sensitivity O +
of O +
cancer O +
cells O +
to O +
anticancer O +
drugs O +
that O +
can O +
be O +
recognized O +
as O +
substrates O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
identify O +
proteins O +
that O +
play O +
a O +
key O +
role O +
in O +
the O +
drug O +
sensitivity O +
of O +
stomach O +
and O +
breast O +
cancer O +
cell O +
lines O +
by O +
measuring O +
the O +
absolute O +
protein O +
expression O +
levels O +
of O +
multiple O +
transporters O +
and O +
other O +
membrane O +
proteins O +
and O +
examining O +
their O +
correlation O +
to O +
drug O +
sensitivity O -
. O +

Absolute O +
protein O +
expression O +
levels O +
of O +
90 O +
membrane O +
proteins O +
were O +
examined O +
by O +
quantitative O +
targeted O +
absolute O +
proteomics O +
using O +
liquid O +
chromatography O -
- O -
linked O +
tandem O +
mass O +
spectrometry O -
. O +

Among O +
them O -
, O +
11 O +
and O +
14 O +
membrane O +
proteins O -
, O +
including O +
transporters O -
, O +
were O +
present O +
in O +
quantifiable O +
amounts O +
in O +
membrane O +
fraction O +
of O +
stomach O +
cancer O +
and O +
breast O +
cancer O +
cell O +
lines O -
, O +
respectively O -
. O +

In O +
stomach O +
cancer O +
cell O +
lines O -
, O +
the O +
protein O +
expression O +
level O +
of O +
multidrug O +
resistance O -
- O -
associated O +
protein O +
1 O +
( O -
MRP1 O -
) O +
was O +
inversely O +
correlated O +
with O +
etoposide B-Chemical +
sensitivity O -
. O +

MK571 B-Chemical -
, O +
an O +
MRP O +
inhibitor O -
, O +
increased O +
both O +
the O +
cell O -
- O -
to O -
- O -
medium O +
ratio O +
of O +
etoposide O +
and O +
the O +
etoposide O +
sensitivity O +
of O +
MRP1-expressing O +
stomach O +
cancer O +
cell O +
lines O -
. O +

In O +
breast O +
cancer O +
cell O +
lines O -
, O +
the O +
protein O +
expression O +
level O +
of O +
reduced O +
folate O +
carrier O +
1 O +
( O -
RFC1 O -
) O +
was O +
directly O +
correlated O +
with O +
methotrexate B-Chemical +
( O -
MTX B-Chemical -
) O +
sensitivity O -
. O +

Initial O +
uptake O +
rate O +
and O +
steady O -
- O -
state O +
cell O -
- O -
to O -
- O -
medium O +
ratio O +
of O +
[ B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
H I-Chemical -
] I-Chemical -
MTX I-Chemical +
were O +
correlated O +
with O +
both O +
RFC1 O +
expression O +
level O +
and O +
MTX B-Chemical +
sensitivity O -
. O +

These O +
results O +
suggest O +
that O +
MRP1 O +
modulates O +
the O +
etoposide B-Chemical +
sensitivity O +
of O +
stomach O +
cancer O +
cell O +
lines O +
and O +
RFC1 O +
modulates O +
the O +
MTX B-Chemical +
sensitivity O +
of O +
breast O +
cancer O +
cell O +
lines O -
. O +

Our O +
results O +
indicate O +
that O +
absolute O +
quantification O +
of O +
multiple O +
membrane O +
proteins O +
could O +
be O +
a O +
useful O +
strategy O +
for O +
identification O +
of O +
candidate O +
proteins O +
involved O +
in O +
drug O +
sensitivity O -
. O +

Assessment O +
of O +
immunotoxicity O +
using O +
precision O -
- O -
cut O +
tissue O +
slices O -
. O +

1.When O +
the O +
immune O +
system O +
encounters O +
incoming O +
infectious O +
agents O -
, O +
this O +
generally O +
leads O +
to O +
immunity O -
. O +

The O +
evoked O +
immune O +
response O +
is O +
usually O +
robust O -
, O +
but O +
can O +
be O +
severely O +
perturbed O +
by O +
potentially O +
harmful O +
environmental O +
agents O +
such O +
as O +
chemicals O -
, O +
pharmaceuticals O +
and O +
allergens O -
. O +

2.Immunosuppression O -
, O +
hypersensitivity O +
and O +
autoimmunity O +
may O +
occur O +
due O +
to O +
changed O +
immune O +
activity O -
. O +

Evaluation O +
of O +
the O +
immunotoxic O +
potency O +
of O +
agents O +
as O +
part O +
of O +
risk O +
assessment O +
is O +
currently O +
established O +
in O +
vivo O +
with O +
animal O +
models O +
and O +
in O +
vitro O +
with O +
cell O +
lines O +
or O +
primary O +
cells O -
. O +

3.Although O +
in O +
vivo O +
testing O +
is O +
usually O +
the O +
most O +
relevant O +
situation O +
for O +
many O +
agents O -
, O +
more O +
and O +
more O +
in O +
vitro O +
models O +
are O +
being O +
developed O +
for O +
assessment O +
of O +
immunotoxicity O -
. O +

In O +
this O +
context O -
, O +
hypersensitivity O +
and O +
immunosuppression O +
are O +
considered O +
to O +
be O +
a O +
primary O +
focus O +
for O +
developing O +
in O +
vitro O +
methods O -
. O +

Three O -
- O -
dimensional O +
organotypic O +
tissue O +
models O +
are O +
also O +
part O +
of O +
current O +
research O +
in O +
immunotoxicology O -
. O +

4.In O +
recent O +
years O -
, O +
there O +
has O +
been O +
a O +
revival O +
of O +
interest O +
in O +
organotypic O +
tissue O +
models O -
. O +

In O +
the O +
context O +
of O +
immunotoxicity O +
testing O -
, O +
precision O -
- O -
cut O +
lung O +
slices O +
in O +
particular O +
have O +
been O +
intensively O +
studied O -
. O +

Therefore O -
, O +
this O +
review O +
is O +
very O +
much O +
focused O +
on O +
pulmonary O +
immunotoxicology O -
. O +

Respiratory O +
hypersensitivity O +
and O +
inflammation O +
are O +
further O +
highlighted O +
aspects O +
of O +
this O +
review O -
. O +

Immunotoxicity O +
assessment O +
currently O +
is O +
of O +
limited O +
use O +
in O +
other O +
tissue O +
models O -
, O +
which O +
are O +
therefore O +
described O +
only O +
briefly O +
within O +
this O +
review O -
. O +

Recently O +
introduced O +
foods O +
as O +
new O +
allergenic O +
sources O -
: O +
sensitisation O +
to O +
Goji O +
berries O +
( O -
Lycium O +
barbarum O -
) O -
. O +

Goji O +
berries O +
( O -
GB O -
) O +
have O +
been O +
introduced O +
in O +
Western O +
diet O -
. O +

Preliminary O +
reports O +
have O +
demonstrated O +
its O +
allergenic O +
capacity O -
. O +

The O +
objectives O +
of O +
the O +
study O +
were O +
to O +
investigate O +
the O +
frequency O +
of O +
sensitisation O +
and O +
the O +
allergens O +
involved O -
. O +

566 O +
individuals O -
, O +
with O +
respiratory O +
or O +
cutaneous O +
symptoms O +
were O +
skin O -
- O -
prick O +
tested O +
with O +
GB O +
extract O -
. O +

Thirty O +
three O +
were O +
positive O +
( O -
5.8 O -
% O -
) O -
. O +

94 O -
% O +
were O +
sensitised O +
to O +
other O +
allergens O -
. O +

Specific O +
IgE O +
to O +
GB O -
, O +
peach O -
, O +
tomato O +
and O +
nut O -
- O -
mix O +
was O +
measured O -
. O +

Thirteen O +
individuals O +
from O +
24 O +
available O +
sera O +
( O -
54.2 O -
% O -
) O +
had O +
positive O +
specific O +
IgE. O +
92.3 O -
% O +
of O +
GB O +
positive O +
patients O +
were O +
positive O +
to O +
peach O -
. O +

Seven O +
individuals O +
recognised O +
8 O +
bands O +
and O +
six O +
recognised O +
a O +
7kDa O +
band O -
. O +

This O +
band O +
was O +
identified O +
as O +
a O +
LTP O +
by O +
MS O -
/ O -
MS O -
. O +

Cross O -
- O -
reactivity O +
was O +
demonstrated O +
with O +
tomato O -
, O +
tobacco O -
, O +
nutmix O -
, O +
Artemisia O +
pollen O +
and O +
purified O +
Lyc O +
e O +
3 O +
and O +
Pru O +
p O +
3 O -
. O +

GB O +
are O +
a O +
new O +
allergenic O +
source O +
with O +
high O +
prevalence O +
of O +
sensitisation O -
. O +

LTP O +
seems O +
to O +
be O +
the O +
major O +
allergen O +
involved O +
in O +
sensitisation O +
and O +
cross O -
- O -
reactivity O -
. O +

Inhibitors O +
of O +
HIV-1 O +
attachment O -
. O +

Part O +
10 O -
. O +

The O +
discovery O +
and O +
structure O -
- O -
activity O +
relationships O +
of O +
4-azaindole B-Chemical +
cores O -
. O +

A O +
series O +
of O +
4-azaindole B-Chemical +
oxoacetic I-Chemical +
acid I-Chemical +
piperazine I-Chemical +
benzamides I-Chemical +
was O +
synthesized O +
and O +
evaluated O +
in O +
an O +
effort O +
to O +
identify O +
an O +
oral O +
HIV-1 O +
attachment O +
inhibitor O +
with O +
the O +
potential O +
to O +
improve O +
upon O +
the O +
pre O -
- O -
clinical O +
profile O +
of O +
BMS-378806 B-Chemical +
( O -
7 O -
) O -
, O +
an O +
initial O +
clinical O +
compound O -
. O +

Modifications O +
at O +
the O +
7-position O +
of O +
the O +
4-azaindole B-Chemical +
core O +
modulated O +
potency O +
significantly O +
and O +
SAR O +
showed O +
that O +
certain O +
compounds O +
with O +
a O +
5-membered O +
ring O +
heteroaryl O +
group O +
at O +
that O +
position O +
were O +
the O +
most O +
potent O -
. O +

Four O +
of O +
the O +
compounds O +
with O +
the O +
best O +
profiles O +
were O +
evaluated O +
in O +
a O +
rat O +
pharmacokinetic O +
model O +
and O +
all O +
had O +
superior O +
oral O +
bioavailability O +
and O +
lower O +
clearance O +
when O +
compared O +
with O +
7 O -
. O +

Phosphodiesterase O +
inhibitors O -
. O +

Part O +
5 O -
: O +
hybrid O +
PDE3 O -
/ O -
4 O +
inhibitors O +
as O +
dual O +
bronchorelaxant O -
/ O -
anti O -
- O -
inflammatory O +
agents O +
for O +
inhaled O +
administration O -
. O +

( B-Chemical -
- I-Chemical -
) I-Chemical -
-6- I-Chemical -
( I-Chemical -
7-Methoxy-2- I-Chemical -
( I-Chemical -
trifluoromethyl I-Chemical -
) I-Chemical -
pyrazolo I-Chemical -
[ I-Chemical -
1,5-a I-Chemical -
] I-Chemical -
pyridin-4-yl I-Chemical -
) I-Chemical -
-5-methyl-4,5-dihydropyridazin-3 I-Chemical -
( I-Chemical -
2H I-Chemical -
) I-Chemical -
-one I-Chemical +
( O -
KCA-1490 B-Chemical -
) O +
exhibits O +
moderate O +
dual O +
PDE3 O -
/ O -
4-inhibitory O +
activity O +
and O +
promises O +
as O +
a O +
combined O +
bronchodilatory O -
/ O -
anti O -
- O -
inflammatory O +
agent O -
. O +

N O -
- O -
alkylation O +
of O +
the O +
pyridazinone B-Chemical +
ring O +
markedly O +
enhances O +
potency O +
against O +
PDE4 O +
but O +
suppresses O +
PDE3 O +
inhibition O -
. O +

Addition O +
of O +
a O +
6-aryl-4,5-dihydropyridazin-3 B-Chemical -
( I-Chemical -
2H I-Chemical -
) I-Chemical -
-one I-Chemical +
extension O +
to O +
the O +
N O -
- O -
alkyl O +
group O +
facilitates O +
both O +
enhancement O +
of O +
PDE4-inhibitory O +
activity O +
and O +
restoration O +
of O +
potent O +
PDE3 O +
inhibition O -
. O +

Both O +
dihydropyridazinone B-Chemical +
rings O -
, O +
in O +
the O +
core O +
and O +
extension O -
, O +
can O +
be O +
replaced O +
by O +
achiral O +
4,4-dimethylpyrazolone B-Chemical +
subunits O +
and O +
the O +
core O +
pyrazolopyridine B-Chemical +
by O +
isosteric O +
bicyclic O +
heteroaromatics O -
. O +

In O +
combination O -
, O +
these O +
modifications O +
afford O +
potent O +
dual O +
PDE3 O -
/ O -
4 O +
inhibitors O +
that O +
suppress O +
histamine B-Chemical -
- O -
induced O +
bronchoconstriction O +
in O +
vivo O +
and O +
exhibit O +
promising O +
anti O -
- O -
inflammatory O +
activity O +
via O +
intratracheal O +
administration O -
. O +

Effects O +
of O +
pubertal O +
exposure O +
to O +
thiazole B-Chemical -
- O -
Zn B-Chemical +
on O +
thyroid O +
function O +
and O +
development O +
in O +
female O +
rats O -
. O +

Thiazole B-Chemical -
- O -
Zn B-Chemical +
is O +
a O +
newly O +
Chinese O -
- O -
created O +
systemic O +
fungicide O -
, O +
and O +
belongs O +
to O +
the O +
sort O +
of O +
thiadiazole B-Chemical +
compounds O -
, O +
some O +
of O +
which O +
have O +
been O +
found O +
to O +
be O +
thyroid O +
disrupters O -
. O +

To O +
determine O +
the O +
probable O +
adverse O +
effects O +
of O +
thiazole B-Chemical -
- O -
Zn B-Chemical +
on O +
thyroid O +
gland O +
and O +
development O +
function O -
, O +
the O +
rodent O +
20-day O +
Pubertal O +
Female O +
Assay O +
in O +
this O +
study O +
was O +
used O -
. O +

Postnatal O +
days O +
( O -
PND O -
) O +
22-old O +
Sprague O -
- O -
Dawley O +
rats O +
were O +
administered O +
with O +
thiazole B-Chemical -
- O -
Zn B-Chemical +
daily O +
by O +
oral O +
gavage O +
at O +
doses O +
0 O -
, O +
40 O -
, O +
100 O -
, O +
200 O +
mg O -
/ O -
kg O -
/ O -
day O +
for O +
20 O +
days O -
. O +

The O +
thyroid O +
endpoints O +
and O +
development O +
endpoints O +
were O +
assessed O -
. O +

The O +
results O +
indicated O +
that O +
serum O +
TT4 O +
and O +
TSH O +
levels O +
were O +
significantly O +
increased O +
at O +
all O +
concentrations O -
, O +
serum O +
TT3 O +
levels O +
were O +
significantly O +
reduced O +
only O +
at O +
40 O +
mg O -
/ O -
kg O +
thiazole B-Chemical -
- O -
Zn B-Chemical -
, O +
but O +
had O +
no O +
difference O +
from O +
controls O +
at O +
the O +
other O +
doses O -
. O +

Thyroid O +
histology O +
was O +
significantly O +
altered O +
at O +
all O +
doses O +
with O +
a O +
clear O +
dose O -
- O -
dependent O +
hypertrophy O +
and O +
hyperplasia O +
of O +
thyroid O +
cell O -
. O +

No O +
histological O +
changes O +
were O +
observed O +
in O +
any O +
of O +
the O +
other O +
observed O +
organs O -
. O +

In O +
addition O -
, O +
this O +
study O +
also O +
found O +
that O +
ovarian O +
weights O +
were O +
significantly O +
decreased O -
, O +
but O +
age O +
and O +
weight O +
at O +
vaginal O +
opening O +
( O -
VO O -
) O -
, O +
serum O +
E2 O +
levels O +
were O +
unaffected O +
in O +
all O +
treatment O +
groups O -
. O +

These O +
results O +
demonstrate O +
that O +
thiazole B-Chemical -
- O -
Zn B-Chemical +
is O +
likely O +
a O +
thyroid O +
disrupter O -
, O +
but O +
did O +
not O +
demonstrate O +
that O +
it O +
has O +
estrogenic O -
/ O -
anti O -
- O -
estrogenic O +
activity O -
. O +

A O +
10-minute O +
point O -
- O -
of O -
- O -
care O +
assay O +
for O +
detection O +
of O +
blood O +
protein O +
adducts O +
resulting O +
from O +
low O +
level O +
exposure O +
to O +
organophosphate B-Chemical +
nerve O +
agents O -
. O +

The O +
OrganoTox O +
test O +
is O +
a O +
rapid O -
, O +
point O -
- O -
of O -
- O -
care O +
assay O +
capable O +
of O +
detecting O +
clinically O +
relevant O +
organophosphate B-Chemical +
( O -
OP O -
) O +
poisoning O +
after O +
low O -
- O -
level O +
exposure O +
to O +
sarin B-Chemical -
, O +
soman B-Chemical -
, O +
tabun B-Chemical -
, O +
or O +
VX O +
chemical O +
nerve O +
agents O -
. O +

The O +
test O +
utilizes O +
either O +
a O +
finger O +
stick O +
peripheral O +
blood O +
sample O +
or O +
plasma O +
specimen O -
. O +

While O +
high O -
- O -
level O +
nerve O +
agent O +
exposure O +
can O +
quickly O +
lead O +
to O +
death O -
, O +
low O -
- O -
level O +
exposure O +
produces O +
vague O -
, O +
nondescript O +
signs O +
and O +
symptoms O +
that O +
are O +
not O +
easily O +
clinically O +
differentiated O +
from O +
other O +
conditions O -
. O +

In O +
initial O +
testing O -
, O +
the O +
OrganoTox O +
test O +
was O +
used O +
to O +
detect O +
the O +
presence O +
of O +
blood O +
protein O -
- O -
nerve O +
agent O +
adducts O +
in O +
exposed O +
blood O +
samples O -
. O +

In O +
order O +
to O +
mimic O +
the O +
in O +
vivo O +
exposure O +
as O +
closely O +
as O +
possible O -
, O +
nerve O +
agents O +
stored O +
in O +
organic O +
solvents O +
were O +
spiked O +
in O +
minute O +
quantities O +
into O +
whole O +
blood O +
samples O -
. O +

For O +
performance O +
testing O -
, O +
40 O +
plasma O +
samples O +
were O +
spiked O +
with O +
sarin B-Chemical -
, O +
soman B-Chemical -
, O +
tabun B-Chemical -
, O +
or O +
VX O +
and O +
10 O +
normal O +
plasma O +
samples O +
were O +
used O +
as O +
the O +
negative O +
control O -
. O +

The O +
40 O +
nerve O +
agent O -
- O -
spiked O +
plasma O +
samples O +
included O +
10 O +
replicates O +
of O +
each O +
agent O -
. O +

At O +
the O +
clinically O +
relevant O +
low O -
- O -
level O +
exposure O +
of O +
10ng O -
/ O -
ml O -
, O +
the O +
OrganoTox O +
test O +
demonstrated O +
100 O -
% O +
sensitivity O +
for O +
soman B-Chemical -
, O +
tabun B-Chemical -
, O +
and O +
VX O +
and O +
80 O -
% O +
sensitivity O +
for O +
sarin B-Chemical -
. O +

The O +
OrganoTox O +
test O +
demonstrated O +
greater O +
than O +
97 O -
% O +
specificity O +
with O +
150 O +
blood O +
samples O +
obtained O +
from O +
healthy O +
adults O -
. O +

No O +
cross O -
- O -
reactivity O +
or O +
interference O +
from O +
pesticide O +
precursor O +
compounds O +
was O +
found O -
. O +

A O +
rapid O +
test O +
for O +
nerve O +
agent O +
exposure O +
will O +
help O +
identify O +
affected O +
patients O +
earlier O +
in O +
the O +
clinical O +
course O +
and O +
trigger O +
more O +
appropriate O +
medical O +
management O +
in O +
a O +
more O +
timely O +
manner O -
. O +

Altered O +
expression O +
of O +
genes O +
involved O +
in O +
progesterone B-Chemical +
biosynthesis O -
, O +
metabolism O +
and O +
action O +
in O +
endometrial O +
cancer O -
. O +

Endometrial O +
cancer O +
( O -
EC O -
) O +
is O +
one O +
of O +
the O +
most O +
common O +
gynecological O +
malignancies O +
worldwide O -
. O +

It O +
is O +
associated O +
with O +
prolonged O +
exposure O +
to O +
estrogens O +
that O +
is O +
unopposed O +
by O +
the O +
protective O +
effects O +
of O +
progesterone B-Chemical -
, O +
which O +
suggests O +
that O +
altered O +
progesterone B-Chemical +
biosynthesis O -
, O +
metabolism O +
and O +
actions O +
might O +
be O +
implicated O +
in O +
the O +
development O +
of O +
EC O -
. O +

Our O +
aim O +
was O +
to O +
evaluate O +
these O +
processes O +
through O +
quantitative O +
real O -
- O -
time O +
PCR O +
expression O +
analysis O +
in O +
up O +
to O +
47 O +
pairs O +
of O +
EC O +
tissue O +
and O +
adjacent O +
control O +
endometrium O -
. O +

First O -
, O +
we O +
examined O +
the O +
expression O +
of O +
genes O +
encoding O +
proteins O +
associated O +
with O +
progesterone B-Chemical +
biosynthesis O -
: O +
steroidogenic O +
acute O +
regulatory O +
protein O +
( O -
STAR O -
) O -
; O +
a O +
side O +
chain O +
cleavage O +
enzyme O +
( O -
CYP11A1 O -
) O -
; O +
and O +
3β B-Chemical -
- I-Chemical -
hydroxysteroid I-Chemical +
dehydrogenase O -
/ O -
ketosteroid B-Chemical +
isomerase O +
( O -
HSD3B O -
) O -
. O +

There O +
were O +
1.9- O +
and O +
10.0-fold O +
decreased O +
expression O +
of O +
STAR O +
and O +
CYP11A1 O -
, O +
respectively O -
, O +
in O +
EC O +
versus O +
adjacent O +
control O +
endometrium O -
, O +
with O +
no O +
significant O +
differences O +
in O +
the O +
expression O +
of O +
HSD3B1 O +
and O +
HSD3B2 O -
. O +

Next O -
, O +
we O +
examined O +
expression O +
of O +
genes O +
encoding O +
five O +
progesterone B-Chemical +
metabolizing O +
enzymes O -
: O +
the O +
3-keto B-Chemical +
and I-Chemical +
20-ketosteroid I-Chemical +
reductases O +
( O -
AKR1C1-AKR1C3 O -
) O +
and O +
5α O -
- O -
reductases O +
( O -
SRD5A1 O +
and O +
SRD5A2 O -
) O -
; O +
and O +
the O +
opposing O +
20α B-Chemical -
- I-Chemical -
hydroxysteroid I-Chemical +
dehydrogenase O +
( O -
HSD17B2 O -
) O -
. O +

These O +
genes O +
are O +
expressed O +
in O +
EC O +
and O +
adjacent O +
control O +
endometrium O -
. O +

No O +
statistically O +
significant O +
differences O +
were O +
seen O +
in O +
mRNA O +
levels O +
of O +
AKR1C1 O -
, O +
AKR1C2 O -
, O +
AKR1C3 O +
and O +
SRD5A1 O -
. O +

Expression O +
of O +
HSD17B2 O +
was O +
3.0-fold O +
increased O -
, O +
and O +
expression O +
of O +
SRD5A2 O +
was O +
3.7-fold O +
decreased O -
, O +
in O +
EC O +
versus O +
adjacent O +
control O +
endometrium O -
. O +

We O +
also O +
examined O +
mRNA O +
levels O +
of O +
progesterone B-Chemical +
receptors O +
A O +
and O +
B O +
( O -
PGR O -
) O -
, O +
and O +
separately O +
the O +
expression O +
of O +
progesterone B-Chemical +
receptor O +
B O +
( O -
PR O -
- O -
B O -
) O -
. O +

Here O +
we O +
saw O +
1.8- O +
and O +
2.0-fold O +
lower O +
mRNA O +
levels O +
of O +
PGR O +
and O +
PR O -
- O -
B O -
, O +
respectively O -
, O +
in O +
EC O +
versus O +
adjacent O +
control O +
endometrium O -
. O +

This O +
down O -
- O -
regulation O +
of O +
STAR O -
, O +
CYP11A1 O +
and O +
PGR O +
in O +
endometrial O +
cancer O +
may O +
lead O +
to O +
decreased O +
progesterone B-Chemical +
biosynthesis O +
and O +
actions O +
although O +
the O +
effects O +
on O +
progesterone B-Chemical +
levels O +
should O +
be O +
further O +
studied O -
. O +

Origin O +
and O +
evolution O +
of O +
medium O +
chain O +
alcohol B-Chemical +
dehydrogenases O -
. O +

Different O +
lines O +
of O +
alcohol B-Chemical +
dehydrogenases O +
( O -
ADHs O -
) O +
have O +
separate O +
superfamily O +
origins O -
, O +
already O +
recognized O +
but O +
now O +
extended O +
and O +
re O -
- O -
evaluated O +
by O +
re O -
- O -
screening O +
of O +
the O +
latest O +
databank O +
update O -
. O +

The O +
short O -
- O -
chain O +
form O +
( O -
SDR O -
) O +
is O +
still O +
the O +
superfamily O +
with O +
most O +
abundant O +
occurrence O -
, O +
most O +
multiple O +
divergence O -
, O +
most O +
prokaryotic O +
emphasis O -
, O +
and O +
most O +
non O -
- O -
complicated O +
architecture O -
. O +

This O +
pattern O +
is O +
compatible O +
with O +
an O +
early O +
appearance O +
at O +
the O +
time O +
of O +
the O +
emergence O +
of O +
prokaryotic O +
cellular O +
life O -
. O +

The O +
medium O -
- O -
chain O +
form O +
( O -
MDR O -
) O +
is O +
also O +
old O +
but O +
second O +
in O +
terms O +
of O +
all O +
the O +
parameters O +
above O -
, O +
and O +
therefore O +
compatible O +
with O +
a O +
second O +
emergence O -
. O +

However O -
, O +
this O +
step O +
appears O +
seemingly O +
earlier O +
than O +
previously O +
considered O -
, O +
and O +
may O +
indicate O +
sub O -
- O -
stages O +
of O +
early O +
emergences O +
at O +
the O +
increased O +
resolution O +
available O +
from O +
the O +
now O +
greater O +
number O +
of O +
data O +
entries O -
. O +

The O +
Zn B-Chemical -
- O -
MDR O +
origin O +
constitutes O +
a O +
third O +
stage O -
, O +
possibly O +
compatible O +
with O +
the O +
transition O +
to O +
oxidative O +
conditions O +
on O +
earth O -
. O +

Within O +
all O +
these O +
three O +
lines O -
, O +
repeated O +
enzymogeneses O +
gave O +
the O +
present O +
divergence O -
. O +

MDR O -
- O -
ADH O +
origin O -
( O -
s O -
) O -
, O +
at O +
a O +
fourth O +
stage O -
, O +
may O +
also O +
be O +
further O +
resolved O +
in O +
multiple O +
or O +
extended O +
modes O -
, O +
but O +
the O +
classical O +
liver O +
MDR O -
- O -
ADH O +
of O +
the O +
liver O +
type O +
can O +
still O +
be O +
traced O +
to O +
a O +
gene O +
duplication O +
~550 O +
MYA O +
( O -
million O +
years O +
ago O -
) O -
, O +
at O +
the O +
early O +
vertebrate O +
radiation O -
, O +
compatible O +
with O +
the O +
post O -
- O -
eon O -
- O -
shift O -
, O +
" O -
Cambrian O +
explosion O -
" O -
. O +

Classes O +
and O +
isozymes O +
correspond O +
to O +
subsequent O +
and O +
recent O +
duplicatory O +
events O -
, O +
respectively O -
. O +

They O +
illustrate O +
a O +
peculiar O +
pattern O +
with O +
functional O +
and O +
emerging O +
evolutionary O +
distinctions O +
between O +
parent O +
and O +
emerging O +
lines O -
, O +
suggesting O +
a O +
parallelism O +
between O +
duplicatory O +
and O +
mutational O +
events O -
, O +
now O +
also O +
visible O +
at O +
separate O +
sub O -
- O -
stages O -
. O +

Combined O -
, O +
all O +
forms O +
show O +
distinctive O +
patterns O +
at O +
different O +
levels O +
and O +
illustrate O +
correlations O +
with O +
global O +
events O -
. O +

They O +
further O +
show O +
that O +
simple O +
molecular O +
observations O +
on O +
patterns O -
, O +
multiplicities O +
and O +
occurrence O +
give O +
much O +
information O -
, O +
suggesting O +
common O +
divergence O +
rules O +
not O +
much O +
disturbed O +
by O +
horizontal O +
gene O +
transfers O +
after O +
the O +
initial O +
origins O -
. O +

Reduced O +
plasma O +
oxytocin B-Chemical +
levels O +
in O +
female O +
patients O +
with O +
borderline O +
personality O +
disorder O -
. O +

The O +
neuropeptide O +
oxytocin B-Chemical +
is O +
involved O +
in O +
social O +
cognition O +
and O +
interaction O +
across O +
species O +
and O +
plays O +
a O +
crucial O +
role O +
in O +
the O +
regulation O +
of O +
affiliative O +
behaviors O -
. O +

Oxytocin B-Chemical +
levels O +
in O +
cerebrospinal O +
fluid O +
( O -
CSF O -
) O -
, O +
but O +
also O +
in O +
plasma O +
or O +
urine O -
, O +
have O +
been O +
shown O +
to O +
be O +
negatively O +
associated O +
with O +
childhood O +
traumata O -
, O +
aggressive O +
behavior O -
, O +
and O +
suicide O +
attempts O -
. O +

Recently O -
, O +
an O +
altered O +
activity O +
of O +
the O +
oxytocin B-Chemical +
system O +
has O +
been O +
discussed O +
to O +
play O +
a O +
prominent O +
role O +
in O +
borderline O +
personality O +
disorder O +
( O -
BPD O -
) O -
, O +
which O +
is O +
thought O +
to O +
be O +
closely O +
related O +
to O +
traumatic O +
experiences O +
in O +
childhood O +
and O +
is O +
characterized O +
by O +
( O -
para O -
) O -
suicidal O +
behaviors O +
as O +
well O +
as O +
aggressive O +
outbursts O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
compared O +
plasma O +
oxytocin B-Chemical +
levels O +
of O +
women O +
with O +
and O +
without O +
BPD O +
in O +
the O +
follicular O +
phase O +
and O +
assessed O +
the O +
relationship O +
between O +
oxytocin B-Chemical +
concentrations O +
and O +
childhood O +
traumata O -
. O +

Women O +
diagnosed O +
with O +
BPD O +
had O +
significantly O +
reduced O +
oxytocin B-Chemical +
concentrations O -
, O +
even O +
after O +
controlling O +
for O +
estrogen B-Chemical -
, O +
progesterone B-Chemical -
, O +
and O +
contraceptive O +
intake O -
. O +

In O +
addition O -
, O +
plasma O +
oxytocin B-Chemical +
correlated O +
negatively O +
with O +
experiences O +
of O +
childhood O +
traumata O -
, O +
in O +
particular O +
with O +
emotional O +
neglect O +
and O +
abuse O -
. O +

The O +
results O +
of O +
mediation O +
analyses O +
do O +
not O +
support O +
a O +
model O +
of O +
oxytocin B-Chemical +
being O +
a O +
prominent O +
mediator O +
in O +
the O +
link O +
between O +
childhood O +
trauma O +
and O +
BPD O -
. O +

Thus O -
, O +
the O +
findings O +
indicate O +
dysregulations O +
in O +
the O +
oxytocin B-Chemical +
system O +
of O +
patients O +
diagnosed O +
with O +
BPD O +
with O +
more O +
longitudinal O +
research O +
being O +
necessary O +
to O +
disentangle O +
the O +
relationship O +
between O +
childhood O +
adversities O -
, O +
oxytocin B-Chemical +
system O -
, O +
and O +
psychopathology O -
. O +

Antimutagenic O +
evaluation O +
of O +
vitamins B-Chemical +
B1 I-Chemical -
, I-Chemical +
B6 I-Chemical +
and I-Chemical +
B12 I-Chemical +
in O +
vitro O +
and O +
in O +
vivo O -
, O +
with O +
the O +
Ames O +
test O -
. O +

The O +
aim O +
of O +
this O +
work O +
is O +
to O +
evaluate O +
vitamins B-Chemical +
B I-Chemical +
antimutagenic O +
effect O +
against O +
alkylatings O +
methyl B-Chemical -
- I-Chemical -
N I-Chemical -
- I-Chemical -
nitro I-Chemical -
- I-Chemical -
N I-Chemical -
- I-Chemical -
nitrosoguanidine I-Chemical +
( O -
MNNG B-Chemical -
) O -
, O +
ethyl B-Chemical -
- I-Chemical -
N I-Chemical -
- I-Chemical -
nitro I-Chemical -
- I-Chemical -
N'- I-Chemical +
nitrosoguanidine I-Chemical +
( O -
ENNG B-Chemical -
) O -
, O +
frameshift O +
mutagens O +
2-aminoanthracene B-Chemical +
( O -
2AA B-Chemical -
) O +
and O +
2-acetyl B-Chemical -
- I-Chemical -
amino I-Chemical -
- I-Chemical -
fluorene I-Chemical +
( O -
2AF B-Chemical -
) O +
and O +
ROS O -
- O -
generating O +
antibiotics O +
norfloxacin B-Chemical +
( O -
NOR B-Chemical -
) O +
and O +
nalidixic B-Chemical +
acid I-Chemical +
( O -
NLX B-Chemical -
) O -
, O +
using O +
the O +
in O +
vitro O +
Ames O +
test O -
. O +

In O +
vivo O +
antimutagenesis O +
studies O +
were O +
performed O +
against O +
urinary O +
mutagens O +
induced O +
by O +
NOR B-Chemical +
( O -
70 O +
mg O -
/ O -
kg O -
) O +
or O +
NLX B-Chemical +
( O -
100 O +
mg O -
/ O -
kg O -
) O +
in O +
CD1 O +
mice O -
. O +

Vitamin B-Chemical +
B1 I-Chemical +
was O +
antimutagenic O +
against O +
alkylatings O +
MNNG B-Chemical +
( O -
P<0.05 O -
) O +
or O +
ENNG B-Chemical +
( O -
P<0.001 O -
) O -
. O +

In O +
fact O +
as O +
per O +
the O +
results O +
observed O +
during O +
the O +
current O +
study O -
, O +
none O +
of O +
the O +
vitamins O +
reduced O +
mutagenesis O +
caused O +
by O +
frameshift O +
mutagens O -
. O +

All O +
of O +
them O +
reduced O +
mutagenesis O +
of O +
NOR B-Chemical +
or O +
NLX B-Chemical +
( O -
P<0.001 O -
) O -
. O +

In O +
vivo O +
studies O +
showed O +
that O +
vitamins B-Chemical +
B1 I-Chemical +
and I-Chemical +
B6 I-Chemical +
( O -
10 O +
or O +
100 O +
mg O -
/ O -
kg O -
) O +
reduced O +
urinary O +
mutagens O +
from O +
NOR B-Chemical +
( O -
P<0.001 O -
) O +
or O +
NLX B-Chemical +
( O -
P<0.02 O -
) O +
either O +
free O +
or O +
β O -
- O -
glucoronidase O -
- O -
conjugates O -
. O +

None O +
of O +
the O +
studied O +
samples O +
were O +
toxic O +
for O +
the O +
employed O +
antimutagenic O +
system O -
. O +

Vitamin B-Chemical +
B12 I-Chemical +
( O -
4 O +
mg O -
/ O -
kg O -
) O +
reduced O +
urinary O +
mutagens O +
of O +
NOR B-Chemical +
or O +
NLX B-Chemical +
( O -
P<0.02 O -
) O -
. O +

Vitamins B-Chemical +
B I-Chemical +
inhibited O +
DNA O +
mutations O +
induced O +
by O +
ROS O +
generated O +
by O +
NLX B-Chemical +
or O +
NOR B-Chemical -
, O +
both O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

Vitamin B-Chemical +
B1is I-Chemical +
antimutagenic O +
against O +
mutations O +
induced O +
by O +
the O +
alkylating O +
MNNG B-Chemical +
or O +
ENNG B-Chemical -
. O +

Based O +
on O +
the O +
observations O -
, O +
employment O +
of O +
vitamins B-Chemical +
B I-Chemical +
in O +
vivo O +
can O +
be O +
a O +
promising O +
alternative O +
to O +
reduce O +
genotoxic O +
risk O +
exposure O +
to O +
ROS O -
. O +

Design O -
, O +
synthesis O +
and O +
crystallographic O +
analysis O +
of O +
nitrile B-Chemical -
- O -
based O +
broad O -
- O -
spectrum O +
peptidomimetic O +
inhibitors O +
for O +
coronavirus O +
3C O -
- O -
like O +
proteases O -
. O +

Coronaviral O +
infection O +
is O +
associated O +
with O +
up O +
to O +
5 O -
% O +
of O +
respiratory O +
tract O +
diseases O -
. O +

The O +
3C O -
- O -
like O +
protease O +
( O -
3CL O -
( O -
pro O -
) O -
) O +
of O +
coronaviruses O +
is O +
required O +
for O +
proteolytic O +
processing O +
of O +
polyproteins O +
and O +
viral O +
replication O -
, O +
and O +
is O +
a O +
promising O +
target O +
for O +
the O +
development O +
of O +
drugs O +
against O +
coronaviral O +
infection O -
. O +

We O +
designed O +
and O +
synthesized O +
four O +
nitrile B-Chemical -
- O -
based O +
peptidomimetic O +
inhibitors O +
with O +
different O +
N O -
- O -
terminal O +
protective O +
groups O +
and O +
different O +
peptide O +
length O -
, O +
and O +
examined O +
their O +
inhibitory O +
effect O +
on O +
the O +
in O -
- O -
vitro O +
enzymatic O +
activity O +
of O +
3CL O -
( O -
pro O -
) O +
of O +
severe O -
- O -
acute O -
- O -
respiratory O -
- O -
syndrome O -
- O -
coronavirus O -
. O +

The O +
IC O -
( O -
50 O -
) O +
values O +
of O +
the O +
inhibitors O +
were O +
in O +
the O +
range O +
of O +
4.6 O -
- O -
49 O +
μM O -
, O +
demonstrating O +
that O +
the O +
nitrile B-Chemical +
warhead O +
can O +
effectively O +
inactivate O +
the O +
3CL O -
( O -
pro O -
) O +
autocleavage O +
process O -
. O +

The O +
best O +
inhibitor O -
, O +
Cbz B-Chemical -
- O -
AVLQ O -
- O -
CN B-Chemical +
with O +
an O +
N O -
- O -
terminal O +
carbobenzyloxy B-Chemical +
group O -
, O +
was O +
~10x O +
more O +
potent O +
than O +
the O +
other O +
inhibitors O +
tested O -
. O +

Crystal O +
structures O +
of O +
the O +
enzyme O -
- O -
inhibitor O +
complexes O +
showed O +
that O +
the O +
nitrile B-Chemical +
warhead O +
inhibits O +
3CL O -
( O -
pro O -
) O +
by O +
forming O +
a O +
covalent O +
bond O +
with O +
the O +
catalytic O +
Cys145 B-Chemical +
residue O -
, O +
while O +
the O +
AVLQ O +
peptide O +
forms O +
a O +
number O +
of O +
favourable O +
interactions O +
with O +
the O +
S1-S4 O +
substrate O -
- O -
binding O +
pockets O -
. O +

We O +
have O +
further O +
showed O +
that O +
the O +
peptidomimetic O +
inhibitor O -
, O +
Cbz B-Chemical -
- O -
AVLQ O -
- O -
CN B-Chemical -
, O +
has O +
broad O -
- O -
spectrum O +
inhibition O +
against O +
3CL O -
( O -
pro O -
) O +
from O +
human O +
coronavirus O +
strains O +
229E O -
, O +
NL63 O -
, O +
OC43 O -
, O +
HKU1 O -
, O +
and O +
infectious O +
bronchitis O +
virus O -
, O +
with O +
IC O -
( O -
50 O -
) O +
values O +
ranging O +
from O +
1.3 O +
to O +
3.7 O +
μM O -
, O +
but O +
no O +
detectable O +
inhibition O +
against O +
caspase-3 O -
. O +

In O +
summary O -
, O +
we O +
have O +
shown O +
that O +
the O +
nitrile B-Chemical -
- O -
based O +
peptidomimetic O +
inhibitors O +
are O +
effective O +
against O +
3CL O -
( O -
pro O -
) O -
, O +
and O +
they O +
inhibit O +
3CL O -
( O -
pro O -
) O +
from O +
a O +
broad O +
range O +
of O +
coronaviruses O -
. O +

Our O +
results O +
provide O +
further O +
insights O +
into O +
the O +
future O +
design O +
of O +
drugs O +
that O +
could O +
serve O +
as O +
a O +
first O +
line O +
defence O +
against O +
coronaviral O +
infection O -
. O +

Synthesis O +
and O +
antibacterial O +
and O +
antifungal O +
evaluation O +
of O +
some O +
chalcone B-Chemical +
based O +
sulfones B-Chemical +
and O +
bisulfones B-Chemical -
. O +

Two O +
series O +
of O +
chalcone B-Chemical +
based O +
sulfone B-Chemical +
and O +
bisulfone B-Chemical +
derivatives O +
were O +
synthesized O +
using O +
chalcone B-Chemical -
, O +
thiophenol B-Chemical +
and O +
sodium B-Chemical +
metal O +
at O +
room O +
temperature O -
, O +
followed O +
by O +
oxidation O +
of O +
chalcone B-Chemical +
sulfides I-Chemical +
with O +
m B-Chemical -
- I-Chemical -
CPBA I-Chemical +
at O +
0 O +
° O -
C O +
in O +
a O +
novel O +
method O -
. O +

Both O +
sulfones B-Chemical +
and O +
bisulfones B-Chemical +
were O +
evaluated O +
for O +
their O +
antimicrobial O +
activities O +
against O +
Aspergillus O +
niger O +
and O +
Candida O +
albicans O +
( O -
yeast O -
) O -
, O +
Bacillus O +
subtilis O +
and O +
Staphylococcus O +
aureus O +
( O -
Gram O +
( O -
+ O -
) O +
bacteria O -
) O +
and O +
Pseudomonas O +
aeruginosa O +
and O +
Salmonella O +
typhimurium O +
( O -
Gram O +
( O -
- O -
) O +
bacteria O -
) O +
strains O -
. O +

Among O +
them O -
, O +
compounds O +
2c O -
, O +
3c O -
, O +
6c O -
, O +
7c O -
, O +
8c O +
and O +
9c O +
have O +
shown O +
high O +
antifungal O +
activity O +
against O +
C. O +
albicans O +
compare O +
to O +
reference O +
drugs O +
viz O -
. O +

Amphotericin B-Chemical -
- I-Chemical -
B I-Chemical +
and O +
Nystatin B-Chemical -
. O +

Compound O +
1c O +
has O +
shown O +
slightly O +
better O +
antibacterial O +
activity O +
against O +
B. O +
subtilis O +
and O +
compounds O +
5c O -
, O +
6c O +
and O +
7c O +
have O +
shown O +
excellent O +
antibacterial O +
activity O +
against O +
S. O +
typhimurium O +
in O +
compare O +
to O +
reference O +
drugs O +
Ampicillin B-Chemical +
and O +
Kanamycin B-Chemical -
. O +

Identification O +
of O +
novel O +
chromenone B-Chemical +
derivatives O +
as O +
interleukin-5 O +
inhibitors O -
. O +

A O +
series O +
of O +
( B-Chemical -
E I-Chemical -
) I-Chemical -
-5-alkoxy-3- I-Chemical -
( I-Chemical -
3-phenyl-3-oxoprop-1-enyl I-Chemical -
) I-Chemical -
-4H I-Chemical -
- I-Chemical -
chromen-4-ones I-Chemical +
( O -
4 O -
) O +
and O +
( B-Chemical -
E I-Chemical -
) I-Chemical -
-5-alkoxy-3- I-Chemical -
( I-Chemical -
3-hydroxy-3-phenylprop-1-enyl I-Chemical -
) I-Chemical -
-4H I-Chemical -
- I-Chemical -
chromen-4-ones I-Chemical +
( O -
5 O -
) O +
were O +
synthesized O +
and O +
evaluated O +
for O +
their O +
IL-5 O +
inhibitory O +
activity O -
. O +

Propenone B-Chemical +
analogs O +
4 O +
possess O +
some O +
of O +
the O +
structurally O +
important O +
characteristics O +
of O +
isoflavone B-Chemical +
2 O +
and O +
chalcone B-Chemical +
3 O +
previously O +
known O +
as O +
potent O +
IL-5 O +
inhibitor O -
. O +

However O -
, O +
the O +
inhibitory O +
activity O +
of O +
4 O +
was O +
weak O +
and O +
therefore O +
this O +
structural O +
hybridization O +
appears O +
to O +
be O +
ineffective O +
for O +
the O +
design O +
of O +
IL-5 O +
inhibitor O -
. O +

Meanwhile O +
the O +
potent O +
activity O +
profile O +
of O +
compounds O +
5 O +
was O +
discovered O -
. O +

This O +
enhanced O +
activity O +
of O +
5 O +
compared O +
to O +
4 O +
could O +
be O +
due O +
to O +
the O +
effective O +
location O +
of O +
hydroxyl B-Chemical +
group O +
of O +
allylic B-Chemical +
alcohol I-Chemical +
moiety O +
of O +
5 O +
in O +
the O +
3D O +
structure O -
. O +

The O +
electron O +
withdrawing O +
substituents O +
at O +
position O +
4 O +
of O +
phenyl B-Chemical +
ring O +
of O +
5 O +
enhances O +
the O +
activity O +
possibly O +
due O +
to O +
an O +
increase O +
in O +
the O +
strength O +
of O +
hydrogen B-Chemical +
bonding O +
property O +
of O +
hydroxyl B-Chemical +
group O +
of O +
allylic B-Chemical +
alcohol I-Chemical +
moiety O -
. O +

Synthesis O -
, O +
antibacterial O +
activity O +
and O +
docking O +
of O +
14-membered B-Chemical +
9-O- I-Chemical -
( I-Chemical -
3-arylalkyl I-Chemical -
) I-Chemical +
oxime I-Chemical +
11,12-cyclic I-Chemical +
carbonate I-Chemical +
ketolides I-Chemical -
. O +

A O +
series O +
of O +
9-O- B-Chemical -
( I-Chemical -
3-aryl-2-propargyl I-Chemical -
) I-Chemical -
oxime I-Chemical +
ketolides I-Chemical +
8 O +
was O +
synthesized O +
and O +
evaluated O +
for O +
in O +
vitro O +
antibacterial O +
activity O -
. O +

Among O +
8 O -
, O +
8b-8d O -
, O +
and O +
8h-8l O +
displayed O +
dramatically O +
improved O +
potency O +
against O +
inducibly O +
MLS O -
( O -
B O -
) O -
-resistant O +
and O +
efflux O -
- O -
resistant O +
pathogens O +
as O +
compared O +
to O +
clarithromycin B-Chemical +
and O +
azithromycin B-Chemical -
. O +

Especially O -
, O +
8i O +
( O -
Ar=4-isoquinolyl O -
) O +
possessed O +
an O +
MIC O +
of O +
0.064 O +
μg O -
/ O -
mL O +
against O +
constitutively O +
MLS O -
( O -
B O -
) O -
-resistant O +
Streptococcus O +
pneumoniae O -
, O +
and O +
MICs O +
of O +
0.032 O -
- O -
0.064 O +
μg O -
/ O -
mL O +
against O +
methicillin B-Chemical -
- O -
resistant O +
Staphylococcus O +
aureus O +
and O +
methicillin B-Chemical -
- O -
resistant O +
Staphylococcus O +
hominis O -
. O +

The O +
analog O +
10 O +
with O +
a O +
propyl B-Chemical +
linker O +
was O +
less O +
effective O +
than O +
both O +
the O +
corresponding O +
8 O +
and O +
9 O +
containing O +
propynyl B-Chemical +
and O +
propenyl B-Chemical +
linkers O -
. O +

A O +
docking O +
study O +
was O +
performed O +
to O +
gain O +
insight O +
into O +
the O +
binding O +
mode O +
of O +
series O +
8 O +
and O +
9 O +
and O +
to O +
rationalize O +
the O +
disparity O +
found O +
in O +
the O +
SAR O +
of O +
8 O +
and O +
9 O -
. O +

Hybrid O +
furoxanyl B-Chemical +
N I-Chemical -
- I-Chemical -
acylhydrazone I-Chemical +
derivatives O +
as O +
hits O +
for O +
the O +
development O +
of O +
neglected O +
diseases O +
drug O +
candidates O -
. O +

Neglected O +
diseases O +
represent O +
a O +
major O +
health O +
problem O -
. O +

It O +
is O +
estimated O +
that O +
one O +
third O +
of O +
the O +
world O +
population O +
is O +
infected O +
with O +
tuberculosis O +
and O +
additionally O +
Leishmaniosis O +
and O +
Chagas O +
disease O +
affect O +
approximately O +
30 O +
million O +
people O -
. O +

N B-Chemical -
- I-Chemical -
Acylhydrazone I-Chemical +
moiety O +
is O +
a O +
repeated O +
functional O +
group O +
present O +
in O +
several O +
prototypes O +
and O +
drug O +
candidates O +
for O +
these O +
neglected O +
diseases O -
. O +

On O +
the O +
other O +
hand O -
, O +
furoxan B-Chemical +
system O +
has O +
been O +
studied O +
as O +
pharmacophore O +
for O +
Leishmaniosis O +
and O +
Chagas O +
diseases O -
. O +

Here O +
we O +
report O +
on O +
the O +
design O +
and O +
preparation O +
of O +
forty O +
hybrid O +
furoxanyl B-Chemical +
N I-Chemical -
- I-Chemical -
acylhydrazones I-Chemical +
and O +
on O +
their O +
activity O +
on O +
Mycobacterium O +
tuberculosis O -
, O +
H37Rv O +
and O +
MDR O +
strains O -
, O +
Trypanosoma O +
cruzi O -
, O +
and O +
Leishmania O +
amazonensis O -
. O +

Among O +
them O -
, O +
four O +
derivatives O +
displayed O +
excellent O +
to O +
good O +
selectivity O +
indexes O +
against O +
the O +
three O +
different O +
microorganisms O -
. O +

Hybrid O +
compound O +
N'- B-Chemical -
( I-Chemical -
4-phenyl-3-furoxanylmethylidene I-Chemical -
) I-Chemical -
isoniazide I-Chemical +
9 O +
showed O +
the O +
best O +
antibacterial O +
profile O +
with O +
MIC O +
value O +
4.5 O +
lesser O +
than O +
the O +
value O +
for O +
the O +
reference O +
isoniazid B-Chemical +
against O +
MDR O +
strain O -
. O +

Furoxanyl B-Chemical +
N I-Chemical -
- I-Chemical -
acylhydrazone I-Chemical +
( B-Chemical -
E I-Chemical -
) I-Chemical -
-2-methyl I-Chemical -
- I-Chemical -
N'- I-Chemical -
( I-Chemical -
4-phenyl-3-furoxanylmethylidene I-Chemical -
) I-Chemical -
-4H I-Chemical -
- I-Chemical -
imidazo I-Chemical -
[ I-Chemical -
1,2-a I-Chemical -
] I-Chemical -
pyridine-3-carbohydrazide I-Chemical +
15 O +
was O +
ten O -
- O -
fold O +
more O +
potent O +
against O +
T. O +
cruzi O +
Amastigotes O +
than O +
the O +
standard O +
drug O +
nifurtimox O -
. O +

On O +
the O +
other O +
hand O -
, O +
derivatives O +
( B-Chemical -
E I-Chemical -
) I-Chemical -
-N'- I-Chemical -
( I-Chemical -
5-benzofuroxanylmethylidene I-Chemical -
) I-Chemical -
benzo I-Chemical -
[ I-Chemical -
d I-Chemical -
] I-Chemical -
[ I-Chemical -
1,3 I-Chemical -
] I-Chemical -
dioxole-5-carbohydrazide I-Chemical +
25 O +
and O +
( B-Chemical -
E I-Chemical -
) I-Chemical -
-N'- I-Chemical -
( I-Chemical -
4-hydroxy-3-methoxyphenylmethylidene I-Chemical -
) I-Chemical -
-3-methylfuroxan-4-carbohydrazide I-Chemical +
37 O +
emerged O +
as O +
leads O +
for O +
the O +
development O +
of O +
new O +
leishmanicidal O +
agents O -
. O +

The O +
adequate O +
stability O -
, O +
in O +
simulated O +
biological O +
system O +
and O +
plasma O -
, O +
and O +
the O +
lack O +
of O +
mutagenicity O +
of O +
these O +
derivatives O +
allow O +
us O +
to O +
propose O +
them O +
as O +
candidates O +
for O +
further O +
pre O -
- O -
clinical O +
studies O -
. O +

Synthesis O -
, O +
characterization O +
and O +
pharmacodynamics O +
of O +
vitamin B-Chemical -
- I-Chemical -
B I-Chemical -
( I-Chemical -
12 I-Chemical -
) I-Chemical -
-conjugated O +
glucagon O -
- O -
like O +
peptide-1 O -
. O +

Clearing O +
the O +
way O -
: O +
Glucagon O -
- O -
like O +
peptide-1 O +
( O -
GLP-1 O -
) O +
receptor O +
agonists O +
are O +
proving O +
a O +
potent O +
weapon O +
in O +
the O +
treatment O +
of O +
type O +
II O +
diabetes O -
. O +

A O +
new O +
vitamin B-Chemical +
B I-Chemical -
( I-Chemical -
12 I-Chemical -
) I-Chemical -
-GLP-1 O +
conjugate O +
is O +
investigated O +
and O +
shown O +
to O +
have O +
insulinotropic O +
properties O +
similar O +
to O +
the O +
unmodified O +
peptide O -
. O +

These O +
results O +
are O +
critical O +
to O +
the O +
exploitation O +
of O +
the O +
vitamin B-Chemical +
B I-Chemical -
( I-Chemical -
12 I-Chemical -
) I-Chemical +
oral O +
uptake O +
pathway O +
for O +
peptide O +
delivery O -
. O +

iReckon O -
: O +
simultaneous O +
isoform O +
discovery O +
and O +
abundance O +
estimation O +
from O +
RNA O -
- O -
seq O +
data O -
. O +

High O -
- O -
throughput O +
RNA O +
sequencing O +
( O -
RNA O -
- O -
seq O -
) O +
promises O +
to O +
revolutionize O +
our O +
understanding O +
of O +
genes O +
and O +
their O +
role O +
in O +
human O +
disease O +
by O +
characterizing O +
the O +
RNA O +
content O +
of O +
tissues O +
and O +
cells O -
. O +

The O +
realization O +
of O +
this O +
promise O -
, O +
however O -
, O +
is O +
conditional O +
on O +
the O +
development O +
of O +
effective O +
computational O +
methods O +
for O +
the O +
identification O +
and O +
quantification O +
of O +
transcripts O +
from O +
incomplete O +
and O +
noisy O +
data O -
. O +

In O +
this O +
article O -
, O +
we O +
introduce O +
iReckon O -
, O +
a O +
method O +
for O +
simultaneous O +
determination O +
of O +
the O +
isoforms O +
and O +
estimation O +
of O +
their O +
abundances O -
. O +

Our O +
probabilistic O +
approach O +
incorporates O +
multiple O +
biological O +
and O +
technical O +
phenomena O -
, O +
including O +
novel O +
isoforms O -
, O +
intron O +
retention O -
, O +
unspliced O +
pre O -
- O -
mRNA O -
, O +
PCR O +
amplification O +
biases O -
, O +
and O +
multimapped O +
reads O -
. O +

iReckon O +
utilizes O +
regularized O +
expectation O -
- O -
maximization O +
to O +
accurately O +
estimate O +
the O +
abundances O +
of O +
known O +
and O +
novel O +
isoforms O -
. O +

Our O +
results O +
on O +
simulated O +
and O +
real O +
data O +
demonstrate O +
a O +
superior O +
ability O +
to O +
discover O +
novel O +
isoforms O +
with O +
a O +
significantly O +
reduced O +
number O +
of O +
false O -
- O -
positive O +
predictions O -
, O +
and O +
our O +
abundance O +
accuracy O +
prediction O +
outmatches O +
that O +
of O +
other O +
state O -
- O -
of O -
- O -
the O -
- O -
art O +
tools O -
. O +

Furthermore O -
, O +
we O +
have O +
applied O +
iReckon O +
to O +
two O +
cancer O +
transcriptome O +
data O +
sets O -
, O +
a O +
triple O -
- O -
negative O +
breast O +
cancer O +
patient O +
sample O +
and O +
the O +
MCF7 O +
breast O +
cancer O +
cell O +
line O -
, O +
and O +
show O +
that O +
iReckon O +
is O +
able O +
to O +
reconstruct O +
the O +
complex O +
splicing O +
changes O +
that O +
were O +
not O +
previously O +
identified O -
. O +

QT O -
- O -
PCR O +
validations O +
of O +
the O +
isoforms O +
detected O +
in O +
the O +
MCF7 O +
cell O +
line O +
confirmed O +
all O +
of O +
iReckon O -
's O +
predictions O +
and O +
also O +
showed O +
strong O +
agreement O +
( O -
r O -
( O -
2 O -
) O +
= O +
0.94 O -
) O +
with O +
the O +
predicted O +
abundances O -
. O +

Effects O +
of O +
the O +
lipid O +
environment O -
, O +
cholesterol B-Chemical +
and O +
bile B-Chemical +
acids I-Chemical +
on O +
the O +
function O +
of O +
the O +
purified O +
and O +
reconstituted O +
human O +
ABCG2 O +
protein O -
. O +

The O +
human O +
ABCG2 O +
multidrug O +
transporter O +
actively O +
extrudes O +
a O +
wide O +
range O +
of O +
hydrophobic O +
drugs O +
and O +
xenobiotics O +
recognized O +
by O +
the O +
transporter O +
in O +
the O +
membrane O +
phase O -
. O +

In O +
order O +
to O +
examine O +
the O +
molecular O +
nature O +
of O +
the O +
transporter O +
and O +
its O +
effects O +
on O +
the O +
lipid O +
environment O -
, O +
we O +
have O +
established O +
an O +
efficient O +
protocol O +
for O +
the O +
purification O +
and O +
reconstitution O +
of O +
the O +
functional O +
protein O -
. O +

We O +
found O +
that O +
the O +
drug O -
- O -
stimulated O +
ATPase O +
and O +
the O +
transport O +
activity O +
of O +
ABCG2 O +
are O +
fully O +
preserved O +
by O +
applying O +
excess O +
lipids O +
and O +
mild O +
detergents O +
during O +
solubilization O -
, O +
whereas O +
a O +
detergent O -
- O -
induced O +
dissociation O +
of O +
the O +
ABCG2 O +
dimer O +
causes O +
an O +
irreversible O +
inactivation O -
. O +

By O +
using O +
the O +
purified O +
and O +
reconstituted O +
protein O +
we O +
demonstrate O +
that O +
cholesterol B-Chemical +
is O +
an O +
essential O +
activator O -
, O +
whereas O +
bile B-Chemical +
acids I-Chemical +
are O +
important O +
modulators O +
of O +
ABCG2 O +
activity O -
. O +

Both O +
wild O -
- O -
type O +
ABCG2 O +
and O +
its O +
R482 O -
G O +
mutant O +
variant O +
require O +
cholesterol B-Chemical +
for O +
full O +
activity O -
, O +
although O +
they O +
exhibit O +
different O +
cholesterol B-Chemical +
sensitivities O -
. O +

Bile B-Chemical +
acids I-Chemical +
strongly O +
decrease O +
the O +
basal O +
ABCG2-ATPase O +
activity O +
both O +
in O +
the O +
wild O -
- O -
type O +
ABCG2 O +
and O +
in O +
the O +
mutant O +
variant O -
. O +

These O +
data O +
reinforce O +
the O +
results O +
for O +
the O +
modulatory O +
effects O +
of O +
cholesterol B-Chemical +
and O +
bile B-Chemical +
acids I-Chemical +
of O +
ABCG2 O +
investigated O +
in O +
a O +
complex O +
cell O +
membrane O +
environment O -
. O +

Moreover O -
, O +
these O +
experiments O +
open O +
the O +
possibility O +
to O +
perform O +
functional O +
and O +
structural O +
studies O +
with O +
a O +
purified O -
, O +
reconstituted O +
and O +
highly O +
active O +
ABCG2 O +
multidrug O +
transporter O -
. O +

Spontaneous O +
periodic O +
diameter O +
oscillations O +
in O +
InP B-Chemical +
nanowires O -
: O +
the O +
role O +
of O +
interface O +
instabilities O -
. O +

We O +
have O +
observed O +
that O +
thin O +
InP B-Chemical +
nanowires O +
generated O +
by O +
vapor O -
- O -
liquid O -
- O -
solid O +
growth O +
display O +
spontaneous O +
periodic O +
diameter O +
oscillations O +
when O +
large O +
group O +
III O +
supersaturations O +
are O +
used O -
. O +

Diameter O +
variations O +
are O +
associated O +
with O +
a O +
large O +
number O +
of O +
stacking O +
faults O +
and O +
crystallographic O +
phase O +
changes O -
( O -
wurtzite B-Chemical -
/ O -
zinc B-Chemical -
- I-Chemical -
blende I-Chemical -
) O -
; O +
also O +
the O +
axial O +
distance O +
between O +
oscillations O +
depends O +
on O +
the O +
indium B-Chemical +
precursor O +
flow O +
used O +
during O +
the O +
run O -
. O +

We O +
attribute O +
the O +
morphology O +
changes O +
to O +
a O +
substantial O +
deformation O +
of O +
the O +
triple O +
phase O +
line O +
( O -
vapor O -
- O -
liquid O -
- O -
solid O -
) O +
at O +
the O +
catalyst O +
nanoparticle O +
edge O +
originated O +
from O +
multistep O +
nucleation O +
during O +
growth O -
. O +

The O +
deformation O +
alters O +
the O +
mechanical O +
force O +
balance O +
acting O +
on O +
the O +
nanoparticle O +
during O +
growth O +
in O +
such O +
a O +
way O +
that O +
the O +
particle O +
displaces O +
from O +
the O +
nanowire O +
top O +
and O +
wets O +
the O +
nanowire O +
sidewall O -
. O +

Subsequently O -
, O +
as O +
catalytic O +
growth O +
occurs O +
at O +
the O +
sidewall O -
, O +
the O +
associated O +
increase O +
in O +
diameter O +
will O +
eventually O +
push O +
the O +
NP O +
back O +
to O +
its O +
original O +
wire O -
- O -
top O +
position O +
until O +
the O +
onset O +
of O +
a O +
new O +
instability O +
at O +
the O +
triple O +
phase O +
line O -
. O +

Flexible O +
fiber O +
nanogenerator O +
with O +
209 O +
V O +
output O +
voltage O +
directly O +
powers O +
a O +
light O -
- O -
emitting O +
diode O -
. O +

On O +
the O +
basis O +
of O +
a O +
vertically O +
aligned O +
ultralong O +
Pb B-Chemical -
( I-Chemical -
Zr I-Chemical -
( I-Chemical -
0.52 I-Chemical -
) I-Chemical -
Ti I-Chemical -
( I-Chemical -
0.48 I-Chemical -
) I-Chemical -
) I-Chemical -
O I-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical +
( O -
PZT B-Chemical -
) O +
nanowire O +
array O +
fabricated O +
using O +
electrospinning O +
nanofibers O -
, O +
we O +
developed O +
a O +
new O +
type O +
of O +
integrated O +
nanogenerator O +
( O -
NG O -
) O +
with O +
ultrahigh O +
output O +
voltage O +
of O +
209 O +
V O +
and O +
current O +
density O +
of O +
23.5 O +
μA O -
/ O -
cm O -
( O -
2 O -
) O -
, O +
which O +
are O +
3.6 O +
times O +
and O +
2.9 O +
times O +
of O +
the O +
previous O +
record O +
values O -
, O +
respectively O -
. O +

The O +
output O +
electricity O +
can O +
be O +
directly O +
used O +
to O +
stimulate O +
the O +
frog O -
's O +
sciatic O +
nerve O +
and O +
to O +
induce O +
a O +
contraction O +
of O +
a O +
frog O -
's O +
gastrocnemius O -
. O +

The O +
NG O +
can O +
instantaneously O +
power O +
a O +
commercial O +
light O -
- O -
emitting O +
diode O +
( O -
LED O -
) O +
without O +
the O +
energy O +
storage O +
process O -
. O +

Interactions O +
of O +
sarin B-Chemical +
with O +
polyelectrolyte O +
membranes O -
: O +
a O +
molecular O +
dynamics O +
simulation O +
study O -
. O +

Nanostructured O +
polyelectrolyte O +
membranes O +
( O -
PEMs O -
) O -
, O +
which O +
are O +
widely O +
used O +
as O +
permselective O +
diffusion O +
barriers O +
in O +
fuel O +
cell O +
technologies O +
and O +
electrochemical O +
processing O -
, O +
are O +
considered O +
as O +
protective O +
membranes O +
suitable O +
for O +
blocking O +
warfare O +
toxins O -
, O +
including O +
water O -
- O -
soluble O +
nerve O +
agents O +
such O +
as O +
sarin B-Chemical -
. O +

In O +
this O +
article O -
, O +
we O +
examine O +
the O +
mechanisms O +
of O +
sorption O +
and O +
diffusion O +
of O +
sarin B-Chemical +
in O +
hydrated O +
PEMs O +
by O +
means O +
of O +
atomistic O +
molecular O +
dynamics O +
simulations O -
. O +

Three O +
PEMs O +
are O +
considered O -
: O +
Nafion B-Chemical -
, O +
sulfonated B-Chemical +
polystyrene I-Chemical +
( O -
sPS B-Chemical -
) O +
that O +
forms O +
the O +
hydrophilic O +
subphase O +
of O +
segregated O +
sPS B-Chemical -
- O -
polyolefin B-Chemical +
block O +
copolymers O -
, O +
and O +
random O +
sPS B-Chemical -
- O -
polyethylene B-Chemical +
copolymer O -
. O +

We O +
found O +
that O +
sarin B-Chemical +
concentrates O +
at O +
the O +
interface O +
between O +
the O +
hydrophilic O +
and O +
hydrophobic O +
subphases O +
of O +
hydrated B-Chemical +
Nafion I-Chemical +
acting O +
as O +
a O +
surfactant O -
. O +

In O +
hydrated B-Chemical +
sPS I-Chemical -
, O +
where O +
the O +
scale O +
of O +
water O -
- O -
polymer O +
segregation O +
is O +
much O +
smaller O +
( O -
1 O -
- O -
2 O +
nm O -
) O -
, O +
sarin B-Chemical +
also O +
interacts O +
favorably O +
with O +
hydrophobic O +
and O +
hydrophilic O +
components O -
. O +

Water O +
diffusion O +
slows O +
as O +
the O +
sarin B-Chemical +
content O +
increases O +
despite O +
the O +
overall O +
increase O +
in O +
solvent O +
content O -
, O +
which O +
suggests O +
that O +
sarin B-Chemical +
and O +
water O +
have O +
somewhat O +
different O +
pathways O +
through O +
the O +
segregated O +
membrane O -
. O +

Upon O +
replacement O +
of O +
counterions O +
of O +
monovalent O +
potassium B-Chemical +
with O +
those O +
of O +
divalent O +
calcium B-Chemical -
, O +
sarin B-Chemical +
diffusion O +
slows O +
but O +
remains O +
substantial O +
in O +
all O +
ionomers O +
considered O -
, O +
especially O +
at O +
high O +
sarin B-Chemical +
concentrations O -
. O +

The O +
behavior O +
of O +
sarin B-Chemical +
is O +
similar O +
to O +
that O +
of O +
its O +
common O +
simulant O -
, O +
dimethyl B-Chemical +
methylphosphonate I-Chemical -
. O +

Invasion O +
genetics O +
of O +
the O +
introduced O +
black O +
rat O +
( O -
Rattus O +
rattus O -
) O +
in O +
Senegal O -
, O +
West O +
Africa O -
. O +

An O +
understanding O +
of O +
the O +
evolutionary O +
history O +
and O +
dynamics O +
of O +
invasive O +
species O +
is O +
required O +
for O +
the O +
construction O +
of O +
predictive O +
models O +
of O +
future O +
spread O +
and O +
the O +
design O +
of O +
biological O +
management O +
measures O -
. O +

The O +
black O +
rat O +
( O -
Rattus O +
rattus O -
) O +
is O +
a O +
major O +
vertebrate O +
invader O +
with O +
a O +
worldwide O +
distribution O -
. O +

Despite O +
the O +
severe O +
ecological O -
, O +
economic O +
and O +
health O +
impacts O +
of O +
this O +
species O -
, O +
its O +
evolutionary O +
history O +
has O +
been O +
little O +
studied O -
. O +

We O +
carried O +
out O +
extensive O +
specimen O +
sampling O +
in O +
Senegal O -
, O +
West O +
Africa O -
, O +
and O +
used O +
microsatellite O +
markers O +
to O +
describe O +
the O +
pattern O +
and O +
processes O +
of O +
invasion O +
in O +
this O +
large O +
continental O +
area O -
. O +

The O +
genetic O +
data O +
obtained O +
were O +
combined O +
with O +
historical O +
knowledge O +
concerning O +
the O +
presence O +
of O +
this O +
species O +
in O +
Senegal O -
. O +

Data O +
were O +
analysed O +
by O +
a O +
combination O +
of O +
Bayesian O +
clustering O +
and O +
approximate O +
Bayesian O +
computation O +
methods O -
. O +

The O +
invasion O +
pathways O +
closely O +
paralleled O +
the O +
history O +
of O +
human O +
trade O +
routes O +
in O +
Senegal O -
. O +

In O +
several O +
places O -
, O +
we O +
detected O +
the O +
occurrence O +
of O +
multiple O +
introductions O +
from O +
genetically O +
different O +
sources O -
. O +

Long O -
- O -
distance O +
migration O +
between O +
towns O +
and O +
villages O +
was O +
also O +
observed O -
. O +

Our O +
findings O +
suggest O +
that O +
genetic O +
bottlenecks O +
and O +
admixture O +
have O +
played O +
a O +
major O +
role O +
in O +
shaping O +
the O +
genetics O +
of O +
invasive O +
black O +
rats O -
. O +

These O +
two O +
processes O +
may O +
generate O +
genetic O +
novelty O +
and O +
favour O +
rapid O +
evolution O +
along O +
the O +
invasion O +
pathways O -
. O +

Multifunctional O +
Fe3O4@Ag B-Chemical -
/ O -
SiO2 B-Chemical -
/ O -
Au B-Chemical +
core O -
- O -
shell O +
microspheres O +
as O +
a O +
novel O +
SERS O -
- O -
activity O +
label O +
via O +
long O -
- O -
range O +
plasmon O +
coupling O -
. O +

Noble O +
metallic O +
nanostructures O +
exhibit O +
a O +
phenomenon O +
known O +
as O +
surface O -
- O -
enhanced O +
Raman O +
scattering O +
( O -
SERS O -
) O +
in O +
which O +
the O +
Raman O +
scattering O +
cross O +
sections O +
are O +
dramatically O +
enhanced O +
for O +
the O +
molecules O +
adsorbed O +
thereon O -
. O +

Due O +
to O +
their O +
wide O +
accessible O +
potential O +
range O +
in O +
aqueous O +
solutions O +
and O +
the O +
high O +
biocompatibility O -
, O +
Au B-Chemical +
supports O +
are O +
preferred O +
for O +
spectro O -
- O -
electrochemical O +
investigations O -
. O +

However O -
, O +
the O +
optical O +
range O +
in O +
SERS O +
spectroscopy O +
is O +
restricted O +
to O +
excitation O +
lines O +
above O +
600 O +
nm O -
, O +
which O +
is O +
shorter O +
than O +
the O +
Ag B-Chemical +
supports O -
. O +

In O +
addition O -
, O +
these O +
SERS O -
- O -
activity O +
materials O +
are O +
not O +
easy O +
to O +
separate O +
and O +
reused O -
. O +

Herein O -
, O +
the O +
present O +
article O +
reports O +
the O +
novel O +
multifunctional O +
Fe B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
O I-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
@Ag O -
/ O -
SiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
/ O -
Au B-Chemical +
core O -
- O -
shell O +
microspheres O +
that O +
display O +
long O -
- O -
range O +
plasmon O +
transfer O +
of O +
Ag B-Chemical +
to O +
Au B-Chemical +
leading O +
to O +
enhanced O +
Raman O +
scattering O -
. O +

The O +
well O -
- O -
designed O +
microspheres O +
have O +
high O +
magnetization O +
and O +
uniform O +
sphere O +
size O -
. O +

As O +
a O +
result O -
, O +
Fe B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
O I-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
@Ag O -
/ O -
SiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
/ O -
Au B-Chemical +
microspheres O +
have O +
the O +
best O +
enhancement O +
effect O +
in O +
the O +
Raman O +
active O +
research O +
by O +
using O +
Rhodamine B-Chemical -
- I-Chemical -
b I-Chemical +
( O -
RdB B-Chemical -
) O +
as O +
a O +
probe O +
molecule O -
. O +

The O +
enhancement O +
factor O +
is O +
estimated O +
to O +
be O +
2.2 O +
× O +
10 O -
( O -
4 O -
) O +
for O +
RdB B-Chemical +
from O +
the O +
long O -
- O -
range O +
plasmon O +
transfer O +
of O +
Ag B-Chemical +
to O +
Au B-Chemical -
, O +
corresponding O +
to O +
an O +
attenuation O +
of O +
the O +
enhancement O +
by O +
a O +
factor O +
of O +
only O +
0.672 O +
× O +
10 O -
( O -
4 O -
) O +
compared O +
to O +
RdB B-Chemical +
adsorbed O +
directly O +
on O +
the O +
Fe B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
O I-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
@Ag O +
microspheres O -
. O +

RdB B-Chemical +
can O +
be O +
detected O +
down O +
to O +
10 O -
( O -
-9 O -
) O +
M O +
even O +
without O +
the O +
resonance O +
SERS O +
effect O -
. O +

The O +
unique O +
nanostructure O +
makes O +
the O +
microspheres O +
novel O +
stable O +
and O +
a O +
high O -
- O -
enhancement O +
effect O +
for O +
Raman O +
detection O -
. O +

Combining O +
QSAR O +
classification O +
models O +
for O +
predictive O +
modeling O +
of O +
human O +
monoamine O +
oxidase O +
inhibitors O -
. O +

Due O +
to O +
their O +
role O +
in O +
the O +
metabolism O +
of O +
monoamine O +
neurotransmitters O -
, O +
MAO O -
- O -
A O +
and O +
MAO O -
- O -
B O +
present O +
a O +
significant O +
pharmacological O +
interest O -
. O +

For O +
instance O +
the O +
inhibitors O +
of O +
human O +
MAO O -
- O -
B O +
are O +
considered O +
useful O +
tools O +
for O +
the O +
treatment O +
of O +
Parkinson O +
Disease O -
. O +

Therefore O -
, O +
the O +
rational O +
design O +
and O +
synthesis O +
of O +
new O +
MAOs O +
inhibitors O +
is O +
considered O +
of O +
great O +
importance O +
for O +
the O +
development O +
of O +
new O +
and O +
more O +
effective O +
treatments O +
of O +
Parkinson O +
Disease O -
. O +

In O +
this O +
work O -
, O +
Quantitative O +
Structure O +
Activity O +
Relationships O +
( O -
QSAR O -
) O +
has O +
been O +
developed O +
to O +
predict O +
the O +
human O +
MAO O +
inhibitory O +
activity O +
and O +
selectivity O -
. O +

The O +
first O +
step O +
was O +
the O +
selection O +
of O +
a O +
suitable O +
dataset O +
of O +
heterocyclic O +
compounds O +
that O +
include O +
chromones B-Chemical -
, O +
coumarins B-Chemical -
, O +
chalcones B-Chemical -
, O +
thiazolylhydrazones B-Chemical -
, O +
etc O -
. O +

These O +
compounds O +
were O +
previously O +
synthesized O +
in O +
one O +
of O +
our O +
laboratories O -
, O +
or O +
elsewhere O -
, O +
and O +
their O +
activities O +
measured O +
by O +
the O +
same O +
assays O +
and O +
for O +
the O +
same O +
laboratory O +
staff O -
. O +

Applying O +
linear O +
discriminant O +
analysis O +
to O +
data O +
derived O +
from O +
a O +
variety O +
of O +
molecular O +
representations O +
and O +
feature O +
selection O +
algorithms O -
, O +
reliable O +
QSAR O +
models O +
were O +
built O +
which O +
could O +
be O +
used O +
to O +
predict O +
for O +
test O +
compounds O +
the O +
inhibitory O +
activity O +
and O +
selectivity O +
toward O +
human O +
MAO O -
. O +

This O +
work O +
also O +
showed O +
how O +
several O +
QSAR O +
models O +
can O +
be O +
combined O +
to O +
make O +
better O +
predictions O -
. O +

The O +
final O +
models O +
exhibit O +
significant O +
statistics O -
, O +
interpretability O -
, O +
as O +
well O +
as O +
displaying O +
predictive O +
power O +
on O +
an O +
external O +
validation O +
set O +
made O +
up O +
of O +
chromone O +
derivatives O +
with O +
unknown O +
activity O +
( O -
that O +
are O +
being O +
reported O +
here O +
for O +
first O +
time O -
) O +
synthesized O +
by O +
our O +
group O -
, O +
and O +
coumarins B-Chemical +
recently O +
reported O +
in O +
the O +
literature O -
. O +

From O +
in O +
situ O +
to O +
in O +
vivo O -
: O +
an O +
in O +
situ O +
click O -
- O -
chemistry O -
- O -
derived O +
carbonic O +
anhydrase O +
II O +
imaging O +
agent O +
for O +
positron O +
emission O +
tomography O -
. O +

CA O +
II O +
makes O +
a O +
good O +
PET O -
: O +
Discovering O +
positron O +
emission O +
tomography O +
( O -
PET O -
) O +
probes O +
with O +
high O +
target O +
affinities O +
is O +
challenging O -
. O +

PET O +
probe O +
discovery O +
using O +
in O +
situ O +
click O +
chemistry O +
uses O +
( B-Chemical -
19 I-Chemical -
) I-Chemical +
F I-Chemical -
- O -
bearing O +
fragments O +
as O +
( B-Chemical -
18 I-Chemical -
) I-Chemical +
F I-Chemical +
surrogates O -
. O +

This O +
ensures O +
that O +
the O +
lead O +
hits O +
and O +
PET O +
probes O +
have O +
equivalent O +
chemical O +
or O +
biological O +
characteristics O -
, O +
making O +
PET O +
probe O +
discovery O +
predictable O +
and O +
reliable O -
. O +

Enantiospecific O +
total O +
synthesis O +
of O +
( B-Chemical -
- I-Chemical -
) I-Chemical -
-bengamide I-Chemical +
E. I-Chemical +
Total O +
synthesis O +
of O +
the O +
polyhydroxy B-Chemical +
caprolactam I-Chemical +
amide I-Chemical +
natural O +
product O -
, O +
bengamide B-Chemical +
E I-Chemical -
, O +
is O +
accomplished O +
starting O +
from O +
tartaric B-Chemical +
acid I-Chemical -
. O +

Key O +
reactions O +
in O +
the O +
synthesis O +
include O +
desymmetrization O +
of O +
the O +
bis B-Chemical -
( I-Chemical -
dimethylamide I-Chemical -
) I-Chemical +
unit O +
of O +
tartaric B-Chemical +
acid I-Chemical -
, O +
Zn B-Chemical -
( I-Chemical -
BH I-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
) I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
-mediated O +
anti O -
- O -
selective O +
reduction O -
, O +
and O +
a O +
Horner O -
- O -
Wadsworth O -
- O -
Emmons O +
olefination O -
. O +

Functional O +
requirement O +
for O +
a O +
highly O +
conserved O +
charged O +
residue O +
at O +
position O +
75 O +
in O +
the O +
gap O +
junction O +
protein O +
connexin O +
32 O -
. O +

Charcot O +
Marie O +
Tooth O +
disease O +
( O -
CMT O -
) O +
is O +
a O +
group O +
of O +
inherited O +
disorders O +
characterized O +
clinically O +
by O +
exclusively O +
or O +
predominantly O +
peripheral O +
nerve O +
dysfunction O -
. O +

CMT1X O -
, O +
the O +
most O +
common O +
form O +
of O +
X O -
- O -
linked O +
CMT O +
is O +
caused O +
by O +
mutations O +
in O +
connexin O +
32 O +
( O -
Cx32 O -
) O -
. O +

In O +
this O +
work O -
, O +
we O +
used O +
dual O +
whole O +
cell O +
patch O +
clamp O +
recording O +
to O +
examine O +
the O +
functional O +
effects O +
of O +
mutations O +
at O +
the O +
Arg B-Chemical -
( O -
75 O -
) O +
position O -
. O +

This O +
residue O +
is O +
highly O +
conserved O +
among O +
members O +
of O +
the O +
connexin O +
family O -
, O +
and O +
disease O -
- O -
causing O +
mutations O +
have O +
been O +
identified O +
at O +
this O +
( O -
or O +
the O +
corresponding O -
) O +
position O +
in O +
Cx26 O -
, O +
Cx43 O -
, O +
and O +
Cx46 O -
. O +

Thus O -
, O +
a O +
better O +
understanding O +
of O +
the O +
effects O +
of O +
mutations O +
of O +
this O +
position O +
in O +
Cx32 O +
may O +
have O +
relevance O +
to O +
pathogenesis O +
of O +
a O +
number O +
of O +
different O +
human O +
diseases O -
. O +

All O +
three O +
mutants O +
associated O +
with O +
CMT1X O +
( O -
R75P O -
, O +
R75Q O -
, O +
and O +
R75W O -
) O +
showed O +
very O +
low O +
levels O +
of O +
coupling O +
similar O +
to O +
those O +
of O +
the O +
cells O +
transfected O +
with O +
vector O +
alone O -
. O +

Heterotypic O +
pairing O +
with O +
Cx32 O +
WT O +
showed O +
that O +
the O +
absence O +
of O +
coupling O +
for O +
these O +
mutants O +
in O +
the O +
homotypic O +
configuration O +
could O +
be O +
explained O +
by O +
shifts O +
in O +
their O +
hemichannel O +
G O -
( O -
j O -
) O -
-V O -
( O -
j O -
) O +
relations O -
. O +

Examination O +
of O +
the O +
expression O +
levels O +
and O +
gating O +
characteristics O +
of O +
seven O +
additional O +
mutants O +
( O -
R75A O -
, O +
R75D O -
, O +
R75E O -
, O +
R75H O -
, O +
R75 O -
K O -
, O +
R75L O -
, O +
and O +
R75V O -
) O +
at O +
this O +
position O +
suggest O +
that O +
the O +
positive O +
charge O +
at O +
position O +
75 O +
in O +
Cx32 O +
is O +
required O +
for O +
normal O +
channel O +
function O +
but O +
not O +
for O +
gap O +
junction O +
assembly O -
. O +

Our O +
studies O +
also O +
suggest O +
that O +
disease O +
treatment O +
strategies O +
for O +
CMT1X O -
, O +
which O +
correct O +
trafficking O +
abnormalities O +
in O +
Cx32 O -
, O +
may O +
be O +
ineffective O +
for O +
the O +
group O +
of O +
mutations O +
also O +
conferring O +
changes O +
in O +
gating O +
properties O +
of O +
Cx32 O +
channels O -
. O +

Simulations O +
of O +
the O +
two O -
- O -
dimensional O +
electronic O +
spectroscopy O +
of O +
the O +
photosystem O +
II O +
reaction O +
center O -
. O +

We O +
report O +
simulations O +
of O +
the O +
two O -
- O -
dimensional O +
electronic O +
spectroscopy O +
of O +
the O +
Q O -
( O -
y O -
) O +
band O +
of O +
the O +
D1-D2-Cyt O +
b559 O +
photosystem O +
II O +
reaction O +
center O +
at O +
77 O +
K. O +
We O +
base O +
the O +
simulations O +
on O +
an O +
existing O +
Hamiltonian O +
that O +
was O +
derived O +
by O +
simultaneous O +
fitting O +
to O +
a O +
wide O +
range O +
of O +
linear O +
spectroscopic O +
measurements O +
and O +
described O +
within O +
modified O +
Redfield O +
theory O -
. O +

The O +
model O +
obtains O +
reasonable O +
agreement O +
with O +
most O +
aspects O +
of O +
the O +
two O -
- O -
dimensional O +
spectra O -
, O +
including O +
the O +
overall O +
peak O +
shapes O +
and O +
excited O +
state O +
absorption O +
features O -
. O +

It O +
does O +
not O +
reproduce O +
the O +
rapid O +
equilibration O +
from O +
high O +
energy O +
to O +
low O +
energy O +
excitonic O +
states O +
evident O +
by O +
a O +
strong O +
cross O -
- O -
peak O +
below O +
the O +
diagonal O -
. O +

We O +
explore O +
modifications O +
to O +
the O +
model O +
to O +
incorporate O +
new O +
structural O +
data O +
and O +
improve O +
agreement O +
with O +
the O +
two O -
- O -
dimensional O +
spectra O -
. O +

We O +
find O +
that O +
strengthening O +
the O +
system O -
- O -
bath O +
coupling O +
and O +
lowering O +
the O +
degree O +
of O +
disorder O +
significantly O +
improves O +
agreement O +
with O +
the O +
cross O -
- O -
peak O +
feature O -
, O +
while O +
lessening O +
agreement O +
with O +
the O +
relative O +
diagonal O -
/ O -
antidiagonal O +
width O +
of O +
the O +
2D O +
spectra O -
. O +

We O +
conclude O +
that O +
two O -
- O -
dimensional O +
electronic O +
spectroscopy O +
provides O +
a O +
sensitive O +
test O +
of O +
excitonic O +
models O +
of O +
the O +
photosystem O +
II O +
reaction O +
center O +
and O +
discuss O +
avenues O +
for O +
further O +
refinement O +
of O +
such O +
models O -
. O +

Stabilization O +
and O +
inhibition O +
of O +
protein O -
- O -
protein O +
interactions O -
: O +
the O +
14 O -
- O -
3 O -
- O -
3 O +
case O +
study O -
. O +

Small O -
- O -
molecule O +
modulation O +
of O +
protein O -
- O -
protein O +
interactions O +
( O -
PPIs O -
) O +
is O +
one O +
of O +
the O +
most O +
exciting O +
but O +
also O +
difficult O +
fields O +
in O +
chemical O +
biology O +
and O +
drug O +
development O -
. O +

As O +
one O +
of O +
the O +
most O +
important O +
" O -
hub O -
" O +
proteins O +
with O +
at O +
least O +
200 O -
- O -
300 O +
interaction O +
partners O -
, O +
the O +
14 O -
- O -
3 O -
- O -
3 O +
proteins O +
are O +
an O +
especially O +
fruitful O +
case O +
for O +
PPI O +
intervention O -
. O +

Here O -
, O +
we O +
summarize O +
recent O +
success O +
stories O +
in O +
small O -
- O -
molecule O +
modulation O -
, O +
both O +
inhibition O +
and O +
stabilization O -
, O +
of O +
14 O -
- O -
3 O -
- O -
3 O +
PPIs O -
. O +

The O +
chemical O +
breath O +
of O +
modulators O +
includes O +
natural O +
products O +
such O +
as O +
fusicoccin B-Chemical +
A I-Chemical +
and O +
derivatives O +
but O +
also O +
compounds O +
identified O +
via O +
high O -
- O -
throughput O +
and O +
in O +
silico O +
screening O -
, O +
which O +
has O +
yielded O +
a O +
toolbox O +
of O +
useful O +
inhibitors O +
and O +
stabilizers O +
for O +
this O +
interesting O +
class O +
of O +
adapter O +
proteins O -
. O +

Protein O -
- O -
protein O +
interactions O +
( O -
PPIs O -
) O +
are O +
involved O +
in O +
almost O +
all O +
biological O +
processes O -
, O +
with O +
any O +
given O +
protein O +
typically O +
engaged O +
in O +
complexes O +
with O +
other O +
proteins O +
for O +
the O +
majority O +
of O +
its O +
lifetime O -
. O +

Hence O -
, O +
proteins O +
function O +
not O +
simply O +
as O +
single O -
, O +
isolated O +
entities O +
but O +
display O +
their O +
roles O +
by O +
interacting O +
with O +
other O +
cellular O +
components O -
. O +

These O +
different O +
interaction O +
patterns O +
are O +
presumably O +
as O +
important O +
as O +
the O +
intrinsic O +
biochemical O +
activity O +
status O +
of O +
the O +
protein O +
itself O -
. O +

The O +
biological O +
role O +
of O +
a O +
protein O +
is O +
therefore O +
decisively O +
dependent O +
on O +
the O +
underlying O +
PPI O +
network O +
that O +
furthermore O +
can O +
show O +
great O +
spatial O +
and O +
temporal O +
variations O -
. O +

A O +
thorough O +
appreciation O +
and O +
understanding O +
of O +
this O +
concept O +
and O +
its O +
regulation O +
mechanisms O +
could O +
help O +
to O +
develop O +
new O +
therapeutic O +
agents O +
and O +
concepts O -
. O +

Protective O +
effect O +
of O +
70 O -
% O +
ethanolic O +
extract O +
of O +
Lindera O +
obtusiloba O +
Blume O +
on O +
tert B-Chemical -
- I-Chemical -
butyl I-Chemical +
hydroperoxide I-Chemical -
- O -
induced O +
oxidative O +
hepatotoxicity O +
in O +
rats O -
. O +

Lindera O +
obtusiloba O +
Blume O -
, O +
a O +
native O +
plant O +
of O +
East O +
Asia O -
, O +
has O +
traditionally O +
been O +
used O +
as O +
a O +
folk O +
medicine O +
for O +
liver O +
disease O -
. O +

We O +
studied O +
the O +
in O +
vitro O +
antioxidant O +
and O +
in O +
vivo O +
hepatoprotective O +
activities O +
of O +
a O +
70 O -
% O +
ethanolic O +
extract O +
of O +
L. O +
obtusiloba O +
( O -
LOE O -
) O +
containing O +
62.9 O -
% O +
quercitrin B-Chemical +
and O +
22.0 O -
% O +
afzelin B-Chemical -
. O +

LOE O +
prevented O +
tert B-Chemical -
- I-Chemical -
butyl I-Chemical +
hydroperoxide I-Chemical +
( O -
t B-Chemical -
- I-Chemical -
BHP I-Chemical -
) O -
-induced O +
oxidative O +
damage O +
in O +
HepG2 O +
cells O -
. O +

Along O +
with O +
its O +
high O +
antioxidant O +
potency O +
in O +
vitro O -
, O +
our O +
animal O +
study O +
confirmed O +
that O +
pretreatment O +
with O +
LOE O +
( O -
500 O +
or O +
2000 O +
mg O -
/ O -
kg O -
) O +
for O +
7 O +
days O +
prior O +
to O +
a O +
single O +
dose O +
of O +
t B-Chemical -
- I-Chemical -
BHP I-Chemical +
( O -
i.p O -
. O -
: O +
0.5 O +
mmol O -
/ O -
kg O -
) O +
significantly O +
lowered O +
the O +
serum O +
levels O +
of O +
alanine B-Chemical +
and O +
aspartate B-Chemical +
aminotransferases O -
. O +

In O +
addition O -
, O +
glutathione B-Chemical +
levels O +
were O +
increased O +
in O +
the O +
liver O -
, O +
and O +
lipid O +
peroxidation O +
levels O +
were O +
decreased O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O +

The O +
histopathological O +
examinations O +
of O +
rat O +
livers O +
showed O +
that O +
LOE O +
significantly O +
reduced O +
the O +
incidence O +
of O +
liver O +
lesions O +
induced O +
by O +
t B-Chemical -
- I-Chemical -
BHP I-Chemical -
. O +

Therefore O -
, O +
we O +
concluded O +
that O +
LOE O +
has O +
merit O +
as O +
a O +
potent O +
candidate O +
to O +
protect O +
the O +
liver O +
against O +
oxidative O +
damage O -
. O +

ADP B-Chemical -
- O -
ribosylation O +
of O +
guanosine B-Chemical +
by O +
SCO5461 O +
protein O +
secreted O +
from O +
Streptomyces O +
coelicolor O -
. O +

The O +
Streptomyces O +
coelicolor O +
A3 O -
( O -
2 O -
) O +
genome O +
encodes O +
a O +
possible O +
secretion O +
protein O -
, O +
SCO5461 O -
, O +
that O +
shares O +
a O +
30 O -
% O +
homology O +
with O +
the O +
activity O +
domains O +
of O +
two O +
toxic O +
ADP B-Chemical -
- O -
ribosyltransferases O -
, O +
pierisins O +
and O +
mosquitocidal O +
toxin O -
. O +

We O +
found O +
ADP B-Chemical -
- O -
ribosylating O +
activity O +
for O +
the O +
SCO5461 O +
protein O +
product O +
through O +
its O +
co O -
- O -
incubation O +
with O +
guanosine B-Chemical +
and O +
NAD B-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical -
, O +
which O +
resulted O +
in O +
the O +
formation O +
of O +
N B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
- I-Chemical -
( I-Chemical -
ADP I-Chemical -
- I-Chemical -
ribos-1-yl I-Chemical -
) I-Chemical -
-guanosine I-Chemical +
( O -
( B-Chemical -
ar2 I-Chemical -
) I-Chemical -
Guo I-Chemical -
) O -
, O +
with O +
a O +
K O -
( O -
m O -
) O +
value O +
of O +
110 O +
μM. O +
SCO5461 O +
was O +
further O +
found O +
to O +
ADP B-Chemical -
- O -
ribosylate O +
deoxyguanosine B-Chemical -
, O +
GMP B-Chemical -
, O +
dGMP B-Chemical -
, O +
GTP B-Chemical -
, O +
dGTP B-Chemical -
, O +
and O +
cyclic B-Chemical +
GMP I-Chemical +
with O +
k O -
( O -
cat O -
) O +
values O +
of O +
150 O -
- O -
370 O +
s O -
( O -
-1 O -
) O -
. O +

Oligo O -
( O -
dG O -
) O -
, O +
oligo O -
( O -
G O -
) O -
, O +
and O +
yeast O +
tRNA O +
were O +
also O +
ADP B-Chemical -
- O -
ribosylated O +
by O +
this O +
protein O -
, O +
although O +
with O +
much O +
lower O +
k O -
( O -
cat O -
) O +
values O +
of O +
0.2 O +
s O -
( O -
-1 O -
) O +
or O +
less O -
. O +

SCO5461 O +
showed O +
maximum O +
ADP B-Chemical -
- O -
ribosylation O +
activity O +
towards O +
guanosine O +
at O +
30 O +
° O -
C O -
, O +
and O +
maintained O +
20 O -
% O +
of O +
these O +
maximum O +
activity O +
levels O +
even O +
at O +
0 O +
° O -
C O -
. O +

This O +
is O +
the O +
first O +
report O +
of O +
the O +
ADP B-Chemical -
- O -
ribosylation O +
of O +
guanosine B-Chemical +
and O +
guanine B-Chemical +
mononucleotides I-Chemical +
among O +
the O +
family O +
members O +
of O +
various O +
ADP B-Chemical -
- O -
ribosylating O +
enzymes O -
. O +

We O +
additionally O +
observed O +
secretion O +
of O +
the O +
putative O +
gene O +
product O -
, O +
SCO5461 O -
, O +
in O +
liquid O +
cultures O +
of O +
S. O +
coelicolor O -
. O +

We O +
thus O +
designated O +
the O +
SCO5461 O +
protein O +
product O +
as O +
S. O +
coelicolor O +
ADP B-Chemical -
- O -
ribosylating O +
protein O -
, O +
ScARP O -
. O +

Our O +
current O +
results O +
could O +
offer O +
new O +
insights O +
into O +
not O +
only O +
the O +
ADP B-Chemical -
- O -
ribosylation O +
of O +
small O +
molecules O +
but O +
also O +
signal O +
transduction O +
events O +
via O +
enzymatic O +
nucleoside B-Chemical +
modification O +
by O +
toxin O -
- O -
related O +
enzymes O -
. O +

Theoretical O +
study O +
of O +
the O +
reaction O +
of O +
CH2XO B-Chemical +
( O -
X O +
= O +
F B-Chemical -
, O +
Cl B-Chemical -
, O +
Br B-Chemical -
) O +
radicals O +
with O +
the O +
NO B-Chemical +
radical O -
. O +

In O +
this O +
paper O -
, O +
we O +
focus O +
on O +
the O +
multiple O -
- O -
channel O +
reactions O +
of O +
CH B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
XO I-Chemical +
( O -
X O +
= O +
F O -
, O +
Cl B-Chemical -
, O +
Br B-Chemical -
) O +
radicals O +
with O +
the O +
NO B-Chemical +
radical O +
by O +
means O +
of O +
direct O +
dynamic O +
methods O -
. O +

All O +
structures O +
of O +
the O +
stationary O +
points O +
were O +
obtained O +
at O +
the O +
MP2 O -
/ O -
6 O -
- O -
311+G O -
( O -
d O -
, O -
p O -
) O +
level O +
and O +
vibrational O +
frequency O +
analysis O +
was O +
also O +
performed O +
at O +
this O +
level O +
of O +
theory O -
. O +

The O +
minimum O +
energy O +
path O +
( O -
MEP O -
) O +
was O +
obtained O +
via O +
the O +
intrinsic O +
reaction O +
coordinate O +
( O -
IRC O -
) O +
theory O +
at O +
the O +
MP2 O -
/ O -
6 O -
- O -
311+G O -
( O -
d O -
, O -
p O -
) O +
level O -
, O +
and O +
higher O -
- O -
level O +
energetic O +
information O +
was O +
refined O +
by O +
the O +
MC O -
- O -
QCISD O +
method O -
. O +

The O +
rate O +
constants O +
for O +
the O +
three O +
hydrogen B-Chemical +
abstraction O +
reaction O +
channels O +
over O +
the O +
temperature O +
range O +
200 O -
- O -
1,500 O +
K O +
were O +
calculated O +
by O +
the O +
improved O +
canonical O +
variational O +
transition O +
state O +
theory O +
( O -
ICVT O -
) O +
with O +
a O +
correction O +
for O +
small O -
- O -
curvature O +
tunneling O +
( O -
SCT O -
) O -
. O +

The O +
rate O +
constants O +
calculated O +
in O +
this O +
manner O +
were O +
in O +
good O +
agreement O +
with O +
the O +
available O +
experimental O +
data O -
, O +
and O +
the O +
three O -
- O -
parameter O +
rate O -
- O -
temperature O +
formulae O +
for O +
the O +
temperature O +
range O +
200 O -
- O -
1,500 O +
K O +
were O +
k O -
( O -
1a O -
) O -
( O -
T O -
) O +
= O +
0.32 O +
× O +
10 O -
( O -
-18 O -
) O +
T O -
( O -
1.83 O -
) O +
exp O -
( O -
1748.54 O -
/ O -
T O -
) O -
, O +
k O -
( O -
2a O -
) O -
( O -
T O -
) O +
= O +
0.22 O +
× O +
10 O -
( O -
-19 O -
) O +
T O -
( O -
2.19 O -
) O +
exp O -
( O -
1770.19 O -
/ O -
T O -
) O -
, O +
k O -
( O -
3a O -
) O -
( O -
T O -
) O +
= O +
0.88 O +
× O +
10 O -
( O -
-20 O -
) O +
T O -
( O -
2.20 O -
) O +
exp O -
( O -
1513.82 O -
/ O -
T O -
) O +
( O -
in O +
units O +
of O +
cm O -
( O -
3 O -
) O +
molecule O -
( O -
-1 O -
) O +
s O -
( O -
-1 O -
) O -
) O -
. O +

The O +
V499G O -
/ O -
Y501H O +
mutation O +
impairs O +
fast O +
motor O +
kinetics O +
of O +
prestin O +
and O +
has O +
significance O +
for O +
defining O +
functional O +
independence O +
of O +
individual O +
prestin O +
subunits O -
. O +

Outer O +
hair O +
cells O +
( O -
OHCs O -
) O +
are O +
a O +
mammalian O +
innovation O +
for O +
mechanically O +
amplifying O +
sound O +
energy O +
to O +
overcome O +
the O +
viscous O +
damping O +
of O +
the O +
cochlear O +
partition O -
. O +

Although O +
the O +
voltage O -
- O -
dependent O +
OHC O +
membrane O +
motor O -
, O +
prestin O -
, O +
has O +
been O +
demonstrated O +
to O +
be O +
essential O +
for O +
mammalian O +
cochlear O +
amplification O -
, O +
the O +
molecular O +
mechanism O +
by O +
which O +
prestin O +
converts O +
electrical O +
energy O +
into O +
mechanical O +
displacement O -
/ O -
force O +
remains O +
elusive O -
. O +

Identifying O +
mutations O +
that O +
alter O +
the O +
motor O +
function O +
of O +
prestin O +
provides O +
vital O +
information O +
for O +
unraveling O +
the O +
energy O +
transduction O +
mechanism O +
of O +
prestin O -
. O +

We O +
show O +
that O +
the O +
V499G O -
/ O -
Y501H O +
mutation O +
does O +
not O +
deprive O +
prestin O +
of O +
its O +
voltage O -
- O -
induced O +
motor O +
activity O -
, O +
but O +
it O +
does O +
significantly O +
impair O +
the O +
fast O +
motor O +
kinetics O +
and O +
voltage O +
operating O +
range O -
. O +

Furthermore O -
, O +
mutagenesis O +
studies O +
suggest O +
that O +
Val-499 B-Chemical +
is O +
the O +
primary O +
site O +
responsible O +
for O +
these O +
changes O -
. O +

We O +
also O +
show O +
that O +
V499G O -
/ O -
Y501H O +
prestin O +
forms O +
heteromers O +
with O +
wild O -
- O -
type O +
prestin O +
and O +
that O +
the O +
fast O +
motor O +
kinetics O +
of O +
wild O -
- O -
type O +
prestin O +
is O +
not O +
affected O +
by O +
heteromer O +
formation O +
with O +
V499G O -
/ O -
Y501H O +
prestin O -
. O +

These O +
results O +
suggest O +
that O +
prestin O +
subunits O +
are O +
individually O +
functional O +
within O +
a O +
given O +
multimer O -
. O +

Adsorption O +
of O +
phenanthrene B-Chemical -
, O +
2-naphthol B-Chemical -
, O +
and O +
1-naphthylamine B-Chemical +
to O +
colloidal O +
oxidized O +
multiwalled O +
carbon B-Chemical +
nanotubes O -
: O +
effects O +
of O +
humic O +
acid O +
and O +
surfactant O +
modification O -
. O +

Carbon B-Chemical +
nanotubes O +
( O -
CNTs O -
) O +
can O +
exist O +
in O +
the O +
form O +
of O +
colloidal O +
suspension O +
in O +
aquatic O +
environments O -
, O +
particularly O +
in O +
the O +
presence O +
of O +
natural O +
organic O +
matter O +
or O +
surfactants O -
, O +
and O +
may O +
significantly O +
affect O +
the O +
fate O +
and O +
transport O +
of O +
organic O +
contaminants O -
. O +

In O +
the O +
present O +
study O -
, O +
the O +
authors O +
examined O +
the O +
adsorption O +
of O +
phenanthrene B-Chemical -
, O +
2-naphthol B-Chemical -
, O +
and O +
1-naphthylamine B-Chemical +
to O +
three O +
colloidal O +
CNTs O -
, O +
including O +
a O +
stable O +
suspension O +
of O +
oxidized O +
multiwalled O +
carbon B-Chemical +
nanotubes O +
( O -
O O -
- O -
MWNT O -
) O -
, O +
a O +
humic O +
acid O +
( O -
HA O -
) O -
-modified O +
colloidal O +
O O -
- O -
MWNT O -
, O +
and O +
a O +
sodium B-Chemical +
dodecyl I-Chemical +
sulfate I-Chemical +
( O -
SDS B-Chemical -
) O -
-modified O +
colloidal O +
O O -
- O -
MWNT O -
. O +

All O +
three O +
colloidal O +
O O -
- O -
MWNTs O +
exhibit O +
strong O +
adsorption O +
affinities O +
to O +
the O +
three O +
test O +
compounds O +
( O -
with O +
K O -
( O -
OC O -
) O +
values O +
orders O +
of O +
magnitude O +
greater O +
than O +
those O +
of O +
natural O +
organic O +
matter O -
) O -
, O +
likely O +
resulting O +
from O +
strong O +
nonhydrophobic O +
interactions O +
such O +
as O +
π O -
- O -
π O +
electron O +
donor O -
- O -
acceptor O +
interactions O +
and O +
Lewis B-Chemical +
acid I-Chemical -
- O -
base O +
interactions O -
. O +

When O +
thoroughly O +
mixed O -
, O +
HA O +
( O -
at O +
∼310 O +
mg O +
HA O -
/ O -
g O +
CNT O -
) O +
and O +
SDS B-Chemical +
( O -
at O +
∼750 O +
mg O +
SDS B-Chemical -
/ O -
g O +
CNT O -
) O +
significantly O +
affected O +
the O +
aggregation O +
properties O +
of O +
O O -
- O -
MWNT O -
, O +
causing O +
individually O +
dispersed O +
tubes O +
to O +
form O +
a O +
loosely O +
entangled O +
network O -
. O +

The O +
effects O +
of O +
HA O +
or O +
SDS B-Chemical +
modification O +
on O +
adsorption O +
are O +
twofold O -
. O +

Adsorption O +
of O +
HA O -
/ O -
SDS B-Chemical +
significantly O +
reduces O +
surface O +
areas O +
of O +
O O -
- O -
MWNT O -
; O +
however O -
, O +
the O +
entangled O +
network O +
allows O +
adsorbate O +
molecules O +
to O +
interact O +
simultaneously O +
with O +
multiple O +
tubes O -
. O +

An O +
important O +
implication O +
is O +
that O +
humic O +
substances O +
and O +
surfactant O -
- O -
like O +
materials O +
not O +
only O +
facilitate O +
the O +
formation O +
of O +
colloidal O +
carbon B-Chemical +
nanoparticles O +
but O +
also O +
affect O +
how O +
these O +
colloidal O +
carbon B-Chemical +
nanoparticles O +
adsorb O +
organic O +
contaminants O -
. O +

Immunological O +
and O +
reproductive O +
health O +
assessment O +
in O +
herring O +
gulls O +
and O +
black O -
- O -
crowned O +
night O +
herons O +
in O +
the O +
Hudson O -
- O -
Raritan O +
Estuary O -
. O +

Previous O +
studies O +
have O +
shown O +
inexplicable O +
declines O +
in O +
breeding O +
waterbirds O +
within O +
western O +
New O +
York O -
/ O -
New O +
Jersey O +
Harbor O +
between O +
1996 O +
and O +
2002 O +
and O +
elevated O +
polychlorinated B-Chemical +
dibenzo I-Chemical -
- I-Chemical -
p I-Chemical -
- I-Chemical -
dioxins I-Chemical +
and O +
polychlorinated B-Chemical +
biphenyls I-Chemical +
( O -
PCBs B-Chemical -
) O +
in O +
double O -
- O -
crested O +
cormorant O +
( O -
Phalacrocorax O +
auritus O -
) O +
eggs O -
. O +

The O +
present O +
study O +
assessed O +
associations O +
between O +
immune O +
function O -
, O +
prefledgling O +
survival O -
, O +
and O +
selected O +
organochlorine B-Chemical +
compounds O +
and O +
metals O +
in O +
herring O +
gulls O +
( O -
Larus O +
argentatus O -
) O +
and O +
black O -
- O -
crowned O +
night O +
herons O +
( O -
Nycticorax O +
nycticorax O -
) O +
in O +
lower O +
New O +
York O +
Harbor O +
during O +
2003 O -
. O +

In O +
pipping O +
gull O +
embryos O -
, O +
lymphoid O +
cells O +
were O +
counted O +
in O +
the O +
thymus O +
and O +
bursa O +
of O +
Fabricius O +
( O -
sites O +
of O +
T O +
and O +
B O +
lymphocyte O +
maturation O -
, O +
respectively O -
) O -
. O +

The O +
phytohemagglutinin O +
( O -
PHA O -
) O +
skin O +
response O +
assessed O +
T O +
cell O +
function O +
in O +
gull O +
and O +
heron O +
chicks O -
. O +

Lymphocyte O +
proliferation O +
was O +
measured O +
in O +
vitro O +
in O +
adult O +
and O +
prefledgling O +
gulls O -
. O +

Reference O +
data O +
came O +
from O +
the O +
Great O +
Lakes O +
and O +
Bay O +
of O +
Fundy O -
. O +

Survival O +
of O +
prefledgling O +
gulls O +
was O +
poor O -
, O +
with O +
only O +
0.68 O +
and O +
0.5 O +
chicks O +
per O +
nest O +
surviving O +
to O +
three O +
and O +
four O +
weeks O +
after O +
hatch O -
, O +
respectively O -
. O +

Developing O +
lymphoid O +
cells O +
were O +
reduced O +
51 O -
% O +
in O +
the O +
thymus O +
and O +
42 O -
% O +
in O +
the O +
bursa O +
of O +
gull O +
embryos O +
from O +
New O +
York O +
Harbor O -
. O +

In O +
vitro O +
lymphocyte O +
assays O +
demonstrated O +
reduced O +
spontaneous O +
proliferation O -
, O +
reduced O +
T O +
cell O +
mitogen O -
- O -
induced O +
proliferation O -
, O +
and O +
increased O +
B O +
cell O +
mitogen O -
- O -
induced O +
proliferation O +
in O +
gull O +
chicks O +
from O +
New O +
York O +
Harbor O -
. O +

The O +
PHA O +
skin O +
response O +
was O +
suppressed O +
70 O +
to O +
80 O -
% O +
in O +
gull O +
and O +
heron O +
chicks O -
. O +

Strong O +
negative O +
correlations O +
( O -
r O +
= O +
-0.95 O +
to O +
-0.98 O -
) O +
between O +
the O +
PHA O +
response O +
and O +
dioxins B-Chemical +
and O +
PCBs B-Chemical +
in O +
gull O +
livers O +
was O +
strong O +
evidence O +
suggesting O +
that O +
these O +
chemicals O +
contribute O +
significantly O +
to O +
immunosuppression O +
in O +
New O +
York O +
Harbor O +
waterbirds O -
. O +

Functional O +
imaging O +
of O +
legumain O +
in O +
cancer O +
using O +
a O +
new O +
quenched O +
activity O -
- O -
based O +
probe O -
. O +

Legumain O +
is O +
a O +
lysosomal O +
cysteine B-Chemical +
protease O +
whose O +
biological O +
function O +
remains O +
poorly O +
defined O -
. O +

Legumain O +
activity O +
is O +
up O -
- O -
regulated O +
in O +
most O +
human O +
cancers O +
and O +
inflammatory O +
diseases O +
most O +
likely O +
as O +
the O +
result O +
of O +
high O +
expression O +
in O +
populations O +
of O +
activated O +
macrophages O -
. O +

Within O +
the O +
tumor O +
microenvironment O -
, O +
legumain O +
activity O +
is O +
thought O +
to O +
promote O +
tumorigenesis O -
. O +

To O +
obtain O +
a O +
greater O +
understanding O +
of O +
the O +
role O +
of O +
legumain O +
activity O +
during O +
cancer O +
progression O +
and O +
inflammation O -
, O +
we O +
developed O +
an O +
activity O -
- O -
based O +
probe O +
that O +
becomes O +
fluorescent O +
only O +
upon O +
binding O +
active O +
legumain O -
. O +

This O +
probe O +
is O +
highly O +
selective O +
for O +
legumain O -
, O +
even O +
in O +
the O +
context O +
of O +
whole O +
cells O +
and O +
tissues O -
, O +
and O +
is O +
also O +
a O +
more O +
effective O +
label O +
of O +
legumain O +
than O +
previously O +
reported O +
probes O -
. O +

Here O +
we O +
present O +
the O +
synthesis O +
and O +
application O +
of O +
our O +
probe O +
to O +
the O +
analysis O +
of O +
legumain O +
activity O +
in O +
primary O +
macrophages O +
and O +
in O +
two O +
mouse O +
models O +
of O +
cancer O -
. O +

We O +
find O +
that O +
legumain O +
activity O +
is O +
highly O +
correlated O +
with O +
macrophage O +
activation O +
and O +
furthermore O +
that O +
it O +
is O +
an O +
ideal O +
marker O +
for O +
primary O +
tumor O +
inflammation O +
and O +
early O +
stage O +
metastatic O +
lesions O -
. O +

Optical O +
pumping O +
of O +
a O +
single O +
electron O +
spin O +
bound O +
to O +
a O +
fluorine B-Chemical +
donor O +
in O +
a O +
ZnSe B-Chemical +
nanostructure O -
. O +

Here O +
we O +
demonstrate O +
optical O +
pumping O +
of O +
a O +
single O +
electron O +
within O +
a O +
semiconductor O +
nanostructure O +
comprised O +
of O +
a O +
single O +
fluorine B-Chemical +
donor O +
located O +
within O +
a O +
ZnSe B-Chemical -
/ O -
ZnMgSe B-Chemical +
quantum O +
well O -
. O +

Experiments O +
were O +
performed O +
to O +
detect O +
optical O +
pumping O +
behavior O +
by O +
observing O +
single O +
photons O +
emitted O +
from O +
the O +
nanostructure O +
when O +
the O +
electron O +
changes O +
spin O +
state O -
. O +

These O +
results O +
demonstrate O +
initialization O +
and O +
read O -
- O -
out O +
of O +
the O +
electron O +
spin O +
qubit O +
and O +
open O +
the O +
door O +
for O +
coherent O +
optical O +
manipulation O +
of O +
a O +
spin O +
by O +
taking O +
advantage O +
of O +
an O +
unconventional O +
nanostructure O -
. O +

Interleukin-6 O +
induces O +
vascular O +
endothelial O +
growth O +
factor O +
expression O +
and O +
promotes O +
angiogenesis O +
through O +
apoptosis O +
signal O -
- O -
regulating O +
kinase O +
1 O +
in O +
human O +
osteosarcoma O -
. O +

Osteosarcoma O +
is O +
characterized O +
by O +
a O +
high O +
malignant O +
and O +
metastatic O +
potential O -
. O +

Angiogenesis O +
is O +
essential O +
for O +
the O +
caner O +
metastasis O -
. O +

Interleukin-6 O +
( O -
IL-6 O -
) O +
is O +
a O +
multifunctional O +
cytokine O +
that O +
is O +
associated O +
with O +
the O +
disease O +
status O +
and O +
outcomes O +
of O +
cancers O -
. O +

However O -
, O +
the O +
relationship O +
between O +
IL-6 O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
expression O +
in O +
human O +
osteosarcoma O +
is O +
mostly O +
unknown O -
. O +

Here O +
we O +
found O +
that O +
the O +
IL-6 O +
and O +
VEGF O +
expression O +
was O +
correlated O +
with O +
tumor O +
stage O +
and O +
significantly O +
higher O +
than O +
that O +
in O +
normal O +
bone O -
. O +

Incubation O +
of O +
osteosarcoma O +
cells O +
with O +
IL-6 O +
increased O +
VEGF O +
mRNA O +
and O +
protein O +
expression O -
. O +

Pretreatment O +
of O +
cells O +
with O +
IL-6R O +
antibody O +
reduced O +
IL-6-mediated O +
VEGF O +
production O -
. O +

The O +
apoptosis O +
signal O -
- O -
regulating O +
kinase O +
1 O +
( O -
ASK1 O -
) O -
/ O -
p38 O -
/ O -
AP-1 O +
pathway O +
was O +
activated O +
after O +
IL-6 O +
treatment O -
, O +
and O +
IL-6-induced O +
VEGF O +
expression O +
was O +
abolished O +
by O +
the O +
specific O +
inhibitor O +
and O +
siRNA O +
of O +
ASK1 O -
, O +
p38 O -
, O +
and O +
AP-1 O +
cascades O -
. O +

Importantly O -
, O +
knockdown O +
IL-6 O +
reduced O +
VEGF O +
expression O +
and O +
abolished O +
osteosarcoma O +
conditional O +
medium O -
- O -
mediated O +
angiogenesis O -
. O +

Taken O +
together O -
, O +
these O +
results O +
indicate O +
that O +
IL-6 O +
occurs O +
through O +
ASK1 O +
and O +
p38 O -
, O +
which O +
in O +
turn O +
activates O +
AP-1 O -
, O +
resulting O +
in O +
the O +
activations O +
of O +
VEGF O +
expression O +
and O +
contributing O +
the O +
angiogenesis O +
of O +
human O +
osteosarcoma O +
cells O -
. O +

4-tert B-Chemical -
- I-Chemical -
Octylphenol I-Chemical +
stimulates O +
the O +
expression O +
of O +
cathepsins O +
in O +
human O +
breast O +
cancer O +
cells O +
and O +
xenografted O +
breast O +
tumors O +
of O +
a O +
mouse O +
model O +
via O +
an O +
estrogen B-Chemical +
receptor O -
- O -
mediated O +
signaling O +
pathway O -
. O +

Endocrine O +
disrupting O +
chemicals O +
( O -
EDCs O -
) O +
are O +
defined O +
as O +
environmental O +
compounds O +
that O +
modulate O +
steroid B-Chemical +
hormone O +
receptor O -
- O -
dependent O +
responses O +
an O +
abnormal O +
manner O -
, O +
resulting O +
in O +
adverse O +
health O +
problems O +
for O +
humans O +
such O +
as O +
cancer O +
growth O +
and O +
metastasis O -
. O +

Cathepsins O +
are O +
proteases O +
that O +
have O +
been O +
implicated O +
in O +
cancer O +
progression O -
. O +

However O -
, O +
there O +
have O +
been O +
few O +
studies O +
about O +
the O +
association O +
between O +
cathepsins O +
and O +
estrogenic O +
chemicals O +
during O +
the O +
cancer O +
progression O -
. O +

In O +
this O +
study O -
, O +
we O +
examined O +
the O +
effect O -
( O -
s O -
) O +
of O +
4-tert B-Chemical -
- I-Chemical -
octylphenol I-Chemical +
( O -
OP O -
) O -
, O +
a O +
potent O +
EDC O -
, O +
on O +
the O +
expression O +
of O +
cathepsins O +
B O +
and O +
D O +
in O +
human O +
MCF-7 O +
breast O +
cancer O +
cells O +
and O +
a O +
xenograft O +
mouse O +
model O -
. O +

Treatment O +
with O +
OP O +
significantly O +
induced O +
the O +
proliferation O +
MCF-7 O +
cells O +
in O +
an O +
MTT B-Chemical +
assay O -
. O +

In O +
addition O -
, O +
the O +
expression O +
of O +
cathepsins O +
B O +
and O +
D O +
was O +
markedly O +
enhanced O +
in O +
MCF-7 O +
cells O +
at O +
both O +
the O +
transcriptional O +
and O +
the O +
translational O +
levels O +
following O +
treatment O +
with O +
E2 O +
or O +
OP O +
up O +
to O +
48h O -
. O +

These O +
results O +
demonstrated O +
the O +
ability O +
of O +
OP O +
to O +
disrupt O +
normal O +
transcriptional O +
regulation O +
of O +
cathepsins O +
B O +
and O +
D O +
in O +
human O +
breast O +
cancer O +
cells O -
. O +

However O -
, O +
the O +
effects O +
of O +
OP O +
on O +
cell O +
growth O +
or O +
overexpression O +
of O +
cathepsins O +
by O +
inhibiting O +
ER O -
- O -
mediated O +
signaling O +
were O +
abolished O +
by O +
an O +
ER O +
antagonist O +
and O +
siRNA O +
specific O +
for O +
ERα O -
. O +

In O +
conclusion O -
, O +
our O +
findings O +
suggest O +
that O +
OP O +
at O +
10 O -
( O -
-6 O -
) O -
M O -
, O +
like O +
E2 O -
, O +
may O +
accelerate O +
breast O +
cancer O +
cell O +
proliferation O +
and O +
the O +
expression O +
of O +
cathepsins O +
through O +
an O +
ER O -
- O -
mediated O +
signaling O +
pathway O -
. O +

In O +
addition O -
, O +
the O +
breast O +
cancer O +
cells O +
exposed O +
with O +
OP O +
to O +
a O +
xenograft O +
mouse O +
model O +
were O +
more O +
aggressive O +
according O +
to O +
our O +
histological O +
analysis O +
and O +
showed O +
markedly O +
increased O +
expression O +
of O +
cathepsin O +
B. O +
These O +
effects O +
of O +
mouse O +
model O +
resulted O +
in O +
an O +
increased O +
potential O +
for O +
metastasis O +
in O +
breast O +
cancer O -
. O +

Taken O +
together O -
, O +
we O +
determined O +
that O +
OP O +
can O +
adversely O +
affect O +
human O +
health O +
by O +
promoting O +
cancer O +
proliferation O +
and O +
metastasis O +
through O +
the O +
amplification O +
of O +
cathepsins O +
B O +
and O +
D O +
via O +
the O +
ER O -
- O -
mediated O +
signaling O +
pathway O -
. O +

Improvement O +
in O +
pelvic O +
pain O +
with O +
botulinum O +
toxin O +
type O +
A O +
- O +
Single O +
vs. O +
repeat O +
injections O -
. O +

The O +
aim O +
of O +
this O +
prospective O +
study O +
was O +
to O +
report O +
the O +
outcomes O +
of O +
pain O +
and O +
vaginal O +
pressures O +
of O +
successive O +
botulinum O +
toxin O +
type O +
A O +
injections O +
for O +
women O +
with O +
objective O +
pelvic O +
floor O +
muscle O +
overactivity O +
and O +
a O +
two O -
- O -
year O +
history O +
of O +
pelvic O +
pain O -
. O +

Between O +
2005 O +
and O +
2008 O -
, O +
37 O +
women O +
underwent O +
injection O +
of O +
100 O +
IU O +
of O +
botulinum O +
toxin O +
type O +
A O +
into O +
the O +
puborectalis O +
and O +
pubococcygeous O +
muscles O +
with O +
dysmenorrhoea O -
, O +
dyspareunia O -
, O +
dyschesia O -
, O +
and O +
non O -
- O -
menstrual O +
pelvic O +
pain O +
assessed O +
using O +
a O +
visual O +
analogue O +
scale O +
( O -
VAS O -
) O -
, O +
and O +
vaginal O +
pressure O +
measured O +
by O +
vaginal O +
manometry O -
, O +
at O +
0 O -
, O +
4 O -
, O +
12 O +
and O +
26 O +
weeks O +
from O +
each O +
injection O -
. O +

26 O +
women O +
( O -
70 O -
% O -
) O +
had O +
one O +
injection O +
of O +
botulinum O +
toxin O +
type O +
A O +
and O +
11 O +
( O -
30 O -
% O -
) O +
had O +
2 O +
or O +
more O +
injections O -
. O +

The O +
second O +
injection O +
was O +
performed O +
at O +
the O +
earliest O +
at O +
26 O +
weeks O +
after O +
the O +
first O -
, O +
with O +
subsequent O +
injections O +
having O +
a O +
median O +
time O +
to O +
re O -
- O -
injection O +
of O +
33.4 O +
weeks O +
( O -
range O +
9.4 O -
- O -
122.7 O +
weeks O -
) O -
. O +

Single O +
and O +
repeated O +
injections O +
both O +
demonstrated O +
a O +
statistically O +
significant O +
reduction O +
in O +
dyspareunia O +
by O +
VAS O +
scores O +
from O +
54 O +
to O +
30 O +
in O +
the O +
single O +
injection O +
group O +
and O +
from O +
51 O +
to O +
23 O +
in O +
the O +
multiple O +
injection O +
group O +
( O -
p O +
= O +
.001 O -
) O -
, O +
non O -
- O -
menstrual O +
pelvic O +
pain O +
VAS O +
from O +
37 O +
to O +
25 O +
( O -
p O +
= O +
.04 O -
) O -
, O +
as O +
well O +
as O +
vaginal O +
pressures O -
; O +
40 O +
versus O +
34 O +
cm O +
H B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
O I-Chemical +
( O -
p O +
= O +
.02 O -
) O -
. O +

No O +
statistically O +
significant O +
difference O +
in O +
dysmenorrhoea O +
or O +
dyschesia O +
was O +
observed O +
for O +
either O +
group O +
from O +
their O +
baseline O +
scores O -
. O +

Multiple O +
injections O +
of O +
botulinum O +
toxin O +
type O +
A O +
in O +
women O +
with O +
pelvic O +
floor O +
muscle O +
overactivity O +
provide O +
significant O +
relief O +
from O +
dyspareunia O +
and O +
non O -
- O -
menstrual O +
pelvic O +
pain O -
. O +

The O +
upper O +
limit O +
between O +
re O -
- O -
injection O +
is O +
not O +
yet O +
determined O -
, O +
nor O +
is O +
the O +
maximum O +
number O +
of O +
treatments O -
. O +

Clinical O +
outcomes O +
for O +
single O +
and O +
subsequent O +
injection O +
of O +
botulinum O +
toxin O +
type O +
A O +
for O +
recurrent O +
pelvic O +
pain O +
are O +
equivalent O -
. O +

Women O +
who O +
have O +
had O +
benefit O +
from O +
a O +
single O +
injection O +
of O +
botulinum O +
toxin O +
type O +
A O +
can O +
be O +
reassured O +
that O +
if O +
symptoms O +
reoccur O -
, O +
repeated O +
injections O +
can O +
be O +
expected O +
to O +
be O +
equally O +
efficacious O -
. O +

A O +
polyacetylene B-Chemical -
- O -
rich O +
extract O +
from O +
Gymnaster O +
koraiensis O +
strongly O +
inhibits O +
colitis O -
- O -
associated O +
colon O +
cancer O +
in O +
mice O -
. O +

Gymnaster O +
koraiensis O +
( O -
GK O -
) O +
is O +
a O +
Korean O +
herb O +
used O +
in O +
folk O +
medicine O +
and O +
recently O +
found O +
to O +
positively O +
impact O +
liver O +
health O -
. O +

Because O +
GK O +
contains O +
polyacetylenes B-Chemical +
and O +
because O +
other O +
polyacetylenes B-Chemical +
have O +
been O +
found O +
to O +
exhibit O +
anti O -
- O -
inflammatory O +
and O +
anti O -
- O -
cancer O +
activities O -
, O +
we O +
hypothesized O +
that O +
the O +
polyacetylene B-Chemical +
gymnasterkoreayne B-Chemical +
B I-Chemical +
( O -
GKB B-Chemical -
) O -
, O +
known O +
to O +
increase O +
hepatic O +
detoxification O +
enzymes O -
, O +
may O +
also O +
exert O +
anti O -
- O -
inflammatory O +
and O +
anti O -
- O -
cancer O +
activities O -
. O +

We O +
fed O +
male O +
C57BL O -
/ O -
6 O +
mice O +
purified O +
AIN93 O -
G O +
diets O +
containing O +
no O +
additions O -
, O +
GKB B-Chemical +
or O +
the O +
GKB B-Chemical -
- O -
rich O +
fraction O +
of O +
an O +
ethanol B-Chemical +
extract O +
( O -
GE O -
) O +
from O +
GK O +
to O +
determine O +
if O +
these O +
diets O +
would O +
slow O +
or O +
prevent O +
either O +
inflammation O +
or O +
inflammation O -
- O -
enhanced O +
colon O +
cancer O -
, O +
using O +
the O +
dextran O +
sulfate O +
sodium B-Chemical -
/ O -
azoxymethane B-Chemical +
mouse O +
model O -
. O +

The O +
GKB B-Chemical +
( O -
500 O +
μmol O -
/ O -
kg O +
diet O +
daily O -
) O +
showed O +
some O +
anti O -
- O -
inflammatory O +
activity O -
, O +
but O +
GE O -
, O +
containing O +
an O +
equal O +
dose O +
of O +
GKB B-Chemical -
, O +
protected O +
strongly O +
against O +
both O +
inflammation O +
and O +
colon O +
cancer O -
, O +
decreasing O +
adenocarcinomas O +
by O +
90 O -
% O -
. O +

These O +
data O +
support O +
further O +
research O +
into O +
GK O +
as O +
a O +
promising O +
potential O +
anti O -
- O -
cancer O +
agent O -
. O +

The O +
diverse O +
roles O +
of O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
drug O +
activated O +
gene O +
( O -
NAG-1 O -
/ O -
GDF15 O -
) O +
in O +
cancer O -
. O +

Nonsteroidal O +
anti O -
- O -
inflammatory O +
drug O +
( O -
NSAID O -
) O +
activated O +
gene-1 O -
, O +
NAG-1 O -
, O +
is O +
a O +
divergent O +
member O +
of O +
the O +
transforming O +
growth O +
factor O -
- O -
beta O +
( O -
TGF O -
- O -
β O -
) O +
superfamily O +
that O +
plays O +
a O +
complex O +
but O +
poorly O +
understood O +
role O +
in O +
several O +
human O +
diseases O +
including O +
cancer O -
. O +

NAG-1 O +
expression O +
is O +
substantially O +
increased O +
during O +
cancer O +
development O +
and O +
progression O +
especially O +
in O +
gastrointestinal O -
, O +
prostate O -
, O +
pancreatic O -
, O +
colorectal O -
, O +
breast O -
, O +
melanoma O -
, O +
and O +
glioblastoma O +
brain O +
tumors O -
. O +

Aberrant O +
increases O +
in O +
the O +
serum O +
levels O +
of O +
secreted O +
NAG-1 O +
correlate O +
with O +
poor O +
prognosis O +
and O +
patient O +
survival O +
rates O +
in O +
some O +
cancers O -
. O +

In O +
contrast O -
, O +
the O +
expression O +
of O +
NAG-1 O +
is O +
up O -
- O -
regulated O +
by O +
several O +
tumor O +
suppressor O +
pathways O +
including O +
p53 O -
, O +
GSK-3β O -
, O +
and O +
EGR-1 O -
. O +

NAG-1 O +
expression O +
is O +
also O +
induced O +
by O +
many O +
drugs O +
and O +
dietary O +
compounds O +
which O +
are O +
documented O +
to O +
prevent O +
the O +
development O +
and O +
progression O +
of O +
cancer O +
in O +
mouse O +
models O -
. O +

Studies O +
with O +
transgenic O +
mice O +
expressing O +
human O +
NAG-1 O +
demonstrated O +
that O +
the O +
expression O +
of O +
NAG-1 O +
inhibits O +
the O +
development O +
of O +
intestinal O +
tumors O +
and O +
prostate O +
tumors O +
in O +
animal O +
models O -
. O +

Laboratory O +
and O +
clinical O +
evidence O +
suggest O +
that O +
NAG-1 O -
, O +
like O +
other O +
TGF O -
- O -
β O +
family O +
members O -
, O +
may O +
have O +
different O +
or O +
pleiotropic O +
functions O +
in O +
the O +
early O +
and O +
late O +
stages O +
of O +
carcinogenesis O -
. O +

Upon O +
understanding O +
the O +
molecular O +
mechanism O +
and O +
function O +
of O +
NAG-1 O +
during O +
carcinogenesis O -
, O +
NAG-1 O +
may O +
serve O +
as O +
a O +
potential O +
biomarker O +
for O +
the O +
diagnosis O +
and O +
prognosis O +
of O +
cancer O +
and O +
a O +
therapeutic O +
target O +
for O +
the O +
inhibition O +
and O +
treatment O +
of O +
cancer O +
development O +
and O +
progression O -
. O +

Induction O +
of O +
hepatic O +
CYP3A O +
enzymes O +
by O +
pregnancy O -
- O -
related O +
hormones O -
: O +
studies O +
in O +
human O +
hepatocytes O +
and O +
hepatic O +
cell O +
lines O -
. O +

CYP3A O +
activity O +
is O +
induced O +
by O +
approximately O +
2-fold O +
during O +
the O +
third O +
trimester O +
of O +
human O +
pregnancy O -
. O +

Placental O +
growth O +
hormone O +
( O -
PGH O -
) O -
, O +
estrogens B-Chemical +
( O -
primarily O +
17β B-Chemical -
- I-Chemical -
estradiol I-Chemical -
) O -
, O +
cortisol B-Chemical -
, O +
and O +
progesterone B-Chemical +
have O +
the O +
potential O +
to O +
modulate O +
CYP3A O +
activity O -
. O +

Therefore O -
, O +
we O +
determined O +
whether O +
the O +
elevated O +
plasma O +
concentrations O +
of O +
these O +
hormones O +
during O +
pregnancy O +
induce O +
hepatic O +
CYP3A O +
expression O -
. O +

We O +
incubated O +
sandwich O -
- O -
cultured O +
human O +
hepatocytes O +
( O -
SCHH O -
) O +
from O +
premenopausal O +
female O +
donors O +
( O -
n O +
= O +
2 O -
) O +
with O +
the O +
physiologic O +
( O -
unbound O -
, O +
1 O -
× O +
total O -
) O +
and O +
the O +
10 O -
× O +
total O +
third O +
trimester O +
hormone O +
plasma O +
concentrations O +
( O -
individually O +
and O +
in O +
combination O -
) O +
and O +
determined O +
their O +
effect O +
on O +
CYP3A O +
activity O +
and O +
the O +
transcripts O +
of O +
CYP3A4 O -
, O +
CYP3A5 O -
, O +
and O +
the O +
respective O +
hormone O +
receptors O +
( O -
growth O +
hormone O +
receptor O -
, O +
glucocorticoid O +
receptor O -
, O +
and O +
estrogen B-Chemical +
receptor O +
alpha O -
) O -
. O +

Of O +
all O +
the O +
hormones O -
, O +
cortisol B-Chemical +
was O +
the O +
most O +
potent O +
inducer O +
of O +
CYP3A O +
activity O +
and O +
CYP3A4 O -
, O +
CYP3A5 O +
mRNA O +
expression O -
. O +

The O +
combination O +
of O +
PGH O -
/ O -
growth O +
hormone O +
and O +
cortisol B-Chemical +
induced O +
CYP3A O +
activity O +
and O +
expression O +
significantly O +
more O +
than O +
did O +
cortisol B-Chemical +
alone O -
. O +

When O +
incubated O +
with O +
the O +
unbound O +
or O +
total O +
plasma O +
concentration O +
of O +
all O +
the O +
hormones O -
, O +
CYP3A O +
activity O +
in O +
SCHH O +
was O +
induced O +
to O +
an O +
extent O +
comparable O +
to O +
that O +
observed O +
in O +
vivo O +
during O +
the O +
third O +
trimester O -
. O +

These O +
hormones O +
had O +
only O +
a O +
modest O +
effect O +
on O +
the O +
mRNA O +
expression O +
of O +
the O +
hormone O +
receptors O -
. O +

The O +
pattern O +
of O +
induction O +
observed O +
in O +
SCHH O +
was O +
reproduced O +
in O +
HepaRG O +
cells O +
but O +
not O +
in O +
HuH7 O -
/ O -
HepG2 O +
cells O -
. O +

SCHH O +
or O +
HepaRG O +
cells O +
could O +
be O +
used O +
to O +
determine O +
the O +
mechanistic O +
basis O +
of O +
CYP3A O +
induction O +
during O +
pregnancy O +
and O +
to O +
predict O +
the O +
magnitude O +
of O +
induction O +
likely O +
to O +
be O +
observed O +
during O +
the O +
first O +
and O +
second O +
trimesters O -
, O +
when O +
phenotyping O +
studies O +
to O +
measure O +
in O +
vivo O +
CYP3A O +
activity O +
are O +
logistically O +
difficult O +
to O +
perform O -
. O +

Membrane O +
protein O +
native O +
state O +
discrimination O +
by O +
implicit O +
membrane O +
models O -
. O +

Four O +
implicit O +
membrane O +
models O +
[ O -
IMM1 O -
, O +
generalized O +
Born O +
( O -
GB O -
) O -
-surface O +
area O -
- O -
implicit O +
membrane O +
( O -
GBSAIM O -
) O -
, O +
GB O +
with O +
a O +
simple O +
switching O +
( O -
GBSW O -
) O -
, O +
and O +
heterogeneous O +
dielectric O +
GB O +
( O -
HDGB O -
) O -
] O +
were O +
tested O +
for O +
their O +
ability O +
to O +
discriminate O +
the O +
native O +
conformation O +
of O +
five O +
membrane O +
proteins O +
from O +
450 O +
decoys O +
generated O +
by O +
the O +
Rosetta O -
- O -
Membrane O +
program O -
. O +

The O +
energy O +
ranking O +
of O +
the O +
native O +
state O +
and O +
Z O -
- O -
scores O +
were O +
used O +
to O +
assess O +
the O +
performance O +
of O +
the O +
models O -
. O +

The O +
effect O +
of O +
membrane O +
thickness O +
was O +
examined O +
and O +
was O +
found O +
to O +
be O +
substantial O -
. O +

Quite O +
satisfactory O +
discrimination O +
was O +
achieved O +
with O +
the O +
all O -
- O -
atom O +
IMM1 O +
and O +
GBSW O +
models O +
at O +
25.4 O +
Å O +
thickness O +
and O +
with O +
the O +
HDGB O +
model O +
at O +
28.5 O +
Å O +
thickness O -
. O +

The O +
energy O +
components O +
by O +
themselves O +
were O +
not O +
discriminative O -
. O +

Both O +
van O +
der O +
Waals O +
and O +
electrostatic O +
interactions O +
contributed O +
to O +
native O +
state O +
discrimination O -
, O +
to O +
a O +
different O +
extent O +
in O +
each O +
model O -
. O +

Computational O +
efficiency O +
of O +
the O +
models O +
decreased O +
in O +
the O +
order O -
: O +
extended O -
- O -
atom O +
IMM1 O +
> O +
all O -
- O -
atom O +
IMM1 O +
> O +
GBSAIM O +
> O +
GBSW O +
> O +
HDGB O -
. O +

These O +
results O +
encourage O +
the O +
further O +
development O +
and O +
use O +
of O +
implicit O +
membrane O +
models O +
for O +
membrane O +
protein O +
structure O +
prediction O -
. O +

2-Phenoxy B-Chemical -
- I-Chemical -
nicotinamides I-Chemical +
are O +
potent O +
agonists O +
at O +
the O +
bile B-Chemical +
acid I-Chemical +
receptor O +
GPBAR1 O +
( O -
TGR5 O -
) O -
. O +

Potency O +
with O +
potential O -
: O +
2-Phenoxy B-Chemical -
- I-Chemical -
nicotinamides I-Chemical +
were O +
identified O +
as O +
potent O +
agonists O +
at O +
the O +
GPBAR1 O +
receptor O -
, O +
a O +
target O +
in O +
the O +
treatment O +
of O +
obesity O -
, O +
type O +
2 O +
diabetes O +
and O +
metabolic O +
syndrome O -
. O +

Extensive O +
structure O -
- O -
activity O +
relationship O +
studies O +
supported O +
by O +
homology O +
modeling O +
and O +
docking O +
resulted O +
in O +
the O +
identification O +
of O +
optimized O +
GPBAR1 O +
agonists O -
, O +
potent O +
against O +
both O +
human O +
and O +
mouse O +
receptors O -
, O +
endowed O +
with O +
favorable O +
physicochemical O +
properties O +
and O +
good O +
metabolic O +
stability O -
. O +

Organotins B-Chemical -
: O +
A O +
review O +
of O +
their O +
reproductive O +
toxicity O -
, O +
biochemistry O -
, O +
and O +
environmental O +
fate O -
. O +

The O +
review O +
purposes O +
are O +
to O +
( O -
1 O -
) O +
evaluate O +
the O +
experimental O +
evidence O +
for O +
adverse O +
effects O +
on O +
reproduction O +
and O +
metabolism O +
and O +
( O -
2 O -
) O +
identify O +
the O +
current O +
knowledge O +
of O +
analytical O +
procedures O -
, O +
biochemistry O +
and O +
environmental O +
aspects O +
relating O +
to O +
organotins B-Chemical -
. O +

Organotins B-Chemical +
are O +
pollutants O +
that O +
are O +
used O +
as O +
biocides O +
in O +
antifouling O +
paints O -
. O +

They O +
produce O +
endocrine O -
- O -
disrupting O +
effects O +
in O +
mollusks O -
, O +
such O +
as O +
imposex O -
. O +

In O +
rodents O -
, O +
organotin B-Chemical +
exposure O +
induces O +
developmental O +
and O +
reproductive O +
toxicity O +
as O +
well O +
as O +
alteration O +
of O +
metabolic O +
homeostasis O +
through O +
its O +
action O +
as O +
an O +
obesogen O -
. O +

The O +
adverse O +
effects O +
that O +
appear O +
in O +
rodents O +
have O +
raised O +
concerns O +
about O +
organotins B-Chemical -
' O +
potential O +
health O +
risk O +
to O +
humans O +
in O +
relation O +
to O +
organotin B-Chemical +
exposure O -
. O +

At O +
present O -
, O +
triorganotin B-Chemical -
, O +
such O +
as O +
tributyltin B-Chemical -
, O +
have O +
been O +
demonstrated O +
to O +
produce O +
imposex O -
, O +
and O +
mammalian O +
reproductive O +
and O +
metabolic O +
toxicity O -
. O +

For O +
most O +
mammals O -
, O +
triorganotin B-Chemical +
exposure O +
predominantly O +
occurs O +
through O +
the O +
ingestion O -
, O +
and O +
this O +
compound O +
can O +
cross O +
the O +
placenta O -
. O +

With O +
these O +
risks O +
in O +
mind O -
, O +
it O +
is O +
important O +
to O +
improve O +
our O +
knowledge O +
of O +
organotins B-Chemical -
' O +
effects O +
on O +
environmental O +
health O -
. O +

Multiple O +
microRNAs O +
may O +
regulate O +
the O +
DNA O +
repair O +
enzyme O +
uracil B-Chemical -
- O -
DNA O +
glycosylase O -
. O +

Human O +
nuclear O +
uracil B-Chemical -
- O -
DNA O +
glycosylase O +
UNG2 O +
is O +
essential O +
for O +
post O -
- O -
replicative O +
repair O +
of O +
uracil B-Chemical +
in O +
DNA O -
, O +
and O +
UNG2 O +
protein O +
and O +
mRNA O +
levels O +
rapidly O +
decline O +
in O +
G2 O -
/ O -
M O +
phase O -
. O +

Previous O +
work O +
has O +
demonstrated O +
regulation O +
of O +
UNG2 O +
at O +
the O +
transcriptional O +
level O -
, O +
as O +
well O +
as O +
by O +
protein O +
phosphorylation O +
and O +
ubiquitylation O -
. O +

UNG2 O +
mRNA O -
, O +
encoded O +
by O +
the O +
UNG O +
gene O -
, O +
contains O +
a O +
long O +
3'untranslated O +
region O +
( O -
3'UTR O -
) O +
of O +
previously O +
unknown O +
function O -
. O +

Here O -
, O +
we O +
demonstrate O +
that O +
several O +
conserved O +
regions O +
in O +
the O +
3'UTR O +
are O +
potential O +
seed O +
sites O +
for O +
microRNAs O +
( O -
miRNAs O -
) O -
, O +
such O +
as O +
miR-16 O -
, O +
miR-34c O -
, O +
and O +
miR-199a O -
. O +

Our O +
results O +
show O +
that O +
these O +
miRNAs O +
down O -
- O -
regulate O +
UNG O +
activity O -
, O +
UNG O +
mRNA O -
, O +
and O +
UNG O +
protein O +
levels O -
. O +

Down O -
- O -
regulation O +
was O +
dependent O +
on O +
the O +
3'UTR O -
, O +
indicating O +
that O +
the O +
miRNAs O +
directly O +
target O +
the O +
conserved O +
seed O +
sites O +
in O +
the O +
3'UTR O -
. O +

These O +
results O +
add O +
miRNAs O +
as O +
a O +
new O +
modality O +
to O +
UNG O -
's O +
increasing O +
list O +
of O +
complex O +
regulatory O +
mechanisms O -
. O +

Synthesis O +
and O +
antibacterial O +
evaluation O +
of O +
novel O +
11,4″-disubstituted B-Chemical +
azithromycin I-Chemical +
analogs O +
with O +
greatly O +
improved O +
activity O +
against O +
erythromycin B-Chemical -
- O -
resistant O +
bacteria O -
. O +

A O +
series O +
of O +
novel O +
11,4″-disubstituted B-Chemical +
azithromycin I-Chemical +
analogs O +
were O +
synthesized O +
and O +
evaluated O +
for O +
their O +
antibacterial O +
activity O -
. O +

All O +
the O +
11,4″-disubstituted O +
analogs O +
exhibited O +
excellent O +
activity O +
( O -
0.03 O -
- O -
0.12 O +
μg O -
/ O -
ml O -
) O +
against O +
erythromycin B-Chemical -
- O -
susceptible O +
Streptococcus O +
pneumoniae O -
, O +
and O +
significantly O +
improved O +
activity O +
against O +
three O +
phenotypes O +
of O +
erythromycin B-Chemical -
- O -
resistant O +
S. O +
pneumoniae O +
compared O +
with O +
erythromycin B-Chemical +
A I-Chemical -
, O +
clarithromycin B-Chemical +
or O +
azithromycin B-Chemical -
. O +

Among O +
them O -
, O +
compounds O +
26 O -
- O -
28 O +
showed O +
the O +
most O +
potent O +
activity O +
( O -
0.25 O -
, O +
0.03 O +
and O +
2 O +
μg O -
/ O -
ml O -
) O +
against O +
S. O +
pneumoniae O +
expressing O +
the O +
erm O +
gene O -
, O +
the O +
mef O +
gene O +
and O +
the O +
erm O +
and O +
mef O +
genes O -
, O +
respectively O -
. O +

In O +
addition O -
, O +
compound O +
28 O +
was O +
the O +
most O +
effective O +
( O -
0.03 O +
and O +
0.12 O +
μg O -
/ O -
ml O -
) O +
against O +
erythromycin B-Chemical -
- O -
susceptible O +
S. O +
pneumoniae O +
and O +
Staphylococcus O +
aureus O +
as O +
well O -
. O +

It O +
is O +
noteworthy O +
that O +
the O +
most O +
active O +
compounds O +
described O +
above O +
possess O +
the O +
same O +
terminal O +
3,5-dinitrophenyl B-Chemical +
groups O +
on O +
their O +
C-4″ O +
bisamide B-Chemical +
side O +
chains O -
. O +

Neutral O +
and O +
charged O +
phosphine B-Chemical -
/ I-Chemical -
scorpionate I-Chemical +
copper I-Chemical -
( I-Chemical -
I I-Chemical -
) I-Chemical +
complexes I-Chemical -
: O +
effects O +
of O +
ligand O +
assembly O +
on O +
their O +
antiproliferative O +
activity O -
. O +

Ligand O -
- O -
exchange O +
reactions O +
of O +
copper B-Chemical -
( I-Chemical -
I I-Chemical -
) I-Chemical +
precursors O +
( O -
[ B-Chemical -
Cu I-Chemical -
( I-Chemical -
CH I-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
CN I-Chemical -
) I-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
] I-Chemical -
BF I-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
, O +
CuCl B-Chemical -
) O +
with O +
a O +
panel O +
of O +
bis B-Chemical -
( I-Chemical -
azolyl I-Chemical -
) I-Chemical -
borates I-Chemical +
or O +
poly B-Chemical -
( I-Chemical -
pyrazolyl I-Chemical -
) I-Chemical -
methanes I-Chemical +
and O +
a O +
tertiary B-Chemical +
monodentate I-Chemical +
phosphine I-Chemical +
( O -
PTA B-Chemical +
= O +
1,3,5-triaza-7-phosphaadamantane B-Chemical -
, O +
PCN B-Chemical +
= O +
tris B-Chemical -
( I-Chemical -
cyanoethyl I-Chemical -
) I-Chemical -
phosphine I-Chemical -
) O +
produced O +
two O +
series O +
of O +
heteroleptic O -
, O +
either O +
' O -
2 O +
+ O +
1 O +
+ O +
1'- O +
or O +
' O -
3 O +
+ O +
1'-type O +
complexes O -
, O +
which O +
have O +
been O +
characterized O +
by O +
elemental O +
analysis O -
, O +
FT O -
- O -
IR O -
, O +
ESI O -
- O -
MS O +
and O +
multinuclear O +
( B-Chemical -
31 I-Chemical -
) I-Chemical -
P I-Chemical +
and O +
( B-Chemical -
1 I-Chemical -
) I-Chemical -
H I-Chemical +
NMR O -
. O +
' O -
2 O +
+ O +
1 O +
+ O +
1'-type O +
complexes O +
include O +
a O +
N O -
, B-Chemical -
N O -
- O -
bidentate O +
chelate O +
and O +
two O +
monodentate O +
phosphines B-Chemical +
( O -
1 O -
- O -
8 O -
) O +
and O +
' O -
3 O +
+ O +
1'-type O +
complexes O +
comprise O +
a O +
N O -
, B-Chemical -
N O -
, B-Chemical -
O- O +
or O +
N O -
, B-Chemical -
N O -
, B-Chemical -
N O -
- O -
tridentate O +
chelate O +
and O +
one O +
monodentate O +
phosphine B-Chemical +
( O -
9 O -
- O -
12 O -
) O -
. O +

All O +
these O +
complexes O +
adopt O +
a O +
four O -
- O -
coordinate O -
, O +
tetrahedral O +
geometry O -
. O +
' O -
3 O +
+ O +
1 O -
' O +
complexes O +
show O +
better O +
red O -
- O -
ox O +
stability O +
and O +
a O +
greater O +
tendency O +
to O +
retain O +
the O +
native O +
' O -
3 O +
+ O +
1 O -
' O +
mixed O -
- O -
ligand O +
structure O -
. O +

Conversely O -
, O +
' O -
2 O +
+ O +
1 O +
+ O +
1 O -
' O +
complexes O +
exhibit O +
increased O +
propensity O +
to O +
dissociation O +
as O +
shown O +
by O +
ESI O -
- O -
MS O +
measurements O +
and O +
X O -
- O -
ray O +
structure O +
determination O +
at O +
low O +
temperature O +
( O -
150 O +
K O -
) O +
of O +
the O +
polymeric O +
complex O +
{ B-Chemical -
[ I-Chemical -
H I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
B I-Chemical -
( I-Chemical -
tz I-Chemical -
( I-Chemical -
NO2 I-Chemical -
) I-Chemical -
) I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
] I-Chemical -
Cu I-Chemical -
[ I-Chemical -
PCN I-Chemical -
] I-Chemical -
} I-Chemical -
( I-Chemical -
n I-Chemical -
) I-Chemical -
6b O -
. O +

In O +
this O +
complex O -
, O +
either O +
the O +
bis B-Chemical -
( I-Chemical -
triazolyl I-Chemical -
) I-Chemical -
borate I-Chemical +
and O +
the O +
PCN B-Chemical +
ligands O +
act O +
as O +
bidentate O -
, O +
with O +
PCN B-Chemical +
being O +
also O +
the O +
μ O -
( O -
2 O -
) O -
-bridiging O +
linker O +
between O +
adjacent O +
monomers O -
. O +

Compound O +
6b O +
is O +
the O +
first O +
reported O +
example O +
of O +
a O +
polymeric O +
PCN B-Chemical +
compound O +
with O +
a O +
tetra O -
- O -
coordinate O +
metal O +
centre O -
. O +

Cytotoxic O +
activity O +
of O +
all O +
compounds O +
has O +
been O +
evaluated O +
by O +
MTT B-Chemical +
test O +
against O +
a O +
panel O +
of O +
several O +
human O +
tumor O +
cell O +
lines O +
including O +
examples O +
of O +
breast O +
( O -
MCF-7 O -
) O -
, O +
colon O +
( O -
HCT-15 O +
and O +
LoVo O -
) O -
, O +
lung O +
( O -
A549 O -
) O -
, O +
cervix O +
( O -
A431 O -
) O +
and O +
ovarian O +
( O -
2008 O +
and O +
its O +
cisplatin B-Chemical +
resistant O +
variant O -
, O +
C13 O -
* O -
) O +
carcinoma O -
, O +
melanoma O +
( O -
A375 O -
) O +
and O +
promyelocytic O +
leukemia O +
( O -
HL60 O -
) O -
. O +

Copper B-Chemical +
complexes O +
generally O +
show O +
in O +
vitro O +
antitumour O +
activity O +
comparable O +
to O +
that O +
of O +
cisplatin B-Chemical -
. O +

In O +
particular O -
, O +
neutral O +
' O -
3 O +
+ O +
1'-type O +
complexes O +
9 O +
and O +
10 O -
, O +
show O +
IC O -
( O -
50 O -
) O +
values O +
appreciably O +
lower O +
than O +
those O +
exhibited O +
by O +
the O +
reference O +
metallodrug O -
. O +

Porphyrin B-Chemical +
metabolisms O +
in O +
human O +
skin O +
commensal O +
Propionibacterium O +
acnes O +
bacteria O -
: O +
potential O +
application O +
to O +
monitor O +
human O +
radiation O +
risk O -
. O +

Propionibacterium O +
acnes O +
( O -
P. O +
acnes O -
) O -
, O +
a O +
Gram O -
- O -
positive O +
anaerobic O +
bacterium O -
, O +
is O +
a O +
commensal O +
organism O +
in O +
human O +
skin O -
. O +

Like O +
human O +
cells O -
, O +
the O +
bacteria O +
produce O +
porphyrins B-Chemical -
, O +
which O +
exhibit O +
fluorescence O +
properties O +
and O +
make O +
bacteria O +
visible O +
with O +
a O +
Wood O -
's O +
lamp O -
. O +

In O +
this O +
review O -
, O +
we O +
compare O +
the O +
porphyrin B-Chemical +
biosynthesis O +
in O +
humans O +
and O +
P. O +
acnes O -
. O +

Also O -
, O +
since O +
P. O +
acnes O +
living O +
on O +
the O +
surface O +
of O +
skin O +
receive O +
the O +
same O +
radiation O +
exposure O +
as O +
humans O -
, O +
we O +
envision O +
that O +
the O +
changes O +
in O +
porphyrin B-Chemical +
profiles O +
( O -
the O +
absorption O +
spectra O +
and/or O +
metabolism O -
) O +
of O +
P. O +
acnes O +
by O +
radiation O +
may O +
mirror O +
the O +
response O +
of O +
human O +
cells O +
to O +
radiation O -
. O +

The O +
porphyrin B-Chemical +
profiles O +
of O +
P. O +
acnes O +
may O +
be O +
a O +
more O +
accurate O +
reflection O +
of O +
radiation O +
risk O +
to O +
the O +
patient O +
than O +
other O +
biodosimeters O -
/ O -
biomarkers O +
such O +
as O +
gene O +
up- O -
/ O -
down O -
- O -
regulation O -
, O +
which O +
may O +
be O +
non O -
- O -
specific O +
due O +
to O +
patient O +
related O +
factors O +
such O +
as O +
autoimmune O +
diseases O -
. O +

Lastly O -
, O +
we O +
discuss O +
the O +
challenges O +
and O +
possible O +
solutions O +
for O +
using O +
the O +
P. O +
acnes O +
response O +
to O +
predict O +
the O +
radiation O +
risk O -
. O +

Design O +
and O +
synthesis O +
of O +
diazatricyclodecane B-Chemical +
agonists O +
of O +
the O +
G O -
- O -
protein O -
- O -
coupled O +
receptor O +
119 O -
. O +

A O +
series O +
of O +
GPR119 O +
agonists O +
based O +
on O +
a O +
2,6-diazatricyclo B-Chemical -
[ I-Chemical -
3.3.1.1∼3,7∼ I-Chemical -
] I-Chemical -
decane I-Chemical +
ring O +
system O +
is O +
described O -
. O +

Also O +
provided O +
is O +
a O +
detailed O +
account O +
of O +
the O +
development O +
of O +
a O +
multigram O +
scale O +
synthesis O +
of O +
the O +
diazatricyclic B-Chemical +
ring O +
system O -
, O +
which O +
was O +
achieved O +
using O +
a O +
Hofmann O -
- O -
Löffler O -
- O -
Freytag O +
reaction O +
as O +
the O +
key O +
step O -
. O +

The O +
basis O +
for O +
the O +
use O +
of O +
this O +
complex O +
framework O +
lies O +
in O +
an O +
attempt O +
to O +
constrain O +
one O +
end O +
of O +
the O +
molecule O +
in O +
the O +
" O -
agonist O +
conformation O -
" O +
as O +
was O +
previously O +
described O +
for O +
3-oxa-7-aza B-Chemical -
- I-Chemical -
bicyclo I-Chemical -
[ I-Chemical -
3.3.1 I-Chemical -
] I-Chemical -
nonanes I-Chemical -
. O +

Optimization O +
of O +
carbamate B-Chemical +
analogues O +
of O +
the O +
diazatricylic B-Chemical +
compounds O +
led O +
to O +
the O +
identification O +
of O +
32i O +
as O +
a O +
potent O +
agonist O +
of O +
the O +
GPR119 O +
receptor O +
with O +
low O +
unbound O +
human O +
liver O +
microsomal O +
clearance O -
. O +

The O +
use O +
of O +
an O +
agonist O +
response O +
weighted O +
ligand O +
lipophilic O +
efficiency O +
( O -
LLE O -
) O +
termed O +
AgLLE O +
is O +
discussed O +
along O +
with O +
the O +
issues O +
of O +
applying O +
efficiency O +
measures O +
to O +
agonist O +
programs O -
. O +

Ultimately O -
, O +
solubility O +
limited O +
absorption O +
and O +
poor O +
exposure O +
reduced O +
further O +
interest O +
in O +
these O +
molecules O -
. O +

Sulfonylureas B-Chemical +
have O +
antifungal O +
activity O +
and O +
are O +
potent O +
inhibitors O +
of O +
Candida O +
albicans O +
acetohydroxyacid O +
synthase O -
. O +

The O +
sulfonylurea B-Chemical +
herbicides O +
exert O +
their O +
activity O +
by O +
inhibiting O +
plant O +
acetohydroxyacid O +
synthase O +
( O -
AHAS O -
) O -
, O +
the O +
first O +
enzyme O +
in O +
the O +
branched O -
- O -
chain O +
amino B-Chemical +
acid I-Chemical +
biosynthesis O +
pathway O -
. O +

It O +
has O +
previously O +
been O +
shown O +
that O +
if O +
the O +
gene O +
for O +
AHAS O +
is O +
deleted O +
in O +
Candida O +
albicans O +
, O +
attenuation O +
of O +
virulence O +
is O +
achieved O -
, O +
suggesting O +
AHAS O +
as O +
an O +
antifungal O +
drug O +
target O -
. O +

Herein O -
, O +
we O +
have O +
cloned O -
, O +
expressed O -
, O +
and O +
purified O +
C. O +
albicans O +
AHAS O +
and O +
shown O +
that O +
several O +
sulfonylureas B-Chemical +
are O +
inhibitors O +
of O +
this O +
enzyme O +
and O +
possess O +
antifungal O +
activity O -
. O +

The O +
most O +
potent O +
of O +
these O +
compounds O +
is O +
ethyl B-Chemical +
2- I-Chemical -
( I-Chemical -
N- I-Chemical -
( I-Chemical -
( I-Chemical -
4-iodo-6-methoxypyrimidin-2-yl I-Chemical -
) I-Chemical -
carbamoyl I-Chemical -
) I-Chemical -
sulfamoyl I-Chemical -
) I-Chemical -
benzoate I-Chemical +
( O -
10c O -
) O -
, O +
which O +
has O +
a O +
K O -
( O -
i O -
) O +
value O +
of O +
3.8 O +
nM O +
for O +
C. O +
albicans O +
AHAS O +
and O +
an O +
MIC₉₀ O +
of O +
0.7 O +
μg O -
/ O -
mL O +
for O +
this O +
fungus O +
in O +
cell O -
- O -
based O +
assays O -
. O +

For O +
the O +
sulfonylureas B-Chemical +
tested O +
there O +
was O +
a O +
strong O +
correlation O +
between O +
inhibitory O +
activity O +
toward O +
C. O +
albicans O +
AHAS O +
and O +
fungicidal O +
activity O -
, O +
supporting O +
the O +
hypothesis O +
that O +
AHAS O +
is O +
the O +
target O +
for O +
their O +
inhibitory O +
activity O +
within O +
the O +
cell O -
. O +

Design O -
, O +
functionalization O +
strategies O +
and O +
biomedical O +
applications O +
of O +
targeted O +
biodegradable O -
/ O -
biocompatible O +
polymer O -
- O -
based O +
nanocarriers O +
for O +
drug O +
delivery O -
. O +

Design O +
and O +
functionalization O +
strategies O +
for O +
multifunctional O +
nanocarriers O +
( O -
e.g. O -
, O +
nanoparticles O -
, O +
micelles O -
, O +
polymersomes O -
) O +
based O +
on O +
biodegradable O -
/ O -
biocompatible O +
polymers O +
intended O +
to O +
be O +
employed O +
for O +
active O +
targeting O +
and O +
drug O +
delivery O +
are O +
reviewed O -
. O +

This O +
review O +
will O +
focus O +
on O +
the O +
nature O +
of O +
the O +
polymers O +
involved O +
in O +
the O +
preparation O +
of O +
targeted O +
nanocarriers O -
, O +
the O +
synthesis O +
methods O +
to O +
achieve O +
the O +
desired O +
macromolecular O +
architecture O -
, O +
the O +
selected O +
coupling O +
strategy O -
, O +
the O +
choice O +
of O +
the O +
homing O +
molecules O +
( O -
vitamins O -
, O +
hormones O -
, O +
peptides O -
, O +
proteins O -
, O +
etc O -
. O -
) O -
, O +
as O +
well O +
as O +
the O +
various O +
strategies O +
to O +
display O +
them O +
at O +
the O +
surface O +
of O +
nanocarriers O -
. O +

The O +
resulting O +
morphologies O +
and O +
the O +
main O +
colloidal O +
features O +
will O +
be O +
given O +
as O +
well O +
as O +
an O +
overview O +
of O +
the O +
biological O +
activities O -
, O +
with O +
a O +
special O +
focus O +
on O +
the O +
main O +
in O +
vivo O +
achievements O -
. O +

Characterization O +
of O +
arsenic B-Chemical +
resistant O +
bacteria O +
from O +
arsenic B-Chemical +
rich O +
groundwater O +
of O +
West O +
Bengal O -
, O +
India O -
. O +

Sixty O -
- O -
four O +
arsenic B-Chemical +
( O -
As B-Chemical -
) O +
resistant O +
bacteria O +
isolated O +
from O +
an O +
arsenic B-Chemical +
rich O +
groundwater O +
sample O +
of O +
West O +
Bengal O +
were O +
characterized O +
to O +
investigate O +
their O +
potential O +
role O +
in O +
subsurface O +
arsenic B-Chemical +
mobilization O -
. O +

Among O +
the O +
isolated O +
strains O +
predominance O +
of O +
genera O +
Agrobacterium O -
/ O -
Rhizobium O -
, O +
Ochrobactrum O +
and O +
Achromobacter O +
which O +
could O +
grow O +
chemolitrophically O +
and O +
utilize O +
arsenic B-Chemical +
as O +
electron O +
donor O +
were O +
detected O -
. O +

Higher O +
tolerance O +
to O +
As B-Chemical -
( I-Chemical -
3 I-Chemical -
+ I-Chemical -
) I-Chemical +
[ O -
maximum O +
tolerable O +
concentration O +
( O -
MTC O -
) O -
: O +
≥10 O +
mM O -
] O -
, O +
As B-Chemical -
( O -
5 O -
+ O -
) O +
( O -
MTC O -
: O +
≥100 O +
mM O -
) O +
and O +
other O +
heavy O +
metals O +
like O +
Cu B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical -
, O +
Cr B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical -
, O +
Ni B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
etc O -
. O +

( O -
MTC O -
: O +
≥10 O +
mM O -
) O -
, O +
presence O +
of O +
arsenate B-Chemical +
reductase O +
and O +
siderophore O +
was O +
frequently O +
observed O +
among O +
the O +
isolates O -
. O +

Ability O +
to O +
produce O +
arsenite B-Chemical +
oxidase O +
and O +
phosphatase O +
enzyme O +
was O +
detected O +
in O +
50 O +
and O +
34 O +
% O +
of O +
the O +
isolates O -
, O +
respectively O -
. O +

Although O +
no O +
direct O +
correlation O +
among O +
taxonomic O +
identity O +
of O +
bacterial O +
strains O +
and O +
their O +
metabolic O +
abilities O +
as O +
mentioned O +
above O +
was O +
apparent O -
, O +
several O +
isolates O +
affiliated O +
to O +
genera O +
Ochrobactrum O -
, O +
Achromobacter O +
and O +
unclassified O +
Rhizobiaceae O +
members O +
were O +
found O +
to O +
be O +
highly O +
resistant O +
to O +
As B-Chemical -
( I-Chemical -
3 I-Chemical -
+ I-Chemical -
) I-Chemical +
and O +
As B-Chemical -
( I-Chemical -
5 I-Chemical -
+ I-Chemical -
) I-Chemical +
and O +
positive O +
for O +
all O +
the O +
test O +
properties O -
. O +

Arsenate B-Chemical +
reductase O +
activity O +
was O +
found O +
to O +
be O +
conferred O +
by O +
arsC O +
gene O -
, O +
which O +
in O +
many O +
strains O +
was O +
coupled O +
with O +
arsenite B-Chemical +
efflux O +
gene O +
arsB O +
as O +
well O -
. O +

Phylogenetic O +
incongruence O +
between O +
the O +
16S O +
rRNA O +
and O +
ars O +
genes O +
lineages O +
indicated O +
possible O +
incidence O +
of O +
horizontal O +
gene O +
transfer O +
for O +
ars O +
genes O -
. O +

Based O +
on O +
the O +
results O +
we O +
propose O +
that O +
under O +
the O +
prevailing O +
low O +
nutrient O +
condition O +
inhabitant O +
bacteria O +
capable O +
of O +
using O +
inorganic O +
electron O +
donors O +
play O +
a O +
synergistic O +
role O +
wherein O +
siderophores O +
and O +
phosphatase O +
activities O +
facilitate O +
the O +
release O +
of O +
sediment O +
bound O +
As B-Chemical -
( I-Chemical -
5 I-Chemical -
+ I-Chemical -
) I-Chemical -
, O +
which O +
is O +
subsequently O +
reduced O +
by O +
arsenate B-Chemical +
reductase O +
resulting O +
into O +
the O +
mobilization O +
of O +
As B-Chemical -
( I-Chemical -
3 I-Chemical -
+ I-Chemical -
) I-Chemical +
in O +
groundwater O -
. O +

Understanding O +
the O +
dark O +
and O +
light O -
- O -
enhanced O +
bactericidal O +
action O +
of O +
cationic O +
conjugated O +
polyelectrolytes O +
and O +
oligomers O -
. O +

A O +
multiscale O +
investigation O +
was O +
carried O +
out O +
to O +
study O +
the O +
dark O +
and O +
light O -
- O -
enhanced O +
bactericidal O +
mechanisms O +
of O +
poly B-Chemical -
( I-Chemical -
phenylene I-Chemical +
ethynylene I-Chemical -
) I-Chemical +

( O -
PPE B-Chemical -
) O -
-based O +
cationic O +
conjugated O +
polyelectrolytes O +
( O -
CPEs O -
) O +
and O +
oligo B-Chemical -
- I-Chemical -
phenylene I-Chemical +
ethynylenes I-Chemical +
( O -
OPEs B-Chemical -
) O -
. O +

On O +
the O +
morphological O +
scale O -
, O +
Gram O -
- O -
negative O +
E. O +
coli O +
cells O +
exposed O +
to O +
CPE O +
and O +
OPE B-Chemical +
compounds O +
in O +
the O +
dark O +
show O +
damage O +
to O +
the O +
cell O +
envelope O -
, O +
plasma O +
membrane O -
, O +
and O +
in O +
some O +
cases O +
the O +
cytoplasm O -
, O +
while O +
with O +
UV O -
- O -
irradiation O -
, O +
E. O +
coli O +
sustained O +
catastrophic O +
damages O +
to O +
both O +
the O +
cell O +
envelope O +
and O +
cytoplasm O -
. O +

In O +
contrast O -
, O +
the O +
Gram O -
- O -
positive O +
S. O +
epi O +
bacteria O +
appeared O +
intact O +
when O +
exposed O +
to O +
CPE O +
and O +
OPE B-Chemical +
compounds O +
in O +
the O +
dark O +
but O +
showed O +
damages O +
to O +
the O +
cell O +
envelope O +
with O +
UV O -
- O -
irradiation O -
. O +

To O +
better O +
understand O +
the O +
molecular O +
basis O +
of O +
CPE- O +
and O +
OPE B-Chemical -
- O -
induced O +
morphological O +
changes O +
and O +
damages O +
to O +
bacteria O -
, O +
we O +
investigated O +
the O +
effect O +
of O +
these O +
compounds O +
on O +
model O +
bacterial O +
plasma O +
membrane O +
and O +
bacterial O +
proteins O +
and O +
plasmid O +
DNA O -
. O +

Measurements O +
of O +
dark O +
membrane O +
perturbation O +
activity O +
of O +
the O +
CPEs O +
and O +
OPEs B-Chemical +
using O +
model O +
lipid O +
membranes O +
support O +
a O +
carpet O +
or O +
detergent O -
- O -
like O +
mechanism O +
by O +
which O +
the O +
antimicrobial O +
compounds O +
induce O +
membrane O +
collapse O +
and O +
phase O +
transitions O -
. O +

Under O +
UV O -
- O -
irradiation O -
, O +
E. O +
coli O +
bacteria O +
exposed O +
to O +
CPEs O +
and O +
OPEs B-Chemical +
showed O +
covalent O +
modifications O +
and O +
damages O +
to O +
both O +
cellular O +
protein O +
and O +
plasmid O +
DNA O -
, O +
likely O +
through O +
oxidative O +
pathways O +
mediated O +
by O +
singlet O +
oxygen B-Chemical +
and O +
subsequent O +
reactive O +
oxygen B-Chemical +
species O +
sensitized O +
by O +
the O +
CPE O +
and O +
OPE B-Chemical +
compounds O -
. O +

Our O +
finding O +
thus O +
show O +
that O +
the O +
antimicrobial O +
polymers O +
and O +
oligomers O +
exert O +
toxicity O +
toward O +
Gram O -
- O -
negative O +
bacteria O +
by O +
disrupting O +
the O +
morphology O +
and O +
structures O +
of O +
cell O +
envelope O +
and O +
cytoplasm O -
, O +
including O +
cellular O +
components O +
such O +
as O +
proteins O +
and O +
DNA O -
, O +
while O +
exert O +
toxicity O +
toward O +
Gram O -
- O -
positive O +
bacteria O +
by O +
binding O +
to O +
and O +
disrupting O +
just O +
the O +
cell O +
wall O -
. O +

Unconventional O +
growth O +
mechanism O +
for O +
monolithic O +
integration O +
of O +
III O -
- O -
V O +
on O +
silicon B-Chemical -
. O +

The O +
heterogeneous O +
integration O +
of O +
III O -
- O -
V O +
optoelectronic O +
devices O +
with O +
Si B-Chemical +
electronic O +
circuits O +
is O +
highly O +
desirable O +
because O +
it O +
will O +
enable O +
many O +
otherwise O +
unattainable O +
capabilities O -
. O +

However O -
, O +
direct O +
growth O +
of O +
III O -
- O -
V O +
thin O +
film O +
on O +
silicon B-Chemical +
substrates O +
has O +
been O +
very O +
challenging O +
because O +
of O +
large O +
mismatches O +
in O +
lattice O +
constants O +
and O +
thermal O +
coefficients O -
. O +

Furthermore O -
, O +
the O +
high O +
epitaxial O +
growth O +
temperature O +
is O +
detrimental O +
to O +
transistor O +
performance O -
. O +

Here O -
, O +
we O +
present O +
a O +
detailed O +
studies O +
on O +
a O +
novel O +
growth O +
mode O +
which O +
yields O +
a O +
catalyst O -
- O -
free O +
( O -
Al B-Chemical -
, O -
In B-Chemical -
) O -
GaAs B-Chemical +
nanopillar O +
laser O +
on O +
a O +
silicon B-Chemical +
substrate O +
by O +
metal O -
- O -
organic O +
chemical O +
vapor O +
deposition O +
at O +
the O +
low O +
temperature O +
of O +
400 O +
° O -
C O -
. O +

We O +
study O +
the O +
growth O +
and O +
misfit O +
stress O +
relaxation O +
mechanism O +
by O +
cutting O +
through O +
the O +
center O +
of O +
the O +
InGaAs B-Chemical -
/ O -
GaAs B-Chemical +
nanopillars O +
using O +
focused O +
ion O +
beam O +
and O +
inspecting O +
with O +
high O -
- O -
resolution O +
transmission O +
electron O +
microscopy O -
. O +

The O +
bulk O +
material O +
of O +
the O +
nanopillar O +
is O +
in O +
pure O +
wurtzite B-Chemical +
crystal O +
phase O -
, O +
despite O +
the O +
6 O -
% O +
lattice O +
mismatch O +
with O +
the O +
substrate O -
, O +
with O +
all O +
stacking O +
disorders O +
well O +
confined O +
in O +
the O +
bottom O -
- O -
most O +
transition O +
region O +
and O +
terminated O +
horizontally O -
. O +

Furthermore O -
, O +
InGaAs B-Chemical +
was O +
found O +
to O +
be O +
in O +
direct O +
contact O +
with O +
silicon B-Chemical -
, O +
in O +
agreement O +
with O +
the O +
observed O +
crystal O +
orientation O +
alignment O +
and O +
good O +
electrical O +
conduction O +
across O +
the O +
interface O -
. O +

This O +
is O +
in O +
sharp O +
contrast O +
to O +
many O +
III O -
- O -
V O +
nanowires O +
on O +
silicon B-Chemical +
which O +
are O +
observed O +
to O +
stem O +
from O +
thin O +
SiN B-Chemical -
( I-Chemical -
x I-Chemical -
) I-Chemical -
, O +
SiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
, O +
or O +
SiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
/ O -
Si B-Chemical +
openings O -
. O +

In O +
addition O -
, O +
GaAs B-Chemical +
was O +
found O +
to O +
grow O +
perfectly O +
as O +
a O +
shell O +
layer O +
on O +
In B-Chemical -
( I-Chemical -
0.2 I-Chemical -
) I-Chemical -
Ga I-Chemical -
( I-Chemical -
0.8 I-Chemical -
) I-Chemical -
As I-Chemical +
with O +
an O +
extraordinary O +
thickness O -
, O +
which O +
is O +
15 O +
times O +
greater O +
than O +
the O +
theoretical O +
thin O -
- O -
film O +
critical O +
thickness O +
for O +
a O +
1.5 O -
% O +
lattice O +
mismatch O -
. O +

This O +
is O +
attributed O +
to O +
the O +
core O -
- O -
shell O +
radial O +
geometry O +
allowing O +
the O +
outer O +
layers O +
to O +
expand O +
and O +
release O +
the O +
strain O +
due O +
to O +
lattice O +
mismatch O -
. O +

The O +
findings O +
in O +
this O +
study O +
redefine O +
the O +
rules O +
for O +
lattice O -
- O -
mismatched O +
growth O +
on O +
heterogeneous O +
substrates O +
and O +
device O +
structure O +
design O -
. O +

Contrasting O +
toxicokinetic O +
evaluations O +
and O +
interspecies O +
pharmacokinetic O +
scaling O +
approaches O +
for O +
small O +
molecules O +
and O +
biologics O -
: O +
applicability O +
to O +
biosimilar O +
development O -
. O +

1 O -
. O +

A O +
2-fold O +
threshold O +
typically O +
used O +
for O +
prediction O +
accuracy O +
of O +
interspecies O +
scaling O +
of O +
clearance O +
( O -
CL O -
) O +
may O +
be O +
too O +
liberal O +
when O +
using O +
pharmacokinetic O +
similarity O +
in O +
animals O +
to O +
advance O +
biosimilar O +
candidate O +
selection O +
for O +
clinical O +
testing O -
. O +

The O +
purpose O +
of O +
this O +
review O +
is O +
to O +
identify O +
interspecies O +
scaling O +
methods O +
for O +
use O +
in O +
de O -
- O -
risking O +
biosimilar O +
development O +
prior O +
to O +
clinical O +
testing O -
. O +

2 O -
. O +

Scaling O +
approaches O +
for O +
predicting O +
macromolecule O +
CL O +
were O +
identified O +
through O +
literature O +
review O -
. O +

Reports O +
that O +
evaluated O +
predicted O +
and O +
observed O +
human O +
CLs O +
for O +
≥5 O +
individual O +
compounds O +
were O +
considered O -
. O +

Absolute O +
average O +
fold O -
- O -
error O +
( O -
AAFE O -
) O +
was O +
calculated O +
for O +
each O +
method O +
along O +
with O +
the O +
proportion O +
of O +
compounds O +
with O +
individual O +
fold O -
- O -
error O +
values O +
within O +
a O +
tighter O +
threshold O +
of O +
0.7 O -
- O -
1.3 O -
. O +

3 O -
. O +

Traditional O +
simple O +
allometry O +
with O +
a O +
minimum O +
of O +
three O +
species O +
and O +
the O +
rule O +
of O +
exponents O +
performed O +
inconsistently O +
with O +
some O +
groups O +
of O +
compounds O +
resulting O +
in O +
a O +
greater O +
than O +
2-fold O +
error O +
( O -
i.e. O +
AAFE O +
> O +
2 O -
) O -
. O +

For O +
monoclonal O +
antibodies O +
( O -
mAbs O -
) O -
, O +
simplified O +
allometric O +
approaches O +
employing O +
a O +
single O +
species O +
( O -
monkey O -
) O +
with O +
a O +
fixed O +
exponent O +
of O +
0.85 O +
consistently O +
resulted O +
in O +
lower O +
AAFEs O +
and O +
a O +
higher O +
proportion O +
of O +
compounds O +
within O +
the O +
tighter O +
range O +
of O +
0.7 O -
- O -
1.3 O -
. O +

4 O -
. O +

For O +
macromolecules O -
, O +
and O +
particularly O +
mAbs O -
, O +
employing O +
single O -
- O -
species O +
monkey O +
" O -
simplified O -
" O +
allometric O +
approaches O +
with O +
a O +
fixed O +
exponent O +
of O +
0.85 O +
may O +
be O +
more O +
appropriate O +
than O +
traditional O +
allometric O +
approaches O -
. O +

Peptide O -
/ O -
protein O +
separation O +
with O +
cationic O +
polymer O +
brush O +
nanosponges O +
for O +
MALDI O -
- O -
MS O +
analysis O -
. O +

A O +
cationic O +
polymer O +
nanobrush O +
was O +
synthesized O -
, O +
attached O +
to O +
a O +
MALDI O +
target O -
, O +
and O +
used O +
for O +
the O +
fractionation O +
of O +
peptides O +
and O +
proteins O +
based O +
on O +
their O +
pI O -
, O +
prior O +
to O +
analysis O +
by O +
MALDI O -
- O -
MS O -
. O +

The O +
cationic O +
polymer O +
nanobrush O +
was O +
synthesized O +
on O +
a O +
gold O +
substrate O +
by O +
AIBN B-Chemical +
photoinitiated O +
polymerization O -
, O +
using O +
a O +
70:30 O +
ratio O +
of O +
2-aminoethyl B-Chemical +
methacrylate I-Chemical +
hydrochloride I-Chemical +
( O -
AEMA B-Chemical -
) O -
:N O -
- B-Chemical -
isopropylacrylamide I-Chemical +
( O -
NIPAAM B-Chemical -
) O -
. O +

This O +
brush O +
showed O +
selectivity O +
for O +
adsorption O +
of O +
acidic O +
peptides O +
and O +
proteins O +
and O +
allowed O +
fractionation O +
of O +
simple O +
two O -
- O -
component O +
mixtures O +
to O +
be O +
completed O +
in O +
less O +
than O +
10 O +
min O -
. O +

The O +
brush O -
- O -
adsorbed O +
biomolecules O +
were O +
recovered O +
by O +
treating O +
the O +
nanobrush O +
with O +
ammonium B-Chemical +
hydroxide I-Chemical -
, O +
which O +
effectively O +
collapsed O +
the O +
brush O -
, O +
thereby O +
releasing O +
the O +
trapped O +
compounds O +
for O +
MALDI O +
MS O +
analysis O -
. O +

These O +
results O +
demonstrate O +
that O +
nanobrush O +
can O +
serve O +
as O +
a O +
convenient O +
platform O +
for O +
rapid O +
fractionation O +
of O +
biomolecules O +
prior O +
to O +
analysis O +
by O +
MALDI O -
- O -
MS O -
. O +

Direct O +
measurement O +
of O +
Dirac O +
point O +
energy O +
at O +
the O +
graphene B-Chemical -
/ O -
oxide B-Chemical +
interface O -
. O +

We O +
report O +
the O +
direct O +
measurement O +
of O +
the O +
Dirac O +
point O -
, O +
the O +
Fermi O +
level O -
, O +
and O +
the O +
work O +
function O +
of O +
graphene B-Chemical +
by O +
performing O +
internal O +
photoemission O +
measurements O +
on O +
a O +
graphene B-Chemical -
/ O -
SiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
/ O -
Si B-Chemical +
structure O +
with O +
a O +
unique O +
optical O -
- O -
cavity O +
enhanced O +
test O +
structure O -
. O +

A O +
complete O +
electronic O +
band O +
alignment O +
at O +
the O +
graphene B-Chemical -
/ O -
SiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
/ O -
Si B-Chemical +
interfaces O +
is O +
accurately O +
established O -
. O +

The O +
observation O +
of O +
enhanced O +
photoemission O +
from O +
a O +
one O -
- O -
atom O +
thick O +
graphene B-Chemical +
layer O +
was O +
possible O +
by O +
taking O +
advantage O +
of O +
the O +
constructive O +
optical O +
interference O +
in O +
the O +
SiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
cavity O -
. O +

The O +
photoemission O +
yield O +
was O +
found O +
to O +
follow O +
the O +
well O -
- O -
known O +
linear O +
density O -
- O -
of O -
- O -
states O +
dispersion O +
in O +
the O +
vicinity O +
of O +
the O +
Dirac O +
point O -
. O +

At O +
the O +
flat O +
band O +
condition O -
, O +
the O +
Fermi O +
level O +
was O +
extracted O +
and O +
found O +
to O +
reside O +
3.3 O +
eV O +
± O +
0.05 O +
eV O +
below O +
the O +
bottom O +
of O +
the O +
SiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
conduction O +
band O -
. O +

When O +
combined O +
with O +
the O +
shift O +
of O +
the O +
Fermi O +
level O +
from O +
the O +
Dirac O +
point O -
, O +
we O +
are O +
able O +
to O +
ascertain O +
the O +
position O +
of O +
the O +
Dirac O +
point O +
at O +
3.6 O +
eV O +
± O +
0.05 O +
eV O +
with O +
respect O +
to O +
the O +
bottom O +
of O +
the O +
SiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
conduction O +
band O +
edge O -
, O +
yielding O +
a O +
work O +
function O +
of O +
4.5 O +
eV O +
± O +
0.05 O +
eV O +
which O +
is O +
in O +
an O +
excellent O +
agreement O +
with O +
theory O -
. O +

The O +
accurate O +
determination O +
of O +
the O +
work O +
function O +
of O +
graphene B-Chemical +
is O +
of O +
significant O +
importance O +
to O +
the O +
engineering O +
of O +
graphene B-Chemical -
- O -
based O +
devices O -
, O +
and O +
the O +
measurement O +
technique O +
we O +
have O +
advanced O +
in O +
this O +
Letter O +
will O +
have O +
significant O +
impact O +
on O +
numerous O +
applications O +
for O +
emerging O +
graphene B-Chemical -
- O -
like O +
2-dimensional O +
material O +
systems O -
. O +

Overexpression O +
of O +
Escherichia O +
coli O +
nucleotide B-Chemical +
excision O +
repair O +
genes O +
after O +
cisplatin B-Chemical -
- O -
induced O +
damage O -
. O +

Cisplatin B-Chemical +
is O +
currently O +
used O +
in O +
tumor O +
chemotherapy O +
to O +
induce O +
the O +
death O +
of O +
malignant O +
cells O +
through O +
blockage O +
of O +
DNA O +
replication O -
. O +

It O +
is O +
a O +
commonly O +
used O +
chemotherapeutic O +
agent O +
binding O +
mono- O +
or O +
bifunctionally O +
to O +
guanines B-Chemical +
in O +
DNA O -
. O +

Escherichia O +
coli O +
K12 O +
mutant O +
strains O +
deficient O +
in O +
nucleotide B-Chemical +
excision O +
repair O +
( O -
NER O -
) O +
were O +
submitted O +
to O +
increasing O +
concentrations O +
of O +
cisplatin B-Chemical -
, O +
and O +
the O +
results O +
revealed O +
that O +
uvrA O +
and O +
uvrB O +
mutants O +
are O +
sensitive O +
to O +
this O +
agent O -
, O +
while O +
uvrC O +
and O +
cho O +
mutants O +
remain O +
as O +
the O +
wild O +
type O +
strain O -
. O +

The O +
time O +
required O +
for O +
both O +
gene O +
expression O +
turn O -
- O -
off O +
and O +
return O +
to O +
normal O +
weight O +
DNA O +
in O +
wild O -
- O -
type O +
E. O +
coli O +
was O +
not O +
accomplished O +
even O +
after O +
4 O +
h O +
post O -
- O -
treatment O +
with O +
cisplatin B-Chemical -
, O +
while O +
the O +
same O +
process O +
takes O +
place O +
within O +
1.5 O +
h O +
after O +
ultraviolet O +
radiation O +
( O -
UV O -
) O -
. O +

Besides O -
, O +
a O +
heavily O +
damaging O +
action O +
of O +
cisplatin B-Chemical +
can O +
be O +
seen O +
not O +
only O +
by O +
persistent O +
nicks O +
on O +
genomic O +
DNA O -
, O +
but O +
also O +
by O +
NER O +
gene O +
expression O +
exceeding O +
manifold O +
that O +
seen O +
after O +
equivalent O +
lethal O +
doses O +
of O +
UV O -
. O +

Moreover O -
, O +
cisplatin B-Chemical +
caused O +
an O +
increase O +
in O +
uvrB O +
gene O +
expression O +
from O +
its O +
putative O +
upstream O +
promoter O +
P3 O +
in O +
an O +
SOS O -
- O -
independent O +
manner O -
. O +

Cockayne O +
syndrome O +
b O +
maintains O +
neural O +
precursor O +
function O -
. O +

Neurodevelopmental O +
defects O +
are O +
observed O +
in O +
the O +
hereditary O +
disorder O +
Cockayne O +
syndrome O +
( O -
CS O -
) O -
. O +

The O +
gene O +
most O +
frequently O +
mutated O +
in O +
CS O -
, O +
Cockayne O +
Syndrome O +
B O +
( O -
CSB O -
) O -
, O +
is O +
required O +
for O +
the O +
repair O +
of O +
bulky O +
DNA O +
adducts O +
in O +
transcribed O +
genes O +
during O +
transcription O -
- O -
coupled O +
nucleotide O +
excision O +
repair O -
. O +

CSB O +
also O +
plays O +
a O +
role O +
in O +
chromatin O +
remodeling O +
and O +
mitochondrial O +
function O -
. O +

The O +
role O +
of O +
CSB O +
in O +
neural O +
development O +
is O +
poorly O +
understood O -
. O +

Here O +
we O +
report O +
that O +
the O +
abundance O +
of O +
neural O +
progenitors O +
is O +
normal O +
in O +
Csb O -
( O -
- O -
/ O -
- O -
) O +
mice O +
and O +
the O +
frequency O +
of O +
apoptotic O +
cells O +
in O +
the O +
neurogenic O +
niche O +
of O +
the O +
adult O +
subependymal O +
zone O +
is O +
similar O +
in O +
Csb O -
( O -
- O -
/ O -
- O -
) O +
and O +
wild O +
type O +
mice O -
. O +

Both O +
embryonic O +
and O +
adult O +
Csb O -
( O -
- O -
/ O -
- O -
) O +
neural O +
precursors O +
exhibited O +
defective O +
self O -
- O -
renewal O +
in O +
the O +
neurosphere O +
assay O -
. O +

In O +
Csb O -
( O -
- O -
/ O -
- O -
) O +
neural O +
precursors O -
, O +
self O -
- O -
renewal O +
progressively O +
decreased O +
in O +
serially O +
passaged O +
neurospheres O -
. O +

The O +
data O +
also O +
indicate O +
that O +
Csb O +
and O +
the O +
nucleotide O +
excision O +
repair O +
protein O +
Xpa O +
preserve O +
embryonic O +
neural O +
stem O +
cell O +
self O -
- O -
renewal O +
after O +
UV O +
DNA O +
damage O -
. O +

Although O +
Csb O -
( O -
- O -
/ O -
- O -
) O +
neural O +
precursors O +
do O +
not O +
exhibit O +
altered O +
neuronal O +
lineage O +
commitment O +
after O +
low O -
- O -
dose O +
UV O +
( O -
1J O -
/ O -
m O -
( O -
2 O -
) O -
) O +
in O +
vitro O -
, O +
neurons O +
differentiated O +
in O +
vitro O +
from O +
Csb O -
( O -
- O -
/ O -
- O -
) O +
neural O +
precursors O +
that O +
had O +
been O +
irradiated O +
with O +
1J O -
/ O -
m O -
( O -
2 O -
) O +
UV O +
exhibited O +
defective O +
neurite O +
outgrowth O -
. O +

These O +
findings O +
identify O +
a O +
function O +
for O +
Csb O +
in O +
neural O +
precursors O -
. O +

Observation O +
of O +
direct O +
vibrational O +
excitation O +
in O +
gas O -
- O -
surface O +
collisions O +
of O +
CO B-Chemical +
with O +
Au B-Chemical -
( O -
111 O -
) O -
: O +
a O +
new O +
model O +
system O +
for O +
surface O +
dynamics O -
. O +

We O +
report O +
vibrational O +
excitation O +
of O +
CO B-Chemical +
from O +
its O +
ground O +
( O -
v O +
= O +
0 O -
) O +
to O +
first O +
excited O +
( O -
v O +
= O +
1 O -
) O +
vibrational O +
state O +
in O +
collision O +
with O +
Au B-Chemical -
( O -
111 O -
) O +
at O +
an O +
incidence O +
energy O +
of O +
translation O +
of O +
E O -
( O -
I O -
) O +
= O +
0.45 O +
eV. O +
Unlike O +
past O +
work O -
, O +
we O +
can O +
exclude O +
an O +
excitation O +
mechanism O +
involving O +
temporary O +
adsorption O +
on O +
the O +
surface O +
followed O +
by O +
thermalization O +
and O +
desorption O -
. O +

The O +
angular O +
distributions O +
of O +
the O +
scattered O +
CO B-Chemical +
molecules O +
are O +
narrow O -
, O +
consistent O +
with O +
direct O +
scattering O +
occurring O +
on O +
a O +
sub O -
- O -
ps O +
time O +
scale O -
. O +

The O +
absolute O +
excitation O +
probabilities O +
are O +
about O +
3 O -
% O +
of O +
those O +
expected O +
from O +
thermal O +
accommodation O -
. O +

The O +
surface O +
temperature O +
dependence O +
of O +
excitation O -
, O +
which O +
was O +
measured O +
between O +
373 O +
and O +
973 O +
K O -
, O +
is O +
Arrhenius O -
- O -
like O +
with O +
an O +
activation O +
energy O +
equal O +
to O +
the O +
energy O +
required O +
for O +
vibrational O +
excitation O -
. O +

Our O +
measurements O +
are O +
consistent O +
with O +
a O +
vibrational O +
excitation O +
mechanism O +
involving O +
coupling O +
of O +
thermally O +
excited O +
electron O -
- O -
hole O +
pairs O +
of O +
the O +
solid O +
to O +
CO B-Chemical +
vibration O -
. O +

Selective O +
focused O -
- O -
ion O -
- O -
beam O +
sculpting O +
of O +
TiO2 B-Chemical +
nanotubes O +
and O +
mechanism O +
understanding O -
. O +

Anodic O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
nanotubes O +
with O +
different O +
structures O -
, O +
doping O +
agents O -
, O +
and O +
decorations O +
have O +
been O +
studied O +
in O +
order O +
to O +
improve O +
energy O +
conversion O +
and O +
storage O +
efficiencies O +
such O +
as O +
in O +
dye O +
sensitized O +
solar O +
cells O -
, O +
solar O +
fuels O -
, O +
and O +
electrochemical O +
supercapacitors O -
. O +

However O -
, O +
the O +
top O +
surface O +
modification O +
of O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
nanotubes O +
has O +
never O +
been O +
addressed O -
. O +

In O +
this O +
study O -
, O +
anodic O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
nanotubes O +
have O +
been O +
selectively O +
closed O +
by O +
high O +
energy O +
focused O +
ion O +
beams O +
and O +
re O -
- O -
opened O +
by O +
low O +
energy O +
focused O +
ion O +
beams O -
. O +

Under O +
a O +
30 O +
kV O +
Ga B-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical +
beam O -
, O +
TiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
nanotubes O +
are O +
closed O +
with O +
a O +
65 O +
nm O +
shield O +
layer O +
covering O +
the O +
top O +
entrance O +
when O +
the O +
ion O +
dose O +
is O +
larger O +
than O +
1.2 O +
× O +
10 O -
( O -
17 O -
) O +
ions O +
per O +
cm O -
( O -
2 O -
) O -
; O +
under O +
a O +
5 O +
kV O +
Ga B-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical +
beam O -
, O +
the O +
shield O +
layer O +
is O +
removed O +
and O +
the O +
closed O +
tubes O +
are O +
re O -
- O -
opened O -
. O +

An O +
ion O -
- O -
induced O +
viscous O +
flow O +
model O +
has O +
been O +
proposed O +
to O +
explain O +
the O +
influence O +
of O +
Ga B-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical +
ion O +
beam O +
flux O -
, O +
substrate O +
temperature O -
, O +
initial O +
tube O +
diameter O -
, O +
ion O +
beam O +
dwell O +
time O -
, O +
and O +
the O +
incidence O +
angle O +
of O +
the O +
ion O +
beam O -
. O +

Gene O +
transcription O +
reflects O +
poor O +
health O +
status O +
of O +
resident O +
European O +
eel O +
chronically O +
exposed O +
to O +
environmental O +
pollutants O -
. O +

Understanding O +
the O +
effects O +
of O +
chronic O +
exposure O +
to O +
pollutants O +
on O +
the O +
genome O +
and O +
transcriptome O +
of O +
diadromous O +
fish O +
populations O +
is O +
crucial O +
for O +
their O +
resilience O +
under O +
combined O +
anthropogenic O +
and O +
environmental O +
selective O +
pressures O -
. O +

The O +
catadromous O +
European O +
eel O +
( O -
Anguilla O +
anguilla O +
L. O -
) O +
has O +
suffered O +
a O +
dramatic O +
decline O +
in O +
recruitment O +
for O +
three O +
decades O -
, O +
necessitating O +
a O +
thorough O +
assessment O +
of O +
the O +
transcriptional O +
effects O +
of O +
environmental O +
pollutants O +
on O +
resident O +
and O +
migrating O +
eels O +
in O +
natural O +
systems O -
. O +

We O +
investigated O +
the O +
relationship O +
between O +
muscular O +
bioaccumulation O +
levels O +
of O +
metals O +
( O -
Hg B-Chemical -
, O +
Cd B-Chemical -
, O +
Pb B-Chemical -
, O +
Cu B-Chemical -
, O +
Zn B-Chemical -
, O +
Ni B-Chemical -
, O +
Cr B-Chemical -
, O +
As B-Chemical +
and O +
Se B-Chemical -
) O -
, O +
PCBs B-Chemical +
and O +
organochlorine O +
pesticides O +
( O -
DDTs B-Chemical -
) O -
, O +
the O +
health O +
status O +
( O -
condition O +
factor O +
and O +
lipid O +
reserves O -
) O +
and O +
the O +
associated O +
transcriptional O +
response O +
in O +
liver O +
and O +
gill O +
tissues O +
for O +
genes O +
involved O +
in O +
metal O +
detoxification O +
( O -
metallothionein O -
, O +
MT O -
) O +
and O +
oxidative O +
metabolism O +
( O -
cytochrome O +
P4501A O -
, O +
CYP1A O -
) O +
of O +
xenobiotic O +
compounds O -
. O +

In O +
total O +
84 O +
resident O +
eels O +
originating O +
from O +
three O +
Belgian O +
river O +
basins O +
( O -
Scheldt O -
, O +
Meuse O +
and O +
Yzer O -
) O +
were O +
analyzed O +
along O +
with O +
five O +
unpolluted O +
aquaculture O +
samples O +
as O +
control O +
group O -
. O +

There O +
was O +
a O +
large O +
spatial O +
variation O +
in O +
individual O +
contaminant O +
intensity O +
and O +
profile O -
, O +
while O +
tissue O +
pollution O +
levels O +
were O +
strongly O +
and O +
negatively O +
associated O +
with O +
condition O +
indices O -
, O +
suggesting O +
an O +
important O +
impact O +
of O +
pollution O +
on O +
the O +
health O +
of O +
sub O -
- O -
adult O +
resident O +
eels O -
. O +

Gene O +
transcription O +
patterns O +
revealed O +
a O +
complex O +
response O +
mechanism O +
to O +
a O +
cocktail O +
of O +
pollutants O -
, O +
with O +
a O +
high O +
variation O +
at O +
low O +
pollution O +
levels O -
, O +
but O +
strongly O +
down O -
- O -
regulated O +
hepatic O +
and O +
gill O +
gene O +
transcription O +
in O +
highly O +
polluted O +
eels O -
. O +

Resident O +
eels O +
clearly O +
experience O +
a O +
high O +
pollution O +
burden O +
and O +
seem O +
to O +
show O +
a O +
dysfunctional O +
gene O +
transcription O +
regulation O +
of O +
detoxification O +
genes O +
at O +
higher O +
pollutant O +
levels O -
, O +
correlated O +
with O +
low O +
energy O +
reserves O +
and O +
condition O -
. O +

To O +
fully O +
understand O +
the O +
evolutionary O +
implications O +
of O +
pollutants O +
on O +
eel O +
reproductive O +
fitness O -
, O +
analyses O +
of O +
mature O +
migrating O +
eels O +
and O +
the O +
characterization O +
of O +
their O +
transcriptome O -
- O -
wide O +
gene O +
transcription O +
response O +
would O +
be O +
appropriate O +
to O +
unveil O +
the O +
complex O +
responses O +
associated O +
with O +
multiple O +
interacting O +
stressors O +
and O +
the O +
long O -
- O -
term O +
consequences O +
at O +
the O +
entire O +
species O +
level O -
. O +

In O +
the O +
meanwhile O -
, O +
jointly O +
monitoring O +
environmental O +
and O +
tissue O +
pollution O +
levels O +
at O +
a O +
European O +
scale O +
should O +
be O +
initiated O -
, O +
while O +
preserving O +
high O +
quality O +
habitats O +
to O +
increase O +
the O +
recovery O +
chance O +
of O +
European O +
eel O +
in O +
the O +
future O -
. O +

A O +
comparative O +
VCD O +
study O +
of O +
methyl B-Chemical +
mandelate I-Chemical +
in O +
methanol B-Chemical -
, O +
dimethyl B-Chemical +
sulfoxide I-Chemical -
, O +
and O +
chloroform B-Chemical -
: O +
explicit O +
and O +
implicit O +
solvation O +
models O -
. O +

Vibrational O +
absorption O +
( O -
VA O -
) O +
and O +
vibrational O +
circular O +
dichroism O +
( O -
VCD O -
) O +
spectra O +
of O +
methyl B-Chemical +
mandelate I-Chemical -
, O +
a O +
prototype O +
chiral O +
molecule O -
, O +
in O +
a O +
series O +
of O +
organic O +
solvents O -
, O +
namely O +
methanol B-Chemical +
( O -
MeOH B-Chemical -
- I-Chemical -
d I-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
) O -
, O +
dimethyl B-Chemical +
sulfoxide I-Chemical +
( O -
DMSO B-Chemical -
- I-Chemical -
d I-Chemical -
( I-Chemical -
6 I-Chemical -
) I-Chemical -
) O -
, O +
and O +
chloroform B-Chemical +
( O -
CDCl B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
) O -
, O +
have O +
been O +
measured O +
in O +
the O +
finger O +
print O +
region O +
from O +
1800 O +
to O +
1150 O +
cm O -
( O -
-1 O -
) O -
. O +

Implicit O +
solvation O +
models O +
in O +
the O +
form O +
of O +
polarizable O +
continuum O +
model O +
and O +
explicit O +
solvation O +
models O +
have O +
been O +
employed O +
independently O +
and O +
simultaneously O -
. O +

The O +
goal O +
is O +
to O +
evaluate O +
their O +
efficiencies O +
in O +
dealing O +
with O +
solvent O +
effects O +
in O +
each O +
solution O +
and O +
to O +
establish O +
a O +
general O +
strategy O +
to O +
adequately O +
account O +
for O +
effects O +
of O +
solvents O -
. O +

Molecular O +
dynamics O +
( O -
MD O -
) O +
simulation O +
and O +
radial O +
distribution O +
function O +
analysis O +
have O +
been O +
performed O +
to O +
aid O +
the O +
construction O +
of O +
the O +
explicit O +
solvation O +
models O -
. O +

Initial O +
geometry O +
searches O +
have O +
been O +
carried O +
out O +
at O +
the O +
B3LYP O -
/ O -
6 O -
- O -
31G O -
( O -
d O -
) O +
level O +
for O +
the O +
methyl B-Chemical +
mandelate I-Chemical +
monomer O +
and O +
its O +
explicit O +
1 O +
: O +
1 O +
and O +
1 O +
: O +
2 O +
solute O -
- O -
solvent O +
hydrogen B-Chemical -
- O -
bonded O +
complexes O -
. O +

B3LYP O -
/ O -
cc O -
- O -
pVTZ O +
has O +
been O +
used O +
for O +
all O +
the O +
final O +
geometry O +
optimizations O -
, O +
the O +
vibrational O +
frequency O -
, O +
VA O +
and O +
VCD O +
intensity O -
, O +
and O +
optical O +
rotation O +
dispersion O +
( O -
ORD O -
) O +
calculations O -
. O +

The O +
results O +
show O +
that O +
inclusion O +
of O +
solvent O +
explicitly O +
and O +
implicitly O +
at O +
the O +
same O +
time O +
has O +
significant O +
impacts O +
on O +
the O +
appearance O +
of O +
the O +
VA O +
and O +
VCD O +
spectra O -
, O +
and O +
is O +
crucial O +
for O +
reliable O +
spectral O +
assignments O +
when O +
solvents O +
are O +
capable O +
of O +
hydrogen B-Chemical -
- O -
bonding O +
interactions O +
with O +
solutes O -
. O +

When O +
no O +
strong O +
solvent O -
- O -
solute O +
hydrogen B-Chemical -
- O -
bonding O +
interactions O +
in O +
the O +
case O +
of O +
chloroform B-Chemical +
are O +
expected O -
, O +
the O +
gas O +
phase O +
monomer O +
model O +
is O +
adequate O +
for O +
spectral O +
interpretation O -
, O +
while O +
inclusion O +
of O +
implicit O +
solvation O +
improves O +
the O +
frequency O +
agreement O +
with O +
experiment O -
. O +

ORD O +
spectra O +
of O +
methyl B-Chemical +
mandelate I-Chemical +
in O +
the O +
aforementioned O +
solvents O +
at O +
different O +
concentrations O +
under O +
5 O +
excitation O +
wavelengths O +
have O +
also O +
been O +
measured O -
. O +

The O +
comparison O +
between O +
the O +
calculated O +
and O +
the O +
experimental O +
ORD O +
spectra O +
supports O +
the O +
conclusions O +
drawn O +
from O +
the O +
VA O +
and O +
VCD O +
investigations O -
. O +

Extremely O +
flexible O +
nanoscale O +
ultrathin O +
body O +
silicon B-Chemical +
integrated O +
circuits O +
on O +
plastic O -
. O +

In O +
recent O +
years O -
, O +
flexible O +
devices O +
based O +
on O +
nanoscale O +
materials O +
and O +
structures O +
have O +
begun O +
to O +
emerge O -
, O +
exploiting O +
semiconductor O +
nanowires O -
, O +
graphene B-Chemical -
, O +
and O +
carbon B-Chemical +
nanotubes O -
. O +

This O +
is O +
primarily O +
to O +
circumvent O +
the O +
existing O +
shortcomings O +
of O +
the O +
conventional O +
flexible O +
electronics O +
based O +
on O +
organic O +
and O +
amorphous O +
semiconductors O -
. O +

The O +
aim O +
of O +
this O +
new O +
class O +
of O +
flexible O +
nanoelectronics O +
is O +
to O +
attain O +
high O -
- O -
performance O +
devices O +
with O +
increased O +
packing O +
density O -
. O +

However O -
, O +
highly O +
integrated O +
flexible O +
circuits O +
with O +
nanoscale O +
transistors O +
have O +
not O +
yet O +
been O +
demonstrated O -
. O +

Here O -
, O +
we O +
show O +
nanoscale O +
flexible O +
circuits O +
on O +
60 O +
Å O +
thick O +
silicon B-Chemical -
, O +
including O +
functional O +
ring O +
oscillators O +
and O +
memory O +
cells O -
. O +

The O +
100-stage O +
ring O +
oscillators O +
exhibit O +
the O +
stage O +
delay O +
of O +
~16 O +
ps O +
at O +
a O +
power O +
supply O +
voltage O +
of O +
0.9 O +
V O -
, O +
the O +
best O +
reported O +
for O +
any O +
flexible O +
circuits O +
to O +
date O -
. O +

The O +
mechanical O +
flexibility O +
is O +
achieved O +
by O +
employing O +
the O +
controlled O +
spalling O +
technology O -
, O +
enabling O +
the O +
large O -
- O -
area O +
transfer O +
of O +
the O +
ultrathin O +
body O +
silicon B-Chemical +
devices O +
to O +
a O +
plastic O +
substrate O +
at O +
room O +
temperature O -
. O +

These O +
results O +
provide O +
a O +
simple O +
and O +
cost O -
- O -
effective O +
pathway O +
to O +
enable O +
ultralight O +
flexible O +
nanoelectronics O +
with O +
unprecedented O +
level O +
of O +
system O +
complexity O +
based O +
on O +
mainstream O +
silicon B-Chemical +
technology O -
. O +

Enhancement O +
of O +
the O +
water O +
solubility O +
of O +
flavone B-Chemical +
glycosides I-Chemical +
by O +
disruption O +
of O +
molecular O +
planarity O +
of O +
the O +
aglycone O +
moiety O -
. O +

Enhancement O +
of O +
the O +
water O +
solubility O +
by O +
disruption O +
of O +
molecular O +
planarity O +
has O +
recently O +
been O +
reviewed O +
as O +
a O +
feasible O +
approach O +
in O +
small O -
- O -
molecule O +
drug O +
discovery O +
programs O -
. O +

We O +
applied O +
this O +
strategy O +
to O +
some O +
natural O +
flavone B-Chemical +
glycosides I-Chemical -
, O +
especially O +
diosmin B-Chemical -
, O +
a O +
highly O +
insoluble O +
citroflavonoid B-Chemical +
prescribed O +
as O +
an O +
oral O +
phlebotropic O +
drug O -
. O +

Disruption O +
of O +
planarity O +
at O +
the O +
aglycone O +
moiety O +
by O +
3-bromination O +
or O +
chlorination O +
afforded O +
3-bromo- B-Chemical +
and I-Chemical +
3-chlorodiosmin I-Chemical -
, O +
displaying O +
a O +
dramatic O +
solubility O +
increase O +
compared O +
with O +
the O +
parent O +
compound O -
. O +

Interplay O +
between O +
structure O +
and O +
relaxations O +
in O +
perfluorosulfonic B-Chemical +
acid I-Chemical +
proton O +
conducting O +
membranes O -
. O +

This O +
study O +
focuses O +
on O +
changes O +
in O +
the O +
structure O +
of O +
ionomer O +
membranes O -
, O +
provided O +
by O +
the O +
3 O -
M O +
Fuel O +
Cells O +
Component O +
Group O -
, O +
as O +
a O +
function O +
of O +
the O +
equivalent O +
weight O +
( O -
EW O -
) O +
and O +
the O +
relationship O +
between O +
the O +
structure O +
and O +
the O +
properties O +
of O +
the O +
membrane O -
. O +

Wide O -
- O -
angle O +
X O -
- O -
ray O +
diffraction O +
results O +
showed O +
evidence O +
of O +
both O +
non O -
- O -
crystalline O +
and O +
crystalline O +
ordered O +
hydrophobic O +
regions O +
in O +
all O +
the O +
EW O +
membranes O +
except O +
the O +
700 O +
EW O +
membrane O -
. O +

The O +
spectral O +
changes O +
evident O +
in O +
the O +
vibrational O +
spectra O +
of O +
the O +
3 O -
M O +
membranes O +
can O +
be O +
associated O +
with O +
two O +
major O +
phenomena O -
: O +
( O -
1 O -
) O +
dissociation O +
of O +
the O +
proton O +
from O +
the O +
sulfonic B-Chemical +
acid I-Chemical +
groups O +
even O +
in O +
the O +
presence O +
of O +
small O +
amounts O +
of O +
water O -
; O +
and O +
( O -
2 O -
) O +
changes O +
in O +
the O +
conformation O +
or O +
the O +
degree O +
of O +
crystallinity O +
of O +
the O +
poly B-Chemical -
( I-Chemical -
tetrafluoroethylene I-Chemical -
) I-Chemical +
hydrophobic O +
domains O +
both O +
as O +
a O +
function O +
of O +
EW O +
and O +
membrane O +
water O +
content O -
. O +

All O +
the O +
membranes O -
, O +
regardless O +
of O +
EW O -
, O +
are O +
thermally O +
stable O +
up O +
to O +
360 O +
° O -
C O -
. O +

The O +
wet O +
membranes O +
have O +
conductivities O +
between O +
7 O +
and O +
20 O +
mS O -
/ O -
cm O +
at O +
125 O +
° O -
C O -
. O +

In O +
this O +
condition O -
, O +
the O +
conductivity O +
values O +
follow O +
VTF O +
behavior O -
, O +
which O +
suggests O +
that O +
the O +
proton O +
migration O +
occurs O +
via O +
proton O +
exchange O +
processes O +
between O +
delocalization O +
bodies O +
( O -
DBs O -
) O +
that O +
are O +
facilitated O +
by O +
the O +
dynamics O +
of O +
the O +
host O +
polymer O -
. O +

The O +
conductivity O +
along O +
the O +
interface O +
between O +
the O +
hydrophobic O +
and O +
hydrophilic O +
domains O +
makes O +
a O +
larger O +
contribution O +
in O +
the O +
smaller O +
EW O +
membranes O +
likely O +
due O +
to O +
the O +
existence O +
of O +
a O +
greater O +
number O +
of O +
interfaces O +
in O +
the O +
membrane O -
. O +

The O +
larger O +
crystalline O +
domains O +
present O +
in O +
the O +
higher O +
EW O +
membranes O +
provide O +
percolation O +
pathways O +
for O +
charge O +
migration O +
between O +
DBs O -
, O +
which O +
reduces O +
the O +
probability O +
of O +
charge O +
transfer O +
along O +
the O +
interface O -
. O +

Therefore O -
, O +
at O +
higher O +
EWs O +
although O +
there O +
is O +
charge O +
migration O +
along O +
the O +
interface O +
within O +
the O +
hydrophobic O -
- O -
hydrophilic O +
domains O -
, O +
the O +
exchange O +
of O +
protons O +
between O +
different O +
DBs O +
is O +
likely O +
the O +
rate O -
- O -
limiting O +
step O +
of O +
the O +
overall O +
conduction O +
process O -
. O +

Phase O +
behavior O +
and O +
molecular O +
dynamics O +
simulation O +
studies O +
of O +
new O +
aqueous O +
two O -
- O -
phase O +
separation O +
systems O +
induced O +
by O +
HEPES O +
buffer O -
. O +

Here O -
, O +
for O +
the O +
first O +
time O -
, O +
we O +
show O +
that O +
with O +
addition O +
of O +
a O +
biological O +
buffer O -
, O +
4- B-Chemical -
( I-Chemical -
2-hydroxyethyl I-Chemical -
) I-Chemical -
piperazine-1-ethanesulfonic I-Chemical +
acid I-Chemical +
( O -
HEPES B-Chemical -
) O -
, O +
into O +
aqueous O +
solutions O +
of O +
tetrahydrofuran B-Chemical +
( O -
THF B-Chemical -
) O -
, O +
1,3-dioxolane B-Chemical -
, I-Chemical +
1,4-dioxane I-Chemical -
, I-Chemical +
1-propanol I-Chemical -
, O +
2-propanol B-Chemical -
, O +
tert B-Chemical -
- I-Chemical -
butanol I-Chemical -
, O +
acetonitrile B-Chemical -
, O +
or O +
acetone B-Chemical -
, O +
the O +
organic O +
solvent O +
can O +
be O +
excluded O +
from O +
water O +
to O +
form O +
a O +
new O +
liquid O +
phase O -
. O +

The O +
phase O +
diagrams O +
have O +
been O +
determined O +
at O +
ambient O +
temperature O -
. O +

In O +
order O +
to O +
understand O +
why O +
and O +
how O +
a O +
zwitterion O +
solute O +
( O -
HEPES B-Chemical -
) O +
induced O +
phase O +
separation O +
of O +
the O +
investigated O +
systems O -
, O +
molecular O +
dynamics O +
( O -
MD O -
) O +
simulation O +
studies O +
are O +
performed O +
for O +
HEPES B-Chemical +
+ O +
water O +
+ O +
THF B-Chemical +
system O -
. O +

The O +
MD O +
simulations O +
were O +
conducted O +
for O +
the O +
aqueous O +
mixtures O +
with O +
12 O +
different O +
compositions O -
. O +

The O +
reliability O +
of O +
the O +
simulation O +
results O +
of O +
HEPES B-Chemical +
in O +
pure O +
water O +
and O +
beyond O +
the O +
phase O +
separation O +
mixtures O +
was O +
justified O +
by O +
comparing O +
the O +
densities O +
obtained O +
from O +
MD O +
with O +
the O +
experimental O +
values O -
. O +

The O +
simulation O +
results O +
of O +
HEPES B-Chemical +
in O +
pure O +
THF B-Chemical +
and O +
in O +
a O +
composition O +
inside O +
the O +
phase O +
separation O +
region O +
were O +
justified O +
qualitatively O -
. O +

Interestingly O -
, O +
all O +
HEPES B-Chemical +
molecules O +
entirely O +
aggregated O +
in O +
pure O +
THF B-Chemical -
. O +

This O +
reveals O +
that O +
HEPES B-Chemical +
is O +
insoluble O +
in O +
pure O +
THF B-Chemical -
, O +
which O +
is O +
consistent O +
with O +
the O +
experimental O +
results O -
. O +

Even O +
more O +
interestingly O -
, O +
the O +
MD O +
simulation O +
for O +
the O +
mixture O +
with O +
composition O +
inside O +
the O +
phase O +
separation O +
region O +
showed O +
the O +
formation O +
of O +
two O +
phases O -
. O +

The O +
THF B-Chemical +
molecules O +
are O +
squeezed O +
out O +
from O +
the O +
water O +
network O +
into O +
a O +
new O +
liquid O +
phase O -
. O +

The O +
hydrogen O +
bonds O +
( O -
HBs O -
) O -
, O +
HB O +
lifetime O -
, O +
HB O +
Gibbs O +
energy O +
( O -
ΔG O -
) O -
, O +
radial O +
distribution O +
functions O +
( O -
RDFs O -
) O -
, O +
coordination O +
numbers O +
( O -
CNs O -
) O -
, O +
electrostatic O +
interactions O -
, O +
and O +
the O +
van O +
der O +
Waals O +
interactions O +
between O +
the O +
different O +
species O +
have O +
been O +
analyzed O -
. O +

Further O -
, O +
MD O +
simulations O +
for O +
the O +
other O +
phase O +
separation O +
systems O +
by O +
choosing O +
a O +
composition O +
inside O +
the O +
two O +
liquids O +
region O +
for O +
each O +
system O +
were O +
also O +
simulated O -
. O +

Our O +
findings O +
will O +
therefore O +
pave O +
the O +
way O +
for O +
designing O +
new O +
benign O +
separation O +
auxiliary O +
agents O -
. O +

Low O -
- O -
noise O +
nano O +
superconducting O +
quantum O +
interference O +
device O +
operating O +
in O +
Tesla O +
magnetic O +
fields O -
. O +

Superconductivity O +
in O +
the O +
cuprate O +
YBa B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Cu I-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
O I-Chemical -
( I-Chemical -
7 I-Chemical -
) I-Chemical +
( O -
YBCO B-Chemical -
) O +
persists O +
up O +
to O +
huge O +
magnetic O +
fields O +
( O -
B O -
) O +
up O +
to O +
several O +
tens O +
of O +
Teslas O -
, O +
and O +
sensitive O +
direct O +
current O +
( O -
dc O -
) O +
superconducting O +
quantum O +
interference O +
devices O +
( O -
SQUIDs O -
) O +
can O +
be O +
realized O +
in O +
epitaxially O +
grown O +
YBCO B-Chemical +
films O +
by O +
using O +
grain O +
boundary O +
Josephson O +
junctions O +
( O -
GBJs O -
) O -
. O +

Here O +
we O +
present O +
the O +
realization O +
of O +
high O -
- O -
quality O +
YBCO B-Chemical +
nanoSQUIDs O -
, O +
patterned O +
by O +
focused O +
ion O +
beam O +
milling O -
. O +

We O +
demonstrate O +
low O -
- O -
noise O +
performance O +
of O +
such O +
a O +
SQUID O +
up O +
to O +
B O +
= O +
1 O +
T O +
applied O +
parallel O +
to O +
the O +
plane O +
of O +
the O +
SQUID O +
loop O +
at O +
the O +
temperature O +
T O +
= O +
4.2 O +
K. O +
The O +
GBJs O +
are O +
shunted O +
by O +
a O +
thin O +
Au B-Chemical +
layer O +
to O +
provide O +
nonhysteretic O +
current O +
voltage O +
characteristics O -
, O +
and O +
the O +
SQUID O +
incorporates O +
a O +
90 O +
nm O +
wide O +
constriction O +
which O +
is O +
used O +
for O +
on O -
- O -
chip O +
modulation O +
of O +
the O +
magnetic O +
flux O +
through O +
the O +
SQUID O +
loop O -
. O +

The O +
white O +
flux O +
noise O +
of O +
the O +
device O +
increases O +
only O +
slightly O +
from O +
1.3 O +
μΦ O -
( O -
0 O -
) O -
/ O -
( O -
Hz O -
) O -
( O -
1 O -
/ O -
2 O -
) O +
at O +
B O +
= O +
0 O +
to O +
2.3 O +
μΦ O -
( O -
0 O -
) O -
/ O -
( O -
Hz O -
) O -
) O -
( O -
1 O -
/ O -
2 O -
) O +
at O +
1 O +
T. O +
Assuming O +
that O +
a O +
point O -
- O -
like O +
magnetic O +
particle O +
with O +
magnetization O +
in O +
the O +
plane O +
of O +
the O +
SQUID O +
loop O +
is O +
placed O +
directly O +
on O +
top O +
of O +
the O +
constriction O +
and O +
taking O +
into O +
account O +
the O +
geometry O +
of O +
the O +
SQUID O -
, O +
we O +
calculate O +
a O +
spin O +
sensitivity O +
S O -
( O -
μ O -
) O -
( O -
1 O -
/ O -
2 O -
) O +
= O +
62 O +
μ O -
( O -
B O -
) O -
/ O -
( O -
Hz O -
) O -
) O -
( O -
1 O -
/ O -
2 O -
) O +
at O +
B O +
= O +
0 O +
and O +
110 O +
μ O -
( O -
B O -
) O -
/ O -
( O -
Hz O -
) O -
) O -
( O -
1 O -
/ O -
2 O -
) O +
at O +
1 O +
T. O +
The O +
demonstration O +
of O +
low O +
noise O +
of O +
such O +
a O +
SQUID O +
in O +
Tesla O +
fields O +
is O +
a O +
decisive O +
step O +
toward O +
utilizing O +
the O +
full O +
potential O +
of O +
ultrasensitive O +
nanoSQUIDs O +
for O +
direct O +
measurements O +
of O +
magnetic O +
hysteresis O +
curves O +
of O +
magnetic O +
nanoparticles O +
and O +
molecular O +
magnets O -
. O +

Role O +
of O +
pharmacogenetics O +
in O +
busulfan B-Chemical -
/ O -
cyclophosphamide B-Chemical +
conditioning O +
therapy O +
prior O +
to O +
hematopoietic O +
stem O +
cell O +
transplantation O -
. O +

Hematopoietic O +
stem O +
cell O +
transplantation O +
( O -
HSCT O -
) O +
is O +
a O +
curative O +
treatment O +
for O +
several O +
malignant O +
and O +
nonmalignant O +
disorders O -
. O +

Busulfan B-Chemical +
( O -
Bu O -
) O +
and O +
cyclophosphamide B-Chemical +
( O -
Cy O -
) O +
are O +
the O +
most O +
commonly O +
used O +
alkylators O +
in O +
high O -
- O -
dose O +
pretransplant O +
conditioning O +
for O +
HSCT O -
; O +
a O +
treatment O +
that O +
is O +
correlated O +
with O +
drug O -
- O -
related O +
toxicity O +
and O +
relapse O -
. O +

Pharmacogenetic O +
investigations O +
have O +
shown O +
that O +
CYP450 O -
, O +
as O +
well O +
as O +
aldehyde B-Chemical +
dehydrogenase O -
, O +
are O +
clearly O +
involved O +
with O +
Cy O +
metabolism O +
and O +
are O +
associated O +
with O +
altered O +
treatment O +
response O -
, O +
Cy O +
metabolism O +
and O +
the O +
unique O +
stem O -
- O -
cell O +
sparing O +
capacity O -
. O +

Moreover O -
, O +
glutathione B-Chemical -
- B-Chemical -
S O -
- O -
transferase O +
isoenzymes O +
have O +
been O +
associated O +
with O +
cellular O +
outward O +
transport O +
of O +
various O +
alkylating O +
agents O -
, O +
including O +
Cy O +
metabolites O -
, O +
melphalan B-Chemical -
, O +
Bu O +
and O +
chlorambucil B-Chemical -
. O +

A O +
shift O +
from O +
genetic O -
- O -
based O +
studies O +
to O +
whole O -
- O -
genome O -
- O -
based O +
investigations O +
of O +
Cy- O +
and O +
Bu O -
- O -
associated O +
markers O +
may O +
contribute O +
to O +
personalizing O +
the O +
conditioning O +
therapy O +
and O +
enhancing O +
the O +
clinical O +
outcome O +
of O +
HSCT O -
. O +

Vasorelaxing O +
effects O +
and O +
inhibition O +
of O +
nitric B-Chemical +
oxide I-Chemical +
in O +
macrophages O +
by O +
new O +
iron B-Chemical -
- O -
containing O +
carbon B-Chemical +
monoxide I-Chemical -
- O -
releasing O +
molecules O +
( O -
CO O -
- O -
RMs O -
) O -
. O +

Carbon B-Chemical +
monoxide I-Chemical -
- O -
releasing O +
molecules O +
( O -
CO B-Chemical -
- O -
RMs O -
) O +
are O +
a O +
class O +
of O +
organometallo B-Chemical +
carbonyl I-Chemical +
complexes O +
capable O +
of O +
delivering O +
controlled O +
quantities O +
of O +
CO B-Chemical +
gas O +
to O +
cells O +
and O +
tissues O +
thus O +
exerting O +
a O +
broad O +
spectrum O +
of O +
pharmacological O +
effects O -
. O +

Here O +
we O +
report O +
on O +
the O +
chemical O +
synthesis O -
, O +
CO B-Chemical +
releasing O +
properties O -
, O +
cytotoxicity O +
profile O +
and O +
pharmacological O +
activities O +
of O +
four O +
novel O +
structurally O +
related O +
iron B-Chemical -
- I-Chemical -
allyl I-Chemical +
carbonyls I-Chemical -
. O +

The O +
major O +
difference O +
among O +
the O +
new O +
CO B-Chemical -
- O -
RMs O +
tested O +
was O +
that O +
three O +
compounds O +
( O -
CORM-307 B-Chemical -
, O +
CORM-308 B-Chemical +
and O +
CORM-314 B-Chemical -
) O +
were O +
soluble O +
in O +
dimethylsulfoxide B-Chemical +
( O -
DMSO B-Chemical -
) O -
, O +
whereas O +
a O +
fourth O +
one O +
( O -
CORM-319 B-Chemical -
) O +
was O +
rendered O +
water O -
- O -
soluble O +
by O +
reacting O +
the O +
iron B-Chemical -
- I-Chemical -
carbonyl I-Chemical +
with O +
hydrogen B-Chemical +
tetrafluoroborate I-Chemical -
. O +

We O +
found O +
that O +
despite O +
the O +
fact O +
all O +
compounds O +
liberated O +
CO B-Chemical -
, O +
CO B-Chemical -
- O -
RMs O +
soluble O +
in O +
DMSO B-Chemical +
caused O +
a O +
more O +
pronounced O +
toxic O +
effect O +
both O +
in O +
vascular O +
and O +
inflammatory O +
cells O +
as O +
well O +
as O +
in O +
isolated O +
vessels O -
. O +

More O +
specifically O -
, O +
iron B-Chemical +
carbonyls I-Chemical +
soluble O +
in O +
DMSO B-Chemical +
released O +
CO B-Chemical +
with O +
a O +
fast O +
kinetic O +
and O +
displayed O +
a O +
marked O +
cytotoxic O +
effect O +
in O +
smooth O +
muscle O +
cells O +
and O +
RAW O +
247.6 O +
macrophages O +
despite O +
exerting O +
a O +
rapid O +
and O +
pronounced O +
vasorelaxation O +
ex O +
vivo O -
. O +

In O +
contrast O -
, O +
CORM-319 B-Chemical +
that O +
is O +
soluble O +
in O +
water O +
and O +
liberated O +
CO B-Chemical +
with O +
a O +
slower O +
rate O -
, O +
preserved O +
smooth O +
muscle O +
cell O +
viability O -
, O +
relaxed O +
aortic O +
tissue O +
and O +
exerted O +
a O +
significant O +
anti O -
- O -
inflammatory O +
effect O +
in O +
macrophages O +
challenged O +
with O +
endotoxin O -
. O +

These O +
data O +
suggest O +
that O +
iron B-Chemical +
carbonyls I-Chemical +
can O +
be O +
used O +
as O +
scaffolds O +
for O +
the O +
design O +
and O +
synthesis O +
of O +
pharmacologically O +
active O +
CO B-Chemical -
- O -
RMs O +
and O +
indicate O +
that O +
increasing O +
water O +
solubility O +
and O +
controlling O +
the O +
rate O +
of O +
CO B-Chemical +
release O +
are O +
important O +
parameters O +
for O +
limiting O +
their O +
potential O +
toxic O +
effects O -
. O +

Capture O +
and O +
stimulated O +
release O +
of O +
circulating O +
tumor O +
cells O +
on O +
polymer O -
- O -
grafted O +
silicon B-Chemical +
nanostructures O -
. O +

A O +
platform O +
for O +
capture O +
and O +
release O +
of O +
circulating O +
tumor O +
cells O +
is O +
demonstrated O +
by O +
utilizing O +
polymer O +
grafted O +
silicon B-Chemical +
nanowires O -
. O +

In O +
this O +
platform O -
, O +
integration O +
of O +
ligand O -
- O -
receptor O +
recognition O -
, O +
nanostructure O +
amplification O -
, O +
and O +
thermal O +
responsive O +
polymers O +
enables O +
a O +
highly O +
efficient O +
and O +
selective O +
capture O +
of O +
cancer O +
cells O -
. O +

Subsequently O -
, O +
these O +
captured O +
cells O +
are O +
released O +
upon O +
a O +
physical O +
stimulation O +
with O +
outstanding O +
cell O +
viability O -
. O +

Nanoscale O +
thermomechanics O +
of O +
wear O -
- O -
resilient O +
polymeric O +
bilayer O +
systems O -
. O +

We O +
explore O +
the O +
effect O +
of O +
an O +
ultrathin O +
elastic O +
coating O +
to O +
optimize O +
the O +
mechanical O +
stability O +
of O +
an O +
underlying O +
polymer O +
film O +
for O +
nanoscale O +
applications O -
. O +

The O +
coating O +
consists O +
of O +
a O +
several O +
nanometer O +
thin O +
plasma O -
- O -
polymerized O +
norbornene B-Chemical +
layer O -
. O +

Scanning O +
probes O +
are O +
used O +
to O +
characterize O +
the O +
system O +
in O +
terms O +
of O +
shear O -
- O -
force O -
- O -
induced O +
wear O +
and O +
thermally O +
assisted O +
indentation O -
. O +

The O +
layer O +
transforms O +
a O +
weakly O +
performing O +
polystyrene B-Chemical +
film O +
into O +
a O +
highly O +
wear O -
- O -
resistive O +
system O -
, O +
ideal O +
for O +
high O -
- O -
density O +
and O +
low O -
- O -
power O +
data O +
storage O +
applications O -
. O +

The O +
result O +
can O +
be O +
understood O +
from O +
the O +
indentation O +
characteristics O +
with O +
a O +
hot O +
and O +
sharp O +
indenter O +
tip O -
. O +

The O +
latter O +
gives O +
rise O +
to O +
a O +
deformation O +
mode O +
in O +
the O +
fully O +
plastic O +
regime O -
, O +
enabling O +
a O +
simple O +
interpretation O +
of O +
the O +
results O -
. O +

The O +
softening O +
transition O +
and O +
the O +
yield O +
stress O +
of O +
the O +
system O +
on O +
a O +
microsecond O +
time O +
scale O +
and O +
a O +
nanometer O +
size O +
scale O +
were O +
obtained O -
. O +

We O +
show O +
that O +
the O +
plastic O +
deformation O +
is O +
governed O +
by O +
yielding O +
in O +
the O +
polystyrene B-Chemical +
sublayer O -
, O +
which O +
renders O +
the O +
overall O +
system O +
soft O +
for O +
plastic O +
deformation O -
. O +

The O +
ultrathin O +
protection O +
layer O +
contributes O +
as O +
an O +
elastic O +
skin O -
, O +
which O +
shields O +
part O +
of O +
the O +
temperature O +
and O +
pressure O +
and O +
enables O +
the O +
high O +
wear O +
resistance O +
against O +
lateral O +
forces O -
. O +

Moreover O -
, O +
the O +
method O +
of O +
probing O +
polymers O +
at O +
microsecond O +
and O +
nanometer O +
size O +
scales O +
opens O +
up O +
new O +
opportunities O +
for O +
studying O +
polymer O +
physics O +
in O +
a O +
largely O +
unexplored O +
regime O -
. O +

Thus O -
, O +
we O +
find O +
softening O +
temperatures O +
of O +
more O +
than O +
100 O +
° O -
C O +
above O +
the O +
polystyrene B-Chemical +
glass O +
transition O -
, O +
which O +
implies O +
that O +
for O +
the O +
short O +
interaction O +
time O +
scales O +
the O +
glassy O +
state O +
of O +
the O +
polymer O +
is O +
preserved O +
up O +
to O +
this O +
temperature O -
. O +

Aspartic O +
protease O +
inhibitors O -
: O +
effective O +
drugs O +
against O +
the O +
human O +
fungal O +
pathogen O +
Candida O +
albicans O -
. O +

Candida O +
albicans O +
can O +
invade O +
humans O +
and O +
may O +
lead O +
to O +
mucosal O +
and O +
skin O +
infections O +
or O +
to O +
deep O -
- O -
seated O +
mycoses O +
of O +
almost O +
all O +
inner O +
organs O -
, O +
especially O +
in O +
immunocompromised O +
patients O -
. O +

In O +
this O +
context O -
, O +
both O +
the O +
host O +
immune O +
status O +
and O +
the O +
ability O +
of O +
C. O +
albicans O +
to O +
modulate O +
the O +
expression O +
of O +
its O +
virulence O +
factors O +
are O +
relevant O +
aspects O +
that O +
drive O +
the O +
candidal O +
susceptibility O +
or O +
resistance O -
; O +
in O +
this O +
last O +
case O -
, O +
culminating O +
in O +
the O +
establishment O +
of O +
successful O +
infection O +
known O +
as O +
candidiasis O -
. O +

C. O +
albicans O +
possesses O +
a O +
potent O +
armamentarium O +
consisting O +
of O +
several O +
virulence O +
molecules O +
that O +
help O +
the O +
fungal O +
cells O +
to O +
escape O +
from O +
the O +
host O +
immune O +
responses O -
. O +

There O +
is O +
no O +
doubt O +
that O +
the O +
secretion O +
of O +
aspartic O +
proteases O -
, O +
designated O +
as O +
Saps O -
, O +
is O +
one O +
of O +
the O +
major O +
virulence O +
attributes O +
produced O +
by O +
C. O +
albicans O +
cells O -
, O +
since O +
these O +
hydrolytic O +
enzymes O +
participate O +
in O +
a O +
wide O +
range O +
of O +
fungal O +
physiological O +
processes O +
as O +
well O +
as O +
in O +
different O +
facets O +
of O +
the O +
fungal O -
- O -
host O +
interactions O -
. O +

For O +
these O +
reasons O -
, O +
Saps O +
clearly O +
hold O +
promise O +
as O +
new O +
potential O +
drug O +
targets O -
. O +

Corroborating O +
this O +
hypothesis O -
, O +
the O +
introduction O +
of O +
anti O -
- O -
human O +
immunodeficiency O +
virus O +
drugs O +
of O +
the O +
aspartic O +
protease O +
inhibitor O -
- O -
type O +
( O -
HIV O +
PIs O -
) O +
have O +
emerged O +
as O +
new O +
agents O +
for O +
the O +
inhibition O +
of O +
Saps O -
. O +

The O +
introduction O +
of O +
HIV O +
PIs O +
has O +
revolutionized O +
the O +
treatment O +
of O +
HIV O +
disease O -
, O +
reducing O +
the O +
opportunistic O +
infections O -
, O +
especially O +
candidiasis O -
. O +

The O +
attenuation O +
of O +
candidal O +
infections O +
in O +
HIV O -
- O -
infected O +
individuals O +
might O +
not O +
solely O +
has O +
not O +
only O +
resulted O +
from O +
improved O +
immunological O +
status O -
, O +
but O +
also O +
as O +
a O +
result O +
of O +
direct O +
inhibition O +
of O +
C. O +
albicans O +
Saps O +
as O +
well O +
as O +
the O +
blockage O +
of O +
several O +
biological O +
processes O +
controlled O +
by O +
these O +
proteolytic O +
enzymes O -
. O +

The O +
present O +
article O +
will O +
discuss O +
the O +
updates O +
on O +
the O +
functional O +
implications O +
of O +
HIV O +
PIs O +
on O +
the O +
development O +
of O +
candidiasis O -
. O +

Optical O +
activity O +
of O +
achiral O +
ligand O +
SCH3 B-Chemical +
adsorbed O +
on O +
achiral O +
Ag55 B-Chemical +
clusters O -
: O +
relationship O +
between O +
adsorption O +
site O +
and O +
circular O +
dichroism O -
. O +

The O +
electronic O +
circular O +
dichroism O +
( O -
CD O -
) O +
spectra O +
of O +
a O +
methyl B-Chemical -
- I-Chemical -
thiol I-Chemical +
adsorbed O +
at O +
different O +
sites O +
on O +
an O +
icosahedral O +
silver B-Chemical +
nanoparticle O +
is O +
studied O +
by O +
using O +
time O -
- O -
perturbed O +
density O +
functional O +
theory O -
. O +

Despite O +
that O +
separately O +
molecule O +
and O +
nanoparticle O +
are O +
achiral O +
and O +
consequently O +
optically O +
inactive O -
, O +
the O +
Ag B-Chemical -
( I-Chemical -
55 I-Chemical -
) I-Chemical -
-SCH I-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical +
compound O +
emerges O +
with O +
a O +
new O +
symmetry O -
, O +
which O +
may O +
be O +
chiral O +
or O +
not O +
depending O +
on O +
the O +
adsorption O +
site O +
and O +
orientation O +
of O +
the O +
molecule O -
. O +

It O +
is O +
found O +
that O +
chirality O +
is O +
favored O +
when O +
the O +
thiol B-Chemical +
is O +
adsorbed O +
between O +
two O +
atoms O +
of O +
different O +
coordination O +
number O -
. O +

Chiral O +
compounds O +
have O +
characteristic O +
CD O +
spectra O +
in O +
the O +
UV O -
- O -
visible O +
region O -
, O +
where O +
Ag B-Chemical -
( I-Chemical -
55 I-Chemical -
) I-Chemical +
shows O +
optical O +
absorption O +
but O +
SCH B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical +
does O +
not O -
; O +
revealing O +
that O +
highly O +
degenerated O +
molecular O -
- O -
like O +
electronic O +
states O +
of O +
Ag B-Chemical -
( I-Chemical -
55 I-Chemical -
) I-Chemical +
are O +
modified O +
by O +
the O +
presence O +
of O +
the O +
molecule O +
inducing O +
optical O +
activity O -
. O +

It O +
is O +
concluded O +
that O +
CD O +
line O -
- O -
shapes O +
and O +
magnitude O +
strongly O +
depend O +
on O +
the O +
site O +
where O +
the O +
adsorption O +
takes O +
place O -
, O +
while O +
its O +
intensity O +
is O +
modulated O +
by O +
the O +
molecule O +
orientation O -
. O +

Surfactant O -
- O -
Assisted O +
Assembly O +
of O +
Fullerene B-Chemical +
( O -
C B-Chemical -
( I-Chemical -
60 I-Chemical -
) I-Chemical -
) O +
Nanorods O +
and O +
Nanotubes O +
Formed O +
at O +
a O +
Liquid O -
- O -
Liquid O +
Interface O -
. O +

Herein O +
we O +
report O +
the O +
surfactant O -
- O -
triggered O +
assembly O +
of O +
fullerene B-Chemical +
( O -
C B-Chemical -
( I-Chemical -
60 I-Chemical -
) I-Chemical -
) O +
into O +
3D O +
flowerlike O +
microcrystals O +
at O +
the O +
liquid O -
- O -
liquid O +
interface O -
. O +

C B-Chemical -
( I-Chemical -
60 I-Chemical -
) I-Chemical +
crystals O +
were O +
grown O +
using O +
a O +
liquid O -
- O -
liquid O +
interfacial O +
precipitation O +
( O -
LLIP O -
) O +
method O +
by O +
layering O +
surfactant O +
solution O +
in O +
butanol B-Chemical +
with O +
a O +
saturated O +
solution O +
of O +
C B-Chemical -
( I-Chemical -
60 I-Chemical -
) I-Chemical +
in O +
benzene B-Chemical -
. O +

In O +
the O +
LLIP O +
method O -
, O +
it O +
is O +
suggested O +
that O +
the O +
crystal O +
formation O +
mechanism O +
is O +
driven O +
by O +
supersaturation O +
related O +
to O +
the O +
low O +
C B-Chemical -
( I-Chemical -
60 I-Chemical -
) I-Chemical +
solubility O +
in O +
alcohol O -
. O +

We O +
found O +
that O +
the O +
dimensions O +
of O +
the O +
synthesized O +
C B-Chemical -
( I-Chemical -
60 I-Chemical -
) I-Chemical +
flowers O +
depend O +
on O +
the O +
concentration O +
and O +
surfactant O +
type O -
. O +

In O +
the O +
absence O +
of O +
surfactant O +
( O -
i.e. O -
, O +
in O +
the O +
butanol B-Chemical -
/ O -
benzene B-Chemical +
system O -
) O -
, O +
1D O +
C B-Chemical -
( I-Chemical -
60 I-Chemical -
) I-Chemical +
nanowhiskers O +
( O -
nanorods O -
) O +
and O +
C B-Chemical -
( I-Chemical -
60 I-Chemical -
) I-Chemical +
nanotubes O +
( O -
diameter O +
400 O +
nm-2 O +
μm O +
and O +
length O +
5 O -
- O -
20 O +
μm O -
) O +
are O +
obtained O -
. O +

However O -
, O +
when O +
surfactants O +
are O +
incorporated O +
into O +
the O +
system O +
flowerlike O +
microcrystals O +
consisting O +
of O +
C B-Chemical -
( I-Chemical -
60 I-Chemical -
) I-Chemical +
nanotubes O +
are O +
observed O -
. O +

For O +
instance O -
, O +
crystals O +
grown O +
at O +
the O +
interface O +
of O +
a O +
0.01 O -
% O +
diglycerol B-Chemical +
monolaurate I-Chemical +
( O -
C B-Chemical -
( I-Chemical -
12 I-Chemical -
) I-Chemical -
G I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
) O +
nonionic O +
surfactant O +
in O +
butanol B-Chemical +
with O +
benzene B-Chemical +
lead O +
to O +
the O +
formation O +
of O +
flower O -
- O -
shaped O +
microcrystals O +
of O +
average O +
sizes O +
in O +
the O +
range O +
of O +
10 O -
- O -
35 O +
μm O -
. O +

To O +
the O +
best O +
of O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
example O +
of O +
the O +
surfactant O -
- O -
assisted O +
assembly O +
of O +
C B-Chemical -
( I-Chemical -
60 I-Chemical -
) I-Chemical +
crystals O -
. O +

X O -
- O -
ray O +
diffraction O +
( O -
XRD O -
) O +
and O +
transmission O +
electron O +
microscopy O +
( O -
TEM O -
) O +
measurements O +
have O +
shown O +
that O +
fullerene B-Chemical +
flowers O +
have O +
a O +
hexagonal O +
structure O +
with O +
cell O +
dimensions O +
of O +
a O +
= O +
2.539 O +
nm O +
and O +
c O +
= O +
1.021 O +
nm O -
, O +
which O +
differ O +
from O +
that O +
of O +
pristine O +
C B-Chemical -
( I-Chemical -
60 I-Chemical -
) I-Chemical -
. O +

Mixtures O +
of O +
flower O -
- O -
shaped O +
C B-Chemical -
( I-Chemical -
60 I-Chemical -
) I-Chemical +
crystals O +
and O +
free O -
- O -
standing O +
C B-Chemical -
( I-Chemical -
60 I-Chemical -
) I-Chemical +
nanotubes O +
are O +
found O +
in O +
the O +
0.1 O -
% O +
C B-Chemical -
( I-Chemical -
12 I-Chemical -
) I-Chemical -
G I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
/ O -
butanol B-Chemical +
system O -
. O +

However O -
, O +
clusters O +
or O +
giant O +
aggregates O +
of O +
nanowhiskers O +
lacking O +
any O +
specific O +
shape O +
are O +
observed O +
in O +
the O +
1 O -
% O +
C B-Chemical -
( I-Chemical -
12 I-Chemical -
) I-Chemical -
G I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
/ O -
butanol O +
system O +
although O +
these O +
crystals O +
exhibit O +
hexagonal O +
close O -
- O -
packed O +
structures O -
. O +

Flower O -
- O -
shaped O +
C B-Chemical -
( I-Chemical -
60 I-Chemical -
) I-Chemical +
microcrystals O +
are O +
also O +
observed O +
with O +
anionic O +
surfactants O +
cetyltrimethylammonium B-Chemical +
bromide I-Chemical +
( O -
CTAB B-Chemical -
) O +
and O +
cetyltrimethylammonium B-Chemical +
chloride I-Chemical +
( O -
CTAC B-Chemical -
) O -
. O +

C B-Chemical -
( I-Chemical -
60 I-Chemical -
) I-Chemical +
flowers O +
obtained O +
from O +
0.01 O -
% O +
CTAB B-Chemical +
and O +
0.01 O -
% O +
CTAC B-Chemical +
also O +
exhibit O +
hexagonal O +
structures O +
with O +
cell O +
dimensions O +
of O +
a O +
= O +
2.329 O +
nm O +
and O +
c O +
= O +
1.273 O +
nm O -
, O +
a O +
= O +
2.459 O +
nm O +
and O +
c O +
= O +
0.938 O +
nm O -
, O +
respectively O -
. O +

Our O +
C B-Chemical -
( I-Chemical -
60 I-Chemical -
) I-Chemical +
flowers O +
exhibit O +
intense O +
photoluminescence O +
( O -
PL O -
) O +
and O +
a O +
blue O -
- O -
shifted O +
PL O +
intensity O +
maximum O +
compared O +
to O +
the O +
same O +
parameters O +
for O +
pristine O +
C B-Chemical -
( I-Chemical -
60 I-Chemical -
) I-Chemical -
, O +
demonstrating O +
the O +
potential O +
to O +
control O +
the O +
optoelectronic O +
properties O +
of O +
fullerene B-Chemical -
- O -
based O +
nanostructures O -
. O +

Evaluation O +
of O +
drug O +
interactions O +
of O +
GSK1292263 B-Chemical +
( O -
a O +
GPR119 O +
agonist O -
) O +
with O +
statins O -
: O +
from O +
in O +
vitro O +
data O +
to O +
clinical O +
study O +
design O -
. O +

1 O -
. O +

This O +
work O +
investigated O +
the O +
drug O +
interaction O +
potential O +
of O +
GSK1292263 B-Chemical -
, O +
a O +
novel O +
GPR119 O +
agonist O -
, O +
with O +
the O +
HMG O -
- O -
coA O +
reductase O +
inhibitors O +
simvastatin B-Chemical +
and O +
rosuvastatin B-Chemical -
. O +

2 O -
. O +

In O +
vitro O +
experiments O +
assessed O +
the O +
inhibition O +
of O +
transporters O +
and O +
CYP O +
enzymes O +
by O +
GSK1292263 B-Chemical -
, O +
and O +
a O +
clinical O +
drug O +
interaction O +
study O +
investigated O +
the O +
effect O +
of O +
GSK1292263 B-Chemical +
( O -
300 O +
mg O +
BID O -
) O +
on O +
the O +
pharmacokinetic O +
profile O +
of O +
simvastatin B-Chemical +
( O -
40 O +
mg O +
single O +
dose O -
) O +
and O +
rosuvastatin B-Chemical +
( O -
10 O +
mg O +
single O +
dose O -
) O -
. O +

3 O -
. O +

In O +
vitro O -
, O +
GSK1292263 B-Chemical +
demonstrated O +
little O -
/ O -
weak O +
inhibition O +
( O -
IC50 O +
values O +
> O -
30 O +
μM O -
) O +
towards O +
CYPs O +
( O -
CYP1A2 O -
, O +
2C9 O -
, O +
2C19 O -
, O +
2D6 O -
, O +
3A4 O -
) O -
, O +
Pgp O -
, O +
OATP1B3 O -
, O +
or O +
OCT2 O -
. O +

However O -
, O +
GSK1292263 B-Chemical +
inhibited O +
BCRP O +
and O +
OATP1B1 O -
, O +
which O +
are O +
transporters O +
involved O +
in O +
statin O +
disposition O -
. O +

4 O -
. O +

In O +
the O +
clinical O +
study O -
, O +
small O +
increases O +
in O +
the O +
AUC O -
( O -
0-inf O -
) O +
of O +
simvastatin B-Chemical +
[ O -
mean O +
ratio O +
( O -
90 O -
% O +
CI O -
) O +
of O +
1.34 O +
( O -
1.22 O -
, O +
1.48 O -
) O -
] O +
and O +
rosuvastatin B-Chemical +
[ O -
mean O +
ratio O +
( O -
90 O -
% O +
CI O -
) O +
of O +
1.39 O +
( O -
1.30 O -
, O +
1.49 O -
) O -
] O +
were O +
observed O +
when O +
co O -
- O -
administered O +
with O +
GSK1292263 B-Chemical -
, O +
which O +
is O +
consistent O +
with O +
an O +
inhibitory O +
effect O +
on O +
intestinal O +
BCRP O +
and O +
CYP3A4 O -
. O +

In O +
contrast O -
, O +
GSK1292263 B-Chemical +
did O +
not O +
inhibit O +
OATP1B1 O +
based O +
on O +
the O +
lack O +
of O +
changes O +
in O +
simvastatin B-Chemical +
acid O +
exposure O +
[ O -
mean O +
AUC O -
( O -
0-inf O -
) O +
ratio O +
( O -
90 O -
% O +
CI O -
) O +
of O +
1.05 O +
( O -
0.91 O -
, O +
1.21 O -
) O -
] O -
. O +

5 O -
. O +
GSK1292263 B-Chemical +
has O +
a O +
weak O +
drug O +
interaction O +
with O +
simvastatin B-Chemical +
and O +
rosuvastain B-Chemical -
. O +

This O +
study O +
provides O +
a O +
mechanistic O +
understanding O +
of O +
the O +
in O +
vivo O +
inhibition O +
of O +
transporters O +
and O +
enzymes O +
by O +
GSK1292263 B-Chemical -
. O +

Characterization O +
of O +
steroidogenic O +
enzyme O +
expression O +
in O +
aldosterone B-Chemical -
- O -
producing O +
adenoma O -
: O +
a O +
comparison O +
with O +
various O +
human O +
adrenal O +
tumors O -
. O +

We O +
analyzed O +
the O +
expression O +
profiles O +
of O +
several O +
steroidogenic O +
enzymes O +
in O +
normal O +
adrenals O -
, O +
aldosterone B-Chemical -
- O -
producing O +
adenomas O +
( O -
APA O -
) O -
, O +
cortisol B-Chemical -
- O -
producing O +
adenomas O +
combined O +
with O +
Cushing O -
's O +
syndrome O +
( O -
CPA O -
) O +
or O +
with O +
subclinical O +
Cushing O -
's O +
syndrome O +
( O -
SCPA O -
) O -
, O +
and O +
nonfunctioning O +
adrenal O +
adenomas O +
( O -
NFA O -
) O +
to O +
clarify O +
the O +
nature O +
and O +
characteristics O +
of O +
steroidogenesis O +
in O +
APA O -
. O +

Clinical O +
data O +
were O +
collected O +
for O +
all O +
subjects O -
. O +

In O +
resected O +
adrenal O +
glands O +
( O -
normal O +
adrenals O -
, O +
APA O -
, O +
CPA O -
, O +
SCPA O -
, O +
and O +
NFA O -
) O -
, O +
the O +
mRNA O +
expression O +
levels O +
of O +
the O +
CYP17 O -
, O +
HSD3B2 O -
, O +
CYP11B1 O -
, O +
and O +
CYP11B2 O +
genes O +
were O +
studied O +
using O +
real O -
- O -
time O +
quantitative O +
PCR O +
and O +
immunohistochemistry O -
. O +

The O +
CYP11B2 O +
mRNA O +
level O +
in O +
APA O +
was O +
significantly O +
higher O +
than O +
that O +
in O +
other O +
groups O -
. O +

The O +
CYP17 O -
/ O -
HSD3B2 O +
ratio O +
for O +
mRNA O +
in O +
APA O +
was O +
significantly O +
lower O +
than O +
those O +
in O +
the O +
other O +
groups O -
. O +

Low O +
ratio O +
of O +
CYP17 O -
/ O -
HSD3B2 O +
with O +
high O +
expression O +
of O +
CYP11B2 O +
seems O +
to O +
explain O +
steroidogenic O +
characteristics O +
of O +
APA O -
. O +

A O +
theoretical O +
analysis O +
of O +
the O +
effect O +
of O +
the O +
hydrogenation O +
of O +
graphene B-Chemical +
to O +
graphane B-Chemical +
on O +
its O +
mechanical O +
properties O -
. O +

We O +
investigated O +
the O +
effect O +
of O +
the O +
hydrogenation O +
of O +
graphene B-Chemical +
to O +
graphane B-Chemical +
on O +
its O +
mechanical O +
properties O +
using O +
first O -
- O -
principles O +
calculations O +
based O +
on O +
density O -
- O -
functional O +
theory O -
. O +

The O +
hydrogenation O +
reduces O +
the O +
ultimate O +
strengths O +
in O +
all O +
three O +
tested O +
deformation O +
modes O -
-- O -
armchair O -
, O +
zigzag O -
, O +
and O +
biaxial O -
-- O -
and O +
the O +
in O -
- O -
plane O +
stiffness O +
by O +
1 O -
/ O -
3 O -
. O +

The O +
Poisson O +
ratio O +
was O +
reduced O +
from O +
0.178 O +
to O +
0.078 O -
, O +
a O +
56 O -
% O +
decrease O -
. O +

However O -
, O +
the O +
ultimate O +
strain O +
in O +
zigzag O +
deformation O +
was O +
increased O +
by O +
8.7 O -
% O -
. O +

The O +
shear O +
mode O +
elastic O +
constants O +
are O +
more O +
sensitive O +
than O +
longitudinal O +
ones O +
to O +
hydrogenation O -
. O +

The O +
fourth O +
and O +
fifth O +
order O +
longitudinal O +
mode O +
elastic O +
constants O +
are O +
inert O +
to O +
the O +
hydrogenation O -
, O +
in O +
contrast O +
to O +
a O +
large O +
decrease O +
of O +
those O +
in O +
second O +
and O +
third O +
order O -
. O +

The O +
hydrogenation O +
does O +
not O +
change O +
the O +
monotonic O +
decrement O +
of O +
the O +
Poisson O +
ratio O +
with O +
increasing O +
pressure O -
, O +
but O +
the O +
rate O +
is O +
tripled O -
. O +

Our O +
results O +
indicate O +
that O +
graphene B-Chemical -
- O -
graphane B-Chemical +
systems O +
could O +
be O +
used O +
for O +
hydrogen B-Chemical +
storage O +
with O +
high O +
speed O +
of O +
charge O -
- O -
discharge O +
of O +
hydrogen B-Chemical -
. O +

( B-Chemical -
4,4' I-Chemical -
) I-Chemical -
-Bipyridine I-Chemical +
in O +
vacuo O +
and O +
in O +
solvents O -
: O +
a O +
quantum O +
chemical O +
study O +
of O +
a O +
prototypical O +
floppy O +
molecule O +
from O +
a O +
molecular O +
transport O +
perspective O -
. O +

We O +
report O +
results O +
of O +
quantum O +
chemical O +
calculations O +
for O +
the O +
neutral O +
and O +
anionic O +
species O +
of O +
( B-Chemical -
4,4' I-Chemical -
) I-Chemical -
-bipyridine I-Chemical +
( O -
44BPY B-Chemical -
) O -
, O +
a O +
prototypical O +
molecule O +
with O +
a O +
floppy O +
degree O +
of O +
freedom O -
, O +
placed O +
in O +
vacuo O +
and O +
in O +
solvents O -
. O +

In O +
addition O +
to O +
equilibrium O +
geometries O +
and O +
vibrational O +
frequencies O +
and O +
spectra O -
, O +
we O +
present O +
adiabatic O +
energy O +
curves O +
for O +
the O +
vibrational O +
modes O +
with O +
significant O +
intramolecular O +
reorganization O +
upon O +
charge O +
transfer O -
. O +

Special O +
attention O +
is O +
paid O +
to O +
the O +
floppy O +
strongly O +
anharmonic O +
degree O +
of O +
freedom O +
of O +
44BPY B-Chemical -
, O +
which O +
is O +
related O +
to O +
the O +
most O +
salient O +
structural O +
feature O -
, O +
namely O +
the O +
twist O +
angle O +
θ O +
between O +
the O +
two O +
pyridine B-Chemical +
rings O -
. O +

The O +
relevance O +
of O +
the O +
present O +
results O +
for O +
molecular O +
transport O +
will O +
be O +
emphasized O -
. O +

We O +
show O +
that O +
the O +
solvent O +
acts O +
as O +
a O +
selective O +
gate O +
electrode O +
and O +
propose O +
a O +
scissor O +
operator O +
to O +
account O +
for O +
solvent O +
effects O +
on O +
molecular O +
transport O -
. O +

Our O +
result O +
on O +
the O +
conductance O +
G O +
vs. O +
cos O -
( O -
2 O -
) O -
θ O +
is O +
consistent O +
with O +
a O +
significant O +
transmission O +
in O +
perpendicular O +
conformation O +
indicated O +
by O +
previous O +
microscopic O +
analysis O -
. O +

Iron B-Chemical +
L O -
- O -
edge O +
X O -
- O -
ray O +
absorption O +
spectroscopy O +
of O +
oxy O -
- O -
picket O +
fence O +
porphyrin B-Chemical -
: O +
experimental O +
insight O +
into O +
Fe B-Chemical -
- O -
O2 B-Chemical +
bonding O -
. O +

The O +
electronic O +
structure O +
of O +
the O +
Fe B-Chemical -
- O -
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
center O +
in O +
oxy O -
- O -
hemoglobin O +
and O +
oxy O -
- O -
myoglobin O +
is O +
a O +
long O -
- O -
standing O +
issue O +
in O +
the O +
field O +
of O +
bioinorganic O +
chemistry O -
. O +

Spectroscopic O +
studies O +
have O +
been O +
complicated O +
by O +
the O +
highly O +
delocalized O +
nature O +
of O +
the O +
porphyrin B-Chemical -
, O +
and O +
calculations O +
require O +
interpretation O +
of O +
multideterminant O +
wave O +
functions O +
for O +
a O +
highly O +
covalent O +
metal O +
site O -
. O +

Here O -
, O +
iron B-Chemical +
L O -
- O -
edge O +
X O -
- O -
ray O +
absorption O +
spectroscopy O -
, O +
interpreted O +
using O +
a O +
valence O +
bond O +
configuration O +
interaction O +
multiplet O +
model O -
, O +
is O +
applied O +
to O +
directly O +
probe O +
the O +
electronic O +
structure O +
of O +
the O +
iron B-Chemical +
in O +
the O +
biomimetic O +
Fe B-Chemical -
- O -
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
heme B-Chemical +
complex O +
[ B-Chemical -
Fe I-Chemical -
( I-Chemical -
pfp I-Chemical -
) I-Chemical -
( I-Chemical -
1-MeIm I-Chemical -
) I-Chemical -
O I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
] I-Chemical +
( O -
pfp B-Chemical +
( O -
" O -
picket B-Chemical +
fence I-Chemical +
porphyrin I-Chemical -
" O -
) O +
= O +
meso B-Chemical -
- I-Chemical -
tetra I-Chemical -
( I-Chemical -
α I-Chemical -
, I-Chemical -
α I-Chemical -
, I-Chemical -
α I-Chemical -
, I-Chemical -
α I-Chemical -
- I-Chemical -
o I-Chemical -
- I-Chemical -
pivalamidophenyl I-Chemical -
) I-Chemical -
porphyrin I-Chemical +
or O +
TpivPP B-Chemical -
) O -
. O +

This O +
method O +
allows O +
separate O +
estimates O +
of O +
σ O -
- O -
donor O -
, O +
π O -
- O -
donor O -
, O +
and O +
π O -
- O -
acceptor O +
interactions O +
through O +
ligand O -
- O -
to O -
- O -
metal O +
charge O +
transfer O +
and O +
metal O -
- O -
to O -
- O -
ligand O +
charge O +
transfer O +
mixing O +
pathways O -
. O +

The O +
L O -
- O -
edge O +
spectrum O +
of O +
[ B-Chemical -
Fe I-Chemical -
( I-Chemical -
pfp I-Chemical -
) I-Chemical -
( I-Chemical -
1-MeIm I-Chemical -
) I-Chemical -
O I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
] I-Chemical +
is O +
further O +
compared O +
to O +
those O +
of O +
[ B-Chemical -
Fe I-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical -
( I-Chemical -
pfp I-Chemical -
) I-Chemical -
( I-Chemical -
1-MeIm I-Chemical -
) I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
] I-Chemical -
, O +
[ B-Chemical -
Fe I-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical -
( I-Chemical -
pfp I-Chemical -
) I-Chemical -
] I-Chemical -
, O +
and O +
[ B-Chemical -
Fe I-Chemical -
( I-Chemical -
III I-Chemical -
) I-Chemical -
( I-Chemical -
tpp I-Chemical -
) I-Chemical -
( I-Chemical -
ImH I-Chemical -
) I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
] I-Chemical -
Cl I-Chemical +
( O -
tpp B-Chemical +
= O +
meso B-Chemical -
- I-Chemical -
tetraphenylporphyrin I-Chemical -
) O +
which O +
have O +
Fe B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical -
S O +
= O +
0 O -
, O +
Fe B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical -
S O +
= O +
1 O -
, O +
and O +
Fe B-Chemical -
( I-Chemical -
III I-Chemical -
) I-Chemical -
S O +
= O +
1 O -
/ O -
2 O +
ground O +
states O -
, O +
respectively O -
. O +

These O +
serve O +
as O +
references O +
for O +
the O +
three O +
possible O +
contributions O +
to O +
the O +
ground O +
state O +
of O +
oxy B-Chemical -
- I-Chemical -
pfp I-Chemical -
. O +

The O +
Fe B-Chemical -
- O -
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
pfp B-Chemical +
site O +
is O +
experimentally O +
determined O +
to O +
have O +
both O +
significant O +
σ O -
- O -
donation O +
and O +
a O +
strong O +
π O -
- O -
interaction O +
of O +
the O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
with O +
the O +
iron B-Chemical -
, O +
with O +
the O +
latter O +
having O +
implications O +
with O +
respect O +
to O +
the O +
spin O +
polarization O +
of O +
the O +
ground O +
state O -
. O +

Probing O +
the O +
Bonding O +
and O +
Electronic O +
Structure O +
of O +
Single O +
Atom O +
Dopants O +
in O +
Graphene B-Chemical +
with O +
Electron O +
Energy O +
Loss O +
Spectroscopy O -
. O +

A O +
combination O +
of O +
scanning O +
transmission O +
electron O +
microscopy O -
, O +
electron O +
energy O +
loss O +
spectroscopy O -
, O +
and O +
ab O +
initio O +
calculations O +
reveal O +
striking O +
electronic O +
structure O +
differences O +
between O +
two O +
distinct O +
single O +
substitutional O +
Si B-Chemical +
defect O +
geometries O +
in O +
graphene B-Chemical -
. O +

Optimised O +
acquisition O +
conditions O +
allow O +
for O +
exceptional O +
signal O -
- O -
to O -
- O -
noise O +
levels O +
in O +
the O +
spectroscopic O +
data O -
. O +

The O +
near O -
- O -
edge O +
fine O +
structure O +
can O +
be O +
compared O +
with O +
great O +
accuracy O +
to O +
simulations O +
and O +
reveal O +
either O +
an O +
sp O -
( O -
3 O -
) O -
-like O +
configuration O +
for O +
a O +
trivalent O +
Si B-Chemical +
or O +
a O +
more O +
complicated O +
hybridized O +
structure O +
for O +
a O +
tetravalent O +
Si B-Chemical +
impurity O -
. O +

Controlling O +
the O +
pulsed O -
- O -
laser O -
- O -
induced O +
size O +
reduction O +
of O +
Au B-Chemical +
and O +
Ag B-Chemical +
nanoparticles O +
via O +
changes O +
in O +
the O +
external O +
pressure O -
, O +
laser O +
intensity O -
, O +
and O +
excitation O +
wavelength O -
. O +

The O +
laser O -
- O -
induced O +
size O +
reduction O +
of O +
aqueous O +
noble O +
metal O +
nanoparticles O +
has O +
been O +
the O +
subject O +
of O +
intensive O +
research O -
, O +
because O +
of O +
the O +
mechanistic O +
interest O +
in O +
the O +
light O -
- O -
nanoparticle O +
interactions O +
and O +
its O +
potential O +
application O +
to O +
size O +
control O -
. O +

The O +
photothermal O +
evaporation O +
hypothesis O +
has O +
gained O +
solid O +
support O -
. O +

However O -
, O +
the O +
polydispersity O +
of O +
the O +
final O +
products O +
is O +
considered O +
as O +
an O +
inherent O +
drawback O +
of O +
the O +
method O -
. O +

It O +
is O +
likely O +
that O +
the O +
polydispersity O +
arises O +
from O +
the O +
uncontrolled O +
heat O +
dissipation O +
caused O +
by O +
vapor O +
bubble O +
formation O +
in O +
the O +
ambient O +
atmosphere O -
. O +

To O +
overcome O +
this O +
problem O -
, O +
we O +
applied O +
high O +
pressures O +
of O +
30 O -
- O -
100 O +
MPa O -
. O +

The O +
particle O +
size O +
was O +
regulated O +
by O +
adjusting O +
three O +
parameters O -
: O +
the O +
pressure O -
, O +
laser O +
intensity O -
, O +
and O +
excitation O +
wavelength O -
. O +

For O +
example O -
, O +
starting O +
from O +
a O +
colloidal O +
solution O +
of O +
100 O +
nm O +
diameter O +
gold O +
nanoparticles O -
, O +
highly O +
monodisperse O +
( O -
±3 O -
- O -
5 O -
% O -
) O +
spheres O +
with O +
various O +
diameters O +
ranging O +
from O +
90 O +
to O +
30 O +
nm O +
were O +
fabricated O +
by O +
tuning O +
the O +
laser O +
intensity O +
at O +
100 O +
MPa O -
, O +
using O +
an O +
excitation O +
wavelength O +
of O +
532 O +
nm O -
. O +

Further O +
size O +
reduction O +
of O +
the O +
diameter O +
to O +
20 O +
nm O +
was O +
achieved O +
by O +
reducing O +
the O +
pressure O +
and O +
switching O +
the O +
excitation O +
wavelength O +
to O +
355 O +
nm O -
. O +

It O +
was O +
found O +
that O +
the O +
application O +
of O +
high O +
pressures O +
led O +
to O +
the O +
heat O +
loss O -
- O -
controlled O +
size O -
- O -
reduction O +
of O +
the O +
gold O +
nanoparticles O -
. O +

More O +
complicated O +
results O +
were O +
obtained O +
for O +
100 O +
nm O +
silver B-Chemical +
nanoparticles O -
, O +
possibly O +
because O +
of O +
the O +
different O +
size O -
- O -
dependent O +
light O -
- O -
absorbing O +
nature O +
of O +
these O +
particles O -
. O +

Based O +
on O +
our O +
extensive O +
experimental O +
studies O -
, O +
a O +
detailed O +
picture O +
was O +
developed O +
for O +
the O +
nanosecond O +
laser O -
- O -
induced O +
fabrication O +
of O +
gold O +
and O +
silver B-Chemical +
nanoparticles O -
, O +
leading O +
to O +
unprecedented O +
size O +
control O -
. O +

Cell O -
- O -
cycle O +
and O +
DNA O +
damage O +
regulation O +
of O +
the O +
DNA O +
mismatch O +
repair O +
protein O +
Msh2 O +
occurs O +
at O +
the O +
transcriptional O +
and O +
post O -
- O -
transcriptional O +
level O -
. O +

DNA O +
mismatch O +
repair O +
during O +
replication O +
is O +
a O +
conserved O +
process O +
essential O +
for O +
maintaining O +
genomic O +
stability O -
. O +

Mismatch O +
repair O +
is O +
also O +
implicated O +
in O +
cell O -
- O -
cycle O +
arrest O +
and O +
apoptosis O +
after O +
DNA O +
damage O -
. O +

Because O +
yeast O +
and O +
human O +
mismatch O +
repair O +
systems O +
are O +
well O +
conserved O -
, O +
we O +
have O +
employed O +
the O +
budding O +
yeast O +
Saccharomyces O +
cerevisiae O +
to O +
understand O +
the O +
regulation O +
and O +
function O +
of O +
the O +
mismatch O +
repair O +
gene O +
MSH2 O -
. O +

Using O +
a O +
luciferase O -
- O -
based O +
transcriptional O +
reporter O -
, O +
we O +
defined O +
a O +
218-bp O +
region O +
upstream O +
of O +
MSH2 O +
that O +
contains O +
cell O -
- O -
cycle O +
and O +
DNA O +
damage O +
responsive O +
elements O -
. O +

The O +
5 O -
' O +
end O +
of O +
the O +
MSH2 O +
transcript O +
was O +
mapped O +
by O +
primer O +
extension O +
and O +
was O +
found O +
to O +
encode O +
a O +
small O +
upstream O +
open O +
reading O +
frame O +
( O -
uORF O -
) O -
. O +

Mutagenesis O +
of O +
the O +
uORF O +
start O +
codon O +
or O +
of O +
the O +
uORF O +
stop O +
codon O -
, O +
which O +
creates O +
a O +
continuous O +
reading O +
frame O +
with O +
MSH2 O -
, O +
increased O +
Msh2 O +
steady O -
- O -
state O +
protein O +
levels O +
∼2-fold O -
. O +

Furthermore O -
, O +
we O +
found O +
that O +
the O +
cell O -
- O -
cycle O +
transcription O +
factors O +
Swi6 O -
, O +
Swi4 O -
, O +
and O +
Mbp1-along O +
with O +
SCB O -
/ O -
MCB O +
cell O -
- O -
cycle O +
binding O +
sites O +
upstream O +
of O +
MSH2-are O +
all O +
required O +
for O +
full O +
basal O +
expression O +
of O +
MSH2 O -
. O +

Mutagenesis O +
of O +
the O +
cell O -
- O -
cycle O +
boxes O +
resulted O +
in O +
a O +
minor O +
reduction O +
in O +
basal O +
Msh2 O +
levels O +
and O +
a O +
3-fold O +
defect O +
in O +
mismatch O +
repair O -
. O +

Disruption O +
of O +
the O +
cell O -
- O -
cycle O +
boxes O +
also O +
affected O +
growth O +
in O +
a O +
DNA O +
polymerase O -
- O -
defective O +
strain O +
background O +
where O +
mismatch O +
repair O +
is O +
essential O -
, O +
particularly O +
in O +
the O +
presence O +
of O +
the O +
DNA O +
damaging O +
agent O +
methyl B-Chemical +
methane I-Chemical +
sulfonate I-Chemical +
( O -
MMS B-Chemical -
) O -
. O +

Promoter O +
replacements O +
conferring O +
constitutive O +
expression O +
of O +
MSH2 O +
revealed O +
that O +
the O +
transcriptional O +
induction O +
in O +
response O +
to O +
MMS B-Chemical +
is O +
required O +
to O +
maintain O +
induced O +
levels O +
of O +
Msh2 O -
. O +

Turnover O +
experiments O +
confirmed O +
an O +
elevated O +
rate O +
of O +
degradation O +
in O +
the O +
presence O +
of O +
MMS B-Chemical -
. O +

Taken O +
together O -
, O +
the O +
data O +
show O +
that O +
the O +
DNA O +
damage O +
regulation O +
of O +
Msh2 O +
occurs O +
at O +
the O +
transcriptional O +
and O +
post O -
- O -
transcriptional O +
levels O -
. O +

The O +
transcriptional O +
and O +
translational O +
control O +
elements O +
identified O +
are O +
conserved O +
in O +
mammalian O +
cells O -
, O +
underscoring O +
the O +
use O +
of O +
yeast O +
as O +
a O +
model O +
system O +
to O +
examine O +
the O +
regulation O +
of O +
MSH2 O -
. O +

Increased O +
urinary O +
excretion O +
of O +
albumin O -
, O +
hemopexin O -
, O +
transferrin O +
and O +
VDBP O +
correlates O +
with O +
chronic O +
sensitization O +
to O +
gentamicin B-Chemical +
nephrotoxicity O +
in O +
rats O -
. O +

Drug O +
nephrotoxicity O +
is O +
a O +
serious O +
health O +
and O +
economic O +
problem O +
worldwide O -
. O +

Rats O +
can O +
be O +
acutely O +
sensitized O +
to O +
acute O +
kidney O +
injury O +
( O -
AKI O -
) O +
by O +
subnephrotoxic O +
treatments O +
with O +
potentially O +
nephrotoxic O +
drugs O -
. O +

Acquired O +
sensitization O +
to O +
AKI O +
poses O +
a O +
silent O +
risk O +
impossible O +
to O +
diagnose O +
pre O -
- O -
emptively O +
with O +
the O +
technology O +
available O +
at O +
the O +
clinical O +
level O -
. O +

Herein O -
, O +
we O +
hypothesized O +
whether O +
a O +
chronic O -
, O +
subnephrotoxic O +
insult O +
to O +
the O +
kidneys O +
might O +
result O +
in O +
chronically O +
acquired O +
sensitization O +
to O +
AKI O -
, O +
and O +
whether O +
chronic O +
sensitization O +
might O +
be O +
detected O +
through O +
specific O +
urinary O +
markers O -
. O +

To O +
this O +
end O -
, O +
rats O +
were O +
treated O +
with O +
a O +
subtoxic O +
dosage O +
of O +
the O +
experimental O +
nephrotoxin O +
uranyl O +
nitrate B-Chemical +
( O -
UN O -
) O +
in O +
the O +
drinking O +
water O +
for O +
21 O +
weeks O -
, O +
or O +
plain O +
water O +
( O -
as O +
control O -
) O -
, O +
and O +
then O +
with O +
low O -
- O -
dose O +
gentamicin B-Chemical +
for O +
7 O +
days O -
. O +

Renal O +
function O +
and O +
renal O +
tissue O +
damage O +
were O +
evaluated O +
through O +
the O +
experiment O -
. O +

The O +
mild O +
renal O +
damage O +
caused O +
by O +
gentamicin B-Chemical +
was O +
markedly O +
magnified O +
in O +
rats O +
having O +
received O +
UN O +
chronically O -
, O +
which O +
was O +
evident O +
both O +
at O +
the O +
functional O +
and O +
histological O +
level O -
. O +

Four O +
proteins O -
, O +
namely O +
albumin O -
, O +
hemopexin O -
, O +
transferrin O +
and O +
vitamin B-Chemical +
D I-Chemical +
binding O +
protein O +
were O +
increased O +
in O +
the O +
urine O +
in O +
temporal O +
association O +
with O +
the O +
appearance O +
of O +
chronic O +
predisposition O -
. O +

Although O +
further O +
studies O +
are O +
necessary O -
, O +
our O +
results O +
suggest O +
that O +
these O +
proteins O +
might O +
be O +
potentially O +
used O +
as O +
markers O +
of O +
hidden O -
, O +
chronic O +
predisposition O +
to O +
gentamicin B-Chemical +
nephrotoxicity O -
, O +
in O +
order O +
to O +
appropriately O +
and O +
pre O -
- O -
emptively O +
stratify O +
and O +
handle O +
individuals O +
according O +
to O +
their O +
specific O +
risk O +
in O +
the O +
long O +
term O -
, O +
and O +
to O +
conveniently O +
optimize O +
their O +
life O +
conditions O +
or O +
additional O +
clinical O +
procedures O +
or O +
treatments O +
that O +
might O +
trigger O +
the O +
disease O -
. O +

This O +
might O +
reduce O +
AKI O +
incidence O +
and O +
severity O +
and O +
the O +
associated O +
costs O -
. O +

Sequential O +
delivery O +
of O +
TAT O -
- O -
HSP27 O +
and O +
VEGF O +
using O +
microsphere O -
/ O -
hydrogel O +
hybrid O +
systems O +
for O +
therapeutic O +
angiogenesis O -
. O +

Ischemic O +
disease O +
is O +
associated O +
with O +
high O +
mortality O +
and O +
morbidity O +
rates O -
, O +
and O +
therapeutic O +
angiogenesis O +
via O +
systemic O +
or O +
local O +
delivery O +
of O +
protein O +
drugs O +
is O +
one O +
potential O +
approach O +
to O +
treat O +
the O +
disease O -
. O +

In O +
this O +
study O -
, O +
we O +
hypothesized O +
that O +
combined O +
delivery O +
of O +
TAT O -
- O -
HSP27 O +
( O -
HSP27 O +
fused O +
with O +
transcriptional O +
activator O -
) O +
and O +
VEGF O +
could O +
enhance O +
the O +
therapeutic O +
efficacy O +
in O +
an O +
ischemic O +
mouse O +
model O -
, O +
and O +
that O +
sequential O +
release O +
could O +
be O +
critical O +
in O +
therapeutic O +
angiogenesis O -
. O +

Alginate O +
hydrogels O +
containing O +
TAT O -
- O -
HSP27 O +
as O +
an O +
anti O -
- O -
apoptotic O +
agent O +
were O +
prepared O -
, O +
and O +
porous O +
PLGA O +
microspheres O +
loaded O +
with O +
VEGF O +
as O +
an O +
angiogenic O +
agent O +
were O +
incorporated O +
into O +
the O +
hydrogels O +
to O +
prepare O +
microsphere O -
/ O -
hydrogel O +
hybrid O +
delivery O +
systems O -
. O +

Sequential O +
in O +
vitro O +
release O +
of O +
TAT O -
- O -
HSP27 O +
and O +
VEGF O +
was O +
achieved O +
by O +
the O +
hybrid O +
systems O -
. O +

TAT O -
- O -
HSP27 O +
was O +
depleted O +
from O +
alginate O +
gels O +
in O +
7 O +
days O -
, O +
while O +
VEGF O +
was O +
continually O +
released O +
for O +
28 O +
days O -
. O +

The O +
release O +
rate O +
of O +
VEGF O +
was O +
attenuated O +
by O +
varying O +
the O +
porous O +
structures O +
of O +
PLGA O +
microspheres O -
. O +

Sequential O +
delivery O +
of O +
TAT O -
- O -
HSP27 O +
and O +
VEGF O +
was O +
critical O +
to O +
protect O +
against O +
muscle O +
degeneration O +
and O +
fibrosis O -
, O +
as O +
well O +
as O +
to O +
promote O +
new O +
blood O +
vessel O +
formation O +
in O +
the O +
ischemic O +
site O +
of O +
a O +
mouse O +
model O -
. O +

This O +
approach O +
to O +
controlling O +
the O +
sequential O +
release O +
behaviors O +
of O +
multiple O +
drugs O +
could O +
be O +
useful O +
in O +
the O +
design O +
of O +
novel O +
drug O +
delivery O +
systems O +
for O +
therapeutic O +
angiogenesis O -
. O +

Synthesis O +
and O +
evaluation O +
of O +
a O +
backbone O +
biodegradable O +
multiblock O +
HPMA B-Chemical +
copolymer O +
nanocarrier O +
for O +
the O +
systemic O +
delivery O +
of O +
paclitaxel B-Chemical -
. O +

The O +
performance O +
and O +
safety O +
of O +
current O +
antineoplastic O +
agents O -
, O +
particularly O +
water O -
- O -
insoluble O +
drugs O -
, O +
are O +
still O +
far O +
from O +
satisfactory O -
. O +

For O +
example O -
, O +
the O +
currently O +
widely O +
used O +
Cremophor O +
EL O -
® O -
-based O +
paclitaxel B-Chemical +
( O -
PTX B-Chemical -
) O +
formulation O +
exhibits O +
pharmacokinetic O +
concerns O +
and O +
severe O +
side O +
effects O -
. O +

Thus O -
, O +
the O +
concept O +
of O +
a O +
biodegradable O +
polymeric O +
drug O -
- O -
delivery O +
system O -
, O +
which O +
can O +
significantly O +
improve O +
therapeutic O +
efficacy O +
and O +
reduce O +
side O +
effects O +
is O +
advocated O -
. O +

The O +
present O +
work O +
aims O +
to O +
develop O +
a O +
new O -
- O -
generation O +
of O +
long O -
- O -
circulating O -
, O +
biodegradable O +
carriers O +
for O +
effective O +
delivery O +
of O +
PTX B-Chemical -
. O +

First O -
, O +
a O +
multiblock O +
backbone O +
biodegradable O +
N- B-Chemical -
( I-Chemical -
2-hydroxypropyl I-Chemical -
) I-Chemical -
methacrylamide I-Chemical -
( O -
HPMA B-Chemical -
) O +
copolymer O -
- O -
PTX B-Chemical +
conjugate O +
( O -
mP O -
- O -
PTX B-Chemical -
) O +
with O +
molecular O +
weight O +
( O -
Mw O -
) O +
of O +
335 O +
kDa O +
was O +
synthesized O +
by O +
RAFT O +
( O -
reversible O +
addition O -
- O -
fragmentation O +
chain O +
transfer O -
) O +
copolymerization O -
, O +
followed O +
by O +
chain O +
extension O -
. O +

In O +
vitro O +
studies O +
on O +
human O +
ovarian O +
carcinoma O +
A2780 O +
cells O +
were O +
carried O +
out O +
to O +
investigate O +
the O +
cytotoxicity O +
of O +
free O +
PTX B-Chemical -
, O +
HPMA B-Chemical +
copolymer O -
- O -
PTX B-Chemical +
conjugate O +
with O +
Mw O +
of O +
48 O +
kDa O +
( O -
P O -
- O -
PTX B-Chemical -
) O -
, O +
and O +
mP O -
- O -
PTX B-Chemical -
. O +

The O +
experiments O +
demonstrated O +
that O +
mP O -
- O -
PTX B-Chemical +
has O +
a O +
similar O +
cytotoxic O +
effect O +
against O +
A2780 O +
cells O +
as O +
free O +
PTX B-Chemical +
and O +
P O -
- O -
PTX B-Chemical -
. O +

To O +
further O +
compare O +
the O +
behavior O +
of O +
this O +
new O +
biodegradable O +
conjugate O +
( O -
mP O -
- O -
PTX B-Chemical -
) O +
with O +
free O +
PTX B-Chemical +
and O +
P O -
- O -
PTX B-Chemical +
in O +
vivo O +
evaluation O +
was O +
performed O +
using O +
female O +
nu O -
/ O -
nu O +
mice O +
bearing O +
orthotopic O +
A2780 O +
ovarian O +
tumors O -
. O +

Pharmacokinetics O +
study O +
showed O +
that O +
high O +
Mw O +
mP O -
- O -
PTX B-Chemical +
was O +
cleared O +
more O +
slowly O +
from O +
the O +
blood O +
than O +
commercial O +
PTX B-Chemical +
formulation O +
and O +
low O +
Mw O +
P O -
- O -
PTX B-Chemical -
. O +

SPECT O -
/ O -
CT O +
imaging O +
and O +
biodistribution O +
studies O +
demonstrated O +
biodegradability O +
as O +
well O +
as O +
elimination O +
of O +
mP O -
- O -
PTX B-Chemical +
from O +
the O +
body O -
. O +

The O +
tumors O +
in O +
the O +
mP O -
- O -
PTX B-Chemical +
treated O +
group O +
grew O +
more O +
slowly O +
than O +
those O +
treated O +
with O +
saline O -
, O +
free O +
PTX B-Chemical -
, O +
and O +
P O -
- O -
PTX B-Chemical +
( O -
single O +
dose O +
at O +
20 O +
mg O +
PTX B-Chemical -
/ O -
kg O +
equivalent O -
) O -
. O +

Moreover O -
, O +
mice O +
treated O +
with O +
mP O -
- O -
PTX B-Chemical +
had O +
no O +
obvious O +
ascites O +
and O +
body O -
- O -
weight O +
loss O -
. O +

Histological O +
analysis O +
indicated O +
that O +
mP O -
- O -
PTX B-Chemical +
had O +
no O +
toxicity O +
in O +
liver O +
and O +
spleen O -
, O +
but O +
induced O +
massive O +
cell O +
death O +
in O +
the O +
tumor O -
. O +

In O +
summary O -
, O +
this O +
biodegradable O +
drug O +
delivery O +
system O +
has O +
a O +
great O +
potential O +
to O +
improve O +
performance O +
and O +
safety O +
of O +
current O +
antineoplastic O +
agents O -
. O +

C B-Chemical -
( I-Chemical -
22 I-Chemical -
) I-Chemical -
-steroidal I-Chemical +
lactone I-Chemical +
glycosides I-Chemical +
from O +
stems O +
and O +
leaves O +
of O +
Paris O +
polyphylla O +
var O -
. O +

yunnanensis O -
. O +

Further O +
phytochemical O +
investigation O +
on O +
the O +
stems O +
and O +
leaves O +
of O +
Paris O +
polyphylla O +
var O -
. O +

yunnanensis O +
has O +
led O +
to O +
the O +
isolation O +
of O +
three O +
C B-Chemical -
( I-Chemical -
22 I-Chemical -
) I-Chemical -
-steroidal I-Chemical +
lactone I-Chemical +
glycosides I-Chemical -
. O +

Two O +
of O +
these O +
are O +
new O +
compounds O -
, O +
designated O +
as O +
chonglouoside B-Chemical +
SL-7 I-Chemical +
( O -
1 O -
) O +
and O +
chonglouoside B-Chemical +
SL-8 I-Chemical +
( O -
2 O -
) O -
. O +

Their O +
structures O +
were O +
elucidated O +
on O +
the O +
basis O +
of O +
extensive O +
spectroscopic O +
analysis O -
, O +
as O +
well O +
as O +
comparison O +
with O +
the O +
reported O +
spectroscopic O +
data O -
. O +

This O +
is O +
the O +
first O +
report O +
of O +
C B-Chemical -
( I-Chemical -
22 I-Chemical -
) I-Chemical -
-steroidal I-Chemical +
lactone I-Chemical +
glycosides I-Chemical +
isolated O +
from O +
the O +
Paris O +
genus O -
. O +

Compounds O +
1 O +
and O +
3 O +
showed O +
moderate O +
antimicrobic O +
activity O +
against O +
Propionibacterium O +
acnes O +
with O +
MIC O +
values O +
of O +
31.3 O +
and O +
3.9μg O -
/ O -
mL O -
, O +
respectively O -
. O +

Caffeine B-Chemical -
- O -
induced O +
inhibition O +
of O +
the O +
activity O +
of O +
glutamate B-Chemical +
transporter O +
type O +
3 O +
expressed O +
in O +
Xenopus O +
oocytes O -
. O +

Caffeine B-Chemical +
has O +
been O +
known O +
to O +
trigger O +
seizures O -
, O +
however O -
, O +
the O +
precise O +
mechanism O +
about O +
the O +
proconvulsive O +
effect O +
of O +
caffeine B-Chemical +
remains O +
unclear O -
. O +

Glutamate B-Chemical +
transporters O +
play O +
an O +
important O +
role O +
to O +
maintain O +
the O +
homeostasis O +
of O +
glutamate B-Chemical +
concentration O +
in O +
the O +
brain O +
tissue O -
. O +

Especially O -
, O +
dysfunction O +
of O +
excitatory O +
amino B-Chemical +
acid I-Chemical +
transporter O +
type O +
3 O +
( O -
EAAT3 O -
) O +
can O +
lead O +
to O +
seizures O -
. O +

We O +
investigated O +
the O +
effects O +
of O +
caffeine B-Chemical +
on O +
the O +
activity O +
of O +
EAAT3 O +
and O +
the O +
involvement O +
of O +
protein O +
kinase O +
C O +
( O -
PKC O -
) O +
and O +
phosphatidylinositol O +
3-kinase O +
( O -
PI3 O -
K O -
) O -
. O +

Rat O +
EAAT3 O +
was O +
expressed O +
in O +
Xenopus O +
oocytes O +
by O +
injecting O +
EAAT3 O +
mRNA O -
. O +

l B-Chemical -
- I-Chemical -
Glutamate I-Chemical +
( O -
30μM O -
) O -
-induced O +
inward O +
currents O +
were O +
recorded O +
via O +
the O +
two O -
- O -
electrode O +
voltage O +
clamp O +
method O -
. O +

Caffeine B-Chemical +
decreased O +
EAAT3 O +
activity O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O +

Caffeine B-Chemical +
( O -
30μM O +
for O +
3min O -
) O +
significantly O +
reduced O +
V O -
( O -
max O -
) O -
, O +
but O +
did O +
not O +
alter O +
K O -
( O -
m O -
) O +
value O +
of O +
EAAT3 O +
for O +
glutamate B-Chemical -
. O +

When O +
preincubated O +
oocytes O +
with O +
phorbol-12-myristate-13-acetate B-Chemical +
( O -
PMA B-Chemical -
, O +
a O +
PKC O +
activator O -
) O +
were O +
exposed O +
to O +
caffeine B-Chemical -
, O +
PMA B-Chemical -
- O -
induced O +
increase O +
in O +
EAAT3 O +
activity O +
was O +
abolished O -
. O +

Two O +
PKC O +
inhibitors O +
( O -
chelerythrine B-Chemical +
and O +
staurosporine B-Chemical -
) O +
significantly O +
reduced O +
basal O +
EAAT3 O +
activity O -
. O +

Whereas O -
, O +
there O +
were O +
no O +
significant O +
differences O +
among O +
the O +
PKC O +
inhibitors O -
, O +
caffeine B-Chemical -
, O +
and O +
PKC O +
inhibitors+caffeine O +
groups O -
. O +

In O +
similarly O +
fashion O -
, O +
wortmannin B-Chemical +
( O -
a O +
PI3 O -
K O +
inhibitor O -
) O +
significantly O +
decreased O +
EAAT3 O +
activity O -
, O +
however O +
no O +
statistical O +
differences O +
were O +
observed O +
among O +
the O +
wortmannin B-Chemical -
, O +
caffeine B-Chemical -
, O +
and O +
wortmannin+caffeine B-Chemical +
groups O -
. O +

Our O +
results O +
demonstrate O +
that O +
caffeine B-Chemical +
attenuates O +
EAAT3 O +
activity O +
and O +
this O +
reducing O +
effect O +
of O +
caffeine B-Chemical +
seems O +
to O +
be O +
mediated O +
by O +
PKC O +
and O +
PI3 O -
K O -
. O +

The O +
response O +
of O +
soil O +
organism O +
communities O +
to O +
the O +
application O +
of O +
the O +
insecticide O +
lindane B-Chemical +
in O +
terrestrial O +
model O +
ecosystems O -
. O +

The O +
EU O +
plant O +
protection O +
regulation O +
1107 O -
/ O -
2009 O -
/ O -
EC O +
defines O +
the O +
requirements O +
for O +
active O +
ingredients O +
to O +
be O +
approved O -
, O +
specifically O +
including O +
the O +
assessment O +
of O +
effects O +
on O +
biodiversity O +
and O +
ecosystems O -
. O +

According O +
to O +
that O -
, O +
semi O -
- O -
field O +
methods O +
are O +
expected O +
to O +
be O +
more O +
important O +
in O +
the O +
near O +
future O -
. O +

Therefore O -
, O +
a O +
higher O -
- O -
tier O +
experiment O +
suitable O +
to O +
assess O +
the O +
risk O +
for O +
soil O +
organisms O +
was O +
conducted O +
to O +
further O +
develop O +
the O +
TME O +
( O -
terrestrial O +
model O +
ecosystems O -
) O +
methodology O +
in O +
a O +
dose O -
- O -
response O +
design O +
with O +
the O +
persistent O +
insecticidal O +
model O +
compound O +
lindane B-Chemical +
( O -
gamma B-Chemical -
- I-Chemical -
HCH I-Chemical -
) O -
. O +

The O +
effects O +
of O +
lindane B-Chemical +
on O +
soil O +
communities O +
such O +
as O +
collembolans O -
, O +
oribatid O +
mites O -
, O +
nematodes O -
, O +
soil O +
fungi O +
and O +
plant O +
biomass O +
were O +
determined O +
in O +
42 O +
TME O -
. O +

Intact O +
TME O -
- O -
soil O +
cores O +
( O -
diameter O +
300 O +
mm O -
, O +
height O +
400 O +
mm O -
) O +
from O +
undisturbed O +
grassland O +
were O +
stored O +
outdoor O +
under O +
natural O +
climatic O +
conditions O -
. O +

Lindane B-Chemical +
was O +
applied O +
in O +
five O +
concentrations O +
between O +
0.032 O +
mg O +
active O +
ingredients O +
( O -
ai O -
) O -
/ O -
kg O +
dry O +
soil O +
and O +
3.2 O +
mg O +
ai O -
/ O -
kg O +
dry O +
weight O +
soil O -
, O +
six O -
- O -
fold O +
replicated O +
each O -
. O +

Twelve O +
TME O +
served O +
as O +
untreated O +
controls O -
. O +

Abundance O +
and O +
community O +
structures O +
of O +
oribatids O -
, O +
collembolans O -
, O +
enchytraeids O -
, O +
nematodes O +
and O +
fungi O +
were O +
recorded O -
. O +

Oribatid O +
mites O -
' O +
community O +
responded O +
3 O +
months O +
after O +
treatment O -
, O +
although O +
they O +
were O +
not O +
significantly O +
affected O +
by O +
the O +
overall O +
treatment O +
regimen O -
. O +

Collembolans O +
in O +
total O +
and O +
species O -
- O -
specific O +
abundance O +
as O +
well O +
as O +
the O +
community O +
endpoints O +
( O -
principal O +
response O +
curves O -
, O +
diversity O +
measures O -
) O +
were O +
adversely O +
affected O +
by O +
moderate O +
dosages O +
of O +
lindane O -
. O +

Effects O +
were O +
transient O +
between O +
3 O +
and O +
5 O +
months O +
after O +
treatment O +
with O +
a O +
recovery O +
within O +
1 O +
year O -
. O +

No O +
significant O +
effects O +
could O +
be O +
detected O +
for O +
enchytraeids O -
, O +
nematodes O +
and O +
fungi O -
. O +

The O +
study O +
design O +
and O +
the O +
obtained O +
results O +
allow O +
for O +
calculations O +
of O +
no O +
observed O +
effect O +
concentrations O +
below O +
the O +
highest O +
treatment O +
level O +
for O +
populations O +
and O +
for O +
soil O +
communities O +
as O +
defined O +
entities O -
, O +
as O +
well O +
as O +
effective O +
concentrations O -
. O +

The O +
paper O +
discusses O +
the O +
limits O +
of O +
effect O +
detection O +
in O +
the O +
light O +
of O +
achievable O +
coefficients O +
of O +
variation O +
and O +
by O +
means O +
of O +
minimum O +
detectable O +
differences O -
. O +

Outdoor O +
TME O +
are O +
useful O +
to O +
analyze O +
and O +
assess O +
functional O +
and O +
structural O +
endpoints O +
in O +
soil O +
organisms O -
' O +
communities O +
and O +
their O +
possible O +
recovery O +
after O +
pesticide O +
treatment O +
within O +
1 O +
year O -
. O +

Dynamic O +
behavior O +
of O +
water O +
droplet O +
impact O +
on O +
microtextured O +
surfaces O -
: O +
the O +
effect O +
of O +
geometrical O +
parameters O +
on O +
anisotropic O +
wetting O +
and O +
the O +
maximum O +
spreading O +
diameter O -
. O +

Textured O +
silicon B-Chemical +
surfaces O +
decorated O +
by O +
square O +
arrays O +
of O +
pillars O +
with O +
adjustable O +
pitch O +
were O +
fabricated O -
. O +

The O +
wetting O +
behavior O -
, O +
especially O +
for O +
direction O -
- O -
dependent O +
water O +
contact O +
angles O +
on O +
textured O +
silicon B-Chemical +
surfaces O +
after O +
silanization O -
, O +
was O +
investigated O +
by O +
incorporating O +
the O +
contact O +
line O +
fraction O +
into O +
a O +
modified O +
Wenzel O +
model O -
. O +

Also O -
, O +
the O +
effect O +
of O +
geometrical O +
parameters O +
on O +
the O +
anisotropic O +
wetting O +
behavior O +
of O +
water O +
was O +
examined O +
with O +
respect O +
to O +
water O +
droplet O +
impact O +
on O +
the O +
textured O +
surface O -
. O +

Moreover O -
, O +
the O +
maximum O +
spreading O +
factor O +
was O +
studied O +
theoretically O +
in O +
terms O +
of O +
energy O +
conservation O -
, O +
allowing O +
for O +
surface O +
topography O +
and O +
viscous O +
friction O +
of O +
the O +
liquid O +
flowing O +
among O +
the O +
arrays O +
of O +
the O +
posts O -
. O +

Theoretical O +
models O +
were O +
found O +
to O +
be O +
in O +
good O +
agreement O +
with O +
experimental O +
data O -
. O +

Mineral O +
and O +
sensory O +
profile O +
of O +
seasoned O +
cracked O +
olives O +
packed O +
in O +
diverse O +
salt O +
mixtures O -
. O +

This O +
work O +
studies O +
the O +
effect O +
of O +
packing O +
cracked O +
seasoned O +
olives O +
with O +
NaCl B-Chemical -
, O +
KCl B-Chemical -
, O +
and O +
CaCl B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
mixture O +
brines O +
on O +
their O +
mineral O +
nutrients O +
and O +
sensory O +
attributes O -
, O +
using O +
RSM O +
methodology O -
. O +

The O +
Na B-Chemical -
, O +
K O -
, O +
Ca B-Chemical -
, O +
and O +
residual O +
natural O +
Mn B-Chemical +
contents O +
in O +
flesh O +
as O +
well O +
as O +
saltiness O -
, O +
bitterness O +
and O +
fibrousness O +
were O +
significantly O +
related O +
to O +
the O +
initial O +
concentrations O +
of O +
salts O +
in O +
the O +
packing O +
solution O -
. O +

This O +
new O +
process O +
led O +
to O +
table O +
olives O +
with O +
a O +
significantly O +
lower O +
sodium B-Chemical +
content O +
( O -
about O +
31 O -
% O -
) O +
than O +
the O +
traditional O +
product O +
but O +
fortified O +
in O +
K O +
and O +
Ca B-Chemical -
. O +

High O +
levels O +
of O +
Na B-Chemical +
and O +
Ca B-Chemical +
in O +
the O +
flesh O +
led O +
to O +
high O +
scores O +
of O +
acidity O +
and O +
saltiness O +
( O -
the O +
first O +
descriptor O -
) O +
and O +
bitterness O +
( O -
the O +
second O -
) O +
while O +
the O +
K O +
content O +
was O +
unrelated O +
to O +
any O +
sensory O +
descriptor O -
. O +

The O +
new O +
presentations O +
using O +
moderate O +
proportions O +
of O +
alternative O +
salts O +
will O +
therefore O +
have O +
improved O +
nutritional O +
value O +
and O +
healthier O +
characteristics O +
but O +
only O +
a O +
slightly O +
modified O +
sensory O +
profile O -
. O +

Direct O +
potentiometric O +
determination O +
of O +
starch O +
using O +
a O +
platinum B-Chemical +
redox O +
sensor O -
. O +

Here O -
, O +
we O +
describe O +
the O +
development O +
of O +
a O +
platinum B-Chemical +
redox O +
sensor O +
for O +
the O +
direct O +
potentiometric O +
quantification O +
of O +
starch O +
in O +
solution O -
. O +

The O +
sensor O +
measures O +
the O +
decrease O +
in O +
free O +
triiodide B-Chemical +
ion O +
after O +
it O +
complexes O +
with O +
starch O +
to O +
form O +
a O +
starch O -
- O -
triiodide B-Chemical +
complex O -
. O +

This O +
decrease O +
was O -
, O +
therefore O -
, O +
correlated O +
with O +
starch O +
concentration O -
, O +
and O +
the O +
composition O +
and O +
stability O +
of O +
the O +
potassium B-Chemical +
triiodide I-Chemical +
solution O +
were O +
optimised O -
. O +

The O +
starch O -
- O -
triiodide B-Chemical +
complex O +
was O +
characterized O +
potentiometrically O +
at O +
variable O +
starch O +
and O +
triiodide B-Chemical +
concentrations O -
. O +

We O +
also O +
propose O +
a O +
response O +
mechanism O +
for O +
the O +
platinum B-Chemical +
redox O +
sensor O +
towards O +
starch O +
and O +
an O +
appropriate O +
theoretical O +
model O -
. O +

The O +
optimised O +
method O +
exhibited O +
satisfactory O +
accuracy O +
and O +
precision O +
and O +
was O +
in O +
good O +
agreement O +
with O +
a O +
standard O +
spectrophotometric O +
method O -
. O +

The O +
sensor O +
was O +
tested O +
over O +
a O +
range O +
of O +
0.4 O -
- O -
9 O +
mg O +
starch O -
, O +
with O +
recoveries O +
ranging O +
from O +
97.8 O -
% O +
to O +
103.4 O -
% O +
and O +
a O +
detection O +
limit O +
of O +
0.01 O +
mg O +
starch O -
. O +

Rapid O +
detection O +
and O +
quantification O +
of O +
milk O +
adulteration O +
using O +
infrared O +
microspectroscopy O +
and O +
chemometrics O +
analysis O -
. O +

The O +
application O +
of O +
attenuated O +
total O +
reflectance O +
mid O -
- O -
infrared O +
microspectroscopy O +
( O -
MIR O -
- O -
microspectroscopy O -
) O +
was O +
evaluated O +
as O +
a O +
rapid O +
method O +
for O +
detection O +
and O +
quantification O +
of O +
milk O +
adulteration O -
. O +

Milk O +
samples O +
were O +
purchased O +
from O +
local O +
grocery O +
stores O +
( O -
Columbus O -
, O +
OH O -
, O +
USA O -
) O +
and O +
spiked O +
at O +
different O +
concentrations O +
of O +
whey O -
, O +
hydrogen B-Chemical +
peroxide I-Chemical -
, O +
synthetic O +
urine O -
, O +
urea B-Chemical +
and O +
synthetic O +
milk O -
. O +

Samples O +
were O +
place O +
on O +
a O +
192-well O +
microarray O +
slide O -
, O +
air O -
- O -
dried O +
and O +
spectra O +
were O +
collected O +
by O +
using O +
MIR O -
- O -
microspectroscopy O -
. O +

Pattern O +
recognition O +
analysis O +
by O +
Soft O +
Independent O +
Modeling O +
of O +
Class O +
Analogy O +
( O -
SIMCA O -
) O +
showed O +
tight O +
and O +
well O -
- O -
separated O +
clusters O +
allowing O +
discrimination O +
of O +
control O +
samples O +
from O +
adulterated O +
milk O -
. O +

Partial O +
Least O +
Squares O +
Regression O +
( O -
PLSR O -
) O +
showed O +
standard O +
error O +
of O +
prediction O +
( O -
SEP O -
) O +
~2.33 O -
, O +
0.06 O -
, O +
0.41 O -
, O +
0.30 O +
and O +
0.014 O +
g O -
/ O -
L O +
for O +
estimation O +
of O +
levels O +
of O +
adulteration O +
with O +
whey O -
, O +
synthetic O +
milk O -
, O +
synthetic O +
urine O -
, O +
urea B-Chemical +
and O +
hydrogen B-Chemical +
peroxide I-Chemical -
, O +
respectively O -
. O +

Results O +
showed O +
that O +
MIR O -
- O -
microspectroscopy O +
can O +
provide O +
an O +
alternative O +
methodology O +
to O +
the O +
dairy O +
industry O +
for O +
screening O +
potential O +
fraudulent O +
practice O +
for O +
economic O +
adulteration O +
of O +
cow O -
's O +
milk O -
. O +

Cashew O +
apple O +
( O -
Anacardium O +
occidentale O +
L. O -
) O +
extract O +
from O +
by O -
- O -
product O +
of O +
juice O +
processing O -
: O +
a O +
focus O +
on O +
carotenoids O -
. O +

Cashew O +
apple O +
fibrous O +
residue O +
is O +
a O +
by O -
- O -
product O +
of O +
the O +
cashew O +
juice O +
industry O -
. O +

After O +
pressing O +
using O +
a O +
helical O +
type O +
continuous O +
press O +
followed O +
by O +
crossflow O +
microfiltration O -
, O +
an O +
aqueous O +
extract O +
was O +
obtained O +
from O +
these O +
cashew O +
apple O +
fibres O -
. O +

It O +
was O +
characterised O +
by O +
an O +
intense O +
yellow O +
colour O +
due O +
to O +
carotenoid O +
pigments O -
. O +

Carotenoids O +
were O +
identified O +
and O +
quantified O +
in O +
the O +
cashew O +
apple O +
before O +
extraction O -
, O +
in O +
its O +
aqueous O +
extract O +
and O +
in O +
the O +
concentrate O +
obtained O +
by O +
microfiltration O -
. O +

Cashew O +
apple O +
aqueous O +
extract O +
and O +
its O +
concentrate O +
presented O +
a O +
carotenoid O +
profile O +
with O +
11 O +
carotenoids O -
, O +
most O +
of O +
them O +
were O +
tentatively O +
identified O +
by O +
HPLC O -
- O -
DAD O -
- O -
MS O +
and O +
are O +
xanthophylls O +
present O +
under O +
an O +
esterified O +
form O -
. O +

Auroxanthin O +
and O +
β B-Chemical -
- I-Chemical -
cryptoxanthin I-Chemical +
represented O +
around O +
50 O -
% O +
of O +
total O +
carotenoids O -
. O +

Concentration O +
of O +
the O +
extract O +
by O +
microfiltration O +
led O +
to O +
epoxy B-Chemical -
- O -
furanoxy B-Chemical +
rearrangement O +
of O +
violaxanthin B-Chemical +
and O +
antheraxanthin B-Chemical -
. O +

The O +
process O +
allowed O +
an O +
increase O +
of O +
10 O +
times O +
total O +
carotenoid O +
content O +
compared O +
with O +
initial O +
cashew O +
apple O -
. O +

Total O +
carotenoid O +
content O +
of O +
the O +
final O +
concentrated O +
extract O +
reached O +
54 O +
mg O -
/ O -
kg O -
. O +

Inhibition O +
effects O +
and O +
induction O +
of O +
apoptosis O +
of O +
flavonoids B-Chemical +
on O +
the O +
prostate O +
cancer O +
cell O +
line O +
PC-3 O +
in O +
vitro O -
. O +

Myricetin B-Chemical +
and O +
myricitrin B-Chemical +
are O +
naturally O +
occurring O +
flavonoids B-Chemical +
have O +
been O +
suggested O +
to O +
play O +
a O +
role O +
in O +
inhibition O +
of O +
proliferation O +
and O +
transformation O +
of O +
carcinogenic O +
cell O -
. O +

However O -
, O +
the O +
underlying O +
molecular O +
mechanisms O +
of O +
their O +
activity O +
have O +
not O +
yet O +
to O +
be O +
revealed O -
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
clarify O +
the O +
molecular O +
mechanisms O +
of O +
apoptosis O +
cell O +
on O +
the O +
prostate O +
cancer O +
induced O +
by O +
myricetin B-Chemical -
, O +
myricitrin B-Chemical -
, O +
quercetin B-Chemical +
and O +
quercitrin B-Chemical -
. O +

The O +
MTT B-Chemical +
assay O +
confirmed O +
that O +
myricetin B-Chemical +
had O +
the O +
strongest O +
inhibitory O +
effect O +
on O +
human O +
prostate O +
cancer O +
cell O +
line O +
PC-3 O -
, O +
myricitrin B-Chemical +
was O +
second O -
, O +
and O +
quercitrin B-Chemical +
was O +
the O +
weakest O -
. O +

A O +
noticeable O +
synergistic O +
effect O +
was O +
observed O +
with O +
the O +
inhibition O +
of O +
cell O +
proliferation O +
when O +
myricetin B-Chemical +
was O +
used O +
in O +
combination O +
with O +
myricitrin B-Chemical -
. O +

In O +
the O +
concentration O +
range O +
of O +
37.5 O -
- O -
300 O +
μmol O -
/ O -
L O -
, O +
the O +
inhibitory O +
effects O +
of O +
these O +
flavonoids B-Chemical +
were O +
enhanced O +
with O +
increasing O +
dose O +
and O +
treatment O +
time O -
. O +

The O +
acridine B-Chemical +
orange I-Chemical +
analysis O +
and O +
annexin O +
V O -
- O -
FITC B-Chemical -
/ O -
PI O +
double O -
- O -
staining O +
results O +
confirmed O +
that O +
myricetin B-Chemical +
and O +
myricitrin B-Chemical +
were O +
effective O +
in O +
inducing O +
PC-3 O +
cell O +
apoptosis O -
. O +

The O +
results O +
showed O +
that O +
myricetin B-Chemical +
was O +
more O +
effective O +
than O +
myricitrin B-Chemical +
in O +
inducing O +
cell O +
apoptosis O -
. O +

The O +
apoptosis O +
rate O +
increased O +
with O +
increasing O +
flavonoid B-Chemical +
concentration O +
in O +
a O +
dose O +
dependent O +
manner O -
. O +

A O +
synergistic O +
effect O +
was O +
observed O +
on O +
the O +
apoptosis O +
rate O +
when O +
myricetin B-Chemical +
was O +
used O +
in O +
combination O +
with O +
myricitrin B-Chemical -
. O +

Assessment O +
of O +
DFG O -
- O -
S19 O +
method O +
for O +
the O +
determination O +
of O +
common O +
endocrine O +
disruptor O +
pesticides O +
in O +
wine O +
samples O +
with O +
an O +
estimation O +
of O +
the O +
uncertainty O +
of O +
the O +
analytical O +
results O -
. O +

A O +
gas O +
chromatographic O +
method O +
for O +
the O +
determination O +
of O +
endocrine O +
disruptor O +
pesticides O +
( O -
Chlorpyrifos B-Chemical -
, O +
Penconazole B-Chemical -
, O +
Procymidone B-Chemical -
, O +
Iprodione B-Chemical -
, O +
Bromopropylate B-Chemical +
and O +
Lambda B-Chemical -
- I-Chemical -
Cyhalothrin I-Chemical -
) O +
in O +
wine O +
samples O +
is O +
described O -
. O +

A O +
general O +
DFG O -
- O -
S19 O +
method O +
for O +
residual O +
pesticide O +
determination O +
in O +
all O +
kind O +
of O +
food O +
stuff O +
was O +
investigated O +
to O +
simplify O +
and O +
adopt O +
for O +
wine O +
samples O +
in O +
this O +
work O -
. O +

Alternative O +
sample O +
preparation O +
routes O +
were O +
elucidated O +
and O +
compared O +
according O +
to O +
their O +
recovery O +
values O -
. O +

Four O +
different O +
separation O +
techniques O +
were O +
tested O +
and O +
the O +
method O +
employing O +
florosil B-Chemical +
column O +
after O +
a O +
LLE O +
procedure O +
was O +
applied O +
for O +
wine O +
samples O +
with O +
satisfactory O +
recovery O +
ratios O +
( O -
72 O -
- O -
97 O -
% O -
) O -
. O +

The O +
pesticides O +
were O +
extracted O +
from O +
the O +
sample O +
by O +
cyclohexane B-Chemical -
- O -
ethyl B-Chemical +
acetate I-Chemical +
mixture O +
( O -
1:1 O +
v O -
/ O -
v O -
) O +
and O +
cleaned O +
up O +
by O +
florosil B-Chemical +
column O -
. O +

The O +
regression O +
coefficients O +
were O +
at O +
least O +
0.99 O +
and O +
relative O +
standard O +
deviations O +
were O +
no O +
higher O +
than O +
16 O -
% O -
. O +

Detection O +
limits O +
were O +
in O +
the O +
range O +
of O +
0.6 O -
- O -
2.9 O +
ng O -
/ O -
mL O +
and O +
the O +
relative O +
expanded O +
measurement O +
uncertainties O +
were O +
calculated O +
in O +
the O +
7 O -
- O -
22 O -
% O +
range O -
. O +

Quality O +
of O +
bread O +
supplemented O +
with O +
mushroom O +
mycelia O -
. O +

Mushroom O +
mycelia O +
of O +
Antrodia O +
camphorata O -
, O +
Agaricus O +
blazei O -
, O +
Hericium O +
erinaceus O +
and O +
Phellinus O +
linteus O +
were O +
used O +
to O +
substitute O +
5 O -
% O +
of O +
wheat O +
flour O +
to O +
make O +
bread O -
. O +

Bread O +
quality O -
, O +
including O +
specific O +
volume O -
, O +
colour O +
property O -
, O +
equivalent O +
umami O +
concentration O +
( O -
EUC O -
) O -
, O +
texture O +
profile O +
analysis O -
, O +
sensory O +
evaluation O +
and O +
functional O +
components O -
, O +
was O +
analysed O -
. O +

Mycelium O -
- O -
supplemented O +
bread O +
was O +
smaller O +
in O +
loaf O +
volume O +
and O +
coloured O -
, O +
and O +
had O +
lower O +
lightness O +
and O +
white O +
index O +
values O -
. O +

White O +
bread O +
contained O +
the O +
lowest O +
amounts O +
of O +
free O +
umami O +
amino B-Chemical +
acids I-Chemical +
and O +
umami O +
5'-nucleotides O +
and O +
showed O +
the O +
lowest O +
EUC O +
value O -
. O +

Incorporating O +
5 O -
% O +
mushroom O +
mycelia O +
into O +
the O +
bread O +
formula O +
did O +
not O +
adversely O +
affect O +
the O +
texture O +
profile O +
of O +
the O +
bread O -
. O +

However O -
, O +
incorporating O +
5 O -
% O +
mushroom O +
mycelia O +
into O +
the O +
bread O +
formula O +
did O +
lower O +
bread O -
's O +
acceptability O -
. O +

After O +
baking O -
, O +
mycelium O -
- O -
supplemented O +
bread O +
still O +
contained O +
substantial O +
amounts O +
of O +
γ B-Chemical -
- I-Chemical -
aminobutyric I-Chemical +
acid I-Chemical +
and O +
ergothioneine B-Chemical +
( O -
0.23 O -
- O -
0.86 O +
and O +
0.79 O -
- O -
2.10 O +
mg O -
/ O -
g O +
dry O +
matter O -
, O +
respectively O -
) O -
. O +

Overall O -
, O +
mushroom O +
mycelium O +
could O +
be O +
incorporated O +
into O +
bread O +
to O +
provide O +
its O +
beneficial O +
health O +
effects O -
. O +

Natural O +
occurrence O +
of O +
deoxynivalenol B-Chemical +
in O +
wheat O +
from O +
Paraná O +
State O -
, O +
Brazil O +
and O +
estimated O +
daily O +
intake O +
by O +
wheat O +
products O -
. O +

The O +
occurrence O +
of O +
deoxynivalenol B-Chemical +
( O -
DON B-Chemical -
) O +
was O +
evaluated O +
in O +
113 O +
wheat O +
samples O +
from O +
the O +
northern O +
and O +
central O -
/ O -
southwestern O +
regions O +
of O +
Paraná O +
State O -
, O +
Brazil O +
during O +
the O +
2008 O +
and O +
2009 O +
growing O +
seasons O -
, O +
and O +
this O +
rate O +
of O +
occurrence O +
was O +
used O +
to O +
estimate O +
the O +
DON B-Chemical +
dietary O +
exposure O -
. O +

The O +
DON B-Chemical +
determination O +
was O +
carried O +
out O +
by O +
an O +
indirect O +
competitive O +
enzyme O -
- O -
linked O +
immunosorbent O +
assay O -
. O +

DON B-Chemical +
was O +
detected O +
in O +
66.4 O -
% O +
samples O +
at O +
levels O +
ranging O +
from O +
206.3 O +
to O +
4732.3 O +
μg O -
/ O -
kg O +
( O -
mean O +
1894.9 O +
μg O -
/ O -
kg O -
) O -
. O +

The O +
estimated O +
daily O +
intake O +
( O -
EDI O -
) O +
of O +
DON B-Chemical +
through O +
bread O +
and O +
pasta O +
was O +
evaluated O +
in O +
the O +
inhabitants O +
of O +
Londrina O +
City O +
in O +
northern O +
Paraná O +
State O -
, O +
Brazil O -
. O +

The O +
average O +
intake O +
of O +
these O +
inhabitants O +
was O +
0.79 O +
μg O -
/ O -
kg O +
body O +
weight O +
( O -
b.w O -
. O -
) O +
for O +
bread O +
and O +
0.35 O +
μg O -
/ O -
kg O +
b.w O -
. O +

for O +
pasta O -
. O +

The O +
total O +
EDI O +
was O +
1.13 O +
μg O -
/ O -
kg O -
, O +
which O +
is O +
above O +
the O +
Provisional O +
Tolerable O +
Daily O +
Maximum O +
Intake O +
( O -
PTDMI O -
) O +
of O +
1 O +
μg O -
/ O -
kg O +
b.w O -
. O +

To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
report O +
on O +
natural O +
DON B-Chemical +
occurrence O +
in O +
wheat O +
and O +
DON B-Chemical +
dietary O +
exposure O +
estimation O +
from O +
Paraná O -
, O +
Brazil O -
. O +

Hepatoprotective O +
effect O +
of O +
2,3-dehydrosilybin B-Chemical +
on O +
carbon B-Chemical +
tetrachloride I-Chemical -
- O -
induced O +
liver O +
injury O +
in O +
rats O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
protective O +
effect O +
of O +
2,3-dehydrosilybin B-Chemical +
( O -
DHS B-Chemical -
) O +
against O +
carbon B-Chemical +
tetrachloride I-Chemical +
( O -
CCl B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
) O -
-induced O +
liver O +
injury O +
in O +
rats O -
. O +

Administration O +
of O +
DHS B-Chemical +
significantly O +
attenuated O +
the O +
levels O +
of O +
serum O +
aspartate B-Chemical +
aminotransferase O -
, O +
alanine B-Chemical +
aminotransferase O -
, O +
and O +
liver O +
lipid O +
peroxidation O +
in O +
CCl B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
-treated O +
rats O -
. O +

Moreover O -
, O +
we O +
showed O +
that O +
DHS B-Chemical +
prevented O +
DNA O +
damage O +
and O +
decreased O +
the O +
protein O +
levels O +
of O +
γ O -
- O -
H2AX O -
, O +
which O +
is O +
a O +
specific O +
DNA O +
damage O +
marker O -
, O +
in O +
CCl B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
-treated O +
rat O +
livers O -
. O +

DHS O +
also O +
markedly O +
increased O +
the O +
activity O +
of O +
antioxidant O +
enzymes O -
, O +
such O +
as O +
superoxide B-Chemical +
dismutase O -
, O +
catalase O -
, O +
glutathione B-Chemical +
peroxidase O -
, O +
and O +
glutathione O +
reductase O +
in O +
CCl B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
-treated O +
rat O +
livers O -
. O +

Furthermore O -
, O +
we O +
found O +
that O +
DHS B-Chemical +
significantly O +
inhibited O +
the O +
production O +
of O +
serum O +
nitric B-Chemical +
oxide I-Chemical +
as O +
well O +
as O +
the O +
levels O +
of O +
serum O +
IL-6 O -
, O +
IFN O -
- O -
γ O -
, O +
and O +
TNF O -
- O -
α O +
in O +
CCl B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
-treated O +
rats O -
. O +

Additionally O -
, O +
DHS B-Chemical +
significantly O +
suppressed O +
iNOS O +
expression O +
on O +
the O +
protein O +
levels O +
in O +
CCl B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
-treated O +
rat O +
livers O -
. O +

Collectively O -
, O +
the O +
present O +
study O +
suggests O +
that O +
DHS B-Chemical +
protects O +
the O +
liver O +
from O +
CCl B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
-induced O +
hepatic O +
damage O +
via O +
antioxidant O +
and O +
anti O -
- O -
inflammatory O +
mechanisms O -
. O +

Development O +
of O +
a O +
rapid O +
and O +
simple O +
voltammetric O +
method O +
to O +
determine O +
total O +
antioxidative O +
capacity O +
of O +
edible O +
oils O -
. O +

In O +
this O +
work O +
we O +
report O +
on O +
a O +
new O -
, O +
rapid O +
and O +
simple O +
voltammetric O +
method O +
to O +
determine O +
the O +
total O +
antioxidant O +
capacity O +
( O -
TAC O -
) O +
of O +
the O +
edible O +
oils O -
. O +

The O +
method O +
explores O +
the O +
ABTS B-Chemical +
radical O +
( O -
2,2'-azinobis B-Chemical -
( I-Chemical -
3-ethylbenzothiazoline-6-sulphonic I-Chemical +
acid I-Chemical -
) I-Chemical -
) O +
assay O +
as O +
a O +
redox O +
probe O +
and O +
it O +
relays O +
on O +
measuring O +
catalytic O +
voltammetric O +
currents O -
. O +

The O +
electrocatalysis O +
comprises O +
redox O +
regeneration O +
of O +
the O +
electrochemically O +
created O +
ABTS B-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical +
radical O +
either O +
by O +
Trolox B-Chemical +
( O -
6-hydroxy-2,5,7,8-tetramethychroman-2-carboxylic B-Chemical +
acid I-Chemical -
) O +
or O +
by O +
antioxidants O +
present O +
in O +
studied O +
oils O -
. O +

The O +
detection O +
limit O +
of O +
the O +
method O +
is O +
determined O +
to O +
be O +
0.5 O +
mg O -
/ O -
L O +
of O +
Trolox B-Chemical +
equivalent O -
, O +
being O +
a O +
slightly O +
lower O +
than O +
the O +
corresponding O +
UV O -
- O -
VIS O +
spectrophotometric O +
method O -
. O +

Applying O +
the O +
proposed O +
voltammetric O +
method O +
the O +
total O +
antioxidant O +
capacity O +
of O +
three O +
types O +
of O +
commercially O +
available O +
cold O -
- O -
pressed O +
edible O +
oils O +
are O +
determined O -
, O +
and O +
the O +
results O +
are O +
found O +
to O +
be O +
in O +
a O +
very O +
good O +
agreement O +
with O +
those O +
obtained O +
by O +
UV O -
- O -
VIS O +
spectrophotometry O -
. O +

The O +
reported O +
voltammetric O +
method O +
is O +
cheap O -
, O +
rapid O +
and O +
simple O -
, O +
and O +
it O +
can O +
be O +
used O +
as O +
a O +
sustainable O +
alternative O +
to O +
the O +
UV O -
- O -
VIS O +
methods O +
for O +
the O +
determination O +
of O +
total O +
antioxidant O +
capacitance O +
of O +
oils O +
and O +
other O +
liquid O +
lipophilic O +
nutrients O -
. O +

Potent O +
antioxidant O +
capacity O +
of O +
studied O +
oils O +
was O +
also O +
confirmed O +
by O +
electron O +
paramagnetic O +
resonance O +
spectroscopy O +
of O +
superoxide B-Chemical +
anion O +
produced O +
by O +
macrophages O -
. O +

Effect O +
of O +
the O +
genistein B-Chemical +
metabolite O +
on O +
leptin O +
secretion O +
in O +
murine O +
adipocytes O +
in O +
vitro O -
. O +

Soy O +
isoflavonoids B-Chemical +
have O +
many O +
useful O +
properties O -
. O +

However O -
, O +
they O +
are O +
metabolized O +
in O +
vivo O -
, O +
including O +
in O +
humans O -
. O +

The O +
effect O +
of O +
the O +
metabolism O +
of O +
soy O +
isoflavonoids B-Chemical +
on O +
their O +
properties O +
is O +
not O +
fully O +
understood O -
. O +

We O +
have O +
isolated O +
the O +
bacterial O +
strain O +
SY8519 O -
, O +
which O +
has O +
been O +
shown O +
to O +
metabolize O +
daidzein B-Chemical +
to O +
O B-Chemical -
- I-Chemical -
desmethylangolensin I-Chemical +
and O +
to O +
produce O +
2- B-Chemical -
( I-Chemical -
4-hydroxyphenyl I-Chemical -
) I-Chemical -
propionic I-Chemical +
acid I-Chemical +
from O +
genistein B-Chemical -
. O +

According O +
to O +
chiral O +
HPLC O +
analysis O -
, O +
the O +
2- B-Chemical -
( I-Chemical -
4-hydroxyphenyl I-Chemical -
) I-Chemical -
propionic I-Chemical +
acid I-Chemical +
obtained O +
from O +
the O +
bacterium O +
was O +
optically O +
active O -
. O +

To O +
determine O +
the O +
absolute O +
stereochemistry O +
of O +
the O +
microbial O +
product O -
, O +
we O +
prepared O +
( B-Chemical -
S I-Chemical -
) I-Chemical -
-2- I-Chemical -
( I-Chemical -
4-hydroxyphenyl I-Chemical -
) I-Chemical -
propionic I-Chemical +
acid I-Chemical +
from O +
( B-Chemical -
S I-Chemical -
) I-Chemical -
-2-phenylpropionic I-Chemical +
and O +
concluded O +
that O +
the O +
microbial O +
product O +
had O +
an O +
R O -
- O -
configuration O +
by O +
chiral O +
HPLC O +
analysis O -
. O +

We O +
also O +
applied O +
the O +
metabolite O +
to O +
mouse O +
adipocytes O +
and O +
found O +
that O +
2-HPPA B-Chemical +
was O +
less O +
effective O +
at O +
reducing O +
leptin O +
secretion O +
than O +
the O +
parent O +
compound O +
genistein B-Chemical -
. O +

Our O +
results O +
suggested O +
that O +
' O -
O B-Chemical -
- I-Chemical -
desmethylangolensin I-Chemical -
- O -
production O -
' O +
attenuates O +
the O +
effect O +
of O +
soy O +
isoflavonoids B-Chemical +
by O +
reducing O +
not O +
only O +
the O +
activity O +
of O +
daidzein B-Chemical +
but O +
also O +
that O +
of O +
genistein B-Chemical -
. O +

Simultaneous O +
detection O +
of O +
flavonoids B-Chemical +
and O +
phenolic B-Chemical +
acids I-Chemical +
in O +
Herba O +
Lysimachiae O +
and O +
Herba O +
Desmodii O +
Styracifolii O +
using O +
liquid O +
chromatography O +
tandem O +
mass O +
spectrometry O -
. O +

A O +
sensitive O +
liquid O +
chromatography O +
and O +
tandem O +
mass O +
spectrometry O +
( O -
LC O -
- O -
MS O -
/ O -
MS O -
) O +
method O +
was O +
developed O +
and O +
validated O +
for O +
the O +
simultaneous O +
analysis O +
of O +
15 O +
flavonoids B-Chemical +
and O +
3 O +
phenolic B-Chemical +
acids I-Chemical +
in O +
Herba O +
Lysimachiae O +
and O +
Herba O +
Desmodii O +
Styracifolii O -
. O +

Separation O +
was O +
performed O +
using O +
a O +
Diamonsil O +
C O -
( O -
18 O -
) O +
column O -
, O +
which O +
was O +
eluted O +
with O +
methanol B-Chemical +
( O -
A O -
) O +
and O +
0.1‰ O +
acetic B-Chemical +
acid I-Chemical +
( O -
B O -
) O -
. O +

The O +
gradient O +
condition O +
was O +
as O +
follows O -
: O +
0 O -
- O -
34 O +
min O -
, O +
20 O -
- O -
34 O -
% O +
A O -
; O +
34 O -
- O -
38 O +
min O -
, O +
34 O -
- O -
95 O -
% O +
A O -
; O +
maintained O +
95 O -
% O +
A O +
for O +
the O +
next O +
4 O +
min O -
. O +

Analytes O +
were O +
detected O +
using O +
a O +
hybrid O +
quadrupole O +
linear O +
ion O +
trap O +
mass O +
spectrometer O +
that O +
was O +
equipped O +
with O +
an O +
electrospray O +
ionisation O +
source O +
in O +
the O +
negative O +
ion O +
and O +
multiple O -
- O -
reaction O +
monitoring O +
modes O -
. O +

A O +
full O +
validation O +
of O +
the O +
method O +
was O +
performed O -
, O +
including O +
the O +
linearity O -
, O +
precision O -
, O +
and O +
accuracy O -
, O +
as O +
well O +
as O +
limits O +
of O +
detection O +
and O +
quantification O -
. O +

The O +
results O +
indicated O +
that O +
the O +
developed O +
method O +
was O +
simple O -
, O +
sensitive O +
and O +
reliable O -
. O +

Furthermore O -
, O +
the O +
method O +
was O +
successfully O +
applied O +
to O +
differentiate O +
16 O +
batches O +
of O +
Herba O +
Lysimachiae O +
and O +
21 O +
batches O +
of O +
Herba O +
Desmodii O +
Styracifolii O -
. O +

Differentiation O +
of O +
Sparidae O +
species O +
by O +
DNA O +
sequence O +
analysis O -
, O +
PCR O -
- O -
SSCP O +
and O +
IEF O +
of O +
sarcoplasmic O +
proteins O -
. O +

The O +
increasing O +
global O +
trade O +
of O +
fishery O +
and O +
aquaculture O +
products O +
makes O +
it O +
necessary O +
to O +
develop O +
methods O +
for O +
species O +
identification O +
in O +
case O +
of O +
fish O +
fillets O +
or O +
other O +
highly O +
processed O +
seafood O +
with O +
external O +
morphological O +
characteristics O +
( O -
e.g. O +
gills O -
, O +
fins O -
) O +
of O +
the O +
original O +
fish O +
being O +
removed O -
. O +

Species O +
identification O +
methods O +
based O +
on O +
DNA- O +
or O +
protein O -
- O -
analysis O -
, O +
like O +
DNA O +
sequencing O +
of O +
PCR O +
products O -
, O +
PCR O -
- O -
SSCP O +
( O -
polymerase O +
chain O +
reaction O +
- O +
single O +
strand O +
conformation O +
polymorphism O -
) O -
, O +
and O +
isoelectric O +
focusing O +
( O -
IEF O -
) O +
of O +
water O -
- O -
soluble O +
proteins O +
of O +
fish O +
fillet O +
were O +
applied O +
successfully O +
to O +
distinguish O +
between O +
various O +
sparid O +
species O +
including O +
Sparus O +
aurata O -
, O +
Spondyliosoma O +
cantharus O -
, O +
Boops O +
boops O -
, O +
Acanthopagrus O +
bifasciatus O -
, O +
Argyrops O +
spinifer O -
, O +
Pagellus O +
bogaraveo O +
and O +
Lithognathus O +
mormyrus O +
of O +
the O +
family O +
Sparidae O +
available O +
on O +
European O +
markets O -
. O +

Indication O +
of O +
the O +
presence O +
of O +
parvalbumins O +
in O +
light O +
muscle O +
of O +
all O +
of O +
the O +
studied O +
species O +
is O +
presented O +
by O +
the O +
location O +
of O +
heat O -
- O -
stable O +
proteins O +
in O +
the O +
anodic O +
range O +
of O +
the O +
IEF O +
gels O -
. O +

Exploration O +
of O +
Vanilla O +
pompona O +
from O +
the O +
Peruvian O +
Amazon O +
as O +
a O +
potential O +
source O +
of O +
vanilla O +
essence O -
: O +
quantification O +
of O +
phenolics B-Chemical +
by O +
HPLC O -
- O -
DAD O -
. O +

This O +
study O +
provides O +
the O +
first O +
chemical O +
investigation O +
of O +
wild O -
- O -
harvested O +
fruits O +
of O +
Vanilla O +
pompona O +
ssp O -
. O +

grandiflora O +
( O -
Lindl O -
. O -
) O +

Soto O -
- O -
Arenas O +
developed O +
in O +
their O +
natural O +
habitat O +
in O +
the O +
Peruvian O +
Amazon O -
. O +

Flowers O +
were O +
hand O -
- O -
pollinated O +
and O +
the O +
resulting O +
fruits O +
were O +
analysed O +
at O +
different O +
developmental O +
stages O +
using O +
an O +
HPLC O -
- O -
DAD O +
method O +
validated O +
for O +
the O +
quantification O +
of O +
glucovanillin B-Chemical +
and O +
seven O +
other O +
compounds O -
. O +

The O +
method O +
showed O +
satisfactory O +
linearity O +
( O -
r O -
( O -
2 O -
) O -
>0.9969 O -
) O -
, O +
precision O +
( O -
coefficient O +
of O +
variation O +
< O -
2 O -
% O -
) O -
, O +
recoveries O +
( O -
70 O -
- O -
100 O -
% O -
) O -
, O +
limit O +
of O +
detection O +
( O -
0.008 O -
- O -
0.212 O +
μg O -
/ O -
ml O -
) O -
, O +
and O +
limit O +
of O +
quantification O +
( O -
0.027 O -
- O -
0.707 O +
μg O -
/ O -
ml O -
) O -
. O +

The O +
evaluation O +
of O +
crude O +
and O +
enzyme O -
- O -
hydrolyzed O +
Soxhlet O -
- O -
extracted O +
samples O +
confirmed O +
the O +
leading O +
role O +
of O +
glucosides O +
in O +
fruit O +
development O -
. O +

LC O -
- O -
ESI O -
- O -
MS O +
studies O +
corroborated O +
the O +
identities O +
of O +
four O +
glucosides O +
and O +
seven O +
aglycones O -
, O +
among O +
them O +
vanillin B-Chemical +
( O -
5.7 O -
/ O -
100 O +
g O -
) O -
, O +
4-hydroxybenzyl B-Chemical +
alcohol I-Chemical +
( O -
3.6 O -
/ O -
100 O +
g O -
) O -
, O +
and O +
anisyl B-Chemical +
alcohol I-Chemical +
( O -
7.1 O -
/ O -
100 O +
g O -
) O +
were O +
found O +
in O +
high O +
concentrations O -
. O +

The O +
attractive O +
flavor O -
/ O -
aroma O +
profile O +
exhibited O +
by O +
wild O +
V. O +
pompona O +
fruits O +
supports O +
studies O +
focused O +
on O +
the O +
development O +
of O +
this O +
species O +
as O +
a O +
specialty O +
crop O -
. O +

Nutritive O +
value O +
of O +
masau O +
( O -
Ziziphus O +
mauritiana O -
) O +
fruits O +
from O +
Zambezi O +
Valley O +
in O +
Zimbabwe O -
. O +

Ziziphus O +
mauritiana O +
( O -
masau O -
) O +
fruits O +
are O +
consumed O +
by O +
many O +
people O +
in O +
Zimbabwe O -
. O +

The O +
fruits O +
contribute O +
significantly O +
to O +
people O -
's O +
diet O +
when O +
they O +
are O +
in O +
season O -
. O +

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
determine O +
the O +
nutritional O +
content O +
of O +
the O +
fruits O +
and O -
, O +
hence O -
, O +
quantify O +
their O +
contribution O +
to O +
the O +
diet O -
. O +

Samples O +
of O +
masau O +
were O +
collected O +
in O +
two O +
seasons O +
( O -
August O +
2006 O +
and O +
August O +
2007 O -
) O -
. O +

Both O +
macronutrients O +
and O +
micronutrients O +
were O +
determined O +
using O +
standard O +
AOAC O +
methods O +
of O +
analysis O -
. O +

Dry O +
matter O +
content O +
ranged O +
from O +
21.1±0.2 O +
to O +
24.1±0.3 O +
g O +
100 O +
g O -
( O -
-1 O -
) O +
of O +
edible O +
portion O +
of O +
the O +
sweet O +
and O +
sour O +
fruits O -
, O +
and O +
84.8±0.2 O +
to O +
87.2±0.2 O +
g O +
100 O +
g O -
( O -
-1 O -
) O +
for O +
the O +
dried O +
fruit O -
. O +

Crude O +
protein O +
per O +
100 O -
g O +
edible O +
portion O +
of O +
dry O +
weight O +
ranged O +
between O +
7.9±0.0 O +
and O +
8.7±0.0 O +
g O -
, O +
crude O +
fat O +
from O +
0.8±0.0 O +
to O +
1.5±0.0 O +
g O -
, O +
crude O +
fibre O +
from O +
4.9±0.0 O +
to O +
7.3±0.0 O +
g O -
, O +
ash O +
between O +
3.0±0.0 O +
and O +
4.3±0.0 O +
g O +
and O +
carbohydrate B-Chemical +
between O +
79.5±0.0 O +
and O +
83.2±0.0 O +
g. O +

The O +
fruits O +
were O +
rich O +
in O +
vitamin B-Chemical +
C I-Chemical +
( O -
15.0±0.0 O -
- O -
43.8±0.02 O +
mg O +
100 O +
g O -
( O -
-1 O -
) O -
) O +
and O +
the O +
energy O +
values O +
ranged O +
between O +
1516.0±1.73 O +
and O +
1575.0±2.3 O +
kJ O +
100 O +
g O -
( O -
-1 O -
) O -
. O +

Furthermore O -
, O +
the O +
fruits O +
contained O +
( O -
mg O +
100 O +
g O -
( O -
-1 O -
) O +
of O +
dry O +
weight O -
) O +
potassium B-Chemical +
from O +
1865.0±1.3 O +
to O +
2441.0±1.1 O -
, O +
calcium B-Chemical +
from O +
160.0±0.3 O +
to O +
254.0±0.1 O -
, O +
sodium B-Chemical +
between O +
185.0±0.1 O +
and O +
223.0±0.2 O -
, O +
magnesium B-Chemical +
between O +
83.0±0.0 O +
and O +
150.0±0.13 O +
and O +
phosphorous B-Chemical +
from O +
87.0±0.1 O +
to O +
148.0±0.5 O -
. O +

Manganese B-Chemical +
and O +
copper B-Chemical +
contents O +
ranged O +
between O +
0.7±0.03 O +
and O +
1.6±0.03 O -
, O +
while O +
iron B-Chemical +
and O +
zinc B-Chemical +
ranged O +
between O +
2.1±0.43 O +
and O +
4.3±0.1 O -
, O +
and O +
0.6±0.0 O -
- O -
0.9±0.0 O +
mg O +
100 O +
g O -
( O -
-1 O -
) O +
of O +
dry O +
weight O -
, O +
respectively O -
. O +

The O +
masau O +
fruit O +
is O +
therefore O +
a O +
good O +
potential O +
source O +
of O +
carbohydrates B-Chemical -
, O +
proteins O +
and O +
micronutrients O -
, O +
such O +
as O +
calcium B-Chemical -
, O +
potassium B-Chemical -
, O +
sodium B-Chemical -
, O +
phosphorous B-Chemical -
, O +
copper B-Chemical -
, O +
iron B-Chemical -
, O +
Vitamin B-Chemical +
C I-Chemical +
and O +
zinc B-Chemical -
. O +

Development O +
of O +
sample O +
preparation O +
method O +
for O +
isoliquiritigenin B-Chemical -
, O +
liquiritin B-Chemical -
, O +
and O +
glycyrrhizic B-Chemical +
acid I-Chemical +
analysis O +
in O +
licorice O +
by O +
ionic O +
liquids O -
- O -
ultrasound O +
based O +
extraction O +
and O +
high O -
- O -
performance O +
liquid O +
chromatography O +
detection O -
. O +

An O +
ionic O +
liquid O -
- O -
based O +
ultrasonic O -
- O -
assisted O +
extraction O +
( O -
ILUAE O -
) O +
method O +
had O +
been O +
used O +
for O +
the O +
effective O +
extraction O +
of O +
isoliquiritigenin B-Chemical +
( O -
IQ O -
) O -
, O +
liquiritin B-Chemical +
( O -
LQ O -
) O +
and O +
glycyrrhizic B-Chemical +
acid I-Chemical +
( O -
GA O -
) O +
from O +
licorice O -
. O +

The O +
ionic O +
liquids O +
with O +
different O +
cations O +
and O +
anions O +
were O +
investigated O +
in O +
this O +
work O +
and O +
0.5 O +
M O +
1-butyl-3-methylimidazolium B-Chemical +
bromide I-Chemical +
solution O +
was O +
selected O +
as O +
solvent O -
. O +

In O +
addition O -
, O +
the O +
technical O +
parameters O +
including O +
soaking O +
time O -
, O +
solid O -
- O -
liquid O +
ratio O -
, O +
ultrasonic O +
power O +
and O +
time O +
were O +
optimized O -
. O +

Compared O +
with O +
the O +
conventional O +
solvent O +
extraction O -
, O +
the O +
proposed O +
approach O +
exhibited O +
higher O +
efficiency O -
, O +
which O +
indicated O +
the O +
ILUAE O +
was O +
an O +
efficient O -
, O +
rapid O +
and O +
simple O +
sample O +
preparation O +
technique O -
. O +

There O +
was O +
no O +
degradation O +
of O +
the O +
target O +
analytes O +
had O +
been O +
observed O +
at O +
the O +
optimum O +
conditions O +
which O +
was O +
evidenced O +
by O +
the O +
stability O +
studies O +
performed O +
with O +
standard O +
of O +
IQ O -
, O +
LQ O +
and O +
GA O -
. O +

The O +
proposed O +
method O +
also O +
showed O +
high O +
reproducibility O +
and O +
was O +
environmental O +
friendly O -
. O +

Comparative O +
formation O +
of O +
2-amino-1-methyl-6-phenylimidazo B-Chemical -
[ I-Chemical -
4,5-b I-Chemical -
] I-Chemical -
pyridine I-Chemical +
( O -
PhIP B-Chemical -
) O +
in O +
creatinine B-Chemical -
/ O -
phenylalanine B-Chemical +
and O +
creatinine B-Chemical -
/ O -
phenylalanine B-Chemical -
/ O -
4-oxo-2-nonenal B-Chemical +
reaction O +
mixtures O -
. O +

The O +
comparative O +
formation O +
of O +
the O +
heterocyclic O +
aromatic O +
amine O +
2-amino-1-methyl-6-phenylimidazo B-Chemical -
[ I-Chemical -
4,5-b I-Chemical -
] I-Chemical -
pyridine I-Chemical +
( O -
PhIP B-Chemical -
) O +
in O +
both O +
creatinine B-Chemical -
/ O -
phenylalanine B-Chemical +
( O -
CRN B-Chemical -
/ O -
Phe B-Chemical -
) O +
and O +
creatinine B-Chemical -
/ O -
phenylalanine B-Chemical -
/ O -
4-oxo-2-nonenal B-Chemical +
( O -
CRN B-Chemical -
/ O -
Phe B-Chemical -
/ O -
ON O -
) O +
systems O +
was O +
studied O +
to O +
analyse O +
the O +
ability O +
of O +
lipid O -
- O -
derived O +
reactive O +
carbonyls B-Chemical +
to O +
promote O +
PhIP B-Chemical +
formation O -
. O +

Although O +
PhIP B-Chemical +
was O +
produced O +
to O +
some O +
extent O +
in O +
the O +
CRN B-Chemical -
/ O -
Phe B-Chemical +
system O -
, O +
the O +
presence O +
of O +
the O +
oxidized O +
lipid O +
increased O +
considerably O +
the O +
amount O +
of O +
PhIP B-Chemical +
produced O -
. O +

This O +
increase O +
seemed O +
to O +
be O +
a O +
consequence O +
of O +
the O +
decrease O +
in O +
the O +
E O -
( O -
a O -
) O +
of O +
the O +
reaction O +
when O +
the O +
lipid O +
was O +
present O -
, O +
which O +
diminished O +
from O +
112.9 O +
to O +
80.9 O +
kJ O -
/ O -
mol O -
. O +

On O +
the O +
other O +
hand O -
, O +
the O +
addition O +
of O +
the O +
lipid O +
did O +
not O +
seem O +
to O +
produce O +
PhIP B-Chemical +
by O +
an O +
alternative O +
mechanism O +
because O +
PhIP B-Chemical +
was O +
formed O +
analogously O +
in O +
both O +
CRN B-Chemical -
/ O -
Phe B-Chemical +
and O +
CRN B-Chemical -
/ O -
Phe B-Chemical -
/ O -
ON O +
systems O +
as O +
a O +
function O +
of O +
pH O -
, O +
creatinine B-Chemical +
concentration O -
, O +
phenylalanine B-Chemical +
concentration O -
, O +
time O -
, O +
temperature O -
, O +
oxygen B-Chemical +
concentration O +
in O +
the O +
reaction O +
atmosphere O -
, O +
and O +
the O +
addition O +
of O +
different O +
amounts O +
of O +
ammonia B-Chemical -
. O +

All O +
these O +
results O +
suggest O +
that O +
the O +
ability O +
of O +
lipid O +
oxidation O +
products O +
to O +
produce O +
PhIP B-Chemical +
is O +
related O +
to O +
their O +
capacity O +
to O +
induce O +
the O +
Strecker O +
degradation O +
of O +
phenylalanine B-Chemical +
to O +
phenylacetaldehyde B-Chemical -
. O +

Therefore O -
, O +
any O +
other O +
reactive O +
carbonyl B-Chemical +
compound O +
that O +
can O +
produce O +
the O +
Strecker O +
degradation O +
of O +
phenylalanine B-Chemical +
should O +
also O +
be O +
considered O +
as O +
a O +
potential O +
inducer O +
of O +
PhIP B-Chemical +
formation O +
under O +
appropriate O +
conditions O -
. O +

Rapid O +
detecting O +
total O +
acid O +
content O +
and O +
classifying O +
different O +
types O +
of O +
vinegar O +
based O +
on O +
near O +
infrared O +
spectroscopy O +
and O +
least O -
- O -
squares O +
support O +
vector O +
machine O -
. O +

More O +
than O +
3.2 O +
million O +
litres O +
of O +
vinegar O +
is O +
consumed O +
every O +
day O +
in O +
China O -
. O +

There O +
are O +
many O +
types O +
of O +
vinegar O +
in O +
China O -
. O +

How O +
to O +
control O +
the O +
quality O +
of O +
vinegar O +
is O +
problem O -
. O +

Near O +
infrared O +
spectroscopy O +
( O -
NIR O -
) O +
transmission O +
technique O +
was O +
applied O +
to O +
achieve O +
this O +
purpose O -
. O +

Ninety O -
- O -
five O +
vinegar O +
samples O +
from O +
14 O +
origins O +
covering O +
11 O +
provinces O +
in O +
China O +
were O +
collected O -
. O +

They O +
were O +
classified O +
into O +
mature O +
vinegar O -
, O +
aromatic O +
vinegar O -
, O +
rice O +
vinegar O -
, O +
fruit O +
vinegar O -
, O +
and O +
white O +
vinegar O -
. O +

Fruit O +
vinegar O +
and O +
white O +
vinegar O +
were O +
separated O +
from O +
the O +
other O +
traditional O +
categories O +
in O +
the O +
two O -
- O -
dimension O +
principal O +
component O +
space O +
of O +
NIR O +
after O +
principle O +
component O +
analysis O +
( O -
PCA O -
) O -
. O +

Least O -
- O -
squares O +
support O +
vector O +
machine O +
( O -
LS O -
- O -
SVM O -
) O +
as O +
the O +
pattern O +
recognition O +
was O +
firstly O +
applied O +
to O +
identify O +
mature O +
vinegar O -
, O +
aromatic O +
vinegar O -
, O +
rice O +
vinegar O +
in O +
this O +
study O -
. O +

The O +
top O +
two O +
principal O +
components O +
( O -
PCs O -
) O +
were O +
extracted O +
as O +
the O +
input O +
of O +
LS O -
- O -
SVM O +
classifiers O +
by O +
principal O +
component O +
analysis O +
( O -
PCA O -
) O -
. O +

The O +
best O +
experimental O +
results O +
were O +
obtained O +
using O +
the O +
radial O +
basis O +
function O +
( O -
RBF O -
) O +
LS O -
- O -
SVM O +
classifier O +
with O +
σ=0.8 O -
. O +

The O +
accuracies O +
of O +
identification O +
were O +
more O +
than O +
85 O -
% O +
for O +
three O +
traditional O +
vinegar O +
categories O -
. O +

Compared O +
with O +
the O +
back O +
propagation O +
artificial O +
neural O +
network O +
( O -
BP O -
- O -
ANN O -
) O +
approach O -
, O +
LS O -
- O -
SVM O +
algorithm O +
showed O +
its O +
excellent O +
generalisation O +
for O +
identification O +
results O -
. O +

As O +
total O +
acid O +
content O +
( O -
TAC O -
) O +
is O +
highly O +
connecting O +
with O +
the O +
quality O +
of O +
vinegar O -
, O +
NIR O +
was O +
used O +
to O +
prediction O +
the O +
TAC O +
of O +
samples O -
. O +

LS O -
- O -
SVM O +
was O +
applied O +
to O +
building O +
the O +
TAC O +
prediction O +
model O +
based O +
on O +
spectral O +
transmission O +
rate O -
. O +

Compared O +
with O +
partial O +
least O -
- O -
square O +
( O -
PLS O -
) O +
model O -
, O +
LS O -
- O -
SVM O +
model O +
gave O +
better O +
precision O +
and O +
accuracy O +
in O +
predicting O +
TAC O -
. O +

The O +
determination O +
coefficient O +
for O +
prediction O +
( O -
R O -
( O -
p O -
) O -
) O +
of O +
the O +
LS O -
- O -
SVM O +
model O +
was O +
0.919 O +
and O +
root O +
mean O +
square O +
error O +
for O +
prediction O +
( O -
RMSEP O -
) O +
was O +
0.3226 O -
. O +

This O +
work O +
demonstrated O +
that O +
near O +
infrared O +
spectroscopy O +
technique O +
coupled O +
with O +
LS O -
- O -
SVM O +
could O +
be O +
used O +
as O +
a O +
quality O +
control O +
method O +
for O +
vinegar O -
. O +

Microwave O +
distillation O +
followed O +
by O +
headspace O +
single O +
drop O +
microextraction O +
coupled O +
to O +
gas O +
chromatography O -
- O -
mass O +
spectrometry O +
( O -
GC O -
- O -
MS O -
) O +
for O +
fast O +
analysis O +
of O +
volatile O +
components O +
of O +
Echinophora O +
platyloba O +
DC O -
. O +

To O +
avoid O +
the O +
traditional O +
and O +
time O +
consuming O +
hydrodistillation O -
, O +
the O +
analyses O +
of O +
volatile O +
components O +
in O +
aerial O +
parts O +
of O +
Echinophora O +
platyloba O +
DC O +
was O +
carried O +
out O +
by O +
a O +
simple O +
microwave O +
distillation O +
followed O +
by O +
headspace O +
single O +
drop O +
microextraction O +
( O -
MD O -
- O -
HS O -
- O -
SDME O -
) O +
coupled O +
to O +
gas O +
chromatography O -
- O -
mass O +
spectrometry O +
( O -
GC O -
- O -
MS O -
) O -
. O +

The O +
headspace O +
volatile O +
compounds O +
were O +
collected O +
after O +
irradiation O +
using O +
a O +
single O +
drop O +
of O +
n B-Chemical -
- I-Chemical -
heptadecan I-Chemical -
. O +

The O +
extraction O +
conditions O +
were O +
optimised O +
using O +
the O +
relative O +
peak O +
areas O +
as O +
index O -
. O +

The O +
chemical O +
composition O +
of O +
the O +
MD O -
- O -
HS O -
- O -
SDME O +
extracts O +
was O +
confirmed O +
according O +
to O +
their O +
retention O +
indexes O +
and O +
mass O +
spectra O -
. O +

Fifty O -
- O -
three O +
components O +
were O +
extracted O +
and O +
identified O +
by O +
using O +
the O +
MD O -
- O -
HS O -
- O -
SDME O +
method O -
. O +

E B-Chemical -
- I-Chemical -
β I-Chemical -
- I-Chemical -
ocimene I-Chemical +
( O -
53.81 O -
% O -
) O -
, O +
R O -
- O -
D O -
- O -
decalactone O +
( O -
12.75 O -
% O -
) O -
, O +
α B-Chemical -
- I-Chemical -
pinene I-Chemical +
( O -
6.43 O -
% O -
) O -
, O +
n B-Chemical -
- I-Chemical -
heptanol I-Chemical +
( O -
6.27 O -
% O -
) O -
, O +
β B-Chemical -
- I-Chemical -
phellanderne I-Chemical +
( O -
2.70 O -
% O -
) O +
and O +
linalool B-Chemical +
( O -
1.89 O -
% O -
) O +
were O +
the O +
major O +
constituents O -
. O +

Compositional O +
analysis O +
of O +
leaf O +
cuticular O +
membranes O +
isolated O +
from O +
tea O +
plants O +
( O -
Camellia O +
sinensis O +
L. O -
) O -
. O +

Chemical O +
constituents O +
of O +
cuticular O +
membranes O +
( O -
CMs O -
) O +
isolated O +
from O +
three O +
tea O +
cultivars O +
( O -
Camellia O +
sinensis O +
( O -
L. O -
) O +
O. O +
Kuntze O +
cvs O -
. O +

Yabukita O -
, O +
Samidori O +
and O +
Gokou O -
) O +
were O +
compared O -
. O +

All O +
CMs O +
from O +
the O +
adaxial O +
side O +
of O +
the O +
leaves O +
showed O +
higher O +
accumulation O +
of O +
wax O -
, O +
cutin O +
and O +
polysaccharide O -
, O +
while O +
those O +
from O +
the O +
abaxial O +
side O +
were O +
abundant O +
in O +
cutan O -
, O +
showing O +
the O +
adaptation O +
of O +
the O +
adaxial O +
side O +
to O +
abiotic O +
stresses O -
, O +
such O +
as O +
wind O +
and O +
rain O -
, O +
in O +
contrast O +
to O +
the O +
abaxial O +
side O -
, O +
which O +
provides O +
defence O +
against O +
pathogens O -
. O +

Yabukita O -
, O +
a O +
major O +
tea O +
cultivar O +
in O +
Japan O -
, O +
developed O +
thick O +
CMs O +
while O +
Samidori O +
and O +
Gokou O -
, O +
shade O -
- O -
cultivated O +
tea O +
cultivars O -
, O +
had O +
lighter O +
CMs O -
, O +
reflecting O +
their O +
thin O +
and O +
soft O +
leaves O -
. O +

CMs O +
rapidly O +
accumulated O +
9,10-epoxy-18-hydroxyoctadecanoic B-Chemical +
acid I-Chemical +
at O +
a O +
very O +
early O +
stage O +
of O +
leaf O +
development O -
. O +

Additionally O -
, O +
shade O +
treatment O +
did O +
not O +
influence O +
cutin O +
biosynthesis O +
in O +
CMs O -
, O +
reflecting O +
high O +
adaptation O +
of O +
tea O +
leaves O +
under O +
low O +
light O +
levels O -
. O +

UPLC O +
and O +
HPLC O +
of O +
caffeoyl B-Chemical +
esters I-Chemical +
in O +
wild O +
and O +
cultivated O +
Arctium O +
lappa O +
L. O +
Analytical O +
methods O +
including O +
ultra O -
- O -
performance O +
liquid O +
chromatography O +
( O -
UPLC O -
) O +
and O +
high O -
- O -
performance O +
liquid O +
chromatography O +
( O -
HPLC O -
) O +
with O +
photodiode O +
array O +
( O -
PDA O -
) O +
detector O +
were O +
developed O +
for O +
the O +
analysis O +
of O +
caffeoylquinic B-Chemical +
acid I-Chemical +
derivatives O +
in O +
seeds O -
, O +
leaves O +
and O +
roots O +
of O +
Arctium O +
lappa O +
L. O +
Separation O +
was O +
performed O +
on O +
C O -
( O -
18 O -
) O +
column O +
utilising O +
5 O -
% O +
( O -
v O -
/ O -
v O -
) O +
acetic B-Chemical +
acid I-Chemical +
in O +
water O +
and O +
acetonitrile B-Chemical +
at O +
330 O +
nm O -
. O +

Both O +
methodologies O +
were O +
validated O +
in O +
terms O +
of O +
linearity O -
, O +
precision O -
, O +
and O +
recovery O -
. O +

The O +
results O +
showed O +
that O +
the O +
major O +
advantages O +
of O +
UPLC O -
, O +
over O +
HPLC O +
were O +
the O +
fast O +
analysis O -
, O +
narrow O +
peaks O -
, O +
high O +
sensitivity O -
, O +
and O +
reduction O +
of O +
solvent O +
consumption O -
. O +

Subsequently O +
the O +
methods O +
were O +
applied O +
for O +
the O +
identification O +
and O +
quantification O +
of O +
chlorogenic B-Chemical +
acid I-Chemical +
( O -
5-CQA B-Chemical -
) O +
and O +
1,5-dicaffeoylquinic B-Chemical +
acid I-Chemical +
( O -
1,5-DCQA B-Chemical -
) O +
as O +
main O +
compounds O +
in O +
samples O -
. O +

The O +
total O +
phenolic O +
content O +
of O +
samples O +
ranged O +
from O +
3.93 O +
to O +
14.13 O +
g O +
of O +
5-CQA B-Chemical +
equivalent O -
/ O -
100 O -
g O +
dry O +
weight O +
( O -
DW O -
) O -
. O +

There O +
was O +
a O +
significant O +
variability O +
from O +
89 O +
to O +
571 O +
mg O -
/ O -
100 O -
g O +
for O +
5-CQA B-Chemical +
and O +
48 O +
to O +
486 O +
mg O -
/ O -
100 O -
g O +
for O +
1,5-DCQA B-Chemical +
in O +
dry O +
material O -
. O +

Structural O +
property O +
of O +
soybean O +
lunasin O +
and O +
development O +
of O +
a O +
method O +
to O +
quantify O +
lunasin O +
in O +
plasma O +
using O +
an O +
optimized O +
immunoassay O +
protocol O -
. O +

Lunasin O +
is O +
a O +
43-amino O +
acid O +
naturally O +
occurring O +
chemopreventive O +
peptide O +
with O +
demonstrated O +
anti O -
- O -
cancer O +
and O +
anti O -
- O -
inflammatory O +
properties O -
. O +

The O +
objectives O +
of O +
this O +
study O +
were O +
to O +
determine O +
the O +
effect O +
of O +
temperature O +
on O +
the O +
secondary O +
structure O +
of O +
lunasin O -
, O +
to O +
develop O +
a O +
method O +
of O +
isolating O +
lunasin O +
from O +
human O +
plasma O +
using O +
an O +
ion O -
- O -
exchange O +
microspin O +
column O +
and O +
to O +
quantify O +
the O +
amount O +
of O +
lunasin O +
using O +
an O +
optimized O +
enzyme O -
- O -
linked O +
immunosorbent O +
assay O -
. O +

Lunasin O +
was O +
purified O +
using O +
a O +
combination O +
of O +
ion O -
- O -
exchange O +
chromatography O -
, O +
ultrafiltration O +
and O +
gel O +
filtration O +
chromatography O -
. O +

Circular O +
dichroism O +
showed O +
that O +
increased O +
in O +
temperature O +
from O +
25 O +
to O +
100 O +
° O -
C O +
resulted O +
in O +
changes O +
on O +
the O +
secondary O +
structure O +
of O +
lunasin O +
and O +
its O +
capability O +
to O +
interact O +
with O +
rabbit O +
polyclonal O +
antibody O -
. O +

Enzyme O +
linked O +
immunosorbent O +
assay O +
showed O +
that O +
lunasin O +
rabbit O +
polyclonal O +
antibody O +
has O +
a O +
titer O +
of O +
250 O +
and O +
a O +
specific O +
activity O +
of O +
0.05 O +
mL O -
/ O -
μg O -
. O +

A O +
linear O +
response O +
was O +
detected O +
between O +
16 O +
to O +
48 O +
ng O +
lunasin O +
per O +
mL O +
( O -
y=0.03x-0.38 O -
, O +
R O -
( O -
2 O -
) O -
=0.96 O -
) O -
. O +

The O +
use O +
of O +
diethylaminoethyl B-Chemical +
microspin O +
column O +
to O +
isolate O +
spiked O +
lunasin O +
in O +
human O +
plasma O +
showed O +
that O +
most O +
lunasin O +
( O -
37.8 O -
- O -
46.5 O -
% O -
) O +
bound O +
to O +
the O +
column O +
eluted O +
with O +
Tris B-Chemical -
- I-Chemical -
HCl I-Chemical +
buffer O -
, O +
pH O +
7.5 O +
with O +
a O +
yield O +
up O +
to O +
76.6 O -
% O -
. O +

In O +
conclusion O -
, O +
lunasin O +
can O +
be O +
isolated O +
from O +
human O +
plasma O +
by O +
a O +
simple O +
DEAE O +
microspin O +
column O +
technique O +
and O +
can O +
be O +
quantified O +
using O +
a O +
validated O +
and O +
optimized O +
immunoassay O +
procedure O -
. O +

This O +
method O +
can O +
be O +
used O +
directly O +
to O +
quantify O +
lunasin O +
from O +
plasma O +
in O +
different O +
human O +
and O +
animal O +
studies O +
aiming O +
to O +
determine O +
its O +
bioavailability O -
. O +

Influence O +
of O +
processing O +
on O +
the O +
volatile O +
profile O +
of O +
strawberry O +
spreads O +
made O +
with O +
isomaltulose B-Chemical -
. O +

A O +
new O +
strawberry O +
spread O +
formulated O +
with O +
fructose B-Chemical +
and O +
isomaltulose B-Chemical +
( O -
replacing O +
sucrose B-Chemical +
partially O +
or O +
totally O -
) O +
and O +
a O +
high O +
percentage O +
of O +
fruit O +
was O +
developed O +
in O +
line O +
with O +
the O +
new O +
trend O +
of O +
healthier O +
products O -
. O +

This O +
work O +
studies O +
the O +
influence O +
of O +
some O +
process O +
variables O +
( O -
percentage O +
of O +
sugar B-Chemical -
, O +
pectin O +
and O +
citric B-Chemical +
acid I-Chemical -
, O +
and O +
time O +
of O +
thermal O +
treatment O -
) O +
on O +
the O +
volatile O +
profile O +
of O +
these O +
spreads O +
with O +
different O +
formulations O -
. O +

The O +
ripeness O +
of O +
the O +
raw O +
strawberries O +
influences O +
the O +
concentrations O +
of O +
some O +
of O +
the O +
compounds O +
in O +
the O +
spreads O -
, O +
such O +
as O +
isobutyl B-Chemical +
acetate I-Chemical -
, O +
butyl B-Chemical +
butyrate I-Chemical -
, O +
3-hexen-1-yl B-Chemical +
acetate I-Chemical +
or O +
propan-2-ol B-Chemical -
. O +

The O +
process O +
conditions O +
have O +
an O +
important O +
effect O +
on O +
the O +
volatile O +
profiles O -
. O +

Most O +
of O +
the O +
esters B-Chemical +
and O +
alcohols B-Chemical +
decreased O +
whereas O +
13 O +
new O +
compounds O +
appear O -
, O +
mostly O +
furans B-Chemical +
( O -
furfural B-Chemical -
, O +
2-acetylfurane B-Chemical -
, O +
5-methyl B-Chemical +
furfural I-Chemical -
, O +
mesifurane B-Chemical -
) O +
and O +
aldehydes B-Chemical +
( O -
octanal B-Chemical -
, O +
nonanal B-Chemical -
, O +
decanal B-Chemical +
and O +
benzaldeyhde B-Chemical -
) O -
. O +

In O +
general O -
, O +
the O +
spreads O +
formulated O +
with O +
sucrose B-Chemical -
- O -
isomaltulose B-Chemical +
that O +
contained O +
higher O +
levels O +
of O +
pectin O +
and O +
citric B-Chemical +
acid I-Chemical +
gave O +
better O +
results O +
in O +
the O +
preservation O +
of O +
the O +
original O +
aromatic O +
compounds O +
in O +
raw O +
strawberries O -
. O +

Optimization O +
of O +
ABTS B-Chemical +
radical I-Chemical +
cation I-Chemical +
assay O +
specifically O +
for O +
determination O +
of O +
antioxidant O +
capacity O +
of O +
intracellular O +
extracts O +
of O +
microalgae O +
and O +
cyanobacteria O -
. O +

A O +
renewed O +
interest O +
in O +
antioxidants O +
has O +
arisen O +
in O +
recent O +
years O -
; O +
microalgae O +
and O +
cyanobacteria O +
are O +
potential O +
sources O +
thereof O +
for O +
use O +
as O +
food O -
/ O -
feed O +
ingredients O -
. O +

However O -
, O +
improved O +
methods O +
for O +
comprehensive O +
screening O +
of O +
antioxidant O +
capacity O +
specifically O +
in O +
intracellular O +
extracts O +
of O +
marine O +
microorganisms O +
are O +
required O +
- O +
encompassing O +
lipophilic O +
and O +
hydrophilic O +
compounds O +
simultaneously O -
. O +

The O +
original O +
ABTS B-Chemical +
method O +
was O +
thus O +
improved O -
, O +
and O +
in O +
particular O +
the O +
procedures O +
of O +
cell O +
disruption O +
and O +
storage O +
were O +
optimized O -
. O +

The O +
best O +
solvent O +
found O +
was O +
ethanol B-Chemical -
/ O -
water O +
( O -
1:1 O -
, O +
v O -
/ O -
v O -
) O -
. O +

The O +
reaction O +
to O +
form O +
ABTS B-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical +
in O +
said O +
solvent O +
was O +
essentially O +
complete O +
by O +
eight O +
hours O -
, O +
and O +
this O +
radical O +
cation O +
was O +
stable O +
for O +
at O +
least O +
6 O +
days O -
; O +
at O +
room O +
temperature O -
, O +
the O +
ABTS B-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical +
solution O +
remained O +
within O +
an O +
allowable O +
analytical O +
range O +
for O +
up O +
to O +
13 O +
h. O +
Ultra O +
Turrax O +
was O +
the O +
best O +
cell O +
disruption O +
method O -
, O +
and O +
refrigeration O +
was O +
the O +
best O +
preservation O +
method O -
. O +

This O +
improved O +
methodology O +
was O +
validated O +
with O +
four O +
representative O +
strains O +
that O +
respond O +
poorly O +
to O +
cell O +
disruption O -
. O +

Biogenic O +
amines B-Chemical +
formation O +
in O +
Streptococcus O +
thermophilus O +
isolated O +
from O +
home O -
- O -
made O +
natural O +
yogurt O -
. O +

Twelve O +
different O +
biogenic O +
amines B-Chemical +
formation O +
in O +
58 O +
isolates O +
of O +
Streptococcus O +
thermophilus O +
from O +
home O -
- O -
made O +
natural O +
yogurt O +
were O +
investigated O +
in O +
histidine B-Chemical +
( O -
HDB O -
) O +
and O +
lysine B-Chemical +
decarboxylase O +
broth O +
( O -
LDB O -
) O -
. O +

All O +
S. O +
thermophilus O +
isolates O +
had O +
an O +
ability O +
to O +
produce O +
twelve O +
different O +
biogenic O +
amines B-Chemical +
in O +
HDB O +
and O +
LDB O -
. O +

Most O +
of O +
the O +
S. O +
thermophilus O +
isolates O +
formed O +
low O +
amounts O +
of O +
histamine B-Chemical +
( O -
1 O -
- O -
50 O +
mg O -
/ O -
L O -
) O +
from O +
histidine B-Chemical -
. O +

Apart O +
from O +
one O +
isolate O -
, O +
S. O +
thermophilus O +
produced O +
tyramine B-Chemical +
at O +
low O +
( O -
47 O +
isolates O -
) O +
and O +
medium O +
( O -
10 O +
isolates O -
) O +
levels O -
. O +

The O +
amount O +
of O +
each O +
specific O +
biogenic O +
amine B-Chemical +
produced O +
by O +
S. O +
thermophilus O +
was O +
generally O +
lower O +
than O +
100 O +
mg O +
L O -
( O -
-1 O -
) O -
. O +

Also O -
, O +
the O +
presence O +
of O +
hdcA O +
gene O +
was O +
investigated O +
using O +
PCR O +
technique O +
and O +
relation O +
between O +
gene O +
and O +
histamine B-Chemical +
production O +
was O +
conducted O +
in O +
S. O +
thermophilus O +
isolates O -
. O +

This O +
study O +
showed O +
that O +
most O +
of O +
the O +
S. O +
thermophilus O +
isolates O +
have O +
the O +
ability O +
to O +
form O +
biogenic O +
amines B-Chemical -
, O +
especially O +
histamine B-Chemical -
, O +
and O +
tyramine B-Chemical -
, O +
which O +
is O +
an O +
important O +
consideration O +
when O +
selecting O +
strains O +
as O +
starter O +
cultures O -
. O +

Shelf O -
- O -
life O +
of O +
infrared O +
dry O -
- O -
roasted O +
almonds O -
. O +

Infrared O +
heating O +
was O +
recently O +
used O +
to O +
develop O +
a O +
more O +
efficient O +
roasting O +
technology O +
than O +
traditional O +
hot O +
air O +
roasting O -
. O +

Therefore O -
, O +
in O +
this O +
study O -
, O +
we O +
evaluated O +
the O +
shelf O -
- O -
life O +
of O +
almonds O +
roasted O +
with O +
three O +
different O +
approaches O -
, O +
namely O +
infrared O +
( O -
IR O -
) O -
, O +
sequential O +
infrared O +
and O +
hot O +
air O +
( O -
SIRHA O -
) O +
and O +
regular O +
hot O +
air O +
( O -
HA O -
) O -
. O +

Nine O +
medium O +
roasted O +
almond O +
samples O +
produced O +
by O +
the O +
aforementioned O +
heating O +
methods O +
were O +
processed O +
at O +
three O +
different O +
temperatures O +
( O -
130 O -
, O +
140 O +
and O +
150 O +
° O -
C O -
) O -
, O +
packed O +
in O +
paper O +
bags O +
and O +
then O +
stored O +
at O +
37 O +
° O -
C O +
for O +
three O -
, O +
six O +
or O +
eight O +
months O -
. O +

Shelf O -
- O -
life O +
of O +
the O +
roasted O +
almonds O +
was O +
determined O +
by O +
measuring O +
the O +
changes O +
in O +
colour O -
, O +
peroxide B-Chemical +
value O -
, O +
moisture O +
content O -
, O +
water O +
activity O -
, O +
volatile O +
components O +
and O +
sensory O +
quality O -
. O +

No O +
significant O +
difference O +
was O +
observed O +
in O +
moisture O +
content O +
and O +
water O +
activity O +
among O +
the O +
almond O +
samples O +
processed O +
with O +
different O +
roasting O +
methods O +
and O +
stored O +
under O +
the O +
same O +
conditions O -
. O +

GC O -
/ O -
MS O +
analysis O +
showed O +
that O +
aldehydes B-Chemical -
, O +
alcohols B-Chemical -
, O +
and O +
pyrazines B-Chemical +
were O +
the O +
main O +
volatile O +
components O +
of O +
almonds O -
. O +

Aliphatic B-Chemical +
aldehydes I-Chemical +
such O +
as O +
hexanal B-Chemical -
, O +
( B-Chemical -
E I-Chemical -
) I-Chemical -
-2-octenal I-Chemical -
, O +
and O +
nonanal B-Chemical +
were O +
produced O +
as O +
off O -
- O -
odours O +
during O +
storage O -
. O +

Although O +
the O +
overall O +
quality O +
of O +
roasted O +
almonds O +
produced O +
with O +
SIRHA O +
and O +
HA O +
heating O +
was O +
similar O +
during O +
the O +
first O +
three O +
months O +
of O +
storage O -
, O +
their O +
peroxide B-Chemical +
value O +
and O +
concentration O +
of O +
aliphatic B-Chemical +
aldehydes I-Chemical +
differed O +
significantly O +
for O +
different O +
roasting O +
methods O +
and O +
increased O +
significantly O +
in O +
all O +
roasted O +
samples O +
during O +
storage O -
. O +

We O +
postulate O +
that O +
hexanal B-Chemical +
and O +
nonanal B-Chemical +
might O +
be O +
better O +
indicators O +
of O +
the O +
shelf O +
life O +
of O +
roasted O +
almonds O +
than O +
the O +
current O +
standard O -
, O +
peroxide B-Chemical +
value O -
. O +

Tri- B-Chemical +
and I-Chemical +
diorganotin I-Chemical -
( I-Chemical -
IV I-Chemical -
) I-Chemical +
complexes O +
of O +
biologically O +
important O +
orotic B-Chemical +
acid I-Chemical -
: O +
synthesis O -
, O +
spectroscopic O +
studies O -
, O +
in O +
vitro O +
anti O -
- O -
cancer O -
, O +
DNA O +
fragmentation O -
, O +
enzyme O +
assays O +
and O +
in O +
vivo O +
anti O -
- O -
inflammatory O +
activities O -
. O +

Tri B-Chemical -
- I-Chemical -
and I-Chemical +
diorganotin I-Chemical -
( I-Chemical -
IV I-Chemical -
) I-Chemical +
orotates I-Chemical +
of O +
general O +
formula O -
, O +
R B-Chemical -
( I-Chemical -
n I-Chemical -
) I-Chemical -
Sn I-Chemical -
( I-Chemical -
H I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Or I-Chemical -
) I-Chemical -
( I-Chemical -
m I-Chemical -
) I-Chemical +
[ O -
n O +
= O +
3 O -
/ O -
2 O -
, O +
m O +
= O +
1 O -
/ O -
2 O -
, O +
R O +
= O +
Me B-Chemical -
, O +
n B-Chemical -
- I-Chemical -
Bu I-Chemical -
, O +
n B-Chemical -
- I-Chemical -
Oct I-Chemical +
and O +
Ph B-Chemical -
; O +
H B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Or I-Chemical -
( I-Chemical -
- I-Chemical -
) I-Chemical +
= O +
monoanion O +
of O +
orotic B-Chemical +
acid I-Chemical +
( O -
H B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
Or I-Chemical -
) O -
] O +
( O -
n B-Chemical -
- I-Chemical -
Bu I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Sn I-Chemical -
( I-Chemical -
HOr I-Chemical -
) I-Chemical +
as O +
an O +
exception O -
) O +
have O +
been O +
synthesized O -
. O +

On O +
the O +
basis O +
of O +
various O +
spectroscopic O +
studies O +
it O +
is O +
revealed O +
that O +
R B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
Sn I-Chemical -
( I-Chemical -
H I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Or I-Chemical -
) I-Chemical +
and O +
R B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Sn I-Chemical -
( I-Chemical -
H I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Or I-Chemical -
) I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
exhibit O +
distorted O +
trigonal O -
- O -
bipyramidal O +
and O +
distorted O +
octahedral O +
geometry O -
, O +
respectively O -
, O +
and O +
n B-Chemical -
- I-Chemical -
Bu I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Sn I-Chemical -
( I-Chemical -
HOr I-Chemical -
) I-Chemical +
shows O +
both O +
five O +
and O +
six O +
coordination O +
geometry O +
around O +
tin O -
. O +

In O +
vitro O +
anti O -
- O -
cancer O +
screening O +
against O +
MCF-7 O +
( O -
mammary O -
) O -
, O +
HEK-293 O +
( O -
kidney O -
) O -
, O +
PC-3 O +
( O -
prostate O -
) O -
, O +
HCT-15 O +
( O -
colon O -
) O +
and O +
HepG-2 O +
( O -
liver O -
) O +
cancer O +
cell O +
lines O +
suggest O +
that O +
the O +
n B-Chemical -
- I-Chemical -
Oct I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Sn I-Chemical -
( I-Chemical -
H I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Or I-Chemical -
) I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
is O +
the O +
most O +
active O +
complex O +
among O +
all O +
of O +
the O +
studied O +
complexes O -
. O +

DNA O +
fragmentation O +
and O +
antioxidant O +
enzyme O +
assays O +
suggest O +
that O +
cytotoxic O +
effect O +
of O +
the O +
complexes O +
is O +
selectively O +
mediated O +
through O +
the O +
induction O +
of O +
apoptosis O -
. O +

They O +
also O +
exhibit O +
low O +
toxicity O +
and O +
good O +
anti O -
- O -
inflammatory O +
activity O +
( O -
in O +
vivo O -
) O -
. O +

Determination O +
of O +
bioactive O -
, O +
free O +
isothiocyanates B-Chemical +
from O +
a O +
glucosinolate B-Chemical -
- O -
containing O +
phytotherapeutic O +
agent O -
: O +
a O +
pilot O +
study O +
with O +
in O +
vitro O +
models O +
and O +
human O +
intervention O -
. O +

Isothiocyanates B-Chemical +
( O -
ITCs B-Chemical -
) O +
derived O +
from O +
plants O +
of O +
the O +
order O +
Brassicales O +
are O +
known O +
for O +
their O +
antibacterial O -
, O +
anti O -
- O -
inflammatory O +
or O +
anticarcinogenic O +
potential O -
. O +

Although O +
only O +
the O +
free O +
ITCs B-Chemical +
exert O +
bioactivity O -
, O +
quantification O +
in O +
vivo O +
is O +
almost O +
exclusively O +
performed O +
on O +
total O +
ITC B-Chemical -
/ O -
metabolite O +
content O -
. O +

We O +
therefore O +
investigated O +
in O +
a O +
pilot O +
study O +
the O +
amount O +
of O +
free O +
ITC B-Chemical +
at O +
different O +
steps O +
critical O +
for O +
therapeutic O +
efficacy O -
. O +

A O +
sensitive O +
and O +
specific O +
GC O -
- O -
MS O -
/ O -
MS O +
method O +
for O +
the O +
simultaneous O +
quantification O +
of O +
individual O +
free O +
ITC B-Chemical +
after O +
solid O -
- O -
phase O +
extraction O +
( O -
SPE O -
) O +
was O +
developed O -
. O +

We O +
show O +
here O +
that O +
release O +
of O +
biologically O +
active O +
ITC B-Chemical +
from O +
plants O +
occurs O +
at O +
not O +
only O +
alkaline O +
but O +
also O +
acidic O +
pH. O +
Furthermore O -
, O +
in O +
human O +
urine O +
conversion O +
of O +
the O +
ultimate O -
, O +
inactive O +
mercapturic B-Chemical +
acid I-Chemical +
conjugate O +
back O +
into O +
its O +
corresponding O +
bioactive O +
form O +
is O +
increased O +
at O +
alkaline O +
as O +
compared O +
to O +
neutral O +
pH. O +
This O +
was O +
also O +
observed O +
in O +
the O +
urine O +
of O +
human O +
volunteers O -
, O +
where O +
- O +
in O +
correlation O +
with O +
the O +
pH O +
value O +
- O +
a O +
mean O +
of O +
0.16 O +
to O +
1.03 O +
μmol O +
ITC B-Chemical +
was O +
detected O +
after O +
oral O +
application O +
of O +
a O +
phytotherapeutic O +
agent O +
containing O +
30.4 O +
μmol O +
of O +
the O +
initial O +
pro O -
- O -
drugs O -
. O +

The O +
amounts O +
of O +
free O +
ITC B-Chemical +
being O +
necessary O +
for O +
bioactivity O +
in O +
vitro O +
were O +
found O +
to O +
be O +
indeed O +
achieved O +
in O +
vivo O -
. O +

These O +
data O +
might O +
be O +
helpful O +
to O +
better O +
understand O +
the O +
beneficial O +
effects O +
of O +
ITC B-Chemical +
observed O +
in O +
vivo O -
. O +

Fucoidan O +
prevents O +
multiple O +
myeloma O +
cell O +
escape O +
from O +
chemotherapy O -
- O -
induced O +
drug O +
cytotoxicity O -
. O +

Minimal O +
residual O +
disease O +
( O -
MRD O -
) O +
occurrence O +
with O +
some O +
chemotherapy O +
drugs O +
that O +
promote O +
tumor O +
cell O +
escape O +
is O +
also O +
a O +
key O +
factor O +
in O +
blood O +
malignancy O +
relapse O -
. O +

We O +
observed O +
that O +
cytarabine B-Chemical +
promotes O +
multiple O +
myeloma O +
( O -
MM O -
) O +
cell O +
escape O +
and O +
that O +
the O +
number O +
of O +
cells O +
in O +
the O +
lower O +
chamber O +
increased O +
with O +
increasing O +
clinical O +
disease O +
stage O +
in O +
in O +
vitro O +
model O +
which O +
was O +
constructed O +
by O +
a O +
Boyden O +
chamber O -
, O +
matrigel O +
glue O +
and O +
serum O +
from O +
MM O +
patients O +
in O +
different O +
disease O +
stages O -
. O +

The O +
mechanism O +
of O +
cytarabine B-Chemical +
that O +
promotes O +
MM O +
cell O +
escape O +
is O +
closely O +
associated O +
with O +
the O +
up O -
- O -
regulation O +
of O +
CXCR4 O -
. O +

SDF-1α O +
can O +
up O -
- O -
regulate O +
the O +
expression O +
of O +
MMP9 O +
and O +
RHoC O +
proteins O +
in O +
MM O +
cells O +
with O +
up O -
- O -
regulated O +
CXCR4 O -
, O +
and O +
further O +
promote O +
the O +
cell O +
escape O -
. O +

Fucoidan O -
, O +
a O +
sulfated O +
polysaccharide O +
in O +
the O +
cell O +
wall O +
matrix O +
of O +
brown O +
algae O -
, O +
has O +
attracted O +
much O +
attention O +
for O +
its O +
multiple O +
biological O +
activities O -
, O +
and O +
we O +
further O +
explored O +
the O +
effects O +
and O +
possible O +
underlying O +
mechanisms O +
of O +
fucoidan O +
on O +
MM O +
cell O +
escape O +
from O +
cytarabine B-Chemical +
cytotoxicity O -
. O +

The O +
results O +
show O +
that O +
fucoidan O +
may O +
decrease O +
MM O +
cell O +
escape O +
from O +
cytarabine B-Chemical +
cytotoxicity O -
, O +
and O +
that O +
fucoidan O +
can O +
down O -
- O -
regulate O +
CXCR4 O -
, O +
MMP9 O +
and O +
RHoC O +
expression O -
. O +

This O +
research O +
provides O +
new O +
direction O +
for O +
investigating O +
MRD O +
occurrence O +
and O +
prevention O -
. O +

Cytotoxicity O +
and O +
structure O +
activity O +
relationships O +
of O +
phytosterol B-Chemical +
from O +
Phyllanthus O +
emblica O -
. O +

Fourteen O +
sterols B-Chemical +
( O -
1 O -
- O -
14 O -
) O -
, O +
including O +
two O +
new O +
sterols B-Chemical -
, O +
trihydroxysitosterol B-Chemical +
( O -
2 O -
) O +
and O +
5α,6β,7α-7α B-Chemical -
- I-Chemical -
acetoxysitosterol I-Chemical +
( O -
3 O -
) O -
, O +
were O +
isolated O +
from O +
the O +
branches O +
and O +
leaves O +
of O +
Phyllanthus O +
emblica O +
L. O +

The O +
isolated O +
compounds O +
and O +
a O +
structurally O +
related O +
sterol B-Chemical +
15 O +
from O +
Aphanamixis O +
grandifolia O +
were O +
screened O +
for O +
cytotoxicity O +
in O +
two O +
tumor O +
cell O +
lines O +
( O -
HL-60 O +
and O +
SMMC-7721 O -
) O +
and O +
a O +
non O -
- O -
tumor O +
cell O +
line O +
( O -
HL-7702 O -
) O +
using O +
RSB O +
assay O -
. O +

Within O +
the O +
series O +
of O +
phytosterol B-Chemical +
derivatives O +
tested O -
, O +
compound O +
15 O +
was O +
the O +
most O +
active O -
, O +
displaying O +
potent O +
cytotoxicity O +
against O +
HL-60 O +
with O +
IC O -
( O -
50 O -
) O +
of O +
5.10μmol O -
/ O -
L O -
, O +
and O +
most O +
of O +
the O +
active O +
compounds O +
showed O +
selective O +
cytotoxicity O +
against O +
tumor O +
and O +
non O -
- O -
tumor O +
cell O +
lines O -
, O +
especially O +
compound O +
10 O +
with O +
a O +
safety O +
index O +
of O +
4.42 O -
. O +

A O +
novel O +
non O -
- O -
radioactive O +
primase O -
- O -
pyrophosphatase O +
activity O +
assay O +
and O +
its O +
application O +
to O +
the O +
discovery O +
of O +
inhibitors O +
of O +
Mycobacterium O +
tuberculosis O +
primase O +
DnaG. O +
Bacterial O +
DNA O +
primase O +
DnaG O +
synthesizes O +
RNA O +
primers O +
required O +
for O +
chromosomal O +
DNA O +
replication O -
. O +

Biochemical O +
assays O +
measuring O +
primase O +
activity O +
have O +
been O +
limited O +
to O +
monitoring O +
formation O +
of O +
radioactively O +
labelled O +
primers O +
because O +
of O +
the O +
intrinsically O +
low O +
catalytic O +
efficiency O +
of O +
DnaG. O +
Furthermore O -
, O +
DnaG O +
is O +
prone O +
to O +
aggregation O +
and O +
proteolytic O +
degradation O -
. O +

These O +
factors O +
have O +
impeded O +
discovery O +
of O +
DnaG O +
inhibitors O +
by O +
high O -
- O -
throughput O +
screening O +
( O -
HTS O -
) O -
. O +

In O +
this O +
study O -
, O +
we O +
expressed O +
and O +
purified O +
the O +
previously O +
uncharacterized O +
primase O +
DnaG O +
from O +
Mycobacterium O +
tuberculosis O +
( O -
Mtb O +
DnaG O -
) O -
. O +

By O +
coupling O +
the O +
activity O +
of O +
Mtb O +
DnaG O +
to O +
that O +
of O +
another O +
essential O +
enzyme O -
, O +
inorganic O +
pyrophosphatase O +
from O +
M. O +
tuberculosis O +
( O -
Mtb O +
PPiase O -
) O -
, O +
we O +
developed O +
the O +
first O +
non O -
- O -
radioactive O +
primase O -
- O -
pyrophosphatase O +
assay O -
. O +

An O +
extensive O +
optimization O +
of O +
the O +
assay O +
enabled O +
its O +
efficient O +
use O +
in O +
HTS O +
( O -
Z O -
' O +
= O +
0.7 O +
in O +
the O +
384-well O +
format O -
) O -
. O +

HTS O +
of O +
2560 O +
small O +
molecules O +
to O +
search O +
for O +
inhibitory O +
compounds O +
yielded O +
several O +
hits O -
, O +
including O +
suramin B-Chemical -
, O +
doxorubicin B-Chemical +
and O +
ellagic B-Chemical +
acid I-Chemical -
. O +

We O +
demonstrate O +
that O +
these O +
three O +
compounds O +
inhibit O +
Mtb O +
DnaG. O +
Both O +
suramin B-Chemical +
and O +
doxorubicin B-Chemical +
are O +
potent O +
( O -
low-µM O -
) O +
DNA- O +
and O +
nucleotide B-Chemical +
triphosphate I-Chemical -
- O -
competitive O +
priming O +
inhibitors O +
that O +
interact O +
with O +
more O +
than O +
one O +
site O +
on O +
Mtb O +
DnaG. O +
This O +
novel O +
assay O +
should O +
be O +
applicable O +
to O +
other O +
primases O +
and O +
inefficient O +
DNA O -
/ O -
RNA O +
polymerases O -
, O +
facilitating O +
their O +
characterization O +
and O +
inhibitor O +
discovery O -
. O +

GBSA O -
: O +
a O +
comprehensive O +
software O +
for O +
analysing O +
whole O +
genome O +
bisulfite B-Chemical +
sequencing O +
data O -
. O +

High O -
- O -
throughput O +
sequencing O +
is O +
increasingly O +
being O +
used O +
in O +
combination O +
with O +
bisulfite B-Chemical +
( O -
BS O -
) O +
assays O +
to O +
study O +
DNA O +
methylation O +
at O +
nucleotide B-Chemical +
resolution O -
. O +

Although O +
several O +
programmes O +
provide O +
genome O -
- O -
wide O +
alignment O +
of O +
BS O -
- O -
treated O +
reads O -
, O +
the O +
resulting O +
information O +
is O +
not O +
readily O +
interpretable O +
and O +
often O +
requires O +
further O +
bioinformatic O +
steps O +
for O +
meaningful O +
analysis O -
. O +

Current O +
post O -
- O -
alignment O +
BS O -
- O -
sequencing O +
programmes O +
are O +
generally O +
focused O +
on O +
the O +
gene O -
- O -
specific O +
level O -
, O +
a O +
restrictive O +
feature O +
when O +
analysis O +
in O +
the O +
non O -
- O -
coding O +
regions O -
, O +
such O +
as O +
enhancers O +
and O +
intergenic O +
microRNAs O -
, O +
is O +
required O -
. O +

Here O -
, O +
we O +
present O +
Genome O +
Bisulfite B-Chemical +
Sequencing O +
Analyser O +
( O -
GBSA-http://ctrad-csi.nus.edu.sg/gbsa O -
) O -
, O +
a O +
free O +
open O -
- O -
source O +
software O +
capable O +
of O +
analysing O +
whole O -
- O -
genome O +
bisulfite B-Chemical +
sequencing O +
data O +
with O +
either O +
a O +
gene O -
- O -
centric O +
or O +
gene O -
- O -
independent O +
focus O -
. O +

Through O +
analysis O +
of O +
the O +
largest O +
published O +
data O +
sets O +
to O +
date O -
, O +
we O +
demonstrate O +
GBSA O -
's O +
features O +
in O +
providing O +
sequencing O +
quality O +
assessment O -
, O +
methylation O +
scoring O -
, O +
functional O +
data O +
management O +
and O +
visualization O +
of O +
genomic O +
methylation O +
at O +
nucleotide O +
resolution O -
. O +

Additionally O -
, O +
we O +
show O +
that O +
GBSA O -
's O +
output O +
can O +
be O +
easily O +
integrated O +
with O +
other O +
high O -
- O -
throughput O +
sequencing O +
data O -
, O +
such O +
as O +
RNA O -
- O -
Seq O +
or O +
ChIP O -
- O -
seq O -
, O +
to O +
elucidate O +
the O +
role O +
of O +
methylated O +
intergenic O +
regions O +
in O +
gene O +
regulation O -
. O +

In O +
essence O -
, O +
GBSA O +
allows O +
an O +
investigator O +
to O +
explore O +
not O +
only O +
known O +
loci O +
but O +
also O +
all O +
the O +
genomic O +
regions O -
, O +
for O +
which O +
methylation O +
studies O +
could O +
lead O +
to O +
the O +
discovery O +
of O +
new O +
regulatory O +
mechanisms O -
. O +

Coming O +
full O +
circle O -
: O +
contributions O +
of O +
central O +
and O +
peripheral O +
oxytocin B-Chemical +
actions O +
to O +
energy O +
balance O -
. O +

The O +
neuropeptide O +
oxytocin B-Chemical +
has O +
emerged O +
as O +
an O +
important O +
anorexigen B-Chemical +
in O +
the O +
regulation O +
of O +
energy O +
balance O -
. O +

Its O +
effects O +
on O +
food O +
intake O +
have O +
largely O +
been O +
attributed O +
to O +
limiting O +
meal O +
size O +
through O +
interactions O +
in O +
key O +
regulatory O +
brain O +
regions O +
such O +
as O +
the O +
hypothalamus O +
and O +
hindbrain O -
. O +

Pharmacologic O +
and O +
pair O -
- O -
feeding O +
studies O +
indicate O +
that O +
its O +
ability O +
to O +
reduce O +
body O +
mass O +
extends O +
beyond O +
that O +
of O +
food O +
intake O -
, O +
affecting O +
multiple O +
factors O +
that O +
determine O +
energy O +
balance O +
such O +
as O +
energy O +
expenditure O -
, O +
lipolysis O -
, O +
and O +
glucose B-Chemical +
regulation O -
. O +

Systemic O +
administration O +
of O +
oxytocin B-Chemical +
recapitulates O +
many O +
of O +
its O +
effects O +
when O +
administered O +
centrally O -
, O +
raising O +
the O +
questions O +
of O +
whether O +
and O +
to O +
what O +
extent O +
circulating O +
oxytocin B-Chemical +
contributes O +
to O +
energy O +
regulation O -
. O +

Its O +
therapeutic O +
potential O +
to O +
treat O +
metabolic O +
conditions O +
remains O +
to O +
be O +
determined O -
, O +
but O +
data O +
from O +
diet O -
- O -
induced O +
and O +
genetically O +
obese O +
rodent O +
models O +
as O +
well O +
as O +
application O +
of O +
oxytocin B-Chemical +
in O +
humans O +
in O +
other O +
areas O +
of O +
research O +
have O +
revealed O +
promising O +
results O +
thus O +
far O -
. O +

Safrole-2',3'-oxide B-Chemical +
induces O +
atherosclerotic O +
plaque O +
vulnerability O +
in O +
apolipoprotein O +
E O -
- O -
knockout O +
mice O -
. O +

Safrole-2',3'-oxide B-Chemical +
( O -
SFO B-Chemical -
) O +
is O +
the O +
major O +
electrophilic O +
metabolite O +
of O +
safrole B-Chemical +
( O -
4-allyl-1 B-Chemical -
, I-Chemical +
2-methylenedioxybenzene I-Chemical -
) O -
, O +
a O +
natural O +
plant O +
constituent O +
found O +
in O +
essential O +
oils O +
of O +
numerous O +
edible O +
herbs O +
and O +
spices O +
and O +
in O +
food O +
containing O +
these O +
herbs O -
, O +
such O +
as O +
pesto O +
sauce O -
, O +
cola O +
beverages O +
and O +
bologna O +
sausages O -
. O +

The O +
effects O +
of O +
SFO B-Chemical +
in O +
mammalian O +
systems O -
, O +
especially O +
the O +
cardiovascular O +
system O -
, O +
are O +
little O +
known O -
. O +

Disruption O +
of O +
vulnerable O +
atherosclerotic O +
plaques O +
in O +
atherosclerosis O -
, O +
a O +
chronic O +
inflammatory O +
disease O -
, O +
is O +
the O +
main O +
cause O +
of O +
cardiovascular O +
events O -
. O +

In O +
this O +
study O -
, O +
we O +
investigated O +
SFO B-Chemical -
- O -
induced O +
atherosclerotic O +
plaque O +
vulnerability O +
( O -
possibility O +
of O +
rupture O -
) O +
in O +
apolipoprotein O +
E O -
- O -
knockout O +
( O -
apoE O -
( O -
- O -
/ O -
- O -
) O -
) O +
mice O -
. O +

Lipid O +
area O +
in O +
vessel O +
wall O +
reached O +
59.8 O -
% O +
in O +
high O +
dose O +
SFO B-Chemical +
( O -
SFO B-Chemical -
- O -
HD O -
) O +
treated O +
group O -
, O +
which O +
is O +
only O +
31.2 O -
% O +
in O +
control O +
group O -
. O +

SFO B-Chemical +
treatment O +
changed O +
the O +
lesion O +
composition O +
to O +
an O +
unstable O +
phenotype O -
, O +
increased O +
the O +
number O +
of O +
apoptotic O +
cells O +
in O +
plaque O +
and O +
the O +
endothelium O +
in O +
plaques O +
was O +
damaged O +
after O +
SFO B-Chemical +
treatment O -
. O +

Furthermore O -
, O +
compared O +
with O +
control O +
groups O -
, O +
the O +
plaque O +
endothelium O +
level O +
of O +
p75 O -
( O -
NTR O -
) O +
was O +
3-fold O +
increased O +
and O +
the O +
liver O +
level O +
of O +
p75 O -
( O -
NTR O -
) O +
was O +
17.4-fold O +
increased O +
by O +
SFO B-Chemical -
- O -
HD O -
. O +

Meanwhile O -
, O +
the O +
serum O +
level O +
of O +
KC O +
( O -
a O +
functional O +
homolog O +
of O +
IL-8 O +
and O +
the O +
main O +
proinflammatory O +
alpha O +
chemokine O +
in O +
mice O -
) O +
in O +
apoE O -
( O -
- O -
/ O -
- O -
) O +
mice O +
was O +
up O +
to O +
357pg O -
/ O -
ml O +
in O +
SFO B-Chemical -
- O -
HD O +
treated O +
group O -
. O +

Thus O -
, O +
SFO B-Chemical +
contributes O +
to O +
the O +
instability O +
of O +
atherosclerotic O +
plaque O +
in O +
apoE O -
( O -
- O -
/ O -
- O -
) O +
mice O +
through O +
activating O +
p75 O -
( O -
NTR O -
) O +
and O +
IL-8 O +
and O +
cell O +
apoptosis O +
in O +
plaque O -
. O +

Nanodomain O +
coupling O +
at O +
an O +
excitatory O +
cortical O +
synapse O -
. O +

The O +
coupling O +
distance O +
between O +
presynaptic O +
Ca B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
influx O +
and O +
the O +
sensor O +
for O +
vesicular O +
transmitter O +
release O +
determines O +
speed O +
and O +
reliability O +
of O +
synaptic O +
transmission O -
. O +

Nanodomain O +
coupling O +
( O -
< O -
100 O +
nm O -
) O +
favors O +
fidelity O +
and O +
is O +
employed O +
by O +
synapses O +
specialized O +
for O +
escape O +
reflexes O +
and O +
by O +
inhibitory O +
synapses O +
involved O +
in O +
synchronizing O +
fast O +
network O +
oscillations O -
. O +

Cortical O +
glutamatergic O +
synapses O +
seem O +
to O +
forgo O +
the O +
benefits O +
of O +
tight O +
coupling O -
, O +
yet O +
quantitative O +
detail O +
is O +
lacking O -
. O +

The O +
reduced O +
transmission O +
fidelity O +
of O +
loose O +
coupling O -
, O +
however O -
, O +
raises O +
the O +
question O +
whether O +
it O +
is O +
indeed O +
a O +
general O +
characteristic O +
of O +
cortical O +
synapses O -
. O +

Here O +
we O +
analyzed O +
excitatory O +
parallel O +
fiber O +
to O +
Purkinje O +
cell O +
synapses O -
, O +
major O +
processing O +
sites O +
for O +
sensory O +
information O +
and O +
well O +
suited O +
for O +
analysis O +
because O +
they O +
typically O +
harbor O +
only O +
a O +
single O +
active O +
zone O -
. O +

We O +
quantified O +
the O +
coupling O +
distance O +
by O +
combining O +
multiprobability O +
fluctuation O +
analyses O -
, O +
presynaptic O +
Ca B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
imaging O -
, O +
and O +
reaction O -
- O -
diffusion O +
simulations O +
in O +
wild O -
- O -
type O +
and O +
calretinin O -
- O -
deficient O +
mice O -
. O +

We O +
found O +
a O +
coupling O +
distance O +
of O +
< O -
30 O +
nm O +
at O +
these O +
synapses O -
, O +
much O +
shorter O +
than O +
at O +
any O +
other O +
glutamatergic O +
cortical O +
synapse O +
investigated O +
to O +
date O -
. O +

Our O +
results O +
suggest O +
that O +
nanodomain O +
coupling O +
is O +
a O +
general O +
characteristic O +
of O +
conventional O +
cortical O +
synapses O +
involved O +
in O +
high O -
- O -
frequency O +
transmission O -
, O +
allowing O +
for O +
dense O +
gray O +
matter O +
packing O +
and O +
cost O -
- O -
effective O +
neurotransmission O -
. O +

The O +
use O +
of O +
Reamer O +
Irrigator O +
Aspirator O +
( O -
RIA O -
) O +
autograft O +
harvest O +
in O +
the O +
treatment O +
of O +
critical O -
- O -
sized O +
iliac O +
wing O +
defects O +
in O +
sheep O -
: O +
investigation O +
of O +
dexamethasone B-Chemical +
and O +
beta B-Chemical -
- I-Chemical -
tricalcium I-Chemical +
phosphate I-Chemical +
augmentation O -
. O +

Bone O +
grafts O +
are O +
commonly O +
used O +
for O +
the O +
treatment O +
of O +
segmental O +
bone O +
defects O +
and O +
fracture O +
non O -
- O -
unions O -
. O +

Recently O -
, O +
osseous O +
particles O +
obtained O +
during O +
intermedullary O +
canal O +
reaming O +
( O -
using O +
a O +
Reamer O -
- O -
Irrigator O -
- O -
Aspirator O +
( O -
RIA O -
) O +
device O -
) O +
have O +
been O +
evaluated O +
as O +
graft O +
material O +
during O +
in O +
vitro O +
and O +
clinical O +
studies O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
evaluate O +
and O +
quantify O +
new O +
bone O +
formation O +
after O +
implantation O +
of O +
bone O +
graft O +
material O +
obtained O +
after O +
reaming O +
of O +
the O +
tibia O +
in O +
a O +
bilateral O +
critical O -
- O -
sized O +
iliac O +
wing O +
defect O +
in O +
sheep O +
and O +
to O +
investigate O +
the O +
effect O +
of O +
the O +
augmentation O +
of O +
this O +
graft O -
. O +

A O +
reamer O +
bone O +
graft O +
alone O -
, O +
or O +
after O +
short O +
term O +
incubation O +
in O +
a O +
dexamethasone B-Chemical +
enriched O +
solution O -
, O +
and O +
a O +
reamer O +
graft O +
collected O +
using O +
beta B-Chemical -
- I-Chemical -
tricalcium I-Chemical +
phosphate I-Chemical +
( O -
β B-Chemical -
- I-Chemical -
TCP I-Chemical -
) O +
granules O +
in O +
the O +
filter O +
of O +
the O +
RIA O +
collection O +
device O +
were O +
compared O +
to O +
autologous O +
iliac O +
wing O +
graft O -
. O +

In O +
addition O -
, O +
reamer O +
graft O +
was O +
combined O +
with O +
the O +
cellular O +
fraction O +
collected O +
from O +
the O +
irrigation O +
fluid O +
with O +
and O +
without O +
short O -
- O -
term O +
incubation O +
in O +
a O +
dexamethasone B-Chemical +
enriched O +
solution O -
. O +

It O +
was O +
hypothesized O +
that O +
the O +
amount O +
of O +
physical O +
bone O +
in O +
the O +
reamer O +
bone O +
graft O +
groups O +
would O +
be O +
higher O +
than O +
the O +
amount O +
in O +
the O +
autologous O +
iliac O +
wing O +
graft O +
group O +
and O +
that O +
augmentation O +
of O +
a O +
reamer O +
bone O +
graft O +
would O +
increase O +
bone O +
formation O -
. O +

Three O +
months O +
after O +
implantation O -
, O +
the O +
amount O +
of O +
new O +
bone O +
formation O +
( O -
as O +
percentage O +
of O +
the O +
total O +
defect O +
volume O -
) O +
in O +
the O +
defects O +
was O +
evaluated O +
ex O -
- O -
vivo O +
by O +
means O +
of O +
micro O -
- O -
CT O +
and O +
histomorphometry O -
. O +

The O +
mean O +
amount O +
of O +
bone O +
in O +
the O +
autologous O +
iliac O +
wing O +
graft O +
group O +
was O +
17.7 O -
% O +
and O +
16.8 O -
% O +
for O +
micro O -
- O -
CT O +
and O +
histomorphometry O -
, O +
respectively O -
. O +

The O +
mean O +
amount O +
of O +
bone O +
in O +
all O +
reamer O +
graft O +
groups O +
ranged O +
between O +
20.4 O -
- O -
29.2 O -
% O +
( O -
micro O -
- O -
CT O -
) O +
and O +
17.0 O -
- O -
25.4 O -
% O +
( O -
histomorphometry O -
) O -
. O +

Reamer O +
graft O +
collected O +
using O +
β B-Chemical -
- I-Chemical -
TCP I-Chemical +
granules O +
( O -
29.2±1.7 O -
% O -
) O +
in O +
the O +
filter O +
produced O +
a O +
significantly O +
higher O +
amount O +
of O +
bone O +
in O +
comparison O +
to O +
an O +
autologous O +
iliac O +
wing O +
graft O +
evaluated O +
by O +
micro O -
- O -
CT O -
. O +

RIA O +
bone O +
grafts O +
added O +
a O +
small O +
increase O +
in O +
bone O +
volume O +
to O +
the O +
3month O +
graft O +
volume O +
in O +
this O +
preclinical O +
sheep O +
model O -
. O +

The O +
current O +
model O +
does O +
not O +
support O +
the O +
use O +
of O +
short O -
- O -
term O +
high O +
concentration O +
dexamethasone B-Chemical +
for O +
augmentation O +
of O +
a O +
graft O +
volume O -
. O +

If O +
avoidance O +
of O +
an O +
iliac O +
wing O +
graft O +
is O +
desirable O -
, O +
or O +
a O +
reaming O +
procedure O +
is O +
required O -
, O +
then O +
a O +
RIA O +
graft O +
or O +
RIA O +
graft O +
plus O +
β B-Chemical -
- I-Chemical -
TCP I-Chemical +
granules O +
are O +
as O +
good O +
as O +
the O +
current O +
gold O +
standard O +
for O +
this O +
model O -
. O +

Pharmacokinetics O +
explain O +
in O +
vivo O -
/ O -
in O +
vitro O +
discrepancies O +
of O +
carcinogen O -
- O -
induced O +
gene O +
expression O +
alterations O +
in O +
rat O +
liver O +
and O +
cultivated O +
hepatocytes O -
. O +

Cultivated O +
hepatocytes O +
represent O +
a O +
well O -
- O -
established O +
in O +
vitro O +
system O -
. O +

However O -
, O +
the O +
applicability O +
of O +
hepatocytes O +
in O +
toxicogenomics O +
is O +
still O +
controversially O +
discussed O -
. O +

Recently O -
, O +
an O +
in O +
vivo O -
/ O -
in O +
vitro O +
discrepancy O +
has O +
been O +
described O -
, O +
whereby O +
the O +
non O -
- O -
genotoxic O +
rat O +
liver O +
carcinogen O +
methapyrilene B-Chemical +
alters O +
the O +
expression O +
of O +
the O +
metabolizing O +
genes O +
SULT1A1 O +
and O +
ABAT O -
, O +
as O +
well O +
as O +
the O +
DNA O +
damage O +
response O +
gene O +
GADD34 O +
in O +
vitro O -
, O +
but O +
not O +
in O +
vivo O -
. O +

If O +
the O +
collagen O +
sandwich O +
cultures O +
of O +
hepatocytes O +
really O +
produce O +
false O -
- O -
positive O +
data O -
, O +
this O +
would O +
compromise O +
its O +
application O +
in O +
toxicogenomics O -
. O +

To O +
revisit O +
the O +
putative O +
in O +
vivo O -
/ O -
in O +
vitro O +
discrepancy O -
, O +
we O +
first O +
analyzed O +
and O +
modeled O +
methapyrilene B-Chemical +
concentrations O +
in O +
the O +
portal O +
vein O +
of O +
rats O -
. O +

The O +
relatively O +
short O +
half O -
- O -
life O +
of O +
2.8 O +
h O +
implies O +
a O +
rapid O +
decrease O +
in O +
orally O +
administered O +
methapyrilene B-Chemical +
in O +
vivo O +
below O +
concentrations O +
that O +
can O +
cause O +
gene O +
expression O +
alterations O -
. O +

This O +
corresponded O +
to O +
the O +
time O -
- O -
dependent O +
alteration O +
levels O +
of O +
GADD34 O -
, O +
ABAT O +
and O +
SULT1A1 O +
RNA O +
in O +
the O +
liver O -
: O +
RNA O +
levels O +
are O +
altered O +
1 O -
, O +
6 O +
and O +
12 O +
h O +
after O +
methapyrilene B-Chemical +
administration O -
, O +
but O +
return O +
to O +
control O +
levels O +
after O +
24 O +
and O +
72 O +
h. O +
In O +
contrast O -
, O +
methapyrilene B-Chemical +
concentrations O +
in O +
the O +
culture O +
medium O +
supernatant O +
of O +
primary O +
rat O +
hepatocyte O +
cultures O +
decreased O +
slowly O -
. O +

This O +
explains O +
why O +
GADD34 O -
, O +
ABAT O +
and O +
SULT1A1 O +
were O +
still O +
deregulated O +
after O +
24 O +
h O +
exposure O +
in O +
vitro O -
, O +
but O +
not O +
in O +
vivo O -
. O +

It O +
should O +
also O +
be O +
considered O +
that O +
the O +
earliest O +
analyzed O +
time O +
point O +
in O +
the O +
previous O +
in O +
vivo O +
studies O +
was O +
24 O +
h O +
after O +
methapyrilene B-Chemical +
administration O -
. O +

In O +
conclusion O -
, O +
previously O +
observed O +
in O +
vitro O -
/ O -
in O +
vivo O +
discrepancy O +
can O +
be O +
explained O +
by O +
different O +
pharmacokinetics O +
present O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

When O +
the O +
in O +
vivo O +
half O -
- O -
life O +
is O +
short O -
, O +
levels O +
of O +
some O +
initially O +
altered O +
genes O +
may O +
have O +
returned O +
to O +
control O +
levels O +
already O +
24 O +
h O +
after O +
administration O -
. O +

RNA O +
dimerization O +
plays O +
a O +
role O +
in O +
ribosomal O +
frameshifting O +
of O +
the O +
SARS O +
coronavirus O -
. O +

Messenger O +
RNA O +
encoded O +
signals O +
that O +
are O +
involved O +
in O +
programmed O +
-1 O +
ribosomal O +
frameshifting O +
( O -
-1 O +
PRF O -
) O +
are O +
typically O +
two O -
- O -
stemmed O +
hairpin O +
( O -
H O -
) O -
-type O +
pseudoknots O +
( O -
pks O -
) O -
. O +

We O +
previously O +
described O +
an O +
unusual O +
three O -
- O -
stemmed O +
pseudoknot O +
from O +
the O +
severe O +
acute O +
respiratory O +
syndrome O +
( O -
SARS O -
) O +
coronavirus O +
( O -
CoV O -
) O +
that O +
stimulated O +
-1 O +
PRF O -
. O +

The O +
conserved O +
existence O +
of O +
a O +
third O +
stem O -
- O -
loop O +
suggested O +
an O +
important O +
hitherto O +
unknown O +
function O -
. O +

Here O +
we O +
present O +
new O +
information O +
describing O +
structure O +
and O +
function O +
of O +
the O +
third O +
stem O +
of O +
the O +
SARS O +
pseudoknot O -
. O +

We O +
uncovered O +
RNA O +
dimerization O +
through O +
a O +
palindromic O +
sequence O +
embedded O +
in O +
the O +
SARS O -
- O -
CoV O +
Stem O +
3 O -
. O +

Further O +
in O +
vitro O +
analysis O +
revealed O +
that O +
SARS O -
- O -
CoV O +
RNA O +
dimers O +
assemble O +
through O +
' O -
kissing O -
' O +
loop O -
- O -
loop O +
interactions O -
. O +

We O +
also O +
show O +
that O +
loop O -
- O -
loop O +
kissing O +
complex O +
formation O +
becomes O +
more O +
efficient O +
at O +
physiological O +
temperature O +
and O +
in O +
the O +
presence O +
of O +
magnesium B-Chemical -
. O +

When O +
the O +
palindromic O +
sequence O +
was O +
mutated O -
, O +
in O +
vitro O +
RNA O +
dimerization O +
was O +
abolished O -
, O +
and O +
frameshifting O +
was O +
reduced O +
from O +
15 O +
to O +
5.7 O -
% O -
. O +

Furthermore O -
, O +
the O +
inability O +
to O +
dimerize O +
caused O +
by O +
the O +
silent O +
codon O +
change O +
in O +
Stem O +
3 O +
of O +
SARS O -
- O -
CoV O +
changed O +
the O +
viral O +
growth O +
kinetics O +
and O +
affected O +
the O +
levels O +
of O +
genomic O +
and O +
subgenomic O +
RNA O +
in O +
infected O +
cells O -
. O +

These O +
results O +
suggest O +
that O +
the O +
homodimeric O +
RNA O +
complex O +
formed O +
by O +
the O +
SARS O +
pseudoknot O +
occurs O +
in O +
the O +
cellular O +
environment O +
and O +
that O +
loop O -
- O -
loop O +
kissing O +
interactions O +
involving O +
Stem O +
3 O +
modulate O +
-1 O +
PRF O +
and O +
play O +
a O +
role O +
in O +
subgenomic O +
and O +
full O -
- O -
length O +
RNA O +
synthesis O -
. O +

Survey O +
of O +
recent O +
literature O +
related O +
to O +
the O +
biologically O +
active O +
4 B-Chemical -
( I-Chemical -
3H I-Chemical -
) I-Chemical -
-quinazolinones I-Chemical +
containing O +
fused O +
heterocycles O -
. O +

The O +
present O +
review O +
focuses O +
on O +
the O +
synthesis O +
and O +
biological O +
evaluation O +
of O +
polycyclic B-Chemical +
4 I-Chemical -
( I-Chemical -
3H I-Chemical -
) I-Chemical -
-quinazolinones I-Chemical +
containing O +
fused O +
aromatic O +
or O +
heteroaromatic O +
rings O -
. O +

The O +
first O +
part O +
of O +
the O +
review O +
is O +
related O +
to O +
compounds O +
with O +
ring O +
fused O +
to O +
the O +
pyrimidine B-Chemical +
part O +
of O +
the O +
quinazoline B-Chemical +
core O -
. O +

Most O +
of O +
the O +
quinazolinone B-Chemical +
alkaloids I-Chemical +
belong O +
to O +
this O +
class O +
of O +
molecules O -
. O +

The O +
second O +
part O +
presents O +
molecules O +
bearing O +
extra O +
ring O -
( O -
s O -
) O +
fused O +
to O +
the O +
benzo B-Chemical +
moiety O +
of O +
the O +
quinazolinone B-Chemical +
skeleton O -
. O +

Their O +
structural O +
diversity O +
opens O +
new O +
fields O +
in O +
the O +
search O +
of O +
active O +
molecules O -
. O +

Deregulation O +
of O +
HOX O +
B13 O +
expression O +
in O +
urinary O +
bladder O +
cancer O +
progression O -
. O +

Urinary O +
bladder O +
cancer O +
is O +
a O +
common O +
malignancy O +
in O +
industrialized O +
countries O -
. O +

More O +
than O +
90 O -
% O +
of O +
bladder O +
cancer O +
originates O +
in O +
the O +
transitional O +
cells O -
. O +

Bladder O +
transitional O +
cancer O +
prognosis O +
is O -
, O +
according O +
to O +
the O +
most O +
recent O +
definition O +
related O +
to O +
the O +
level O +
of O +
tumor O +
infiltration O -
, O +
characterized O +
by O +
two O +
main O +
phenotypes O -
, O +
Non O +
Muscle O +
Invasive O +
Bladder O +
Transitional O +
Cancer O +
( O -
NMIBC O -
) O +
and O +
Muscle O +
Invasive O +
Bladder O +
Transitional O +
Cancer O +
( O -
MIBC O -
) O -
. O +

The O +
genetic O +
profile O +
and O +
the O +
clinical O +
course O +
of O +
the O +
two O +
subtypes O +
are O +
completely O +
different O -
, O +
however O +
among O +
NMIBC O +
the O +
prognosis O +
is O +
not O +
completely O +
predictable O -
, O +
since O +
20 O -
% O +
of O +
the O +
cases O +
experience O +
a O +
relapse O -
, O +
even O +
in O +
the O +
form O +
of O +
MIBC O -
. O +

It O +
has O +
recently O +
been O +
reported O +
that O +
the O +
chromosomal O +
region O +
12q13 O -
- O -
15 O -
, O +
containing O +
crucial O +
cancer O +
genes O +
such O +
as O +
MDM2 O -
, O +
CDK4 O -
, O +
GLI O +
and O +
an O +
entire O +
cluster O +
of O +
HOX O +
genes O -
, O +
is O +
amplified O +
in O +
bladder O +
cancer O -
. O +

HOX O +
genes O +
codify O +
for O +
transcriptionl O +
factor O -
, O +
involved O +
in O +
embryonal O +
development O +
and O +
cancer O +
progression O -
, O +
with O +
main O +
nuclear O +
expression O -
. O +

Particularly O +
it O +
was O +
also O +
described O +
the O +
strong O +
involvement O +
of O +
HOX O +
B13 O +
in O +
several O +
tumors O +
of O +
urogenital O +
system O -
. O +

In O +
this O +
study O +
we O +
have O +
been O +
investigated O -
, O +
by O +
immunohistochemisty O +
and O +
quantitative O +
Real O +
Time O +
PCR O -
, O +
the O +
HOX O +
B13 O +
expression O +
in O +
bladder O +
cancer O +
evolution O +
and O +
progression O -
, O +
evaluating O +
its O +
ability O +
to O +
discriminate O +
between O +
NMIBC O +
and O +
MBCI O +
phenotypes O -
. O +

Cytoplasmic O +
HOX O +
B13 O +
delocalization O +
significantly O +
relates O +
with O +
muscle O +
invasion O +
( O -
p O +
0.004 O -
) O -
. O +

In O +
addition O +
in O +
the O +
series O +
of O +
NMIBC O +
nuclear O +
HOX O +
B13 O +
expression O +
loss O +
is O +
significantly O +
associated O +
to O +
shorter O +
disease O +
free O +
survival O +
( O -
p O -
- O -
value=0.038 O -
) O +
defining O +
a O +
potential O +
prognostic O +
role O -
. O +

Overexpression O +
of O +
HOX O +
B13 O +
in O +
more O +
aggressive O +
phenotype O +
is O +
also O +
demonstrate O +
at O +
gene O +
level O +
by O +
quantitative O +
RT O -
- O -
PCR O -
. O +

The O +
de O -
- O -
regulation O +
and O +
delocalization O +
of O +
HOX O +
B13 O +
in O +
urinary O +
bladder O +
cancer O +
supports O +
again O +
the O +
important O +
role O +
of O +
HOX O +
genes O +
in O +
tumor O +
evolution O +
and O +
represents O +
a O +
starting O +
point O +
to O +
establish O +
an O +
integrated O +
analysis O -
, O +
in O +
which O +
HOX O +
genes O +
represent O +
important O +
prognostic O +
and O +
predictive O +
markers O +
for O +
bladder O +
cancer O -
. O +

Display O +
of O +
amino B-Chemical +
groups O +
on O +
substrate O +
surfaces O +
by O +
simple O +
dip O -
- O -
coating O +
of O +
methacrylate B-Chemical -
- O -
based O +
polymers O +
and O +
its O +
application O +
to O +
DNA O +
immobilization O -
. O +

The O +
implementation O +
of O +
a O +
reactive O +
functional O +
group O +
onto O +
a O +
material O +
surface O +
is O +
of O +
great O +
importance O -
. O +

Reactive O +
functional O +
groups O +
( O -
e.g. O -
, O +
an O +
amino B-Chemical +
group O +
and O +
a O +
hydroxyl B-Chemical +
group O -
) O +
are O +
usually O +
hydrophilic O -
, O +
which O +
makes O +
it O +
difficult O +
to O +
display O +
them O +
on O +
a O +
dry O +
polymer O +
surface O -
. O +

We O +
here O +
propose O +
a O +
novel O +
method O +
for O +
displaying O +
amino B-Chemical +
groups O +
on O +
the O +
surfaces O +
of O +
polymeric O +
substrates O +
through O +
dip O -
- O -
coating O +
of O +
a O +
methacrylate B-Chemical -
- O -
based O +
copolymer O -
. O +

We O +
synthesized O +
copolymers O +
composed O +
of O +
methyl B-Chemical +
methacrylate I-Chemical +
and O +
2-aminoethyl B-Chemical +
methacrylate I-Chemical +
with O +
different O +
protecting O +
groups O +
or O +
ion O -
- O -
complexes O +
on O +
their O +
amino B-Chemical +
groups O -
, O +
then O +
dip O -
- O -
coated O +
the O +
copolymers O +
onto O +
a O +
poly B-Chemical -
( I-Chemical -
methyl I-Chemical +
methacrylate I-Chemical -
) I-Chemical +
( O -
PMMA B-Chemical -
) O +
substrate O -
. O +

Evaluation O +
using O +
a O +
cleavable O +
fluorescent O +
compound O -
, O +
which O +
was O +
synthesized O +
in O +
the O +
present O +
study O +
to O +
quantify O +
a O +
small O +
amount O +
( O -
pmol O -
/ O -
cm O -
( O -
2 O -
) O -
) O +
of O +
amino B-Chemical +
groups O +
on O +
a O +
solid O +
surface O -
, O +
revealed O +
that O +
the O +
protection O +
of O +
amino B-Chemical +
groups O +
affected O +
their O +
surface O +
segregation O +
in O +
the O +
copolymer O +
coating O -
. O +

p B-Chemical -
- I-Chemical -
Toluenesulfonate I-Chemical +
ion O -
- O -
complex O +
and O +
tert B-Chemical -
- I-Chemical -
butoxycarbonyl I-Chemical +
( O -
Boc B-Chemical -
) O +
protection O +
of O +
amino B-Chemical +
groups O +
were O +
found O +
to O +
effectively O +
display O +
amino B-Chemical +
groups O +
on O +
the O +
surface O +
( O -
more O +
than O +
70 O +
pmol O -
/ O -
cm O -
( O -
2 O -
) O -
) O -
. O +

The O +
density O +
of O +
amino B-Chemical +
groups O +
displayed O +
on O +
a O +
surface O +
can O +
be O +
easily O +
controlled O +
by O +
mixing O +
the O +
copolymer O +
and O +
PMMA B-Chemical +
before O +
dip O -
- O -
coating O -
. O +

Dip O -
- O -
coating O +
of O +
the O +
copolymer O +
with O +
Boc B-Chemical +
protection O +
on O +
various O +
polymeric O +
substrates O +
also O +
successfully O +
displayed O +
amino B-Chemical +
groups O +
on O +
their O +
surfaces O -
. O +

Finally O -
, O +
we O +
demonstrated O +
that O +
the O +
amino B-Chemical +
groups O +
displayed O +
can O +
be O +
utilized O +
for O +
the O +
immobilization O +
of O +
a O +
DNA O +
oligonucleotide O +
on O +
a O +
substrate O +
surface O -
. O +

Kinetics O +
of O +
the O +
reaction O +
of O +
crystal B-Chemical +
violet I-Chemical +
with O +
hydroxide B-Chemical +
ion O +
in O +
the O +
critical O +
solution O +
of O +
2-butoxyethanol B-Chemical +
+ O +
water O -
. O +

The O +
kinetics O +
of O +
alkaline O +
fading O +
of O +
crystal B-Chemical +
violet I-Chemical +
( O -
CV O -
) O +
has O +
been O +
studied O +
by O +
UV O +
spectrophotometry O +
and O +
microcalorimetry O +
in O +
the O +
critical O +
binary O +
solution O +
of O +
2-butoxyethanol B-Chemical +
+ O +
water O +
at O +
the O +
initial O +
reaction O +
stage O +
and O +
various O +
temperatures O -
. O +

It O +
was O +
found O +
that O +
the O +
first O -
- O -
order O +
rate O +
constants O +
obtained O +
from O +
these O +
two O +
methods O +
are O +
well O +
accorded O +
with O +
each O +
other O -
, O +
and O +
the O +
temperature O +
dependence O +
of O +
the O +
rate O +
constant O +
obeyed O +
the O +
Arrhenius O +
equation O +
in O +
a O +
temperature O +
region O +
far O +
from O +
the O +
critical O +
point O -
. O +

The O +
critical O +
slowing O +
down O +
was O +
detected O +
by O +
both O +
methods O +
near O +
the O +
critical O +
point O -
. O +

A O +
simple O +
empirical O +
crossover O +
model O +
was O +
proposed O +
and O +
used O +
to O +
analyze O +
the O +
experimental O +
data O +
to O +
obtain O +
the O +
critical O +
exponents O -
, O +
which O +
were O +
0.158 O +
± O +
0.013 O +
and O +
0.133 O +
± O +
0.012 O +
from O +
UV O +
spectrophotometry O +
and O +
microcalorimetry O -
, O +
respectively O -
, O +
and O +
the O +
former O +
was O +
in O +
good O +
agreement O +
with O +
the O +
theoretical O +
prediction O +
of O +
0.151 O -
. O +

The O +
slight O +
lower O +
value O +
derived O +
from O +
microcalorimetry O +
was O +
attributed O +
to O +
the O +
stirring O +
in O +
the O +
microcalorimeter O -
, O +
which O +
weakened O +
the O +
critical O +
reduction O +
of O +
the O +
diffusion O +
coefficient O -
. O +

Spatial O +
variation O +
of O +
available O +
electronic O +
excitations O +
within O +
individual O +
quantum O +
dots O -
. O +

Quantum O +
dots O +
( O -
QDs O -
) O +
allow O +
for O +
manipulation O +
of O +
the O +
position O +
and O +
energy O +
levels O +
of O +
electrons O +
at O +
sub-10 O +
nm O +
length O +
scales O +
through O +
control O +
of O +
material O +
chemistry O -
, O +
size O -
, O +
and O +
shape O -
. O +

It O +
is O +
known O +
from O +
optical O +
studies O +
that O +
the O +
bandgap O +
of O +
semiconductor O +
QDs O +
increases O +
as O +
their O +
size O +
decreases O +
due O +
to O +
the O +
narrowing O +
of O +
the O +
quantum O +
confinement O +
potential O -
. O +

The O +
mechanism O +
of O +
quantum O +
confinement O +
also O +
indicates O +
that O +
the O +
localized O +
properties O +
within O +
individual O +
QDs O +
should O +
depend O +
on O +
their O +
shape O +
in O +
addition O +
to O +
their O +
size O -
, O +
but O +
direct O +
observations O +
of O +
this O +
effect O +
have O +
proven O +
challenging O +
due O +
to O +
the O +
limited O +
spatial O +
resolution O +
of O +
measurement O +
techniques O +
at O +
this O +
scale O +
and O +
the O +
ability O +
to O +
remove O +
contributions O +
from O +
the O +
surroundings O -
. O +

Here O +
we O +
present O +
experimental O +
evidence O +
of O +
spatial O +
variations O +
in O +
the O +
lowest O +
available O +
electron O +
transition O +
energy O +
within O +
a O +
series O +
of O +
single O +
electrically O +
isolated O +
QDs O +
due O +
to O +
a O +
dome O -
- O -
shaped O +
geometry O -
, O +
measured O +
using O +
electron O +
energy O -
- O -
loss O +
spectroscopy O +
in O +
a O +
( O -
scanning O -
) O +
transmission O +
electron O +
microscope O +
[ O -
( O -
S O -
) O -
TEM O -
- O -
EELS O -
] O -
. O +

We O +
observe O +
a O +
consistent O +
increase O +
in O +
the O +
energy O +
onset O +
of O +
electronic O +
excitations O +
from O +
the O +
lateral O +
center O +
of O +
the O +
dot O +
toward O +
the O +
edges O -
, O +
which O +
we O +
attribute O +
purely O +
to O +
shape O -
. O +

This O +
trend O +
is O +
in O +
qualitative O +
agreement O +
with O +
a O +
simple O +
quantum O +
simulation O +
of O +
the O +
local O +
density O +
of O +
states O +
in O +
a O +
dome O -
- O -
shaped O +
QD O -
. O +

PXR O -
- O -
mediated O +
P O -
- O -
glycoprotein O +
induction O +
by O +
small O +
molecule O +
tyrosine B-Chemical +
kinase O +
inhibitors O -
. O +

The O +
rapid O +
development O +
of O +
drug O +
resistance O +
as O +
a O +
result O +
of O +
exposure O +
to O +
small O +
molecule O +
tyrosine B-Chemical +
kinase O +
inhibitors O +
( O -
TKIs O -
) O +
is O +
an O +
important O +
drawback O +
to O +
the O +
successful O +
use O +
of O +
these O +
agents O +
in O +
the O +
clinic O -
. O +

Although O +
one O +
of O +
the O +
most O +
established O +
mechanisms O +
by O +
which O +
cells O +
acquire O +
drug O +
resistance O +
to O +
anticancer O +
drugs O +
is O +
the O +
up O +
regulation O +
of O +
drug O +
efflux O +
transporters O +
such O +
as O +
P O -
- O -
glycoprotein O +
( O -
PGP O -
) O -
, O +
it O +
is O +
currently O +
still O +
unknown O +
whether O +
TKIs O +
have O +
the O +
propensity O +
to O +
induce O +
PGP O -
. O +

The O +
effect O +
of O +
TKIs O +
on O +
the O +
protein O +
expression O +
and O +
activity O +
of O +
PGP O +
was O +
assessed O +
after O +
treatment O +
of O +
LS180 O +
cells O +
with O +
clinically O +
relevant O +
concentrations O +
of O +
the O +
TKIs O -
. O +

In O +
addition O -
, O +
the O +
involvement O +
of O +
the O +
nuclear O +
pregnane B-Chemical +
X O +
receptor O +
( O -
PXR O -
) O -
, O +
a O +
known O +
regulator O +
of O +
PGP O +
expression O -
, O +
was O +
determined O -
. O +

At O +
least O +
five O +
out O +
of O +
the O +
nine O +
tested O +
TKIs O +
( O -
erlotinib B-Chemical -
, O +
gefitinib B-Chemical -
, O +
nilotinib B-Chemical -
, O +
sorafenib B-Chemical -
, O +
vandetanib B-Chemical -
) O +
were O +
able O +
to O +
induce O +
the O +
expression O +
of O +
PGP O +
within O +
48 O +
h O +
in O +
LS180 O +
cells O -
. O +

Accordingly O -
, O +
these O +
TKIs O +
were O +
also O +
shown O +
to O +
affect O +
the O +
accumulation O +
of O +
a O +
P O -
- O -
glycoprotein O +
specific O +
probe O +
substrate O -
. O +

Furthermore O -
, O +
we O +
showed O +
that O +
the O +
pregnane B-Chemical +
X O +
receptor O +
( O -
PXR O -
) O -
, O +
which O +
is O +
an O +
important O +
regulator O +
of O +
PGP O +
induction O -
, O +
is O +
involved O +
in O +
the O +
upregulation O +
of O +
PGP O +
protein O +
expression O +
following O +
exposure O +
to O +
these O +
TKIs O -
. O +

Our O +
data O +
show O +
that O +
PXR O -
- O -
mediated O +
upregulation O +
of O +
PGP O +
expression O +
by O +
TKIs O +
might O +
be O +
a O +
possible O +
mechanism O +
underlying O +
acquired O +
drug O +
resistance O +
in O +
cancer O +
cells O -
. O +

Development O +
of O +
a O +
dry O -
, O +
stable O +
and O +
inhalable O +
acyl B-Chemical -
- I-Chemical -
homoserine I-Chemical -
- I-Chemical -
lactone I-Chemical -
- O -
acylase O +
powder O +
formulation O +
for O +
the O +
treatment O +
of O +
pulmonary O +
Pseudomonas O +
aeruginosa O +
infections O -
. O +

In O +
the O +
lungs O +
of O +
cystic O +
fibrosis O +
( O -
CF O -
) O +
patients O -
, O +
Pseudomonas O +
aeruginosa O +
commonly O +
causes O +
chronic O +
infections O -
. O +

It O +
has O +
been O +
shown O +
that O +
the O +
P. O +
aeruginosa O +
quorum O +
sensing O +
( O -
QS O -
) O +
system O +
controls O +
the O +
expression O +
of O +
virulence O +
factors O +
during O +
invasion O +
and O +
infection O +
to O +
host O +
cells O -
. O +

PvdQ O +
is O +
an O +
acyl B-Chemical -
- I-Chemical -
homoserine I-Chemical +
lactone I-Chemical +
( O -
AHL B-Chemical -
) O +
acylase O +
able O +
to O +
degrade O +
the O +
signal O +
molecule O +
of O +
P. O +
aeruginosa O +
QS O -
. O +

The O +
role O +
of O +
PvdQ O +
in O +
inhibiting O +
the O +
QS O +
and O +
its O +
successive O +
virulence O +
determinants O +
has O +
been O +
established O +
in O +
in O +
vitro O +
as O +
well O +
as O +
in O +
in O +
vivo O -
, O +
the O +
latter O +
in O +
a O +
Caenorabdhitis O +
elegans O +
model O -
. O +

For O +
the O +
treatment O +
of O +
pulmonary O +
P. O +
aeruginosa O +
infections O -
, O +
we O +
propose O +
that O +
PvdQ O +
can O +
be O +
best O +
administered O +
directly O +
to O +
the O +
lungs O +
of O +
the O +
patients O +
as O +
a O +
dry O +
powder O +
because O +
this O +
is O +
expected O +
to O +
give O +
specific O +
advantages O +
in O +
delivery O +
as O +
compared O +
to O +
nebulizing O -
. O +

Therefore O +
in O +
this O +
study O +
we O +
investigated O +
the O +
production O +
of O +
a O +
PvdQ O +
powder O +
by O +
spray O -
- O -
freeze O +
drying O +
using O +
mannitol B-Chemical -
, O +
trehalose B-Chemical +
and O +
inulin O +
as O +
excipient O -
. O +

The O +
activity O +
of O +
PvdQ O +
in O +
the O +
powder O +
was O +
determined O +
immediately O +
after O +
production O +
and O +
after O +
subsequent O +
storage O +
during O +
4 O +
weeks O +
at O +
20 O -
° O -
C O +
and O +
55 O -
° O -
C O -
. O +

We O +
found O +
that O +
the O +
enzymatic O +
activity O +
of O +
PvdQ O +
is O +
fully O +
maintained O +
during O +
spray O -
- O -
freeze O +
drying O +
using O +
mannitol B-Chemical -
, O +
trehalose B-Chemical +
or O +
inulin O +
as O +
excipient O -
. O +

However O -
, O +
mannitol B-Chemical +
was O +
not O +
able O +
to O +
stabilize O +
the O +
protein O +
during O +
storage O -
, O +
while O +
PvdQ O +
incorporated O +
in O +
trehalose B-Chemical +
or O +
inulin O +
was O +
fully O +
stabilized O +
even O +
during O +
storage O +
at O +
55 O -
° O -
C O +
for O +
at O +
least O +
4 O +
weeks O -
. O +

The O +
poor O +
stabilizing O +
capacities O +
of O +
mannitol B-Chemical +
during O +
storage O +
could O +
be O +
related O +
to O +
its O +
crystalline O +
nature O +
while O +
the O +
excellent O +
stabilizing O +
capacities O +
of O +
trehalose B-Chemical +
and O +
inulin O +
during O +
storage O +
could O +
be O +
related O +
to O +
their O +
amorphous O +
nature O -
. O +

The O +
trehalose B-Chemical +
and O +
inulin O -
- O -
based O +
particles O +
consisted O +
of O +
porous O +
spheres O +
with O +
a O +
volume O +
average O +
aerodynamical O +
diameter O +
of O +
∼1.8 O +
μm O +
implying O +
that O +
they O +
are O +
suitable O +
for O +
pulmonary O +
delivery O -
. O +

This O +
is O +
the O +
first O +
study O +
in O +
which O +
an O +
AHL B-Chemical -
- O -
degrading O +
enzyme O +
is O +
processed O +
into O +
spray O -
- O -
freeze O -
- O -
dried O +
powder O +
suitable O +
for O +
inhalation O -
. O +

( B-Chemical -
R I-Chemical -
) I-Chemical -
-β I-Chemical -
- I-Chemical -
lysine I-Chemical -
- O -
modified O +
elongation O +
factor O +
P O +
functions O +
in O +
translation O +
elongation O -
. O +

Post O -
- O -
translational O +
modification O +
of O +
bacterial O +
elongation O +
factor O +
P O +
( O -
EF O -
- O -
P O -
) O +
with O +
( B-Chemical -
R I-Chemical -
) I-Chemical -
-β I-Chemical -
- I-Chemical -
lysine I-Chemical +
at O +
a O +
conserved O +
lysine O +
residue O +
activates O +
the O +
protein O +
in O +
vivo O +
and O +
increases O +
puromycin O +
reactivity O +
of O +
the O +
ribosome O +
in O +
vitro O -
. O +

The O +
additional O +
hydroxylation O +
of O +
EF O -
- O -
P O +
at O +
the O +
same O +
lysine B-Chemical +
residue O +
by O +
the O +
YfcM O +
protein O +
has O +
also O +
recently O +
been O +
described O -
. O +

The O +
roles O +
of O +
modified O +
and O +
unmodified O +
EF O -
- O -
P O +
during O +
different O +
steps O +
in O +
translation O -
, O +
and O +
how O +
this O +
correlates O +
to O +
its O +
physiological O +
role O +
in O +
the O +
cell O -
, O +
have O +
recently O +
been O +
linked O +
to O +
the O +
synthesis O +
of O +
polyproline B-Chemical +
stretches O +
in O +
proteins O -
. O +

Polysome O +
analysis O +
indicated O +
that O +
EF O -
- O -
P O +
functions O +
in O +
translation O +
elongation O -
, O +
rather O +
than O +
initiation O +
as O +
proposed O +
previously O -
. O +

This O +
was O +
further O +
supported O +
by O +
the O +
inability O +
of O +
EF O -
- O -
P O +
to O +
enhance O +
the O +
rate O +
of O +
formation O +
of O +
fMet B-Chemical -
- I-Chemical -
Lys I-Chemical +
or O +
fMet B-Chemical -
- I-Chemical -
Phe I-Chemical -
, O +
indicating O +
that O +
the O +
role O +
of O +
EF O -
- O -
P O +
is O +
not O +
to O +
specifically O +
stimulate O +
formation O +
of O +
the O +
first O +
peptide O +
bond O -
. O +

Investigation O +
of O +
hydroxyl- B-Chemical -
( I-Chemical -
β I-Chemical -
) I-Chemical -
-lysyl I-Chemical -
- O -
EF O -
- O -
P O +
showed O +
30 O -
% O +
increased O +
puromycin B-Chemical +
reactivity O +
but O +
no O +
differences O +
in O +
dipeptide O +
synthesis O +
rates O +
when O +
compared O +
with O +
the O +
β O -
- O -
lysylated O +
form O -
. O +

Unlike O +
disruption O +
of O +
the O +
other O +
genes O +
required O +
for O +
EF O -
- O -
P O +
modification O -
, O +
deletion O +
of O +
yfcM O +
had O +
no O +
phenotypic O +
consequences O +
in O +
Salmonella O -
. O +

Taken O +
together O -
, O +
our O +
findings O +
indicate O +
that O +
EF O -
- O -
P O +
functions O +
in O +
translation O +
elongation O -
, O +
a O +
role O +
critically O +
dependent O +
on O +
post O -
- O -
translational O +
β O -
- O -
lysylation O +
but O +
not O +
hydroxylation O -
. O +

Synthesis O +
and O +
Biological O +
Evaluation O +
of O +
[ B-Chemical -
1,2,4 I-Chemical -
] I-Chemical -
Triazolo I-Chemical -
[ I-Chemical -
3,4-a I-Chemical -
] I-Chemical -
phthalazine I-Chemical +
and O +
Tetrazolo B-Chemical -
[ I-Chemical -
5,1-a I-Chemical -
] I-Chemical -
phthalazine I-Chemical +
Derivatives O +
Bearing O +
Substituted O +
Benzylpiperazine B-Chemical +
Moieties O +
as O +
Positive O +
Inotropic O +
Agents O -
. O +

Two O +
series O +
of O +
[ B-Chemical -
1,2,4 I-Chemical -
] I-Chemical -
triazolo I-Chemical -
[ I-Chemical -
3,4-a I-Chemical -
] I-Chemical -
phthalazine I-Chemical +
and O +
tetrazolo B-Chemical -
[ I-Chemical -
5,1-a I-Chemical -
] I-Chemical -
phthalazine I-Chemical +
derivatives O +
bearing O +
substituted O +
benzylpiperazine B-Chemical +
moieties O +
have O +
been O +
synthesized O +
and O +
evaluated O +
for O +
their O +
positive O +
inotropic O +
activity O +
by O +
measuring O +
left O +
atrium O +
stroke O +
volume O +
on O +
isolated O +
rabbit O +
heart O +
preparations O -
. O +

The O +
majority O +
of O +
the O +
derivatives O +
exhibited O +
better O +
in O +
vitro O +
activity O +
than O +
the O +
existing O +
drug O -
, O +
milrinone B-Chemical -
, O +
and O +
6- B-Chemical -
( I-Chemical -
( I-Chemical -
4- I-Chemical -
( I-Chemical -
4-methoxyphenyl I-Chemical -
) I-Chemical -
piperazin-1-yl I-Chemical -
) I-Chemical -
methyl I-Chemical -
) I-Chemical -
tetrazolo I-Chemical -
[ I-Chemical -
5,1-a I-Chemical -
] I-Chemical -
phthalazine I-Chemical -
. O +

8 O +
m O +
in O +
particular O +
was O +
identified O +
as O +
the O +
most O +
potent O +
with O +
an O +
increased O +
stroke O +
volume O +
of O +
12.02 O +
± O +
0.20 O -
% O +
( O -
milrinone B-Chemical -
: O +
2.46 O +
± O +
0.07 O -
% O -
) O +
at O +
a O +
concentration O +
of O +
3 O +
× O +
10 O -
( O -
-5 O -
) O +
m. O +
The O +
chronotropic O +
effects O +
of O +
the O +
compounds O +
that O +
exhibited O +
good O +
potency O +
were O +
also O +
evaluated O -
. O +

Modulation O +
of O +
esterified O +
drug O +
metabolism O +
by O +
tanshinones O +
from O +
Salvia O +
miltiorrhiza O +
( O -
" O -
Danshen O -
" O -
) O -
. O +

The O +
roots O +
of O +
Salvia O +
miltiorrhiza O +
( O -
" O -
Danshen O -
" O -
) O +
are O +
used O +
in O +
traditional O +
Chinese O +
medicine O +
for O +
the O +
treatment O +
of O +
numerous O +
ailments O +
including O +
cardiovascular O +
disease O -
, O +
hypertension O -
, O +
and O +
ischemic O +
stroke O -
. O +

Extracts O +
of O +
S. O +
miltiorrhiza O +
roots O +
in O +
the O +
formulation O +
" O -
Compound O +
Danshen O +
Dripping O +
Pill O -
" O +
are O +
undergoing O +
clinical O +
trials O +
in O +
the O +
United O +
States O -
. O +

To O +
date O -
, O +
the O +
active O +
components O +
of O +
this O +
material O +
have O +
not O +
been O +
conclusively O +
identified O -
. O +

We O +
have O +
determined O +
that O +
S. O +
miltiorrhiza O +
roots O +
contain O +
potent O +
human O +
carboxylesterase O +
( O -
CE O -
) O +
inhibitors O -
, O +
due O +
to O +
the O +
presence O +
of O +
tanshinones O -
. O +

K O -
( O -
i O -
) O +
values O +
in O +
the O +
nM O +
range O +
were O +
determined O +
for O +
inhibition O +
of O +
both O +
the O +
liver O +
and O +
intestinal O +
CEs O -
. O +

As O +
CEs O +
hydrolyze O +
clinically O +
used O +
drugs O -
, O +
the O +
ability O +
of O +
tanshinones O +
and O +
S. O +
miltiorrhiza O +
root O +
extracts O +
to O +
modulate O +
the O +
metabolism O +
of O +
the O +
anticancer O +
prodrug O +
irinotecan B-Chemical +
( O -
CPT-11 B-Chemical -
) O +
was O +
assessed O -
. O +

Our O +
results O +
indicate O +
that O +
marked O +
inhibition O +
of O +
human O +
CEs O +
occurs O +
following O +
incubation O +
with O +
both O +
pure O +
compounds O +
and O +
crude O +
material O +
and O +
that O +
drug O +
hydrolysis O +
is O +
significantly O +
reduced O -
. O +

Consequently O -
, O +
a O +
reduction O +
in O +
the O +
cytotoxicity O +
of O +
irinotecan O +
is O +
observed O +
following O +
dosing O +
with O +
either O +
purified O +
tanshinones O +
or O +
S. O +
miltiorrhiza O +
root O +
extracts O -
. O +

It O +
is O +
concluded O +
that O +
remedies O +
containing O +
tanshinones O +
should O +
be O +
avoided O +
when O +
individuals O +
are O +
taking O +
esterified O +
agents O +
and O +
that O +
patients O +
should O +
be O +
warned O +
of O +
the O +
potential O +
drug O -
- O -
drug O +
interaction O +
that O +
may O +
occur O +
with O +
this O +
material O -
. O +

Differential O +
anti O -
- O -
ischemic O +
efficacy O +
and O +
therapeutic O +
time O +
window O +
of O +
trans- B-Chemical +
and I-Chemical +
cis I-Chemical -
- I-Chemical -
hinokiresinols I-Chemical -
: O +
Stereo O -
- O -
specific O +
antioxidant O +
and O +
anti O -
- O -
inflammatory O +
activities O -
. O +

During O +
cerebral O +
ischemia O -
, O +
neurons O +
are O +
injured O +
by O +
various O +
mechanisms O +
including O +
excitotoxicity O -
, O +
oxidative O +
stress O -
, O +
and O +
inflammatory O +
responses O -
. O +

Thus O -
, O +
pharmacological O +
manipulation O +
of O +
multiple O +
cytotoxic O +
pathways O +
has O +
been O +
pursued O +
for O +
the O +
treatment O +
of O +
ischemic O +
injury O -
. O +

Cis B-Chemical -
- I-Chemical -
hinokiresinol I-Chemical -
, O +
a O +
naturally O +
occurring O +
phenylpropanoid B-Chemical -
, O +
was O +
previously O +
reported O +
to O +
possess O +
anti O -
- O -
oxidant O -
, O +
anti O -
- O -
inflammatory O +
and O +
estrogen B-Chemical -
- O -
like O +
activities O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
investigated O +
anti O -
- O -
ischemic O +
effects O +
of O +
trans- B-Chemical +
and I-Chemical +
cis I-Chemical -
- I-Chemical -
hinokiresinols I-Chemical +
using O +
in O +
vitro O +
as O +
well O +
as O +
in O +
vivo O +
experimental O +
models O -
. O +

The O +
ORAC O +
and O +
DPPH B-Chemical +
assays O +
showed O +
that O +
two O +
isomers O +
had O +
similar O +
free O +
radical O +
scavenging O +
activities O -
. O +

However O -
, O +
only O +
trans B-Chemical -
- I-Chemical -
hinokiresinol I-Chemical +
significantly O +
decreased O +
neuronal O +
injury O +
in O +
cultured O +
cortical O +
neurons O +
exposed O +
to O +
oxygen B-Chemical -
- O -
glucose B-Chemical +
deprivation O +
( O -
75 O +
min O -
) O +
followed O +
by O +
re O -
- O -
oxygenation O +
( O -
9 O +
h O -
) O -
. O +

The O +
differential O +
neuroprotective O +
effect O +
could O +
be O +
due O +
to O +
the O +
stereo O -
- O -
specific O +
augmentation O +
of O +
Cu B-Chemical -
/ O -
Zn B-Chemical -
- O -
SOD O +
activity O +
by O +
trans B-Chemical -
- I-Chemical -
hinokiresinol I-Chemical -
, O +
when O +
compared O +
with O +
cis B-Chemical -
- I-Chemical -
hinokiresinol I-Chemical -
. O +

Similarly O -
, O +
in O +
rats O +
subjected O +
to O +
transient O +
middle O +
cerebral O +
artery O +
occlusion O +
( O -
1.5 O +
h O -
) O +
followed O +
by O +
24-h O +
reperfusion O -
, O +
pre O -
- O -
ischemic O +
treatment O +
with O +
trans B-Chemical -
- I-Chemical -
hinokiresinol I-Chemical -
, O +
but O +
not O +
with O +
cis O -
- O -
isomer O -
, O +
reduced O +
cerebral O +
infarct O +
volume O -
. O +

Interestingly O -
, O +
however O -
, O +
post O -
- O -
ischemic O +
treatment O +
with O +
both O +
hinokiresinols B-Chemical +
( O -
2 O +
and O +
7 O +
h O +
after O +
onset O +
of O +
ischemia O -
) O +
significantly O +
reduced O +
cerebral O +
infarct O -
. O +

When O +
administered O +
after O +
onset O +
of O +
ischemia O -
, O +
trans B-Chemical -
- I-Chemical -
hinokiresinol I-Chemical -
, O +
but O +
not O +
its O +
cis O -
- O -
isomer O +
reduced O +
nitrotyrosine B-Chemical +
immunoreactivity O +
in O +
ischemic O +
regions O -
. O +

In O +
contrast O -
, O +
both O +
hinokiresinols B-Chemical +
suppressed O +
neutrophil O +
infiltration O +
and O +
IL-1β O +
release O +
to O +
a O +
similar O +
extent O -
. O +

The O +
observed O +
differential O +
anti O -
- O -
oxidant O -
, O +
but O +
comparable O +
anti O -
- O -
inflammatory O -
, O +
activities O +
may O +
explain O +
the O +
stereo O -
- O -
specific O +
anti O -
- O -
ischemic O +
activities O +
and O +
different O +
therapeutic O +
time O +
windows O +
of O +
the O +
hinokiresinols B-Chemical +
examined O -
. O +

More O +
detailed O +
delineation O +
of O +
the O +
anti O -
- O -
ischemic O +
mechanism O -
( O -
s O -
) O +
of O +
hinokiresinols B-Chemical +
may O +
provide O +
a O +
better O +
strategy O +
for O +
development O +
of O +
efficacious O +
regimens O +
for O +
cerebral O +
ischemic O +
stroke O -
. O +

Influence O +
of O +
DNA O +
repair O +
on O +
nonlinear O +
dose O -
- O -
responses O +
for O +
mutation O -
. O +

Recent O +
evidence O +
has O +
challenged O +
the O +
default O +
assumption O +
that O +
all O +
DNA O -
- O -
reactive O +
alkylating O +
agents O +
exhibit O +
a O +
linear O +
dose O -
- O -
response O -
. O +

Emerging O +
evidence O +
suggests O +
that O +
the O +
model O +
alkylating O +
agents O +
methyl- B-Chemical +
and O +
ethylmethanesulfonate B-Chemical +
and O +
methylnitrosourea B-Chemical +
( O -
MNU B-Chemical -
) O +
and O +
ethylnitrosourea B-Chemical +
observe O +
a O +
nonlinear O +
dose O -
- O -
response O +
with O +
a O +
no O +
observed O +
genotoxic O +
effect O +
level O +
( O -
NOGEL O -
) O -
. O +

Follow O -
- O -
up O +
mechanistic O +
studies O +
are O +
essential O +
to O +
understand O +
the O +
mechanism O +
of O +
cellular O +
tolerance O +
and O +
biological O +
relevance O +
of O +
such O +
NOGELs O -
. O +

MNU B-Chemical +
is O +
one O +
of O +
the O +
most O +
mutagenic O +
simple O +
alkylators O -
. O +

Therefore O -
, O +
understanding O +
the O +
mechanism O +
of O +
mutation O +
induction O -
, O +
following O +
low O -
- O -
dose O +
MNU B-Chemical +
treatment O -
, O +
sets O +
precedence O +
for O +
weaker O +
mutagenic O +
alkylating O +
agents O -
. O +

Here O -
, O +
we O +
tested O +
MNU B-Chemical +
at O +
10-fold O +
lower O +
concentrations O +
than O +
a O +
previous O +
study O +
and O +
report O +
a O +
NOGEL O +
of O +
0.0075 O +
µg O -
/ O -
ml O +
( O -
72.8nM O -
) O +
in O +
human O +
lymphoblastoid O +
cells O -
, O +
quantified O +
through O +
the O +
hypoxanthine B-Chemical +
( O -
guanine B-Chemical -
) O +
phosphoribosyltransferase O +
assay O +
( O -
OECD O +
476 O -
) O -
. O +

Mechanistic O +
studies O +
reveal O +
that O +
the O +
NOGEL O +
is O +
dependent O +
upon O +
repair O +
of O +
O B-Chemical -
( I-Chemical -
6 I-Chemical -
) I-Chemical -
-methylguanine I-Chemical +
( O -
O B-Chemical -
( I-Chemical -
6 I-Chemical -
) I-Chemical -
MeG I-Chemical -
) O +
by O +
the O +
suicide O +
enzyme O +
O B-Chemical -
( I-Chemical -
6 I-Chemical -
) I-Chemical -
MeG I-Chemical -
- O -
DNA O +
methyltransferase O +
( O -
MGMT O -
) O -
. O +

Inactivation O +
of O +
MGMT O +
sensitizes O +
cells O +
to O +
MNU B-Chemical -
- O -
induced O +
mutagenesis O +
and O +
shifts O +
the O +
NOGEL O +
to O +
the O +
left O +
on O +
the O +
dose O +
axis O -
. O +

An O +
animal O +
model O +
of O +
marginal O +
iodine B-Chemical +
deficiency O +
during O +
development O -
: O +
the O +
thyroid O +
axis O +
and O +
neurodevelopmental O +
outcome O -
. O +

Thyroid O +
hormones O +
( O -
THs O -
) O +
are O +
essential O +
for O +
brain O +
development O -
, O +
and O +
iodine B-Chemical +
is O +
required O +
for O +
TH O +
synthesis O -
. O +

Environmental O +
chemicals O +
that O +
perturb O +
the O +
thyroid O +
axis O +
result O +
in O +
modest O +
reductions O +
in O +
TH O -
, O +
yet O +
there O +
is O +
a O +
paucity O +
of O +
data O +
on O +
the O +
extent O +
of O +
neurological O +
impairments O +
associated O +
with O +
low O -
- O -
level O +
TH O +
disruption O -
. O +

This O +
study O +
examined O +
the O +
dose O -
- O -
response O +
characteristics O +
of O +
marginal O +
iodine B-Chemical +
deficiency O +
( O -
ID O -
) O +
on O +
parameters O +
of O +
thyroid O +
function O +
and O +
neurodevelopment O -
. O +

Diets O +
deficient O +
in O +
iodine B-Chemical +
were O +
prepared O +
by O +
adding O +
975 O -
, O +
200 O -
, O +
125 O -
, O +
25 O -
, O +
or O +
0 O +
µg O -
/ O -
kg O +
potassium B-Chemical +
iodate I-Chemical +
to O +
the O +
base O +
casein O +
diet O +
to O +
produce O +
five O +
nominal O +
iodine B-Chemical +
levels O +
ranging O +
from O +
ample O +
( O -
Diet O +
1 O -
: O +
1000 O +
μg O +
iodine B-Chemical -
/ O -
kg O +
chow O -
, O +
D1 O -
) O +
to O +
deficient O +
( O -
Diet O +
5 O -
: O +
25 O +
µg O +
iodine B-Chemical -
/ O -
kg O +
chow O -
, O +
D5 O -
) O -
. O +

Female O +
Long O +
Evans O +
rats O +
were O +
maintained O +
on O +
these O +
diets O +
beginning O +
7 O +
weeks O +
prior O +
to O +
breeding O +
until O +
the O +
end O +
of O +
lactation O -
. O +

Dams O +
were O +
sacrificed O +
on O +
gestational O +
days O +
16 O +
and O +
20 O -
, O +
or O +
when O +
pups O +
were O +
weaned O +
on O +
postnatal O +
day O +
( O -
PN O -
) O +
21 O -
. O +

Fetal O +
tissue O +
was O +
harvested O +
from O +
the O +
dams O -
, O +
and O +
pups O +
were O +
sacrificed O +
on O +
PN14 O +
and O +
PN21 O -
. O +

Blood O -
, O +
thyroid O +
gland O -
, O +
and O +
brain O +
were O +
collected O +
for O +
analysis O +
of O +
iodine B-Chemical -
, O +
TH O -
, O +
and O +
TH O +
precursors O +
and O +
metabolites O -
. O +

Serum O +
and O +
thyroid O +
gland O +
iodine B-Chemical +
and O +
TH O +
were O +
reduced O +
in O +
animals O +
receiving O +
two O +
diets O +
that O +
were O +
most O +
deficient O +
in O +
iodine B-Chemical -
. O +

T4 O +
was O +
reduced O +
in O +
the O +
fetal O +
brain O +
but O +
was O +
not O +
altered O +
in O +
the O +
neonatal O +
brain O -
. O +

Neurobehavior O -
, O +
assessed O +
by O +
acoustic O +
startle O -
, O +
water O +
maze O +
learning O -
, O +
and O +
fear O +
conditioning O -
, O +
was O +
unchanged O +
in O +
adult O +
offspring O -
, O +
but O +
excitatory O +
synaptic O +
transmission O +
was O +
impaired O +
in O +
the O +
dentate O +
gyrus O +
in O +
animals O +
receiving O +
two O +
diets O +
that O +
were O +
most O +
deficient O +
in O +
iodine B-Chemical -
. O +

A O +
15 O -
% O +
reduction O +
in O +
cortical O +
T4 O +
in O +
the O +
fetal O +
brain O +
was O +
sufficient O +
to O +
induce O +
permanent O +
reductions O +
in O +
synaptic O +
function O +
in O +
adults O -
. O +

These O +
findings O +
have O +
implications O +
for O +
regulation O +
of O +
TH O -
- O -
disrupting O +
chemicals O +
and O +
suggest O +
that O +
standard O +
behavioral O +
assays O +
do O +
not O +
readily O +
detect O +
neurotoxicity O +
induced O +
by O +
modest O +
developmental O +
TH O +
disruption O -
. O +

Regiospecificity O +
and O +
stereospecificity O +
of O +
human O +
UDP B-Chemical -
- O -
glucuronosyltransferases O +
in O +
the O +
glucuronidation O +
of O +
estriol B-Chemical -
, O +
16-epiestriol B-Chemical -
, O +
17-epiestriol B-Chemical -
, O +
and O +
13-epiestradiol B-Chemical -
. O +

The O +
glucuronidation O +
of O +
estriol B-Chemical -
, O +
16-epiestriol B-Chemical -
, O +
and O +
17-epiestriol B-Chemical +
by O +
the O +
human O +
UDP B-Chemical -
- O -
glucuronosyltransferases O +
( O -
UGTs O -
) O +
of O +
subfamilies O +
1A O -
, O +
2A O -
, O +
and O +
2B O +
was O +
examined O -
. O +

UGT1A10 O +
is O +
highly O +
active O +
in O +
the O +
conjugation O +
of O +
the O +
3-OH B-Chemical +
in O +
all O +
these O +
estriols B-Chemical -
, O +
whereas O +
UGT2B7 O +
is O +
the O +
most O +
active O +
UGT O +
toward O +
one O +
of O +
the O +
ring O +
D O +
hydroxyls O -
, O +
the O +
16-OH B-Chemical +
in O +
estriol B-Chemical +
and O +
16-epiestriol B-Chemical -
, O +
but O +
the O +
17-OH B-Chemical +
in O +
17-epiestriol B-Chemical -
. O +

Kinetic O +
analyses O +
indicated O +
that O +
the O +
17-OH B-Chemical +
configuration O +
plays O +
a O +
major O +
role O +
in O +
the O +
affinity O +
of O +
UGT2B7 O +
for O +
estrogens B-Chemical -
. O +

The O +
glucuronidation O +
of O +
the O +
different O +
estriols B-Chemical +
by O +
the O +
human O +
liver O +
and O +
intestine O +
microsomes O +
reflects O +
the O +
activity O +
of O +
UGT1A10 O +
and O +
UGT2B7 O +
in O +
combination O +
with O +
the O +
tissues O -
' O +
difference O +
in O +
UGT1A10 O +
expression O -
. O +

The O +
UGT1A10 O +
mutant O +
1A10-F93 O -
G O +
exhibited O +
much O +
higher O +
V O -
( O -
max O -
) O +
values O +
than O +
UGT1A10 O +
in O +
estriol B-Chemical +
and O +
17-epiestriol B-Chemical +
glucuronidation O -
, O +
but O +
a O +
significantly O +
lower O +
value O +
in O +
16-epiestriol B-Chemical +
glucuronidation O -
. O +

To O +
this O +
study O +
on O +
estriol B-Chemical +
glucuronidation O +
we O +
have O +
added O +
experiments O +
with O +
13-epiestradiol B-Chemical -
, O +
a O +
synthetic O +
estradiol B-Chemical +
in O +
which O +
the O +
spatial O +
arrangement O +
of O +
the O +
methyl B-Chemical +
on O +
C18 O +
and O +
the O +
hydroxyl B-Chemical +
on O +
C17 O +
is O +
significantly O +
different O +
than O +
in O +
other O +
estrogens B-Chemical -
. O +

In O +
comparison O +
with O +
estradiol B-Chemical +
glucuronidation O -
, O +
the O +
C13 O +
configuration O +
change O +
decreases O +
the O +
turnover O +
of O +
UGTs O +
that O +
conjugate O +
the O +
3-OH B-Chemical -
, O +
but O +
increases O +
it O +
in O +
UGTs O +
that O +
primarily O +
conjugate O +
the O +
17-OH B-Chemical -
. O +

Unexpectedly O -
, O +
UGT2B17 O +
exhibited O +
similar O +
conjugation O +
rates O +
of O +
both O +
the O +
17-OH B-Chemical +
and O +
3-OH B-Chemical +
of O +
13-espiestradiol B-Chemical -
. O +

The O +
combined O +
results O +
reveal O +
the O +
strong O +
preference O +
of O +
UGT1A10 O +
for O +
the O +
3-OH B-Chemical +
of O +
physiologic O +
estrogens B-Chemical +
and O +
the O +
equivalently O +
strong O +
preference O +
of O +
UGT2B7 O +
and O +
UGT2B17 O +
for O +
the O +
hydroxyls B-Chemical +
on O +
ring O +
D O +
of O +
such O +
steroid B-Chemical +
hormones I-Chemical -
. O +

Aβ O +
interacts O +
with O +
both O +
the O +
iron B-Chemical +
center O +
and O +
the O +
porphyrin B-Chemical +
ring O +
of O +
heme B-Chemical -
: O +
mechanism O +
of O +
heme B-Chemical -
's O +
action O +
on O +
Aβ O +
aggregation O +
and O +
disaggregation O -
. O +

Amyloid O +
β O +
peptide O +
( O -
Aβ O -
) O +
aggregation O +
is O +
a O +
pathological O +
hallmark O +
of O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O -
. O +

Modulation O +
of O +
the O +
self O -
- O -
assembly O +
processes O -
, O +
therefore O -
, O +
is O +
thought O +
to O +
be O +
an O +
attractive O +
strategy O +
for O +
the O +
prevention O +
and O +
treatment O +
of O +
AD O -
. O +

Interestingly O -
, O +
heme B-Chemical +
has O +
been O +
found O +
to O +
inhibit O +
Aβ O +
aggregation O +
and O +
even O +
dismantle O +
Aβ O +
aggregates O -
. O +

However O -
, O +
the O +
mechanism O +
remains O +
unresolved O -
. O +

Recent O +
research O +
has O +
shown O +
that O +
heme B-Chemical +
binds O +
preferentially O +
to O +
the O +
His B-Chemical -
( O -
13 O -
) O +
residue O +
of O +
Aβ O +
with O +
the O +
iron B-Chemical +
center O -
, O +
while O +
the O +
hydrophobic O +
domain O +
of O +
Aβ O +
is O +
also O +
able O +
to O +
bind O +
to O +
heme B-Chemical -
. O +

Herein O -
, O +
absorption O +
spectrometric O -
, O +
Thioflavin B-Chemical +
T I-Chemical +
fluorescence O -
, O +
and O +
circular O +
dichroism O +
spectroscopic O +
and O +
transmission O +
electron O +
microscopic O +
measurements O +
revealed O +
that O +
the O +
iron B-Chemical +
center O +
is O +
not O +
required O +
for O +
the O +
inhibition O +
of O +
Aβ O +
aggregation O +
but O +
do O +
influence O +
the O +
binding O +
affinity O +
of O +
heme B-Chemical +
toward O +
Aβ O +
and O +
the O +
dismantlement O +
rate O +
and O +
degree O +
of O +
the O +
Aβ O +
aggregates O -
. O +

By O +
studying O +
the O +
interaction O +
of O +
different O +
truncated O +
or O +
mutated O +
Aβ O +
peptides O +
with O +
heme B-Chemical +
or O +
protoporphyrin B-Chemical -
, O +
we O +
further O +
found O +
that O +
the O +
porphyrin B-Chemical +
ring O +
of O +
heme B-Chemical +
is O +
implicated O +
to O +
interact O +
preferentially O +
with O +
the O +
Phe B-Chemical -
( O -
19 O -
) O +
residue O -
, O +
facilitating O +
the O +
binding O +
of O +
heme B-Chemical +
to O +
Aβ O +
and O +
disturbing O +
the O +
interstrand O +
aromatic O +
interaction O +
between O +
the O +
Phe B-Chemical +
residues O -
, O +
which O +
is O +
crucial O +
for O +
Aβ O +
fibrillation O -
. O +

These O +
findings O +
open O +
new O +
avenues O +
in O +
the O +
understanding O +
of O +
the O +
interaction O +
between O +
the O +
heme B-Chemical +
and O +
Aβ O +
and O +
the O +
pathways O +
for O +
modulation O +
of O +
Aβ O +
aggregation O +
and O +
disaggregation O -
, O +
which O +
would O +
be O +
helpful O +
in O +
designing O +
therapeutic O +
strategies O +
against O +
AD O -
. O +

Aryl B-Chemical +
hydrocarbon I-Chemical +
receptor O +
activation O +
attenuates O +
Per1 O +
gene O +
induction O +
and O +
influences O +
circadian O +
clock O +
resetting O -
. O +

Light O -
- O -
stimulated O +
adjustment O +
of O +
the O +
circadian O +
clock O +
is O +
an O +
important O +
adaptive O +
physiological O +
response O +
that O +
allows O +
maintenance O +
of O +
behavioral O +
synchrony O +
with O +
solar O +
time O -
. O +

Our O +
previous O +
studies O +
indicate O +
that O +
the O +
aryl B-Chemical +
hydrocarbon I-Chemical +
receptor O +
( O -
AhR O -
) O +
agonist O +
2,3,7,8- B-Chemical +
tetrachlorodibenzo I-Chemical -
- I-Chemical -
p I-Chemical -
- I-Chemical -
dioxin I-Chemical +
attenuates O +
light O -
- O -
induced O +
phase O +
resetting O +
in O +
early O +
night O -
. O +

However O -
, O +
the O +
mechanism O +
of O +
inhibition O +
remains O +
unclear O -
. O +

In O +
this O +
study O -
, O +
we O +
showed O +
that O +
another O +
potent O +
AhR O +
agonist O -
- O -
β B-Chemical -
- I-Chemical -
naphthoflavone I-Chemical +
( O -
BNF B-Chemical -
) O -
-significantly O +
decreased O +
light O -
- O -
induced O +
phase O +
shifts O +
in O +
wild O -
- O -
type O +
( O -
WT O -
) O +
mice O -
, O +
whereas O +
AhR O +
knockout O +
mice O +
had O +
an O +
enhanced O +
response O +
to O +
light O +
that O +
was O +
unaffected O +
by O +
BNF B-Chemical -
. O +

Mechanistically O -
, O +
BNF B-Chemical +
blocked O +
light O +
induction O +
of O +
the O +
Per1 O +
transcript O +
in O +
suprachiasmatic O +
nucleus O +
and O +
liver O +
in O +
WT O +
mice O -
, O +
and O +
BNF B-Chemical +
blocked O +
forskolin B-Chemical +
( O -
FSK B-Chemical -
) O -
-induced O +
Per1 O +
transcripts O +
in O +
Hepa-1c1c7 O +
( O -
c7 O -
) O +
cells O -
. O +

An O +
E O -
- O -
box O +
decoy O +
did O +
not O +
affect O +
BNF B-Chemical +
inhibition O +
of O +
FSK B-Chemical -
- O -
induced O +
Per1 O +
transcripts O +
in O +
c7 O +
cells O -
. O +

cAMP B-Chemical -
- O -
response O +
element O +
( O -
CRE O -
) O -
-dependent O +
induction O +
of O +
Per1 O +
promoter O +
activity O +
in O +
response O +
to O +
FSK B-Chemical +
in O +
combination O +
with O +
phorbol B-Chemical +
12-tetradecanoate I-Chemical +
13-acetate I-Chemical +
was O +
suppressed O +
in O +
cells O +
that O +
expressed O +
high O +
levels O +
of O +
AhR O +
( O -
c7 O -
) O +
compared O +
with O +
cells O +
lacking O +
functional O +
AhR O +
activity O +
( O -
c12 O -
) O -
. O +

In O +
addition O -
, O +
the O +
inhibitory O +
effect O +
of O +
BNF B-Chemical +
on O +
FSK B-Chemical -
- O -
induced O +
Per1 O +
was O +
dependent O +
on O +
phosphorylation O +
of O +
JNK O -
. O +

Together O -
, O +
these O +
results O +
suggest O +
that O +
AhR O +
activation O +
inhibits O +
light O -
- O -
induced O +
phase O +
resetting O +
through O +
the O +
activation O +
of O +
JNK O -
, O +
negative O +
regulation O +
of O +
CREs O +
in O +
the O +
Per1 O +
promoter O -
, O +
and O +
suppression O +
of O +
Per1 O -
. O +

Preparation O -
, O +
preliminary O +
screening O +
of O +
new O +
types O +
of O +
steroid B-Chemical +
conjugates O +
and O +
their O +
activities O +
on O +
steroid B-Chemical +
receptors O -
. O +

There O +
were O +
synthesized O +
new O +
types O +
of O +
ribbon O +
type O +
steroidal O +
dimers O +
derived O +
from O +
three O +
types O +
of O +
steroidal O +
skeletons O +
( O -
cholic B-Chemical +
acid I-Chemical -
, O +
etienic B-Chemical +
acid I-Chemical -
, O +
estrone B-Chemical -
) O +
using O +
Cu B-Chemical -
( I-Chemical -
I I-Chemical -
) I-Chemical +
catalyzed O +
1 O -
, O +
3-dipolar O +
cycloaddition O +
reaction O -
. O +

Steroid B-Chemical +
parts O +
of O +
the O +
molecular O +
" O -
ribbons O -
" O +
are O +
linked O +
by O +
heterocyclic O +
moiety O -
, O +
namely O +
by O +
2,6-bis B-Chemical -
( I-Chemical -
( I-Chemical -
1H-1,2,3-triazol-1-yl I-Chemical -
) I-Chemical -
-methyl I-Chemical -
) I-Chemical -
pyridine I-Chemical -
. O +

Compounds O +
synthesized O +
possess O +
different O +
cytotoxic O +
and O +
hormone O +
receptor O +
modulating O +
activities O -
. O +

Altered O +
matrix O +
mineralization O +
in O +
a O +
case O +
of O +
a O +
sclerosing O +
osteosarcoma O -
. O +

Little O +
is O +
known O +
about O +
the O +
tumor O +
matrix O +
mineralization O +
of O +
highly O +
sclerotic O +
osteosarcoma O -
. O +

We O +
used O +
quantitative O +
backscattered O +
electron O +
imaging O +
( O -
qBEI O -
) O +
to O +
determine O +
the O +
Bone O +
mineralization O +
density O +
distribution O +
( O -
BMDD O -
) O +
of O +
a O +
highly O +
sclerosing O +
osteosarcoma O +
of O +
the O +
proximal O +
tibia O +
as O +
well O +
as O +
adjacent O +
normal O +
bone O +
of O +
a O +
10-year O -
- O -
old O +
girl O +
following O +
chemotherapy O +
according O +
to O +
the O +
EURAMOS-1 O +
protocol O -
. O +

Data O +
were O +
compared O +
to O +
recently O +
published O +
normative O +
reference O +
data O +
for O +
young O +
individuals O -
. O +

Backscattered O +
electron O +
imaging O +
of O +
the O +
tumor O +
region O +
revealed O +
a O +
dense O +
accumulation O +
of O +
mineralized O +
tumor O +
bone O +
matrix O +
( O -
up O +
to O +
90 O -
% O +
of O +
the O +
medullar O +
space O -
) O -
. O +

The O +
BMDD O +
was O +
shifted O +
tremendously O +
towards O +
higher O +
matrix O +
mineralization O +
( O -
CaMean O +
+ O -
18.5 O -
% O -
, O +
CaPeak O +
+ O -
22.5 O -
% O -
, O +
CaHigh O +
+ O -
100 O +
fold O -
) O +
compared O +
to O +
normal O +
bone O -
. O +

Additionally O +
the O +
BMDD O +
became O +
much O +
wider O -
, O +
indicating O +
a O +
higher O +
heterogeneity O +
in O +
mineralization O +
( O -
CaWidth O +
+ O -
40 O -
% O -
) O -
. O +

In O +
contrast O +
to O +
lamellar O +
bone O -
, O +
which O +
mineralizes O +
via O +
a O +
mineralization O +
front O -
, O +
the O +
mineralization O +
of O +
the O +
tumor O +
matrix O +
starts O +
by O +
randomly O +
distributed O +
spots O +
of O +
mineral O +
clusters O +
fusing O +
together O +
to O +
a O +
highly O +
mineralized O +
non O -
- O -
lamellar O +
bone O +
matrix O -
. O +

We O +
also O +
found O +
an O +
altered O +
BMDD O +
of O +
the O +
patient O -
's O +
normal O +
bone O +
when O +
compared O +
with O +
the O +
reference O +
BMDD O +
of O +
young O +
individuals O -
. O +

In O +
conclusion O +
this O +
high O +
radiodensity O +
region O +
of O +
the O +
sclerosing O +
sarcoma O +
is O +
not O +
only O +
due O +
to O +
the O +
high O +
amount O +
of O +
tumor O +
matrix O +
but O +
also O +
to O +
its O +
high O +
mineralization O +
density O -
. O +

Chemotherapy O +
may O +
lead O +
to O +
altered O +
matrix O +
mineralization O +
of O +
normal O +
bone O +
due O +
to O +
suppression O +
of O +
bone O +
turnover O -
. O +

The O +
mechanism O +
of O +
matrix O +
mineralization O +
in O +
a O +
sclerosing O +
osteosarcoma O +
warrants O +
further O +
studies O -
. O +

Pregabalin B-Chemical +
abuse O +
and O +
dependence O +
in O +
Germany O -
: O +
results O +
from O +
a O +
database O +
query O -
. O +

PURPOSE O -
: O +
Pregabalin B-Chemical +
( O -
PRG B-Chemical -
) O +
is O +
approved O +
for O +
the O +
treatment O +
of O +
neuropathic O +
pain O -
, O +
partial O +
seizures O +
and O +
generalised O +
anxiety O +
disorder O +
in O +
many O +
countries O +
and O +
currently O +
under O +
study O +
for O +
other O +
indications O -
. O +

Supported O +
by O +
case O +
reports O +
and O +
the O +
results O +
of O +
a O +
limited O +
number O +
of O +
studies O +
there O +
is O +
an O +
ongoing O +
debate O +
on O +
the O +
potential O +
of O +
PRG B-Chemical +
to O +
cause O +
addictive O +
behaviours O -
. O +

However O -
, O +
currently O +
available O +
evidence O +
on O +
this O +
issue O +
is O +
sparse O -
, O +
and O +
any O +
definitive O +
assessment O +
of O +
PRG B-Chemical -
's O +
potential O +
for O +
abuse O +
and O +
dependence O +
is O +
not O +
yet O +
in O +
sight O -
. O +

The O +
aim O +
of O +
our O +
study O +
was O +
to O +
identify O +
the O +
number O +
of O +
cases O +
of O +
PRG B-Chemical +
abuse O +
or O +
dependence O +
reported O +
to O +
the O +
database O +
of O +
a O +
German O +
medical O +
regulatory O +
body O +
and O +
to O +
obtain O +
insights O +
into O +
further O +
usage O -
- O -
specific O +
parameters O -
. O +

METHODS O -
: O +
We O +
conducted O +
a O +
query O +
of O +
the O +
entire O +
database O +
of O +
the O +
German O +
Federal O +
Institute O +
for O +
Drugs O +
and O +
Medical O +
Devices O +
( O -
BfArM O -
) O +
regarding O +
reports O +
of O +
PRG B-Chemical +
abuse O +
or O +
dependence O +
and O +
analysed O +
these O +
cases O +
on O +
the O +
basis O +
of O +
several O +
parameters O -
. O +

RESULTS O -
: O +
A O +
total O +
of O +
55 O +
reports O +
of O +
PRG B-Chemical +
abuse O +
or O +
dependence O +
were O +
identified O +
( O -
mean O +
age O +
36 O +
years O -
, O +
64 O +
% O +
of O +
reports O +
involved O +
males O -
) O -
. O +

The O +
first O +
reports O +
were O +
submitted O +
to O +
BfArM O +
in O +
2008 O -
, O +
and O +
the O +
reporting O +
frequency O +
has O +
increased O +
up O +
to O +
the O +
present O -
. O +

Mean O +
daily O +
PRG B-Chemical +
dosage O +
was O +
1424 O +
mg O -
. O +

Current O +
or O +
previous O +
polytoxicomania O +
was O +
present O +
in O +
40 O +
and O +
42 O +
% O +
of O +
cases O -
, O +
respectively O -
. O +

Psychiatric O +
diagnoses O +
other O +
than O +
substance O -
- O -
related O +
disorders O +
were O +
reported O +
in O +
13 O +
( O -
24 O +
% O -
) O +
cases O -
. O +

In O +
about O +
one O -
- O -
third O +
of O +
the O +
patients O +
withdrawal O +
syndromes O +
subsequent O +
to O +
discontinuation O +
of O +
PRG B-Chemical +
were O +
reported O -
. O +

CONCLUSIONS O -
: O +
Cases O +
of O +
PRG B-Chemical +
abuse O +
or O +
dependence O +
have O +
been O +
reported O +
to O +
the O +
BfArM O +
since O +
2008 O -
, O +
with O +
a O +
marked O +
increase O +
of O +
such O +
reports O +
in O +
subsequent O +
years O -
. O +

Male O +
sex O +
and O +
a O +
history O +
of O +
polytoxicomania O +
may O +
be O +
possible O +
risk O +
factors O +
for O +
the O +
development O +
of O +
addictive O +
behaviours O +
related O +
to O +
PRG B-Chemical -
. O +

Marked O +
decline O +
in O +
beta O +
cell O +
function O +
during O +
pregnancy O +
leads O +
to O +
the O +
development O +
of O +
glucose B-Chemical +
intolerance O +
in O +
Japanese O +
women O -
. O +

The O +
aim O +
of O +
this O +
study O +
is O +
to O +
investigate O +
glucose B-Chemical +
metabolism O +
longitudinally O +
during O +
pregnancy O +
to O +
explore O +
mechanisms O +
underlying O +
gestational O +
diabetes O +
mellitus O +
( O -
GDM O -
) O -
. O +

We O +
reviewed O +
a O +
total O +
of O +
62 O +
pregnant O +
Japanese O +
women O +
who O +
underwent O +
a O +
75 O -
g O +
oral O +
glucose B-Chemical +
tolerance O +
test O +
( O -
OGTT O -
) O +
twice O +
during O +
pregnancy O +
( O -
median O -
: O +
early O -
, O +
13 O -
; O +
late O -
, O +
28 O +
weeks O -
' O +
gestation O -
) O +
because O +
of O +
positive O +
GDM O +
screening O -
. O +

All O +
showed O +
normal O +
OGTT O +
results O +
in O +
early O +
pregnancy O -
. O +

Based O +
on O +
late O +
OGTT O -
, O +
15 O +
had O +
GDM O +
( O -
late O -
- O -
onset O +
GDM O -
) O +
and O +
47 O +
normal O +
glucose B-Chemical +
tolerance O +
( O -
NGT O -
) O -
. O +

In O +
early O +
pregnancy O -
, O +
there O +
were O +
no O +
significant O +
differences O +
in O +
insulin O +
sensitivity O +
( O -
insulin O +
sensitivity O +
index O +
derived O +
from O +
OGTT O +
[ O -
ISOGTT O -
] O +
and O +
homeostasis O +
model O +
assessment O +
for O +
insulin O +
resistance O +
[ O -
HOMA O -
- O -
IR O -
] O -
) O +
and O +
insulin O +
secretion O +
( O -
a O +
ratio O +
of O +
the O +
total O +
area O -
- O -
under O -
- O -
the O -
- O -
insulin O -
- O -
curve O +
to O +
the O +
total O +
area O -
- O -
under O -
- O -
the O -
- O -
glucose B-Chemical -
- O -
curve O +
[ O -
AUCins O -
/ O -
glu O -
] O +
and O +
insulinogenic O +
index O +
[ O -
IGI O -
] O -
) O +
between O +
the O +
NGT O +
and O +
late O -
- O -
onset O +
GDM O +
groups O -
. O +

In O +
each O +
group O -
, O +
insulin O +
sensitivity O +
significantly O +
decreased O +
from O +
early O +
to O +
late O +
pregnancy O -
, O +
most O +
in O +
the O +
late O -
- O -
onset O +
GDM O +
group O +
( O -
each O +
p O +
< O +
0.05 O -
) O -
. O +

The O +
insulin O +
secretion O +
showed O +
no O +
significant O +
changes O +
with O +
advancing O +
pregnancy O +
in O +
both O +
of O +
the O +
groups O -
, O +
although O +
late O -
- O -
onset O +
GDM O +
showed O +
significantly O +
lower O +
IGI O +
compared O +
with O +
NGT O +
in O +
late O +
OGTT O +
( O -
p O +
< O +
0.05 O -
) O -
. O +

When O +
assessed O +
beta O +
cell O +
function O +
by O +
OGTT O -
- O -
derived O +
disposition O +
index O +
( O -
i.e. O +
Insulin O +
Secretion O -
- O -
Sensitivity O +
Index-2 O +
and O +
IGI O -
/ O -
fasting O +
insulin O -
) O -
, O +
the O +
indices O +
significantly O +
decreased O +
from O +
early O +
to O +
late O +
pregnancy O +
in O +
the O +
both O +
groups O +
( O -
each O +
p O +
< O +
0.05 O -
) O -
. O +

Women O +
with O +
late O -
- O -
onset O +
GDM O +
showed O +
significantly O +
lower O +
indices O +
compared O +
with O +
NGT O +
( O -
each O +
p O +
< O +
0.05 O -
) O -
. O +

The O +
failure O +
of O +
beta O +
cell O +
to O +
compensate O +
for O +
decreased O +
insulin O +
sensitivity O +
could O +
contribute O +
to O +
the O +
development O +
of O +
the O +
late O -
- O -
onset O +
GDM O -
. O +

In O +
vitro O +
assessment O +
of O +
drug O -
- O -
drug O +
interaction O +
potential O +
of O +
boceprevir B-Chemical +
associated O +
with O +
drug O +
metabolizing O +
enzymes O +
and O +
transporters O -
. O +

The O +
inhibitory O +
effect O +
of O +
boceprevir B-Chemical +
( O -
BOC B-Chemical -
) O -
, O +
an O +
inhibitor O +
of O +
hepatitis O +
C O +
virus O +
nonstructural O +
protein O +
3 O +
protease O +
was O +
evaluated O +
in O +
vitro O +
against O +
a O +
panel O +
of O +
drug O -
- O -
metabolizing O +
enzymes O +
and O +
transporters O -
. O +

BOC B-Chemical -
, O +
a O +
known O +
substrate O +
for O +
cytochrome O +
P450 O +
( O -
P450 O -
) O +
CYP3A O +
and O +
aldo O -
- O -
ketoreductases O -
, O +
was O +
a O +
reversible O +
time O -
- O -
dependent O +
inhibitor O +
( O -
k O -
( O -
inact O -
) O +
= O +
0.12 O +
minute O -
( O -
-1 O -
) O -
, O +
K O -
( O -
I O -
) O +
= O +
6.1 O +
µM O -
) O +
of O +
CYP3A4 O -
/ O -
5 O +
but O +
not O +
an O +
inhibitor O +
of O +
other O +
major O +
P450s O -
, O +
nor O +
of O +
UDP B-Chemical -
- O -
glucuronosyltransferases O +
1A1 O +
and O +
2B7 O -
. O +

BOC B-Chemical +
showed O +
weak O +
to O +
no O +
inhibition O +
of O +
breast O +
cancer O +
resistance O +
protein O +
( O -
BCRP O -
) O -
, O +
P O -
- O -
glycoprotein O +
( O -
Pgp O -
) O -
, O +
or O +
multidrug O +
resistance O +
protein O +
2 O -
. O +

It O +
was O +
a O +
moderate O +
inhibitor O +
of O +
organic O +
anion O +
transporting O +
polypeptide O +
( O -
OATP O -
) O +
1B1 O +
and O +
1B3 O -
, O +
with O +
an O +
IC O -
( O -
50 O -
) O +
of O +
18 O +
and O +
4.9 O +
µM O -
, O +
respectively O -
. O +

In O +
human O +
hepatocytes O -
, O +
BOC B-Chemical +
inhibited O +
CYP3A O -
- O -
mediated O +
metabolism O +
of O +
midazolam O -
, O +
OATP1B O -
- O -
mediated O +
hepatic O +
uptake O +
of O +
pitavastatin B-Chemical -
, O +
and O +
both O +
the O +
uptake O +
and O +
metabolism O +
of O +
atorvastatin B-Chemical -
. O +

The O +
inhibitory O +
potency O +
of O +
BOC B-Chemical +
was O +
lower O +
than O +
known O +
inhibitors O +
of O +
CYP3A O +
( O -
ketoconazole B-Chemical -
) O -
, O +
OATP1B O +
( O -
rifampin B-Chemical -
) O -
, O +
or O +
both O +
( O -
telaprevir B-Chemical -
) O -
. O +

BOC B-Chemical +
was O +
a O +
substrate O +
for O +
Pgp O +
and O +
BCRP O +
but O +
not O +
for O +
OATP1B1 O -
, O +
OATP1B3 O -
, O +
OATP2B1 O -
, O +
organic O +
cation O +
transporter O -
, O +
or O +
sodium B-Chemical -
/ O -
taurocholate B-Chemical +
cotransporting O +
peptide O -
. O +

Overall O -
, O +
our O +
data O +
suggest O +
that O +
BOC B-Chemical +
has O +
the O +
potential O +
to O +
cause O +
pharmacokinetic O +
interactions O +
via O +
inhibition O +
of O +
CYP3A O +
and O +
CYP3A O -
/ O -
OATP1B O +
interplay O -
, O +
with O +
the O +
interaction O +
magnitude O +
lower O +
than O +
those O +
observed O +
with O +
known O +
potent O +
inhibitors O -
. O +

Conversely O -
, O +
pharmacokinetic O +
interactions O +
of O +
BOC B-Chemical -
, O +
either O +
as O +
a O +
perpetrator O +
or O +
victim O -
, O +
via O +
other O +
major O +
P450s O +
and O +
transporters O +
tested O +
are O +
less O +
likely O +
to O +
be O +
of O +
clinical O +
significance O -
. O +

The O +
results O +
from O +
clinical O +
drug O -
- O -
drug O +
interaction O +
studies O +
conducted O +
thus O +
far O +
are O +
generally O +
supportive O +
of O +
these O +
conclusions O -
. O +

Inhibitors O +
of O +
the O +
Yersinia O +
protein O +
tyrosine B-Chemical +
phosphatase O +
through O +
high O +
throughput O +
and O +
virtual O +
screening O +
approaches O -
. O +

The O +
bacterial O +
protein O +
tyrosine B-Chemical +
phosphatase O +
YopH O +
is O +
an O +
essential O +
virulence O +
determinant O +
in O +
Yersinia O +
pestis O +
and O +
a O +
potential O +
antibacterial O +
drug O +
target O -
. O +

Here O +
we O +
report O +
our O +
studies O +
of O +
screening O +
for O +
small O +
molecule O +
inhibitors O +
of O +
YopH O +
using O +
both O +
high O +
throughput O +
and O +
in O +
silico O +
approaches O -
. O +

The O +
identified O +
inhibitors O +
represent O +
a O +
diversity O +
of O +
chemotypes O +
and O +
novel O +
pTyr O +
mimetics O -
, O +
providing O +
a O +
starting O +
point O +
for O +
further O +
development O +
and O +
fragment O -
- O -
based O +
design O +
of O +
multi O -
- O -
site O +
binding O +
inhibitors O -
. O +

We O +
demonstrate O +
that O +
the O +
applications O +
of O +
high O +
throughput O +
and O +
virtual O +
screening O -
, O +
when O +
guided O +
by O +
structural O +
binding O +
mode O +
analysis O -
, O +
is O +
an O +
effective O +
approach O +
for O +
identifying O +
potent O +
and O +
selective O +
inhibitors O +
of O +
YopH O +
and O +
other O +
protein O +
phosphatases O +
for O +
rational O +
drug O +
design O -
. O +

S B-Chemical -
- I-Chemical -
nitrosoglutathione I-Chemical +
covalently O +
modifies O +
cysteine B-Chemical +
residues O +
of O +
human O +
carbonyl B-Chemical +
reductase O +
1 O +
and O +
affects O +
its O +
activity O -
. O +

Carbonyl B-Chemical +
reductase O +
1 O +
( O -
CBR1 O +
or O +
SDR21C1 O -
) O +
is O +
a O +
ubiquitously O -
- O -
expressed O -
, O +
cytosolic O -
, O +
monomeric O -
, O +
and O +
NADPH B-Chemical -
- O -
dependent O +
enzyme O -
. O +

CBR1 O +
participates O +
in O +
apoptosis O -
, O +
carcinogenesis O +
and O +
drug O +
resistance O -
, O +
and O +
has O +
a O +
protective O +
role O +
in O +
oxidative O +
stress O -
, O +
cancer O +
and O +
neurodegeneration O -
. O +

S B-Chemical -
- I-Chemical -
Nitrosoglutathione I-Chemical +
( O -
GSNO B-Chemical -
) O +
represents O +
the O +
newest O +
addition O +
to O +
its O +
diverse O +
substrate O +
spectrum O -
, O +
which O +
includes O +
a O +
wide O +
range O +
of O +
xenobiotics O +
and O +
endogenous O +
substances O -
. O +

GSNO B-Chemical +
has O +
also O +
been O +
shown O +
to O +
covalently O +
modify O +
and O +
inhibit O +
CBR1 O -
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
quantify O +
and O +
characterize O +
the O +
resulting O +
modifications O -
. O +

Of O +
five O +
candidate O +
cysteines O +
for O +
modification O +
by O +
2 O +
mM O +
GSNO B-Chemical +
( O -
positions O +
26 O -
, O +
122 O -
, O +
150 O -
, O +
226 O -
, O +
227 O -
) O -
, O +
the O +
last O +
four O +
were O +
analyzed O +
using O +
MALDI O -
- O -
TOF O -
/ O -
TOF O +
mass O +
spectrometry O +
and O +
then O +
quantified O +
using O +
the O +
Selected O +
Reaction O +
Monitoring O +
Approach O +
on O +
hyphenated O +
HPLC O +
with O +
a O +
triple O +
quadrupole O +
mass O +
spectrometer O -
. O +

The O +
analysis O +
confirmed O +
GSNO B-Chemical +
concentration O -
- O -
dependent O +
S B-Chemical -
- I-Chemical -
glutathionylation I-Chemical +
of O +
cysteines B-Chemical +
at O +
positions O +
122 O -
, O +
150 O -
, O +
226 O -
, O +
227 O +
which O +
was O +
2 O -
- O -
700 O +
times O +
higher O +
compared O +
to O +
wild O -
- O -
type O +
CBR1 O +
( O -
WT O -
- O -
CBR1 O -
) O -
. O +

Moreover O -
, O +
a O +
disulfide B-Chemical +
bond O +
between O +
neighboring O +
Cys-226 B-Chemical +
and O +
Cys-227 B-Chemical +
was O +
detected O -
. O +

We O +
suggest O +
a O +
role O +
of O +
these O +
two O +
cysteines B-Chemical +
as O +
a O +
redox O -
- O -
sensitive O +
cysteine O +
pair O -
. O +

The O +
catalytic O +
properties O +
of O +
wild O -
- O -
type O +
and O +
enzyme O +
modified O +
with O +
2 O +
mM O +
GSNO B-Chemical +
were O +
also O +
investigated O +
by O +
steady O +
state O +
kinetic O +
experiments O +
with O +
various O +
substrates O -
. O +

GSNO B-Chemical +
treatment O +
of O +
CBR1 O +
resulted O +
in O +
a O +
2 O -
- O -
5-fold O +
decrease O +
in O +
kcat O +
with O +
menadione B-Chemical -
, O +
4-benzoylpyridine B-Chemical -
, O +
2,3-hexanedione B-Chemical -
, O +
daunorubicin B-Chemical +
and O +
1,4-naphthoquinone B-Chemical -
. O +

In O +
contrast O -
, O +
the O +
same O +
treatment O +
increased O +
kcat O +
for O +
substrates O +
containing O +
a O +
1,2-diketo B-Chemical +
group O +
in O +
a O +
ring O +
structure O +
( O -
1,2-naphthoquinone B-Chemical -
, O +
9,10-phenanthrenequinone B-Chemical -
, O +
isatin B-Chemical -
) O -
. O +

Except O +
for O +
9,10-phenanthrenequinone B-Chemical -
, O +
all O +
changes O +
in O +
kcat O +
were O +
at O +
least O +
in O +
part O +
compensated O +
for O +
by O +
a O +
similar O +
change O +
in O +
Km O -
, O +
overall O +
yielding O +
no O +
drastic O +
changes O +
in O +
catalytic O +
efficiency O -
. O +

The O +
findings O +
indicate O +
that O +
GSNO B-Chemical -
- O -
induced O +
covalent O +
modification O +
of O +
cysteine B-Chemical +
residues O +
affects O +
the O +
kinetic O +
mechanism O +
of O +
CBR1 O +
both O +
in O +
terms O +
of O +
substrate O +
binding O +
and O +
turnover O +
rate O -
, O +
probably O +
by O +
covalent O +
modification O +
of O +
Cys-226 B-Chemical +
and/or O +
Cys-227 B-Chemical -
. O +

The O +
antinociceptive O +
effect O +
of O +
milnacipran B-Chemical +
in O +
the O +
monosodium B-Chemical +
iodoacetate I-Chemical +
model O +
of O +
osteoarthritis O +
pain O +
and O +
its O +
relation O +
to O +
changes O +
in O +
descending O +
inhibition O -
. O +

Osteoarthritis O +
( O -
OA O -
) O +
is O +
a O +
chronic O +
joint O +
disorder O +
whose O +
principal O +
symptom O +
is O +
chronic O +
pain O -
. O +

Current O +
analgesics O +
are O +
inadequate O +
and O +
the O +
mechanisms O +
contributing O +
to O +
this O +
pain O +
are O +
poorly O +
understood O +
but O +
likely O +
to O +
include O +
both O +
local O +
joint O +
changes O +
and O +
central O +
consequences O -
. O +

These O +
studies O +
used O +
monoamine B-Chemical +
receptor O +
agents O +
combined O +
with O +
behavioral O +
studies O +
and O +
single O -
- O -
unit O +
dorsal O +
horn O +
recordings O +
to O +
examine O +
whether O +
descending O +
noradrenergic O +
and O +
serotonergic O +
inhibitions O +
are O +
altered O +
in O +
the O +
monosodium B-Chemical +
iodoacetate I-Chemical +
model O +
of O +
OA O +
pain O -
, O +
and O +
whether O +
increasing O +
these O +
inhibitions O +
with O +
the O +
serotonin B-Chemical -
/ O -
noradrenaline B-Chemical +
reuptake O +
inhibitor O +
milnacipran B-Chemical +
can O +
attenuate O +
the O +
attendant O +
hypersensitivity O -
. O +

Early O +
and O +
late O +
in O +
the O +
course O +
of O +
this O +
model O -
, O +
milnacipran B-Chemical +
( O -
s.c O -
. O -
) O +
reduced O +
behavioral O +
hypersensitivity O -
, O +
and O +
inhibited O +
evoked O +
responses O +
from O +
sensitized O +
dorsal O +
horn O +
neurons O -
. O +

In O +
naïve O +
animals O +
and O +
the O +
early O -
, O +
but O +
not O +
late O -
, O +
phase O +
of O +
the O +
model O -
, O +
spinal O +
administration O +
of O +
the O +
α O -
( O -
2 O -
) O -
-adrenoceptor O +
antagonist O +
atipamezole B-Chemical +
fully O +
reversed O +
this O +
neuronal O +
inhibition O -
, O +
whereas O +
atipamezole B-Chemical +
administered O +
alone O +
revealed O +
that O +
endogenous O +
noradrenergic O +
inhibition O +
was O +
reduced O +
in O +
the O +
late O +
phase O -
. O +

Blocking O +
spinal O +
5-hydroxytryptamine-7 B-Chemical +
receptors O +
with O +
( B-Chemical -
2R I-Chemical -
) I-Chemical -
-1- I-Chemical -
[ I-Chemical -
( I-Chemical -
3-hydroxyphenyl I-Chemical -
) I-Chemical -
sulfonyl I-Chemical -
] I-Chemical -
-2- I-Chemical -
[ I-Chemical -
2- I-Chemical -
( I-Chemical -
4-methyl-1-piperidinyl I-Chemical -
) I-Chemical -
ethyl I-Chemical -
] I-Chemical -
pyrrolidine I-Chemical +
hydrochloride I-Chemical +
suggested O +
that O +
the O +
effects O +
of O +
milnacipran B-Chemical +
in O +
the O +
late O +
phase O +
were O +
partly O +
mediated O +
by O +
these O +
receptors O -
, O +
and O +
that O +
descending O +
serotonergic O +
inhibition O +
was O +
increased O +
in O +
this O +
phase O -
. O +

An O +
opioidergic O +
mechanism O +
behind O +
the O +
effects O +
of O +
milnacipran B-Chemical +
was O +
indicated O +
by O +
a O +
partial O +
reversal O +
of O +
these O +
effects O +
with O +
naloxone B-Chemical -
. O +

These O +
studies O +
demonstrate O +
antinociceptive O +
effects O +
for O +
milnacipran B-Chemical +
in O +
a O +
model O +
of O +
OA O +
pain O -
, O +
whose O +
effects O +
come O +
via O +
descending O +
serotonergic O +
and O +
noradrenergic O -
, O +
as O +
well O +
as O +
opioidergic O -
, O +
pathways O -
. O +

Variations O +
in O +
the O +
activity O +
of O +
these O +
pathways O +
over O +
the O +
course O +
of O +
this O +
model O +
may O +
contribute O +
to O +
the O +
presence O +
of O +
behavioral O +
hypersensitivity O +
and O +
determine O +
through O +
which O +
endogenous O +
systems O +
milnacipran B-Chemical +
exerts O +
its O +
effects O -
. O +

Effects O +
of O +
garlic O +
fractions O +
consumption O +
on O +
male O +
reproductive O +
functions O -
. O +

Many O +
researchers O +
have O +
focused O +
on O +
the O +
preventive O +
and O +
curative O +
effects O +
of O +
garlic O +
( O -
Allium O +
sativum O -
) O -
, O +
particularly O +
on O +
cardiovascular O +
diseases O +
and O +
cancer O -
. O +

However O -
, O +
its O +
impacts O +
on O +
the O +
male O +
reproductive O +
system O +
have O +
not O +
been O +
clearly O +
defined O -
. O +

In O +
this O +
study O -
, O +
the O +
effect O +
of O +
chronic O +
consumption O +
of O +
two O +
garlic O +
fractions O +
was O +
tested O -
: O +
one O +
soluble O +
in O +
water O +
( O -
aqueous O +
solution O +
obtained O +
by O +
grinding O +
and O +
centrifugation O -
) O +
and O +
the O +
other O +
one O +
precipitated O +
by O +
ethanol B-Chemical +
( O -
alcoholic O +
precipitate O +
obtained O +
by O +
precipitation O +
of O +
the O +
aqueous O +
solution O -
) O -
, O +
on O +
different O +
variables O +
of O +
male O +
rats O -
' O +
reproductive O +
functions O -
. O +

These O +
two O +
fractions O +
were O +
targeted O +
to O +
try O +
to O +
identify O +
the O +
nature O +
of O +
the O +
active O +
garlic O +
compounds O +
responsible O +
for O +
the O +
different O +
modifications O +
observed O +
on O +
testicular O +
parameters O -
. O +

The O +
observation O +
of O +
seminiferous O +
tubules O +
of O +
rats O +
treated O +
with O +
garlic O +
fractions O +
showed O +
an O +
increased O +
number O +
of O +
tubules O +
deprived O +
of O +
spermatozoa O -
. O +

In O +
addition O -
, O +
garlic O +
fractions O +
induced O +
apoptosis O +
of O +
testicular O +
germ O +
cells O +
( O -
TdT O -
- O -
mediated O +
dUTP B-Chemical -
- O -
X O +
nick O -
- O -
end O +
labeling O +
[ O -
TUNEL O -
] O +
approach O -
) O +
and O +
a O +
decrease O +
of O +
serum O +
testosterone B-Chemical +
levels O +
and O +
seminiferous O +
tubule O +
DNA O +
concentrations O -
. O +

In O +
summary O -
, O +
our O +
histological O +
and O +
molecular O +
results O +
suggest O +
that O +
one O +
or O +
several O +
substances O -
, O +
soluble O +
in O +
water O +
and O +
precipitated O +
by O +
alcohol B-Chemical -
, O +
impaired O +
spermatogenesis O -
. O +

Essential O +
oils O +
of O +
Thymus O +
leucospermus O +
Hartvig O -
, O +
a O +
Greek O +
endemic O +
rich O +
in O +
phenolic B-Chemical +
monoterpenes I-Chemical -
. O +

Thymus O +
leucospermus O +
Hartvig O +
is O +
a O +
Greek O +
endemic O +
species O +
of O +
Section O +
Teucrioides O +
Jalas O -
. O +

The O +
essential O +
oils O +
obtained O +
from O +
five O +
populations O +
growing O +
wild O +
in O +
the O +
National O +
Park O +
of O +
Northern O +
Pindhos O +
( O -
NW O +
Greece O -
) O +
were O +
studied O -
. O +

The O +
oil O +
content O +
ranged O +
between O +
1.1 O +
and O +
2.0 O +
mL O +
per O +
100 O +
g O +
of O +
dry O +
plant O +
weight O -
. O +

The O +
oils O +
were O +
particularly O +
rich O +
in O +
phenolic B-Chemical +
monoterpenes I-Chemical -
: O +
they O +
had O +
a O +
high O +
thymol B-Chemical +
( O -
64.7 O -
- O -
92.0 O -
% O -
) O +
or O +
carvacrol B-Chemical +
( O -
93.4 O -
% O -
) O +
content O -
, O +
whereas O +
in O +
one O +
of O +
the O +
oils O +
considerable O +
amount O +
of O +
both O +
compounds O +
was O +
found O +
( O -
thymol B-Chemical +
61.6 O -
% O +
and O +
carvacrol B-Chemical +
26.4 O -
% O -
) O -
. O +

Our O +
results O +
show O +
that O +
T. O +
leucospermus O +
is O +
a O +
high O -
- O -
quality O +
thyme O +
species O -
, O +
with O +
respect O +
to O +
both O +
oil O +
content O +
and O +
composition O -
. O +

Systematic O +
literature O +
review O +
of O +
the O +
effects O +
of O +
food O +
and O +
drink O +
advertising O +
on O +
food O +
and O +
drink O -
- O -
related O +
behaviour O -
, O +
attitudes O +
and O +
beliefs O +
in O +
adult O +
populations O -
. O +

A O +
large O +
body O +
of O +
research O +
confirms O +
that O +
food O +
advertising O +
affects O +
the O +
food O +
preferences O +
and O +
behaviour O +
of O +
children O -
. O +

The O +
impact O +
of O +
food O +
advertising O +
on O +
adults O +
is O +
less O +
clear O -
. O +

We O +
conducted O +
a O +
systematic O +
review O +
exploring O +
the O +
effects O +
of O +
advertising O +
of O +
food O +
and O +
non O -
- O -
alcoholic O +
drinks O +
( O -
referred O +
to O +
as O +
' O -
food O -
' O +
throughout O -
) O +
on O +
food O -
- O -
related O +
behaviour O -
, O +
attitudes O +
and O +
beliefs O +
in O +
adult O +
populations O -
. O +

We O +
searched O +
seven O +
electronic O +
databases O -
, O +
grey O +
literature O +
sources O -
, O +
and O +
references O +
and O +
citations O +
of O +
included O +
material O +
for O +
experimental O +
studies O +
written O +
in O +
English O +
investigating O +
the O +
effects O +
of O +
commercial O +
food O +
advertising O +
on O +
the O +
food O -
- O -
related O +
behaviours O -
, O +
attitudes O +
and O +
beliefs O +
of O +
adults O +
aged O +
16 O +
years O +
and O +
over O -
. O +

Nine O +
studies O -
, O +
rated O +
moderate O +
to O +
poor O +
quality O -
, O +
were O +
included O +
in O +
the O +
review O -
; O +
all O +
were O +
from O +
developed O +
countries O +
and O +
explored O +
the O +
impact O +
of O +
televised O +
food O +
advertising O -
. O +

Overall O -
, O +
the O +
results O +
did O +
not O +
show O +
conclusively O +
whether O +
or O +
not O +
food O +
advertising O +
affects O +
food O -
- O -
related O +
behaviour O -
, O +
attitudes O +
or O +
beliefs O +
in O +
adults O -
, O +
but O +
suggest O +
that O +
the O +
impact O +
varies O +
inconsistently O +
within O +
subgroups O -
, O +
including O +
gender O -
, O +
weight O +
and O +
existing O +
food O +
psychology O -
. O +

The O +
identification O +
of O +
a O +
small O +
number O +
of O +
relevant O +
studies O -
, O +
none O +
of O +
which O +
were O +
high O +
quality O -
, O +
and O +
with O +
substantial O +
heterogeneity O -
, O +
highlights O +
the O +
need O +
for O +
further O +
research O -
. O +

Future O +
studies O +
investigating O +
longer O +
term O +
outcomes O -
, O +
diverse O +
advertising O +
formats O -
, O +
and O +
in O +
countries O +
with O +
different O +
levels O +
of O +
economic O +
development O +
will O +
be O +
of O +
particular O +
value O -
. O +

Tunable O +
morphology O +
and O +
mesophase O +
formation O +
by O +
naphthalene B-Chemical -
- O -
containing O +
poly B-Chemical -
( I-Chemical -
aryl I-Chemical +
ether I-Chemical -
) I-Chemical +
dendron O -
- O -
based O +
low O -
- O -
molecular O -
- O -
weight O +
fluorescent O +
gels O -
. O +

Novel O +
poly B-Chemical -
( I-Chemical -
aryl I-Chemical +
ether I-Chemical -
) I-Chemical +
dendron O -
- O -
based O +
low O -
- O -
molecular O -
- O -
weight O +
organogelaters O +
( O -
LMWG O -
) O +
containing O +
naphthalene B-Chemical +
units O +
at O +
the O +
core O +
have O +
been O +
synthesized O -
, O +
and O +
the O +
self O -
- O -
assembly O +
of O +
the O +
system O +
has O +
been O +
examined O +
in O +
a O +
variety O +
of O +
solvents O +
and O +
solvent O +
mixtures O -
. O +

The O +
compounds O +
readily O +
form O +
gels O +
with O +
attractive O +
critical O +
gel O +
concentration O +
values O +
associated O +
with O +
gelation O -
- O -
induced O +
enhanced O +
emission O +
( O -
GIEE O -
) O -
. O +

In O +
addition O +
to O +
the O +
remarkable O +
properties O +
of O +
the O +
previously O +
reported O +
anthracene B-Chemical +
and O +
pyrene B-Chemical +
analogues O +
( O -
Rajamalli O -
, O +
P. O -
; O +
Prasad O -
, O +
E. O +
Org O -
. O +

Lett.2011 O -
, O +
13 O -
, O +
3714 O +
and O +
Rajamalli O -
, O +
P. O -
; O +
Prasad O -
, O +
E. O +
Soft O +
Matter2012 O -
, O +
8 O -
, O +
8896 O -
) O -
, O +
the O +
self O -
- O -
assembled O +
systems O +
exhibit O +
distinctly O +
different O +
structure O -
- O -
property O +
relationships O -
. O +

Unlike O +
the O +
reported O +
ones O -
, O +
the O +
present O +
system O +
forms O +
sheetlike O +
morphology O +
in O +
nonpolar O +
solvent O +
mixtures O -
, O +
giant O +
vesicles O +
in O +
polar O +
solvent O +
mixtures O -
, O +
and O +
lamellar O +
or O +
hexagonal O +
columnar O +
phases O +
in O +
single O +
solvents O -
. O +

The O +
unique O +
properties O +
of O +
the O +
self O -
- O -
assembled O +
systems O -
, O +
which O +
were O +
analyzed O +
through O +
electron O +
microscopic O +
( O -
SEM O -
, O +
TEM O -
, O +
AFM O -
) O +
and O +
spectroscopic O +
techniques O +
( O -
POM O -
, O +
fluorescence O -
) O -
, O +
are O +
attributed O +
to O +
the O +
replacement O +
of O +
anthracene B-Chemical -
/ O -
pyrene B-Chemical +
units O +
by O +
naphthalene B-Chemical +
units O -
. O +

The O +
present O +
work O +
unravels O +
the O +
subtle O +
role O +
of O +
minute O +
structural O +
change O +
in O +
altering O +
the O +
properties O +
of O +
LMWGs O +
based O +
on O +
poly B-Chemical -
( I-Chemical -
aryl I-Chemical +
ether I-Chemical -
) I-Chemical +
dendrons O -
. O +

Mechanism O +
of O +
solid O +
state O +
amorphization O +
of O +
glucose B-Chemical +
upon O +
milling O -
. O +

Crystalline O +
α B-Chemical -
- I-Chemical -
glucose I-Chemical +
is O +
known O +
to O +
amorphize O +
upon O +
milling O +
at O +
-15 O +
° O -
C O +
while O +
it O +
remains O +
structurally O +
invariant O +
upon O +
milling O +
at O +
room O +
temperature O -
. O +

We O +
have O +
taken O +
advantage O +
of O +
this O +
behavior O +
to O +
compare O +
the O +
microstructural O +
evolutions O +
of O +
the O +
material O +
in O +
both O +
conditions O +
in O +
order O +
to O +
identify O +
the O +
essential O +
microstructural O +
features O +
which O +
drive O +
the O +
amorphization O +
process O +
upon O +
milling O -
. O +

The O +
investigations O +
have O +
been O +
performed O +
by O +
differential O +
scanning O +
calorimetry O +
and O +
by O +
powder O +
X O -
- O -
ray O +
diffraction O -
. O +

The O +
results O +
indicate O +
that O +
two O +
different O +
amorphization O +
mechanisms O +
occur O +
upon O +
milling O -
: O +
an O +
amorphization O +
at O +
the O +
surface O +
of O +
crystallites O +
due O +
to O +
the O +
mechanical O +
shocks O +
and O +
a O +
spontaneous O +
amorphization O +
of O +
the O +
crystallites O +
as O +
they O +
reach O +
a O +
critical O +
size O -
, O +
which O +
is O +
close O +
to O +
200 O +
Å O +
in O +
the O +
particular O +
case O +
of O +
α B-Chemical -
- I-Chemical -
glucose I-Chemical -
. O +

Novel O +
P2 O +
tris B-Chemical -
- I-Chemical -
tetrahydrofuran I-Chemical +
group O +
in O +
antiviral O +
compound O +
1 O +
( O -
GRL-0519 B-Chemical -
) O +
fills O +
the O +
S2 O +
binding O +
pocket O +
of O +
selected O +
mutants O +
of O +
HIV-1 O +
protease O -
. O +

GRL-0519 B-Chemical +
( O -
1 O -
) O +
is O +
a O +
potent O +
antiviral O +
inhibitor O +
of O +
HIV-1 O +
protease O +
( O -
PR O -
) O +
possessing O +
tris B-Chemical -
- I-Chemical -
tetrahydrofuran I-Chemical +
( O -
tris B-Chemical -
- I-Chemical -
THF I-Chemical -
) O +
at O +
P2 O -
. O +

The O +
high O +
resolution O +
X O -
- O -
ray O +
crystal O +
structures O +
of O +
inhibitor O +
1 O +
in O +
complexes O +
with O +
single O +
substitution O +
mutants O +
PR O -
( O -
R8Q O -
) O -
, O +
PR O -
( O -
D30N O -
) O -
, O +
PR O -
( O -
I50V O -
) O -
, O +
PR O -
( O -
I54 O -
M O -
) O -
, O +
and O +
PR O -
( O -
V82A O -
) O +
were O +
analyzed O +
in O +
relation O +
to O +
kinetic O +
data O -
. O +

The O +
smaller O +
valine O +
side O +
chain O +
in O +
PR O -
( O -
I50V O -
) O +
eliminated O +
hydrophobic O +
interactions O +
with O +
inhibitor O +
and O +
the O +
other O +
subunit O +
consistent O +
with O +
60-fold O +
worse O +
inhibition O -
. O +

Asn30 O +
in O +
PR O -
( O -
D30N O -
) O +
showed O +
altered O +
interactions O +
with O +
neighboring O +
residues O +
and O +
18-fold O +
worse O +
inhibition O -
. O +

Mutations O +
V82A O +
and O +
I54 O -
M O +
showed O +
compensating O +
structural O +
changes O +
consistent O +
with O +
6 O -
- O -
7-fold O +
lower O +
inhibition O -
. O +

Gln8 O +
in O +
PR O -
( O -
R8Q O -
) O +
replaced O +
the O +
ionic O +
interactions O +
of O +
wild O +
type O +
Arg8 O +
with O +
hydrogen B-Chemical +
bond O +
interactions O +
without O +
changing O +
the O +
inhibition O +
significantly O -
. O +

The O +
carbonyl B-Chemical +
oxygen B-Chemical +
of O +
Gly48 O +
showed O +
two O +
alternative O +
conformations O +
in O +
all O +
structures O +
likely O +
due O +
to O +
the O +
snug O +
fit O +
of O +
the O +
large O +
tris B-Chemical -
- I-Chemical -
THF I-Chemical +
group O +
in O +
the O +
S2 O +
subsite O +
in O +
agreement O +
with O +
high O +
antiviral O +
efficacy O +
of O +
1 O +
on O +
resistant O +
virus O -
. O +

A O +
design O +
of O +
experiments O +
to O +
optimize O +
a O +
new O +
manufacturing O +
process O +
for O +
high O +
activity O +
protein O -
- O -
containing O +
submicron O +
particles O -
. O +

A O +
novel O +
method O +
for O +
the O +
manufacture O +
of O +
protein O -
/ O -
peptide O -
- O -
containing O +
submicron O +
particles O +
was O +
developed O +
in O +
an O +
attempt O +
to O +
provide O +
particles O +
with O +
increased O +
activity O +
while O +
using O +
high O +
energy O +
input O +
technologies O -
. O +

The O +
method O +
consists O +
of O +
antisolvent O +
co O -
- O -
precipitation O +
from O +
an O +
aqueous O +
solution O +
containing O +
both O +
an O +
amino B-Chemical +
acid I-Chemical +
core O +
material O +
( O -
e.g. O +
D B-Chemical -
, I-Chemical -
L I-Chemical -
- I-Chemical -
valine I-Chemical -
) O -
, O +
and O +
either O +
bovine O +
serum O +
albumin O +
( O -
BSA O -
) O +
or O +
lysozyme O +
( O -
Lys O -
) O +
as O +
model O +
proteins O -
. O +

The O +
aqueous O +
solution O +
was O +
added O +
to O +
the O +
organic O +
phase O +
by O +
means O +
of O +
a O +
nebulizer O +
to O +
increase O +
the O +
total O +
surface O +
area O +
of O +
interaction O +
for O +
the O +
precipitation O +
process O -
. O +

Sonication O +
proved O +
to O +
be O +
an O +
effective O +
method O +
to O +
produce O +
small O +
particle O +
sizes O +
while O +
maintaining O +
high O +
activity O +
of O +
Lys O -
. O +

The O +
use O +
of O +
a O +
polysorbate B-Chemical +
or O +
sorbitan B-Chemical +
ester I-Chemical +
derivatives O +
as O +
stabilizers O +
proved O +
to O +
be O +
necessary O +
to O +
yield O +
submicron O +
particles O -
. O +

Particles O +
with O +
very O +
high O +
yields O +
( O -
approximately O +
100 O -
% O -
) O +
and O +
very O +
high O +
activity O +
after O +
manufacture O +
( O -
approximately O +
100 O -
% O -
) O +
could O +
be O +
obtained O -
. O +

A O +
particle O +
size O +
of O +
439.0 O +
nm O -
, O +
with O +
a O +
yield O +
of O +
48.8 O -
% O +
and O +
with O +
final O +
remaining O +
activity O +
of98.7 O -
% O +
was O +
obtained O -
. O +

By O +
studying O +
various O +
factors O +
using O +
a O +
design O +
of O +
experiments O +
strategy O +
( O -
DoE O -
) O +
we O +
were O +
able O +
to O +
establish O +
the O +
critical O +
controlling O +
factors O +
for O +
this O +
new O +
method O +
of O +
manufacture O -
. O +

A O +
Serum O -
- O -
Tolerant O +
Hydroxyl B-Chemical -
- O -
Modified O +
Polyethylenimine B-Chemical +
as O +
Versatile O +
Carriers O +
of O +
pDNA O -
/ O -
siRNA O -
. O +

The O +
polyethylenimine B-Chemical +
( O -
PEI B-Chemical -
) O +
derivatives O +
( O -
PTn O -
) O +
are O +
prepared O +
by O +
treating O +
PEI25k O +
with O +
Tris B-Chemical -
( I-Chemical -
hydroxymethyl I-Chemical -
) I-Chemical +
acrylamidomethane I-Chemical +
via O +
the O +
Michael O +
addition O -
. O +

These O +
PTns O +
can O +
effectively O +
condense O +
nucleic O +
acids O +
into O +
nanosized O +
particles O +
with O +
positive O +
surface O +
charges O -
. O +

The O +
PTns O +
show O +
lower O +
cytotoxicity O +
and O +
better O +
serum O -
- O -
resistant O +
capacity O +
than O +
PEI25k O -
. O +

Specially O -
, O +
the O +
transfection O +
efficiency O +
of O +
PT26 O -
/ O -
DNA O +
is O +
29-fold O +
higher O +
than O +
that O +
of O +
PEI25k O +
in O +
HeLa O +
cells O +
in O +
serum O -
- O -
containing O +
medium O -
. O +

The O +
PTn O -
/ O -
siRNA O +
complexes O +
show O +
superior O +
knockdown O +
effect O +
in O +
CT26 O +
cells O +
in O +
serum O -
- O -
containing O +
medium O -
. O +

In O +
addition O -
, O +
flow O +
cytometry O +
analysis O +
shows O +
that O +
the O +
PTns O +
can O +
efficiently O +
mediate O +
the O +
entry O +
of O +
nucleic O +
acids O +
into O +
the O +
cell O -
. O +

Thus O -
, O +
PTns O +
are O +
potentially O +
applicable O +
as O +
non O -
- O -
viral O +
carriers O +
of O +
nucleic O +
acids O +
and O +
warrant O +
further O +
development O +
for O +
use O +
in O +
gene O +
therapy O -
. O +

Sociocultural O +
behavior O -
, O +
sex O -
- O -
biased O +
admixture O -
, O +
and O +
effective O +
population O +
sizes O +
in O +
Central O +
African O +
Pygmies O +
and O +
non O -
- O -
Pygmies O -
. O +

Sociocultural O +
phenomena O -
, O +
such O +
as O +
exogamy O +
or O +
phylopatry O -
, O +
can O +
largely O +
determine O +
human O +
sex O -
- O -
specific O +
demography O -
. O +

In O +
Central O +
Africa O -
, O +
diverging O +
patterns O +
of O +
sex O -
- O -
specific O +
genetic O +
variation O +
have O +
been O +
observed O +
between O +
mobile O +
hunter O -
- O -
gatherer O +
Pygmies O +
and O +
sedentary O +
agricultural O +
non O -
- O -
Pygmies O -
. O +

However O -
, O +
their O +
sex O -
- O -
specific O +
demography O +
remains O +
largely O +
unknown O -
. O +

Using O +
population O +
genetics O +
and O +
approximate O +
Bayesian O +
computation O +
approaches O -
, O +
we O +
inferred O +
male O +
and O +
female O +
effective O +
population O +
sizes O -
, O +
sex O -
- O -
specific O +
migration O -
, O +
and O +
admixture O +
rates O +
in O +
23 O +
Central O +
African O +
Pygmy O +
and O +
non O -
- O -
Pygmy O +
populations O -
, O +
genotyped O +
for O +
autosomal O -
, O +
X O -
- O -
linked O -
, O +
Y O -
- O -
linked O -
, O +
and O +
mitochondrial O +
markers O -
. O +

We O +
found O +
much O +
larger O +
effective O +
population O +
sizes O +
and O +
migration O +
rates O +
among O +
non O -
- O -
Pygmy O +
populations O +
than O +
among O +
Pygmies O -
, O +
in O +
agreement O +
with O +
the O +
recent O +
expansions O +
and O +
migrations O +
of O +
non O -
- O -
Pygmies O +
and O -
, O +
conversely O -
, O +
the O +
isolation O +
and O +
stationary O +
demography O +
of O +
Pygmy O +
groups O -
. O +

We O +
found O +
larger O +
effective O +
sizes O +
and O +
migration O +
rates O +
for O +
males O +
than O +
for O +
females O +
for O +
Pygmies O -
, O +
and O +
vice O +
versa O +
for O +
non O -
- O -
Pygmies O -
. O +

Thus O -
, O +
although O +
most O +
Pygmy O +
populations O +
have O +
patrilocal O +
customs O -
, O +
their O +
sex O -
- O -
specific O +
genetic O +
patterns O +
resemble O +
those O +
of O +
matrilocal O +
populations O -
. O +

In O +
fact O -
, O +
our O +
results O +
are O +
consistent O +
with O +
a O +
lower O +
prevalence O +
of O +
polygyny O +
and O +
patrilocality O +
in O +
Pygmies O +
compared O +
with O +
non O -
- O -
Pygmies O +
and O +
a O +
potential O +
female O +
transmission O +
of O +
reproductive O +
success O +
in O +
Pygmies O -
. O +

Finally O -
, O +
Pygmy O +
populations O +
showed O +
variable O +
admixture O +
levels O +
with O +
the O +
non O -
- O -
Pygmies O -
, O +
with O +
often O +
much O +
larger O +
introgression O +
from O +
male O +
than O +
from O +
female O +
lineages O -
. O +

Social O +
discrimination O +
against O +
Pygmies O +
triggering O +
complex O +
movements O +
of O +
spouses O +
in O +
intermarriages O +
can O +
explain O +
these O +
male O -
- O -
biased O +
admixture O +
patterns O +
in O +
a O +
patrilocal O +
context O -
. O +

We O +
show O +
how O +
gender O -
- O -
related O +
sociocultural O +
phenomena O +
can O +
determine O +
highly O +
variable O +
sex O -
- O -
specific O +
demography O +
among O +
populations O -
, O +
and O +
how O +
population O +
genetic O +
approaches O +
contrasting O +
chromosomal O +
types O +
allow O +
inferring O +
detailed O +
human O +
sex O -
- O -
specific O +
demographic O +
history O -
. O +

Lower O +
Adiponectin O +
Levels O +
at O +
First O +
Trimester O +
of O +
Pregnancy O +
Are O +
Associated O +
With O +
Increased O +
Insulin O +
Resistance O +
and O +
Higher O +
Risk O +
of O +
Developing O +
Gestational O +
Diabetes O +
Mellitus O -
. O +

OBJECTIVETo O +
evaluate O +
the O +
associations O +
between O +
adiponectin O +
levels O +
and O +
1 O -
) O +
the O +
risk O +
of O +
developing O +
gestational O +
diabetes O +
mellitus O +
( O -
GDM O -
) O -
, O +
and O +
2 O -
) O +
insulin O +
resistance O -
/ O -
sensitivity O -
, O +
β O -
- O -
cell O +
function O -
, O +
and O +
compensation O +
indices O +
in O +
a O +
prospective O +
cohort O +
representative O +
of O +
the O +
general O +
population O +
of O +
pregnant O +
women O -
. O +

RESEARCH O +
DESIGN O +
AND O +
METHODSWe O +
performed O +
anthropometric O +
measurements O +
and O +
collected O +
blood O +
samples O +
at O +
1st O +
( O -
6 O -
- O -
13 O +
weeks O -
) O +
and O +
2nd O +
( O -
24 O -
- O -
28 O +
weeks O -
) O +
trimesters O -
. O +

Diagnosis O +
of O +
GDM O +
was O +
made O +
at O +
2nd O +
trimester O -
, O +
based O +
on O +
a O +
75-g O +
oral O +
glucose B-Chemical +
tolerance O +
test O +
( O -
International O +
Association O +
of O +
Diabetes O +
and O +
Pregnancy O +
Study O +
Group O +
criteria O -
) O -
. O +

Insulin O +
was O +
measured O +
( O -
ELISA O -
; O +
Luminex O -
) O +
to O +
estimate O +
homeostasis O +
model O +
assessment O +
of O +
insulin O +
resistance O +
( O -
HOMA O -
- O -
IR O -
) O -
, O +
β O -
- O -
cell O +
function O +
( O -
HOMA O -
- O -
B O -
) O -
, O +
insulin O +
sensitivity O +
( O -
Matsuda O +
index O -
) O -
, O +
insulin O +
secretion O +
( O -
AUC O -
( O -
insulin O -
/ O -
glucose B-Chemical -
) O -
) O -
, O +
and O +
β O -
- O -
cell O +
compensation O +
( O -
insulin O +
secretion O +
sensitivity O +
index-2 O -
) O -
. O +

Adiponectin O +
was O +
measured O +
by O +
radioimmunoassay O -
. O +

RESULTSAmong O +
the O +
445 O +
participants O +
included O +
in O +
this O +
study O -
, O +
38 O +
women O +
developed O +
GDM O -
. O +

Women O +
who O +
developed O +
GDM O +
had O +
lower O +
1st O -
- O -
trimester O +
adiponectin O +
levels O +
( O -
9.67 O +
± O +
3.84 O +
vs. O +
11.92 O +
± O +
4.59 O +
µg O -
/ O -
mL O +
in O +
women O +
with O +
normal O +
glucose B-Chemical +
tolerance O -
) O -
. O +

Lower O +
adiponectin O +
levels O +
were O +
associated O +
with O +
higher O +
risk O +
of O +
developing O +
GDM O +
( O -
OR O -
, O +
1.12 O +
per O +
1 O +
µg O -
/ O -
mL O +
decrease O +
of O +
adiponectin O +
levels O -
; O +
P O +
= O +
0.02 O -
, O +
adjusted O +
for O +
BMI O +
and O +
HbA O -
( O -
1c O -
) O +
at O +
1st O +
trimester O -
) O -
. O +

Adiponectin O +
levels O +
at O +
1st O +
and O +
2nd O +
trimesters O +
were O +
associated O +
with O +
HOMA O -
- O -
IR O +
( O -
both O -
: O +
r O +
= O +
-0.22 O -
, O +
P O +
< O +
0.0001 O -
) O +
and O +
Matsuda O +
index O +
( O -
r O +
= O +
0.28 O -
, O +
P O +
< O +
0.0001 O -
, O +
and O +
r O +
= O +
0.29 O -
, O +
P O +
< O +
0.0001 O -
) O -
. O +

After O +
adjustment O +
for O +
confounding O +
factors O -
, O +
we O +
found O +
no O +
significant O +
association O +
with O +
HOMA O -
- O -
B O +
and O +
AUC O -
( O -
insulin O -
/ O -
glucose B-Chemical -
) O -
.CONCLUSIONSPregnant O +
women O +
with O +
lower O +
adiponectin O +
levels O +
at O +
1st O +
trimester O +
have O +
higher O +
levels O +
of O +
insulin O +
resistance O +
and O +
are O +
more O +
likely O +
to O +
develop O +
GDM O +
independently O +
of O +
adiposity O +
or O +
glycemic O +
measurements O -
. O +

Nanoparticle O +
adhesion O +
to O +
the O +
cell O +
membrane O +
and O +
its O +
effect O +
on O +
nanoparticle O +
uptake O +
efficiency O -
. O +

The O +
interactions O +
between O +
nanosized O +
particles O +
and O +
living O +
systems O +
are O +
commonly O +
mediated O +
by O +
what O +
adsorbs O +
to O +
the O +
nanoparticle O +
in O +
the O +
biological O +
environment O -
, O +
its O +
biomolecular O +
corona O -
, O +
rather O +
than O +
the O +
pristine O +
surface O -
. O +

Here O -
, O +
we O +
characterize O +
the O +
adhesion O +
toward O +
the O +
cell O +
membrane O +
of O +
nanoparticles O +
of O +
different O +
material O +
and O +
size O +
and O +
study O +
how O +
this O +
is O +
modulated O +
by O +
the O +
presence O +
or O +
absence O +
of O +
a O +
corona O +
on O +
the O +
nanoparticle O +
surface O -
. O +

The O +
results O +
are O +
corroborated O +
with O +
adsorption O +
to O +
simple O +
model O +
supported O +
lipid O +
bilayers O +
using O +
a O +
quartz B-Chemical +
crystal O +
microbalance O -
. O +

We O +
conclude O +
that O +
the O +
adsorption O +
of O +
proteins O +
on O +
the O +
nanoparticle O +
surface O +
strongly O +
reduces O +
nanoparticle O +
adhesion O +
in O +
comparison O +
to O +
what O +
is O +
observed O +
for O +
the O +
bare O +
material O -
. O +

Nanoparticle O +
uptake O +
is O +
described O +
as O +
a O +
two O -
- O -
step O +
process O -
, O +
where O +
the O +
nanoparticles O +
initially O +
adhere O +
to O +
the O +
cell O +
membrane O +
and O +
subsequently O +
are O +
internalized O +
by O +
the O +
cells O +
via O +
energy O -
- O -
dependent O +
pathways O -
. O +

The O +
lowered O +
adhesion O +
in O +
the O +
presence O +
of O +
proteins O +
thereby O +
causes O +
a O +
concomitant O +
decrease O +
in O +
nanoparticle O +
uptake O +
efficiency O -
. O +

The O +
presence O +
of O +
a O +
biomolecular O +
corona O +
may O +
confer O +
specific O +
interactions O +
between O +
the O +
nanoparticle O -
- O -
corona O +
complex O +
and O +
the O +
cell O +
surface O +
including O +
triggering O +
of O +
regulated O +
cell O +
uptake O -
. O +

An O +
important O +
effect O +
of O +
the O +
corona O +
is O -
, O +
however O -
, O +
a O +
reduction O +
in O +
the O +
purely O +
unspecific O +
interactions O +
between O +
the O +
bare O +
material O +
and O +
the O +
cell O +
membrane O -
, O +
which O +
in O +
itself O +
disregarding O +
specific O +
interactions O -
, O +
causes O +
a O +
decrease O +
in O +
cellular O +
uptake O -
. O +

We O +
suggest O +
that O +
future O +
nanoparticle O -
- O -
cell O +
studies O +
include O -
, O +
together O +
with O +
characterization O +
of O +
size O -
, O +
charge O -
, O +
and O +
dispersion O +
stability O -
, O +
an O +
evaluation O +
of O +
the O +
adhesion O +
properties O +
of O +
the O +
material O +
to O +
relevant O +
membranes O -
. O +

Aminoalkyl B-Chemical +
derivatives O +
of O +
guanidine B-Chemical +
diaromatic O +
minor O +
groove O +
binders O +
with O +
antiprotozoal O +
activity O -
. O +

Considering O +
the O +
strong O +
DNA O +
minor O +
groove O +
binding O +
observed O +
for O +
our O +
previous O +
series O +
of O +
diaromatic O +
symmetric O +
and O +
asymmetric O +
guanidinium B-Chemical +
and O +
2-aminoimidazolinium B-Chemical +
derivatives O -
, O +
we O +
report O +
now O +
the O +
synthesis O +
of O +
new O +
aminoalkyl B-Chemical +
derivatives O +
of O +
diaromatic O +
guanidines O +
with O +
potential O +
as O +
DNA O +
minor O +
groove O +
binders O +
and O +
antiprotozoal O +
activity O -
. O +

The O +
preparation O +
of O +
these O +
aminoalkyl B-Chemical +
derivatives O +
( O -
12a O -
- O -
e O -
, O +
13a O -
- O -
e O -
, O +
14a O -
- O -
c O -
, O -
e O -
, O +
15a O -
- O -
e O -
, O +
16a O -
- O -
e O -
) O +
is O +
presented O +
as O +
well O +
as O +
their O +
affinity O +
for O +
DNA O +
which O +
was O +
evaluated O +
by O +
means O +
of O +
DNA O +
thermal O +
denaturation O +
experiments O -
. O +

Finally O -
, O +
the O +
antiprotozoal O +
activity O +
of O +
most O +
of O +
these O +
aminoalkyl B-Chemical +
minor O +
groove O +
binders O +
was O +
evaluated O +
in O +
vitro O +
against O +
Trypanosoma O +
brucei O +
rhodesiense O +
( O -
8 O +
compounds O -
) O +
and O +
Plasmodium O +
falciparum O +
( O -
18 O +
compounds O -
) O -
. O +

The O +
O O -
- O -
linked O +
derivatives O +
13c O +
and O +
14c O +
showed O +
100 O +
nM O +
activities O +
against O +
P. O +
falciparum O -
, O +
whereas O +
for O +
T. O +
b. O +
rhodesiense O +
all O +
compounds O +
tested O +
showed O +
micromolar O +
activity O -
. O +

Some O +
of O +
the O +
derivatives O +
prepared O +
seem O +
to O +
exert O +
the O +
antimalarial O +
activity O +
by O +
binding O +
to O +
the O +
DNA O +
minor O +
groove O +
whereas O +
other O +
sets O +
of O +
compounds O +
could O +
exert O +
this O +
antimalarial O +
activity O +
by O +
inhibiting O +
the O +
parasite O +
dihydrofolate B-Chemical +
reductase O -
, O +
for O +
example O -
. O +

A O +
powerful O +
aluminum B-Chemical +
catalyst O +
for O +
the O +
synthesis O +
of O +
highly O +
functional O +
organic B-Chemical +
carbonates I-Chemical -
. O +

An O +
aluminum B-Chemical +
complex O +
based O +
on O +
an O +
amino B-Chemical +
triphenolate I-Chemical +
ligand O +
scaffold O +
shows O +
unprecedented O +
high O +
activity O +
( O -
initial O +
TOFs O +
up O +
to O +
36,000 O +
h O -
( O -
-1 O -
) O -
) O -
, O +
broad O +
substrate O +
scope O -
, O +
and O +
functional O +
group O +
tolerance O +
in O +
the O +
formation O +
of O +
highly O +
functional O +
organic B-Chemical +
carbonates I-Chemical +
prepared O +
from O +
epoxides B-Chemical +
and O +
CO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
. O +

The O +
developed O +
catalytic O +
protocol O +
is O +
further O +
characterized O +
by O +
low O +
catalyst O +
loadings O +
and O +
relative O +
mild O +
reaction O +
conditions O +
using O +
a O +
cheap O -
, O +
abundant O -
, O +
and O +
nontoxic O +
metal O -
. O +

Lactobacillus O +
johnsonii O +
inhibits O +
indoleamine B-Chemical +
2,3-dioxygenase O +
and O +
alters O +
tryptophan B-Chemical +
metabolite O +
levels O +
in O +
BioBreeding O +
rats O -
. O +

In O +
our O +
previous O +
work O -
, O +
we O +
found O +
that O +
feeding O +
Lactobacillus O +
johnsonii O +
to O +
BioBreeding O +
diabetes O -
- O -
prone O +
( O -
BBDP O -
) O +
rats O +
decreased O +
the O +
incidence O +
of O +
diabetes O +
development O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O +
host O +
pathways O +
affected O +
by O +
L. O +
johnsonii O -
, O +
with O +
specific O +
focus O +
on O +
the O +
rate O -
- O -
limiting O +
enzyme O +
of O +
tryptophan B-Chemical +
catabolism O -
, O +
indoleamine B-Chemical +
2,3-dioxygenase O +
( O -
IDO O -
) O -
. O +

Suspensions O +
of O +
L. O +
johnsonii O +
or O +
an O +
equal O +
volume O +
of O +
vehicle O +
were O +
orally O +
administered O +
to O +
BBDP O +
rats O -
. O +

Tissue O +
IDO O +
was O +
investigated O +
using O +
quantitative O +
RT O -
- O -
PCR O +
and O +
Western O +
blot O -
, O +
whereas O +
tryptophan B-Chemical -
, O +
kynurenine B-Chemical -
, O +
and O +
5-hydroxytryptamine B-Chemical +
( O -
5-HT B-Chemical -
) O +
concentrations O +
were O +
quantified O +
by O +
HPLC O +
and O +
ELISA O -
. O +

IDO O +
activity O +
was O +
also O +
investigated O +
using O +
L. O +
johnsonii O +
culture O +
cell O -
- O -
free O +
supernatant O +
( O -
CFS O -
) O +
with O +
affinity O -
- O -
purified O +
IDO O +
and O +
HT-29 O +
intestinal O +
epithelial O +
cells O -
. O +

L. O +
johnsonii O +
feeding O +
resulted O +
in O +
a O +
17 O -
% O +
reduction O +
in O +
serum O +
kynurenine B-Chemical +
compared O +
with O +
that O +
in O +
vehicle O -
- O -
fed O +
controls O -
, O +
correlating O +
with O +
a O +
1.4-fold O +
elevation O +
in O +
5-HT B-Chemical +
levels O -
. O +

H2O2 B-Chemical +
produced O +
by O +
L. O +
johnsonii O +
abolished O +
IDO O +
activity O +
in O +
vitro O -
, O +
and O +
L. O +
johnsonii O +
feeding O +
resulted O +
in O +
a O +
3.9-fold O +
increase O +
in O +
ileum O +
lumen O +
H2O2 B-Chemical -
. O +

L. O +
johnsonii O +
CFS O +
significantly O +
reduced O +
IDO O +
activity O +
in O +
HT-29 O +
intestinal O +
epithelial O +
cells O +
( O -
47 O -
% O +
reduction O -
) O +
compared O +
with O +
that O +
in O +
vehicle O -
- O -
treated O +
controls O -
, O +
an O +
effect O +
abolished O +
by O +
catalase O +
treatment O -
. O +

These O +
data O +
support O +
the O +
role O +
of O +
H2O2 B-Chemical +
in O +
commensal O +
bacteria O -
- O -
host O +
interactions O +
and O +
highlight O +
the O +
influence O +
of O +
commensal O +
bacteria O -
- O -
derived O +
H2O2 B-Chemical +
on O +
host O +
physiology O -
.- O -
Valladares O -
, O +
R. O -
, O +
Bojilova O -
, O +
L. O -
, O +
Potts O -
, O +
A. O +
H. O -
, O +
Cameron O -
, O +
E. O -
, O +
Gardner O -
, O +
C. O -
, O +
Lorca O -
, O +
G. O -
, O +
Gonzalez O -
, O +
C. O +
F. O +
Lactobacillus O +
johnsonii O +
inhibits O +
indoleamine B-Chemical +
2,3-dioxygenase O +
and O +
alters O +
tryptophan B-Chemical +
metabolite O +
levels O +
in O +
BioBreeding O +
rats O -
. O +

Roughening O +
of O +
Pt B-Chemical +
nanoparticles O +
induced O +
by O +
surface O -
- O -
oxide B-Chemical +
formation O -
. O +

Using O +
density O +
functional O +
theory O +
( O -
DFT O -
) O +
and O +
thermodynamic O +
considerations O +
we O +
studied O +
the O +
equilibrium O +
shape O +
of O +
Pt B-Chemical +
nanoparticles O +
( O -
NPs O -
) O +
under O +
electrochemical O +
conditions O -
. O +

We O +
found O +
that O +
at O +
very O +
high O +
oxygen B-Chemical +
coverage O -
, O +
obtained O +
at O +
high O +
electrode O +
potentials O -
, O +
the O +
experimentally O -
- O -
observed O +
tetrahexahedral O +
( O -
THH O -
) O +
NPs O +
consist O +
of O +
high O -
- O -
index O +
( O -
520 O -
) O +
faces O -
. O +

Since O +
high O -
- O -
index O +
surfaces O +
often O +
show O +
higher O +
( O -
electro- O -
) O -
chemical O +
activity O +
in O +
comparison O +
to O +
their O +
close O -
- O -
packed O +
counterparts O -
, O +
the O +
THH O +
NPs O +
can O +
be O +
promising O +
candidates O +
for O +
various O +
( O -
electro- O -
) O -
catalytic O +
applications O -
. O +

Sample O +
solution O +
constraints O +
on O +
motor O -
- O -
driven O +
diagnostic O +
nanodevices O -
. O +

The O +
last O +
decade O +
has O +
seen O +
appreciable O +
advancements O +
in O +
efforts O +
towards O +
increased O +
portability O +
of O +
lab O -
- O -
on O -
- O -
a O -
- O -
chip O +
devices O +
by O +
substituting O +
microfluidics O +
with O +
molecular O +
motor O -
- O -
based O +
transportation O -
. O +

As O +
of O +
now O -
, O +
first O +
proof O -
- O -
of O -
- O -
principle O +
devices O +
have O +
analyzed O +
protein O +
mixtures O +
of O +
low O +
complexity O -
, O +
such O +
as O +
target O +
protein O +
molecules O +
in O +
buffer O +
solutions O +
optimized O +
for O +
molecular O +
motor O +
performance O -
. O +

However O -
, O +
in O +
a O +
diagnostic O +
work O -
- O -
up O -
, O +
lab O -
- O -
on O -
- O -
a O -
- O -
chip O +
devices O +
need O +
to O +
be O +
compatible O +
with O +
complex O +
biological O +
samples O -
. O +

While O +
it O +
has O +
been O +
shown O +
that O +
such O +
samples O +
do O +
not O +
interfere O +
with O +
crucial O +
steps O +
in O +
molecular O +
diagnostics O +
( O -
for O +
example O +
antibody O -
- O -
antigen O +
recognition O -
) O -
, O +
their O +
effect O +
on O +
molecular O +
motors O +
is O +
unknown O -
. O +

This O +
critical O +
and O +
long O +
overlooked O +
issue O +
is O +
addressed O +
here O -
. O +

In O +
particular O -
, O +
we O +
studied O +
the O +
effects O +
of O +
blood O -
, O +
cell O +
lysates O +
and O +
solutions O +
containing O +
genomic O +
DNA O +
extracts O +
on O +
actomyosin O +
and O +
kinesin O -
- O -
microtubule O -
- O -
based O +
transport O -
, O +
the O +
two O +
biomolecular O +
motor O +
systems O +
that O +
are O +
most O +
promising O +
for O +
lab O -
- O -
on O -
- O -
a O -
- O -
chip O +
applications O -
. O +

We O +
found O +
that O +
motor O +
function O +
is O +
well O +
preserved O +
at O +
defined O +
dilutions O +
of O +
most O +
of O +
the O +
investigated O +
biological O +
samples O +
and O +
demonstrated O +
a O +
molecular O +
motor O -
- O -
driven O +
label O -
- O -
free O +
blood O +
type O +
test O -
. O +

Our O +
results O +
support O +
the O +
feasibility O +
of O +
molecular O -
- O -
motor O +
driven O +
nanodevices O +
for O +
diagnostic O +
point O -
- O -
of O -
- O -
care O +
applications O +
and O +
also O +
demonstrate O +
important O +
constraints O +
imposed O +
by O +
sample O +
composition O +
and O +
device O +
design O +
that O +
apply O +
both O +
to O +
kinesin O -
- O -
microtubule O +
and O +
actomyosin O +
driven O +
applications O -
. O +

Enhancing O +
catalytic O +
selectivity O +
of O +
supported O +
metal O +
nanoparticles O +
with O +
capping O +
ligands O -
. O +

Enhancing O +
catalytic O +
selectivity O +
of O +
supported O +
metal O +
nanoparticles O +
with O +
capping O +
ligands O +
is O +
demonstrated O +
using O +
an O +
Au B-Chemical -
/ O -
SiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
catalyst O +
in O +
liquid O +
phase O +
aerobic O +
oxidation O +
of O +
benzyl B-Chemical +
alcohol I-Chemical -
. O +

Chemisorption O +
of O +
an O +
appropriate O +
amount O +
of O +
polyvinylpyrrolidone B-Chemical +
on O +
the O +
Au B-Chemical -
/ O -
SiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
catalyst O +
greatly O +
enhances O +
the O +
benzaldehyde B-Chemical +
selectivity O +
from O +
43 O -
% O +
to O +
~100 O -
% O +
and O +
its O +
yield O +
from O +
4.9 O -
% O +
to O +
7.2 O -
% O -
. O +

Voltage O +
tuning O +
of O +
ferromagnetic O +
resonance O +
with O +
bistable O +
magnetization O +
switching O +
in O +
energy O -
- O -
efficient O +
magnetoelectric O +
composites O -
. O +

Dual O +
E- O +
and O +
H O -
- O -
field O +
control O +
of O +
microwave O +
performance O +
with O +
enhanced O +
ferromagnetic O +
resonance O +
( O -
FMR O -
) O +
tunability O +
has O +
been O +
demonstrated O +
in O +
microwave O +
composites O +
FeGaB B-Chemical -
/ O -
PZN B-Chemical -
- I-Chemical -
PT I-Chemical -
( O -
011 O -
) O -
. O +

A O +
voltage O -
- O -
impulse O -
- O -
induced O +
non O -
- O -
volatile O +
magnetization O +
switching O +
was O +
also O +
realized O +
in O +
this O +
work O -
, O +
resulting O +
from O +
the O +
hysteretic O +
type O +
of O +
phase O +
transition O +
in O +
PZN B-Chemical -
- I-Chemical -
PT I-Chemical -
( O -
011 O -
) O +
at O +
high O +
electric O +
fields O -
. O +

The O +
results O +
provide O +
a O +
framework O +
for O +
developing O +
lightweight O -
, O +
energy O +
efficient O -
, O +
voltage O -
- O -
tunable O +
RF O -
/ O -
microwave O +
devices O -
. O +

Identification O +
of O +
aldo O -
- O -
keto O +
reductases O +
as O +
NRF2-target O +
marker O +
genes O +
in O +
human O +
cells O -
. O +

Transcription O +
factor O +
NF O -
- O -
E2-related O +
factor O +
2 O +
( O -
NRF2 O -
) O +
plays O +
a O +
crucial O +
role O +
in O +
the O +
cellular O +
defense O +
against O +
oxidative O -
/ O -
electrophilic O +
stress O +
by O +
up O -
- O -
regulating O +
multiple O +
antioxidant O +
genes O -
. O +

Numerous O +
studies O +
with O +
genetically O +
modified O +
animals O +
have O +
demonstrated O +
that O +
Nrf2 O +
is O +
a O +
sensitivity O +
determining O +
factor O +
upon O +
the O +
exposure O +
to O +
environmental O +
chemicals O +
including O +
carcinogens O -
. O +

Moreover O -
, O +
recent O +
studies O +
have O +
demonstrated O +
that O +
polymorphism O +
in O +
the O +
human O +
NRF2 O +
promoter O +
is O +
associated O +
with O +
higher O +
risks O +
for O +
developing O +
acute O +
lung O +
injury O -
, O +
gastric O +
mucosal O +
inflammation O -
, O +
and O +
nephritis O -
. O +

Therefore O -
, O +
the O +
identification O +
of O +
reliable O +
and O +
effective O +
human O +
target O +
genes O +
of O +
NRF2 O +
may O +
allow O +
the O +
monitoring O +
of O +
NRF2 O +
activity O +
and O +
to O +
predict O +
individual O +
sensitivity O +
to O +
environmental O +
stress O -
- O -
induced O +
damage O -
. O +

For O +
this O +
purpose O -
, O +
we O +
investigated O +
genes O +
that O +
are O +
tightly O +
controlled O +
by O +
NRF2 O +
to O +
establish O +
markers O +
for O +
NRF2 O +
activity O +
in O +
human O +
cells O -
. O +

Firstly O -
, O +
in O +
the O +
normal O +
human O +
renal O +
epithelial O +
HK-2 O +
cells O -
, O +
the O +
measurement O +
of O +
the O +
expression O +
of O +
30 O +
previously O +
reported O +
NRF2 O +
target O +
genes O +
in O +
response O +
to O +
NRF2 O +
inducers O +
( O -
sulforaphane B-Chemical -
, O +
tert B-Chemical -
- I-Chemical -
butylhydroquinone I-Chemical -
, O +
cinnamic B-Chemical +
aldehyde I-Chemical -
, O +
and O +
hydrogen B-Chemical +
peroxide I-Chemical -
) O +
showed O +
that O +
the O +
aldo O -
- O -
keto O +
reductase O +
( O -
AKR O -
) O +
1C1 O +
is O +
highly O +
inducible O +
by O +
all O +
treatments O -
. O +

Accordantly O -
, O +
the O +
basal O +
and O +
inducible O +
expressions O +
of O +
AKRs O +
were O +
significantly O +
attenuated O +
in O +
NRF2-silenced O +
HK-2 O +
cells O -
. O +

Whereas O -
, O +
cells O +
with O +
stable O +
KEAP1 O +
knockdown O -
, O +
which O +
causes O +
a O +
modest O +
NRF2 O +
activation O -
, O +
demonstrated O +
substantially O +
increased O +
levels O +
of O +
AKR1A1 O -
, O +
1B1 O -
, O +
1B10 O -
, O +
1C1 O -
, O +
1C2 O -
, O +
and O +
1C3 O -
. O +

Secondly O -
, O +
the O +
linkage O +
between O +
NRF2 O +
and O +
the O +
AKRs O +
was O +
confirmed O +
in O +
human O +
monocytic O +
leukemia O +
cell O +
line O +
U937 O -
, O +
which O +
can O +
be O +
a O +
model O +
of O +
peripherally O +
available O +
blood O +
cells O -
. O +

The O +
treatment O +
of O +
U937 O +
cells O +
with O +
NRF2 O +
inducers O +
including O +
sulforaphane B-Chemical +
effectively O +
elevated O +
the O +
expression O +
of O +
AKR1B1 O -
, O +
1B10 O -
, O +
1C1 O -
, O +
1C2 O -
, O +
and O +
1C3 O -
. O +

Whereas O -
, O +
the O +
levels O +
of O +
both O +
the O +
basal O +
and O +
sulforaphane B-Chemical -
- O -
inducible O +
expression O +
of O +
AKR1C1 O +
were O +
significantly O +
reduced O +
in O +
NRF2-silenced O +
stable O +
U937 O +
cells O +
compared O +
to O +
the O +
control O +
cells O -
. O +

Similarly O -
, O +
the O +
inducible O +
expression O +
of O +
AKR1C1 O +
was O +
observed O +
in O +
another O +
human O +
monocytic O +
leukemia O +
cell O +
line O +
THP-1 O +
as O +
well O +
as O +
in O +
human O +
primary O +
blood O +
CD14 O -
( O -
+ O -
) O +
monocytes O -
. O +

In O +
conclusion O -
, O +
together O +
with O +
the O +
high O +
inducibility O +
and O +
NRF2 O +
dependency O +
shown O +
in O +
renal O +
epithelial O +
cells O +
as O +
well O +
as O +
in O +
peripherally O +
available O +
blood O +
cells O -
, O +
current O +
findings O +
suggest O +
that O +
AKRs O +
can O +
be O +
utilized O +
as O +
a O +
marker O +
of O +
NRF2 O +
activity O +
in O +
human O +
cells O -
. O +

Mitochondrial O +
dysfunction O +
contributes O +
to O +
the O +
cytotoxicity O +
of O +
some O +
3,5-bis B-Chemical -
( I-Chemical -
benzylidene I-Chemical -
) I-Chemical -
-4-piperidone I-Chemical +
derivatives O +
in O +
colon O +
HCT-116 O +
cells O -
. O +

The O +
objectives O +
of O +
this O +
study O +
are O +
to O +
investigate O +
the O +
possible O +
ways O +
by O +
which O +
the O +
curcumin O +
analogs O +
2a O +
and O +
2b O +
exert O +
their O +
antiproliferative O +
properties O -
. O +

The O +
analogs O +
2a O +
and O +
2b O +
have O +
submicromolar O +
IC O -
( O -
50 O -
) O +
values O +
towards O +
human O +
HCT-116 O +
colon O +
cancer O +
cells O +
but O +
are O +
far O +
less O +
toxic O +
to O +
human O +
non O -
- O -
malignant O +
CRL-1790 O +
colon O +
cells O -
. O +

Both O +
compounds O +
affected O +
a O +
number O +
of O +
mitochondrial O +
functions O +
in O +
HCT-116 O +
cells O +
namely O +
increasing O +
the O +
intracellular O +
concentrations O +
of O +
reactive O +
oxygen B-Chemical +
species O -
, O +
inhibiting O +
oxygen B-Chemical +
consumption O +
and O +
decreasing O +
the O +
mitochondrial O +
membrane O +
potential O -
. O +

These O +
molecules O +
also O +
produced O +
swelling O +
of O +
isolated O +
rat O +
liver O +
mitochondria O -
, O +
supporting O +
a O +
mitochondrial O +
mechanism O +
of O +
cytotoxicity O -
. O +

Both O +
compounds O +
reacted O +
with O +
glutathione B-Chemical +
in O +
the O +
presence O +
of O +
glutathione B-Chemical +
S O -
- O -
transferase O +
π O +
and O +
hence O +
they O +
may O +
be O +
classified O +
as O +
thiol B-Chemical +
alkylators O -
. O +

Preparation O +
of O +
apigenin B-Chemical +
nanocrystals O +
using O +
supercritical O +
antisolvent O +
process O +
for O +
dissolution O +
and O +
bioavailability O +
enhancement O -
. O +

The O +
aim O +
of O +
the O +
study O +
was O +
to O +
investigate O +
the O +
potential O +
of O +
nanocrystals O +
to O +
enhance O +
the O +
oral O +
bioavailability O +
of O +
apigenin B-Chemical +
( O -
AP O -
) O -
, O +
a O +
bioactive O +
flavonoid B-Chemical +
with O +
various O +
pharmacological O +
activities O +
but O +
poor O +
aqueous O +
solubility O -
. O +

In O +
the O +
present O +
investigation O -
, O +
the O +
AP O +
nanocrystals O +
were O +
prepared O +
by O +
the O +
supercritical O +
antisolvent O +
process O -
. O +

In O +
vitro O +
characterization O +
was O +
performed O +
by O +
scanning O +
electron O +
microscopy O -
, O +
FT O -
- O -
IR O -
, O +
differential O +
scanning O +
calorimetry O -
, O +
X O -
- O -
ray O +
powder O +
diffractometry O -
. O +

In O +
vitro O +
dissolution O +
of O +
prepared O +
nanocrystals O +
was O +
studied O +
and O +
compared O +
with O +
untreated O +
coarse O +
powder O -
. O +

In O +
addition O -
, O +
the O +
pharmacokinetic O +
study O +
of O +
AP O +
nanocrystals O -
, O +
in O +
comparison O +
to O +
coarse O +
powder O -
, O +
was O +
also O +
performed O +
in O +
rats O +
after O +
a O +
single O +
oral O +
dose O -
. O +

The O +
prepared O +
AP O +
nanocrystals O -
, O +
without O +
change O +
in O +
crystalline O +
structure O -
, O +
appeared O +
in O +
spherical O +
shape O +
with O +
particle O +
size O +
of O +
about O +
400 O -
- O -
800 O +
nm O -
. O +

The O +
reduction O +
of O +
particle O +
size O +
resulted O +
in O +
a O +
more O +
rapid O +
dissolution O +
of O +
AP O +
from O +
nanocrystals O +
than O +
from O +
coarse O +
powder O -
. O +

In O +
comparison O +
to O +
coarse O +
powder O -
, O +
AP O +
nanocrystals O +
exhibited O +
a O +
significantly O +
decreased O +
t O -
( O -
max O -
) O -
, O +
a O +
3.6-fold O +
higher O +
peak O +
plasma O +
concentration O +
( O -
C O -
( O -
max O -
) O -
) O +
and O +
3.4-fold O +
higher O +
area O +
under O +
the O +
curve O +
( O -
AUC O -
) O -
. O +

Probing O +
circulating O +
tumor O +
cells O +
in O +
microfluidics O -
. O +

Circulating O +
tumor O +
cells O +
( O -
CTCs O -
) O +
are O +
important O +
targets O +
for O +
study O +
as O +
we O +
strive O +
to O +
better O +
understand O -
, O +
diagnose O -
, O +
and O +
treat O +
cancers O -
. O +

However O -
, O +
CTCs O +
are O +
found O +
in O +
blood O +
at O +
extremely O +
low O +
concentrations O -
; O +
this O +
makes O +
isolation O -
, O +
enrichment O -
, O +
and O +
characterization O +
of O +
CTCs O +
technically O +
challenging O -
. O +

Recently O -
, O +
the O +
development O +
of O +
CTC O +
separation O +
devices O +
has O +
grown O +
rapidly O +
in O +
both O +
academia O +
and O +
industry O -
. O +

Part O +
of O +
this O +
development O +
effort O +
centered O +
on O +
microfluidic O +
platforms O -
, O +
exploiting O +
the O +
advantages O +
of O +
microfluidics O +
to O +
improve O +
CTC O +
separation O +
performance O +
and O +
device O +
integration O -
. O +

In O +
this O +
Focus O +
article O -
, O +
we O +
highlight O +
some O +
of O +
the O +
recent O +
work O +
in O +
microfluidic O +
CTC O +
separation O +
and O +
detection O +
systems O +
and O +
discuss O +
our O +
appraisal O +
of O +
what O +
the O +
field O +
should O +
do O +
next O -
. O +

Tuning O +
optical O +
properties O +
of O +
Si B-Chemical +
quantum O +
dots O +
by O +
π O -
- O -
conjugated O +
capping O +
molecules O -
. O +

The O +
absorption O +
and O +
photoluminescence O +
( O -
PL O -
) O +
properties O +
of O +
silicon B-Chemical +
quantum O +
dots O +
( O -
QDs O -
) O +
are O +
greatly O +
influenced O +
by O +
their O +
size O +
and O +
surface O +
chemistry O -
. O +

Herein O -
, O +
we O +
examined O +
the O +
optical O +
properties O +
of O +
three O +
Si B-Chemical +
QDs O +
with O +
increasing O +
σ O -
- O -
π O +
conjugation O +
length O -
: O +
octyl- B-Chemical -
, O +
( B-Chemical -
trimethylsilyl I-Chemical -
) I-Chemical -
vinyl- I-Chemical -
, O +
and O +
2-phenylvinyl B-Chemical -
- O -
capped O +
Si B-Chemical +
QDs O -
. O +

The O +
PL O +
photon O +
energy O +
obtained O +
from O +
as O -
- O -
prepared O +
samples O +
decreased O +
by O +
0.1 O -
- O -
0.3 O +
eV O -
, O +
while O +
the O +
PL O +
excitation O +
( O -
PLE O -
) O +
extended O +
from O +
360 O +
nm O +
( O -
octyl B-Chemical -
- O -
capped O +
Si B-Chemical +
QDs O -
) O +
to O +
400 O +
nm O +
( O -
2-phenylvinyl B-Chemical -
- O -
capped O +
Si B-Chemical +
QDs O -
) O -
. O +

A O +
vibrational O +
PL O +
feature O +
was O +
observed O +
in O +
all O +
samples O +
with O +
an O +
energy O +
separation O +
of O +
about O +
0.192±0.013 O +
eV O -
, O +
which O +
was O +
explained O +
based O +
on O +
electron O -
- O -
phonon O +
coupling O -
. O +

After O +
soft O +
oxidization O +
through O +
drying O -
, O +
all O +
samples O +
showed O +
blue O +
PL O +
with O +
maxima O +
at O +
approximately O +
410 O +
nm O -
. O +

A O +
similar O +
high O -
- O -
energy O +
peak O +
was O +
observed O +
with O +
the O +
bare O +
Si B-Chemical +
QD O +
sample O -
. O +

The O +
changes O +
in O +
the O +
optical O +
properties O +
of O +
Si B-Chemical +
QDs O +
were O +
mainly O +
explained O +
by O +
the O +
formation O +
of O +
additional O +
states O +
arising O +
from O +
the O +
strong O +
σ O -
- O -
π O +
conjugation O +
and O +
QD O +
oxidation O -
. O +

Fine O +
Needle O +
Aspiration O +
of O +
Thyroid O +
Nodules O +
with O +
Macrocalcification O -
. O +

Background O -
: O +
The O +
presence O +
of O +
microcalcification O +
is O +
highly O +
suggestive O +
of O +
malignancy O -
; O +
however O -
, O +
the O +
association O +
of O +
macrocalcification O +
with O +
cancer O +
remains O +
unclear O +
and O +
controversial O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
evaluate O +
the O +
diagnostic O +
yield O +
and O +
accuracy O +
of O +
ultrasound O +
( O -
US O -
) O -
-guided O +
fine O +
needle O +
aspiration O +
( O -
FNA O -
) O +
of O +
thyroid O +
nodules O +
with O +
macrocalcification O +
and O +
to O +
investigate O +
the O +
association O +
between O +
macrocalcification O +
subtype O +
and O +
malignancy O +
risk O -
. O +

Methods O -
: O +
We O +
retrospectively O +
reviewed O +
sonographic O +
findings O +
and O +
pathologic O +
results O +
of O +
thyroid O +
nodules O +
with O +
macrocalcification O +
in O +
patients O +
who O +
underwent O +
US O -
- O -
guided O +
FNA O +
in O +
our O +
hospital O +
from O +
January O +
2009 O +
through O +
December O +
2010 O -
. O +

Inclusion O +
criteria O +
were O +
as O +
follows O -
: O +
( O -
a O -
) O +
malignant O +
or O +
benign O +
nodules O +
confirmed O +
on O +
histologic O +
examination O +
of O +
surgical O +
specimens O +
after O +
US O -
- O -
guided O +
FNA O +
and O +
( O -
b O -
) O +
nodules O +
not O +
histologically O +
confirmed O +
that O +
were O +
subjected O +
to O +
FNA O +
at O +
least O +
twice O +
and O +
follow O -
- O -
up O +
US O +
examinations O +
for O +
2 O +
years O -
. O +

Thyroid O +
nodules O +
with O +
macrocalcification O +
were O +
classified O +
into O +
4 O +
groups O -
: O +
smooth O +
total O +
( O -
eggshell O -
) O +
calcification O -
, O +
smooth O +
partial O +
calcification O -
, O +
irregular O +
calcification O -
, O +
and O +
nodular O +
calcification O -
. O +

Diagnostic O +
yield O +
of O +
FNA O +
for O +
thyroid O +
nodules O +
with O +
macrocalcification O +
was O +
determined O +
by O +
cytology O -
. O +

Sensitivity O -
, O +
specificity O -
, O +
and O +
diagnostic O +
accuracy O +
of O +
preoperative O +
FNA O +
cytology O +
were O +
calculated O +
and O +
compared O +
with O +
those O +
of O +
histologic O +
examination O +
of O +
surgical O +
specimens O -
. O +

Results O -
: O +
There O +
were O +
188 O +
nodules O +
with O +
macrocalcification O +
in O +
167 O +
patients O -
; O +
of O +
these O -
, O +
95 O +
were O +
benign O -
, O +
80 O +
were O +
malignant O -
, O +
and O +
13 O +
were O +
nondiagnostic O -
. O +

Diagnostic O +
yield O +
of O +
FNA O +
for O +
thyroid O +
nodules O +
with O +
macrocalcification O +
was O +
93.08 O -
% O -
. O +

Sensitivity O -
, O +
specificity O -
, O +
positive O +
predictive O +
value O -
, O +
and O +
negative O +
predictive O +
value O +
were O +
98.51 O -
% O -
, O +
90.91 O -
% O -
, O +
95.65 O -
% O -
, O +
and O +
96.77 O -
% O -
, O +
respectively O -
. O +

The O +
false O -
- O -
positive O +
value O +
and O +
false O -
- O -
negative O +
value O +
were O +
9.09 O -
% O +
and O +
1.49 O -
% O -
, O +
respectively O -
. O +

The O +
diagnostic O +
accuracy O +
was O +
96 O -
% O -
. O +

There O +
was O +
no O +
statistically O +
significant O +
difference O +
in O +
the O +
association O +
between O +
macrocalcification O +
subtype O +
and O +
malignancy O +
risk O +
( O -
P O +
> O +
0.05 O -
) O -
. O +

Conclusions O -
: O +
Macrocalcification O +
associated O +
with O +
thyroid O +
nodules O +
is O +
not O +
a O +
reliable O +
criterion O +
for O +
malignancy O -
. O +

FNA O +
of O +
thyroid O +
nodules O +
with O +
macrocalcification O +
had O +
significantly O +
high O +
diagnostic O +
yield O +
and O +
reliable O +
accuracy O -
. O +

Consistency O +
between O +
FNA O +
and O +
histology O +
was O +
almost O +
perfect O -
. O +

Therefore O -
, O +
FNA O +
is O +
a O +
good O +
screening O +
method O +
for O +
malignancy O +
of O +
thyroid O +
nodules O +
with O +
macrocalcification O -
. O +

Trimethylamine B-Chemical -
- I-Chemical -
N I-Chemical -
- I-Chemical -
oxide I-Chemical -
, O +
a O +
metabolite O +
associated O +
with O +
atherosclerosis O -
, O +
exhibits O +
complex O +
genetic O +
and O +
dietary O +
regulation O -
. O +

Circulating O +
trimethylamine B-Chemical -
- I-Chemical -
N I-Chemical -
- I-Chemical -
oxide I-Chemical +
( O -
TMAO B-Chemical -
) O +
levels O +
are O +
strongly O +
associated O +
with O +
atherosclerosis O -
. O +

We O +
now O +
examine O +
genetic O -
, O +
dietary O -
, O +
and O +
hormonal O +
factors O +
regulating O +
TMAO B-Chemical +
levels O -
. O +

We O +
demonstrate O +
that O +
two O +
flavin B-Chemical +
mono O -
- O -
oxygenase O +
family O +
members O -
, O +
FMO1 O +
and O +
FMO3 O -
, O +
oxidize O +
trimethylamine B-Chemical +
( O -
TMA B-Chemical -
) O -
, O +
derived O +
from O +
gut O +
flora O +
metabolism O +
of O +
choline B-Chemical -
, O +
to O +
TMAO B-Chemical -
. O +

Further O -
, O +
we O +
show O +
that O +
FMO3 O +
exhibits O +
10-fold O +
higher O +
specific O +
activity O +
than O +
FMO1 O -
. O +

FMO3 O +
overexpression O +
in O +
mice O +
significantly O +
increases O +
plasma O +
TMAO B-Chemical +
levels O +
while O +
silencing O +
FMO3 O +
decreases O +
TMAO B-Chemical +
levels O -
. O +

In O +
both O +
humans O +
and O +
mice O -
, O +
hepatic O +
FMO3 O +
expression O +
is O +
reduced O +
in O +
males O +
compared O +
to O +
females O -
. O +

In O +
mice O -
, O +
this O +
reduction O +
in O +
FMO3 O +
expression O +
is O +
due O +
primarily O +
to O +
downregulation O +
by O +
androgens B-Chemical -
. O +

FMO3 O +
expression O +
is O +
induced O +
by O +
dietary O +
bile B-Chemical +
acids I-Chemical +
by O +
a O +
mechanism O +
that O +
involves O +
the O +
farnesoid O +
X O +
receptor O +
( O -
FXR O -
) O -
, O +
a O +
bile B-Chemical +
acid I-Chemical -
- O -
activated O +
nuclear O +
receptor O -
. O +

Analysis O +
of O +
natural O +
genetic O +
variation O +
among O +
inbred O +
strains O +
of O +
mice O +
indicates O +
that O +
FMO3 O +
and O +
TMAO B-Chemical +
are O +
significantly O +
correlated O -
, O +
and O +
TMAO B-Chemical +
levels O +
explain O +
11 O -
% O +
of O +
the O +
variation O +
in O +
atherosclerosis O -
. O +

Diminutive O +
effect O +
on O +
T O +
and O +
B O -
- O -
cell O +
proliferation O +
of O +
non O -
- O -
cytotoxic O +
α B-Chemical -
- I-Chemical -
santonin I-Chemical +
derived O +
1,2,3-triazoles B-Chemical -
: O +
a O +
report O -
. O +

α B-Chemical -
- I-Chemical -
Santonin I-Chemical +
derived O +
new O +
series O +
of O +
1,2,3-triazoles B-Chemical +
synthesized O +
through O +
Azide B-Chemical -
- I-Chemical -
Alkyne I-Chemical +
Huisgen O +
1,3-dipolar O +
cycloaddition O +
reaction O +
between O +
substituted O +
aryl B-Chemical +
azide I-Chemical +
and O +
a O +
propargylated B-Chemical +
α I-Chemical -
- I-Chemical -
desmotrosantonin I-Chemical +
were O +
bio O -
- O -
evaluated O +
for O +
their O +
diminutive O +
effect O +
on O +
ConA O +
induced O +
T O -
- O -
cell O +
and O +
LPS O +
induced O +
B O -
- O -
cell O +
proliferation O -
. O +

Interestingly O -
, O +
most O +
of O +
the O +
synthesized O +
compounds O +
showed O +
better O +
immunosuppressant O +
activity O +
than O +
α B-Chemical -
- I-Chemical -
santonin I-Chemical -
. O +

Triazole B-Chemical +
derivatives O +
9 O -
, O +
10 O -
, O +
17 O -
, O +
18 O -
, O +
29 O -
, O +
and O +
30 O +
displayed O +
significant O +
diminutive O +
effect O +
on O +
cell O +
proliferation O -
. O +

Compounds O +
12 O +
and O +
13 O +
were O +
found O +
selective O +
against O +
ConA O +
T O -
- O -
cell O +
proliferation O +
exhibiting O +
> O -
90 O -
% O +
inhibition O +
at O +
1 O +
× O +
10 O -
( O -
-6 O -
) O +
M O +
concentration O -
. O +

The O +
present O +
study O +
resulted O +
in O +
identification O +
of O +
several O +
triazole B-Chemical +
derivatives O +
as O +
effective O +
immunosuppressive O +
agents O -
. O +

Silica B-Chemical +
nanoparticles O -
- O -
induced O +
cytotoxicity O -
, O +
oxidative O +
stress O +
and O +
apoptosis O +
in O +
cultured O +
A431 O +
and O +
A549 O +
cells O -
. O +

In O +
medicine O -
, O +
the O +
use O +
of O +
silica B-Chemical +
nanoparticles O +
( O -
SiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
NPs O -
) O +
offers O +
new O +
perspectives O +
in O +
biosensor O -
, O +
drug O +
delivery O +
and O +
cancer O +
therapy O -
. O +

However O -
, O +
questions O +
about O +
potential O +
toxic O +
and O +
deleterious O +
effects O +
of O +
SiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
NPs O +
have O +
also O +
been O +
raised O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
induction O +
of O +
cytotoxicity O -
, O +
oxidative O +
stress O +
and O +
apoptosis O +
by O +
SiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
NPs O +
( O -
size O +
15 O +
nm O -
) O +
in O +
human O +
skin O +
epithelial O +
( O -
A431 O -
) O +
and O +
human O +
lung O +
epithelial O +
( O -
A549 O -
) O +
cells O -
. O +

SiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
NPs O +
( O -
concentration O +
range O +
25 O -
- O -
200 O +
µg O -
/ O -
ml O -
) O +
induced O +
dose O -
- O -
dependent O +
cytotoxicity O +
in O +
both O +
types O +
of O +
cells O -
, O +
which O +
was O +
demonstrated O +
by O +
cell O +
viability O +
( O -
3- B-Chemical -
( I-Chemical -
4,5-dimethylthiazol-2-yl I-Chemical -
) I-Chemical -
-2,5-diphenyltetrazoliumbromide I-Chemical -
) O +
and O +
lactate B-Chemical +
dehydrogenase O +
leakage O +
assays O -
. O +

SiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
NPs O +
were O +
also O +
found O +
to O +
induce O +
oxidative O +
stress O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
, O +
indicated O +
by O +
depletion O +
of O +
glutathione B-Chemical +
and O +
induction O +
of O +
reactive O +
oxygen B-Chemical +
species O +
( O -
ROS O -
) O +
generation O +
and O +
lipid O +
peroxidation O -
. O +

Quantitative O +
real O -
- O -
time O +
polymerase O +
chain O +
reaction O +
analysis O +
showed O +
that O +
following O +
the O +
exposure O +
of O +
cells O +
to O +
SiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
NPs O -
, O +
the O +
messenger O +
RNA O +
level O +
of O +
apoptotic O +
genes O +
( O -
caspase-3 O +
and O +
caspase-9 O -
) O +
were O +
upregulated O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O +

Moreover O -
, O +
activities O +
of O +
caspase-3 O +
and O +
caspase-9 O +
enzymes O +
were O +
also O +
significantly O +
higher O +
in O +
both O +
kinds O +
of O +
cells O +
exposed O +
to O +
SiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
NPs O -
. O +

This O +
study O +
suggested O +
that O +
SiO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
NPs O +
induce O +
cytotoxicity O +
and O +
apoptosis O +
in O +
A431 O +
and O +
A549 O +
cells O -
, O +
which O +
is O +
likely O +
to O +
be O +
mediated O +
through O +
ROS O +
generation O +
and O +
oxidative O +
stress O -
. O +

Decreased O +
RB1 O +
mRNA O -
, O +
Protein O -
, O +
and O +
Activity O +
Reflect O +
Obesity O -
- O -
Induced O +
Altered O +
Adipogenic O +
Capacity O +
in O +
Human O +
Adipose O +
Tissue O -
. O +

Retinoblastoma O +
( O -
Rb1 O -
) O +
has O +
been O +
described O +
as O +
an O +
essential O +
player O +
in O +
white O +
adipocyte O +
differentiation O +
in O +
mice O -
. O +

No O +
studies O +
have O +
been O +
reported O +
thus O +
far O +
in O +
human O +
adipose O +
tissue O +
or O +
human O +
adipocytes O -
. O +

We O +
aimed O +
to O +
investigate O +
the O +
possible O +
role O +
and O +
regulation O +
of O +
RB1 O +
in O +
adipose O +
tissue O +
in O +
obesity O +
using O +
human O +
samples O +
and O +
animal O +
and O +
cell O +
models O -
. O +

Adipose O +
RB1 O +
( O -
mRNA O -
, O +
protein O -
, O +
and O +
activity O -
) O +
was O +
negatively O +
associated O +
with O +
BMI O +
and O +
insulin O +
resistance O +
( O -
HOMA O -
- O -
IR O -
) O +
while O +
positively O +
associated O +
with O +
the O +
expression O +
of O +
adipogenic O +
genes O +
( O -
PPARγ O +
and O +
IRS1 O -
) O +
in O +
both O +
visceral O +
and O +
subcutaneous O +
human O +
adipose O +
tissue O -
. O +

BMI O +
increase O +
was O +
the O +
main O +
contributor O +
to O +
adipose O +
RB1 O +
downregulation O -
. O +

In O +
rats O -
, O +
adipose O +
Rb1 O +
gene O +
expression O +
and O +
activity O +
decreased O +
in O +
parallel O +
to O +
dietary O -
- O -
induced O +
weight O +
gain O +
and O +
returned O +
to O +
baseline O +
with O +
weight O +
loss O -
. O +

RB1 O +
gene O +
and O +
protein O +
expression O +
and O +
activity O +
increased O +
significantly O +
during O +
human O +
adipocyte O +
differentiation O -
. O +

In O +
fully O +
differentiated O +
adipocytes O -
, O +
transient O +
knockdown O +
of O +
Rb1 O +
led O +
to O +
loss O +
of O +
the O +
adipogenic O +
phenotype O -
. O +

In O +
conclusion O -
, O +
Rb1 O +
seems O +
to O +
play O +
a O +
permissive O +
role O +
for O +
human O +
adipose O +
tissue O +
function O -
, O +
being O +
downregulated O +
in O +
obesity O +
and O +
increased O +
during O +
differentiation O +
of O +
human O +
adipocytes O -
. O +

Rb1 O +
knockdown O +
findings O +
further O +
implicate O +
Rb1 O +
as O +
necessary O +
for O +
maintenance O +
of O +
adipogenic O +
characteristics O +
in O +
fully O +
differentiated O +
adipocytes O -
. O +

Solphenazines B-Chemical +
A I-Chemical -
- I-Chemical -
F I-Chemical -
, O +
glycosylated B-Chemical +
phenazines I-Chemical +
from O +
Streptomyces O +
sp. O +
strain O +
DL-93 O -
. O +

During O +
a O +
survey O +
of O +
actinobacteria O +
known O +
to O +
suppress O +
the O +
growth O +
of O +
Streptomyces O +
scabies O +
( O -
the O +
causative O +
agent O +
of O +
potato O +
scab O +
disease O -
) O +
in O +
vivo O -
, O +
six O +
new O +
rhamnosylated O +
alkaloids O -
, O +
the O +
solphenazines B-Chemical +
A I-Chemical -
- I-Chemical -
F I-Chemical +
( O -
1 O -
- O -
6 O -
) O -
, O +
were O +
isolated O +
from O +
a O +
biological O +
control O +
strain O +
of O +
Streptomyces O +
( O -
DL-93 O -
) O -
. O +

The O +
known O +
rhamnosyl B-Chemical +
analogue O +
of O +
paraben B-Chemical +
( O -
9 O -
) O +
was O +
also O +
isolated O +
along O +
with O +
a O +
new O +
rhamnosylated O +
derivative O +
of O +
N B-Chemical -
- I-Chemical -
methyl I-Chemical -
- I-Chemical -
p I-Chemical -
- I-Chemical -
aminobenzoic I-Chemical +
acid I-Chemical +
( O -
10 O -
) O -
. O +

None O +
of O +
the O +
compounds O +
exhibited O +
any O +
antibacterial O +
or O +
antifungal O +
activity O +
against O +
a O +
standard O +
panel O +
of O +
microorganisms O -
, O +
but O +
compounds O +
1 O -
, O +
2 O -
, O +
and O +
6 O +
displayed O +
some O +
cytotoxicity O +
against O +
HCT-116 O +
cancer O +
cells O -
. O +

Additional O +
in O +
vitro O +
testing O +
provided O +
data O +
suggesting O +
that O +
the O +
cytotoxic O +
activity O +
is O +
not O +
due O +
to O +
DNA O +
intercalation O +
or O +
topoisomerase O +
inhibition O -
. O +

Synthesis O +
and O +
biological O +
evaluation O +
as O +
microtubule O -
- O -
active O +
agents O +
of O +
several O +
tetrahydrofuran B-Chemical +
and O +
spiroacetal B-Chemical +
derivatives O -
. O +

The O +
stereoselective O +
preparation O +
of O +
several O +
molecules O +
containing O +
structural O +
fragments O +
of O +
the O +
tetrahydrofuran B-Chemical +
and O +
spiroacetal B-Chemical +
type O +
is O +
described O -
. O +

Their O +
degree O +
of O +
cytotoxicity O +
and O +
their O +
interactions O +
with O +
tubulin O +
have O +
been O +
investigated O -
. O +

It O +
has O +
been O +
confirmed O +
that O +
the O +
tetrahydrofuran B-Chemical +
derivatives O +
are O +
cytotoxic O +
but O -
, O +
in O +
contrast O +
to O +
previous O +
reports O -
, O +
it O +
has O +
been O +
found O +
that O +
the O +
cytoxicity O +
is O +
not O +
due O +
to O +
interactions O +
with O +
the O +
microtubule O +
network O -
. O +

Furthermore O -
, O +
and O +
also O +
in O +
contrast O +
to O +
a O +
previous O +
report O +
on O +
closely O +
related O +
compounds O -
, O +
the O +
spiroacetal B-Chemical +
derivatives O +
do O +
show O +
interactions O +
with O +
tubulin O -
, O +
even O +
though O +
the O +
precise O +
mechanism O +
and O +
the O +
binding O +
site O +
still O +
remain O +
to O +
be O +
established O -
. O +

The O +
oxygen B-Chemical +
therapy O -
. O +

Oxygen B-Chemical +
( O -
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
) O +
is O +
a O +
vital O +
element O -
. O +

Shortage O +
of O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
results O +
in O +
deranged O +
metabolism O +
and O +
important O +
changes O +
in O +
vascular O +
tone O +
with O +
opposite O +
effects O +
on O +
the O +
systemic O +
and O +
pulmonary O +
circulation O -
. O +

During O +
hypoxemia O -
, O +
oxidative O +
stress O +
exposes O +
the O +
organism O +
to O +
a O +
sort O +
of O +
accelerated O +
senescence O +
as O +
well O +
as O +
to O +
several O +
acute O +
untoward O +
effects O -
. O +

Thus O -
, O +
hypoxemia O +
should O +
be O +
promptly O +
recognized O +
and O +
treated O -
, O +
hopefully O +
by O +
measures O +
tailored O +
to O +
the O +
pathophysiological O +
mechanisms O +
underlying O +
hypoxemia O -
. O +

However O -
, O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
therapy O +
remains O +
the O +
most O +
common O +
therapy O +
of O +
hypoxemia O -
, O +
but O +
it O +
must O +
be O +
carefully O +
tailored O +
to O +
relieve O +
hypoxemia O +
without O +
provoking O +
hyperoxia O +
or O +
hypercarbia O -
. O +

Then O -
, O +
the O +
individual O +
response O +
to O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
as O +
well O +
as O +
changing O +
needs O +
of O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
during O +
sleep O +
or O +
exercise O +
must O +
be O +
evaluated O +
to O +
provide O +
the O +
best O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
therapy O -
. O +

Hyperoxia O -
, O +
the O +
effect O +
of O +
overcorrection O +
of O +
hypoxia O -
, O +
can O +
dramatically O +
impact O +
the O +
health O +
status O +
and O +
threaten O +
the O +
survival O +
of O +
the O +
newborn O +
and O -
, O +
through O +
different O +
mechanisms O +
and O +
effects O -
, O +
the O +
adult O -
. O +

A O +
thorough O +
knowledge O +
of O +
the O +
pathophysiological O +
bases O +
of O +
hypoxemia O +
and O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
storage O +
and O +
delivery O +
devices O +
is O +
then O +
mandatory O +
to O +
administer O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
therapy O +
guaranteeing O +
for O +
optimal O +
correction O +
of O +
hypoxemia O +
and O +
minimizing O +
the O +
risk O +
of O +
hyperoxia O -
. O +

Consistent O +
with O +
this O +
aim O +
also O +
is O +
a O +
careful O +
scrutiny O +
of O +
instruments O +
and O +
procedures O +
for O +
monitoring O +
the O +
individual O +
response O +
to O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
over O +
time O -
. O +

Thus O -
, O +
at O +
variance O +
from O +
classical O +
pharmacological O +
therapy O -
, O +
performing O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
therapy O +
requires O +
a O +
vast O +
array O +
of O +
clinical O +
and O +
technical O +
competences O -
. O +

The O +
optimal O +
integration O +
of O +
these O +
competences O +
is O +
needed O +
to O +
optimize O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
therapy O +
on O +
individual O +
bases O -
. O +

Recent O +
Developments O +
of O +
p38α O +
MAP O +
Kinase O +
Inhibitors O +
as O +
Antiinflammatory O +
Agents O +
Based O +
on O +
the O +
Imidazole B-Chemical +
Scaffolds O -
. O +

Rheumatoid O +
arthritis O +
( O -
RA O -
) O +
and O +
other O +
chronic O +
inflammatory O +
diseases O +
are O +
always O +
the O +
major O +
therapeutic O +
challenges O -
. O +

Recent O +
research O +
efforts O +
provided O +
new O +
insights O +
into O +
the O +
molecular O +
basis O +
of O +
these O +
diseases O +
and O +
new O +
opportunities O +
for O +
developing O +
improved O +
anti O -
- O -
inflammatory O +
drugs O -
. O +

The O +
p38 O +
mitogen O -
- O -
activated O +
protein O +
( O -
MAP O -
) O +
kinase O +
plays O +
a O +
central O +
role O +
in O +
the O +
regulation O +
of O +
the O +
biosynthesis O +
and O +
release O +
of O +
several O +
proinflammatory O +
cytokines O +
including O +
tumor O +
necrosis O +
factor O +
alpha O +
( O -
TNF O -
- O -
α O -
) O +
and O +
interleukin-1 O +
beta O +
( O -
IL-1β O -
) O -
. O +

Hence O -
, O +
inhibition O +
of O +
the O +
p38 O +
MAP O +
kinase O +
is O +
regarded O +
as O +
a O +
promising O +
therapeutic O +
strategy O +
for O +
controlling O +
inflammatory O +
diseases O -
. O +

A O +
diverse O +
range O +
of O +
p38α O +
MAP O +
kinase O +
inhibitors O +
have O +
been O +
developed O +
as O +
potential O +
anti O -
- O -
inflammatory O +
agents O -
, O +
and O +
some O +
of O +
them O +
have O +
entered O +
the O +
phase O +
II O +
clinical O +
trials O -
. O +

The O +
imidazole B-Chemical +
derivatives O +
are O +
known O +
as O +
competitive O +
inhibitors O +
at O +
the O +
ATP B-Chemical +
binding O +
site O +
of O +
the O +
p38α O +
MAP O +
kinase O -
. O +

Modifications O +
on O +
the O +
imidazole B-Chemical +
scaffold O +
have O +
led O +
to O +
a O +
large O +
amount O +
of O +
potent O +
p38α O +
MAP O +
kinase O +
inhibitors O -
. O +

This O +
review O +
will O +
summarize O +
the O +
developments O +
of O +
small O +
molecule O +
p38α O +
MAP O +
kinase O +
inhibitors O +
based O +
on O +
the O +
imidazole B-Chemical +
core O +
scaffolds O +
in O +
recent O +
10 O +
years O -
. O +

Variations O +
at O +
the O +
N1 O -
, O +
C2 O -
, O +
C4 O +
and O +
C5 O +
positions O +
of O +
imidazole B-Chemical +
were O +
introduced O -
, O +
and O +
the O +
structure O -
- O -
activity O +
relationships O +
of O +
these O +
imidazole B-Chemical +
inhibitors O +
were O +
also O +
discussed O -
. O +

Atomic O +
pair O +
distribution O +
functions O +
analysis O +
of O +
disordered O +
low O -
- O -
Z O +
materials O -
. O +

Results O +
of O +
high O -
- O -
energy O +
X O -
- O -
ray O +
diffraction O +
experiments O +
coupled O +
to O +
atomic O +
pair O +
distribution O +
function O +
analysis O +
of O +
disordered O +
low O -
- O -
Z O +
materials O +
are O +
presented O -
. O +

Several O +
scientifically O +
and O +
technologically O +
important O +
classes O +
of O +
disordered O +
low O -
- O -
Z O +
materials O +
such O +
as O +
small O +
and O +
large O +
organic O +
molecules O -
, O +
graphitic B-Chemical +
powders O -
, O +
polymers O +
and O +
liquids O +
are O +
intentionally O +
explored O +
to O +
certify O +
the O +
technique O -
's O +
performance O -
. O +

Results O +
clearly O +
show O +
that O +
disordered O +
low O -
- O -
Z O +
materials O +
can O +
be O +
well O +
characterized O +
in O +
terms O +
of O +
material O -
's O +
phase O +
identity O -
, O +
relative O +
abundance O +
in O +
mixtures O +
and O +
atomic O -
- O -
scale O +
structure O -
. O +

The O +
demonstrated O +
efficiency O +
of O +
the O +
technique O +
provides O +
the O +
scientific O +
community O +
with O +
much O +
needed O +
confidence O +
to O +
apply O +
it O +
more O +
often O +
than O +
now O -
. O +

ErbB2 O -
, O +
FoxM1 O +
and O +
14 O -
- O -
3 O -
- O -
3ζ O +
prime O +
breast O +
cancer O +
cells O +
for O +
invasion O +
in O +
response O +
to O +
ionizing O +
radiation O -
. O +

ErbB2 O +
is O +
frequently O +
highly O +
expressed O +
in O +
premalignant O +
breast O +
cancers O -
, O +
including O +
ductal O +
carcinoma O +
in O +
situ O +
( O -
DCIS O -
) O -
; O +
however O -
, O +
little O +
is O +
known O +
about O +
the O +
signals O +
or O +
pathways O +
it O +
contributes O +
to O +
progression O +
into O +
the O +
invasive O -
/ O -
malignant O +
state O -
. O +

Radiotherapy O +
is O +
often O +
used O +
to O +
treat O +
early O +
premalignant O +
lesions O +
regardless O +
of O +
ErbB2 O +
status O -
. O +

Here O -
, O +
we O +
show O +
that O +
clinically O +
relevant O +
doses O +
of O +
ionizing O +
radiation O +
( O -
IR O -
) O -
-induce O +
cellular O +
invasion O +
of O +
ErbB2-expressing O +
breast O +
cancer O +
cells O -
, O +
as O +
well O +
as O +
MCF10A O +
cells O +
overexpressing O +
ErbB2 O -
. O +

ErbB2-negative O +
breast O +
cancer O +
cells O -
, O +
such O +
as O +
MCF7 O +
and O +
T47D O -
, O +
do O +
not O +
invade O +
following O +
treatment O +
with O +
IR O +
nor O +
do O +
MCF10A O +
cells O +
overexpressing O +
epidermal O +
growth O +
factor O +
receptor O -
. O +

ErbB2 O +
becomes O +
phosphorylated O +
at O +
tyrosine B-Chemical +
877 O +
in O +
a O +
dose- O +
and O +
time- O +
dependent O +
manner O +
following O +
exposure O +
to O +
X O -
- O -
rays O -
, O +
and O +
activates O +
downstream O +
signaling O +
cascades O +
including O +
PI3K O -
/ O -
Akt O -
. O +

Inhibition O +
of O +
these O +
pathways O -
, O +
as O +
well O +
as O +
inhibition O +
of O +
reactive O +
oxygen B-Chemical +
species O +
( O -
ROS O -
) O +
with O +
antioxidants O -
, O +
prevents O +
IR O -
- O -
induced O +
invasion O -
. O +

Activation O +
of O +
ErbB2-dependent O +
signaling O +
results O +
in O +
upregulation O +
of O +
the O +
forkhead O +
family O +
transcription O +
factor O -
, O +
FoxM1 O -
, O +
and O +
its O +
transcriptional O +
targets O -
, O +
including O +
matrix O +
metalloproteinase O +
2 O +
( O -
MMP2 O -
) O -
. O +

Inhibition O +
of O +
FoxM1 O +
by O +
RNA O +
interference O +
prevented O +
induction O +
of O +
invasion O +
by O +
IR O -
, O +
and O +
overexpression O +
of O +
FoxM1 O +
in O +
MCF10A O +
cells O +
was O +
sufficient O +
to O +
promote O +
IR O -
- O -
induced O +
invasion O -
. O +

Moreover O -
, O +
we O +
found O +
that O +
14 O -
- O -
3 O -
- O -
3ζ O +
is O +
also O +
upregulated O +
by O +
IR O +
in O +
cancer O +
cells O +
in O +
a O +
ROS O -
- O -
dependent O +
manner O -
, O +
is O +
required O +
for O +
IR O -
- O -
induced O +
invasion O +
in O +
ErbB2-positive O +
breast O +
cancer O +
cells O +
and O +
together O +
with O +
FoxM1 O +
is O +
sufficient O +
for O +
invasion O +
in O +
ErbB2-negative O +
breast O +
cancer O +
cells O -
. O +

Thus O -
, O +
our O +
data O +
show O +
that O +
IR O -
- O -
mediated O +
activation O +
of O +
ErbB2 O +
and O +
induction O +
of O +
14 O -
- O -
3 O -
- O -
3ζ O +
collaborate O +
to O +
regulate O +
FoxM1 O +
and O +
promote O +
invasion O +
of O +
breast O +
cancer O +
cells O +
and O +
furthermore O -
, O +
may O +
serve O +
as O +
therapeutic O +
targets O +
to O +
enhance O +
radiosensitivity O +
of O +
breast O +
cancers O -
. O +

Oncogene O +
advance O +
online O +
publication O -
, O +
14 O +
January O +
2013 O -
; O +
doi:10.1038 O -
/ O -
onc.2012.629 O -
. O +

TRIM3 O -
, O +
a O +
tumor O +
suppressor O +
linked O +
to O +
regulation O +
of O +
p21 O -
( O -
Waf1 O -
/ O -
Cip1 O -
) O -
. O +

The O +
TRIM O +
family O +
of O +
genes O +
is O +
largely O +
studied O +
because O +
of O +
their O +
roles O +
in O +
development O -
, O +
differentiation O +
and O +
host O +
cell O +
antiviral O +
defenses O -
; O +
however O -
, O +
roles O +
in O +
cancer O +
biology O +
are O +
emerging O -
. O +

Loss O +
of O +
heterozygosity O +
of O +
the O +
TRIM3 O +
locus O +
in O +
∼20 O -
% O +
of O +
human O +
glioblastomas O +
raised O +
the O +
possibility O +
that O +
this O +
NHL O -
- O -
domain O +
containing O +
member O +
of O +
the O +
TRIM O +
gene O +
family O +
might O +
be O +
a O +
mammalian O +
tumor O +
suppressor O -
. O +

Consistent O +
with O +
this O -
, O +
reducing O +
TRIM3 O +
expression O +
increased O +
the O +
incidence O +
of O +
and O +
accelerated O +
the O +
development O +
of O +
platelet O -
- O -
derived O +
growth O +
factor O +
-induced O +
glioma O +
in O +
mice O -
. O +

Furthermore O -
, O +
TRIM3 O +
can O +
bind O +
to O +
the O +
cdk O +
inhibitor O +
p21 O -
( O -
WAF1 O -
/ O -
CIP1 O -
) O -
. O +

Thus O -
, O +
we O +
conclude O +
that O +
TRIM3 O +
is O +
a O +
tumor O +
suppressor O +
mapping O +
to O +
chromosome O +
11p15.5 O +
and O +
that O +
it O +
might O +
block O +
tumor O +
growth O +
by O +
sequestering O +
p21 O +
and O +
preventing O +
it O +
from O +
facilitating O +
the O +
accumulation O +
of O +
cyclin O +
D1-cdk4.Oncogene O +
advance O +
online O +
publication O -
, O +
14 O +
January O +
2013 O -
; O +
doi:10.1038 O -
/ O -
onc.2012.596 O -
. O +

Determinants O +
of O +
regioselectivity O +
and O +
chemoselectivity O +
in O +
fosfomycin B-Chemical +
resistance O +
protein O +
FosA O +
from O +
QM O -
/ O -
MM O +
calculations O -
. O +

FosA O +
is O +
a O +
manganese B-Chemical -
- O -
dependent O +
enzyme O +
that O +
utilizes O +
a O +
Mn B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
ion O +
to O +
catalyze O +
the O +
inactivation O +
of O +
the O +
fosfomycin B-Chemical +
antibiotic O +
by O +
glutathione B-Chemical +
( O -
GSH B-Chemical -
) O +
addition O -
. O +

We O +
report O +
a O +
theoretical O +
study O +
on O +
the O +
catalytic O +
mechanism O +
and O +
the O +
factors O +
governing O +
the O +
regioselectivity O +
and O +
chemoselectivity O +
of O +
FosA. O +
Density O +
functional O +
theory O +
( O -
DFT O -
) O +
calculations O +
on O +
the O +
uncatalyzed O +
reaction O +
give O +
high O +
barriers O +
and O +
almost O +
no O +
regioselectivity O +
even O +
when O +
adding O +
two O +
water O +
molecules O +
to O +
assist O +
the O +
proton O +
transfer O -
. O +

According O +
to O +
quantum O +
mechanics O -
/ O -
molecular O +
mechanics O +
( O -
QM O -
/ O -
MM O -
) O +
calculations O +
on O +
the O +
full O +
solvated O +
protein O -
, O +
the O +
enzyme O -
- O -
catalyzed O +
glutathione B-Chemical +
addition O +
reaction O +
involves O +
two O +
major O +
chemical O +
steps O +
that O +
both O +
proceed O +
in O +
the O +
sextet O +
state O -
: O +
proton O +
transfer O +
from O +
the O +
GSH B-Chemical +
thiol I-Chemical +
group O +
to O +
the O +
Tyr39 B-Chemical +
anion O +
and O +
nucleophilic O +
attack O +
by O +
the O +
GSH B-Chemical +
thiolate I-Chemical +
leading O +
to O +
epoxide B-Chemical +
ring O -
- O -
opening O -
. O +

The O +
second O +
step O +
is O +
rate O -
- O -
limiting O +
and O +
is O +
facilitated O +
by O +
the O +
presence O +
of O +
the O +
high O -
- O -
spin O +
Mn B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
ion O +
that O +
functions O +
as O +
a O +
Lewis B-Chemical +
acid I-Chemical +
and O +
stabilizes O +
the O +
leaving O +
oxyanion O +
through O +
direct O +
coordination O -
. O +

The O +
barrier O +
for O +
C1 O +
attack O +
is O +
computed O +
to O +
be O +
8.9 O +
kcal O -
/ O -
mol O +
lower O +
than O +
that O +
for O +
C2 O +
attack O -
, O +
in O +
agreement O +
with O +
the O +
experimentally O +
observed O +
regioselectivity O +
of O +
the O +
enzyme O -
. O +

Further O +
QM O -
/ O -
MM O +
calculations O +
on O +
the O +
alternative O +
water O +
attack O +
predict O +
a O +
concerted O +
mechanism O +
for O +
this O +
reaction O -
, O +
where O +
the O +
deprotonation O +
of O +
water O -
, O +
nucleophilic O +
attack O -
, O +
and O +
epoxide B-Chemical +
ring O -
- O -
opening O +
take O +
place O +
via O +
the O +
same O +
transition O +
state O -
. O +

The O +
calculated O +
barrier O +
is O +
8.3 O +
kcal O -
/ O -
mol O +
higher O +
than O +
that O +
for O +
GSH B-Chemical +
attack O -
, O +
in O +
line O +
with O +
the O +
observed O +
chemoselectivity O +
of O +
the O +
enzyme O -
, O +
which O +
manages O +
to O +
catalyze O +
the O +
addition O +
of O +
GSH B-Chemical +
in O +
the O +
presence O +
of O +
water O +
molecules O +
around O +
its O +
active O +
site O -
. O +

The O +
catalytic O +
efficiency O -
, O +
regioselectivity O -
, O +
and O +
chemoselectivity O +
of O +
FosA O +
are O +
rationalized O +
in O +
terms O +
of O +
the O +
influence O +
of O +
the O +
active O -
- O -
site O +
protein O +
environment O +
and O +
the O +
different O +
stabilization O +
of O +
the O +
distorted O +
substrates O +
in O +
the O +
relevant O +
transition O +
states O -
. O +

Lessons O +
on O +
conditional O +
gene O +
targeting O +
in O +
mouse O +
adipose O +
tissue O -
. O +

Conditional O +
gene O +
targeting O +
has O +
been O +
extensively O +
used O +
for O +
in O +
vivo O +
analysis O +
of O +
gene O +
function O +
in O +
adipocyte O +
cell O +
biology O +
but O +
often O +
with O +
debate O +
over O +
the O +
tissue O +
specificity O +
and O +
the O +
efficacy O +
of O +
inactivation O -
. O +

To O +
directly O +
compare O +
the O +
specificity O +
and O +
efficacy O +
of O +
different O +
Cre O +
lines O +
in O +
mediating O +
adipocyte O +
specific O +
recombination O -
, O +
transgenic O +
Cre O +
lines O +
driven O +
by O +
the O +
adipocyte O +
protein O +
2 O +
( O -
aP2 O -
) O +
and O +
adiponectin O +
( O -
Adipoq O -
) O +
gene O +
promoters O -
, O +
as O +
well O +
as O +
a O +
tamoxifen B-Chemical -
- O -
inducible O +
Cre O +
driven O +
by O +
the O +
aP2 O +
gene O +
promoter O +
( O -
iaP2 O -
) O -
, O +
were O +
bred O +
to O +
the O +
Rosa26R O +
( O -
R26R O -
) O +
reporter O -
. O +

All O +
three O +
Cre O +
lines O +
demonstrated O +
recombination O +
in O +
the O +
brown O +
and O +
white O +
fat O +
pads O -
. O +

Using O +
different O +
floxed O +
loci O -
, O +
the O +
individual O +
Cre O +
lines O +
displayed O +
a O +
range O +
of O +
efficacy O +
to O +
Cre O -
- O -
mediated O +
recombination O +
that O +
ranged O +
from O +
no O +
observable O +
recombination O +
to O +
complete O +
recombination O +
within O +
the O +
fat O -
. O +

The O +
Adipoq O -
- O -
Cre O +
exhibited O +
no O +
observable O +
recombination O +
in O +
any O +
other O +
tissues O +
examined O -
, O +
whereas O +
both O +
aP2-Cre O +
lines O +
resulted O +
in O +
recombination O +
in O +
endothelial O +
cells O +
of O +
the O +
heart O +
and O +
nonendothelial O -
, O +
nonmyocyte O +
cells O +
in O +
the O +
skeletal O +
muscle O -
. O +

In O +
addition O -
, O +
the O +
aP2-Cre O +
line O +
can O +
lead O +
to O +
germline O +
recombination O +
of O +
floxed O +
alleles O +
in O +
~2 O -
% O +
of O +
spermatozoa O -
. O +

Thus O -
, O +
different O +
" O -
adipocyte O -
- O -
specific O -
" O +
Cre O +
lines O +
display O +
different O +
degrees O +
of O +
efficiency O +
and O +
specificity O -
, O +
illustrating O +
important O +
differences O +
that O +
must O +
be O +
taken O +
into O +
account O +
in O +
their O +
use O +
for O +
studying O +
adipose O +
biology O -
. O +

Regulation O +
of O +
μ O -
- O -
opioid O +
receptors O -
: O +
desensitization O -
, O +
phosphorylation O -
, O +
internalization O -
, O +
and O +
tolerance O -
. O +

Morphine B-Chemical +
and O +
related O +
µ-opioid O +
receptor O +
( O -
MOR O -
) O +
agonists O +
remain O +
among O +
the O +
most O +
effective O +
drugs O +
known O +
for O +
acute O +
relief O +
of O +
severe O +
pain O -
. O +

A O +
major O +
problem O +
in O +
treating O +
painful O +
conditions O +
is O +
that O +
tolerance O +
limits O +
the O +
long O -
- O -
term O +
utility O +
of O +
opioid O +
agonists O -
. O +

Considerable O +
effort O +
has O +
been O +
expended O +
on O +
developing O +
an O +
understanding O +
of O +
the O +
molecular O +
and O +
cellular O +
processes O +
that O +
underlie O +
acute O +
MOR O +
signaling O -
, O +
short O -
- O -
term O +
receptor O +
regulation O -
, O +
and O +
the O +
progression O +
of O +
events O +
that O +
lead O +
to O +
tolerance O +
for O +
different O +
MOR O +
agonists O -
. O +

Although O +
great O +
progress O +
has O +
been O +
made O +
in O +
the O +
past O +
decade O -
, O +
many O +
points O +
of O +
contention O +
and O +
controversy O +
cloud O +
the O +
realization O +
of O +
this O +
progress O -
. O +

This O +
review O +
attempts O +
to O +
clarify O +
some O +
confusion O +
by O +
clearly O +
defining O +
terms O -
, O +
such O +
as O +
desensitization O +
and O +
tolerance O -
, O +
and O +
addressing O +
optimal O +
pharmacological O +
analyses O +
for O +
discerning O +
relative O +
importance O +
of O +
these O +
cellular O +
mechanisms O -
. O +

Cellular O +
and O +
molecular O +
mechanisms O +
regulating O +
MOR O +
function O +
by O +
phosphorylation O +
relative O +
to O +
receptor O +
desensitization O +
and O +
endocytosis O +
are O +
comprehensively O +
reviewed O -
, O +
with O +
an O +
emphasis O +
on O +
agonist O -
- O -
biased O +
regulation O +
and O +
areas O +
where O +
knowledge O +
is O +
lacking O +
or O +
controversial O -
. O +

The O +
implications O +
of O +
these O +
mechanisms O +
for O +
understanding O +
the O +
substantial O +
contribution O +
of O +
MOR O +
signaling O +
to O +
opioid O +
tolerance O +
are O +
then O +
considered O +
in O +
detail O -
. O +

While O +
some O +
functional O +
MOR O +
regulatory O +
mechanisms O +
contributing O +
to O +
tolerance O +
are O +
clearly O +
understood O -
, O +
there O +
are O +
large O +
gaps O +
in O +
understanding O +
the O +
molecular O +
processes O +
responsible O +
for O +
loss O +
of O +
MOR O +
function O +
after O +
chronic O +
exposure O +
to O +
opioids O -
. O +

Further O +
elucidation O +
of O +
the O +
cellular O +
mechanisms O +
that O +
are O +
regulated O +
by O +
opioids O +
will O +
be O +
necessary O +
for O +
the O +
successful O +
development O +
of O +
MOR O -
- O -
based O +
approaches O +
to O +
new O +
pain O +
therapeutics O +
that O +
limit O +
the O +
development O +
of O +
tolerance O -
. O +

Microwave O +
absorption O +
in O +
powders O +
of O +
small O +
conducting O +
particles O +
for O +
heating O +
applications O -
. O +

In O +
microwave O +
chemistry O +
there O +
is O +
a O +
common O +
misconception O +
that O +
small O -
, O +
highly O +
conducting O +
particles O +
heat O +
profusely O +
when O +
placed O +
in O +
a O +
large O +
microwave O +
electric O +
field O -
. O +

However O -
, O +
this O +
is O +
not O +
the O +
case O -
; O +
with O +
the O +
simple O +
physical O +
explanation O +
that O +
the O +
electric O +
field O +
( O -
which O +
drives O +
the O +
heating O -
) O +
within O +
a O +
highly O +
conducting O +
particle O +
is O +
highly O +
screened O -
. O +

Instead O -
, O +
it O +
is O +
the O +
magnetic O +
absorption O +
associated O +
with O +
induction O +
that O +
accounts O +
for O +
the O +
large O +
experimental O +
heating O +
rates O +
observed O +
for O +
small O +
metal O +
particles O -
. O +

We O +
present O +
simple O +
principles O +
for O +
the O +
effective O +
heating O +
of O +
particles O +
in O +
microwave O +
fields O +
from O +
calculations O +
of O +
electric O +
and O +
magnetic O +
dipole O +
absorptions O +
for O +
a O +
range O +
of O +
practical O +
values O +
of O +
particle O +
size O +
and O +
conductivity O -
. O +

For O +
highly O +
conducting O +
particles O -
, O +
magnetic O +
absorption O +
dominates O +
electric O +
absorption O +
over O +
a O +
wide O +
range O +
of O +
particle O +
radii O -
, O +
with O +
an O +
optimum O +
absorption O +
set O +
by O +
the O +
ratio O +
of O +
mean O +
particle O +
radius O +
a O +
to O +
the O +
skin O +
depth O +
δ O +
( O -
specifically O -
, O +
by O +
the O +
condition O +
a O +
= O +
2.41δ O -
) O -
. O +

This O +
means O +
that O +
for O +
particles O +
of O +
any O +
conductivity O -
, O +
optimized O +
magnetic O +
absorption O +
( O -
and O +
hence O +
microwave O +
heating O +
by O +
magnetic O +
induction O -
) O +
can O +
be O +
achieved O +
by O +
simple O +
selection O +
of O +
the O +
mean O +
particle O +
size O -
. O +

For O +
weakly O +
conducting O +
samples O -
, O +
electric O +
dipole O +
absorption O +
dominates O -
, O +
and O +
is O +
maximized O +
when O +
the O +
conductivity O +
is O +
approximately O +
σ O +
≈ O +
3ωε O -
( O -
0 O -
) O +
≈ O +
0.4 O +
S O +
m O -
( O -
-1 O -
) O -
, O +
independent O +
of O +
particle O +
radius O -
. O +

Therefore O -
, O +
although O +
electric O +
dipole O +
heating O +
can O +
be O +
as O +
effective O +
as O +
magnetic O +
dipole O +
heating O +
for O +
a O +
powder O +
sample O +
of O +
the O +
same O +
volume O -
, O +
it O +
is O +
harder O +
to O +
obtain O +
optimized O +
conditions O +
at O +
a O +
fixed O +
frequency O +
of O +
microwave O +
field O -
. O +

The O +
absorption O +
of O +
sub O -
- O -
micron O +
particles O +
is O +
ineffective O +
in O +
both O +
magnetic O +
and O +
electric O +
fields O -
. O +

However O -
, O +
if O +
the O +
particles O +
are O +
magnetic O -
, O +
with O +
a O +
lossy O +
part O +
to O +
their O +
complex O +
permeability O -
, O +
then O +
magnetic O +
dipole O +
losses O +
are O +
dramatically O +
enhanced O +
compared O +
to O +
their O +
values O +
for O +
non O -
- O -
magnetic O +
particles O -
. O +

An O +
interesting O +
application O +
of O +
this O +
is O +
the O +
use O +
of O +
very O +
small O +
magnetic O +
particles O +
for O +
the O +
selective O +
microwave O +
heating O +
of O +
biological O +
samples O -
. O +

Insights O +
into O +
TIM O -
- O -
barrel O +
prenyl O +
transferase O +
mechanisms O -
: O +
crystal O +
structures O +
of O +
PcrB O +
from O +
Bacillus O +
subtilis O +
and O +
Staphylococcus O +
aureus O -
. O +

Well O +
structured O -
: O +
As O +
a O +
new O +
triose B-Chemical +
phosphate I-Chemical +
isomerase O +
( O -
TIM O -
) O +
barrel O -
- O -
fold O +
prenyl O +
transferase O -
, O +
PcrB O +
catalyzes O +
the O +
production O +
of O +
heptaprenylglyceryl B-Chemical +
phosphate I-Chemical +
from O +
heptaprenyl B-Chemical +
diphosphate I-Chemical +
and O +
glycerol-1-phosphate B-Chemical -
. O +

Crystal O +
structures O +
of O +
PcrB O +
from O +
Bacillus O +
subtilis O +
and O +
Staphylococcus O +
aureus O +
in O +
complex O +
with O +
ligands O +
were O +
solved O -
, O +
and O +
together O +
with O +
site O -
- O -
directed O +
mutagenesis O +
and O +
bioinformatics O +
analyses O -
, O +
clearly O +
reveal O +
the O +
catalytic O +
mechanism O +
of O +
the O +
enzyme O -
. O +

Four O +
new O +
koumine B-Chemical +
metabolites O +
in O +
rat O +
liver O +
microsomes O -
. O +

Four O +
new O +
metabolites O +
M-1 O +
[ O -
1,2,18,19-tetradehydro-4-demethyl-3,17-epoxy-7,20 B-Chemical -
( I-Chemical -
2H,19H I-Chemical -
) I-Chemical -
-cyclovobasan I-Chemical -
] O -
, O +
M-2 O +
[ O -
1,2,4,21,18,19-hexadehydro-4-demethyl-3,17-epoxy-7,20 B-Chemical -
( I-Chemical -
2H,19H I-Chemical -
) I-Chemical -
-cyclovobasan I-Chemical -
] O -
, O +
M-3 O +
[ O -
1,2,18,19-tetradehydro-4-demethyl-4-formaldehyde-3,17-epoxy-7,20 B-Chemical -
( I-Chemical -
2H,19H I-Chemical -
) I-Chemical -
-cyclovobasan I-Chemical -
] O -
, O +
and O +
M-4 O +
[ O -
1,2,4,21,18,19-hexadehydro-4-demethyl-4-oxy-3,17-epoxy-7,20 B-Chemical -
( I-Chemical -
2H,19H I-Chemical -
) I-Chemical -
-cyclovobasan I-Chemical -
] O +
were O +
isolated O +
from O +
the O +
chloroform B-Chemical +
extract O +
of O +
koumine B-Chemical +
incubated O +
with O +
phenobarbital B-Chemical -
- O -
treated O +
rat O +
liver O +
microsomes O -
. O +

The O +
structures O +
of O +
M-1 O -
, O +
M-2 O -
, O +
M-3 O -
, O +
and O +
M-4 O +
were O +
elucidated O +
by O +
spectroscopic O +
methods O +
including O +
ESI O -
- O -
TOF O -
- O -
MS O -
, O +
1D O -
, O +
and O +
2D O +
NMR O +
experiments O -
. O +

The O +
metabolic O +
pathway O +
of O +
koumine B-Chemical +
was O +
proposed O -
. O +

The O +
cytotoxic O +
activities O +
between O +
koumine B-Chemical +
and O +
its O +
metabolites O +
were O +
also O +
compared O +
in O +
the O +
A549 O +
cell O +
line O -
. O +

Polymorphism O +
of O +
GeSbTe B-Chemical +
superlattice O +
nanowires O -
. O +

Scaling O -
- O -
down O +
of O +
phase O +
change O +
materials O +
to O +
a O +
nanowire O +
( O -
NW O -
) O +
geometry O +
is O +
critical O +
to O +
a O +
fast O +
switching O +
speed O +
of O +
nonvolatile O +
memory O +
devices O -
. O +

Herein O -
, O +
we O +
report O +
novel O +
composition O -
- O -
phase O -
- O -
tuned O +
GeSbTe B-Chemical +
NWs O -
, O +
synthesized O +
by O +
a O +
chemical O +
vapor O +
transport O +
method O -
, O +
which O +
guarantees O +
promising O +
applications O +
in O +
the O +
field O +
of O +
nanoscale O +
electric O +
devices O -
. O +

As O +
the O +
Sb B-Chemical +
content O +
increased O -
, O +
they O +
showed O +
a O +
distinctive O +
rhombohedral O -
- O -
cubic O -
- O -
rhombohedral O +
phase O +
evolution O -
. O +

Remarkable O +
superlattice O +
structures O +
were O +
identified O +
for O +
the O +
Ge B-Chemical -
( I-Chemical -
8 I-Chemical -
) I-Chemical -
Sb I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Te I-Chemical -
( I-Chemical -
11 I-Chemical -
) I-Chemical -
, O +
Ge B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
Sb I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Te I-Chemical -
( I-Chemical -
6 I-Chemical -
) I-Chemical -
, O +
Ge B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
Sb I-Chemical -
( I-Chemical -
8 I-Chemical -
) I-Chemical -
Te I-Chemical -
( I-Chemical -
6 I-Chemical -
) I-Chemical -
, O +
and O +
Ge B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Sb I-Chemical -
( I-Chemical -
7 I-Chemical -
) I-Chemical -
Te I-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical +
NWs O -
. O +

The O +
coexisting O +
cubic O -
- O -
rhombohedral O +
phase O +
Ge B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
Sb I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Te I-Chemical -
( I-Chemical -
6 I-Chemical -
) I-Chemical +
NWs O +
exhibited O +
an O +
exclusively O +
uniform O +
superlattice O +
structure O +
consisting O +
of O +
2.2 O +
nm O +
period O +
slabs O -
. O +

The O +
rhombohedral O +
phase O +
Ge B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
Sb I-Chemical -
( I-Chemical -
8 I-Chemical -
) I-Chemical -
Te I-Chemical -
( I-Chemical -
6 I-Chemical -
) I-Chemical +
and O +
Ge B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Sb I-Chemical -
( I-Chemical -
7 I-Chemical -
) I-Chemical -
Te I-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical +
NWs O +
adopted O +
an O +
innovative O +
structure O -
; O +
3Sb B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
layers O +
intercalated O +
the O +
Ge B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
Sb I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Te I-Chemical -
( I-Chemical -
6 I-Chemical -
) I-Chemical +
and O +
Ge B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Sb I-Chemical -
( I-Chemical -
1 I-Chemical -
) I-Chemical -
Te I-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical +
domains O -
, O +
respectively O -
, O +
producing O +
3.4 O +
and O +
2.7 O +
nm O +
period O +
slabs O -
. O +

The O +
current O -
- O -
voltage O +
measurement O +
of O +
the O +
individual O +
NW O +
revealed O +
that O +
the O +
vacancy O +
layers O +
of O +
Ge B-Chemical -
( I-Chemical -
8 I-Chemical -
) I-Chemical -
Sb I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Te I-Chemical -
( I-Chemical -
11 I-Chemical -
) I-Chemical +
and O +
Ge B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
Sb I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Te I-Chemical -
( I-Chemical -
6 I-Chemical -
) I-Chemical +
decreased O +
the O +
electrical O +
conductivity O -
. O +

A O +
new O +
flavonoid B-Chemical +
with O +
6-phenyl B-Chemical +
substituent O +
from O +
Selaginella O +
uncinata O -
. O +

A O +
new O +
flavonoid B-Chemical -
, O +
6- B-Chemical -
( I-Chemical -
5-acetyl-2-methoxyphenyl I-Chemical -
) I-Chemical -
-apigenin I-Chemical +
( O -
1 O -
) O -
, O +
together O +
with O +
nine O +
known O +
compounds O +
( O -
2 O -
- O -
10 O -
) O -
, O +
was O +
isolated O +
from O +
Selaginella O +
uncinata O +
( O -
Desv O -
. O -
) O +

Spring O -
. O +

This O +
is O +
the O +
first O +
report O +
of O +
the O +
spectroscopic O +
data O +
of O +
compound O +
3 O -
. O +

Compound O +
2 O +
was O +
first O +
reported O +
from O +
this O +
species O -
. O +

The O +
structure O +
of O +
the O +
new O +
compound O +
was O +
elucidated O +
on O +
the O +
basis O +
of O +
spectroscopic O +
evidence O -
, O +
including O +
1D O +
and O +
2D O +
NMR O +
as O +
well O +
as O +
HR O -
- O -
EI O -
- O -
MS O +
analysis O -
. O +

Controlled O +
assembly O +
and O +
release O +
of O +
retinoic B-Chemical +
acid I-Chemical +
based O +
on O +
the O +
layer O -
- O -
by O -
- O -
layer O +
method O -
. O +

All B-Chemical -
- I-Chemical -
trans I-Chemical +
retinoic I-Chemical +
acid I-Chemical +
( O -
RA O -
) O +
has O +
been O +
proved O +
to O +
play O +
important O +
roles O +
in O +
regulating O +
cell O +
growth O +
in O +
various O +
types O +
of O +
cells O -
. O +

Yet O +
most O +
experiments O +
were O +
performed O +
by O +
adding O +
RA O +
in O +
solution O +
previously O -
. O +

In O +
this O +
Article O -
, O +
we O +
focus O +
on O +
the O +
incorporation O +
of O +
RA O -
, O +
as O +
a O +
negatively O +
charged O +
moiety O -
, O +
into O +
layered O +
polyelectrolyte O +
films O +
on O +
surfaces O +
by O +
means O +
of O +
layer O -
- O -
by O -
- O -
layer O +
( O -
LbL O -
) O +
deposition O -
, O +
followed O +
by O +
adding O +
of O +
capping O +
layers O +
to O +
regulate O +
the O +
release O +
of O +
RA O +
from O +
the O +
films O -
. O +

The O +
incorporated O +
RA O +
was O +
designed O +
to O +
release O +
over O +
5 O +
days O +
in O +
buffer O +
solution O -
. O +

The O +
assembly O +
and O +
release O +
of O +
RA O +
were O +
verified O +
by O +
UV O +
and O +
QCM O +
results O -
. O +

The O +
controlled O +
release O +
of O +
RA O +
from O +
multilayer O +
films O +
can O +
serve O +
as O +
a O +
model O +
system O +
to O +
study O +
the O +
influence O +
of O +
small O +
molecules O +
on O +
cell O +
growth O -
. O +

Phase O +
separation O +
induced O +
by O +
Au B-Chemical +
catalysts O +
in O +
ternary O +
InGaAs B-Chemical +
nanowires O -
. O +

We O +
report O +
a O +
novel O +
phase O +
separation O +
phenomenon O +
observed O +
in O +
the O +
growth O +
of O +
ternary O +
In B-Chemical -
( I-Chemical -
x I-Chemical -
) I-Chemical -
Ga I-Chemical -
( I-Chemical -
1-x I-Chemical -
) I-Chemical -
As I-Chemical +
nanowires O +
by O +
metalorganic O +
chemical O +
vapor O +
deposition O -
. O +

A O +
spontaneous O +
formation O +
of O +
core O -
- O -
shell O +
nanowires O +
is O +
investigated O +
by O +
cross O -
- O -
sectional O +
transmission O +
electron O +
microscopy O -
, O +
revealing O +
the O +
compositional O +
complexity O +
within O +
the O +
ternary O +
nanowires O -
. O +

It O +
has O +
been O +
found O +
that O +
for O +
In B-Chemical -
( I-Chemical -
x I-Chemical -
) I-Chemical -
Ga I-Chemical -
( I-Chemical -
1-x I-Chemical -
) I-Chemical -
As I-Chemical +
nanowires O +
high O +
precursor O +
flow O +
rates O +
generate O +
ternary O +
In B-Chemical -
( I-Chemical -
x I-Chemical -
) I-Chemical -
Ga I-Chemical -
( I-Chemical -
1-x I-Chemical -
) I-Chemical -
As I-Chemical +
cores O +
with O +
In O -
- O -
rich O +
shells O -
, O +
while O +
low O +
precursor O +
flow O +
rates O +
produce O +
binary O +
GaAs B-Chemical +
cores O +
with O +
ternary O +
In B-Chemical -
( I-Chemical -
x I-Chemical -
) I-Chemical -
Ga I-Chemical -
( I-Chemical -
1-x I-Chemical -
) I-Chemical -
As I-Chemical +
shells O -
. O +

First O -
- O -
principle O +
calculations O +
combined O +
with O +
thermodynamic O +
considerations O +
suggest O +
that O +
this O +
phenomenon O +
is O +
due O +
to O +
competitive O +
alloying O +
of O +
different O +
group O -
- O -
III O +
elements O +
with O +
Au B-Chemical +
catalysts O -
, O +
and O +
variations O +
in O +
elemental O +
concentrations O +
of O +
group O -
- O -
III O +
materials O +
in O +
the O +
catalyst O +
under O +
different O +
precursor O +
flow O +
rates O -
. O +

This O +
study O +
shows O +
that O +
precursor O +
flow O +
rates O +
are O +
critical O +
factors O +
for O +
manipulating O +
Au B-Chemical +
catalysts O +
to O +
produce O +
nanowires O +
of O +
desired O +
composition O -
. O +

Synthesis O +
and O +
antibacterial O +
evaluation O +
of O +
typharin B-Chemical +
analog O -
: O +
6,8-dihydroxy-7-methyl-3-styryl-3,4-dihydroisocoumarin B-Chemical -
. O +

Synthesis O +
of O +
the O +
6-hydroxy-7-methyl B-Chemical +
analog O +
of O +
typharin B-Chemical +
( O -
8-dihydroxy-3-styryl-3,4-dihydroisocoumarin B-Chemical -
) O +
isolated O +
from O +
the O +
rhizomes O +
of O +
Typha O +
capensis O +
has O +
been O +
described O -
. O +

Direct O +
condensation O +
of O +
3,5-dimethoxy-4-methylhomophthalic B-Chemical +
acid I-Chemical +
( O -
1 O -
) O +
with O +
cinnamoyl B-Chemical +
chloride I-Chemical +
at O +
elevated O +
temperature O +
under O +
inert O +
conditions O +
afforded O +
6,8-dihydroxy-7-methyl-3-styrylisocoumarin B-Chemical +
( O -
2 O -
) O -
. O +

Hydrolysis O +
of O +
isocoumarin B-Chemical +
to O +
keto B-Chemical +
acid I-Chemical +
( O -
3 O -
) O +
followed O +
by O +
reduction O +
and O +
cyclodehydration O +
of O +
hydroxy B-Chemical +
acid I-Chemical +
analog O +
( O -
4 O -
) O +
afforded O +
( B-Chemical +
± I-Chemical +
) I-Chemical -
-6,8-dimethoxy-3- I-Chemical -
( I-Chemical -
4-methoxyphenyl I-Chemical -
) I-Chemical -
-3,4-dihydroisocoumarin I-Chemical +
( O -
5 O -
) O -
. O +

Demethylation O +
of O +
the O +
latter O +
using O +
anhydrous O +
aluminum B-Chemical +
chloride I-Chemical -
/ O -
ethane B-Chemical +
thiol I-Chemical +
furnished O +
the O +
title O +
isocoumarin B-Chemical +
( O -
6 O -
) O -
. O +

Compounds O +
( O -
1 O -
- O -
6 O -
) O +
were O +
screened O +
for O +
in O +
vitro O +
antibacterial O +
activity O +
against O +
a O +
representative O +
panel O +
of O +
Gram O -
- O -
positive O +
and O +
Gram O -
- O -
negative O +
bacteria O +
using O +
levofloxacin B-Chemical +
as O +
the O +
reference O +
drug O -
. O +

Losmapimod B-Chemical +
concentration O -
- O -
QT O +
relationship O +
in O +
healthy O +
volunteers O -
: O +
meta O -
- O -
analysis O +
of O +
data O +
from O +
six O +
clinical O +
trials O -
. O +

PURPOSE O -
: O +
The O +
objective O +
of O +
this O +
work O +
was O +
to O +
describe O +
the O +
losmapimod B-Chemical +
concentration O -
- O -
QT O +
relationship O +
using O +
meta O -
- O -
analysis O +
of O +
data O +
from O +
clinical O +
trials O +
with O +
healthy O +
volunteers O +
and O +
to O +
evaluate O +
the O +
covariates O +
that O +
have O +
significant O +
impact O +
on O +
the O +
QT O +
prolongation O -
. O +

METHODS O -
: O +
Losmapimod B-Chemical +
plasma O +
concentration O +
and O +
QT O +
interval O +
data O +
were O +
collected O +
from O +
six O +
early O +
clinical O +
studies O +
with O +
healthy O +
volunteers O -
. O +

The O +
electrocardiograms O +
( O -
ECGs O -
) O +
were O +
collected O +
at O +
baseline O +
and O +
at O +
a O +
number O +
of O +
post O -
- O -
dose O +
time O +
points O +
( O -
losmapimod B-Chemical +
or O +
placebo O -
) O -
. O +

The O +
population O +
pharmacokinetic O -
/ O -
pharmacodynamic O +
( O -
PK O -
/ O -
PD O -
) O +
modelling O +
approach O +
was O +
applied O +
to O +
investigate O +
the O +
relationship O +
between O +
losmapimod B-Chemical +
concentration O +
and O +
QT O +
prolongation O -
. O +

RESULTS O -
: O +
The O +
dataset O +
for O +
analysis O +
comprised O +
190 O +
healthy O +
adults O +
who O +
took O +
at O +
least O +
one O +
dose O +
of O +
losmapimod B-Chemical +
or O +
placebo O -
. O +

Of O +
the O +
2,494 O +
QT O +
observations O +
collected O -
, O +
1,532 O +
observations O +
had O +
matched O +
QT O +
and O +
losmapimod B-Chemical +
plasma O +
concentration O +
data O -
. O +

Population O +
PK O -
/ O -
PD O +
analyses O +
indicated O +
that O +
the O +
model O +
with O +
the O +
individual O +
heart O +
rate O +
correction O +
factor O +
( O -
α O -
) O +
fitted O +
the O +
data O +
better O +
than O +
those O +
using O +
fixed O +
α O +
( O -
0.33 O +
for O +
Fridericia O -
's O +
correction O +
or O +
0.5 O +
for O +
Bazett O -
's O +
correction O -
) O +
and O +
that O +
there O +
was O +
no O +
relationship O +
between O +
losmapimod B-Chemical +
concentration O +
and O +
QT O +
interval O -
. O +

Female O +
volunteers O +
had O +
about O +
a O +
3 O +
% O +
higher O +
QT O +
interval O +
at O +
baseline O +
than O +
the O +
male O +
volunteers O -
. O +

No O +
other O +
covariates O +
had O +
a O +
significant O +
effect O +
on O +
the O +
QT O +
interval O -
. O +

CONCLUSIONS O -
: O +
It O +
is O +
appropriate O +
to O +
apply O +
population O +
PK O -
/ O -
PD O +
analysis O +
to O +
investigate O +
the O +
effect O +
of O +
drug O +
concentration O +
on O +
QT O +
prolongation O -
. O +

Our O +
meta O -
- O -
analysis O +
of O +
healthy O +
volunteer O +
data O +
indicated O +
no O +
relationship O +
between O +
systemic O +
losmapimod B-Chemical +
concentration O +
and O +
QT O +
interval O +
in O +
healthy O +
volunteers O -
. O +

Activation O +
of O +
AMP B-Chemical -
- O -
activated O +
Protein O +
Kinase O +
and O +
Phosphorylation O +
of O +
Glycogen O +
Synthase O +
Kinase3 O +
β O +
Mediate O +
Ursolic B-Chemical +
Acid I-Chemical +
Induced O +
Apoptosis O +
in O +
HepG2 O +
Liver O +
Cancer O +
Cells O -
. O +

Despite O +
the O +
antitumour O +
effect O +
of O +
ursolic B-Chemical +
acid I-Chemical +
observed O +
in O +
several O +
cancers O -
, O +
the O +
underlying O +
mechanism O +
remains O +
unclear O -
. O +

Thus O -
, O +
in O +
the O +
present O +
study O -
, O +
the O +
roles O +
of O +
AMP B-Chemical -
- O -
activated O +
protein O +
kinase O +
( O -
AMPK O -
) O +
and O +
glycogen O +
synthase O +
kinase O +
3 O +
beta O +
( O -
GSK3β O -
) O +
were O +
examined O +
in O +
ursolic O +
acid O +
induced O +
apoptosis O +
in O +
HepG2 O +
hepatocellular O +
carcinoma O +
cells O -
. O +

Ursolic B-Chemical +
acid I-Chemical +
significantly O +
exerted O +
cytotoxicity O -
, O +
increased O +
the O +
sub O -
- O -
G1 O +
population O +
and O +
the O +
number O +
of O +
ethidium B-Chemical +
homodimer O +
and O +
terminal O +
deoxynucleotidyl O +
transferase O -
( O -
TdT O -
) O +
mediated O +
dUTP B-Chemical +
nick O +
end O +
labeling O +
positive O +
cells O +
in O +
HepG2 O +
cells O -
. O +

Also O -
, O +
ursolic O +
acid O +
enhanced O +
the O +
cleavages O +
of O +
poly B-Chemical -
- I-Chemical -
ADP I-Chemical -
- I-Chemical -
ribose I-Chemical +
polymerase O +
( O -
PARP O -
) O +
and O +
caspase3 O -
, O +
attenuated O +
the O +
expression O +
of O +
astrocyte O +
elevated O +
gene O +
( O -
AEG1 O -
) O +
and O +
survivin O +
in O +
HepG2 O +
cells O -
. O +

Interestingly O -
, O +
ursolic B-Chemical +
acid I-Chemical +
increased O +
the O +
phosphorylation O +
of O +
AMPK O +
and O +
coenzyme O +
A O +
carboxylase O +
and O +
also O +
enhanced O +
phosphorylation O +
of O +
GSK3β O +
at O +
inactive O +
form O +
serine B-Chemical +
9 O -
, O +
whereas O +
ursolic B-Chemical +
acid I-Chemical +
attenuated O +
the O +
phosphorylation O +
of O +
AKT O +
and O +
mTOR O +
in O +
HepG2 O +
cells O -
. O +

Conversely O -
, O +
AMPK O +
inhibitor O +
compound B-Chemical +
C I-Chemical +
or O +
GSK3β O +
inhibitor O +
SB216763 B-Chemical +
blocked O +
the O +
cleavages O +
of O +
PARP O +
and O +
caspase O +
3 O +
induced O +
by O +
ursolic B-Chemical +
acid I-Chemical +
in O +
HepG2 O +
cells O -
. O +

Furthermore O -
, O +
proteosomal O +
inhibitor O +
MG132 B-Chemical +
suppressed O +
AMPK O +
activation O -
, O +
GSK3β O +
phosphorylation O -
, O +
cleaved O +
PARP O +
and O +
deceased O +
AEG-1 O +
induced O +
by O +
ursolic B-Chemical +
acid I-Chemical +
in O +
HepG2 O +
cells O -
. O +

Overall O -
, O +
our O +
findings O +
suggest O +
that O +
ursolic B-Chemical +
acid I-Chemical +
induced O +
apoptosis O +
in O +
HepG2 O +
cells O +
via O +
AMPK O +
activation O +
and O +
GSK3β O +
phosphorylation O +
as O +
a O +
potent O +
chemopreventive O +
agent O -
. O +

Copyright O +
© O +
2013 O +
John O +
Wiley O +
& O +
Sons O -
, O +
Ltd. O +

A O +
thermoplastic O +
elastomer O +
patch O +
matrix O +
for O +
traditional O +
Chinese O +
medicine O -
: O +
design O +
and O +
evaluation O -
. O +

Abstract O +
Objective O -
: O +
To O +
design O +
and O +
evaluate O +
a O +
novel O +
pressure O +
sensitive O +
adhesive O +
( O -
PSA O -
) O +
patch O +
containing O +
traditional O +
Chinese O +
medicine O +
( O -
TCM O -
) O +
using O +
styrene B-Chemical -
- I-Chemical -
isoprene I-Chemical -
- I-Chemical -
styrene I-Chemical +
( O -
SIS B-Chemical -
) O +
copolymer O -
. O +

Method O -
: O +
A O +
mixture O +
D O -
- O -
optimal O +
design O +
with O +
ternary O +
response O +
surface O +
diagram O +
was O +
employed O +
in O +
the O +
optimization O +
process O -
. O +

The O +
proportions O +
of O +
SIS B-Chemical +
copolymer O -
, O +
tackifying O +
resin O +
and O +
plasticizer O +
were O +
selected O +
as O +
the O +
independent O +
variables O +
while O +
tack O +
force O -
, O +
peel O +
strength O +
of O +
the O +
patch O +
and O +
skin O +
penetrability O +
of O +
methyl B-Chemical +
salicylate I-Chemical +
were O +
selected O +
as O +
the O +
dependent O +
variables O -
. O +

The O +
optimized O +
patch O +
was O +
then O +
evaluated O +
including O +
in O +
vivo O +
absorption O -
, O +
pharmacological O +
activities O +
and O +
skin O +
irritation O -
, O +
by O +
comparing O +
with O +
a O +
commercial O +
patch O +
based O +
on O +
natural O +
rubber O -
. O +

Results O -
: O +
The O +
optimized O +
patch O -
, O +
which O +
comprised O +
30.0 O -
% O +
SIS B-Chemical +
copolymer O -
, O +
26.6 O -
% O +
tackifying O +
resin O +
and O +
43.4 O -
% O +
plasticizer O -
, O +
was O +
superior O +
to O +
commercial O +
patch O +
in O +
skin O +
permeation O -
, O +
pharmacological O +
activities O +
and O +
skin O +
biocompatibility O -
. O +

Conclusion O -
: O +
SIS B-Chemical +
copolymer O +
was O +
a O +
suitable O +
substitute O +
to O +
natural O +
rubber O +
in O +
producing O +
patches O +
containing O +
TCM O +
formula O -
. O +

High O -
- O -
contrast O +
electrooptic O +
modulation O +
of O +
a O +
photonic O +
crystal O +
nanocavity O +
by O +
electrical O +
gating O +
of O +
graphene B-Chemical -
. O +

We O +
demonstrate O +
high O -
- O -
contrast O +
electro O -
- O -
optic O +
modulation O +
of O +
a O +
photonic O +
crystal O +
nanocavity O +
integrated O +
with O +
an O +
electrically O +
gated O +
monolayer O +
graphene B-Chemical -
. O +

A O +
silicon O +
air O -
- O -
slot O +
nanocavity O +
provides O +
strong O +
overlap O +
between O +
the O +
resonant O +
optical O +
field O +
and O +
graphene B-Chemical -
. O +

Tuning O +
the O +
Fermi O +
energy O +
of O +
the O +
graphene B-Chemical +
layer O +
to O +
0.85 O +
eV O +
enables O +
strong O +
control O +
of O +
its O +
optical O +
conductivity O +
at O +
telecom O +
wavelengths O -
, O +
which O +
allows O +
modulation O +
of O +
cavity O +
reflection O +
in O +
excess O +
of O +
10 O +
dB O +
for O +
a O +
swing O +
voltage O +
of O +
only O +
1.5 O +
V. O +
The O +
cavity O +
resonance O +
at O +
1570 O +
nm O +
is O +
found O +
to O +
undergo O +
a O +
shift O +
in O +
wavelength O +
of O +
nearly O +
2 O +
nm O -
, O +
together O +
with O +
a O +
3-fold O +
increase O +
in O +
quality O +
factor O -
. O +

These O +
observations O +
enable O +
a O +
cavity O -
- O -
enhanced O +
determination O +
of O +
graphene B-Chemical -
's O +
complex O +
optical O +
sheet O +
conductivity O +
at O +
different O +
doping O +
levels O -
. O +

Our O +
simple O +
device O +
demonstrates O +
the O +
feasibility O +
of O +
high O -
- O -
contrast O -
, O +
low O -
- O -
power O -
, O +
and O +
frequency O -
- O -
selective O +
electro O -
- O -
optic O +
modulators O +
in O +
graphene B-Chemical -
- O -
integrated O +
silicon B-Chemical +
photonic O +
integrated O +
circuits O -
. O +

Nucleophosmin O +
mutations O +
alter O +
its O +
nucleolar O +
localization O +
by O +
impairing O +
G O -
- O -
quadruplex O +
binding O +
at O +
ribosomal O +
DNA O -
. O +

Nucleophosmin O +
( O -
NPM1 O -
) O +
is O +
an O +
abundant O +
nucleolar O +
protein O +
implicated O +
in O +
ribosome O +
maturation O +
and O +
export O -
, O +
centrosome O +
duplication O +
and O +
response O +
to O +
stress O +
stimuli O -
. O +

NPM1 O +
is O +
the O +
most O +
frequently O +
mutated O +
gene O +
in O +
acute O +
myeloid O +
leukemia O -
. O +

Mutations O +
at O +
the O +
C O -
- O -
terminal O +
domain O +
led O +
to O +
variant O +
proteins O +
that O +
aberrantly O +
and O +
stably O +
translocate O +
to O +
the O +
cytoplasm O -
. O +

We O +
have O +
previously O +
shown O +
that O +
NPM1 O +
C O -
- O -
terminal O +
domain O +
binds O +
with O +
high O +
affinity O +
G O -
- O -
quadruplex O +
DNA O -
. O +

Here O -
, O +
we O +
investigate O +
the O +
structural O +
determinants O +
of O +
NPM1 O +
nucleolar O +
localization O -
. O +

We O +
show O +
that O +
NPM1 O +
interacts O +
with O +
several O +
G O -
- O -
quadruplex O +
regions O +
found O +
in O +
ribosomal O +
DNA O -
, O +
both O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

Furthermore O -
, O +
the O +
most O +
common O +
leukemic O +
NPM1 O +
variant O +
completely O +
loses O +
this O +
activity O -
. O +

This O +
is O +
the O +
consequence O +
of O +
G O -
- O -
quadruplex O -
- O -
binding O +
domain O +
destabilization O -
, O +
as O +
mutations O +
aimed O +
at O +
refolding O +
the O +
leukemic O +
variant O +
also O +
result O +
in O +
rescuing O +
the O +
G O -
- O -
quadruplex O -
- O -
binding O +
activity O +
and O +
nucleolar O +
localization O -
. O +

Finally O -
, O +
we O +
show O +
that O +
treatment O +
of O +
cells O +
with O +
a O +
G O -
- O -
quadruplex O +
selective O +
ligand O +
results O +
in O +
wild O -
- O -
type O +
NPM1 O +
dislocation O +
from O +
nucleoli O +
into O +
nucleoplasm O -
. O +

In O +
conclusion O -
, O +
this O +
work O +
establishes O +
a O +
direct O +
correlation O +
between O +
NPM1 O +
G O -
- O -
quadruplex O +
binding O +
at O +
rDNA O +
and O +
its O +
nucleolar O +
localization O -
, O +
which O +
is O +
impaired O +
in O +
the O +
acute O +
myeloid O +
leukemia O -
- O -
associated O +
protein O +
variants O -
. O +

Novel O +
anticoagulants O +
in O +
the O +
therapy O +
of O +
peripheral O +
arterial O +
and O +
coronary O +
artery O +
disease O -
. O +

Anticoagulant O +
and O +
antiplatelet O +
drugs O +
are O +
used O +
and O +
studied O +
in O +
numerous O +
trials O +
for O +
primary O +
and O +
secondary O +
prevention O +
of O +
atherothrombosis O +
since O +
decades O -
. O +

The O +
annual O +
rate O +
for O +
cardiovascular O +
morbidity O +
and O +
mortality O +
is O +
high O +
in O +
patients O +
following O +
an O +
acute O +
coronary O +
syndrome O +
and O +
in O +
patients O +
with O +
peripheral O +
arterial O +
disease O +
( O -
PAD O -
) O +
due O +
to O +
concomitant O +
cardiac O +
and O +
cerebrovascular O +
diseases O -
. O +

Plaque O +
rupture O +
and O +
subsequent O +
thrombosis O +
involves O +
activation O +
of O +
both O +
platelets O +
and O +
coagulation O +
factors O -
. O +

Therefore O +
the O +
combination O +
of O +
aspirin B-Chemical +
and O +
warfarin B-Chemical +
to O +
improve O +
prevention O +
of O +
atherothrombosis O +
compared O +
to O +
antiplatelet O +
therapy O +
alone O +
was O +
studied O +
but O +
could O +
not O +
be O +
established O +
due O +
to O +
significantly O +
increased O +
risk O +
of O +
major O +
bleeding O +
compared O +
to O +
a O +
nonsignificant O +
reduction O +
in O +
ischemic O +
events O -
. O +

During O +
the O +
past O +
two O +
decades O -
, O +
clinical O +
trials O +
focused O +
on O +
combined O +
antiplatelet O +
therapies O +
for O +
the O +
prevention O +
of O +
secondary O +
events O +
following O +
acute O +
coronary O +
syndromes O +
and O +
very O +
recently O +
on O +
the O +
new O +
oral O +
anticoagulants O +
in O +
combination O +
with O +
antiplatelet O +
therapy O -
. O +

This O +
review O +
discusses O +
the O +
role O +
of O +
the O +
new O +
oral O +
anticoagulants O +
such O +
as O +
Factor O +
IIa O +
( O -
thrombin O -
) O +
and O +
Factor O +
Xa O +
inhibitors O +
in O +
atherothrombosis O -
, O +
their O +
pharmacological O +
properties O +
and O +
recently O +
published O +
clinical O +
data O +
in O +
secondary O +
prevention O +
of O +
atherothrombotic O +
events O +
and O +
potential O +
implications O +
for O +
patients O +
with O +
PAD O -
. O +

Mineralocorticoid O +
receptor O +
antagonists O +
for O +
therapy O +
of O +
coronary O +
artery O +
disease O +
and O +
related O +
complications O -
. O +

The O +
perception O +
of O +
aldosterone B-Chemical +
action O +
to O +
be O +
restricted O +
to O +
regulation O +
of O +
fluid O +
balance O +
via O +
sodium B-Chemical +
reabsorption O +
and O +
potassium B-Chemical +
excretion O +
is O +
incomplete O -
; O +
plenty O +
of O +
experimental O +
and O +
clinical O +
studies O +
have O +
shown O +
that O +
aldosterone B-Chemical +
plays O +
a O +
pivotal O +
role O +
in O +
a O +
variety O +
of O +
( O -
patho- O -
) O +
physiologic O +
conditions O +
within O +
the O +
cardiovascular O +
continuum O -
. O +

Deleterious O +
effects O +
include O +
cardiovascular O +
inflammation O -
, O +
endothelial O +
dysfunction O -
, O +
structural O +
and O +
electrical O +
remodelling O -
. O +

Mineralocorticoid O +
receptor O +
antagonists O +
( O -
MRAs O -
) O -
, O +
such O +
as O +
spironolactone B-Chemical +
and O +
eplerenone B-Chemical -
, O +
prevent O +
some O +
of O +
these O +
maladaptive O +
effects O +
on O +
the O +
cardiovascular O +
system O +
and O +
have O +
proven O +
to O +
be O +
a O +
highly O +
efficacious O +
pharmacological O +
therapy O -
. O +

In O +
this O +
article O +
we O +
review O +
the O +
current O +
clinical O +
impact O +
of O +
MRAs O +
in O +
the O +
treatment O +
of O +
coronary O +
artery O +
disease O +
( O -
CAD O -
) O +
and O +
its O +
related O +
complications O -
, O +
for O +
example O -
, O +
acute O +
myocardial O +
infarction O +
( O -
MI O -
) O +
and O +
chronic O +
heart O +
failure O -
. O +

Cryptotanshinone B-Chemical +
and O +
dihydrotanshinone B-Chemical +
I I-Chemical +
exhibit O +
strong O +
inhibition O +
towards O +
human O +
liver O +
microsome O +
( O -
HLM O -
) O -
-catalyzed O +
propofol B-Chemical +
glucuronidation O -
. O +

Danshen O +
is O +
one O +
of O +
the O +
most O +
famous O +
herbs O +
in O +
the O +
world O -
, O +
and O +
more O +
and O +
more O +
danshen O -
- O -
prescribed O +
drugs O +
interactions O +
have O +
been O +
reported O +
in O +
recent O +
years O -
. O +

Evaluation O +
of O +
inhibition O +
potential O +
of O +
danshen O -
's O +
major O +
ingredients O +
towards O +
UDP B-Chemical -
- O -
glucuronosyltransferases O +
( O -
UGTs O -
) O +
will O +
be O +
helpful O +
for O +
understanding O +
detailed O +
mechanisms O +
for O +
danshen O -
- O -
drugs O +
interaction O -
. O +

Therefore O -
, O +
the O +
aim O +
of O +
the O +
present O +
study O +
is O +
to O +
investigate O +
the O +
inhibitory O +
situation O +
of O +
cryptotanshinone B-Chemical +
and O +
dihydrotanshinone B-Chemical +
I I-Chemical +
towards O +
UGT O +
enzyme O -
- O -
catalyzed O +
propofol B-Chemical +
glucuronidation O -
. O +

In O +
vitro O +
the O +
human O +
liver O +
microsome O +
( O -
HLM O -
) O +
incubation O +
system O +
was O +
used O -
, O +
and O +
the O +
results O +
showed O +
that O +
cryptotanshinone B-Chemical +
and O +
dihydrotanshinone B-Chemical +
I I-Chemical +
exhibited O +
dose O -
- O -
dependent O +
inhibition O +
towards O +
HLM O -
- O -
catalyzed O +
propofol B-Chemical +
glucuronidation O -
. O +

Dixon O +
plot O +
and O +
Lineweaver O -
- O -
Burk O +
plot O +
showed O +
that O +
the O +
inhibition O +
type O +
was O +
best O +
fit O +
to O +
competitive O +
inhibition O +
type O +
for O +
both O +
cryptotanshinone B-Chemical +
and O +
dihydrotanshinone B-Chemical +
I. I-Chemical +
The O +
second O +
plot O +
using O +
the O +
slopes O +
from O +
the O +
Lineweaver O -
- O -
Burk O +
plot O +
versus O +
the O +
concentrations O +
of O +
cryptotanshinone B-Chemical +
or O +
dihydrotanshinone B-Chemical +
I I-Chemical +
was O +
employed O +
to O +
calculate O +
the O +
inhibition O +
parameters O +
( O -
Ki O -
) O +
to O +
be O +
0.4 O +
and O +
1.7μM O -
, O +
respectively O -
. O +

Using O +
the O +
reported O +
maximum O +
plasma O +
concentration O +
( O -
Cmax O -
) O -
, O +
the O +
altered O +
in O +
vivo O +
exposure O +
of O +
propofol B-Chemical +
increased O +
by O +
10 O -
% O +
and O +
8.2 O -
% O +
for O +
the O +
co O -
- O -
administration O +
of O +
dihydrotanshinone B-Chemical +
I I-Chemical +
and O +
cryptotanshinone B-Chemical -
, O +
respectively O -
. O +

All O +
these O +
results O +
indicated O +
the O +
possible O +
danshen O -
- O -
propofol B-Chemical +
interaction O +
due O +
to O +
the O +
inhibition O +
of O +
dihydrotanshinone B-Chemical +
I I-Chemical +
and O +
cryptotanshinone B-Chemical +
towards O +
the O +
glucuronidation O +
reaction O +
of O +
propofol B-Chemical -
. O +

Investigations O +
of O +
dipeptide B-Chemical +
structures O +
containing O +
pyrrolysine B-Chemical +
as O +
N B-Chemical -
- O -
terminal O +
residues O -
: O +
a O +
DFT O +
study O +
in O +
gas O +
and O +
aqueous O +
phase O -
. O +

A O +
set O +
of O +
six O +
dipeptides B-Chemical +
containing O +
pyrrolysine B-Chemical +
invariably O +
at O +
their O +
N O -
- O -
terminal O +
positions O +
is O +
studied O +
in O +
gas O +
and O +
aqueous O +
phase O +
using O +
a O +
polarizable O +
continuum O +
model O +
( O -
PCM O -
) O -
. O +

The O +
molecular O +
geometries O +
of O +
the O +
dipeptides B-Chemical +
are O +
fully O +
optimized O +
at O +
B3LYP O -
/ O -
6 O -
- O -
31++G O -
( O -
d O -
, O -
p O -
) O +
level O +
of O +
theory O +
and O +
a O +
second O +
derivative O +
( O -
frequency O -
) O +
analysis O +
confirms O +
that O +
all O +
the O +
optimized O +
geometries O +
are O +
true O +
minima O -
. O +

The O +
effects O +
of O +
solvation O +
and O +
identity O +
of O +
the O +
varying O +
C O -
- O -
terminal O +
residue O +
on O +
the O +
energetics O -
, O +
structural O +
features O +
of O +
the O +
peptide O +
planes O -
, O +
values O +
of O +
the O +
ψ O +
and O +
ϕ O +
dihedrals O -
, O +
geometry O +
around O +
the O +
α B-Chemical -
- I-Chemical -
carbon I-Chemical +
atoms O +
and O +
theoretically O +
predicted O +
vibrational O +
spectra O +
of O +
the O +
dipeptides B-Chemical +
are O +
thoroughly O +
analyzed O -
. O +

Solvation O +
effects O +
are O +
found O +
to O +
modify O +
the O +
gas O +
phase O +
conformation O +
of O +
the O +
dipeptides B-Chemical +
around O +
ψ O +
dihedrals O +
while O +
the O +
identity O +
of O +
the O +
varying O +
C O -
- O -
terminal O +
residue O +
affect O +
the O +
values O +
of O +
ϕ O -
, O +
planarity O +
of O +
the O +
peptide O +
planes O +
and O +
geometry O +
around O +
the O +
α B-Chemical -
- I-Chemical -
carbon I-Chemical +
atoms O -
. O +

The O +
presence O +
or O +
absence O +
of O +
three O +
types O +
of O +
intramolecular O +
H O -
- O -
bonds O -
, O +
namely O +
O O -
... O -
H B-Chemical -
- I-Chemical -
N I-Chemical -
, O +
N O -
... O -
H B-Chemical -
- I-Chemical -
N I-Chemical +
and O +
O O -
... O -
H B-Chemical -
- I-Chemical -
C I-Chemical +
that O +
leave O +
noticeable O +
signatures O +
in O +
the O +
IR O +
spectra O -
, O +
play O +
crucial O +
roles O +
in O +
influencing O +
the O +
geometry O +
of O +
the O +
peptide O +
planes O +
and O +
in O +
determining O +
the O +
energetics O +
of O +
the O +
dipeptides B-Chemical -
. O +

NMR O +
investigation O +
on O +
the O +
DNA O +
binding O +
and O +
B O -
- O -
Z O +
transition O +
pathway O +
of O +
the O +
Zα O +
domain O +
of O +
human O +
ADAR1 O -
. O +

Human O +
ADAR1 O -
, O +
which O +
has O +
two O +
left O -
- O -
handed O +
Z O -
- O -
DNA O +
binding O +
domains O -
, O +
preferentially O +
binds O +
Z O -
- O -
DNA O +
rather O +
than O +
B O -
- O -
DNA O +
with O +
a O +
high O +
binding O +
affinity O -
. O +

Z O -
- O -
DNA O +
can O +
be O +
induced O +
in O +
long O +
genomic O +
DNA O +
by O +
Z O -
- O -
DNA O +
binding O +
proteins O +
through O +
the O +
formation O +
of O +
two O +
B O -
- O -
Z O +
junctions O +
with O +
the O +
extrusion O +
of O +
one O +
base O +
pair O +
from O +
each O +
junction O -
. O +

We O +
performed O +
NMR O +
experiments O +
on O +
complexes O +
of O +
Zα O -
( O -
ADAR1 O -
) O +
with O +
three O +
DNA O +
duplexes O +
at O +
a O +
variety O +
of O +
protein O -
- O -
to O -
- O -
DNA O +
molar O +
ratios O -
. O +

This O +
study O +
confirmed O +
that O +
the O +
Zα O -
( O -
ADAR1 O -
) O +
first O +
binds O +
to O +
an O +
8-bp O +
CG O -
- O -
rich O +
DNA O +
segment O +
via O +
a O +
unique O +
conformation O +
during O +
B O -
- O -
Z O +
transition O +
and O +
the O +
neighboring O +
AT O -
- O -
rich O +
region O +
becomes O +
destabilized O -
. O +

We O +
also O +
found O +
that O -
, O +
when O +
DNA O +
duplexes O +
have O +
only O +
6-bp O +
CG O -
- O -
rich O +
segment O -
, O +
the O +
interaction O +
with O +
Zα O -
( O -
ADAR1 O -
) O +
did O +
not O +
affect O +
the O +
thermal O +
stabilities O +
of O +
the O +
6-bp O +
CG O -
- O -
rich O +
segment O +
as O +
well O +
as O +
the O +
neighboring O +
two O +
A·T O +
base O +
pairs O -
. O +

These O +
results O +
indicate O +
that O +
four O +
Zα O -
( O -
ADAR1 O -
) O +
proteins O +
interact O +
with O +
the O +
8-bp O +
DNA O +
sequence O +
containing O +
a O +
6-bp O +
CG O -
- O -
repeat O +
segment O +
as O +
well O +
as O +
a O +
dinucleotide O +
step O -
, O +
even O +
though O +
the O +
dinucleotid O +
step O +
contains O +
A∙T O +
base O +
pairs O -
. O +

Thus O +
this O +
study O +
suggests O +
that O +
the O +
length O +
of O +
the O +
CG O -
- O -
rich O +
region O +
is O +
more O +
important O +
than O +
the O +
specific O +
DNA O +
sequence O +
for O +
determining O +
which O +
base O -
- O -
pair O +
is O +
extruded O +
from O +
the O +
B O -
- O -
Z O +
junction O +
structure O -
. O +

This O +
study O +
also O +
found O +
that O +
the O +
Zα O -
( O -
ADAR1 O -
) O +
in O +
complex O +
with O +
a O +
11-bp O +
DNA O +
duplex O +
exhibits O +
a O +
Z O -
- O -
DNA O -
- O -
bound O +
conformation O +
distinct O +
from O +
that O +
of O +
free O +
Zα O -
( O -
ADAR1 O -
) O +
and O +
the O +
initial O +
contact O +
conformations O +
of O +
Zα O -
( O -
ADAR1 O -
) O +
complexed O +
with O +
13-bp O +
DNA O +
duplexes O -
. O +

Room O -
- O -
temperature O +
ferromagnetism O +
in O +
ZnO B-Chemical -
- O -
encapsulated O +
1.9 O +
nm O +
FePt3 B-Chemical +
nanoparticle O -
- O -
composite O +
thin O +
films O +
with O +
giant O +
interfacial O +
anisotropy O -
. O +

As O +
synthesized O +
1.9-nm O +
FePt3 B-Chemical +
nanoparticles O +
are O +
superparamagnetic O +
at O +
room O +
temperature O -
. O +

Coating O +
those O +
nanoparticles O +
with O +
ZnO B-Chemical +
renders O +
them O +
permanently O +
ferromagnetic O +
with O +
coercivity O +
field O +
of O +
650 O +
Oe O +
at O +
room O +
temperature O -
. O +

First O -
- O -
principles O +
calculations O +
indicate O +
that O +
giant O +
interfacial O +
anisotropy O -
, O +
induced O +
by O +
the O +
strong O +
spin O -
- O -
orbit O +
interaction O +
of O +
enhanced O +
orbit O +
momentum O +
of O +
Fe B-Chemical -
, O +
overcomes O +
the O +
superparamagnetic O +
limit O -
, O +
leading O +
to O +
exceptional O +
room O -
- O -
temperature O +
permanent O +
ferromagnetism O -
. O +

The O +
findings O +
are O +
important O +
for O +
the O +
understanding O +
of O +
the O +
origin O +
of O +
permanent O +
ferromagnetism O +
at O +
ultrasmall O +
size O +
and O +
critical O +
for O +
ultrahigh O +
density O +
recording O +
and O +
information O +
processing O -
. O +

ZnO B-Chemical +
is O +
a O +
CO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
-selective O +
steam O +
reforming O +
catalyst O -
. O +

ZnO B-Chemical +
was O +
tested O +
as O +
possible O +
methanol B-Chemical +
and O +
- O +
since O +
formaldehyde B-Chemical +
is O +
one O +
of O +
the O +
key O +
intermediates O +
in O +
methanol B-Chemical +
conversion O +
reactions O +
- O +
also O +
as O +
formaldehyde B-Chemical +
steam O +
reforming O +
catalyst O -
. O +

Catalytic O +
experiments O +
in O +
a O +
batch O +
as O +
well O +
as O +
a O +
flow O +
reactor O +
resulted O +
in O +
highly O +
selective O +
steam O +
reforming O -
, O +
though O +
at O +
low O +
specific O +
activities O -
, O +
of O +
formaldehyde B-Chemical +
and O +
methanol B-Chemical +
over O +
ZnO B-Chemical +
toward O +
CO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
( O -
selectivity O +
of O +
95 O -
- O -
99.6 O -
% O -
) O -
. O +

Comparison O +
of O +
the O +
behavior O +
of O +
ZnPd B-Chemical +
near O -
- O -
surface O +
intermetallic O +
phases O -
, O +
unsupported O +
intermetallic O +
ZnPd B-Chemical +
and O +
supported O +
ZnPd B-Chemical -
/ O -
ZnO B-Chemical +
catalysts O +
reveals O +
that O +
formaldehyde B-Chemical +
is O +
formed O +
from O +
methanol B-Chemical +
in O +
parallel O +
with O +
CO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
on O +
the O +
former O -
, O +
while O +
on O +
unsupported O +
intermetallic O +
ZnPd B-Chemical +
and O +
ZnO B-Chemical -
- O -
supported O +
ZnPd B-Chemical -
, O +
it O +
is O +
efficiently O +
reacted O +
toward O +
CO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
, O +
thus O -
, O +
a O +
beneficial O +
role O +
of O +
ZnO B-Chemical +
in O +
oxidizing O +
formaldehyde B-Chemical -
- O -
derived O +
intermediates O +
toward O +
CO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
is O +
evident O -
. O +

Economic O +
and O +
technological O +
drivers O +
of O +
generic O +
sterile O +
injectable O +
drug O +
shortages O -
. O +

Over O +
the O +
past O +
few O +
years O -
, O +
an O +
increasing O +
number O +
of O +
critically O +
needed O +
medicines O +
have O +
been O +
in O +
short O +
supply O -
. O +

Using O +
economic O +
theory O +
to O +
frame O +
the O +
drug O -
- O -
shortage O +
problem O -
, O +
this O +
paper O +
explores O +
why O +
and O +
how O +
manufacturing O -
- O -
quality O +
problems O +
could O +
combine O +
with O +
other O +
economic O +
and O +
technological O +
factors O +
to O +
result O +
in O +
shortages O +
of O +
generic O +
sterile O +
injectable O +
drugs O -
. O +

The O +
fundamental O +
problem O +
we O +
identify O +
is O +
the O +
inability O +
of O +
the O +
market O +
to O +
observe O +
and O +
reward O +
quality O -
. O +

This O +
lack O +
of O +
reward O +
for O +
quality O +
can O +
reinforce O +
price O +
competition O +
and O +
encourage O +
manufacturers O +
to O +
keep O +
costs O +
down O +
by O +
minimizing O +
quality O +
investments O -
. O +

The O +
US O +
Food O +
and O +
Drug O +
Administration O -
's O +
( O -
FDA O -
's O -
) O +
need O +
to O +
use O +
its O +
regulatory O +
flexibility O -
, O +
on O +
behalf O +
of O +
patients O -
, O +
to O +
avoid O +
shortages O +
of O +
medically O +
necessary O +
drugs O +
may O +
further O +
strengthen O +
the O +
incentive O +
to O +
" O -
push O +
the O +
envelope O -
" O +
on O +
quality O -
. O +

These O +
dynamics O +
may O +
have O +
produced O +
a O +
market O +
situation O +
in O +
which O +
quality O +
problems O +
have O +
become O +
sufficiently O +
common O +
and O +
severe O +
to O +
result O +
in O +
drug O +
shortages O -
. O +

Reversal O +
of O +
diet O -
- O -
induced O +
obesity O +
increases O +
insulin O +
transport O +
into O +
cerebrospinal O +
fluid O +
and O +
restores O +
sensitivity O +
to O +
the O +
anorexic O +
action O +
of O +
central O +
insulin O +
in O +
male O +
rats O -
. O +

Diet O -
- O -
induced O +
obesity O +
( O -
DIO O -
) O +
reduces O +
the O +
ability O +
of O +
centrally O +
administered O +
insulin O +
to O +
reduce O +
feeding O +
behavior O +
and O +
also O +
reduces O +
the O +
transport O +
of O +
insulin O +
from O +
the O +
periphery O +
to O +
the O +
central O +
nervous O +
system O +
( O -
CNS O -
) O -
. O +

The O +
current O +
study O +
was O +
designed O +
to O +
determine O +
whether O +
reversal O +
of O +
high O -
- O -
fat O +
DIO O +
restores O +
the O +
anorexic O +
efficacy O +
of O +
central O +
insulin O +
and O +
whether O +
this O +
is O +
accompanied O +
by O +
restoration O +
of O +
the O +
compromised O +
insulin O +
transport O -
. O +

Adult O +
male O +
Long O -
- O -
Evans O +
rats O +
were O +
initially O +
maintained O +
on O +
either O +
a O +
low O -
- O -
fat O +
chow O +
diet O +
( O -
LFD O -
) O +
or O +
a O +
high O -
- O -
fat O +
diet O +
( O -
HFD O -
) O -
. O +

After O +
22 O +
weeks O -
, O +
half O +
of O +
the O +
animals O +
on O +
the O +
HFD O +
were O +
changed O +
to O +
the O +
LFD O -
, O +
whereas O +
the O +
other O +
half O +
continued O +
on O +
the O +
HFD O +
for O +
an O +
additional O +
8 O +
weeks O -
, O +
such O +
that O +
there O +
were O +
3 O +
groups O -
: O +
1 O -
) O +
a O +
LFD O +
control O +
group O +
( O -
Con O -
; O +
n O +
= O +
18 O -
) O -
, O +
2 O -
) O +
a O +
HFD O -
- O -
fed O -
, O +
DIO O +
group O +
( O -
n O +
= O +
17 O -
) O -
, O +
and O +
3 O -
) O +
a O +
HFD O +
to O +
LFD O -
, O +
DIO O -
- O -
reversal O +
group O +
( O -
DIO O -
- O -
rev O -
; O +
n O +
= O +
18 O -
) O -
. O +

The O +
DIO O +
reversal O +
resulted O +
in O +
a O +
significant O +
reduction O +
of O +
body O +
weight O +
and O +
epididymal O +
fat O +
weight O +
relative O +
to O +
the O +
DIO O +
group O -
. O +

Acute O +
central O +
insulin O +
administration O +
( O -
8 O +
mU O -
) O +
reduced O +
food O +
intake O +
and O +
caused O +
weight O +
loss O +
in O +
Con O +
and O +
DIO O -
- O -
rev O +
but O +
not O +
DIO O +
rats O -
. O +

Fasting O +
cerebrospinal O +
fluid O +
insulin O +
was O +
higher O +
in O +
DIO O +
than O +
Con O +
animals O -
. O +

However O -
, O +
after O +
a O +
peripheral O +
bolus O +
injection O +
of O +
insulin O -
, O +
cerebrospinal O +
fluid O +
insulin O +
increased O +
in O +
Con O +
and O +
DIO O -
- O -
rev O +
rats O +
but O +
not O +
in O +
the O +
DIO O +
group O -
. O +

These O +
data O +
provide O +
support O +
for O +
previous O +
reports O +
that O +
DIO O +
inhibits O +
both O +
the O +
central O +
effects O +
of O +
insulin O +
and O +
insulin O -
's O +
transport O +
to O +
the O +
CNS O -
. O +

Importantly O -
, O +
DIO O -
- O -
rev O +
restored O +
sensitivity O +
to O +
the O +
effects O +
of O +
central O +
insulin O +
on O +
food O +
intake O +
and O +
insulin O +
transport O +
into O +
the O +
CNS O -
. O +

Osteoblasts O +
survive O +
the O +
arsenic B-Chemical +
trioxide I-Chemical +
treatment O +
by O +
activation O +
of O +
ATM O -
- O -
mediated O +
pathway O -
. O +

Arsenic B-Chemical +
trioxide I-Chemical +
( O -
ATO B-Chemical -
) O +
is O +
widely O +
used O +
in O +
tumor O +
treatment O -
, O +
but O +
excessive O +
arsenic B-Chemical +
exposure O +
can O +
have O +
adverse O +
effects O -
. O +

We O +
recently O +
found O +
that O -
, O +
in O +
primary O +
osteoblasts O -
, O +
ATO B-Chemical +
produces O +
oxidative O +
stress O +
and O +
causes O +
DNA O +
tailing O -
, O +
but O +
does O +
not O +
induce O +
apoptosis O -
. O +

We O +
further O +
examined O +
the O +
signaling O +
pathway O +
by O +
which O +
osteoblasts O +
survive O +
ATO B-Chemical +
treatment O -
, O +
and O +
found O +
that O +
they O +
were O +
arrested O +
at O +
G2 O -
/ O -
M O +
phase O +
of O +
the O +
cell O +
cycle O +
at O +
30h O +
and O +
overrode O +
the O +
G2 O -
/ O -
M O +
boundary O +
at O +
48h O -
. O +

After O +
treatment O +
for O +
30h O -
, O +
there O +
was O +
increased O +
Cdc2 O +
phosphorylation O +
and O +
expression O +
of O +
Wee1 O -
, O +
a O +
Cdc2 O +
kinase O -
, O +
and O +
expression O +
of O +
the O +
cell O +
cycle O +
inhibitor O -
, O +
p21 O -
( O -
waf1 O -
/ O -
cip1 O -
) O -
, O +
which O +
interacts O +
with O +
Cdc2 O -
. O +

Furthermore O -
, O +
levels O +
of O +
the O +
phosphatase O +
Cdc25C O -
, O +
which O +
activates O +
Cdc2 O -
, O +
were O +
decreased O -
, O +
while O +
the O +
ratio O +
of O +
its O +
phosphorylated O -
/ O -
inactivated O +
form O +
to O +
the O +
total O +
amount O +
was O +
increased O -
. O +

Moreover O -
, O +
phosphorylation O -
/ O -
activation O +
of O +
the O +
checkpoint O +
kinases O +
Chk1 O -
, O +
Chk2 O +
and O +
p53 O +
levels O +
were O +
increased O -
, O +
as O +
were O +
levels O +
of O +
activated O +
ATM O +
and O +
γ O -
- O -
H2AX O -
. O +

The O +
cell O +
viability O +
was O +
decreased O +
as O +
an O +
ATM O +
inhibitor O +
was O +
added O -
. O +

Additionally O -
, O +
these O +
effects O +
of O +
ATO B-Chemical +
on O +
γ O -
- O -
H2AX O -
, O +
Chk1 O -
, O +
Chk2 O -
, O +
p53 O -
, O +
and O +
p21 O -
( O -
waf1 O -
/ O -
cip1 O -
) O +
were O +
reduced O +
by O +
an O +
ATM O +
inhibitor O -
. O +

These O +
findings O +
suggest O +
that O +
G2 O -
/ O -
M O +
phase O +
arrest O +
of O +
osteoblasts O +
is O +
mediated O +
by O +
Chk1 O -
/ O -
Chk2 O +
activation O +
via O +
an O +
ATM O -
- O -
dependent O +
pathway O +
by O +
which O +
osteoblasts O +
survive O -
. O +

Anti O -
- O -
obesity O +
effects O +
of O +
3-hydroxychromone B-Chemical +
derivative O -
, O +
a O +
novel O +
small O -
- O -
molecule O +
inhibitor O +
of O +
glycogen O +
synthase O +
kinase-3 O -
. O +

Glycogen O +
synthase O +
kinase O +
3 O +
( O -
GSK-3 O -
) O +
plays O +
a O +
central O +
role O +
in O +
cellular O +
energy O +
metabolism O -
, O +
and O +
dysregulation O +
of O +
GSK-3 O +
activity O +
is O +
implicated O +
in O +
a O +
variety O +
of O +
metabolic O +
disorders O -
, O +
including O +
obesity O -
, O +
type O +
2 O +
diabetes O -
, O +
and O +
cancer O -
. O +

Hence O -
, O +
GSK-3 O +
has O +
emerged O +
as O +
an O +
attractive O +
target O +
molecule O +
for O +
the O +
treatment O +
of O +
metabolic O +
disorders O -
. O +

Therefore O -
, O +
this O +
research O +
focused O +
on O +
identification O +
and O +
characterization O +
of O +
a O +
novel O +
small O -
- O -
molecule O +
GSK-3 O +
inhibitor O -
. O +

Compound O +
1a O -
, O +
a O +
structure O +
based O +
on O +
3-hydroxychromone B-Chemical +
bearing O +
isothiazolidine-1,1-dione B-Chemical -
, O +
was O +
identified O +
from O +
chemical O +
library O +
as O +
a O +
highly O +
potent O +
GSK-3 O +
inhibitor O -
. O +

An O +
in O +
vitro O +
kinase O +
assay O +
utilizing O +
a O +
panel O +
of O +
kinases O +
demonstrated O +
that O +
compound O +
1a O +
strongly O +
inhibits O +
GSK-3β O -
. O +

The O +
potential O +
effects O +
of O +
compound O +
1a O +
on O +
the O +
inactivation O +
of O +
GSK-3 O +
were O +
confirmed O +
in O +
human O +
liver O +
HepG2 O +
and O +
human O +
embryonic O +
kidney O +
HEK293 O +
cells O -
. O +

Stabilization O +
of O +
glycogen O +
synthase O +
and O +
β O -
- O -
catenin O -
, O +
which O +
are O +
direct O +
targets O +
of O +
GSK-3 O -
, O +
by O +
compound O +
1a O +
was O +
assessed O +
in O +
comparison O +
with O +
two O +
other O +
GSK-3 O +
inhibitors O -
: O +
LiCl B-Chemical +
and O +
SB-415286 B-Chemical -
. O +

In O +
mouse O +
3T3-L1 O +
preadipocytes O -
, O +
compound O +
1a O +
markedly O +
blocked O +
adipocyte O +
differentiation O -
. O +

Consistently O -
, O +
intraperitoneal O +
administration O +
of O +
compound O +
1a O +
to O +
diet O -
- O -
induced O +
obese O +
mice O +
significantly O +
ameliorated O +
their O +
key O +
symptoms O +
such O +
as O +
body O +
weight O +
gain O -
, O +
increased O +
adiposity O -
, O +
dyslipidemia O -
, O +
and O +
hepatic O +
steatosis O +
due O +
to O +
the O +
marked O +
reduction O +
of O +
whole O -
- O -
body O +
lipid O +
level O -
. O +

In O +
vitro O +
and O +
in O +
vivo O +
effects O +
were O +
accompanied O +
by O +
upregulation O +
of O +
β O -
- O -
catenin O +
stability O +
and O +
downregulation O +
of O +
the O +
expression O +
of O +
several O +
critical O +
genes O +
related O +
to O +
lipid O +
metabolism O -
. O +

From O +
these O +
results O -
, O +
it O +
can O +
be O +
concluded O +
that O +
compound O +
1a O -
, O +
a O +
novel O +
small O -
- O -
molecule O +
inhibitor O +
of O +
GSK-3 O -
, O +
has O +
potential O +
as O +
a O +
new O +
class O +
of O +
therapeutic O +
agent O +
for O +
obesity O +
treatment O -
. O +

Understanding O +
drugs O +
and O +
diseases O +
by O +
systems O +
biology O -
? O +

Systems O +
biology O +
aims O +
to O +
provide O +
a O +
holistic O +
and O +
in O +
many O +
cases O +
dynamic O +
picture O +
of O +
biological O +
function O +
and O +
malfunction O -
, O +
in O +
case O +
of O +
disease O -
. O +

Technology O +
developments O +
in O +
the O +
generation O +
of O +
genome O -
- O -
wide O +
datasets O +
and O +
massive O +
improvements O +
in O +
computer O +
power O +
now O +
allow O +
to O +
obtain O +
new O +
insights O +
into O +
complex O +
biological O +
networks O +
and O +
to O +
copy O +
nature O +
by O +
computing O +
these O +
interactions O +
and O +
their O +
kinetics O +
and O +
by O +
generating O +
in O +
silico O +
models O +
of O +
cells O -
, O +
tissues O +
and O +
organs O -
. O +

The O +
expectations O +
are O +
high O +
that O +
systems O +
biology O +
will O +
pave O +
the O +
way O +
to O +
the O +
identification O +
of O +
novel O +
disease O +
genes O -
, O +
to O +
the O +
selection O +
of O +
successful O +
drug O +
candidates O -
-- O -
that O +
do O +
not O +
fail O +
in O +
clinical O +
studies O +
due O +
to O +
toxicity O +
or O +
lack O +
of O +
human O +
efficacy O -
-- O -
and O +
finally O +
to O +
a O +
more O +
successful O +
discovery O +
of O +
novel O +
therapeutics O -
. O +

However O -
, O +
further O +
research O +
is O +
necessary O +
to O +
fully O +
unleash O +
the O +
potential O +
of O +
systems O +
biology O -
. O +

Within O +
this O +
review O +
we O +
aim O +
to O +
highlight O +
the O +
most O +
important O +
and O +
promising O +
top O -
- O -
down O +
and O +
bottom O -
- O -
up O +
systems O +
biology O +
applications O +
in O +
drug O +
discovery O -
. O +

Polyoxometalate B-Chemical -
- O -
biomolecule O +
conjugates O -
: O +
a O +
new O +
approach O +
to O +
create O +
hybrid O +
drugs O +
for O +
cancer O +
therapeutics O -
. O +

Some O +
polyoxometalate B-Chemical +
( O -
POM B-Chemical -
) O +
clusters O +
have O +
demonstrated O +
attractive O +
anticancer O +
properties O -
. O +

Unfortunately O -
, O +
their O +
cytotoxicity O +
upon O +
normal O +
cell O +
is O +
one O +
of O +
fateful O +
side O +
effects O +
obstructing O +
their O +
further O +
clinic O +
application O +
as O +
inorganic O +
drugs O -
. O +

In O +
this O +
communication O -
, O +
we O +
report O +
a O +
new O +
approach O +
to O +
create O +
hybrid O +
drugs O +
potentially O +
for O +
cancer O +
therapeutics O -
. O +

At O +
first O -
, O +
the O +
POM B-Chemical +
cluster O +
bioconjugates O +
were O +
created O +
by O +
attaching O +
the O +
bioactive O +
ligands O +
on O +
an O +
amine B-Chemical +
grafted O +
POM O +
via O +
simple O +
amidation O +
reaction O -
. O +

The O +
cytotoxicity O +
study O +
with O +
breast O +
cancer O +
cells O +
( O -
MCF-7 O +
and O +
MDA O -
- O -
MB-231 O -
) O +
and O +
non O -
- O -
cancerous O +
breast O +
epithelial O +
cell O +
( O -
MCF-10A O -
) O +
showed O +
that O +
rationally O +
selected O +
ligands O +
with O +
cancer O -
- O -
cell O +
targeting O +
ability O +
on O +
POM B-Chemical -
- O -
biomolecule O +
conjugates O +
can O +
impart O +
enhanced O +
anti O -
- O -
tumor O +
activity O +
and O +
selectivity O -
, O +
thus O +
representing O +
a O +
new O +
concept O +
to O +
develop O +
novel O +
POM B-Chemical -
- O -
biomolecule O +
hybrid O +
drugs O +
with O +
the O +
potential O +
synergistic O +
effect O -
: O +
increased O +
bioactivity O +
and O +
lower O +
side O +
effect O -
. O +

Novel O +
naphthoquinone B-Chemical +
derivatives O -
: O +
synthesis O +
and O +
activity O +
against O +
human O +
African O +
trypanosomiasis O -
. O +

A O +
series O +
of O +
naphthoquinone B-Chemical +
derivatives O +
has O +
been O +
synthesized O +
and O +
tested O +
for O +
its O +
biological O +
activity O +
against O +
human O +
African O +
trypanosomiasis O -
. O +

The O +
use O +
of O +
reverse O +
micellar O +
medium O +
not O +
only O +
enhanced O +
the O +
conversion O +
rate O -
, O +
but O +
also O +
showed O +
selectivity O +
towards O +
mono O -
- O -
coupled O +
product O +
in O +
aryl B-Chemical +
chloride I-Chemical -
- O -
aniline B-Chemical +
coupling O +
reactions O -
. O +

Two O +
derivatives O +
of O +
naphthoquinone B-Chemical +
( O -
9b O +
and O +
9c O -
) O +
exhibited O +
potent O +
activity O +
against O +
Trypanosoma O +
brucei O +
in O +
vitro O +
with O +
low O +
cytotoxicity O -
. O +

Electronic O +
and O +
EPR O +
spectra O +
of O +
the O +
species O +
involved O +
in O +
[ B-Chemical -
W10O32 I-Chemical -
] I-Chemical -
4- I-Chemical +
photocatalysis O -
. O +

A O +
relativistic O +
DFT O +
investigation O -
. O +

The O +
decatungstate O +
anion O +
[ B-Chemical -
W I-Chemical -
( I-Chemical -
10 I-Chemical -
) I-Chemical -
O I-Chemical -
( I-Chemical -
32 I-Chemical -
) I-Chemical -
] I-Chemical -
( I-Chemical -
4- I-Chemical -
) I-Chemical +
is O +
widely O +
used O +
as O +
a O +
photocatalyst O +
in O +
different O +
transformations O -
, O +
during O +
which O +
it O +
undergoes O +
one O -
- O -
electron O +
reduction O +
to O +
[ B-Chemical -
W I-Chemical -
( I-Chemical -
10 I-Chemical -
) I-Chemical -
O I-Chemical -
( I-Chemical -
32 I-Chemical -
) I-Chemical -
] I-Chemical -
( I-Chemical -
5- I-Chemical -
) I-Chemical -
, O +
possibly O +
protonated O -
; O +
the O +
bi O -
- O -
reduced O +
species O +
[ B-Chemical -
W I-Chemical -
( I-Chemical -
10 I-Chemical -
) I-Chemical -
O I-Chemical -
( I-Chemical -
32 I-Chemical -
) I-Chemical -
] I-Chemical -
( I-Chemical -
6- I-Chemical -
) I-Chemical +
is O +
obtained O +
by O +
ensuing O +
disproportionation O -
. O +

Relativistic O +
DFT O +
calculations O +
were O +
used O +
to O +
predict O +
the O +
UV O -
- O -
VIS O +
spectra O +
and O +
EPR O +
parameters O +
of O +
all O +
such O +
species O -
. O +

Local O +
deposition O +
of O +
anisotropic O +
nanoparticles O +
using O +
scanning O +
electrochemical O +
microscopy O +
( O -
SECM O -
) O -
. O +

We O +
demonstrate O +
localized O +
electrodeposition O +
of O +
anisotropic O +
metal O +
nanoobjects O -
, O +
namely O +
Au B-Chemical +
nanorods O +
( O -
GNR O -
) O -
, O +
on O +
indium B-Chemical +
tin I-Chemical +
oxide I-Chemical +
( O -
ITO B-Chemical -
) O +
using O +
scanning O +
electrochemical O +
microscopy O +
( O -
SECM O -
) O -
. O +

A O +
gold O +
microelectrode O +
was O +
the O +
source O +
of O +
the O +
gold O +
ions O +
whereby O +
double O +
pulse O +
chronoamperometry O +
was O +
employed O +
to O +
generate O +
initially O +
Au B-Chemical +
seeds O +
which O +
were O +
further O +
grown O +
under O +
controlled O +
conditions O -
. O +

The O +
distance O +
between O +
the O +
microelectrode O +
and O +
the O +
ITO B-Chemical +
surface O +
as O +
well O +
as O +
the O +
different O +
experimental O +
parameters O +
( O -
electrodeposition O +
regime O -
, O +
solution O +
composition O +
and O +
temperature O -
) O +
were O +
optimized O +
to O +
produce O +
faceted O +
gold O +
seeds O +
with O +
the O +
required O +
characteristics O +
( O -
size O +
and O +
distribution O -
) O -
. O +

Colloidal O +
chemical O +
synthesis O +
was O +
successfully O +
exploited O +
for O +
better O +
understanding O +
the O +
role O +
of O +
the O +
surfactant O +
and O +
different O +
additives O +
in O +
breaking O +
the O +
crystallographic O +
symmetry O +
and O +
anisotropic O +
growth O +
of O +
GNR O -
. O +

Experiments O +
performed O +
in O +
a O +
conventional O +
three O -
- O -
electrode O +
cell O +
revealed O +
the O +
most O +
appropriate O +
electrochemical O +
conditions O +
allowing O +
high O +
yield O +
synthesis O +
of O +
nanorods O +
with O +
well O -
- O -
defined O +
shape O +
as O +
well O +
as O +
nanocubes O +
and O +
bipyramids O -
. O +

Impaired O +
fertility O +
and O +
FSH O +
synthesis O +
in O +
gonadotrope O -
- O -
specific O +
Foxl2 O +
knockout O +
mice O -
. O +

Impairments O +
in O +
pituitary O +
FSH O +
synthesis O +
or O +
action O +
cause O +
infertility O -
. O +

However O -
, O +
causes O +
of O +
FSH O +
dysregulation O +
are O +
poorly O +
described O -
, O +
in O +
part O +
because O +
of O +
our O +
incomplete O +
understanding O +
of O +
mechanisms O +
controlling O +
FSH O +
synthesis O -
. O +

Previously O -
, O +
we O +
discovered O +
a O +
critical O +
role O +
for O +
forkhead O +
protein O +
L2 O +
( O -
FOXL2 O -
) O +
in O +
activin O -
- O -
stimulated O +
FSH O +
β O -
- O -
subunit O +
( O -
Fshb O -
) O +
transcription O +
in O +
immortalized O +
cells O +
in O +
vitro O -
. O +

Here O -
, O +
we O +
tested O +
the O +
hypothesis O +
that O +
FOXL2 O +
is O +
required O +
for O +
FSH O +
synthesis O +
in O +
vivo O -
. O +

Using O +
a O +
Cre O -
/ O -
lox O +
approach O -
, O +
we O +
selectively O +
ablated O +
Foxl2 O +
in O +
murine O +
anterior O +
pituitary O +
gonadotrope O +
cells O -
. O +

Conditional O +
knockout O +
( O -
cKO O -
) O +
mice O +
developed O +
overtly O +
normally O +
but O +
were O +
subfertile O +
in O +
adulthood O -
. O +

Testis O +
size O +
and O +
spermatogenesis O +
were O +
significantly O +
impaired O +
in O +
cKO O +
males O -
. O +

cKO O +
females O +
exhibited O +
reduced O +
ovarian O +
weight O +
and O +
ovulated O +
fewer O +
oocytes O +
in O +
natural O +
estrous O +
cycles O +
compared O +
with O +
controls O -
. O +

In O +
contrast O -
, O +
ovaries O +
of O +
juvenile O +
cKO O +
females O +
showed O +
normal O +
responses O +
to O +
exogenous O +
gonadotropin O +
stimulation O -
. O +

Both O +
male O +
and O +
female O +
cKO O +
mice O +
were O +
FSH O +
deficient O -
, O +
secondary O +
to O +
diminished O +
pituitary O +
Fshb O +
mRNA O +
production O -
. O +

Basal O +
and O +
activin O -
- O -
stimulated O +
Fshb O +
expression O +
was O +
similarly O +
impaired O +
in O +
Foxl2 O +
depleted O +
primary O +
pituitary O +
cultures O -
. O +

Collectively O -
, O +
these O +
data O +
definitively O +
establish O +
FOXL2 O +
as O +
the O +
first O +
identified O +
gonadotrope O -
- O -
restricted O +
transcription O +
factor O +
required O +
for O +
selective O +
FSH O +
synthesis O +
in O +
vivo O -
. O +

The O +
endocrine O +
disrupting O +
chemical O +
tolylfluanid B-Chemical +
alters O +
adipocyte O +
metabolism O +
via O +
glucocorticoid O +
receptor O +
activation O -
. O +

Glucocorticoid O +
signaling O +
plays O +
a O +
critical O +
role O +
in O +
regulating O +
energy O +
metabolism O -
. O +

Emerging O +
data O +
implicate O +
environmental O +
endocrine O -
- O -
disrupting O +
chemicals O +
as O +
contributors O +
to O +
the O +
obesity O +
and O +
diabetes O +
epidemics O -
. O +

Previous O +
studies O +
have O +
shown O +
that O +
the O +
phenylsulfamide B-Chemical +
fungicide O +
tolylfluanid B-Chemical +
( O -
TF O -
) O +
augments O +
glucocorticoid O +
receptor O +
( O -
GR O -
) O -
-dependent O +
luciferase O +
expression O +
in O +
3T3-L1 O +
preadipocytes O +
while O +
modulating O +
insulin O +
action O +
in O +
primary O +
murine O +
and O +
human O +
adipocytes O -
. O +

Studies O +
were O +
performed O +
to O +
interrogate O +
glucocorticoid O +
signaling O +
in O +
primary O +
adipocytes O +
exposed O +
to O +
TF O -
. O +

TF O +
mimicked O +
the O +
gene O +
transcription O +
profile O +
of O +
the O +
murine O +
glucocorticoid O +
corticosterone B-Chemical +
( O -
Cort B-Chemical -
) O -
. O +

Cellular O +
fractionation O +
assays O +
demonstrated O +
that O +
TF O +
treatment O +
promoted O +
the O +
activating O +
serine B-Chemical +
phosphorylation O +
of O +
GR O -
, O +
augmenting O +
its O +
cytoplasmic O -
- O -
to O -
- O -
nuclear O +
translocation O +
as O +
well O +
as O +
its O +
enrichment O +
at O +
glucocorticoid O +
response O +
elements O +
on O +
the O +
glucocorticoid O -
- O -
induced O +
leucine B-Chemical +
zipper O +
gene O +
promoter O -
. O +

After O +
acute O +
treatment O -
, O +
Cort B-Chemical +
or O +
TF O +
promoted O +
insulin O +
receptor O +
substrate-1 O +
( O -
IRS-1 O -
) O +
gene O +
and O +
protein O +
expression O -
. O +

Either O +
treatment O +
also O +
enriched O +
GR O +
binding O +
at O +
an O +
identified O +
glucocorticoid O +
response O +
element O +
in O +
the O +
IRS-1 O +
gene O -
. O +

TF O +
or O +
Cort B-Chemical +
each O +
increased O +
insulin O -
- O -
stimulated O +
lipogenesis O -
, O +
an O +
effect O +
resulting O +
from O +
increased O +
lipogenic O +
gene O +
expression O +
and O +
enhanced O +
insulin O -
- O -
stimulated O +
dephosphorylation O +
of O +
acetyl B-Chemical -
- I-Chemical -
coenzyme I-Chemical +
A I-Chemical +
carboxylase O -
. O +

The O +
augmentation O +
of O +
insulin O -
- O -
stimulated O +
lipogenesis O +
was O +
mediated O +
through O +
a O +
specific O +
enhancement O +
of O +
Akt O +
phosphorylation O +
at O +
T308 O -
. O +

These O +
findings O +
support O +
modulation O +
of O +
IRS-1 O +
levels O +
as O +
a O +
mechanism O +
for O +
glucocorticoid O -
- O -
mediated O +
changes O +
in O +
insulin O +
action O +
in O +
primary O +
adipocytes O -
. O +

Albeit O +
with O +
less O +
affinity O +
than O +
Cort B-Chemical -
, O +
in O +
silico O +
analysis O +
suggests O +
that O +
TF O +
can O +
interact O +
with O +
the O +
ligand O +
binding O +
pocket O +
of O +
GR O -
. O +

Collectively O -
, O +
these O +
studies O +
identify O +
TF O +
as O +
a O +
structurally O +
unique O +
environmental O +
glucocorticoid O -
. O +

Glucocorticoid O +
signaling O +
may O +
thus O +
represent O +
a O +
novel O +
pathway O +
by O +
which O +
environmental O +
toxicants O +
promote O +
the O +
development O +
of O +
metabolic O +
diseases O -
. O +

Perfluoroalkylated O +
compounds O +
induce O +
cell O +
death O +
and O +
formation O +
of O +
reactive O +
oxygen B-Chemical +
species O +
in O +
cultured O +
cerebellar O +
granule O +
cells O -
. O +

The O +
present O +
communication O +
investigates O +
the O +
effects O +
of O +
different O +
perfluoroalkylated O +
compounds O +
( O -
PFCs O -
) O +
on O +
formation O +
of O +
reactive O +
oxygen B-Chemical +
species O +
( O -
ROS O -
) O +
and O +
cell O +
death O +
in O +
cultured O +
cerebellar O +
granule O +
cells O -
. O +

This O +
allows O +
direct O +
comparison O +
with O +
similar O +
effects O +
found O +
for O +
other O +
environmental O +
contaminants O +
like O +
polychlorinated B-Chemical +
biphenyls I-Chemical +
and O +
brominated O +
flame O -
- O -
retardants O -
. O +

The O +
increase O +
in O +
ROS O +
formation O +
and O +
cell O +
death O +
was O +
assayed O +
using O +
the O +
fluorescent O +
probe O +
2,7-dichlorofluorescin B-Chemical +
diacetate I-Chemical +
( O -
DCFH B-Chemical -
- I-Chemical -
DA I-Chemical -
) O +
and O +
the O +
trypan B-Chemical +
blue I-Chemical +
exclusion O +
assay O -
. O +

The O +
effects O +
of O +
the O +
PFCs O +
were O +
structure O +
dependent O -
. O +

Cell O +
death O +
was O +
induced O +
at O +
relatively O +
low O +
concentrations O +
by O +
perfluorooctyl B-Chemical +
sulfonate I-Chemical +
( O -
PFOS B-Chemical -
) O -
, O +
perfluorooctane B-Chemical +
sulfonylamide I-Chemical +
( O -
PFOSA B-Chemical -
) O +
and O +
the O +
fluorotelomer B-Chemical +
alcohol I-Chemical +
1H B-Chemical -
, I-Chemical +
1H I-Chemical -
, I-Chemical +
2H I-Chemical -
, I-Chemical +
2H I-Chemical -
- I-Chemical -
perfluorodecanol I-Chemical +
( O -
FTOH B-Chemical +
8:2 I-Chemical -
) O +
with O +
EC O -
( O -
50 O -
) O -
-values O +
of O +
62 O +
± O +
7.6 O -
, O +
13 O +
± O +
1.8 O +
and O +
15 O +
± O +
4.2 O +
μM O +
( O -
mean O +
± O +
SD O -
) O +
respectively O -
. O +

PFOS B-Chemical -
, O +
perfluorooctanoic B-Chemical +
acid I-Chemical +
( O -
PFOA B-Chemical -
) O +
and O +
PFOSA B-Chemical +
induced O +
a O +
concentration O +
dependent O +
increase O +
in O +
ROS O +
formation O +
with O +
EC O -
( O -
50 O -
) O -
-values O +
of O +
27 O +
± O +
9.0 O -
, O +
25 O +
± O +
11 O +
and O +
57 O +
± O +
19μM O +
respectively O -
. O +

Reduced O +
cell O +
viability O +
and O +
ROS O +
formation O +
were O +
observed O +
at O +
concentration O +
level O +
close O +
to O +
what O +
is O +
found O +
in O +
serum O +
of O +
occupationally O +
exposed O +
workers O -
. O +

The O +
effect O +
of O +
PFCs O +
on O +
ROS O +
formation O +
and O +
cell O +
viability O +
was O +
compared O +
with O +
other O +
halogenated O +
compounds O +
and O +
future O +
investigations O +
should O +
emphasize O +
effects O +
of O +
mixtures O +
and O +
how O +
physical O +
chemical O +
properties O +
of O +
the O +
compounds O +
influence O +
their O +
toxicity O -
. O +

SeDeM O +
expert O +
system O +
a O +
new O +
innovator O +
tool O +
to O +
develop O +
pharmaceutical O +
forms O -
. O +

Abstract O +
Context O -
: O +

The O +
SeDeM O +
expert O +
system O +
is O +
based O +
on O +
the O +
experimental O +
study O +
and O +
quantitative O +
determination O +
of O +
the O +
characterization O +
parameters O +
of O +
powdered O +
substances O -
, O +
the O +
aim O +
being O +
to O +
determine O +
whether O +
a O +
substance O +
is O +
suitable O +
for O +
producing O +
tablets O +
by O +
means O +
of O +
direct O +
compression O +
( O -
DC O -
) O +
technology O -
, O +
thereby O +
reducing O +
the O +
lead O +
time O +
for O +
pre O -
- O -
formulation O +
studies O -
. O +

Additionally O -
, O +
this O +
expert O +
system O +
also O +
provides O +
formulations O +
with O +
a O +
minimum O +
number O +
of O +
excipients O -
. O +

Objective O -
: O +
We O +
used O +
this O +
system O +
to O +
analyze O +
suitable O +
formulas O +
for O +
the O +
production O +
of O +
orodispersible O +
ibuprofen B-Chemical +
tablets O -
. O +

Method O -
: O +
Twenty O -
- O -
one O +
disintegrants O +
and O +
ibuprophen B-Chemical +
were O +
characterized O +
using O +
SeDeM O +
methodology O -
. O +

Results O -
: O +
The O +
results O +
indicated O +
that O +
production O +
of O +
ibuprofen B-Chemical +
tablets O +
by O +
DC O +
would O +
require O +
improvements O +
in O +
the O +
dimension O +
and O +
compressibility O +
factors O +
of O +
the O +
active O +
pharmaceutical O +
ingredient O -
. O +

The O +
expert O +
system O +
analysis O +
provided O +
the O +
specific O +
percentage O +
of O +
disintegrant O +
needed O +
to O +
blend O +
with O +
ibuprofen B-Chemical +
and O +
a O +
standardized O +
formula O +
of O +
lubricants O +
in O +
order O +
to O +
obtain O +
a O +
powder O +
mix O +
that O +
would O +
successfully O +
produce O +
tablets O +
by O +
DC O -
. O +

The O +
eight O +
formulas O +
proposed O +
by O +
SeDeM O +
were O +
produced O +
and O +
tested O +
in O +
the O +
laboratory O -
. O +

Conclusion O -
: O +
All O +
eight O +
formulas O +
successfully O +
produced O +
tablets O +
by O +
DC O -
, O +
but O +
only O +
four O +
of O +
them O +
could O +
be O +
considered O +
suitable O +
for O +
use O +
as O +
an O +
orodispersible O +
tablet O +
and O +
accomplishes O +
all O +
the O +
pharmaceutical O +
quality O +
parameters O -
. O +

So O -
, O +
in O +
fact O -
, O +
the O +
use O +
of O +
the O +
SeDeM O +
system O +
reduced O +
the O +
time O +
of O +
medicine O -
's O +
development O +
and O +
therefore O +
the O +
cost O +
of O +
the O +
activity O -
. O +

Efficient O +
two O -
- O -
electron O +
reduction O +
of O +
dioxygen B-Chemical +
to O +
hydrogen B-Chemical +
peroxide I-Chemical +
with O +
one O -
- O -
electron O +
reductants O +
with O +
a O +
small O +
overpotential O +
catalyzed O +
by O +
a O +
cobalt B-Chemical +
chlorin I-Chemical +
complex O -
. O +

A O +
cobalt B-Chemical +
chlorin I-Chemical +
complex O +
( O -
Co B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical -
( I-Chemical -
Ch I-Chemical -
) I-Chemical -
) O +
efficiently O +
and O +
selectively O +
catalyzed O +
two O -
- O -
electron O +
reduction O +
of O +
dioxygen B-Chemical +
( O -
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
) O +
by O +
one O -
- O -
electron O +
reductants O +
( O -
ferrocene B-Chemical +
derivatives O -
) O +
to O +
produce O +
hydrogen B-Chemical +
peroxide I-Chemical +
( O -
H B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
O I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
) O +
in O +
the O +
presence O +
of O +
perchloric B-Chemical +
acid I-Chemical +
( O -
HClO B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
) O +
in O +
benzonitrile B-Chemical +
( O -
PhCN B-Chemical -
) O +
at O +
298 O +
K. O +
The O +
catalytic O +
reactivity O +
of O +
Co B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical -
( I-Chemical -
Ch I-Chemical -
) I-Chemical +
was O +
much O +
higher O +
than O +
that O +
of O +
a O +
cobalt B-Chemical +
porphyrin I-Chemical +
complex O +
( O -
Co B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical -
( I-Chemical -
OEP I-Chemical -
) I-Chemical -
, O +
OEP B-Chemical -
( I-Chemical -
2- I-Chemical -
) I-Chemical +
= O +
octaethylporphyrin B-Chemical +
dianion O -
) O -
, O +
which O +
is O +
a O +
typical O +
porphyrinoid O +
complex O -
. O +

The O +
two O -
- O -
electron O +
reduction O +
of O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
by O +
1,1'-dibromoferrocene B-Chemical +
( O -
Br B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
Fc I-Chemical -
) O +
was O +
catalyzed O +
by O +
Co B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical -
( I-Chemical -
Ch I-Chemical -
) I-Chemical -
, O +
whereas O +
virtually O +
no O +
reduction O +
of O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
occurred O +
with O +
Co B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical -
( I-Chemical -
OEP I-Chemical -
) I-Chemical -
. O +

In O +
addition O -
, O +
Co B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical -
( I-Chemical -
Ch I-Chemical -
) I-Chemical +
is O +
more O +
stable O +
than O +
Co B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical -
( I-Chemical -
OEP I-Chemical -
) I-Chemical -
, O +
where O +
the O +
catalytic O +
turnover O +
number O +
( O -
TON O -
) O +
of O +
the O +
two O -
- O -
electron O +
reduction O +
of O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
catalyzed O +
by O +
Co B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical -
( I-Chemical -
Ch I-Chemical -
) I-Chemical +
exceeded O +
30000 O -
. O +

The O +
detailed O +
kinetic O +
studies O +
have O +
revealed O +
that O +
the O +
rate O -
- O -
determining O +
step O +
in O +
the O +
catalytic O +
cycle O +
is O +
the O +
proton O -
- O -
coupled O +
electron O +
transfer O +
reduction O +
of O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
with O +
the O +
protonated O +
Co B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical -
( I-Chemical -
Ch I-Chemical -
) I-Chemical +
( O -
[ B-Chemical -
Co I-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical -
( I-Chemical -
ChH I-Chemical -
) I-Chemical -
] I-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical -
) O +
that O +
is O +
produced O +
by O +
facile O +
electron O -
- O -
transfer O +
reduction O +
of O +
[ B-Chemical -
Co I-Chemical -
( I-Chemical -
III I-Chemical -
) I-Chemical -
( I-Chemical -
ChH I-Chemical -
) I-Chemical -
] I-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
by O +
ferrocene B-Chemical +
derivative O +
in O +
the O +
presence O +
of O +
HClO B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
. O +

The O +
one O -
- O -
electron O -
- O -
reduction O +
potential O +
of O +
[ B-Chemical -
Co I-Chemical -
( I-Chemical -
III I-Chemical -
) I-Chemical -
( I-Chemical -
Ch I-Chemical -
) I-Chemical -
] I-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical +
was O +
positively O +
shifted O +
from O +
0.37 O +
V O +
( O -
vs O +
SCE O -
) O +
to O +
0.48 O +
V O +
by O +
the O +
addition O +
of O +
HClO B-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical +
due O +
to O +
the O +
protonation O +
of O +
[ B-Chemical -
Co I-Chemical -
( I-Chemical -
III I-Chemical -
) I-Chemical -
( I-Chemical -
Ch I-Chemical -
) I-Chemical -
] I-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical -
. O +

Such O +
a O +
positive O +
shift O +
of O +
[ B-Chemical -
Co I-Chemical -
( I-Chemical -
III I-Chemical -
) I-Chemical -
( I-Chemical -
Ch I-Chemical -
) I-Chemical -
] I-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical +
by O +
protonation O +
resulted O +
in O +
enhancement O +
of O +
the O +
catalytic O +
reactivity O +
of O +
[ B-Chemical -
Co I-Chemical -
( I-Chemical -
III I-Chemical -
) I-Chemical -
( I-Chemical -
ChH I-Chemical -
) I-Chemical -
] I-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
for O +
the O +
two O -
- O -
electron O +
reduction O +
of O +
O B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
with O +
a O +
lower O +
overpotential O +
as O +
compared O +
with O +
that O +
of O +
[ B-Chemical -
Co I-Chemical -
( I-Chemical -
III I-Chemical -
) I-Chemical -
( I-Chemical -
OEP I-Chemical -
) I-Chemical -
] I-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical -
. O +

Electrocatalytic O +
hydrogenation O +
and O +
deoxygenation O +
of O +
glucose B-Chemical +
on O +
solid O +
metal O +
electrodes O -
. O +

This O +
Full O +
Paper O +
addresses O +
the O +
electrocatalytic O +
hydrogenation O +
of O +
glucose B-Chemical +
to O +
sorbitol B-Chemical +
or O +
2-deoxysorbitol B-Chemical +
on O +
solid O +
metal O +
electrodes O +
in O +
neutral O +
media O -
. O +

Combining O +
voltammetry O +
and O +
online O +
product O +
analysis O +
with O +
high O -
- O -
performance O +
liquid O +
chromatography O +
( O -
HPLC O -
) O -
, O +
provides O +
both O +
qualitative O +
and O +
quantitative O +
information O +
regarding O +
the O +
reaction O +
products O +
as O +
a O +
function O +
of O +
potential O -
. O +

Three O +
groups O +
of O +
catalysts O +
clearly O +
show O +
affinities O +
toward O -
: O +
( O -
1 O -
) O +
hydrogen B-Chemical +
formation O +
[ O -
on O +
early O +
transition B-Chemical +
metals I-Chemical +
( O -
Ti B-Chemical -
, O +
V O -
, O +
Cr B-Chemical -
, O +
Mn B-Chemical -
, O +
Zr B-Chemical -
, O +
Nb B-Chemical -
, O +
Mo B-Chemical -
, O +
Hf B-Chemical -
, O +
Ta B-Chemical -
, O +
We B-Chemical -
, O +
and O +
Re B-Chemical -
) O +
and O +
platinum B-Chemical +
group O +
metals O +
( O -
Ru B-Chemical -
, O +
Rh B-Chemical -
, O +
Ir B-Chemical -
, O +
and O +
Pt B-Chemical -
) O -
] O -
, O +
( O -
2 O -
) O +
sorbitol B-Chemical +
formation O +
[ O -
on O +
late O +
transition B-Chemical +
metals I-Chemical +
( O -
Fe B-Chemical -
, O +
Co B-Chemical -
, O +
Ni B-Chemical -
, O +
Cu B-Chemical -
, O +
Pd B-Chemical -
, O +
Au B-Chemical -
, O +
and O +
Ag B-Chemical -
) O +
and O +
Al B-Chemical +
( O -
sp O +
metal O -
) O -
] O -
, O +
and O +
( O -
3 O -
) O +
sorbitol B-Chemical +
and O +
2-deoxysorbitol B-Chemical +
formation O +
[ O -
on O +
post O -
- O -
transition B-Chemical +
metals I-Chemical +
( O -
In B-Chemical -
, O +
Sn B-Chemical -
, O +
Sb B-Chemical -
, O +
Pb B-Chemical -
, O +
and O +
Bi B-Chemical -
) O -
, O +
as O +
well O +
as O +
Zn B-Chemical +
and O +
Cd B-Chemical +
( O -
d O +
metals O -
) O -
] O -
. O +

Ni B-Chemical +
shows O +
the O +
lowest O +
overpotential O +
for O +
the O +
onset O +
of O +
sorbitol B-Chemical +
formation O +
( O -
-0.25 O +
V O -
) O +
whereas O +
Pb B-Chemical +
generates O +
sorbitol B-Chemical +
with O +
the O +
highest O +
yield O +
( O -
< O -
0.7 O +
mM O +
cm O -
( O -
-2 O -
) O +
) O -
. O +

Different O +
from O +
a O +
smooth O +
Pt B-Chemical +
electrode O -
, O +
a O +
large O -
- O -
surface O -
- O -
area O +
Pt B-Chemical -
/ B-Chemical -
C O +
electrode O +
hydrogenates O +
glucose B-Chemical +
to O +
sorbitol B-Chemical +
from O +
-0.21 O +
V O +
with O +
relatively O +
low O +
current O -
. O +

This O +
emphasizes O +
the O +
importance O +
of O +
the O +
active O +
sites O +
and O +
the O +
surface O +
area O +
of O +
the O +
catalyst O -
. O +

The O +
mechanism O +
to O +
form O +
2-deoxysorbitol B-Chemical +
from O +
glucose B-Chemical +
and/or O +
fructose B-Chemical +
is O +
discussed O +
according O +
to O +
the O +
observed O +
reaction O +
products O -
. O +

The O +
yield O +
and O +
selectivity O +
of O +
hydrogenated O +
products O +
are O +
highly O +
sensitive O +
to O +
the O +
chemical O +
nature O +
and O +
state O +
of O +
the O +
catalyst O +
surface O -
. O +

Characterisation O +
of O +
Nox4 O +
inhibitors O +
from O +
edible O +
plants O -
. O +

NADPH B-Chemical +
oxidases O +
transport O +
electrons O +
from O +
cytosolic O +
NADPH B-Chemical +
through O +
biological O +
membranes O +
to O +
generate O +
reactive O +
oxygen B-Chemical +
species O -
. O +

NADPH B-Chemical +
oxidase O +
4 O -
, O +
broadly O +
expressed O +
in O +
humans O -
, O +
is O +
an O +
interesting O +
pharmacological O +
target O -
, O +
since O +
its O +
activity O +
is O +
deregulated O +
in O +
several O +
diseases O -
, O +
including O +
pulmonary O +
fibrosis O -
, O +
diabetic O +
nephropathy O -
, O +
and O +
cardiac O +
hypertrophy O -
. O +

Whereas O +
several O +
candidate O +
NADPH B-Chemical +
oxidase O +
4 O +
inhibitors O +
were O +
recently O +
described O -
, O +
most O +
of O +
these O +
compounds O +
are O +
either O +
unspecific O +
or O +
toxic O -
. O +

Here O +
we O +
set O +
out O +
to O +
identify O +
new O +
NADPH B-Chemical +
oxidase O +
4 O +
inhibitors O +
from O +
edible O +
plants O -
, O +
in O +
an O +
attempt O +
to O +
decrease O +
the O +
number O +
of O +
hits O +
with O +
toxic O +
side O +
effects O -
. O +

We O +
screened O +
a O +
compound O +
library O +
prepared O +
from O +
edible O +
plants O +
for O +
new O +
bioactives O +
with O +
the O +
ability O +
to O +
inhibit O +
the O +
activity O +
of O +
NADPH B-Chemical +
oxidase O +
4 O -
. O +

Using O +
both O +
cell O -
- O -
based O +
and O +
cell O -
- O -
free O +
assays O -
, O +
we O +
identified O +
several O +
compounds O +
with O +
significant O +
inhibitory O +
activity O +
towards O +
NADPH B-Chemical +
oxidase O +
4 O -
. O +

For O +
selected O +
compounds O -
, O +
the O +
activity O +
profile O +
towards O +
NADPH B-Chemical +
oxidase O +
2 O +
and O +
NADPH B-Chemical +
oxidase O +
5 O +
was O +
established O -
, O +
and O +
controls O +
were O +
carried O +
out O +
to O +
exclude O +
general O +
reactive O +
oxygen B-Chemical +
species O +
scavengers O -
. O +

A O +
number O +
of O +
promising O +
NADPH B-Chemical +
oxidase O +
4 O +
inhibitors O +
from O +
edible O +
plants O +
was O +
identified O +
and O +
characterised O -
. O +

Several O +
new O +
chemical O +
entities O +
are O +
disclosed O +
which O +
act O +
as O +
NADPH B-Chemical +
oxidase O +
4 O +
inhibitors O -
, O +
and O +
the O +
efficacies O +
of O +
our O +
best O +
hits O -
, O +
in O +
particular O +
several O +
diarylheptanoids B-Chemical +
and O +
lignans B-Chemical -
, O +
are O +
comparable O +
to O +
the O +
best O +
available O +
pharmacological O +
NADPH B-Chemical +
oxidase O +
4 O +
inhibitors O -
. O +

These O +
findings O +
will O +
provide O +
valuable O +
tools O +
to O +
study O +
mechanisms O +
of O +
NADPH B-Chemical +
oxidase O +
inhibition O -
. O +

Structural O +
and O +
mechanical O +
heterogeneity O +
of O +
the O +
erythrocyte O +
membrane O +
reveals O +
hallmarks O +
of O +
membrane O +
stability O -
. O +

The O +
erythrocyte O +
membrane O -
, O +
a O +
metabolically O +
regulated O +
active O +
structure O +
that O +
comprises O +
lipid O +
molecules O -
, O +
junctional O +
complexes O -
, O +
and O +
the O +
spectrin O +
network O -
, O +
enables O +
the O +
cell O +
to O +
undergo O +
large O +
passive O +
deformations O +
when O +
passing O +
through O +
the O +
microvascular O +
system O -
. O +

Here O +
we O +
use O +
atomic O +
force O +
microscopy O +
( O -
AFM O -
) O +
imaging O +
and O +
quantitative O +
mechanical O +
mapping O +
at O +
nanometer O +
resolution O +
to O +
correlate O +
structure O +
and O +
mechanics O +
of O +
key O +
components O +
of O +
the O +
erythrocyte O +
membrane O -
, O +
crucial O +
for O +
cell O +
integrity O +
and O +
function O -
. O +

Our O +
data O +
reveal O +
structural O +
and O +
mechanical O +
heterogeneity O +
modulated O +
by O +
the O +
metabolic O +
state O +
at O +
unprecedented O +
nanometer O +
resolution O -
. O +

ATP B-Chemical -
- O -
depletion O -
, O +
reducing O +
skeletal O +
junction O +
phosphorylation O +
in O +
RBC O +
cells O -
, O +
leads O +
to O +
membrane O +
stiffening O -
. O +

Analysis O +
of O +
ghosts O +
and O +
shear O -
- O -
force O +
opened O +
erythrocytes O +
show O +
that O -
, O +
in O +
the O +
absence O +
of O +
cytosolic O +
kinases O -
, O +
spectrin O +
phosphorylation O +
results O +
in O +
membrane O +
stiffening O +
at O +
the O +
extracellular O +
face O +
and O +
a O +
reduced O +
junction O +
remodeling O +
in O +
response O +
to O +
loading O +
forces O -
. O +

Topography O +
and O +
mechanical O +
mapping O +
of O +
single O +
components O +
at O +
the O +
cytoplasmic O +
face O +
reveal O +
that O -
, O +
surprisingly O -
, O +
spectrin O +
phosphorylation O +
by O +
ATP B-Chemical +
softens O +
individual O +
filaments O -
. O +

Our O +
findings O +
suggest O +
that O -
, O +
besides O +
the O +
mechanical O +
signature O +
of O +
each O +
component O -
, O +
the O +
RBC O +
membrane O +
mechanics O +
is O +
regulated O +
by O +
the O +
metabolic O +
state O +
and O +
the O +
assembly O +
of O +
its O +
structural O +
elements O -
. O +

The O +
influence O +
of O +
endocrine O +
disruptors O +
in O +
a O +
selected O +
population O +
of O +
infertile O +
women O -
. O +

Abstract O +
Several O +
studies O +
report O +
that O +
endocrine O +
disrupting O +
chemicals O +
( O -
EDC O -
) O +
able O +
to O +
interfere O +
with O +
endocrine O +
homeostasis O +
may O +
affect O +
women O -
's O +
reproductive O +
health O -
. O +

We O +
analyzed O +
EDC O +
serum O +
levels O +
and O +
nuclear O +
receptors O +
( O -
NRs O -
) O +
expression O +
in O +
order O +
to O +
have O +
an O +
indication O +
of O +
the O +
internal O +
dose O +
of O +
biologically O +
active O +
compounds O +
and O +
a O +
measurement O +
of O +
indicators O +
of O +
their O +
effects O -
, O +
as O +
a O +
result O +
of O +
the O +
repeated O +
uptake O +
from O +
environmental O +
source O -
. O +

The O +
percentage O +
of O +
patients O +
with O +
detectable O +
bisphenol B-Chemical +
A I-Chemical +
( O -
BPA B-Chemical -
) O +
concentrations O +
was O +
significantly O +
higher O +
in O +
the O +
infertile O +
patients O +
compared O +
with O +
fertile O +
subjects O -
. O +

No O +
significant O +
difference O +
was O +
found O +
between O +
the O +
groups O +
with O +
regard O +
to O +
perfluorooctane B-Chemical +
sulfonate I-Chemical +
( O -
PFOS B-Chemical -
) O -
, O +
perfluorooctanoic B-Chemical +
acid I-Chemical +
( O -
PFOA B-Chemical -
) O -
, O +
mono B-Chemical -
- I-Chemical -
ethylhexyl I-Chemical +
phthalate I-Chemical +
( O -
MEHP B-Chemical -
) O +
and O +
di- B-Chemical -
( I-Chemical -
2-ethylhexyl I-Chemical -
) I-Chemical +
phthalate I-Chemical +
( O -
DEHP B-Chemical -
) O +
concentrations O -
. O +

Among O +
infertile O +
women O -
, O +
the O +
mean O +
expression O +
of O +
estrogen B-Chemical +
receptor O +
alpha O +
( O -
ERα O -
) O +
and O +
beta O +
( O -
Erβ O -
) O -
, O +
androgen B-Chemical +
receptor O +
( O -
AR O -
) O +
and O +
pregnane B-Chemical +
X O +
receptor O +
( O -
PXR O -
) O +
was O +
significantly O +
higher O +
than O +
fertile O +
patients O -
. O +

The O +
mean O +
expression O +
of O +
aryl B-Chemical +
hydrocarbon I-Chemical +
receptor O +
( O -
AhR O -
) O +
and O +
peroxisome O +
proliferator O -
- O -
activated O +
receptor O +
gamma O +
( O -
PPARγ O -
) O +
did O +
not O +
show O +
significant O +
differences O +
between O +
two O +
groups O -
. O +

Patients O +
with O +
endometriosis O +
had O +
higher O +
levels O +
of O +
PPARγ O +
than O +
all O +
women O +
with O +
other O +
causes O +
of O +
infertility O -
. O +

This O +
study O +
led O +
further O +
support O +
to O +
EDC O +
exposure O +
as O +
a O +
risk O +
factor O +
for O +
women O -
's O +
fertility O -
. O +

A O +
novel O +
coating O +
concept O +
for O +
ileo O -
- O -
colonic O +
drug O +
targeting O -
: O +
Proof O +
of O +
concept O +
in O +
humans O +
using O +
scintigraphy O -
. O +

The O +
in O +
vivo O +
proof O +
of O +
concept O +
of O +
a O +
novel O +
double O -
- O -
coating O +
system O -
, O +
based O +
on O +
enteric O +
polymers O -
, O +
which O +
accelerated O +
drug O +
release O +
in O +
the O +
ileo O -
- O -
colonic O +
region O -
, O +
was O +
investigated O +
in O +
humans O -
. O +

Prednisolone B-Chemical +
tablets O +
were O +
coated O +
with O +
a O +
double O -
- O -
coating O +
formulation O +
by O +
applying O +
an O +
inner O +
layer O +
composed O +
of O +
EUDRAGIT B-Chemical -
® O +
S O +
neutralised O +
to O +
pH O +
8.0 O +
and O +
a O +
buffer O +
salt O +
( O -
10 O -
% O +
KH B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
PO I-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
) O -
, O +
which O +
was O +
overcoated O +
with O +
layer O +
of O +
standard O +
EUDRAGIT B-Chemical -
® O +
S O +
organic O +
solution O -
. O +

For O +
comparison O -
, O +
a O +
single O +
coating O +
system O +
was O +
produced O +
by O +
applying O +
the O +
same O +
amount O +
of O +
EUDRAGIT B-Chemical -
® O +
S O +
organic O +
solution O +
on O +
the O +
tablet O +
cores O -
. O +

Dissolution O +
tests O +
on O +
the O +
tablets O +
were O +
carried O +
out O +
using O +
USP O +
II O +
apparatus O +
in O +
0.1N O +
HCl B-Chemical +
for O +
2h O +
and O +
subsequently O +
in O +
pH O +
7.4 O +
Krebs O +
bicarbonate O +
buffer O -
. O +

For O +
comparison O -
, O +
tablets O +
were O +
also O +
tested O +
under O +
the O +
USP O +
method O +
established O +
for O +
modified O +
release O +
mesalamine B-Chemical +
formulations O -
. O +

Ten O +
fasted O +
volunteers O +
received O +
the O +
double O -
- O -
coated O +
and O +
single O -
- O -
coated O +
tablets O +
in O +
a O +
two O -
- O -
way O +
crossover O +
study O -
. O +

The O +
formulations O +
were O +
radiolabelled O +
and O +
followed O +
by O +
gamma O +
scintigraphy O -
; O +
the O +
disintegration O +
times O +
and O +
positions O +
were O +
recorded O -
. O +

There O +
was O +
no O +
drug O +
release O +
from O +
the O +
single O -
- O -
coated O +
or O +
double O -
- O -
coated O +
tablets O +
in O +
0.1N O +
HCl B-Chemical +
for O +
2h O -
. O +

The O +
single O -
- O -
coated O +
tablets O +
showed O +
slow O +
release O +
in O +
subsequent O +
Krebs O +
bicarbonate O +
buffer O +
with O +
a O +
lag O +
time O +
of O +
120min O -
, O +
while O +
in O +
contrast O +
drug O +
release O +
from O +
the O +
double O -
- O -
coated O +
tablets O +
was O +
initiated O +
at O +
60min O -
. O +

In O +
contrast O -
, O +
using O +
the O +
USP O +
dissolution O +
method O -
, O +
normally O +
employed O +
for O +
modified O +
release O +
mesalamine B-Chemical +
products O -
, O +
no O +
discrimination O +
was O +
attained O -
. O +

The O +
in O +
vivo O +
disintegration O +
of O +
the O +
single O -
- O -
coated O +
EUDRAGIT B-Chemical -
® O +
S O +
tablets O +
in O +
the O +
large O +
intestine O +
was O +
erratic O -
. O +

Furthermore O -
, O +
in O +
2 O +
volunteers O -
, O +
the O +
single O -
- O -
coated O +
tablet O +
was O +
voided O +
intact O -
. O +

Double O -
- O -
coated O +
tablets O +
disintegrated O +
in O +
a O +
more O +
consistent O +
way O -
, O +
mainly O +
in O +
the O +
ileo O -
- O -
caecal O +
junction O +
or O +
terminal O +
ileum O -
. O +

The O +
accelerated O +
in O +
vivo O +
disintegration O +
of O +
the O +
double O -
- O -
coating O +
EUDRAGIT B-Chemical -
® O +
S O +
system O +
can O +
overcome O +
the O +
limitations O +
of O +
conventional O +
enteric O +
coatings O +
targeting O +
the O +
colon O +
and O +
avoid O +
the O +
pass O -
- O -
through O +
of O +
intact O +
tablets O -
. O +

Moreover O -
, O +
Krebs O +
bicarbonate B-Chemical +
buffer O +
has O +
the O +
ability O +
to O +
discriminate O +
between O +
formulations O +
designed O +
to O +
target O +
the O +
ileo O -
- O -
colonic O +
region O -
. O +

Disruption O +
of O +
the O +
cereblon O +
gene O +
enhances O +
hepatic O +
AMPK O +
activity O +
and O +
prevents O +
high O +
fat O +
diet O -
- O -
induced O +
obesity O +
and O +
insulin O +
resistance O +
in O +
mice O -
. O +

A O +
nonsense O +
mutation O +
in O +
cereblon O +
( O -
CRBN O -
) O +
causes O +
a O +
mild O +
type O +
of O +
mental O +
retardation O +
in O +
humans O -
. O +

An O +
earlier O +
study O +
showed O +
that O +
CRBN O +
negatively O +
regulates O +
the O +
functional O +
activity O +
of O +
AMP B-Chemical -
- O -
activated O +
protein O +
kinase O +
( O -
AMPK O -
) O +
in O +
vitro O +
by O +
binding O +
directly O +
to O +
the O +
α1 O +
subunit O +
of O +
the O +
AMPK O +
complex O -
. O +

However O -
, O +
the O +
in O +
vivo O +
role O +
of O +
CRBN O +
was O +
not O +
studied O -
. O +

To O +
elucidate O +
the O +
physiological O +
functions O +
of O +
Crbn O -
, O +
a O +
mouse O +
strain O +
was O +
generated O +
in O +
which O +
the O +
Crbn O +
gene O +
was O +
deleted O +
throughout O +
the O +
whole O +
body O -
. O +

In O +
Crbn O -
- O -
deficient O +
mice O +
fed O +
a O +
normal O +
diet O -
, O +
AMPK O +
in O +
the O +
liver O +
showed O +
hyper O -
- O -
phosphorylation O -
, O +
which O +
indicated O +
the O +
constitutive O +
activation O +
of O +
AMPK O -
. O +

Since O +
Crbn O -
- O -
deficient O +
mice O +
showed O +
significantly O +
less O +
weight O +
gain O +
when O +
fed O +
a O +
high O +
fat O +
diet O +
and O +
their O +
insulin O +
sensitivity O +
was O +
considerably O +
improved O -
, O +
the O +
functions O +
of O +
Crbn O +
in O +
the O +
liver O +
were O +
primarily O +
investigated O -
. O +

These O +
results O +
provide O +
the O +
first O +
in O +
vivo O +
evidence O +
that O +
Crbn O +
is O +
a O +
negative O +
modulator O +
of O +
AMPK O -
, O +
which O +
suggests O +
that O +
Crbn O +
may O +
be O +
a O +
potential O +
target O +
for O +
metabolic O +
disorders O +
of O +
the O +
liver O -
. O +

β O -
- O -
Cells O +
Are O +
Not O +
Generated O +
in O +
Pancreatic O +
Duct O +
Ligation O -
- O -
Induced O +
Injury O +
in O +
Adult O +
Mice O -
. O +

The O +
existence O +
of O +
adult O +
β O -
- O -
cell O +
progenitors O +
remains O +
the O +
most O +
controversial O +
developmental O +
biology O +
topic O +
in O +
diabetes O +
research O -
. O +

It O +
has O +
been O +
reported O +
that O +
β O -
- O -
cell O +
progenitors O +
can O +
be O +
activated O +
by O +
ductal O +
ligation O -
- O -
induced O +
injury O +
of O +
adult O +
mouse O +
pancreas O +
and O +
apparently O +
act O +
in O +
a O +
cell O -
- O -
autonomous O +
manner O +
to O +
double O +
the O +
functional O +
β O -
- O -
cell O +
mass O +
within O +
a O +
week O +
by O +
differentiation O +
and O +
proliferation O -
. O +

Here O -
, O +
we O +
demonstrate O +
that O +
pancreatic O +
duct O +
ligation O +
( O -
PDL O -
) O +
does O +
not O +
activate O +
progenitors O +
to O +
contribute O +
to O +
β O -
- O -
cell O +
mass O +
expansion O -
. O +

Rather O -
, O +
PDL O +
stimulates O +
massive O +
pancreatic O +
injury O -
, O +
which O +
alters O +
pancreatic O +
composition O +
and O +
thus O +
complicates O +
accurate O +
measurement O +
of O +
β O -
- O -
cell O +
content O +
via O +
traditional O +
morphometry O +
methodologies O +
that O +
superficially O +
sample O +
the O +
pancreas O -
. O +

To O +
overcome O +
this O +
potential O +
bias O -
, O +
we O +
quantified O +
β O -
- O -
cells O +
from O +
the O +
entire O +
pancreas O +
and O +
observed O +
that O +
β O -
- O -
cell O +
mass O +
and O +
insulin O +
content O +
are O +
totally O +
unchanged O +
by O +
PDL O -
- O -
induced O +
injury O -
. O +

Lineage O -
- O -
tracing O +
studies O +
using O +
sequential O +
administration O +
of O +
thymidine B-Chemical +
analogs O -
, O +
rat O +
insulin O +
2 O +
promoter O -
- O -
driven O +
cre O -
- O -
lox O -
, O +
and O +
low O -
- O -
frequency O +
ubiquitous O +
cre O -
- O -
lox O +
reveal O +
that O +
PDL O +
does O +
not O +
convert O +
progenitors O +
to O +
the O +
β O -
- O -
cell O +
lineage O -
. O +

Thus O -
, O +
we O +
conclude O +
that O +
β O -
- O -
cells O +
are O +
not O +
generated O +
in O +
injured O +
adult O +
mouse O +
pancreas O -
. O +

Galectin-3 O +
Deficiency O +
Accelerates O +

High O -
- O -
Fat O +
Diet O +
Induced O +
Obesity O +
and O +
Amplifies O +
Inflammation O +
in O +
Adipose O +
Tissue O +
and O +
Pancreatic O +
Islets O -
. O +

Obesity O -
- O -
induced O +
diabetes O +
is O +
associated O +
with O +
low O -
- O -
grade O +
inflammation O +
in O +
adipose O +
tissue O +
and O +
macrophage O +
infiltration O +
of O +
islets O -
. O +

We O +
show O +
that O +
ablation O +
of O +
Galectin-3 O -
, O +
a O +
galactoside O -
- O -
binding O +
lectin O -
, O +
accelerates O +
high O -
- O -
fat O +
diet O -
- O -
induced O +
obesity O +
and O +
diabetes O -
. O +

Obese O +
LGALS3 O -
( O -
- O -
/ O -
- O -
) O +
mice O +
have O +
increased O +
body O +
weight O -
, O +
amount O +
of O +
total O +
visceral O +
adipose O +
tissue O -
, O +
fasting O +
blood O +
glucose B-Chemical +
and O +
insulin O +
levels O -
, O +
HOMA O -
- O -
IR O +
and O +
markers O +
of O +
systemic O +
inflammation O +
compared O +
to O +
diet O -
- O -
matched O +
WT O +
animals O -
. O +

Obese O +
LGALS3 O -
( O -
- O -
/ O -
- O -
) O +
visceral O +
adipose O +
tissue O +
exhibited O +
increased O +
incidence O +
of O +
Type-1 O +
T O +
and O +
NKT O +
lymphocytes O +
and O +
pro O -
- O -
inflammatory O +
CD11c+CD11b O +
macrophages O +
and O +
decreased O +
CD4+CD25+FoxP3 O -
+ O +
Tregs O +
and O +
M2 O +
macrophages O -
. O +

Pronounced O +
mononuclear O +
cell O +
infiltrate O -
, O +
increased O +
expression O +
of O +
NLRP3 O +
inflammasome O +
and O +
IL-1β O +
in O +
macrophages O +
and O +
increased O +
accumulation O +
of O +
advanced O +
glycation O +
endproducts O +
( O -
AGE O -
) O +
and O +
receptor O +
for O +
AGE O +
( O -
RAGE O -
) O +
expression O +
were O +
present O +
in O +
pancreatic O +
islets O +
of O +
obese O +
LGALS3 O -
( O -
- O -
/ O -
- O -
) O +
animals O +
accompanied O +
with O +
elevated O +
phosphorilated O +
NFκB O +
p65 O +
and O +
mature O +
Caspase-1 O +
protein O +
expression O +
in O +
pancreatic O +
and O +
visceral O +
adipose O +
tissue O -
. O +

In O +
vitro O +
stimulation O +
of O +
LGALS3 O -
( O -
- O -
/ O -
- O -
) O +
peritoneal O +
macrophages O +
with O +
lypopolysaccharide O +
( O -
LPS O -
) O +
and O +
saturated O +
fatty O +
acid O +
palmitate B-Chemical +
caused O +
increased O +
Caspase-1 O +
dependent O +
IL-1β O +
production O +
and O +
increased O +
phosphorilation O +
of O +
NFκB O +
p65 O +
compared O +
to O +
WT O +
cells O -
. O +

Transfection O +
of O +
LGALS3 O -
( O -
- O -
/ O -
- O -
) O +
macrophages O +
with O +
NLRP3 O +
siRNA O +
attenuated O +
IL-1β O +
production O +
in O +
response O +
to O +
palmitate B-Chemical +
and O +
LPS O +
plus O +
palmitate B-Chemical -
. O +

Obtained O +
results O +
suggest O +
important O +
protective O +
roles O +
for O +
Gal-3 O +
in O +
obesity O -
- O -
induced O +
inflammation O +
and O +
diabetes O -
. O +

TSG-6 O +
produced O +
by O +
hMSCs O +
delays O +
the O +
onset O +
of O +
autoimmune O +
diabetes O +
by O +
suppressing O +
Th1 O +
development O +
and O +
enhancing O +
tolerogenicity O -
. O +

Genetic O +
and O +
immunological O +
screening O +
for O +
type O +
1 O +
diabetes O +
has O +
led O +
to O +
the O +
possibility O +
of O +
preventing O +
disease O +
in O +
susceptible O +
individuals O -
. O +

Here O -
, O +
we O +
show O +
that O +
human O +
Mesenchymal O +
Stem O -
/ O -
Stromal O +
Cells O +
( O -
hMSCs O -
) O +
and O +
TNF O -
- O -
α O -
- O -
stimulated O +
gene O +
6 O +
( O -
TSG-6 O -
) O -
, O +
a O +
protein O +
produced O +
by O +
hMSCs O +
in O +
response O +
to O +
signals O +
from O +
injured O +
tissues O -
, O +
delayed O +
the O +
onset O +
of O +
spontaneous O +
autoimmune O +
diabetes O +
in O +
NOD O +
mice O +
by O +
inhibiting O +
insulitis O +
and O +
augmenting O +
regulatory O +
T O +
cells O +
( O -
Tregs O -
) O +
within O +
the O +
pancreas O -
. O +

Importantly O -
, O +
hMSCs O +
with O +
a O +
knockdown O +
of O +
tsg-6 O +
were O +
ineffective O +
at O +
delaying O +
insulitis O +
and O +
the O +
onset O +
of O +
diabetes O +
in O +
mice O -
. O +

TSG-6 O +
inhibited O +
the O +
activation O +
of O +
both O +
T O +
cell O +
and O +
antigen O +
presenting O +
cells O +
( O -
APCs O -
) O +
in O +
a O +
CD44-dependent O +
manner O -
. O +

Moreover O -
, O +
multiple O +
treatments O +
of O +
TSG-6 O +
rendered O +
APCs O +
more O +
tolerogenic O -
, O +
capable O +
of O +
enhancing O +
Treg O +
generation O +
and O +
delaying O +
diabetes O +
in O +
an O +
adoptive O +
transfer O +
model O -
. O +

Therefore O -
, O +
these O +
results O +
could O +
provide O +
the O +
basis O +
for O +
a O +
novel O +
therapy O +
for O +
the O +
prevention O +
of O +
type O +
1 O +
diabetes O -
. O +

The O +
role O +
of O +
GH O +
in O +
adipose O +
tissue O -
: O +
lessons O +
from O +
adipose O -
- O -
specific O +
GH O +
receptor O +
gene O -
- O -
disrupted O +
mice O -
. O +

GH O +
receptor O +
( O -
GHR O -
) O +
gene O -
- O -
disrupted O +
mice O +
( O -
GHR- O -
/ O -
- O -
) O +
have O +
provided O +
countless O +
discoveries O +
as O +
to O +
the O +
numerous O +
actions O +
of O +
GH O -
. O +

Many O +
of O +
these O +
discoveries O +
highlight O +
the O +
importance O +
of O +
GH O +
in O +
adipose O +
tissue O -
. O +

For O +
example O +
GHR- O -
/ O -
- O +
mice O +
are O +
insulin O +
sensitive O +
yet O +
obese O +
with O +
preferential O +
enlargement O +
of O +
the O +
sc O +
adipose O +
depot O -
. O +

GHR- O -
/ O -
- O +
mice O +
also O +
have O +
elevated O +
levels O +
of O +
leptin O -
, O +
resistin O -
, O +
and O +
adiponectin O -
, O +
compared O +
with O +
controls O +
leading O +
some O +
to O +
suggest O +
that O +
GH O +
may O +
negatively O +
regulate O +
certain O +
adipokines O -
. O +

To O +
help O +
clarify O +
the O +
role O +
that O +
GH O +
exerts O +
specifically O +
on O +
adipose O +
tissue O +
in O +
vivo O -
, O +
we O +
selectively O +
disrupted O +
GHR O +
in O +
adipose O +
tissue O +
to O +
produce O +
Fat O +
GHR O +
Knockout O +
( O -
FaGHRKO O -
) O +
mice O -
. O +

Surprisingly O -
, O +
FaGHRKOs O +
shared O +
only O +
a O +
few O +
characteristics O +
with O +
global O +
GHR- O -
/ O -
- O +
mice O -
. O +

Like O +
the O +
GHR- O -
/ O -
- O +
mice O -
, O +
FaGHRKO O +
mice O +
are O +
obese O +
with O +
increased O +
total O +
body O +
fat O +
and O +
increased O +
adipocyte O +
size O -
. O +

However O -
, O +
FaGHRKO O +
mice O +
have O +
increases O +
in O +
all O +
adipose O +
depots O +
with O +
no O +
improvements O +
in O +
measures O +
of O +
glucose B-Chemical +
homeostasis O -
. O +

Furthermore O -
, O +
resistin O +
and O +
adiponectin O +
levels O +
in O +
FaGHRKO O +
mice O +
are O +
similar O +
to O +
controls O +
( O -
or O +
slightly O +
decreased O -
) O +
unlike O +
the O +
increased O +
levels O +
found O +
in O +
GHR- O -
/ O -
- O +
mice O -
, O +
suggesting O +
that O +
GH O +
does O +
not O +
regulate O +
these O +
adipokines O +
directly O +
in O +
adipose O +
tissue O +
in O +
vivo O -
. O +

Other O +
features O +
of O +
FaGHRKO O +
mice O +
include O +
decreased O +
levels O +
of O +
adipsin O -
, O +
a O +
near O -
- O -
normal O +
GH O -
/ O -
IGF-1 O +
axis O -
, O +
and O +
minimal O +
changes O +
to O +
a O +
large O +
assortment O +
of O +
circulating O +
factors O +
that O +
were O +
measured O +
such O +
as O +
IGF O -
- O -
binding O +
proteins O -
. O +

In O +
conclusion O -
, O +
specific O +
removal O +
of O +
GHR O +
in O +
adipose O +
tissue O +
is O +
sufficient O +
to O +
increase O +
adipose O +
tissue O +
and O +
decrease O +
circulating O +
adipsin O -
. O +

However O -
, O +
removal O +
of O +
GHR O +
in O +
adipose O +
tissue O +
alone O +
is O +
not O +
sufficient O +
to O +
increase O +
levels O +
of O +
resistin O +
or O +
adiponectin O +
and O +
does O +
not O +
alter O +
glucose B-Chemical +
metabolism O -
. O +

Mineralocorticoid O +
receptor O -
- O -
mediated O +
vascular O +
insulin O +
resistance O -
: O +
an O +
early O +
contributor O +
to O +
diabetes O -
- O -
related O +
vascular O +
disease O -
? O +

Two O -
- O -
thirds O +
of O +
adults O +
in O +
the O +
U.S. O +
are O +
overweight O +
or O +
obese O -
, O +
and O +
another O +
26 O +
million O +
have O +
type O +
2 O +
diabetes O +
( O -
T2D O -
) O -
. O +

Patients O +
with O +
diabetes O +
and/or O +
the O +
metabolic O +
syndrome O +
have O +
a O +
significantly O +
increased O +
risk O +
of O +
heart O +
attack O +
and O +
stroke O +
compared O +
with O +
people O +
with O +
normal O +
insulin O +
sensitivity O -
. O +

Decreased O +
insulin O +
sensitivity O +
in O +
cardiovascular O +
tissues O +
as O +
well O +
as O +
in O +
traditional O +
targets O +
of O +
insulin O +
metabolic O +
signaling O -
, O +
such O +
as O +
skeletal O +
muscle O -
, O +
is O +
an O +
underlying O +
abnormality O +
in O +
obesity O -
, O +
hypertension O -
, O +
and O +
T2D O -
. O +

In O +
the O +
vasculature O -
, O +
insulin O +
signaling O +
plays O +
a O +
critical O +
role O +
in O +
normal O +
vascular O +
function O +
via O +
endothelial O +
cell O +
nitric B-Chemical +
oxide I-Chemical +
production O +
and O +
modulation O +
of O +
Ca B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
handling O +
and O +
sensitivity O +
in O +
vascular O +
smooth O +
muscle O +
cells O -
. O +

Available O +
evidence O +
suggests O +
that O +
impaired O +
vascular O +
insulin O +
sensitivity O +
may O +
be O +
an O +
early O -
, O +
perhaps O +
principal O -
, O +
defect O +
of O +
vascular O +
function O +
and O +
contributor O +
to O +
the O +
pathogenesis O +
of O +
vascular O +
disease O +
in O +
persons O +
with O +
obesity O -
, O +
hypertension O -
, O +
and O +
T2D O -
. O +

In O +
the O +
overweight O +
and O +
obese O +
individual O -
, O +
as O +
well O +
as O +
in O +
persons O +
with O +
hypertension O -
, O +
systemic O +
and O +
vascular O +
insulin O +
resistance O +
often O +
occur O +
in O +
concert O +
with O +
elevations O +
in O +
plasma O +
aldosterone B-Chemical -
. O +

Indeed O -
, O +
basic O +
and O +
clinical O +
studies O +
have O +
demonstrated O +
that O +
elevated O +
plasma O +
aldosterone B-Chemical +
levels O +
predict O +
the O +
development O +
of O +
insulin O +
resistance O +
and O +
that O +
aldosterone B-Chemical +
directly O +
interferes O +
with O +
insulin O +
signaling O +
in O +
vascular O +
tissues O -
. O +

Furthermore O -
, O +
elevated O +
plasma O +
aldosterone B-Chemical +
levels O +
are O +
associated O +
with O +
increased O +
heart O +
attack O +
and O +
stroke O +
risk O -
. O +

Conversely O -
, O +
renin O -
- O -
angiotensin O -
- O -
aldosterone B-Chemical +
system O +
and O +
mineralocorticoid O +
receptor O +
( O -
MR O -
) O +
antagonism O +
reduces O +
cardiovascular O +
risk O +
in O +
these O +
patient O +
populations O -
. O +

Recent O +
and O +
accumulating O +
evidence O +
in O +
this O +
area O +
has O +
implicated O +
excessive O +
Ser B-Chemical +
phosphorylation O +
and O +
proteosomal O +
degradation O +
of O +
the O +
docking O +
protein O -
, O +
insulin O +
receptor O +
substrate O -
, O +
and O +
enhanced O +
signaling O +
through O +
hybrid O +
insulin O -
/ O -
IGF-1 O +
receptor O +
as O +
important O +
mechanisms O +
underlying O +
aldosterone B-Chemical -
- O -
mediated O +
interruption O +
of O +
downstream O +
vascular O +
insulin O +
signaling O -
. O +

Prevention O +
or O +
restoration O +
of O +
these O +
changes O +
via O +
blockade O +
of O +
aldosterone B-Chemical +
action O +
in O +
the O +
vascular O +
wall O +
with O +
MR O +
antagonists O +
( O -
i.e. O -
, O +
spironolactone B-Chemical -
, O +
eplerenone B-Chemical -
) O +
may O +
therefore O +
account O +
for O +
the O +
clinical O +
benefit O +
of O +
these O +
compounds O +
in O +
obese O +
and O +
diabetic O +
patients O +
with O +
cardiovascular O +
disease O -
. O +

This O +
review O +
will O +
highlight O +
recent O +
evidence O +
supporting O +
the O +
hypothesis O +
that O +
aldosterone B-Chemical +
and O +
MR O +
signaling O +
represent O +
an O +
ideal O +
candidate O +
pathway O +
linking O +
early O +
promoters O +
of O +
diabetes O -
, O +
especially O +
overnutrition O +
and O +
obesity O -
, O +
to O +
vascular O +
insulin O +
resistance O -
, O +
dysfunction O -
, O +
and O +
disease O -
. O +

In O +
vivo O +
microdialysis O +
for O +
the O +
evaluation O +
of O +
transfersomes O +
as O +
a O +
novel O +
transdermal O +
delivery O +
vehicle O +
for O +
cinnamic B-Chemical +
acid I-Chemical -
. O +

Abstract O +
In O +
this O +
study O -
, O +
cinnamic B-Chemical +
acid I-Chemical -
- O -
loaded O +
transfersomes O +
were O +
prepared O +
and O +
dermal O +
microdialysis O +
sampling O +
was O +
used O +
in O +
Sprague O -
- O -
Dawley O +
rats O +
to O +
compare O +
the O +
amount O +
of O +
drug O +
released O +
into O +
the O +
skin O +
using O +
transfersomes O +
as O +
transdermal O +
carriers O +
with O +
that O +
released O +
on O +
using O +
conventional O +
liposomes O -
. O +

The O +
formulation O +
of O +
cinnamic B-Chemical +
acid I-Chemical -
- O -
loaded O +
transfersomes O +
was O +
optimized O +
by O +
a O +
uniform O +
design O +
through O +
in O +
vitro O +
transdermal O +
permeation O +
studies O -
. O +

Hydration O +
time O +
was O +
confirmed O +
as O +
a O +
significant O +
factor O +
influencing O +
the O +
entrapment O +
efficiency O +
of O +
transfersomes O -
, O +
further O +
affecting O +
their O +
transdermal O +
flux O +
in O +
vitro O -
. O +

The O +
fluxes O +
of O +
cinnamic B-Chemical +
acid I-Chemical +
from O +
transfersomes O +
were O +
all O +
higher O +
than O +
those O +
from O +
conventional O +
liposomes O -
, O +
and O +
the O +
flux O +
from O +
the O +
optimal O +
transfersome O +
formulation O +
was O +
3.01-fold O +
higher O +
than O +
that O +
from O +
the O +
conventional O +
liposomes O +
( O -
p O +
< O +
0.05 O -
) O -
. O +

An O +
in O +
vivo O +
microdialysis O +
sampling O +
method O +
revealed O +
that O +
the O +
dermal O +
drug O +
concentrations O +
from O +
transfersomes O +
applied O +
on O +
various O +
skin O +
regions O +
were O +
much O +
lower O +
than O +
those O +
required O +
with O +
conventional O +
liposomes O -
. O +

After O +
the O +
administration O +
of O +
drug O -
- O -
containing O +
transfersomes O +
and O +
liposomes O +
on O +
abdominal O +
skin O +
regions O +
of O +
rats O +
for O +
a O +
period O +
of O +
10 O +
h O -
, O +
the O +
C O -
( O -
max O -
) O +
of O +
cinnamic B-Chemical +
acid I-Chemical +
from O +
the O +
compared O +
liposomes O +
was O +
3.21 O +
± O +
0.25 O +
μg O -
/ O -
mL O +
and O +
that O +
from O +
the O +
transfersomes O +
was O +
merely O +
0.59 O +
± O +
0.02 O +
μg O -
/ O -
mL. O +
The O +
results O +
suggest O +
that O +
transfersomes O +
can O +
be O +
used O +
as O +
carriers O +
to O +
enhance O +
the O +
transdermal O +
delivery O +
of O +
cinnamic B-Chemical +
acid I-Chemical -
, O +
and O +
that O +
these O +
vehicles O +
may O +
penetrate O +
the O +
skin O +
in O +
the O +
complete O +
form O -
, O +
given O +
their O +
significant O +
deformability O -
. O +

Iontophoresis O +
of O +
amoxicillin B-Chemical +
and O +
cefuroxime B-Chemical -
: O +
rapid O +
therapeutic O +
concentrations O +
in O +
skin O -
. O +

Abstract O +
Context O -
: O +
Amoxicillin B-Chemical +
( O -
AMX B-Chemical -
) O +
and O +
cefuroxime B-Chemical +
( O -
CFX B-Chemical -
) O +
are O +
antibiotics O +
used O +
often O +
to O +
treat O +
skin O +
bacterial O +
infections O -
. O +

Typically O -
, O +
high O +
oral O +
doses O +
are O +
required O +
to O +
achieve O +
minimum O +
inhibitory O +
concentration O +
( O -
MIC O -
) O +
at O +
the O +
site O +
of O +
infection O +
that O +
may O +
affect O +
only O +
a O +
very O +
small O +
area O +
of O +
skin O -
. O +

Objectives O -
: O +
To O +
lower O +
side O +
effects O +
and O +
increase O +
therapeutic O +
effectiveness O -
, O +
the O +
percutaneous O +
absorption O +
and O +
retention O +
of O +
AMX B-Chemical +
and O +
CFX B-Chemical +
administered O +
by O +
iontophoresis O +
was O +
investigated O +
in O +
a O +
rabbit O +
model O +
by O +
measuring O +
dermis O +
concentrations O +
via O +
microdialysis O -
. O +

Methods O -
: O +
Iontophoresis O +
was O +
performed O +
using O +
a O +
stainless O +
steel O +
electrode O +
and O +
a O +
non O -
- O -
woven O +
polypropylene B-Chemical +
pad O -
. O +

The O +
cartridge O +
pad O +
was O +
soaked O +
with O +
a O +
solution O +
of O +
AMX B-Chemical +
in O +
glycerin O +
or O +
of O +
CFX B-Chemical +
in O +
glycerin O -
/ O -
water O +
( O -
60:40 O -
) O -
. O +

Constant O +
current O +
density O +
of O +
0 O -
, O +
100 O -
, O +
200 O +
or O +
300 O +
µA O -
/ O -
cm O -
( O -
2 O -
) O +
was O +
applied O +
for O +
60 O +
min O -
. O +

Results O -
: O +
For O +
AMX B-Chemical -
, O +
therapeutically O +
effective O +
skin O +
concentrations O +
were O +
detected O +
immediately O +
after O +
the O +
application O +
of O +
electrical O +
current O +
for O +
any O +
of O +
the O +
current O +
density O +
tested O +
and O +
remained O +
above O +
it O +
for O +
at O +
least O +
2 O +
h O +
from O +
the O +
end O +
of O +
iontophoresis O -
. O +

For O +
CFX B-Chemical -
, O +
skin O +
concentrations O +
rose O +
above O +
MIC O +
only O +
at O +
the O +
higher O +
current O +
densities O +
and O +
fell O +
below O +
the O +
MIC O +
by O +
the O +
end O +
of O +
the O +
experiment O -
. O +

Conclusion O -
: O +

Iontophoresis O +
is O +
a O +
promising O +
method O +
to O +
obtain O +
a O +
fast O +
and O +
sustained O +
concentration O +
of O +
AMX B-Chemical +
and O +
CFX B-Chemical +
in O +
skin O -
. O +

Nano O -
- O -
optomechanical O +
actuator O +
and O +
pull O -
- O -
back O +
instability O -
. O +

This O +
paper O +
studies O +
the O +
nonlinear O +
behavior O +
of O +
a O +
nano O -
- O -
optomechanical O +
actuator O -
, O +
consisting O +
of O +
a O +
free O -
- O -
standing O +
arc O +
in O +
a O +
ring O +
resonator O +
that O +
is O +
coupled O +
to O +
a O +
bus O +
waveguide O +
through O +
evanescent O +
waves O -
. O +

The O +
arc O +
deflects O +
when O +
a O +
control O +
light O +
of O +
a O +
fixed O +
wavelength O +
and O +
optical O +
power O +
is O +
pumped O +
into O +
the O +
bus O +
waveguide O -
, O +
while O +
the O +
amount O +
of O +
deflection O +
is O +
monitored O +
by O +
measuring O +
the O +
transmission O +
spectrum O +
of O +
a O +
broadband O +
probe O +
light O -
. O +

This O +
nanoactuator O +
achieves O +
a O +
maximal O +
deflection O +
of O +
43.1 O +
nm O -
, O +
with O +
a O +
resolution O +
of O +
0.28 O +
nm O -
. O +

The O +
optical O +
force O +
is O +
a O +
nonlinear O +
function O +
of O +
the O +
deflection O +
of O +
the O +
arc O -
, O +
leading O +
to O +
pull O -
- O -
back O +
instability O +
when O +
the O +
control O +
light O +
is O +
red O -
- O -
tuned O -
. O +

This O +
instability O +
is O +
studied O +
by O +
a O +
combination O +
of O +
experiment O +
and O +
modeling O -
. O +

Potential O +
applications O +
of O +
the O +
nanoactuator O +
include O +
bio O -
- O -
nanomotor O -
, O +
optical O +
switches O -
, O +
and O +
optomechanical O +
memories O -
. O +

Increased O +
protein O +
sorption O +
in O +
poly B-Chemical -
( I-Chemical -
acrylic I-Chemical +
acid I-Chemical -
) I-Chemical -
-containing O +
films O +
through O +
incorporation O +
of O +
comb O -
- O -
like O +
polymers O +
and O +
film O +
adsorption O +
at O +
low O +
pH O +
and O +
high O +
ionic O +
strength O -
. O +

In O +
principle O -
, O +
incorporation O +
of O +
comb O -
- O -
like O +
block O +
copolymers O +
in O +
multilayer O +
polyelectrolyte O +
films O +
can O +
both O +
increase O +
film O +
thickness O +
relative O +
to O +
coatings O +
containing O +
linear O +
polymers O +
and O +
provide O +
more O +
swollen O +
films O +
for O +
increased O +
sorption O +
of O +
proteins O -
. O +

In O +
the O +
absence O +
of O +
added O +
salt O -
, O +
alternating O +
adsorption O +
of O +
5 O +
bilayers O +
of O +
protonated O +
poly B-Chemical -
( I-Chemical -
allylamine I-Chemical -
) I-Chemical +
( O -
PAH B-Chemical -
) O +
and O +
comb O -
- O -
like O +
poly B-Chemical -
( I-Chemical -
2-hydroxyethyl I-Chemical +
methacrylate I-Chemical -
) I-Chemical -
-graft I-Chemical -
- I-Chemical -
poly I-Chemical -
( I-Chemical -
acrylic I-Chemical +
acid I-Chemical -
) I-Chemical +
( O -
PHEMA B-Chemical -
- I-Chemical -
g I-Chemical -
- I-Chemical -
PAA I-Chemical -
) O +
leads O +
to O +
∼2-fold O +
thicker O +
coatings O +
than O +
adsorption O +
of O +
PAH B-Chemical +
and O +
linear O +
PAA B-Chemical -
, O +
and O +
the O +
difference O +
in O +
the O +
thicknesses O +
of O +
the O +
two O +
coatings O +
increases O +
with O +
the O +
number O +
of O +
bilayers O -
. O +

Moreover O -
, O +
the O +
( O -
PAH B-Chemical -
/ O -
PHEMA B-Chemical -
- I-Chemical -
g I-Chemical -
- I-Chemical -
PAA I-Chemical -
) O -
n O +
films O +
sorb O +
2- O +
to O +
4-fold O +
more O +
protein O +
than O +
corresponding O +
films O +
prepared O +
with O +
linear O +
PAA B-Chemical -
, O +
and O +
coatings O +
deposited O +
at O +
pH O +
3.0 O +
sorb O +
more O +
protein O +
than O +
coatings O +
adsorbed O +
at O +
pH O +
5.0 O -
, O +
7.0 O -
, O +
or O +
9.0 O -
. O +

In O +
fact O +
changes O +
in O +
deposition O +
pH O +
and O +
addition O +
of O +
0.5 O +
M O +
NaCl B-Chemical +
to O +
polyelectrolyte O +
adsorption O +
solutions O +
alter O +
protein O +
sorption O +
more O +
dramatically O +
than O +
variations O +
in O +
the O +
constituent O +
polymer O +
architecture O -
. O +

When O +
deposited O +
from O +
0.5 O +
M O +
NaCl B-Chemical +
at O +
pH O +
3.0 O -
, O +
both O +
( O -
PAH B-Chemical -
/ O -
PHEMA B-Chemical -
- I-Chemical -
g I-Chemical -
- I-Chemical -
PAA I-Chemical -
) O -
5 O +
and O +
( O -
PAH B-Chemical -
/ O -
PAA B-Chemical -
) O -
5 O +
films O +
increase O +
in O +
thickness O +
more O +
than O +
400 O -
% O +
upon O +
adsorption O +
of O +
lysozyme O -
. O +

These O +
films O +
contain O +
a O +
high O +
concentration O +
of O +
free O +
-COOH O +
groups O -
, O +
and O +
subsequent O +
deprotonation O +
of O +
these O +
groups O +
at O +
neutral O +
pH O +
likely O +
contributes O +
to O +
increased O +
protein O +
binding O -
. O +

Lysozyme O +
sorption O +
stabilizes O +
these O +
films O -
, O +
as O +
without O +
lysozyme O +
films O +
deposited O +
at O +
pH O +
3.0 O +
from O +
0.5 O +
M O +
NaCl B-Chemical +
desorb O +
at O +
neutral O +
pH. O +
Films O +
deposited O +
at O +
pH O +
9.0 O +
from O +
0.5 O +
M O +
NaCl B-Chemical +
are O +
more O +
stable O +
and O +
also O +
bind O +
large O +
amounts O +
of O +
lysozyme O -
. O +

The O +
high O +
binding O +
capacities O +
of O +
these O +
films O +
make O +
them O +
attractive O +
for O +
potential O +
applications O +
in O +
protein O +
isolation O +
or O +
immobilization O +
of O +
enzymes O -
. O +

Labdane B-Chemical +
diterpenoids I-Chemical +
and O +
lignans B-Chemical +
from O +
Calocedrus O +
macrolepis O -
. O +

Three O +
new O +
labdane B-Chemical +
diterpenoids I-Chemical -
, O +
calomacrins B-Chemical +
A I-Chemical -
- I-Chemical -
C I-Chemical +
( O -
1 O -
- O -
3 O -
) O -
, O +
and O +
a O +
new O +
diaryl B-Chemical +
butyrolactone I-Chemical -
- O -
type O +
lignan B-Chemical -
, O +
calomacrol B-Chemical +
A I-Chemical +
( O -
8) O -
, O +
as O +
well O +
as O +
four O +
known O +
labdane B-Chemical +
diterpenoids I-Chemical +
and O +
six O +
known O +
lignans B-Chemical -
, O +
were O +
isolated O +
from O +
the O +
twigs O +
and O +
leaves O +
of O +
Calocedrus O +
macrolepis O -
. O +

Structures O +
of O +
the O +
new O +
compounds O +
were O +
elucidated O +
on O +
the O +
basis O +
of O +
their O +
spectroscopic O +
methods O -
, O +
including O +
1D O +
and O +
2D O +
NMR O +
techniques O -
. O +

Compounds O +
3 O -
- O -
14 O +
were O +
evaluated O +
for O +
cytotoxicity O +
against O +
HL-60 O -
, O +
SMMC-7721 O -
, O +
A-549 O -
, O +
MCF-7 O -
, O +
and O +
SW480 O +
cell O +
lines O -
. O +

Tamoxifen B-Chemical +
magnifies O +
therapeutic O +
impact O +
of O +
ceramide B-Chemical +
in O +
human O +
colorectal O +
cancer O +
cells O +
independent O +
of O +
p53 O -
. O +

Poor O +
prognosis O +
in O +
patients O +
with O +
later O +
stage O +
colorectal O +
cancer O +
( O -
CRC O -
) O +
necessitates O +
the O +
search O +
for O +
new O +
treatment O +
strategies O -
. O +

Ceramide B-Chemical -
, O +
because O +
of O +
its O +
role O +
in O +
orchestrating O +
death O +
cascades O +
in O +
cancer O +
cells O -
, O +
is O +
a O +
versatile O +
alternative O -
. O +

Ceramide B-Chemical +
can O +
be O +
generated O +
by O +
exposure O +
to O +
chemotherapy O +
or O +
ionizing O +
radiation O -
, O +
or O +
it O +
can O +
be O +
administered O +
in O +
the O +
form O +
of O +
short O -
- O -
chain O +
analogs O +
( O -
C6-ceramide B-Chemical -
) O -
. O +

Because O +
intracellular O +
P O -
- O -
glycoprotein O +
( O -
P O -
- O -
gp O -
) O +
plays O +
a O +
role O +
in O +
catalyzing O +
the O +
conversion O +
of O +
ceramide B-Chemical +
to O +
higher O +
sphingolipids B-Chemical -
, O +
we O +
hypothesized O +
that O +
administration O +
of O +
P O -
- O -
gp O +
antagonists O +
with O +
C6-ceramide B-Chemical +
would O +
magnify O +
cell O +
death O +
cascades O -
. O +

Human O +
CRC O +
cell O +
lines O +
were O +
employed O -
, O +
HCT-15 O -
, O +
HT-29 O -
, O +
and O +
LoVo O -
. O +

The O +
addition O +
of O +
either O +
tamoxifen B-Chemical -
, O +
VX-710 B-Chemical -
, O +
verapamil B-Chemical -
, O +
or O +
cyclosporin B-Chemical +
A I-Chemical -
, O +
antagonists O +
of O +
P O -
- O -
gp O -
, O +
enhanced O +
C6-ceramide B-Chemical +
cytotoxicity O +
in O +
all O +
cell O +
lines O -
. O +

In O +
depth O +
studies O +
with O +
C6-ceramide B-Chemical +
and O +
tamoxifen B-Chemical +
in O +
LoVo O +
cells O +
showed O +
the O +
regimen O +
induced O +
PARP O +
cleavage O -
, O +
caspase O -
- O -
dependent O +
apoptosis O -
, O +
mitochondrial O +
membrane O +
permeabilization O +
( O -
MMP O -
) O -
, O +
and O +
cell O +
cycle O +
arrest O +
at O +
G1 O +
and O +
G2 O -
. O +

At O +
the O +
molecular O +
level O -
, O +
the O +
regimen O -
, O +
but O +
not O +
single O +
agents O -
, O +
induced O +
time O -
- O -
dependent O +
upregulation O +
of O +
tumor O +
suppressor O +
protein O +
p53 O -
; O +
however O -
, O +
introduction O +
of O +
a O +
p53 O +
inhibitor O +
staved O +
neither O +
MMP O +
nor O +
apoptosis O -
. O +

Nanoliposomal O +
formulations O +
of O +
C6-ceramide B-Chemical +
and O +
tamoxifen B-Chemical +
were O +
also O +
effective O -
, O +
yielding O +
synergistic O +
cell O +
kill O -
. O +

We O +
conclude O +
that O +
tamoxifen B-Chemical +
is O +
a O +
favorable O +
adjuvant O +
for O +
enhancing O +
C6-ceramide B-Chemical +
cytotoxicity O +
in O +
CRC O -
, O +
and O +
demonstrates O +
uniquely O +
integrated O +
effects O -
. O +

The O +
high O +
frequency O +
of O +
expression O +
of O +
P O -
- O -
gp O +
in O +
CRC O +
presents O +
an O +
adventitious O +
target O +
for O +
complementing O +
ceramide B-Chemical -
- O -
based O +
therapies O -
, O +
a O +
strategy O +
that O +
could O +
hold O +
promise O +
for O +
treatment O +
of O +
resistant O +
disease O -
. O +

Involvement O +
of O +
Src O +
and O +
the O +
actin O +
cytoskeleton O +
in O +
the O +
antitumorigenic O +
action O +
of O +
adenosine B-Chemical +
dialdehyde I-Chemical -
. O +

Transmethylation O +
is O +
an O +
important O +
reaction O +
that O +
transfers O +
a O +
methyl B-Chemical +
group O +
in O +
S B-Chemical -
- I-Chemical -
adenosylmethionine I-Chemical +
( O -
SAM B-Chemical -
) O +
to O +
substrates O +
such O +
as O +
DNA O -
, O +
RNA O -
, O +
and O +
proteins O -
. O +

It O +
is O +
known O +
that O +
transmethylation O +
plays O +
critical O +
roles O +
in O +
various O +
cellular O +
responses O -
. O +

In O +
this O +
study O -
, O +
we O +
examined O +
the O +
effects O +
of O +
transmethylation O +
on O +
tumorigenic O +
responses O +
and O +
its O +
regulatory O +
mechanism O +
using O +
an O +
upregulation O +
strategy O +
of O +
adenosylhomocysteine B-Chemical +
( O -
SAH B-Chemical -
) O +
acting O +
as O +
a O +
negative O +
feedback O +
inhibitor O -
. O +

Treatment O +
with O +
adenosine B-Chemical +
dialdehyde I-Chemical +
( O -
AdOx B-Chemical -
) O -
, O +
an O +
inhibitor O +
of O +
transmethylation O -
- O -
suppressive O +
adenosylhomocysteine B-Chemical +
( O -
SAH B-Chemical -
) O +
hydrolase O +
( O -
SAHH O -
) O -
, O +
enhanced O +
the O +
level O +
of O +
SAH B-Chemical +
and O +
effectively O +
blocked O +
the O +
proliferation O -
, O +
migration O -
, O +
and O +
invasion O +
of O +
cancer O +
cells O -
; O +
the O +
treatment O +
also O +
induced O +
the O +
differentiation O +
of O +
C6 O +
glioma O +
cells O +
and O +
suppressed O +
the O +
neovascular O +
genesis O +
of O +
eggs O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O +

Through O +
immunoblotting O +
analysis O -
, O +
it O +
was O +
found O +
that O +
AdOx B-Chemical +
was O +
capable O +
of O +
indirectly O +
diminishing O +
the O +
phosphorylation O +
of O +
oncogenic O +
Src O +
and O +
its O +
kinase O +
activity O -
. O +

Interestingly O -
, O +
AdOx B-Chemical +
disrupted O +
actin O +
cytoskeleton O +
structures O -
, O +
leading O +
to O +
morphological O +
changes O -
, O +
and O +
suppressed O +
the O +
formation O +
of O +
a O +
signaling O +
complex O +
composed O +
of O +
Src O +
and O +
p85 O -
/ O -
PI3 O -
K O -
, O +
which O +
is O +
linked O +
to O +
various O +
tumorigenic O +
responses O -
. O +

In O +
agreement O +
with O +
these O +
data O -
, O +
the O +
exogenous O +
treatment O +
of O +
SAH B-Chemical +
or O +
inhibition O +
of O +
SAHH O +
by O +
specific O +
siRNA O +
or O +
another O +
type O +
of O +
inhibitor O -
, O +
3-deazaadenosine B-Chemical +
( O -
DAZA B-Chemical -
) O -
, O +
similarly O +
resulted O +
in O +
antitumorigenic O +
responses O -
, O +
suppressive O +
activity O +
on O +
Src O -
, O +
the O +
alteration O +
of O +
actin O +
cytoskeleton O -
, O +
and O +
a O +
change O +
of O +
the O +
colocalization O +
pattern O +
between O +
actin O +
and O +
Src O -
. O +

Taken O +
together O -
, O +
these O +
results O +
suggest O +
that O +
SAH B-Chemical -
/ O -
SAHH O -
- O -
mediated O +
transmethylation O +
could O +
be O +
linked O +
to O +
the O +
tumorigenic O +
processes O +
through O +
cross O -
- O -
regulation O +
between O +
the O +
actin O +
cytoskeleton O +
and O +
Src O +
kinase O +
activity O -
. O +

Synthesis O +
of O +
derivatives O +
of O +
methyl B-Chemical +
rosmarinate I-Chemical +
and O +
their O +
inhibitory O +
activities O +
against O +
matrix O +
metalloproteinase-1 O +
( O -
MMP-1 O -
) O -
. O +

A O +
series O +
of O +
MMP-1 O +
inhibitors O +
have O +
been O +
identified O +
based O +
upon O +
a O +
methyl B-Chemical +
rosmarinate I-Chemical +
scaffold O +
using O +
structure O -
- O -
based O +
drug O +
design O +
methods O -
. O +

The O +
best O +
compound O +
in O +
the O +
series O +
showed O +
an O +
IC50 O +
value O +
of O +
0.4 O +
μM. O +
A O +
docking O +
study O +
was O +
conducted O +
for O +
compound O +
( O -
S O -
) O -
-10n O +
in O +
order O +
to O +
investigate O +
its O +
binding O +
interactions O +
with O +
MMP-1 O -
. O +

The O +
structure O -
- O -
activity O +
relationships O +
( O -
SAR O -
) O +
were O +
also O +
briefly O +
discussed O -
. O +

Useful O +
SAR O +
was O +
established O +
which O +
provides O +
important O +
guidelines O +
for O +
the O +
design O +
of O +
future O +
generations O +
of O +
potent O +
inhibitors O +
against O +
MMP-1 O -
. O +

Design O -
, O +
synthesis O +
and O +
anticancer O +
properties O +
of O +
5-arylbenzoxepins B-Chemical +
as O +
conformationally O +
restricted O +
isocombretastatin B-Chemical +
A-4 I-Chemical +
analogs O -
. O +

A O +
series O +
of O +
novel O +
benzoxepins B-Chemical +
6 O +
was O +
designed O +
and O +
prepared O +
as O +
rigid O -
- O -
isoCA-4 B-Chemical +
analogs O +
according O +
to O +
a O +
convergent O +
strategy O +
using O +
the O +
coupling O +
of O +
N B-Chemical -
- I-Chemical -
tosylhydrazones I-Chemical +
with O +
aryl B-Chemical +
iodides I-Chemical +
under O +
palladium B-Chemical +
catalysis O -
. O +

The O +
most O +
potent O +
compound O +
6b O -
, O +
having O +
the O +
greatest O +
resemblance O +
to O +
CA-4 B-Chemical +
and O +
isoCA-4 B-Chemical +
displayed O +
antiproliferative O +
activity O +
at O +
nanomolar O +
concentrations O +
against O +
various O +
cancer O +
cell O +
lines O +
and O +
inhibited O +
tubulin O +
assembly O +
at O +
a O +
micromolar O +
range O -
. O +

In O +
addition O -
, O +
benzoxepin B-Chemical +
6b O +
led O +
to O +
the O +
arrest O +
of O +
HCT116 O -
, O +
K562 O -
, O +
H1299 O +
and O +
MDA O -
- O -
MB231 O +
cancer O +
cell O +
lines O +
in O +
the O +
G2 O -
/ O -
M O +
phase O +
of O +
the O +
cell O +
cycle O -
, O +
and O +
strongly O +
induced O +
apoptosis O +
at O +
low O +
concentrations O -
. O +

Docking O +
studies O +
demonstrated O +
that O +
benzoxepin B-Chemical +
6b O +
adopt O +
an O +
orientation O +
similar O +
to O +
that O +
of O +
isoCA-4 B-Chemical +
at O +
the O +
colchicine O +
binding O +
site O +
on O +
β O -
- O -
tubulin O -
. O +

Cytotoxicity O +
of O +
lapachol B-Chemical -
, O +
β B-Chemical -
- I-Chemical -
lapachone I-Chemical +
and O +
related O +
synthetic O +
1,4-naphthoquinones B-Chemical +
against O +
oesophageal O +
cancer O +
cells O -
. O +

Naphthoquinones B-Chemical +
have O +
been O +
found O +
to O +
have O +
a O +
wide O +
range O +
of O +
biological O +
activities O -
, O +
including O +
cytotoxicity O +
to O +
cancer O +
cells O -
. O +

The O +
secondary O +
metabolites O +
lapachol O -
, O +
α- B-Chemical +
and I-Chemical +
β I-Chemical -
- I-Chemical -
lapachone I-Chemical +
and O +
a O +
series O +
of O +
25 O +
related O +
synthetic O +
1,4-naphthoquinones B-Chemical +
were O +
screened O +
against O +
the O +
oesophageal O +
cancer O +
cell O +
line O +
( O -
WHCO1 O -
) O -
. O +

Most O +
of O +
the O +
compounds O +
exhibited O +
enhanced O +
cytotoxicity O +
( O -
IC50 O +
1.6 O -
- O -
11.7 O +
μM O -
) O +
compared O +
to O +
the O +
current O +
drug O +
of O +
choice O +
cisplatin B-Chemical +
( O -
IC50 O +
= O +
16.5 O +
μM O -
) O -
. O +

This O +
study O +
also O +
established O +
that O +
the O +
two O +
new O +
synthetic O +
halogenated O +
compounds O +
12a O +
and O +
16a O +
( O -
IC50 O +
= O +
3.0 O +
and O +
7.3 O +
μM O -
) O +
and O +
the O +
previously O +
reported O +
compound O +
11a O +
( O -
IC50 O +
= O +
3.9 O +
μM O -
) O -
, O +
were O +
non O -
- O -
toxic O +
to O +
NIH3T3 O +
normal O +
fibroblast O +
cells O -
. O +

Cell O +
death O +
of O +
oesophageal O +
cancer O +
cells O +
by O +
processes O +
involving O +
PARP O +
cleavage O +
caused O +
by O +
11a O +
was O +
shown O +
to O +
be O +
associated O +
with O +
elevated O +
c O -
- O -
Jun O +
levels O -
, O +
suggesting O +
a O +
role O +
for O +
this O +
pathway O +
in O +
the O +
mechanism O +
of O +
action O +
of O +
this O +
cohort O +
of O +
naphthoquinone B-Chemical +
compounds O -
. O +

Synthesis O +
of O +
an O +
MIF-1 B-Chemical +
analogue O +
containing O +
enantiopure O +
( B-Chemical -
S I-Chemical -
) I-Chemical -
-α I-Chemical -
- I-Chemical -
trifluoromethyl I-Chemical -
- I-Chemical -
proline I-Chemical +
and O +
biological O +
evaluation O +
on O +
nociception O -
. O +

The O +
synthesis O +
and O +
the O +
effect O +
of O +
a O +
novel O +
MIF-1 B-Chemical +
analogue O +
on O +
nociception O +
during O +
acute O +
pain O +
in O +
rat O +
model O +
are O +
reported O -
. O +

The O +
synthesis O +
of O +
this O +
enantiopure O +
trifluoromethyl B-Chemical +
group O +
containing O +
tripeptide B-Chemical +
was O +
performed O +
through O +
a O +
peptide O +
coupling O +
reaction O +
between O +
the O +
HCl B-Chemical -
. I-Chemical +

Leu B-Chemical -
- I-Chemical -
Gly I-Chemical -
- I-Chemical -
NH2 I-Chemical +
and O +
the O +
( B-Chemical -
S I-Chemical -
) I-Chemical -
-α I-Chemical -
- I-Chemical -
Tfm I-Chemical -
- I-Chemical -
proline I-Chemical -
. O +

The O +
analgesic O +
effect O +
of O +
the O +
CF3- B-Chemical -
( I-Chemical -
MIF-1 I-Chemical -
) I-Chemical +
2 O +
has O +
been O +
evaluated O +
in O +
vivo O +
on O +
rat O +
model O +
by O +
paw O +
pressure O +
( O -
PP O -
) O +
and O +
hot O +
plate O +
( O -
HP O -
) O +
tests O +
and O +
compared O +
to O +
the O +
native O +
peptide O +
MIF-1 B-Chemical -
. O +

Highest O +
analgesic O +
effect O +
was O +
observed O +
with O +
CF3- B-Chemical -
( I-Chemical -
MIF-1 I-Chemical -
) I-Chemical +
2 O +
only O +
in O +
PP O +
test O -
. O +

In O +
order O +
to O +
study O +
the O +
mechanisms O +
of O +
nociception O +
induced O +
by O +
the O +
studied O +
peptides O -
, O +
the O +
involvement O +
of O +
the O +
opioid O +
and O +
the O +
nitric B-Chemical +
oxideergic O +
systems O +
was O +
investigated O -
. O +

The O +
results O +
are O +
in O +
favor O +
of O +
a O +
participation O +
of O +
both O +
system O +
since O +
pretreatment O -
, O +
20 O +
min O +
before O +
injection O +
of O +
the O +
CF3- B-Chemical -
( I-Chemical -
MIF-1 I-Chemical -
) I-Chemical +
2 O -
, O +
with O +
the O +
non O -
- O -
competitive O +
antagonist O +
of O +
opiate O +
receptors O +
naloxone B-Chemical -
, O +
the O +
nitric B-Chemical +
oxide I-Chemical +
synthase O +
( O -
NOS O -
) O +
inhibitor O +
l B-Chemical -
- I-Chemical -
N I-Chemical -
( I-Chemical -
G I-Chemical -
) I-Chemical -
-nitroarginine I-Chemical +
ester I-Chemical +
( O -
l B-Chemical -
- I-Chemical -
NAME I-Chemical -
) O +
or O +
the O +
nitric B-Chemical +
oxide I-Chemical +
( O -
NO B-Chemical -
) O +
donor O +
l B-Chemical -
- I-Chemical -
arginine I-Chemical +
( O -
l B-Chemical -
- I-Chemical -
Arg I-Chemical -
) O +
significantly O +
decreased O +
the O +
pain O +
perception O +
in O +
PP O +
and O +
HP O +
tests O -
. O +

Synthesis O -
, O +
characterization O -
, O +
cytotoxicity O +
and O +
antimicrobial O +
studies O +
on O +
bis B-Chemical -
( I-Chemical -
N I-Chemical -
- I-Chemical -
furfuryl I-Chemical -
- I-Chemical -
N- I-Chemical -
( I-Chemical -
2-phenylethyl I-Chemical -
) I-Chemical -
dithiocarbamato I-Chemical -
- I-Chemical -
S I-Chemical -
, I-Chemical -
S' I-Chemical -
) I-Chemical -
zinc I-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical +
and O +
its O +
nitrogen B-Chemical +
donor O +
adducts O -
. O +

[ O -
Zn B-Chemical -
( I-Chemical -
fpedtc I-Chemical -
) I-Chemical -
2 I-Chemical -
] O +
( O -
1 O -
) O -
, O +
[ O -
Zn B-Chemical -
( I-Chemical -
fpedtc I-Chemical -
) I-Chemical -
2 I-Chemical -
( I-Chemical -
py I-Chemical -
) I-Chemical -
] O +
( O -
2 O -
) O -
, O +
[ O -
Zn B-Chemical -
( I-Chemical -
fpedtc I-Chemical -
) I-Chemical -
2 I-Chemical -
( I-Chemical -
1,10-phen I-Chemical -
) I-Chemical -
] O +
( O -
3 O -
) O +
and O +
[ O -
Zn B-Chemical -
( I-Chemical -
fpedtc I-Chemical -
) I-Chemical -
2 I-Chemical -
( I-Chemical -
2,2'-bipy I-Chemical -
) I-Chemical -
] O +
( O -
4 O -
) O +
( O -
where O +
fpedtc B-Chemical +
= O +
N B-Chemical -
- I-Chemical -
furfuryl I-Chemical -
- I-Chemical -
N- I-Chemical -
( I-Chemical -
2-phenylethyl I-Chemical -
) I-Chemical -
dithiocarbamate I-Chemical -
, O +
py O +
= O +
pyridine B-Chemical -
, O +
1,10-phen B-Chemical +
= O +
1,10-phenanthroline B-Chemical +
and O +
2,2'-bipy B-Chemical +
= O +
2,2'-bipyridine B-Chemical -
) O +
were O +
synthesized O -
. O +

Characterization O +
of O +
the O +
complexes O +
were O +
achieved O +
by O +
IR O +
and O +
NMR O +
( O -
( B-Chemical -
1 I-Chemical -
) I-Chemical -
H I-Chemical +
and O +
( B-Chemical -
13 I-Chemical -
) I-Chemical -
C I-Chemical -
) O +
spectra O +
and O +
in O +
addition O -
, O +
for O +
2 O +
and O +
3 O -
, O +
by O +
X O -
- O -
ray O +
crystallography O -
. O +

Single O +
crystal O +
X O -
- O -
ray O +
structural O +
analysis O +
of O +
2 O +
and O +
3 O +
showed O +
that O +
complex O +
2 O +
is O +
almost O +
half O +
way O +
between O +
trigonal O +
bipyramidal O +
and O +
square O +
pyramidal O +
and O +
complex O +
3 O +
has O +
a O +
distorted O +
octahedral O +
geometry O -
. O +

Zn B-Chemical -
- B-Chemical -
N O +
distances O +
in O +
2 O +
is O +
shorter O +
than O +
that O +
found O +
in O +
a O +
six O +
coordinate O +
complex O +
3 O +
due O +
to O +
the O +
change O +
in O +
coordination O +
number O -
. O +

These O +
complexes O +
were O +
also O +
screened O +
for O +
in O +
vitro O +
antibacterial O +
and O +
antifungal O +
activities O +
and O +
significant O +
activities O +
have O +
been O +
found O -
. O +

In O +
vitro O +
cytotoxic O +
activity O +
of O +
all O +
the O +
synthesized O +
complexes O +
was O +
evaluated O +
on O +
HeLa O +
cell O +
line O -
. O +

Complex O +
1 O +
exhibits O +
maximum O +
inhibitory O +
effect O +
at O +
a O +
concentration O +
of O +
40 O +
μg O +
mL O -
( O -
-1 O -
) O +
on O +
HeLa O +
cell O +
line O -
. O +

Novel O +
agmatine B-Chemical +
dipeptide I-Chemical +
inhibitors O +
against O +
the O +
West O +
Nile O +
virus O +
NS2B O -
/ O -
NS3 O +
protease O -
: O +
A O +
P3 O +
and O +
N O -
- O -
cap O +
optimization O +
study O -
. O +

This O +
communication O +
describes O +
the O +
synthesis O +
and O +
inhibitory O +
activities O +
of O +
thirty O -
- O -
seven O +
novel O +
C O -
- O -
terminal O +
agmatine B-Chemical +
dipeptides I-Chemical +
used O +
as O +
screening O +
compounds O +
to O +
study O +
the O +
structure O -
- O -
activity O +
relationship O +
between O +
active O -
- O -
site O +
peptidomimetics O +
and O +
the O +
West O +
Nile O +
virus O +
( O -
WNV O -
) O +
NS2B O -
/ O -
NS3 O +
serine B-Chemical +
protease O -
. O +

Our O +
efforts O +
lead O +
to O +
the O +
discovery O +
of O +
a O +
novel O +
agmatine B-Chemical +
dipeptide I-Chemical +
inhibitor O +
( O -
compound O +
33 O -
, O +
IC50 O +
2.6 O +
± O +
0.3 O +
μM O -
) O +
with O +
improved O +
inhibitory O +
activity O +
in O +
comparison O +
to O +
the O +
most O +
potent O +
inhibitor O +
described O +
in O +
our O +
recent O +
report O +
[ O -
IC50 O +
4.7 O +
± O +
1.2 O +
μM O -
; O +
Lim O +
et O +
al. O -
, O +
Eur O -
. O +

J. O +
Med O -
. O +

Chem O -
. O +

46 O +
( O -
2011 O -
) O +
3130 O -
- O -
3134 O -
] O -
. O +

In O +
addition O -
, O +
our O +
study O +
cleared O +
the O +
contention O +
surrounding O +
the O +
previous O +
X O -
- O -
ray O +
co O -
- O -
crystallization O +
study O +
and O +
an O +
enzyme O +
inhibition O +
report O +
on O +
the O +
binding O +
conformation O +
adopted O +
by O +
active O -
- O -
site O +
peptide O +
aldehydes B-Chemical -
. O +

Our O +
data O +
should O +
provide O +
valuable O +
insights O +
into O +
the O +
design O +
of O +
future O +
peptidomimetic O +
antivirals O +
against O +
WNV O +
infections O -
. O +

Synthesis O -
, O +
pharmacological O +
evaluation O +
and O +
QSAR O +
modeling O +
of O +
mono O -
- O -
substituted O +
4-phenylpiperidines B-Chemical +
and O +
4-phenylpiperazines B-Chemical -
. O +

A O +
series O +
of O +
mono B-Chemical -
- I-Chemical -
substituted I-Chemical +
4-phenylpiperidines I-Chemical +
and I-Chemical +
-piperazines I-Chemical +
have O +
been O +
synthesized O +
and O +
their O +
effects O +
on O +
the O +
dopaminergic O +
system O +
tested O +
in O +
vivo O -
. O +

The O +
structure O +
activity O +
relationship O +
( O -
SAR O -
) O +
revealed O +
that O +
the O +
position O +
and O +
physicochemical O +
character O +
of O +
the O +
aromatic O +
substituent O +
proved O +
to O +
be O +
critical O +
for O +
the O +
levels O +
of O +
3,4-dihydroxyphenylacetic B-Chemical +
acid I-Chemical +
( O -
DOPAC B-Chemical -
) O +
in O +
the O +
brain O +
of O +
freely O +
moving O +
rats O -
. O +

In O +
order O +
to O +
investigate O +
how O +
the O +
structural O +
properties O +
of O +
these O +
compounds O +
affect O +
the O +
response O -
, O +
a O +
set O +
of O +
tabulated O +
and O +
calculated O +
physicochemical O +
descriptors O +
were O +
modeled O +
against O +
the O +
in O +
vivo O +
effects O +
using O +
partial O +
least O +
square O +
( O -
PLS O -
) O +
regression O -
. O +

Furthermore O -
, O +
the O +
binding O +
affinities O +
to O +
the O +
dopamine B-Chemical +
D2 O +
( O -
DA O +
D2 O -
) O +
receptor O +
and O +
monoamine B-Chemical +
oxidase O +
A O +
( O -
MAO O +
A O -
) O +
enzyme O +
were O +
determined O +
for O +
a O +
chosen O +
subset O +
and O +
QSAR O +
models O +
using O +
the O +
same O +
descriptors O +
as O +
in O +
the O +
in O +
vivo O +
model O +
were O +
produced O +
to O +
investigate O +
the O +
mechanisms O +
leading O +
to O +
the O +
observed O +
DOPAC B-Chemical +
response O -
. O +

These O +
models O -
, O +
in O +
combination O +
with O +
a O +
strong O +
correlation O +
between O +
the O +
levels O +
of O +
striatal O +
DOPAC B-Chemical +
and O +
the O +
affinities O +
to O +
DA O +
D2 O +
and O +
MAO O +
A O -
, O +
provides O +
a O +
comprehensive O +
understanding O +
of O +
the O +
biological O +
response O +
for O +
compounds O +
in O +
this O +
class O -
. O +

Population O +
pharmacokinetics O +
of O +
piperacillin B-Chemical -
/ O -
tazobactam B-Chemical +
in O +
neonates O +
and O +
young O +
infants O -
. O +

OBJECTIVES O -
: O +
To O +
develop O +
population O +
pharmacokinetic O +
( O -
PK O -
) O +
models O +
for O +
piperacillin B-Chemical -
/ O -
tazobactam B-Chemical +
in O +
neonates O +
and O +
infants O +
of O +
less O +
than O +
2 O +
months O +
of O +
age O +
in O +
order O +
to O +
determine O +
the O +
appropriate O +
dosing O +
regimen O +
and O +
provide O +
a O +
rational O +
basis O +
for O +
the O +
development O +
of O +
preliminary O +
dosing O +
guidelines O +
suitable O +
for O +
this O +
population O -
. O +

METHODS O -
: O +
A O +
two O -
- O -
stage O -
, O +
open O -
- O -
label O +
study O +
was O +
conducted O +
in O +
neonates O +
and O +
infants O +
less O +
than O +
2 O +
months O +
of O +
age O +
in O +
the O +
neonatal O +
intensive O +
care O +
unit O +
( O -
NICU O -
) O -
. O +

A O +
total O +
of O +
207 O +
piperacillin B-Chemical +
and O +
204 O +
tazobactam B-Chemical +
concentration O -
- O -
time O +
data O +
sets O +
from O +
71 O +
patients O +
were O +
analyzed O +
using O +
a O +
nonlinear O +
mixed O -
- O -
effect O +
modeling O +
approach O +
( O -
NONMEM O +
VII O -
) O -
. O +

PK O +
models O +
were O +
developed O +
for O +
piperacillin B-Chemical +
and O +
tazobactam B-Chemical -
. O +

The O +
final O +
models O +
were O +
evaluated O +
using O +
both O +
bootstrap O +
and O +
visual O +
predictive O +
checks O -
. O +

External O +
model O +
evaluations O +
were O +
made O +
in O +
20 O +
additional O +
patients O -
. O +

RESULTS O -
: O +
For O +
neonates O +
and O +
young O +
infants O +
less O +
than O +
2 O +
months O +
of O +
age O -
, O +
the O +
median O +
central O +
clearance O +
was O +
0.133 O +
and O +
0.149 O +
L O -
/ O -
h O -
/ O -
kg O +
for O +
piperacillin B-Chemical +
and O +
tazobactam B-Chemical -
, O +
respectively O -
. O +

Postmenstrual O +
age O +
( O -
PMA O -
) O +
was O +
identified O +
as O +
the O +
most O +
significant O +
covariate O +
on O +
central O +
clearance O +
of O +
piperacillin B-Chemical +
and O +
tazobactam B-Chemical -
. O +

However O -
, O +
the O +
combination O +
of O +
current O +
bodyweight O +
( O -
BW O -
) O +
and O +
postnatal O +
age O +
proved O +
to O +
be O +
superior O +
to O +
PMA O +
alone O -
. O +

BW O +
was O +
the O +
most O +
important O +
covariate O +
for O +
apparent O +
central O +
volume O +
of O +
distribution O -
. O +

Both O +
internal O +
and O +
external O +
evaluations O +
supported O +
the O +
prediction O +
of O +
the O +
final O +
piperacillin B-Chemical +
and O +
tazobactam B-Chemical +
PK O +
models O -
. O +

The O +
dosing O +
strategy O +
44.44 O -
/ O -
5.56 O +
mg O -
/ O -
kg O -
/ O -
dose O +
piperacillin B-Chemical -
/ O -
tazobactam B-Chemical +
every O +
8 O +
or O +
12 O +
h O +
evaluated O +
in O +
this O +
study O +
achieved O +
the O +
pharmacodynamic O +
target O +
( O -
free O +
piperacillin B-Chemical +
concentrations O +
> O -
4 O +
mg O -
/ O -
L O +
for O +
more O +
than O +
50 O +
% O +
of O +
the O +
dosing O +
interval O -
) O +
in O +
about O +
67 O +
% O +
of O +
infants O -
. O +

CONCLUSIONS O -
: O +
Population O +
PK O +
models O +
accurately O +
described O +
the O +
PK O +
profiles O +
of O +
piperacillin B-Chemical -
/ O -
tazobactam B-Chemical +
in O +
infants O +
less O +
than O +
2 O +
months O +
of O +
age O -
. O +

The O +
results O +
indicated O +
that O +
higher O +
doses O +
or O +
more O +
frequent O +
dosing O +
regimens O +
may O +
be O +
required O +
for O +
controlling O +
infection O +
in O +
this O +
population O +
in O +
NICU O -
. O +

Structural O +
Basis O +
of O +
Signaling O +
Blockade O +
by O +
Anti O -
- O -
IL-13 O +
Antibody O +
Lebrikizumab O -
. O +

The O +
cytokine O +
interleukin O +
13 O +
( O -
IL-13 O -
) O +
is O +
a O +
major O +
effector O +
molecule O +
for O +
T O -
- O -
helper O +
type O +
2 O +
inflammation O +
and O +
is O +
pathogenic O +
in O +
allergic O +
diseases O +
such O +
as O +
asthma O -
. O +

The O +
effects O +
of O +
IL-13 O +
are O +
mediated O +
via O +
a O +
pathway O +
that O +
is O +
initiated O +
by O +
binding O +
to O +
a O +
heterodimeric O +
receptor O +
consisting O +
of O +
IL-13Rα1 O +
and O +
IL-4Rα O -
. O +

Antibodies O +
raised O +
against O +
IL-13 O +
can O +
block O +
its O +
inflammatory O +
effects O +
by O +
interfering O +
with O +
binding O +
to O +
either O +
of O +
the O +
two O +
receptor O +
polypeptides O -
. O +

Lebrikizumab O +
is O +
a O +
monoclonal O +
anti O -
- O -
IL-13 O +
antibody O +
that O +
has O +
shown O +
clinical O +
benefit O +
in O +
a O +
phase O +
II O +
study O +
for O +
the O +
treatment O +
of O +
moderate O -
- O -
to O -
- O -
severe O +
uncontrolled O +
asthma O -
. O +

Here O +
we O +
report O +
the O +
molecular O +
structure O +
of O +
IL-13 O +
in O +
complex O +
with O +
the O +
Fab O +
from O +
lebrikizumab O +
by O +
X O -
- O -
ray O +
crystallography O +
at O +
1.9Å O +
resolution O -
. O +

We O +
show O +
that O +
lebrikizumab O +
inhibits O +
IL-13 O +
signaling O +
by O +
binding O +
to O +
IL-13 O +
with O +
very O +
high O +
affinity O +
and O +
blocking O +
IL-13 O +
binding O +
to O +
IL-4Rα O -
. O +

In O +
addition O -
, O +
we O +
use O +
site O -
- O -
directed O +
mutations O +
to O +
identify O +
the O +
most O +
important O +
antibody O +
contributors O +
to O +
binding O -
. O +

Our O +
studies O +
define O +
key O +
features O +
of O +
lebrikizumab O +
binding O +
and O +
its O +
mechanism O +
of O +
action O +
that O +
may O +
contribute O +
to O +
its O +
clinical O +
effects O -
. O +

Constitutively O +
active O +
group O +
I O +
mGlu O +
receptors O +
and O +
PKMzeta O +
regulate O +
synaptic O +
transmission O +
in O +
developing O +
perirhinal O +
cortex O -
. O +

Synaptic O +
transmission O +
is O +
essential O +
for O +
early O +
development O +
of O +
the O +
central O +
nervous O +
system O -
. O +

However O -
, O +
the O +
mechanisms O +
that O +
regulate O +
early O +
synaptic O +
transmission O +
in O +
the O +
cerebral O +
cortex O +
are O +
unclear O -
. O +

PKMζ O +
is O +
a O +
kinase O +
essential O +
for O +
the O +
maintenance O +
of O +
LTP O -
. O +

We O +
show O +
for O +
the O +
first O +
time O +
that O +
inhibition O +
of O +
PKMζ O +
produces O +
a O +
profound O +
depression O +
of O +
basal O +
synaptic O +
transmission O +
in O +
neonatal O -
, O +
but O +
not O +
adult O -
, O +
rat O +
perirhinal O +
cortex O -
. O +

This O +
suggests O +
that O +
synapses O +
in O +
early O +
development O +
are O +
in O +
a O +
constitutive O +
LTP O -
- O -
like O +
state O -
. O +

Furthermore O -
, O +
basal O +
synaptic O +
transmission O +
in O +
immature O -
, O +
but O +
not O +
mature O -
, O +
perirhinal O +
cortex O +
relies O +
on O +
persistent O +
activity O +
of O +
metabotropic O +
glutamate B-Chemical +
( O -
mGlu O -
) O +
receptor O -
, O +
PI3Kinase O +
and O +
mammalian O +
target O +
of O +
rapamycin B-Chemical +
( O -
mTOR O -
) O -
. O +

Thus O +
early O +
in O +
development O -
, O +
cortical O +
synapses O +
exist O +
in O +
an O +
LTP O -
- O -
like O +
state O +
maintained O +
by O +
tonically O +
active O +
mGlu O +
receptor- O -
, O +
mTOR- O +
and O +
PKMζ- O +
dependent O +
cascades O -
. O +

These O +
results O +
provide O +
new O +
understanding O +
of O +
the O +
molecular O +
mechanisms O +
that O +
control O +
synapses O +
during O +
development O +
and O +
may O +
aid O +
our O +
understanding O +
of O +
developmental O +
disorders O +
such O +
as O +
autism O +
and O +
schizophrenia O -
. O +

This O +
article O +
is O +
part O +
of O +
a O +
Special O +
Issue O +
entitled O +
' O -
Metabotropic O +
Glutamate B-Chemical +
Receptors O -
' O -
. O +

Synthesis O -
, O +
DNA O +
binding O +
and O +
antitumor O +
evaluation O +
of O +
styelsamine B-Chemical +
and O +
cystodytin B-Chemical +
analogues O -
. O +

A O +
series O +
of O +
N-14 O +
sidechain O +
substituted O +
analogues O +
of O +
styelsamine B-Chemical +
( O -
pyrido B-Chemical -
[ I-Chemical -
4,3,2-mn I-Chemical -
] I-Chemical -
acridine I-Chemical -
) O +
and O +
cystodytin B-Chemical +
( O -
pyrido B-Chemical -
[ I-Chemical -
4,3,2-mn I-Chemical -
] I-Chemical -
acridin-4-one I-Chemical -
) O +
alkaloids O +
have O +
been O +
prepared O +
and O +
evaluated O +
for O +
their O +
DNA O +
binding O +
affinity O +
and O +
antiproliferative O +
activity O +
towards O +
a O +
panel O +
of O +
human O +
tumor O +
cell O +
lines O -
. O +

Overall O +
it O +
was O +
found O +
that O +
styelsamine B-Chemical +
analogues O +
were O +
stronger O +
DNA O +
binders O -
, O +
with O +
the O +
natural O +
products O +
styelsamines B-Chemical +
B I-Chemical +
and I-Chemical +
D I-Chemical +
having O +
particularly O +
high O +
affinity O +
( O -
K O -
( O -
app O -
) O +
5.33 O +
× O +
10 O -
( O -
6 O -
) O +
and O +
3.64 O +
× O +
10 O -
( O -
6 O -
) O +
M O -
( O -
-1 O -
) O -
, O +
respectively O -
) O -
. O +

In O +
comparison O -
, O +
the O +
cystodytin B-Chemical +
iminoquinone I-Chemical +
alkaloids I-Chemical +
showed O +
lower O +
affinity O +
for O +
DNA O -
, O +
but O +
were O +
typically O +
just O +
as O +
active O +
as O +
styelsamine B-Chemical +
analogues O +
at O +
inhibiting O +
proliferation O +
of O +
tumor O +
cells O +
in O +
vitro O -
. O +

Sub O -
- O -
panel O +
selectivity O +
towards O +
non O -
- O -
small O +
cell O +
lung O -
, O +
melanoma O +
and O +
renal O +
cancer O +
cell O +
lines O +
were O +
observed O +
for O +
a O +
number O +
of O +
the O +
analogues O -
. O +

Correlation O +
was O +
observed O +
between O +
whole O +
cell O +
activity O +
and O +
clogP O -
, O +
with O +
the O +
most O +
potent O +
antiproliferative O +
activity O +
being O +
observed O +
for O +
3-phenylpropanamide B-Chemical +
analogues O +
37 O +
and O +
41 O +
( O -
NCI O +
panel O +
average O +
GI O -
( O -
50 O -
) O +
0.4 O +
μM O +
and O +
0.32 O +
μM O -
, O +
respectively O -
) O +
with O +
clogP O +
~4.0 O -
- O -
4.5 O -
. O +

Anti O -
- O -
inflammatory O +
effects O +
of O +
a O +
special O +
carbohydrate B-Chemical -
- O -
whey O +
protein O +
cake O +
after O +
exhaustive O +
cycling O +
in O +
humans O -
. O +

Intense O +
exercise O +
induces O +
increased O +
levels O +
of O +
pro O -
- O -
inflammatory O +
and O +
anti O -
- O -
inflammatory O +
cytokines O -
. O +

Thus O -
, O +
the O +
purpose O +
of O +
this O +
study O +
was O +
to O +
examine O +
the O +
effects O +
of O +
a O +
special O +
cake O +
( O -
consisting O +
of O +
carbohydrate B-Chemical +
to O +
whey O +
protein O +
3.5:1 O -
) O +
vs. O +
an O +
isocaloric O +
carbohydrate B-Chemical +
cake O +
on O +
inflammatory O +
markers O +
after O +
exhaustive O +
cycling O +
in O +
humans O -
. O +

Nine O +
subjects O +
received O +
either O +
the O +
experimental O +
or O +
placebo O +
cake O +
in O +
a O +
counterbalanced O +
fashion O +
using O +
a O +
crossover O -
, O +
double O -
- O -
blind O -
, O +
repeated O -
- O -
measures O +
design O -
. O +

They O +
performed O +
one O +
trial O +
involving O +
a O +
2h O +
exercise O +
on O +
a O +
cycle O +
ergometer O +
at O +
60 O -
- O -
65 O -
% O +
VO2max O +
followed O +
by O +
a O +
4h O +
recovery O +
and O +
then O +
a O +
second O +
trial O +
involving O +
an O +
1h O +
exercise O +
at O +
60 O -
- O -
65 O -
% O +
VO2max O +
which O +
was O +
increased O +
at O +
95 O -
% O +
VO2max O -
. O +

Blood O +
samples O +
were O +
collected O +
pre O -
- O -
exercise O -
, O +
30min O +
and O +
4h O +
post O -
- O -
exercise O -
, O +
post O -
- O -
time O +
Trial O +
and O +
48h O +
post O -
- O -
time O +
Trial O -
. O +

Cakes O +
were O +
consumed O +
immediately O +
post O -
- O -
exercise O +
and O +
every O +
1h O +
for O +
the O +
next O +
3h O -
. O +

The O +
results O +
showed O +
that O +
consumption O +
of O +
the O +
experimental O +
cake O +
reduced O +
significantly O +
( O -
p<0.05 O -
) O -
, O +
4h O +
post O -
- O -
exercise O -
, O +
the O +
pro O -
- O -
inflammatory O +
protein O +
levels O +
IL-6 O +
and O +
CRP O +
compared O +
to O +
the O +
control O +
group O +
by O +
50 O -
% O +
and O +
46 O -
% O +
respectively O -
. O +

Moreover O -
, O +
in O +
the O +
experimental O +
cake O +
group O -
, O +
the O +
level O +
of O +
the O +
anti O -
- O -
inflammatory O +
cytokine O +
IL-10 O +
was O +
higher O +
by O +
118 O -
% O -
, O +
4h O +
post O -
- O -
exercise O -
, O +
compared O +
to O +
the O +
control O +
group O +
but O +
not O +
statistically O +
significant O -
. O +

Self O -
- O -
assembly O +
of O +
mesoporous O +
CuO B-Chemical +
nanosheets O -
- O -
CNT O +
3D O -
- O -
network O +
composites O +
for O +
lithium B-Chemical -
- O -
ion O +
batteries O -
. O +

A O +
facile O -
, O +
flexible O +
and O +
large O -
- O -
scale O +
technique O +
was O +
proposed O +
to O +
prepare O +
a O +
CuO B-Chemical -
- O -
CNT O +
3D O -
- O -
network O +
composite O +
with O +
the O +
aid O +
of O +
electrostatic O +
interactions O +
in O +
aqueous O +
solution O -
. O +

The O +
composite O +
greatly O +
improves O +
the O +
electrochemical O +
performance O -
. O +

At O +
a O +
rate O +
of O +
0.1 O +
C O -
, O +
the O +
cycling O +
discharge O +
capacity O +
of O +
the O +
optimal O +
composite O +
is O +
more O +
than O +
2.3 O +
times O +
of O +
that O +
of O +
unmodified O +
mesoporous O +
CuO B-Chemical +
nanosheets O +
as O +
the O +
active O +
material O +
in O +
an O +
anode O +
after O +
40 O +
cycles O -
. O +

Adsorbed O +
and O +
near O +
surface O +
structure O +
of O +
ionic O +
liquids O +
at O +
a O +
solid O +
interface O -
. O +

The O +
structure O +
of O +
solid O -
- O -
ionic O +
liquid O +
( O -
IL O -
) O +
interfaces O +
has O +
been O +
characterised O +
with O +
unprecedented O +
clarity O +
by O +
employing O +
a O +
range O +
of O +
atomic O +
force O +
microscopy O +
( O -
AFM O -
) O +
imaging O +
techniques O +
and O +
tip O +
pressures O +
appropriate O +
for O +
the O +
system O +
under O +
study O -
. O +

Soft O +
contact O +
and O +
amplitude O -
- O -
modulation O +
( O -
AM O -
) O +
AFM O +
imaging O +
have O +
been O +
used O +
to O +
elucidate O +
the O +
lateral O +
structure O +
of O +
ILs O +
adsorbed O +
onto O +
mica O -
, O +
and O +
in O +
the O +
near O +
surface O +
ion O +
layers O -
. O +

Data O +
is O +
presented O +
for O +
ethylammonium B-Chemical +
nitrate I-Chemical +
( O -
EAN B-Chemical -
) O +
and O +
1-ethyl-3-methylimidazolium B-Chemical +
bis I-Chemical -
( I-Chemical -
trifluoro I-Chemical -
- I-Chemical -
methylsulfonyl I-Chemical -
) I-Chemical -
imide I-Chemical +
( O -
EMIm B-Chemical +
TFSI I-Chemical -
) O -
. O +

Whereas O +
EAN B-Chemical +
is O +
a O +
protic O +
IL O +
that O +
forms O +
a O +
nanostructured O +
sponge O +
phase O +
in O +
the O +
bulk O -
, O +
EMIm B-Chemical +
TFSI I-Chemical +
is O +
aprotic O +
and O +
has O +
weak O +
( O -
or O +
absent O -
) O +
bulk O +
association O +
structure O -
. O +

Comparison O +
of O +
results O +
obtained O +
for O +
the O +
two O +
liquids O +
elucidates O +
how O +
the O +
strength O +
of O +
bulk O +
liquid O +
morphology O +
effects O +
lateral O +
organisation O +
at O +
the O +
surface O -
, O +
and O +
any O +
effect O +
of O +
IL O +
class O -
, O +
i.e. O +
protic O +
versus O +
aprotic O -
. O +

Imaging O +
reveals O +
EAN B-Chemical +
self O +
assembles O +
at O +
the O +
solid O +
surface O +
in O +
a O +
worm O -
- O -
like O +
morphology O -
, O +
whereas O +
EMIm B-Chemical +
cations O +
adsorb O +
in O +
a O +
more O +
isolated O +
fashion O -
, O +
but O +
still O +
in O +
rows O +
templated O +
by O +
the O +
mica O +
surface O -
. O +

To O +
the O +
authors O -
' O +
knowledge O -
, O +
the O +
wormlike O +
structures O +
present O +
at O +
the O +
EAN B-Chemical -
- O -
mica O +
interface O +
are O +
the O +
smallest O +
self O -
- O -
assembled O +
aggregates O +
ever O +
imaged O +
on O +
a O +
solid O +
surface O -
. O +

Review O +
of O +
clinical O +
trials O +
for O +
mitochondrial O +
disorders O -
: O +
1997 O -
- O -
2012 O -
. O +

Over O +
the O +
last O +
15 O +
years O -
, O +
some O +
16 O +
open O +
and O +
controlled O +
clinical O +
trials O +
for O +
potential O +
treatments O +
of O +
mitochondrial O +
diseases O +
have O +
been O +
reported O +
or O +
are O +
in O +
progress O -
, O +
and O +
are O +
summarized O +
and O +
reviewed O +
herein O -
. O +

These O +
include O +
trials O +
of O +
administering O +
dichloroacetate B-Chemical +
( O -
an O +
activator O +
of O +
pyruvate B-Chemical +
dehydrogenase O +
complex O -
) O -
, O +
arginine B-Chemical +
or O +
citrulline B-Chemical +
( O -
precursors O +
of O +
nitric B-Chemical +
oxide I-Chemical -
) O -
, O +
coenzyme B-Chemical +
Q10 I-Chemical +
( O -
CoQ10 B-Chemical -
; O +
part O +
of O +
the O +
electron O +
transport O +
chain O +
and O +
an O +
antioxidant O -
) O -
, O +
idebenone B-Chemical +
( O -
a O +
synthetic O +
analogue O +
of O +
CoQ10 B-Chemical -
) O -
, O +
EPI-743 B-Chemical +
( O -
a O +
novel O +
oral O +
potent O +
2-electron O +
redox O +
cycling O +
agent O -
) O -
, O +
creatine B-Chemical +
( O -
a O +
precursor O +
of O +
phosphocreatine B-Chemical -
) O -
, O +
combined O +
administration O +
( O -
of O +
creatine B-Chemical -
, O +
α B-Chemical -
- I-Chemical -
lipoate I-Chemical -
, O +
and O +
CoQ10 B-Chemical -
) O -
, O +
and O +
exercise O +
training O +
( O -
to O +
increase O +
muscle O +
mitochondria O -
) O -
. O +

These O +
trials O +
have O +
included O +
patients O +
with O +
various O +
mitochondrial O +
disorders O -
, O +
a O +
selected O +
subcategory O +
of O +
mitochondrial O +
disorders O -
, O +
or O +
specific O +
mitochondrial O +
disorders O +
( O -
Leber O +
hereditary O +
optic O +
neuropathy O +
or O +
mitochondrial O +
encephalopathy O -
, O +
lactic O +
acidosis O -
, O +
and O +
stroke O -
- O -
like O +
episodes O -
) O -
. O +

The O +
trial O +
designs O +
have O +
varied O +
from O +
open O -
- O -
label O -
/ O -
uncontrolled O -
, O +
open O -
- O -
label O -
/ O -
controlled O -
, O +
or O +
double O -
- O -
blind O -
/ O -
placebo O -
- O -
controlled O -
/ O -
crossover O -
. O +

Primary O +
outcomes O +
have O +
ranged O +
from O +
single O -
, O +
clinically O -
- O -
relevant O +
scores O +
to O +
multiple O +
measures O -
. O +

Eight O +
of O +
these O +
trials O +
have O +
been O +
well O -
- O -
controlled O -
, O +
completed O +
trials O -
. O +

Of O +
these O +
only O +
1 O +
( O -
treatment O +
with O +
creatine O -
) O +
showed O +
a O +
significant O +
change O +
in O +
primary O +
outcomes O -
, O +
but O +
this O +
was O +
not O +
reproduced O +
in O +
2 O +
subsequent O +
trials O +
with O +
creatine B-Chemical +
with O +
different O +
patients O -
. O +

One O +
trial O +
( O -
idebenone B-Chemical +
treatment O +
of O +
Leber O +
hereditary O +
optic O +
neuropathy O -
) O +
did O +
not O +
show O +
significant O +
improvement O +
in O +
the O +
primary O +
outcome O -
, O +
but O +
there O +
was O +
significant O +
improvement O +
in O +
a O +
subgroup O +
of O +
patients O -
. O +

Despite O +
the O +
paucity O +
of O +
benefits O +
found O +
so O +
far O -
, O +
well O -
- O -
controlled O +
clinical O +
trials O +
are O +
essential O +
building O +
blocks O +
in O +
the O +
continuing O +
search O +
for O +
more O +
effective O +
treatment O +
of O +
mitochondrial O +
disease O -
, O +
and O +
current O +
trials O +
based O +
on O +
information O +
gained O +
from O +
these O +
prior O +
experiences O +
are O +
in O +
progress O -
. O +

Because O +
of O +
difficulties O +
in O +
recruiting O +
sufficient O +
mitochondrial O +
disease O +
patients O +
and O +
the O +
relatively O +
large O +
expense O +
of O +
conducting O +
such O +
trials O -
, O +
advantageous O +
strategies O +
include O +
crossover O +
designs O +
( O -
where O +
possible O -
) O -
, O +
multicenter O +
collaboration O -
, O +
and O +
the O +
selection O +
of O +
very O +
few O -
, O +
clinically O +
relevant O -
, O +
primary O +
outcomes O -
. O +

Antenatal O +
manifestations O +
of O +
mitochondrial O +
disorders O -
. O +

Mitochondrial O +
respiratory O +
chain O +
diseases O +
are O +
a O +
heterogeneous O +
group O +
of O +
pathologies O +
caused O +
by O +
genetic O +
alterations O +
affecting O +
mitochondrial O +
energy O +
production O -
. O +

Theoretically O -
, O +
this O +
deficiency O +
may O +
lead O +
to O +
any O +
symptoms O -
, O +
in O +
any O +
organ O +
or O +
tissue O -
, O +
at O +
any O +
age O +
even O +
before O +
birth O -
. O +

The O +
aim O +
of O +
our O +
study O +
was O +
to O +
identify O +
the O +
frequency O +
and O +
characterize O +
antenatal O +
manifestations O +
identifying O +
possible O +
associations O +
between O +
mitochondrial O +
disease O +
and O +
more O +
specific O +
and O +
earlier O +
manifestation O -
. O +

We O +
retrospectively O +
review O +
the O +
files O +
of O +
44 O +
paediatric O +
subjects O +
with O +
genetic O +
and O +
biochemical O +
alterations O +
of O +
respiratory O +
chain O +
identified O +
in O +
the O +
first O +
decade O +
of O +
life O +
and O +
compare O +
data O +
with O +
a O +
control O +
group O +
( O -
n O +
= O +
88 O -
) O -
. O +

Our O +
results O +
show O +
that O +
maternal O +
age O +
was O +
similar O +
in O +
both O +
groups O -
. O +

The O +
female O +
gender O +
was O +
predominant O +
in O +
patients O +
group O -
. O +

Gestational O +
age O +
at O +
delivery O +
was O +
similar O +
in O +
both O +
groups O -
. O +

Concerning O +
birth O +
weight O -
, O +
it O +
was O +
significantly O +
lower O +
( O -
p O +
= O +
0.001 O -
) O +
in O +
patients O +
( O -
2899.9 O +
± O +
538.3 O +
vs. O +
3246.6 O +
± O +
460.2 O +
g O -
) O -
. O +

Fifteen O +
pregnancies O +
of O +
the O +
patients O +
group O +
were O +
considered O +
abnormal O -
. O +

Our O +
findings O +
show O +
that O +
intrauterine O +
growth O +
restriction O +
was O +
the O +
most O +
frequent O +
antenatal O +
feature O +
observed O -
. O +

Neonatal O +
morbidity O +
was O +
significantly O +
higher O +
( O -
fivefold O -
) O +
in O +
patients O +
( O -
p O +
< O +
0.001 O -
) O -
. O +

The O +
clinical O +
findings O +
are O +
independent O +
of O +
the O +
molecular O +
defect O +
type O -
. O +

Our O +
results O +
are O +
preliminary O +
and O +
more O +
studies O +
are O +
needed O -
, O +
in O +
order O +
to O +
learn O +
more O +
about O +
mitochondrial O +
physiology O +
and O +
activity O +
in O +
embryological O +
development O +
for O +
the O +
assessment O +
of O +
mitochondrial O +
disease O +
progress O +
in O +
fetal O +
life O -
. O +

However O -
, O +
the O +
present O +
work O +
is O +
a O +
significant O +
contribution O -
, O +
given O +
the O +
scarcity O +
of O +
information O +
in O +
this O +
field O -
. O +

Left O +
ventricular O +
noncompaction O +
( O -
LVNC O -
) O +
and O +
low O +
mitochondrial O +
membrane O +
potential O +
are O +
specific O +
for O +
Barth O +
syndrome O -
. O +

Barth O +
syndrome O +
( O -
BTHS O -
) O +
is O +
an O +
X O -
- O -
linked O +
mitochondrial O +
defect O +
characterised O +
by O +
dilated O +
cardiomyopathy O -
, O +
neutropaenia O +
and O +
3-methylglutaconic O +
aciduria O +
( O -
3-MGCA O -
) O -
. O +

We O +
report O +
on O +
two O +
affected O +
brothers O +
with O +
c.646 O -
G O +
> O +
A O +
( O -
p. O +

G216R O -
) O +
TAZ O +
gene O +
mutations O -
. O +

The O +
pathogenicity O +
of O +
the O +
mutation O -
, O +
as O +
indicated O +
by O +
the O +
structure O -
- O -
based O +
functional O +
analyses O -
, O +
was O +
further O +
confirmed O +
by O +
abnormal O +
monolysocardiolipin B-Chemical -
/ O -
cardiolipin B-Chemical +
ratio O +
in O +
dry O +
blood O +
spots O +
of O +
the O +
patients O +
as O +
well O +
as O +
the O +
occurrence O +
of O +
this O +
mutation O +
in O +
another O +
reported O +
BTHS O +
proband O -
. O +

In O +
both O +
brothers O -
, O +
2D O -
- O -
echocardiography O +
revealed O +
some O +
features O +
of O +
left O +
ventricular O +
noncompaction O +
( O -
LVNC O -
) O +
despite O +
marked O +
differences O +
in O +
the O +
course O +
of O +
the O +
disease O -
; O +
the O +
eldest O +
child O +
presented O +
with O +
isolated O +
cardiomyopathy O +
from O +
late O +
infancy O -
, O +
whereas O +
the O +
youngest O +
showed O +
severe O +
lactic O +
acidosis O +
without O +
3-MGCA O +
during O +
the O +
neonatal O +
period O -
. O +

An O +
examination O +
of O +
the O +
patients O -
' O +
fibroblast O +
cultures O +
revealed O +
that O +
extremely O +
low O +
mitochondrial O +
membrane O +
potentials O +
( O -
mtΔΨ O +
about O +
50 O +
% O +
of O +
the O +
control O +
value O -
) O +
dominated O +
other O +
unspecific O +
mitochondrial O +
changes O +
detected O +
( O -
respiratory O +
chain O +
dysfunction O -
, O +
abnormal O +
ROS O +
production O +
and O +
depressed O +
antioxidant O +
defense O -
) O -
. O +

1 O -
) O +
Our O +
studies O +
confirm O +
generalised O +
mitochondrial O +
dysfunction O +
in O +
the O +
skeletal O +
muscle O +
and O +
the O +
fibroblasts O +
of O +
BTHS O +
patients O -
, O +
especially O +
a O +
severe O +
impairment O +
in O +
the O +
mtΔΨ O +
and O +
the O +
inhibition O +
of O +
complex O +
V O +
activity O -
. O +

It O +
can O +
be O +
hypothesised O +
that O +
impaired O +
mtΔΨ O +
and O +
mitochondrial O +
ATP B-Chemical +
synthase O +
activity O +
may O +
contribute O +
to O +
episodes O +
of O +
cardiac O +
arrhythmia O +
that O +
occurred O +
unexpectedly O +
in O +
BTHS O +
patients O -
. O +

2 O -
) O +
Severe O +
lactic O +
acidosis O +
without O +
3-methylglutaconic O +
aciduria O +
in O +
male O +
neonates O +
as O +
well O +
as O +
an O +
asymptomatic O +
mild O +
left O +
ventricular O +
noncompaction O +
may O +
characterise O +
the O +
ranges O +
of O +
natural O +
history O +
of O +
Barth O +
syndrome O -
. O +

Facile O +
solution O +
synthesis O +
of O +
Ag@Pt B-Chemical +
core O -
- O -
shell O +
nanoparticles O +
with O +
dendritic O +
Pt B-Chemical +
shells O -
. O +

Ag@Pt B-Chemical +
nanoparticles O +
with O +
various O +
dendritic O +
Pt B-Chemical +
shells O +
were O +
successfully O +
synthesized O +
by O +
using O +
nonionic O +
surfactants O +
at O +
room O +
temperature O -
. O +

Our O +
recent O +
study O +
demonstrated O +
that O +
the O +
addition O +
of O +
nonionic O +
surfactant O +
plays O +
an O +
important O +
key O +
role O +
in O +
the O +
synthesis O +
of O +
dendritic O +
Pt B-Chemical +
nanostructures O +
( O -
J. O +
Am O -
. O +

Chem O -
. O +

Soc O -
. O -
, O +
2010 O -
, O +
132 O -
, O +
13636 O -
) O -
. O +

Here O +
we O +
extend O +
this O +
synthetic O +
concept O +
to O +
prepare O +
various O +
Ag@Pt B-Chemical +
nanoarchitectures O -
. O +

The O +
different O +
nanostructured O +
Pt B-Chemical +
shells O +
on O +
the O +
Ag B-Chemical +
core O +
were O +
confirmed O +
by O +
ultraviolet O -
- O -
visible O +
absorption O +
spectroscopy O +
and O +
transmission O +
electron O +
microscopy O -
. O +

As O +
a O +
preliminary O +
electrochemical O +
application O -
, O +
the O +
obtained O +
Ag@Pt B-Chemical +
nanostructures O +
were O +
applied O +
in O +
the O +
methanol B-Chemical +
oxidation O +
reaction O +
( O -
MOR O -
) O +
in O +
0.5 O +
M O +
H B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
SO I-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical +
solution O +
containing O +
0.5 O +
M O +
methanol B-Chemical -
. O +

The O +
Ag@Pt B-Chemical +
nanoparticles O +
with O +
thin O +
dendritic O +
Pt B-Chemical +
shells O +
show O +
superior O +
CO B-Chemical -
- O -
tolerance O +
performance O +
with O +
a O +
I O -
( O -
f O -
) O -
/ O -
I O -
( O -
b O -
) O +
value O +
reaching O +
3.71 O -
. O +

Our O +
Ag@Pt B-Chemical +
nanostructures O +
with O +
good O +
CO B-Chemical +
tolerant O +
activity O +
will O +
be O +
prominent O +
catalysts O +
for O +
MOR O -
. O +

Carboxylic B-Chemical +
acid I-Chemical +
( O -
bio O -
) O -
isosteres O +
in O +
drug O +
design O -
. O +

The O +
carboxylic B-Chemical +
acid I-Chemical +
functional O +
group O +
can O +
be O +
an O +
important O +
constituent O +
of O +
a O +
pharmacophore O -
, O +
however O -
, O +
the O +
presence O +
of O +
this O +
moiety O +
can O +
also O +
be O +
responsible O +
for O +
significant O +
drawbacks O -
, O +
including O +
metabolic O +
instability O -
, O +
toxicity O -
, O +
as O +
well O +
as O +
limited O +
passive O +
diffusion O +
across O +
biological O +
membranes O -
. O +

To O +
avoid O +
some O +
of O +
these O +
shortcomings O +
while O +
retaining O +
the O +
desired O +
attributes O +
of O +
the O +
carboxylic B-Chemical +
acid I-Chemical +
moiety O -
, O +
medicinal O +
chemists O +
often O +
investigate O +
the O +
use O +
of O +
carboxylic B-Chemical +
acid I-Chemical +
( O -
bio O -
) O -
isosteres O -
. O +

The O +
same O +
type O +
of O +
strategy O +
can O +
also O +
be O +
effective O +
for O +
a O +
variety O +
other O +
purposes O -
, O +
for O +
example O -
, O +
to O +
increase O +
the O +
selectivity O +
of O +
a O +
biologically O +
active O +
compound O +
or O +
to O +
create O +
new O +
intellectual O +
property O -
. O +

Several O +
carboxylic B-Chemical +
acid I-Chemical +
isosteres O +
have O +
been O +
reported O -
, O +
however O -
, O +
the O +
outcome O +
of O +
any O +
isosteric O +
replacement O +
can O -
not O +
be O +
readily O +
predicted O +
as O +
this O +
strategy O +
is O +
generally O +
found O +
to O +
be O +
dependent O +
upon O +
the O +
particular O +
context O +
( O -
i.e. O -
, O +
the O +
characteristic O +
properties O +
of O +
the O +
drug O +
and O +
the O +
drug O -
- O -
target O -
) O -
. O +

As O +
a O +
result O -
, O +
screening O +
of O +
a O +
panel O +
of O +
isosteres O +
is O +
typically O +
required O -
. O +

In O +
this O +
context O -
, O +
the O +
discovery O +
and O +
development O +
of O +
novel O +
carboxylic B-Chemical +
acid I-Chemical +
surrogates O +
that O +
could O +
complement O +
the O +
existing O +
palette O +
of O +
isosteres O +
remains O +
an O +
important O +
area O +
of O +
research O -
. O +

The O +
goal O +
of O +
this O +
Minireview O +
is O +
to O +
provide O +
an O +
overview O +
of O +
the O +
most O +
commonly O +
employed O +
carboxylic B-Chemical +
acid I-Chemical +
( O -
bio O -
) O -
isosteres O +
and O +
to O +
present O +
representative O +
examples O +
demonstrating O +
the O +
use O +
and O +
utility O +
of O +
each O +
isostere O +
in O +
drug O +
design O -
. O +

Development O +
of O +
Inhibitors O +
of O +
the O +
PAS O -
- O -
B O +
Domain O +
of O +
the O +
HIF-2α O +
Transcription O +
Factor O -
. O +

Hypoxia O +
inducible O +
factors O +
( O -
HIFs O -
) O +
are O +
heterodimeric O +
transcription O +
factors O +
induced O +
in O +
a O +
variety O +
of O +
pathophysiological O +
settings O -
, O +
including O +
cancer O -
. O +

We O +
describe O +
the O +
first O +
detailed O +
structure O -
- O -
activity O +
relationship O +
study O +
of O +
small O +
molecules O +
designed O +
to O +
inhibit O +
HIF-2α O -
- O -
ARNT O +
heterodimerization O +
by O +
binding O +
an O +
internal O +
cavity O +
of O +
the O +
HIF-2α O +
PAS O -
- O -
B O +
domain O -
. O +

Through O +
a O +
series O +
of O +
biophysical O +
characterizations O +
of O +
inhibitor O -
- O -
protein O +
interactions O +
( O -
NMR O +
and O +
X O -
- O -
ray O +
crystallography O -
) O -
, O +
we O +
have O +
established O +
the O +
structural O +
requirements O +
for O +
artificial O +
inhibitors O +
of O +
the O +
HIF-2α O -
- O -
ARNT O +
PAS O -
- O -
B O +
interaction O -
. O +

These O +
results O +
may O +
serve O +
as O +
a O +
foundation O +
for O +
discovering O +
therapeutic O +
agents O +
that O +
function O +
by O +
a O +
novel O +
mode O +
of O +
action O -
. O +

Adverse O +
effects O +
of O +
wood O +
smoke O +
PM O -
( O -
2.5 O -
) O +
exposure O +
on O +
macrophage O +
functions O -
. O +

Epidemiological O +
studies O +
have O +
shown O +
a O +
correlation O +
between O +
chronic O +
biomass O +
smoke O +
exposure O +
and O +
increased O +
respiratory O +
infection O -
. O +

Pulmonary O +
macrophages O +
are O +
instrumental O +
in O +
both O +
the O +
innate O +
and O +
the O +
adaptive O +
immune O +
responses O +
to O +
respiratory O +
infection O -
. O +

In O +
the O +
present O +
study O -
, O +
in O +
vitro O +
systems O +
were O +
utilized O +
where O +
alveolar O +
macrophages O +
( O -
AM O -
) O +
and O +
bone O +
marrow O -
- O -
derived O +
macrophages O +
( O -
BMdM O -
) O +
were O +
exposed O +
to O +
concentrated O +
wood O +
smoke O -
- O -
derived O +
particulate O +
matter O +
( O -
WS O -
- O -
PM O -
) O +
and O +
mice O +
were O +
exposed O +
in O +
vivo O +
to O +
either O +
concentrated O +
WS O -
- O -
PM O +
or O +
inhaled O +
WS O -
. O +

In O +
vivo O +
studies O +
demonstrated O +
that O +
WS O -
- O -
exposed O +
mice O +
inoculated O +
with O +
Streptococcus O +
pneumoniae O +
had O +
a O +
higher O +
bacterial O +
load O +
24 O +
h O +
post O -
- O -
exposure O -
, O +
and O +
corresponding O +
AM O +
were O +
found O +
to O +
have O +
decreased O +
lymphocyte O +
activation O +
activity O -
. O +

Additionally O -
, O +
while O +
classic O +
markers O +
of O +
inflammation O +
( O -
cellular O +
infiltration O -
, O +
total O +
protein O -
, O +
neutrophils O -
) O +
were O +
not O +
affected O -
, O +
there O +
were O +
changes O +
in O +
pulmonary O +
macrophages O +
populations O -
, O +
including O +
significant O +
decreases O +
in O +
macrophages O +
expressing O +
markers O +
of O +
activation O +
in O +
WS O -
- O -
exposed O +
mice O -
. O +

The O +
lymphocyte O +
activation O +
activity O +
of O +
WS O -
- O -
PM O -
- O -
exposed O +
AM O +
was O +
significantly O +
suppressed O -
, O +
but O +
the O +
phagocytic O +
activity O +
appeared O +
unchanged O -
. O +

In O +
an O +
effort O +
to O +
determine O +
a O +
pathway O +
for O +
WS O -
- O -
induced O +
suppression O -
, O +
RelB O +
activation O -
, O +
assessed O +
by O +
nuclear O +
translocation O -
, O +
was O +
observed O +
in O +
AM O +
exposed O +
to O +
either O +
inhaled O +
WS O +
or O +
instilled O +
WS O -
- O -
PM O -
. O +

Finally O -
, O +
an O +
analysis O +
of O +
WS O -
- O -
PM O +
fractions O +
determined O +
the O +
presence O +
of O +
4 O -
- O -
5 O +
polycyclic B-Chemical +
aromatic I-Chemical +
hydrocarbons I-Chemical +
( O -
PAHs B-Chemical -
) O -
, O +
and O +
preliminary O +
work O +
suggests O +
a O +
potential O +
role O +
for O +
these O +
PAHs B-Chemical +
to O +
alter O +
macrophage O +
functions O -
. O +

These O +
studies O +
show O +
a O +
decreased O +
ability O +
of O +
WS O -
- O -
exposed O +
pulmonary O +
macrophages O +
to O +
effectively O +
mount O +
a O +
defense O +
against O +
infection O -
, O +
the O +
effect O +
lasts O +
at O +
least O +
a O +
week O +
post O -
- O -
exposure O -
, O +
and O +
appears O +
to O +
be O +
mediated O +
via O +
RelB O +
activation O -
. O +

Association O +
of O +
Inhalation O +
Toxicologists O -
' O +
( O -
AIT O -
) O +
review O +
of O +
regulatory O +
aspects O +
for O +
inhalation O +
toxicology O +
studies O -
. O +

Regulatory O +
guidelines O +
are O +
intended O +
to O +
provide O +
recommendations O +
on O +
ways O +
to O +
achieve O +
greater O +
harmonization O +
in O +
the O +
interpretation O +
and O +
application O +
of O +
technical O +
procedures O +
and O +
requirements O +
for O +
product O +
registration O +
in O +
order O +
to O +
reduce O +
or O +
obviate O +
replication O +
of O +
the O +
testing O +
carried O +
out O +
during O +
the O +
research O +
and O +
development O +
of O +
new O +
products O -
. O +

The O +
objectives O +
of O +
such O +
harmonization O +
are O +
more O +
economical O +
use O +
of O +
human O -
, O +
animal O +
and O +
material O +
resources O -
; O +
the O +
elimination O +
of O +
unnecessary O +
delay O +
in O +
the O +
global O +
development O +
and O +
availability O +
of O +
new O +
products O +
while O +
maintaining O +
safeguards O +
on O +
quality O -
, O +
safety O +
and O +
efficacy O -
; O +
and O +
the O +
fulfillment O +
of O +
regulatory O +
obligations O +
to O +
protect O +
public O +
health O -
. O +

Tetrabenzoporphyrins B-Chemical -
: O +
synthetic O +
developments O +
and O +
applications O -
. O +

Tetrabenzoporphyrins B-Chemical +
have O +
attracted O +
considerable O +
worldwide O +
attention O +
over O +
the O +
last O +
few O +
decades O -
. O +

Since O +
the O +
discovery O +
of O +
these O +
pigments O -
, O +
chemists O -
, O +
biologists O -
, O +
medical O +
professionals O +
and O +
material O +
scientists O +
have O +
devoted O +
pronounced O +
efforts O +
in O +
order O +
to O +
develop O +
synthetic O +
methods O +
and O +
discover O +
useful O +
applications O +
for O +
these O +
compounds O -
. O +

Nowadays O -
, O +
tetrabenzoporphyrins B-Chemical +
occupy O +
a O +
prominent O +
position O +
in O +
porphyrin B-Chemical +
chemistry O -
, O +
and O +
this O +
review O +
is O +
intended O +
to O +
cover O +
the O +
main O +
synthetic O +
methods O +
and O +
applications O +
of O +
these O +
compounds O -
. O +

Engineering O +
a O +
serum O -
- O -
resistant O +
and O +
thermostable O +
vesicular O +
stomatitis O +
virus O +
G O +
glycoprotein O +
for O +
pseudotyping O +
retroviral O +
and O +
lentiviral O +
vectors O -
. O +

Vesicular O +
stomatitis O +
virus O +
G O +
glycoprotein O +
( O -
VSV O -
- O -
G O -
) O +
is O +
the O +
most O +
widely O +
used O +
envelope O +
protein O +
for O +
retroviral O +
and O +
lentiviral O +
vector O +
pseudotyping O -
; O +
however O -
, O +
serum O +
inactivation O +
of O +
VSV O -
- O -
G O +
pseudotyped O +
vectors O +
is O +
a O +
significant O +
challenge O +
for O +
in O +
vivo O +
gene O +
delivery O -
. O +

To O +
address O +
this O +
problem O -
, O +
we O +
conducted O +
directed O +
evolution O +
of O +
VSV O -
- O -
G O +
to O +
increase O +
its O +
resistance O +
to O +
human O +
serum O +
neutralization O -
. O +

After O +
six O +
selection O +
cycles O -
, O +
numerous O +
common O +
mutations O +
were O +
present O -
. O +

On O +
the O +
basis O +
of O +
their O +
location O +
within O +
VSV O -
- O -
G O -
, O +
we O +
analyzed O +
whether O +
substitutions O +
in O +
several O +
surface O +
exposed O +
residues O +
could O +
endow O +
viral O +
vectors O +
with O +
higher O +
resistance O +
to O +
serum O -
. O +

S162 O -
T O -
, O +
T230N O +
and O +
T368A O +
mutations O +
enhanced O +
serum O +
resistance O -
, O +
and O +
additionally O +
K66 O -
T O -
, O +
T368A O +
and O +
E380 O -
K O +
substitutions O +
increased O +
the O +
thermostability O +
of O +
VSV O -
- O -
G O +
pseudotyped O +
retroviral O +
vectors O -
, O +
an O +
advantageous O +
byproduct O +
of O +
the O +
selection O +
strategy O -
. O +

Analysis O +
of O +
a O +
number O +
of O +
combined O +
mutants O +
revealed O +
that O +
VSV O -
- O -
G O +
harboring O +
T230N+T368A O +
or O +
K66T+S162T+T230N+T368A O +
mutations O +
exhibited O +
both O +
higher O +
in O +
vitro O +
resistance O +
to O +
human O +
serum O +
and O +
higher O +
thermostability O -
, O +
as O +
well O +
as O +
enhanced O +
resistance O +
to O +
rabbit O +
and O +
mouse O +
serum O -
. O +

Finally O -
, O +
lentiviral O +
vectors O +
pseudotyped O +
with O +
these O +
variants O +
were O +
more O +
resistant O +
to O +
human O +
serum O +
in O +
a O +
murine O +
model O -
. O +

These O +
serum O -
- O -
resistant O +
and O +
thermostable O +
VSV O -
- O -
G O +
variants O +
may O +
aid O +
the O +
application O +
of O +
retroviral O +
and O +
lentiviral O +
vectors O +
to O +
gene O +
therapy O -
. O +

Gene O +
Therapy O +
advance O +
online O +
publication O -
, O +
31 O +
January O +
2013 O -
; O +
doi:10.1038 O -
/ O -
gt.2013.1 O -
. O +

The O +
impact O +
of O +
functionalization O +
on O +
the O +
stability O -
, O +
work O +
function O -
, O +
and O +
photoluminescence O +
of O +
reduced B-Chemical +
graphene I-Chemical +
oxide I-Chemical -
. O +

Reduced B-Chemical +
graphene I-Chemical +
oxide I-Chemical +
( O -
rGO B-Chemical -
) O +
is O +
a O +
promising O +
material O +
for O +
a O +
variety O +
of O +
thin O -
- O -
film O +
optoelectronic O +
applications O -
. O +

Two O +
main O +
barriers O +
to O +
its O +
widespread O +
use O +
are O +
the O +
lack O +
of O +
( O -
1 O -
) O +
fabrication O +
protocols O +
leading O +
to O +
tailored O +
functionalization O +
of O +
the O +
graphene B-Chemical +
sheet O +
with O +
oxygen B-Chemical -
- O -
containing O +
chemical O +
groups O -
, O +
and O +
( O -
2 O -
) O +
understanding O +
of O +
the O +
impact O +
of O +
such O +
functional O +
groups O +
on O +
the O +
stability O +
and O +
on O +
the O +
optical O +
and O +
electronic O +
properties O +
of O +
rGO B-Chemical -
. O +

We O +
carry O +
out O +
classical O +
molecular O +
dynamics O +
and O +
density O +
functional O +
theory O +
calculations O +
on O +
a O +
large O +
set O +
of O +
realistic O +
rGO B-Chemical +
structures O +
to O +
decompose O +
the O +
effects O +
of O +
different O +
functional O +
groups O +
on O +
the O +
stability O -
, O +
work O +
function O -
, O +
and O +
photoluminescence O -
. O +

Our O +
calculations O +
indicate O +
the O +
metastable O +
nature O +
of O +
carbonyl B-Chemical -
- O -
rich O +
rGO B-Chemical +
and O +
its O +
favorable O +
transformation O +
to O +
hydroxyl B-Chemical -
- O -
rich O +
rGO B-Chemical +
at O +
room O +
temperature O +
via O +
carbonyl B-Chemical -
- O -
to O -
- O -
hydroxyl B-Chemical +
conversion O +
reactions O +
near O +
carbon B-Chemical +
vacancies O +
and O +
holes O -
. O +

We O +
demonstrate O +
a O +
significant O +
tunability O +
in O +
the O +
work O +
function O +
of O +
rGO B-Chemical +
up O +
to O +
2.5 O +
eV O +
by O +
altering O +
the O +
composition O +
of O +
oxygen B-Chemical -
- O -
containing O +
functional O +
groups O +
for O +
a O +
fixed O +
oxygen B-Chemical +
concentration O -
, O +
and O +
of O +
the O +
photoluminescence O +
emission O +
by O +
modulating O +
the O +
fraction O +
of O +
epoxy B-Chemical +
and O +
carbonyl B-Chemical +
groups O -
. O +

Taken O +
together O -
, O +
our O +
results O +
guide O +
the O +
application O +
of O +
tailored O +
rGO B-Chemical +
structures O +
in O +
devices O +
for O +
optoelectronics O +
and O +
renewable O +
energy O -
. O +

pH O -
- O -
dependent O +
motion O +
of O +
self O -
- O -
propelled O +
droplets O +
due O +
to O +
Marangoni O +
effect O +
at O +
neutral O +
pH. O +
Oil O +
droplets O +
loaded O +
with O +
surfactant O +
propel O +
themselves O +
with O +
a O +
velocity O +
up O +
to O +
6 O +
mm O +
s O -
( O -
-1 O -
) O +
when O +
they O +
are O +
placed O +
in O +
an O +
aqueous O +
phase O +
of O +
NaOH B-Chemical +
solution O +
or O +
buffer O +
solution O -
. O +

The O +
required O +
driving O +
force O +
for O +
such O +
motion O +
is O +
generated O +
on O +
the O +
interface O +
of O +
the O +
droplets O +
by O +
the O +
change O +
in O +
interfacial O +
tension O -
, O +
due O +
to O +
deprotonation O +
of O +
the O +
surfactant O -
. O +

This O +
force O +
induces O +
Marangoni O +
convection O -
, O +
which O +
gives O +
rise O +
to O +
a O +
circulating O +
flow O +
inside O +
the O +
droplets O -
. O +

The O +
droplets O +
begin O +
to O +
move O +
when O +
the O +
axis O +
of O +
this O +
circulation O +
deviates O +
from O +
the O +
vertical O +
line O -
. O +

This O +
motion O +
depends O +
on O +
the O +
pH O +
condition O +
of O +
the O +
aqueous O +
phase O -
. O +

When O +
the O +
initial O +
value O +
of O +
pH O +
is O +
adjusted O +
such O +
that O +
the O +
pH O +
exceeds O +
the O +
threshold O +
at O +
the O +
equilibrium O +
state O -
, O +
the O +
droplets O +
move O +
spontaneously O -
. O +

It O +
was O +
seen O +
that O +
the O +
droplets O +
were O +
independent O +
of O +
the O +
material O +
of O +
the O +
solid O +
substrates O +
because O +
the O +
droplets O +
were O +
not O +
directly O +
in O +
contact O +
with O +
the O +
surface O +
of O +
the O +
substrate O -
. O +

The O +
condition O +
for O +
the O +
onset O +
of O +
this O +
spontaneous O +
motion O +
was O +
verified O +
by O +
comparing O +
the O +
prediction O +
from O +
the O +
linear O +
stability O +
analysis O +
with O +
experiments O -
. O +

The O +
stability O +
analysis O +
overestimates O +
the O +
value O +
of O +
the O +
driving O +
force O -
, O +
causing O +
instability O -
. O +

Synthesis O +
and O +
characterization O +
of O +
a O +
matrix O -
- O -
metalloproteinase O +
responsive O +
silk O -
- O -
elastinlike O +
protein O +
polymer O -
. O +

Silk O -
- O -
elastinlike O +
protein O +
polymers O +
( O -
SELPs O -
) O +
are O +
recombinant O +
polymers O +
consisting O +
of O +
tandem O +
repeats O +
of O +
silk O +
( O -
GAGAGS O -
) O +
and O +
elastin O +
( O -
GVGVP O -
) O +
units O -
. O +

By O +
modification O +
of O +
the O +
length O +
and O +
composition O +
of O +
these O +
repeats O -
, O +
the O +
properties O +
of O +
SELP O +
hydrogels O +
can O +
be O +
controlled O +
for O +
specific O +
applications O +
including O +
nucleic O +
acid O +
and O +
virus O +
delivery O +
and O +
tissue O +
engineering O -
. O +

Here O -
, O +
the O +
structure O +
of O +
SELPs O +
is O +
further O +
modified O +
to O +
include O +
a O +
sequence O +
that O +
is O +
sensitive O +
to O +
matrix O -
- O -
metalloproteinases O +
( O -
MMPs O -
) O -
. O +

MMPs O +
are O +
a O +
ubiquitous O +
family O +
of O +
extracellular O +
matrix O -
- O -
modifying O +
enzymes O +
that O +
are O +
commonly O +
associated O +
with O +
numerous O +
vital O +
processes O -
. O +

Increased O +
levels O +
of O +
MMPs O +
are O +
found O +
at O +
high O +
levels O +
locally O +
in O +
many O +
types O +
of O +
solid O +
tumors O -
. O +

By O +
modifying O +
the O +
SELP O +
backbone O +
with O +
MMP O -
- O -
sensitive O +
peptide O +
sequences O -
, O +
a O +
hydrogel O +
that O +
is O +
degradable O +
by O +
MMPs O +
was O +
produced O -
. O +

The O +
MMP O -
- O -
sensitivity O +
of O +
the O +
polymer O +
was O +
examined O +
by O +
incubation O +
with O +
MMP-2 O +
and O +
MMP-9 O -
, O +
which O +
yielded O +
complete O +
cleavage O +
of O +
all O +
full O -
- O -
length O +
polymers O +
by O +
36 O +
hours O +
and O +
48 O +
hours O -
, O +
respectively O -
, O +
with O +
no O +
observable O +
effect O +
on O +
unmodified O +
SELP O -
. O +

Hydrogel O +
sensitivity O +
was O +
tested O +
by O +
exposure O +
to O +
MMP-2 O +
or O +
MMP-9 O +
for O +
2 O +
weeks O -
, O +
during O +
which O +
samples O +
were O +
taken O +
to O +
analyze O +
protein O +
loss O +
from O +
the O +
hydrogel O +
and O +
release O +
of O +
100 O +
nm O +
fluorescent O +
beads O -
. O +

Following O +
the O +
incubation O +
period O -
, O +
hydrogels O +
were O +
tested O +
in O +
mechanical O +
compression O +
to O +
examine O +
the O +
loss O +
of O +
hydrogel O +
stiffness O +
due O +
to O +
degradation O -
. O +

It O +
was O +
found O +
that O +
MMP-2 O +
and O +
MMP-9 O +
caused O +
63 O -
% O +
and O +
44 O -
% O +
increased O +
protein O +
loss O +
and O +
65 O -
% O +
and O +
95 O -
% O +
increased O +
release O +
from O +
MMP O -
- O -
sensitive O +
hydrogels O -
, O +
while O +
the O +
compressive O +
modulus O +
decreased O +
by O +
41 O -
% O +
and O +
29 O -
% O -
. O +

These O +
results O +
suggest O +
the O +
potential O +
of O +
MMP O -
- O -
responsive O +
SELPs O +
for O +
localized O +
delivery O +
of O +
bioactive O +
agents O +
where O +
MMPs O +
are O +
overexpressed O -
. O +

Biobased O +
polyesters B-Chemical +
with O +
composition O -
- O -
dependent O +
thermomechanical O +
properties O -
: O +
synthesis O +
and O +
characterization O +
of O +
poly B-Chemical -
( I-Chemical -
butylene I-Chemical +
succinate I-Chemical -
- I-Chemical -
co I-Chemical -
- I-Chemical -
butylene I-Chemical +
azelate I-Chemical -
) I-Chemical -
. O +

Environmentally O +
friendly O +
poly B-Chemical -
( I-Chemical -
butylenesuccinate I-Chemical -
- I-Chemical -
co I-Chemical -
- I-Chemical -
butyleneazelate I-Chemical -
) I-Chemical +
( O -
P B-Chemical -
( I-Chemical -
BS I-Chemical -
- I-Chemical -
co I-Chemical -
- I-Chemical -
BAz I-Chemical -
) I-Chemical -
s I-Chemical -
) O +
aliphatic B-Chemical +
copolyesters I-Chemical +
with O +
composition O -
- O -
dependent O +
thermomechanical O +
properties O +
were O +
synthesized O +
from O +
succinic B-Chemical +
acid I-Chemical +
( O -
SuA B-Chemical -
) O -
, O +
1,4-butanediol B-Chemical +
( O -
BDO B-Chemical -
) O -
, O +
and O +
dimethylazelate B-Chemical +
( O -
DMAz B-Chemical -
) O +
through O +
a O +
two O -
- O -
step O +
polycondensation O +
reaction O -
. O +

The O +
molar O +
SuA B-Chemical -
/ O -
AzA B-Chemical +
ratio O +
was O +
varied O +
from O +
4:1 O +
to O +
1:4 O -
, O +
and O +
the O +
chemical O +
structure O +
and O +
molecular O +
characteristics O +
of O +
resulting O +
( B-Chemical -
co I-Chemical -
) I-Chemical -
polyesters I-Chemical +
were O +
characterized O +
by O +
NMR O +
and O +
SEC O -
, O +
whereas O +
thermal O +
properties O +
and O +
crystallinity O +
were O +
studied O +
by O +
differential O +
scanning O +
calorimetry O +
( O -
DSC O -
) O -
, O +
dynamic O +
mechanical O +
thermal O +
analyses O +
( O -
DMTA O -
) O -
, O +
and O +
X O -
- O -
ray O +
diffraction O +
( O -
XRD O -
) O -
. O +

A O +
good O +
agreement O +
between O +
theoretical O +
and O +
experimental O +
SuA B-Chemical -
/ O -
AzA B-Chemical +
molar O +
ratios O +
in O +
the O +
copolyesters B-Chemical +
was O +
achieved O -
, O +
together O +
with O +
the O +
recovery O +
of O +
semicrystalline O +
random O +
copolymers O +
of O +
uniform O +
composition O +
along O +
the O +
chains O -
. O +

NMR O -
, O +
DSC O -
, O +
DMTA O -
, O +
and O +
XRD O +
results O +
show O +
that O +
depending O +
on O +
their O +
composition O +
the O +
P B-Chemical -
( I-Chemical -
BS I-Chemical -
- I-Chemical -
co I-Chemical -
- I-Chemical -
BAz I-Chemical -
) I-Chemical +
copolyesters I-Chemical +
might O +
find O +
applications O +
from O +
elastomers O +
to O +
high O -
- O -
impact O +
thermoplastics O -
. O +

Formulation O -
, O +
in O +
vitro O +
evaluation O +
and O +
study O +
of O +
variables O +
on O +
tri O -
- O -
layered O +
gastro O -
- O -
retentive O +
delivery O +
system O +
of O +
diltiazem B-Chemical +
HCl I-Chemical -
. O +

Abstract O +
Context O -
: O +
Tri O -
- O -
layered O +
floating O +
tablets O +
using O +
only O +
one O +
grade O +
of O +
polyethylene B-Chemical +
oxide I-Chemical +
( O -
PEO B-Chemical -
) O +
would O +
enable O +
easy O +
manufacturing O -
, O +
reproducibility O +
and O +
controlled O +
release O +
for O +
highly O +
soluble O +
drugs O -
. O +

Objective O -
: O +
To O +
evaluate O +
the O +
potential O +
of O +
PEO B-Chemical +
as O +
a O +
sole O +
polymer O +
for O +
the O +
controlled O +
release O +
and O +
to O +
study O +
the O +
effect O +
of O +
formulation O +
variables O +
on O +
release O +
and O +
gastric O +
retention O +
of O +
highly O +
soluble O +
Diltiazem B-Chemical +
hydrochloride I-Chemical +
( O -
DTZ B-Chemical -
) O -
. O +

Methods O -
: O +
Tablets O +
were O +
compressed O +
with O +
middle O +
layer O +
consisting O +
of O +
drug O +
and O +
polymer O +
while O +
outer O +
layers O +
consisted O +
of O +
polymer O +
with O +
sodium B-Chemical +
bicarbonate I-Chemical -
. O +

Design O +
of O +
formulation O +
to O +
obtain O +
12 O +
h O -
, O +
zero O -
- O -
order O +
release O +
and O +
rapid O +
floatation O +
was O +
done O +
by O +
varying O +
the O +
grades O -
, O +
quantity O +
of O +
PEO B-Chemical +
and O +
sodium B-Chemical +
bicarbonate I-Chemical -
. O +

Dissolution O +
data O +
were O +
fitted O +
in O +
drug O +
release O +
models O +
and O +
swelling O -
/ O -
erosion O +
studies O +
were O +
undertaken O +
to O +
verify O +
the O +
drug O +
release O +
mechanism O -
. O +

Effect O +
of O +
formulation O +
variables O +
and O +
tablet O +
surface O +
morphology O +
using O +
scanning O +
electron O +
microscopy O +
were O +
studied O -
. O +

Results O +
and O +
discussion O -
: O +
The O +
optimized O +
formula O +
passed O +
the O +
criteria O +
of O +
USP O +
dissolution O +
test O +
I O +
and O +
exhibited O +
floating O +
lag O -
- O -
time O +
of O +
3 O -
- O -
4 O +
min O -
. O +

Drug O +
release O +
was O +
faster O +
from O +
low O +
molecular O +
weight O +
( O -
MW O -
) O +
PEO B-Chemical +
as O +
compared O +
to O +
high O +
MW O -
. O +

With O +
an O +
increase O +
in O +
the O +
amount O +
of O +
sodium B-Chemical +
bicarbonate I-Chemical -
, O +
faster O +
buoyancy O +
was O +
achieved O +
due O +
to O +
the O +
increased O +
CO B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
gas O +
formation O -
. O +

Drug O +
release O +
followed O +
zero O -
- O -
order O +
and O +
gave O +
a O +
good O +
fit O +
to O +
the O +
Korsmeyer O -
- O -
Peppas O +
model O -
, O +
which O +
suggested O +
that O +
drug O +
release O +
was O +
due O +
to O +
diffusion O +
through O +
polymer O +
swelling O -
. O +

Conclusion O -
: O +
Zero O -
- O -
order O -
, O +
controlled O +
release O +
profile O +
with O +
the O +
desired O +
buoyancy O +
can O +
be O +
achieved O +
by O +
using O +
optimum O +
formula O +
quantities O +
of O +
sodium B-Chemical +
bicarbonate I-Chemical +
and O +
polymer O -
. O +

The O +
tri O -
- O -
layered O +
system O +
shows O +
promising O +
delivery O +
of O +
DTZ B-Chemical -
, O +
and O +
possibly O +
other O +
water O -
- O -
soluble O +
drugs O -
. O +

Short O -
- O -
term O +
assessment O +
of O +
toxicological O +
aspects O -
, O +
oxidative O +
and O +
inflammatory O +
response O +
to O +
dietary O +
melon O +
superoxide B-Chemical +
dismutase O +
in O +
rats O -
. O +

The O +
protective O +
effects O +
of O +
SODB O -
, O +
a O +
gastro O -
- O -
resistant O +
encapsulated O +
melon O +
superoxide B-Chemical +
dismutase O -
, O +
on O +
haematological O +
and O +
biochemical O +
parameters O +
and O +
inflammatory O +
and O +
oxidative O +
status O -
, O +
were O +
evaluated O +
in O +
the O +
blood O +
and O +
liver O +
tissue O -
. O +

The O +
study O +
consisted O +
in O +
a O +
28-day O +
experiment O +
on O +
rats O +
supplemented O +
with O +
three O +
doses O +
( O -
10 O -
, O +
40 O +
and O +
160USOD O -
/ O -
day O -
) O +
of O +
SODB O -
- O -
M O -
, O +
SODB O -
- O -
D O +
or O +
SODB O -
- O -
S O -
, O +
different O +
depending O +
on O +
the O +
nature O +
of O +
the O +
coating O +
( O -
palm O +
oil O -
, O +
shellac O +
or O +
gum O +
Arabic O +
respectively O -
) O -
. O +

No O +
mortality O -
, O +
abnormal O +
clinical O +
signs O -
, O +
behavioural O +
changes O +
or O +
macroscopic O +
findings O +
were O +
observed O +
whatever O +
the O +
groups O -
. O +

Haematological O +
parameters O +
( O -
total O +
red O +
blood O +
cell O +
count O -
, O +
haemoglobin O +
content O -
, O +
haematocrit O -
, O +
red O +
cell O +
indices O -
, O +
white O +
blood O +
cell O +
count O +
and O +
platelets O +
count O -
) O +
were O +
not O +
modified O +
in O +
SODB O +
treated O -
- O -
groups O -
. O +

No O +
marked O +
change O +
was O +
recorded O +
in O +
biochemical O +
parameters O +
( O -
plasma O +
urea B-Chemical -
, O +
creatinine B-Chemical -
, O +
lipids O -
, O +
electrolytes O -
, O +
bilirubin B-Chemical -
, O +
transaminases O +
and O +
gamma B-Chemical -
- I-Chemical -
glutamyl I-Chemical +
transferase O -
) O -
. O +

The O +
liver O +
endogenous O +
antioxidant O +
enzymes O +
( O -
copper B-Chemical -
/ O -
zinc B-Chemical +
and O +
manganese B-Chemical +
superoxide I-Chemical +
dismutase O -
) O +
expressions O +
were O +
significantly O +
increased O +
in O +
the O +
rats O +
receiving O +
the O +
highest O +
dose O +
of O +
SODB O +
( O -
160USOD O -
/ O -
day O -
) O +
whatever O +
the O +
coating O -
. O +

Moreover O -
, O +
interleukin-6 O -
, O +
a O +
marker O +
of O +
inflammation O -
, O +
was O +
significantly O +
decreased O +
in O +
these O +
high O +
dose O -
- O -
treated O -
- O -
groups O -
. O +

The O +
present O +
study O +
indicates O +
that O +
dietary O +
supplementation O +
of O +
SODB O +
on O +
rats O +
has O +
no O +
harmful O +
side O +
effects O +
and O +
could O +
be O +
beneficial O +
especially O +
at O +
high O +
doses O -
. O +

Anti O -
- O -
oxidant O +
and O +
natural O +
killer O +
cell O +
activity O +
of O +
Korean O +
red O +
ginseng O +
( O -
Panax O +
ginseng O -
) O +
and O +
urushiol B-Chemical +
( O -
Rhus O +
vernicifera O +
Stokes O -
) O +
on O +
non O -
- O -
alcoholic O +
fatty O +
liver O +
disease O +
of O +
rat O -
. O +

Anti O -
- O -
oxidative O +
and O +
immunologic O +
effects O +
of O +
the O +
Korea O +
red O +
ginseng O +
( O -
KRG O -
; O +
Panax O +
ginseng O -
) O +
and O +
urushiol B-Chemical +
( O -
Rhus O +
vernicifera O +
Stokes O -
) O +
on O +
non O -
- O -
alcoholic O +
fatty O +
liver O +
disease O +
( O -
NAFLD O -
) O +
were O +
evaluated O -
. O +

Forty O -
- O -
five O +
rats O +
( O -
five O +
Long O -
- O -
Evans O +
Tokushima O +
Otsuka O +
and O +
40 O +
Otsuka O +
Long O -
- O -
Evans O +
Tokushima O +
Fatty O +
[ O -
OLETF O -
] O +
rats O -
) O +
received O +
chew O +
diets O +
for O +
10months O -
; O +
after O +
this O +
period O -
. O +

The O +
OLETF O +
rats O +
were O +
divided O +
into O +
the O +
following O +
four O +
groups O +
according O +
to O +
diet O +
for O +
2months O -
: O +
NAFLD O +
( O -
chew O -
) O -
, O +
KRG O +
( O -
chew+KRG O +
[ O -
200mg O -
/ O -
kg O -
/ O -
day O -
] O -
) O -
, O +
urushiol B-Chemical +
( O -
chew+urushiol O +
[ O -
0.5mg O -
/ O -
kg O -
/ O -
day O -
] O -
) O -
, O +
and O +
ursodeoxycholic B-Chemical +
acid I-Chemical +
( O -
UDCA B-Chemical -
) O +
( O -
chew+UDCA O +
[ O -
15mg O -
/ O -
kg O -
/ O -
day O -
] O -
) O +
groups O -
. O +

Liver O +
function O -
, O +
lipid O +
profiles O +
and O +
anti O -
- O -
oxidant O +
activity O +
of O +
liver O +
and O +
serum O -
, O +
natural O +
killer O +
( O -
NK O -
) O +
cell O +
activity O -
, O +
and O +
pathology O +
were O +
compared O -
. O +

In O +
KRG O +
and O +
urushiol B-Chemical +
groups O -
, O +
the O +
level O +
of O +
serum O +
triglyceride B-Chemical +
( O -
[ O -
302.0±70.4 O +
and O +
275.2±63.8 O -
] O +
vs. O +
527.7±153.3mg O -
/ O -
dL O -
) O +
were O +
lower O +
compared O +
with O +
that O +
of O +
NAFLD O +
group O +
( O -
p<0.05 O -
) O -
. O +

The O +
levels O +
of O +
HDL O -
- O -
cholesterol B-Chemical +
( O -
liver O +
tissue O -
: O +
[ O -
4.8±0.2 O +
and O +
4.8±0.5 O -
] O +
vs. O +
4.2±0.2mg O -
/ O -
g O -
) O +
and O +
NK O +
cell O +
activity O +
( O -
[ O -
3485±910 O +
and O +
3559±910 O -
] O +
vs. O +
2486±619 O +
counts O -
) O +
were O +
significantly O +
higher O +
than O +
those O +
of O +
the O +
NAFLD O +
group O +
( O -
p<0.001 O -
) O -
. O +

Inflammation O +
with O +
neutrophil O +
infiltration O +
was O +
observed O +
in O +
only O +
two O +
rats O +
in O +
the O +
NAFLD O +
group O -
. O +

These O +
results O +
suggest O +
that O +
2months O +
of O +
oral O +
KRG O +
or O +
urushiol B-Chemical +
administration O +
improves O +
lipid O +
profiles O +
and O +
stimulates O +
NK O +
cell O +
activity O -
, O +
while O +
inhibiting O +
steatohepatitis O +
in O +
OLEFT O +
rats O -
. O +

TNFα O +
and O +
Fas O -
/ O -
FasL O +
pathways O +
are O +
involved O +
in O +
9-Methoxycamptothecin B-Chemical -
- O -
induced O +
apoptosis O +
in O +
cancer O +
cells O +
with O +
oxidative O +
stress O +
and O +
G2 O -
/ O -
M O +
cell O +
cycle O +
arrest O -
. O +

9-Methoxycamptothecin B-Chemical +
( O -
MCPT B-Chemical -
) O +
has O +
been O +
recently O +
reported O +
to O +
have O +
a O +
strong O +
anticancer O +
activity O -
. O +

However O -
, O +
its O +
detailed O +
mechanism O +
of O +
action O +
in O +
human O +
cancer O +
cells O +
has O +
not O +
been O +
well O +
clarified O -
. O +

The O +
results O +
showed O +
that O +
MCPT B-Chemical +
induced O +
cytotoxicity O +
in O +
seven O +
human O +
cancer O +
cell O +
lines O +
in O +
a O +
dose O +
dependent O +
manner O +
after O +
72h O -
, O +
with O +
A2780 O +
and O +
Hela O +
cell O +
lines O +
more O +
sensitive O -
, O +
so O +
the O +
two O +
cell O +
lines O +
were O +
chosen O +
to O +
do O +
further O +
studies O -
. O +

MCPT B-Chemical +
induced O +
strong O +
G2 O -
/ O -
M O +
arrest O +
in O +
both O +
A2780 O +
cells O +
and O +
Hela O +
cells O +
after O +
24h O -
, O +
following O +
by O +
substantial O +
sub O -
- O -
G1 O +
arrest O +
( O -
indicating O +
apoptosis O -
) O -
. O +

The O +
apoptosis O +
was O +
verified O +
by O +
staining O +
with O +
Annexin O +
V O -
- O -
FITC B-Chemical +
and O +
propidium B-Chemical +
iodide I-Chemical -
. O +

ROS O +
generation O +
increased O +
significantly O +
in O +
MCPT B-Chemical -
- O -
induced O +
apoptosis O -
. O +

Meanwhile O -
, O +
the O +
apoptosis O +
appeared O +
to O +
be O +
dependent O +
on O +
caspase-3 O -
, O +
-8 O +
and O +
-9 O +
in O +
A2780 O +
cells O -
, O +
and O +
caspase-3 O +
in O +
Hela O +
cells O -
. O +

In O +
addition O -
, O +
MCPT B-Chemical +
induced O +
up O -
- O -
regulation O +
expression O +
of O +
most O +
of O +
seventeen O +
genes O +
in O +
both O +
cell O +
lines O -
. O +

Western O +
blot O +
verified O +
that O +
changes O +
of O +
TNFα O -
, O +
Fas O -
, O +
P53 O +
and O +
P27 O +
protein O +
level O +
were O +
consistent O +
with O +
their O +
gene O +
expression O +
changes O -
. O +

Taken O +
together O -
, O +
MCPT B-Chemical +
plays O +
an O +
important O +
role O +
in O +
tumor O +
growth O +
suppression O +
by O +
inducing O +
apoptosis O +
in O +
both O +
cell O +
lines O +
via O +
extrinsic O +
and O +
intrinsic O +
apoptotic O +
pathways O -
, O +
and O +
has O +
the O +
potential O +
to O +
be O +
developed O +
into O +
an O +
antitumor O +
agent O -
. O +

Hierarchical O +
organization O +
of O +
osteoblasts O +
reveals O +
the O +
significant O +
role O +
of O +
CD166 O +
in O +
hematopoietic O +
stem O +
cell O +
maintenance O +
and O +
function O -
. O +

The O +
role O +
of O +
osteoblasts O +
( O -
OB O -
) O +
in O +
maintaining O +
hematopoietic O +
stem O +
cells O +
( O -
HSC O -
) O +
in O +
their O +
niche O +
is O +
well O +
elucidated O -
, O +
but O +
the O +
exact O +
definition O -
, O +
both O +
phenotypically O +
and O +
hierarchically O +
of O +
OB O +
responsible O +
for O +
these O +
functions O +
is O +
not O +
clearly O +
known O -
. O +

We O +
previously O +
demonstrated O +
that O +
OB O +
maturational O +
status O +
influences O +
HSC O +
function O +
whereby O +
immature O +
OB O +
with O +
high O +
Runx2 O +
expression O +
promote O +
hematopoietic O +
expansion O -
. O +

Here O -
, O +
we O +
show O +
that O +
Activated O +
Leukocyte O +
Cell O +
Adhesion O +
Molecule O +
( O -
ALCAM O -
) O +
or O +
CD166 O +
expression O +
on O +
OB O +
is O +
directly O +
correlated O +
with O +
Runx2 O +
expression O +
and O +
high O +
hematopoiesis O +
enhancing O +
activity O +
( O -
HEA O -
) O -
. O +

Fractionation O +
of O +
OB O +
with O +
lineage O +
markers O -
: O +
Sca1 O -
, O +
osteopontin O +
( O -
OPN O -
) O -
, O +
CD166 O -
, O +
CD44 O -
, O +
and O +
CD90 O +
revealed O +
that O +
Lin O -
- O -
Sca1-OPN+CD166 O -
+ O +
cells O +
( O -
CD166 O -
+ O -
) O +
and O +
their O +
subpopulations O +
fractionated O +
with O +
CD44 O +
and O +
CD90 O +
expressed O +
high O +
levels O +
of O +
Runx2 O +
and O +
low O +
levels O +
of O +
osteocalcin O +
( O -
OC O -
) O +
demonstrating O +
the O +
relatively O +
immature O +
status O +
of O +
these O +
cells O -
. O +

Conversely O -
, O +
the O +
majority O +
of O +
the O +
Lin O -
- O -
Sca1-OPN+CD166- O +
cells O +
( O -
CD166- O -
) O +
expressed O +
high O +
OC O +
levels O +
suggesting O +
that O +
CD166- O +
OB O +
are O +
more O +
mature O -
. O +

In O +
vitro O +
hematopoietic O +
potential O +
of O +
LSK O +
cells O +
co O -
- O -
cultured O +
for O +
7days O +
with O +
fresh O +
OB O +
or O +
OB O +
pre O -
- O -
cultured O +
for O +
1 O -
, O +
2 O -
, O +
or O +
3 O +
weeks O +
declined O +
precipitously O +
with O +
increasing O +
culture O +
duration O +
concomitant O +
with O +
loss O +
of O +
CD166 O +
expression O -
. O +

Importantly O -
, O +
LSK O +
cells O +
co O -
- O -
cultured O +
with O +
CD166+CD44+CD90 O -
+ O +
OB O +
maintained O +
their O +
in O +
vivo O +
repopulating O +
potential O +
through O +
primary O +
and O +
secondary O +
transplantation O -
, O +
suggesting O +
that O +
robust O +
HEA O +
activity O +
is O +
best O +
mediated O +
by O +
immature O +
CD166 O -
+ O +
OB O +
with O +
high O +
Runx2 O +
and O +
low O +
OC O +
expression O -
. O +

These O +
studies O +
begin O +
to O +
define O +
the O +
hierarchical O +
organization O +
of O +
osteoblastic O +
cells O +
and O +
provide O +
a O +
more O +
refined O +
definition O +
of O +
OB O +
that O +
can O +
mediate O +
HEA O -
. O +

Alteration O +
of O +
proteoglycan O +
sulfation O +
affects O +
bone O +
growth O +
and O +
remodeling O -
. O +

Diastrophic O +
dysplasia O +
( O -
DTD O -
) O +
is O +
a O +
chondrodysplasia O +
caused O +
by O +
mutations O +
in O +
the O +
SLC26A2 O +
gene O -
, O +
leading O +
to O +
reduced O +
intracellular O +
sulfate B-Chemical +
pool O +
in O +
chondrocytes O -
, O +
osteoblasts O +
and O +
fibroblasts O -
. O +

Hence O -
, O +
proteoglycans O +
are O +
undersulfated O +
in O +
the O +
cartilage O +
and O +
bone O +
of O +
DTD O +
patients O -
. O +

To O +
characterize O +
the O +
bone O +
phenotype O +
of O +
this O +
skeletal O +
dysplasia O +
we O +
used O +
the O +
Slc26a2 O +
knock O -
- O -
in O +
mouse O +
( O -
dtd O +
mouse O -
) O -
, O +
that O +
was O +
previously O +
validated O +
as O +
an O +
animal O +
model O +
of O +
DTD O +
in O +
humans O -
. O +

X O -
- O -
rays O -
, O +
bone O +
densitometry O -
, O +
static O +
and O +
dynamic O +
histomorphometry O -
, O +
and O +
in O +
vitro O +
studies O +
revealed O +
a O +
primary O +
bone O +
defect O +
in O +
the O +
dtd O +
mouse O +
model O -
. O +

We O +
showed O +
in O +
vivo O +
that O +
this O +
primary O +
bone O +
defect O +
in O +
dtd O +
mice O +
is O +
due O +
to O +
decreased O +
bone O +
accrual O +
associated O +
with O +
a O +
decreased O +
trabecular O +
and O +
periosteal O +
appositional O +
rate O +
at O +
the O +
cell O +
level O +
in O +
one O +
month O -
- O -
old O +
mice O -
. O +

Although O +
the O +
osteoclast O +
number O +
evaluated O +
by O +
histomorphometry O +
was O +
not O +
different O +
in O +
dtd O +
compared O +
to O +
wild O -
- O -
type O +
mice O -
, O +
urine O +
analysis O +
of O +
deoxypyridinoline B-Chemical +
cross O -
- O -
links O +
and O +
serum O +
levels O +
of O +
type O +
I O +
collagen O +
C O -
- O -
terminal O +
telopeptides O +
showed O +
a O +
higher O +
resorption O +
rate O +
in O +
dtd O +
mice O +
compared O +
to O +
wild O -
- O -
type O +
littermates O -
. O +

Electron O +
microscopy O +
studies O +
showed O +
that O +
collagen O +
fibrils O +
in O +
bone O +
were O +
thinner O +
and O +
less O +
organized O +
in O +
dtd O +
compared O +
to O +
wild O -
- O -
type O +
mice O -
. O +

These O +
data O +
suggest O +
that O +
the O +
low O +
bone O +
mass O +
observed O +
in O +
mutant O +
mice O +
could O +
possibly O +
be O +
linked O +
to O +
the O +
different O +
bone O +
matrix O +
compositions O -
/ O -
organizations O +
in O +
dtd O +
mice O +
triggering O +
changes O +
in O +
osteoblast O +
and O +
osteoclast O +
activities O -
. O +

Overall O -
, O +
these O +
results O +
suggest O +
that O +
proteoglycan O +
undersulfation O +
not O +
only O +
affects O +
the O +
properties O +
of O +
hyaline O +
cartilage O -
, O +
but O +
can O +
also O +
lead O +
to O +
unbalanced O +
bone O +
modeling O +
and O +
remodeling O +
activities O -
, O +
demonstrating O +
the O +
importance O +
of O +
proteoglycan O +
sulfation O +
in O +
bone O +
homeostasis O -
. O +

APE1 O -
/ O -
Ref-1 O +
prevents O +
oxidative O +
inactivation O +
of O +
ERK O +
for O +
G1-to O -
- O -
S O +
progression O +
following O +
lead B-Chemical +
acetate I-Chemical +
exposure O -
. O +

Apurinic O -
/ O -
apyrimidinic O +
endonuclease O +
1 O +
( O -
APE1 O -
) O -
/ O -
redox O +
effector O +
factor-1 O +
is O +
a O +
multifunctional O +
enzyme O +
involved O +
in O +
DNA O +
base O +
excision O +
repair O +
and O +
protein O +
redox O +
regulation O -
. O +

Previously O -
, O +
we O +
have O +
showed O +
that O +
lead B-Chemical +
acetate I-Chemical +
( O -
Pb B-Chemical -
) O +
elicits O +
EGFR O +
activation O +
to O +
initiate O +
the O +
SFK O -
/ O -
PKCα O -
/ O -
Ras O -
/ O -
Raf-1 O -
/ O -
MKK1 O -
/ O -
2 O -
/ O -
ERK O +
signaling O +
cascade O +
functioning O +
against O +
genotoxicity O -
. O +

Here O -
, O +
we O +
explore O +
whether O +
APE1 O +
and O +
reactive O +
oxygen B-Chemical +
species O +
( O -
ROS O -
) O +
affect O +
ERK O +
signaling O +
and O +
cell O +
cycle O +
progression O +
following O +
Pb B-Chemical +
exposure O -
. O +

We O +
found O +
that O +
Pb B-Chemical +
induced O +
APE1 O +
expression O +
and O +
ROS O +
generation O +
in O +
CL3 O +
human O +
lung O +
cancer O +
cells O -
. O +

The O +
Pb B-Chemical -
- O -
elicited O +
ROS O +
levels O +
and O +
cytotoxicity O +
were O +
further O +
enhanced O +
by O +
introducing O +
small O +
interfering O +
RNA O +
specific O +
for O +
APE1 O +
( O -
siAPE1 O -
) O -
. O +

E3330 O -
, O +
an O +
inhibitor O +
of O +
APE1 O +
redox O +
activity O -
, O +
also O +
augmented O +
the O +
ROS O +
levels O +
and O +
cytotoxicity O +
in O +
Pb B-Chemical -
- O -
treated O +
cells O -
. O +

Intriguingly O -
, O +
the O +
capability O +
of O +
Pb B-Chemical +
to O +
activate O +
ERK O +
was O +
abolished O +
under O +
siAPE1 O +
or O +
E3330 O +
co O -
- O -
treatments O -
; O +
conversely O -
, O +
forced O +
expression O +
of O +
APE1 O +
up O -
- O -
regulated O +
the O +
ERK O +
activation O +
by O +
Pb B-Chemical +
or O +
serum O +
in O +
both O +
Cys65-redox B-Chemical +
activity O +
dependent O +
and O +
independent O +
manners O -
. O +

Moreover O -
, O +
APE1 O +
formed O +
complex O +
with O +
ERK2 O -
, O +
and O +
its O +
redox O +
activity O +
could O +
rescue O +
ERK O +
oxidative O +
inactivation O -
. O +

APE1 O +
redox O +
activity O +
also O +
facilitated O +
the O +
Cyclin O +
D1 O +
expression O +
and O +
G1-to O -
- O -
S O +
progression O +
following O +
Pb B-Chemical +
exposure O -
. O +

In O +
summary O -
, O +
the O +
results O +
indicate O +
that O +
APE1 O +
is O +
a O +
direct O +
redox O +
regulator O +
of O +
ERK O +
for O +
maintaining O +
the O +
kinase O +
activity O +
to O +
promote O +
cell O +
proliferation O -
. O +

Synthesis O -
, O +
quantitative O +
structure O -
- O -
activity O +
relationship O +
and O +
biological O +
evaluation O +
of O +
1,3,4-oxadiazole B-Chemical +
derivatives O +
possessing O +
diphenylamine B-Chemical +
moiety O +
as O +
potential O +
anticancer O +
agents O -
. O +

Synthesis O +
of O +
2,5-disubstituted-1,3,4-oxadiazole B-Chemical +
( O -
2a O -
- O -
c O -
) O -
, O +
3-substituted B-Chemical +
aminomethyl-5-substituted-1,3,4-oxadiazole-2 I-Chemical -
( I-Chemical -
3H I-Chemical -
) I-Chemical -
-thione I-Chemical +
( O -
4a O -
- O -
m O -
) O +
and O +
2-substituted B-Chemical +
thio-5-substituted-1,3,4-oxadiazole I-Chemical +
( O -
5a O -
, O +
b O -
) O +
had O +
been O +
described O -
. O +

All O +
the O +
synthesized O +
derivatives O +
were O +
screened O +
for O +
anticancer O +
activity O +
against O +
HT29 O +
and O +
MCF7 O +
cancer O +
cell O +
lines O +
using O +
Sulfo B-Chemical -
- I-Chemical -
Rodamine I-Chemical +
B I-Chemical +
( O -
SRB B-Chemical -
) O +
standard O +
method O -
. O +

Most O +
of O +
the O +
tested O +
compounds O +
exploited O +
potent O +
antiproliferative O +
activity O +
against O +
HT29 O +
cancer O +
cell O +
line O +
rather O +
than O +
MCF7 O +
cancer O +
cell O +
line O -
. O +

Compounds O +
2a O -
- O -
c O -
, O +
4f O +
and O +
5a O +
exhibited O +
potent O +
cytotoxicity O +
( O -
IC O -
( O -
50 O -
) O +
1.3 O -
- O -
2.0 O +
µM O -
) O +
and O +
selectivity O +
against O +
HT29 O +
cancer O +
cell O +
line O -
. O +

Quantitative O +
structure O -
- O -
activity O +
relationship O +
( O -
QSAR O -
) O +
study O +
was O +
applied O +
to O +
find O +
a O +
correlation O +
between O +
the O +
experimental O +
antiproliferative O +
activities O +
of O +
the O +
newly O +
synthesized O +
oxadiazole B-Chemical +
derivatives O +
with O +
their O +
physicochemical O +
parameter O +
and O +
topological O +
index O -
. O +

Statistical O +
modeling O -
, O +
optimization O +
and O +
characterization O +
of O +
spray O -
- O -
dried O +
solid O +
self O -
- O -
microemulsifying O +
drug O +
delivery O +
system O +
using O +
design O +
of O +
experiments O -
. O +

The O +
present O +
study O +
systematically O +
and O +
simultaneously O +
investigates O +
the O +
influence O +
of O +
process O +
variables O +
of O +
spray O -
- O -
drying O +
on O +
the O +
properties O +
of O +
solid O +
self O -
- O -
microemulsifying O +
drug O +
delivery O +
system O +
( O -
SMEDDS O -
) O +
using O +
design O +
of O +
experiment O +
( O -
DOE O -
) O +
and O +
optimizes O +
them O +
in O +
order O +
to O +
produce O +
solid O -
- O -
SMEDDS O +
satisfying O +
pre O -
- O -
defined O +
powder O +
quality O +
attributes O -
. O +

Flurbiprofen B-Chemical -
- O -
loaded O +
liquid O -
- O -
SMEDDS O +
was O +
dispersed O +
in O +
dextran O +
and O +
spray O -
- O -
dried O -
. O +

After O +
preliminary O +
screening O -
, O +
the O +
independent O +
factors O +
selected O +
according O +
to O +
three O -
- O -
factor O -
, O +
three O -
- O -
level O +
Box O -
- O -
Behnken O +
design O +
were O +
inlet O +
temperature O +
( O -
X O -
( O -
1 O -
) O -
) O -
, O +
feed O +
rate O +
( O -
X O -
( O -
2 O -
) O -
) O +
and O +
carrier O +
concentration O +
( O -
X O -
( O -
3 O -
) O -
) O -
. O +

The O +
responses O +
used O +
to O +
compute O +
the O +
effects O +
of O +
independent O +
factors O +
were O +
moisture O +
content O +
( O -
Y O -
( O -
1 O -
) O -
) O -
, O +
yield O +
( O -
Y O -
( O -
2 O -
) O -
) O -
, O +
drug O +
content O +
( O -
Y O -
( O -
3 O -
) O -
) O +
and O +
droplet O +
size O +
( O -
Y O -
( O -
4 O -
) O -
) O +
of O +
the O +
micro O -
- O -
emulsion O -
. O +

SMEDDS O +
powder O +
characteristics O +
such O +
as O +
morphology O -
, O +
thermal O +
behavior O -
, O +
crystallinity O +
and O +
flowability O +
were O +
also O +
considered O -
. O +

Models O +
were O +
developed O +
and O +
model O +
fitting O +
analysis O +
showed O +
an O +
adequate O +
fit O +
for O +
all O +
responses O -
, O +
indicating O +
good O +
predictability O -
. O +

Significant O +
effects O +
of O +
processing O +
parameters O +
on O +
powder O +
characteristics O +
were O +
observed O -
. O +

The O +
spray O -
- O -
drying O +
process O +
parameters O +
were O +
optimized O +
as O +
inlet O +
temperature O +
( O -
134 O -
° O -
C O -
) O -
, O +
feed O +
rate O +
( O -
5 O -
% O -
) O +
and O +
carrier O +
concentration O +
( O -
0.6 O -
% O -
) O +
to O +
produce O +
solid O -
- O -
SMEDDS O +
with O +
acceptable O +
moisture O +
content O +
( O -
0.72±0.02 O -
% O -
) O -
, O +
yield O +
( O -
58.5±2.9 O -
% O -
) O -
, O +
drug O +
content O +
( O -
70.1±2.7 O +
mg O -
/ O -
g O -
) O +
and O +
droplet O +
size O +
( O -
166.8±13.8 O +
nm O -
) O -
. O +

Validation O +
of O +
the O +
optimization O +
process O +
in O +
five O +
batches O +
showed O +
experimental O +
value O +
very O +
close O +
to O +
the O +
predicted O +
one O -
, O +
ensuring O +
the O +
reproducibility O +
of O +
the O +
developed O +
models O -
. O +

Furthermore O -
, O +
optimized O +
parameters O +
resulted O +
a O +
highly O +
crystalline O +
flurbiprofen B-Chemical +
changed O +
to O +
an O +
amorphous O +
form O -
. O +

In O +
conclusion O -
, O +
this O +
study O +
demonstrated O +
the O +
applicability O +
of O +
the O +
DOE O +
approach O +
for O +
optimizing O +
the O +
process O +
parameters O +
to O +
manufacture O +
solid O -
- O -
SMEDDS O +
with O +
desired O +
quality O +
attributes O -
. O +

Organosilicon B-Chemical +
compounds O +
as O +
adult O +
T O -
- O -
cell O +
leukemia O +
cell O +
proliferation O +
inhibitors O -
. O +

Aggressive O +
forms O +
of O +
adult O +
T O -
- O -
cell O +
leukemia O +
( O -
ATL O -
) O +
respond O +
poorly O +
to O +
conventional O +
anticancer O +
chemotherapy O -
, O +
and O +
new O +
lead O +
compounds O +
are O +
required O +
for O +
the O +
development O +
of O +
drugs O +
to O +
treat O +
this O +
fatal O +
disease O -
. O +

Recently O -
, O +
we O +
developed O +
ATL O +
cell O -
- O -
selective O +
proliferation O +
inhibitors O +
based O +
on O +
a O +
tetrahydrotetramethylnaphthalene B-Chemical +
( O -
TMN B-Chemical -
) O +
skeleton O +
1 O -
, O +
and O +
here O +
we O +
report O +
the O +
design O +
and O +
synthesis O +
of O +
silicon B-Chemical +
analogs O +
of O +
TMN B-Chemical +
derivatives O -
. O +

Among O +
them O -
, O +
compound O +
13 O +
showed O +
the O +
most O +
potent O +
growth O -
- O -
inhibitory O +
activity O +
towards O +
the O +
ATL O +
cell O +
line O +
S1 O -
T O -
, O +
though O +
its O +
selectivity O +
for O +
S1 O -
T O +
over O +
the O +
non O -
- O -
ATL O +
cell O +
line O +
MOLT-4 O +
was O +
only O +
moderate O -
. O +

This O +
result O -
, O +
as O +
well O +
as O +
computational O +
studies O -
, O +
suggests O +
that O +
sila O -
- O -
substitution O +
( B-Chemical -
C O -
/ O -
Si B-Chemical +
exchange O -
) O +
is O +
useful O +
for O +
structure O +
optimization O +
of O +
these O +
inhibitors O -
. O +

Temporal O +
stability O +
of O +
magic O -
- O -
number O +
metal O +
clusters O -
: O +
beyond O +
the O +
shell O +
closing O +
model O -
. O +

The O +
anomalous O +
stability O +
of O +
magic O -
- O -
number O +
metal O +
clusters O +
has O +
been O +
associated O +
with O +
closed O +
geometric O +
and O +
electronic O +
shells O +
and O +
the O +
opening O +
of O +
HOMO O -
- O -
LUMO O +
gaps O -
. O +

Despite O +
this O +
enhanced O +
stability O -
, O +
magic O -
- O -
number O +
clusters O +
are O +
known O +
to O +
decay O +
and O +
react O +
in O +
the O +
condensed O +
phase O +
to O +
form O +
other O +
products O -
. O +

Improving O +
our O +
understanding O +
of O +
their O +
decay O +
mechanisms O +
and O +
developing O +
strategies O +
to O +
control O +
or O +
eliminate O +
cluster O +
instability O +
is O +
a O +
priority O -
, O +
to O +
develop O +
a O +
more O +
complete O +
theory O +
of O +
their O +
stability O -
, O +
to O +
avoid O +
studying O +
mixtures O +
of O +
clusters O +
produced O +
by O +
the O +
decay O +
of O +
purified O +
materials O -
, O +
and O +
to O +
enable O +
technology O +
development O -
. O +

Silver B-Chemical +
clusters O +
are O +
sufficiently O +
reactive O +
to O +
facilitate O +
the O +
study O +
of O +
the O +
ambient O +
temporal O +
stability O +
of O +
magic O -
- O -
number O +
metal O +
clusters O +
and O +
to O +
begin O +
to O +
understand O +
their O +
decay O +
mechanisms O -
. O +

Here O -
, O +
the O +
solution O +
phase O +
stability O +
of O +
a O +
series O +
of O +
silver B-Chemical -
: O -
glutathione B-Chemical +
( O -
Ag B-Chemical -
: O -
SG O -
) O +
clusters O +
was O +
studied O +
as O +
a O +
function O +
of O +
size O -
, O +
pH O +
and O +
chemical O +
environment O -
. O +

Cluster O +
stability O +
was O +
found O +
to O +
be O +
a O +
non O -
- O -
monotonic O +
function O +
of O +
size O -
. O +

Electrophoretic O +
separations O +
showed O +
that O +
the O +
dominant O +
mechanism O +
involved O +
the O +
redistribution O +
of O +
mass O +
toward O +
smaller O +
sizes O -
, O +
where O +
the O +
products O +
were O +
almost O +
exclusively O +
previously O +
known O +
cluster O +
sizes O -
. O +

Optical O +
absorption O +
spectra O +
showed O +
that O +
the O +
smaller O +
clusters O +
evolved O +
toward O +
the O +
two O +
most O +
stable O +
cluster O +
sizes O -
. O +

The O +
net O +
surface O +
charge O +
was O +
found O +
to O +
play O +
an O +
important O +
role O +
in O +
cluster O +
stabilization O +
although O +
charge O +
screening O +
had O +
no O +
effect O +
on O +
stability O -
, O +
contrary O +
to O +
DLVO O +
theory O -
. O +

The O +
decay O +
mechanism O +
was O +
found O +
to O +
involve O +
the O +
loss O +
of O +
Ag B-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical +
ions O +
and O +
silver B-Chemical +
glutathionates I-Chemical -
. O +

Clusters O +
could O +
be O +
stabilized O +
by O +
the O +
addition O +
of O +
Ag B-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical +
ions O +
and O +
destabilized O +
by O +
either O +
the O +
addition O +
of O +
glutathione B-Chemical +
or O +
the O +
removal O +
of O +
Ag B-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical +
ions O -
. O +

Clusters O +
were O +
also O +
found O +
to O +
be O +
most O +
stable O +
in O +
near O +
neutral O +
pH O -
, O +
where O +
they O +
had O +
a O +
net O +
negative O +
surface O +
charge O -
. O +

These O +
results O +
provide O +
new O +
mechanistic O +
insights O +
into O +
the O +
control O +
of O +
post O -
- O -
synthesis O +
stability O +
and O +
chemical O +
decay O +
of O +
magic O -
- O -
number O +
metal O +
clusters O -
, O +
which O +
could O +
be O +
used O +
to O +
develop O +
design O +
principles O +
for O +
synthesizing O +
specific O +
cluster O +
species O -
. O +

The O +
role O +
of O +
cortisol B-Chemical +
and O +
psychopathy O +
in O +
the O +
cycle O +
of O +
violence O -
. O +

RATIONALE O -
: O +
Child O +
abuse O +
and O +
neglect O +
are O +
universal O +
risk O +
factors O +
for O +
delinquency O -
, O +
violence O -
, O +
and O +
aggression O -
; O +
this O +
phenomenon O +
is O +
known O +
as O +
the O +
cycle O +
of O +
violence O -
. O +

Additional O +
factors O -
- O -
psychopathy O -
, O +
impulsiveness O -
, O +
and O +
disruptions O +
in O +
the O +
hypothalamic O -
- O -
pituitary O -
- O -
adrenal O +
( O -
HPA O -
) O +
axis O -
- O -
play O +
a O +
role O +
in O +
aggressive O +
behavior O +
but O +
have O +
rarely O +
been O +
examined O +
in O +
the O +
same O +
conceptual O +
and O +
experimental O +
framework O -
. O +

OBJECTIVES O -
: O +
We O +
sought O +
to O +
examine O +
the O +
above O -
- O -
mentioned O +
risk O +
factors O +
for O +
aggression O +
in O +
a O +
prospective O +
study O +
employing O +
psychopharmacologic O +
and O +
psychometric O +
techniques O -
. O +

METHODS O -
: O +
Sixty O -
- O -
seven O +
adult O +
participants O +
were O +
given O +
an O +
acute O +
dose O +
of O +
20 O +
mg O +
cortisol B-Chemical +
in O +
a O +
placebo O -
- O -
controlled O -
, O +
within O -
- O -
subject O -
, O +
counter O -
- O -
balanced O +
dosing O +
design O -
. O +

Salivary O +
cortisol B-Chemical +
was O +
measured O +
at O +
baseline O +
and O +
at O +
regular O +
intervals O +
across O +
a O +
5 O +
h O +
testing O +
period O -
. O +

Following O +
dosing O -
, O +
state O -
- O -
aggressive O +
behavior O +
was O +
measured O +
by O +
a O +
laboratory O +
task O -
, O +
the O +
Point O -
- O -
Subtraction O +
Aggression O +
Paradigm O -
. O +

History O +
of O +
child O +
abuse O -
/ O -
neglect O -
, O +
psychopathy O -
, O +
impulsivity O -
, O +
and O +
a O +
trait O +
measure O +
of O +
aggression O +
were O +
assessed O +
through O +
self O -
- O -
report O +
questionnaires O -
. O +

RESULTS O -
: O +
Using O +
multiple O +
regression O -
, O +
a O +
model O +
including O +
abuse O -
/ O -
neglect O -
, O +
psychopathy O -
, O +
impulsivity O -
, O +
and O +
baseline O +
cortisol B-Chemical +
explained O +
58 O +
% O +
of O +
the O +
variance O +
in O +
trait O +
aggression O +
and O +
26 O +
% O +
of O +
the O +
variance O +
in O +
state O +
aggression O -
. O +

Abuse O -
/ O -
neglect O +
predicted O +
diminished O +
HPA O -
- O -
axis O +
reactivity O +
and O +
HPA O -
- O -
axis O +
reactivity O +
showed O +
a O +
trend O +
toward O +
predicting O +
state O +
and O +
trait O +
aggression O -
, O +
although O +
it O +
was O +
not O +
a O +
significant O +
mediating O +
variable O +
between O +
abuse O -
/ O -
neglect O +
and O +
aggression O -
. O +

CONCLUSIONS O -
: O +
The O +
results O +
indicate O +
that O +
child O +
maltreatment O -
, O +
psychopathy O +
and O +
HPA O -
- O -
axis O +
reactivity O +
interact O +
to O +
provide O +
a O +
confluence O +
over O +
aggressive O +
behavior O -
, O +
and O +
intervention O +
efforts O +
need O +
to O +
consider O +
all O +
these O +
factors O -
. O +

Manganese B-Chemical +
supplementation O +
protects O +
against O +
diet O -
- O -
induced O +
diabetes O +
in O +
wild O +
type O +
mice O +
by O +
enhancing O +
insulin O +
secretion O -
. O +

Mitochondrial O +
dysfunction O +
is O +
both O +
a O +
contributing O +
mechanism O +
and O +
complication O +
of O +
diabetes O -
, O +
and O +
oxidative O +
stress O +
contributes O +
to O +
that O +
dysfunction O -
. O +

Mitochondrial O +
manganese B-Chemical -
- O -
superoxide B-Chemical +
dismutase O +
( O -
MnSOD O -
) O +
is O +
a O +
metalloenzyme O +
that O +
provides O +
antioxidant O +
protection O -
. O +

We O +
have O +
previously O +
shown O +
in O +
a O +
mouse O +
model O +
of O +
hereditary O +
iron O +
overload O +
that O +
cytosolic O +
iron B-Chemical +
levels O +
affected O +
mitochondrial O +
manganese B-Chemical +
availability O -
, O +
MnSOD B-Chemical +
activity O -
, O +
and O +
insulin O +
secretion O -
. O +

We O +
therefore O +
sought O +
to O +
determine O +
the O +
metallation O +
status O +
of O +
MnSOD B-Chemical +
in O +
wild O -
- O -
type O +
mice O +
and O +
whether O +
altering O +
that O +
status O +
affected O +
β O -
- O -
cell O +
function O -
. O +

129 O -
/ O -
SvEVTac O +
mice O +
given O +
supplemental O +
manganese O +
exhibited O +
a O +
73 O -
% O +
increase O +
in O +
hepatic O +
MnSOD B-Chemical +
activity O +
and O +
increased O +
metallation O +
of O +
MnSOD B-Chemical -
. O +

To O +
determine O +
whether O +
manganese O +
supplementation O +
offered O +
glucose B-Chemical +
homeostasis O +
under O +
a O +
situation O +
of O +
β O -
- O -
cell O +
stress O -
, O +
we O +
challenged O +
C57BL O -
/ O -
6J O +
mice O -
, O +
which O +
are O +
more O +
susceptible O +
to O +
diet O -
- O -
induced O +
diabetes O -
, O +
with O +
a O +
high O -
- O -
fat O +
diet O +
for O +
12 O +
weeks O -
. O +

Manganese B-Chemical +
was O +
supplemented O +
or O +
not O +
for O +
the O +
final O +
8 O +
weeks O +
on O +
that O +
diet O -
, O +
after O +
which O +
we O +
examined O +
glucose B-Chemical +
tolerance O +
and O +
the O +
function O +
of O +
isolated O +
islets O -
. O +

Liver O +
mitochondria O +
from O +
manganese B-Chemical -
- O -
injected O +
C57BL O -
/ O -
6J O +
mice O +
had O +
similar O +
increases O +
in O +
MnSOD B-Chemical +
activity O +
( O -
81 O -
% O -
) O +
and O +
metallation O +
as O +
were O +
seen O +
in O +
129 O -
/ O -
SvEVTac O +
mice O -
. O +

The O +
manganese B-Chemical -
- O -
treated O +
group O +
fed O +
high O +
fat O +
had O +
improved O +
glucose B-Chemical +
tolerance O +
( O -
24 O -
% O +
decrease O +
in O +
fasting O +
glucose B-Chemical +
and O +
41 O -
% O +
decrease O +
in O +
area O +
under O +
the O +
glucose B-Chemical +
curve O -
) O -
, O +
comparable O +
with O +
mice O +
on O +
normal O +
chow O +
and O +
increased O +
serum O +
insulin O +
levels O -
. O +

Isolated O +
islets O +
from O +
the O +
manganese B-Chemical -
- O -
treated O +
group O +
exhibited O +
improved O +
insulin O +
secretion O -
, O +
decreased O +
lipid O +
peroxidation O -
, O +
and O +
improved O +
mitochondrial O +
function O -
. O +

In O +
conclusion O -
, O +
MnSOD B-Chemical +
metallation O +
and O +
activity O +
can O +
be O +
augmented O +
with O +
manganese B-Chemical +
supplementation O +
in O +
normal O +
mice O +
on O +
normal O +
chow O -
, O +
and O +
manganese B-Chemical +
treatment O +
can O +
increase O +
insulin O +
secretion O +
to O +
improve O +
glucose B-Chemical +
tolerance O +
under O +
conditions O +
of O +
dietary O +
stress O -
. O +

Enter O +
the O +
matrix O -
: O +
shape O -
, O +
signal O +
and O +
superhighway O -
. O +

Mammalian O +
skeletal O +
muscle O +
is O +
notable O +
for O +
both O +
its O +
highly O +
ordered O +
biophysical O +
structure O +
and O +
its O +
regenerative O +
capacity O +
following O +
trauma O -
. O +

Critical O +
to O +
both O +
of O +
these O +
features O +
is O +
the O +
specialized O +
muscle O +
extracellular O +
matrix O -
, O +
comprising O +
both O +
the O +
multiple O +
concentric O +
sheaths O +
of O +
connective O +
tissue O +
surrounding O +
structural O +
units O +
from O +
single O +
myofibers O +
to O +
whole O +
muscles O +
and O +
the O +
dense O +
interstitial O +
matrix O +
that O +
occupies O +
the O +
space O +
between O +
them O -
. O +

Extracellular O +
matrix O -
- O -
dependent O +
interactions O +
affect O +
all O +
activities O +
of O +
the O +
resident O +
muscle O +
stem O +
cell O +
population O +
( O -
the O +
satellite O +
cells O -
) O -
, O +
from O +
maintenance O +
of O +
quiescence O +
and O +
stem O +
cell O +
potential O +
to O +
the O +
regulation O +
of O +
proliferation O +
and O +
differentiation O -
. O +

This O +
review O +
focuses O +
on O +
the O +
role O +
of O +
the O +
extracellular O +
matrix O +
in O +
muscle O +
regeneration O -
, O +
with O +
a O +
particular O +
emphasis O +
on O +
regulation O +
of O +
satellite O -
- O -
cell O +
activity O -
. O +

3'-R B-Chemical -
/ I-Chemical -
S I-Chemical -
- I-Chemical -
Hydroxyvoacamine I-Chemical -
, O +
a O +
potent O +
acetylcholinesterase O +
inhibitor O +
from O +
Tabernaemontana O +
divaricata O -
. O +

Guided O +
by O +
the O +
acetylcholinesterase O +
inhibiting O +
activity O -
, O +
the O +
bisindole B-Chemical +
alkaloid I-Chemical +
3'-R B-Chemical -
/ I-Chemical -
S I-Chemical -
- I-Chemical -
hydroxyvoacamine I-Chemical +
was O +
isolated O +
from O +
a O +
stem O +
extract O +
of O +
Tabernaemontana O +
divaricata O -
, O +
a O +
plant O +
used O +
in O +
Thailand O +
in O +
traditional O +
rejuvenation O +
remedies O +
for O +
improving O +
the O +
memory O -
. O +

The O +
structure O +
of O +
the O +
alkaloid O +
was O +
elucidated O +
by O +
extensive O +
use O +
of O +
NMR O +
spectroscopy O +
and O +
the O +
complete O +
assignment O +
of O +
the O +
( B-Chemical -
1 I-Chemical -
) I-Chemical -
H I-Chemical +
and O +
( B-Chemical -
13 I-Chemical -
) I-Chemical -
C I-Chemical +
NMR O +
spectra O +
is O +
reported O -
. O +

The O +
alkaloid O +
acted O +
as O +
a O +
non O -
- O -
competitive O +
inhibitor O +
against O +
AChE O +
with O +
an O +
IC50 O +
value O +
of O +
7.00±1.99μM. O +
An O +
HPLC O +
method O +
was O +
developed O +
for O +
the O +
quantitative O +
analysis O +
of O +
the O +
AChE O +
inhibitor O -
. O +

It O +
suggested O +
that O +
there O +
was O +
12.4 O -
% O +
( O -
w O -
/ O -
w O -
) O +
of O +
3'-R B-Chemical -
/ I-Chemical -
S I-Chemical -
- I-Chemical -
hydroxyvoacamine I-Chemical +
in O +
the O +
alkaloid O +
enriched O +
fraction O +
of O +
T. O +
divaricata O +
stem O -
. O +

Fibroblast O -
- O -
mediated O +
drug O +
resistance O +
in O +
cancer O -
. O +

Tumor O +
progression O +
relies O +
upon O +
the O +
dynamic O +
interaction O +
of O +
cancer O +
cells O +
with O +
host O +
fibroblasts O -
, O +
endothelial O +
cells O -
, O +
immune O +
cells O +
and O +
components O +
of O +
the O +
extracellular O +
matrix O -
, O +
collectively O +
known O +
as O +
the O +
tumor O +
microenvironment O -
. O +

Despite O +
this O -
, O +
relatively O +
little O +
is O +
known O +
about O +
how O +
normal O +
host O +
cells O +
dictate O +
the O +
response O +
of O +
tumors O +
to O +
anti O -
- O -
cancer O +
therapies O -
. O +

Emerging O +
data O +
suggests O +
that O +
host O +
factors O +
play O +
a O +
critical O +
role O +
in O +
determining O +
risks O +
for O +
tumor O +
progression O +
and O +
decreased O +
therapeutic O +
responses O -
. O +

In O +
particular O -
, O +
recent O +
findings O +
have O +
provided O +
evidence O +
that O +
the O +
tumor O +
microenvironment O +
provides O +
a O +
protective O +
niche O +
that O +
allows O +
minor O +
populations O +
of O +
cancer O +
cells O +
to O +
escape O +
from O +
the O +
cytotoxic O +
effects O +
of O +
radiation O -
, O +
chemotherapy O +
and O +
targeted O +
therapies O -
. O +

In O +
this O +
review O +
we O +
will O +
outline O +
the O +
mechanisms O +
by O +
which O +
tumor O +
cells O +
and O +
host O +
fibroblasts O +
co O -
- O -
operate O +
to O +
drive O +
tumor O +
initiation O +
and O +
progression O -
. O +

In O +
particular O -
, O +
we O +
will O +
focus O +
upon O +
the O +
mechanisms O +
by O +
which O +
tumor O +
cells O +
exposed O +
to O +
targeted O +
therapies O +
co O -
- O -
opt O +
the O +
host O +
leading O +
to O +
therapeutic O +
escape O +
and O +
resistance O -
. O +

We O +
will O +
end O +
by O +
discussing O +
the O +
idea O +
that O +
long O -
- O -
term O +
responses O +
to O +
targeted O +
anticancer O +
therapies O +
will O +
only O +
be O +
achieved O +
through O +
strategies O +
that O +
target O +
both O +
the O +
tumor O +
and O +
host O -
. O +

Characterization O +
of O +
the O +
mouse O +
promoter O +
region O +
of O +
the O +
acyl B-Chemical -
- I-Chemical -
CoA I-Chemical +
synthetase O +
4 O +
gene O -
: O +
role O +
of O +
Sp1 O +
and O +
CREB O -
. O +

Acyl B-Chemical -
- I-Chemical -
CoA I-Chemical +
synthetase O +
4 O +
( O -
Acsl4 O -
) O +
is O +
involved O +
in O +
several O +
cellular O +
functions O +
including O +
steroidogenesis O -
, O +
synaptic O +
development O +
and O +
cancer O +
metastasis O -
. O +

Although O +
the O +
expression O +
of O +
Acsl4 O +
seems O +
to O +
be O +
regulated O +
by O +
tissue- O +
and O +
cell O -
- O -
specific O +
factors O +
as O +
well O +
as O +
pituitary O +
hormones O +
and O +
growth O +
factors O -
, O +
the O +
transcriptional O +
mechanisms O +
involved O +
remain O +
unknown O -
. O +

We O +
demonstrated O +
hCG O +
and O +
cAMP B-Chemical +
regulation O +
of O +
Acsl4 O +
mRNA O +
in O +
mouse O +
steroidogenic O +
MA-10 O +
Leydig O +
cells O -
. O +

We O +
characterized O +
the O +
transcription O +
initiation O +
site O +
and O +
promoter O +
of O +
the O +
Acsl4 O +
mouse O +
gene O +
and O +
identified O +
three O +
alternative O +
splice O +
variants O +
present O +
in O +
MA-10 O +
cells O -
. O +

Sequence O +
analysis O +
of O +
a O +
1.5-kb O +
fragment O +
of O +
the O +
Acsl4 O +
promoter O +
revealed O +
the O +
absence O +
of O +
a O +
TATA O +
box O +
and O +
the O +
presence O +
of O +
many O +
putative O +
binding O +
sites O +
for O +
transcription O +
factors O +
including O +
Sp1 O +
and O +
CREB O -
. O +

Functional O +
characterization O +
revealed O +
that O +
the O +
specificity O +
protein O -
/ O -
Krüppel O -
- O -
like O +
factor O +
Sp1 O +
binding O +
site O +
in O +
the O +
proximal O +
promoter O +
is O +
involved O +
in O +
basal O +
activity O +
and O +
that O +
the O +
cAMP B-Chemical +
response O +
element O -
- O -
binding O +
site O +
is O +
involved O +
in O +
cAMP B-Chemical +
stimulation O +
of O +
Acsl4 O +
transcription O -
. O +

Synthesis O +
and O +
biological O +
evaluation O +
of O +
thieno B-Chemical +
[ I-Chemical -
2',3':4,5 I-Chemical -
] I-Chemical -
pyrimido I-Chemical -
[ I-Chemical -
1,2-b I-Chemical -
] I-Chemical -
[ I-Chemical -
1,2,4 I-Chemical -
] I-Chemical -
triazines I-Chemical +
and O +
thieno B-Chemical -
[ I-Chemical -
2,3-d I-Chemical -
] I-Chemical -
[ I-Chemical -
1,2,4 I-Chemical -
] I-Chemical -
triazolo I-Chemical -
[ I-Chemical -
1,5-a I-Chemical -
] I-Chemical -
pyrimidines I-Chemical +
as O +
anti O -
- O -
inflammatory O +
and O +
analgesic O +
agents O -
. O +

A O +
new O +
series O +
of O +
thieno B-Chemical -
[ I-Chemical -
2',3':4,5 I-Chemical -
] I-Chemical -
pyrimido I-Chemical -
[ I-Chemical -
1,2-b I-Chemical -
] I-Chemical -
[ I-Chemical -
1,2,4 I-Chemical -
] I-Chemical -
triazines I-Chemical +
and O +
thieno B-Chemical -
[ I-Chemical -
2,3-d I-Chemical -
] I-Chemical -
[ I-Chemical -
1,2,4 I-Chemical -
] I-Chemical -
triazolo I-Chemical -
[ I-Chemical -
1,5-a I-Chemical -
] I-Chemical -
pyrimidines I-Chemical +
was O +
synthesized O -
. O +

The O +
newly O +
synthesized O +
compounds O +
were O +
evaluated O +
for O +
their O +
anti O -
- O -
inflammatory O +
and O +
analgesic O +
activity O +
using O +
diclofenac B-Chemical +
Na I-Chemical +
as O +
a O +
reference O +
standard O -
. O +

Additionally O -
, O +
the O +
ulcerogenic O +
effects O +
and O +
acute O +
toxicity O +
( O -
ALD50 O -
) O +
values O +
of O +
the O +
active O +
compounds O +
were O +
also O +
determined O -
. O +

In O +
general O -
, O +
the O +
thieno B-Chemical -
[ I-Chemical -
2,3-d I-Chemical -
] I-Chemical -
[ I-Chemical -
1,2,4 I-Chemical -
] I-Chemical -
triazolo I-Chemical -
[ I-Chemical -
1,5-a I-Chemical -
] I-Chemical -
pyrimidine I-Chemical +
derivatives O +
exhibited O +
better O +
biological O +
activities O +
than O +
the O +
thieno B-Chemical -
[ I-Chemical -
2',3':4,5 I-Chemical -
] I-Chemical -
pyrimido I-Chemical -
[ I-Chemical -
1,2-b I-Chemical -
] I-Chemical -
[ I-Chemical -
1,2,4 I-Chemical -
] I-Chemical -
triazines I-Chemical -
. O +

Collectively O -
, O +
the O +
thienotriazolopyrimidine B-Chemical +
derivatives O +
9 O -
, O +
13 O +
and O +
14a O +
were O +
proved O +
to O +
display O +
distinctive O +
anti O -
- O -
inflammatory O +
activity O +
at O +
the O +
acute O +
and O +
subacute O +
models O +
as O +
well O +
as O +
good O +
analgesic O +
profile O +
with O +
a O +
delayed O +
onset O +
of O +
action O -
. O +

Moreover O -
, O +
they O +
revealed O +
good O +
gastrointestinal O +
safety O +
profile O +
and O +
are O +
well O +
tolerated O +
by O +
experimental O +
animals O +
with O +
high O +
safety O +
margin O +
( O -
ALD50 O +
> O +
0.3 O +
g O -
/ O -
kg O -
) O -
. O +

Molecular O +
insight O +
into O +
the O +
inhibition O +
mechanism O +
of O +
cyrtominetin B-Chemical +
to O +
α O -
- O -
hemolysin O +
by O +
molecular O +
dynamics O +
simulation O -
. O +

The O +
protein O +
α O -
- O -
hemolysin O +
( O -
α O -
- O -
HL O -
) O +
is O +
a O +
self O -
- O -
assembling O +
exotoxin O +
that O +
binds O +
to O +
the O +
membrane O +
of O +
a O +
susceptible O +
host O +
cell O -
. O +

In O +
this O +
paper O -
, O +
experimental O +
studies O +
show O +
that O +
cyrtominetin B-Chemical +
( O -
CTM B-Chemical -
) O +
can O +
inhibit O +
the O +
hemolytic O +
activity O +
of O +
α O -
- O -
HL O -
. O +

To O +
understand O +
how O +
CTM B-Chemical +
can O +
affect O +
hemolytic O +
activity O -
, O +
molecular O +
dynamics O +
simulations O +
were O +
carried O +
out O +
for O +
α O -
- O -
HL O -
- O -
CTM B-Chemical +
complex O +
and O +
these O +
results O +
were O +
compared O +
with O +
the O +
crystal O +
structure O +
of O +
monomeric O +
α O -
- O -
HL O -
. O +

With O +
this O +
approach O -
, O +
the O +
analysis O +
revealed O +
that O +
the O +
inhibition O +
of O +
CTM B-Chemical +
involves O +
CTM B-Chemical +
directly O +
binding O +
to O +
α O -
- O -
HL O -
. O +

Due O +
to O +
the O +
binding O +
of O +
CTM B-Chemical -
, O +
the O +
conformation O +
of O +
the O +
critical O +
" O -
Loop O -
" O +
region O +
was O +
restrained O -
. O +

This O +
mechanism O +
was O +
confirmed O +
by O +
the O +
experimental O +
data O -
. O +

These O +
findings O +
indicate O +
that O +
CTM B-Chemical +
hinders O +
the O +
lysis O +
activity O +
of O +
α O -
- O -
HL O +
through O +
a O +
novel O +
mechanism O -
. O +

Influence O +
of O +
environmentally O +
relevant O +
concentrations O +
of O +
vinclozolin B-Chemical +
on O +
quality O -
, O +
DNA O +
integrity O -
, O +
and O +
antioxidant O +
responses O +
of O +
sterlet O +
Acipenser O +
ruthenus O +
spermatozoa O -
. O +

The O +
effects O +
of O +
vinclozolin B-Chemical +
( O -
VIN B-Chemical -
) O -
, O +
an O +
anti O -
- O -
androgenic O +
fungicide O -
, O +
on O +
quality O -
, O +
oxidative O +
stress O -
, O +
DNA O +
integrity O -
, O +
and O +
ATP B-Chemical +
level O +
of O +
sterlet O +
( O -
Acipenser O +
ruthenus O -
) O +
spermatozoa O +
were O +
investigated O +
in O +
vitro O -
. O +

Fish O +
spermatozoa O +
were O +
incubated O +
with O +
different O +
concentrations O +
of O +
vinclozolin B-Chemical +
( O -
0.5 O -
, O +
2 O -
, O +
10 O -
, O +
15 O -
, O +
20 O +
and O +
50μg O -
/ O -
l O -
) O +
for O +
2h O -
. O +

A O +
dose O -
- O -
dependent O +
reduction O +
in O +
spermatozoa O +
motility O +
and O +
velocity O +
was O +
observed O +
at O +
concentrations O +
of O +
2 O -
- O -
50μg O -
/ O -
l O -
. O +

A O +
dramatic O +
increase O +
in O +
DNA O +
fragmentation O +
was O +
recorded O +
at O +
concentrations O +
10μg O -
/ O -
l O +
and O +
above O -
. O +

After O +
2h O +
exposure O +
at O +
higher O +
test O +
concentrations O +
( O -
10 O -
- O -
50μg O -
/ O -
l O -
) O -
, O +
oxidative O +
stress O +
was O +
apparent O -
, O +
as O +
reflected O +
by O +
significantly O +
higher O +
levels O +
of O +
protein O +
and O +
lipid O +
oxidation O +
and O +
significantly O +
greater O +
superoxide B-Chemical +
dismutase O +
activity O -
. O +

Intracellular O +
ATP B-Chemical +
content O +
of O +
spermatozoa O +
decreased O +
with O +
increasing O +
concentrations O +
of O +
VIN B-Chemical -
. O +

The O +
results O +
demonstrated O +
that O +
VIN B-Chemical +
can O +
induce O +
reactive O +
oxygen B-Chemical +
species O +
stress O +
in O +
fish O +
spermatozoa O -
, O +
which O +
could O +
impair O +
the O +
sperm O +
quality O -
, O +
DNA O +
integrity O -
, O +
ATP B-Chemical +
content O -
, O +
and O +
the O +
antioxidant O +
defense O +
system O -
. O +

Elimination O +
and O +
utilization O +
of O +
oxidized O +
guanine B-Chemical +
nucleotides I-Chemical +
in O +
the O +
synthesis O +
of O +
RNA O +
and O +
its O +
precursors O -
. O +

Reactive O +
oxygen B-Chemical +
species O +
are O +
produced O +
as O +
side O +
products O +
of O +
oxygen B-Chemical +
utilization O +
and O +
can O +
lead O +
to O +
the O +
oxidation O +
of O +
nucleic O +
acids O +
and O +
their O +
precursor O +
nucleotides B-Chemical -
. O +

Among O +
the O +
various O +
oxidized O +
bases O -
, O +
8-oxo-7,8-dihydroguanine B-Chemical +
seems O +
to O +
be O +
the O +
most O +
critical O +
during O +
the O +
transfer O +
of O +
genetic O +
information O +
because O +
it O +
can O +
pair O +
with O +
both O +
cytosine B-Chemical +
and O +
adenine B-Chemical -
. O +

During O +
the O +
de O +
novo O +
synthesis O +
of O +
guanine B-Chemical +
nucleotides I-Chemical -
, O +
GMP B-Chemical +
is O +
formed O +
first O -
, O +
and O +
it O +
is O +
converted O +
to O +
GDP B-Chemical +
by O +
guanylate B-Chemical +
kinase O -
. O +

This O +
enzyme O +
hardly O +
acts O +
on O +
an O +
oxidized O +
form O +
of O +
GMP B-Chemical +
( O -
8-oxo B-Chemical -
- I-Chemical -
GMP I-Chemical -
) O +
formed O +
by O +
the O +
oxidation O +
of O +
GMP B-Chemical +
or O +
by O +
the O +
cleavage O +
of O +
8-oxo B-Chemical -
- I-Chemical -
GDP I-Chemical +
and O +
8-oxo B-Chemical -
- I-Chemical -
GTP I-Chemical +
by O +
MutT O +
protein O -
. O +

Although O +
the O +
formation O +
of O +
8-oxo B-Chemical -
- I-Chemical -
GDP I-Chemical +
from O +
8-oxo B-Chemical -
- I-Chemical -
GMP I-Chemical +
is O +
thus O +
prevented O -
, O +
8-oxo B-Chemical -
- I-Chemical -
GDP I-Chemical +
itself O +
may O +
be O +
produced O +
by O +
the O +
oxidation O +
of O +
GDP B-Chemical +
by O +
reactive O +
oxygen B-Chemical +
species O -
. O +

The O +
8-oxo B-Chemical -
- I-Chemical -
GDP I-Chemical +
thus O +
formed O +
can O +
be O +
converted O +
to O +
8-oxo B-Chemical -
- I-Chemical -
GTP I-Chemical +
because O +
nucleoside B-Chemical -
- I-Chemical -
diphosphate I-Chemical +
kinase O +
and O +
adenylate B-Chemical +
kinase O -
, O +
both O +
of O +
which O +
catalyze O +
the O +
conversion O +
of O +
GDP B-Chemical +
to O +
GTP B-Chemical -
, O +
do O +
not O +
discriminate O +
8-oxo B-Chemical -
- I-Chemical -
GDP I-Chemical +
from O +
normal O +
GDP B-Chemical -
. O +

The O +
8-oxo B-Chemical -
- I-Chemical -
GTP I-Chemical +
produced O +
in O +
this O +
way O +
and O +
by O +
the O +
oxidation O +
of O +
GTP B-Chemical +
can O +
be O +
used O +
for O +
RNA O +
synthesis O -
. O +

This O +
misincorporation O +
is O +
prevented O +
by O +
MutT O +
protein O -
, O +
which O +
has O +
the O +
potential O +
to O +
cleave O +
8-oxo B-Chemical -
- I-Chemical -
GTP I-Chemical +
as O +
well O +
as O +
8-oxo B-Chemical -
- I-Chemical -
GDP I-Chemical +
to O +
8-oxo B-Chemical -
- I-Chemical -
GMP I-Chemical -
. O +

When O +
( B-Chemical -
14 I-Chemical -
) I-Chemical -
C I-Chemical -
- I-Chemical -
labeled I-Chemical +
8-oxo I-Chemical -
- I-Chemical -
GTP I-Chemical +
was O +
applied O +
to O +
CaCl2-permeabilized B-Chemical +
cells O +
of O +
a O +
mutT O -
( O -
- O -
) O +
mutant O +
strain O -
, O +
it O +
could O +
be O +
incorporated O +
into O +
RNA O +
at O +
4 O -
% O +
of O +
the O +
rate O +
for O +
GTP B-Chemical -
. O +

Escherichia O +
coli O +
cells O +
appear O +
to O +
possess O +
mechanisms O +
to O +
prevent O +
misincorporation O +
of O +
8-oxo-7,8-dihydroguanine B-Chemical +
into O +
RNA O -
. O +

Bradykinin B-Chemical +
modulates O +
spontaneous O +
nerve O +
growth O +
factor O +
production O +
and O +
stretch O -
- O -
induced O +
ATP B-Chemical +
release O +
in O +
human O +
urothelium O -
. O +

The O +
urothelium O +
plays O +
a O +
crucial O +
role O +
in O +
integrating O +
urinary O +
bladder O +
sensory O +
outputs O -
, O +
responding O +
to O +
mechanical O +
stress O +
and O +
chemical O +
stimulation O +
by O +
producing O +
several O +
diffusible O +
mediators O -
, O +
including O +
ATP B-Chemical +
and O -
, O +
possibly O -
, O +
neurotrophin O +
nerve O +
growth O +
factor O +
( O -
NGF O -
) O -
. O +

Such O +
urothelial O +
mediators O +
activate O +
underlying O +
afferents O +
and O +
thus O +
may O +
contribute O +
to O +
normal O +
bladder O +
sensation O +
and O +
possibly O +
to O +
the O +
development O +
of O +
bladder O +
overactivity O -
. O +

The O +
muscle O -
- O -
contracting O +
and O +
pain O -
- O -
inducing O +
peptide O +
bradykinin B-Chemical +
is O +
produced O +
in O +
various O +
inflammatory O +
and O +
non O -
- O -
inflammatory O +
pathologies O +
associated O +
with O +
bladder O +
overactivity O -
, O +
but O +
the O +
effect O +
of O +
bradykinin B-Chemical +
on O +
human O +
urothelial O +
function O +
has O +
not O +
yet O +
been O +
characterized O -
. O +

The O +
human O +
urothelial O +
cell O +
line O +
UROtsa O +
expresses O +
mRNA O +
for O +
both O +
B1 O +
and O +
B2 O +
subtypes O +
of O +
bradykinin B-Chemical +
receptors O -
, O +
as O +
determined O +
by O +
real O -
- O -
time O +
PCR O -
. O +

Bradykinin B-Chemical +
concentration O -
- O -
dependently O +
( O -
pEC50=8.3 O -
, O +
Emax O +
4434±277nM O -
) O +
increased O +
urothelial O +
intracellular O +
calcium O +
levels O +
and O +
induced O +
phosphorylation O +
of O +
the O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O -
MAPK O -
) O +
ERK1 O -
/ O -
2 O -
. O +

Activation O +
of O +
both O +
bradykinin B-Chemical -
- O -
induced O +
signaling O +
pathways O +
was O +
completely O +
abolished O +
by O +
the O +
B2 O +
antagonist O +
icatibant O +
( O -
1μM O -
) O -
, O +
but O +
not O +
the O +
B1 O +
antagonist O +
R715 O +
( O -
1μM O -
) O -
. O +

Bradykinin B-Chemical -
- O -
induced O +
( O -
100nM O -
) O +
B2 O +
receptor O +
activation O +
markedly O +
increased O +
( O -
192±13 O -
% O +
of O +
control O +
levels O -
) O +
stretch O -
- O -
induced O +
ATP B-Chemical +
release O +
from O +
UROtsa O +
in O +
hypotonic O +
medium O -
, O +
the O +
effect O +
being O +
dependent O +
on O +
intracellular O +
calcium O +
elevations O -
. O +

UROtsa O +
cells O +
also O +
expressed O +
mRNA O +
and O +
protein O +
for O +
NGF O +
and O +
spontaneously O +
released O +
NGF O +
to O +
the O +
medium O +
in O +
the O +
course O +
of O +
hours O +
( O -
11.5±1.4pgNGF O -
/ O -
mgprotein O -
/ O -
h O -
) O -
. O +

Bradykinin B-Chemical +
increased O +
NGF O +
mRNA O +
expression O +
and O +
accelerated O +
urothelial O +
NGF O +
release O +
to O +
127±5 O -
% O +
in O +
a O +
protein O +
kinase O +
C- O +
and O +
ERK1 O -
/ O -
2-dependent O +
manner O -
. O +

Finally O -
, O +
bradykinin B-Chemical +
up O -
- O -
regulated O +
mRNA O +
for O +
transient O -
- O -
receptor O +
potential O +
vanilloid O +
( O -
TRPV1 O -
) O +
sensory O +
ion O +
channel O +
in O +
UROtsa O -
. O +

In O +
conclusion O -
, O +
we O +
show O +
that O +
bradykinin B-Chemical +
represents O +
a O +
versatile O +
modulator O +
of O +
human O +
urothelial O +
phenotype O -
, O +
accelerating O +
stretch O -
- O -
induced O +
ATP B-Chemical +
release O -
, O +
spontaneous O +
release O +
of O +
NGF O -
, O +
as O +
well O +
as O +
expression O +
of O +
sensory O +
ion O +
channel O +
TRPV1 O -
. O +

Bradykinin B-Chemical -
- O -
induced O +
changes O +
in O +
urothelial O +
sensory O +
function O +
might O +
contribute O +
to O +
the O +
development O +
of O +
bladder O +
dysfunction O -
. O +

3D O +
Organotypic O +
Cultures O +
of O +
Human O +
HepaRG O +
Cells O -
: O +

A O +
Tool O +
for O +
In O +
Vitro O +
Toxicity O +
Studies O -
. O +

Drug O -
- O -
induced O +
human O +
hepatotoxicity O +
is O +
difficult O +
to O +
predict O +
using O +
the O +
current O +
in O +
vitro O +
systems O -
. O +

In O +
this O +
study O -
, O +
long O -
- O -
term O +
3D O +
organotypic O +
cultures O +
of O +
the O +
human O +
hepatoma O +
HepaRG O +
cell O +
line O +
were O +
prepared O +
using O +
a O +
high O -
- O -
throughput O +
hanging O +
drop O +
method O -
. O +

The O +
organotypic O +
cultures O +
were O +
maintained O +
for O +
3 O +
weeks O +
and O +
assessed O +
for O +
( O -
1 O -
) O +
liver O +
specific O +
functions O -
, O +
including O +
phase O +
I O +
enzyme O +
and O +
transporter O +
activities O -
, O +
( O -
2 O -
) O +
expression O +
of O +
liver O -
- O -
specific O +
proteins O -
, O +
and O +
( O -
3 O -
) O +
responses O +
to O +
three O +
drugs O +
( O -
acetaminophen B-Chemical -
, O +
troglitazone B-Chemical -
, O +
and O +
rosiglitazone B-Chemical -
) O -
. O +

Our O +
results O +
show O +
that O +
the O +
organotypic O +
cultures O +
maintain O +
high O +
liver O -
- O -
specific O +
functionality O +
during O +
3 O +
weeks O +
of O +
culture O -
. O +

The O +
immunohistochemistry O +
analyses O +
illustrate O +
that O +
the O +
organotypic O +
cultures O +
express O +
liver O -
- O -
specific O +
markers O +
such O +
as O +
albumin O -
, O +
CYP3A4 O -
, O +
CYP2E1 O -
, O +
and O +
MRP-2 O +
throughout O +
the O +
cultivation O +
period O -
. O +

Accordingly O -
, O +
the O +
production O +
rates O +
of O +
albumin O +
and O +
glucose B-Chemical -
, O +
as O +
well O +
as O +
CYP2E1 O +
activity O -
, O +
were O +
significantly O +
higher O +
in O +
the O +
3D O +
versus O +
the O +
2D O +
cultures O -
. O +

Toxicity O +
studies O +
show O +
that O +
the O +
organotypic O +
cultures O +
are O +
more O +
sensitive O +
to O +
acetaminophen- B-Chemical +
and O +
rosiglitazone B-Chemical -
- O -
induced O +
toxicity O +
but O +
less O +
sensitive O +
to O +
troglitazone B-Chemical -
- O -
induced O +
toxicity O +
than O +
the O +
2D O +
cultures O -
. O +

Furthermore O -
, O +
the O +
EC50 O +
value O +
( O -
2.7mM O -
) O +
for O +
acetaminophen B-Chemical +
on O +
the O +
3D O +
cultures O +
was O +
similar O +
to O +
in O +
vivo O +
toxicity O -
. O +

In O +
summary O -
, O +
the O +
results O +
from O +
our O +
study O +
suggest O +
that O +
the O +
3D O +
organotypic O +
HepaRG O +
culture O +
is O +
a O +
promising O +
in O +
vitro O +
tool O +
for O +
more O +
accurate O +
assessment O +
of O +
acute O +
and O +
also O +
possibly O +
for O +
chronic O +
drug O -
- O -
induced O +
hepatotoxicity O -
. O +

Mending O +
leaky O +
blood O +
vessels O -
: O +
the O +
angiopoietin O -
- O -
Tie2 O +
pathway O +
in O +
sepsis O -
. O +

Sepsis O +
is O +
a O +
systemic O +
inflammatory O +
response O +
to O +
infection O -
. O +

A O +
common O +
end O -
- O -
feature O -
, O +
these O +
patients O +
regularly O +
suffer O +
from O +
is O +
the O +
so O -
- O -
called O +
multiple O +
organ O +
dysfunction O +
syndrome O -
, O +
an O +
often O +
fatal O +
consequence O +
of O +
organ O +
hypoperfusion O -
, O +
coagulopathy O -
, O +
immune O +
dysregulation O -
, O +
and O +
mitochondrial O +
dysfunction O -
. O +

Microvascular O +
dysfunction O +
critically O +
contributes O +
to O +
the O +
morbidity O +
and O +
mortality O +
of O +
this O +
disease O -
. O +

The O +
angiopoietin O +
( O -
Angpt O -
) O -
/ O -
Tie2 O +
system O +
consists O +
of O +
the O +
transmembrane O +
endothelial O +
tyrosine B-Chemical +
kinase O +
Tie2 O +
and O +
its O +
circulating O +
ligands O +
( O -
Angpt-1 O -
, O +
-2 O -
, O +
and O +
-3 O -
/ O -
4 O -
) O -
. O +

The O +
balance O +
between O +
the O +
canonical O +
agonist O +
Angpt-1 O +
and O +
its O +
competitive O +
inhibitor O -
, O +
Angpt-2 O -
, O +
regulates O +
basal O +
endothelial O +
barrier O +
function O +
and O +
the O +
leakage O +
and O +
vascular O +
inflammation O +
that O +
develop O +
in O +
response O +
to O +
pathogens O +
and O +
cytokines O -
. O +

Here O +
we O +
summarize O +
recent O +
work O +
in O +
mice O +
and O +
men O +
to O +
highlight O +
the O +
therapeutic O +
potential O +
in O +
this O +
pathway O +
to O +
prevent O +
or O +
even O +
reverse O +
microvascular O +
dysfunction O +
in O +
this O +
deadly O +
disease O -
. O +

Structural O +
Modifications O +
to O +
Tetrahydropyridine-3-carboxylate B-Chemical +
Esters I-Chemical +
en O +
Route O +
to O +
the O +
Discovery O +
of O +
M O -
( O -
5 O -
) O -
-Preferring O +
Muscarinic O +
Receptor O +
Orthosteric O +
Antagonists O -
. O +

The O +
M O -
( O -
5 O -
) O +
muscarinic O +
acetylcholine B-Chemical +
receptor O +
is O +
suggested O +
to O +
be O +
a O +
potential O +
pharmacotherapeutic O +
target O +
for O +
the O +
treatment O +
of O +
drug O +
abuse O -
. O +

We O +
describe O +
herein O +
the O +
discovery O +
of O +
a O +
series O +
of O +
M O -
( O -
5 O -
) O -
-preferring O +
orthosteric O +
antagonists O +
based O +
on O +
the O +
scaffold O +
of O +
1,2,5,6-tetrahydropyridine-3-carboxylic B-Chemical +
acid I-Chemical -
. O +

Compound O +
56 O -
, O +
the O +
most O +
selective O +
compound O +
in O +
this O +
series O -
, O +
possesses O +
an O +
11-fold O +
selectivity O +
for O +
the O +
M O -
( O -
5 O -
) O +
over O +
M O -
( O -
1 O -
) O +
receptor O +
and O +
shows O +
little O +
activity O +
at O +
M O -
( O -
2 O -
) O -
-M O -
( O -
4 O -
) O -
. O +

This O +
compound O -
, O +
although O +
exhibiting O +
modest O +
affinity O +
( O -
K O -
( O -
i O -
) O +
= O +
2.24 O +
μM O -
) O +
for O +
the O +
[ B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
H I-Chemical -
] I-Chemical -
N I-Chemical -
- I-Chemical -
methylscopolamine I-Chemical +
binding O +
site O +
on O +
the O +
M O -
( O -
5 O -
) O +
receptor O -
, O +
is O +
potent O +
( O -
IC O -
( O -
50 O -
) O +
= O +
0.45 O +
nM O -
) O +
in O +
inhibiting O +
oxotremorine B-Chemical -
- O -
evoked O +
[ B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
H I-Chemical -
] I-Chemical -
DA I-Chemical +
release O +
from O +
rat O +
striatal O +
slices O -
. O +

Further O -
, O +
a O +
homology O +
model O +
of O +
human O +
M O -
( O -
5 O -
) O +
receptor O +
based O +
on O +
the O +
crystal O +
structure O +
of O +
the O +
rat O +
M O -
( O -
3 O -
) O +
receptor O +
was O +
constructed O -
, O +
and O +
docking O +
studies O +
of O +
compounds O +
28 O +
and O +
56 O +
were O +
performed O +
in O +
an O +
attempt O +
to O +
understand O +
the O +
possible O +
binding O +
mode O +
of O +
these O +
novel O +
analogues O +
to O +
the O +
receptor O -
. O +

Bifunctional O +
inhibition O +
of O +
HIV-1 O +
reverse O +
transcriptase O -
: O +
a O +
first O +
step O +
in O +
designing O +
a O +
bifunctional O +
triphosphate B-Chemical -
. O +

The O +
onset O +
of O +
resistance O +
to O +
approved O +
anti O -
- O -
AIDS O +
drugs O +
by O +
HIV O +
necessitates O +
the O +
search O +
for O +
novel O +
inhibitors O +
of O +
HIV-1 O +
reverse O +
transcriptase O +
( O -
RT O -
) O -
. O +

Developing O +
single O +
molecular O +
agents O +
concurrently O +
occupying O +
the O +
nucleoside B-Chemical +
and O +
nonnucleoside O +
binding O +
sites O +
in O +
RT O +
is O +
an O +
intriguing O +
idea O +
but O +
the O +
proof O +
of O +
concept O +
has O +
so O +
far O +
been O +
elusive O -
. O +

As O +
a O +
first O +
step O -
, O +
we O +
describe O +
molecular O +
modeling O +
to O +
guide O +
focused O +
chemical O +
syntheses O +
of O +
conjugates O +
having O +
nucleoside B-Chemical +
( O -
d4 B-Chemical -
T I-Chemical -
) O +
and O +
nonnucleoside O +
( O -
TIBO B-Chemical -
) O +
moieties O +
tethered O +
by O +
a O +
flexible O +
polyethylene B-Chemical +
glycol I-Chemical +
( O -
PEG B-Chemical -
) O +
linker O -
. O +

A O +
triphosphate B-Chemical +
of O +
d4T-6PEG B-Chemical -
- I-Chemical -
TIBO I-Chemical +
conjugate O +
was O +
successfully O +
synthesized O +
that O +
is O +
recognized O +
as O +
a O +
substrate O +
by O +
HIV-1 O +
RT O +
and O +
incorporated O +
into O +
a O +
double O -
- O -
stranded O +
DNA O -
. O +

Differential O +
autophagic O +
cell O +
death O +
under O +
stress O +
with O +
ectopic O +
cytoplasmic O +
and O +
mitochondrial O -
- O -
specific O +
PPP2R2B O +
in O +
human O +
neuroblastoma O +
cells O -
. O +

Protein O +
phosphatase O +
2A O +
is O +
one O +
of O +
four O +
major O +
classes O +
of O +
serine B-Chemical -
/ O -
threonine B-Chemical +
phosphatases O -
. O +

Overexpression O +
of O +
brain O -
- O -
specific O +
regulatory O +
subunit O +
PPP2R2 O +
in O +
neuron O +
cells O +
is O +
implicated O +
in O +
pathogenesis O -
. O +

The O +
alternative O +
splicing O +
of O +
PPP2R2B O +
encodes O +
two O +
isoforms O -
. O +

They O +
are O +
subunit O +
of O +
cytoplasmic O +
specific O +
Bβ1 O +
and O +
mitochondria O -
- O -
targeted O +
Bβ2 O -
. O +

The O +
two O +
constructs O +
were O +
transfected O +
into O +
human O +
neuroblastoma O +
cells O -
, O +
SK O -
- O -
N O -
- O -
SH O -
, O +
respectively O -
, O +
and O +
the O +
stable O +
clones O +
overexpressing O +
either O +
Bβ1 O +
or O +
Bβ2 O +
established O -
. O +

We O +
have O +
reported O +
that O +
Bβ2 O +
clones O +
are O +
sensitive O +
to O +
reactive O +
oxygen B-Chemical +
species O +
( O -
ROS O -
) O +
treatment O +
by O +
inducing O +
autophagic O +
cell O +
death O -
. O +

To O +
study O +
more O +
on O +
the O +
onset O +
of O +
neuropathogenesis O +
under O +
strain O -
, O +
both O +
clones O +
were O +
exposed O +
to O +
different O +
environmental O +
stress O -
, O +
e.g. O +
starvation O +
and O +
endoplasmic O +
reticulum O +
( O -
ER O -
) O +
stress O -
. O +

To O +
learn O +
how O +
PPP2R2B O +
overexpression O +
responds O +
to O +
starvation O -
, O +
cells O +
were O +
incubated O +
in O +
Hank O -
's O +
buffered O +
salt O +
solution O +
of O +
deprived O +
nutrient O -
. O +

Cell O +
death O +
was O +
induced O +
in O +
Bβ1 O +
clones O +
after O +
6 O +
h O +
starvation O -
, O +
but O +
not O +
in O +
Bβ2 O +
clones O -
. O +

The O +
pharmacological O +
inhibitor O -
, O +
Bafilomycin B-Chemical +
A1 I-Chemical -
, O +
rescued O +
the O +
cell O +
death O +
while O +
suppressing O +
autophagy O -
. O +

On O +
the O +
other O +
hand O -
, O +
to O +
assess O +
how O +
cells O +
respond O +
to O +
ER O +
stress O -
, O +
the O +
cells O +
were O +
treated O +
with O +
0.1 O +
μM O +
of O +
N O -
- O -
glycosylation O +
inhibitor O -
, O +
tunicamycin B-Chemical +
( O -
TM O -
) O -
. O +

In O +
contrast O +
with O +
Bβ1 O -
, O +
the O +
apoptotic O +
cell O +
death O +
appeared O +
in O +
Bβ2 O +
after O +
48 O +
h O +
treatment O -
. O +

The O +
formation O +
of O +
autophagolysosome O +
was O +
detected O +
in O +
Bβ2 O +
following O +
12 O +
h O +
treatment O +
with O +
TM O +
as O +
evidenced O +
by O +
lysotracker O +
and O +
GFP O -
- O -
LC3 O +
staining O +
for O +
fluorescence O +
microscopy O +
analysis O -
. O +

The O +
autophagy O +
inhibitor O -
, O +
3-methyladenine B-Chemical -
, O +
salvaged O +
the O +
final O +
apoptosis O -
. O +

The O +
stable O +
cell O +
lines O +
with O +
ectopically O +
transfected O +
PPP2R2B O +
genes O +
encoding O +
isoforms O +
of O +
brain O -
- O -
specific O +
regulatory O +
subunit O +
exhibit O +
distinct O +
apoptosis O +
under O +
different O +
stressors O -
. O +

The O +
induced O +
autophagic O +
apoptotic O +
cell O +
death O +
is O +
related O +
to O +
mitochondrial O +
membrane O +
potential O +
drop O +
and O +
ROS O +
generation O -
. O +

Disturbance O +
of O +
autophagy O +
alleviates O +
the O +
induced O +
cell O +
death O -
. O +

The O +
results O +
promised O +
a O +
good O +
model O +
for O +
understanding O +
the O +
onset O +
in O +
pathogenesis O +
under O +
stress O +
in O +
neuron O +
cells O +
with O +
aberrant O +
PPP2R2B O +
expression O -
. O +

Absence O +
of O +
edge O +
States O +
in O +
covalently O +
bonded O +
zigzag O +
edges O +
of O +
graphene B-Chemical +
on O +
ir B-Chemical -
( I-Chemical -
111 I-Chemical -
) I-Chemical -
. O +

The O +
zigzag O +
edges O +
of O +
graphene B-Chemical +
on O +
Ir B-Chemical -
( I-Chemical -
111 I-Chemical -
) I-Chemical +
are O +
studied O +
by O +
ab O +
initio O +
simulations O +
and O +
low O -
- O -
temperature O +
scanning O +
tunneling O +
spectroscopy O -
, O +
providing O +
information O +
about O +
their O +
structural O -
, O +
electronic O -
, O +
and O +
magnetic O +
properties O -
. O +

No O +
edge O +
state O +
is O +
found O +
to O +
exist O -
, O +
which O +
is O +
explained O +
in O +
terms O +
of O +
the O +
interplay O +
between O +
a O +
strong O +
geometrical O +
relaxation O +
at O +
the O +
edge O +
and O +
a O +
hybridization O +
of O +
the O +
d O +
orbitals O +
of O +
Ir O +
atoms O +
with O +
the O +
graphene B-Chemical +
orbitals O +
at O +
the O +
edge O -
. O +

Therapeutic O +
potential O +
of O +
neuregulin-1 O +
in O +
cardiovascular O +
disease O -
. O +

Neuregulin-1 O +
( O -
NRG-1 O -
) O -
/ O -
ErbB O +
signaling O +
has O +
an O +
indispensable O +
role O +
in O +
cardiac O +
development O +
and O +
in O +
the O +
maintenance O +
of O +
the O +
structural O +
and O +
functional O +
integrity O +
of O +
the O +
human O +
adult O +
heart O +
in O +
health O +
and O +
disease O -
. O +

Several O +
animal O +
studies O +
have O +
now O +
demonstrated O +
the O +
therapeutic O +
effects O +
of O +
NRG-1 O +
during O +
acute O +
cardiac O +
injury O +
and O +
during O +
chronic O +
heart O +
failure O -
, O +
with O +
improvements O +
in O +
cardiac O +
performance O +
and O +
animal O +
survival O -
. O +

Phase O +
I O +
and O +
II O +
clinical O +
trials O +
for O +
chronic O +
heart O +
failure O +
in O +
humans O +
are O +
now O +
in O +
progress O -
. O +

Glucocorticoid O -
- O -
induced O +
suppression O +
of O +
β O -
- O -
cell O +
proliferation O +
is O +
mediated O +
by O +
Mig6 O -
. O +

Glucocorticoids O +
can O +
cause O +
steroid B-Chemical -
- O -
induced O +
diabetes O +
or O +
accelerate O +
the O +
progression O +
to O +
diabetes O +
by O +
creating O +
systemic O +
insulin O +
resistance O +
and O +
decreasing O +
functional O +
β O -
- O -
cell O +
mass O -
, O +
which O +
is O +
influenced O +
by O +
changes O +
in O +
β O -
- O -
cell O +
function O -
, O +
growth O -
, O +
and O +
death O -
. O +

The O +
synthetic O +
glucocorticoid O +
agonist O +
dexamethasone B-Chemical +
( O -
Dex B-Chemical -
) O +
is O +
deleterious O +
to O +
functional O +
β O -
- O -
cell O +
mass O +
by O +
decreasing O +
β O -
- O -
cell O +
function O -
, O +
survival O -
, O +
and O +
proliferation O -
. O +

However O -
, O +
the O +
mechanism O +
by O +
which O +
Dex B-Chemical +
decreases O +
β O -
- O -
cell O +
proliferation O +
is O +
unknown O -
. O +

Interestingly O -
, O +
Dex B-Chemical +
induces O +
the O +
transcription O +
of O +
an O +
antiproliferative O +
factor O +
and O +
negative O +
regulator O +
of O +
epidermal O +
growth O +
factor O +
receptor O +
signaling O -
, O +
Mig6 O +
( O -
also O +
known O +
as O +
gene O +
33 O -
, O +
RALT O -
, O +
and O +
Errfi1 O -
) O -
. O +

We O -
, O +
therefore O -
, O +
hypothesized O +
that O +
Dex B-Chemical +
impairs O +
β O -
- O -
cell O +
proliferation O +
by O +
increasing O +
the O +
expression O +
of O +
Mig6 O +
and O +
thereby O +
decreasing O +
downstream O +
signaling O +
of O +
epidermal O +
growth O +
factor O +
receptor O -
. O +

We O +
found O +
that O +
Dex B-Chemical +
induced O +
Mig6 O +
and O +
decreased O +
[ B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
H I-Chemical -
] I-Chemical -
thymidine I-Chemical +
incorporation O -
, O +
an O +
index O +
of O +
cellular O +
replication O -
, O +
in O +
mouse O -
, O +
rat O -
, O +
and O +
human O +
islets O -
. O +

Using O +
adenovirally O +
delivered O +
small O +
interfering O +
RNA O +
targeted O +
to O +
Mig6 O +
in O +
rat O +
islets O -
, O +
we O +
were O +
able O +
to O +
limit O +
the O +
induction O +
of O +
Mig6 O +
upon O +
exposure O +
to O +
Dex B-Chemical -
, O +
compared O +
with O +
islets O +
treated O +
with O +
a O +
control O +
virus O -
, O +
and O +
completely O +
rescued O +
the O +
Dex B-Chemical -
- O -
mediated O +
impairment O +
in O +
replication O -
. O +

We O +
demonstrated O +
that O +
both O +
Dex B-Chemical +
and O +
overexpression O +
of O +
Mig6 O +
attenuated O +
the O +
phosphorylation O +
of O +
ERK1 O -
/ O -
2 O +
and O +
blocked O +
the O +
G O -
( O -
1 O -
) O -
/ O -
S O +
transition O +
of O +
the O +
cell O +
cycle O -
. O +

In O +
conclusion O -
, O +
Mig6 O +
functions O +
as O +
a O +
molecular O +
brake O +
for O +
β O -
- O -
cell O +
proliferation O +
during O +
glucocorticoid O +
treatment O +
in O +
β O -
- O -
cells O -
, O +
and O +
thus O -
, O +
Mig6 O +
may O +
be O +
a O +
novel O +
target O +
for O +
preventing O +
glucocorticoid O -
- O -
induced O +
impairments O +
in O +
functional O +
β O -
- O -
cell O +
mass O -
. O +

Design O +
and O +
synthesis O +
of O +
imidazole B-Chemical +
and O +
triazole B-Chemical +
derivatives O +
as O +
Lp O -
- O -
PLA₂ O +
inhibitors O +
and O +
the O +
unexpected O +
discovery O +
of O +
highly O +
potent O +
quaternary B-Chemical +
ammonium I-Chemical +
salts I-Chemical -
. O +

New O +
Lp O -
- O -
PLA O -
( O -
2 O -
) O +
inhibitors O +
were O +
synthesized O +
by O +
the O +
bioisosteric O +
replacement O +
of O +
the O +
amide B-Chemical +
group O +
of O +
Darapladib B-Chemical +
with O +
an O +
imidazole B-Chemical +
or O +
a O +
triazole B-Chemical -
. O +

Unfortunately O -
, O +
the O +
inhibitory O +
activities O +
of O +
these O +
derivatives O +
were O +
lower O +
than O +
that O +
of O +
Darapladib B-Chemical -
. O +

But O +
interestingly O -
, O +
a O +
series O +
of O +
quaternary B-Chemical +
ammonium I-Chemical +
salts I-Chemical +
that O +
were O +
isolated O +
as O +
by O -
- O -
products O +
during O +
this O +
synthetic O +
work O +
were O +
found O +
with O +
high O +
potency O -
. O +

Of O +
these O +
by O -
- O -
products O -
, O +
compound O +
22c O +
showed O +
a O +
similar O +
profile O +
to O +
Darapladib B-Chemical +
both O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

Synthesis O +
and O +
antibacterial O +
activities O +
of O +
new O +
piperidine B-Chemical +
substituted O +
( B-Chemical -
5R I-Chemical -
) I-Chemical -
- I-Chemical -
[ I-Chemical -
1,2,3 I-Chemical -
] I-Chemical -
triazolylmethyl I-Chemical +
and I-Chemical +
( I-Chemical -
5R I-Chemical -
) I-Chemical -
- I-Chemical -
[ I-Chemical -
( I-Chemical -
4-F- I-Chemical -
[ I-Chemical -
1,2,3 I-Chemical -
] I-Chemical -
triazolyl I-Chemical -
) I-Chemical -
methyl I-Chemical -
] I-Chemical +
oxazolidinones I-Chemical -
. O +

A O +
novel O +
series O +
of O +
5 B-Chemical -
( I-Chemical -
R I-Chemical -
) I-Chemical -
- I-Chemical -
[ I-Chemical -
1,2,3 I-Chemical -
] I-Chemical -
triazolylmethyl I-Chemical +
and I-Chemical +
( I-Chemical -
5R I-Chemical -
) I-Chemical -
- I-Chemical -
[ I-Chemical -
( I-Chemical -
4-F- I-Chemical -
[ I-Chemical -
1,2,3 I-Chemical -
] I-Chemical -
triazolyl I-Chemical -
) I-Chemical -
methyl I-Chemical -
] I-Chemical -
oxazolidinones I-Chemical +
having O +
various O +
piperidine B-Chemical +
group O +
were O +
synthesized O +
and O +
evaluated O +
antibacterial O +
activity O +
against O +
clinically O +
isolated O +
resistant O +
strains O +
of O +
Gram O -
- O -
positive O +
and O +
Gram O -
- O -
negative O +
bacteria O -
. O +

The O +
compound O +
12a O +
having O +
exo B-Chemical -
- I-Chemical -
cyanoethylidene I-Chemical +
group O +
in O +
the O +
4-position O +
of O +
piperidine B-Chemical +
ring O +
was O +
found O +
to O +
be O +
two O +
to O +
threefold O +
more O +
potent O +
than O +
the O +
linezolid B-Chemical +
against O +
penicillin B-Chemical -
- O -
resistant O +
Staphylococcus O +
pneumonia O +
and O +
Staphylococcus O +
agalactiae O -
, O +
and O +
also O +
exhibited O +
reduced O +
MAO O -
- O -
B O +
inhibitory O +
activity O -
. O +

Integrated O +
analysis O +
of O +
transcriptomics O +
and O +
metabonomics O +
profiles O +
in O +
aflatoxin B-Chemical +
B1-induced I-Chemical +
hepatotoxicity O +
in O +
rat O -
. O +

The O +
aim O +
of O +
this O +
work O +
was O +
to O +
identify O +
mechanisms O +
and O +
potential O +
biomarkers O +
for O +
predicting O +
the O +
development O +
and O +
progression O +
of O +
aflatoxin B-Chemical +
B1 I-Chemical +
( O -
AFB1 B-Chemical -
) O -
-induced O +
acute O +
hepatotoxicity O -
. O +

In O +
this O +
study O -
, O +
microarray O +
analysis O +
and O +
metabolites O +
profiles O +
were O +
used O +
to O +
identify O +
shifts O +
in O +
gene O +
expression O +
and O +
metabolite O +
levels O +
associated O +
with O +
the O +
affected O +
physiological O +
processes O +
of O +
rats O +
treated O +
with O +
AFB1 B-Chemical -
. O +

Histopathological O +
examinations O +
and O +
serum O +
biochemical O +
analysis O +
were O +
simultaneously O +
performed O -
; O +
the O +
results O +
indicated O +
that O +
hepatotoxicity O +
occurred O +
in O +
higher O +
dosage O +
groups O -
. O +

However O -
, O +
gene O +
expression O +
analysis O +
and O +
metabolite O +
profiles O +
are O +
more O +
sensitive O +
than O +
general O +
toxicity O +
studies O +
for O +
detecting O +
AFB1-induced B-Chemical +
acute O +
hepatotoxicity O +
as O +
the O +
patterns O +
of O +
low O -
- O -
dose O +
AFB1-treated B-Chemical +
rats O +
in O +
these O +
two O +
technique O +
platforms O +
were O +
more O +
similar O +
to O +
the O +
rats O +
in O +
higher O +
dosage O +
groups O +
than O +
to O +
the O +
control O +
rats O -
. O +

Integrated O +
analysis O +
of O +
the O +
results O +
from O +
general O +
toxicity O +
studies O -
, O +
transcriptomics O +
and O +
metabonomics O +
profiles O +
suggested O +
that O +
p53 O +
signaling O +
pathway O +
induced O +
by O +
oxidative O +
damage O +
was O +
the O +
crucial O +
step O +
in O +
AFB1-induced B-Chemical +
acute O +
hepatotoxicity O -
, O +
whereas O +
gluconeogenesis O +
and O +
lipid O +
metabolism O +
disorder O +
were O +
found O +
to O +
be O +
the O +
major O +
metabolic O +
effects O +
after O +
acute O +
AFB1 B-Chemical +
exposure O -
. O +

The O +
genes O +
and O +
metabolites O +
significantly O +
affected O +
in O +
common O +
in O +
rat O +
liver O +
or O +
serum O +
of O +
three O +
doses O +
AFB1 B-Chemical +
treatments O +
served O +
as O +
potential O +
biomarkers O +
for O +
detecting O +
AFB1-induced B-Chemical +
acute O +
hepatotoxicity O -
. O +

Preparation O +
and O +
evaluation O +
of O +
sustained O -
- O -
release O +
doxazosin B-Chemical +
mesylate I-Chemical +
pellets O -
. O +

Doxazosin B-Chemical +
mesylate I-Chemical +
( O -
DXM B-Chemical -
) O +
sustained O +
release O +
pellets O +
were O +
prepared O +
by O +
an O +
extrusion O -
- O -
spheronization O +
and O +
fluid O -
- O -
bed O +
coating O +
technique O -
. O +

The O +
core O +
pellets O +
containing O +
DXM B-Chemical +
were O +
prepared O +
by O +
extrusion O -
- O -
spheronization O +
technique O -
, O +
and O +
coated O +
by O +
a O +
fluid O -
- O -
bed O +
coater O +
to O +
control O +
the O +
release O +
of O +
DXM B-Chemical -
. O +

The O +
factors O +
affecting O +
to O +
properties O +
of O +
pellets O -
, O +
such O +
as O +
diluent O +
content O -
, O +
type O +
and O +
coating O +
level O +
of O +
coating O +
agents O +
and O +
plasticizers O +
were O +
studied O +
in O +
the O +
present O +
study O -
. O +

Polymethacrylate B-Chemical +
derivatives O +
( O -
Eudragit B-Chemical -
® O +
RS O +
PO O +
and O +
RL O +
PO O -
) O +
were O +
used O +
for O +
coating O +
agents O -
, O +
and O +
polyethylene B-Chemical +
glycol I-Chemical +
6000 I-Chemical +
( O -
PEG B-Chemical +
6000 I-Chemical -
) O -
, O +
triethyl B-Chemical +
citrate I-Chemical +
( O -
TEC B-Chemical -
) O +
and O +
castor O +
oil O +
were O +
as O +
plasticizers O -
. O +

To O +
evaluate O +
the O +
properties O +
of O +
prepared O +
pellets O -
, O +
the O +
size O +
of O +
prepared O +
pellets O +
was O +
investigated O +
by O +
sieve O +
analysis O +
technique O +
and O +
the O +
morphology O +
of O +
pellets O +
was O +
evaluated O +
by O +
scanning O +
electron O +
microscopy O -
. O +

Through O +
the O +
dissolution O +
test O -
, O +
factors O +
that O +
have O +
an O +
effect O +
on O +
the O +
dissolution O +
of O +
the O +
drug O +
were O +
evaluated O -
. O +

As O +
the O +
content O +
ratio O +
of O +
microcrystalline O +
cellulose O +
( O -
MCC O -
) O +
had O +
increased O -
, O +
the O +
dissolution O +
was O +
proportionally O +
sustained O -
. O +

Eudragit B-Chemical -
® O +
RS O +
PO O +
had O +
more O +
marked O +
sustaining O +
effect O +
on O +
the O +
dissolution O +
rate O +
than O +
Eudragit B-Chemical -
® O +
RL O +
PO O -
, O +
and O +
the O +
effect O +
was O +
more O +
pronounced O +
with O +
the O +
increased O +
coating O +
level O -
. O +

PEG B-Chemical +
6000 I-Chemical +
was O +
an O +
appropriate O +
plasticizer O +
for O +
DXM B-Chemical +
pellets O -
, O +
and O +
increasing O +
the O +
content O +
of O +
PEG B-Chemical +
6000 I-Chemical -
, O +
was O +
also O +
slightly O +
decreasing O +
the O +
dissolution O +
rate O -
. O +

CYP21A2 O +
Mutations O +
in O +
Women O +
with O +
Polycystic O +
Ovary O +
Syndrome O +
( O -
PCOS O -
) O -
. O +

The O +
question O +
of O +
the O +
contribution O +
of O +
CYP21A2 O +
heterozygosity O +
to O +
the O +
development O +
of O +
polycystic O +
ovary O +
syndrome O +
( O -
PCOS O -
) O +
has O +
repeatedly O +
been O +
raised O +
in O +
the O +
literature O -
. O +

The O +
available O +
data O -
, O +
however O -
, O +
do O +
not O +
offer O +
a O +
satisfactory O +
answer O -
. O +

The O +
discrepancy O +
must O +
be O +
attributed O -
, O +
primarily O -
, O +
to O +
the O +
small O +
number O +
of O +
subjects O +
in O +
the O +
various O +
studies O -
, O +
the O +
type O +
of O +
selected O +
phenotype O -
, O +
and O +
the O +
number O +
of O +
searched O +
mutations O -
. O +

The O +
aim O +
of O +
the O +
study O +
was O +
to O +
define O +
the O +
contribution O +
of O +
CYP21A2 O +
heterozygous O +
mutations O +
to O +
the O +
pathogenesis O +
of O +
PCOS O -
. O +

We O +
searched O +
for O +
14 O +
molecular O +
defects O +
of O +
the O +
CYP21A2 O +
gene O +
in O +
197 O +
PCOS O +
women O -
, O +
employing O +
allele O +
specific O +
PCR O -
. O +

Androgen B-Chemical +
levels O +
were O +
determined O +
at O +
baseline O +
by O +
appropriate O +
methodology O +
in O +
the O +
follicular O +
phase O -
. O +

PCOS O +
women O +
with O +
17-hydroxyprogesterone B-Chemical +
( O -
17OHP B-Chemical -
) O +
basal O +
values O +
> O -
2 O +
ng O -
/ O -
ml O +
and/or O +
post O -
- O -
ACTH O +
> O -
10 O +
ng O -
/ O -
ml O +
were O +
excluded O -
. O +

Appropriate O +
controls O +
were O +
included O -
. O +

The O +
frequency O +
of O +
the O +
CYP21A2 O +
heterozygous O +
mutations O +
in O +
PCOS O +
women O +
and O +
in O +
controls O +
was O +
7.6 O -
% O +
and O +
5.9 O -
% O -
, O +
respectively O +
[ O -
p O -
- O -
value O +
( O -
PCOS O +
vs. O +
controls O -
) O -
: O +
0.663 O -
] O -
. O +

Homozygosity O +
for O +
CYP21A2 O +
gene O +
defects O +
was O +
not O +
detected O -
. O +

In O +
conclusion O -
, O +
the O +
contribution O +
of O +
CYP21A2 O +
heterozygous O +
mutations O +
to O +
the O +
pathogenesis O +
of O +
PCOS O +
is O +
not O +
substantiated O +
by O +
our O +
data O -
. O +

Moreover O -
, O +
17-hydroxyprogesterone B-Chemical +
values O +
of O +
< O +
10 O +
ng O -
/ O -
ml O +
post O -
- O -
ACTH O +
exclude O +
homozygosity O +
of O +
CYP21A2 O +
mutations O -
. O +

Effectiveness O +
of O +
an O +
educational O +
intervention O +
on O +
prescription O +
writing O +
skill O +
of O +
preclerkship O +
medical O +
students O +
in O +
a O +
problem O -
- O -
based O +
learning O +
curriculum O -
. O +

Medical O +
school O +
training O +
for O +
students O +
in O +
pharmacotherapy O +
is O +
suboptimal O +
and O +
junior O +
doctors O +
are O +
not O +
confident O +
to O +
prescribe O +
drugs O -
. O +

This O +
study O +
evaluated O +
the O +
effectiveness O +
of O +
an O +
optional O +
educational O +
intervention O +
on O +
prescribing O +
skill O +
of O +
pre O -
- O -
clerkship O +
medical O +
students O +
in O +
a O +
problem O -
- O -
based O +
learning O +
( O -
PBL O -
) O +
program O -
. O +

Performance O +
was O +
assessed O +
in O +
seven O +
end O -
- O -
unit O +
objective O +
structured O +
practical O +
examinations O +
( O -
OSPE O -
) O -
. O +

Physician O -
- O -
related O +
prescription O +
components O +
( O -
PRCs O -
) O +
and O +
drug O -
- O -
related O +
prescription O +
components O +
( O -
DRCs O -
) O +
were O +
assessed O -
. O +

The O +
performance O +
of O +
students O +
who O +
attended O +
the O +
intervention O +
sessions O +
( O -
attendees O -
) O +
and O +
non O -
- O -
attendees O +
was O +
compared O -
. O +

Approximately O +
half O +
of O +
the O +
students O +
attended O +
the O +
sessions O -
. O +

PRCs O +
were O +
written O +
appropriately O +
by O +
most O +
of O +
the O +
students O -
. O +

DRCs O +
were O +
written O +
less O +
competently O +
by O +
both O +
attendees O +
and O +
non O -
- O -
attendees O -
, O +
specifically O +
the O +
dosage O +
form O -
, O +
quantity O +
to O +
be O +
dispensed O +
and O +
directions O -
. O +

Performance O +
on O +
individual O +
DRCs O +
was O +
significantly O +
better O +
for O +
attendees O +
compared O +
to O +
non O -
- O -
attendees O -
. O +

The O +
mean O +
total O +
score O +
for O +
all O +
prescription O +
components O +
of O +
attendees O +
was O +
significantly O +
greater O +
than O +
that O +
of O +
non O -
- O -
attendees O -
. O +

The O +
percentage O +
of O +
high O +
achievers O +
was O +
significantly O +
greater O +
for O +
attendees O -
. O +

A O +
positive O +
correlation O +
was O +
found O +
between O +
student O +
attendance O +
and O +
the O +
total O +
score O -
. O +

An O +
optional O +
educational O +
intervention O +
during O +
the O +
preclerkship O +
phase O +
is O +
an O +
important O +
determinant O +
of O +
prescribing O +
performance O +
of O +
medical O +
students O -
. O +

Sesquiterpenes B-Chemical +
from O +
the O +
rhizomes O +
of O +
Curcuma O +
heyneana O -
. O +

Four O +
new O +
germacranes B-Chemical +
[ O -
heyneanones B-Chemical +
A I-Chemical -
- I-Chemical -
D I-Chemical +
( O -
1 O -
- O -
4 O -
) O -
] O -
, O +
three O +
new O +
guaianes B-Chemical +
[ O -
4,10-epizedoarondiol B-Chemical +
( O -
5 O -
) O -
, O +
15-hydroxyprocurcumenol B-Chemical +
( O -
6 O -
) O -
, O +
12-hydroxycurcumenol B-Chemical +
( O -
7 O -
) O -
] O -
, O +
and O +
two O +
new O +
spirolactones B-Chemical +
[ O -
curcumanolides B-Chemical +
C O +
( O -
8) O +
and O +
D O +
( O -
9 O -
) O -
] O +
were O +
isolated O +
from O +
the O +
rhizomes O +
of O +
Curcuma O +
heyneana O +
together O +
with O +
13 O +
known O +
sesquiterpenes B-Chemical +
and O +
two O +
known O +
labdane B-Chemical -
- O -
type O +
diterpenes B-Chemical -
. O +

Among O +
the O +
isolated O +
compounds O -
, O +
heyneanone B-Chemical +
A I-Chemical +
( O -
1 O -
) O -
, O +
heyneanone B-Chemical +
C I-Chemical +
( O -
3 O -
) O -
, O +
4,10-epizedoarondiol B-Chemical +
( O -
5 O -
) O -
, O +
procurcumenol B-Chemical +
( O -
16 O -
) O -
, O +
aerugidiol B-Chemical +
( O -
17 O -
) O -
, O +
zerumin B-Chemical +
A I-Chemical +
( O -
23 O -
) O -
, O +
and O +
( B-Chemical -
E I-Chemical -
) I-Chemical -
-15,16-bisnorlabda-8 I-Chemical -
( I-Chemical -
17 I-Chemical -
) I-Chemical -
,11-dien-13-one I-Chemical +
( O -
24 O -
) O +
inhibited O +
protein O +
tyrosine B-Chemical +
phosphatase O +
1B O +
( O -
PTP1B O -
) O +
with O +
IC O -
( O -
50 O -
) O +
values O +
of O +
42.5 O -
, O +
35.2 O -
, O +
35.1 O -
, O +
45.6 O -
, O +
35.7 O -
, O +
10.4 O -
, O +
and O +
14.7 O +
μM O -
, O +
respectively O -
. O +

Public O +
health O +
challenges O +
and O +
prospects O +
for O +
malaria O +
control O +
and O +
elimination O -
. O +

The O +
past O +
decade O +
witnessed O +
unprecedented O +
efforts O +
to O +
control O +
malaria O -
, O +
including O +
renewed O +
political O +
and O +
financial O +
commitment O +
and O +
increased O +
availability O +
of O +
both O +
old O +
and O +
new O +
strategies O +
and O +
tools O -
. O +

However O -
, O +
malaria O +
still O +
represents O +
a O +
major O +
health O +
burden O -
, O +
particularly O +
in O +
Africa O -
. O +

Important O +
challenges O +
such O +
as O +
the O +
fragility O +
of O +
many O +
health O +
systems O -
, O +
the O +
rise O +
of O +
insecticide O +
and O +
drug O +
resistance O -
, O +
and O +
particularly O +
the O +
expected O +
decline O +
both O +
in O +
funding O +
and O +
in O +
the O +
coverage O +
of O +
key O +
interventions O +
if O +
they O +
are O +
not O +
replaced O +
as O +
needed O -
, O +
urgently O +
need O +
to O +
be O +
addressed O -
. O +

Further O +
research O +
and O +
development O +
is O +
also O +
becoming O +
increasingly O +
crucial O -
. O +

Among O +
other O +
needs O -
, O +
common O +
methodologies O +
for O +
estimating O +
and O +
tracking O +
the O +
malaria O +
burden O -
, O +
new O +
strategies O +
to O +
measure O +
transmission O -
, O +
better O +
understanding O +
of O +
immunity O -
, O +
and O +
increased O +
knowledge O +
of O +
the O +
mechanisms O +
and O +
effects O +
of O +
resistance O +
to O +
drugs O +
and O +
insecticides O +
stand O +
out O -
. O +

The O +
ongoing O +
efforts O +
in O +
research O +
and O +
development O +
for O +
new O +
antimalarial O +
drugs O -
, O +
more O +
sensitive O +
point O -
- O -
of O -
- O -
care O +
rapid O +
diagnostic O +
tests O +
and O +
new O +
insecticides O +
need O +
further O +
innovation O +
and O +
substantial O +
strengthening O -
. O +

Clearly O -
, O +
efforts O +
should O +
focus O +
not O +
only O +
on O +
Plasmodium O +
falciparum O +
but O +
also O +
and O +
increasingly O +
on O +
Plasmodium O +
vivax O -
, O +
the O +
neglected O +
human O +
malaria O +
parasite O -
. O +

Addressing O +
these O +
challenges O +
in O +
a O +
comprehensive O +
and O +
timely O +
way O +
will O +
allow O +
us O +
to O +
sustain O +
the O +
gains O +
made O +
so O +
far O +
and O +
make O +
further O +
progress O +
in O +
control O +
and O +
progressive O +
elimination O -
. O +

Signature O +
of O +
singlet O +
open O -
- O -
shell O +
character O +
on O +
the O +
optically O +
allowed O +
singlet O +
excitation O +
energy O +
and O +
singlet O -
- O -
triplet O +
energy O +
gap O -
. O +

A O +
signature O +
of O +
singlet O +
open O -
- O -
shell O +
character O +
on O +
the O +
optically O +
allowed O +
singlet O +
excitation O +
energy O +
and O +
singlet O -
- O -
triplet O +
energy O +
gap O +
is O +
theoretically O +
illuminated O +
for O +
open O -
- O -
shell O +
singlet O +
molecules O -
. O +

On O +
the O +
basis O +
of O +
a O +
two O -
- O -
site O +
diradical O +
model O +
with O +
two O +
electrons O +
in O +
two O +
orbitals O -
, O +
the O +
linear O +
dependence O +
of O +
these O +
excitation O +
energies O +
on O +
the O +
transfer O +
integral O -
, O +
which O +
is O +
equivalent O +
to O +
the O +
energy O +
gap O +
between O +
the O +
highest O +
occupied O +
( O -
HOMO O -
) O +
and O +
the O +
lowest O +
unoccupied O +
( O -
LUMO O -
) O +
molecular O +
orbitals O +
in O +
the O +
Hückel O +
theory O -
, O +
is O +
found O +
to O +
be O +
broken O +
down O +
in O +
the O +
high O +
diradical O +
character O +
region O +
due O +
to O +
an O +
increase O +
in O +
electron O +
correlation O +
in O +
the O +
open O -
- O -
shell O +
singlet O +
ground O +
state O -
. O +

A O +
series O +
of O +
polyacenes B-Chemical +
shows O +
the O +
similar O +
behavior O +
of O +
the O +
optically O +
allowed O +
singlet O +
excitation O +
energies O +
obtained O +
by O +
time O -
- O -
dependent O +
spin O -
- O -
flip O +
density O +
functional O +
theory O +
calculations O +
and O +
experiments O -
, O +
which O +
bears O +
testimony O +
to O +
the O +
singlet O +
open O -
- O -
shell O +
character O +
in O +
long O +
polyacenes O -
. O +

High O -
- O -
resolution O +
zero O -
- O -
field O +
NMR O +
J O -
- O -
spectroscopy O +
of O +
aromatic O +
compounds O -
. O +

We O +
report O +
the O +
acquisition O +
and O +
interpretation O +
of O +
nuclear O +
magnetic O +
resonance O +
( O -
NMR O -
) O +
J O -
- O -
spectra O +
at O +
zero O +
magnetic O +
field O +
for O +
a O +
series O +
of O +
benzene B-Chemical +
derivatives O -
, O +
demonstrating O +
the O +
analytical O +
capabilities O +
of O +
zero O -
- O -
field O +
NMR O -
. O +

The O +
zeroth O -
- O -
order O +
spectral O +
patterns O +
do O +
not O +
overlap O -
, O +
which O +
allows O +
for O +
straightforward O +
determination O +
of O +
the O +
spin O +
interactions O +
of O +
substituent O +
functional O +
groups O -
. O +

Higher O -
- O -
order O +
effects O +
cause O +
additional O +
line O +
splittings O -
, O +
revealing O +
additional O +
molecular O +
information O -
. O +

We O +
demonstrate O +
resonance O +
linewidths O +
as O +
narrow O +
as O +
11 O +
mHz O -
, O +
permitting O +
resolution O +
of O +
minute O +
frequency O +
differences O +
and O +
precise O +
determination O +
of O +
long O -
- O -
range O +
J O -
- O -
couplings O -
. O +

The O +
measurement O +
of O +
J O -
- O -
couplings O +
with O +
the O +
high O +
precision O +
offered O +
by O +
zero O -
- O -
field O +
NMR O +
may O +
allow O +
further O +
refinements O +
in O +
the O +
determination O +
of O +
molecular O +
structure O +
and O +
conformation O -
. O +

Solvent O +
and O +
pressure O +
effects O +
on O +
the O +
motions O +
of O +
encapsulated O +
guests O -
: O +
tuning O +
the O +
flexibility O +
of O +
a O +
supramolecular O +
host O -
. O +

The O +
supramolecular O +
host O +
assembly O +
[ B-Chemical -
Ga4L6 I-Chemical -
] I-Chemical -
( I-Chemical -
12- I-Chemical -
) I-Chemical +
[ O -
1 O -
; O +
L O +
= O +
1,5-bis B-Chemical -
( I-Chemical -
2,3-dihydroxybenzamido I-Chemical -
) I-Chemical -
naphthalene I-Chemical -
] O +
contains O +
a O +
flexible O -
, O +
hydrophobic O +
interior O +
cavity O +
that O +
can O +
encapsulate O +
cationic O +
guest O +
molecules O +
and O +
catalyze O +
a O +
variety O +
of O +
chemical O +
transformations O -
. O +

The O +
Ar B-Chemical -
- I-Chemical -
CH2 I-Chemical +
bond O +
rotational O +
barrier O +
for O +
encapsulated O +
ortho B-Chemical -
- I-Chemical -
substituted I-Chemical +
benzyl I-Chemical +
phosphonium I-Chemical +
guest O +
molecules O +
is O +
sensitive O +
to O +
the O +
size O +
and O +
shape O +
of O +
the O +
host O +
interior O +
space O -
. O +

Here O +
we O +
examine O +
how O +
changes O +
in O +
bulk O +
solvent O +
( O -
water O -
, O +
methanol B-Chemical -
, O +
or O +
DMF B-Chemical -
) O +
or O +
applied O +
pressure O +
( O -
up O +
to O +
150 O +
MPa O -
) O +
affect O +
the O +
rotational O +
dynamics O +
of O +
encapsulated O +
benzyl B-Chemical +
phosphonium I-Chemical +
guests O -
, O +
as O +
a O +
way O +
to O +
probe O +
changes O +
in O +
host O +
cavity O +
size O +
or O +
flexibility O -
. O +

When O +
host O +
1 O +
is O +
dissolved O +
in O +
organic O +
solvents O +
with O +
large O +
solvent O +
internal O +
pressures O +
( O -
∂U O -
/ O -
∂V O -
) O -
T O -
, O +
we O +
find O +
that O +
the O +
free O +
energy O +
barrier O +
to O +
Ar B-Chemical -
- I-Chemical -
CH2 I-Chemical +
bond O +
rotation O +
increases O +
by O +
1 O -
- O -
2 O +
kcal O -
/ O -
mol O -
, O +
compared O +
with O +
that O +
in O +
aqueous O +
solution O -
. O +

Likewise O -
, O +
when O +
external O +
pressure O +
is O +
applied O +
to O +
the O +
host O -
- O -
guest O +
complex O +
in O +
solution O -
, O +
the O +
bond O +
rotational O +
rates O +
for O +
the O +
encapsulated O +
guests O +
decrease O -
. O +

The O +
magnitude O +
of O +
these O +
rate O +
changes O +
and O +
the O +
volumes O +
of O +
activation O +
obtained O +
using O +
either O +
solvent O +
internal O +
pressure O +
or O +
applied O +
external O +
pressure O +
are O +
very O +
similar O -
. O +

NOE O +
distance O +
measurements O +
reveal O +
shorter O +
average O +
host O -
- O -
guest O +
distances O +
( O -
~0.3 O +
Å O -
) O +
in O +
organic O +
versus O +
aqueous O +
solution O -
. O +

These O +
experiments O +
demonstrate O +
that O +
increasing O +
solvent O +
internal O +
pressure O +
or O +
applied O +
external O +
pressure O +
reduces O +
the O +
host O +
cavity O +
size O +
or O +
flexibility O -
, O +
resulting O +
in O +
more O +
restricted O +
motions O +
for O +
encapsulated O +
guest O +
molecules O -
. O +

Changing O +
bulk O +
solvent O +
or O +
external O +
pressure O +
might O +
therefore O +
be O +
used O +
to O +
tune O +
the O +
physical O +
properties O +
or O +
reactivity O +
of O +
guest O +
molecules O +
encapsulated O +
in O +
a O +
flexible O +
supramolecular O +
host O -
. O +

Time O -
- O -
of O -
- O -
flight O +
magnetic O +
flow O +
cytometry O +
in O +
whole O +
blood O +
with O +
integrated O +
sample O +
preparation O -
. O +

Rapid O +
and O +
specific O +
rare O +
cell O +
detection O +
for O +
point O -
- O -
of O -
- O -
care O +
testing O +
requires O +
an O +
integration O +
of O +
the O +
sample O +
preparation O +
for O +
flow O +
cytometry O -
. O +

To O +
achieve O +
such O +
a O +
challenging O +
goal O +
we O +
have O +
developed O +
a O +
magnetic O +
flow O +
cytometry O +
technique O +
which O +
applies O +
magnetophoresis O +
to O +
perform O +
cell O +
enrichment O -
, O +
focusing O -
, O +
and O +
background O +
elimination O +
in O +
a O +
single O +
step O -
. O +

Time O -
- O -
of O -
- O -
flight O +
measurements O +
are O +
performed O +
with O +
integrated O +
magnetic O +
sensors O +
to O +
detect O +
specifically O +
cancer O +
cells O +
and O +
cell O +
diameters O +
in O +
whole O +
blood O -
. O +

Ventral O +
tegmental O +
area O +
GABA B-Chemical +
neurons O +
and O +
opiate O +
motivation O -
. O +

RATIONALE O -
: O +
Past O +
research O +
has O +
demonstrated O +
that O +
when O +
an O +
animal O +
changes O +
from O +
a O +
previously O +
drug O -
- O -
naive O +
to O +
an O +
opiate O -
- O -
dependent O +
and O +
withdrawn O +
state O -
, O +
morphine B-Chemical -
's O +
motivational O +
effects O +
are O +
switched O +
from O +
a O +
tegmental O +
pedunculopontine O +
nucleus O +
( O -
TPP O -
) O -
-dependent O +
to O +
a O +
dopamine B-Chemical -
- O -
dependent O +
pathway O -
. O +

Interestingly O -
, O +
a O +
corresponding O +
change O +
is O +
observed O +
in O +
ventral O +
tegmental O +
area O +
( O -
VTA O -
) O +
GABA B-Chemical -
( O -
A O -
) O +
receptors O -
, O +
which O +
change O +
from O +
mediating O +
hyperpolarization O +
of O +
VTA O +
GABA B-Chemical +
neurons O +
to O +
mediating O +
depolarization O -
. O +

OBJECTIVES O -
: O +
The O +
present O +
study O +
investigated O +
whether O +
pharmacological O +
manipulation O +
of O +
VTA O +
GABA B-Chemical -
( O -
A O -
) O +
receptor O +
activity O +
could O +
directly O +
influence O +
the O +
mechanisms O +
underlying O +
opiate O +
motivation O -
. O +

RESULTS O -
: O +
Using O +
an O +
unbiased O +
place O +
conditioning O +
procedure O -
, O +
we O +
demonstrated O +
that O +
in O +
Wistar O +
rats O -
, O +
intra O -
- O -
VTA O +
administration O +
of O +
furosemide B-Chemical -
, O +
a O +
Cl B-Chemical -
( I-Chemical -
- I-Chemical -
) I-Chemical +
cotransporter O +
inhibitor O -
, O +
was O +
able O +
to O +
promote O +
a O +
switch O +
in O +
the O +
mechanisms O +
underlying O +
morphine B-Chemical -
's O +
motivational O +
properties O -
, O +
one O +
which O +
is O +
normally O +
observed O +
only O +
after O +
chronic O +
opiate O +
exposure O -
. O +

This O +
behavioral O +
switch O +
was O +
prevented O +
by O +
intra O -
- O -
VTA O +
administration O +
of O +
acetazolamide B-Chemical -
, O +
an O +
inhibitor O +
of O +
the O +
bicarbonate B-Chemical +
ion O -
- O -
producing O +
carbonic O +
anhydrase O +
enzyme O -
. O +

Electrophysiological O +
recordings O +
of O +
mouse O +
VTA O +
showed O +
that O +
furosemide B-Chemical +
reduced O +
the O +
sensitivity O +
of O +
VTA O +
GABA B-Chemical +
neurons O +
to O +
inhibition O +
by O +
the O +
GABA B-Chemical -
( O -
A O -
) O +
receptor O +
agonist O +
muscimol B-Chemical -
, O +
instead O +
increasing O +
the O +
firing O +
rate O +
of O +
a O +
significant O +
subset O +
of O +
these O +
GABA B-Chemical +
neurons O -
. O +

CONCLUSIONS O -
: O +
Our O +
results O +
suggest O +
that O +
the O +
carbonic O +
anhydrase O +
enzyme O +
may O +
constitute O +
part O +
of O +
a O +
common O +
VTA O +
GABA B-Chemical +
neuron O -
- O -
based O +
biological O +
pathway O +
responsible O +
for O +
controlling O +
the O +
mechanisms O +
underlying O +
opiate O +
motivation O -
, O +
supporting O +
the O +
hypothesis O +
that O +
VTA O +
GABA B-Chemical -
( O -
A O -
) O +
receptor O +
hyperpolarization O +
or O +
depolarization O +
is O +
responsible O +
for O +
selecting O +
TPP- O +
or O +
dopamine B-Chemical -
- O -
dependent O +
motivational O +
outputs O -
, O +
respectively O -
. O +

Hyperbranched O +
Polyester B-Chemical +
Hydrogels O +
with O +
Controlled O +
Drug O +
Release O +
and O +
Cell O +
Adhesion O +
Properties O -
. O +

Hyperbranched O +
polyesters B-Chemical +
( O -
HPE O -
) O +
have O +
a O +
high O +
efficiency O +
to O +
encapsulate O +
bioactive O +
agents O -
, O +
including O +
drugs O -
, O +
genes O -
, O +
and O +
proteins O -
, O +
due O +
to O +
their O +
globe O -
- O -
like O +
nanostructure O -
. O +

However O -
, O +
the O +
use O +
of O +
these O +
highly O +
branched O +
polymeric O +
systems O +
for O +
tissue O +
engineering O +
applications O +
has O +
not O +
been O +
broadly O +
investigated O -
. O +

Here O -
, O +
we O +
report O +
synthesis O +
and O +
characterization O +
of O +
photocrosslinkable O +
HPE O +
hydrogels O +
with O +
sustained O +
drug O +
release O +
characteristics O +
for O +
cellular O +
therapies O -
. O +

These O +
HPE O +
can O +
encapsulate O +
hydrophobic O +
drug O +
molecules O +
within O +
the O +
HPE O +
cavities O +
due O +
to O +
the O +
presence O +
of O +
a O +
hydrophobic O +
inner O +
structure O +
that O +
is O +
otherwise O +
difficult O +
to O +
achieve O +
in O +
conventional O +
hydrogels O -
. O +

The O +
functionalization O +
of O +
HPE O +
with O +
photocrosslinkable O +
acrylate B-Chemical +
moieties O +
renders O +
the O +
formation O +
of O +
hydrogels O +
with O +
a O +
highly O +
porous O +
interconnected O +
structure O +
and O +
mechanically O +
tough O +
network O -
. O +

The O +
compressive O +
modulus O +
of O +
HPE O +
hydrogels O +
was O +
tunable O +
by O +
changing O +
the O +
crosslinking O +
density O -
. O +

The O +
feasibility O +
of O +
using O +
these O +
HPE O +
networks O +
for O +
cellular O +
therapies O +
was O +
investigated O +
by O +
evaluating O +
cell O +
adhesion O -
, O +
spreading O -
, O +
and O +
proliferation O +
on O +
hydrogel O +
surface O -
. O +

Highly O +
crosslinked O +
and O +
mechanically O +
stiff O +
HPE O +
hydrogels O +
have O +
higher O +
cell O +
adhesion O -
, O +
spreading O -
, O +
and O +
proliferation O +
compared O +
to O +
soft O +
and O +
complaint O +
HPE O +
hydrogels O -
. O +

Overall O -
, O +
we O +
showed O +
that O +
hydrogels O +
made O +
from O +
HPE O +
could O +
be O +
used O +
for O +
biomedical O +
applications O +
that O +
require O +
spatial O +
control O +
of O +
cell O +
adhesion O +
and O +
controlled O +
release O +
of O +
hydrophobic O +
clues O -
. O +

One O -
- O -
pot O -
, O +
exchange O -
- O -
free O -
, O +
room O -
- O -
temperature O +
synthesis O +
of O +
sub-10 O +
nm O +
aqueous O -
, O +
noninteracting O -
, O +
and O +
stable O +
zwitterated B-Chemical +
iron I-Chemical +
oxide I-Chemical +
nanoparticles O -
. O +

Stable O +
aqueous O +
dispersions O +
of O +
superparamagnetic O +
iron B-Chemical +
oxide I-Chemical +
nanoparticles O +
were O +
synthesized O +
in O +
one O +
step O +
in O +
the O +
presence O +
of O +
a O +
zwitterionic B-Chemical +
siloxane I-Chemical +
as O +
the O +
stabilizing O -
/ O -
capping O -
/ O -
solubilizing O +
ligand O -
. O +

The O +
hydrodynamic O +
diameter O +
of O +
the O +
particles O +
was O +
tuned O +
by O +
controlling O +
the O +
concentration O +
of O +
zwitterion B-Chemical +
siloxane I-Chemical -
, O +
which O +
ultimately O +
yielded O +
monodisperse O +
nanoparticles O +
small O +
enough O +
for O +
renal O +
filtration O +
( O -
< O -
6 O +
nm O +
diameter O -
) O -
. O +

The O +
zwitterated O +
nanoparticles O +
were O +
readily O +
dispersed O +
and O +
stable O +
in O +
aqueous O +
media O +
in O +
the O +
pH O +
range O +
6 O -
- O -
9 O +
but O +
exhibited O +
lower O +
magnetization O +
values O +
than O +
nonzwitterated O +
materials O +
due O +
to O +
amorphous O +
content O +
and O +
spin O +
canting O -
, O +
typical O +
for O +
particles O +
of O +
such O +
size O -
. O +

Turbidimetry O +
and O +
light O +
scattering O +
studies O +
revealed O +
no O +
interaction O +
between O +
the O +
particles O +
and O +
proteins O -
, O +
suggesting O +
the O +
materials O +
will O +
circulate O +
well O +
in O +
vivo O -
. O +

Saturable O +
active O +
efflux O +
by O +
p O -
- O -
glycoprotein O +
and O +
breast O +
cancer O +
resistance O +
protein O +
at O +
the O +
blood O -
- O -
brain O +
barrier O +
leads O +
to O +
nonlinear O +
distribution O +
of O +
elacridar B-Chemical +
to O +
the O +
central O +
nervous O +
system O -
. O +

The O +
study O +
objective O +
was O +
to O +
investigate O +
factors O +
that O +
affect O +
the O +
central O +
nervous O +
system O +
( O -
CNS O -
) O +
distribution O +
of O +
elacridar B-Chemical -
. O +

Elacridar B-Chemical +
inhibits O +
transport O +
mediated O +
by O +
P O -
- O -
glycoprotein O +
( O -
P O -
- O -
gp O -
) O +
and O +
breast O +
cancer O +
resistance O +
protein O +
( O -
Bcrp O -
) O +
and O +
has O +
been O +
used O +
to O +
study O +
the O +
influence O +
of O +
transporters O +
on O +
brain O +
distribution O +
of O +
chemotherapeutics O -
. O +

Adequate O +
distribution O +
of O +
elacridar B-Chemical +
across O +
the O +
blood O -
- O -
brain O +
barrier O +
( O -
BBB O -
) O +
and O +
into O +
the O +
brain O +
parenchyma O +
is O +
necessary O +
to O +
target O +
tumor O +
cells O +
in O +
the O +
brain O +
that O +
overexpress O +
transporters O +
and O +
reside O +
behind O +
an O +
intact O +
BBB O -
. O +

We O +
examined O +
the O +
role O +
of O +
P O -
- O -
gp O +
and O +
Bcrp O +
on O +
brain O +
penetration O +
of O +
elacridar B-Chemical +
using O +
Friend O +
leukemia O +
virus O +
strain O +
B O +
wild O -
- O -
type O -
, O +
Mdr1a O -
/ O -
b O -
( O -
- O -
/ O -
- O -
) O -
, O +
Bcrp1 O -
( O -
- O -
/ O -
- O -
) O -
, O +
and O +
Mdr1a O -
/ O -
b O -
( O -
- O -
/ O -
- O -
) O -
Bcrp1 O -
( O -
- O -
/ O -
- O -
) O +
mice O -
. O +

Initially O -
, O +
the O +
mice O +
were O +
administered O +
2.5 O +
mg O -
/ O -
kg O +
of O +
elacridar B-Chemical +
intravenously O -
, O +
and O +
the O +
plasma O +
and O +
brain O +
concentrations O +
were O +
determined O -
. O +

The O +
brain O -
- O -
to O -
- O -
plasma O +
partition O +
coefficient O +
of O +
elacridar B-Chemical +
in O +
the O +
wild O -
- O -
type O +
mice O +
was O +
0.82 O -
, O +
as O +
compared O +
with O +
3.5 O +
in O +
Mdr1a O -
/ O -
b O -
( O -
- O -
/ O -
- O -
) O +
mice O -
, O +
6.6 O +
in O +
Bcrp1 O -
( O -
- O -
/ O -
- O -
) O +
mice O -
, O +
and O +
15 O +
in O +
Mdr1a O -
/ O -
b O -
( O -
- O -
/ O -
- O -
) O -
Bcrp1 O -
( O -
- O -
/ O -
- O -
) O +
mice O -
, O +
indicating O +
that O +
both O +
P O -
- O -
gp O +
and O +
Bcrp O +
limit O +
the O +
brain O +
distribution O +
of O +
elacridar B-Chemical -
. O +

The O +
four O +
genotypes O +
were O +
then O +
administered O +
increasing O +
doses O +
of O +
elacridar B-Chemical -
, O +
and O +
the O +
CNS O +
distribution O +
of O +
elacridar B-Chemical +
was O +
determined O -
. O +

The O +
observed O +
and O +
model O +
predicted O +
maximum O +
brain O -
- O -
to O -
- O -
plasma O +
ratios O +
( O -
Emax O -
) O +
at O +
the O +
highest O +
dose O +
were O +
not O +
significantly O +
different O +
in O +
all O +
genotypes O -
. O +

However O -
, O +
the O +
ED50 O +
was O +
lower O +
for O +
Mdr1a O -
/ O -
b O -
( O -
- O -
/ O -
- O -
) O +
mice O +
compared O +
with O +
Bcrp1 O -
( O -
- O -
/ O -
- O -
) O +
mice O -
. O +

These O +
findings O +
correlate O +
with O +
the O +
relative O +
expression O +
of O +
P O -
- O -
gp O +
and O +
Bcrp O +
at O +
the O +
BBB O +
in O +
these O +
mice O +
and O +
demonstrate O +
the O +
quantitative O +
enhancement O +
in O +
elacridar O +
CNS O +
distribution O +
as O +
a O +
function O +
of O +
its O +
dose O -
. O +

Overall O -
, O +
this O +
study O +
provides O +
useful O +
concepts O +
for O +
future O +
applications O +
of O +
elacridar B-Chemical +
as O +
an O +
adjuvant O +
therapy O +
to O +
improve O +
targeting O +
of O +
chemotherapeutic O +
agents O +
to O +
tumor O +
cells O +
in O +
the O +
brain O +
parenchyma O -
. O +

Strong O +
effects O +
of O +
cluster O +
size O +
and O +
air O +
exposure O +
on O +
oxygen B-Chemical +
reduction O +
and O +
carbon B-Chemical +
oxidation O +
electrocatalysis O +
by O +
size O -
- O -
selected O +
Pt B-Chemical -
( I-Chemical -
n I-Chemical -
) I-Chemical +
( O -
n O +
≤ O +
11 O -
) O +
on O +
glassy B-Chemical +
carbon I-Chemical +
electrodes O -
. O +

Model O +
Pt B-Chemical -
( I-Chemical -
n I-Chemical -
) I-Chemical -
/ O -
glassy B-Chemical +
carbon I-Chemical +
electrodes O +
( O -
Pt B-Chemical -
( I-Chemical -
n I-Chemical -
) I-Chemical -
/ O -
GCE O -
) O +
were O +
prepared O +
by O +
deposition O +
of O +
mass O -
- O -
selected O +
Pt B-Chemical -
( I-Chemical -
n I-Chemical -
) I-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical +
( O -
n O +
≤ O +
11 O -
) O +
on O +
GCE O +
substrates O +
in O +
ultrahigh O +
vacuum O -
. O +

Electrocatalysis O +
under O +
conditions O +
appropriate O +
for O +
the O +
oxygen B-Chemical +
reduction O +
reaction O +
( O -
ORR O -
) O +
was O +
studied O -
, O +
for O +
samples O +
both O +
in O +
situ O +
with O +
no O +
exposure O +
to O +
laboratory O +
air O +
and O +
with O +
air O +
exposure O +
prior O +
to O +
electrochemical O +
measurements O -
. O +

Of O +
the O +
small O +
clusters O -
, O +
only O +
a O +
few O +
cluster O +
sizes O +
show O +
the O +
expected O +
ORR O +
activity O -
, O +
and O +
in O +
those O +
cases O -
, O +
the O +
activity O +
per O +
Pt B-Chemical +
atom O +
is O +
similar O +
to O +
that O +
seen O +
under O +
identical O +
conditions O +
with O +
a O +
conventionally O +
prepared O +
electrode O +
with O +
Pt B-Chemical +
nanoparticles O +
grown O +
on O +
a O +
GCE O -
. O +

For O +
other O +
small O +
Pt B-Chemical -
( I-Chemical -
n I-Chemical -
) I-Chemical +
on O +
GCE O -
, O +
any O +
ORR O +
signal O +
is O +
overwhelmed O +
by O +
large O +
oxidative O +
currents O +
attributed O +
to O +
catalysis O +
of O +
carbon B-Chemical +
oxidation O +
by O +
water O -
. O +

If O +
the O +
samples O +
are O +
exposed O +
to O +
air O +
prior O +
to O +
electrochemistry O -
, O +
both O +
ORR O +
and O +
carbon B-Chemical +
oxidation O +
signals O +
are O +
absent O -
, O +
and O +
instead O +
only O +
small O +
capacitive O +
currents O +
or O +
currents O +
attributed O +
to O +
redox O +
chemistry O +
of O +
adventitious O +
organic O +
adsorbates O +
are O +
observed O -
, O +
indicating O +
that O +
air O +
exposure O +
results O +
in O +
passivation O +
of O +
the O +
small O +
Pt B-Chemical +
clusters O -
. O +

Chromogenic O +
and O +
fluorogenic O +
chemosensors O +
and O +
reagents O +
for O +
anions O -
. O +

A O +
comprehensive O +
review O +
of O +
the O +
years O +
2010 O -
- O -
2011 O -
. O +

This O +
review O +
focuses O +
on O +
examples O +
reported O +
in O +
the O +
years O +
2010 O -
- O -
2011 O +
dealing O +
with O +
the O +
design O +
of O +
chromogenic O +
and O +
fluorogenic O +
chemosensors O +
or O +
reagents O +
for O +
anions O -
. O +

Tacticity O -
- O -
induced O +
changes O +
in O +
the O +
micellization O +
and O +
degradation O +
properties O +
of O +
poly B-Chemical -
( I-Chemical -
lactic I-Chemical +
acid I-Chemical -
) I-Chemical -
-block I-Chemical -
- I-Chemical -
poly I-Chemical -
( I-Chemical -
ethylene I-Chemical +
glycol I-Chemical -
) I-Chemical +
copolymers O -
. O +

Poly B-Chemical -
( I-Chemical -
lactic I-Chemical +
acid I-Chemical -
) I-Chemical -
-block I-Chemical -
- I-Chemical -
poly I-Chemical -
( I-Chemical -
ethylene I-Chemical +
glycol I-Chemical -
) I-Chemical +
copolymers O +
( O -
PLA B-Chemical -
- I-Chemical -
b I-Chemical -
- I-Chemical -
PEG I-Chemical -
) O +
featuring O +
varying O +
tacticities O +
( O -
atactic O -
, O +
heterotactic O -
, O +
isotactic O -
) O +
in O +
the O +
PLA B-Chemical +
block O +
were O +
synthesized O +
and O +
investigated O +
for O +
their O +
micellar O +
stability O -
, O +
degradation O -
, O +
and O +
thermal O +
properties O -
. O +

Utilizing O +
tin B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical +
bis I-Chemical -
( I-Chemical -
2-ethylhexanoate I-Chemical -
) I-Chemical -
, O +
aluminum B-Chemical +
salan I-Chemical -
, O +
and O +
aluminum B-Chemical +
salen I-Chemical +
catalysts O -
, O +
the O +
copolymers O +
were O +
synthesized O +
through O +
the O +
ring O -
- O -
opening O +
polymerization O +
of O +
d- O -
, O +
l- O -
, O +
rac- O -
, O +
or O +
a O +
blend O +
of O +
l- B-Chemical +
and I-Chemical +
rac I-Chemical -
- I-Chemical -
lactide I-Chemical +
using O +
monomethoxy B-Chemical -
- I-Chemical -
poly I-Chemical -
( I-Chemical -
ethylene I-Chemical +
glycol I-Chemical -
) I-Chemical +
as O +
a O +
macroinitiator O -
. O +

The O +
critical O +
micelle O +
concentration O -
, O +
which O +
reflects O +
the O +
micellar O +
stability O -
, O +
was O +
probed O +
using O +
a O +
fluorescence O +
spectroscopic O +
method O +
with O +
pyrene B-Chemical +
as O +
the O +
probe O -
. O +

The O +
copolymers O +
were O +
degraded O +
in O +
a O +
methanolic O +
solution O +
of O +
1,5,7-triaza B-Chemical -
- I-Chemical -
bicyclo I-Chemical -
[ I-Chemical -
4.4.0 I-Chemical -
] I-Chemical -
dec-5-ene I-Chemical +
and O +
the O +
degradation O +
was O +
measured O +
by O +
( B-Chemical -
1 I-Chemical -
) I-Chemical -
H I-Chemical +
NMR O +
spectroscopic O +
and O +
gel O +
permeation O +
chromatographic O +
analyses O -
. O +

Differential O +
scanning O +
calorimetry O +
and O +
thermogravimetric O +
analysis O +
provided O +
information O +
on O +
the O +
thermal O +
properties O +
of O +
the O +
copolymers O -
. O +

Atactic O +
and O +
heterotactic O +
microstructures O +
in O +
the O +
PLA B-Chemical +
block O +
resulted O +
in O +
lower O +
micellar O +
stability O -
, O +
as O +
well O +
as O +
faster O +
degradation O +
and O +
shorter O +
erosion O +
time O +
compared O +
to O +
polymers O +
with O +
high O +
isotactic O +
enchainment O +
( O -
Pm O -
) O -
. O +

By O +
modification O +
of O +
the O +
Pm O -
, O +
micellar O +
stability O -
, O +
degradation O -
, O +
and O +
erosion O +
rates O +
of O +
the O +
copolymers O +
can O +
be O +
tuned O +
to O +
specific O +
biomedical O +
applications O -
. O +

Interestingly O -
, O +
while O +
tin B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical +
bis I-Chemical -
( I-Chemical -
2-ethylhexanoate I-Chemical -
) I-Chemical +
and O +
aluminum B-Chemical +
salan I-Chemical -
- O -
catalyzed O +
PLA B-Chemical -
- I-Chemical -
b I-Chemical -
- I-Chemical -
PEG I-Chemical +
copolymers O +
exhibited O +
similar O +
micellization O +
behavior O -
, O +
the O +
aluminum B-Chemical +
salen I-Chemical -
- O -
catalyzed O +
PLA B-Chemical -
- I-Chemical -
b I-Chemical -
- I-Chemical -
PEG I-Chemical +
exhibited O +
unique O +
behavior O +
at O +
high O +
micelle O +
concentration O +
in O +
the O +
presence O +
of O +
the O +
pyrene B-Chemical +
probe O -
. O +

This O +
unique O +
behavior O +
can O +
be O +
attributed O +
to O +
the O +
disintegration O +
of O +
the O +
micelles O +
through O +
the O +
interactions O +
of O +
long O +
isotactic O +
stereoblock O +
segments O -
. O +

HIV O +
protease O +
inhibitors O +
in O +
pregnancy O +
: O +
pharmacology O +
and O +
clinical O +
use O -
. O +

The O +
impact O +
of O +
antiretroviral O +
therapy O +
( O -
ART O -
) O +
on O +
the O +
natural O +
history O +
of O +
HIV-1 O +
infection O +
has O +
resulted O +
in O +
dramatic O +
reductions O +
in O +
disease O -
- O -
associated O +
morbidity O +
and O +
mortality O -
. O +

Additionally O -
, O +
the O +
epidemiology O +
of O +
HIV-1 O +
infection O +
worldwide O +
is O +
changing O -
, O +
as O +
women O +
now O +
represent O +
a O +
substantial O +
proportion O +
of O +
infected O +
adults O -
. O +

As O +
more O +
highly O +
effective O +
and O +
tolerable O +
antiretroviral O +
regimens O +
become O +
available O -
, O +
and O +
as O +
the O +
prevention O +
of O +
mother O -
- O -
to O -
- O -
child O +
transmission O +
becomes O +
an O +
attainable O +
goal O +
in O +
the O +
management O +
of O +
HIV O -
- O -
infected O +
individuals O -
, O +
more O +
and O +
more O +
HIV O -
- O -
positive O +
women O +
are O +
choosing O +
to O +
become O +
pregnant O +
and O +
have O +
children O -
. O +

Consequently O -
, O +
it O +
is O +
important O +
to O +
consider O +
the O +
efficacy O +
and O +
safety O +
of O +
antiretroviral O +
agents O +
in O +
pregnancy O -
. O +

Protease O +
inhibitors O +
are O +
a O +
common O +
class O +
of O +
medication O +
used O +
in O +
the O +
treatment O +
of O +
HIV-1 O +
infection O +
and O +
are O +
increasingly O +
being O +
used O +
in O +
pregnancy O -
. O +

However O -
, O +
several O +
studies O +
have O +
raised O +
concerns O +
regarding O +
pharmacokinetic O +
alterations O +
in O +
pregnancy O -
, O +
particularly O +
in O +
the O +
third O +
trimester O -
, O +
which O +
results O +
in O +
suboptimal O +
drug O +
concentrations O +
and O +
a O +
theoretically O +
higher O +
risk O +
of O +
virologic O +
failure O +
and O +
perinatal O +
transmission O -
. O +

Drug O +
level O +
reductions O +
have O +
been O +
observed O +
with O +
each O +
individual O +
protease O +
inhibitor O +
and O +
dose O +
adjustments O +
in O +
pregnancy O +
are O +
suggested O +
for O +
certain O +
agents O -
. O +

Furthermore O -
, O +
studies O +
have O +
also O +
raised O +
concerns O +
regarding O +
the O +
safety O +
of O +
protease O +
inhibitors O +
in O +
pregnancy O -
, O +
particularly O +
as O +
they O +
may O +
increase O +
the O +
risk O +
of O +
pre O -
- O -
term O +
birth O +
and O +
metabolic O +
disturbances O -
. O +

Overall O -
, O +
protease O +
inhibitors O +
are O +
safe O +
and O +
effective O +
for O +
the O +
treatment O +
of O +
HIV O -
- O -
infected O +
pregnant O +
women O -
. O +

Specifically O -
, O +
ritonavir B-Chemical -
- O -
boosted O +
lopinavir- B-Chemical +
and O +
atazanavir B-Chemical -
- O -
based O +
regimens O +
are O +
preferred O +
in O +
pregnancy O -
, O +
while O +
ritonavir B-Chemical -
- O -
boosted O +
darunavir- B-Chemical +
and O +
saquinavir B-Chemical -
- O -
based O +
therapies O +
are O +
reasonable O +
alternatives O -
. O +

This O +
paper O +
reviews O +
the O +
use O +
of O +
protease O +
inhibitors O +
in O +
pregnancy O -
, O +
focusing O +
on O +
pharmacokinetic O +
and O +
safety O +
considerations O -
, O +
and O +
outlines O +
the O +
recommendations O +
for O +
use O +
of O +
this O +
class O +
of O +
medication O +
in O +
the O +
HIV-1-infected O +
pregnant O +
woman O -
. O +

Increased O +
immunoreactive O +
11-ketotestosterone B-Chemical +
concentrations O +
in O +
sheep O +
feces O +
after O +
acth O +
challenge O -
. O +

11-Oxoetiocholanolone B-Chemical +
and O +
related O +
substances O +
are O +
important O +
metabolites O +
of O +
cortisol B-Chemical +
and O +
are O +
excreted O +
via O +
feces O +
in O +
ruminants O -
. O +

To O +
investigate O +
whether O +
11-ketotestosterone B-Chemical +
( O -
11-KT B-Chemical -
) O +
or O +
its O +
immunoreactive O +
metabolites O +
are O +
formed O +
and O +
excreted O +
in O +
ruminant O +
feces O -
, O +
an O +
enzyme O +
immunoassay O +
( O -
EIA O -
) O +
was O +
developed O +
and O +
validated O -
. O +

The O +
antibody O +
was O +
raised O +
in O +
rabbits O +
against O +
11-KT-3-CMO B-Chemical -
: O -
bovine O +
serum O +
albumin O +
with O +
biotinylated B-Chemical +
11-KT I-Chemical +
as O +
a O +
label O -
. O +

The O +
assay O +
showed O +
a O +
sensitivity O +
of O +
0.3 O +
pg O -
/ O -
well O -
. O +

To O +
validate O +
the O +
assay O +
biologically O -
, O +
6 O +
rams O +
were O +
injected O +
with O +
a O +
synthetic O +
analogue O +
of O +
the O +
adrenocorticotropic O +
hormone O +
( O -
Synacthen O -
, O +
2 O +
µg O -
/ O -
kg O +
body O +
wt O -
) O -
. O +

An O +
aliquot O +
was O +
collected O +
of O +
each O +
fecal O +
portion O +
spontaneously O +
defecated O +
8 O +
h O +
before O +
Synacthen O +
injection O +
to O +
24 O +
h O +
after O +
injection O +
and O +
stored O +
at O +
-20 O +
° O -
C O +
until O +
analysis O -
. O +

Samples O +
( O -
0.5 O +
g O -
) O +
were O +
extracted O +
using O +
80 O -
% O +
methanol B-Chemical +
and O +
immunoreactive O +
metabolites O +
measured O +
using O +
the O +
11-KT B-Chemical +
EIA O +
and O +
an O +
already O +
established O +
11,17-dioxoandrostane B-Chemical +
( O -
11,17-DOA B-Chemical -
) O +
EIA O -
. O +

High O -
- O -
performance O +
liquid O +
chromatography O +
separation O +
revealed O +
no O +
peak O +
in O +
the O +
same O +
elution O +
position O +
as O +
authentic O +
11-KT B-Chemical -
; O +
therefore O -
, O +
reacting O +
substances O +
were O +
referred O +
to O +
as O +
11-KT B-Chemical +
equivalents O -
. O +

In O +
the O +
case O +
of O +
11-KT B-Chemical +
immunoreactive O +
substances O -
, O +
the O +
values O +
increased O +
from O +
baseline O +
( O -
median O -
, O +
136 O +
ng O -
/ O -
g O +
feces O -
) O +
to O +
a O +
peak O +
concentration O +
( O -
median O -
, O +
424 O +
ng O -
/ O -
g O -
) O +
10 O +
to O +
14 O +
h O +
after O +
Synacthen O +
injection O +
and O +
declined O +
afterwards O -
. O +

Concentrations O +
of O +
11,17-DOA B-Chemical +
showed O +
the O +
same O +
pattern O -
, O +
but O +
the O +
values O +
were O +
2 O +
to O +
4 O +
times O +
higher O -
. O +

From O +
this O +
data O -
, O +
the O +
authors O +
conclude O +
that O +
11-KT B-Chemical -
- O -
like O +
substances O -
, O +
specifically O +
C19 B-Chemical +
O3 I-Chemical +
-androgens I-Chemical +
with O +
a O +
17ß B-Chemical -
- I-Chemical -
hydroxy I-Chemical +
group O -
, O +
were O +
present O +
in O +
the O +
feces O -
. O +

These O +
substances O +
originate O +
from O +
the O +
adrenals O +
and O +
are O +
most O +
likely O +
cortisol B-Chemical +
metabolites O -
. O +

Environ O +
Toxicol O +
Chem O +
2013;32:1332 O -
- O -
1336 O -
. O +

© O +
2013 O +
SETAC O -
. O +

Fractionation O +
of O +
organosolv O +
lignin O +
from O +
olive O +
tree O +
clippings O +
and O +
its O +
valorization O +
to O +
simple O +
phenolic B-Chemical +
compounds O -
. O +

Lignin O +
valorization O +
practices O +
have O +
attracted O +
a O +
great O +
deal O +
of O +
interest O +
in O +
recent O +
years O +
due O +
to O +
the O +
large O +
excess O +
of O +
lignin O +
produced O +
by O +
the O +
pulp O +
and O +
paper O +
industry O -
, O +
together O +
with O +
second O -
- O -
generation O +
bioethanol O +
plants O -
. O +

In O +
this O +
work O -
, O +
a O +
new O +
lignin O +
valorization O +
approach O +
is O +
proposed O -
. O +

It O +
involves O +
ultrafiltration O +
as O +
a O +
fractionation O +
process O +
to O +
separate O +
different O +
molecular O +
weight O +
lignin O +
fractions O +
followed O +
by O +
a O +
hydrogen B-Chemical -
- O -
free O -
, O +
mild O -
, O +
hydrogenolytic O -
, O +
heterogeneously O +
catalyzed O +
methodology O +
assisted O +
by O +
microwave O +
irradiation O +
to O +
obtain O +
simple O +
phenolic B-Chemical -
, O +
monomeric O +
products O +
by O +
depolymerization O +
using O +
a O +
nickel O -
- O -
based O +
catalyst O -
. O +

The O +
main O +
products O +
obtained O +
were O +
desaspidinol B-Chemical -
, O +
syringaldehyde B-Chemical -
, O +
and O +
syringol B-Chemical -
; O +
this O +
proves O +
the O +
efficiency O +
of O +
the O +
depolymerization O +
conditions O +
applied O -
. O +

The O +
concentration O +
of O +
these O +
observed O +
compounds O +
increased O +
when O +
the O +
molecular O +
weights O +
of O +
the O +
lignin O +
fractions O +
increased O -
. O +

The O +
applied O +
depolymerization O +
conditions O -
, O +
which O +
take O +
advantage O +
of O +
the O +
use O +
of O +
formic B-Chemical +
acid I-Chemical +
as O +
a O +
hydrogen B-Chemical -
- O -
donating O +
solvent O -
, O +
did O +
not O +
generate O +
any O +
biochar O +
in O +
the O +
systems O -
. O +

Searching O +
the O +
coding O +
region O +
for O +
microRNA O +
targets O -
. O +

Finding O +
microRNA O +
targets O +
in O +
the O +
coding O +
region O +
is O +
difficult O +
due O +
to O +
the O +
overwhelming O +
signal O +
encoding O +
the O +
amino B-Chemical +
acid I-Chemical +
sequence O -
. O +

Here O -
, O +
we O +
introduce O +
an O +
algorithm O +
( O -
called O +
PACCMIT O -
- O -
CDS O -
) O +
that O +
finds O +
potential O +
microRNA O +
targets O +
within O +
coding O +
sequences O +
by O +
searching O +
for O +
conserved O +
motifs O +
that O +
are O +
complementary O +
to O +
the O +
microRNA O +
seed O +
region O +
and O +
also O +
overrepresented O +
in O +
comparison O +
with O +
a O +
background O +
model O +
preserving O +
both O +
codon O +
usage O +
and O +
amino B-Chemical +
acid I-Chemical +
sequence O -
. O +

Precision O +
and O +
sensitivity O +
of O +
PACCMIT O -
- O -
CDS O +
are O +
evaluated O +
using O +
PAR O -
- O -
CLIP O +
and O +
proteomics O +
data O +
sets O -
. O +

Thanks O +
to O +
the O +
properly O +
constructed O +
background O -
, O +
the O +
new O +
algorithm O +
achieves O +
a O +
lower O +
rate O +
of O +
false O +
positives O +
and O +
better O +
ranking O +
of O +
predictions O +
than O +
do O +
currently O +
available O +
algorithms O -
, O +
which O +
were O +
designed O +
to O +
find O +
microRNA O +
targets O +
within O +
3 O -
' O +
UTRs O -
. O +

Switchable O +
Elastin O -
- O -
Like O +
Polypeptides O +
that O +
Respond O +
to O +
Chemical O +
Inducers O +
of O +
Dimerization O -
. O +

Elastin O -
- O -
like O +
polypeptides O +
( O -
ELPs O -
) O +
are O +
protein O +
polymers O +
that O +
reversibly O +
phase O +
separate O +
in O +
response O +
to O +
increased O +
temperature O -
, O +
pressure O -
, O +
concentration O -
, O +
ionic O +
strength O -
, O +
and O +
molecular O +
weight O -
. O +

If O +
it O +
were O +
possible O +
to O +
engineer O +
their O +
phase O +
separation O +
to O +
respond O +
to O +
specific O +
molecular O +
substrates O -
, O +
ELP O +
fusion O +
proteins O +
might O +
be O +
engineered O +
as O +
biosensors O -
, O +
smart O +
biomaterials O -
, O +
diagnostic O +
imaging O +
agents O -
, O +
and O +
targeted O +
therapies O -
. O +

What O +
has O +
been O +
lacking O +
is O +
a O +
strategy O +
to O +
design O +
ELPs O +
to O +
respond O +
to O +
specific O +
substrates O -
. O +

To O +
address O +
this O +
deficiency O -
, O +
we O +
report O +
that O +
ELP O +
fusion O +
proteins O +
phase O +
separate O +
in O +
response O +
to O +
chemical O +
inducers O +
of O +
dimerization O +
( O -
CID O -
) O -
. O +

The O +
rationale O +
is O +
that O +
ELP O +
phase O +
separation O +
depends O +
on O +
molecular O +
weight O -
, O +
concentration O -
, O +
and O +
local O +
hydrophobicity O -
; O +
therefore O -
, O +
processes O +
that O +
affect O +
these O +
properties O -
, O +
including O +
noncovalent O +
dimerization O -
, O +
can O +
be O +
tuned O +
to O +
produce O +
isothermal O +
phase O +
separation O -
. O +

To O +
test O +
this O +
hypothesis O -
, O +
constructs O +
were O +
evaluated O +
consisting O +
of O +
an O +
immunophilin O -
: O +
human O +
FK-506 B-Chemical +
binding O +
protein O +
12 O +
( O -
FKBP O -
) O +
attached O +
to O +
an O +
ELP O -
. O +

Under O +
stoichiometric O +
binding O +
of O +
a O +
CID O -
, O +
the O +
fusion O +
protein O +
homodimerizes O +
and O +
triggers O +
phase O +
separation O -
. O +

This O +
dimerization O +
is O +
reversible O +
upon O +
saturation O +
with O +
excess O +
CID O +
or O +
competitive O +
binding O +
of O +
a O +
small O +
lipophilic O +
macrolide O +
to O +
FKBP O -
. O +

By O +
modulating O +
the O +
ELP O +
molecular O +
weight O -
, O +
phase O +
separation O +
was O +
tuned O +
for O +
isothermal O +
response O +
to O +
CID O +
at O +
physiological O +
ionic O +
strength O +
and O +
temperature O +
( O -
37 O +
° O -
C O -
) O -
. O +

To O +
interpret O +
the O +
relationship O +
between O +
transition O +
temperature O +
and O +
equilibrium O +
binding O +
constants O -
, O +
an O +
empirical O +
mathematical O +
model O +
was O +
employed O -
. O +

To O +
the O +
best O +
of O +
our O +
knowledge O -
, O +
this O +
report O +
is O +
the O +
first O +
demonstration O +
of O +
reversible O +
ELP O +
switching O +
in O +
response O +
to O +
controlled O +
dimerization O -
. O +

Due O +
to O +
its O +
simplicity O -
, O +
this O +
strategy O +
may O +
be O +
useful O +
to O +
design O +
ELP O +
fusion O +
proteins O +
that O +
respond O +
to O +
specific O +
dimeric O +
biological O +
entities O -
. O +

Cause O +
and O +
prevention O +
of O +
moisture O -
- O -
induced O +
degradation O +
of O +
resistance O +
random O +
access O +
memory O +
nanodevices O -
. O +

Dielectric O +
thin O +
films O +
in O +
nanodevices O +
may O +
absorb O +
moisture O -
, O +
leading O +
to O +
physical O +
changes O +
and O +
property O -
/ O -
performance O +
degradation O -
, O +
such O +
as O +
altered O +
data O +
storage O +
and O +
readout O +
in O +
resistance O +
random O +
access O +
memory O -
. O +

Here O +
we O +
demonstrate O +
using O +
a O +
nanometallic O +
memory O +
that O +
such O +
degradation O +
proceeds O +
via O +
nanoporosity O -
, O +
which O +
facilitates O +
water O +
wetting O +
in O +
otherwise O +
nonwetting O +
dielectrics O -
. O +

Electric O +
degradation O +
only O +
occurs O +
when O +
the O +
device O +
is O +
in O +
the O +
charge O -
- O -
storage O +
state O -
, O +
which O +
provides O +
a O +
nanoscale O +
dielectrophoretic O +
force O +
directing O +
H2O B-Chemical +
to O +
internal O +
field O +
centers O +
( O -
sites O +
of O +
trapped O +
charge O -
) O +
to O +
enable O +
bond O +
rupture O +
and O +
charged O +
hydroxyl B-Chemical +
formation O -
. O +

While O +
these O +
processes O +
are O +
dramatically O +
enhanced O +
by O +
an O +
external O +
DC O +
or O +
AC O +
field O +
and O +
electron O -
- O -
donating O +
electrodes O -
, O +
they O +
can O +
be O +
completely O +
prevented O +
by O +
eliminating O +
nanoporosity O -
, O +
depositing O +
a O +
barrier O +
layer O -
, O +
or O +
using O +
an O +
oxidation O -
- O -
resistant O +
electrode O -
. O +

These O +
findings O +
provide O +
insight O +
for O +
understanding O +
high O -
- O -
performance O +
memory O +
and O +
field O -
- O -
assisted O +
degradation O +
of O +
nanodevices O -
. O +

Faecal O +
Excretion O +
Dynamic O +
during O +
Subacute O +
Oral O +
Exposure O +
to O +
Different O +
Pb B-Chemical +
Species O +
in O +
Rattus O +
norvegicus O -
. O +

Faecal O +
excretion O +
is O +
a O +
basic O +
means O +
of O +
detoxification O +
upon O +
ingestion O +
of O +
Pb B-Chemical -
- O -
contaminated O +
feed O -
. O +

In O +
order O +
to O +
determine O +
a O +
time O +
course O +
of O +
Pb B-Chemical +
elimination O +
after O +
oral O +
exposure O +
to O +
two O +
different O +
forms O +
of O +
this O +
heavy O +
metal O +
( O -
lead B-Chemical +
acetate I-Chemical +
vs. O +
phyto O -
- O -
bound O +
Pb B-Chemical -
) O -
, O +
a O +
feeding O +
study O +
was O +
carried O +
out O +
in O +
experimental O +
rats O +
using O +
the O +
Pb B-Chemical +
phyto O -
- O -
hyperaccumulator O +
Pistia O +
stratiotes O +
as O +
a O +
model O +
diet O -
. O +

The O +
effect O +
of O +
starvation O +
on O +
Pb B-Chemical +
excretion O +
was O +
further O +
studied O +
in O +
rats O +
that O +
were O +
fed O +
plant O +
material O -
. O +

Twelve O +
Pb B-Chemical +
doses O +
( O -
7 O +
μg O +
Pb B-Chemical -
/ O -
1 O +
g O +
BW O -
) O +
were O +
administered O +
orally O +
over O +
a O +
5-week O +
period O -
. O +

Faeces O +
samples O +
were O +
collected O +
24 O +
and O +
72 O +
h O +
post O -
- O -
exposure O -
. O +

Inductively O +
coupled O +
plasma O +
optical O +
emission O +
spectrometry O +
and O +
electrothermal O +
absorption O +
spectrometry O +
methods O +
were O +
used O +
for O +
determination O +
of O +
heavy O +
metal O +
concentrations O -
. O +

Up O +
to O +
53 O +
% O +
of O +
ingested O +
Pb B-Chemical +
was O +
rapidly O +
eliminated O +
from O +
the O +
exposed O +
rats O +
via O +
faeces O +
within O +
24 O +
h O +
after O +
exposure O -
. O +

Faecal O +
excretion O +
in O +
exposed O +
rats O +
differed O +
significantly O +
when O +
compared O +
to O +
that O +
of O +
the O +
control O +
group O -
. O +

Fasting O +
before O +
exposure O +
reduced O +
Pb B-Chemical +
excretion O +
by O +
up O +
to O +
50 O +
% O -
. O +

Faecal O +
excretions O +
of O +
both O +
examined O +
Pb B-Chemical +
forms O +
exhibited O +
almost O +
identical O +
patterns O -
. O +

Considerable O +
differences O +
were O +
revealed O +
concerning O +
total O +
excretion O +
levels O -
; O +
lead B-Chemical +
acetate I-Chemical +
was O +
excreted O +
in O +
amount O +
greater O +
extent O +
than O +
those O +
of O +
phytobound O +
Pb B-Chemical -
. O +

Results O +
of O +
our O +
study O +
suggest O +
that O +
Pb B-Chemical +
forms O +
occurring O +
in O +
the O +
P. O +
stratiotes O +
tissues O +
are O +
absorbed O +
through O +
the O +
gastrointestinal O +
tract O +
to O +
a O +
greater O +
extent O +
than O +
Pb B-Chemical +
from O +
lead B-Chemical +
acetate I-Chemical -
. O +

Therefore O -
, O +
higher O +
portions O +
of O +
ingested O +
Pb B-Chemical +
can O +
be O +
available O +
for O +
potential O +
accumulation O +
in O +
tissues O +
of O +
exposed O +
subjects O -
. O +

Echinacea O +
sanguinea O +
and O +
Echinacea O +
pallida O +
extracts O +
stimulate O +
glucuronidation O +
and O +
basolateral O +
transfer O +
of O +
Bauer O +
alkamides B-Chemical +
8 O +
and O +
10 O +
and O +
ketone B-Chemical +
24 O +
and O +
inhibit O +
P O -
- O -
glycoprotein O +
transporter O +
in O +
Caco-2 O +
cells O -
. O +

The O +
use O +
of O +
Echinacea O +
as O +
a O +
medicinal O +
herb O +
is O +
prominent O +
in O +
the O +
United O +
States O -
, O +
and O +
many O +
studies O +
have O +
assessed O +
the O +
effectiveness O +
of O +
Echinacea O +
as O +
an O +
immunomodulator O -
. O +

We O +
hypothesized O +
that O +
Bauer O +
alkamides B-Chemical +
8 O -
, O +
10 O -
, O +
and O +
11 O +
and O +
ketone B-Chemical +
24 O +
were O +
absorbed O +
similarly O +
either O +
as O +
pure O +
compounds O +
or O +
from O +
Echinacea O +
sanguinea O +
and O +
Echinacea O +
pallida O +
ethanol B-Chemical +
extracts O -
, O +
and O +
that O +
these O +
Echinacea O +
extracts O +
could O +
inhibit O +
the O +
P O -
- O -
glycoprotein O +
transporter O +
in O +
Caco-2 O +
human O +
intestinal O +
epithelial O +
cells O -
. O +

Using O +
HPLC O +
analysis O -
, O +
the O +
permeation O +
rate O +
of O +
Bauer O +
alkamides B-Chemical +
by O +
passive O +
diffusion O +
across O +
Caco-2 O +
cells O +
corresponded O +
with O +
compound O +
hydrophilicity O +
( O -
alkamide B-Chemical +
8 O +
> O +
10 O +
> O +
11 O -
) O -
, O +
independent O +
of O +
the O +
plant O +
extract O +
matrix O -
. O +

Both O +
Echinacea O +
ethanol B-Chemical +
extracts O +
stimulated O +
apparent O +
glucuronidation O +
and O +
basolateral O +
efflux O +
of O +
glucuronides O +
of O +
alkamides B-Chemical +
8 O +
and O +
10 O +
but O +
not O +
alkamide B-Chemical +
11 O -
. O +

Bauer O +
ketone B-Chemical +
24 O +
was O +
totally O +
metabolized O +
to O +
more O +
hydrophilic O +
metabolites O +
when O +
administered O +
as O +
a O +
single O +
compound O -
, O +
but O +
was O +
also O +
glucuronidated O +
when O +
present O +
in O +
Echinacea O +
extracts O -
. O +

Bauer O +
alkamides B-Chemical +
8 O -
, O +
10 O -
, O +
and O +
11 O +
( O -
175 O -
- O -
230 O +
µM O -
) O +
and O +
ethanol B-Chemical +
extracts O +
of O +
E. O +
sanguinea O +
( O -
1 O +
mg O -
/ O -
mL O -
, O +
containing O +
~ O +
90 O +
µM O +
total O +
alkamides B-Chemical -
) O +
and O +
E. O +
pallida O +
( O -
5 O +
mg O -
/ O -
mL O -
, O +
containing O +
285 O +
µM O +
total O +
alkamides O -
) O +
decreased O +
the O +
efflux O +
of O +
the O +
P O -
- O -
glycoprotein O +
transporter O +
probe O +
calcein O -
- O -
AM O +
from O +
Caco-2 O +
cells O -
. O +

These O +
results O +
suggest O +
that O +
other O +
constituents O +
in O +
these O +
Echinacea O +
extracts O +
facilitated O +
the O +
metabolism O +
and O +
efflux O +
of O +
alkamides B-Chemical +
and O +
ketones B-Chemical -
, O +
which O +
might O +
improve O +
therapeutic O +
benefits O -
. O +

Alkamides B-Chemical +
and O +
Echinacea O +
extracts O +
might O +
be O +
useful O +
in O +
potentiating O +
some O +
chemotherapeutics O -
, O +
which O +
are O +
substrates O +
for O +
the O +
P O -
- O -
glycoprotein O +
transporter O -
. O +

Concentrations O +
and O +
trends O +
of O +
halogenated O +
flame O +
retardants O +
in O +
the O +
pooled O +
serum O +
of O +
residents O +
of O +
Laizhou O +
Bay O -
, O +
China O -
. O +

The O +
south O +
coast O +
of O +
Laizhou O +
Bay O -
, O +
in O +
northeastern O +
China O -
, O +
is O +
a O +
production O +
area O +
for O +
halogenated O +
flame O +
retardants O +
( O -
HFR O -
) O -
. O +

In O +
2007 O -
, O +
the O +
authors O +
measured O +
serum O +
concentrations O +
of O +
polybrominated B-Chemical +
diphenyl I-Chemical +
ethers I-Chemical +
( O -
PBDEs B-Chemical -
) O +
in O +
Laizhou O +
Bay O +
residents O -
. O +

To O +
assess O +
the O +
PBDE B-Chemical +
concentration O +
trend O -
, O +
and O +
determine O +
the O +
concentrations O +
of O +
the O +
emerging O +
flame O +
retardants O +
Dechlorane B-Chemical +
Plus I-Chemical +
( O -
DP O -
) O +
and O +
bis B-Chemical -
( I-Chemical -
2-ethylhexyl I-Chemical -
) I-Chemical -
-3,4,5,6-tetrabromophthalate I-Chemical +
( O -
TBPH B-Chemical -
) O -
, O +
the O +
authors O +
measured O +
the O +
concentrations O +
of O +
8 O +
PBDE B-Chemical +
congeners O -
, O +
2 O +
DP O +
isomers O -
, O +
and O +
TBPH B-Chemical +
in O +
10 O +
composite O +
samples O -
, O +
which O +
were O +
pooled O +
from O +
the O +
serum O +
collected O +
from O +
305 O +
Laizhou O +
Bay O +
residents O +
in O +
October O +
2011 O -
. O +

The O +
average O +
concentration O +
of O +
the O +
total O +
PBDE B-Chemical +
( O -
∑8 O +
PBDE B-Chemical -
) O +
concentration O +
in O +
all O +
serum O +
pools O +
was O +
240 O +
ng O -
/ O -
g O +
lipid O +
weight O -
, O +
and O +
the O +
highest O +
serum O +
pool O +
concentration O +
( O -
in O +
the O +
30- O +
to O +
39-yr O -
- O -
old O +
male O +
group O -
) O +
was O +
780 O +
ng O -
/ O -
g O +
lipid O +
weight O -
. O +

Brominated B-Chemical +
diphenyl I-Chemical +
ether-209 I-Chemical +
was O +
the O +
dominant O +
congener O -
, O +
accounting O +
for O +
87 O -
% O +
of O +
∑8 O +
PBDE B-Chemical -
. O +

Compared O +
with O +
a O +
previous O +
study O -
, O +
∑8 O +
PBDE B-Chemical +
serum O +
concentrations O +
in O +
the O +
present O +
study O +
showed O +
no O +
change O +
in O +
order O +
of O +
magnitude O -
, O +
but O +
the O +
relative O +
contribution O +
of O +
BDE-209 B-Chemical +
to O +
∑8 O +
PBDE B-Chemical +
was O +
higher O -
. O +

The O +
average O +
concentration O +
of O +
∑DP O +
in O +
all O +
serum O +
pools O +
was O +
3.6 O +
ng O -
/ O -
g O +
lipid O +
weight O -
, O +
ranging O +
from O +
1.4 O +
ng O -
/ O -
g O +
lipid O +
weight O +
( O -
in O +
the O +
50- O +
to O +
59-yr O -
- O -
old O +
male O +
group O -
) O +
to O +
11 O +
ng O -
/ O -
g O +
lipid O +
weight O +
( O -
in O +
the O +
20- O +
to O +
29-yr O -
- O -
old O +
male O +
group O -
) O -
. O +

The O +
concentration O +
of O +
DP O +
was O +
lower O +
than O +
in O +
other O +
reported O +
studies O -
. O +

The O +
study O +
also O +
detected O +
TBPH B-Chemical +
in O +
the O +
30- O +
to O +
39-yr O -
- O -
old O +
female O +
group O -
, O +
suggesting O +
that O +
TBPH B-Chemical -
, O +
as O +
an O +
emerging O +
HFR O -
, O +
requires O +
further O +
monitoring O -
. O +

Environ O +
Toxicol O +
Chem O +
2013;32:1242 O -
- O -
1247 O -
. O +

© O +
2013 O +
SETAC O -
. O +

The O +
renin O -
- O -
angiotensin O +
system O -
: O +
new O +
insight O +
into O +
old O +
therapies O -
. O +

Although O +
the O +
renin O -
- O -
angiotensin O +
system O +
( O -
RAS O -
) O +
is O +
already O +
an O +
old O +
acquaintance O -
, O +
there O +
are O +
often O +
exciting O +
discoveries O +
that O +
improve O +
our O +
knowledge O +
of O +
it O +
and O +
open O +
new O +
therapeutic O +
possibilities O -
. O +

Moreover O -
, O +
well O -
- O -
established O +
drugs O -
, O +
such O +
as O +
angiotensin O -
- O -
converting O +
enzyme O +
inhibitors O +
( O -
ACEI O -
) O -
, O +
angiotensin O +
receptor O +
blockers O +
( O -
ARB O -
) O -
, O +
or O +
beta O -
- O -
blockers O -
, O +
show O +
that O +
their O +
mechanism O +
of O +
action O +
may O +
be O +
the O +
result O +
of O +
parallel O +
pathways O +
other O +
than O +
the O +
ones O +
initially O +
established O -
. O +

A O +
detailed O +
analysis O +
of O +
the O +
RAS O +
can O +
be O +
carried O +
out O +
in O +
part O +
through O +
the O +
study O +
of O +
the O +
enzymes O -
, O +
named O +
angiotensinases O -
, O +
involved O +
in O +
its O +
cascade O -
, O +
whose O +
activity O +
is O +
a O +
reflection O +
of O +
the O +
functionality O +
of O +
their O +
peptide O +
substrates O -
. O +

The O +
study O +
of O +
these O +
enzymes O +
offers O +
the O +
possibility O +
of O +
controlling O +
the O +
effects O +
of O +
angiotensins O +
through O +
various O +
pharmacological O +
manipulations O -
. O +

For O +
example O -
, O +
angiotensinase O +
inhibitors O +
or O +
activators O +
are O +
being O +
used O +
or O +
have O +
been O +
proposed O +
as O +
antihypertensive O +
agents O -
. O +

They O +
have O +
also O +
been O +
suggested O +
as O +
analgesic O +
and O +
antidepressant O +
drugs O +
or O +
targets O +
for O +
drug O +
development O +
against O +
different O +
pathologies O +
such O +
as O +
Alzheimer O -
's O +
disease O -
, O +
epilepsy O +
or O +
ischemia O -
. O +

On O +
the O +
other O +
hand O -
, O +
the O +
analysis O +
of O +
brain O +
asymmetry O +
has O +
revealed O +
surprising O +
results O +
about O +
the O +
laterality O +
of O +
central O +
and O +
peripheral O +
components O +
of O +
the O +
RAS O -
. O +

Such O +
studies O +
indicate O +
that O +
the O +
neurovisceral O +
integration O -
, O +
already O +
proposed O +
by O +
Claude O +
Bernard O +
( O -
1867 O -
) O +
should O +
also O +
be O +
analyzed O +
from O +
a O +
bilateral O +
perspective O -
. O +

In O +
this O +
review O -
, O +
the O +
RAS O +
and O +
the O +
role O +
of O +
various O +
angiotensinases O +
implicated O +
in O +
the O +
cascade O +
are O +
revisited O -
. O +

Therapeutic O +
strategies O +
involving O +
some O +
components O +
of O +
the O +
RAS O +
with O +
an O +
unusual O +
vision O +
resulting O +
from O +
a O +
bilateral O +
perspective O +
added O +
to O +
their O +
study O +
are O +
discussed O -
. O +

Myeloid O +
derived O +
suppressor O +
cells O +
and O +
their O +
role O +
in O +
diseases O -
. O +

Myeloid O +
derived O +
suppressor O +
cells O +
( O -
MDSCs O -
) O +
are O +
a O +
heterogeneous O +
population O +
of O +
myeloid O +
progenitors O +
that O +
can O +
play O +
a O +
major O +
role O +
in O +
tumour O +
development O +
and O +
chronic O +
inflammation O -
. O +

The O +
importance O +
of O +
the O +
suppressive O +
function O +
ofMDSCs O +
was O +
first O +
suggested O +
by O +
studies O +
involving O +
cancer O +
patients O +
and O +
cancer O -
- O -
bearing O +
mice O -
. O +

In O +
addition O -
, O +
recent O +
studies O +
have O +
demonstrated O +
that O +
MDSCs O +
can O +
also O +
be O +
involved O +
in O +
many O +
other O +
pathological O +
conditions O -
. O +

MDSCs O +
have O +
unique O +
ways O +
of O +
abrogatingan O +
immune O +
response O +
in O +
addition O +
to O +
those O +
utilised O +
by O +
other O +
immune O -
- O -
suppressive O +
cell O +
types O -
, O +
for O +
example O +
via O +
the O +
induction O +
of O +
arginase-1 O +
and O +
consequent O +
upregulation O +
in O +
reactive O +
oxygen B-Chemical +
species O +
( O -
ROS O -
) O +
production O -
. O +

Due O +
to O +
their O +
heterogeneity O -
, O -
they O +
further O +
can O +
express O +
a O +
variety O +
of O +
lineage O +
markers O -
, O +
which O +
overlap O +
with O +
other O +
myeloid O +
cell O +
types O +
such O +
as O +
Gr1,CD11b O -
, O +
MHCIIlo O -
, O +
Ly6C O +
and O +
Ly6 O -
G O -
, O +
making O +
it O +
difficult O +
to O +
identify O +
them O +
by O +
surface O +
phenotype O +
alone O -
. O +

The O +
disparity O +
between O +
mouse O +
and O +
human O +
MDSCs O +
further O +
complicates O +
the O +
identification O +
of O +
these O +
elusive O +
cell O +
populations O -
. O +

In O +
this O +
review O -
, O +
we O +
will O +
summarise O +
the O +
recent O +
updates O +
on O +
the O +
methods O +
for O +
eliciting O +
and O +
studying O +
different O +
MDSC O +
subsets O -
, O +
including O +
newly O +
proposed O +
surface O +
phenotypes O -
, O +
as O +
well O +
as O +
insights O +
into O +
how O +
their O +
function O +
is O +
being O +
characterised O +
in O +
both O +
mice O +
and O +
humans O -
. O +

In O +
addition O -
, O +
exciting O +
new O +
discoveries O +
suggesting O +
their O +
involvement O +
across O +
a O +
number O +
of O +
different O +
pathological O +
settings O -
, O +
such O +
as O +
sepsis O -
, O +
autoimmunity O +
and O +
Leishmaniasis O -
, O +
will O +
be O +
discussed O -
. O +

Developing O +
FGFR4 O +
inhibitors O +
as O +
potential O +
anti O -
- O -
cancer O +
agents O +
via O +
in O +
silico O +
design O -
, O +
supported O +
by O +
in O +
vitro O +
and O +
cell O -
- O -
based O +
testing O -
. O +

Fibroblast O +
growth O +
factor O +
receptor-4 O +
( O -
FGFR4 O -
) O +
is O +
a O +
tyrosine B-Chemical +
kinase O +
with O +
a O +
range O +
of O +
important O +
physiological O +
functions O -
. O +

However O -
, O +
it O +
is O +
also O +
frequently O +
mutated O +
in O +
various O +
cancers O +
and O +
is O +
now O +
generating O +
significant O +
interest O +
as O +
a O +
potential O +
therapeutic O +
target O -
. O +

Unfortunately O -
, O +
biochemical O +
characterization O +
of O +
its O +
role O +
in O +
disease O -
, O +
and O +
further O +
evaluation O +
as O +
a O +
drug O +
target O +
is O +
hampered O +
by O +
lack O +
of O +
a O +
specific O +
inhibitor O -
. O +

We O +
aimed O +
to O +
discover O +
new O +
inhibitors O +
for O +
FGFR4 O +
ab O +
initio O +
using O +
a O +
strategy O +
combining O +
in O +
silico O -
, O +
in O +
vitro O +
and O +
cell O -
- O -
based O +
assays O -
. O +

We O +
used O +
the O +
homologous O +
FGFR1 O +
to O +
calculate O +
docking O +
scores O +
of O +
a O +
chemically O -
- O -
diverse O +
library O +
of O +
approximately O +
2000 O +
potential O +
kinase O +
inhibitors O -
. O +

Nineteen O +
potential O +
inhibitors O +
and O +
ten O +
randomly- O +
selected O +
negative O +
controls O +
were O +
taken O +
forward O +
for O +
in O +
vitro O +
FGFR4 O +
kinase O +
assays O -
. O +

All O +
compounds O +
with O +
good O +
docking O +
scores O +
significantly O +
inhibited O +
FGFR4 O +
kinase O +
activity O -
, O +
some O +
with O +
sub O -
- O -
micromolar O +
( O -
most O +
potent O +
being O +
V4 B-Chemical -
- I-Chemical -
015 I-Chemical +
with O +
an O +
IC O -
( O -
50 O -
) O +
of O +
0.04 O +
μM O -
) O -
. O +

Four O +
of O +
these O +
compounds O +
also O +
demonstrated O +
substantial O +
activity O +
in O +
cellular O +
assays O +
using O +
the O +
FGFR4- O +
overexpressing O +
breast O +
carcinoma O +
cell O +
line O -
, O +
MDA O -
- O -
MB453 O -
. O +

Through O +
immunoblot O +
assays O -
, O +
these O +
compounds O +
were O +
shown O +
to O +
block O +
the O +
phosphorylation O +
of O +
the O +
FGFR4 O +
adaptor O +
protein O -
, O +
FGFR O +
substrate O +
protein-2α O +
( O -
FRS2α O -
) O -
. O +

The O +
most O +
potent O +
compound O +
to O +
date O -
, O +
V4 B-Chemical -
- I-Chemical -
015 I-Chemical -
, O +
suppressed O +
proliferation O +
of O +
MDA O -
- O -
MB453 O +
cells O +
at O +
sub O -
- O -
micromolar O +
concentrations O -
, O +
activated O +
the O +
pro O -
- O -
apoptotic O +
caspases O +
3 O -
/ O -
7 O +
and O +
inhibited O +
cellular O +
migration O -
. O +

While O +
achieving O +
complete O +
selectivity O +
of O +
this O +
compound O +
for O +
FGFR4 O +
will O +
require O +
further O +
lead O +
optimization O -
, O +
this O +
study O +
has O +
successfully O +
identified O +
new O +
chemical O +
scaffolds O +
with O +
unprecedented O +
FGFR4 O +
inhibition O +
capacities O +
that O +
will O +
support O +
mechanism O +
of O +
action O +
studies O +
and O +
future O +
anti O -
- O -
cancer O +
drug O +
design O -
. O +

Long O -
- O -
Acting O +
Beta O -
- O -
Agonists O +
and O +
their O +
Association O +
with O +
Inhaled O +
Corticosteroids O +
in O +
COPD O -
. O +

Inhaled O +
bronchodilators O -
, O +
including O +
beta2-agonists O +
and O +
antimuscaric O +
receptor O +
antagonists O -
, O +
are O +
the O +
mainstay O +
of O +
pharmacotherapy O +
in O +
chronic O +
obstructive O +
pulmonary O +
disease O +
( O -
COPD O -
) O -
. O +

The O +
short O -
- O -
acting O +
beta2-agonists O -
, O +
including O +
salbutamol B-Chemical -
, O +
and O +
fenoterol B-Chemical -
, O +
have O +
a O +
rapid O +
onset O +
of O +
action O -
, O +
a O +
bronchodilating O +
effect O +
for O +
3 O -
- O -
6 O +
h O +
and O +
are O +
used O +
on O +
demand O -
. O +

The O +
longacting O +
beta2-agonists O +
( O -
LABAs O -
) O -
, O +
including O +
salmeterol B-Chemical +
and O +
formoterol B-Chemical -
, O +
have O +
12-hour O +
duration O +
of O +
action O +
and O +
are O +
used O +
with O +
a O +
twice O -
- O -
daily O +
dosing O +
regimen O +
for O +
long O -
- O -
term O +
COPD O +
treatment O -
. O +

Unlike O +
salmeterol B-Chemical -
, O +
formoterol B-Chemical +
has O +
a O +
rapid O +
onset O +
of O +
action O -
. O +

Pharmacological O +
characteristics O +
required O +
by O +
novel O +
inhaled O +
LABAs O +
include O +
24 O +
h O +
bronchodilator O +
effect O +
in O +
vivo O +
which O +
would O +
make O +
them O +
suitable O +
for O +
once O +
daily O +
administration O +
( O -
ultra O -
- O -
LABA O -
) O -
, O +
high O +
potency O +
and O +
selectivity O +
for O +
beta2-adrenoceptors O -
, O +
rapid O +
onset O +
of O +
action O -
, O +
low O +
oral O +
bioavailability O +
( O -
< O +
5 O -
% O -
) O +
after O +
inhalation O -
, O +
and O +
high O +
systemic O +
clearance O -
. O +

Indacaterol B-Chemical -
, O +
which O +
has O +
been O +
approved O +
for O +
long O -
- O -
term O +
treatment O +
of O +
COPD O +
in O +
Europe O +
and O +
in O +
the O +
USA O -
, O +
has O +
a O +
24-h O +
duration O +
of O +
action O +
and O +
a O +
once O -
- O -
daily O +
dosing O +
regimen O -
. O +

Newer O +
ultra O -
- O -
LABAs O -
, O +
including O +
olodaterol B-Chemical -
, O +
vilanterol B-Chemical -
, O +
milveterol B-Chemical -
, O +
carmoterol B-Chemical -
, O +
and O +
abediterol B-Chemical -
, O +
are O +
in O +
development O -
. O +

Combination O +
with O +
ICS O +
( O -
fluticasone B-Chemical -
/ O -
salmeterol B-Chemical -
, O +
budesonide B-Chemical -
/ O -
formoterol B-Chemical -
, O +
beclomethasone B-Chemical -
/ O -
formoterol B-Chemical -
) O +
appears O +
to O +
provide O +
an O +
additional O +
benefit O +
over O +
the O +
monocomponent O +
therapy O -
, O +
although O +
the O +
extent O +
of O +
this O +
benefit O +
is O +
variable O +
and O +
often O +
not O +
clinically O +
significant O +
in O +
all O +
the O +
endpoints O +
assessed O -
. O +

In O +
patients O +
with O +
COPD O -
, O +
treatment O +
with O +
ICS O +
is O +
associated O +
with O +
increased O +
risk O +
of O +
pneumonia O +
which O +
should O +
be O +
carefully O +
considered O +
when O +
assessing O +
the O +
risk O -
/ O -
benefit O +
ratio O +
of O +
ICS O -
/ O -
LABA O +
combinations O -
. O +

Subphenotyping O +
of O +
patients O +
with O +
COPD O +
( O -
e.g. O -
, O +
frequent O +
exacerbations O -
, O +
sputum O +
eosinophilia O -
, O +
mixed O +
asthma O -
/ O -
COPD O +
phenotype O -
) O +
might O +
help O +
identify O +
those O +
patients O +
who O +
are O +
most O +
likely O +
to O +
benefit O +
from O +
addition O +
of O +
ICS O +
to O +
bronchodilating O +
treatment O -
. O +

Ultra O -
- O -
LABA O -
/ O +
long O -
- O -
acting O +
muscarinic O +
receptor O +
antagonist O +
( O -
LAMA O -
) O +
combination O +
treatment O +
is O +
under O +
development O +
and O +
is O +
likely O +
to O +
become O +
a O +
standard O +
pharmacological O +
strategy O +
for O +
COPD O -
. O +

Dual O -
- O -
pharmacology O +
inhaled O +
muscarinic O +
antagonist O -
- O -
beta2 O +
agonist O +
( O -
MABA O -
) O +
molecules O +
provide O +
a O +
new O +
approach O +
to O +
the O +
treatment O +
of O +
COPD O -
. O +

The O +
therapeutic O +
potential O +
of O +
allosteric O +
ligands O +
for O +
free O +
fatty B-Chemical +
acid I-Chemical +
sensitive O +
GPCRs O -
. O +

G O +
protein O +
coupled O +
receptors O +
( O -
GPCRs O -
) O +
are O +
the O +
most O +
historically O +
successful O +
therapeutic O +
targets O -
. O +

Despite O +
this O +
success O +
there O +
are O +
many O +
important O +
aspects O +
of O +
GPCR O +
pharmacology O +
and O +
function O +
that O +
have O +
yet O +
to O +
be O +
exploited O +
to O +
their O +
full O +
therapeutic O +
potential O -
. O +

One O +
in O +
particular O +
that O +
has O +
been O +
gaining O +
attention O +
in O +
recent O +
times O +
is O +
that O +
of O +
GPCR O +
ligands O +
that O +
bind O +
to O +
allosteric O +
sites O +
on O +
the O +
receptor O +
distinct O +
from O +
the O +
orthosteric O +
site O +
of O +
the O +
endogenous O +
ligand O -
. O +

As O +
therapeutics O -
, O +
allosteric O +
ligands O +
possess O +
many O +
theoretical O +
advantages O +
over O +
their O +
orthosteric O +
counterparts O -
, O +
including O +
more O +
complex O +
modes O +
of O +
action O -
, O +
improved O +
safety O -
, O +
more O +
physiologically O +
appropriate O +
responses O -
, O +
better O +
target O +
selectivity O -
, O +
and O +
reduced O +
likelihood O +
of O +
desensitisation O +
and O +
tachyphylaxis O -
. O +

Despite O +
these O +
advantages O -
, O +
the O +
development O +
of O +
allosteric O +
ligands O +
is O +
often O +
difficult O +
from O +
a O +
medicinal O +
chemistry O +
standpoint O +
due O +
to O +
the O +
more O +
complex O +
challenge O +
of O +
identifying O +
allosteric O +
leads O +
and O +
their O +
often O +
flat O +
or O +
confusing O +
SAR O -
. O +

The O +
present O +
review O +
will O +
consider O +
the O +
advantages O +
and O +
challenges O +
associated O +
with O +
allosteric O +
GPCR O +
ligands O -
, O +
and O +
examine O +
how O +
the O +
particular O +
properties O +
of O +
these O +
ligands O +
may O +
be O +
exploited O +
to O +
uncover O +
the O +
therapeutic O +
potential O +
for O +
free O +
fatty B-Chemical +
acid I-Chemical +
sensitive O +
GPCRs O -
. O +

Aspulvinones B-Chemical +
from O +
a O +
mangrove O +
rhizosphere O +
soil O -
- O -
derived O +
fungus O +
Aspergillus O +
terreus O +
Gwq-48 O +
with O +
anti O -
- O -
influenza O +
A O +
viral O +
( O -
H1N1 O -
) O +
activity O -
. O +

A O +
new O +
butenolide B-Chemical +
isoaspulvinone B-Chemical +
E I-Chemical +
( O -
1 O -
) O -
, O +
together O +
with O +
two O +
known O +
butenolides B-Chemical +
aspulvinone B-Chemical +
E I-Chemical +
( O -
2 O -
) O +
and O +
pulvic B-Chemical +
acid I-Chemical +
( O -
3 O -
) O +
were O +
isolated O +
from O +
the O +
marine O -
- O -
derived O +
fungus O -
, O +
Aspergillus O +
terreus O +
Gwq-48 O -
. O +

They O +
showed O +
significant O +
anti O -
- O -
influenza O +
A O +
H1N1 O +
virus O +
activities O -
, O +
with O +
IC50 O +
values O +
of O +
32.3 O -
, O +
56.9 O -
, O +
and O +
29.1μg O -
/ O -
mL O -
, O +
respectively O -
. O +

Moreover O -
, O +
only O +
compound O +
1 O +
exhibited O +
effective O +
inhibitory O +
activity O +
against O +
H1N1 O +
viral O +
neuraminidase O +
( O -
NA O -
) O -
, O +
and O +
docking O +
of O +
two O +
isomers O +
( O -
1 O -
- O -
2 O -
) O +
into O +
the O +
active O +
sites O +
of O +
NA O +
showed O +
that O +
the O +
E O +
double O +
bond O +
Δ O -
( O -
5 O -
( O -
10 O -
) O -
) O +
was O +
essential O +
to O +
achieve O +
activity O -
. O +

A O +
novel O +
fluorogenic O +
substrate O +
for O +
dinuclear O +
Zn B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical -
-containing O +
metallo O -
- O -
β O -
- O -
lactamases O -
. O +

In O +
an O +
effort O +
to O +
prepare O +
a O +
fluorogenic O +
substrate O +
to O +
be O +
used O +
in O +
activity O +
assays O +
with O +
metallo O -
- O -
β O -
- O -
lactamases O -
, O +
( B-Chemical -
6R,7R I-Chemical -
) I-Chemical -
-8-oxo-7- I-Chemical -
( I-Chemical -
2-oxo-2H I-Chemical -
- I-Chemical -
chromene-3-carboxamido I-Chemical -
) I-Chemical -
-3- I-Chemical -
( I-Chemical -
( I-Chemical -
4- I-Chemical -
( I-Chemical -
2-oxo-2H I-Chemical -
- I-Chemical -
chromene-3-carboxamido I-Chemical -
) I-Chemical -
-phenylthio I-Chemical -
) I-Chemical -
methyl I-Chemical -
) I-Chemical -
-5-thia-1-azabicyclo I-Chemical -
[ I-Chemical -
4.2.0 I-Chemical -
] I-Chemical -
oct-2-ene-2-carboxylic I-Chemical +
acid I-Chemical +
( O -
CA O -
) O +
was O +
synthesized O +
and O +
characterized O -
. O +

CA O +
exhibited O +
a O +
fluorescence O +
quantum O +
yield O +
( O -
φ O -
) O +
of O +
0.0059 O -
, O +
two O +
fluorescence O +
lifetimes O +
of O +
3.63 O -
× O -
10 O -
( O -
-10 O -
) O +
and O +
5.38 O -
× O -
10 O -
( O -
-9 O -
) O -
s O -
, O +
and O +
fluorescence O +
intensity O +
that O +
is O +
concentration O -
- O -
dependent O -
. O +

Steady O -
- O -
state O +
kinetic O +
assays O +
revealed O +
that O +
CA O +
is O +
a O +
substrate O +
for O +
metallo O -
- O -
β O -
- O -
lactamases O +
( O -
MβLs O -
) O +
L1 O +
and O +
CcrA O -
, O +
exhibiting O +
Km O +
and O +
kcat O +
values O +
of O +
18μM O +
and O +
5s O -
( O -
-1 O -
) O +
and O +
11μM O +
and O +
17s O -
( O -
-1 O -
) O -
, O +
respectively O -
. O +

Synthesis O +
and O +
physicochemical O +
properties O +
of O +
new O +
tripodal O +
amphiphiles O +
bearing O +
fatty B-Chemical +
acids I-Chemical +
as O +
a O +
hydrophobic O +
group O -
. O +

Saturated B-Chemical +
fatty I-Chemical +
acids I-Chemical +
( O -
FA O -
) O +
were O +
grafted O +
using O +
tyrosine B-Chemical +
as O +
a O +
spacer O +
group O +
to O +
the O +
cyclotriphosphazene B-Chemical +
ring O +
along O +
with O +
equimolar O +
hydrophilic O +
methoxy B-Chemical +
poly I-Chemical -
( I-Chemical -
ethylene I-Chemical +
glycol I-Chemical -
) I-Chemical +
( O -
MPEG B-Chemical -
) O +
in O +
cis O -
- O -
nongeminal O +
way O -
. O +

Seven O +
new O +
cyclotriphosphazene B-Chemical +
amphiphiles O +
were O +
prepared O +
from O +
combinations O +
of O +
hydrophilic O +
MPEGs B-Chemical +
with O +
different O +
molecular O +
weights O +
of O +
350 O -
, O +
550 O -
, O +
750 O +
and O +
1000 O +
and O +
four O +
different O +
fatty B-Chemical +
acids I-Chemical +
of O +
different O +
hydrophobicity O +
including O +
lauric B-Chemical -
, I-Chemical +
myristic I-Chemical -
, I-Chemical +
palmitic I-Chemical +
and I-Chemical +
stearic I-Chemical +
acids I-Chemical -
. O +

These O +
steric O +
amphiphiles O +
bearing O +
fatty B-Chemical +
acids I-Chemical +
as O +
a O +
hydrophobic O +
group O +
were O +
found O +
to O +
form O +
more O +
stable O +
micelles O +
with O +
very O +
low O +
critical O +
micelle O +
concentrations O +
( O -
CMC O -
) O +
( O -
2.95 O -
- O -
7.80mg O -
/ O -
L O -
) O +
compared O +
with O +
oligopeptide O +
analogues O -
, O +
and O +
their O +
highly O +
hydrophobic O +
core O +
environment O +
is O +
unique O +
and O +
potentially O +
useful O +
for O +
various O +
biomedical O +
applications O -
. O +

Electrochemical O +
determination O +
of O +
Sudan B-Chemical +
I I-Chemical +
in O +
food O +
samples O +
at O +
graphene B-Chemical +
modified O +
glassy O +
carbon B-Chemical +
electrode O +
based O +
on O +
the O +
enhancement O +
effect O +
of O +
sodium B-Chemical +
dodecyl I-Chemical +
sulphonate I-Chemical -
. O +

This O +
paper O +
describes O +
a O +
novel O +
electrochemical O +
method O +
for O +
the O +
determination O +
of O +
Sudan B-Chemical +
I I-Chemical +
in O +
food O +
samples O +
based O +
on O +
the O +
electrochemical O +
catalytic O +
activity O +
of O +
graphene B-Chemical +
modified O +
glassy O +
carbon B-Chemical +
electrode O +
( O -
GMGCE O -
) O +
and O +
the O +
enhancement O +
effect O +
of O +
an O +
anionic O +
surfactant O -
: O +
sodium B-Chemical +
dodecyl I-Chemical +
sulphonate I-Chemical +
( O -
SDS B-Chemical -
) O -
. O +

Using O +
pH O +
6.0 O +
phosphate B-Chemical +
buffer O +
solution O +
( O -
PBS O -
) O +
as O +
supporting O +
electrolyte O +
and O +
in O +
the O +
presence O +
of O +
1.5 O +
× O +
10 O -
( O -
-4 O -
) O -
mol O +
L O -
( O -
-1 O -
) O +
SDS B-Chemical -
, O +
Sudan B-Chemical +
I I-Chemical +
yielded O +
a O +
well O -
- O -
defined O +
and O +
sensitive O +
oxidation O +
peak O +
at O +
a O +
GMGCE O -
. O +

The O +
oxidation O +
peak O +
current O +
of O +
Sudan B-Chemical +
I I-Chemical +
remarkably O +
increased O +
in O +
the O +
presence O +
of O +
SDS B-Chemical -
. O +

The O +
experimental O +
parameters O -
, O +
such O +
as O +
supporting O +
electrolyte O -
, O +
concentration O +
of O +
SDS B-Chemical -
, O +
and O +
accumulation O +
time O -
, O +
were O +
optimised O +
for O +
Sudan B-Chemical +
I I-Chemical +
determination O -
. O +

The O +
oxidation O +
peak O +
current O +
showed O +
a O +
linear O +
relationship O +
with O +
the O +
concentrations O +
of O +
Sudan B-Chemical +
I I-Chemical +
in O +
the O +
range O +
of O +
7.50 O +
× O +
10 O -
( O -
-8 O -
) O -
-7.50 O +
× O +
10 O -
( O -
-6 O -
) O -
mol O +
L O -
( O -
-1 O -
) O -
, O +
with O +
the O +
detection O +
limit O +
of O +
4.0 O +
× O +
10 O -
( O -
-8 O -
) O -
mol O +
L O -
( O -
-1 O -
) O -
. O +

This O +
new O +
voltammetric O +
method O +
was O +
successfully O +
used O +
to O +
determine O +
Sudan B-Chemical +
I I-Chemical +
in O +
food O +
products O +
such O +
as O +
ketchup O +
and O +
chili O +
sauce O +
with O +
satisfactory O +
results O -
. O +

Pterostilbene B-Chemical +
inhibits O +
dimethylnitrosamine B-Chemical -
- O -
induced O +
liver O +
fibrosis O +
in O +
rats O -
. O +

Pterostilbene B-Chemical -
, O +
found O +
in O +
grapes O +
and O +
berries O -
, O +
exhibits O +
pleiotropic O +
effects O -
, O +
including O +
anti O -
- O -
inflammatory O -
, O +
antioxidant O -
, O +
and O +
anti O -
- O -
proliferative O +
activities O -
. O +

This O +
study O +
was O +
conducted O +
to O +
investigate O +
the O +
effect O +
of O +
pterostilbene B-Chemical +
on O +
liver O +
fibrosis O +
and O +
the O +
potential O +
underlying O +
mechanism O +
for O +
such O +
effect O -
. O +

Sprague O -
- O -
Dawley O +
rats O +
were O +
intraperitoneally O +
given O +
dimethyl B-Chemical +
n I-Chemical -
- I-Chemical -
nitrosamine I-Chemical +
( O -
DMN B-Chemical -
) O +
( O -
10mg O -
/ O -
kg O -
) O +
3 O +
days O +
per O +
week O +
for O +
4 O +
weeks O -
. O +

Pterostilbene B-Chemical +
( O -
10 O +
or O +
20mg O -
/ O -
kg O -
) O +
was O +
administered O +
by O +
oral O +
gavage O +
daily O -
. O +

Liver O +
function O -
, O +
morphology O -
, O +
histochemistry O -
, O +
and O +
fibrotic O +
parameters O +
were O +
examined O -
. O +

Pterostilbene B-Chemical +
supplementation O +
alleviated O +
the O +
DMN B-Chemical -
- O -
induced O +
changes O +
in O +
the O +
serum O +
levels O +
of O +
alanine O +
transaminase O +
and O +
aspartate O +
transaminase O +
( O -
p<0.05 O -
) O -
. O +

Fibrotic O +
status O +
and O +
the O +
activation O +
of O +
hepatic O +
stellate O +
cells O +
were O +
improved O +
upon O +
pterostilbene B-Chemical +
supplementation O +
as O +
evidenced O +
by O +
histopathological O +
examination O +
as O +
well O +
as O +
the O +
expression O +
of O +
α O -
- O -
smooth O +
muscle O +
actin O +
( O -
α O -
- O -
SMA O -
) O -
, O +
transforming O +
growth O +
factor O -
- O -
β1 O +
( O -
TGF O -
- O -
β1 O -
) O -
, O +
and O +
matrix O +
metalloproteinase O +
2 O +
( O -
MMP2 O -
) O -
. O +

These O +
data O +
demonstrated O +
that O +
pterostilbene B-Chemical +
exhibited O +
hepatoprotective O +
effects O +
on O +
experimental O +
fibrosis O -
, O +
potentially O +
by O +
inhibiting O +
the O +
TGF O -
- O -
β1 O -
/ O -
Smad O +
signaling O -
. O +

Thermal O -
- O -
induced O +
changes O +
of O +
kale O -
's O +
antioxidant O +
activity O +
analyzed O +
by O +
HPLC O -
- O -
UV O -
/ O -
Vis O -
- O -
online O -
- O -
TEAC O +
detection O -
. O +

Generally O -
, O +
boiling O +
of O +
vegetables O +
is O +
assumed O +
leading O +
to O +
lower O +
nutritional O +
values O +
because O +
of O +
leaching O +
effects O +
and O +
activity O +
loss O +
of O +
bioactive O +
compounds O -
. O +

Kale O +
( O -
Brassica O +
oleracea O +
var O -
. O +

sabellica O -
) O +
reveals O +
a O +
great O +
diversity O +
of O +
flavonoids B-Chemical -
, O +
which O +
have O +
been O +
shown O +
to O +
be O +
good O +
antioxidants O -
. O +

As O +
Brassica O +
vegetables O +
are O +
mainly O +
consumed O +
cooked O -
, O +
the O +
influence O +
of O +
boiling O +
on O +
kale O -
's O +
flavonoids B-Chemical +
and O +
their O +
antioxidant O +
activity O +
was O +
investigated O -
. O +

Therefore O -
, O +
three O +
kale O +
cultivars O +
were O +
cooked O +
at O +
100 O -
° O -
C O +
for O +
2 O +
and O +
4h O +
prior O +
to O +
analysis O -
. O +

The O +
total O +
phenolic O +
content O +
( O -
TPC O -
) O +
and O +
the O +
total O +
antioxidant O +
activity O +
( O -
TEAC O +
assay O +
and O +
EPR O +
spectrometry O -
) O +
of O +
each O +
cultivar O +
were O +
determined O +
and O +
revealed O +
no O +
change O -
, O +
independent O +
of O +
cooking O +
time O -
, O +
although O +
kale O +
samples O +
visually O +
altered O -
. O +

Using O +
the O +
HPLC O -
- O -
UV O -
/ O -
Vis O -
- O -
online O -
- O -
TEAC O +
approach O -
, O +
distinct O +
changes O +
in O +
composition O +
and O +
antioxidant O +
activity O +
of O +
the O +
flavonoids B-Chemical +
were O +
detectable O -
. O +

Thus O -
, O +
it O +
was O +
observable O -
, O +
that O +
the O +
antioxidant O +
activities O +
of O +
the O +
reaction O +
products O +
compensated O +
the O +
" O -
loss O -
" O +
of O +
the O +
antioxidant O +
activity O +
of O +
the O +
original O +
compounds O +
of O +
the O +
uncooked O +
material O -
. O +

Dispersive O +
liquid O -
- O -
liquid O +
microextraction O +
combined O +
with O +
field O -
- O -
amplified O +
sample O +
stacking O +
in O +
capillary O +
electrophoresis O +
for O +
the O +
determination O +
of O +
non O -
- O -
steroidal B-Chemical +
anti O -
- O -
inflammatory O +
drugs O +
in O +
milk O +
and O +
dairy O +
products O -
. O +

Dispersive O +
liquid O -
- O -
liquid O +
microextraction O +
( O -
DLLME O -
) O +
was O +
coupled O +
with O +
field O -
- O -
amplified O +
sample O +
stacking O +
in O +
capillary O +
electrophoresis O +
( O -
FASS O -
) O +
for O +
the O +
determination O +
of O +
five O +
non O -
- O -
steroidal B-Chemical +
anti O -
- O -
inflammatory O +
drugs O +
( O -
NSAIDs O -
) O +
in O +
bovine O +
milk O +
and O +
dairy O +
products O -
. O +

After O +
extraction O -
, O +
the O +
enriched O +
analytes O +
were O +
back O -
- O -
extracted O +
into O +
a O +
basic O +
aqueous O +
solution O +
for O +
injection O +
into O +
CE O -
. O +

Under O +
optimum O +
conditions O -
, O +
enrichment O +
factors O +
were O +
in O +
the O +
range O +
46 O -
- O -
229 O -
. O +

Limits O +
of O +
detection O +
of O +
the O +
analytes O +
ranged O +
from O +
3.0 O +
to O +
13.1 O +
μg O +
kg O -
( O -
-1 O -
) O +
for O +
all O +
matrices O +
analysed O -
. O +

Calibration O +
graphs O +
showed O +
good O +
linearity O +
with O +
coefficients O +
of O +
determination O +
( O -
R O -
( O -
2 O -
) O -
) O -
≥ O +
0.9915 O +
and O +
relative O +
standard O +
deviations O +
( O -
RSD% O -
) O +
of O +
the O +
analyses O +
in O +
the O +
range O +
of O +
0.6 O -
- O -
6.2 O -
% O +
( O -
n=5 O -
) O -
. O +

Recoveries O +
of O +
all O +
NSAIDs O +
from O +
bottled O +
milk O -
, O +
raw O +
milk O -
, O +
yogurt O +
and O +
white O +
cheese O +
samples O +
were O +
in O +
the O +
ranges O +
of O +
86.6 O -
- O -
109.3 O -
% O -
, O +
84.3 O -
- O -
100.5 O -
% O -
, O +
77.4 O -
- O -
107.3 O -
% O -
, O +
and O +
90.9 O -
- O -
101.6 O -
% O -
, O +
respectively O -
. O +

DLLME O -
- O -
FASS O -
- O -
CE O +
was O +
demonstrated O +
to O +
be O +
a O +
rapid O +
and O +
convenient O +
method O +
for O +
the O +
determination O +
of O +
NSAIDs O +
in O +
milk O +
and O +
dairy O +
products O -
. O +

Antioxidant O +
activities O +
of O +
the O +
synthesized O +
thiol B-Chemical -
- O -
contained O +
peptides O +
derived O +
from O +
computer O -
- O -
aided O +
pepsin O +
hydrolysis O +
of O +
yam O +
tuber O +
storage O +
protein O -
, O +
dioscorin B-Chemical -
. O +

Our O +
previous O +
report O +
showed O +
that O +
yam O +
dioscorin B-Chemical +
and O +
its O +
peptic O +
hydrolysates O +
exhibit O +
radical O +
scavenging O +
activities O -
; O +
however O -
, O +
the O +
functions O +
of O +
these O +
peptic O +
hydrolases O +
are O +
still O +
under O +
investigation O -
. O +

In O +
this O +
study O -
, O +
the O +
thiol B-Chemical -
- O -
containing O +
peptides O +
derived O +
from O +
computer O -
- O -
aided O +
simulation O +
of O +
pepsin O +
hydrolysis O +
of O +
dioscorin B-Chemical -
, O +
namely O -
, O +
KTCGNGME O +
( O -
diotide1 O -
) O -
, O +
PPCSE O +
( O -
diotide2 O -
) O -
, O +
CDDRVIRTPLT O +
( O -
diotide3 O -
) O -
, O +
KTCGY O +
( O -
diotide4 O -
) O -
, O +
and O +
PPCTE O +
( O -
diotide5 O -
) O +
were O +
synthesized O +
to O +
compare O +
their O +
antioxidant O +
activities O +
with O +
GSH B-Chemical +
and/or O +
carnosine B-Chemical +
by O +
examining O +
hydroxyl B-Chemical +
radical O +
scavenging O +
activity O +
by O +
electron O +
spin O +
resonance O +
spectrometry O -
, O +
anti O -
- O -
low O -
- O -
density O +
lipoprotein O +
peroxidation O -
, O +
anti O -
- O -
AAPH B-Chemical -
- O -
induced O +
hemolysis O -
, O +
and O +
oxygen B-Chemical +
radical O +
absorbance O +
capacity O +
activity O -
. O +

We O +
found O +
that O +
while O +
all O +
the O +
synthesized O +
diotides O +
showed O +
antioxidant O +
activity O -
, O +
diotide4 O +
exhibited O +
the O +
highest O +
levels O -
. O +

Moreover O -
, O +
all O +
diotides O +
( O -
100 O +
μM O -
) O +
showed O +
protective O +
effects O +
against O +
methylglyoxal B-Chemical -
- O -
induced O +
human O +
umbilical O +
vein O +
endothelial O +
cell O +
death O -
. O +

These O +
results O +
suggest O +
that O +
thiol B-Chemical -
- O -
containing O +
diotides O +
derived O +
from O +
dioscorin B-Chemical +
hydrolysis O +
exhibit O +
antioxidant O +
activities O +
and O +
reveal O +
the O +
benefits O +
of O +
yam O +
tuber O +
as O +
an O +
antioxidant O -
- O -
rich O +
food O -
. O +

Winter O +
wheat O +
hull O +
( O -
husk O -
) O +
is O +
a O +
valuable O +
source O +
for O +
tricin B-Chemical -
, O +
a O +
potential O +
selective O +
cytotoxic O +
agent O -
. O +

The O +
flavone B-Chemical -
, O +
tricin B-Chemical +
( O -
5,7,4'-trihydroxy-3',5'-dimethoxyflavone B-Chemical -
) O +
has O +
great O +
potential O +
as O +
an O +
anticancer O +
agent O -
, O +
due O +
to O +
its O +
specific O +
chemopreventive O +
activity O -
. O +

In O +
spite O +
of O +
these O +
characteristics O -
, O +
its O +
use O +
in O +
preclinical O +
studies O +
is O +
still O +
limited O -
, O +
mainly O +
because O +
of O +
its O +
limited O +
availability O +
and O +
high O +
production O +
cost O -
. O +

Tricin B-Chemical +
is O +
found O +
mainly O +
in O +
cereal O +
grains O -
, O +
such O +
as O +
wheat O -
, O +
rice O -
, O +
barley O -
, O +
oat O +
and O +
maize O -
. O +

However O -
, O +
its O +
concentration O +
in O +
these O +
plants O +
is O +
not O +
sufficient O +
for O +
commercial O +
use O -
. O +

To O +
find O +
a O +
reliable O -
, O +
rich O +
source O +
of O +
tricin B-Chemical -
, O +
we O +
investigated O +
its O +
distribution O +
in O +
different O +
parts O +
of O +
wheat O +
( O -
Triticum O +
aestivum O -
) O +
and O +
designed O +
an O +
efficient O +
method O +
for O +
its O +
isolation O +
and O +
purification O -
. O +

The O +
highest O +
amount O +
( O -
770 O +
± O +
157 O +
mg O -
/ O -
kg O +
dry O +
weight O -
) O +
was O +
found O +
in O +
the O +
husks O +
of O +
winter O +
wheat O -
. O +

This O +
concentration O +
is O +
one O +
of O +
the O +
highest O +
in O +
any O +
plant O +
species O +
and O +
is O +
considered O +
as O +
a O +
cheap O +
source O +
of O +
natural O +
tricin B-Chemical -
. O +

The O +
purified O +
wheat O +
husks O +
tricin B-Chemical +
was O +
found O +
to O +
be O +
a O +
selective O +
potent O +
inhibitor O +
of O +
two O +
cancer O +
cell O +
lines O +
of O +
liver O +
and O +
pancreas O -
, O +
while O +
having O +
no O +
side O +
effects O +
on O +
normal O +
cells O -
. O +

This O +
selective O +
action O +
suggests O +
that O +
tricin B-Chemical +
could O +
be O +
considered O +
as O +
a O +
potential O +
candidate O +
for O +
pre O -
- O -
clinical O +
trials O +
as O +
a O +
chemopreventive O +
agent O -
. O +

In O +
addition O -
, O +
fibre O -
- O -
rich O +
crude O +
wheat O +
husk O +
could O +
be O +
used O +
as O +
a O +
natural O +
chemopreventive O +
agent O +
in O +
food O +
supplement O -
. O +

Multidisciplinary O +
analytical O +
investigation O +
of O +
phospholipids O +
and O +
triglycerides B-Chemical +
in O +
offshore O +
farmed O +
gilthead O +
sea O +
bream O +
( O -
Sparus O +
aurata O -
) O +
fed O +
commercial O +
diets O -
. O +

In O +
this O +
work O -
, O +
a O +
quantitative O +
characterisation O +
of O +
lipid O +
( O -
both O +
triglycerides B-Chemical +
and O +
phospholipids O -
) O +
rearrangements O +
in O +
the O +
muscle O +
of O +
offshore O -
- O -
raised O +
gilthead O +
sea O +
bream O +
was O +
carried O +
out O +
as O +
a O +
function O +
of O +
fish O +
growth O +
between O +
April O +
and O +
September O -
. O +

Relative O +
percentages O +
of O +
lipid O +
classes O +
and O +
fatty O +
acids B-Chemical -
/ O -
acyls B-Chemical +
composition O +
of O +
the O +
commercial O +
feeds O +
and O +
fish O +
dorsal O +
muscles O +
were O +
assessed O +
by O +
means O +
of O +
an O +
interdisciplinary O +
analytical O +
approach O -
. O +

A O +
combination O +
of O +
preparative O +
chemistry O +
and O +
experimental O +
results O +
from O +
NMR O +
spectroscopy O -
, O +
GC O -
, O +
3D O -
- O -
TLC O +
as O +
well O +
as O +
proximate O +
analysis O +
permitted O +
the O +
observed O +
growth O +
parameters O +
in O +
key O +
metabolic O +
events O +
to O +
be O +
linked O +
with O +
fish O +
fattening O +
and O +
lipid O +
turnover O -
. O +

While O +
defined O +
effects O +
of O +
feed O +
composition O +
on O +
fatty B-Chemical +
acid I-Chemical +
profiles O +
of O +
fillets O +
were O +
ascertained O -
, O +
the O +
relative O +
increase O +
of O +
fatty B-Chemical +
acyls I-Chemical +
in O +
triglycerides B-Chemical +
and O +
phospholipids O +
were O +
also O +
estimated O +
enabling O +
detailed O +
evaluation O +
of O +
TAG O -
: O -
PL O +
ratio O +
in O +
adult O +
offshore O -
- O -
farmed O +
gilthead O +
sea O +
bream O -
. O +

NMR O +
was O +
also O +
used O +
to O +
quantify O +
PUFA B-Chemical +
regiospecific O +
distribution O +
in O +
TAG B-Chemical +
and O +
PL O -
. O +

Non O -
- O -
destructive O +
determination O +
of O +
chemical O +
composition O +
in O +
intact O +
and O +
minced O +
pork O +
using O +
near O -
- O -
infrared O +
hyperspectral O +
imaging O -
. O +

In O +
this O +
study O +
a O +
near O -
- O -
infrared O +
( O -
NIR O -
) O +
hyperspectral O +
imaging O +
technique O +
was O +
investigated O +
for O +
non O -
- O -
destructive O +
determination O +
of O +
chemical O +
composition O +
of O +
intact O +
and O +
minced O +
pork O -
. O +

Hyperspectral O +
images O +
( O -
900 O -
- O -
1700 O +
nm O -
) O +
were O +
acquired O +
for O +
both O +
intact O +
and O +
minced O +
pork O +
samples O +
and O +
the O +
mean O +
spectra O +
were O +
extracted O +
by O +
automatic O +
segmentation O -
. O +

Protein O -
, O +
moisture O +
and O +
fat O +
contents O +
were O +
determined O +
by O +
traditional O +
methods O +
and O +
then O +
related O +
with O +
the O +
spectral O +
information O +
by O +
partial O +
least O -
- O -
squares O +
( O -
PLS O -
) O +
regression O +
models O -
. O +

The O +
coefficient O +
of O +
determination O +
obtained O +
by O +
cross O -
- O -
validated O +
PLS O +
models O +
indicated O +
that O +
the O +
NIR O +
spectral O +
range O +
had O +
an O +
excellent O +
ability O +
to O +
predict O +
the O +
content O +
of O +
protein O +
( O -
R O -
( O -
2 O -
) O -
( O -
cv O -
) O -
=0.88 O -
) O -
, O +
moisture O +
( O -
R O -
( O -
2 O -
) O -
( O -
cv O -
) O -
=0.87 O -
) O +
and O +
fat O +
( O -
R O -
( O -
2 O -
) O -
( O -
cv O -
) O -
=0.95 O -
) O +
in O +
pork O -
. O +

Regression O +
models O +
using O +
a O +
few O +
selected O +
feature O -
- O -
related O +
wavelengths O +
showed O +
that O +
chemical O +
composition O +
could O +
be O +
predicted O +
with O +
coefficients O +
of O +
determination O +
of O +
0.92 O -
, O +
0.87 O +
and O +
0.95 O +
for O +
protein O -
, O +
moisture O +
and O +
fat O -
, O +
respectively O -
. O +

Prediction O +
of O +
chemical O +
contents O +
in O +
each O +
pixel O +
of O +
the O +
hyperspectral O +
image O +
using O +
these O +
prediction O +
models O +
yielded O +
spatially O +
distributed O +
visualisations O +
of O +
the O +
sample O +
composition O -
. O +

Simple O -
, O +
fast O -
, O +
and O +
efficient O +
process O +
for O +
producing O +
and O +
purifying O +
trehalulose B-Chemical -
. O +

A O +
new O +
property O +
of O +
recombinant O +
trehalose B-Chemical +
synthase O +
( O -
GTase O -
) O +
from O +
Thermus O +
thermophilus O +
HB-8 O +
( O -
ATCC O +
27634 O -
) O +
was O +
found O +
and O +
described O +
in O +
this O +
study O -
. O +

GTase O +
can O +
act O +
on O +
sucrose B-Chemical +
and O +
catalyze O +
trehalulose B-Chemical +
formation O +
without O +
isomaltose B-Chemical -
, O +
isomaltulose B-Chemical -
, O +
or O +
isomelezitose B-Chemical -
, O +
releasing O +
small O +
amounts O +
of O +
glucose B-Chemical +
and O +
fructose B-Chemical +
as O +
byproducts O -
. O +

Maximum O +
trehalulose B-Chemical +
yield O +
( O -
approximately O +
81 O -
% O -
) O +
was O +
obtained O +
at O +
an O +
optimum O +
temperature O +
of O +
65 O -
° O -
C O +
and O +
was O +
independent O +
of O +
substrate O +
concentration O -
. O +

A O +
simple O -
, O +
fast O -
, O +
and O +
efficient O +
method O +
of O +
producing O +
and O +
purifying O +
trehalulose B-Chemical +
is O +
then O +
described O -
. O +

In O +
the O +
first O +
step O -
, O +
GTase O +
catalyzed O +
trehalulose B-Chemical +
formation O +
using O +
a O +
20 O -
% O +
sucrose B-Chemical +
substrate O -
. O +

Miscellaneous O +
sugars B-Chemical +
were O +
then O +
rapidly O +
removed O -
, O +
while O +
trehalulose B-Chemical +
was O +
completely O +
preserved O +
by O +
Saccharomyces O +
cerevisiae O +
cells O -
. O +

Finally O -
, O +
the O +
cells O +
were O +
separated O +
by O +
centrifugation O -
, O +
and O +
salt O +
ions O +
were O +
removed O +
by O +
an O +
ion O -
- O -
exchange O +
resin O -
, O +
subsequently O +
obtaining O +
a O +
high O -
- O -
purity O +
trehalulose B-Chemical +
solution O -
. O +

A O +
trehalulose B-Chemical +
recovery O +
rate O +
of O +
over O +
95 O -
% O +
was O +
achieved O +
using O +
this O +
process O -
. O +

This O +
method O +
has O +
a O +
simple O +
process O -
, O +
fast O +
separation O +
efficiency O -
, O +
and O +
low O +
investment O +
in O +
production O +
equipment O -
, O +
so O +
greatly O +
to O +
improve O +
production O +
efficiency O +
and O +
reduce O +
production O +
costs O -
. O +

Immunosensor O +
based O +
on O +
immobilization O +
of O +
antigenic O +
peptide O +
NS5A-1 O +
from O +
HCV O +
and O +
silk O +
fibroin O +
in O +
nanostructured O +
films O -
. O +

The O +
peptide O +
NS5A-1 O +
( O -
PPLLESWKDPDYVPPWHG O -
) O -
, O +
derived O +
from O +
hepatitis O +
C O +
virus O +
( O -
HCV O -
) O +
NS5A O +
protein O -
, O +
was O +
immobilized O +
into O +
layer O -
- O -
by O -
- O -
layer O +
( O -
LbL O -
) O +
silk O +
fibroin O +
( O -
SF O -
) O +
films O -
. O +

Deposition O +
was O +
monitored O +
by O +
UV O -
- O -
vis O +
absorption O +
measurements O +
at O +
each O +
bilayer O +
deposited O -
. O +

The O +
interaction O +
SF O -
/ O -
peptide O +
film O +
induced O +
secondary O +
structure O +
in O +
NS5A-1 O +
as O +
indicated O +
by O +
fluorescence O +
and O +
circular O +
dichroism O +
( O -
CD O -
) O +
measurements O -
. O +

Voltammetric O +
sensor O +
( O -
SF O -
/ O -
NS5A-1 O -
) O +
properties O +
were O +
observed O +
when O +
the O +
composite O +
film O +
was O +
tested O +
in O +
the O +
presence O +
of O +
anti O -
- O -
HCV O -
. O +

The O +
peptide O -
- O -
silk O +
fibroin O +
interaction O +
studied O +
here O +
showed O +
new O +
architectures O +
for O +
immunosensors O +
based O +
on O +
antigenic O +
peptides O +
and O +
SF O +
as O +
a O +
suitable O +
immobilization O +
matrix O -
. O +

Developing O +
the O +
potential O +
ophthalmic O +
applications O +
of O +
pilocarpine B-Chemical +
entrapped O +
into O +
polyvinylpyrrolidone B-Chemical -
- O -
poly B-Chemical -
( I-Chemical -
acrylic I-Chemical +
acid I-Chemical -
) I-Chemical +
nanogel O +
dispersions O +
prepared O +
by O +
γ O +
radiation O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
improve O +
the O +
stability O +
and O +
bioavailability O +
of O +
pilocarpine B-Chemical +
in O +
order O +
to O +
maintain O +
an O +
adequate O +
concentration O +
of O +
the O +
pilocarpine B-Chemical +
at O +
the O +
site O +
of O +
action O +
for O +
prolonged O +
period O +
of O +
time O -
. O +

Thus O -
, O +
pH O -
- O -
sensitive O +
polyvinylpyrrolidone B-Chemical -
- O -
poly B-Chemical -
( I-Chemical -
acrylic I-Chemical +
acid I-Chemical -
) I-Chemical +
( O -
PVP B-Chemical -
/ O -
PAAc B-Chemical -
) O +
nanogels O +
prepared O +
by O +
γ O +
radiation O -
- O -
induced O +
polymerization O +
of O +
acrylic B-Chemical +
acid I-Chemical +
( O -
AAc B-Chemical -
) O +
in O +
an O +
aqueous O +
solution O +
of O +
polyvinylpyrrolidone B-Chemical +
( O -
PVP B-Chemical -
) O +
as O +
a O +
template O +
polymer O +
were O +
used O +
to O +
encapsulate O +
pilocarpine B-Chemical -
. O +

Factors O +
affecting O +
size O +
and O +
encapsulation O +
efficiency O +
were O +
optimized O +
to O +
obtain O +
nanogel O +
suitable O +
for O +
entrapping O +
drug O +
efficiently O -
. O +

The O +
PVP B-Chemical -
/ O -
PAAc B-Chemical +
nanogel O +
particles O +
were O +
characterized O +
by O +
dynamic O +
light O +
scattering O +
( O -
DLS O -
) O -
, O +
zeta O +
potential O -
, O +
Fourier O +
transform O +
infrared O +
spectroscopy O +
( O -
FTIR O -
) O -
, O +
and O +
transmission O +
electron O +
microscopy O +
( O -
TEM O -
) O -
, O +
and O +
their O +
size O +
can O +
be O +
controlled O +
by O +
the O +
feed O +
composition O +
and O +
concentration O +
as O +
well O +
as O +
the O +
irradiation O +
dose O -
. O +

Pilocarpine B-Chemical +
was O +
loaded O +
into O +
the O +
nanogel O +
particles O +
through O +
electrostatic O +
interactions O +
where O +
the O +
AAc B-Chemical -
- O -
rich O +
nanogels O +
exhibited O +
the O +
highest O +
loading O +
efficiency O -
. O +

The O +
transmittance O -
, O +
mucoadhesion O -
, O +
and O +
rheological O +
characteristics O +
of O +
the O +
nanogel O +
particles O +
were O +
studied O +
to O +
evaluate O +
their O +
ocular O +
applicability O -
. O +

The O +
in O +
vitro O +
release O +
study O +
conducted O +
in O +
simulated O +
tear O +
fluid O +
showed O +
a O +
relatively O +
long O +
sustained O +
release O +
of O +
pilocarpine B-Chemical +
from O +
the O +
prepared O +
PVP B-Chemical -
/ O -
PAAc B-Chemical +
nanogel O +
particles O +
if O +
compared O +
with O +
pilocarpine B-Chemical +
in O +
solution O -
. O +

High O -
- O -
Performance O +
Surface O +
Acoustic O +
Wave O +
Immunosensing O +
System O +
on O +
a O +
PEG B-Chemical -
/ O -
Aptamer O +
Hybridized O +
Surface O -
. O +

Label O -
- O -
free O +
immunoassay O +
systems O +
have O +
the O +
advantages O +
of O +
procedural O +
simplicity O +
and O +
a O +
low O +
construction O +
cost O +
of O +
surfaces O +
for O +
immunosensing O -
. O +

When O +
label O -
- O -
free O +
immunoassay O +
systems O +
are O +
considered O -
, O +
the O +
nonspecific O +
adsorption O +
of O +
unwanted O +
materials O +
should O +
be O +
eliminated O +
unless O +
it O +
aids O +
in O +
the O +
detection O +
of O +
error O -
. O +

PEG B-Chemical +
is O +
well O -
- O -
known O +
as O +
a O +
blocking O +
agent O +
for O +
the O +
prevention O +
of O +
the O +
adsorption O +
of O +
nonspecific O +
binding O +
materials O +
when O +
coimmobilized O +
with O +
ligands O +
for O +
targets O +
such O +
as O +
antibodies O +
and O +
oligonucleotides O -
. O +

The O +
construction O +
strategy O +
for O +
PEG B-Chemical -
/ O -
ligand O +
coimmobilized O +
surfaces O +
is O +
an O +
important O +
point O +
in O +
the O +
preparation O +
of O +
a O +
high O -
- O -
performance O +
assays O +
because O +
the O +
physiological O +
condition O +
of O +
the O +
ligand O +
depends O +
strongly O +
on O +
its O +
interaction O +
with O +
the O +
PEG B-Chemical +
chain O -
. O +

In O +
this O +
report O -
, O +
we O +
investigate O +
the O +
interaction O +
between O +
thrombin O +
and O +
a O +
thrombin O -
- O -
binding O +
aptamer O +
( O -
TBA O -
) O +
on O +
a O +
PEG B-Chemical -
/ O -
TBA O +
coimmobilized O +
surface O +
by O +
using O +
a O +
shear O +
horizontal O +
surface O +
acoustic O +
wave O +
( O -
SAW O -
) O +
sensor O -
. O +

The O +
thrombin O -
- O -
TBA O +
binding O +
property O +
shows O +
remarkable O +
differences O +
with O +
changes O +
in O +
the O +
PEG B-Chemical +
density O +
and O +
the O +
distance O +
from O +
the O +
gold O +
surface O +
to O +
the O +
aptamer O -
. O +

Influence O +
of O +
the O +
bifunctional O +
chelator O +
on O +
the O +
pharmacokinetic O +
properties O +
of O +
99mTc B-Chemical -
( I-Chemical -
CO I-Chemical -
) I-Chemical -
3-labeled I-Chemical +
cyclic B-Chemical +
α I-Chemical -
- I-Chemical -
melanocyte I-Chemical +
stimulating I-Chemical +
hormone I-Chemical +
analog O -
. O +

Aiming O +
at O +
the O +
design O +
of O +
specific O +
melanocortin-1 O +
receptor O +
( O -
MC1R O -
) O +
targeted O +
imaging O +
probes O -
, O +
we O +
report O +
on O +
the O +
effect O +
of O +
different O +
azolyl B-Chemical -
- O -
ring O +
substitution O +
patterns O +
( O -
carboxylate B-Chemical +
at O +
the O +
4-position O +
and/or O +
methyl B-Chemical +
groups O +
at O +
the O +
3,5 O +
positions O -
) O +
of O +
pyrazolyl B-Chemical -
- I-Chemical -
diamine I-Chemical +
bifunctional O +
chelators O +
( O -
Pz O -
( O -
2 O -
) O -
-Pz O -
( O -
4 O -
) O -
) O +
on O +
the O +
pharmacokinetic O +
profile O +
of O +
the O +
( B-Chemical -
99m I-Chemical -
) I-Chemical -
Tc I-Chemical -
( I-Chemical -
CO I-Chemical -
) I-Chemical -
3-labeled I-Chemical +
lactam B-Chemical +
bridge O -
- O -
cyclized B-Chemical +
α I-Chemical -
- I-Chemical -
melanocyte I-Chemical +
stimulating I-Chemical +
hormone I-Chemical +
derivative O -
, O +
βAlaNleCycMSH B-Chemical -
( I-Chemical -
hex I-Chemical -
) I-Chemical -
. O +

Three O +
pyrazolyl B-Chemical -
- I-Chemical -
diamine I-Chemical -
- O -
containing O +
chelators O +
were O +
conjugated O +
to O +
βAlaNleCycMSHhex B-Chemical -
, O +
with O +
the O +
resulting O +
peptide O +
conjugates O +
displaying O +
subnanomolar O +
MC1R O +
binding O +
affinity O -
. O +

Biodistribution O +
studies O +
in O +
B16F1 O +
melanoma O -
- O -
bearing O +
mice O +
show O +
that O +
all O +
radiopeptides O +
present O +
a O +
good O +
melanoma O +
uptake O -
. O +

The O +
introduction O +
of O +
a O +
carboxylate B-Chemical +
group O +
in O +
the O +
azolyl B-Chemical -
- O -
ring O +
leads O +
to O +
a O +
remarkable O +
reduction O +
of O +
the O +
kidney O +
( O -
> O -
89 O -
% O -
) O +
and O +
liver O +
( O -
> O -
91 O -
% O -
) O +
accumulation O +
for O +
( B-Chemical -
99m I-Chemical -
) I-Chemical -
Tc I-Chemical -
( I-Chemical -
CO I-Chemical -
) I-Chemical -
3-Pz I-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
-βAlaNleCycMSH I-Chemical -
( I-Chemical -
hex I-Chemical -
) I-Chemical +
and O +
( B-Chemical -
99m I-Chemical -
) I-Chemical -
Tc I-Chemical -
( I-Chemical -
CO I-Chemical -
) I-Chemical -
3-Pz I-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
-βAlaNleCycMSH I-Chemical -
( I-Chemical -
hex I-Chemical -
) I-Chemical +
when O +
compared O +
to O +
the O +
radiopeptide O +
( B-Chemical -
99m I-Chemical -
) I-Chemical -
Tc I-Chemical -
( I-Chemical -
CO I-Chemical -
) I-Chemical -
3-Pz I-Chemical -
( I-Chemical -
1 I-Chemical -
) I-Chemical -
-βAlaNleCycMSH I-Chemical -
( I-Chemical -
hex I-Chemical -
) I-Chemical -
, O +
where O +
that O +
group O +
is O +
absent O -
. O +

The O +
good O +
tumor O +
uptake O +
and O +
favorable O +
tumor O -
- O -
to O -
- O -
nontarget O -
- O -
organs O +
ratios O +
of O +
( B-Chemical -
99m I-Chemical -
) I-Chemical -
Tc I-Chemical -
( I-Chemical -
CO I-Chemical -
) I-Chemical -
3-Pz I-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
-βAlaNleCycMSH I-Chemical -
( I-Chemical -
hex I-Chemical -
) I-Chemical +
and O +
( B-Chemical -
99m I-Chemical -
) I-Chemical -
Tc I-Chemical -
( I-Chemical -
CO I-Chemical -
) I-Chemical -
3-Pz I-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
-βAlaNleCycMSH I-Chemical -
( I-Chemical -
hex I-Chemical -
) I-Chemical +
highlights O +
the O +
potential O +
of O +
both O +
compounds O +
as O +
melanoma O +
imaging O +
agents O -
. O +

Vegfrecine B-Chemical -
, O +
an O +
Inhibitor O +
of O +
VEGF O +
Receptor O +
Tyrosine B-Chemical +
Kinases O +
Isolated O +
from O +
the O +
Culture O +
Broth O +
of O +
Streptomyces O +
sp. O +
A O +
new O +
inhibitor O +
of O +
VEGF O +
receptor O +
tyrosine B-Chemical +
kinases O -
, O +
vegfrecine B-Chemical +
( O -
1 O -
) O -
, O +
was O +
isolated O +
from O +
the O +
culture O +
broth O +
of O +
Streptomyces O +
sp. O +
MK931-CF8 O -
. O +

The O +
molecular O +
structure O +
of O +
1 O +
was O +
determined O +
by O +
NMR O +
and O +
MS O +
analysis O +
combined O +
with O +
synthesis O -
. O +

Compound O +
1 O +
showed O +
potent O +
inhibitory O +
activity O +
against O +
vascular O +
endothelial O +
growth O +
factor O +
receptor O +
( O -
VEGFR O -
) O +
tyrosine O +
kinases O +
in O +
in O +
vitro O +
enzyme O +
assays O -
, O +
but O +
platelet O -
- O -
derived O +
growth O +
factor O +
receptors O +
( O -
PDGFRs O -
) O -
, O +
fibroblast O +
growth O +
factor O +
receptor O +
( O -
FGFR O -
) O -
, O +
and O +
epidermal O +
growth O +
factor O +
receptor O +
( O -
EGFR O -
) O +
responded O +
only O +
weakly O -
. O +

Compound O +
1 O +
is O +
a O +
promising O +
new O +
selective O +
VEGFR O +
inhibitor O +
for O +
investigating O +
new O +
treatments O +
of O +
cancer O +
and O +
inflammatory O +
diseases O -
. O +

Stability O +
of O +
black O +
cohosh O +
triterpene B-Chemical +
glycosides I-Chemical +
and O +
polyphenols B-Chemical -
: O +
Potential O +
clinical O +
relevance O -
. O +

Concurrent O +
to O +
a O +
clinical O +
trial O +
of O +
black O +
cohosh O +
for O +
menopausal O +
hot O +
flashes O -
, O +
the O +
long O -
- O -
term O +
stability O +
of O +
the O +
black O +
cohosh O -
, O +
over O +
the O +
duration O +
of O +
the O +
clinical O +
trial O -
, O +
was O +
examined O -
. O +

Analytical O +
results O +
showed O +
that O +
the O +
major O +
constituents O -
, O +
both O +
triterpene B-Chemical +
glycosides I-Chemical +
and O +
polyphenols B-Chemical -
, O +
were O +
stable O +
over O +
the O +
3-year O +
period O +
of O +
testing O -
. O +

These O +
results O +
indicate O +
that O +
a O +
black O +
cohosh O +
product O +
stored O +
for O +
several O +
years O +
in O +
a O +
controlled O +
environment O +
does O +
not O +
undergo O +
significant O +
changes O +
in O +
its O +
major O +
constituents O -
. O +

These O +
results O +
have O +
implications O +
not O +
only O +
for O +
clinical O +
research O +
in O +
natural O +
products O -
, O +
but O +
for O +
basic O +
science O -
, O +
as O +
well O +
as O +
the O +
dietary O +
supplements O +
industry O -
. O +

Design O +
and O +
synthesis O +
of O +
bicyclic B-Chemical +
pyrazinone I-Chemical +
and I-Chemical +
pyrimidinone I-Chemical +
amides I-Chemical +
as O +
potent O +
TF O -
- O -
FVIIa O +
inhibitors O -
. O +

Bicyclic B-Chemical +
pyrazinone I-Chemical +
and I-Chemical +
pyrimidinone I-Chemical +
amides I-Chemical +
were O +
designed O +
and O +
synthesized O +
as O +
potent O +
TF O -
- O -
FVIIa O +
inhibitors O -
. O +

SAR O +
demonstrated O +
that O +
the O +
S2 O +
and O +
S3 O +
pockets O +
of O +
FVIIa O +
prefer O +
to O +
bind O +
small O -
, O +
lipophilic O +
groups O -
. O +

An O +
X O -
- O -
ray O +
crystal O +
structure O +
of O +
optimized O +
compound O +
9b O +
bound O +
in O +
the O +
active O +
site O +
of O +
FVIIa O +
showed O +
that O +
the O +
bicyclic O +
scaffold O +
provides O +
5 O +
hydrogen B-Chemical +
bonding O +
interactions O +
in O +
addition O +
to O +
projecting O +
groups O +
for O +
interactions O +
within O +
the O +
S1 O -
, O +
S2 O +
and O +
S3 O +
pockets O -
. O +

Compound O +
9b O +
showed O +
excellent O +
FVIIa O +
potency O -
, O +
good O +
selectivity O +
against O +
FIXa O -
, O +
Xa O -
, O +
XIa O +
and O +
chymotrypsin O -
, O +
and O +
good O +
clotting O +
activity O -
. O +

Efficient O +
synthesis O +
of O +
anacardic B-Chemical +
acid I-Chemical +
analogues O +
and O +
their O +
antibacterial O +
activities O -
. O +

Anacardic B-Chemical +
acid I-Chemical +
derivatives O +
exhibit O +
a O +
broad O +
range O +
of O +
biological O +
activities O -
. O +

In O +
this O +
report O -
, O +
an O +
efficient O +
method O +
for O +
the O +
synthesis O +
of O +
anacardic B-Chemical +
acid I-Chemical +
derivatives O +
was O +
explored O -
, O +
and O +
a O +
small O +
set O +
of O +
salicylic B-Chemical +
acid I-Chemical +
variants O +
synthesised O +
retaining O +
a O +
constant O +
hydrophobic O +
element O +
( O -
a O +
naphthyl B-Chemical +
tail O -
) O -
. O +

The O +
naphthyl B-Chemical +
side O +
chain O +
was O +
introduced O +
via O +
Wittig O +
reaction O +
and O +
the O +
aldehyde B-Chemical +
installed O +
using O +
directed O +
ortho O -
- O -
metalation O +
reaction O +
of O +
the O +
substituted O +
o B-Chemical -
- I-Chemical -
anisic I-Chemical +
acids I-Chemical -
. O +

The O +
failure O +
of O +
ortho O -
- O -
metalation O +
using O +
unprotected O +
carboxylic B-Chemical +
acid I-Chemical +
group O +
compelled O +
us O +
to O +
use O +
directed O +
ortho O -
- O -
metalation O +
in O +
which O +
a O +
tertiary B-Chemical +
amide I-Chemical +
was O +
used O +
as O +
a O +
strong O +
ortho O -
- O -
directing O +
group O -
. O +

In O +
the O +
initial O +
route O -
, O +
tertiary B-Chemical +
amide I-Chemical +
cleavage O +
during O +
final O +
step O +
was O +
challenging O -
, O +
but O +
cleaving O +
the O +
tertiary B-Chemical +
amide I-Chemical +
before O +
Wittig O +
reaction O +
was O +
beneficial O -
. O +

The O +
Wittig O +
reaction O +
with O +
protected O +
carboxylic B-Chemical +
group O +
( O -
methyl B-Chemical +
ester I-Chemical -
) O +
resulted O +
in O +
side O -
- O -
products O +
whereas O +
using O +
sodium B-Chemical +
salt O +
resulted O +
in O +
higher O +
yields O -
. O +

The O +
novel O +
compounds O +
were O +
screened O +
for O +
antibacterial O +
activity O +
and O +
cytotoxicity O -
. O +

Although O +
substitution O +
on O +
the O +
salicylic B-Chemical +
head O +
group O +
enhanced O +
antibacterial O +
activities O +
they O +
also O +
enhanced O +
cytotoxicity O -
. O +

Substituted O +
piperidinyl B-Chemical +
glycinyl I-Chemical +
2-cyano-4,5-methano I-Chemical +
pyrrolidines I-Chemical +
as O +
potent O +
and O +
stable O +
dipeptidyl O +
peptidase O +
IV O +
inhibitors O -
. O +

Synthesis O +
and O +
structure O -
- O -
activity O +
relationship O +
of O +
a O +
series O +
of O +
substituted O +
piperidinyl B-Chemical +
glycine I-Chemical +
2-cyano-4,5-methano I-Chemical +
pyrroline I-Chemical +
DPP O -
- O -
IV O +
inhibitors O +
are O +
described O -
. O +

Improvement O +
of O +
the O +
inhibitory O +
activity O +
and O +
chemical O +
stability O +
of O +
this O +
series O +
of O +
compounds O +
was O +
respectively O +
achieved O +
by O +
the O +
introduction O +
of O +
bulky O +
groups O +
at O +
the O +
4-position O +
and O +
1-position O +
of O +
the O +
piperidinyl B-Chemical +
glycine I-Chemical -
, O +
leading O +
to O +
a O +
series O +
of O +
potent O +
and O +
stable O +
DPP O -
- O -
IV O +
inhibitors O -
. O +

A O +
multivalent O +
peptide O +
as O +
an O +
activator O +
of O +
hypoxia O +
inducible O +
factor-1α O -
. O +

Hypoxia O +
inducible O +
factor-1α O +
( O -
HIF-1α O -
) O +
is O +
a O +
transcription O +
factor O +
found O +
in O +
mammalian O +
cells O +
under O +
hypoxia O -
. O +

While O +
HIF-1α O +
in O +
hypoxia O +
translocates O +
to O +
the O +
nucleus O +
where O +
it O +
transcribes O +
the O +
target O +
genes O +
including O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
mRNA O -
, O +
HIF-1α O +
is O +
degraded O +
under O +
normoxia O -
, O +
which O +
involves O +
its O +
proline B-Chemical +
hydroxylation O +
and O +
subsequent O +
binding O +
to O +
the O +
von O +
Hippel O -
- O -
Lindau O +
protein O -
- O -
Elongin O +
B O -
- O -
Elogin O +
C O +
( O -
VBC O -
) O +
complex O -
. O +

Previously O -
, O +
peptide O +
inhibitors O +
against O +
this O +
interaction O +
between O +
hydroxylated O +
HIF-1α O +
and O +
VBC O +
have O +
been O +
developed O +
to O +
stabilize O +
the O +
transcriptional O +
activity O +
of O +
HIF-1α O +
by O +
preventing O +
the O +
degradation O +
of O +
the O +
protein O +
even O +
under O +
normoxia O -
. O +

Despite O +
the O +
specific O +
inhibition O +
by O +
these O +
peptides O -
, O +
their O +
poor O +
inhibition O +
potency O +
needs O +
to O +
be O +
improved O +
for O +
further O +
clinical O +
application O -
. O +

In O +
this O +
work O -
, O +
we O +
have O +
designed O +
and O +
prepared O +
a O +
streptavidin O -
- O -
based O +
multivalent O +
peptide O +
inhibitor O +
against O +
the O +
HIF-1α O -
- O -
VBC O +
complexation O -
. O +

We O +
have O +
evaluated O +
the O +
potency O +
of O +
the O +
multivalent O +
peptide O +
in O +
terms O +
of O +
stabilization O +
of O +
HIF-1α O +
and O +
the O +
downstream O +
effect O -
. O +

As O +
the O +
result O -
, O +
we O +
have O +
found O +
that O +
the O +
inhibitor O +
showed O +
about O +
13-fold O +
lowered O +
IC50 O +
value O +
compared O +
with O +
that O +
of O +
the O +
corresponding O +
monovalent O +
peptide O -
, O +
thereby O +
activating O +
HIF-1α O +
and O +
leading O +
to O +
up O -
- O -
regulation O +
of O +
VEGF O +
protein O +
at O +
the O +
cellular O +
level O -
. O +

The O +
α3β4 O -
* O +
nicotinic O +
acetylcholine B-Chemical +
receptor O +
subtype O +
mediates O +
nicotine B-Chemical +
reward O +
and O +
physical O +
nicotine B-Chemical +
withdrawal O +
signs O +
independently O +
of O +
the O +
α5 O +
subunit O +
in O +
the O +
mouse O -
. O +

The O +
15q25 O +
gene O +
cluster O +
contains O +
genes O +
that O +
code O +
for O +
the O +
α5 O -
, O +
α3 O -
, O +
and O +
β4 O +
nicotinic O +
acetylcholine B-Chemical +
receptor O +
( O -
nAChRs O -
) O +
subunits O -
, O +
and O +
in O +
human O +
genetic O +
studies O -
, O +
has O +
shown O +
the O +
most O +
robust O +
association O +
with O +
smoking O +
behavior O +
and O +
nicotine B-Chemical +
dependence O +
to O +
date O -
. O +

The O +
limited O +
available O +
animal O +
studies O +
implicate O +
a O +
role O +
for O +
the O +
α5 O +
and O +
β4 O +
nAChR O +
subunits O +
in O +
nicotine B-Chemical +
dependence O +
and O +
withdrawal O -
; O +
however O +
studies O +
focusing O +
on O +
the O +
behavioral O +
role O +
of O +
the O +
α3β4 O -
* O +
nAChR O +
receptor O +
subtype O +
in O +
nicotine B-Chemical +
dependence O +
are O +
lacking O -
. O +

Because O +
of O +
the O +
apparent O +
role O +
of O +
the O +
α3β4 O -
* O +
nAChR O +
subtype O +
in O +
nicotine B-Chemical +
dependence O -
, O +
the O +
goal O +
of O +
the O +
current O +
study O +
was O +
to O +
better O +
evaluate O +
the O +
involvement O +
of O +
this O +
subtype O +
in O +
nicotine B-Chemical +
mediated O +
behavioral O +
responses O -
. O +

Using O +
the O +
selective O +
α3β4 O -
* O +
nAChR O +
antagonist O -
, O +
α O -
- O -
conotoxin O +
AuIB O -
, O +
we O +
assessed O +
the O +
role O +
of O +
α3β4 O -
* O +
nAChRs O +
in O +
acute O +
nicotine B-Chemical -
, O +
nicotine B-Chemical +
reward O -
, O +
and O +
physical O +
and O +
affective O +
nicotine B-Chemical +
withdrawal O -
. O +

Because O +
α5 O +
has O +
also O +
been O +
implicated O +
in O +
nicotine B-Chemical +
dependence O +
behaviors O +
in O +
mice O +
and O +
can O +
form O +
functional O +
receptors O +
with O +
α3β4 O -
* O -
, O +
we O +
also O +
evaluated O +
the O +
role O +
of O +
the O +
α3β4α5 O -
* O +
nAChR O +
subtype O +
in O +
nicotine B-Chemical +
reward O +
and O +
somatic O +
nicotine B-Chemical +
withdrawal O +
signs O +
by O +
blocking O +
the O +
α3β4 O -
* O +
nAChR O +
subtype O +
in O +
α5 O +
nAChR O +
knockout O +
mice O +
with O +
AuIB O -
. O +

AuIB O +
had O +
no O +
significant O +
effect O +
on O +
acute O +
nicotine B-Chemical +
behaviors O -
, O +
but O +
dose O -
- O -
dependently O +
attenuated O +
nicotine B-Chemical +
reward O +
and O +
physical O +
withdrawal O +
signs O -
, O +
with O +
no O +
significant O +
effect O +
in O +
affective O +
withdrawal O +
measures O -
. O +

Interestingly O -
, O +
AuIB O +
also O +
attenuated O +
nicotine B-Chemical +
reward O +
and O +
somatic O +
signs O +
in O +
α5 O +
nAChR O +
knockout O +
mice O -
. O +

This O +
study O +
shows O +
that O +
α3β4 O -
* O +
nAChRs O +
mediate O +
nicotine B-Chemical +
reward O +
and O +
physical O +
nicotine B-Chemical +
withdrawal O -
, O +
but O +
not O +
acute O +
nicotine B-Chemical +
behaviors O +
or O +
affective O +
nicotine B-Chemical +
withdrawal O +
signs O +
in O +
mice O -
. O +

The O +
α5 O +
subunit O +
is O +
not O +
required O +
in O +
the O +
receptor O +
assembly O +
to O +
mediate O +
these O +
effects O -
. O +

Our O +
findings O +
suggest O +
an O +
important O +
role O +
for O +
the O +
α3β4 O -
* O +
nAChR O +
subtype O +
in O +
nicotine B-Chemical +
reward O +
and O +
physical O +
aspects O +
of O +
the O +
nicotine B-Chemical +
withdrawal O +
syndrome O -
. O +

Human O +
serum O +
albumin O -
- O -
based O +
design O +
of O +
a O +
diflunisal B-Chemical +
prodrug O -
. O +

The O +
cyclooxygenase-2 O +
inhibitor O -
, O +
diflunisal B-Chemical -
, O +
is O +
used O +
in O +
the O +
clinic O +
for O +
its O +
anti O -
- O -
inflammatory O +
activity O -
. O +

About O +
99 O -
% O +
of O +
a O +
dose O +
of O +
diflunisal B-Chemical +
is O +
unavailable O +
for O +
reaction O +
with O +
the O +
target O +
enzyme O -
, O +
because O +
diflunisal B-Chemical +
strongly O +
binds O +
to O +
human O +
serum O +
albumin O +
( O -
HSA O -
) O -
. O +

To O +
reduce O +
the O +
binding O +
affinity O +
of O +
diflunisal B-Chemical +
to O +
albumin O -
, O +
we O +
designed O +
and O +
synthesized O +
the O +
prodrug O +
acetyldiflunisal B-Chemical -
. O +

The O +
crystal O +
structure O +
of O +
HSA O +
complexed O +
with O +
fatty B-Chemical +
acid I-Chemical +
and O +
acetyldiflunisal B-Chemical +
revealed O +
that O +
acetyldiflunisal B-Chemical +
binds O +
to O +
the O +
IIA O +
subdomain O +
and O +
that O +
upon O +
binding O -
, O +
it O +
acetylates O +
lysine B-Chemical +
199 O -
. O +

Mass O +
spectrometry O +
confirmed O +
that O +
acetyldiflunisal B-Chemical +
acetylates O +
Lys199 B-Chemical -
. O +

The O +
acetylated O +
albumin O +
had O +
twofold O +
weaker O +
binding O +
affinity O +
for O +
diflunisal B-Chemical +
as O +
demonstrated O +
by O +
fluorescence O +
quenching O -
. O +

Reduced O +
binding O +
affinity O +
means O +
that O +
diflunisal B-Chemical +
is O +
more O +
easily O +
released O +
from O +
acetylated O +
albumin O +
into O +
the O +
circulation O -
. O +

Therefore O -
, O +
lower O +
doses O +
of O +
acetyldiflunisal B-Chemical +
compared O +
to O +
diflunisal B-Chemical +
will O +
be O +
required O -
. O +

Taken O +
together O -
, O +
our O +
results O +
not O +
only O +
provide O +
a O +
template O +
for O +
design O +
of O +
HSA O -
- O -
based O +
prodrugs O -
, O +
but O +
also O +
pave O +
the O +
way O +
toward O +
more O +
effective O +
use O +
of O +
diflunisal B-Chemical +
in O +
the O +
clinic O -
. O +

Molecular O +
phylogeny O +
of O +
the O +
Indian O +
Ocean O +
Terpsiphone O +
paradise O +
flycatchers O -
: O +
Undetected O +
evolutionary O +
diversity O +
revealed O +
amongst O +
island O +
populations O -
. O +

We O +
construct O +
a O +
molecular O +
phylogeny O +
of O +
Terpsiphone O +
flycatchers O +
of O +
the O +
Indian O +
Ocean O +
and O +
use O +
this O +
to O +
investigate O +
their O +
evolutionary O +
relationships O -
. O +

A O +
total O +
of O +
4.4 O -
kb O +
of O +
mitochondrial O +
( O -
cyt O -
- O -
b O -
, O +
ND3 O -
, O +
ND2 O -
, O +
control O +
region O -
) O +
and O +
nuclear O +
( O -
G3PDH O -
, O +
MC1R O -
) O +
sequence O +
data O +
were O +
obtained O +
from O +
all O +
species O -
, O +
sub O -
- O -
species O +
and O +
island O +
populations O +
of O +
the O +
region O -
. O +

Colonisation O +
of O +
the O +
western O +
Indian O +
Ocean O +
has O +
been O +
within O +
the O +
last O +
two O +
million O +
years O +
and O +
greatly O +
postdates O +
the O +
formation O +
of O +
the O +
older O +
islands O +
of O +
the O +
region O -
. O +

A O +
minimum O +
of O +
two O +
independent O +
continent O -
- O -
island O +
colonisation O +
events O +
must O +
have O +
taken O +
place O +
in O +
order O +
to O +
explain O +
the O +
current O +
distribution O +
and O +
phylogenetic O +
placement O +
of O +
Terpsiphone O +
in O +
this O +
region O -
. O +

While O +
five O +
well O -
- O -
diverged O +
Indian O +
Ocean O +
clades O +
are O +
detected O -
, O +
the O +
relationship O +
between O +
them O +
is O +
unclear O -
. O +

Short O +
intermodal O +
branches O +
are O +
indicative O +
of O +
rapid O +
range O +
expansion O +
across O +
the O +
region O -
, O +
masking O +
exact O +
routes O +
and O +
chronology O +
of O +
colonisation O -
. O +

The O +
Indian O +
Ocean O +
Terpsiphone O +
taxa O +
fall O +
into O +
five O +
well O +
supported O +
clades O -
, O +
two O +
of O +
which O +
( O -
the O +
Seychelles O +
paradise O +
flycatcher O +
and O +
the O +
Mascarene O +
paradise O +
flycatcher O -
) O +
correspond O +
with O +
currently O +
recognised O +
species O -
, O +
whilst O +
a O +
further O +
three O +
( O -
within O +
the O +
Madagascar O +
paradise O +
flycatcher O -
) O +
are O +
not O +
entirely O +
predicted O +
by O +
taxonomy O -
, O +
and O +
are O +
neither O +
consistent O +
with O +
distance O -
- O -
based O +
nor O +
island O +
age O -
- O -
based O +
models O +
of O +
colonisation O -
. O +

We O +
identify O +
the O +
four O +
non O -
- O -
Mascarene O +
clades O +
as O +
Evolutionarily O +
Significant O +
Units O +
( O -
ESUs O -
) O -
, O +
while O +
the O +
Mascarene O +
paradise O +
flycatcher O +
contains O +
two O +
ESUs O +
corresponding O +
to O +
the O +
Mauritius O +
and O +
Réunion O +
subspecies O -
. O +

All O +
six O +
ESUs O +
are O +
sufficiently O +
diverged O +
to O +
be O +
worthy O +
of O +
management O +
as O +
if O +
they O +
were O +
separate O +
species O -
. O +

This O +
phylogenetic O +
reconstruction O +
highlights O +
the O +
importance O +
of O +
sub O -
- O -
specific O +
molecular O +
phylogenetic O +
reconstructions O +
in O +
complex O +
island O +
archipelago O +
settings O +
in O +
clarifying O +
phylogenetic O +
history O +
and O +
ESUs O +
that O +
may O +
otherwise O +
be O +
overlooked O +
and O +
inadvertently O +
lost O -
. O +

Our O +
phylogenetic O +
reconstruction O +
has O +
identified O +
hidden O +
pockets O +
of O +
evolutionary O +
distinctiveness O -
, O +
which O +
provide O +
a O +
valuable O +
platform O +
upon O +
which O +
to O +
re O -
- O -
evaluate O +
investment O +
of O +
conservation O +
resources O +
within O +
the O +
Terpsiphone O +
flycatchers O +
of O +
the O +
Indian O +
Ocean O -
. O +

Improving O +
correlated O +
SERS O +
measurements O +
with O +
scanning O +
electron O +
microscopy O -
: O +
an O +
assessment O +
of O +
the O +
problem O +
arising O +
from O +
the O +
deposition O +
of O +
amorphous O +
carbon B-Chemical -
. O +

For O +
surface O -
- O -
enhanced O +
Raman O +
scattering O +
( O -
SERS O -
) O +
substrates O +
with O +
nonspherical O +
symmetry O -
, O +
it O +
is O +
critical O +
to O +
correlate O +
spectroscopy O +
measurements O +
with O +
imaging O +
by O +
scanning O +
electron O +
microscopy O +
( O -
SEM O -
) O -
. O +

However O -
, O +
the O +
deposition O +
of O +
carbon B-Chemical +
resulting O +
from O +
e O -
- O -
beam O +
exposure O +
during O +
SEM O +
imaging O +
contaminates O +
the O +
surface O +
of O +
nanoparticles O -
, O +
potentially O +
preventing O +
their O +
further O +
functionalization O +
with O +
Raman O +
probe O +
molecules O -
. O +

In O +
addition O -
, O +
the O +
deposited O +
carbon B-Chemical +
leads O +
to O +
unwanted O +
background O +
SERS O +
signals O -
. O +

In O +
this O +
study O -
, O +
we O +
systematically O +
investigated O +
the O +
deposition O +
of O +
carbon B-Chemical +
during O +
SEM O +
imaging O +
and O +
examined O +
how O +
it O +
affects O +
the O +
functionalization O +
of O +
nanoparticles O +
with O +
probe O +
molecules O +
and O +
impacts O +
the O +
detection O +
of O +
SERS O +
signals O -
. O +

Significantly O -
, O +
we O +
found O +
that O +
the O +
carbon B-Chemical +
could O +
be O +
removed O +
or O +
replaced O +
from O +
the O +
surface O +
of O +
Ag B-Chemical +
nanoparticles O +
through O +
chemical O +
or O +
physical O +
means O -
, O +
rendering O +
the O +
nanoparticles O +
the O +
capability O +
for O +
correlated O +
SEM O -
/ O -
SERS O +
studies O -
. O +

The O +
first O +
report O +
on O +
some O +
toxic O +
effects O +
of O +
green O +
scat O -
, O +
Scatophagus O +
argus O +
an O +
Iranian O +
Persian O +
Gulf O +
venomous O +
fish O -
. O +

Green O +
scat O +
namely O +
as O +
Scatophagus O +
argus O +
is O +
a O +
venomous O +
aquarium O +
fish O +
belonging O +
to O +
Scatophagidae O +
family O -
. O +

It O +
can O +
induce O +
painful O +
wounds O +
in O +
injured O +
hand O +
with O +
partial O +
paralysis O +
to O +
whom O +
that O +
touch O +
the O +
spines O -
. O +

Dorsal O +
and O +
ventral O +
rough O +
spines O +
contain O +
cells O +
that O +
produce O +
venom O +
with O +
toxic O +
activities O -
. O +

According O +
to O +
unpublished O +
data O +
collected O +
from O +
local O +
hospitals O +
in O +
southern O +
coastal O +
region O +
of O +
Iran O -
, O +
S. O +
argus O +
is O +
reported O +
as O +
a O +
venomous O +
fish O -
. O +

Envenomation O +
induces O +
clinical O +
symptoms O +
such O +
as O +
local O +
pain O -
, O +
partial O +
paralysis O -
, O +
erythema O +
and O +
itching O -
. O +

In O +
the O +
present O +
study O +
green O +
scat O +
( O -
spotted O +
scat O -
) O +
was O +
collected O +
from O +
Persian O +
Gulf O +
coastal O +
waters O -
. O +

SDS B-Chemical -
- O -
PAGE O +
indicated O +
12 O +
distinct O +
bands O +
in O +
the O +
venom O +
ranged O +
between O +
7 O +
and O +
250 O +
kDa O -
. O +

The O +
crude O +
venom O +
had O +
hemolytic O +
activity O +
on O +
human O +
erythrocytes O +
( O -
1 O -
% O -
) O +
with O +
an O +
LC100 O +
( O -
Lytic O +
Concentration O -
) O +
of O +
about O +
1.7 O +
μg O -
. O +

The O +
crude O +
venom O +
can O +
release O +
813 O +
μg O +
protein O +
from O +
0.5 O -
% O +
casein O -
. O +

Phospholipase O +
C O +
activity O +
was O +
recorded O +
at O +
3.125 O +
μg O +
of O +
total O +
venom O -
. O +

Our O +
findings O +
showed O +
that O +
the O +
edematic O +
activity O +
remained O +
over O +
24 O +
h O +
after O +
injection O -
. O +

The O +
results O +
demonstrated O +
that O +
crude O +
venom O +
extracted O +
from O +
Iranian O +
coastal O +
border O +
has O +
different O +
toxic O +
and O +
enzymatic O +
activities O -
. O +

This O +
study O +
is O +
pending O +
to O +
further O +
investigation O +
on O +
animal O +
model O +
regarding O +
protein O +
purification O +
and O +
in O +
vivo O +
studies O -
. O +

Chimera O +
of O +
IL-2 O +
Linked O +
to O +
Light O +
Chain O +
of O +
anti O -
- O -
IL-2 O +
mAb O +
Mimics O +
IL-2 O -
/ O -
anti O -
- O -
IL-2 O +
mAb O +
Complexes O +
Both O +
Structurally O +
and O +
Functionally O -
. O +

IL-2 O -
/ O -
anti O -
- O -
IL-2 O +
mAb O +
immunocomplexes O +
were O +
described O +
to O +
have O +
dramatically O +
higher O +
activity O +
than O +
free O +
IL-2 O +
in O +
vivo O -
. O +

We O +
designed O +
protein O +
chimera O +
consisting O +
of O +
IL-2 O +
linked O +
to O +
light O +
chain O +
of O +
anti O -
- O -
IL-2 O +
mAb O +
S4B6 O +
through O +
flexible O +
oligopeptide O +
spacer O +
( O -
Gly4Ser O -
) O -
3 O -
. O +

This O +
protein O +
chimera O +
mimics O +
the O +
structure O +
of O +
IL-2 O -
/ O -
S4B6 O +
mAb O +
immunocomplexes O +
but O +
eliminates O +
general O +
disadvantages O +
of O +
immunocomplexes O +
like O +
possible O +
excess O +
of O +
either O +
IL-2 O +
or O +
anti O -
- O -
IL-2 O +
mAb O +
and O +
their O +
dissociation O +
to O +
antibody O +
and O +
IL-2 O +
at O +
low O +
concentrations O -
. O +

This O +
novel O +
kind O +
of O +
protein O +
chimera O +
is O +
characterized O +
by O +
an O +
intramolecular O +
interaction O +
between O +
IL-2 O +
and O +
binding O +
site O +
of O +
S4B6 O +
mAb O +
similarly O +
as O +
in O +
IL-2 O -
/ O -
S4B6 O +
mAb O +
immunocomplexes O -
. O +

Our O +
protein O +
chimera O +
has O +
biological O +
activity O +
comparable O +
to O +
IL-2 O -
/ O -
S4B6 O +
mAb O +
immunocomplexes O +
in O +
vitro O -
, O +
as O +
shown O +
by O +
stimulation O +
of O +
proliferation O +
of O +
purified O +
and O +
activated O +
OT O -
- O -
I O +
CD8 O -
( O -
+ O -
) O +
T O +
cells O -
. O +

The O +
protein O +
chimera O +
exerts O +
higher O +
stimulatory O +
activity O +
to O +
drive O +
expansion O +
of O +
purified O +
CFSE B-Chemical -
- O -
labeled O +
OT O -
- O -
I O +
CD8 O -
( O -
+ O -
) O +
T O +
cells O +
activated O +
by O +
an O +
injection O +
of O +
a O +
low O +
dose O +
of O +
SIINFEKL O +
peptide O +
than O +
IL-2 O -
/ O -
S4B6 O +
mAb O +
immunocomplexes O +
in O +
vivo O -
. O +

Infected O +
nail O +
plate O +
model O +
made O +
of O +
human O +
hair O +
keratin O +
for O +
evaluating O +
the O +
efficacy O +
of O +
different O +
topical O +
antifungal O +
formulations O +
against O +
Trichophyton O +
rubrum O +
in O +
vitro O -
. O +

A O +
novel O +
model O +
of O +
infected O +
nail O +
plate O +
for O +
testing O +
the O +
efficacy O +
of O +
topical O +
antifungal O +
formulations O +
has O +
been O +
developed O -
. O +

This O +
model O +
utilized O +
keratin O +
film O +
made O +
of O +
human O +
hair O +
keratin O +
as O +
a O +
nail O +
plate O +
model O -
. O +

Subsequent O +
to O +
infection O +
by O +
Trichophyton O +
rubrum O -
, O +
the O +
common O +
causative O +
agent O +
of O +
onychomycosis O -
, O +
keratin O +
films O +
as O +
infected O +
nail O +
plate O +
models O +
were O +
treated O +
with O +
selected O +
topical O +
formulations O -
, O +
that O +
is O +
cream O -
, O +
gel O -
, O +
and O +
nail O +
lacquer O -
. O +

Bovine O +
hoof O +
was O +
compared O +
to O +
keratin O +
film O -
. O +

In O +
contrast O +
to O +
the O +
common O +
antifungal O +
susceptibility O +
test O -
, O +
the O +
antifungal O +
drugs O +
tested O +
were O +
applied O +
as O +
ready O -
- O -
to O -
- O -
use O +
formulations O +
because O +
the O +
vehicle O +
may O +
modify O +
and O +
control O +
the O +
drug O +
action O +
both O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

Extrapolating O +
the O +
potency O +
of O +
an O +
antifungal O +
drug O +
from O +
an O +
in O +
vitro O +
susceptibility O +
test O +
only O +
would O +
not O +
be O +
representative O +
of O +
the O +
in O +
vivo O +
situation O +
since O +
these O +
drugs O +
are O +
applied O +
as O +
ready O -
- O -
to O -
- O -
use O +
formulations O -
, O +
for O +
example O +
as O +
a O +
nail O +
lacquer O -
. O +

Although O +
terbinafine B-Chemical +
has O +
been O +
acknowledged O +
to O +
be O +
the O +
most O +
effective O +
antifungal O +
agent O +
against O +
T. O +
rubrum O -
, O +
its O +
antifungal O +
efficacy O +
was O +
improved O +
by O +
its O +
incorporation O +
into O +
an O +
optimal O +
formulation O -
. O +

Different O +
gels O +
proved O +
superior O +
to O +
cream O -
. O +

Therefore O -
, O +
this O +
study O +
is O +
able O +
to O +
discriminate O +
between O +
efficacies O +
of O +
different O +
topical O +
antifungal O +
formulations O +
based O +
on O +
their O +
activities O +
against O +
T. O +
rubrum O -
. O +

Use O +
of O +
near O -
- O -
infrared O +
spectroscopy O +
to O +
quantify O +
drug O +
content O +
on O +
a O +
continuous O +
blending O +
process O -
: O +
Influence O +
of O +
mass O +
flow O +
and O +
rotation O +
speed O +
variations O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
develop O +
a O +
quantitative O +
Near O -
- O -
Infrared O +
( O -
NIR O -
) O +
method O +
which O +
monitors O +
the O +
homogeneity O +
of O +
a O +
pharmaceutical O +
formulation O +
coming O +
out O +
of O +
a O +
continuous O +
blender O -
. O +

For O +
this O +
purpose O -
, O +
a O +
NIR O +
diode O +
array O +
spectrometer O +
with O +
fast O +
data O +
acquisition O +
was O +
selected O -
. O +

Additionally O -
, O +
the O +
dynamic O +
aspects O +
of O +
a O +
continuous O +
blending O +
process O +
were O +
studied O -
; O +
the O +
results O +
showed O +
a O +
well O -
- O -
defined O +
cluster O +
for O +
the O +
steady O +
state O -
, O +
and O +
the O +
paths O +
for O +
the O +
start O -
- O -
up O +
and O +
emptying O +
stages O +
were O +
clearly O +
identified O -
. O +

The O +
end O +
point O +
of O +
the O +
start O -
- O -
up O +
phase O +
was O +
detected O +
by O +
moving O +
block O +
of O +
standard O +
deviation O -
, O +
relative O +
standard O +
deviation O -
, O +
and O +
principal O +
component O +
analysis O -
. O +

A O +
partial O +
least O +
square O +
( O -
PLS O -
) O +
model O +
was O +
generated O +
for O +
the O +
quantification O +
of O +
the O +
drug O -
, O +
with O +
a O +
standard O +
error O +
of O +
prediction O +
of O +
0.2 O -
% O +
m O -
/ O -
m O -
. O +

The O +
PLS O +
model O +
was O +
successfully O +
applied O +
for O +
monitoring O +
the O +
drug O +
level O +
at O +
the O +
outlet O +
of O +
the O +
continuous O +
blender O -
. O +

Furthermore O -
, O +
the O +
PLS O +
model O +
was O +
tested O +
under O +
different O +
flow O +
and O +
stirring O +
rates O -
. O +

Flow O +
and O +
stirring O +
rate O +
variations O +
caused O +
different O +
powder O +
flow O +
dynamics O -
, O +
which O +
were O +
reflected O +
on O +
the O +
NIR O +
measurements O -
. O +

Therefore O -
, O +
the O +
PLS O +
model O +
was O +
sensitive O +
to O +
changes O +
in O +
mass O +
flow O +
and O +
rotation O +
speeds O -
. O +

Charge O +
affects O +
the O +
oral O +
toxicity O +
of O +
poly B-Chemical -
( I-Chemical -
amidoamine I-Chemical -
) I-Chemical +
dendrimers O -
. O +

Poly B-Chemical -
( I-Chemical -
amidoamine I-Chemical -
) I-Chemical +
( O -
PAMAM B-Chemical -
) O +
dendrimers O +
have O +
been O +
evaluated O +
for O +
the O +
influence O +
of O +
surface O +
functionality O +
and O +
size O +
on O +
the O +
epithelial O +
barrier O +
of O +
the O +
gut O +
with O +
the O +
goal O +
of O +
identifying O +
safe O +
carriers O +
that O +
can O +
be O +
used O +
for O +
oral O +
drug O +
delivery O -
. O +

Limited O +
studies O +
are O +
conducted O +
to O +
date O -
, O +
however O -
, O +
to O +
assess O +
the O +
toxicity O +
of O +
PAMAM B-Chemical +
dendrimers O +
in O +
vivo O +
when O +
administered O +
by O +
the O +
oral O +
route O -
. O +

The O +
goal O +
of O +
this O +
research O +
was O +
to O +
conduct O +
an O +
oral O +
acute O +
toxicity O +
study O +
of O +
PAMAM B-Chemical +
dendrimers O +
as O +
a O +
function O +
of O +
size O +
and O +
charge O +
in O +
immune O +
competent O +
CD-1 O +
mice O -
. O +

Maximum O +
tolerated O +
doses O +
( O -
MTD O -
) O +
of O +
PAMAM B-Chemical +
dendrimers O +
as O +
a O +
function O +
of O +
size O +
and O +
surface O +
functionality O +
were O +
established O +
and O +
clinical O +
signs O +
of O +
toxicity O +
monitored O -
. O +

Results O +
demonstrate O +
that O +
positively O +
charged O +
dendrimers O +
caused O +
more O +
toxicity O -
, O +
whereas O +
their O +
anionic O +
counterparts O +
were O +
tolerated O +
at O +
ten O +
times O +
higher O +
doses O -
. O +

Severe O +
signs O +
of O +
toxicity O +
observed O +
for O +
large O +
( O -
G7 O -
) O +
cationic O +
amine- B-Chemical +
or O +
hydroxyl B-Chemical -
- O -
terminated O +
dendrimers O +
include O +
hemobilia O +
and O +
spleenomegaly O -
. O +

The O +
MTD O +
for O +
these O +
dendrimers O +
ranged O +
from O +
30mg O -
/ O -
kg O +
to O +
200mg O -
/ O -
kg O -
. O +

Anionic O +
G6.5 O +
or O +
smaller O +
molecular O +
weight O +
carboxyl- B-Chemical -
, O +
amine- B-Chemical -
, O +
or O +
hydroxyl B-Chemical -
- O -
terminated O +
dendrimers O +
( O -
G3.5-COOH O -
, O +
G4-NH2 O -
, O +
G4-OH O -
) O +
on O +
the O +
other O +
hand O +
were O +
tolerated O +
at O +
doses O +
of O +
up O +
to O +
500mg O -
/ O -
kg O +
( O -
300mg O -
/ O -
kg O +
in O +
some O +
cases O -
) O +
with O +
minimal O +
or O +
no O +
signs O +
of O +
toxicity O -
. O +

Establishing O +
the O +
MTD O +
of O +
orally O +
delivered O +
PAMAM B-Chemical +
dendrimers O +
and O +
the O +
influence O +
of O +
surface O +
functionality O +
and O +
size O +
on O +
toxicity O +
aids O +
in O +
the O +
rational O +
design O +
of O +
PAMAM B-Chemical -
- O -
drug O +
conjugates O +
for O +
oral O +
drug O +
delivery O +
applications O -
. O +

Modulation O +
of O +
mitochondrial O +
glutathione B-Chemical +
status O +
and O +
cellular O +
energetics O +
in O +
primary O +
cultures O +
of O +
proximal O +
tubular O +
cells O +
from O +
remnant O +
kidney O +
of O +
uninephrectomized O +
rats O -
. O +

Compensatory O +
renal O +
hypertrophy O +
following O +
reduction O +
in O +
renal O +
mass O +
leads O +
to O +
a O +
hypermetabolic O +
state O +
and O +
increases O +
in O +
basal O +
mitochondrial O +
oxidative O +
stress O +
and O +
susceptibility O +
to O +
several O +
nephrotoxicants O -
. O +

Previous O +
studies O +
provide O +
conflicting O +
data O +
on O +
whether O +
renal O +
mitochondria O +
after O +
reduction O +
in O +
renal O +
mass O +
undergo O +
proliferation O +
or O +
hypertrophy O +
or O +
both O -
. O +

In O +
the O +
present O +
study O -
, O +
our O +
goal O +
was O +
to O +
determine O +
whether O +
mitochondria O +
of O +
hypertrophied O +
kidney O +
undergo O +
hypertrophy O +
or O +
proliferation O +
after O +
uninephrectomy O +
using O +
the O +
uninephrectomized O +
( O -
NPX O -
) O +
rat O +
model O -
. O +

Renal O +
proximal O +
tubular O +
( O -
PT O -
) O +
cells O +
from O +
NPX O +
rats O +
exhibited O +
increased O +
mitochondrial O +
density O -
, O +
membrane O +
potential O +
and O +
protein O +
but O +
no O +
significant O +
difference O +
in O +
mitochondrial O +
DNA O -
, O +
as O +
compared O +
to O +
PT O +
cells O +
from O +
control O +
rats O -
. O +

Our O +
previous O +
studies O +
showed O +
that O +
overexpression O +
of O +
two O +
mitochondrial O +
anion O +
transporters O -
, O +
the O +
dicarboxylate B-Chemical +
( O -
DIC B-Chemical -
, O +
Slc25a10 O -
) O +
and O +
oxoglutarate B-Chemical +
( O -
OGC B-Chemical -
, O +
Slc25a11 O -
) O +
carriers O -
, O +
in O +
NRK-52E O +
cells O +
resulted O +
in O +
increased O +
mitochondrial O +
uptake O +
of O +
glutathione B-Chemical +
( O -
GSH B-Chemical -
) O +
and O +
protection O +
from O +
chemically O +
induced O +
apoptosis O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
overexpressed O +
DIC- B-Chemical +
and O +
OGC B-Chemical -
- O -
cDNA O +
plasmids O +
to O +
assess O +
their O +
function O +
in O +
renal O +
PT O +
cells O +
after O +
compensatory O +
renal O +
hypertrophy O -
. O +

PT O +
cells O +
from O +
NPX O +
rats O +
that O +
were O +
first O +
preincubated O +
with O +
GSH B-Chemical +
were O +
protected O +
from O +
cytotoxicity O +
due O +
to O +
the O +
mitochondrial O +
inhibitor O +
antimycin B-Chemical +
A I-Chemical +
by O +
overexpression O +
of O +
either O +
of O +
the O +
two O +
mitochondrial O +
GSH B-Chemical +
transporters O -
. O +

Our O +
present O +
results O +
provide O +
further O +
evidence O +
that O +
compensatory O +
renal O +
hypertrophy O +
is O +
associated O +
primarily O +
with O +
mitochondrial O +
hypertrophy O +
and O +
hyperpolarization O +
and O +
that O +
manipulation O +
of O +
mitochondrial O +
GSH B-Chemical +
transporters O +
in O +
PT O +
cells O +
of O +
hypertrophied O +
kidney O +
can O +
alter O +
susceptibility O +
to O +
chemically O +
induced O +
injury O +
under O +
appropriate O +
conditions O +
and O +
may O +
be O +
a O +
suitable O +
therapeutic O +
approach O -
. O +

Screening O +
of O +
transition O +
and O +
post O -
- O -
transition O +
metals O +
to O +
incorporate O +
into O +
copper B-Chemical +
oxide I-Chemical +
and O +
copper B-Chemical +
bismuth I-Chemical +
oxide I-Chemical +
for O +
photoelectrochemical O +
hydrogen B-Chemical +
evolution O -
. O +

A O +
new O +
dispenser O +
and O +
scanner O +
system O +
is O +
used O +
to O +
create O +
and O +
screen O +
Bi B-Chemical -
- O -
M O -
- O -
Cu B-Chemical +
oxide B-Chemical +
arrays O +
for O +
cathodic O +
photoactivity O -
, O +
where O +
M O +
represents O +
1 O +
of O +
22 O +
different O +
transition O +
and O +
post O -
- O -
transition O +
metals O -
. O +

Over O +
3000 O +
unique O +
Bi B-Chemical +
: O +
M O +
: O +
Cu B-Chemical +
atomic O +
ratios O +
are O +
screened O -
. O +

Of O +
the O +
22 O +
metals O +
tested O -
, O +
10 O +
show O +
a O +
M O -
- O -
Cu B-Chemical +
oxide I-Chemical +
with O +
higher O +
photoactivity O +
than O +
CuO B-Chemical +
and O +
10 O +
show O +
a O +
Bi B-Chemical -
- O -
M O -
- O -
Cu B-Chemical +
oxide B-Chemical +
with O +
higher O +
photoactivity O +
than O +
CuBi2O4 B-Chemical -
. O +

Cd B-Chemical -
, O +
Zn B-Chemical -
, O +
Sn B-Chemical -
, O +
and O +
Co B-Chemical +
produce O +
the O +
most O +
photoactive O +
M O -
- O -
Cu B-Chemical +
oxides B-Chemical -
, O +
all O +
showing O +
a O +
200 O -
- O -
300 O -
% O +
improvement O +
in O +
photocurrent O +
over O +
CuO. B-Chemical +
Ag B-Chemical -
, O +
Cd B-Chemical -
, O +
and O +
Zn B-Chemical +
produce O +
the O +
highest O +
photoactivity O +
Bi B-Chemical -
- O -
M O -
- O -
Cu B-Chemical +
oxides B-Chemical +
with O +
a O +
200 O -
- O -
400 O -
% O +
improvement O +
over O +
CuBi2O4 B-Chemical -
. O +

Most O +
notable O +
is O +
a O +
Bi B-Chemical -
- I-Chemical -
Ag I-Chemical -
- I-Chemical -
Cu I-Chemical +
oxide I-Chemical +
( O -
Bi B-Chemical +
: O +
Ag B-Chemical +
: O +
Cu B-Chemical +
atomic O +
ratio O +
of O +
22 O +
: O +
3 O +
: O +
11 O -
) O +
which O +
shows O +
4 O +
times O +
higher O +
photocurrent O +
than O +
CuBi2O4 B-Chemical -
. O +

This O +
material O +
is O +
capable O +
of O +
evolving O +
hydrogen B-Chemical +
under O +
illumination O +
in O +
neutral O +
electrolyte O +
solutions O +
at O +
0.6 O +
V O +
vs. O +
RHE O +
when O +
Pt B-Chemical +
is O +
added O +
to O +
the O +
surface O +
as O +
an O +
electrocatalyst O -
. O +

Glyconanosomes O -
: O +
disk O -
- O -
shaped O +
nanomaterials O +
for O +
the O +
water O +
solubilization O +
and O +
delivery O +
of O +
hydrophobic O +
molecules O -
. O +

Herein O -
, O +
we O +
describe O +
the O +
first O +
report O +
on O +
a O +
new O +
class O +
of O +
disk O -
- O -
shaped O +
and O +
quite O +
monodisperse O +
water O -
- O -
soluble O +
nanomaterials O +
that O +
we O +
named O +
glyconanosomes O +
( O -
GNS O -
) O -
. O +

GNSs O +
were O +
obtained O +
by O +
sliding O +
out O +
the O +
cylindrical O +
structures O +
formed O +
upon O +
self O -
- O -
organization O +
and O +
photopolymerization O +
of O +
glycolipid O +
1 O +
on O +
single O -
- O -
walled O +
carbon O +
nanotube O +
( O -
SWCNT O -
) O +
sidewalls O -
. O +

GNSs O +
present O +
a O +
sheltered O +
hydrophobic O +
inner O +
cavity O +
formed O +
by O +
the O +
carbonated O +
tails O -
, O +
surrounded O +
by O +
PEG B-Chemical +
and O +
lactose O +
moieties O -
. O +

The O +
amphiphilic O +
character O +
of O +
GNSs O +
allows O +
the O +
water O +
solubility O +
of O +
insoluble O +
hydrophobic O +
cargos O +
such O +
as O +
a O +
perylene B-Chemical -
- I-Chemical -
bisimide I-Chemical +
derivative O -
, O +
[ B-Chemical -
60 I-Chemical -
] I-Chemical -
fullerene I-Chemical -
, O +
or O +
the O +
anti O -
- O -
carcinogenic O +
drug O +
camptothecin B-Chemical +
( O -
CPT B-Chemical -
) O -
. O +

GNS O -
/ O -
C60 B-Chemical +
inclusion O +
complexes O +
are O +
able O +
to O +
establish O +
specific O +
interactions O +
between O +
peanut O +
agglutinin O +
( O -
PNA O -
) O +
lectin O +
and O +
the O +
lactose O +
moiety O +
surrounding O +
the O +
complexes O -
, O +
while O +
CPT B-Chemical +
solubilized O +
by O +
GNS O +
shows O +
higher O +
cytotoxicity O +
toward O +
MCF7-type O +
breast O +
cancer O +
cells O +
than O +
CPT B-Chemical +
alone O -
. O +

Thus O -
, O +
GNS O +
represents O +
an O +
attractive O +
extension O +
of O +
nanoparticle O -
- O -
based O +
drug O +
delivery O +
systems O -
. O +

Three O +
new O +
lanostanoid B-Chemical +
triterpenes I-Chemical +
from O +
the O +
fruiting O +
bodies O +
of O +
Ganoderma O +
tropicum O -
. O +

Three O +
new O +
lanostanoid B-Chemical +
triterpenes I-Chemical -
, O +
3β,7β,15β B-Chemical -
- I-Chemical -
trihydroxy-11,23-dioxo I-Chemical -
- I-Chemical -
lanost-8,16-dien-26-oic I-Chemical +
acid I-Chemical +
( O -
1 O -
) O -
, O +
3β,7β,15β B-Chemical -
- I-Chemical -
trihydroxy-11,23-dioxo I-Chemical -
- I-Chemical -
lanost-8,16-dien-26-oic I-Chemical +
acid I-Chemical +
methyl I-Chemical +
ester I-Chemical +
( O -
2 O -
) O -
, O +
and O +
3β,15β B-Chemical -
- I-Chemical -
dihydroxy-7,11,23-trioxo I-Chemical -
- I-Chemical -
lanost-8,16-dien-26-oic I-Chemical +
acid I-Chemical +
methyl I-Chemical +
ester I-Chemical +
( O -
3 O -
) O +
were O +
isolated O +
from O +
the O +
EtOAc B-Chemical +
extract O +
of O +
the O +
fruiting O +
bodies O +
of O +
Ganoderma O +
tropicum O -
. O +

Their O +
structures O +
were O +
elucidated O +
on O +
the O +
basis O +
of O +
1D O +
and O +
2D O +
NMR O +
spectroscopy O +
as O +
well O +
as O +
MS O -
. O +

The O +
bioassay O +
of O +
inhibitory O +
activity O +
against O +
acetylcholinesterase O +
( O -
AChE O -
) O +
of O +
these O +
isolates O +
was O +
evaluated O +
and O +
compound O +
2 O +
exhibited O +
definite O +
inhibitory O +
activity O +
against O +
AChE. O +

Strategies O +
to O +
control O +
morphology O +
in O +
hybrid O +
group O +
III O -
- O -
V O -
/ O -
group O +
IV O +
heterostructure O +
nanowires O -
. O +

By O +
combining O +
in O +
situ O +
and O +
ex O +
situ O +
transmission O +
electron O +
microscopy O +
measurements O -
, O +
we O +
examine O +
the O +
factors O +
that O +
control O +
the O +
morphology O +
of O +
" O -
hybrid O -
" O +
nanowires O +
that O +
include O +
group O +
III O -
- O -
V O +
and O +
group O +
IV O +
materials O -
. O +

We O +
focus O +
on O +
one O +
materials O +
pair O -
, O +
GaP B-Chemical -
/ O -
Si B-Chemical -
, O +
for O +
which O +
we O +
use O +
a O +
wide O +
range O +
of O +
growth O +
parameters O -
. O +

We O +
show O +
through O +
video O +
imaging O +
that O +
nanowire O +
morphology O +
depends O +
on O +
growth O +
conditions O -
, O +
but O +
that O +
a O +
general O +
pattern O +
emerges O +
where O +
either O +
single O +
kinks O +
or O +
inclined O +
defects O +
form O +
some O +
distance O +
after O +
the O +
heterointerface O -
. O +

We O +
show O +
that O +
pure O +
Si B-Chemical +
nanowires O +
can O +
be O +
made O +
to O +
exhibit O +
the O +
same O +
kinks O +
and O +
defects O +
by O +
changing O +
their O +
droplet O +
volume O -
. O +

From O +
this O +
we O +
derive O +
a O +
model O +
where O +
droplet O +
geometry O +
drives O +
growth O +
morphology O +
and O +
discuss O +
optimization O +
strategies O -
. O +

We O +
finally O +
discuss O +
morphology O +
control O +
for O +
material O +
pairs O +
where O +
the O +
second O +
material O +
kinks O +
immediately O +
at O +
the O +
heterointerface O +
and O +
show O +
that O +
an O +
interlayer O +
between O +
segments O +
can O +
enable O +
the O +
growth O +
of O +
unkinked O +
hybrid O +
nanowires O -
. O +

Molecular O +
tweezers O +
modulate O +
14 O -
- O -
3 O -
- O -
3 O +
protein O -
- O -
protein O +
interactions O -
. O +

Supramolecular O +
chemistry O +
has O +
recently O +
emerged O +
as O +
a O +
promising O +
way O +
to O +
modulate O +
protein O +
functions O -
, O +
but O +
devising O +
molecules O +
that O +
will O +
interact O +
with O +
a O +
protein O +
in O +
the O +
desired O +
manner O +
is O +
difficult O +
as O +
many O +
competing O +
interactions O +
exist O +
in O +
a O +
biological O +
environment O +
( O -
with O +
solvents O -
, O +
salts O +
or O +
different O +
sites O +
for O +
the O +
target O +
biomolecule O -
) O -
. O +

We O +
now O +
show O +
that O +
lysine B-Chemical -
- O -
specific O +
molecular O +
tweezers O +
bind O +
to O +
a O +
14 O -
- O -
3 O -
- O -
3 O +
adapter O +
protein O +
and O +
modulate O +
its O +
interaction O +
with O +
partner O +
proteins O -
. O +

The O +
tweezers O +
inhibit O +
binding O +
between O +
the O +
14 O -
- O -
3 O -
- O -
3 O +
protein O +
and O +
two O +
partner O +
proteins O -
-- O -
a O +
phosphorylated O +
( O -
C O -
- O -
Raf O -
) O +
protein O +
and O +
an O +
unphosphorylated O +
one O +
( O -
ExoS O -
) O -
--in O +
a O +
concentration O -
- O -
dependent O +
manner O -
. O +

Protein O +
crystallography O +
shows O +
that O +
this O +
effect O +
arises O +
from O +
the O +
binding O +
of O +
the O +
tweezers O +
to O +
a O +
single O +
surface O -
- O -
exposed O +
lysine B-Chemical +
( O -
Lys214 B-Chemical -
) O +
of O +
the O +
14 O -
- O -
3 O -
- O -
3 O +
protein O +
in O +
the O +
proximity O +
of O +
its O +
central O +
channel O -
, O +
which O +
normally O +
binds O +
the O +
partner O +
proteins O -
. O +

A O +
combination O +
of O +
structural O +
analysis O +
and O +
computer O +
simulations O +
provides O +
rules O +
for O +
the O +
tweezers O -
' O +
binding O +
preferences O -
, O +
thus O +
allowing O +
us O +
to O +
predict O +
their O +
influence O +
on O +
this O +
type O +
of O +
protein O -
- O -
protein O +
interactions O -
. O +

SIRT1 O +
inhibits O +
NADPH B-Chemical +
oxidase O +
activation O +
and O +
protects O +
endothelial O +
function O +
in O +
the O +
rat O +
aorta O -
: O +
Implications O +
for O +
vascular O +
aging O -
. O +

Vascular O +
aging O +
is O +
characterized O +
by O +
up O -
- O -
regulation O +
of O +
NADPH B-Chemical +
oxidase O -
, O +
oxidative O +
stress O +
and O +
endothelial O +
dysfunction O -
. O +

Previous O +
studies O +
demonstrate O +
that O +
the O +
activity O +
of O +
the O +
evolutionarily O +
conserved O +
NAD B-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical -
-dependent O +
deacetylase O +
SIRT1 O +
declines O +
with O +
age O +
and O +
that O +
pharmacological O +
activators O +
of O +
SIRT1 O +
confer O +
significant O +
anti O -
- O -
aging O +
cardiovascular O +
effects O -
. O +

To O +
determine O +
whether O +
dysregulation O +
of O +
SIRT1 O +
promotes O +
NADPH B-Chemical +
oxidase O -
- O -
dependent O +
production O +
of O +
reactive O +
oxygen B-Chemical +
species O +
( O -
ROS O -
) O +
and O +
impairs O +
endothelial O +
function O +
we O +
assessed O +
the O +
effects O +
of O +
three O +
structurally O +
different O +
inhibitors O +
of O +
SIRT1 O +
( O -
nicotinamide B-Chemical -
, O +
sirtinol B-Chemical -
, O +
EX527 B-Chemical -
) O +
in O +
aorta O +
segments O +
isolated O +
from O +
young O +
Wistar O +
rats O -
. O +

Inhibition O +
of O +
SIRT1 O +
induced O +
endothelial O +
dysfunction O -
, O +
as O +
shown O +
by O +
the O +
significantly O +
reduced O +
relaxation O +
to O +
the O +
endothelium O -
- O -
dependent O +
vasodilators O +
acetylcholine B-Chemical +
and O +
the O +
calcium B-Chemical +
ionophore O +
A23187 B-Chemical -
. O +

Endothelial O +
dysfunction O +
induced O +
by O +
SIRT1 O +
inhibition O +
was O +
prevented O +
by O +
treatment O +
of O +
the O +
vessels O +
with O +
the O +
NADPH B-Chemical +
oxidase O +
inhibitor O +
apocynin B-Chemical +
or O +
superoxide B-Chemical +
dismutase O -
. O +

Inhibition O +
of O +
SIRT1 O +
significantly O +
increased O +
vascular O +
superoxide B-Chemical +
production O -
, O +
enhanced O +
NADPH B-Chemical +
oxidase O +
activity O -
, O +
and O +
mRNA O +
expression O +
of O +
its O +
subunits O +
p22 O -
( O -
phox O -
) O +
and O +
NOX4 O -
, O +
which O +
were O +
prevented O +
by O +
resveratrol B-Chemical -
. O +

Peroxisome O +
proliferator O -
- O -
activated O +
receptor O -
- O -
α O +
( O -
PPARα O -
) O +
activation O +
mimicked O +
the O +
effects O +
of O +
resveratrol B-Chemical +
while O +
PPARα O +
inhibition O +
prevented O +
the O +
effects O +
of O +
this O +
SIRT1 O +
activator O -
. O +

SIRT1 O +
co O -
- O -
precipitated O +
with O +
PPARα O +
and O +
nicotinamide B-Chemical +
increased O +
the O +
acetylation O +
of O +
the O +
PPARα O +
coactivator O +
PGC-1α O -
, O +
which O +
was O +
suppressed O +
by O +
resveratrol B-Chemical -
. O +

In O +
conclusion O -
, O +
impaired O +
activity O +
of O +
SIRT1 O +
induces O +
endothelial O +
dysfunction O +
and O +
up O -
- O -
regulates O +
NADPH B-Chemical +
oxidase O -
- O -
derived O +
ROS O +
production O +
in O +
the O +
vascular O +
wall O -
, O +
mimicking O +
the O +
vascular O +
aging O +
phenotype O -
. O +

Moreover O -
, O +
a O +
new O +
mechanism O +
for O +
controlling O +
endothelial O +
function O +
after O +
SIRT1 O +
activation O +
involves O +
a O +
decreased O +
PGC-1α O +
acetylation O +
and O +
the O +
subsequent O +
PPARα O +
activation O -
, O +
resulting O +
in O +
both O +
decreased O +
NADPH B-Chemical +
oxidase O -
- O -
driven O +
ROS O +
production O +
and O +
NO B-Chemical +
inactivation O -
. O +

Block O -
/ O -
homo O +
polyplex O +
micelle O -
- O -
based O +
GM O -
- O -
CSF O +
gene O +
therapy O +
via O +
intraperitoneal O +
administration O +
elicits O +
antitumor O +
immunity O +
against O +
peritoneal O +
dissemination O +
and O +
exhibits O +
safety O +
potentials O +
in O +
mice O +
and O +
cynomolgus O +
monkeys O -
. O +

A O +
block O -
/ O -
homo O -
- O -
mixed O +
polyplex O +
micelle O -
, O +
comprising O +
of O +
cationic O +
homo O +
polymer O -
: O +
poly B-Chemical -
{ I-Chemical -
N'- I-Chemical -
[ I-Chemical -
N- I-Chemical -
( I-Chemical -
2-aminoethyl I-Chemical -
) I-Chemical -
-2-aminoethyl I-Chemical -
] I-Chemical -
aspartamide I-Chemical -
} I-Chemical +
P B-Chemical -
[ I-Chemical -
Asp I-Chemical -
( I-Chemical -
DET I-Chemical -
) I-Chemical -
] I-Chemical +
and O +
block O +
copolymer O -
: O +
polyethylene B-Chemical +
glycol I-Chemical +
( B-Chemical -
PEG I-Chemical -
) I-Chemical -
-b I-Chemical -
- I-Chemical -
P I-Chemical -
[ I-Chemical -
Asp I-Chemical -
( I-Chemical -
DET I-Chemical -
) I-Chemical -
] I-Chemical -
, O +
has O +
been O +
reported O +
to O +
exhibit O +
the O +
efficient O +
transgene O +
expression O +
in O +
vivo O +
by O +
intratracheal O +
and O +
systemic O +
administration O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
investigated O +
the O +
potential O +
of O +
immunogene O +
therapy O +
by O +
intraperitoneal O +
( O -
i.p O -
. O -
) O +
administration O +
of O +
block O -
/ O -
homo O +
polyplex O +
micelles O +
for O +
peritoneal O +
dissemination O -
. O +

For O +
evaluation O +
of O +
transgene O +
expression O +
in O +
vivo O -
, O +
block O -
/ O -
homo O +
polyplex O +
micelles O +
showed O +
12-fold O +
higher O +
level O +
in O +
luciferase O +
expression O +
evaluated O +
by O +
bioluminescence O +
imaging O +
system O +
at O +
24h O +
after O +
the O +
i.p O -
. O +

administration O +
compared O +
with O +
block O +
polyplex O +
micelles O +
composed O +
with O +
only O +
PEG B-Chemical -
- I-Chemical -
b I-Chemical -
- I-Chemical -
P I-Chemical -
[ I-Chemical -
Asp I-Chemical -
( I-Chemical -
DET I-Chemical -
) I-Chemical -
] I-Chemical +
in O +
nude O +
mice O +
bearing O +
peritoneal O +
dissemination O -
. O +

The O +
distribution O +
of O +
block O -
/ O -
homo O +
polyplex O +
micelles O +
and O +
intracellular O +
uptake O +
of O +
pDNA O +
was O +
observed O +
in O +
tumor O +
nodules O -
. O +

The O +
tumor O +
growth O +
and O +
the O +
prolonged O +
survival O +
rate O +
for O +
the O +
mice O +
harboring O +
disseminated O +
pancreatic O +
cancer O +
more O +
significantly O +
compared O +
with O +
the O +
mock O -
. O +

The O +
antitumor O +
effect O +
of O +
GM O -
- O -
CSF O +
gene O +
therapy O +
was O +
mediated O +
via O +
the O +
activation O +
of O +
natural O +
killer O +
cells O -
. O +

For O +
safety O +
evaluation O -
, O +
block O -
/ O -
homo O +
polyplex O +
micelles O +
indicated O +
almost O +
no O +
adverse O +
events O +
for O +
patho O -
- O -
physical O +
findings O +
and O +
blood O +
examinations O +
in O +
mice O +
and O +
cynomolgus O +
monkeys O -
, O +
although O +
slight O +
increases O +
in O +
serum O +
fibrinogen O +
were O +
observed O +
in O +
the O +
monkey O +
model O -
. O +

In O +
conclusion O -
, O +
block O -
/ O -
homo O +
polyplex O +
micelle O -
- O -
based O +
immunogene O +
therapy O +
via O +
i.p O -
. O +

administration O +
may O +
be O +
a O +
safe O +
and O +
effective O +
approach O +
for O +
suppressing O +
intractable O +
peritoneal O +
dissemination O -
. O +

Nuclear O +
Flux O +
Densities O +
during O +
a O +
Model O +
Pericyclic O +
Reaction O +
with O +
Energies O +
Well O +
Above O +
and O +
Below O +
the O +
Potential O +
Barrier O -
. O +

Pericyclic O +
reactions O +
with O +
energies O +
E O +
well O +
above O +
the O +
potential O +
energy O +
barrier O +
B O +
( O -
case O +
E O -
> O -
B O -
) O +
proceed O +
with O +
quantum O +
nuclear O +
flux O +
densities O +
〈 O -
j O -
〉 O +
which O +
are O +
essentially O +
proportional O +
to O +
the O +
nuclear O +
densities O +
ρ O +
in O +
the O +
femtosecond O +
time O +
domain O -
. O +

This O +
corresponds O +
to O +
the O +
definition O +
of O +
classical O +
( O -
cl O -
) O +
mechanics O -
, O +
jcl O +
= O -
υcl O +
ρcl O +
, O +
with O +
almost O +
constant O +
velocity O +
vcl O +
. O +

For O +
the O +
other O +
case O +
E O -
< O -
B O -
, O +
however O -
, O +
that O +
is O -
, O +
in O +
the O +
domain O +
of O +
coherent O +
tunneling O -
, O +
we O +
discover O +
the O +
opposite O +
trend O -
, O +
that O +
is O -
, O +
〈 O -
j O -
〉 O +
has O +
maximum O +
value O +
close O +
to O +
the O +
barrier O +
where O +
ρ O +
is O +
a O +
minimum O +
( O -
in O +
fact O +
where O +
ρ O +
is O +
close O +
to O +
zero O -
) O -
. O +

The O +
general O +
conclusion O +
is O +
that O +
quantum O +
mechanical O +
nuclear O +
flux O +
densities O +
may O +
be O +
at O +
variance O +
from O +
traditional O +
expectations O +
based O +
on O +
classical O +
trajectories O -
. O +

This O +
prediction O +
calls O +
for O +
experimental O +
demonstration O -
. O +

The O +
counter O -
- O -
intuitive O +
proof O -
- O -
of O -
- O -
principle O +
is O +
demonstrated O +
for O +
a O +
simple O -
, O +
one O -
- O -
dimensional O +
model O +
of O +
the O +
Cope O +
rearrangement O +
of O +
semibullvalene O -
. O +

The O +
influence O +
of O +
salinity O +
on O +
acute O +
nickel B-Chemical +
toxicity O +
to O +
the O +
two O +
euryhaline O +
fish O +
species O -
, O +
Fundulus O +
heteroclitus O +
and O +
Kryptolebias O +
marmoratus O -
. O +

Nickel B-Chemical +
( O -
Ni B-Chemical -
) O +
is O +
a O +
common O +
pollutant O +
found O +
in O +
aquatic O +
environments O +
and O +
may O +
be O +
harmful O +
at O +
elevated O +
concentrations O -
. O +

Increasing O +
salinity O +
has O +
been O +
shown O +
to O +
decrease O +
the O +
bioavailability O +
and O +
toxicity O +
of O +
other O +
metals O +
to O +
aquatic O +
organisms O -
. O +

In O +
the O +
present O +
study O -
, O +
acute O +
Ni B-Chemical +
toxicity O +
experiments O +
( O -
96-h O -
) O +
were O +
conducted O +
at O +
various O +
salinities O +
( O -
0 O -
- O -
36 O +
ppt O -
) O +
to O +
determine O +
the O +
effects O +
of O +
salinity O +
on O +
Ni B-Chemical +
toxicity O +
to O +
2 O +
euryhaline O +
fish O +
species O -
, O +
Kryptolebias O +
marmoratus O +
and O +
Fundulus O +
heteroclitus O -
. O +

Nickel B-Chemical +
concentrations O +
causing O +
lethality O +
to O +
50 O -
% O +
of O +
the O +
fish O +
ranged O +
from O +
2 O +
mg O -
/ O -
L O +
in O +
moderately O +
hard O +
freshwater O +
to O +
66.6 O +
mg O -
/ O -
L O +
in O +
36 O +
ppt O +
saltwater O -
. O +

Nickel B-Chemical +
toxicity O +
to O +
F. O +
heteroclitus O +
decreased O +
linearly O +
with O +
increasing O +
salinity O -
; O +
however O -
, O +
Ni B-Chemical +
toxicity O +
to O +
K. O +
marmoratus O +
was O +
only O +
lowered O +
by O +
salinities O +
above O +
6 O +
ppt O -
, O +
demonstrating O +
potential O +
physiological O +
differences O +
between O +
the O +
2 O +
species O +
when O +
they O +
are O +
functioning O +
as O +
freshwater O +
fish O -
. O +

Furthermore O -
, O +
the O +
authors O +
investigated O +
the O +
influence O +
of O +
Mg B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
, O +
Ca B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
, O +
Na B-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical +
, O +
and O +
Cl B-Chemical -
( I-Chemical -
- I-Chemical -
) I-Chemical +
on O +
Ni B-Chemical +
toxicity O +
to O +
F. O +
heteroclitus O -
. O +

Freshwater O +
with O +
up O +
to O +
120 O +
mg O -
/ O -
L O +
Ca B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
as O +
CaSO4 B-Chemical +
, O +
250 O +
mg O -
/ O -
L O +
Mg B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
as O +
MgSO4 B-Chemical +
, O +
or O +
250 O +
mg O -
/ O -
L O +
Na B-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical +
as O +
NaHCO3 B-Chemical +
did O +
not O +
provide O +
protection O +
against O +
Ni B-Chemical +
toxicity O -
. O +

Alternatively O -
, O +
250 O +
mg O -
/ O -
L O +
Na B-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical +
, O +
as O +
NaCl B-Chemical -
, O +
was O +
protective O +
against O +
Ni B-Chemical +
toxicity O -
; O +
and O +
the O +
extent O +
of O +
protection O +
was O +
similar O +
to O +
that O +
demonstrated O +
from O +
salt O +
water O +
with O +
the O +
same O +
Cl B-Chemical -
( I-Chemical -
- I-Chemical -
) I-Chemical +
concentration O -
. O +

These O +
results O +
suggest O +
that O +
Cl B-Chemical -
( I-Chemical -
- I-Chemical -
) I-Chemical +
is O +
the O +
predominant O +
ion O +
responsible O +
for O +
reducing O +
Ni B-Chemical +
toxicity O +
to O +
K. O +
marmoratus O +
and O +
F. O +
heteroclitus O +
in O +
higher O +
salinity O +
waters O -
. O +

Environ O +
Toxicol O +
Chem O +
2013;32:1354 O -
- O -
1359 O -
. O +

© O +
2013 O +
SETAC O -
. O +

Evaluation O +
of O +
phytotoxicity O +
and O +
genotoxicity O +
of O +
nitrobenzene B-Chemical +
with O +
A O +
battery O +
of O +
Vicia O +
Faba O +
assay O +
system O -
. O +

Nitrobenzene B-Chemical +
( O -
NB O -
) O +
is O +
an O +
important O +
organic O +
compound O +
intermediate O +
that O +
is O +
used O +
widely O +
in O +
industry O -
. O +

In O +
the O +
present O +
study O -
, O +
to O +
evaluate O +
the O +
phytotoxicity O +
and O +
genotoxicity O +
of O +
NB O +
on O +
plants O -
, O +
Vicia O +
faba O +
was O +
exposed O +
to O +
increasing O +
concentrations O +
of O +
NB O +
( O -
5 O +
mg O +
L O -
( O -
-1 O -
) O +
, O +
10 O +
mg O +
L O -
( O -
-1 O -
) O +
, O +
25 O +
mg O +
L O -
( O -
-1 O -
) O +
, O +
50 O +
mg O +
L O -
( O -
-1 O -
) O +
, O +
and O +
100 O +
mg O +
L O -
( O -
-1 O -
) O +
) O -
. O +

The O +
data O +
revealed O +
that O +
germination O +
rate O +
and O +
radicle O +
length O +
of O +
V. O +
faba O +
seedlings O +
were O +
promoted O +
by O +
low O +
NB O +
concentrations O +
and O +
short O +
exposure O +
periods O -
, O +
whereas O +
these O +
parameters O +
were O +
inhibited O +
at O +
greater O +
NB O +
concentrations O +
and O +
longer O +
exposures O -
. O +

When O +
assessed O +
by O +
mitotic O +
index O -
, O +
micronucleus O -
, O +
and O +
chromosomal O +
aberration O +
assays O -
, O +
NB O +
showed O +
dose O -
- O -
dependent O +
genotoxicity O +
at O +
0 O +
mg O +
L O -
( O -
-1 O -
) O +
to O +
50 O +
mg O +
L O -
( O -
-1 O -
) O +
. O +

Environ O +
Toxicol O +
Chem O +
2013;32:1426 O -
- O -
1432 O -
. O +

© O +
2013 O +
SETAC O -
. O +

Experimental O +
models O +
of O +
disseminated O +
scedosporiosis O +
with O +
cerebral O +
involvement O -
. O +

Scedosporium O +
apiospermum O +
is O +
a O +
soil O +
fungus O +
which O +
can O +
cause O +
severe O +
and O +
often O +
fatal O +
cerebral O +
infections O +
in O +
both O +
immunocompetent O +
patients O +
in O +
the O +
event O +
of O +
near O +
drowning O +
and O +
immunosuppressed O +
patients O +
such O +
as O +
lung O +
transplant O +
recipients O -
. O +

Because O +
of O +
the O +
low O +
susceptibility O +
of O +
this O +
fungus O +
to O +
antifungal O +
drugs O -
, O +
and O +
the O +
low O +
permeability O +
of O +
the O +
blood O -
- O -
brain O +
barrier O +
( O -
BBB O -
) O -
, O +
therapeutic O +
drug O +
monitoring O +
is O +
necessary O +
to O +
reach O +
an O +
effective O +
tissue O +
concentration O +
with O +
limited O +
side O +
effects O -
. O +

Indeed O -
, O +
diffusion O +
of O +
the O +
drug O +
in O +
the O +
brain O +
is O +
dependent O +
on O +
several O +
parameters O -
, O +
such O +
as O +
the O +
integrity O +
of O +
the O +
BBB O +
and O +
the O +
activity O +
of O +
efflux O +
pumps O -
. O +

To O +
evaluate O +
drug O +
diffusion O -
, O +
two O +
experimental O +
models O +
were O +
developed O +
in O +
immunocompetent O +
and O +
immunosuppressed O +
rats O -
. O +

Inocula O +
were O +
administered O +
via O +
the O +
penile O +
vein O +
and O +
a O +
clinical O +
scale O +
( O -
0 O -
- O -
9 O -
) O +
was O +
established O -
, O +
based O +
on O +
weight O +
and O +
clinical O +
and O +
neurologic O +
signs O +
evaluated O +
by O +
the O +
tail O +
suspension O +
test O -
. O +

Cerebral O +
involvement O +
was O +
confirmed O +
by O +
magnetic O +
resonance O +
imaging O +
and O +
histologic O +
examination O +
of O +
brain O +
sections O +
after O +
hematoxylin B-Chemical -
- O -
eosin B-Chemical -
- O -
safran O +
or O +
silver B-Chemical +
staining O -
. O +

Voriconazole B-Chemical +
or O +
posaconazole B-Chemical +
was O +
given O +
to O +
the O +
rats O +
at O +
doses O +
ranging O +
from O +
10 O +
to O +
75 O +
mg O -
/ O -
kg O -
/ O -
day O +
via O +
i.v O -
. O +
or O +
oral O +
routes O -
, O +
respectively O -
. O +

Whatever O +
the O +
immune O +
status O -
, O +
the O +
effective O +
doses O +
( O -
defined O +
by O +
a O +
doubling O +
of O +
the O +
survival O +
time O +
and O +
the O +
absence O +
of O +
neurologic O +
sequelae O -
) O +
were O +
30 O +
mg O -
/ O -
kg O -
/ O -
day O +
for O +
voriconazole B-Chemical +
and O +
50 O +
mg O -
/ O -
kg O -
/ O -
day O +
for O +
posaconazole B-Chemical -
. O +

Overall O -
, O +
the O +
results O +
demonstrated O +
that O +
these O +
models O +
may O +
constitute O +
valuable O +
tools O +
for O +
the O +
performance O +
of O +
pharmacokinetic O +
and O +
pharmacodynamic O +
studies O +
for O +
pharmacokinetic O -
- O -
pharmacodynamic O +
modeling O -
. O +

Serial O +
infusions O +
of O +
low O -
- O -
dose O +
ketamine B-Chemical +
for O +
major O +
depression O -
. O +

Background O -
: O +
Single O +
infusions O +
of O +
ketamine B-Chemical +
have O +
been O +
used O +
successfully O +
to O +
achieve O +
improvement O +
in O +
depressed O +
patients O -
. O +

Side O +
effects O +
during O +
the O +
infusions O +
have O +
been O +
common O -
. O +

It O +
is O +
not O +
known O +
whether O +
serial O +
infusions O +
or O +
lower O +
infusion O +
rates O +
result O +
in O +
greater O +
efficacy O -
. O +

Methods O -
: O +
Ten O +
depressed O +
patients O +
were O +
treated O +
with O +
twice O +
weekly O +
ketamine B-Chemical +
infusions O +
of O +
ketamine B-Chemical +
0.5 O +
mg O -
/ O -
kg O +
administered O +
over O +
100 O +
min O +
until O +
either O +
remission O +
was O +
achieved O +
or O +
four O +
infusions O +
were O +
given O -
. O +

Side O +
effects O +
were O +
assessed O +
with O +
the O +
Young O +
Mania O +
Rating O +
Scale O +
( O -
YMRS O -
) O +
and O +
the O +
Brief O +
Psychiatric O +
Rating O +
Scale O +
( O -
BPRS O -
) O -
. O +

Patients O +
were O +
followed O +
naturalistically O +
at O +
weekly O +
intervals O +
for O +
four O +
weeks O +
after O +
completion O +
of O +
the O +
infusions O -
. O +

Results O -
: O +
Five O +
of O +
10 O +
patients O +
achieved O +
remission O +
status O -
. O +

There O +
were O +
no O +
significant O +
increases O +
on O +
the O +
BPRS O +
or O +
YMRS O -
. O +

Two O +
of O +
the O +
remitting O +
patients O +
sustained O +
their O +
improvement O +
throughout O +
the O +
four O +
week O +
follow O -
- O -
up O +
period O -
. O +

Conclusions O -
: O +
Ketamine B-Chemical +
infusions O +
at O +
a O +
lower O +
rate O +
than O +
previously O +
reported O +
have O +
demonstrated O +
similar O +
efficacy O +
and O +
excellent O +
tolerability O +
and O +
may O +
be O +
more O +
practically O +
available O +
for O +
routine O +
clinical O +
care O -
. O +

Serial O +
ketamine B-Chemical +
infusions O +
appear O +
to O +
be O +
more O +
effective O +
than O +
a O +
single O +
infusion O -
. O +

Further O +
research O +
to O +
test O +
relapse O +
prevention O +
strategies O +
with O +
continuation O +
ketamine B-Chemical +
infusions O +
is O +
indicated O -
. O +

Nephroprotective O +
effect O +
of O +
calcium B-Chemical +
channel O +
blockers O +
against O +
toxicity O +
of O +
lead O +
exposure O +
in O +
mice O -
. O +

Exposure O +
to O +
lead O +
( O -
Pb B-Chemical -
) O +
can O +
induce O +
kidney O +
damage O -
, O +
which O +
is O +
related O +
to O +
induction O +
of O +
oxidative O +
damage O +
and O +
disturbance O +
of O +
intracellular O +
calcium B-Chemical +
homeostasis O -
. O +

Pb B-Chemical +
can O +
readily O +
permeate O +
through O +
dihydropyridine O -
- O -
sensitive O +
L O -
- O -
type O +
calcium B-Chemical +
channels O +
and O +
accumulate O +
within O +
cells O -
. O +

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
investigate O +
protective O +
effects O +
of O +
calcium B-Chemical +
channel O +
blockers O +
( O -
CCBs O -
) O +
verapamil B-Chemical +
and O +
nimodipine B-Chemical +
on O +
nephrotoxicity O +
induced O +
by O +
Pb B-Chemical +
acetate I-Chemical +
in O +
mice O -
. O +

One O +
hundred O +
and O +
twenty O +
male O +
mice O +
were O +
randomly O +
divided O +
into O +
6 O +
groups O -
: O +
control O -
, O +
Pb B-Chemical -
, O +
low O -
- O -
dose O +
verapamil B-Chemical -
, O +
high O -
- O -
dose O +
verapamil B-Chemical -
, O +
low O -
- O -
dose O +
nimodipine B-Chemical +
and O +
high O -
- O -
dose O +
nimodipine B-Chemical +
( O -
n=20 O +
per O +
group O -
) O -
. O +

Pb B-Chemical +
acetate I-Chemical +
was O +
injected O +
intraperitoneally O +
( O -
i.p O -
. O -
) O +
at O +
40 O +
mg O -
/ O -
kg O +
body O +
weight O -
/ O -
day O +
for O +
10 O +
days O +
to O +
establish O +
the O +
Pb B-Chemical +
toxicity O +
model O -
. O +

While O +
control O +
mice O +
received O +
saline O -
, O +
mice O +
of O +
the O +
treated O +
groups O +
simultaneously O +
received O +
i.p O -
. O +

injections O +
of O +
verapamil B-Chemical +
or O +
nimodipine B-Chemical +
daily O +
for O +
10 O +
days O -
. O +

Both O +
verapamil B-Chemical +
and O +
nimodipine B-Chemical +
showed O +
protection O +
against O +
Pb B-Chemical -
- O -
induced O +
kidney O +
injury O -
, O +
including O +
alleviation O +
of O +
renal O +
pathological O +
damage O +
and O +
decreasing O +
the O +
level O +
of O +
Pb B-Chemical +
in O +
kidney O +
homogenate O +
and O +
extent O +
of O +
apoptosis O +
in O +
nephrocytes O -
. O +

Moreover O -
, O +
verapamil B-Chemical +
and O +
nimodipine B-Chemical +
significantly O +
down O -
- O -
regulated O +
levels O +
of O +
blood O +
urea B-Chemical +
nitrogen B-Chemical +
and O +
creatinine B-Chemical +
in O +
the O +
serum O -
. O +

In O +
addition O -
, O +
verapamil B-Chemical +
and O +
nimodipine B-Chemical +
administration O +
decreased O +
malondialdehyde B-Chemical +
content O +
and O +
increased O +
activities O +
of O +
super B-Chemical +
oxide I-Chemical +
dismutase O +
activity O +
and O +
glutathione B-Chemical +
peroxidase O +
in O +
the O +
kidney O +
homogenate O -
. O +

The O +
findings O +
in O +
the O +
present O +
study O +
implicate O +
the O +
therapeutic O +
potential O +
of O +
CCBs O +
for O +
Pb B-Chemical -
- O -
induced O +
nephrotoxicity O -
, O +
which O +
were O +
at O +
least O +
partly O +
due O +
to O +
the O +
decrease O +
of O +
Pb B-Chemical +
uptake O +
and O +
inhibition O +
of O +
lipid O +
peroxidation O -
. O +

The O +
role O +
of O +
lipid O +
domains O +
in O +
bacterial O +
cell O +
processes O -
. O +

Membranes O +
are O +
vital O +
structures O +
for O +
cellular O +
life O +
forms O -
. O +

As O +
thin O -
, O +
hydrophobic O +
films O -
, O +
they O +
provide O +
a O +
physical O +
barrier O +
separating O +
the O +
aqueous O +
cytoplasm O +
from O +
the O +
outside O +
world O +
or O +
from O +
the O +
interiors O +
of O +
other O +
cellular O +
compartments O -
. O +

They O +
maintain O +
a O +
selective O +
permeability O +
for O +
the O +
import O +
and O +
export O +
of O +
water O -
- O -
soluble O +
compounds O -
, O +
enabling O +
the O +
living O +
cell O +
to O +
maintain O +
a O +
stable O +
chemical O +
environment O +
for O +
biological O +
processes O -
. O +

Cell O +
membranes O +
are O +
primarily O +
composed O +
of O +
two O +
crucial O +
substances O -
, O +
lipids O +
and O +
proteins O -
. O +

Bacterial O +
membranes O +
can O +
sense O +
environmental O +
changes O +
or O +
communication O +
signals O +
from O +
other O +
cells O +
and O +
they O +
support O +
different O +
cell O +
processes O -
, O +
including O +
cell O +
division O -
, O +
differentiation O -
, O +
protein O +
secretion O +
and O +
supplementary O +
protein O +
functions O -
. O +

The O +
original O +
fluid O +
mosaic O +
model O +
of O +
membrane O +
structure O +
has O +
been O +
recently O +
revised O +
because O +
it O +
has O +
become O +
apparent O +
that O +
domains O +
of O +
different O +
lipid O +
composition O +
are O +
present O +
in O +
both O +
eukaryotic O +
and O +
prokaryotic O +
cell O +
membranes O -
. O +

In O +
this O +
review O -
, O +
we O +
summarize O +
different O +
aspects O +
of O +
phospholipid O +
domain O +
formation O +
in O +
bacterial O +
membranes O -
, O +
mainly O +
in O +
Gram O -
- O -
negative O +
Escherichia O +
coli O +
and O +
Gram O -
- O -
positive O +
Bacillus O +
subtilis O -
. O +

We O +
describe O +
the O +
role O +
of O +
these O +
lipid O +
domains O +
in O +
membrane O +
dynamics O +
and O +
the O +
localization O +
of O +
specific O +
proteins O +
and O +
protein O +
complexes O +
in O +
relation O +
to O +
the O +
regulation O +
of O +
cellular O +
function O -
. O +

Intracellular O +
localization O +
of O +
the O +
BCL-2 O +
family O +
member O +
BOK O +
and O +
functional O +
implications O -
. O +

The O +
pro O -
- O -
apoptotic O +
BCL-2 O +
family O +
member O +
BOK O +
is O +
widely O +
expressed O +
and O +
resembles O +
the O +
multi O -
- O -
BH O +
domain O +
proteins O +
BAX O +
and O +
BAK O +
based O +
on O +
its O +
amino B-Chemical +
acid I-Chemical +
sequence O -
. O +

The O +
genomic O +
region O +
encoding O +
BOK O +
was O +
reported O +
to O +
be O +
frequently O +
deleted O +
in O +
human O +
cancer O +
and O +
it O +
has O +
therefore O +
been O +
hypothesized O +
that O +
BOK O +
functions O +
as O +
a O +
tumor O +
suppressor O -
. O +

However O -
, O +
little O +
is O +
known O +
about O +
the O +
molecular O +
functions O +
of O +
BOK O -
. O +

We O +
show O +
that O +
enforced O +
expression O +
of O +
BOK O +
activates O +
the O +
intrinsic O +
( O -
mitochondrial O -
) O +
apoptotic O +
pathway O +
in O +
BAX O -
/ O -
BAK O -
- O -
proficient O +
cells O +
but O +
fails O +
to O +
kill O +
cells O +
lacking O +
both O +
BAX O +
and O +
BAK O +
or O +
sensitize O +
them O +
to O +
cytotoxic O +
insults O -
. O +

Interestingly O -
, O +
major O +
portions O +
of O +
endogenous O +
BOK O +
are O +
localized O +
to O +
and O +
partially O +
inserted O +
into O +
the O +
membranes O +
of O +
the O +
Golgi O +
apparatus O +
as O +
well O +
as O +
the O +
endoplasmic O +
reticulum O +
( O -
ER O -
) O +
and O +
associated O +
membranes O -
. O +

The O +
C O -
- O -
terminal O +
transmembrane O +
domain O +
of O +
BOK O +
thereby O +
constitutes O +
a O +
' O -
tail O -
- O -
anchor O -
' O +
specific O +
for O +
targeting O +
to O +
the O +
Golgi O +
and O +
ER O -
. O +

Overexpression O +
of O +
full O -
- O -
length O +
BOK O +
causes O +
early O +
fragmentation O +
of O +
ER O +
and O +
Golgi O +
compartments O -
. O +

A O +
role O +
for O +
BOK O +
on O +
the O +
Golgi O +
apparatus O +
and O +
the O +
ER O +
is O +
supported O +
by O +
an O +
abnormal O +
response O +
of O +
Bok O -
- O -
deficient O +
cells O +
to O +
the O +
Golgi O -
/ O -
ER O +
stressor O +
brefeldin B-Chemical +
A. I-Chemical +
Based O +
on O +
these O +
results O -
, O +
we O +
propose O +
that O +
major O +
functions O +
of O +
BOK O +
are O +
exerted O +
at O +
the O +
Golgi O +
and O +
ER O +
membranes O +
and O +
that O +
BOK O +
induces O +
apoptosis O +
in O +
a O +
manner O +
dependent O +
on O +
BAX O +
and O +
BAK O -
. O +

Cyclic O +
stretch O +
induces O +
inducible O +
nitric B-Chemical +
oxide I-Chemical +
synthase O +
and O +
soluble O +
guanylate B-Chemical +
cyclase O +
in O +
pulmonary O +
artery O +
smooth O +
muscle O +
cells O -
. O +

In O +
the O +
pulmonary O +
vasculature O -
, O +
mechanical O +
forces O +
such O +
as O +
cyclic O +
stretch O +
induce O +
changes O +
in O +
vascular O +
signaling O -
, O +
tone O +
and O +
remodeling O -
. O +

Nitric B-Chemical +
oxide I-Chemical +
is O +
a O +
potent O +
regulator O +
of O +
soluble O +
guanylate B-Chemical +
cyclase O +
( O -
sGC O -
) O -
, O +
which O +
drives O +
cGMP B-Chemical +
production O -
, O +
causing O +
vasorelaxation O -
. O +

Pulmonary O +
artery O +
smooth O +
muscle O +
cells O +
( O -
PASMCs O -
) O +
express O +
inducible O +
nitric B-Chemical +
oxide I-Chemical +
synthase O +
( O -
iNOS O -
) O -
, O +
and O +
while O +
iNOS O +
expression O +
increases O +
during O +
late O +
gestation O -
, O +
little O +
is O +
known O +
about O +
how O +
cyclic O +
stretch O +
impacts O +
this O +
pathway O -
. O +

In O +
this O +
study O -
, O +
PASMC O +
were O +
subjected O +
to O +
cyclic O +
stretch O +
of O +
20 O -
% O +
amplitude O +
and O +
frequency O +
of O +
1 O +
Hz O +
for O +
24 O +
h O +
and O +
compared O +
to O +
control O +
cells O +
maintained O +
under O +
static O +
conditions O -
. O +

Cyclic O +
stretch O +
significantly O +
increased O +
cytosolic O +
oxidative O +
stress O +
as O +
compared O +
to O +
static O +
cells O +
( O -
62.9 O +
± O +
5.9 O -
% O +
vs. O +
33.3 O +
± O +
5.7 O -
% O +
maximal O +
oxidation O -
) O -
, O +
as O +
measured O +
by O +
the O +
intracellular O +
redox O +
sensor O +
roGFP O -
. O +

Cyclic O +
stretch O +
also O +
increased O +
sGCβ O +
protein O +
expression O +
( O -
2.5 O +
± O +
0.9-fold O -
) O -
, O +
sGC O +
activity O +
( O -
1.5 O +
± O +
0.2-fold O -
) O +
and O +
cGMP B-Chemical +
levels O +
( O -
1.8 O +
± O +
0.2-fold O -
) O -
, O +
as O +
well O +
as O +
iNOS O +
mRNA O +
and O +
protein O +
expression O +
( O -
3.0 O +
± O +
0.9 O +
and O +
2.6 O +
± O +
0.7-fold O -
, O +
respectively O -
) O +
relative O +
to O +
control O +
cells O -
. O +

An O +
antioxidant O -
, O +
recombinant O +
human O +
superoxide B-Chemical +
dismutase O +
( O -
rhSOD O -
) O -
, O +
significantly O +
decreased O +
stretch O -
- O -
induced O +
cytosolic O +
oxidative O +
stress O -
, O +
but O +
did O +
not O +
block O +
stretch O -
- O -
induced O +
sGC O +
activity O -
. O +

Inhibition O +
of O +
iNOS O +
with O +
1400 O +
W O +
or O +
an O +
iNOS O -
- O -
specific O +
siRNA O +
inhibited O +
stretch O -
- O -
induced O +
sGC O +
activity O +
by O +
30 O -
% O +
and O +
68 O -
% O +
respectively O +
vs. O +
static O +
controls O -
. O +

In O +
conclusion O -
, O +
cyclic O +
stretch O +
increases O +
sGC O +
expression O +
and O +
activity O +
in O +
an O +
iNOS O -
- O -
dependent O +
manner O +
in O +
PASMC O +
from O +
fetal O +
lambs O -
. O +

The O +
mechanism O +
that O +
produces O +
iNOS O +
and O +
sGC O +
upregulation O +
is O +
not O +
yet O +
known O -
, O +
but O +
we O +
speculate O +
these O +
effects O +
represent O +
an O +
early O +
compensatory O +
mechanism O +
to O +
counteract O +
the O +
effects O +
of O +
stretch O -
- O -
induced O +
oxidative O +
stress O -
. O +

A O +
better O +
understanding O +
of O +
the O +
interplay O +
between O +
these O +
two O +
distinct O +
pathways O +
could O +
provide O +
key O +
insights O +
into O +
future O +
avenues O +
to O +
treat O +
infants O +
with O +
pulmonary O +
hypertension O -
. O +

Hypoxaemia O +
affects O +
male O +
reproduction O -
: O +
a O +
case O +
study O +
of O +
how O +
to O +
differentiate O +
between O +
primary O +
and O +
secondary O +
hypoxic O +
testicular O +
toxicity O +
due O +
to O +
chemical O +
exposure O -
. O +

Classification O +
for O +
fertility O +
is O +
based O +
on O +
two O +
conditions O -
, O +
namely O +
on O +
evidence O +
of O +
an O +
adverse O +
effect O +
on O +
sexual O +
function O +
and O +
fertility O +
and O +
that O +
the O +
effect O +
is O +
not O +
secondary O +
to O +
other O +
toxic O +
effects O -
. O +

To O +
decide O +
on O +
an O +
adverse O +
effect O +
is O +
a O +
relatively O +
simple O +
day O -
- O -
to O -
- O -
day O +
decision O +
in O +
toxicology O +
but O +
whether O +
this O +
effect O +
is O +
secondary O +
often O +
leads O +
to O +
serious O +
controversy O -
. O +

As O +
the O +
seminiferous O +
epithelium O +
operates O +
on O +
the O +
verge O +
of O +
hypoxia O -
, O +
oxygen B-Chemical +
deficit O +
can O +
lead O +
to O +
secondary O +
impairment O +
of O +
testicular O +
function O -
. O +

This O +
is O +
well O +
known O +
from O +
healthy O +
mountaineers O +
exposing O +
themselves O +
to O +
high O +
altitude O -
. O +

They O +
have O +
reduced O +
blood O +
oxygen B-Chemical +
content O +
that O +
goes O +
in O +
parallel O +
with O +
impairment O +
of O +
testicular O +
function O +
and O +
this O +
effect O +
remains O +
for O +
some O +
time O +
in O +
spite O +
of O +
a O +
compensatory O +
polycythaemia O -
. O +

Similar O +
findings O +
are O +
described O +
for O +
experimental O +
animals O +
exposed O +
to O +
hypobaric O +
oxygen B-Chemical -
/ O -
high O +
altitude O -
. O +

In O +
addition O -
, O +
testicular O +
function O +
is O +
affected O +
in O +
severe O +
diseases O +
in O +
humans O +
associated O +
with O +
systemic O +
oxygen B-Chemical +
deficit O +
like O +
chronic O +
obstructive O +
pulmonary O +
disease O -
, O +
sickle O +
cell O +
disease O +
or O +
beta O -
- O -
thalassaemia O +
as O +
well O +
as O +
in O +
transgenic O +
animals O +
simulating O +
haemolytic O +
anaemia O +
or O +
sickle O +
cell O +
disease O -
. O +

The O +
problem O +
of O +
insufficient O +
oxygen B-Chemical +
supply O +
as O +
the O +
underlying O +
cause O +
for O +
testicular O +
impairment O +
has O +
received O +
relatively O +
little O +
attention O +
in O +
toxicology O -
, O +
mainly O +
because O +
blood O +
oxygen B-Chemical +
content O +
is O +
generally O +
not O +
measured O +
in O +
these O +
animal O +
experiments O -
. O +

The O +
difficulties O +
associated O +
with O +
the O +
decision O +
whether O +
testicular O +
toxicity O +
is O +
primary O +
or O +
secondary O +
to O +
hypoxia O +
are O +
exemplified O +
by O +
the O +
results O +
of O +
inhalation O +
studies O +
with O +
nickel B-Chemical +
subsulphide I-Chemical +
and O +
gallium B-Chemical +
arsenide I-Chemical +
( O -
GaAs B-Chemical -
) O -
. O +

Both O +
of O +
these O +
particulate O +
substances O +
lead O +
to O +
severe O +
lung O +
toxicity O +
that O +
might O +
impair O +
oxygen B-Chemical +
uptake O -
, O +
but O +
testicular O +
toxicity O +
is O +
only O +
observed O +
with O +
GaAs B-Chemical -
. O +

This O +
may O +
first O +
be O +
explained O +
by O +
different O +
effects O +
on O +
the O +
blood O -
: O +
nickel B-Chemical +
subsulphide I-Chemical +
inhalation O +
leads O +
to O +
a O +
compensatory O +
erythropoiesis O +
that O +
may O +
mitigate O +
pulmonary O +
lack O +
of O +
oxygen B-Chemical +
uptake O -
. O +

In O +
contrast O -
, O +
GaAs B-Chemical +
exposure O +
is O +
associated O +
with O +
microcytic O +
haemolytic O +
anaemia O +
thereby O +
aggravating O +
any O +
possible O +
oxygen B-Chemical +
undersupply O -
. O +

Furthermore O -
, O +
the O +
predominant O +
pulmonary O +
effect O +
caused O +
by O +
GaAs B-Chemical +
( O -
but O +
not O +
by O +
nickel B-Chemical +
subsulphide I-Chemical -
) O +
is O +
alveolar O +
proteinosis O -
. O +

Pulmonary O +
alveolar O +
proteinosis O +
is O +
also O +
known O +
as O +
a O +
severe O +
disease O +
in O +
humans O +
associated O +
with O +
hypoxaemia O -
. O +

Therefore O -
, O +
we O +
conclude O +
that O +
the O +
testicular O +
effects O +
observed O +
after O +
GaAs B-Chemical +
are O +
secondary O +
to O +
hypoxaemia O +
caused O +
by O +
the O +
combination O +
of O +
pulmonary O +
proteinosis O +
and O +
haemolytic O +
anaemia O -
. O +

This O +
publication O +
tries O +
to O +
raise O +
awareness O +
to O +
the O +
severe O +
consequences O +
of O +
hypoxaemia O +
on O +
testicular O +
function O +
that O +
may O +
already O +
be O +
caused O +
by O +
reduced O +
oxygen B-Chemical +
pressure O +
at O +
high O +
altitude O +
without O +
any O +
chemical O +
exposure O -
. O +

Bacterial O +
infection O +
probes O +
and O +
imaging O +
strategies O +
in O +
clinical O +
nuclear O +
medicine O +
and O +
preclinical O +
molecular O +
imaging O -
. O +

At O +
present O -
, O +
a O +
limited O +
number O +
of O +
strategies O +
exist O +
for O +
diagnostic O +
imaging O +
of O +
patients O +
with O +
bacterial O +
infection O -
. O +

While O +
radiolabeled O +
probes O +
and O +
white O +
blood O +
cells O +
provide O +
robust O +
solutions O +
to O +
detect O +
bacteria O +
in O +
humans O -
, O +
they O +
also O +
give O +
false O +
positives O +
in O +
cases O +
of O +
sterile O +
inflammation O -
. O +

With O +
the O +
onset O +
of O +
bacterial O +
drug O +
resistance O -
, O +
and O +
a O +
clinical O +
trend O +
toward O +
reducing O +
the O +
prescription O +
of O +
antibiotics O -
, O +
the O +
need O +
for O +
highly O +
specific O +
infection O +
detection O +
protocols O +
has O +
been O +
renewed O -
. O +

The O +
preclinical O +
research O +
community O +
has O +
recently O +
utilized O +
new O +
optical O +
imaging O +
strategies O -
, O +
alongside O +
traditional O +
radioimaging O +
research O -
, O +
to O +
develop O +
novel O +
infection O +
probes O +
with O +
translational O +
potential O -
. O +

Here O +
we O +
review O +
the O +
current O +
clinical O +
methods O +
for O +
imaging O +
bacteria O +
in O +
humans O -
, O +
and O +
discuss O +
the O +
efforts O +
within O +
the O +
preclinical O +
community O +
to O +
validate O +
new O +
strategies O -
. O +

The O +
review O +
of O +
preclinical O +
infection O +
imaging O +
probes O +
is O +
limited O +
to O +
those O +
probes O +
that O +
could O +
be O +
feasibly O +
adapted O +
for O +
use O +
in O +
humans O +
with O +
currently O +
available O +
clinical O +
modalities O -
. O +

Transient O +
Receptor O +
Potential O +
( O -
TRP O -
) O +
Channels O +
and O +
Cardiac O +
Fibrosis O -
. O +

Cardiac O +
fibrosis O +
is O +
associated O +
with O +
most O +
cardiac O +
diseases O -
. O +

Fibrosis O +
is O +
an O +
accumulation O +
of O +
excessive O +
extracellular O +
matrix O +
proteins O +
( O -
ECM O -
) O +
synthesized O +
by O +
cardiac O +
fibroblasts O +
and O +
myofibroblasts O -
. O +

Fibroblasts O +
are O +
the O +
most O +
prevalent O +
cell O +
type O +
in O +
the O +
heart O -
, O +
comprising O +
75 O -
% O +
of O +
cardiac O +
cells O -
. O +

Myofibroblasts O +
are O +
hardly O +
present O +
in O +
healthy O +
normal O +
heart O +
tissue O -
, O +
but O +
appear O +
abundantly O +
in O +
diseased O +
hearts O -
. O +

Cardiac O +
fibroblasts O +
are O +
activated O +
by O +
a O +
variety O +
of O +
pathological O +
stimuli O -
, O +
such O +
as O +
myocardial O +
injury O -
, O +
oxidative O +
stress O -
, O +
mechanical O +
stretch O -
, O +
and O +
elevated O +
autocrine O -
- O -
paracrine O +
mediators O -
, O +
thereby O +
undergoing O +
proliferation O -
, O +
differentiation O +
to O +
myofibroblasts O -
, O +
and O +
production O +
of O +
various O +
cytokines O +
and O +
ECM O +
proteins O -
. O +

A O +
number O +
of O +
signaling O +
pathways O +
and O +
bioactive O +
molecules O +
are O +
involved O +
and O +
work O +
in O +
concert O +
to O +
activate O +
fibroblasts O +
and O +
myofibroblasts O +
in O +
the O +
fibrogenesis O +
cascade O -
. O +

Fibroblasts O +
and O +
myofibroblasts O +
are O +
not O +
only O +
principal O +
ECM O +
producers O -
, O +
but O +
also O +
play O +
a O +
central O +
role O +
in O +
fibrogenesis O +
and O +
myocardial O +
remodeling O +
in O +
fibrotic O +
heart O +
disease O -
. O +

Thus O -
, O +
understanding O +
the O +
biological O +
processes O +
of O +
cardiac O +
fibroblasts O +
will O +
provide O +
novel O +
insights O +
into O +
the O +
underlying O +
mechanisms O +
of O +
fibrosis O +
and O +
provide O +
potential O +
targets O +
for O +
developing O +
antifibrotic O +
drugs O -
. O +

Recent O +
studies O +
demonstrate O +
that O +
Ca2 B-Chemical -
+ I-Chemical +
signal O +
is O +
essential O +
for O +
fibroblast O +
proliferation O -
, O +
differentiation O -
, O +
and O +
ECM O -
- O -
protein O +
production O -
. O +

This O +
review O +
focuses O +
on O +
the O +
recent O +
advances O +
in O +
understanding O +
molecular O +
mechanisms O +
of O +
Ca2 B-Chemical -
+ I-Chemical +
signaling O +
in O +
cardiac O +
fibrogenesis O -
, O +
and O +
potential O +
role O +
of O +
Ca2 B-Chemical -
+ I-Chemical -
-permeable O +
channels O -
, O +
in O +
particular O -
, O +
the O +
transient O +
potential O +
( O -
TRP O -
) O +
channels O +
in O +
fibrotic O +
heart O +
disease O -
. O +

TRP O +
channels O +
are O +
highly O +
expressed O +
in O +
cardiac O +
fibroblasts O -
. O +

TRPM7 O +
has O +
been O +
shown O +
to O +
be O +
essential O +
in O +
TGFβ1 O +
mediated O +
fibrogenesis O -
, O +
and O +
TRPC3 O +
has O +
been O +
demonstrated O +
to O +
play O +
an O +
essential O +
role O +
in O +
regulating O +
fibroblast O +
function O -
. O +

Thus O -
, O +
the O +
Ca2 B-Chemical -
+ I-Chemical -
-permeable O +
TRP O +
channels O +
may O +
serve O +
as O +
potential O +
novel O +
targets O +
for O +
developing O +
anti O -
- O -
fibrotic O +
drugs O -
. O +

TRP O +
Channels O +
in O +
Vascular O +
Disorders O -
. O +

In O +
recent O +
years O -
, O +
research O +
on O +
the O +
roles O +
of O +
TRP O +
channels O +
in O +
vascular O +
function O +
and O +
disease O +
has O +
undergone O +
a O +
rapid O +
expansion O +
from O +
tens O +
of O +
reports O +
published O +
in O +
the O +
early O +
2000s O +
to O +
several O +
hundreds O +
of O +
papers O +
published O +
to O +
date O -
. O +

Multiple O +
TRP O +
subtypes O +
are O +
expressed O +
in O +
vascular O +
smooth O +
muscle O +
cells O +
and O +
endothelial O +
cells O -
, O +
where O +
they O +
form O +
diverse O +
non O -
- O -
selective O +
cation O +
channels O +
permeable O +
to O +
Ca2 B-Chemical -
+ I-Chemical -
. O +

These O +
channels O +
mediate O +
Ca2 B-Chemical -
+ I-Chemical +
entry O +
following O +
receptor O +
stimulation O -
, O +
Ca2 B-Chemical -
+ I-Chemical +
store O +
depletion O +
and O +
mechanical O +
stimulation O +
of O +
vascular O +
myocytes O +
and O +
endothelial O +
cells O -
. O +

The O +
complex O +
molecular O +
composition O +
and O +
signalling O +
pathways O +
leading O +
to O +
the O +
activation O +
of O +
various O +
vascular O +
TRP O +
channels O +
and O +
the O +
growing O +
evidence O +
for O +
their O +
involvement O +
in O +
various O +
vascular O +
disorders O -
, O +
including O +
dysregulation O +
of O +
vascular O +
tone O +
and O +
hypertension O -
, O +
impaired O +
endothelium O -
- O -
dependent O +
vasodilatation O -
, O +
increased O +
endothelial O +
permeability O -
, O +
occlusive O +
vascular O +
disease O -
, O +
vascular O +
injury O +
and O +
oxidative O +
stress O -
, O +
are O +
summarised O +
and O +
discussed O +
in O +
this O +
review O -
. O +

Oncogenic O +
and O +
anti O -
- O -
oncogenic O +
effects O +
of O +
transient O +
receptor O +
potential O +
channels O -
. O +

Transient O +
Receptor O +
Potential O +
( O -
TRP O -
) O +
channels O +
affect O +
several O +
inflammatory O +
and O +
neoplastic O +
conditions O -
. O +

About O +
thirty O +
TRPs O +
have O +
been O +
identified O +
to O +
date O +
and O +
divided O +
into O +
seven O +
families O -
: O +
TRPC O +
( O -
Canonical O -
) O -
, O +
TRPV O +
( O -
Vanilloid B-Chemical -
) O -
, O +
TRPM O +
( O -
Melastatin O -
) O -
, O +
TRPML O +
( O -
Mucolipin O -
) O -
, O +
TRPP O +
( O -
Polycystin O -
) O -
, O +
and O +
TRPA O +
( O -
Ankyrin O +
transmembrane O +
protein O -
) O +
and O +
TRPN O +
( O -
NomPClike O -
) O -
. O +

Among O +
these O -
, O +
the O +
TRPC O -
, O +
TRPM O -
, O +
and O +
TRPV O +
families O +
have O +
been O +
mainly O +
correlated O +
with O +
malignant O +
growth O +
and O +
progression O -
. O +

The O +
aim O +
of O +
this O +
review O +
is O +
to O +
summarize O +
data O +
reported O +
so O +
far O +
on O +
the O +
expression O +
and O +
functional O +
role O +
of O +
TRP O +
channels O +
in O +
different O +
types O +
of O +
cancers O -
. O +

TRP O +
channels O +
have O +
been O +
recently O +
implicated O +
in O +
the O +
triggering O +
of O +
enhanced O +
proliferation O -
, O +
aberrant O +
differentiation O -
, O +
and O +
resistance O +
to O +
apoptotic O +
cell O +
death O -
, O +
leading O +
to O +
uncontrolled O +
tumor O +
growth O +
and O +
progression O -
. O +

Depending O +
on O +
cancer O +
stage O -
, O +
up O +
and O +
down O -
- O -
regulation O +
of O +
TRP O +
mRNAs O +
and O +
protein O +
expression O +
have O +
been O +
reported O -
. O +

These O +
changes O +
have O +
been O +
shown O +
to O +
exhibit O +
cancer O +
promoting O +
( O -
oncogenic O -
) O +
or O +
inhibiting O -
/ O -
delaying O +
( O -
tumor O +
suppressor O -
) O +
effects O -
. O +

We O +
are O +
only O +
at O +
the O +
beginning O -
, O +
and O +
more O +
detailed O +
study O +
on O +
the O +
physiopathologic O +
role O +
of O +
TRP O +
channels O +
is O +
required O +
to O +
understand O +
how O +
the O +
deregulation O +
of O +
TRP O +
channel O +
expression O +
and O +
function O +
contributes O +
to O +
tumor O +
development O +
and O +
progression O -
. O +

It O +
is O +
hoped O +
that O +
greater O +
knowledge O +
about O +
TRP O +
biology O +
will O +
enable O +
future O +
development O +
of O +
new O +
chemotherapeutic O +
agents O +
for O +
specific O +
TRP O +
targets O -
, O +
and O +
the O +
use O +
of O +
TRP O +
channels O +
as O +
evaluable O +
markers O +
in O +
diagnostic O +
and/or O +
prognostic O +
analysis O -
. O +

Multiple O +
Roles O +
of O +
Transient O +
Receptor O +
Potential O +
( O -
TRP O -
) O +
Channels O +
in O +
Inflammatory O +
Conditions O +
and O +
Current O +
Status O +
of O +
Drug O +
Development O -
. O +

During O +
inflammation O -
, O +
several O +
Transient O +
Receptor O +
Potential O +
( O -
TRP O -
) O +
channels O +
are O +
directly O +
or O +
indirectly O +
activated O +
by O +
inflammatory O +
signaling O +
molecules O +
and O +
microenvironmental O +
changes O +
including O +
heat O -
, O +
oxidative O +
conditions O +
or O +
low O +
pH. O +
In O +
either O +
case O -
, O +
specific O +
TRP O +
isoforms O +
participate O +
in O +
chains O +
of O +
pro- O +
or O +
anti O -
- O -
inflammatory O +
signaling O +
cascades O +
often O +
including O +
activation O +
of O +
transcription O +
factors O -
, O +
protein O +
kinases O +
and O +
phospholipases O -
, O +
which O +
result O +
in O +
signal O +
integration O +
or O +
amplification O -
. O +

In O +
a O +
few O +
cases O -
, O +
their O +
potentials O +
as O +
therapeutic O +
targets O +
for O +
inflammatory O +
conditions O +
like O +
pruritis O -
, O +
cystitis O -
, O +
dermatitis O -
, O +
asthma O +
among O +
other O +
conditions O +
are O +
investigated O +
pre O -
- O -
clinically O +
or O +
clinically O +
by O +
pioneering O +
academic O +
groups O +
and O +
industries O -
. O +

Significant O +
efforts O +
are O +
still O +
devoted O +
to O +
the O +
understanding O +
of O +
the O +
detailed O +
physiological O +
roles O +
played O +
by O +
TRP O +
channels O +
during O +
inflammation O -
. O +

This O +
review O +
intends O +
to O +
summarize O +
key O +
biological O +
findings O +
and O +
reports O +
of O +
drug O +
discovery O +
activities O +
when O +
available O -
, O +
in O +
an O +
overview O +
of O +
the O +
current O +
status O +
and O +
recent O +
developments O +
in O +
the O +
field O -
. O +

Correlation O +
between O +
structural O -
, O +
spectroscopic O -
, O +
and O +
reactivity O +
properties O +
within O +
a O +
series O +
of O +
structurally O +
analogous O +
metastable O +
manganese B-Chemical -
( I-Chemical -
III I-Chemical -
) I-Chemical -
-alkylperoxo I-Chemical +
complexes I-Chemical -
. O +

Manganese B-Chemical -
- I-Chemical -
peroxos I-Chemical +
are O +
proposed O +
as O +
key O +
intermediates O +
in O +
a O +
number O +
of O +
important O +
biochemical O +
and O +
synthetic O +
transformations O -
. O +

Our O +
understanding O +
of O +
the O +
structural O -
, O +
spectroscopic O -
, O +
and O +
reactivity O +
properties O +
of O +
these O +
metastable O +
species O +
is O +
limited O -
, O +
however O -
, O +
and O +
correlations O +
between O +
these O +
properties O +
have O +
yet O +
to O +
be O +
established O +
experimentally O -
. O +

Herein O +
we O +
report O +
the O +
crystallographic O +
structures O +
of O +
a O +
series O +
of O +
structurally O +
related O +
metastable O +
Mn B-Chemical -
( I-Chemical -
III I-Chemical -
) I-Chemical -
-OOR I-Chemical +
compounds O -
, O +
and O +
examine O +
their O +
spectroscopic O +
and O +
reactivity O +
properties O -
. O +

The O +
four O +
reported O +
Mn B-Chemical -
( I-Chemical -
III I-Chemical -
) I-Chemical -
-OOR I-Chemical +
compounds O +
extend O +
the O +
number O +
of O +
known O +
end O -
- O -
on O +
Mn B-Chemical -
( I-Chemical -
III I-Chemical -
) I-Chemical -
- I-Chemical -
( I-Chemical -
η I-Chemical -
( I-Chemical -
1 I-Chemical -
) I-Chemical -
-peroxos I-Chemical -
) I-Chemical +
to O +
six O -
. O +

The O +
ligand O +
backbone O +
is O +
shown O +
to O +
alter O +
the O +
metal O -
- O -
ligand O +
distances O +
and O +
modulate O +
the O +
electronic O +
properties O +
key O +
to O +
bonding O +
and O +
activation O +
of O +
the O +
peroxo O -
. O +

The O +
mechanism O +
of O +
thermal O +
decay O +
of O +
these O +
metastable O +
species O +
is O +
examined O +
via O +
variable O -
- O -
temperature O +
kinetics O -
. O +

Strong O +
correlations O +
between O +
structural O +
( O -
O B-Chemical -
- I-Chemical -
O I-Chemical +
and O +
Mn···N B-Chemical -
( B-Chemical -
py I-Chemical -
, I-Chemical -
quin I-Chemical -
) I-Chemical +
distances O -
) O -
, O +
spectroscopic O +
( O -
E O -
( O -
πv* O -
( O -
O B-Chemical -
- I-Chemical -
O I-Chemical -
) O +
→ O +
Mn B-Chemical +
CT O +
band O -
) O -
, O +
ν O -
( O -
O B-Chemical -
- I-Chemical -
O I-Chemical -
) O -
) O -
, O +
and O +
kinetic O +
( O -
ΔH O -
( O -
‡ O -
) O +
and O +
ΔS O -
( O -
‡ O -
) O -
) O +
parameters O +
for O +
these O +
complexes O +
provide O +
compelling O +
evidence O +
for O +
rate O -
- O -
limiting O +
O B-Chemical -
- I-Chemical -
O I-Chemical +
bond O +
cleavage O -
. O +

Products O +
identified O +
in O +
the O +
final O +
reaction O +
mixtures O +
of O +
Mn B-Chemical -
( I-Chemical -
III I-Chemical -
) I-Chemical -
-OOR I-Chemical +
decay O +
are O +
consistent O +
with O +
homolytic O +
O B-Chemical -
- I-Chemical -
O I-Chemical +
bond O +
scission O -
. O +

The O +
N B-Chemical -
- I-Chemical -
heterocyclic I-Chemical +
amines I-Chemical +
and O +
ligand O +
backbone O +
( O -
Et O +
vs O +
Pr O -
) O +
are O +
found O +
to O +
modulate O +
structural O +
and O +
reactivity O +
properties O -
, O +
and O +
O B-Chemical -
- I-Chemical -
O I-Chemical +
bond O +
activation O +
is O +
shown O -
, O +
both O +
experimentally O +
and O +
theoretically O -
, O +
to O +
track O +
with O +
metal O +
ion O +
Lewis O +
acidity O -
. O +

The O +
peroxo B-Chemical +
O I-Chemical -
- I-Chemical -
O I-Chemical +
bond O +
is O +
shown O +
to O +
gradually O +
become O +
more O +
activated O +
as O +
the O +
N B-Chemical -
- I-Chemical -
heterocyclic I-Chemical +
amines I-Chemical +
move O +
closer O +
to O +
the O +
metal O +
ion O +
causing O +
a O +
decrease O +
in O +
π O -
- O -
donation O +
from O +
the O +
peroxo O +
πv* O -
( O -
O B-Chemical -
- I-Chemical -
O I-Chemical -
) O +
orbital O -
. O +

The O +
reported O +
work O +
represents O +
one O +
of O +
very O +
few O +
examples O +
of O +
experimentally O +
verified O +
relationships O +
between O +
structure O +
and O +
function O -
. O +

Phase O +
discrimination O +
through O +
oxidant O +
selection O +
in O +
low O -
- O -
temperature O +
atomic O +
layer O +
deposition O +
of O +
crystalline O +
iron B-Chemical +
oxides I-Chemical -
. O +

Control O +
over O +
the O +
oxidation O +
state O +
and O +
crystalline O +
phase O +
of O +
thin O -
- O -
film O +
iron B-Chemical +
oxides I-Chemical +
was O +
achieved O +
by O +
low O -
- O -
temperature O +
atomic O +
layer O +
deposition O +
( O -
ALD O -
) O -
, O +
utilizing O +
a O +
novel O +
iron B-Chemical +
precursor O -
, O +
bis B-Chemical -
( I-Chemical -
2,4-methylpentadienyl I-Chemical -
) I-Chemical -
iron I-Chemical -
. O +

This O +
low O -
- O -
temperature O +
( O -
T O +
= O +
120 O +
° O -
C O -
) O +
route O +
to O +
conformal O +
deposition O +
of O +
crystalline O +
Fe3O4 B-Chemical +
or O +
α B-Chemical -
- I-Chemical -
Fe2O3 I-Chemical +
thin O +
films O +
is O +
determined O +
by O +
the O +
choice O +
of O +
oxygen B-Chemical +
source O +
selected O +
for O +
the O +
second O +
surface O +
half O -
- O -
reaction O -
. O +

The O +
approach O +
employs O +
ozone O +
to O +
produce O +
fully O +
oxidized O +
α B-Chemical -
- I-Chemical -
Fe2O3 I-Chemical +
or O +
a O +
milder O +
oxidant O -
, O +
H2O2 B-Chemical -
, O +
to O +
generate O +
the O +
Fe B-Chemical -
( I-Chemical -
2+ I-Chemical -
) I-Chemical -
/ O -
Fe B-Chemical -
( I-Chemical -
3 I-Chemical -
+ I-Chemical -
) I-Chemical +
spinel O -
, O +
Fe3O4 B-Chemical -
. O +

Both O +
processes O +
show O +
self O -
- O -
limiting O +
surface O +
reactions O +
and O +
deposition O +
rates O +
of O +
at O +
least O +
0.6 O +
Å O -
/ O -
cycle O -
, O +
a O +
significantly O +
high O +
growth O +
rate O +
at O +
such O +
mild O +
conditions O -
. O +

We O +
utilized O +
this O +
process O +
to O +
prepare O +
conformal O +
iron B-Chemical +
oxide I-Chemical +
thin O +
films O +
on O +
a O +
porous O +
framework O -
, O +
for O +
which O +
α B-Chemical -
- I-Chemical -
Fe2O3 I-Chemical +
is O +
active O +
for O +
photocatalytic O +
water O +
splitting O -
. O +

Comprehensive O +
insights O +
into O +
the O +
structural O +
and O +
chemical O +
changes O +
in O +
mixed O -
- O -
anion O +
FeOF B-Chemical +
electrodes O +
by O +
using O +
operando O +
PDF O +
and O +
NMR O +
spectroscopy O -
. O +

In O -
- O -
depth O +
analysis O +
of O +
operando O +
X O -
- O -
ray O +
pair O +
distribution O +
function O +
( O -
PDF O -
) O +
data O +
is O +
combined O +
with O +
Li B-Chemical +
NMR O +
spectroscopy O +
to O +
gain O +
comprehensive O +
insights O +
into O +
the O +
electrochemical O +
reaction O +
mechanism O +
of O +
high O -
- O -
performance O +
iron B-Chemical +
oxyfluoride I-Chemical +
electrodes O -
. O +

While O +
the O +
full O +
discharge O +
capacity O +
could O +
be O +
recovered O +
upon O +
charge O -
, O +
implying O +
reversibility O +
of O +
the O +
electrochemical O +
reaction O -
, O +
the O +
atomic O +
structure O +
of O +
the O +
electrode O +
formed O +
after O +
cycling O +
( O -
discharge O -
- O -
charge O -
) O +
differs O +
from O +
the O +
pristine O +
uncycled O +
electrode O +
material O -
. O +

Instead O -
, O +
the O +
" O -
active O -
" O +
electrode O +
that O +
forms O +
upon O +
cycling O +
is O +
a O +
nanocomposite O +
of O +
an O +
amorphous O +
rutile O +
phase O +
and O +
a O +
nanoscale O +
rock O +
salt O +
phase O -
. O +

Bond O +
valence O +
sum O +
analysis O -
, O +
based O +
on O +
the O +
precise O +
structural O +
parameters O +
( O -
bond O +
lengths O +
and O +
coordination O +
number O -
) O +
extracted O +
from O +
the O +
in O +
situ O +
PDF O +
data O -
, O +
suggests O +
that O +
anion O +
partitioning O +
occurs O +
during O +
the O +
electrochemical O +
reaction O -
, O +
with O +
the O +
rutile O +
phase O +
being O +
F O -
- O -
rich O +
and O +
the O +
rock O +
salt O +
phase O +
being O +
O O -
- O -
rich O -
. O +

The O +
F- O +
and O +
O O -
- O -
rich O +
phases O +
react O +
sequentially O -
; O +
Fe B-Chemical +
in O +
a O +
F O -
- O -
rich O +
environment O +
reacts O +
preferentially O +
during O +
both O +
discharge O +
and O +
charge O -
. O +

Coenzyme B-Chemical +
Q10 I-Chemical +
protects O +
Pc12 O +
cells O +
from O +
cisplatin B-Chemical -
- O -
induced O +
DNA O +
damage O +
and O +
neurotoxicity O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
neuroprotective O +
effect O +
of O +
a O +
water O -
- O -
soluble O +
formulation O +
of O +
coenzyme B-Chemical +
Q10 I-Chemical +
( O -
WS O -
- O -
CoQ10 B-Chemical -
) O +
in O +
PC12 O +
cells O +
exposed O +
to O +
cisplatin B-Chemical -
, O +
a O +
chemotherapeutic O +
agent O +
with O +
a O +
dose O -
- O -
limiting O +
factor O +
due O +
to O +
neurotoxicity O -
. O +

In O +
the O +
cytokinesis O -
- O -
block O +
micronucleus O +
cytome O +
assay O +
( O -
CBMN O +
Cyt O -
) O -
, O +
WS O -
- O -
CoQ10 B-Chemical +
( O -
at O +
concentrations O +
of O +
0.1 O -
, O +
0.5 O +
and O +
1.0μgmL O -
( O -
-1 O -
) O -
) O +
protected O +
PC12 O +
cells O +
from O +
cisplatin B-Chemical -
- O -
induced O +
DNA O +
damage O +
( O -
0.1μgmL O -
( O -
-1 O -
) O -
) O -
, O +
reducing O +
the O +
frequency O +
of O +
micronuclei O +
( O -
MNi O -
) O +
and O +
nuclear O +
buds O +
( O -
NBUDs O -
) O -
. O +

WS O -
- O -
CoQ10 B-Chemical +
did O +
not O +
alter O +
the O +
mRNA O +
expression O +
levels O +
of O +
Tp53 O +
( O -
at O +
a O +
concentration O +
of O +
1.0μgmL O -
( O -
-1 O -
) O -
) O +
and O +
exhibited O +
neuroprotective O +
activity O +
by O +
stimulating O +
cisplatin B-Chemical -
- O -
inhibited O +
neurite O +
outgrowth O +
in O +
nerve O +
growth O +
factor O +
( O -
NGF O -
) O -
-differentiated O +
PC12 O +
cells O +
( O -
at O +
a O +
concentration O +
of O +
0.1μgmL O -
( O -
-1 O -
) O -
) O -
. O +

In O +
conclusion O -
, O +
WS O -
- O -
CoQ10 B-Chemical +
protected O +
the O +
PC12 O +
cells O +
from O +
cisplatin B-Chemical -
- O -
induced O +
DNA O +
damage O +
and O +
neurotoxicity O -
. O +

Moreover O -
, O +
the O +
neuroprotective O +
effects O +
of O +
WS O -
- O -
CoQ10 B-Chemical +
suggest O +
a O +
possible O +
application O +
in O +
chemotherapeutic O +
protocols O -
. O +

Rapid O +
and O +
Sensitive O +
Determination O +
of O +
Timosaponin B-Chemical +
AIII I-Chemical +
in O +
Rat O +
Plasma O +
by O +
LC O -
- O -
MS O -
/ O -
MS O +
and O +
Its O +
Pharmacokinetic O +
Application O -
. O +

A O +
rapid O +
sensitive O +
and O +
selective O +
liquid O +
chromatography O -
- O -
tandem O +
mass O +
spectrometry O +
( O -
LC O -
- O -
MS O -
/ O -
MS O -
) O +
method O +
was O +
developed O +
for O +
determination O +
of O +
timosaponin B-Chemical +
AIII I-Chemical +
( O -
TA B-Chemical -
- I-Chemical -
III I-Chemical -
) O +
in O +
rat O +
plasma O -
, O +
using O +
ginsenoside B-Chemical +
Re I-Chemical +
as O +
an O +
internal O +
standard O +
( O -
IS O -
) O -
. O +

TA B-Chemical -
- I-Chemical -
III I-Chemical +
and O +
the O +
IS O +
were O +
detected O +
in O +
MRM O +
mode O +
with O +
a O +
negative O +
ionization O +
electrospray O +
mass O +
spectrometer O -
. O +

The O +
calibration O +
curves O +
were O +
linear O +
over O +
the O +
concentration O +
ranges O +
from O +
11.14 O +
to O +
1114 O +
ng O -
/ O -
mL O +
and O +
the O +
lower O +
limit O +
of O +
quantification O +
( O -
LLOQ O -
) O +
was O +
11.14 O +
ng O -
/ O -
mL. O +
Intra O -
- O -
day O +
and O +
inter O -
- O -
day O +
precisions O +
( O -
RSD O -
) O +
were O +
within O +
10 O -
% O -
, O +
and O +
accuracy O +
ranged O +
from O +
6.4 O -
% O +
to O +
9.1 O -
% O -
. O +

The O +
extraction O +
recovery O +
at O +
three O +
concentrations O +
ranged O +
from O +
92.3 O -
% O +
to O +
95.5 O -
% O -
. O +

The O +
validated O +
method O +
was O +
successfully O +
applied O +
to O +
monitor O +
the O +
concentrations O +
of O +
TA B-Chemical -
- I-Chemical -
III I-Chemical +
in O +
rat O +
plasma O +
after O +
intragastric O +
administration O -
. O +

The O +
best O +
fit O +
pharmacokinetic O +
model O +
to O +
estimate O +
the O +
pharmacokinetic O +
parameters O +
was O +
a O +
single O +
compartment O +
model O +
with O +
weight O +
of O +
1 O -
/ O -
x2 O +
for O +
oral O +
administration O +
groups O +
of O +
rats O +
for O +
TA B-Chemical -
- I-Chemical -
III I-Chemical -
. O +

International O +
journal O +
of O +
molecular O +
science O +
best O +
paper O +
award O +
2013 O -
. O +

Since O +
2012 O -
, O +
International O +
Journal O +
of O +
Molecular O +
Science O +
has O +
instituted O +
an O +
annual O +
award O +
to O +
recognize O +
outstanding O +
papers O +
in O +
the O +
area O +
of O +
chemistry O -
, O +
molecular O +
physics O +
and O +
molecular O +
biology O +
that O +
meet O +
the O +
aims O -
, O +
scope O +
and O +
high O +
standards O +
of O +
this O +
journal O +
[ O -
1 O -
] O -
. O +

We O +
are O +
pleased O +
to O +
announce O +
the O +
second O +
" O -
International O +
Journal O +
of O +
Molecular O +
Science O +
Best O +
Paper O +
Award O -
" O +
for O +
2013 O -
. O +

Nominations O +
were O +
made O +
by O +
the O +
Section O +
Editor O -
- O -
in O -
- O -
Chiefs O +
of O +
International O +
Journal O +
of O +
Molecular O +
Science O -
, O +
with O +
all O +
papers O +
published O +
in O +
2009 O +
eligible O +
for O +
consideration O -
. O +

The O +
awards O +
are O +
issued O +
for O +
reviews O +
and O +
articles O +
separately O -
. O +

All O -
- O -
Cause O +
and O +
Cardiovascular O +
Mortality O +
in O +
Middle O -
- O -
Aged O +
People O +
With O +
Type O +
2 O +
Diabetes O +
Compared O +
With O +
People O +
Without O +
Diabetes O +
in O +
a O +
Large O +
U.K. O +
Primary O +
Care O +
Database O -
. O +

OBJECTIVEMiddle O -
- O -
aged O +
people O +
with O +
diabetes O +
have O +
been O +
reported O +
to O +
have O +
significantly O +
higher O +
risks O +
of O +
cardiovascular O +
events O +
than O +
people O +
without O +
diabetes O -
. O +

However O -
, O +
recent O +
falls O +
in O +
cardiovascular O +
disease O +
rates O +
and O +
more O +
active O +
management O +
of O +
risk O +
factors O +
may O +
have O +
abolished O +
the O +
increased O +
risk O -
. O +

We O +
aimed O +
to O +
provide O +
an O +
up O -
- O -
to O -
- O -
date O +
assessment O +
of O +
the O +
relative O +
risks O +
associated O +
with O +
type O +
2 O +
diabetes O +
of O +
all O -
- O -
cause O +
and O +
cardiovascular O +
mortality O +
in O +
middle O -
- O -
aged O +
people O +
in O +
the O +
U.K.RESEARCH O +
DESIGN O +
AND O +
METHODSUsing O +
data O +
from O +
the O +
General O +
Practice O +
Research O +
Database O -
, O +
from O +
2004 O +
to O +
2010 O -
, O +
we O +
conducted O +
a O +
cohort O +
study O +
of O +
87,098 O +
people O -
, O +
40 O -
- O -
65 O +
years O +
of O +
age O +
at O +
baseline O -
, O +
comparing O +
21,798 O +
with O +
type O +
2 O +
diabetes O +
and O +
65,300 O +
without O +
diabetes O -
, O +
matched O +
on O +
age O -
, O +
sex O -
, O +
and O +
general O +
practice O -
. O +

We O +
produced O +
hazard O +
ratios O +
( O -
HRs O -
) O +
for O +
mortality O +
and O +
compared O +
rates O +
of O +
blood O +
pressure O +
testing O -
, O +
cholesterol B-Chemical +
monitoring O -
, O +
and O +
use O +
of O +
aspirin B-Chemical -
, O +
statins O -
, O +
and O +
antihypertensive O +
drugs O -
. O +

RESULTSPeople O +
with O +
type O +
2 O +
diabetes O -
, O +
compared O +
with O +
people O +
without O +
diabetes O -
, O +
had O +
a O +
twofold O +
increased O +
risk O +
of O +
all O -
- O -
cause O +
mortality O +
( O -
HR O +
2.07 O +
[ O -
95 O -
% O +
CI O +
1.95 O -
- O -
2.20 O -
] O -
, O +
adjusted O +
for O +
smoking O -
) O +
and O +
a O +
threefold O +
increased O +
risk O +
of O +
cardiovascular O +
mortality O +
( O -
3.25 O +
[ O -
2.87 O -
- O -
3.68 O -
] O -
, O +
adjusted O +
for O +
smoking O -
) O -
. O +

Women O +
had O +
a O +
higher O +
relative O +
risk O +
than O +
men O -
, O +
and O +
people O +
< O -
55 O +
years O +
of O +
age O +
had O +
a O +
higher O +
relative O +
risk O +
than O +
those O +
> O -
55 O +
years O +
of O +
age O -
. O +

Monitoring O +
and O +
medication O +
rates O +
were O +
higher O +
in O +
those O +
with O +
diabetes O +
( O -
all O +
P O +
< O +
0.001 O -
) O -
.CONCLUSIONSDespite O +
efforts O +
to O +
manage O +
risk O +
factors O -
, O +
administer O +
effective O +
treatments O -
, O +
and O +
develop O +
new O +
therapies O -
, O +
middle O -
- O -
aged O +
people O +
with O +
type O +
2 O +
diabetes O +
remain O +
at O +
significantly O +
increased O +
risk O +
of O +
death O -
. O +

Reduced O +
Heart O +
Rate O +
Variability O +
Is O +
Associated O +
With O +
Increased O +
Arterial O +
Stiffness O +
in O +
Youth O +
With O +
Type O +
1 O +
Diabetes O -
: O +

The O +
SEARCH O +
Cardiovascular O +
Disease O +
Study O -
. O +

OBJECTIVEReduced O +
heart O +
rate O +
variability O +
( O -
HRV O -
) O +
and O +
increased O +
arterial O +
stiffness O +
( O -
AS O -
) O +
are O +
both O +
present O +
in O +
youth O +
with O +
type O +
1 O +
diabetes O -
. O +

However O -
, O +
it O +
is O +
unclear O +
whether O +
they O +
are O +
associated O +
and O +
whether O +
their O +
association O +
is O +
independent O +
of O +
cardiovascular O +
disease O +
( O -
CVD O -
) O +
risk O +
factors O -
. O +

RESEARCH O +
DESIGN O +
AND O +
METHODSThe O +
SEARCH O +
Cardiovascular O +
Disease O +
Study O +
explored O +
the O +
cross O -
- O -
sectional O +
relationships O +
between O +
HRV O +
and O +
several O +
measures O +
of O +
AS O +
in O +
youth O +
with O +
( O -
n O +
= O +
344 O -
) O +
and O +
without O +
( O -
n O +
= O +
171 O -
) O +
type O +
1 O +
diabetes O -
. O +

The O +
SphygmoCor O +
device O +
( O -
AtCor O +
Medical O -
, O +
Sydney O -
, O +
Australia O -
) O +
was O +
used O +
to O +
measure O +
HRV O +
using O +
SD O +
of O +
normal O +
R O -
- O -
R O +
interval O +
( O -
SDNN O -
) O -
, O +
as O +
well O +
as O +
AS O -
, O +
using O +
pulse O +
wave O +
velocity O +
in O +
the O +
carotid O +
to O +
femoral O +
segment O +
( O -
PWV O -
- O -
trunk O -
) O +
and O +
augmentation O +
index O +
adjusted O +
to O +
a O +
heart O +
rate O +
of O +
75 O +
bpm O +
( O -
AIx75 O -
) O -
. O +

Brachial O +
distensibility O +
( O -
BrachD O -
) O -
, O +
another O +
index O +
of O +
AS O -
, O +
was O +
measured O +
with O +
a O +
DynaPulse O +
instrument O +
( O -
Pulse O +
Metric O -
, O +
San O +
Diego O -
, O +
CA O -
) O -
. O +

Multiple O +
linear O +
regression O +
analyses O +
explored O +
the O +
associations O +
between O +
HRV O +
and O +
each O +
of O +
the O +
three O +
AS O +
measures O -
, O +
after O +
adjusting O +
for O +
demographic O +
characteristics O +
and O +
traditional O +
CVD O +
risk O +
factors O +
( O -
blood O +
pressure O -
, O +
lipids O -
, O +
obesity O -
, O +
microalbuminuria O -
, O +
and O +
smoking O -
) O +
separately O -
, O +
for O +
youth O +
with O +
and O +
without O +
type O +
1 O +
diabetes O -
. O +

RESULTSAmong O +
youth O +
with O +
type O +
1 O +
diabetes O -
, O +
lower O +
SDNN O +
was O +
associated O +
with O +
peripheral O +
AS O +
( O -
lower O +
BrachD O -
, O +
P O +
= O +
0.01 O -
; O +
r O -
( O -
2 O -
) O +
= O +
0.30 O -
) O +
and O +
central O +
AS O +
( O -
higher O +
PVW O -
- O -
trunk O -
, O +
P O +
< O +
0.0001 O -
; O +
r O -
( O -
2 O -
) O +
= O +
0.37 O -
; O +
and O +
higher O +
AIx75 O -
, O +
P O +
= O +
0.007 O -
; O +
r O -
( O -
2 O -
) O +
= O +
0.08 O -
) O -
. O +

These O +
associations O +
were O +
attenuated O +
with O +
adjustment O +
for O +
CVD O +
risk O +
factors O -
, O +
but O +
remained O +
statistically O +
significant O +
for O +
BrachD O +
and O +
PWV O -
- O -
trunk O -
. O +

While O +
a O +
similar O +
association O +
between O +
HRV O +
and O +
BrachD O +
was O +
present O +
in O +
control O +
youth O -
, O +
lower O +
HRV O +
was O +
not O +
associated O +
with O +
increased O +
central O +
AS O +
or O +
with O +
AIx75.CONCLUSIONSLongitudinal O +
studies O +
are O +
needed O +
to O +
understand O +
the O +
pathways O +
responsible O +
for O +
these O +
associations O -
. O +

Changes O +
in O +
A1C O +
Levels O +
Are O +
Significantly O +
Associated O +
With O +
Changes O +
in O +
Levels O +
of O +
the O +
Cardiovascular O +
Risk O +
Biomarker O +
hs O -
- O -
CRP O -
: O +
Results O +
from O +
SteP O +
Study O -
. O +

OBJECTIVEThe O +
effect O +
of O +
therapeutic O +
strategies O +
on O +
cardiovascular O +
( O -
CV O -
) O +
disease O +
can O +
be O +
evaluated O +
by O +
monitoring O +
changes O +
in O +
CV O +
risk O +
biomarkers O -
. O +

This O +
study O +
investigated O +
the O +
effect O +
of O +
a O +
structured O +
self O -
- O -
monitoring O +
of O +
blood O +
glucose B-Chemical +
( O -
SMBG O -
) O +
protocol O +
and O +
the O +
resulting O +
improvements O +
in O +
glycemic O +
control O +
on O +
changes O +
in O +
high O -
- O -
sensitivity O +
C O -
- O -
reactive O +
protein O +
( O -
hs O -
- O -
CRP O -
) O +
in O +
insulin O -
- O -
naïve O +
patients O +
with O +
type O +
2 O +
diabetes O -
. O +

RESEARCH O +
DESIGN O +
AND O +
METHODSThe O +
Structured O +
Testing O +
Program O +
( O -
STeP O -
) O +
study O +
was O +
a O +
prospective O -
, O +
cluster O -
- O -
randomized O -
, O +
multicenter O +
trial O +
in O +
which O +
483 O +
poorly O +
controlled O -
, O +
insulin O -
- O -
naïve O +
patients O +
with O +
type O +
2 O +
diabetes O +
were O +
randomized O +
to O +
active O +
control O +
( O -
ACG O -
) O +
or O +
structured O +
testing O +
( O -
STG O -
) O +
that O +
included O +
quarterly O +
structured O +
SMBG O -
. O +

Changes O +
in O +
A1C O -
, O +
hs O -
- O -
CRP O -
, O +
and O +
glycemic O +
variability O +
( O -
STG O +
subjects O +
only O -
) O +
were O +
measured O +
at O +
baseline O +
and O +
quarterly O -
. O +

RESULTSReductions O +
in O +
geometric O +
mean O +
hs O -
- O -
CRP O +
values O +
were O +
significantly O +
greater O +
in O +
the O +
STG O +
group O +
at O +
months O +
3 O +
( O -
P O +
= O +
0.005 O -
) O -
, O +
6 O +
( O -
P O +
= O +
0.0003 O -
) O -
, O +
and O +
12 O +
( O -
P O +
= O +
0.04 O -
) O +
than O +
in O +
the O +
ACG O +
group O -
. O +

STG O +
patients O +
at O +
high O +
CV O +
risk O +
( O -
> O -
3 O +
mg O -
/ O -
L O -
) O +
showed O +
significantly O +
greater O +
reductions O +
in O +
hs O -
- O -
CRP O +
levels O +
than O +
ACG O +
patients O +
at O +
high O +
CV O +
risk O -
: O +
-3.64 O +
mg O -
/ O -
dL O +
( O -
95 O -
% O +
CI O +
-4.21 O +
to O +
-3.06 O -
) O +
versus O +
-2.18 O +
mg O -
/ O -
dL O +
( O -
-2.93 O +
to O +
-1.43 O -
) O -
, O +
respectively O +
( O -
P O +
= O +
0.002 O -
) O -
. O +

There O +
was O +
a O +
strong O +
correlation O +
between O +
reductions O +
in O +
hs O -
- O -
CRP O +
and O +
A1C O +
in O +
both O +
groups O -
: O +
standardized O +
coefficient O +
( O -
β O -
) O +
was O +
0.25 O +
for O +
the O +
entire O +
cohort O +
( O -
P O +
< O +
0.0001 O -
) O -
, O +
0.31 O +
for O +
STG O +
( O -
P O +
< O +
0.0001 O -
) O -
, O +
and O +
0.16 O +
for O +
ACG O +
( O -
P O +
= O +
0.02 O -
) O -
.CONCLUSIONSReductions O +
in O +
hs O -
- O -
CRP O +
level O +
are O +
associated O +
with O +
reductions O +
in O +
A1C O +
but O +
not O +
reductions O +
in O +
lipids O +
or O +
glycemic O +
variability O -
. O +

Comprehensive O +
structured O +
SMBG O -
- O -
based O +
interventions O +
that O +
lower O +
A1C O +
may O +
translate O +
into O +
improvements O +
in O +
CV O +
risk O -
, O +
as O +
evidenced O +
by O +
levels O +
of O +
the O +
biomarker O +
hs O -
- O -
CRP O -
. O +

The O +
characteristics O +
of O +
genistin B-Chemical -
- O -
induced O +
inhibitory O +
effects O +
on O +
intestinal O +
motility O -
. O +

Genistin B-Chemical +
belongs O +
to O +
isoflavones B-Chemical -
. O +

Based O +
on O +
the O +
facts O +
that O +
genistin B-Chemical +
exerts O +
inhibitory O +
effects O +
on O +
the O +
contractility O +
of O +
vascular O +
smooth O +
muscle O -
, O -
the O +
present O +
study O +
was O +
designed O +
to O +
characterize O +
the O +
effects O +
of O +
genistin B-Chemical +
on O +
intestinal O +
contractility O +
and O +
evaluate O +
its O +
potential O +
clinical O +
implication O -
. O +

Ex O +
vivo O +
[ O -
isolated O +
jejunal O +
segment O +
( O -
IJS O -
) O +
of O +
rat O -
] O -
, O +
in O +
vitro O -
, O +
and O +
in O +
vivo O +
assays O +
were O +
used O +
in O +
the O +
study O -
. O +

The O +
results O +
indicated O +
that O +
genistin B-Chemical +
( O -
5 O -
- O -
80 O +
μmol O -
/ O -
L O -
) O +
inhibited O +
the O +
contraction O +
of O +
IJS O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
and O +
inhibited O +
the O +
increased O -
- O -
contractility O +
of O +
IJS O +
induced O +
by O +
acetylcholine B-Chemical +
( O -
ACh B-Chemical -
) O -
, O +
histamine B-Chemical -
, O +
high O +
Ca B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical -
, O +
and O +
erythromycin B-Chemical -
, O +
respectively O -
. O +

The O +
inhibitory O +
effects O +
of O +
genistin B-Chemical +
were O +
correlated O +
with O +
the O +
stimulation O +
of O +
alpha O +
adrenergic O +
and O +
beta O +
adrenergic O +
receptors O +
since O +
these O +
inhibitory O +
effects O +
were O +
significantly O +
blocked O +
in O +
the O +
presence O +
of O +
phentolamine B-Chemical +
and O +
propranolol B-Chemical +
respectively O -
. O +

No O +
further O +
inhibitory O +
effects O +
of O +
genistin B-Chemical +
were O +
observed O +
in O +
the O +
presence O +
of O +
verapamil B-Chemical +
or O +
in O +
Ca B-Chemical -
( I-Chemical -
2+ I-Chemical -
) I-Chemical -
-free O +
condition O -
, O +
indicating O +
genistin B-Chemical -
- O -
induced O +
inhibitory O +
effects O +
are O +
Ca B-Chemical -
( I-Chemical -
2+ I-Chemical -
) I-Chemical -
-dependent O -
. O +

Genistin B-Chemical +
decreased O +
myosin O +
light O +
chain O +
kinase O +
( O -
MLCK O -
) O +
protein O +
contents O +
and O +
MLCK O +
mRNA O +
expression O +
in O +
IJS O -
, O +
and O +
inhibited O +
both O +
phosphorylation O +
and O +
Mg B-Chemical -
( I-Chemical -
2+ I-Chemical -
) I-Chemical -
-ATPase O +
activity O +
of O +
purified O +
myosin O -
, O +
implicating O +
that O +
the O +
decrease O +
of O +
MLCK O +
contents O +
and O +
inhibition O +
of O +
MLCK O +
activity O +
are O +
involved O +
in O +
the O +
genistin B-Chemical -
- O -
induced O +
inhibitory O +
effects O -
. O +

The O +
study O +
suggests O +
the O +
potential O +
clinical O +
implications O +
of O +
genistin B-Chemical +
in O +
relieving O +
intestinal O +
hypercontractility O -
. O +

Effect O +
of O +
excipients O +
on O +
acetaminophen B-Chemical +
metabolism O +
and O +
its O +
implications O +
for O +
prevention O +
of O +
liver O +
injury O -
. O +

Acetaminophen B-Chemical +
poisoning O +
is O +
the O +
most O +
frequent O +
cause O +
of O +
acute O +
hepatic O +
failure O +
in O +
the O +
US O -
. O +

Toxicity O +
requires O +
reductive O +
metabolism O +
of O +
acetaminophen B-Chemical -
, O +
primarily O +
via O +
CYP2E1 O -
. O +

Liquid O +
acetaminophen B-Chemical +
preparations O +
contain O +
propylene B-Chemical +
glycol I-Chemical -
, O +
a O +
common O +
excipient O +
that O +
has O +
been O +
shown O +
to O +
reduce O +
hepatocellular O +
injury O +
in O +
vitro O +
and O +
in O +
rodents O -
. O +

Children O +
are O +
less O +
susceptible O +
to O +
acetaminophen B-Chemical +
toxicity O +
for O +
unclear O +
reasons O -
. O +

We O +
conducted O +
a O +
pharmacokinetic O +
single O -
- O -
blinded O +
crossover O +
study O +
of O +
15 O +
healthy O +
adult O +
volunteers O +
comparing O +
the O +
CYP2E1 O +
and O +
conjugative O +
metabolism O +
of O +
a O +
15 O +
mg O -
/ O -
kg O +
dose O +
of O +
liquid O +
versus O +
solid O +
preparations O +
of O +
acetaminophen B-Chemical -
. O +

Measured O +
AUC O -
's O +
for O +
the O +
CYP2E1 O +
metabolites O +
were O +
16 O -
- O -
17 O -
% O +
lower O +
and O +
extrapolated O +
AUC O -
's O +
were O +
25 O -
- O -
28 O -
% O +
lower O +
in O +
the O +
liquid O +
formulation O +
arm O +
while O +
there O +
was O +
no O +
difference O +
in O +
conjugative O +
metabolite O +
production O -
. O +

The O +
formation O +
rate O +
constants O +
for O +
reductive O +
metabolites O +
were O +
equivalent O +
between O +
solid O +
and O +
liquid O +
formulations O +
indicating O +
that O +
enzyme O +
inhibition O +
was O +
competitive O -
. O +

Propylene B-Chemical +
glycol I-Chemical -
, O +
an O +
established O +
CYP2E1 O +
competitive O +
antagonist O -
, O +
was O +
detected O +
in O +
the O +
liquid O +
formulation O +
but O +
not O +
solid O +
formulation O +
arm O -
. O +

Since O +
children O +
tend O +
to O +
ingest O +
liquid O +
preparations O -
, O +
the O +
protective O +
effect O +
of O +
this O +
excipient O +
could O +
explain O +
their O +
decreased O +
susceptibility O +
to O +
acetaminophen B-Chemical +
toxicity O -
. O +

A O +
less O +
hepatotoxic O +
formulation O +
of O +
acetaminophen B-Chemical +
could O +
potentially O +
be O +
developed O +
if O +
co O -
- O -
formulated O +
with O +
a O +
CYP2E1 O +
inhibitor O -
. O +

Addition O +
of O +
cilostazol B-Chemical +
to O +
conventional O +
dual O +
antiplatelet O +
therapy O +
reduces O +
the O +
risk O +
of O +
cardiac O +
events O +
and O +
restenosis O +
after O +
drug O -
- O -
eluting O +
stent O +
implantation O -
: O +
a O +
meta O -
- O -
analysis O -
. O +

This O +
meta O -
- O -
analysis O +
was O +
performed O +
to O +
compare O +
the O +
risk O +
of O +
cardiac O +
events O +
and O +
restenosis O +
between O +
triple O +
antiplatelet O +
therapy O +
( O -
TAT O -
, O +
addition O +
of O +
cilostazol B-Chemical +
to O +
aspirin B-Chemical +
and O +
clopidogrel B-Chemical -
) O +
and O +
conventional O +
dual O +
antiplatelet O +
therapy O +
( O -
DAT O -
, O +
aspirin B-Chemical +
and O +
clopidogrel B-Chemical -
) O +
in O +
drug O -
- O -
eluting O +
stents O +
( O -
DES O -
) O +
implantation O +
patients O -
. O +

We O +
performed O +
PUBMED O -
, O +
MEDLINE O -
, O +
EMBASE O -
, O +
and O +
Cochrane O +
CENTRAL O +
searches O +
for O +
randomized O +
clinical O +
trials O +
of O +
TAT O +
versus O +
DAT O +
in O +
patients O +
after O +
DES O +
implantation O -
. O +

Five O +
clinical O +
trials O +
were O +
involved O +
in O +
the O +
study O -
. O +

TAT O +
was O +
associated O +
with O +
a O +
36 O -
% O +
reduction O +
in O +
major O +
adverse O +
cardiac O +
events O +
( O -
MACE O -
; O +
odds O +
ratio O +
( O -
OR O -
) O +
= O +
0.64 O -
; O +
95 O -
% O +
confidence O +
interval O +
( O -
CI O -
) O +
= O +
0.51 O -
- O -
0.81 O -
, O +
P O +
< O +
.01 O -
) O -
, O +
a O +
40 O -
% O +
reduction O +
( O -
OR O +
= O +
0.60 O -
, O +
95 O -
% O +
CI O +
= O +
0.44 O -
- O -
0.80 O -
; O +
P O +
< O +
.01 O -
) O +
in O +
target O +
vessel O +
revascularization O +
( O -
TVR O -
) O -
, O +
a O +
44 O -
% O +
reduction O +
( O -
OR O +
= O +
0.56 O -
, O +
95 O -
% O +
CI O +
= O +
0.34 O -
- O -
0.91 O -
; O +
P O +
= O +
.02 O -
) O +
in O +
target O +
lesion O +
revascularization O +
( O -
TLR O -
) O +
and O +
a O +
47% O -
/ O -
44 O -
% O +
reduction O +
in O +
in O -
- O -
segment O -
/ O -
in O -
- O -
stent O +
restenosis O +
( O -
P O +
< O +
.01 O -
) O +
and O +
lower O +
in O -
- O -
segment O -
/ O -
in O -
- O -
stent O +
late O +
loss O +
( O -
P O +
< O +
.01 O -
) O -
. O +

As O +
regards O +
to O +
the O +
safety O +
assessment O -
, O +
there O +
was O +
no O +
significant O +
difference O +
about O +
the O +
risk O +
of O +
stent O +
thrombosis O +
and O +
bleeding O +
between O +
TAT O +
and O +
DAT O +
group O -
, O +
while O +
the O +
risk O +
of O +
gastrointestinal O +
trouble O +
was O +
significantly O +
higher O +
in O +
TAT O +
group O +
( O -
OR O +
= O +
2.46 O -
, O +
95 O -
% O +
CI O +
= O +
1.25 O -
- O -
4.86 O -
; O +
P O +
< O +
.01 O -
) O -
. O +

Addition O +
of O +
cilostazol B-Chemical +
to O +
DAT O +
reduced O +
the O +
incidence O +
of O +
MACE O -
, O +
TVR O -
, O +
and O +
TLR O +
after O +
DES O +
implantation O -
. O +

TAT O +
also O +
reduced O +
the O +
risk O +
of O +
restenosis O +
and O +
late O +
loss O +
in O +
patients O +
after O +
DES O +
implantation O -
. O +

Blood O +
Pressure O +
Lowering O +
Effect O +
of O +
Nigella O +
sativa O +
L. O +
Seed O +
Oil O +
in O +
Healthy O +
Volunteers O -
: O +

A O +
Randomized O -
, O +
Double O -
- O -
Blind O -
, O +
Placebo O -
- O -
controlled O +
Clinical O +
Trial O -
. O +

Nigella O +
sativa O +
L. O +
seeds O +
( O -
N. O +
sativa O -
) O +
have O +
been O +
used O +
as O +
a O +
traditional O +
remedy O +
for O +
a O +
wide O +
range O +
of O +
diseases O +
including O +
hypertension O -
. O +

The O +
present O +
study O +
was O +
performed O +
to O +
explore O +
the O +
effects O +
of O +
N. O +
sativa O +
oil O +
on O +
blood O +
pressure O +
( O -
BP O -
) O +
in O +
healthy O +
volunteers O -
. O +

In O +
a O +
double O -
- O -
blind O -
, O +
randomized O +
study O -
, O +
70 O +
healthy O +
volunteers O +
aged O +
34 O +
to O +
63 O +
years O +
with O +
systolic O +
BP O +
from O +
110 O +
to O +
140 O +
mmHg O +
and O +
diastolic O +
BP O +
from O +
60 O +
to O +
90 O +
mmHg O +
were O +
randomly O +
allocated O +
to O +
receive O +
2.5 O +
mL O +
N. O +
sativa O +
oil O +
or O +
placebo O +
two O +
times O +
a O +
day O +
for O +
8 O +
weeks O -
. O +

The O +
systolic O +
and O +
diastolic O +
BPs O -
, O +
body O +
mass O +
index O +
and O +
blood O +
levels O +
of O +
aspartate B-Chemical +
transaminase O -
, O +
alanine B-Chemical +
transaminase O -
, O +
alkaline O +
phosphatase O -
, O +
creatinine B-Chemical +
and O +
blood O +
urea B-Chemical +
nitrogen B-Chemical +
were O +
determined O +
at O +
baseline O +
and O +
endpoint O -
. O +

Results O +
showed O +
that O +
in O +
N. O +
sativa O +
oil O +
treated O +
group O +
the O +
systolic O +
and O +
diastolic O +
BPs O +
decreased O +
significantly O +
compared O +
with O +
baseline O +
and O +
placebo O +
group O +
at O +
the O +
endpoint O -
. O +

Other O +
parameters O +
did O +
not O +
significantly O +
change O +
in O +
both O +
groups O +
at O +
the O +
endpoint O -
. O +

No O +
adverse O +
effects O +
were O +
reported O -
. O +

In O +
conclusion O -
, O +
oral O +
daily O +
administration O +
of O +
5 O +
mL O +
N. O +
sativa O +
oil O +
to O +
healthy O +
volunteers O +
for O +
8 O +
weeks O +
lowers O +
systolic O +
and O +
diastolic O +
BPs O +
without O +
any O +
adverse O +
effects O -
. O +

Copyright O +
© O +
2013 O +
John O +
Wiley O +
& O +
Sons O -
, O +
Ltd. O +

Readily O +
accessible O +
fluorescent O +
probes O +
for O +
sensitive O +
biological O +
imaging O +
of O +
hydrogen B-Chemical +
peroxide I-Chemical -
. O +

Hydrogen B-Chemical +
peroxide I-Chemical +
is O +
a O +
major O +
component O +
of O +
oxygen B-Chemical +
metabolism O +
in O +
biological O +
systems O +
that O -
, O +
when O +
present O +
in O +
high O +
concentrations O -
, O +
can O +
lead O +
to O +
oxidative O +
stress O +
in O +
cells O -
. O +

Noninvasive O +
molecular O +
imaging O +
of O +
H B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
O I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
using O +
fluorogenic O +
systems O +
represents O +
an O +
effective O +
way O +
to O +
detect O +
and O +
measure O +
the O +
accumulation O +
of O +
this O +
metabolite O -
. O +

Herein O -
, O +
we O +
detail O +
the O +
development O +
of O +
robust O +
H B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
O I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
-sensitive O +
fluorescent O +
probes O +
using O +
a O +
boronic B-Chemical +
ester I-Chemical +
trigger O +
appended O +
to O +
the O +
fluorophore O +
through O +
a O +
benzyl B-Chemical +
ether I-Chemical +
linkage O -
. O +

A O +
major O +
advantage O +
of O +
the O +
probes O +
presented O +
here O +
is O +
their O +
synthetic O +
accessibility O -
, O +
with O +
only O +
one O +
step O +
needed O +
to O +
generate O +
the O +
probes O +
on O +
the O +
gram O +
scale O -
. O +

The O +
sensitivity O +
of O +
the O +
probes O +
was O +
evaluated O +
in O +
simulated O +
physiological O +
conditions O -
, O +
showing O +
micromolar O +
sensitivity O +
to O +
H B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
O I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
. O +

The O +
probes O +
were O +
tested O +
in O +
biological O +
model O +
systems O -
, O +
demonstrating O +
effective O +
imaging O +
of O +
unstimulated O -
, O +
endogenous O +
H B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
O I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
levels O +
in O +
RAW O +
264.7 O +
cells O +
and O +
murine O +
brain O +
tissue O -
. O +

Mifepristone B-Chemical +
for O +
management O +
of O +
Cushing O -
's O +
syndrome O -
. O +

Cushing O -
's O +
syndrome O +
is O +
a O +
debilitating O +
endocrine O +
disorder O +
caused O +
by O +
elevated O +
circulating O +
glucocorticoid O +
levels O -
. O +

Although O +
uncommon O -
, O +
Cushing O -
's O +
syndrome O +
is O +
associated O +
with O +
significant O +
morbidity O +
necessitating O +
rapid O +
reversal O +
of O +
hypercortisolemia O -
. O +

Primary O +
therapy O +
for O +
most O +
patients O +
with O +
Cushing O -
's O +
syndrome O +
is O +
surgical O -
, O +
but O +
many O +
patients O +
will O +
require O +
additional O +
treatments O +
with O +
radiation O +
or O +
drugs O -
. O +

Although O +
several O +
options O +
for O +
drug O +
therapy O +
exist O -
, O +
few O +
are O +
readily O +
available O +
and O +
all O +
have O +
dose O -
- O -
limiting O +
adverse O +
effects O -
. O +

Mifepristone B-Chemical +
( O -
RU B-Chemical +
486 I-Chemical -
) O -
, O +
a O +
first O -
- O -
in O -
- O -
class O +
glucocorticoid O +
receptor O +
antagonist O -
, O +
was O +
approved O +
by O +
the O +
United O +
States O +
Food O +
and O +
Drug O +
Administration O +
in O +
2012 O +
for O +
use O +
in O +
Cushing O -
's O +
syndrome O +
to O +
control O +
hyperglycemia O +
in O +
patients O +
who O +
are O +
not O +
surgical O +
candidates O +
or O +
have O +
not O +
achieved O +
remission O +
from O +
surgery O -
. O +

The O +
drug O +
is O +
approved O +
for O +
oral O +
once O -
- O -
daily O +
administration O -
. O +

In O +
its O +
pivotal O +
trial O -
, O +
60 O -
% O +
of O +
patients O +
responded O +
to O +
mifepristone B-Chemical +
with O +
significant O +
improvements O +
in O +
glycemic O +
control O +
and O +
38 O -
% O +
had O +
a O +
reduction O +
in O +
diastolic O +
blood O +
pressure O -
. O +

The O +
most O +
common O +
adverse O +
events O +
were O +
nausea O -
, O +
fatigue O -
, O +
headache O -
, O +
endometrial O +
hyperplasia O -
, O +
and O +
hypokalemia O -
. O +

Adrenal O +
insufficiency O +
occurred O +
in O +
fewer O +
than O +
5 O -
% O +
of O +
patients O -
. O +

The O +
recommended O +
starting O +
dosage O +
of O +
mifepristone B-Chemical +
is O +
300 O +
mg O -
/ O -
day O -
. O +

The O +
dosage O +
may O +
be O +
increased O +
every O +
2 O -
- O -
4 O +
weeks O +
up O +
to O +
a O +
maximum O +
of O +
1200 O +
mg O -
/ O -
day O -
, O +
although O +
it O +
should O +
not O +
exceed O +
20 O +
mg O -
/ O -
kg O -
/ O -
day O -
. O +

Significant O +
drug O -
- O -
drug O +
interactions O +
exist O +
due O +
to O +
mifepristone B-Chemical -
's O +
effects O +
on O +
a O +
number O +
of O +
cytochrome O +
P450 O +
enzymes O -
. O +

Despite O +
its O +
limitations O -
, O +
mifepristone B-Chemical +
is O +
a O +
welcome O +
addition O +
and O +
an O +
appropriate O +
alternative O +
to O +
the O +
available O +
drug O +
therapy O +
for O +
Cushing O -
's O +
syndrome O -
. O +

Pu O -
- O -
erh O +
tea O +
hot O -
- O -
water O +
extract O +
activates O +
Akt O +
and O +
induces O +
insulin O -
- O -
independent O +
glucose B-Chemical +
transport O +
in O +
rat O +
skeletal O +
muscle O -
. O +

Skeletal O +
muscle O +
is O +
a O +
major O +
organ O +
that O +
is O +
important O +
for O +
whole O -
- O -
body O +
glucose B-Chemical +
metabolism O -
. O +

We O +
found O +
that O +
when O +
isolated O +
rat O +
epitrochlearis O +
muscle O +
was O +
incubated O +
with O +
a O +
Pu O -
- O -
erh O +
tea O +
hot O -
- O -
water O +
extract O +
( O -
PTE O -
) O +
for O +
30 O +
min O -
, O +
the O +
rate O +
of O +
3-O B-Chemical -
- I-Chemical -
methyl I-Chemical -
- I-Chemical -
D I-Chemical -
- I-Chemical -
glucose I-Chemical +
( O -
3MG B-Chemical -
) O +
transport O +
increased O +
in O +
the O +
absence O +
of O +
insulin O -
. O +

This O +
activation O +
was O +
associated O +
with O +
an O +
increase O +
in O +
Ser B-Chemical -
( O -
473 O -
) O +
phosphorylation O +
of O +
Akt O -
, O +
a O +
signaling O +
intermediary O +
leading O +
to O +
insulin O -
- O -
dependent O +
glucose B-Chemical +
transport O -
, O +
but O +
not O +
Tyr B-Chemical -
( O -
458 O -
) O +
phosphorylation O +
of O +
phosphoinositide O +
3-kinase O +
p85 O -
, O +
an O +
upstream O +
molecule O +
of O +
Akt O -
. O +

PTE O -
- O -
stimulated O +
3MG O +
transport O +
was O +
also O +
not O +
accompanied O +
by O +
Thr B-Chemical -
( O -
172 O -
) O +
phosphorylation O +
of O +
the O +
catalytic O +
α O -
- O -
subunit O +
of O +
5'-AMP O -
- O -
activated O +
protein O +
kinase O +
( O -
AMPK O -
) O -
. O +

Gallic B-Chemical +
acid I-Chemical -
, O +
a O +
water O -
- O -
soluble O +
ingredient O +
in O +
Pu O -
- O -
erh O +
tea O -
, O +
stimulated O +
Akt O +
phosphorylation O -
, O +
but O +
not O +
AMPK O +
phosphorylation O -
. O +

These O +
results O +
suggest O +
that O +
Pu O -
- O -
erh O +
tea O +
potentially O +
promotes O +
skeletal O +
muscle O +
glucose B-Chemical +
transport O +
at O +
least O +
in O +
part O +
by O +
activating O +
Akt O -
. O +

Potential O +
for O +
preventive O +
effects O +
of O +
cocoa O +
and O +
cocoa O +
polyphenols B-Chemical +
in O +
cancer O -
. O +

Prevention O +
of O +
cancer O +
through O +
the O +
diet O +
is O +
receiving O +
increasing O +
interest O -
, O +
and O +
cocoa O +
because O +
of O +
its O +
polyphenolic B-Chemical +
compounds O +
has O +
become O +
an O +
important O +
potential O +
chemopreventive O +
and O +
therapeutic O +
natural O +
agent O -
. O +

Cocoa O +
and O +
its O +
main O +
polyphenols B-Chemical +
have O +
been O +
reported O +
to O +
interfere O +
at O +
the O +
initiation O -
, O +
promotion O +
and O +
progression O +
of O +
cancer O -
. O +

Cocoa O +
flavonoids B-Chemical +
have O +
been O +
demonstrated O +
to O +
influence O +
several O +
important O +
biological O +
functions O +
in O +
vitro O +
and O +
in O +
vivo O +
by O +
their O +
free O +
radical O +
scavenging O +
ability O +
or O +
through O +
the O +
regulation O +
of O +
signal O +
transduction O +
pathways O +
to O +
stimulate O +
apoptosis O +
and O +
to O +
inhibit O +
inflammation O -
, O +
cellular O +
proliferation O -
, O +
apoptosis O -
, O +
angiogenesis O +
and O +
metastasis O -
. O +

Nevertheless O -
, O +
these O +
molecular O +
mechanisms O +
of O +
action O +
are O +
not O +
completely O +
characterized O +
and O +
many O +
features O +
remain O +
to O +
be O +
elucidated O -
. O +

The O +
aim O +
of O +
this O +
review O +
is O +
to O +
provide O +
insights O +
into O +
the O +
molecular O +
basis O +
of O +
the O +
potential O +
chemopreventive O +
activity O +
of O +
cocoa O +
and O +
its O +
polyphenolic B-Chemical +
components O +
by O +
summarizing O +
cell O +
culture O +
and O +
animal O +
models O +
studies O -
, O +
as O +
well O +
as O +
interventional O +
and O +
epidemiological O +
studies O +
on O +
humans O -
. O +

Biosafety O +
and O +
antioxidant O +
effects O +
of O +
a O +
beverage O +
containing O +
silymarin O +
and O +
arginine B-Chemical -
. O +

A O +
pilot O -
, O +
human O +
intervention O +
cross O -
- O -
over O +
trial O -
. O +

The O +
study O +
objective O +
was O +
to O +
investigate O +
the O +
potential O +
of O +
a O +
beverage O +
containing O +
silymarin O +
and O +
l B-Chemical -
- I-Chemical -
arginine I-Chemical +
to O +
alter O +
basic O +
physiological O +
and O +
urodynamic O +
parameters O +
in O +
22 O +
normal O +
healthy O +
men O +
aged O +
38 O -
- O -
59years O -
. O +

The O +
volunteers O +
drank O +
500ml O -
/ O -
day O +
beverage O +
without O +
silymarin O +
and O +
l B-Chemical -
- I-Chemical -
arginine I-Chemical +
for O +
10days O +
followed O -
, O +
after O +
a O +
7-day O +
washout O +
period O -
, O +
by O +
the O +
beverage O +
with O +
400 O -
mg O +
silymarin O +
and O +
295 O -
mg O +
l B-Chemical -
- I-Chemical -
arginine I-Chemical +
for O +
10days O -
. O +

Blood O +
and O +
urine O +
samples O +
were O +
collected O +
on O +
days O +
0 O -
, O +
10 O +
and O +
27 O -
. O +

The O +
beverages O +
were O +
well O -
- O -
tolerated O +
with O +
no O +
adverse O +
effects O -
. O +

Most O +
of O +
the O +
biochemical O -
, O +
hematological O +
and O +
urodynamic O +
parameters O +
remained O +
unchanged O -
. O +

Total O +
antioxidant O +
capacity O -
, O +
total O +
level O +
of O +
antioxidants O -
, O +
lipoperoxidation O +
products O +
( O -
malondialdehyde B-Chemical -
) O -
, O +
advanced O +
oxidation O +
products O +
of O +
proteins O +
in O +
plasma O +
and O +
glutathione B-Chemical -
, O +
glutathione B-Chemical +
peroxidase O -
, O +
glutathione B-Chemical +
reductase O -
, O +
superoxide B-Chemical +
dismutase O +
and O +
catalase O +
levels O +
in O +
erythrocytes O +
were O +
not O +
influenced O -
. O +

Serum O +
γ O -
- O -
glutamyl O +
transferase O -
, O +
malondialdehyde B-Chemical +
level O +
and O +
activity O +
of O +
glutathione B-Chemical +
S O -
- O -
transferase O +
in O +
erythrocytes O +
were O +
lowered O +
at O +
day O +
27 O +
and O +
the O +
concentration O +
of O +
total O +
plasma O +
SH B-Chemical -
- O -
groups O +
was O +
higher O +
on O +
day O +
10 O -
. O +

Using O +
an O +
ex O +
vivo O +
system O -
, O +
we O +
found O +
that O +
silymarin O -
/ O -
silybin B-Chemical +
at O +
10 O -
- O -
100μM O +
is O +
able O +
to O +
adsorb O +
onto O +
human O +
erythrocytes O +
and O +
the O +
complexes O +
displayed O +
antioxidant O +
properties O +
as O +
studied O +
using O +
ex O +
situ O +
square O -
- O -
wave O +
voltammetry O -
. O +

The O +
trial O +
showed O +
that O +
silymarin O +
in O +
vivo O +
may O +
protect O +
erythrocytes O +
against O +
oxidative O +
damage O -
. O +

Ghrelin O +
inhibits O +
sodium B-Chemical +
metabisulfite I-Chemical +
induced O +
oxidative O +
stress O +
and O +
apoptosis O +
in O +
rat O +
gastric O +
mucosa O -
. O +

This O +
study O +
aimed O +
to O +
investigate O +
the O +
effect O +
of O +
ghrelin O +
administration O +
on O +
sulfite B-Chemical +
induced O +
oxidative O +
and O +
apoptotic O +
changes O +
in O +
rat O +
gastric O +
mucosa O -
. O +

Forty O +
male O +
albino O +
Wistar O +
rats O +
were O +
randomized O +
into O +
control O +
( O -
C O -
) O -
, O +
sodium B-Chemical +
metabisulfite I-Chemical +
( O -
Na2S2O5 B-Chemical -
) O +
treated O +
( O -
S O -
) O -
, O +
ghrelin O +
treated O +
( O -
G O -
) O +
and O -
, O +
Na2S2O5+ghrelin B-Chemical +
treated O +
( O -
SG O -
) O +
groups O -
. O +

Sodium B-Chemical +
metabisulfite I-Chemical +
( O -
100mg O -
/ O -
kg O -
/ O -
day O -
) O +
was O +
given O +
by O +
gastric O +
gavage O +
and O -
, O +
ghrelin O +
( O -
20μg O -
/ O -
kg O -
/ O -
day O -
) O +
was O +
given O +
intraperitoneally O +
for O +
5weeks O -
. O +

Plasma O -
- B-Chemical -
S O -
- O -
sulfonate B-Chemical +
level O +
was O +
increased O +
in O +
S O +
and O +
SG O +
groups O -
. O +

Na2S2O5 B-Chemical +
administration O +
significantly O +
elevated O +
total O +
oxidant O +
status O +
( O -
TOS O -
) O +
levels O +
while O +
depleting O +
total O +
antioxidant O +
status O +
( O -
TAS O -
) O +
levels O +
in O +
gastric O +
mucosa O -
. O +

Ghrelin O +
significantly O +
decreased O +
gastric O +
TOS O +
levels O +
in O +
the O +
SG O +
group O +
compared O +
with O +
the O +
S O +
group O -
. O +

Additionally O -
, O +
TAS O +
levels O +
were O +
found O +
to O +
be O +
higher O +
in O +
SG O +
group O +
in O +
reference O +
to O +
S O +
group O -
. O +

Na2S2O5 B-Chemical +
administration O +
also O +
markedly O +
increased O +
the O +
number O +
of O +
apoptotic O +
cells O -
, O +
cleaved O +
caspase-3 O +
and O +
PAR O +
expression O +
( O -
PARP O +
activity O +
indicator O -
) O +
and O -
, O +
decreased O +
Ki67 O +
expression O +
( O -
cell O +
proliferation O +
index O -
) O +
in O +
gastric O +
mucosal O +
cells O -
. O +

Ghrelin O +
treatment O +
decreased O +
the O +
number O +
apoptotic O +
cells O -
, O +
cytochrome O +
C O +
release O -
, O +
PAR O +
and O -
, O +
caspase-3 O +
expressions O +
while O +
increasing O +
Ki67 O +
expression O +
in O +
gastric O +
mucosa O +
exposed O +
to O +
Na2S2O5 B-Chemical -
. O +

In O +
conclusion O -
, O +
we O +
suggest O +
that O +
ghrelin O +
treatment O +
might O +
ameliorate O +
ingested O -
- O -
Na2S2O5 B-Chemical +
induced O +
gastric O +
mucosal O +
injury O +
stemming O +
from O +
apoptosis O +
and O +
oxidative O +
stress O +
in O +
rats O -
. O +

Vitamin B-Chemical +
A I-Chemical +
and O +
retinoid B-Chemical +
signaling O -
: O +
genomic O +
and O +
non O -
- O -
genomic O +
effects O -
. O +

Vitamin B-Chemical +
A I-Chemical +
or O +
retinol B-Chemical +
is O +
arguably O +
the O +
most O +
multifunctional O +
vitamin B-Chemical +
in O +
the O +
human O +
body O +
as O +
it O +
is O +
essential O +
from O +
embryogenesis O +
to O +
adulthood O -
. O +

The O +
pleiotropic O +
effects O +
of O +
vitamin B-Chemical +
A I-Chemical +
are O +
exerted O +
mainly O +
by O +
one O +
active O +
metabolite O -
, O +
all B-Chemical -
- I-Chemical -
trans I-Chemical +
retinoic I-Chemical +
acid I-Chemical +
( O -
atRA B-Chemical -
) O -
, O +
which O +
regulates O +
the O +
expression O +
of O +
a O +
battery O +
of O +
target O +
genes O +
through O +
several O +
families O +
of O +
nuclear O +
receptors O +
( O -
RARs O -
, O +
RXRs O +
and O +
PPARβ O -
/ O -
δ O -
) O -
, O +
polymorphic O +
retinoic B-Chemical +
acid I-Chemical +
( O -
RA O -
) O +
response O +
elements O +
and O +
multiple O +
coregulators O -
. O +

It O +
also O +
involves O +
extra O +
nuclear O +
and O +
non O -
- O -
transcriptional O +
effects O +
such O +
as O +
the O +
activation O +
of O +
kinase O +
cascades O -
, O +
which O +
are O +
integrated O +
in O +
the O +
nucleus O +
via O +
the O +
phosphorylation O +
of O +
several O +
actors O +
of O +
RA O +
signaling O -
. O +

However O -
, O +
vitamin B-Chemical +
A I-Chemical +
itself O +
proved O +
recently O +
to O +
be O +
active O +
and O +
RARs O +
to O +
be O +
present O +
in O +
the O +
cytosol O +
to O +
regulate O +
translation O +
and O +
cell O +
plasticity O -
. O +

All O +
these O +
new O +
concepts O +
expand O +
the O +
scope O +
of O +
the O +
biologic O +
functions O +
of O +
vitamin B-Chemical +
A I-Chemical +
and O +
RA O -
. O +

Synthesis O +
and O +
antiproliferative O +
activity O +
evaluation O +
of O +
imidazole B-Chemical -
- O -
based O +
indeno B-Chemical -
[ I-Chemical -
1,2-b I-Chemical -
] I-Chemical -
quinoline-9,11-dione I-Chemical +
derivatives O -
. O +

A O +
series O +
of O +
new O +
imidazole B-Chemical +
substituted O +
indeno B-Chemical -
[ I-Chemical -
1,2-b I-Chemical -
] I-Chemical -
quinoline-9,11-dione I-Chemical +
derivatives O +
were O +
synthesized O +
and O +
evaluated O +
for O +
their O +
antiproliferative O +
effects O +
on O +
HeLa O -
, O +
LS180 O -
, O +
MCF-7 O +
and O +
Jurkat O +
human O +
cancer O +
cell O +
lines O -
. O +

Antiproliferative O +
effects O +
were O +
evaluated O +
using O +
MTT B-Chemical +
assay O -
. O +

Prepared O +
compounds O +
exhibited O +
weak O +
to O +
good O +
antiproliferative O +
activity O +
in O +
evaluated O +
cell O +
lines O -
. O +

Prepared O +
compounds O +
were O +
more O +
potent O +
in O +
Jurkat O +
cell O +
line O +
when O +
compared O +
to O +
LS180 O -
, O +
HeLa O +
and O +
MCF-7 O +
cell O +
lines O -
. O +

Compounds O +
29 O +
( O -
IC16 O +
= O +
0.7 O +
μM O -
) O +
and O +
31 O +
( O -
IC16 O +
= O +
1.7 O +
μM O -
) O +
and O +
33 O +
( O -
IC16 O +
= O +
1.7 O +
μM O -
) O +
were O +
found O +
to O +
be O +
the O +
most O +
potent O +
molecules O +
on O +
Jurkat O +
cell O +
lines O -
. O +

Moreover O -
; O +
it O +
was O +
found O +
that O +
some O +
of O +
the O +
tested O +
compounds O +
bearing O +
imidazole-2-yl B-Chemical +
moiety O +
on O +
the O +
C11-position O +
of O +
dihydropyridine B-Chemical +
ring O +
exhibited O +
superior O +
antiproliferative O +
activity O +
in O +
comparison O +
to O +
cis B-Chemical -
- I-Chemical -
platin I-Chemical +
especially O +
in O +
Jurkat O +
cell O +
line O +
( O -
compounds O +
29 O -
, O +
31 O -
, O +
and O +
33 O -
) O -
. O +

It O +
seemed O +
that O +
the O +
introduction O +
of O +
electron O -
- O -
withdrawing O +
groups O +
on O +
the O +
imidazole B-Chemical +
ring O +
enhanced O +
the O +
antiproliferative O +
potential O +
of O +
these O +
compounds O +
( O -
compounds O +
27 O -
, O +
29 O +
and O +
31 O -
) O -
. O +

The O +
results O +
of O +
this O +
study O +
proposed O +
that O +
some O +
of O +
the O +
imidazole B-Chemical +
substituted O +
indeno B-Chemical -
[ I-Chemical -
1,2-b I-Chemical -
] I-Chemical -
quinoline-9,11-dione I-Chemical +
compounds O +
may O +
act O +
as O +
efficient O +
anticancer O +
agents O +
in O +
vitro O -
, O +
emphasizing O +
their O +
potential O +
role O +
as O +
a O +
source O +
for O +
rational O +
design O +
of O +
potent O +
antiproliferative O +
agents O -
. O +

Epigenetic O +
regulation O +
of O +
hypoxia O +
inducible O +
factor O +
in O +
diseases O +
and O +
therapeutics O -
. O +

Hypoxia O -
- O -
inducible O +
factors O +
( O -
HIFs O -
) O +
are O +
master O +
regulators O +
of O +
angiogenesis O +
and O +
cellular O +
adaptation O +
in O +
hypoxic O +
microenvironments O -
. O +

Accumulating O +
evidence O +
indicates O +
that O +
HIFs O +
also O +
regulate O +
cell O +
survival O -
, O +
glucose B-Chemical +
metabolism O -
, O +
microenvironmental O +
remodeling O -
, O +
cancer O +
metastasis O -
, O +
and O +
tumor O +
progression O -
, O +
and O +
thus O -
, O +
HIFs O +
are O +
viewed O +
as O +
therapeutic O +
targets O +
in O +
many O +
diseases O -
. O +

Epigenetic O +
changes O +
are O +
involved O +
in O +
the O +
switching O +
' O -
on O -
' O +
and O +
' O -
off O -
' O +
of O +
many O +
genes O -
, O +
and O +
it O +
has O +
been O +
suggested O +
that O +
the O +
DNA O +
hypermethylation O +
of O +
specific O +
gene O +
promoters O -
, O +
histone O +
modifications O +
( O -
acetylation O -
, O +
phosphorylation O -
, O +
and O +
methylation O -
) O +
and O +
small O +
interfering O +
or O +
micro O +
RNAs O +
be O +
regarded O +
epigenetic O +
gene O +
targets O +
for O +
the O +
regulation O +
of O +
disease O -
- O -
associated O +
cellular O +
changes O -
. O +

Furthermore O -
, O +
the O +
hypoxic O +
microenvironment O +
is O +
one O +
of O +
the O +
most O +
important O +
cellular O +
stress O +
stimuli O +
in O +
terms O +
of O +
the O +
regulation O +
of O +
cellular O +
epigenetic O +
status O +
via O +
histone O +
modification O -
. O +

Therefore O -
, O +
drug O +
development O +
and O +
therapeutic O +
approaches O +
to O +
ischemic O +
diseases O +
or O +
cancer O +
for O +
targeting O +
HIFs O +
by O +
modulation O +
of O +
epigenetic O +
status O +
become O +
an O +
attractive O +
area O -
. O +

Here O -
, O +
the O +
authors O +
provide O +
a O +
review O +
of O +
the O +
literature O +
regarding O +
the O +
targeting O +
of O +
HIF O -
, O +
a O +
key O +
modulator O +
of O +
hypoxic O -
- O -
cell O +
response O +
under O +
various O +
disease O +
conditions O -
, O +
by O +
modulating O +
histone O +
or O +
DNA O +
using O +
endogenous O +
small O +
RNAs O +
or O +
exogenous O +
chemicals O -
. O +

Phase O +
stability O +
and O +
elastic O +
properties O +
of O +
chromium B-Chemical +
borides I-Chemical +
with O +
various O +
stoichiometries O -
. O +

Phase O +
stability O +
is O +
important O +
to O +
the O +
application O +
of O +
materials O -
. O +

By O +
first O -
- O -
principles O +
calculations O -
, O +
we O +
establish O +
the O +
phase O +
stability O +
of O +
chromium B-Chemical +
borides I-Chemical +
with O +
various O +
stoichiometries O -
. O +

Moreover O -
, O +
the O +
phases O +
of O +
CrB3 B-Chemical +
and O +
CrB4 B-Chemical +
have O +
been O +
predicted O +
by O +
using O +
a O +
newly O +
developed O +
particle O +
swarm O +
optimization O +
( O -
PSO O -
) O +
algorithm O -
. O +

Formation O +
enthalpy O -
- O -
pressure O +
diagrams O +
reveal O +
that O +
the O +
MoB B-Chemical -
- O -
type O +
structure O +
is O +
more O +
energetically O +
favorable O +
than O +
the O +
TiI B-Chemical -
- O -
type O +
structure O +
for O +
CrB. B-Chemical +
For O +
CrB2 B-Chemical +
, O +
the O +
WB2 B-Chemical +
-type O +
structure O +
is O +
preferred O +
at O +
zero O +
pressure O -
. O +

The O +
predicted O +
new O +
phase O +
of O +
CrB3 B-Chemical +
belongs O +
to O +
the O +
hexagonal O +
P-6m2 O +
space O +
group O +
and O +
it O +
transforms O +
into O +
an O +
orthorhombic O +
phase O +
as O +
the O +
pressure O +
exceeds O +
93 O +
GPa O -
. O +

The O +
predicted O +
CrB4 B-Chemical +
( O -
space O +
group O -
: O +
Pnnm O -
) O +
phase O +
is O +
more O +
energetically O +
favorable O +
than O +
the O +
previously O +
proposed O +
Immm O +
structure O -
. O +

The O +
mechanical O +
and O +
thermodynamic O +
stabilities O +
of O +
predicted O +
CrB3 B-Chemical +
and O +
CrB4 B-Chemical +
are O +
verified O +
by O +
the O +
calculated O +
elastic O +
constants O +
and O +
formation O +
enthalpies O -
. O +

The O +
full O +
phonon O +
dispersion O +
calculations O +
confirm O +
the O +
dynamic O +
stability O +
of O +
WB2 B-Chemical +
-type O +
CrB2 B-Chemical +
and O +
predicted O +
CrB3 B-Chemical +
. O +

The O +
large O +
shear O +
moduli O -
, O +
large O +
Young O -
's O +
moduli O -
, O +
low O +
Poisson O +
ratios O -
, O +
and O +
low O +
bulk O +
and O +
shear O +
modulus O +
ratios O +
of O +
CrB4 B-Chemical +
PSC O +
and O +
CrB4 B-Chemical +
PSD O +
indicate O +
that O +
they O +
are O +
potential O +
hard O +
materials O -
. O +

Analyses O +
of O +
Debye O +
temperature O -
, O +
electronic O +
localization O +
function O -
, O +
and O +
electronic O +
structure O +
provide O +
further O +
understanding O +
of O +
the O +
chemical O +
and O +
physical O +
properties O +
of O +
these O +
borides O -
. O +

Nanomechanical O +
properties O +
of O +
proteins O +
and O +
membranes O +
depend O +
on O +
loading O +
rate O +
and O +
electrostatic O +
interactions O -
. O +

Knowing O +
the O +
dynamic O +
mechanical O +
response O +
of O +
tissue O -
, O +
cells O -
, O +
membranes O -
, O +
proteins O -
, O +
nucleic O +
acids O -
, O +
and O +
carbohydrates B-Chemical +
to O +
external O +
perturbations O +
is O +
important O +
to O +
understand O +
various O +
biological O +
and O +
biotechnological O +
problems O -
. O +

Atomic O +
force O +
microscopy O +
( O -
AFM O -
) O -
-based O +
approaches O +
are O +
the O +
most O +
frequently O +
used O +
nanotechnologies O +
to O +
determine O +
the O +
mechanical O +
properties O +
of O +
biological O +
samples O +
that O +
range O +
in O +
size O +
from O +
microscopic O +
to O +
( O -
sub O -
) O -
nanoscopic O -
. O +

However O -
, O +
the O +
dynamic O +
nature O +
of O +
biomechanical O +
properties O +
has O +
barely O +
been O +
addressed O +
by O +
AFM O +
imaging O -
. O +

In O +
this O +
work O -
, O +
we O +
characterizethe O +
viscoelastic O +
properties O +
of O +
the O +
native O +
light O -
- O -
driven O +
proton O +
pump O +
bacteriorhodopsin O +
of O +
the O +
purple O +
membrane O +
of O +
Halobacterium O +
salinarum O -
. O +

Using O +
force O -
- O -
distance O +
curve O +
( O -
F O -
- O -
D O -
) O -
-based O +
AFM O +
we O +
imaged O +
purple O +
membranes O +
while O +
force O +
probing O +
their O +
mechanical O +
response O +
over O +
a O +
wide O +
range O +
of O +
loading O +
rates O +
( O -
from O +
∼0.5 O +
to O +
100 O +
μN O -
/ O -
s O -
) O -
. O +

Our O +
results O +
show O +
that O +
the O +
mechanical O +
stiffness O +
of O +
protein O +
and O +
membrane O +
increases O +
with O +
the O +
loading O +
rate O +
up O +
to O +
a O +
factor O +
of O +
10 O +
( O -
from O +
∼0.3 O +
to O +
3.2 O +
N O -
/ O -
m O -
) O -
. O +

In O +
addition O -
, O +
the O +
electrostatic O +
repulsion O +
between O +
AFM O +
tip O +
and O +
sample O +
can O +
alter O +
the O +
mechanical O +
stiffness O +
measured O +
by O +
AFM O +
up O +
to O +
∼60 O -
% O +
( O -
from O +
∼0.8 O +
to O +
1.3 O +
N O -
/ O -
m O -
) O -
.These O +
findings O +
indicate O +
that O +
the O +
mechanical O +
response O +
of O +
membranes O +
and O +
proteins O +
and O +
probably O +
of O +
other O +
biomolecular O +
systems O +
should O +
be O +
determined O +
at O +
different O +
loading O +
rates O +
to O +
fully O +
understand O +
their O +
properties O -
. O +

Through O +
the O +
looking O +
glass O -
: O +
adventures O +
in O +
kinase O +
inhibitor O +
design O +
and O +
optimization O -
. O +

Developing O +
a O +
viable O +
new O +
drug O +
candidate O +
is O +
difficult O -
. O +

Developing O +
one O +
that O +
is O +
a O +
small O +
molecule O +
kinase O +
inhibitor O +
that O +
binds O +
competitively O +
with O +
respect O +
to O +
ATP B-Chemical +
with O +
superb O +
selectivity O +
is O +
even O +
more O +
difficult O -
, O +
which O +
makes O +
the O +
design O +
and O +
optimization O +
work O +
described O +
by O +
Jimenez O +
et O +
al. O +
( O -
J. O +
Med O -
. O +

Chem O -
. O -
, O +
DOI O -
: O +
10.1021 O -
/ O -
jm301465a O -
) O +
particularly O +
remarkable O -
. O +

They O +
took O +
a O +
lead O +
from O +
a O +
high O -
- O -
throughput O +
screen O +
against O +
protein O +
kinase O +
C O +
θ O +
( O -
PKCθ O -
) O +
through O +
a O +
series O +
of O +
optimization O +
steps O -
, O +
culminating O +
in O +
the O +
demonstration O +
of O +
in O +
vivo O +
activity O +
in O +
mice O -
. O +

Having O +
identified O +
and O +
improved O +
the O +
hinge O -
- O -
binding O +
" O -
warhead O -
" O +
at O +
one O +
end O +
of O +
their O +
lead O +
molecule O -
, O +
they O +
proceeded O +
to O +
use O +
structure O -
- O -
based O +
design O +
tools O +
to O +
guide O +
modification O +
of O +
the O +
other O +
end O +
to O +
enhance O +
selectivity O +
over O +
a O +
closely O +
related O +
isoform O +
of O +
the O +
kinase O -
. O +

With O +
that O +
accomplished O -
, O +
they O +
used O +
a O +
series O +
of O +
protection O +
and O +
deprotection O +
maneuvers O +
to O +
modify O +
the O +
central O +
portion O +
of O +
the O +
series O +
scaffold O +
to O +
further O +
enhance O +
potency O +
against O +
the O +
target O +
while O +
also O +
improving O +
pharmacokinetic O +
properties O -
. O +

The O +
project O +
was O +
a O +
success O +
at O +
the O +
preclinical O +
level O -
: O +
oral O +
administration O +
of O +
the O +
ultimate O +
analogue O +
obtained O +
was O +
effective O +
at O +
suppressing O +
interleukin-2 O +
induction O +
in O +
mice O -
. O +

Correlation O +
of O +
photobleaching O -
, O +
oxidation O +
and O +
metal O +
induced O +
fluorescence O +
quenching O +
of O +
DNA O -
- O -
templated O +
silver B-Chemical +
nanoclusters O -
. O +

Few O -
- O -
atom O +
noble O +
metal O +
nanoclusters O +
have O +
attracted O +
a O +
lot O +
of O +
interest O +
due O +
to O +
their O +
potential O +
applications O +
in O +
biosensor O +
development O -
, O +
imaging O +
and O +
catalysis O -
. O +

DNA O -
- O -
templated O +
silver B-Chemical +
nanoclusters O +
( O -
AgNCs O -
) O +
are O +
of O +
particular O +
interest O +
as O +
different O +
emission O +
colors O +
can O +
be O +
obtained O +
by O +
changing O +
the O +
DNA O +
sequence O -
. O +

A O +
popular O +
analytical O +
application O +
is O +
fluorescence O +
quenching O +
by O +
Hg B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical -
, O +
where O +
d O -
( O -
10 O -
) O -
-d O -
( O -
10 O -
) O +
metallophilic O +
interaction O +
has O +
often O +
been O +
proposed O +
for O +
associating O +
Hg B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
with O +
nanoclusters O -
. O +

However O -
, O +
it O +
can O -
not O +
explain O +
the O +
lack O +
of O +
response O +
to O +
other O +
d O -
( O -
10 O -
) O +
ions O +
such O +
as O +
Zn B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
and O +
Cd B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical -
. O +

In O +
our O +
effort O +
to O +
elucidate O +
the O +
quenching O +
mechanism O -
, O +
we O +
studied O +
a O +
total O +
of O +
eight O +
AgNCs O +
prepared O +
by O +
different O +
hairpin O +
DNA O +
sequences O -
; O +
they O +
showed O +
different O +
sensitivity O +
to O +
Hg B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical -
, O +
and O +
DNA O +
with O +
a O +
larger O +
cytosine B-Chemical +
loop O +
size O +
produced O +
more O +
sensitive O +
AgNCs O -
. O +

In O +
all O +
the O +
cases O -
, O +
samples O +
strongly O +
quenched O +
by O +
Hg B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
were O +
also O +
more O +
easily O +
photobleached O -
. O +

Light O +
of O +
shorter O +
wavelengths O +
bleached O +
AgNCs O +
more O +
potently O -
, O +
and O +
photobleached O +
samples O +
can O +
be O +
recovered O +
by O +
NaBH4 B-Chemical -
. O +

Strong O +
fluorescence O +
quenching O +
was O +
also O +
observed O +
with O +
high O +
redox O +
potential O +
metal O +
ions O +
such O +
as O +
Ag B-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical -
, O +
Au B-Chemical -
( I-Chemical -
3 I-Chemical -
+ I-Chemical -
) I-Chemical -
, O +
Cu B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
and O +
Hg B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical -
, O +
but O +
not O +
with O +
low O +
redox O +
potential O +
ions O -
. O +

Such O +
metal O +
induced O +
quenching O +
can O -
not O +
be O +
recovered O +
by O +
NaBH4 B-Chemical -
. O +

Electronic O +
absorption O +
and O +
mass O +
spectrometry O +
studies O +
offered O +
further O +
insights O +
into O +
the O +
oxidation O +
reaction O -
. O +

Our O +
results O +
correlate O +
many O +
important O +
experimental O +
observations O +
and O +
will O +
fuel O +
the O +
further O +
growth O +
of O +
this O +
field O -
. O +

Eugenol B-Chemical +
alters O +
the O +
integrity O +
of O +
cell O +
membrane O +
and O +
acts O +
against O +
the O +
nosocomial O +
pathogen O +
Proteus O +
mirabilis O -
. O +

Eugenol B-Chemical -
, O +
a O +
member O +
of O +
the O +
phenylpropanoids O +
class O +
of O +
chemical O +
compounds O -
, O +
is O +
a O +
clear O +
to O +
pale O +
yellow O +
oily O +
liquid O +
extracted O +
from O +
certain O +
essential O +
oils O +
especially O +
from O +
clove O +
oil O -
, O +
nutmeg O -
, O +
cinnamon O -
, O +
and O +
bay O +
leaf O -
. O +

The O +
antibacterial O +
activity O +
of O +
eugenol B-Chemical +
and O +
its O +
mechanism O +
of O +
bactericidal O +
action O +
against O +
Proteus O +
mirabilis O +
were O +
evaluated O -
. O +

Treatment O +
with O +
eugenol B-Chemical +
at O +
their O +
minimum O +
inhibitory O +
concentration O +
[ O -
0.125 O +
% O +
( O -
v O -
/ O -
v O -
) O -
] O +
and O +
minimum O +
bactericidal O +
concentration O +
[ O -
0.25 O +
% O +
( O -
v O -
/ O -
v O -
) O -
] O +
reduced O +
the O +
viability O +
and O +
resulted O +
in O +
complete O +
inhibition O +
of O +
P. O +
mirabilis O -
. O +

A O +
strong O +
bactericidal O +
effect O +
on O +
P. O +
mirabilis O +
was O +
also O +
evident O -
, O +
as O +
eugenol B-Chemical +
inactivated O +
the O +
bacterial O +
population O +
within O +
30 O +
min O +
exposure O -
. O +

Chemo O -
- O -
attractant O +
property O +
and O +
the O +
observance O +
of O +
highest O +
antibacterial O +
activity O +
at O +
alkaline O +
pH O +
suggest O +
that O +
eugenol B-Chemical +
can O +
work O +
more O +
effectively O +
when O +
given O +
in O +
vivo O -
. O +

Eugenol B-Chemical +
inhibits O +
the O +
virulence O +
factors O +
produced O +
by O +
P. O +
mirabilis O +
as O +
observed O +
by O +
swimming O +
motility O -
, O +
swarming O +
behavior O +
and O +
urease O +
activity O -
. O +

It O +
interacts O +
with O +
cellular O +
membrane O +
of O +
P. O +
mirabilis O +
and O +
makes O +
it O +
highly O +
permeable O -
, O +
forming O +
nonspecific O +
pores O +
on O +
plasma O +
membrane O -
, O +
which O +
in O +
turn O +
directs O +
the O +
release O +
of O +
260 O +
nm O +
absorbing O +
materials O +
and O +
uptake O +
of O +
more O +
crystal B-Chemical +
violet I-Chemical +
from O +
the O +
medium O +
into O +
the O +
cells O -
. O +

SDS B-Chemical -
- O -
polyacrylamide B-Chemical +
gel O -
, O +
scanning O +
electron O +
microscopy O +
and O +
Fourier O +
transform O +
infrared O +
analysis O +
further O +
proves O +
the O +
disruptive O +
action O +
of O +
eugenol B-Chemical +
on O +
the O +
plasma O +
membrane O +
of O +
P. O +
mirabilis O -
. O +

The O +
findings O +
reveal O +
that O +
eugenol B-Chemical +
shows O +
an O +
excellent O +
bactericidal O +
activity O +
against O +
P. O +
mirabilis O +
by O +
altering O +
the O +
integrity O +
of O +
cell O +
membrane O -
. O +

miR-7641 O +
modulates O +
the O +
expression O +
of O +
CXCL1 O +
during O +
endothelial O +
differentiation O +
derived O +
from O +
human O +
embryonic O +
stem O +
cells O -
. O +

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
a O +
class O +
of O +
small O +
noncoding O +
RNAs O +
that O +
negatively O +
regulate O +
gene O +
expression O +
through O +
binding O +
to O +
3 O -
' O +
untranslated O +
region O -
. O +

We O +
identified O +
and O +
characterized O +
the O +
novel O +
miRNA O -
, O +
miR-7641 O -
, O +
in O +
human O +
mesenchymal O +
stem O +
cells O -
. O +

The O +
expression O +
of O +
miR-7641 O +
was O +
downregulated O +
during O +
differentiation O +
from O +
human O +
embryonic O +
stem O +
cells O +
to O +
endothelial O +
cells O -
. O +

The O +
CXCL1 O -
, O +
a O +
member O +
of O +
the O +
CXC O +
chemokine O +
family O -
, O +
is O +
known O +
as O +
promoting O +
neovascularization O +
by O +
binding O +
G O -
- O -
protein O +
coupled O +
receptors O +
and O +
is O +
related O +
to O +
endothelial O +
cells O +
biogenesis O +
such O +
as O +
angiogenesis O -
, O +
and O +
it O +
was O +
predicted O +
as O +
target O +
gene O +
of O +
miR-7641 O +
by O +
computerized O +
analysis O +
and O +
the O +
luciferase O +
reporter O +
assay O -
. O +

The O +
miR-7641 O +
significantly O +
suppressed O +
CXCL1 O +
of O +
transcriptional O +
and O +
post O -
- O -
translational O +
levels O -
. O +

These O +
data O +
suggest O +
that O +
miR-7641 O +
might O +
be O +
related O +
with O +
differentiation O +
of O +
human O +
endothelial O +
cells O -
. O +

Phenolic B-Chemical +
constituents O +
from O +
Parakmeria O +
yunnanensis O +
and O +
their O +
anti O -
- O -
HIV-1 O +
activity O -
. O +

Three O +
new O +
phenolic B-Chemical +
compounds O -
, O +
yunnanensins B-Chemical +
A I-Chemical -
- I-Chemical -
C I-Chemical +
( O -
1 O -
- O -
3 O -
) O -
, O +
together O +
with O +
fourteen O +
known O +
ones O +
( O -
4 O -
- O -
17 O -
) O -
, O +
were O +
isolated O +
from O +
the O +
leaves O +
and O +
stems O +
of O +
Parakmeria O +
yunnanensis O -
. O +

The O +
structures O +
of O +
new O +
compounds O +
were O +
established O +
on O +
the O +
basis O +
of O +
extensive O +
spectroscopic O +
analyses O -
. O +

Several O +
compounds O +
showed O +
weak O +
anti O -
- O -
HIV-1 O +
activity O -
. O +

Selective O +
inhibition O +
of O +
an O +
apicoplastic O +
aminoacyl B-Chemical -
- O -
tRNA O +
synthetase O +
from O +
Plasmodium O +
falciparum O -
. O +

The O +
resistance O +
of O +
malaria O +
parasites O +
to O +
available O +
drugs O +
continues O +
to O +
grow O -
, O +
and O +
this O +
makes O +
the O +
need O +
for O +
new O +
antimalarial O +
therapies O +
pressing O -
. O +

Aminoacyl B-Chemical -
- O -
tRNA O +
synthetases O +
( O -
ARSs O -
) O +
are O +
essential O +
enzymes O +
and O +
well O -
- O -
established O +
antibacterial O +
targets O +
and O +
so O +
constitute O +
a O +
promising O +
set O +
of O +
targets O +
for O +
the O +
development O +
of O +
new O +
antimalarials O -
. O +

Despite O +
their O +
potential O +
as O +
drug O +
targets O -
, O +
apicoplastic O +
ARSs O +
remain O +
unexplored O -
. O +

We O +
have O +
characterized O +
the O +
lysylation O +
system O +
of O +
Plasmodium O +
falciparum O -
, O +
and O +
designed O -
, O +
synthesized O -
, O +
and O +
tested O +
a O +
set O +
of O +
inhibitors O +
based O +
on O +
the O +
structure O +
of O +
the O +
natural O +
substrate O +
intermediate O -
: O +
lysyl B-Chemical -
- I-Chemical -
adenylate I-Chemical -
. O +

Here O +
we O +
demonstrate O +
that O +
selective O +
inhibition O +
of O +
apicoplastic O +
ARSs O +
is O +
feasible O +
and O +
describe O +
new O +
compounds O +
that O +
that O +
specifically O +
inhibit O +
Plasmodium O +
apicoplastic O +
lysyl B-Chemical -
- O -
tRNA O +
synthetase O +
and O +
show O +
antimalarial O +
activities O +
in O +
the O +
micromolar O +
range O -
. O +

Characterization O -
, O +
pharmacokinetics O -
, O +
tissue O +
distribution O +
and O +
antitumor O +
activity O +
of O +
honokiol B-Chemical +
submicron O +
lipid O +
emulsions O +
in O +
tumor O -
- O -
burdened O +
mice O -
. O +

Honokiol B-Chemical -
, O +
isolated O +
from O +
the O +
Chinese O +
traditional O +
herb O +
magnolia O -
, O +
is O +
a O +
poorly O +
water O -
- O -
soluble O +
component O +
and O +
has O +
been O +
found O +
to O +
have O +
anti O -
- O -
tumor O +
properties O -
. O +

In O +
the O +
current O +
study O -
, O +
honokiol B-Chemical +
submicron O +
lipid O +
emulsions O +
( O -
HK O -
- O -
SLEs O -
) O +
were O +
prepared O +
by O +
high O +
pressure O +
homogenization O +
technology O -
. O +

After O +
HK O -
- O -
SLEs O +
were O +
physically O +
characterized O -
, O +
their O +
pharmacokinetics O -
, O +
tissue O +
distribution O +
and O +
antitumor O +
activity O +
after O +
intravenous O +
( O -
i.v O -
. O -
) O +
administration O +
to O +
tumor O -
- O -
burdened O +
mice O +
were O +
examined O -
, O +
using O +
honokiol B-Chemical +
solution O +
( O -
HK O -
- O -
SOL O -
) O +
as O +
the O +
control O -
. O +

The O +
results O +
showed O +
that O +
the O +
mean O +
particle O +
size O -
, O +
zeta O +
potential O -
, O +
pH O +
value O -
, O +
osmolality O -
, O +
drug O +
loading O +
( O -
DL O -
) O -
% O +
and O +
entrapment O +
efficiency O +
( O -
EE O -
) O -
% O +
of O +
HK O -
- O -
SLEs O +
were O +
186.6 O +
+ O -
/- O +

1.7 O +
nm O -
, O +
-35.65 O +
+ O -
/- O +

0.67 O +
mV O -
, O +
7.22 O +
+ O -
/- O +

0.26 O -
, O +
298 O +
+ O -
/- O +

2.3 O +
mOsm O -
/ O -
L O -
, O +
7.1 O +
+ O -
/- O +

0.2 O -
% O +
and O +
95.5 O +
+ O -
/- O +

0.2 O -
% O -
, O +
respectively O -
. O +

HK O -
- O -
SLEs O +
were O +
stable O +
for O +
at O +
least O +
12 O +
months O +
when O +
stored O +
at O +
4 O +
+ O -
/- O +

2 O +
degrees O +
C. O +
The O +
pharmacokinetic O +
results O +
showed O +
that O +
the O +
drug O +
concentration O -
- O -
time O +
curves O +
of O +
HK O -
- O -
SLEs O +
and O +
HK O -
- O -
SOL O +
could O +
both O +
be O +
described O +
by O +
an O +
open O +
two O -
- O -
compartment O +
model O -
. O +

The O +
half O -
- O -
life O +
of O +
HK O -
- O -
SLEs O +
( O -
t1 O -
/ O -
2 O -
( O -
alpha O -
) O +
= O +
8.014 O +
min O -
, O +
t1 O -
/ O -
2 O -
( O -
beta O -
) O +
= O +
35.784 O +
min O -
) O +
was O +
remarkably O +
prolonged O +
compared O +
to O +
that O +
of O +
HK O -
- O -
SOL O +
( O -
t1 O -
/ O -
2 O -
( O -
alpha O -
) O +
= O +
4.318 O +
min O -
, O +
t1 O -
/ O -
2 O -
( O -
beta O -
) O +
= O +
15.522 O +
min O -
) O -
. O +

HK O -
- O -
SLEs O +
exhibited O +
a O +
greater O +
AUC O +
and O +
reduced O +
plasma O +
clearance O -
. O +

The O +
tissue O +
distribution O +
results O +
indicated O +
that O +
HK O -
- O -
SLEs O +
have O +
better O +
targeting O +
properties O +
to O +
lung O +
and O +
tumor O +
tissues O +
compared O +
with O +
those O +
of O +
HK O -
- O -
SOL O -
. O +

Both O +
HK O -
- O -
SLEs O +
and O +
HK O -
- O -
SOL O +
tended O +
to O +
accumulate O +
in O +
brain O +
tissue O -
. O +

In O +
vivo O +
study O +
showed O +
that O +
HK O -
- O -
SLEs O +
treatment O +
caused O +
significant O +
inhibition O +
of O +
mouse O +
sarcoma O +
S180 O +
tumor O +
growth O +
compared O +
to O +
HK O -
- O -
SOL O -
. O +

These O +
results O +
suggest O +
that O +
HK O -
- O -
SLEs O +
might O +
be O +
an O +
effective O +
parenteral O +
carrier O +
for O +
honokiol B-Chemical +
delivery O +
in O +
cancer O +
treatment O -
. O +

Rapid O +
method O +
for O +
the O +
separation O +
and O +
recovery O +
of O +
endocrine O -
- O -
disrupting O +
compound O +
bisphenol B-Chemical +
AP I-Chemical +
from O +
wastewater O -
. O +

The O +
removal O +
of O +
bisphenol B-Chemical +
AP I-Chemical +
( O -
BPAP B-Chemical -
) O +
by O +
a O +
multiwalled O +
carbon B-Chemical +
nanotube O +
( O -
MWCNT O -
) O +
was O +
investigated O -
. O +

BPAP B-Chemical -
, O +
representing O +
typical O +
scenarios O +
for O +
the O +
BPAP B-Chemical -
- O -
MWCNT O +
interactions O -
, O +
was O +
employed O +
as O +
a O +
probe O +
molecule O -
. O +

It O +
was O +
found O +
that O +
BPAP B-Chemical +
exhibited O +
great O +
adsorptive O +
affinity O +
to O +
MWCNT O -
, O +
and O +
the O +
adsorption O +
kinetics O +
equilibrium O +
was O +
arrived O +
within O +
4.0 O +
min O +
following O +
the O +
pseudo O -
- O -
second O -
- O -
order O +
model O -
. O +

The O +
overall O +
rate O +
process O +
was O +
mainly O +
controlled O +
by O +
the O +
external O +
mass O +
transfer O -
. O +

The O +
hydrogen B-Chemical +
bond O -
, O +
hydrophobic O -
, O +
and O +
π O -
- O -
π O +
stacking O +
interactions O +
were O +
dominant O +
factors O +
for O +
the O +
strong O +
adsorption O +
of O +
BPAP B-Chemical -
, O +
instead O +
of O +
the O +
pH O +
ionic O +
strength O +
and O +
other O +
ionic O +
species O +
in O +
contaminated O +
water O -
. O +

The O +
MWCNT O +
has O +
higher O +
stability O +
within O +
8 O +
removal O -
- O -
regeneration O +
recycles O -
, O +
and O +
up O +
to O +
95 O -
% O +
of O +
recovery O +
could O +
be O +
obtained O +
by O +
eluting O +
the O +
adsorbed O +
BPAP B-Chemical +
on O +
MWCNT O +
adsorbent O +
using O +
ethanol B-Chemical -
/ O -
sodium B-Chemical +
hydrate I-Chemical +
solution O -
. O +

The O +
results O +
of O +
the O +
experiment O +
on O +
real O +
samples O +
verified O +
the O +
effectiveness O +
for O +
the O +
recovery O +
and O +
removal O +
of O +
BPAP B-Chemical +
from O +
wastewater O +
samples O -
. O +

Hydrocarbons B-Chemical +
( O -
jet O +
fuel O +
JP-8 O -
) O +
induce O +
epigenetic O +
transgenerational O +
inheritance O +
of O +
obesity O -
, O +
reproductive O +
disease O +
and O +
sperm O +
epimutations O -
. O +

Environmental O +
compounds O +
have O +
been O +
shown O +
to O +
promote O +
epigenetic O +
transgenerational O +
inheritance O +
of O +
disease O -
. O +

The O +
current O +
study O +
was O +
designed O +
to O +
determine O +
if O +
a O +
hydrocarbon B-Chemical +
mixture O +
involving O +
jet O +
fuel O +
( O -
JP-8 O -
) O +
promotes O +
epigenetic O +
transgenerational O +
inheritance O +
of O +
disease O -
. O +

Gestating O +
F0 O +
generation O +
female O +
rats O +
were O +
transiently O +
exposed O +
during O +
the O +
fetal O +
gonadal O +
development O +
period O -
. O +

The O +
direct O +
exposure O +
F1 O +
generation O +
had O +
an O +
increased O +
incidence O +
of O +
kidney O +
abnormalities O +
in O +
both O +
females O +
and O +
males O -
, O +
prostate O +
and O +
pubertal O +
abnormalities O +
in O +
males O -
, O +
and O +
primordial O +
follicle O +
loss O +
and O +
polycystic O +
ovarian O +
disease O +
in O +
females O -
. O +

The O +
first O +
transgenerational O +
generation O +
is O +
the O +
F3 O +
generation O -
, O +
and O +
the O +
jet O +
fuel O +
lineage O +
had O +
an O +
increased O +
incidence O +
of O +
primordial O +
follicle O +
loss O +
and O +
polycystic O +
ovarian O +
disease O +
in O +
females O -
, O +
and O +
obesity O +
in O +
both O +
females O +
and O +
males O -
. O +

Analysis O +
of O +
the O +
jet O +
fuel O +
lineage O +
F3 O +
generation O +
sperm O +
epigenome O +
identified O +
33 O +
differential O +
DNA O +
methylation O +
regions O -
, O +
termed O +
epimutations O -
. O +

Observations O +
demonstrate O +
hydrocarbons B-Chemical +
can O +
promote O +
epigenetic O +
transgenerational O +
inheritance O +
of O +
disease O +
and O +
sperm O +
epimutations O -
, O +
potential O +
biomarkers O +
for O +
ancestral O +
exposures O -
. O +

The O +
n O -
- O -
SET O +
domain O +
of O +
Set1 O +
regulates O +
H2B O +
ubiquitylation O -
- O -
dependent O +
H3K4 O +
methylation O -
. O +

Past O +
studies O +
have O +
documented O +
a O +
crosstalk O +
between O +
H2B O +
ubiquitylation O +
( O -
H2Bub O -
) O +
and O +
H3K4 O +
methylation O -
, O +
but O +
little O +
( O -
if O +
any O -
) O +
direct O +
evidence O +
exists O +
explaining O +
the O +
mechanism O +
underlying O +
H2Bub O -
- O -
dependent O +
H3K4 O +
methylation O +
on O +
chromatin O +
templates O -
. O +

Here O -
, O +
we O +
took O +
advantage O +
of O +
an O +
in O +
vitro O +
histone O +
methyltransferase O +
assay O +
employing O +
a O +
reconstituted O +
yeast O +
Set1 O +
complex O +
( O -
ySet1C O -
) O +
and O +
a O +
recombinant O +
chromatin O +
template O +
containing O +
fully O +
ubiquitylated O +
H2B O +
to O +
gain O +
valuable O +
insights O -
. O +

Combined O +
with O +
genetic O +
analyses O -
, O +
we O +
demonstrate O +
that O +
the O +
n O -
- O -
SET O +
domain O +
within O +
Set1 O -
, O +
but O +
not O +
Swd2 O -
, O +
is O +
essential O +
for O +
H2Bub O -
- O -
dependent O +
H3K4 O +
methylation O -
. O +

Spp1 O -
, O +
a O +
homolog O +
of O +
human O +
CFP1 O -
, O +
is O +
conditionally O +
involved O +
in O +
this O +
crosstalk O -
. O +

Our O +
findings O +
extend O +
to O +
the O +
human O +
Set1 O +
complex O -
, O +
underscoring O +
the O +
conserved O +
nature O +
of O +
this O +
disease O -
- O -
relevant O +
crosstalk O +
pathway O -
. O +

As O +
not O +
all O +
members O +
of O +
the O +
H3K4 O +
methyltransferase O +
family O +
contain O +
n O -
- O -
SET O +
domains O -
, O +
our O +
studies O +
draw O +
attention O +
to O +
the O +
n O -
- O -
SET O +
domain O +
as O +
a O +
predictor O +
of O +
an O +
H2B O +
ubiquitylation O -
- O -
sensing O +
mechanism O +
that O +
leads O +
to O +
downstream O +
H3K4 O +
methylation O -
. O +

Synthesis O +
and O +
anti O -
- O -
acetylcholinesterase O +
properties O +
of O +
novel O +
β- B-Chemical +
and I-Chemical +
γ I-Chemical -
- I-Chemical -
substituted I-Chemical +
alkoxy I-Chemical +
organophosphonates I-Chemical -
. O +

Activated O +
organophosphate B-Chemical +
( O -
OP O -
) O +
insecticides O +
and O +
chemical O +
agents O +
inhibit O +
acetylcholinesterase O +
( O -
AChE O -
) O +
to O +
form O +
OP O -
- O -
AChE O +
adducts O -
. O +

Whereas O +
the O +
structure O +
of O +
the O +
OP O +
correlates O +
with O +
the O +
rate O +
of O +
inhibition O -
, O +
the O +
structure O +
of O +
the O +
OP O -
- O -
AChE O +
adduct O +
influences O +
the O +
rate O +
at O +
which O +
post O -
- O -
inhibitory O +
reactivation O +
or O +
aging O +
phenomena O +
occurs O -
. O +

In O +
this O +
report O -
, O +
we O +
prepared O +
a O +
panel O +
of O +
β B-Chemical -
- I-Chemical -
substituted I-Chemical +
ethoxy I-Chemical +
and I-Chemical +
γ I-Chemical -
- I-Chemical -
substituted I-Chemical +
propoxy I-Chemical +
phosphonoesters I-Chemical +
of O +
the O +
type O +
p B-Chemical -
- I-Chemical -
NO I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
PhO I-Chemical -
- I-Chemical -
P I-Chemical -
( I-Chemical -
X I-Chemical -
) I-Chemical -
( I-Chemical -
R I-Chemical -
) I-Chemical -
[ I-Chemical -
( I-Chemical -
O I-Chemical -
( I-Chemical -
CH I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
) I-Chemical -
( I-Chemical -
n I-Chemical -
) I-Chemical -
Z I-Chemical -
] I-Chemical +
( O -
R O -
= O -
Me B-Chemical -
, O +
Et B-Chemical -
; O +
X O -
= B-Chemical -
O O -
, O +
S O -
; O +
n=2 O -
, O +
3 O -
; O +
Z O -
= O -
halogen B-Chemical -
, O +
OTs B-Chemical -
) O +
and O +
examined O +
the O +
inhibition O +
of O +
three O +
AChEs O +
by O +
select O +
structures O +
in O +
the O +
panel O -
. O +

The O +
β B-Chemical -
- I-Chemical -
fluoroethoxy I-Chemical +
methylphosphonate I-Chemical +
analog O +
( O -
R O -
= O -
Me B-Chemical -
, O +
Z O -
= B-Chemical -
F O -
, O +
n=2 O -
) O +
was O +
the O +
most O +
potent O +
anti O -
- O -
AChE O +
compound O +
comparable O +
( O -
ki O +
∼6 O +
× O +
10 O -
( O -
6 O -
) O -
M O -
( O -
-1 O -
) O -
min O -
( O -
-1 O -
) O -
) O +
to O +
paraoxon B-Chemical +
against O +
EEAChE. O +
Analogs O +
with O +
Z O -
= O -
Br B-Chemical -
, O +
I O -
, O +
or O +
OTs B-Chemical +
were O +
weak O +
inhibitors O +
of O +
the O +
AChEs O -
, O +
and O +
methyl B-Chemical +
phosphonates I-Chemical +
( O -
R B-Chemical -
= I-Chemical -
Me I-Chemical -
) O +
were O +
more O +
potent O +
than O +
the O +
corresponding O +
ethyl B-Chemical +
phosphonates I-Chemical +
( O -
R B-Chemical -
= I-Chemical -
Et I-Chemical -
) O -
. O +

As O +
expected O -
, O +
analogs O +
with O +
a O +
thionate B-Chemical +
linkage O +
( O -
PS O -
) O +
were O +
poor O +
inhibitors O +
of O +
the O +
AChEs O -
. O +

N B-Chemical -
- I-Chemical -
Alkyldeoxynojirimycin I-Chemical +
derivatives O +
with O +
novel O +
terminal O +
tertiary B-Chemical +
amide I-Chemical +
substitution O +
for O +
treatment O +
of O +
bovine O +
viral O +
diarrhea O +
virus O +
( O -
BVDV O -
) O -
, O +
Dengue O -
, O +
and O +
Tacaribe O +
virus O +
infections O -
. O +

Novel O +
N B-Chemical -
- I-Chemical -
alkyldeoxynojirimycins I-Chemical +
( O -
NADNJs B-Chemical -
) O +
with O +
two O +
hydrophobic O +
groups O +
attached O +
to O +
a O +
nitrogen O +
linker O +
on O +
the O +
alkyl B-Chemical +
chain O +
were O +
designed O -
. O +

A O +
novel O +
NADNJ B-Chemical +
containing O +
a O +
terminal O +
tertiary B-Chemical +
carboxamide I-Chemical +
moiety O +
was O +
discovered O +
that O +
was O +
a O +
potent O +
inhibitor O +
against O +
BVDV O -
. O +

Further O +
optimization O +
resulted O +
in O +
a O +
structurally O +
more O +
stable O +
lead O +
compound O +
24 O +
with O +
a O +
submicromolar O +
EC50 O +
against O +
BVDV O -
, O +
Dengue O -
, O +
and O +
Tacaribe O -
; O +
and O +
low O +
cytotoxicity O -
. O +

2-Substituted-2-amino-6-boronohexanoic B-Chemical +
acids I-Chemical +
as O +
arginase O +
inhibitors O -
. O +

Substitution O +
at O +
the O +
alpha O +
center O +
of O +
the O +
known O +
human O +
arginase O +
inhibitor O +
2-amino-6-boronohexanoic B-Chemical +
acid I-Chemical +
( O -
ABH B-Chemical -
) O +
is O +
acceptable O +
in O +
the O +
active O +
site O +
pockets O +
of O +
both O +
human O +
arginase O +
I O +
and O +
arginase O +
II O -
. O +

In O +
particular O -
, O +
substituents O +
with O +
a O +
tertiary B-Chemical +
amine I-Chemical +
linked O +
via O +
a O +
two O +
carbon B-Chemical +
chain O +
show O +
improved O +
inhibitory O +
potency O +
for O +
both O +
enzyme O +
isoforms O -
. O +

This O +
potency O +
improvement O +
can O +
be O +
rationalized O +
by O +
X O -
- O -
ray O +
crystallography O -
, O +
which O +
shows O +
a O +
water O -
- O -
mediated O +
contact O +
between O +
the O +
basic O +
nitrogen B-Chemical +
and O +
the O +
carboxylic B-Chemical +
acid I-Chemical +
side O +
chain O +
of O +
Asp200 B-Chemical -
, O +
which O +
is O +
situated O +
at O +
the O +
mouth O +
of O +
the O +
active O +
site O +
pocket O +
of O +
arginase O +
II O +
( O -
Asp181 B-Chemical +
in O +
arginase O +
I O -
) O -
. O +

We O +
believe O +
that O +
this O +
is O +
the O +
first O +
literature O +
report O +
of O +
compounds O +
with O +
improved O +
arginase O +
inhibitory O +
activity O -
, O +
relative O +
to O +
ABH B-Chemical -
, O +
and O +
represents O +
a O +
promising O +
starting O +
point O +
for O +
further O +
optimization O +
of O +
in O +
vitro O +
potency O +
and O +
the O +
identification O +
of O +
better O +
tool O +
molecules O +
for O +
in O +
vivo O +
investigations O +
of O +
the O +
potential O +
pathophysiological O +
roles O +
of O +
arginases O -
. O +

Tumor O +
delivery O +
of O +
Photofrin B-Chemical -
® O +
by O +
PLL B-Chemical -
- I-Chemical -
g I-Chemical -
- I-Chemical -
PEG I-Chemical +
for O +
photodynamic O +
therapy O -
. O +

Photofrin B-Chemical -
® O +
( O -
porfimer B-Chemical +
sodium I-Chemical -
) O +
is O +
a O +
photosensitive O +
reagent O +
used O +
for O +
photodynamic O +
therapy O +
( O -
PDT O -
) O +
of O +
tumors O +
and O +
dysplasias O -
. O +

Because O +
only O +
photo O -
- O -
irradiated O +
sites O +
are O +
damaged O -
, O +
PDT O +
is O +
less O +
invasive O +
than O +
systemic O +
treatments O -
. O +

However O -
, O +
a O +
photosensitive O +
reaction O +
is O +
a O +
major O +
side O +
effect O +
of O +
systemically O +
delivered O +
Photofrin B-Chemical -
. O +

To O +
enhance O +
localization O +
of O +
Photofrin B-Chemical +
to O +
tumors O -
, O +
we O +
have O +
formulated O +
Photofrin B-Chemical +
with O +
the O +
tumor O -
- O -
localizing O +
graft O +
copolymer O +
poly B-Chemical -
( I-Chemical -
ethylene I-Chemical +
glycol I-Chemical -
) I-Chemical -
-grafted I-Chemical +
poly I-Chemical -
( I-Chemical -
l I-Chemical -
- I-Chemical -
lysine I-Chemical -
) I-Chemical -
, O +
PLL B-Chemical -
- I-Chemical -
g I-Chemical -
- I-Chemical -
PEG I-Chemical -
. O +

We O +
demonstrate O +
that O +
Photofrin B-Chemical +
preferentially O +
interacts O +
with O +
PLL B-Chemical -
- I-Chemical -
g I-Chemical -
- I-Chemical -
PEG I-Chemical +
through O +
both O +
ionic O +
and O +
hydrophobic O +
interactions O -
. O +

The O +
serum O +
competitive O +
study O +
showed O +
that O +
the O +
highly O +
PEG B-Chemical -
- I-Chemical -
grafted I-Chemical +
PLL I-Chemical +
is O +
better O +
for O +
preventing O +
serum O +
binding O +
to O +
the O +
Photofrin B-Chemical -
/ O -
PLL B-Chemical -
- I-Chemical -
g I-Chemical -
- I-Chemical -
PEG I-Chemical +
complex O -
. O +

In O +
tumor O -
- O -
bearing O +
mice O -
, O +
formulation O +
of O +
Photofrin B-Chemical +
with O +
PLL B-Chemical -
- I-Chemical -
g I-Chemical -
- I-Chemical -
PEG I-Chemical +
enhanced O +
tumor O +
localization O +
of O +
Photofrin B-Chemical +
as O +
twice O +
as O +
Photofrin B-Chemical +
alone O +
and O +
concomitantly O +
suppressed O +
the O +
photosensitivity O +
reaction O +
drastically O -
. O +

Examination O +
of O +
the O +
effect O +
of O +
increasing O +
the O +
number O +
of O +
intra O -
- O -
disulfide B-Chemical +
amino I-Chemical +
functional O +
groups O +
on O +
the O +
performance O +
of O +
small O +
molecule O +
cyclic O +
polyamine B-Chemical +
disulfide I-Chemical +
vectors O -
. O +

Establishing O +
structure O -
- O -
activity O +
relationships O +
is O +
vital O +
if O +
the O +
efficacy O +
of O +
non O -
- O -
viral O +
vectors O +
is O +
to O +
match O +
that O +
of O +
their O +
viral O +
counter O -
- O -
parts O -
. O +

Recently O -
, O +
we O +
reported O +
on O +
the O +
ability O +
of O +
a O +
series O +
of O +
small O +
molecule O -
, O +
cyclic B-Chemical +
polyamine I-Chemical +
disulfides I-Chemical +
to O +
condense O +
and O +
cage O +
plasmid O +
DNA O +
( O -
pDNA O -
) O +
by O +
a O +
process O +
of O +
thermodynamically O +
controlled O +
template O +
polymerization O -
, O +
leading O +
to O +
a O +
series O +
of O +
corresponding O +
pDNA O -
- O -
polyplex O +
nanoparticles O +
able O +
to O +
mediate O +
high O +
levels O +
of O +
transfection O +
with O +
no O +
associated O +
cytotoxicities O -
. O +

The O +
leading O +
cyclic B-Chemical +
polyamine I-Chemical +
disulfide I-Chemical +
was O +
shown O +
to O +
be O +
the O +
spermine B-Chemical +
tetra I-Chemical -
- I-Chemical -
amine I-Chemical +
disulfide I-Chemical +
( O -
TetraN-3,4,3 B-Chemical -
) O -
. O +

Herein O +
we O +
report O +
on O +
the O +
significantly O +
more O +
challenging O +
syntheses O +
of O +
cyclic B-Chemical +
disulfides I-Chemical +
with O +
longer O +
polyamine O +
motifs O -
. O +

Two O +
new O +
cyclic B-Chemical +
polyamine I-Chemical +
disulfides I-Chemical -
, O +
based O +
on O +
hexa- B-Chemical +
and I-Chemical +
octa I-Chemical -
- I-Chemical -
amine I-Chemical +
inserts O -
, O +
were O +
prepared O +
and O +
their O +
transfection O +
efficacies O +
and O +
cytotoxicities O +
compared O +
with O +
our O +
previously O +
reported O +
cyclic B-Chemical +
tri- I-Chemical +
and I-Chemical +
tetra I-Chemical -
- I-Chemical -
amine I-Chemical +
disulfides I-Chemical -
. O +

The O +
new O +
cyclic B-Chemical +
hexa- I-Chemical +
and I-Chemical +
octa I-Chemical -
- I-Chemical -
amine I-Chemical +
disulfides I-Chemical +
prove O +
more O +
effective O +
at O +
transfection O +
in O +
vitro O -
, O +
especially O +
of O +
lung O +
epithelial O +
A549 O +
cell O +
line O -
. O +

By O +
contrast O -
, O +
our O +
original O +
cyclic B-Chemical +
tetra I-Chemical -
- I-Chemical -
amine I-Chemical +
disulfide I-Chemical +
remains O +
the O +
most O +
efficient O +
agent O +
for O +
the O +
transfection O +
of O +
lung O +
epithelial O +
cells O +
in O +
vivo O +
following O +
intra O -
- O -
nasal O +
administration O -
. O +

Hypothetical O +
mechanistic O +
reasons O +
are O +
presented O +
to O +
explain O +
this O +
outcome O -
. O +

Our O +
data O +
in O +
toto O +
support O +
the O +
concept O +
of O +
shorter O +
cyclic B-Chemical +
polyamine I-Chemical +
disulfides I-Chemical +
as O +
preferred O +
agents O +
for O +
polycation O -
- O -
mediated O +
controlled O +
condensation O +
and O +
functional O +
delivery O +
of O +
pDNA O +
to O +
lung O +
epithelial O +
cells O +
in O +
vivo O -
. O +

DNA O +
delivery O +
via O +
cationic O +
solid O +
lipid O +
nanoparticles O +
( O -
SLNs O -
) O -
. O +

In O +
recent O +
years O +
the O +
use O +
of O +
solid O +
lipid O +
nanoparticles O +
( O -
SLNs O -
) O +
as O +
transport O +
systems O +
for O +
the O +
delivery O +
of O +
drugs O +
and O +
biomolecules O +
has O +
become O +
particularly O +
important O -
. O +

The O +
use O +
of O +
cationic O +
SLNs O +
developed O +
by O +
the O +
technique O +
of O +
microemulsion O -
, O +
which O +
are O +
complexed O +
with O +
DNA O +
in O +
order O +
to O +
study O +
their O +
application O +
as O +
non O -
- O -
viral O +
vectors O +
in O +
gene O +
therapy O -
, O +
is O +
reported O -
. O +

The O +
nanoparticles O +
are O +
characterized O +
by O +
scanning O +
electron O +
microscopy O +
and O +
transmission O +
electron O +
microscopy O +
( O -
SEM O +
and O +
TEM O -
) O -
, O +
atomic O +
force O +
microscopy O +
( O -
AFM O -
) O +
and O +
differential O +
scanning O +
calorimetry O +
( O -
DSC O -
) O -
. O +

Furthermore O -
, O +
the O +
process O +
of O +
lyophilization O +
of O +
the O +
samples O +
and O +
their O +
stability O +
was O +
studied O -
. O +

The O +
nanoparticles O +
obtained O +
presented O +
a O +
particle O +
size O +
of O +
340 O -
nm O +
with O +
a O +
positive O +
surface O +
charge O +
of O +
44mV O +
and O +
the O +
capability O +
of O +
forming O +
lipoplexes O +
with O +
DNA O +
plasmids O +
was O +
stated O -
. O +

Nitrosylation O -
: O +
An O +
adverse O +
factor O +
in O +
Uremic O +
Hemolytic O +
Syndrome O -
. O +

Antitoxin O +
effect O +
of O +
Ziziphus O +
mistol O +
Griseb O -
. O +

Toxins O +
of O +
Escherichia O +
coli O +
( O -
STEC O -
) O +
causing O +
Uremic O +
Hemolytic O +
Syndrome O +
( O -
UHS O -
) O +
generate O +
oxidative O +
stress O +
in O +
human O +
blood O +
with O +
more O +
production O +
of O +
nitric B-Chemical +
oxide I-Chemical +
( O -
NO B-Chemical -
) O +
than O +
reactive O +
oxygen B-Chemical +
species O +
( O -
ROS O -
) O -
. O +

Shiga O +
toxin O +
( O -
Stx O -
) O +
together O +
with O +
the O +
hemolysin O +
( O -
Hly O -
) O +
increased O +
lipid O +
oxidation O -
, O +
as O +
evaluated O +
by O +
malondialdehyde B-Chemical +
MDA B-Chemical +
and O +
oxidation O +
of O +
proteins O -
. O +

The O +
addition O +
of O +
Ziziphus O +
mistol O +
Griseb O +
extracts O +
decreased O +
NO B-Chemical -
, O +
ROS O -
, O +
MDA B-Chemical +
and O +
simultaneously O +
caused O +
an O +
increase O +
in O +
the O +
degradation O +
of O +
oxidized O +
proteins O +
to O +
advanced O +
oxidation O +
protein O +
products O +
( O -
AOPPs O -
) O +
in O +
controls O +
and O +
samples O +
with O +
toxins O -
. O +

Furthermore O -
, O +
the O +
nitrosylated O +
proteins O -
/ O -
AOPP O +
ratio O +
was O +
reduced O -
, O +
due O +
to O +
the O +
increase O +
of O +
AOPP O -
. O +

Z. O +
mistol O +
Griseb O +
extracts O +
exhibited O +
a O +
high O +
proportion O +
of O +
polyphenols B-Chemical +
and O +
flavonoids B-Chemical -
, O +
with O +
evident O +
correlation O +
with O +
ferrous B-Chemical +
reduction O +
antioxidant O +
potential O +
( O -
FRAP O -
) O -
. O +

The O +
plasma O +
of O +
eight O +
children O +
with O +
UHS O +
showed O +
oxidative O +
stress O +
and O +
NO B-Chemical +
stimulus O -
, O +
comparable O +
to O +
the O +
effect O +
of O +
toxins O +
during O +
the O +
assays O +
in O +
vitro O -
. O +

UHS O +
children O +
presented O +
high O +
levels O +
of O +
nitrosylated O +
proteins O +
respect O +
to O +
control O +
children O +
of O +
similar O +
age O -
. O +

Although O +
the O +
degradation O +
of O +
oxidized O +
proteins O +
to O +
AOPP O +
rose O +
in O +
UHS O +
children O -
, O +
the O +
nitrosylated O +
proteins O -
/ O -
AOPP O +
rate O +
increased O +
as O +
a O +
consequence O +
of O +
the O +
elevated O +
nitrosative O +
stress O +
observed O +
in O +
these O +
patients O -
. O +

PK O -
/ O -
PD O +
assessment O +
in O +
CNS O +
drug O +
discovery O -
: O +
Prediction O +
of O +
CSF O +
concentration O +
in O +
rodents O +
for O +
P O -
- O -
glycoprotein O +
substrates O +
and O +
application O +
to O +
in O +
vivo O +
potency O +
estimation O -
. O +

The O +
unbound O +
drug O +
concentration O +
in O +
brain O +
parenchyma O +
is O +
considered O +
to O +
be O +
the O +
relevant O +
driver O +
for O +
interaction O +
with O +
central O +
nervous O +
system O +
( O -
CNS O -
) O +
biological O +
targets O -
. O +

Drug O +
levels O +
in O +
cerebrospinal O +
fluid O +
( O -
C_CSF O -
) O +
are O +
frequently O +
used O +
surrogates O +
for O +
the O +
unbound O +
concentrations O +
in O +
brain O -
. O +

For O +
drugs O +
actively O +
transported O +
across O +
the O +
blood O -
- O -
brain O +
barrier O +
( O -
BBB O -
) O -
, O +
C_CSF O +
differs O +
from O +
unbound O +
plasma O +
concentration O +
( O -
Cu_p O -
) O +
to O +
an O +
extent O +
that O +
is O +
commonly O +
unknown O -
. O +

In O +
this O +
study O -
, O +
the O +
relationship O +
between O +
CSF O -
- O -
to O -
- O -
unbound O +
plasma O +
drug O +
partitioning O +
in O +
rats O +
and O +
the O +
mouse O +
Pgp O +
( O -
Mdr1a O -
) O +
efflux O +
ratio O +
( O -
ER O -
) O +
obtained O +
from O +
in O +
vitro O +
transcellular O +
studies O +
has O +
been O +
investigated O +
for O +
a O +
set O +
of O +
61 O +
CNS O +
compounds O +
exhibiting O +
substantial O +
diversity O +
in O +
chemical O +
structure O +
and O +
physico O -
- O -
chemical O +
properties O -
. O +

In O +
order O +
to O +
understand O +
the O +
in O +
vitro O -
- O -
in O +
vivo O +
extrapolation O +
of O +
Pgp O +
efflux O -
, O +
a O +
mechanistic O +
model O +
was O +
derived O +
relating O +
in O +
vivo O +
CNS O +
distribution O +
kinetics O +
to O +
in O +
vitro O +
active O +
transport O -
. O +

The O +
model O +
was O +
applied O +
to O +
predict O +
C_CSF O +
from O +
Cu_p O +
and O +
ER O +
data O +
for O +
19 O +
proprietary O +
Roche O +
CNS O +
drug O +
candidates O -
. O +

The O +
calculated O +
CSF O +
concentrations O +
were O +
correlated O +
with O +
CNS O +
pharmacodynamic O +
responses O +
observed O +
in O +
rodent O +
models O -
. O +

The O +
correlation O +
between O +
in O +
vitro O +
and O +
in O +
vivo O +
potency O +
for O +
different O +
pharmacological O +
endpoints O +
indicated O +
that O +
the O +
predicted O +
C_CSF O +
is O +
a O +
valuable O +
surrogate O +
of O +
the O +
concentration O +
at O +
the O +
target O +
site O -
. O +

Overall O -
, O +
C_CSF O +
proved O +
superior O +
description O +
of O +
PK O -
/ O -
PD O +
data O +
than O +
unbound O +
plasma O +
or O +
total O +
brain O +
concentration O +
for O +
Mdr1a O +
substrates O -
. O +

Predicted O +
C_CSF O +
can O +
be O +
used O +
as O +
a O +
default O +
approach O +
to O +
understand O +
the O +
PK O -
/ O -
PD O +
relationships O +
in O +
CNS O +
efficacy O +
models O +
and O +
can O +
support O +
the O +
extrapolation O +
of O +
efficacious O +
brain O +
exposure O +
for O +
new O +
drug O +
candidates O +
from O +
rodent O +
to O +
man O -
. O +

Three O -
- O -
month O +
subchronic O +
intramuscular O +
toxicity O +
study O +
of O +
rotigotine B-Chemical -
- O -
loaded O +
microspheres O +
in O +
SD O +
rats O -
. O +

Continuous O +
dopaminergic O +
stimulation O +
( O -
CDS O -
) O +
has O +
been O +
an O +
important O +
strategy O +
of O +
drug O +
development O +
for O +
the O +
treatment O +
of O +
Parkinson O -
's O +
disease O +
( O -
PD O -
) O -
. O +

Rotigotine B-Chemical +
is O +
a O +
non O -
- O -
ergoline B-Chemical +
D3 O -
/ O -
D2 O -
/ O -
D1 O +
dopamine B-Chemical +
agonist O +
for O +
treating O +
PD O -
. O +

As O +
a O +
new O +
treatment O +
option O +
for O +
CDS O -
, O +
rotigotine B-Chemical -
- O -
loaded O +
microspheres O +
( O -
RoMS O -
) O -
, O +
a O +
long O -
- O -
acting O +
sustained O -
- O -
release O +
microspheres O +
for O +
injection O +
with O +
poly B-Chemical -
( I-Chemical -
lactide I-Chemical -
- I-Chemical -
co I-Chemical -
- I-Chemical -
glycolide I-Chemical -
) I-Chemical +
as O +
drug O +
carrier O -
, O +
are O +
now O +
being O +
evaluated O +
in O +
clinical O +
trial O -
. O +

In O +
this O +
study O -
, O +
subchronic O +
toxicity O +
of O +
RoMS O +
in O +
SD O +
rats O +
has O +
been O +
characterized O +
via O +
intramuscular O +
administration O +
with O +
RoMS O +
( O -
0 O -
- O -
240mg O -
/ O -
kg O -
/ O -
week O -
) O +
on O +
a O +
consecutive O +
weekly O +
dosing O +
schedule O +
for O +
3months O +
followed O +
by O +
1-month O +
recovery O +
period O -
. O +

The O +
No O +
Observed O +
Adverse O +
Effect O +
Level O +
( O -
NOAEL O -
) O +
was O +
45mg O -
/ O -
kg O -
/ O -
week O -
. O +

One O +
male O +
at O +
240mg O -
/ O -
kg O +
died O +
from O +
an O +
extensive O +
pulmonary O +
embolism O -
. O +

The O +
major O +
toxicological O +
effects O +
were O +
associated O +
with O +
the O +
dopamine B-Chemical +
agonist O -
- O -
related O +
pharmacodynamic O +
properties O +
of O +
rotigotine B-Chemical +
( O -
e.g. O +
hyperactivity O +
and O +
stereotype O -
, O +
enlarged O +
ovary O -
, O +
sporadic O +
gastric O +
mucous O +
membrane O +
lesions O -
, O +
decreased O +
body O +
weight O -
, O +
food O +
consumption O +
and O +
prolactin O -
, O +
and O +
increased O +
mononuclear O +
cell O -
, O +
neutrophil O +
granulocyte O -
, O +
aspartate B-Chemical +
aminotransferase O +
and O +
alanine B-Chemical +
aminotransferase O -
) O +
and O +
foreign O +
body O +
removal O +
reaction O +
induced O +
by O +
poly B-Chemical -
( I-Chemical -
lactide I-Chemical -
- I-Chemical -
co I-Chemical -
- I-Chemical -
glycolide I-Chemical -
) I-Chemical +
and O +
carboxymethycellulose O +
sodium B-Chemical -
. O +

At O +
the O +
end O +
of O +
recovery O +
period O -
, O +
all O +
findings O +
had O +
recovered O +
to O +
a O +
normal O +
level O +
or O +
to O +
a O +
certain O +
degree O +
except O +
foreign O +
body O +
reaction O +
at O +
injection O +
sites O -
. O +

RoMS O +
has O +
exhibited O +
high O +
safety O +
on O +
SD O +
rats O -
. O +

A O +
cell O -
- O -
penetrating O +
peptide O +
suppresses O +
the O +
hypoxia O +
inducible O +
factor-1 O +
function O +
by O +
binding O +
to O +
the O +
helix O -
- O -
loop O -
- O -
helix O +
domain O +
of O +
the O +
aryl B-Chemical +
hydrocarbon I-Chemical +
receptor O +
nuclear O +
translocator O -
. O +

The O +
heterodimeric O +
hypoxia O +
inducible O +
factor-1 O +
( O -
HIF-1 O -
) O +
complex O +
is O +
composed O +
of O +
the O +
hypoxia O +
inducible O +
factor-1 O +
alpha O +
( O -
HIF-1α O -
) O +
and O +
the O +
aryl B-Chemical +
hydrocarbon I-Chemical +
receptor O +
nuclear O +
translocator O +
( O -
ARNT O -
) O -
. O +

Activation O +
of O +
the O +
HIF-1 O +
function O +
is O +
essential O +
for O +
tumor O +
growth O +
and O +
metastasis O -
. O +

We O +
previously O +
showed O +
that O +
transfection O +
of O +
a O +
plasmid O +
containing O +
an O +
ARNT O -
- O -
interacting O +
peptide O +
( O -
Ainp1 O -
) O +
cDNA O +
suppresses O +
the O +
HIF-1 O +
signaling O +
in O +
Hep3B O +
cells O -
. O +

Here O +
we O +
generated O +
TAT O +
fusion O +
of O +
the O +
Ainp1 O +
peptide O +
( O -
6His B-Chemical -
- O -
TAT O -
- O -
Ainp1 O -
) O +
to O +
determine O +
whether O +
and O +
how O +
the O +
Ainp1 O +
peptide O +
suppresses O +
the O +
HIF-1 O +
function O -
. O +

The O +
bacterially O +
expressed O +
6His B-Chemical -
- O -
TAT O -
- O -
Ainp1 O +
was O +
purified O +
under O +
denatured O +
condition O +
and O +
then O +
refolded O +
by O +
limited O +
dialysis O -
. O +

The O +
refolded O +
6His B-Chemical -
- O -
TAT O -
- O -
Ainp1 O +
interacts O +
with O +
the O +
helix O -
- O -
loop O -
- O -
helix O +
( O -
HLH O -
) O +
domain O +
of O +
ARNT O +
in O +
a O +
similar O +
fashion O +
as O +
the O +
native O +
6His B-Chemical -
- O -
Ainp1 O -
. O +

6His B-Chemical -
- O -
TAT O -
- O -
Ainp1 O +
colocalizes O +
with O +
ARNT O +
in O +
the O +
nucleus O +
of O +
HeLa O +
and O +
Hep3B O +
cells O +
after O +
protein O +
transduction O -
. O +

The O +
transduced O +
protein O +
reaches O +
the O +
maximum O +
intracellular O +
levels O +
within O +
2h O +
while O +
remains O +
detectable O +
up O +
to O +
96h O +
in O +
HeLa O +
cells O -
. O +

At O +
2μM O +
concentration O -
, O +
6His B-Chemical -
- O -
TAT O -
- O -
Ainp1 O +
is O +
not O +
cytotoxic O +
in O +
HeLa O +
cells O +
but O +
suppresses O +
the O +
cobalt B-Chemical +
chloride I-Chemical -
- O -
activated O -
, O +
hypoxia O +
responsive O +
enhancer O -
- O -
driven O +
luciferase O +
expression O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O +

In O +
addition O -
, O +
it O +
decreases O +
the O +
cobalt B-Chemical +
chloride I-Chemical -
- O -
dependent O +
induction O +
of O +
the O +
HIF-1 O +
target O +
genes O +
at O +
both O +
the O +
message O +
( O -
vascular O +
endothelial O +
growth O +
factor O +
and O +
aldolase O +
C O -
) O +
and O +
protein O +
( O -
carbonic O +
anhydrase O +
IX O +
and O +
glucose B-Chemical +
transporter O +
1 O -
) O +
levels O -
. O +

The O +
protein O +
levels O +
of O +
HIF-1α O +
and O +
ARNT O +
are O +
not O +
altered O +
in O +
the O +
presence O +
of O +
6His B-Chemical -
- O -
TAT O -
- O -
Ainp1 O -
. O +

In O +
summary O -
, O +
we O +
provided O +
evidence O +
to O +
support O +
that O +
the O +
Ainp1 O +
peptide O +
directly O +
suppresses O +
the O +
HIF-1 O +
function O +
by O +
interacting O +
with O +
the O +
ARNT O +
HLH O +
domain O -
, O +
and O +
in O +
turn O +
interfering O +
with O +
the O +
heterodimerization O +
of O +
HIF-1α O +
and O +
ARNT O -
. O +

Genotoxicity O +
assessment O +
of O +
vaccine O +
adjuvant O +
squalene B-Chemical -
. O +

The O +
genotoxic O +
potential O +
of O +
the O +
vaccine O +
adjuvant O +
Squalene B-Chemical +
was O +
assessed O +
by O +
the O +
chromosomal O +
aberrations O +
( O -
CAs O -
) O -
, O +
sister O +
chromatid O +
exchanges O +
( O -
SCEs O -
) O +
and O +
micronucleus O +
( O -
MNs O -
) O +
tests O +
in O +
human O +
lymphocytes O +
and O +
comet O +
assay O +
in O +
both O +
human O +
and O +
rat O +
lymphocytes O -
. O +

Five O +
different O +
concentrations O +
of O +
squalene B-Chemical +
( O -
1250 O -
- O -
20,000μg O -
/ O -
ml O +
for O +
human O +
lymphocytes O +
and O +
0.07 O -
- O -
1.12mg O -
/ O -
kg O +
for O +
rat O +
lymphocytes O -
) O +
were O +
studied O -
. O +

Squalene B-Chemical +
did O +
not O +
affect O +
the O +
CAs O +
and O +
MN O +
frequency O -
, O +
in O +
all O +
treatments O +
in O +
vitro O -
. O +

A O +
significant O +
increase O +
in O +
SCEs O +
was O +
observed O +
in O +
almost O +
all O +
concentrations O +
at O +
24h O +
treatment O -
. O +

Squalene B-Chemical +
did O +
not O +
affect O +
significantly O +
the O +
comet O +
tail O +
length O +
( O -
CTL O -
) O +
( O -
except O +
2500μg O -
/ O -
ml O -
) O +
and O +
comet O +
tail O +
intensity O +
( O -
CTI O -
) O +
at O +
all O +
treatments O +
in O +
vitro O -
. O +

In O +
rats O -
, O +
squalene B-Chemical +
significantly O +
increased O +
and O +
decreased O +
CTL O +
and O +
CTI O +
in O +
some O +
doses O -
. O +

Although O +
there O +
are O +
increasing O +
and O +
reduction O +
in O +
the O +
effect O -
, O +
squalene B-Chemical +
can O -
not O +
be O +
regarded O +
as O +
genotoxic O +
in O +
human O +
lymphocytes O -
. O +

However O -
, O +
further O +
in O +
vivo O +
studies O +
are O +
required O +
to O +
be O +
sure O +
on O +
the O +
effect O -
. O +

Phenotypic O +
analysis O +
of O +
ovine O +
antigen O +
presenting O +
cells O +
loaded O +
with O +
nanoparticles O +
migrating O +
from O +
the O +
site O +
of O +
vaccination O -
. O +

Virus O -
- O -
sized O +
particulate O +
adjuvants O +
such O +
as O +
ISCOMs O -
, O +
polystyrene B-Chemical +
nanoparticles O +
and O +
virus O -
- O -
like O +
particles O +
have O +
been O +
shown O +
to O +
target O +
dendritic O +
cells O -
, O +
resulting O +
in O +
the O +
activation O +
of O +
T O +
and O +
B O +
cells O +
in O +
vivo O -
. O +

Using O +
an O +
ovine O +
pseudo O -
- O -
afferent O +
lymph O +
cannulation O +
model O +
to O +
capture O +
APC O +
that O +
traffic O +
from O +
the O +
site O +
of O +
injection O +
to O +
the O +
local O +
lymph O +
node O -
, O +
we O +
show O +
that O +
40 O -
- O -
50 O -
nm O +
nanoparticles O +
are O +
taken O +
up O +
at O +
the O +
site O +
of O +
injection O +
by O +
dendritic O +
cells O +
( O -
DCs O -
) O +
migrating O +
to O +
the O +
draining O +
lymph O +
node O -
. O +

These O +
DCs O +
can O +
express O +
CD11c O -
, O +
CD1b O -
, O +
CD5 O -
, O +
MHC O +
class O +
II O +
and O +
CD8 O -
. O +

Nanoparticles O +
transported O +
by O +
DCs O +
migrating O +
from O +
the O +
site O +
of O +
injection O +
to O +
the O +
local O +
lymph O +
node O +
therefore O +
needs O +
to O +
be O +
considered O +
as O +
a O +
new O +
mechanism O +
underlying O +
the O +
immunogenicity O +
of O +
virus O -
- O -
sized O +
vaccine O +
delivery O +
systems O -
. O +

Toxic O +
and O +
genotoxic O +
effects O +
of O +
Roundup B-Chemical +
on O +
tadpoles O +
of O +
the O +
Indian O +
skittering O +
frog O +
( O -
Euflictis O +
cyanophlyctis O -
) O +
in O +
the O +
presence O +
and O +
absence O +
of O +
predator O +
stress O -
. O +

Glyphosate B-Chemical -
, O +
a O +
post O +
emergent O +
herbicide O -
, O +
has O +
become O +
the O +
backbone O +
of O +
no O -
- O -
till O +
agriculture O +
and O +
is O +
considered O +
safe O +
for O +
animals O -
. O +

However O -
, O +
the O +
impact O +
of O +
glyphosate B-Chemical +
on O +
non O -
- O -
target O +
organisms O -
, O +
especially O +
on O +
amphibians O -
, O +
is O +
the O +
subject O +
of O +
major O +
concern O +
and O +
debate O +
in O +
recent O +
times O -
. O +

We O +
examined O +
the O +
toxic O +
and O +
genotoxic O +
effects O +
of O +
Roundup B-Chemical -
, O +
a O +
commercial O +
formulation O +
of O +
glyphosate B-Chemical -
, O +
in O +
the O +
tadpoles O +
of O +
the O +
Indian O +
skittering O +
frog O +
( O -
Euflictis O +
cyanophlyctis O -
) O -
. O +

Roundup B-Chemical +
at O +
different O +
concentrations O +
( O -
0 O -
, O +
1 O -
, O +
2 O -
, O +
3 O -
, O +
4 O +
and O +
8 O -
mg O +
acid O +
equivalent O +
( O -
ae O -
) O -
/ O -
L O -
) O -
, O +
tested O +
in O +
a O +
2 O -
× O -
6 O +
factorial O +
design O +
in O +
the O +
presence O +
and O +
absence O +
of O +
predator O +
stress O -
, O +
induced O +
concentration O -
- O -
dependent O +
lethality O +
in O +
tadpoles O -
. O +

The O +
96-h O +
LC50 O +
for O +
Roundup B-Chemical +
in O +
the O +
absence O +
and O +
presence O +
of O +
predator O +
stress O +
were O +
3.76mgae O -
/ O -
L O +
and O +
3.39mgae O -
/ O -
L O -
, O +
respectively O -
. O +

The O +
10-day O +
LC50 O +
value O +
for O +
Roundup B-Chemical +
was O +
significantly O +
lower O -
, O +
2.12mgae O -
/ O -
L O +
and O +
1.91mgae O -
/ O -
L O +
in O +
the O +
absence O +
and O +
presence O +
of O +
predator O +
stress O -
, O +
respectively O -
. O +

Lower O +
concentrations O +
of O +
Roundup B-Chemical +
( O -
1 O -
, O +
2 O +
and O +
3mgae O -
/ O -
L O -
) O +
induced O +
the O +
formation O +
of O +
micronuclei O +
( O -
MN O -
) O +
in O +
the O +
erythrocytes O +
of O +
tadpoles O +
at O +
24-h O +
( O -
F3,56=10.286 O -
, O +
p<0.001 O -
) O -
, O +
48-h O +
( O -
F3,56=48.255 O -
, O +
p<0.001 O -
) O -
, O +
72-h O +
( O -
F3,56=118.933 O -
, O +
p<0.001 O -
) O +
and O +
96-h O +
( O -
F3,56=85.414 O -
, O +
p<0.001 O -
) O +
in O +
a O +
concentration O -
- O -
dependent O +
manner O -
. O +

Presence O +
of O +
predator O +
stress O +
apparently O +
increased O +
the O +
toxicity O +
and O +
genotoxicity O +
of O +
Roundup B-Chemical -
; O +
but O +
these O +
effects O +
were O +
not O +
statistically O +
significant O -
. O +

These O +
findings O +
suggest O +
that O +
Roundup B-Chemical +
at O +
environmentally O +
relevant O +
concentrations O +
has O +
lethal O +
and O +
genotoxic O +
impact O +
on O +
E. O +
cyanophlyctis O -
; O +
which O +
may O +
have O +
long O -
- O -
term O +
fitness O +
consequence O +
to O +
the O +
species O -
. O +

Insula O -
's O +
functional O +
connectivity O +
with O +
ventromedial O +
prefrontal O +
cortex O +
mediates O +
the O +
impact O +
of O +
trait O +
alexithymia O +
on O +
state O +
tobacco O +
craving O -
. O +

RATIONALE O -
: O +
Alexithymia O +
is O +
a O +
personality O +
trait O +
characterized O +
by O +
difficulty O +
indentifying O +
and O +
describing O +
subjective O +
emotional O +
experiences O -
. O +

Decreased O +
aptitude O +
in O +
the O +
perception O -
, O +
evaluation O -
, O +
and O +
communication O +
of O +
affectively O +
laden O +
mental O +
states O +
has O +
been O +
associated O +
with O +
reduced O +
emotion O +
regulation O -
, O +
more O +
severe O +
drug O +
craving O +
in O +
addicts O -
, O +
and O +
structural O -
/ O -
functional O +
alterations O +
in O +
insula O +
and O +
anterior O +
cingulate O +
cortex O +
( O -
ACC O -
) O -
. O +

The O +
insula O +
and O +
ACC O +
represent O +
sites O +
of O +
convergence O +
between O +
the O +
putative O +
neural O +
substrates O +
of O +
alexithymia O +
and O +
those O +
perpetuating O +
cigarette O +
smoking O -
. O +

OBJECTIVES O -
: O +
We O +
examined O +
the O +
interrelations O +
between O +
alexithymia O -
, O +
tobacco O +
craving O -
, O +
and O +
insula O -
/ O -
ACC O +
neurocircuitry O +
using O +
resting O -
- O -
state O +
functional O +
connectivity O +
( O -
rsFC O -
) O -
. O +

METHODS O -
: O +
Overnight O -
- O -
deprived O +
smokers O +
( O -
n O +
= O +
24 O -
) O +
and O +
nonsmokers O +
( O -
n O +
= O +
20 O -
) O +
completed O +
six O +
neuroimaging O +
assessments O +
on O +
different O +
days O +
both O +
in O +
the O +
absence O +
of O -
, O +
and O +
following O -
, O +
varenicline B-Chemical +
and/or O +
nicotine B-Chemical +
administration O -
. O +

In O +
this O +
secondary O +
analysis O +
of O +
data O +
from O +
a O +
larger O +
study O -
, O +
we O +
assessed O +
trait O +
alexithymia O +
and O +
state O +
tobacco O +
craving O +
using O +
self O -
- O -
reports O +
and O +
examined O +
the O +
rsFC O +
of O +
bilateral O +
insular O +
subregions O +
( O -
anterior O -
, O +
middle O -
, O +
posterior O -
) O +
and O +
dorsal O +
ACC O -
. O +

RESULTS O -
: O +
Higher O +
alexithymia O +
in O +
smokers O +
predicted O +
reduced O +
rsFC O +
strength O +
between O +
the O +
right O +
anterior O +
insula O +
( O -
aI O -
) O +
and O +
ventromedial O +
prefrontal O +
cortex O +
( O -
vmPFC O -
) O -
. O +

Higher O +
alexithymia O +
also O +
predicted O +
more O +
severe O +
tobacco O +
craving O +
during O +
nicotine B-Chemical +
withdrawal O -
. O +

Critically O -
, O +
the O +
identified O +
aI O -
- O -
vmPFC O +
circuit O +
fully O +
mediated O +
this O +
alexithymia O -
- O -
craving O +
relation O -
. O +

That O +
is O -
, O +
elevated O +
alexithymia O +
predicted O +
decreased O +
aI O -
- O -
vmPFC O +
rsFC O +
and O -
, O +
in O +
turn O -
, O +
decreased O +
aI O -
- O -
vmPFC O +
rsFC O +
predicted O +
increased O +
craving O +
during O +
withdrawal O -
. O +

A O +
moderated O +
mediation O +
analysis O +
indicated O +
that O +
this O +
aI O -
- O -
vmPFC O +
mediational O +
effect O +
was O +
not O +
observed O +
following O +
drug O +
administration O -
. O +

CONCLUSIONS O -
: O +
These O +
results O +
suggest O +
that O +
a O +
weakened O +
right O +
aI O -
- O -
vmPFC O +
functional O +
circuit O +
confers O +
increased O +
liability O +
for O +
tobacco O +
craving O +
during O +
smoking O +
abstinence O -
. O +

Individual O +
differences O +
in O +
alexithymia O +
and/or O +
aI O -
- O -
vmPFC O +
functional O +
coupling O +
may O +
be O +
relevant O +
factors O +
for O +
smoking O +
cessation O +
success O -
. O +

Acute O +
behavioural O +
effects O +
of O +
bupropion B-Chemical +
and O +
naltrexone B-Chemical -
, O +
alone O +
and O +
in O +
combination O -
, O +
in O +
non O -
- O -
deprived O +
male O +
rats O +
presented O +
with O +
palatable O +
mash O -
. O +

RATIONALE O -
: O +
In O +
appetite O +
research O -
, O +
drugs O +
frequently O +
progress O +
to O +
clinical O +
trials O +
on O +
the O +
basis O +
of O +
outcome O +
( O -
reduced O +
food O +
intake O -
/ O -
body O +
weight O +
gain O -
) O +
with O +
insufficient O +
attention O +
to O +
process O +
( O -
behavioural O +
analysis O -
) O -
. O +

Although O +
bupropion B-Chemical +
and O +
naltrexone B-Chemical +
( O -
alone O +
and O +
in O +
combination O -
) O +
reduce O +
food O +
consumption O +
in O +
rodents O +
and O +
humans O -
, O +
their O +
effects O +
on O +
behaviour O +
during O +
feeding O +
tests O +
have O +
not O +
been O +
thoroughly O +
investigated O -
. O +

OBJECTIVES O -
: O +
This O +
study O +
aimed O +
to O +
assess O +
the O +
behavioural O +
specificity O +
of O +
anorectic O +
responses O +
to O +
bupropion B-Chemical -
, O +
naltrexone B-Chemical +
and O +
their O +
combination O -
. O +

METHODS O -
: O +
Video O +
analysis O +
was O +
employed O +
to O +
characterise O +
the O +
behavioural O +
effects O +
of O +
acute O +
systemic O +
treatment O +
with O +
bupropion B-Chemical +
( O -
10.0 O -
- O -
40.0 O +
mg O -
/ O -
kg O -
) O -
, O +
naltrexone B-Chemical +
( O -
0.1 O -
- O -
3.0 O +
mg O -
/ O -
kg O -
) O +
and O +
combined O +
bupropion B-Chemical +
( O -
20 O +
mg O -
/ O -
kg O -
) O +
plus O +
naltrexone B-Chemical +
( O -
0.1 O -
- O -
1.0 O +
mg O -
/ O -
kg O -
) O +
in O +
non O -
- O -
deprived O +
male O +
rats O +
exposed O +
for O +
1 O +
h O +
to O +
palatable O +
mash O -
. O +

Particular O +
attention O +
was O +
paid O +
to O +
the O +
behavioural O +
satiety O +
sequence O +
( O -
BSS O -
) O -
. O +

RESULTS O -
: O +
In O +
experiment O +
1 O -
, O +
the O +
anorectic O +
response O +
to O +
40 O +
mg O -
/ O -
kg O +
bupropion B-Chemical +
was O +
associated O +
with O +
significant O +
psychomotor O +
stimulation O +
and O +
a O +
complete O +
disruption O +
of O +
the O +
BSS O -
. O +

In O +
experiment O +
2 O -
, O +
the O +
anorectic O +
response O +
to O +
3 O +
mg O -
/ O -
kg O +
naltrexone B-Chemical +
was O +
associated O +
with O +
an O +
accelerated O +
but O +
otherwise O +
normal O +
BSS O -
. O +

In O +
experiment O +
3 O -
, O +
the O +
co O -
- O -
administration O +
of O +
20 O +
mg O -
/ O -
kg O +
bupropion B-Chemical +
and O +
naltrexone B-Chemical +
( O -
0.1 O +
and O +
1.0 O +
mg O -
/ O -
kg O -
) O +
not O +
only O +
produced O +
an O +
additive O +
anorectic O +
profile O +
( O -
including O +
a O +
reduced O +
rate O +
of O +
eating O -
) O -
, O +
but O +
the O +
addition O +
of O +
the O +
opioid O +
receptor O +
antagonist O +
also O +
concurrently O +
attenuated O +
the O +
psychomotor O +
stimulant O +
response O +
to O +
the O +
atypical O +
antidepressant O -
. O +

CONCLUSIONS O -
: O +
Low O -
- O -
dose O +
co O -
- O -
treatment O +
with O +
naltrexone B-Chemical +
and O +
bupropion B-Chemical +
produces O +
a O +
stronger O +
suppression O +
of O +
appetite O +
than O +
that O +
seen O +
with O +
either O +
agent O +
alone O +
and O +
has O +
the O +
additional O +
advantage O +
of O +
reducing O +
some O +
of O +
the O +
unwanted O +
effects O +
of O +
bupropion B-Chemical -
. O +

Genotoxic O -
, O +
antigenotoxic O +
and O +
antioxidant O +
properties O +
of O +
methanol B-Chemical +
extracts O +
obtained O +
from O +
Peltigera O +
horizontalis O +
and O +
Peltigera O +
praetextata O -
. O +

Now O -
- O -
a O -
- O -
days O -
, O +
there O +
is O +
a O +
big O +
need O +
to O +
reduce O +
genotoxic O +
effects O +
of O +
mutagenic O +
and O +
carcinogenic O +
agents O +
in O +
environment O -
, O +
which O +
are O +
increased O +
by O +
the O +
technological O +
development O -
. O +

Lichens O +
produce O +
a O +
wide O +
variety O +
of O +
unique O +
metabolites O +
due O +
to O +
being O +
in O +
various O +
extreme O +
areas O +
and O +
being O +
symbiotic O +
organisms O +
of O +
fungi O +
and O +
algae O -
. O +

Therefore O -
, O +
this O +
study O +
was O +
planned O +
to O +
search O +
new O +
sources O +
having O +
antimutagenic O +
activity O +
by O +
researching O +
two O +
different O +
lichen O +
species O +
and O +
to O +
determine O +
whether O +
their O +
usage O +
is O +
safe O -
. O +

With O +
this O +
respect O -
, O +
the O +
mutagenic O +
and O +
antimutagenic O +
properties O +
of O +
methanol B-Chemical +
extracts O +
of O +
the O +
lichens O +
were O +
determined O +
by O +
the O +
bacterial O +
reverse O +
mutation O +
and O +
sister O +
chromatid O +
exchange O +
assays O -
. O +

Furthermore O -
, O +
the O +
malondialdehyde B-Chemical +
level O -
, O +
superoxide B-Chemical +
dismutase O -
, O +
glutathione B-Chemical +
and O +
glutathione B-Chemical +
peroxidase O +
activities O +
against O +
aflatoxin B-Chemical +
B1 I-Chemical +
were O +
determined O +
for O +
understanding O +
the O +
ways O +
in O +
which O +
the O +
lichens O +
showed O +
their O +
genotoxic O +
properties O -
. O +

Rapid O +
cortical O +
bone O +
loss O +
in O +
patients O +
with O +
chronic O +
kidney O +
disease O -
. O +

Chronic O +
kidney O +
disease O +
( O -
CKD O -
) O +
patients O +
may O +
have O +
high O +
rates O +
of O +
bone O +
loss O +
and O +
fractures O -
, O +
but O +
microarchitectural O +
and O +
biochemical O +
mechanisms O +
of O +
bone O +
loss O +
in O +
CKD O +
patients O +
have O +
not O +
been O +
fully O +
described O -
. O +

In O +
this O +
longitudinal O +
study O +
of O +
53 O +
patients O +
with O +
CKD O +
Stages O +
2 O -
- O -
5D O -
, O +
we O +
used O +
dual O +
energy O +
X O -
- O -
ray O +
absorptiometry O +
( O -
DXA O -
) O -
, O +
high O +
resolution O +
peripheral O +
quantitative O +
computed O +
tomography O +
( O -
HRpQCT O -
) O +
and O +
biochemical O +
markers O +
of O +
bone O +
metabolism O +
to O +
elucidate O +
effects O +
of O +
CKD O +
on O +
the O +
skeleton O -
. O +

Median O +
follow O -
- O -
up O +
was O +
1.5 O +
years O +
( O -
Range O +
0.9 O +
to O +
4.3 O +
years O -
) O -
; O +
bone O +
changes O +
were O +
annualized O +
and O +
compared O +
to O +
baseline O -
. O +

By O +
DXA O -
, O +
there O +
were O +
significant O +
declines O +
in O +
areal O +
bone O +
mineral O +
density O +
( O -
BMD O -
) O +
of O +
the O +
total O +
hip O +
and O +
ultradistal O +
radius O -
: O +
-1.3 O -
% O +
( O -
95 O -
% O +
CI O -
: O +
-2.1 O +
to O +
-0.6 O -
) O +
and O +
-2.4 O -
% O +
( O -
95 O -
% O +
CI O -
: O +
-4.0 O +
to O +
-0.9 O -
) O -
, O +
respectively O -
. O +

By O +
HRpQCT O +
at O +
the O +
distal O +
radius O -
, O +
there O +
were O +
significant O +
declines O +
in O +
cortical O +
area O -
, O +
density O +
and O +
thickness O -
, O +
and O +
increases O +
in O +
porosity O -
: O +
-2.9 O -
% O +
( O -
95 O -
% O +
CI O +
-3.7 O +
to O +
-2.2 O -
) O -
, O +
-1.3 O -
% O +
( O -
95 O -
% O +
CI O +
-1.6 O +
to O +
-0.6 O -
) O -
, O +
-2.8 O -
% O +
( O -
95 O -
% O +
CI O +
-3.6 O +
to O +
-1.9 O -
) O -
, O +
and O +
+ O -
4.2 O -
% O +
( O -
95 O -
% O +
CI O +
2.0 O +
to O +
6.4 O -
) O +
respectively O -
. O +

Radius O +
trabecular O +
area O +
increased O +
significantly O -
: O +
+ O -
0.4 O -
% O +
( O -
95 O -
% O +
CI O +
0.2 O +
to O +
0.6 O -
) O -
, O +
without O +
significant O +
changes O +
in O +
trabecular O +
density O +
or O +
microarchitecture O -
. O +

Elevated O +
time O -
- O -
averaged O +
levels O +
of O +
parathyroid O +
hormone O +
( O -
PTH O -
) O +
and O +
bone O +
turnover O +
markers O +
predicted O +
cortical O +
deterioration O -
. O +

Higher O +
levels O +
of O +
serum O +
25-hydroxyvitamin B-Chemical +
D I-Chemical +
predicted O +
decreases O +
in O +
trabecular O +
network O +
heterogeneity O -
. O +

These O +
data O +
suggest O +
that O +
significant O +
cortical O +
loss O +
occurs O +
with O +
CKD O -
, O +
which O +
is O +
mediated O +
by O +
hyperparathyroidism O +
and O +
elevated O +
turnover O -
. O +

Future O +
investigations O +
are O +
required O +
to O +
determine O +
whether O +
these O +
cortical O +
losses O +
can O +
be O +
attenuated O +
by O +
treatments O +
that O +
reduce O +
PTH O +
levels O +
and O +
remodeling O +
rates O -
. O +

© O +
2013 O +
American O +
Society O +
for O +
Bone O +
and O +
Mineral O +
Research O -
. O +

TRAIL O -
- O -
Based O +
Therapeutic O +
Approaches O +
for O +
the O +
Treatment O +
of O +
Pediatric O +
Malignancies O -
. O +

Tumor O +
necrosis O +
factor O -
- O -
related O +
apoptosis O +
inducing O +
ligand O +
( O -
TRAIL O -
) O +
is O +
a O +
pro O -
- O -
apoptotic O +
ligand O +
that O +
has O +
shown O +
the O +
exquisite O +
ability O +
to O +
trigger O +
extrinsic O +
apoptosis O +
in O +
various O +
types O +
of O +
cancer O +
cells O +
without O +
significant O +
toxicity O +
toward O +
normal O +
cells O -
, O +
when O +
compared O +
to O +
other O +
pro O -
- O -
apoptotic O +
ligands O +
such O +
as O +
tumor O +
necrosis O +
factor O +
( O -
TNF O -
) O +
α O +
or O +
Fas O +
ligand O -
. O +

Consequently O -
, O +
TRAIL O -
- O -
based O +
therapies O +
aim O +
to O +
trigger O +
apoptosis O +
in O +
cancer O +
cells O +
by O +
providing O +
the O +
soluble O +
TRAIL O +
or O +
monoclonal O +
antibodies O +
targeting O +
the O +
death O +
receptors O +
TRAIL O -
- O -
R1 O +
or O +
TRAIL O -
- O -
R2 O -
. O +

In O +
this O +
review O -
, O +
we O +
start O +
by O +
highlighting O +
the O +
relevance O +
of O +
the O +
tumor O +
microenvironment O +
in O +
tumor O +
development O +
and O +
elimination O -
. O +

We O +
then O +
address O +
conventional O +
and O +
targeted O +
therapeutic O +
approaches O +
for O +
cancer O +
treatment O -
, O +
highlighting O +
the O +
mechanisms O +
involved O +
or O +
targeted O -
. O +

We O +
describe O +
the O +
extrinsic O +
and O +
intrinsic O +
pro O -
- O -
apoptotic O +
pathways O +
of O +
TRAIL O -
, O +
together O +
with O +
the O +
evidences O +
for O +
its O +
pro O -
- O -
survival O +
signaling O -
, O +
and O +
with O +
the O +
relevance O +
of O +
these O +
pathways O +
in O +
therapy O -
. O +

Possible O +
mechanisms O +
of O +
resistance O +
to O +
TRAIL O -
- O -
induced O +
apoptosis O +
are O +
highlighted O +
( O -
i.e. O +
c O -
- O -
FLIP O -
, O +
Bcl-2 O -
, O +
IAPs O -
, O +
p53 O -
, O +
NF O -
- O -
κ O +
B O -
) O +
and O +
the O +
rationale O +
for O +
the O +
combined O +
administration O +
of O +
TRAIL O +
with O +
drugs O +
targeting O +
these O +
mechanisms O +
is O +
provided O -
. O +

Preclinical O +
data O +
are O +
reported O +
and O +
show O +
encouraging O +
evidences O +
for O +
TRAIL O +
consideration O +
in O +
pediatric O +
malignancies O +
( O -
i.e. O -
, O +
leukemia O -
, O +
lymphomas O -
, O +
neuroblastoma O -
, O +
osteosarcoma O -
, O +
medulloblastoma O -
) O -
. O +

Clinical O +
trials O +
of O +
TRAIL O -
- O -
based O +
therapies O +
on O +
the O +
overall O +
population O +
are O +
in O +
phase O +
I O +
or O +
II O -
, O +
and O +
we O +
put O +
particular O +
focus O +
on O +
the O +
pediatric O +
population O -
, O +
on O +
which O +
only O +
few O +
trials O +
have O +
been O +
conducted O +
or O +
are O +
ongoing O -
. O +

Finally O -
, O +
we O +
consider O +
emerging O +
cellular O +
therapies O +
based O +
on O +
TRAIL O -
, O +
such O +
as O +
TRAIL O -
- O -
engineered O +
mesenchymal O +
stem O +
cells O +
or O +
' O -
inflammatory O -
' O +
dendritic O +
cells O -
. O +

Potential O +
Advantages O +
of O +
Using O +
Synchrotron O +
X O -
- O -
ray O +
Based O +
Techniques O +
in O +
Pediatric O +
Research O -
. O +

Synchrotron O +
radiation O +
( O -
SR O -
) O -
, O +
which O +
combines O +
extremely O +
high O +
intensity O -
, O +
high O +
collimation O -
, O +
tunability O -
, O +
and O +
continuous O +
energy O +
spectrum O -
, O +
allows O +
the O +
development O +
of O +
advanced O +
X O -
- O -
ray O +
based O +
techniques O +
that O +
are O +
becoming O +
a O +
uniquely O +
useful O +
tool O +
in O +
life O +
science O +
research O -
, O +
along O +
providing O +
exciting O +
opportunities O +
in O +
biomedical O +
imaging O +
and O +
radiotherapy O -
. O +

This O +
review O +
summarize O +
emerging O +
techniques O +
and O +
their O +
potential O +
to O +
greatly O +
enhance O +
the O +
exploration O +
of O +
dynamical O +
biological O +
process O +
occurring O +
across O +
various O +
spatial O +
and O +
temporal O +
regimes O -
, O +
from O +
whole O +
body O +
physiology O -
, O +
down O +
to O +
the O +
location O +
of O +
individual O +
chemical O +
species O +
within O +
single O +
cells O -
. O +

In O +
recent O +
years O +
pediatric O +
research O +
and O +
clinic O +
practice O +
have O +
started O +
to O +
profit O +
from O +
these O +
new O +
opportunities O -
, O +
particularly O +
by O +
extending O +
the O +
diagnostic O +
and O +
therapeutic O +
capabilities O +
of O +
these O +
X O -
- O -
ray O +
based O +
techniques O -
. O +

In O +
diagnosis O -
, O +
technical O +
advances O +
in O +
DEI O +
and O +
KES O +
imaging O +
modalities O +
have O +
been O +
demonstrated O +
as O +
particularly O +
valuable O +
for O +
children O +
and O +
women O +
since O +
SR O +
allows O +
dose O +
minimization O -
, O +
with O +
significant O +
reductions O +
compared O +
to O +
conventional O +
approaches O -
. O +

However O -
, O +
the O +
greatest O +
expectations O +
are O +
in O +
the O +
field O +
of O +
SR O +
based O +
radiotherapy O -
, O +
increasingly O +
studies O +
are O +
demonstrating O +
SR O +
radiotherapy O +
provides O +
improved O +
chances O +
of O +
recovery O -
; O +
this O +
is O +
especially O +
the O +
case O +
for O +
pediatric O +
patients O -
. O +

In O +
addition O -
, O +
we O +
report O +
on O +
the O +
applicability O +
of O +
advanced O +
X O -
- O -
ray O +
microscopy O +
techniques O +
that O +
offer O +
exceptional O +
spatial O +
and O +
quantitative O +
resolution O +
in O +
elemental O +
detection O -
. O +

These O +
techniques O -
, O +
which O +
are O +
useful O +
for O +
in O +
vitro O +
studies O -
, O +
will O +
be O +
particularly O +
advantageous O +
where O +
investigators O +
seek O +
deeper O +
understanding O +
of O +
diseases O +
where O +
mismetabolism O +
of O +
metals O -
, O +
either O +
physiological O +
important O +
( O -
i.e. O +
Cu B-Chemical -
, O +
Zn B-Chemical -
) O +
or O +
outright O +
toxic O +
( O -
i.e. O +
Pb B-Chemical -
) O -
, O +
underlies O +
pathogenesis O -
. O +

Pharmacogenomic O +
approaches O +
for O +
tailored O +
anti O -
- O -
leukemic O +
therapy O +
in O +
children O -
. O +

Several O +
lympholytic O +
and O +
cytotoxic O +
agents O +
are O +
used O +
in O +
acute O +
lymphoblastic O +
leukemia O +
( O -
ALL O -
) O +
polychemotherapy O -
. O +

Genetic O +
variants O +
for O +
cellular O +
components O +
involved O +
in O +
the O +
pharmacokinetics O +
and O +
pharmacodynamics O +
of O +
these O +
drugs O +
can O +
influence O +
the O +
pharmacological O +
response O -
, O +
and O +
molecular O +
characterization O +
of O +
these O +
genetic O +
variants O +
could O +
be O +
helpful O +
for O +
the O +
comprehension O +
of O +
the O +
mechanisms O +
of O +
resistance O +
or O +
increased O +
sensitivity O -
. O +

The O +
purpose O +
of O +
this O +
review O +
is O +
to O +
carry O +
out O +
an O +
update O +
of O +
recent O +
publications O +
on O +
genes O +
that O +
might O +
influence O +
ALL O +
treatment O +
in O +
terms O +
of O +
outcome O +
and/or O +
toxicity O +
and O +
to O +
underlie O +
the O +
role O +
of O +
genetic O +
variants O -
, O +
particularly O +
single O +
nucleotide O +
polymorphisms O +
( O -
SNP O -
) O -
, O +
in O +
predicting O +
clinical O +
response O -
, O +
with O +
particular O +
reference O +
to O +
the O +
current O +
protocol O +
for O +
ALL O +
therapy O +
used O +
in O +
Italy O -
, O +
AIEOP O -
- O -
BFM O +
ALL O +
2009 O -
. O +

Potential O +
use O +
of O +
polymeric O +
nanoparticles O +
for O +
drug O +
delivery O +
across O +
the O +
blood O -
- O -
brain O +
barrier O -
. O +

Nanomedicine O +
is O +
certainly O +
one O +
of O +
the O +
scientific O +
and O +
technological O +
challenges O +
of O +
the O +
coming O +
years O -
. O +

In O +
particular O -
, O +
biodegradable O +
nanoparticles O +
formulated O +
from O +
poly B-Chemical +
( I-Chemical -
D I-Chemical -
, I-Chemical -
L I-Chemical -
- I-Chemical -
lactide I-Chemical -
- I-Chemical -
co I-Chemical -
- I-Chemical -
glycolide I-Chemical -
) I-Chemical +
( O -
PLGA B-Chemical -
) O +
have O +
been O +
extensively O +
investigated O +
for O +
sustained O +
and O +
targeted O +
delivery O +
of O +
different O +
agents O -
, O +
including O +
recombinant O +
proteins O -
, O +
plasmid O +
DNA O -
, O +
and O +
low O +
molecular O +
weight O +
compounds O -
. O +

PLGA B-Chemical +
NPs O +
present O +
some O +
very O +
attractive O +
properties O +
such O +
as O +
biodegradability O +
and O +
biocompatibility O -
, O +
protection O +
of O +
drug O +
from O +
degradation O -
, O +
possibility O +
of O +
sustained O +
release O -
, O +
and O +
the O +
possibility O +
to O +
modify O +
surface O +
properties O +
to O +
target O +
nanoparticles O +
to O +
specific O +
organs O +
or O +
cells O -
. O +

Moreover O -
, O +
PLGA B-Chemical +
NPs O +
have O +
received O +
the O +
FDA O +
and O +
European O +
Medicine O +
Agency O +
approval O +
in O +
drug O +
delivery O +
systems O +
for O +
parenteral O +
administration O -
, O +
thus O +
reducing O +
the O +
time O +
for O +
human O +
clinical O +
applications O -
. O +

This O +
review O +
in O +
particular O +
deals O +
on O +
surface O +
modification O +
of O +
PLGA B-Chemical +
NPs O +
and O +
their O +
possibility O +
of O +
clinical O +
applications O -
, O +
including O +
treatment O +
for O +
brain O +
pathologies O +
such O +
as O +
brain O +
tumors O +
and O +
Lysosomal O +
Storage O +
Disorders O +
with O +
neurological O +
involvement O -
. O +

Since O +
a O +
great O +
number O +
of O +
pharmacologically O +
active O +
molecules O +
are O +
not O +
able O +
to O +
cross O +
the O +
Blood O -
- O -
Brain O +
Barrier O +
( O -
BBB O -
) O +
and O +
reach O +
the O +
Central O +
Nervous O +
System O +
( O -
CNS O -
) O -
, O +
new O +
brain O +
targeted O +
polymeric O +
PLGA B-Chemical +
NPs O +
modified O +
with O +
glycopeptides O +
( O -
g7- O +
NPs O -
) O +
have O +
been O +
recently O +
produced O -
. O +

In O +
this O +
review O +
several O +
in O +
vivo O +
biodistribution O +
studies O +
and O +
pharmacological O +
proof O -
- O -
of O +
evidence O +
of O +
brain O +
delivery O +
of O +
model O +
drugs O +
are O +
reported O -
, O +
demonstrating O +
the O +
ability O +
of O +
g7-NPs O +
to O +
create O +
BBB O +
interaction O +
and O +
trigger O +
an O +
efficacious O +
BBB O +
crossing O -
. O +

Moreover O -
, O +
another O +
relevant O +
development O +
of O +
NPs O +
surface O +
engineering O +
was O +
achieved O +
by O +
conjugating O +
to O +
the O +
surface O +
of O +
g7-NPs O -
, O +
some O +
specific O +
and O +
selective O +
antibodies O +
to O +
drive O +
NPs O +
directly O +
to O +
a O +
specific O +
cell O +
type O +
once O +
inside O +
the O +
CNS O +
parenchyma O -
. O +

In O +
vitro O +
and O +
in O +
vivo O +
evaluation O +
of O +
superparamagnetic O +
iron B-Chemical +
oxide I-Chemical +
nanoparticles O +
coated O +
by O +
bisphosphonates B-Chemical -
: O +
The O +
effects O +
of O +
electrical O +
charge O +
and O +
molecule O +
length O -
. O +

Physicochemical O +
coating O +
properties O +
are O +
often O +
considered O +
to O +
be O +
determining O +
factors O +
for O +
in O +
vivo O +
characteristics O +
of O +
superparamagnetic O +
iron B-Chemical +
oxide I-Chemical +
nanoparticles O -
, O +
used O +
as O +
contrast O +
agent O +
in O +
Magnetic O +
Resonance O +
Imaging O +
( O -
MRI O -
) O -
. O +

To O +
investigate O +
the O +
electrical O +
charge O +
( O -
modified O +
by O +
zero O -
, O +
one O +
or O +
two O +
ammonium B-Chemical +
groups O -
) O +
and O +
the O +
molecule O +
length O +
( O -
3 O -
, O +
5 O +
or O +
7 O +
methylene B-Chemical +
chains O -
) O +
effects O +
of O +
bisphosphonate B-Chemical -
- O -
type O +
coatings O -
, O +
we O +
assessed O +
the O +
complement O +
activation O -
, O +
in O +
vivo O +
plasma O +
and O +
tissue O +
relaxation O +
time O +
alterations O +
of O +
intravenously O +
injected O +
small O +
iron B-Chemical +
oxide I-Chemical +
nanoparticles O +
( O -
< O -
25 O -
nm O -
) O +
on O +
male O +
healthy O +
Wistar O +
rats O -
. O +

The O +
presence O +
of O +
ammonium B-Chemical +
groups O +
induces O +
a O +
weak O +
activation O +
of O +
the O +
complement O +
whatever O +
the O +
size O +
and O +
the O +
concentration O +
of O +
particles O -
, O +
whereas O +
hydroxyethylenebisphosphonate B-Chemical +
( O -
HEBP B-Chemical -
) O -
-coated O +
particles O +
are O +
poor O +
complement O +
activators O +
only O +
at O +
the O +
lowest O +
concentration O -
. O +

In O +
vivo O -
, O +
HEBP B-Chemical -
- O -
coated O +
nanoparticles O +
have O +
the O +
greatest O +
prolonged O +
relaxation O +
time O +
effects O -
, O +
despite O +
their O +
higher O +
negative O +
electrical O +
charge O -
, O +
contrary O +
to O +
two O +
ammonium B-Chemical +
bearing O +
coatings O -
. O +

No O +
significant O +
differences O +
were O +
observed O +
between O +
mono B-Chemical -
- I-Chemical -
ammonium I-Chemical +
molecular O +
coatings O -
. O +

Exploring O +
the O +
genetic O +
basis O +
of O +
chronic O +
periodontitis O -
: O +
a O +
genome O -
- O -
wide O +
association O +
study O -
. O +

Chronic O +
periodontitis O +
( O -
CP O -
) O +
is O +
a O +
common O +
oral O +
disease O +
that O +
confers O +
substantial O +
systemic O +
inflammatory O +
and O +
microbial O +
burden O +
and O +
is O +
a O +
major O +
cause O +
of O +
tooth O +
loss O -
. O +

Here O -
, O +
we O +
present O +
the O +
results O +
of O +
a O +
genome O -
- O -
wide O +
association O +
study O +
of O +
CP O +
that O +
was O +
carried O +
out O +
in O +
a O +
cohort O +
of O +
4504 O +
European O +
Americans O +
( O -
EA O -
) O +
participating O +
in O +
the O +
Atherosclerosis O +
Risk O +
in O +
Communities O +
( O -
ARIC O -
) O +
Study O +
( O -
mean O +
age-62 O +
years O -
, O +
moderate O +
CP-43 O -
% O +
and O +
severe O +
CP-17 O -
% O -
) O -
. O +

We O +
detected O +
no O +
genome O -
- O -
wide O +
significant O +
association O +
signals O +
for O +
CP O -
; O +
however O -
, O +
we O +
found O +
suggestive O +
evidence O +
of O +
association O +
( O -
P O +
< O +
5 O +
× O +
10 O -
( O -
-6 O -
) O -
) O +
for O +
six O +
loci O -
, O +
including O +
NIN O -
, O +
NPY O -
, O +
WNT5A O +
for O +
severe O +
CP O +
and O +
NCR2 O -
, O +
EMR1 O -
, O +
10p15 O +
for O +
moderate O +
CP O -
. O +

Three O +
of O +
these O +
loci O +
had O +
concordant O +
effect O +
size O +
and O +
direction O +
in O +
an O +
independent O +
sample O +
of O +
656 O +
adult O +
EA O +
participants O +
of O +
the O +
Health O -
, O +
Aging O -
, O +
and O +
Body O +
Composition O +
( O -
Health O +
ABC O -
) O +
Study O -
. O +

Meta O -
- O -
analysis O +
pooled O +
estimates O +
were O +
severe O +
CP O +
( O -
n O +
= O +
958 O +
versus O +
health O -
: O +
n O +
= O +
1909 O -
) O -
-NPY O -
, O +
rs2521634 O +
[ O -
G O -
] O -
: O +
odds O +
ratio O +
[ O -
OR O +
= O +
1.49 O +
( O -
95 O -
% O +
confidence O +
interval O +
( O -
CI O +
= O +
1.28 O -
- O -
1.73 O -
, O +
P O +
= O +
3.5 O +
× O +
10 O -
( O -
-7 O -
) O -
) O -
) O -
] O -
; O +
moderate O +
CP O +
( O -
n O +
= O +
2293 O -
) O -
-NCR2 O -
, O +
rs7762544 O +
[ O -
G O -
] O -
: O +
OR O +
= O +
1.40 O +
( O -
95 O -
% O +
CI O +
= O +
1.24 O -
- O -
1.59 O -
, O +
P O +
= O +
7.5 O +
× O +
10 O -
( O -
-8 O -
) O -
) O -
, O +
EMR1 O -
, O +
rs3826782 O +
[ O -
A O -
] O -
: O +
OR O +
= O +
2.01 O +
( O -
95 O -
% O +
CI O +
= O +
1.52 O -
- O -
2.65 O -
, O +
P O +
= O +
8.2 O +
× O +
10 O -
( O -
-7 O -
) O -
) O -
. O +

Canonical O +
pathway O +
analysis O +
indicated O +
significant O +
enrichment O +
of O +
nervous O +
system O +
signaling O -
, O +
cellular O +
immune O +
response O +
and O +
cytokine O +
signaling O +
pathways O -
. O +

A O +
significant O +
interaction O +
of O +
NUAK1 O +
( O -
rs11112872 O -
, O +
interaction O +
P O +
= O +
2.9 O +
× O +
10 O -
( O -
-9 O -
) O -
) O +
with O +
smoking O +
in O +
ARIC O +
was O +
not O +
replicated O +
in O +
Health O +
ABC O -
, O +
although O +
estimates O +
of O +
heritable O +
variance O +
in O +
severe O +
CP O +
explained O +
by O +
all O +
single O +
nucleotide O +
polymorphisms O +
increased O +
from O +
18 O +
to O +
52 O -
% O +
with O +
the O +
inclusion O +
of O +
a O +
genome O -
- O -
wide O +
interaction O +
term O +
with O +
smoking O -
. O +

These O +
genome O -
- O -
wide O +
association O +
results O +
provide O +
information O +
on O +
multiple O +
candidate O +
regions O +
and O +
pathways O +
for O +
interrogation O +
in O +
future O +
genetic O +
studies O +
of O +
CP O -
. O +

Carrier O +
free O +
rapamycin B-Chemical +
loaded O +
drug O +
eluting O +
stent O -
: O +
In O +
vitro O +
and O +
in O +
vivo O +
evaluation O -
. O +

In O +
the O +
search O +
for O +
improving O +
the O +
performance O +
of O +
drug O +
eluting O +
stent O +
( O -
DES O -
) O +
various O +
developments O +
are O +
in O +
progress O +
worldwide O +
including O +
use O +
of O +
carrier O +
free O +
DES O -
, O +
use O +
of O +
biodegradable O +
polymers O -
, O +
biodegradable O +
stents O +
etc O -
. O +

In O +
this O +
work O -
, O +
carrier O +
free O -
- O -
rapamycin B-Chemical +
( O -
RM O -
) O +
coated O +
DES O +
has O +
been O +
prepared O -
, O +
and O +
evaluated O +
by O +
in O +
vitro O +
and O +
in O +
vivo O +
procedures O +
necessary O +
for O +
clinical O +
development O -
. O +

In O +
vitro O +
drug O +
release O +
from O +
the O +
developed O +
stents O +
was O +
carried O +
in O +
different O +
release O +
media O -
, O +
normal O +
saline O -
- O -
isopropanol B-Chemical +
( O -
NS O -
- O -
IP O -
) O -
, O +
phosphate B-Chemical +
buffer O +
( O -
PB O -
) O -
, O +
phosphate B-Chemical +
buffer O +
saline O +
( O -
PBS O -
) O +
and O +
in O +
human O +
plasma O -
. O +

Simultaneously O -
, O +
drug O +
released O +
at O +
site O +
of O +
implantation O +
and O +
biocompatibility O +
of O +
developed O +
stents O +
was O +
determined O +
after O +
subcutaneous O +
implantation O +
in O +
the O +
SD O +
rats O -
. O +

Developed O +
stent O +
coating O +
method O +
enables O +
fabrication O +
of O +
controllable O +
and O +
homogeneous O +
crystalline O +
RM O +
coatings O +
on O +
stent O +
scaffolds O -
. O +

Continuous O +
release O +
of O +
RM O +
was O +
observed O +
in O +
different O +
release O +
conditions O +
with O +
different O +
release O +
rate O -
, O +
maximum O +
in O +
NS O -
- O -
IP O +
and O +
least O +
in O +
PB O -
. O +

Similarly O -
, O +
after O +
subcutaneous O +
implantation O +
of O +
these O +
stents O -
, O +
RM O +
was O +
found O +
in O +
surrounding O +
tissues O +
and O +
in O +
implanted O +
stent O +
up O +
to O +
28days O -
. O +

Biocompatibility O +
studies O +
showed O +
no O +
evidence O +
for O +
presence O +
of O +
necrosis O -
, O +
foreign O +
body O +
giant O +
cell O +
reaction O +
or O +
any O +
type O +
of O +
increased O +
severity O +
of O +
inflammatory O +
reaction O -
, O +
proving O +
potential O +
of O +
developed O +
stents O +
for O +
further O +
clinical O +
development O -
. O +

Polyalkylcyanoacrylates B-Chemical +
as O +
in O +
situ O +
formed O +
diffusion O +
barriers O +
in O +
multimaterial O +
drug O +
carriers O -
. O +

Polymeric O +
hydrogels O +
typically O +
release O +
their O +
drug O +
payload O +
rapidly O +
due O +
to O +
their O +
high O +
water O +
content O +
and O +
the O +
diffusivity O +
for O +
drug O +
molecules O -
. O +

This O +
study O +
proposes O +
a O +
multimaterial O +
system O +
to O +
sustain O +
the O +
release O +
by O +
covering O +
the O +
hydrogel O +
with O +
a O +
poly B-Chemical -
( I-Chemical -
alkyl-2-cyanoacrylate I-Chemical -
) I-Chemical +
[ O -
PACA B-Chemical -
] O -
-based O +
film O -
, O +
which O +
should O +
be O +
formed O +
by O +
an O +
in O +
situ O +
polymerization O +
on O +
the O +
hydrogel O +
surface O +
initiated O +
upon O +
contact O +
with O +
water O -
. O +

A O +
series O +
of O +
PACA B-Chemical -
- O -
hydrogel O +
hybrid O +
systems O +
with O +
increasing O +
PACA B-Chemical +
side O +
chain O +
hydrophobicity O +
was O +
prepared O +
using O +
physically O +
crosslinked O +
alginate O +
films O +
and O +
hydrophilic O +
diclofenac B-Chemical +
sodium I-Chemical +
as O +
model O +
hydrogel O -
/ O -
drug O +
system O -
. O +

Successful O +
synthesis O +
of O +
PACA B-Chemical +
at O +
the O +
hydrogel O +
surface O +
was O +
confirmed O +
and O +
the O +
PACA B-Chemical +
layer O +
was O +
identified O +
to O +
be O +
most O +
homogeneous O +
for O +
poly B-Chemical -
( I-Chemical -
n I-Chemical -
- I-Chemical -
butyl-2-cyanoacrylate I-Chemical -
) I-Chemical +
on O +
both O +
the O +
micro- O +
and O +
nanolevel O -
. O +

At O +
the O +
same O +
time O -
, O +
the O +
diclofenac B-Chemical +
release O +
from O +
the O +
hybrid O +
systems O +
was O +
substantially O +
sustained O +
from O +
~1day O +
for O +
unmodified O +
hydrogels O +
up O +
to O +
> O -
14days O +
depending O +
on O +
the O +
type O +
of O +
PACA B-Chemical +
employed O +
as O +
diffusion O +
barrier O -
. O +

Overall O -
, O +
in O +
situ O +
polymerized O +
PACA B-Chemical +
films O +
on O +
hydrogels O +
may O +
be O +
widely O +
applicable O +
to O +
various O +
hydrogel O +
matrices O -
, O +
different O +
matrix O +
sizes O +
as O +
well O +
as O +
more O +
complex O +
shaped O +
hydrogel O +
carriers O -
. O +

Comparison O +
of O +
the O +
metabolic O +
effects O +
of O +
sustained O +
CCK1 O +
receptor O +
activation O +
alone O +
and O +
in O +
combination O +
with O +
upregulated O +
leptin O +
signalling O +
in O +
high O -
- O -
fat O -
- O -
fed O +
mice O -
. O +

AIMS O -
/ O -
HYPOTHESIS O -
: O +
Cholecystokinin O +
( O -
CCK O -
) O +
and O +
leptin O +
are O +
important O +
hormones O +
with O +
effects O +
on O +
energy O +
balance O -
. O +

The O +
present O +
study O +
assessed O +
the O +
biological O +
effects O +
of O +
( O -
pGlu O -
- O -
Gln O -
) O -
-CCK-8 O +
and O +
[ O -
D O -
- O -
Leu-4 O -
] O -
-OB3 O -
, O +
smaller O +
isoforms O +
of O +
CCK O +
and O +
leptin O -
, O +
respectively O -
. O +

METHODS O -
: O +
The O +
actions O +
and O +
overall O +
therapeutic O +
use O +
of O +
( O -
pGlu O -
- O -
Gln O -
) O -
-CCK-8 O +
and O +
[ O -
D O -
- O -
Leu-4 O -
] O -
-OB3 O -
, O +
alone O +
and O +
in O +
combination O -
, O +
were O +
evaluated O +
in O +
normal O +
and O +
high O -
- O -
fat O -
- O -
fed O +
mice O -
. O +

RESULTS O -
: O +
( O -
pGlu O -
- O -
Gln O -
) O -
-CCK-8 O +
had O +
prominent O +
( O -
p O +
< O +
0.01 O +
to O +
p O +
< O +
0.001 O -
) O -
, O +
acute O +
feeding O -
- O -
suppressive O +
effects O -
, O +
which O +
were O +
significantly O +
augmented O +
( O -
p O +
< O +
0.05 O +
to O +
p O +
< O +
0.01 O -
) O +
by O +
[ O -
D O -
- O -
Leu-4 O -
] O -
-OB3 O -
. O +

In O +
agreement O -
, O +
the O +
acute O +
dose O -
- O -
dependent O +
glucose B-Chemical -
- O -
lowering O +
and O +
insulinotropic O +
actions O +
of O +
( O -
pGlu O -
- O -
Gln O -
) O -
-CCK-8 O +
were O +
significantly O +
enhanced O +
by O +
concurrent O +
administration O +
of O +
[ O -
D O -
- O -
Leu-4 O -
] O -
-OB3 O -
. O +

Twice O +
daily O +
injection O +
of O +
( O -
pGlu O -
- O -
Gln O -
) O -
-CCK-8 O +
alone O +
and O +
in O +
combination O +
with O +
[ O -
D O -
- O -
Leu-4 O -
] O -
-OB3 O +
in O +
high O -
- O -
fat O -
- O -
fed O +
mice O +
for O +
18 O +
days O +
decreased O +
body O +
weight O +
( O -
p O +
< O +
0.05 O +
to O +
p O +
< O +
0.001 O -
) O -
, O +
energy O +
intake O +
( O -
p O +
< O +
0.01 O -
) O -
, O +
circulating O +
triacylglycerol B-Chemical +
( O -
p O +
< O +
0.01 O -
) O -
, O +
non O -
- O -
fasting O +
glucose O +
( O -
p O +
< O +
0.05 O +
to O +
p O +
< O +
0.001 O -
) O +
and O +
triacylglycerol B-Chemical +
deposition O +
in O +
liver O +
and O +
adipose O +
tissue O +
( O -
p O +
< O +
0.001 O -
) O -
. O +

All O +
treatment O +
regimens O +
improved O +
glucose B-Chemical +
tolerance O +
( O -
p O +
< O +
0.05 O +
to O +
p O +
< O +
0.001 O -
) O +
and O +
insulin O +
sensitivity O +
( O -
p O +
< O +
0.001 O -
) O -
. O +

Combined O +
treatment O +
with O +
( O -
pGlu O -
- O -
Gln O -
) O -
-CCK-8 O +
and O +
[ O -
D O -
- O -
Leu-4 O -
] O -
-OB3 O +
resulted O +
in O +
significantly O +
lowered O +
plasma O +
insulin O +
levels O -
, O +
normalisation O +
of O +
circulating O +
LDL O -
- O -
cholesterol B-Chemical +
and O +
decreased O +
triacylglycerol B-Chemical +
deposition O +
in O +
muscle O -
. O +

These O +
effects O +
were O +
superior O +
to O +
either O +
treatment O +
regimen O +
alone O -
. O +

There O +
were O +
no O +
changes O +
in O +
overall O +
locomotor O +
activity O +
or O +
respiratory O +
exchange O +
ratio O -
, O +
but O +
treatment O +
with O +
( O -
pGlu O -
- O -
Gln O -
) O -
-CCK-8 O +
significantly O +
reduced O +
( O -
p O +
< O +
0.001 O -
) O +
energy O +
expenditure O -
. O +

CONCLUSIONS O -
/ O -
INTERPRETATION O -
: O +
These O +
studies O +
highlight O +
the O +
potential O +
of O +
( O -
pGlu O -
- O -
Gln O -
) O -
-CCK-8 O +
alone O +
and O +
in O +
combination O +
with O +
[ O -
D O -
- O -
Leu-4 O -
] O -
-OB3 O +
in O +
the O +
treatment O +
of O +
obesity O +
and O +
diabetes O -
. O +

Protein O +
fibrillation O +
and O +
nanoparticle O +
interactions O -
: O +
opportunities O +
and O +
challenges O -
. O +

Due O +
to O +
their O +
ultra O -
- O -
small O +
size O -
, O +
nanoparticles O +
( O -
NPs O -
) O +
have O +
distinct O +
properties O +
compared O +
with O +
the O +
bulk O +
form O +
of O +
the O +
same O +
materials O -
. O +

These O +
properties O +
are O +
rapidly O +
revolutionizing O +
many O +
areas O +
of O +
medicine O +
and O +
technology O -
. O +

NPs O +
are O +
recognized O +
as O +
promising O +
and O +
powerful O +
tools O +
to O +
fight O +
against O +
the O +
human O +
brain O +
diseases O +
such O +
as O +
multiple O +
sclerosis O +
or O +
Alzheimer O -
's O +
disease O -
. O +

In O +
this O +
review O -
, O +
after O +
an O +
introductory O +
part O +
on O +
the O +
nature O +
of O +
protein O +
fibrillation O +
and O +
the O +
existing O +
approaches O +
for O +
its O +
investigations O -
, O +
the O +
effects O +
of O +
NPs O +
on O +
the O +
fibrillation O +
process O +
have O +
been O +
considered O -
. O +

More O +
specifically O -
, O +
the O +
role O +
of O +
biophysicochemical O +
properties O +
of O +
NPs O -
, O +
which O +
define O +
their O +
affinity O +
for O +
protein O +
monomers O -
, O +
unfolded O +
monomers O -
, O +
oligomers O -
, O +
critical O +
nuclei O -
, O +
and O +
other O +
prefibrillar O +
states O -
, O +
together O +
with O +
their O +
influence O +
on O +
protein O +
fibrillation O +
kinetics O +
has O +
been O +
described O +
in O +
detail O -
. O +

In O +
addition O -
, O +
current O +
and O +
possible O -
- O -
future O +
strategies O +
for O +
controlling O +
the O +
desired O +
effect O +
of O +
NPs O +
and O +
their O +
corresponding O +
effects O +
on O +
the O +
conformational O +
changes O +
of O +
the O +
proteins O -
, O +
which O +
have O +
significant O +
roles O +
in O +
the O +
fibrillation O +
process O -
, O +
have O +
been O +
presented O -
. O +

Tubulin O -
: O +
an O +
example O +
of O +
targeted O +
chemotherapy O -
. O +

Anticancer O +
drugs O +
directed O +
against O +
the O +
microtubule O -
, O +
including O +
taxanes B-Chemical +
and O +
vinca B-Chemical +
alkaloids I-Chemical -
, O +
have O +
been O +
the O +
backbone O +
of O +
many O +
chemotherapy O +
regimes O +
for O +
decades O -
. O +

These O +
drugs O +
have O -
, O +
however O -
, O +
significant O +
limitations O -
, O +
which O +
have O +
prompted O +
the O +
development O +
of O +
novel O +
microtubule O +
targeting O +
agents O +
( O -
MTAs O -
) O -
. O +

This O +
article O +
will O +
discuss O +
MTAs O +
for O +
anticancer O +
therapies O +
and O +
recent O +
debates O +
regarding O +
their O +
mechanisms O +
of O +
action O -
. O +

Furthermore O -
, O +
the O +
limitations O +
of O +
taxanes B-Chemical -
, O +
including O +
hypersensitivity O +
reactions O -
, O +
neurotoxicity O -
, O +
drug O +
resistance O +
and O +
lack O +
of O +
validated O +
biomarkers O +
to O +
guide O +
therapy O +
will O +
be O +
discussed O -
, O +
all O +
of O +
which O +
have O +
driven O +
the O +
development O +
of O +
novel O +
agents O -
. O +

The O +
mechanisms O +
of O +
action O +
and O +
drug O +
development O +
of O +
new O +
generations O +
of O +
MTAs O +
will O +
also O +
be O +
outlined O -
. O +

Agents O +
demonstrating O +
utility O +
in O +
Phase O +
III O +
clinical O +
trials O -
, O +
including O +
eribulin B-Chemical -
, O +
ixabepilone B-Chemical -
, O +
cabazitaxel B-Chemical +
and O +
trastuzumab O -
- O -
DM1 B-Chemical +
will O +
be O +
highlighted O -
, O +
as O +
well O +
as O +
novel O +
agents O +
currently O +
in O +
development O +
and O +
future O +
directions O +
for O +
MTAs O -
. O +

Hierarchical O +
or O +
not O -
? O +

Effect O +
of O +
the O +
length O +
scale O +
and O +
hierarchy O +
of O +
the O +
surface O +
roughness O +
on O +
omniphobicity O +
of O +
lubricant O -
- O -
infused O +
substrates O -
. O +

Lubricant O -
- O -
infused O +
textured O +
solid O +
substrates O +
are O +
gaining O +
remarkable O +
interest O +
as O +
a O +
new O +
class O +
of O +
omni O -
- O -
repellent O +
nonfouling O +
materials O +
and O +
surface O +
coatings O -
. O +

We O +
investigated O +
the O +
effect O +
of O +
the O +
length O +
scale O +
and O +
hierarchy O +
of O +
the O +
surface O +
topography O +
of O +
the O +
underlying O +
substrates O +
on O +
their O +
ability O +
to O +
retain O +
the O +
lubricant O +
under O +
high O +
shear O +
conditions O -
, O +
which O +
is O +
important O +
for O +
maintaining O +
nonwetting O +
properties O +
under O +
application O -
- O -
relevant O +
conditions O -
. O +

By O +
comparing O +
the O +
lubricant O +
loss O -
, O +
contact O +
angle O +
hysteresis O -
, O +
and O +
sliding O +
angles O +
for O +
water O +
and O +
ethanol B-Chemical +
droplets O +
on O +
flat O -
, O +
microscale O -
, O +
nanoscale O -
, O +
and O +
hierarchically O +
textured O +
surfaces O +
subjected O +
to O +
various O +
spinning O +
rates O +
( O -
from O +
100 O +
to O +
10 O +
000 O +
rpm O -
) O -
, O +
we O +
show O +
that O +
lubricant O -
- O -
infused O +
textured O +
surfaces O +
with O +
uniform O +
nanofeatures O +
provide O +
the O +
most O +
shear O -
- O -
tolerant O +
liquid O -
- O -
repellent O +
behavior O -
, O +
unlike O +
lotus O +
leaf O -
- O -
inspired O +
superhydrophobic O +
surfaces O -
, O +
which O +
generally O +
favor O +
hierarchical O +
structures O +
for O +
improved O +
pressure O +
stability O +
and O +
low O +
contact O +
angle O +
hysteresis O -
. O +

On O +
the O +
basis O +
of O +
these O +
findings O -
, O +
we O +
present O +
generalized O -
, O +
low O -
- O -
cost O -
, O +
and O +
scalable O +
methods O +
to O +
manufacture O +
uniform O +
or O +
regionally O +
patterned O +
nanotextured O +
coatings O +
on O +
arbitrary O +
materials O +
and O +
complex O +
shapes O -
. O +

After O +
functionalization O +
and O +
lubrication O -
, O +
these O +
coatings O +
show O +
robust O -
, O +
shear O -
- O -
tolerant O +
omniphobic O +
behavior O -
, O +
transparency O -
, O +
and O +
nonfouling O +
properties O +
against O +
highly O +
contaminating O +
media O -
. O +

PF-04859989 B-Chemical +
as O +
a O +
template O +
for O +
structure O -
- O -
based O +
drug O +
design O -
: O +
identification O +
of O +
new O +
pyrazole B-Chemical +
series O +
of O +
irreversible O +
KAT O +
II O +
inhibitors O +
with O +
improved O +
lipophilic O +
efficiency O -
. O +

The O +
structure O -
- O -
based O +
design O -
, O +
synthesis O -
, O +
and O +
biological O +
evaluation O +
of O +
a O +
new O +
pyrazole B-Chemical +
series O +
of O +
irreversible O +
KAT O +
II O +
inhibitors O +
are O +
described O +
herein O -
. O +

The O +
modification O +
of O +
the O +
inhibitor O +
scaffold O +
of O +
1 O +
and O +
2 O +
from O +
a O +
dihydroquinolinone B-Chemical +
core O +
to O +
a O +
tetrahydropyrazolopyridinone B-Chemical +
core O +
led O +
to O +
discovery O +
of O +
a O +
new O +
series O +
of O +
potent O +
KAT O +
II O +
inhibitors O +
with O +
excellent O +
physicochemical O +
properties O -
. O +

Compound O +
20 O +
is O +
the O +
most O +
potent O +
and O +
lipophilically O +
efficient O +
of O +
these O +
new O +
pyrazole B-Chemical +
analogs O -
, O +
with O +
a O +
k O -
( O -
inact O -
) O -
/ O -
K O -
( O -
i O -
) O +
value O +
of O +
112,000 O +
M O -
( O -
-1 O -
) O -
s O -
( O -
-1 O -
) O +
and O +
lipophilic O +
efficiency O +
( O -
LipE O -
) O +
of O +
8.53 O -
. O +

The O +
X O -
- O -
ray O +
crystal O +
structure O +
of O +
20 O +
with O +
KAT O +
II O +
demonstrates O +
key O +
features O +
that O +
contribute O +
to O +
this O +
remarkable O +
potency O +
and O +
binding O +
efficiency O -
. O +

Design O -
, O +
synthesis O +
and O +
antithrombotic O +
evaluation O +
of O +
novel O +
dabigatran B-Chemical +
prodrugs O +
containing O +
methyl B-Chemical +
ferulate I-Chemical -
. O +

A O +
novel O +
series O +
of O +
prodrugs O +
containing O +
dabigatran B-Chemical +
and O +
methyl B-Chemical +
( I-Chemical -
E I-Chemical -
) I-Chemical -
-3- I-Chemical -
( I-Chemical -
4-hydroxy-2-methoxyphenyl I-Chemical -
) I-Chemical -
propenoate I-Chemical +
( O -
methyl B-Chemical +
ferulate I-Chemical -
) O +
were O +
synthesized O -
. O +

All O +
of O +
them O +
reveal O +
the O +
effect O +
of O +
thrombin O -
- O -
induced O +
anti O -
- O -
platelet O +
aggregation O +
in O +
vitro O -
. O +

In O +
addition O -
, O +
in O +
vivo O +
experiment O +
shows O +
that O +
one O +
of O +
the O +
target O +
compounds O -
, O +
X-2 O +
( O -
ED50=3.7 O +
± O +
1.0 O +
μmol O -
/ O -
kg O -
) O +
possesses O +
a O +
more O +
potent O +
activity O +
for O +
inhibiting O +
venous O +
thrombosis O +
than O +
that O +
of O +
dabigatran B-Chemical +
etexilate I-Chemical +
( O -
ED50=7.8 O +
± O +
1.5 O +
μmol O -
/ O -
kg O -
) O -
. O +

A O +
new O +
series O +
of O +
N2-substituted-5- B-Chemical -
( I-Chemical -
p I-Chemical -
- I-Chemical -
toluenesulfonylamino I-Chemical -
) I-Chemical -
phthalimide I-Chemical +
analogues O +
as O +
α O -
- O -
glucosidase O +
inhibitors O -
. O +

Several O +
members O +
of O +
a O +
new O +
family O +
of O +
non O -
- O -
sugar B-Chemical -
- O -
type O +
α O -
- O -
glycosidase O +
inhibitors O -
, O +
bearing O +
a O +
5- B-Chemical -
( I-Chemical -
p I-Chemical -
- I-Chemical -
toluenesulfonylamino I-Chemical -
) I-Chemical -
phthalimide I-Chemical +
moiety O +
and O +
various O +
substituent O +
at O +
the O +
N2 O +
position O -
, O +
were O +
synthesized O +
and O +
their O +
activities O +
were O +
investigated O -
. O +

The O +
newly O +
synthesized O +
compounds O +
displayed O +
different O +
inhibition O +
profile O +
towards O +
yeast O +
α O -
- O -
glycosidase O +
and O +
rat O +
intestinal O +
α O -
- O -
glycosidase O -
. O +

Almost O +
all O +
the O +
compounds O +
had O +
strong O +
inhibitory O +
activities O +
against O +
yeast O +
α O -
- O -
glycosidase O -
. O +

Regarding O +
rat O +
intestinal O +
α O -
- O -
glycosidase O -
, O +
only O +
analogs O +
with O +
N2-aromatic O +
substituents O +
displayed O +
varying O +
degrees O +
of O +
inhibitory O +
activities O +
on O +
rat O +
intestinal O +
maltase O +
and O +
lactase O +
and O +
nearly O +
all O +
compounds O +
showed O +
no O +
inhibition O +
against O +
rat O +
intestinal O +
α O -
- O -
amylase O -
. O +

Structure O -
- O -
activity O +
relationship O +
studies O +
indicated O +
that O +
5- B-Chemical -
( I-Chemical -
p I-Chemical -
- I-Chemical -
toluenesulfonylamino I-Chemical -
) I-Chemical -
phthalimide I-Chemical +
moiety O +
is O +
a O +
favorable O +
scaffold O +
to O +
exert O +
the O +
α O -
- O -
glucosidase O +
inhibitory O +
activity O +
and O +
substituents O +
at O +
the O +
N2 O +
position O +
have O +
considerable O +
influence O +
on O +
the O +
efficacy O +
of O +
the O +
inhibition O +
activities O -
. O +

Efficient O +
synthesis O +
and O +
antimicrobial O +
activity O +
of O +
some O +
novel O +
S B-Chemical -
- I-Chemical -
β I-Chemical -
- I-Chemical -
d I-Chemical -
- I-Chemical -
glucosides I-Chemical +
of O +
5-aryl-1,2,4-triazole-3-thiones B-Chemical +
derivatives O -
. O +

A O +
series O +
of O +
3-S B-Chemical -
- I-Chemical -
β I-Chemical -
- I-Chemical -
d I-Chemical -
- I-Chemical -
glucosides-4-arylideneamino-5-aryl-1,2,4-triazoles I-Chemical +
were O +
rationally O +
designed O +
and O +
synthesized O +
according O +
to O +
the O +
principle O +
of O +
superposition O +
of O +
bioactive O +
substructures O +
by O +
the O +
combination O +
of O +
1,2,4-triazole B-Chemical -
, O +
Schiff B-Chemical +
base I-Chemical +
and O +
glucosides B-Chemical -
. O +

The O +
structures O +
of O +
the O +
target O +
compounds O +
have O +
been O +
characterized O +
by O +
( B-Chemical -
1 I-Chemical -
) I-Chemical -
H I-Chemical +
NMR O -
, O +
( B-Chemical -
13 I-Chemical -
) I-Chemical -
C I-Chemical +
NMR O -
, O +
IR O -
, O +
MS O +
and O +
HRMS O -
. O +

All O +
the O +
newly O +
synthesized O +
compounds O +
have O +
been O +
evaluated O +
for O +
their O +
antimicrobial O +
activities O +
in O +
vitro O +
against O +
Staphylococcus O +
aureus O +
( O -
ATCC O +
6538 O -
) O -
, O +
Escherichia O +
coli O +
( O -
ATCC O +
8099 O -
) O +
as O +
well O +
as O +
Monilia O +
albican O +
( O -
ATCC O +
10231 O -
) O -
. O +

The O +
bioactive O +
assay O +
showed O +
that O +
most O +
of O +
the O +
tested O +
compounds O +
displayed O +
variable O +
inhibitory O +
effects O +
on O +
the O +
growth O +
of O +
the O +
Gram O -
- O -
positive O +
bacterial O +
strain O +
( O -
Staphylococcus O +
aureus O -
) O -
, O +
Gram O -
- O -
negative O +
bacterial O +
strains O +
( O -
Escherichia O +
coli O -
) O +
and O +
fungal O +
strains O +
( O -
Monilia O +
albican O -
) O -
. O +

All O +
the O +
target O +
compounds O +
exhibited O +
better O +
antifungal O +
activity O +
than O +
antibacterial O +
activity O -
. O +

Especially O -
, O +
compounds O +
6b O -
, O +
6c O -
, O +
6f O -
, O +
6j O -
, O +
6k O +
and O +
6l O +
showed O +
excellent O +
activity O +
against O +
fungus O +
Monilia O +
albican O +
with O +
MIC O +
values O +
of O +
16 O +
μg O -
/ O -
mL. O +

Noradrenergic O +
control O +
of O +
the O +
bed O +
nucleus O +
of O +
the O +
stria O +
terminalis O +
in O +
stress O +
and O +
reward O -
. O +

The O +
bed O +
nucleus O +
of O +
the O +
stria O +
terminalis O +
( O -
BNST O -
) O +
is O +
a O +
group O +
of O +
inter O -
- O -
connected O +
subnuclei O +
that O +
play O +
critical O +
roles O +
in O +
stress O -
- O -
reward O +
interactions O -
. O +

An O +
interesting O +
feature O +
of O +
this O +
brain O +
region O +
is O +
the O +
massive O +
noradrenergic O +
input O +
that O +
it O +
receives O -
. O +

Important O +
roles O +
for O +
norepinephrine B-Chemical +
in O +
this O +
region O +
have O +
been O +
documented O +
in O +
a O +
number O +
of O +
stress O +
and O +
reward O +
related O +
behaviors O -
. O +

This O +
work O +
has O +
been O +
paralleled O +
over O +
the O +
last O +
several O +
years O +
by O +
efforts O +
to O +
understand O +
the O +
actions O +
of O +
norepinephrine B-Chemical +
on O +
neuronal O +
function O +
in O +
the O +
region O -
. O +

In O +
this O +
review O -
, O +
we O +
will O +
summarize O +
the O +
current O +
state O +
of O +
these O +
research O +
areas O -
. O +

The O +
two O +
faces O +
of O +
the O +
pharmacological O +
interaction O +
of O +
mGlu2 O +
and O +
5-HT2A O +
- O +
Relevance O +
of O +
receptor O +
heterocomplexes O +
and O +
interaction O +
through O +
functional O +
brain O +
pathways O -
. O +

Important O +
functional O +
interactions O +
between O +
the O +
metabotropic O +
glutamate B-Chemical +
2 O +
( O -
mGlu2 O -
) O +
and O +
5-hydroxytryptamine2A O +
( O -
5-HT2A O -
) O +
neurotransmitter O +
receptors O +
have O +
been O +
established O +
based O +
on O +
electrophysiological O -
, O +
biochemical O +
and O +
behavioral O +
evidence O -
. O +

Over O +
the O +
last O +
several O +
years O -
, O +
dimerization O +
between O +
5-HT2A O +
and O +
mGlu2 O +
receptors O +
has O +
been O +
proposed O +
to O +
account O +
for O +
the O +
functional O +
cross O -
- O -
talk O +
between O +
these O +
two O +
receptors O +
in O +
the O +
prefrontal O +
cortex O -
. O +

The O +
pros O +
and O +
cons O +
for O +
the O +
existence O +
of O +
a O +
heteromeric O +
complex O +
between O +
5-HT2A O +
and O +
mGlu2 O +
receptors O +
will O +
be O +
reviewed O +
here O -
. O +

First O -
, O +
the O +
fundamental O +
criteria O +
needing O +
to O +
establish O +
evidence O +
for O +
heteromeric O +
complexes O +
will O +
be O +
reviewed O -
. O +

Then O -
, O +
the O +
in O +
vitro O +
evidence O +
for O +
and O +
against O +
heteromeric O +
complexes O +
between O +
5-HT2A O +
and O +
mGlu2 O +
receptors O +
will O +
be O +
discussed O +
in O +
regard O +
to O +
physical O +
and O +
functional O +
interactions O -
. O +

Finally O -
, O +
the O +
data O +
with O +
native O +
in O +
situ O +
mGlu2 O +
and O +
5-HT2A O +
receptors O +
will O +
be O +
discussed O +
with O +
respect O +
to O +
whether O +
heteromeric O +
complexes O +
or O +
a O +
simple O +
functional O +
interaction O +
between O +
two O +
distinct O +
GPCRs O +
based O +
on O +
brain O +
network O +
activity O +
is O +
the O +
more O +
simple O +
explanation O +
for O +
a O +
range O +
of O +
in O +
vivo O +
data O -
. O +

Reversal O +
of O +
P O -
- O -
glycoprotein O -
- O -
mediated O +
multidrug O +
resistance O +
is O +
induced O +
by O +
mollugin B-Chemical +
in O +
MCF-7 O -
/ O -
adriamycin O +
cells O -
. O +

P O -
- O -
glycoprotein O +
( O -
P O -
- O -
gp O -
) O -
, O +
an O +
important O +
efflux O +
transporter O -
, O +
is O +
encoded O +
by O +
the O +
MDR1 O +
class O +
of O +
genes O +
and O +
is O +
a O +
central O +
element O +
of O +
the O +
multidrug O +
resistance O +
( O -
MDR O -
) O +
phenomenon O +
in O +
cancer O +
cells O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
investigated O +
whether O +
mollugin B-Chemical -
, O +
purified O +
from O +
roots O +
of O +
Rubica O +
cordifolia O +
L. O -
, O +
down O -
- O -
regulated O +
MDR1 O +
expression O +
in O +
MCF-7 O -
/ O -
adriamycin B-Chemical +
( O -
MCF-7 O -
/ O -
adr O -
) O +
cells O -
, O +
a O +
human O +
breast O +
multidrug O -
- O -
resistant O +
cancer O +
cell O +
line O -
. O +

Mollugin B-Chemical +
treatment O +
significantly O +
inhibited O +
MDR1 O +
expression O +
by O +
blocking O +
MDR1 O +
transcription O -
. O +

Mollugin B-Chemical +
treatment O +
also O +
significantly O +
increased O +
intracellular O +
accumulation O +
of O +
the O +
fluorescently O -
- O -
tagged O +
P O -
- O -
gp O +
substrate O -
, O +
rhodamine-123 B-Chemical -
. O +

The O +
suppression O +
of O +
MDR1 O +
promoter O +
activity O +
and O +
protein O +
expression O +
was O +
mediated O +
through O +
mollugin B-Chemical -
- O -
induced O +
activation O +
of O +
AMP B-Chemical -
- O -
activated O +
protein O +
kinase O +
( O -
AMPK O -
) O -
. O +

Furthermore O -
, O +
mollugin B-Chemical +
inhibited O +
MDR1 O +
expression O +
through O +
the O +
suppression O +
of O +
NF O -
- O -
κB O +
and O +
CREB O +
activation O -
. O +

Interestingly O -
, O +
mollugin B-Chemical +
also O +
inhibited O +
COX-2 O +
expression O -
. O +

These O +
results O +
suggest O +
that O +
mollugin B-Chemical +
treatment O +
enhanced O +
suppression O +
of O +
P O -
- O -
gp O +
expression O +
by O +
inhibiting O +
the O +
NF O -
- O -
κB O +
signaling O +
pathway O +
and O +
COX-2 O +
expression O -
, O +
as O +
well O +
as O +
attenuating O +
CRE O +
transcriptional O +
activity O +
through O +
AMPK O +
activation O -
. O +

Optimizing O +
Small O +
Molecule O +
Inhibitors O +
of O +
Calcium B-Chemical -
- O -
Dependent O +
Protein O +
Kinase O +
1 O +
to O +
Prevent O +
Infection O +
by O +
Toxoplasma O +
gondii O -
. O +

Toxoplasma O +
gondii O +
is O +
sensitive O +
to O +
bulky O +
pyrazolo B-Chemical +
[ I-Chemical -
3,4-d I-Chemical -
] I-Chemical +
pyrimidine I-Chemical +
( O -
PP O -
) O +
inhibitors O +
due O +
to O +
the O +
presence O +
of O +
a O +
Gly B-Chemical +
gatekeeper O +
in O +
the O +
essential O +
calcium B-Chemical +
dependent O +
protein O +
kinase O +
1 O +
( O -
CDPK1 O -
) O -
. O +

Here O +
we O +
synthesized O +
a O +
number O +
of O +
new O +
derivatives O +
of O +
3-methyl B-Chemical -
- I-Chemical -
benzyl I-Chemical -
- I-Chemical -
PP I-Chemical +
( O -
3-MB B-Chemical -
- I-Chemical -
PP I-Chemical -
, O +
or O +
1 O -
) O -
. O +

The O +
potency O +
of O +
PP O +
analogues O +
in O +
inhibiting O +
CDPK1 O +
enzyme O +
activity O +
in O +
vitro O +
( O -
low O +
nM O +
IC50 O +
values O -
) O +
and O +
blocking O +
parasite O +
growth O +
in O +
host O +
cell O +
monolayers O +
in O +
vivo O +
( O -
low O +
μM O +
EC50 O +
values O -
) O +
were O +
highly O +
correlated O +
and O +
occurred O +
in O +
a O +
CDPK1-specific O +
manner O -
. O +

Chemical O +
modification O +
of O +
the O +
PP O +
scaffold O +
to O +
increase O +
half O -
- O -
life O +
in O +
the O +
presence O +
of O +
microsomes O +
in O +
vitro O +
led O +
to O +
identification O +
of O +
compounds O +
with O +
enhanced O +
stability O +
while O +
retaining O +
activity O -
. O +

Several O +
of O +
these O +
more O +
potent O +
compounds O +
were O +
able O +
to O +
prevent O +
lethal O +
infection O +
with O +
T. O +
gondii O +
in O +
the O +
mouse O +
model O -
. O +

Collectively O -
, O +
the O +
strategies O +
outlined O +
here O +
provide O +
a O +
route O +
for O +
development O +
of O +
more O +
effective O +
compounds O +
for O +
treatment O +
of O +
toxoplasmosis O +
and O +
perhaps O +
related O +
parasitic O +
diseases O -
. O +

A O +
newly O +
synthesized O +
sinapic B-Chemical +
Acid I-Chemical +
derivative O +
inhibits O +
endothelial O +
activation O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

Inhibition O +
of O +
oxidative O +
stress O +
and O +
inflammation O +
in O +
vascular O +
endothelial O +
cells O +
( O -
ECs O -
) O +
may O +
represent O +
a O +
new O +
therapeutic O +
strategy O +
against O +
endothelial O +
activation O -
. O +

Sinapic B-Chemical +
acid I-Chemical +
( O -
SA O -
) O -
, O +
a O +
phenylpropanoid B-Chemical +
compound O -
, O +
is O +
found O +
in O +
natural O +
herbs O +
and O +
high O -
- O -
bran O +
cereals O +
and O +
has O +
moderate O +
antioxidant O +
activity O -
. O +

We O +
aimed O +
to O +
develop O +
new O +
SA O +
agents O +
with O +
the O +
properties O +
of O +
antioxidation O +
and O +
blocking O +
EC O +
activation O +
for O +
possible O +
therapy O +
of O +
cardiovascular O +
disease O -
. O +

We O +
designed O +
and O +
synthesized O +
10 O +
SA O +
derivatives O +
according O +
to O +
their O +
chemical O +
structures O -
. O +

Preliminary O +
screening O +
of O +
the O +
compounds O +
involved O +
scavenging O +
hydroxyl B-Chemical +
radicals O +
and O +
2,2-diphenyl-1-picrylhydrazyl B-Chemical +
( O -
DPPH B-Chemical -
( I-Chemical -
⋅ I-Chemical -
) I-Chemical -
) O -
, O +
croton O +
oil O -
- O -
induced O +
ear O +
edema O +
in O +
mice O -
, O +
and O +
analysis O +
of O +
the O +
mRNA O +
expression O +
of O +
adhesion O +
molecules O +
in O +
ECs O -
. O +

1-Acetyl B-Chemical -
- I-Chemical -
sinapic I-Chemical +
acyl-4- I-Chemical -
( I-Chemical -
3'-chlorine- I-Chemical -
) I-Chemical -
benzylpiperazine I-Chemical +
( O -
SA9 B-Chemical -
) O +
had O +
the O +
strongest O +
antioxidant O +
and O +
anti O -
- O -
inflammatory O +
activities O +
both O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

Thus O -
, O +
the O +
effect O +
of O +
SA9 B-Chemical +
was O +
further O +
studied O -
. O +

SA9 B-Chemical +
inhibited O +
tumor O +
necrosis O +
factor O +
α O -
- O -
induced O +
upregulation O +
of O +
adhesion O +
molecules O +
in O +
ECs O +
at O +
both O +
mRNA O +
and O +
protein O +
levels O -
, O +
as O +
well O +
as O +
the O +
consequent O +
monocyte O +
adhesion O +
to O +
ECs O -
. O +

In O +
vivo O -
, O +
result O +
of O +
face O -
- O -
to O -
- O -
face O +
immunostaining O +
showed O +
that O +
SA9 O +
reduced O +
lipopolysaccharide O -
- O -
induced O +
expression O +
of O +
intercellular O +
adhesion O +
molecule-1 O +
in O +
mouse O +
aortic O +
intima O -
. O +

To O +
study O +
the O +
molecular O +
mechanism O -
, O +
results O +
from O +
luciferase O +
assay O -
, O +
nuclear O +
translocation O +
of O +
NF O -
- O -
κB O -
, O +
and O +
Western O +
blot O +
indicated O +
that O +
the O +
mechanism O +
of O +
the O +
anti O -
- O -
inflammatory O +
effects O +
of O +
SA9 B-Chemical +
might O +
be O +
suppression O +
of O +
intracellular O +
generation O +
of O +
ROS O +
and O +
inhibition O +
of O +
NF O -
- O -
κB O +
activation O +
in O +
ECs O -
. O +

SA9 B-Chemical +
is O +
a O +
prototype O +
of O +
a O +
novel O +
class O +
of O +
antioxidant O +
with O +
anti O -
- O -
inflammatory O +
effects O +
in O +
ECs O -
. O +

It O +
may O +
represent O +
a O +
new O +
therapeutic O +
approach O +
for O +
preventing O +
endothelial O +
activation O +
in O +
cardiovascular O +
disorders O -
. O +

A O +
new O +
anti O -
- O -
inflammatory O +
triterpene B-Chemical +
saponin I-Chemical +
isolated O +
from O +
Anabasis O +
setifera O -
. O +

A O +
bio O -
- O -
guided O +
fractionation O +
of O +
Anabasis O +
setifera O +
Moq O -
. O +

( O -
Chenopodiaceae O -
) O +
for O +
anti O -
- O -
inflammatory O +
activity O +
was O +
carried O +
out O +
using O +
carrageenin O +
rat O +
paw O +
edema O +
model O +
in O +
rats O -
. O +

On O +
the O +
basis O +
of O +
percent O +
edema O +
inhibition O +
after O +
3 O +
h O +
of O +
carrageenin O +
injection O -
, O +
n B-Chemical -
- I-Chemical -
butanol I-Chemical +
fraction O +
showed O +
promising O +
activity O +
through O +
a O +
significant O +
( O -
p O +
< O +
0.05 O -
) O +
decrease O +
in O +
paw O +
volume O +
by O +
85.6 O +
% O +
from O +
control O +
using O +
indomethacin B-Chemical +
as O +
reference O +
standard O -
. O +

Moreover O -
, O +
the O +
n B-Chemical -
- I-Chemical -
butanol I-Chemical +
fraction O +
significantly O +
( O -
p O +
< O +
0.05 O -
) O +
decreased O +
PGE2 B-Chemical +
and O +
TNF O -
- O -
α O +
in O +
the O +
exudates O +
of O +
rat O +
paw O +
edema O -
. O +

Chemical O +
investigation O +
of O +
n B-Chemical -
- I-Chemical -
butanol I-Chemical +
fraction O +
afforded O +
α B-Chemical -
- I-Chemical -
amyrin I-Chemical +
3-O I-Chemical -
- I-Chemical -
glucopyranoside I-Chemical +
( O -
1 O -
) O -
, O +
patuletin B-Chemical +
7-O I-Chemical -
- I-Chemical -
glucopyranoside I-Chemical +
( O -
2 O -
) O -
, O +
myricitrin B-Chemical +
( O -
3 O -
) O +
and O +
a O +
new O +
oleanane B-Chemical +
triterpene I-Chemical +
saponin I-Chemical +
derivative O +
( O -
4 O -
) O -
, O +
sophradiol B-Chemical +
3-O I-Chemical -
- I-Chemical -
α I-Chemical -
- I-Chemical -
L- I-Chemical -
( I-Chemical -
1 I-Chemical -
) I-Chemical -
C4-rhamnopyranosyl- I-Chemical -
( I-Chemical -
1'''→4'' I-Chemical -
) I-Chemical -
-O I-Chemical -
- I-Chemical -
β I-Chemical -
- I-Chemical -
D- I-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
C1-galactopyranosyl I-Chemical +
( I-Chemical -
1''→6' I-Chemical -
) I-Chemical -
-O I-Chemical -
- I-Chemical -
β I-Chemical -
- I-Chemical -
D- I-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
C1-glucopyranoside I-Chemical -
. O +

The O +
structure O +
of O +
the O +
new O +
compound O +
was O +
determined O +
by O +
comprehensive O +
analyses O +
of O +
their O +
1D O +
and O +
2D O +
NMR O -
, O +
mass O +
spectral O +
data O +
and O +
comparison O +
with O +
previously O +
known O +
analogs O -
. O +

Only O +
compound O +
4 O +
revealed O +
a O +
significant O +
( O -
p O +
< O +
0.05 O -
) O +
inhibition O +
of O +
cyclooxygenase O +
1 O +
and O +
2 O +
( O -
COX O -
) O +
activities O -
. O +

Bladder O +
Polypoid O +
Cystitis O -
- O -
Derived O +
A20 O +
Associates O +
with O +
Tumorigenesis O -
. O +

Bladder O +
chronic O +
inflammation O +
is O +
associated O +
with O +
the O +
pathogenesis O +
of O +
bladder O +
cancer O -
; O +
the O +
underlying O +
mechanism O +
is O +
unclear O -
. O +

The O +
PT53 O +
gene O +
is O +
an O +
important O +
anticancer O +
gene O +
in O +
the O +
body O -
, O +
which O +
is O +
suppressed O +
in O +
cancer O -
. O +

The O +
ubiquitin O +
E3 O +
ligase O +
A20 O +
( O -
A20 O -
) O +
plays O +
a O +
role O +
in O +
regulating O +
the O +
activities O +
of O +
epithelial O +
cells O -
. O +

This O +
study O +
was O +
designed O +
to O +
investigate O +
the O +
correlation O +
between O +
A20 O +
and O +
the O +
pathogenesis O +
of O +
bladder O +
cancer O -
. O +

The O +
biopsy O +
tissues O +
of O +
human O +
bladder O +
cancer O -
, O +
bladder O +
polypoid O +
cystitis O -
, O +
and O +
chronic O +
inflammation O +
were O +
collected O -
; O +
the O +
levels O +
of O +
A20 O +
and O +
p53 O +
were O +
analyzed O +
by O +
quantitative O +
real O -
- O -
time O +
RT O -
- O -
PCR O -
, O +
Western O +
blotting O -
, O +
and O +
immune O +
precipitation O -
. O +

HEK293 O +
cells O +
were O +
employed O +
to O +
test O +
the O +
role O +
of O +
overexpression O +
of O +
A20 O +
in O +
the O +
suppression O +
of O +
the O +
p53 O +
gene O +
in O +
the O +
cells O -
. O +

Fifty O -
- O -
six O +
patients O +
with O +
bladder O +
cancer O -
, O +
48 O +
patients O +
with O +
bladder O +
polypoid O +
cystitis O -
, O +
and O +
16 O +
patients O +
with O +
bladder O +
chronic O +
inflammation O +
were O +
recruited O +
into O +
this O +
study O -
. O +

Human O +
bladder O +
cancer O +
tissue O +
and O +
the O +
polypoid O +
tissue O +
showed O +
high O +
levels O +
of O +
A20 O -
, O +
which O +
had O +
a O +
positive O +
correlation O +
with O +
the O +
tumorigenesis O +
in O +
the O +
bladder O -
; O +
12 O +
out O +
of O +
46 O +
( O -
26.1 O +
% O -
) O +
patients O +
with O +
bladder O +
polypoid O +
cystitis O +
were O +
diagnosed O +
as O +
bladder O +
cancer O -
. O +

A20 O +
bound O +
to O +
p53 O +
to O +
form O +
complexes O +
in O +
bladder O +
cancer O +
tissue O +
and O +
bladder O +
polypoid O +
tissue O -
. O +

The O +
overexpression O +
of O +
A20 O +
suppresses O +
p53 O +
protein O +
levels O +
in O +
HEK293 O +
cells O -
. O +

A20 O +
has O +
a O +
positive O +
correlation O +
in O +
the O +
tumorigenesis O +
of O +
bladder O +
polypoid O +
disorders O -
. O +

Presence O +
of O +
hydrophobic O +
groups O +
may O +
modify O +
the O +
specific O +
ion O +
effect O +
in O +
aqueous O +
polyelectrolyte O +
solutions O -
. O +

Enthalpies O +
of O +
dilution O +
of O +
aqueous O +
solutions O +
of O +
aliphatic B-Chemical +
6,12- I-Chemical +
and I-Chemical +
12,12-ionene I-Chemical +
bromides I-Chemical +
and I-Chemical +
fluorides I-Chemical +
and O +
enthalpies O +
of O +
mixing O +
with O +
low O +
molecular O -
- O -
weight O +
salts O -
, O +
such O +
as O +
sodium B-Chemical +
fluoride I-Chemical +
and I-Chemical +
bromide I-Chemical -
, O +
are O +
determined O -
. O +

In O +
the O +
second O +
part O +
of O +
the O +
study O -
, O +
the O +
various O +
x O -
, O -
y O -
- O -
ionenes O +
( O -
x O -
, O +
y O +
are O +
numbers O +
of O +
methylene B-Chemical +
groups O +
between O +
the O +
adjacent O +
charges O -
) O +
with O +
fluoride B-Chemical -
, O +
bromide B-Chemical -
, O +
and O +
iodide B-Chemical +
counterions O +
are O +
mixed O +
with O +
aqueous O +
sodium B-Chemical +
sulfate I-Chemical +
solution O -
. O +

The O +
polyelectrolytes O +
examined O +
in O +
this O +
part O +
of O +
the O +
work O +
are O +
3,3- B-Chemical -
, I-Chemical +
6,9- I-Chemical -
, I-Chemical +
6,12- I-Chemical -
, I-Chemical +
and I-Chemical +
12,12-ionenes I-Chemical -
. O +

A O +
comparison O +
with O +
theoretical O +
results O -
, O +
based O +
on O +
the O +
Poisson O -
- O -
Boltzmann O +
cell O +
model O -
, O +
is O +
presented O -
. O +

The O +
theory O +
predicts O +
for O +
the O +
enthalpy O +
of O +
dilution O +
to O +
be O +
exothermic O +
and O +
the O +
enthalpy O +
of O +
mixing O +
endothermic O -
, O +
while O +
experiments O +
show O +
that O +
signs O +
of O +
the O +
heat O +
effects O +
depend O +
on O +
the O +
nature O +
of O +
the O +
counterion O +
of O +
the O +
added O +
salt O -
, O +
as O +
also O +
on O +
the O +
hydrophobicity O +
( O -
numbers O +
x O -
, O +
y O +
of O +
methylene B-Chemical +
groups O -
) O +
of O +
the O +
ionene O -
. O +

We O +
show O +
that O +
the O +
salts O +
when O +
ordered O +
by O +
heat O +
effects O +
produced O +
by O +
mixing O +
of O +
NaF B-Chemical +
and O +
NaBr B-Chemical +
with O +
3,3- B-Chemical -
, I-Chemical +
6,9- I-Chemical -
, I-Chemical +
or I-Chemical +
6,12-ionene I-Chemical +
fluorides I-Chemical +
and I-Chemical +
bromides I-Chemical +
follow O +
the O +
opposite O +
ordering O +
than O +
in O +
the O +
case O +
when O +
the O +
same O +
alkali B-Chemical +
halide I-Chemical +
salts O +
are O +
mixed O +
with O +
more O +
hydrophobic O +
12,12-ionene B-Chemical +
salts O -
. O +

The O +
results O +
for O +
the O +
enthalpy O +
of O +
mixing O +
of O +
ionenes O +
under O +
study O +
with O +
Na2SO4 B-Chemical +
follow O +
the O +
same O +
order O +
as O +
obtained O +
for O +
monovalent O +
salts O -
. O +

Do O +
the O +
physical O +
properties O +
of O +
water O +
in O +
mixed O +
reverse O +
micelles O +
follow O +
a O +
synergistic O +
effect O -
: O +
a O +
spectroscopic O +
investigation O -
. O +

In O +
this O +
contribution O +
we O +
have O +
tried O +
to O +
investigate O +
whether O +
the O +
mechanical O +
properties O +
of O +
the O +
reverse O +
micellar O +
( O -
RM O -
) O +
interface O +
dictate O +
the O +
physical O +
properties O +
of O +
entrapped O +
water O +
molecules O +
in O +
the O +
RM O +
waterpool O -
. O +

We O +
choose O +
AOT B-Chemical -
/ O -
Igepal-520 B-Chemical -
/ O -
cyclohexane B-Chemical +
( O -
Cy O -
) O +
mixed O +
RM O +
as O +
a O +
model O +
system O +
which O +
exhibits O +
synergistic O +
water O +
solubilization O +
behavior O +
as O +
a O +
function O +
of O +
interfacial O +
stoichiometry O -
. O +

Such O +
a O +
phenomenon O +
associates O +
systematic O +
modification O +
of O +
the O +
interface O +
curvature O -
. O +

Dynamic O +
light O +
scattering O +
( O -
DLS O -
) O +
studies O +
reveal O +
linear O +
increase O +
in O +
the O +
droplet O +
size O +
and O +
aggregation O +
number O +
of O +
the O +
RMs O +
with O +
increasing O +
XIgepal O +
( O -
mole O +
fraction O +
of O +
Igepal B-Chemical +
in O +
the O +
surfactant O +
mixture O -
) O -
. O +

FTIR O +
study O +
in O +
the O +
3000 O -
- O -
3800 O +
cm O -
( O -
-1 O -
) O +
region O +
identifies O +
that O +
the O +
relative O +
population O +
of O +
the O +
surface O -
- O -
bound O +
water O +
molecules O +
is O +
higher O +
in O +
AOT B-Chemical +
RM O +
compared O +
to O +
that O +
in O +
Igepal B-Chemical +
RM O -
, O +
and O +
in O +
mixed O +
systems O +
it O +
also O +
follows O +
a O +
linear O +
trend O +
with O +
XIgepal O -
. O +

Water O +
relaxation O +
dynamics O +
as O +
probed O +
by O +
time O -
- O -
resolved O +
fluorescence O +
spectroscopy O +
using O +
Coumarin-500 B-Chemical +
also O +
reveals O +
an O +
overall O +
linear O +
trend O +
with O +
no O +
characteristic O +
feature O +
around O +
the O +
solubilization O +
inflation O +
point O -
. O +

Our O +
study O +
clearly O +
identifies O +
that O +
the O +
physical O +
properties O +
of O +
water O +
in O +
RM O +
are O +
mostly O +
governed O +
by O +
the O +
interfacial O +
stoichiometry O +
and O +
water O +
content O -
, O +
and O +
merely O +
bares O +
any O +
dependence O +
on O +
the O +
mechanical O +
properties O +
of O +
the O +
interface O -
. O +

Discovery O +
of O +
( B-Chemical -
R I-Chemical -
) I-Chemical -
-2-amino-6-borono-2- I-Chemical -
( I-Chemical -
2- I-Chemical -
( I-Chemical -
piperidin-1-yl I-Chemical -
) I-Chemical -
ethyl I-Chemical -
) I-Chemical -
hexanoic I-Chemical +
acid I-Chemical +
and O +
congeners O +
as O +
highly O +
potent O +
inhibitors O +
of O +
human O +
arginases O +
I O +
and O +
II O +
for O +
treatment O +
of O +
myocardial O +
reperfusion O +
injury O -
. O +

Recent O +
efforts O +
to O +
identify O +
treatments O +
for O +
myocardial O +
ischemia O +
reperfusion O +
injury O +
have O +
resulted O +
in O +
the O +
discovery O +
of O +
a O +
novel O +
series O +
of O +
highly O +
potent O +
α B-Chemical -
, I-Chemical -
α I-Chemical -
- I-Chemical -
disubstituted I-Chemical +
amino I-Chemical +
acid I-Chemical -
- O -
based O +
arginase O +
inhibitors O -
. O +

The O +
lead O +
candidate O -
, O +
( B-Chemical -
R I-Chemical -
) I-Chemical -
-2-amino-6-borono-2- I-Chemical -
( I-Chemical -
2- I-Chemical -
( I-Chemical -
piperidin-1-yl I-Chemical -
) I-Chemical -
ethyl I-Chemical -
) I-Chemical -
hexanoic I-Chemical +
acid I-Chemical -
, O +
compound O +
9 O -
, O +
inhibits O +
human O +
arginases O +
I O +
and O +
II O +
with O +
IC50s O +
of O +
223 O +
and O +
509 O +
nM O -
, O +
respectively O -
, O +
and O +
is O +
active O +
in O +
a O +
recombinant O +
cellular O +
assay O +
overexpressing O +
human O +
arginase O +
I O +
( O -
CHO O +
cells O -
) O -
. O +

It O +
is O +
28 O -
% O +
orally O +
bioavailable O +
and O +
significantly O +
reduces O +
the O +
infarct O +
size O +
in O +
a O +
rat O +
model O +
of O +
myocardial O +
ischemia O -
/ O -
reperfusion O +
injury O -
. O +

Herein O -
, O +
we O +
report O +
the O +
design O -
, O +
synthesis O -
, O +
and O +
structure O -
- O -
activity O +
relationships O +
( O -
SAR O -
) O +
for O +
this O +
novel O +
series O +
of O +
inhibitors O +
along O +
with O +
pharmacokinetic O +
and O +
in O +
vivo O +
efficacy O +
data O +
for O +
compound O +
9 O +
and O +
X O -
- O -
ray O +
crystallography O +
data O +
for O +
selected O +
lead O +
compounds O +
cocrystallized O +
with O +
arginases O +
I O +
and O +
II O -
. O +

Engineered O +
Magnetic O +
Shape O +
Anisotropy O +
in O +
BiFeO3-CoFe2O4 B-Chemical +
Self O -
- O -
Assembled O +
Thin O +
Films O -
. O +

We O +
report O +
growth O +
of O +
various O +
phase O +
architectures O +
of O +
self O -
- O -
assembled O +
BiFeO3-CoFe2O4 B-Chemical +
( O -
BFO B-Chemical -
- O -
CFO B-Chemical -
) O +
thin O +
films O +
on O +
differently O +
oriented O +
SrTiO3 B-Chemical +
( O -
STO B-Chemical -
) O +
substrates O -
. O +

CFO B-Chemical +
forms O +
segregated O +
square O -
, O +
stripe O -
, O +
and O +
triangular O +
nanopillars O +
embedded O +
in O +
a O +
coherent O +
BFO B-Chemical +
matrix O +
on O +
( O -
001 O -
) O -
- O -
, O +
( O -
110 O -
) O -
- O -
, O +
and O +
( O -
111 O -
) O -
-oriented O +
STO B-Chemical +
substrates O -
, O +
respectively O -
. O +

Nanostructures O +
with O +
an O +
aspect O +
ratio O +
of O +
up O +
to O +
5:1 O +
with O +
a O +
prominent O +
magnetic O +
anisotropy O +
were O +
obtained O +
on O +
both O +
( O -
001 O -
) O +
and O +
( O -
110 O -
) O +
STO B-Chemical +
along O +
out O -
- O -
of O -
- O -
plane O +
and O +
in O -
- O -
plane O +
directions O -
. O +

Magnetic O +
easy O +
axis O +
rotation O +
from O +
in O -
- O -
plane O +
to O +
out O -
- O -
of O -
- O -
plane O +
directions O +
was O +
realized O +
through O +
aspect O +
ratio O +
control O -
. O +

An O +
intractable O +
in O -
- O -
plane O +
anisotropy O +
was O +
fixed O +
in O +
CFO B-Chemical +
on O +
( O -
111 O -
) O +
STO B-Chemical +
due O +
to O +
the O +
triangular O +
shape O +
of O +
the O +
ferromagnetic O +
phase O +
nanopillars O -
. O +

These O +
studies O +
established O +
a O +
detailed O +
relationship O +
of O +
magnetic O +
anisotropy O +
with O +
specific O +
shape O +
and O +
dimensions O +
of O +
ordered O +
magnetic O +
arrays O -
. O +

The O +
results O +
suggest O +
a O +
way O +
to O +
effectively O +
control O +
the O +
magnetic O +
anisotropy O +
in O +
patterned O +
ferromagnetic O +
oxide B-Chemical +
arrays O +
with O +
tunable O +
shape O -
, O +
aspect O +
ratio O -
, O +
and O +
elastic O +
strain O +
conditions O +
of O +
the O +
nanostructures O -
. O +

Biotransformation O +
of O +
Two O +
β O -
- O -
Secretase O +
Inhibitors O +
Including O +
Ring O +
Opening O +
and O +
Contraction O +
of O +
a O +
Pyrimidine B-Chemical +
Ring O -
. O +

Recently O -
, O +
the O +
discovery O +
of O +
the O +
aminoisoindoles B-Chemical +
as O +
potent O +
and O +
selective O +
inhibitors O +
of O +
β O -
- O -
secretase O +
was O +
reported O -
, O +
including O +
the O +
close O +
structural O +
analogs O +
compound O +
( B-Chemical -
S I-Chemical -
) I-Chemical -
-1-pyridin-4-yl-4-fluoro-1- I-Chemical -
( I-Chemical -
3- I-Chemical -
( I-Chemical -
pyrimidin-5-yl I-Chemical -
) I-Chemical -
phenyl I-Chemical -
) I-Chemical -
-1H I-Chemical -
- I-Chemical -
isoindol-3-amine I-Chemical +
[ O -
( O -
S O -
) O -
-25 O -
] O +
and O +
( B-Chemical -
S I-Chemical -
) I-Chemical -
-1- I-Chemical -
( I-Chemical -
2- I-Chemical -
( I-Chemical -
difluoromethyl I-Chemical -
) I-Chemical -
pyridin-4-yl I-Chemical -
) I-Chemical -
-4-fluoro-1- I-Chemical -
( I-Chemical -
3- I-Chemical -
( I-Chemical -
pyrimidin-5-yl I-Chemical -
) I-Chemical -
phenyl I-Chemical -
) I-Chemical -
-1H I-Chemical -
- I-Chemical -
isoindol-3-amine I-Chemical +
hemifumarate I-Chemical +
( O -
AZD3839 B-Chemical -
) O -
, O +
the O +
latter O +
being O +
recently O +
progressed O +
to O +
the O +
clinic O -
. O +

The O +
biotransformation O +
of O +
( O -
S O -
) O -
-25 O +
was O +
investigated O +
in O +
vitro O +
and O +
in O +
vivo O +
in O +
rat O -
, O +
rabbit O -
, O +
and O +
human O +
and O +
compared O +
with O +
AZD3839 B-Chemical +
to O +
further O +
understand O +
the O +
metabolic O +
fate O +
of O +
these O +
compounds O -
. O +

In O +
vitro O -
, O +
CYP3A4 O +
was O +
the O +
major O +
responsible O +
enzyme O +
and O +
metabolized O +
both O +
compounds O +
to O +
a O +
large O +
extent O +
in O +
the O +
commonly O +
shared O +
pyridine B-Chemical +
and O +
pyrimidine B-Chemical +
rings O -
. O +

The O +
main O +
proposed O +
metabolic O +
pathways O +
in O +
various O +
in O +
vitro O +
systems O +
were O +
N O -
- O -
oxidation O +
of O +
the O +
pyridine B-Chemical +
and/or O +
pyrimidine B-Chemical +
ring O +
and O +
conversion O +
to O +
4-pyrimidone B-Chemical +
and O +
pyrimidine-2,4-dione B-Chemical -
. O +

Both O +
compounds O +
were O +
extensively O +
metabolized O -
, O +
and O +
more O +
than O +
90 O -
% O +
was O +
excreted O +
in O +
feces O +
after O +
intravenous O +
administration O +
of O +
radiolabeled O +
compound O +
to O +
the O +
rat O -
. O +

Here O -
, O +
the O +
main O +
pathways O +
were O +
N O -
- O -
oxidation O +
of O +
the O +
pyridine B-Chemical +
and/or O +
pyrimidine B-Chemical +
ring O +
and O +
a O +
ring O +
contraction O +
of O +
the O +
pyrimidine B-Chemical +
ring O +
into O +
an O +
imidazole B-Chemical +
ring O -
. O +

Ring O -
- O -
contracted O +
metabolites O +
accounted O +
for O +
25 O -
% O +
of O +
the O +
total O +
metabolism O +
in O +
the O +
rat O +
for O +
( O -
S O -
) O -
-25 O -
, O +
whereas O +
the O +
contribution O +
was O +
much O +
smaller O +
for O +
AZD3839 B-Chemical -
. O +

This O +
metabolic O +
pathway O +
was O +
not O +
foreseen O +
on O +
the O +
basis O +
of O +
the O +
obtained O +
in O +
vitro O +
data O -
. O +

In O +
conclusion O -
, O +
we O +
discovered O +
an O +
unusual O +
metabolic O +
pathway O +
of O +
aryl B-Chemical -
- I-Chemical -
pyrimidine I-Chemical -
- O -
containing O +
compounds O +
by O +
a O +
ring O -
- O -
opening O +
reaction O +
followed O +
by O +
elimination O +
of O +
a O +
carbon B-Chemical +
atom O +
and O +
a O +
ring O +
closure O +
to O +
form O +
an O +
imidazole B-Chemical +
ring O -
. O +

Mapping O +
genetic O +
alterations O +
causing O +
chemoresistance O +
in O +
cancer O -
: O +
identifying O +
the O +
roads O +
by O +
tracking O +
the O +
drivers O -
. O +

Although O +
new O +
agents O +
are O +
implemented O +
to O +
cancer O +
therapy O -
, O +
we O +
lack O +
fundamental O +
understandings O +
of O +
the O +
mechanisms O +
of O +
chemoresistance O -
, O +
the O +
main O +
obstacle O +
to O +
cure O +
in O +
cancer O -
. O +

Here O +
we O +
review O +
clinical O +
evidence O +
linking O +
molecular O +
defects O +
to O +
drug O +
resistance O +
across O +
different O +
tumour O +
forms O +
and O +
discuss O +
contemporary O +
experimental O +
evidence O +
exploring O +
these O +
mechanisms O -
. O +

Although O +
evidence O -
, O +
in O +
general O -
, O +
is O +
sparse O +
and O +
fragmentary O -
, O +
merging O +
knowledge O +
links O +
drug O +
resistance O -
, O +
and O +
also O +
sensitivity O -
, O +
to O +
defects O +
in O +
functional O +
pathways O +
having O +
a O +
key O +
role O +
in O +
cell O +
growth O +
arrest O +
or O +
death O +
and O +
DNA O +
repair O -
. O +

As O +
these O +
pathways O +
may O +
act O +
in O +
concert O -
, O +
there O +
is O +
a O +
need O +
to O +
explore O +
multiple O +
mechanisms O +
in O +
parallel O -
. O +

Taking O +
advantage O +
of O +
massive O +
parallel O +
sequencing O +
and O +
other O +
novel O +
high O -
- O -
throughput O +
technologies O +
and O +
base O +
research O +
on O +
biological O +
hypotheses O -
, O +
we O +
now O +
have O +
the O +
possibility O +
to O +
characterize O +
functional O +
defects O +
related O +
to O +
these O +
key O +
pathways O +
and O +
to O +
design O +
a O +
new O +
generation O +
of O +
studies O +
identifying O +
the O +
mechanisms O +
controlling O +
resistance O +
to O +
different O +
treatment O +
regimens O +
in O +
different O +
tumour O +
forms O -
. O +

Oncogene O +
advance O +
online O +
publication O -
, O +
11 O +
March O +
2013 O -
; O +
doi:10.1038 O -
/ O -
onc.2013.48 O -
. O +

Isoflavone B-Chemical +
supplementation O +
influenced O +
levels O +
of O +
triglyceride B-Chemical +
and O +
luteunizing O +
hormone O +
in O +
Korean O +
postmenopausal O +
women O -
. O +

We O +
conducted O +
a O +
double O -
- O -
blind O -
, O +
randomized O -
, O +
placebo O -
- O -
controlled O +
trial O +
to O +
evaluate O +
the O +
effects O +
of O +
soy O -
- O -
derived O +
isoflavone B-Chemical +
on O +
blood O +
glucose B-Chemical -
, O +
lipid O +
profiles O -
, O +
and O +
sex O +
hormones O +
related O +
to O +
cardiovascular O +
disease O +
in O +
Korean O +
postmenopausal O +
women O -
. O +

One O +
hundred O +
thirteen O +
postmenopausal O +
women O +
were O +
recruited O +
from O +
the O +
Seoul O +
metropolitan O +
area O -
. O +

To O +
confirm O +
postmenopausal O +
and O +
gynecologic O +
status O -
, O +
the O +
subjects O +
were O +
clinically O +
examined O +
by O +
a O +
gynecologist O +
using O +
ultra O +
sound O +
and O +
X O -
- O -
ray O -
. O +

Finally O -
, O +
85 O +
postmenopausal O +
women O +
whose O +
follicle O -
- O -
stimulating O +
hormone O +
( O -
FSH O -
) O +
levels O +
were O +
higher O +
than O +
40 O +
IU O -
/ O -
ml O +
were O +
enrolled O -
. O +

Subjects O +
received O +
either O +
70 O +
mg O +
isoflavone B-Chemical +
or O +
placebo O +
capsules O +
daily O +
for O +
12 O +
weeks O -
. O +

As O +
a O +
result O -
, O +
the O +
values O +
of O +
fasting O +
glucose B-Chemical -
, O +
insulin O +
and O +
HOMA O -
- O -
IR O -
, O +
as O +
well O +
as O +
those O +
of O +
TC O -
, O +
LDL O -
- O -
C O -
, O +
HDL O -
- O -
C O +
and O +
FFA O -
, O +
were O +
not O +
different O +
between O +
the O +
groups O +
after O +
supplementation O -
. O +

However O -
, O +
triglyceride B-Chemical +
( O -
TG O -
) O +
levels O +
in O +
the O +
treatment O +
group O +
decreased O +
significantly O +
compared O +
with O +
those O +
of O +
the O +
placebo O +
group O +
( O -
p O +
= O +
0.0215 O -
) O -
. O +

The O +
levels O +
of O +
luteinizing O +
hormone O +
( O -
LH O -
) O +
significantly O +
decreased O +
in O +
the O +
treatment O +
group O +
( O -
p O +
= O +
0.027 O -
) O -
; O +
however O -
, O +
the O +
levels O +
of O +
FSH O -
, O +
estrone B-Chemical +
and O +
estradiol B-Chemical +
were O +
not O +
changed O +
after O +
intervention O -
. O +

In O +
conclusion O -
, O +
isoflavone B-Chemical +
supplement O +
of O +
70 O +
mg O -
/ O -
day O +
for O +
12 O +
weeks O +
decreased O +
blood O +
levels O +
of O +
TG O +
and O +
LH O +
in O +
Korean O +
postmenopausal O +
women O -
. O +

A O +
novel O +
nontoxic O +
inhibitor O +
of O +
the O +
activation O +
of O +
NADPH B-Chemical +
oxidase O +
reduces O +
reactive O +
oxygen B-Chemical +
species O +
production O +
in O +
mouse O +
lung O -
. O +

1-Hexadecyl-3-trifluoroethylglycero B-Chemical -
- I-Chemical -
sn-2-phosphomethanol I-Chemical +
( O -
MJ33 B-Chemical -
) O +
is O +
a O +
fluorinated O +
phospholipid O +
analog O +
that O +
inhibits O +
the O +
phospholipase O +
A2 O +
( O -
PLA2 O -
) O +
activity O +
of O +
peroxiredoxin O +
6 O +
( O -
Prdx6 O -
) O -
. O +

Prdx6 O +
PLA2 O +
activity O +
is O +
required O +
for O +
activation O +
of O +
NADPH B-Chemical +
oxidase O +
2 O +
and O +
subsequent O +
generation O +
of O +
reactive O +
oxygen B-Chemical +
species O +
( O -
ROS O -
) O -
. O +

In O +
vitro O -
, O +
MJ33 B-Chemical +
inhibited O +
agonist O -
- O -
stimulated O +
production O +
of O +
ROS O +
by O +
the O +
isolated O +
perfused O +
mouse O +
lung O -
, O +
lung O +
microvascular O +
endothelial O +
cells O -
, O +
and O +
polymorphonuclear O +
leukocytes O -
. O +

MJ33 B-Chemical +
( O -
0.02 O -
- O -
0.5 O +
µmol O +
MJ33 B-Chemical -
/ O -
kg O +
body O +
weight O -
) O +
in O +
mixed O +
unilamellar O +
liposomes O +
was O +
administered O +
to O +
C57BL O -
/ O -
6 O +
mice O +
by O +
either O +
intratracheal O +
( O -
i.t O -
. O -
) O +
or O +
i.v O -
. O +

routes O -
. O +

Lung O +
MJ33 B-Chemical +
content O -
, O +
measured O +
by O +
liquid O +
chromatography O -
/ O -
mass O +
spectroscopy O -
, O +
showed O +
uptake O +
of O +
67 O -
- O -
87 O -
% O +
of O +
the O +
injected O +
dose O +
for O +
i.t O -
. O +

and O +
23 O -
- O -
42 O -
% O +
for O +
i.v O -
. O +

administration O +
at O +
4 O +
hours O +
postinjection O -
. O +

PLA2 O +
activity O +
of O +
lung O +
homogenates O +
was O +
markedly O +
inhibited O +
( O -
> O -
85 O -
% O -
) O +
at O +
4 O +
hours O +
postadministration O -
. O +

Both O +
MJ33 B-Chemical +
content O +
and O +
PLA2 O +
activity O +
gradually O +
returned O +
to O +
near O +
control O +
levels O +
over O +
the O +
subsequent O +
24 O -
- O -
72 O +
hours O -
. O +

Mice O +
treated O +
with O +
MJ33 B-Chemical +
at O +
12.5 O -
- O -
25 O +
µmol O -
/ O -
kg O +
did O +
not O +
show O +
changes O +
( O -
compared O +
with O +
control O -
) O +
in O +
clinical O +
symptomatology O -
, O +
body O +
weight O -
, O +
hematocrit O -
, O +
and O +
histology O +
of O +
lung O -
, O +
liver O -
, O +
and O +
kidney O +
during O +
a O +
30- O +
to O +
50-day O +
observation O +
period O -
. O +

Thus O -
, O +
the O +
toxic O +
dose O +
of O +
MJ33 B-Chemical +
was O +
> O -
25 O +
µmol O -
/ O -
kg O -
, O +
whereas O +
the O +
PLA2 O +
inhibitory O +
dose O +
was O +
approximately O +
0.02 O +
µmol O -
/ O -
kg O -
, O +
indicating O +
a O +
high O +
margin O +
of O +
safety O -
. O +

MJ33 B-Chemical +
administered O +
to O +
mice O +
prior O +
to O +
lung O +
isolation O +
markedly O +
reduced O +
ROS O +
production O +
and O +
tissue O +
lipid O +
and O +
protein O +
oxidation O +
during O +
ischemia O +
followed O +
by O +
reperfusion O -
. O +

Thus O -
, O +
MJ33 B-Chemical +
could O +
be O +
useful O +
as O +
a O +
therapeutic O +
agent O +
to O +
prevent O +
ROS O -
- O -
mediated O +
tissue O +
injury O +
associated O +
with O +
lung O +
inflammation O +
or O +
in O +
harvested O +
lungs O +
prior O +
to O +
transplantation O -
. O +

Discovery O +
and O +
gram O -
- O -
scale O +
synthesis O +
of O +
BMS-593214 B-Chemical -
, O +
a O +
potent O -
, O +
selective O +
FVIIa O +
inhibitor O -
. O +

A O +
6-amidinotetrahydroquinoline B-Chemical +
screening O +
hit O +
was O +
driven O +
to O +
a O +
structurally O +
novel O -
, O +
potent O -
, O +
and O +
selective O +
FVIIa O +
inhibitor O +
through O +
a O +
combination O +
of O +
library O +
synthesis O +
and O +
rational O +
design O -
. O +

An O +
efficient O +
gram O -
- O -
scale O +
synthesis O +
of O +
the O +
active O +
enantiomer O +
BMS-593214 B-Chemical +
was O +
developed O -
, O +
which O +
required O +
significant O +
optimization O +
of O +
the O +
key O +
Povarov O +
annulation O -
. O +

Importantly O -
, O +
BMS-593214 B-Chemical +
showed O +
antithrombotic O +
efficacy O +
in O +
a O +
rabbit O +
arterial O +
thrombosis O +
model O -
. O +

A O +
crystal O +
structure O +
of O +
BMS-593214 B-Chemical +
bound O +
to O +
FVIIa O +
highlights O +
key O +
contacts O +
with O +
Asp B-Chemical +
189 O -
, O +
Lys B-Chemical +
192 O -
, O +
and O +
the O +
S2 O +
pocket O -
. O +

Physicochemical O +
Properties O +
and O +
Supernucleophilicity O +
of O +
Oxime B-Chemical -
- O -
Functionalized O +
Surfactants O -
: O +
Hydrolytic O +
Catalysts O +
toward O +
Dephosphorylation O +
of O +
Di- B-Chemical +
and I-Chemical +
Triphosphate I-Chemical +
Esters I-Chemical -
. O +

Aggregation O +
and O +
kinetic O +
studies O +
have O +
been O +
performed O +
to O +
understand O +
the O +
hydrolytic O +
potencies O +
of O +
the O +
series O +
of O +
oxime B-Chemical -
- O -
functionalized O +
surfactants O -
, O +
viz O -
. O -
, O +
3- B-Chemical +
hydroxyiminomethyl-1-alkylpyridinium I-Chemical +
bromide I-Chemical +
( O -
alkyl B-Chemical +
= O +
CnH2n+1 B-Chemical -
, O +
n O +
= O +
10 O -
, O +
12 O -
, O +
14 O -
, O +
16 O -
, O +
18 O -
) O +
in O +
the O +
cleavage O +
of O +
phosphate B-Chemical +
esters I-Chemical -
, O +
p B-Chemical -
- I-Chemical -
nitrophenyl I-Chemical +
diphenyl I-Chemical +
phosphate I-Chemical +
( O -
PNPDPP B-Chemical -
) O +
and O +
bis B-Chemical -
( I-Chemical -
2,4-dinitrophenyl I-Chemical -
) I-Chemical +
phosphate I-Chemical +
( O -
BNDPP B-Chemical -
) O -
, O +
in O +
mixed O +
micelles O +
with O +
cetylpyridinium B-Chemical +
bromide I-Chemical +
( O -
CPB B-Chemical -
) O -
. O +

Micellization O +
and O +
surface O +
properties O +
of O +
mixed O +
micelles O +
functional O +
surfactants O +
with O +
CPB B-Chemical +
were O +
studied O +
by O +
conductivity O +
and O +
surface O +
tension O +
measurements O -
. O +

Acid O +
dissociation O +
constants O +
( O -
pKa O -
) O +
were O +
determined O -
, O +
the O +
effect O +
of O +
functional O +
surfactant O +
alkyl B-Chemical +
chain O +
length O +
and O +
pH O +
on O +
the O +
observed O +
rate O +
constant O +
( O -
kobs O -
) O +
for O +
phosphate B-Chemical +
ester I-Chemical +
cleavage O +
has O +
been O +
discussed O -
, O +
and O +
the O +
effect O +
of O +
substrate O +
on O +
the O +
supernucleophilicities O +
of O +
the O +
studied O +
oximes B-Chemical +
was O +
monitored O -
. O +

Functionalized O +
oxime B-Chemical -
- O -
based O +
surfactants O +
were O +
proved O +
to O +
be O +
supernucleophiles O +
to O +
attack O +
on O +
the O +
P B-Chemical -
═ I-Chemical -
O I-Chemical +
center O +
of O +
tri- B-Chemical +
and I-Chemical +
diphosphate I-Chemical +
esters I-Chemical -
. O +

Oximes B-Chemical +
with O +
hexadecyl B-Chemical +
alkyl B-Chemical +
chain O +
length O +
( O -
3-C16 B-Chemical -
) O +
showed O +
maximum O +
micellar O +
effect O +
on O +
the O +
rate O +
constants O +
toward O +
PNPDPP B-Chemical -
. O +

Micellar O +
effects O +
were O +
analyzed O +
in O +
terms O +
of O +
the O +
pseudophase O +
model O -
. O +

Comparative O +
annotation O +
of O +
functional O +
regions O +
in O +
the O +
human O +
genome O +
using O +
epigenomic O +
data O -
. O +

Epigenetic O +
regulation O +
is O +
dynamic O +
and O +
cell O -
- O -
type O +
dependent O -
. O +

The O +
recently O +
available O +
epigenomic O +
data O +
in O +
multiple O +
cell O +
types O +
provide O +
an O +
unprecedented O +
opportunity O +
for O +
a O +
comparative O +
study O +
of O +
epigenetic O +
landscape O -
. O +

We O +
developed O +
a O +
machine O -
- O -
learning O +
method O +
called O +
ChroModule O +
to O +
annotate O +
the O +
epigenetic O +
states O +
in O +
eight O +
ENCyclopedia O +
Of O +
DNA O +
Elements O +
cell O +
types O -
. O +

The O +
trained O +
model O +
successfully O +
captured O +
the O +
characteristic O +
histone O -
- O -
modification O +
patterns O +
associated O +
with O +
regulatory O +
elements O -
, O +
such O +
as O +
promoters O +
and O +
enhancers O -
, O +
and O +
showed O +
superior O +
performance O +
on O +
identifying O +
enhancers O +
compared O +
with O +
the O +
state O -
- O -
of O -
- O -
art O +
methods O -
. O +

In O +
addition O -
, O +
given O +
the O +
fixed O +
number O +
of O +
epigenetic O +
states O +
in O +
the O +
model O -
, O +
ChroModule O +
allows O +
straightforward O +
illustration O +
of O +
epigenetic O +
variability O +
in O +
multiple O +
cell O +
types O -
. O +

Using O +
this O +
feature O -
, O +
we O +
found O +
that O +
invariable O +
and O +
variable O +
epigenetic O +
states O +
across O +
cell O +
types O +
correspond O +
to O +
housekeeping O +
functions O +
and O +
stimulus O +
response O -
, O +
respectively O -
. O +

Especially O -
, O +
we O +
observed O +
that O +
enhancers O -
, O +
but O +
not O +
the O +
other O +
regulatory O +
elements O -
, O +
dictate O +
cell O +
specificity O -
, O +
as O +
similar O +
cell O +
types O +
share O +
common O +
enhancers O -
, O +
and O +
cell O -
- O -
type O -
- O -
specific O +
enhancers O +
are O +
often O +
bound O +
by O +
transcription O +
factors O +
playing O +
critical O +
roles O +
in O +
that O +
cell O +
type O -
. O +

More O +
interestingly O -
, O +
we O +
found O +
some O +
genomic O +
regions O +
are O +
dormant O +
in O +
cell O +
type O +
but O +
primed O +
to O +
become O +
active O +
in O +
other O +
cell O +
types O -
. O +

These O +
observations O +
highlight O +
the O +
usefulness O +
of O +
ChroModule O +
in O +
comparative O +
analysis O +
and O +
interpretation O +
of O +
multiple O +
epigenomes O -
. O +

Direct O +
modulation O +
of O +
microtubule O +
stability O +
contributes O +
to O +
anthracene B-Chemical +
general O +
anesthesia O -
. O +

Recently O -
, O +
we O +
identified O +
1-aminoanthracene B-Chemical +
as O +
a O +
fluorescent O +
general O +
anesthetic O -
. O +

To O +
investigate O +
the O +
mechanism O +
of O +
action O -
, O +
a O +
photoactive O +
analogue O -
, O +
1-azidoanthracene B-Chemical -
, O +
was O +
synthesized O -
. O +

Administration O +
of O +
1-azidoanthracene B-Chemical +
to O +
albino O +
stage O +
40 O -
- O -
47 O +
tadpoles O +
was O +
found O +
to O +
immobilize O +
animals O +
upon O +
near O -
- O -
UV O +
irradiation O +
of O +
the O +
forebrain O +
region O -
. O +

The O +
immobilization O +
was O +
often O +
reversible O -
, O +
but O +
it O +
was O +
characterized O +
by O +
a O +
longer O +
duration O +
consistent O +
with O +
covalent O +
attachment O +
of O +
the O +
ligand O +
to O +
functionally O +
important O +
targets O -
. O +

IEF O -
/ O -
SDS O -
- O -
PAGE O +
examination O +
of O +
irradiated O +
tadpole O +
brain O +
homogenate O +
revealed O +
labeled O +
protein O -
, O +
identified O +
by O +
mass O +
spectrometry O +
as O +
β O -
- O -
tubulin O -
. O +

In O +
vitro O +
assays O +
with O +
aminoanthracene B-Chemical -
- O -
cross O -
- O -
linked O +
tubulin O +
indicated O +
inhibition O +
of O +
microtubule O +
polymerization O -
, O +
similar O +
to O +
colchicine B-Chemical -
. O +

Tandem O +
mass O +
spectrometry O +
confirmed O +
anthracene B-Chemical +
binding O +
near O +
the O +
colchicine B-Chemical +
site O -
. O +

Stage O +
40 O -
- O -
47 O +
tadpoles O +
were O +
also O +
incubated O +
1 O +
h O +
with O +
microtubule O +
stabilizing O +
agents O -
, O +
epothilone B-Chemical +
D I-Chemical +
or O +
discodermolide B-Chemical -
, O +
followed O +
by O +
dosing O +
with O +
1-aminoanthracene B-Chemical -
. O +

The O +
effective O +
concentration O +
of O +
1-aminoanthracene B-Chemical +
required O +
to O +
immobilize O +
the O +
tadpoles O +
was O +
significantly O +
increased O +
in O +
the O +
presence O +
of O +
either O +
microtubule O +
stabilizing O +
agent O -
. O +

Epothilone B-Chemical +
D I-Chemical +
similarly O +
mitigated O +
the O +
effects O +
of O +
a O +
clinical O +
neurosteroid O +
general O +
anesthetic O -
, O +
allopregnanolone B-Chemical -
, O +
believed O +
to O +
occupy O +
the O +
colchicine B-Chemical +
site O +
in O +
tubulin O -
. O +

We O +
conclude O +
that O +
neuronal O +
microtubules O +
are O +
" O -
on O -
- O -
pathway O -
" O +
targets O +
for O +
anthracene B-Chemical +
general O +
anesthetics O +
and O +
may O +
also O +
represent O +
functional O +
targets O +
for O +
some O +
neurosteroid O +
general O +
anesthetics O -
. O +

Unraveling O +
the O +
Role O +
of O +
the O +
Protein O +
Environment O +
for O +
[ B-Chemical -
FeFe I-Chemical -
] I-Chemical -
-Hydrogenase O -
: O +
A O +
New O +
Application O +
of O +
Coarse O -
- O -
Graining O -
. O +

Hydrogenase O +
enzymes O +
are O +
natural O +
biocatalysts O +
that O +
might O +
be O +
harnessed O +
to O +
reduce O +
the O +
cost O +
of O +
hydrogen B-Chemical +
gas O +
production O -
. O +

[ B-Chemical -
FeFe I-Chemical -
] I-Chemical -
-hydrogenases O +
are O +
the O +
most O +
effective O +
of O +
three O +
such O +
enzymes O +
at O +
catalyzing O +
H B-Chemical -
( I-Chemical -
+ I-Chemical -
) I-Chemical +
reduction O -
. O +

In O +
this O +
study O -
, O +
we O +
develop O +
and O +
apply O +
a O +
novel O +
combination O +
of O +
all O -
- O -
atom O +
molecular O +
dynamics O +
and O +
coarse O -
- O -
grained O +
( O -
CG O -
) O +
analysis O +
to O +
characterize O +
two O +
important O +
steps O +
of O +
the O +
catalytic O +
cycle O +
of O +
[ B-Chemical -
FeFe I-Chemical -
] I-Chemical -
-hydrogenase O -
. O +

The O +
first O +
is O +
the O +
electron O +
transport O +
through O +
FeS B-Chemical +
clusters O +
to O +
the O +
active O +
site O -
. O +

We O +
use O +
a O +
Marcus O +
formulation O +
to O +
compute O +
the O +
free O +
energy O +
and O +
the O +
reorganization O +
energy O +
of O +
three O +
electron O +
transport O +
steps O +
and O +
decompose O +
these O +
values O +
into O +
contributions O +
from O +
the O +
CG O +
protein O +
sites O +
and O +
the O +
solvent O -
. O +

The O +
three O -
- O -
step O +
transport O +
process O +
is O +
found O +
to O +
be O +
downhill O +
with O +
relative O +
free O +
energies O +
of O +
-11.7 O +
for O +
the O +
first O +
step O -
, O +
-14.8 O +
for O +
the O +
second O +
step O -
, O +
and O +
-17.1 O +
kcal O -
/ O -
mol O +
for O +
the O +
third O +
step O -
. O +

The O +
electron O -
- O -
transport O +
process O +
is O +
also O +
found O +
to O +
activate O +
a O +
water O +
channel O +
suggesting O +
a O +
coupled O +
mechanism O +
for O +
proton O +
and O +
electron O +
transport O +
to O +
the O +
active O +
site O -
. O +

The O +
channel O +
opening O +
is O +
orchestrated O +
by O +
three O +
CG O +
sites O +
located O +
in O +
the O +
active O -
- O -
site O +
domain O +
of O +
the O +
protein O +
with O +
one O +
of O +
the O +
sites O +
also O +
contributing O +
a O +
strong O +
attractive O +
electrostatic O +
potential O +
( O -
ESP O -
) O +
to O +
help O +
shuttle O +
protons O +
to O +
the O +
active O +
site O -
. O +

Overall O -
, O +
our O +
CG O +
analysis O +
points O +
to O +
a O +
concerted O +
mechanism O +
of O +
electron O +
and O +
proton O +
delivery O +
to O +
the O +
active O +
site O +
in O +
these O +
proteins O +
thus O +
providing O +
important O +
insight O +
for O +
the O +
development O +
of O +
biomimetic O +
devices O -
. O +

Therapeutic O +
effectiveness O +
of O +
botulinum O +
neurotoxin O +
A O -
: O +
Potent O +
blockade O +
of O +
autonomic O +
transmission O +
by O +
targeted O +
cleavage O +
of O +
only O +
the O +
pertinent O +
SNAP-25 O -
. O +

In O +
search O +
of O +
a O +
basis O +
for O +
the O +
impressive O +
potency O +
of O +
an O +
endoprotease O +
that O +
cleaves O +
SNAP-25 O -
, O +
botulinum O +
neurotoxin O +
type O +
A O +
( O -
BoNT O -
/ O -
A O -
) O -
, O +
in O +
treating O +
numerous O +
diseases O +
due O +
to O +
hyper O -
- O -
active O +
autonomic O +
nerves O -
, O +
truncation O +
of O +
its O +
target O +
and O +
inhibition O +
of O +
neurotransmission O +
were O +
studied O +
in O +
rat O +
sympathetic O +
neurons O -
. O +

Tetrodotoxin B-Chemical -
- O -
sensitive O +
spontaneous O +
cholinergic O +
neurotransmission O +
was O +
blocked O +
> O -
80 O -
% O +
by O +
1 O +
pM O +
BoNT O -
/ O -
A O +
despite O +
cleaving O +
< O -
20 O -
% O +
of O +
the O +
SNAP-25 O -
. O +

A O +
maximum O +
cleavage O +
of O +
∼60 O -
% O +
SNAP-25 O +
could O +
be O +
achieved O +
with O +
> O -
1 O +
nM O +
BoNT O -
/ O -
A O -
, O +
despite O +
an O +
absence O +
of O +
non O -
- O -
cleavable O +
SNAP-25 O +
in O +
the O +
detergent O -
- O -
solubilised O +
neurons O -
. O +

In O +
contrast O -
, O +
BoNT O -
/ O -
E O +
( O -
100 O +
nM O -
) O +
truncated O +
nearly O +
all O +
the O +
SNAP-25 O +
in O +
the O +
intact O +
cells O -
, O +
but O +
was O +
unable O +
to O +
block O +
neurotransmission O +
at O +
low O +
concentrations O +
like O +
BoNT O -
/ O -
A. O +
Chimeras O +
created O +
by O +
inserting O +
the O +
acceptor O -
- O -
binding O +
HC O +
domain O +
of O +
BoNT O -
/ O -
A O +
into O +
BoNT O -
/ O -
E O +
still O +
cleaved O +
all O +
the O +
SNAP-25 O -
, O +
indicating O +
ubiquitous O +
expression O +
of O +
BoNT O -
/ O -
A O +
acceptors O -
. O +

Accordingly O -
, O +
SV2 O +
and O +
SNAP-25 O +
were O +
found O +
to O +
be O +
co O -
- O -
expressed O +
and O +
broadly O +
co O -
- O -
localised O +
in O +
neurons O -
, O +
but O +
absent O +
from O +
non O -
- O -
neuronal O +
cells O -
. O +

On O +
the O +
other O +
hand O -
, O +
partial O +
cleavage O +
by O +
the O +
BoNT O -
/ O -
A O +
protease O +
persisted O +
upon O +
replacing O +
its O +
HC O +
with O +
counterparts O +
from O +
BoNT O -
/ O -
E O +
or O +
BoNT O -
/ O -
B. O +
Moreover O -
, O +
limited O +
cleavage O +
of O +
SNAP-25 O +
was O +
conferred O +
onto O +
the O +
protease O +
from O +
BoNT O -
/ O -
E O +
when O +
fused O +
to O +
the O +
N O -
- O -
terminus O +
of O +
BoNT O -
/ O -
A. O +
Thus O -
, O +
the O +
BoNT O -
/ O -
A O +
protease O +
is O +
uniquely O +
well O -
- O -
adapted O +
for O +
selectively O +
inactivating O +
the O +
SNAP-25 O +
directly O +
involved O +
in O +
neurotransmission O -
; O +
this O +
together O +
with O +
the O +
toxin O -
's O +
acceptor O +
and O +
its O +
target O +
being O +
localised O +
on O +
the O +
peri O -
- O -
somatic O +
boutons O +
likely O +
contribute O +
to O +
its O +
exceptional O +
therapeutic O +
utility O +
in O +
the O +
clinic O -
. O +

Structural O +
modifications O +
of O +
polymethacrylates B-Chemical -
: O +
Impact O +
on O +
thermal O +
behavior O +
and O +
release O +
characteristics O +
of O +
glassy O +
solid O +
solutions O -
. O +

Polymethacrylates B-Chemical +
such O +
as O +
Eudragit B-Chemical -
® O +
polymers O +
are O +
well O +
established O +
as O +
drug O +
delivery O +
matrix O -
. O +

Here O -
, O +
we O +
synthesize O +
several O +
Eudragit B-Chemical +
E I-Chemical +
PO I-Chemical +
( O -
n B-Chemical -
- I-Chemical -
butyl- I-Chemical -
, O +
dimethylaminoethyl- B-Chemical -
, O +
methyl B-Chemical -
- I-Chemical -
methacrylate I-Chemical -
- O -
terpolymer B-Chemical -
) O +
analogues O +
via O +
free O +
radical O +
polymerization O -
. O +

These O +
polymers O +
are O +
processed O +
via O +
hot O +
melt O +
extrusion O -
, O +
followed O +
by O +
injection O +
molding O +
and O +
evaluated O +
as O +
carriers O +
to O +
produce O +
immediate O +
release O +
solid O +
solution O +
tablets O -
. O +

Three O +
chemical O +
modifications O +
increased O +
the O +
glass O +
transition O +
temperature O +
of O +
the O +
polymer O -
: O +
( O -
a O -
) O +
substitution O +
of O +
n B-Chemical -
- I-Chemical -
butyl I-Chemical +
by O +
t B-Chemical -
- I-Chemical -
butyl I-Chemical +
groups O -
, O +
( O -
b O -
) O +
reduction O +
of O +
the O +
dimethylaminoethyl B-Chemical +
methacrylate I-Chemical +
( O -
DMAEMA B-Chemical -
) O +
content O -
, O +
and O +
( O -
c O -
) O +
incorporation O +
of O +
a O +
bulky O +
isobornyl B-Chemical +
repeating O +
unit O -
. O +

These O +
structural O +
modifications O +
revealed O +
the O +
possibility O +
to O +
increase O +
the O +
mechanical O +
stability O +
of O +
the O +
tablets O +
via O +
altering O +
the O +
polymer O +
Tg O +
without O +
influencing O +
the O +
drug O +
release O +
characteristics O +
and O +
glassy O +
solid O +
solution O +
forming O +
properties O -
. O +

The O +
presence O +
of O +
DMAEMA B-Chemical +
units O +
proved O +
to O +
be O +
crucial O +
with O +
respect O +
to O +
API O -
/ O -
polymer O +
interaction O +
( O -
essential O +
in O +
creating O +
glassy O +
solid O +
solutions O -
) O +
and O +
drug O +
release O +
characteristics O -
. O +

Moreover O -
, O +
these O +
chemical O +
modifications O +
accentuate O +
the O +
need O +
for O +
a O +
more O +
rational O +
design O +
of O +
( O -
methacrylate B-Chemical -
) O +
polymer O +
matrix O +
excipients O +
for O +
drug O +
formulation O +
via O +
hot O +
melt O +
extrusion O +
and O +
injection O +
molding O -
. O +

Mercury B-Chemical +
in O +
fishes O +
from O +
Augusta O +
Bay O +
( O -
southern O +
Italy O -
) O -
: O +
Risk O +
assessment O +
and O +
health O +
implication O -
. O +

Our O +
study O +
reports O +
on O +
the O +
total O +
mercury B-Chemical +
( O -
HgT O -
) O +
concentrations O +
measured O +
in O +
the O +
muscles O +
and O +
livers O +
of O +
several O +
benthic O -
, O +
demersal O +
and O +
pelagic O +
fish O +
species O +
caught O +
inside O +
and O +
outside O +
of O +
Augusta O +
Bay O +
( O -
southern O +
Italy O -
) O -
, O +
a O +
semi O -
- O -
enclosed O +
marine O +
area O -
, O +
highly O +
contaminated O +
by O +
the O +
uncontrolled O +
( O -
since O +
the O +
1950s O +
to O +
1978s O -
) O +
discharge O +
of O +
the O +
largest O +
European O +
petrochemical O +
plant O -
. O +

Mercury B-Chemical +
levels O +
in O +
fish O +
tissues O +
are O +
discussed O +
with O +
regard O +
to O +
specific O +
habitat O -
, O +
size O +
and/or O +
age O +
of O +
the O +
specimens O +
and O +
HgT O +
distribution O +
in O +
the O +
bottom O +
sediments O -
. O +

Results O +
suggest O +
a O +
still O +
active O +
Hg B-Chemical +
release O +
mechanism O +
from O +
the O +
polluted O +
sediments O +
to O +
the O +
marine O +
environment O -
. O +

Also O -
, O +
the O +
high O +
HgT O +
concentrations O +
measured O +
in O +
fishes O +
caught O +
in O +
the O +
external O +
area O +
of O +
the O +
bay O +
imply O +
a O +
potential O +
role O +
of O +
Augusta O +
Bay O +
as O +
a O +
pollutant O +
source O +
for O +
the O +
Mediterranean O +
ecosystem O -
. O +

Finally O -
, O +
values O +
of O +
hazard O +
target O +
quotient O +
( O -
THQ O -
) O +
and O +
estimated O +
weekly O +
intake O +
( O -
EWI O -
) O +
demonstrate O +
that O +
consumption O +
of O +
fishes O +
caught O +
inside O +
the O +
bay O +
represents O +
a O +
serious O +
risk O +
for O +
human O +
health O -
. O +

Also O -
, O +
data O +
indicate O +
that O +
intake O +
of O +
fishes O +
caught O +
from O +
the O +
external O +
area O +
of O +
the O +
bay O -
, O +
especially O +
for O +
that O +
concern O +
demersal O +
and O +
benthic O +
species O -
, O +
could O +
be O +
represent O +
a O +
significant O +
component O +
of O +
risk O +
for O +
the O +
local O +
population O -
. O +

A O +
systematic O +
comparison O +
of O +
the O +
properties O +
of O +
clinically O +
used O +
angiotensin O +
II O +
type O +
1 O +
receptor O +
antagonists O -
. O +

Angiotensin O +
II O +
type O +
1 O +
receptor O +
antagonists O +
( O -
ARBs O -
) O +
have O +
become O +
an O +
important O +
drug O +
class O +
in O +
the O +
treatment O +
of O +
hypertension O +
and O +
heart O +
failure O +
and O +
the O +
protection O +
from O +
diabetic O +
nephropathy O -
. O +

Eight O +
ARBs O +
are O +
clinically O +
available O +
[ O -
azilsartan B-Chemical -
, O +
candesartan B-Chemical -
, O +
eprosartan B-Chemical -
, O +
irbesartan B-Chemical -
, O +
losartan B-Chemical -
, O +
olmesartan B-Chemical -
, O +
telmisartan B-Chemical -
, O +
valsartan B-Chemical -
] O -
. O +

Azilsartan B-Chemical +
( O -
in O +
some O +
countries O -
) O -
, O +
candesartan B-Chemical -
, O +
and O +
olmesartan B-Chemical +
are O +
orally O +
administered O +
as O +
prodrugs O -
, O +
whereas O +
the O +
blocking O +
action O +
of O +
some O +
is O +
mediated O +
through O +
active O +
metabolites O -
. O +

On O +
the O +
basis O +
of O +
their O +
chemical O +
structures O -
, O +
ARBs O +
use O +
different O +
binding O +
pockets O +
in O +
the O +
receptor O -
, O +
which O +
are O +
associated O +
with O +
differences O +
in O +
dissociation O +
times O +
and O -
, O +
in O +
most O +
cases O -
, O +
apparently O +
insurmountable O +
antagonism O -
. O +

The O +
physicochemical O +
differences O +
between O +
ARBs O +
also O +
manifest O +
in O +
different O +
tissue O +
penetration O -
, O +
including O +
passage O +
through O +
the O +
blood O -
- O -
brain O +
barrier O -
. O +

Differences O +
in O +
binding O +
mode O +
and O +
tissue O +
penetration O +
are O +
also O +
associated O +
with O +
differences O +
in O +
pharmacokinetic O +
profile O -
, O +
particularly O +
duration O +
of O +
action O -
. O +

Although O +
generally O +
highly O +
specific O +
for O +
angiotensin O +
II O +
type O +
1 O +
receptors O -
, O +
some O +
ARBs O -
, O +
particularly O +
telmisartan B-Chemical -
, O +
are O +
partial O +
agonists O +
at O +
peroxisome O +
proliferator O -
- O -
activated O +
receptor O -
- O -
γ O -
. O +

All O +
of O +
these O +
properties O +
are O +
comprehensively O +
reviewed O +
in O +
this O +
article O -
. O +

Although O +
there O +
is O +
general O +
consensus O +
that O +
a O +
continuous O +
receptor O +
blockade O +
over O +
a O +
24-hour O +
period O +
is O +
desirable O -
, O +
the O +
clinical O +
relevance O +
of O +
other O +
pharmacological O +
differences O +
between O +
individual O +
ARBs O +
remains O +
to O +
be O +
assessed O -
. O +

Understanding O +
multi O -
- O -
quantum O +
NMR O +
through O +
secular O +
approximation O -
. O +

With O +
the O +
development O +
of O +
technology O +
and O +
improved O +
understanding O +
of O +
nuclear O +
spin O -
- O -
spin O +
interactions O +
and O +
their O +
behavior O +
in O +
static O -
/ O -
oscillating O +
magnetic O +
fields O -
, O +
NMR O +
spectroscopy O +
has O +
emerged O +
as O +
a O +
powerful O +
tool O +
for O +
characterizing O +
molecular O +
structure O +
in O +
a O +
wide O +
range O +
of O +
systems O +
of O +
chemical O -
, O +
physical O +
and O +
biological O +
relevance O -
. O +

Here O +
in O +
this O +
article O -
, O +
we O +
revisit O +
the O +
important O +
connection O +
between O +
" O -
Secular O -
- O -
Approximation O -
" O +
( O -
a O +
well O -
- O -
known O +
fundamental O +
concept O -
) O +
and O +
NMR O +
spectroscopy O -
. O +

Employing O +
recent O +
experimental O +
results O +
as O +
the O +
background O -
, O +
an O +
alternate O +
interpretation O +
of O +
the O +
secular O +
approximation O +
is O +
presented O +
for O +
describing O +
and O +
understanding O +
the O +
nuances O +
of O +
Multi O -
- O -
Quantum O +
( O -
MQ O -
) O +
NMR O +
spectroscopy O +
of O +
quadrupolar O +
nuclei O -
. O +

Since O +
MQ O +
NMR O +
spectroscopy O +
of O +
quadrupolar O +
nuclei O +
forms O +
the O +
basis O +
of O +
the O +
structural O +
characterization O +
of O +
inorganic O +
solids O +
and O +
clusters O -
, O +
we O +
believe O +
that O +
the O +
analytic O +
theory O +
presented O +
herein O +
would O +
be O +
beneficial O +
both O +
in O +
the O +
understanding O +
and O +
design O +
of O +
MQ O +
NMR O +
experiments O -
. O +

Additionally O -
, O +
the O +
analytic O +
results O +
are O +
corroborated O +
with O +
rigorous O +
numerical O +
simulations O +
and O +
could O +
be O +
employed O +
in O +
the O +
quantitative O +
interpretation O +
of O +
experimental O +
results O -
. O +

Heterogeneous O +
OH B-Chemical +
oxidation O +
of O +
biomass O +
burning O +
organic O +
aerosol O +
surrogate O +
compounds O -
: O +
assessment O +
of O +
volatilisation O +
products O +
and O +
the O +
role O +
of O +
OH B-Chemical +
concentration O +
on O +
the O +
reactive O +
uptake O +
kinetics O -
. O +

The O +
reactive O +
uptake O +
coefficients O +
( O -
γ O -
) O +
of O +
OH B-Chemical +
by O +
levoglucosan B-Chemical -
, O +
abietic B-Chemical +
acid I-Chemical -
, O +
and O +
nitroguaiacol B-Chemical +
serving O +
as O +
surrogate O +
compounds O +
for O +
biomass O +
burning O +
aerosol O +
have O +
been O +
determined O +
employing O +
a O +
chemical O +
ionisation O +
mass O +
spectrometer O +
coupled O +
to O +
a O +
rotating O -
- O -
wall O +
flow O -
- O -
tube O +
reactor O +
over O +
a O +
wide O +
range O +
of O +
[ O -
OH B-Chemical -
] O +
∼10 O -
( O -
7 O -
) O -
-10 O -
( O -
11 O -
) O +
molecule O +
cm O -
( O -
-3 O -
) O -
. O +

Volatilisation O +
products O +
of O +
these O +
organic O +
substrates O +
due O +
to O +
heterogeneous O +
oxidation O +
by O +
OH B-Chemical +
have O +
been O +
determined O +
at O +
1 O +
atm O +
using O +
a O +
high O +
resolution O +
proton O +
transfer O +
reaction O +
time O -
- O -
of O -
- O -
flight O +
mass O +
spectrometer O +
( O -
HR O -
- O -
PTR O -
- O -
ToF O -
- O -
MS O -
) O -
. O +

γ O +
range O +
within O +
0.05 O -
- O -
1 O +
for O +
[ O -
OH B-Chemical -
] O +
= O +
2.6 O +
× O +
10 O -
( O -
7 O -
) O -
-3 O +
× O +
10 O -
( O -
9 O -
) O +
molecule O +
cm O -
( O -
-3 O -
) O +
for O +
all O +
investigated O +
organic O +
compounds O -
, O +
but O +
decrease O +
to O +
0.008 O -
- O -
0.034 O +
for O +
[ O -
OH B-Chemical -
] O +
= O +
4.1 O +
× O +
10 O -
( O -
10 O -
) O -
-6.7 O +
× O +
10 O -
( O -
10 O -
) O +
molecule O +
cm O -
( O -
-3 O -
) O -
. O +

γ O +
as O +
a O +
function O +
of O +
[ O -
OH B-Chemical -
] O +
can O +
be O +
described O +
by O +
a O +
Langmuir O -
- O -
Hinshelwood O +
model O -
, O +
neglecting O +
bulk O +
processes O -
, O +
suggesting O +
that O +
despite O +
its O +
strong O +
reactivity O -
, O +
OH B-Chemical +
is O +
mobile O +
on O +
surfaces O +
prior O +
to O +
reaction O -
. O +

The O +
best O +
fit O +
Langmuir O -
- O -
Hinshelwood O +
parameters O +
on O +
average O +
are O +
K O -
( O -
OH B-Chemical -
) O +
= O +
3.81 O +
× O +
10 O -
( O -
-10 O -
) O +
cm O -
( O -
3 O -
) O +
molecule O -
( O -
-1 O -
) O +
and O +
k O -
( O -
s O -
) O +
= O +
9.71 O +
× O +
10 O -
( O -
-17 O -
) O +
cm O -
( O -
2 O -
) O +
molecule O -
( O -
-1 O -
) O +
s O -
( O -
-1 O -
) O +
for O +
all O +
of O +
the O +
investigated O +
organic O +
compounds O -
. O +

Volatilised O +
products O +
have O +
been O +
identified O +
indicating O +
enhancements O +
over O +
background O +
of O +
50 O -
% O +
up O +
to O +
a O +
factor O +
of O +
15 O -
. O +

Amongst O +
the O +
common O +
volatile O +
organic O +
compounds O +
( O -
VOCs O -
) O +
identified O +
between O +
levoglucosan B-Chemical -
, O +
abietic B-Chemical +
acid I-Chemical -
, O +
and O +
nitroguaiacol B-Chemical +
were O +
methanol B-Chemical -
, O +
acetaldehyde B-Chemical -
, O +
formic B-Chemical +
acid I-Chemical -
, O +
and O +
acetic B-Chemical +
acid I-Chemical -
. O +

VOCs O +
having O +
the O +
greatest O +
enhancement O +
over O +
background O +
were O +
glucic B-Chemical +
acid I-Chemical +
from O +
levoglucosan B-Chemical -
, O +
glycolic B-Chemical +
acid I-Chemical +
from O +
abietic B-Chemical +
acid I-Chemical -
, O +
and O +
methanol B-Chemical +
and O +
nitric B-Chemical +
acid I-Chemical +
from O +
nitroguaiacol B-Chemical -
. O +

Reaction O +
mechanisms O +
leading O +
to O +
the O +
formation O +
of O +
glucic B-Chemical +
acid I-Chemical -
, O +
glycolic B-Chemical +
acid I-Chemical -
, O +
methanol B-Chemical -
, O +
and O +
nitric B-Chemical +
acid I-Chemical +
are O +
proposed O -
. O +

Estimated O +
lower O +
limits O +
of O +
atmospheric O +
lifetimes O +
of O +
biomass O +
burning O +
aerosol O +
particles O -
, O +
200 O +
nm O +
in O +
diameter O -
, O +
by O +
heterogeneous O +
OH B-Chemical +
oxidation O +
under O +
fresh O +
biomass O +
burning O +
plume O +
conditions O +
are O +
∼2 O +
days O +
and O +
up O +
to O +
∼2 O +
weeks O +
for O +
atmospheric O +
background O +
conditions O -
. O +

However O -
, O +
estimated O +
lifetimes O +
depend O +
crucially O +
on O +
[ O -
OH B-Chemical -
] O +
and O +
corresponding O +
γ O -
, O +
emphasising O +
the O +
need O +
to O +
determine O +
γ O +
under O +
relevant O +
conditions O -
. O +

Synthesis O -
, O +
crystal O +
structure O +
and O +
biological O +
evaluation O +
of O +
a O +
main O +
group O +
seven O -
- O -
coordinated O +
bismuth B-Chemical -
( I-Chemical -
III I-Chemical -
) I-Chemical +
complex O +
with O +
2-acetylpyridine B-Chemical +
N4-phenylthiosemicarbazone I-Chemical -
. O +

Up O +
to O +
now O -
, O +
bismuth B-Chemical -
( I-Chemical -
III I-Chemical -
) I-Chemical +
complexes O +
with O +
thiosemicarbazones B-Chemical +
have O +
been O +
comparatively O +
rare O -
. O +

Here O -
, O +
a O +
main O +
group O +
seven O -
- O -
coordinated O +
bismuth B-Chemical -
( I-Chemical -
III I-Chemical -
) I-Chemical +
complex O +
[ O -
Bi B-Chemical -
( I-Chemical -
L I-Chemical -
) I-Chemical -
( I-Chemical -
NO3 I-Chemical -
) I-Chemical -
2 I-Chemical -
( I-Chemical -
CH3CH2OH I-Chemical -
) I-Chemical -
] O +
( O -
1 O -
) O +
( O -
HL O +
= O +
2-acetylpyridine B-Chemical +
N I-Chemical -
( I-Chemical -
4 I-Chemical -
) I-Chemical -
-phenylthiosemicarbazone I-Chemical -
) O +
has O +
been O +
synthesized O +
and O +
characterized O +
by O +
elemental O +
analysis O -
, O +
IR O -
, O +
( B-Chemical -
1 I-Chemical -
) I-Chemical -
H I-Chemical +
NMR O +
and O +
single O -
- O -
crystal O +
X O -
- O -
ray O +
diffraction O +
studies O -
. O +

The O +
cytotoxicity O +
data O +
suggest O +
that O +
1 O +
exhibits O +
higher O +
in O +
vitro O +
antiproliferative O +
activity O +
in O +
four O +
human O +
cancer O +
cells O +
tested O -
. O +

Its O +
possible O +
apoptotic O +
mechanism O +
has O +
been O +
evaluated O +
in O +
HepG2 O +
cells O -
. O +

Compound O +
1 O +
promotes O +
a O +
dose O -
- O -
dependent O +
apoptosis O +
in O +
HepG2 O +
cells O +
and O +
the O +
apoptosis O +
is O +
associated O +
with O +
an O +
increase O +
in O +
intracellular O +
reactive O +
oxygen B-Chemical +
species O +
( O -
ROS O -
) O +
production O +
and O +
reduction O +
of O +
mitochondrial O +
membrane O +
potential O +
( O -
MMP O -
) O -
. O +

Identification O +
and O +
synthesis O +
of O +
N- B-Chemical -
( I-Chemical -
thiophen-2-yl I-Chemical -
) I-Chemical +
benzamide I-Chemical +
derivatives O +
as O +
BRAF O -
( O -
V600E O -
) O +
inhibitors O -
. O +

The O +
V600E O +
BRAF O +
kinase O +
mutation O -
, O +
which O +
activates O +
the O +
downstream O +
MAPK O +
signaling O +
pathway O -
, O +
commonly O +
occurs O +
in O +
about O +
8 O -
% O +
of O +
all O +
human O +
malignancies O +
and O +
about O +
50 O -
% O +
of O +
all O +
melanomas O -
. O +

In O +
this O +
study O -
, O +
we O +
employed O +
virtual O +
screening O +
and O +
chemical O +
synthesis O +
to O +
identify O +
a O +
series O +
of O +
N- B-Chemical -
( I-Chemical -
thiophen-2-yl I-Chemical -
) I-Chemical +
benzamide I-Chemical +
derivatives O +
as O +
potent O +
BRAF O -
( O -
V600E O -
) O +
inhibitors O -
. O +

Structure O -
- O -
activity O +
relationship O +
studies O +
of O +
these O +
derivatives O +
revealed O +
that O +
compounds O +
b40 O +
and O +
b47 O +
are O +
the O +
two O +
most O +
potent O +
BRAF O -
( O -
V600E O -
) O +
inhibitors O +
in O +
this O +
series O -
. O +

Atmospheric O +
chemistry O +
of O +
CF3O2 B-Chemical -
: O +
a O +
theoretical O +
study O +
on O +
mechanisms O +
and O +
pathways O +
of O +
the O +
CF3O2 B-Chemical +
+ O +
IO B-Chemical +
reaction O -
. O +

The O +
mechanisms O +
and O +
reaction O +
pathways O +
for O +
the O +
CF3O2 B-Chemical +
+ O +
IO B-Chemical +
reaction O +
have O +
been O +
investigated O +
by O +
quantum O +
chemistry O +
methods O -
. O +

It O +
has O +
been O +
found O +
that O +
the O +
title O +
reaction O +
takes O +
place O +
on O +
both O +
the O +
singlet O +
and O +
triplet O +
potential O +
energy O +
surfaces O +
( O -
PES O -
) O -
. O +

On O +
the O +
singlet O +
PES O -
, O +
the O +
most O +
important O +
products O +
include O +
CF3OOOI B-Chemical -
, O +
CF3OOIO B-Chemical -
, O +
CF3OIO2 B-Chemical -
, O +
and O +
CF2O B-Chemical +
+ O +
FIO2 B-Chemical -
, O +
while O +
other O +
products O +
such O +
as O +
CF2O B-Chemical +
+ O +
FOIO B-Chemical -
, O +
CF2O B-Chemical +
+ O +
FOOI B-Chemical -
, O +
CF3OOI B-Chemical +
+ O +
O O -
( O -
( O -
3 O -
) O -
P O -
) O -
, O +
CF3OI B-Chemical +
+ O +
O2 B-Chemical +
( O -
( O -
1 O -
) O -
Δ O +
and O +
( O -
3 O -
) O -
Σ O -
) O -
, O +
and O +
CF3O B-Chemical +
+ O +
OIO B-Chemical +
are O +
negligible O +
due O +
to O +
high O +
barriers O +
or O +
unstable O +
formations O -
. O +

On O +
the O +
triplet O +
PES O -
, O +
CF3O B-Chemical +
+ O +
OIO B-Chemical +
is O +
the O +
dominant O +
product O +
with O +
a O +
lower O +
barrier O -
. O +

As O +
for O +
FIO2 B-Chemical +
and O +
it O +
isomers O -
, O +
the O +
most O +
stable O +
one O +
is O +
FIO2 B-Chemical -
. O +

TDDFT O +
( O -
Time O +
Dependent O +
Density O +
Functional O +
Theory O -
) O +
calculation O +
indicates O +
that O +
CF3OOOI B-Chemical -
, O +
CF3OOIO B-Chemical +
and O +
CF3OIO2 B-Chemical +
undergo O +
photolysis O +
easily O +
under O +
sunlight O -
. O +

Moreover O -
, O +
a O +
minor O +
contribution O +
relative O +
to O +
hydrogen B-Chemical +
is O +
found O +
in O +
the O +
CX3O2 B-Chemical +
+ O +
IO B-Chemical +
( O -
X O +
= O +
H O +
and O +
F O -
) O +
reactions O -
. O +

Optically O +
healable O +
polymers O -
. O +

Polymers O +
that O +
can O +
easily O +
be O +
repaired O +
after O +
being O +
damaged O +
are O +
attractive O +
as O +
this O +
characteristic O +
can O +
improve O +
the O +
reliability O -
, O +
functionality O -
, O +
and O +
lifetime O +
of O +
many O +
products O -
. O +

In O +
the O +
last O +
decade O -
, O +
researchers O +
have O +
thus O +
developed O +
new O +
approaches O +
to O +
create O +
stimuli O -
- O -
responsive O +
polymer O +
systems O -
, O +
which O +
have O +
the O +
ability O +
to O +
autonomously O +
heal O +
or O +
can O +
be O +
repaired O +
upon O +
exposure O +
to O +
an O +
external O +
stimulus O -
. O +

This O +
review O +
summarizes O +
the O +
current O +
knowledge O +
of O +
optically O +
healable O +
or O +
photo O -
- O -
healable O +
polymers O -
. O +

The O +
use O +
of O +
light O +
as O +
a O +
stimulus O +
for O +
healing O +
offers O +
several O +
attractive O +
features O -
, O +
including O +
the O +
ability O +
to O +
deliver O +
the O +
stimulus O +
locally O -
, O +
which O +
opens O +
up O +
the O +
possibility O +
of O +
healing O +
the O +
material O +
under O +
load O -
, O +
as O +
well O +
as O +
the O +
ability O +
to O +
tailor O +
the O +
wavelength O +
of O +
light O +
to O +
selectively O +
address O +
a O +
specific O +
component O +
of O +
the O +
material O -
, O +
e.g. O +
only O +
the O +
damaged O +
parts O -
. O +

So O +
far O -
, O +
two O +
main O +
classes O +
of O +
optically O +
healable O +
polymers O +
have O +
been O +
explored O -
, O +
which O +
are O +
structurally O +
dynamic O +
polymers O +
and O +
mechanically O +
activated O +
reactive O +
systems O -
. O +

Multiple O +
nicotine B-Chemical +
training O +
doses O +
in O +
mice O +
as O +
a O +
basis O +
for O +
differentiating O +
the O +
effects O +
of O +
smoking O +
cessation O +
aids O -
. O +

RATIONALE O -
: O +
Receptor O +
mechanisms O +
underlying O +
the O +
behavioral O +
effects O +
of O +
clinically O +
used O +
nicotinic O +
acetylcholine B-Chemical +
receptor O +
agonists O +
have O +
not O +
been O +
fully O +
established O -
. O +

OBJECTIVE O -
: O +
Drug O +
discrimination O +
was O +
used O +
to O +
compare O +
receptor O +
mechanisms O +
underlying O +
the O +
effects O +
of O +
smoking O +
cessation O +
aids O -
. O +

METHODS O -
: O +
Separate O +
groups O +
of O +
male O +
C57BL O -
/ O -
6J O +
mice O +
discriminated O +
0.56 O -
, O +
1 O -
, O +
or O +
1.78 O +
mg O -
/ O -
kg O +
of O +
nicotine B-Chemical +
base O -
. O +

Nicotine B-Chemical -
, O +
varenicline B-Chemical -
, O +
and O +
cytisine B-Chemical +
were O +
administered O +
alone O -
, O +
in O +
combination O +
with O +
each O +
other O -
, O +
and O +
in O +
combination O +
with O +
mecamylamine B-Chemical +
and O +
dihydro B-Chemical -
- I-Chemical -
β I-Chemical -
- I-Chemical -
erythroidine I-Chemical +
( O -
DHβE B-Chemical -
) O -
. O +

Midazolam B-Chemical +
and O +
morphine B-Chemical +
were O +
tested O +
to O +
examine O +
sensitivity O +
to O +
non O -
- O -
nicotinics O -
. O +

RESULTS O -
: O +
The O +
ED50 O +
value O +
of O +
nicotine B-Chemical +
to O +
produce O +
discriminative O +
stimulus O +
effects O +
systematically O +
increased O +
as O +
training O +
dose O +
increased O -
. O +

Varenicline B-Chemical +
and O +
cytisine B-Chemical +
did O +
not O +
fully O +
substitute O +
for O +
nicotine B-Chemical +
and O -
, O +
as O +
compared O +
with O +
nicotine B-Chemical -
, O +
their O +
ED50 O +
values O +
varied O +
less O +
systematically O +
as O +
a O +
function O +
of O +
nicotine B-Chemical +
training O +
dose O -
. O +

Morphine B-Chemical +
did O +
not O +
substitute O +
for O +
nicotine B-Chemical -
, O +
whereas O +
midazolam B-Chemical +
substituted O +
for O +
the O +
low O +
and O +
not O +
the O +
higher O +
training O +
doses O +
of O +
nicotine B-Chemical -
. O +

As O +
training O +
dose O +
increased O -
, O +
the O +
dose O +
of O +
mecamylamine B-Chemical +
needed O +
to O +
produce O +
a O +
significant O +
rightward O +
shift O +
in O +
the O +
nicotine O +
dose O -
- O -
effect O +
function O +
also O +
increased O -
. O +

DHβE B-Chemical +
antagonized O +
nicotine B-Chemical +
in O +
animals O +
discriminating O +
the O +
smallest O +
dose O +
of O +
nicotine B-Chemical -
. O +

Varenicline B-Chemical +
did O +
not O +
antagonize O +
the O +
effects O +
of O +
nicotine B-Chemical -
, O +
whereas O +
cytisine B-Chemical +
produced O +
a O +
modest O +
though O +
significant O +
antagonism O +
of O +
nicotine B-Chemical -
. O +

CONCLUSIONS O -
: O +
These O +
results O +
suggest O +
that O +
differences O +
in O +
pharmacologic O +
mechanism O +
between O +
nicotine B-Chemical -
, O +
varenicline B-Chemical -
, O +
and O +
cytisine B-Chemical +
include O +
not O +
only O +
differences O +
in O +
efficacy O +
at O +
a O +
common O +
subtype O +
of O +
nicotinic O +
acetylcholine B-Chemical +
receptor O -
, O +
but O +
also O +
differential O +
affinity O +
and/or O +
efficacy O +
at O +
multiple O +
receptor O +
subtypes O -
. O +

Reinforcement O +
enhancing O +
effects O +
of O +
nicotine B-Chemical +
via O +
smoking O -
. O +

RATIONALE O -
: O +
In O +
animals O -
, O +
nicotine B-Chemical +
enhances O +
reinforcement O +
from O +
stimuli O +
unrelated O +
to O +
nicotine B-Chemical +
intake O -
. O +

Human O +
research O +
is O +
suggestive O +
but O +
has O +
not O +
clearly O +
shown O +
a O +
similar O +
influence O +
of O +
nicotine B-Chemical -
. O +

OBJECTIVES O -
: O +
We O +
assessed O +
acute O +
effects O +
of O +
nicotine B-Chemical +
via O +
smoking O +
on O +
enhancement O +
of O +
positive O +
( O -
money O -
, O +
music O -
) O +
or O +
negative O +
( O -
termination O +
of O +
noise O -
) O +
reinforcers O -
, O +
or O +
no O +
" O -
reward O -
" O +
( O -
control O -
) O -
. O +

These O +
different O +
rewards O +
determined O +
the O +
generalizability O +
of O +
nicotine B-Chemical +
effects O -
. O +

MATERIALS O +
AND O +
METHODS O -
: O +
Dependent O +
( O -
n O +
= O +
25 O -
) O +
and O +
nondependent O +
( O -
n O +
= O +
27 O -
) O +
smokers O +
participated O +
in O +
three O +
sessions O -
, O +
each O +
after O +
overnight O +
abstinence O -
. O +

Using O +
a O +
within O -
- O -
subjects O +
design O -
, O +
sessions O +
involved O +
no O +
smoking O +
or O +
smoking O +
denicotinized O +
( O -
0.05 O +
mg O -
) O +
or O +
nicotine B-Chemical +
( O -
0.6 O +
mg O -
) O +
Quest O -
( O -
R O -
) O +
brand O +
cigarettes O -
. O +

For O +
comparison O -
, O +
a O +
fourth O +
session O +
involved O +
no O +
abstinence O +
prior O +
to O +
smoking O +
one O -
's O +
own O +
brand O +
to O +
gauge O +
responses O +
under O +
typical O +
nicotine B-Chemical +
satiation O -
. O +

Reinforcement O +
was O +
assessed O +
by O +
responses O +
on O +
a O +
simple O +
operant O +
computer O +
task O +
for O +
the O +
rewards O -
, O +
each O +
available O +
singly O +
on O +
a O +
progressive O +
ratio O +
schedule O +
during O +
separate O +
trials O -
. O +

RESULTS O -
: O +
The O +
reinforcing O +
effect O +
of O +
music O -
, O +
but O +
not O +
other O +
rewards O -
, O +
was O +
greater O +
due O +
to O +
the O +
nicotine B-Chemical +
cigarette O -
, O +
compared O +
to O +
the O +
denicotinized O +
cigarette O +
or O +
no O +
smoking O -
. O +

Reinforcement O +
enhancing O +
effects O +
of O +
nicotine B-Chemical +
did O +
not O +
differ O +
between O +
dependent O +
and O +
nondependent O +
groups O -
, O +
indicating O +
no O +
influence O +
of O +
withdrawal O +
relief O -
. O +

Responding O +
due O +
to O +
acute O +
nicotine B-Chemical +
after O +
abstinence O +
was O +
very O +
similar O +
to O +
responding O +
to O +
one O -
's O +
own O +
brand O +
after O +
no O +
abstinence O -
. O +

CONCLUSIONS O -
: O +
Acute O +
nicotine B-Chemical +
intake O +
per O +
se O +
from O +
smoking O +
after O +
abstinence O +
enhances O +
the O +
reinforcing O +
value O +
of O +
rewards O +
unassociated O +
with O +
smoking O -
, O +
perhaps O +
in O +
a O +
manner O +
comparable O +
to O +
ad O +
lib O +
smoking O +
after O +
no O +
abstinence O -
. O +

Nicotine B-Chemical -
's O +
reinforcement O +
enhancing O +
effects O +
may O +
be O +
specific O +
to O +
certain O +
rewards O -
, O +
perhaps O +
those O +
sensory O +
in O +
nature O -
. O +

P2X O +
and O +
P2Y O +
nucleotide B-Chemical +
receptors O +
as O +
targets O +
in O +
cardiovascular O +
disease O -
. O +

Endogenous O +
nucleotides B-Chemical +
have O +
widespread O +
actions O +
in O +
the O +
cardiovascular O +
system O -
, O +
but O +
it O +
is O +
only O +
recently O +
that O +
the O +
P2X O +
and O +
P2Y O +
receptor O +
subtypes O -
, O +
at O +
which O +
they O +
act O -
, O +
have O +
been O +
identified O +
and O +
subtype O -
- O -
selective O +
agonists O +
and O +
antagonists O +
developed O -
. O +

These O +
advances O +
have O +
greatly O +
increased O +
our O +
understanding O +
of O +
the O +
physiological O +
and O +
pathophysiological O +
functions O +
of O +
P2X O +
and O +
P2Y O +
receptors O -
, O +
but O +
investigation O +
of O +
the O +
clinical O +
usefulness O +
of O +
selective O +
ligands O +
is O +
at O +
an O +
early O +
stage O -
. O +

Nonetheless O -
, O +
the O +
evidence O +
considered O +
in O +
this O +
review O +
demonstrates O +
clearly O +
that O +
various O +
cardiovascular O +
disorders O -
, O +
including O +
vasospasm O -
, O +
hypertension O -
, O +
congestive O +
heart O +
failure O +
and O +
cardiac O +
damage O +
during O +
ischemic O +
episodes O -
, O +
may O +
be O +
viable O +
targets O -
. O +

With O +
further O +
development O +
of O +
novel O -
, O +
selective O +
agonists O +
and O +
antagonists O -
, O +
our O +
understanding O +
will O +
continue O +
to O +
improve O +
and O +
further O +
therapeutic O +
applications O +
are O +
likely O +
to O +
be O +
discovered O -
. O +

Therapeutic O +
applications O +
of O +
PI3 O -
K O +
inhibitors O +
in O +
cardiovascular O +
diseases O -
. O +

PI3Ks O +
are O +
signaling O +
enzymes O +
engaged O +
by O +
different O +
types O +
of O +
membrane O +
receptors O +
and O +
activated O +
in O +
cardiovascular O +
diseases O +
such O +
as O +
hypertension O -
, O +
atherosclerosis O -
, O +
thrombosis O +
and O +
heart O +
failure O -
. O +

Studies O +
performed O +
on O +
genetically O +
modified O +
animals O +
have O +
provided O +
proof O -
- O -
of O -
- O -
concept O +
that O +
general O +
or O +
isoform O -
- O -
specific O +
blockade O +
of O +
these O +
enzymes O +
can O +
modify O +
disease O +
development O +
and O +
progression O -
. O +

Hence O -
, O +
therapeutic O +
inhibition O +
of O +
PI3Ks O +
with O +
novel O +
pharmacological O +
compounds O +
constitutes O +
a O +
promising O +
area O +
of O +
drug O +
development O -
. O +

In O +
particular O -
, O +
inhibitors O +
of O +
PI3Ks O +
have O +
the O +
potential O +
to O +
reduce O +
blood O +
pressure O -
, O +
restrain O +
the O +
development O +
of O +
atherosclerosis O +
and/or O +
stabilize O +
atherosclerotic O +
plaques O -
, O +
blunt O +
platelet O +
aggregation O -
, O +
prevent O +
left O +
ventricular O +
remodeling O +
and O +
preserve O +
myocardial O +
contractility O +
in O +
heart O +
failure O -
. O +

This O +
review O +
summarizes O +
the O +
rationale O +
of O +
PI3 O -
K O +
inhibition O +
in O +
the O +
most O +
prevalent O +
cardiovascular O +
diseases O -
, O +
and O +
the O +
available O +
data O +
on O +
the O +
therapeutic O +
effects O +
of O +
PI3 O -
K O +
inhibitors O +
in O +
their O +
preclinical O +
models O -
. O +

Implications O +
for O +
future O +
drug O +
development O +
and O +
human O +
therapy O +
are O +
also O +
discussed O -
. O +

Structural O +
Rearrangement O +
in O +
the O +
Formation O +
of O +
Jet O -
- O -
Cooled O +
Complexes O +
of O +
Chiral O +
( B-Chemical -
S I-Chemical -
) I-Chemical -
-1,2,3,4-Tetrahydro-3-isoquinolinemethanol I-Chemical +
with O +
Methyl B-Chemical +
Lactate I-Chemical -
: O +
Chirality O +
Effect O +
in O +
Conformer O +
Selection O -
. O +

The O +
jet O -
- O -
cooled O +
complexes O +
between O +
the O +
two O +
enantiomers O +
of O +
methyl B-Chemical +
lactate I-Chemical +
( O -
ML O -
) O +
and O +
( B-Chemical -
S I-Chemical -
) I-Chemical -
-1,2,3,4-tetrahydro-3-isoquinolinemethanol I-Chemical +
( O -
THIQM B-Chemical -
) O +
are O +
studied O +
by O +
double O +
resonance O +
spectroscopy O +
combined O +
with O +
ab O +
initio O +
calculations O -
. O +

Both O +
diastereomer O +
complexes O +
exist O +
in O +
different O +
isomers O -
, O +
involving O +
either O +
direct O +
addition O +
of O +
THIQM B-Chemical +
on O +
ML O +
with O +
no O +
structural O +
rearrangement O +
of O +
the O +
subunits O +
or O +
formation O +
of O +
very O +
stable O +
structures O +
involving O +
multiple O +
intermolecular O +
hydrogen B-Chemical +
bonds O +
and O +
extensive O +
deformation O +
of O +
the O +
subunits O -
. O +

Competition O +
between O +
these O +
two O +
processes O +
and O +
its O +
dependence O +
upon O +
chirality O +
are O +
discussed O -
. O +

It O +
is O +
shown O +
that O +
the O +
most O +
stable O +
form O +
of O +
the O +
chromophore O +
( O -
THIQMI B-Chemical +
with O +
an O +
OH···N B-Chemical +
hydrogen B-Chemical +
bond O -
) O +
prefers O +
to O +
directly O +
stick O +
to O +
ML O +
to O +
form O +
the O +
addition O +
complex O +
whereas O +
the O +
second O +
conformer O +
( O -
THIQMII B-Chemical +
with O +
NH···O B-Chemical +
hydrogen B-Chemical +
bond O -
) O +
rearranges O +
to O +
form O +
a O +
strongly O +
bound O +
structure O -
. O +

The O +
two O +
structures O +
are O +
formed O +
for O +
the O +
homochiral O +
as O +
well O +
the O +
heterochiral O +
complex O -
, O +
however O +
with O +
different O +
relative O +
abundance O -
. O +

This O +
shows O +
an O +
enantioselective O +
binding O +
preference O +
of O +
ML O +
for O +
one O +
of O +
the O +
conformers O +
of O +
the O +
chromophore O -
. O +

Synthesis O -
, O +
preliminary O +
structure O -
- O -
activity O +
relationships O -
, O +
and O +
in O +
vitro O +
biological O +
evaluation O +
of O +
6-aryl-3-amino B-Chemical -
- I-Chemical -
thieno I-Chemical -
[ I-Chemical -
2,3-b I-Chemical -
] I-Chemical -
pyridine I-Chemical +
derivatives O +
as O +
potential O +
anti O -
- O -
inflammatory O +
agents O -
. O +

In O +
our O +
previous O +
study O -
, O +
a O +
series O +
of O +
6-aryl-3-amino B-Chemical -
- I-Chemical -
thieno I-Chemical -
[ I-Chemical -
2,3-b I-Chemical -
] I-Chemical -
pyridine I-Chemical +
derivatives O +
exhibited O +
potent O +
antiproliferative O +
activities O +
and O +
an O +
unique O +
hepatocellular O +
carcinoma O +
( O -
HCC O -
) O -
-specific O +
anticancer O +
activity O +
was O +
also O +
observed O -
. O +

In O +
further O +
anti O -
- O -
inflammatory O +
research O -
, O +
thienopyridine B-Chemical +
derivative O +
1a O +
showed O +
potent O +
inhibition O +
of O +
nitric B-Chemical +
oxide I-Chemical +
( O -
NO B-Chemical -
) O +
production O -
. O +

So O +
a O +
series O +
of O +
thienopyridine B-Chemical +
analogues O +
of O +
1a O +
were O +
synthesized O +
and O +
evaluated O +
for O +
anti O -
- O -
inflammatory O +
activities O -
. O +

The O +
structure O -
- O -
activity O +
relationships O +
( O -
SARs O -
) O +
revealed O +
that O +
the O +
most O +
potent O +
analogues O +
1f O +
and O +
1o O +
were O +
identified O +
as O +
potent O +
inhibitors O +
of O +
NO B-Chemical +
production O +
with O +
IC50 O +
values O +
of O +
3.30 O +
and O +
3.24 O +
μM O -
, O +
respectively O -
. O +

These O +
results O +
suggest O +
that O +
these O +
6-aryl-3-amino B-Chemical -
- I-Chemical -
thieno I-Chemical -
[ I-Chemical -
2,3-b I-Chemical -
] I-Chemical -
pyridine I-Chemical +
derivatives O +
might O +
potentially O +
constitute O +
a O +
novel O +
class O +
of O +
anti O -
- O -
inflammatory O +
agents O -
, O +
which O +
require O +
further O +
studies O -
. O +

Recombinant O +
proteins O +
that O +
trigger O +
production O +
of O +
antibodies O +
recognizing O +
botulinum O +
neurotoxin O +
while O +
not O +
possessing O +
sequences O +
of O +
this O +
toxin O -
. O +

Sequences O +
mimicking O +
epitopes O +
of O +
pathogens O +
can O +
be O +
used O +
as O +
effective O +
tools O +
for O +
fast O +
development O +
and O +
characterization O +
of O +
pathogen O -
- O -
specific O +
antibodies O -
. O +

To O +
demonstrate O +
this O -
, O +
we O +
used O +
phage O +
displays O +
and O +
isolated O +
a O +
number O +
of O +
short O +
peptides O +
mimicking O +
epitopes O +
of O +
botulinum O +
neurotoxin O +
serotype O +
A O +
( O -
BoNT O -
/ O -
A O -
) O -
. O +

Presented O +
data O +
suggest O +
that O +
some O +
of O +
these O +
peptides O +
mimic O +
linear O +
epitopes O +
while O +
others O +
mimic O +
structural O +
epitopes O +
of O +
BoNT O -
/ O -
A. O +
All O +
tested O +
peptides O +
retained O +
their O +
ability O +
to O +
be O +
recognized O +
by O +
BoNT O -
/ O -
A O -
- O -
specific O +
antibodies O +
even O +
when O +
transferred O +
into O +
new O +
carrier O +
proteins O -
. O +

We O +
demonstrated O +
how O +
such O +
new O +
hybrids O +
can O +
be O +
used O +
for O +
fast O +
conversion O +
of O +
pathogen O -
- O -
specific O +
serums O +
into O +
panels O +
of O +
mono O -
- O -
epitope O +
specific O +
antibodies O -
. O +

We O +
also O +
demonstrated O +
that O +
hybrid O +
proteins O +
carrying O +
multiple O +
isolated O +
peptides O +
can O +
be O +
used O +
as O +
a O +
substitute O +
for O +
BoNT O -
/ O -
A O +
in O +
immunization O +
studies O +
and O +
triggers O +
production O +
of O +
BoNT O -
/ O -
A O -
- O -
specific O +
antibodies O -
. O +

Synthesis O +
and O +
antifungal O +
activity O +
of O +
C-21 O +
steroids B-Chemical +
with O +
an O +
aromatic O +
D O +
ring O -
. O +

Six O +
analogues O +
of O +
salpichrolides B-Chemical +
with O +
a O +
simplified O +
side O +
chain O +
( O -
6 O -
- O -
11 O -
) O +
were O +
synthesized O +
using O +
a O +
new O +
methodology O +
to O +
obtain O +
steroids B-Chemical +
with O +
an O +
aromatic O +
D O -
- O -
ring O -
. O +

The O +
key O +
step O +
was O +
the O +
elimination O +
of O +
HBr B-Chemical +
in O +
a O +
vicinal B-Chemical +
dibromo I-Chemical +
D I-Chemical -
- I-Chemical -
homosteroid I-Chemical +
by O +
treatment O +
with O +
1,4-diazabicyclo B-Chemical -
[ I-Chemical -
2.2.2 I-Chemical -
] I-Chemical -
octane I-Chemical +
( O -
DABCO B-Chemical -
) O -
. O +

All O +
new O +
compounds O +
were O +
completely O +
characterized O +
by O +
2D O +
NMR O +
techniques O +
and O +
tested O +
on O +
two O +
fungal O +
pathogenic O +
species O -
, O +
Fusarium O +
virguliforme O +
and O +
Fusarium O +
solani O -
. O +

DNA O +
barcoding O +
in O +
plants O -
: O +
Evolution O +
and O +
applications O +
of O +
in O +
silico O +
approaches O +
and O +
resources O -
. O +

Bioinformatics O +
has O +
played O +
an O +
important O +
role O +
in O +
the O +
analysis O +
of O +
DNA O +
barcoding O +
data O -
. O +

The O +
process O +
of O +
DNA O +
barcoding O +
initially O +
involves O +
the O +
available O +
data O +
collection O +
from O +
the O +
existing O +
databases O -
. O +

Many O +
databases O +
have O +
been O +
developed O +
in O +
recent O +
years O -
, O +
e.g. O +
MMDBD O +
[ O -
Medicinal O +
Materials O +
DNA O +
Barcode O +
Database O -
] O -
, O +
BioBarcode O -
, O +
etc O -
. O +

In O +
case O +
of O +
non O -
- O -
availability O +
of O +
sequences O -
, O +
sequencing O +
has O +
to O +
be O +
done O +
in O +
vitro O +
for O +
which O +
a O +
recently O +
developed O +
software O +
ecoPrimers O +
can O +
be O +
helpful O -
. O +

This O +
is O +
followed O +
by O +
multiple O +
sequence O +
alignment O -
. O +

Further O -
, O +
basic O +
sequence O +
statistics O +
computation O +
and O +
phylogenetic O +
analysis O +
can O +
be O +
performed O +
by O +
MEGA O +
and O +
PHYLIP O -
/ O -
PAUP O +
tools O +
respectively O -
. O +

Some O +
of O +
the O +
recent O +
tools O +
for O +
in O +
silico O +
and O +
statistical O +
analysis O +
specifically O +
designed O +
for O +
barcoding O +
viz O -
. O +

CAOS O +
( O -
Character O +
Based O +
DNA O +
Barcoding O -
) O -
, O +
BRONX O +
( O -
DNA O +
Barcode O +
Sequence O +
Identification O +
Incorporating O +
Taxonomic O +
Hierarchy O +
and O +
within O +
Taxon O +
Variability O -
) O -
, O +
Spider O +
( O -
Analysis O +
of O +
species O +
identity O +
and O +
evolution O -
, O +
particularly O +
DNA O +
barcoding O -
) O -
, O +
jMOTU O +
and O +
Taxonerator O +
( O -
Turning O +
DNA O +
Barcode O +
Sequences O +
into O +
Annotated O +
OTUs O -
) O -
, O +
OTUbase O +
( O -
Analysis O +
of O +
OTU O +
data O +
and O +
taxonomic O +
data O -
) O -
, O +
SAP O +
( O -
Statistical O +
Assignment O +
Package O -
) O -
, O +
etc O -
. O +
have O +
been O +
discussed O +
and O +
analysed O +
in O +
this O +
review O -
. O +

The O +
paper O +
presents O +
a O +
comprehensive O +
overview O +
of O +
the O +
various O +
in O +
silico O +
methods O -
, O +
tools O -
, O +
softwares O +
and O +
databases O +
used O +
for O +
DNA O +
barcoding O +
of O +
plants O -
. O +

Structural O +
Basis O +
for O +
the O +
ATP B-Chemical -
- O -
Induced O +
Isomerization O +
of O +
Kinesin O -
. O +

Kinesin O +
superfamily O +
proteins O +
( O -
KIFs O -
) O +
are O +
microtubule O -
- O -
based O +
molecular O +
motors O +
driven O +
by O +
the O +
energy O +
derived O +
from O +
the O +
hydrolysis O +
of O +
ATP B-Chemical -
. O +

Previous O +
studies O +
have O +
revealed O +
that O +
the O +
ATP B-Chemical +
binding O +
step O +
is O +
crucial O +
both O +
for O +
the O +
power O +
stroke O +
to O +
produce O +
motility O +
and O +
for O +
the O +
inter O -
- O -
domain O +
regulation O +
of O +
ATPase O +
activity O +
to O +
guarantee O +
the O +
processive O +
movement O +
of O +
dimeric O +
KIFs O -
. O +

Here O -
, O +
we O +
report O +
the O +
first O +
crystal O +
structure O +
of O +
KIF4 O +
complexed O +
with O +
the O +
non O -
- O -
hydrolyzable O +
ATP B-Chemical +
analog O -
, O +
AMPPNP B-Chemical +
( O -
adenylyl B-Chemical +
imidodiphosphate I-Chemical -
) O -
, O +
at O +
1.7Å O +
resolution O -
. O +

By O +
combining O +
our O +
structure O +
with O +
previously O +
solved O +
KIF1A O +
structures O +
complexed O +
with O +
two O +
ATP B-Chemical +
analogs O -
, O +
molecular O +
snapshots O +
during O +
ATP B-Chemical +
binding O +
reveal O +
that O +
the O +
closure O +
of O +
the O +
nucleotide B-Chemical -
- O -
binding O +
pocket O +
during O +
ATP B-Chemical +
binding O +
is O +
achieved O +
by O +
closure O +
of O +
the O +
backdoor O -
. O +

Closure O +
of O +
the O +
backdoor O +
stabilizes O +
two O +
mobile O +
regions O -
, O +
switch O +
I O +
and O +
switch O +
II O -
, O +
to O +
generate O +
the O +
phosphate B-Chemical +
tube O +
from O +
which O +
hydrolyzed O +
phosphate B-Chemical +
is O +
released O -
. O +

Through O +
the O +
stabilization O +
of O +
switch O +
II O -
, O +
the O +
local O +
conformational O +
change O +
at O +
the O +
catalytic O +
center O +
is O +
further O +
relayed O +
to O +
the O +
neck O -
- O -
linker O +
element O +
that O +
fully O +
docks O +
to O +
the O +
catalytic O +
core O +
to O +
produce O +
the O +
power O +
stroke O -
. O +

Because O +
the O +
neck O +
linker O +
is O +
a O +
sole O +
element O +
that O +
connects O +
the O +
partner O +
heads O +
in O +
dimeric O +
KIFs O -
, O +
this O +
tight O +
structural O +
coordination O +
between O +
the O +
catalytic O +
center O +
and O +
neck O +
linker O +
enables O +
inter O -
- O -
domain O +
communication O +
between O +
the O +
partner O +
heads O -
. O +

This O +
study O +
also O +
revealed O +
the O +
putative O +
microtubule O -
- O -
binding O +
site O +
of O +
KIF4 O -
, O +
thus O +
providing O +
structural O +
insights O +
that O +
describe O +
the O +
specific O +
binding O +
of O +
KIF4 O +
to O +
the O +
microtubule O -
. O +

A O +
Two O -
- O -
State O +
Cooperative O +
Expansion O +
Converts O +
the O +
Procapsid O +
Shell O +
of O +
Bacteriophage O +
T5 O +
into O +
a O +
Highly O +
Stable O +
Capsid O +
Isomorphous O +
to O +
the O +
Final O +
Virion O +
Head O -
. O +

Capsids O +
of O +
double O -
- O -
stranded O +
DNA O +
( O -
dsDNA O -
) O +
bacteriophages O +
initially O +
assemble O +
into O +
compact O +
procapsids O -
, O +
which O +
undergo O +
expansion O +
upon O +
the O +
genome O +
packaging O -
. O +

This O +
shell O +
remodeling O +
results O +
from O +
a O +
structural O +
rearrangement O +
of O +
head O +
protein O +
subunits O -
. O +

It O +
is O +
a O +
critical O +
step O +
in O +
the O +
capsid O +
maturation O +
pathway O +
that O +
yields O +
final O +
particles O +
capable O +
to O +
withstand O +
the O +
huge O +
internal O +
pressure O +
generated O +
by O +
the O +
packed O +
DNA O -
. O +

Here O -
, O +
we O +
report O +
on O +
the O +
expansion O +
process O +
of O +
the O +
large O +
capsid O +
( O -
T=13 O -
) O +
of O +
bacteriophage O +
T5 O -
. O +

We O +
purified O +
the O +
intermediate O +
prohead O +
II O +
form O -
, O +
which O +
is O +
competent O +
for O +
packaging O +
the O +
121-kbp O +
dsDNA O +
genome O -
, O +
and O +
we O +
investigated O +
its O +
morphology O +
and O +
dimensions O +
using O +
cryo O -
- O -
electron O +
microscopy O +
and O +
small O -
- O -
angle O +
X O -
- O -
ray O +
scattering O -
. O +

Decreasing O +
the O +
pH O +
or O +
the O +
ionic O +
strength O +
triggers O +
expansion O +
of O +
prohead O +
II O -
, O +
converting O +
them O +
into O +
thinner O +
and O +
more O +
faceted O +
capsids O +
isomorphous O +
to O +
the O +
mature O +
virion O +
particles O -
. O +

At O +
low O +
pH O -
, O +
prohead O +
II O +
expansion O +
is O +
a O +
highly O +
cooperative O +
process O +
lacking O +
any O +
detectable O +
intermediate O -
. O +

This O +
two O -
- O -
state O +
reorganization O +
of O +
the O +
capsid O +
lattice O +
per O +
se O +
leads O +
to O +
a O +
remarkable O +
stabilization O +
of O +
the O +
particle O -
. O +

The O +
melting O +
temperature O +
of O +
expanded O +
T5 O +
capsid O +
is O +
virtually O +
identical O +
with O +
that O +
of O +
more O +
complex O +
shells O +
that O +
are O +
reinforced O +
by O +
inter O -
- O -
subunit O +
cross O -
- O -
linking O +
( O -
HK97 O -
) O +
or O +
by O +
additional O +
cementing O +
proteins O +
( O -
T4 O -
) O -
. O +

The O +
T5 O +
capsid O +
with O +
its O +
" O -
simple O -
" O +
two O -
- O -
state O +
conversion O +
thus O +
appears O +
to O +
be O +
a O +
very O +
attractive O +
model O +
for O +
investigating O +
the O +
mechanism O +
of O +
the O +
large O -
- O -
scale O +
allosteric O +
transition O +
that O +
takes O +
place O +
upon O +
the O +
genome O +
packaging O +
of O +
dsDNA O +
bacteriophages O -
. O +

Sorting O +
out O +
Semiconducting O +
Single O -
- O -
Walled O +
Carbon B-Chemical +
Nanotube O +
Arrays O +
by O +
Washing O +
off O +
Metallic O +
Tubes O +
Using O +
SDS B-Chemical +
Aqueous O +
Solution O -
. O +

Semiconducting O +
single O -
- O -
walled O +
carbon B-Chemical +
nanotube O +
( O -
s O -
- O -
SWNT O -
) O +
arrays O +
are O +
produced O +
via O +
a O +
procedure O +
analogous O +
to O +
a O +
surfactant O -
- O -
assisted O +
decontamination O +
process O -
. O +

Aligned O +
individual O +
SWNT O +
arrays O +
grow O +
on O +
a O +
quartz B-Chemical +
surface O +
as O +
a O +
mixture O +
of O +
metallic O +
SWNTs O +
( O -
m O -
- O -
SWNTs O -
) O +
and O +
s O -
- O -
SWNTs O -
. O +

They O +
are O +
immersed O +
in O +
a O +
sodium B-Chemical +
dodecyl I-Chemical +
sulfate I-Chemical +
( O -
SDS B-Chemical -
) O +
solution O -
, O +
and O +
the O +
SDS B-Chemical +
molecules O +
selectively O +
adsorb O +
onto O +
m O -
- O -
SWNTs O -
. O +

This O +
SDS B-Chemical +
coating O +
minimizes O +
the O +
interaction O +
between O +
m O -
- O -
SWNTs O +
and O +
the O +
substrate O -
, O +
thus O +
the O +
m O -
- O -
SWNTs O +
are O +
easily O +
washed O +
off O +
during O +
ultrasonication O +
while O +
the O +
s O -
- O -
SWNT O +
arrays O +
remain O +
on O +
the O +
substrate O -
. O +

The O +
percentage O +
of O +
s O -
- O -
SWNTs O +
in O +
the O +
arrays O +
can O +
be O +
higher O +
than O +
90 O -
% O -
. O +

Electrochemical O +
Oxygen B-Chemical +
Reduction O +
Behavior O +
of O +
Selectively O +
Deposited O +
Platinum B-Chemical +
Atoms O +
on O +
Gold O +
Nanoparticles O -
. O +

Carbon B-Chemical -
- O -
supported O +
Pt@Au B-Chemical +
" O -
core O -
- O -
shell O -
" O +
nanoparticles O +
with O +
varying O +
surface O +
concentration O +
of O +
platinum B-Chemical +
atoms O +
have O +
been O +
synthesized O +
using O +
a O +
novel O +
redox O -
- O -
mediated O +
synthesis O +
approach O -
. O +

The O +
synthesis O +
technique O +
allows O +
for O +
a O +
selective O +
deposition O +
of O +
platinum B-Chemical +
atoms O +
on O +
the O +
surface O +
of O +
prefabricated O +
gold O +
nanoparticles O -
. O +

Energy O +
dispersive O +
spectroscopic O +
analyses O +
in O +
a O +
scanning O +
electron O +
microscope O +
reveal O +
that O +
the O +
platinum B-Chemical +
to O +
gold O +
atomic O +
ratios O +
are O +
close O +
to O +
the O +
nominal O +
values O -
, O +
validating O +
the O +
synthesis O +
scheme O -
. O +

X O -
- O -
ray O +
diffraction O +
data O +
indicate O +
an O +
un O -
- O -
alloyed O +
structure O -
. O +

The O +
platinum B-Chemical +
to O +
gold O +
surface O +
atomic O +
ratio O +
determined O +
from O +
cyclic O +
voltammetry O +
and O +
copper B-Chemical +
under O -
- O -
potential O +
deposition O +
experiments O +
reveal O +
good O +
agreement O +
with O +
the O +
calculated O +
values O +
at O +
low O +
platinum B-Chemical +
concentration O -
. O +

However O -
, O +
there O +
is O +
an O +
increase O +
in O +
non O -
- O -
uniformity O +
in O +
the O +
deposition O +
process O +
upon O +
increasing O +
the O +
platinum B-Chemical +
concentration O -
. O +

Koutecky O -
- O -
Levich O +
analysis O +
of O +
the O +
samples O +
indicates O +
a O +
transition O +
of O +
the O +
total O +
number O +
of O +
electrons O +
transferred O +
( O -
n O -
) O +
in O +
the O +
electrochemical O +
oxygen B-Chemical +
reduction O +
reaction O +
from O +
two O +
to O +
four O +
electrons O +
upon O +
increasing O +
the O +
surface O +
concentration O +
of O +
platinum B-Chemical +
atoms O -
. O +

Furthermore O -
, O +
the O +
data O +
indicate O +
that O +
isolated O +
platinum B-Chemical +
atoms O +
can O +
reduce O +
molecular O +
oxygen B-Chemical +
but O +
via O +
a O +
two O -
- O -
electron O +
route O -
. O +

Moreover O -
, O +
successful O +
four O -
- O -
electron O +
reduction O +
of O +
molecular O +
oxygen B-Chemical +
requires O +
clusters O +
of O +
platinum B-Chemical +
atoms O -
. O +

Synthesis O +
of O +
phenyleneethynylene B-Chemical -
- O -
doped O +
poly B-Chemical -
( I-Chemical -
pphenylenebutadiynylene I-Chemical -
) I-Chemical +
s I-Chemical +
for O +
live O +
cell O +
imaging O -
. O +

We O +
developed O +
a O +
new O +
synthetic O +
approach O +
to O +
high O +
molecular O +
weight O +
poly B-Chemical -
( I-Chemical -
p I-Chemical -
- I-Chemical -
phenylenebutadiynylene I-Chemical -
) I-Chemical +
s I-Chemical +
( O -
PPBs B-Chemical -
) O +
by O +
increasing O +
backbone O +
flexibility O -
. O +

The O +
introduction O +
of O +
a O +
small O +
amount O +
of O +
flexible O +
units O +
along O +
the O +
backbone O +
improved O +
both O +
the O +
physical O +
and O +
photophysical O +
properties O +
of O +
the O +
polymers O -
. O +

These O +
materials O +
were O +
successfully O +
fabricated O +
into O +
conjugated O +
polymer O +
nanoparticles O +
( O -
CPNs O -
) O +
and O +
used O +
for O +
fluorescent O +
live O +
cell O +
imaging O +
for O +
the O +
first O +
time O -
. O +

Transition O +
to O +
Reinforced O +
State O +
by O +
Percolating O +
Domains O +
of O +
Intercalated O +
Brush O -
- O -
Modified O +
Cellulose O +
Nanocrystals O +
and O +
Poly B-Chemical -
( I-Chemical -
butadiene I-Chemical -
) I-Chemical +
in O +
Cross O -
- O -
Linked O +
Composites O +
Based O +
on O +
Thiol B-Chemical -
- I-Chemical -
ene I-Chemical +
Click O +
Chemistry O -
. O +

The O +
classic O +
nanocomposite O +
approach O +
aims O +
at O +
percolation O +
of O +
low O +
fraction O +
of O +
exfoliated O +
individual O +
reinforcing O +
nanoscale O +
elements O +
within O +
a O +
polymeric O +
matrix O -
. O +

By O +
contrast O -
, O +
many O +
of O +
the O +
mechanically O +
excellent O +
biological O +
nanocomposites O +
involve O +
self O -
- O -
assembled O +
and O +
space O -
- O -
filled O +
structures O +
of O +
hard O +
reinforcing O +
and O +
soft O +
toughening O +
domains O -
, O +
with O +
high O +
weight O +
fraction O +
of O +
reinforcements O -
. O +

Here O +
we O +
inspect O +
a O +
new O +
concept O +
toward O +
mimicking O +
such O +
structures O +
by O +
studying O +
whether O +
percolation O +
of O +
intercalated O +
domains O +
consisting O +
of O +
alternating O +
rigid O +
and O +
reinforcing O -
, O +
and O +
soft O +
rubbery O +
domains O +
could O +
allow O +
a O +
transition O +
to O +
a O +
reinforced O +
state O -
. O +

Toward O +
that O -
, O +
we O +
present O +
the O +
functionalization O +
of O +
rigid O +
native O +
cellulose O +
nanocrystals O +
( O -
CNCs O -
) O +
by O +
esterification O +
with O +
a O +
dense O +
hydrocarbon B-Chemical +
chain O +
brush O +
containing O +
cross O -
- O -
linkable O +
double O +
bonds O -
. O +

Composite O +
films O +
with O +
0 O -
- O -
80 O +
wt O +
% O +
of O +
such O +
modified O +
CNCs O +
( O -
mCNCs O -
) O +
within O +
a O +
poly B-Chemical -
( I-Chemical -
butadiene I-Chemical -
) I-Chemical +
( O -
PBD B-Chemical -
) O +
rubber O +
matrix O +
were O +
prepared O +
via O +
cross O -
- O -
linking O +
by O +
UV O -
- O -
light O +
initiated O +
thiol B-Chemical -
- I-Chemical -
ene I-Chemical +
click O +
reaction O -
. O +

Transmission O +
electron O +
microscopy O +
showed O +
structures O +
at O +
two O +
length O +
scales O -
, O +
where O +
the O +
mCNCs O +
and O +
PBD B-Chemical +
form O +
domains O +
having O +
internal O +
aligned O +
self O -
- O -
assemblies O +
of O +
alternating O +
hard O +
mCNCs O +
and O +
soft O +
PBD B-Chemical +
with O +
periodicity O +
of O +
ca O -
. O +

40 O +
nm O -
, O +
and O +
where O +
additional O +
PBD B-Chemical +
connects O +
such O +
domains O -
. O +

Increasing O +
the O +
weight O +
fraction O +
of O +
mCNCs O +
causes O +
an O +
uncommon O +
abrupt O +
transition O +
from O +
PBD B-Chemical -
- O -
dominated O +
soft O +
materials O +
to O +
significantly O +
reinforced O +
mCNC O -
- O -
dominated O +
mechanical O +
properties O -
, O +
suggesting O +
that O +
the O +
intercalated O +
self O -
- O -
assembled O +
mCNC O -
/ O -
PBD B-Chemical +
domains O +
percolate O +
in O +
PBD B-Chemical +
upon O +
passing O +
30 O -
- O -
35 O +
wt O +
% O +
of O +
mCNCs O -
. O +

Maximum O +
stress O +
of O +
16 O +
MPa O +
at O +
mCNC O +
fraction O +
of O +
80 O +
wt O +
% O +
was O +
obtained O -
. O +

The O +
mechanical O +
properties O +
of O +
the O +
composites O +
show O +
exceptional O +
insensitivity O +
to O +
air O +
humidity O -
. O +

The O +
shown O +
simple O +
concept O +
of O +
percolative O +
intercalated O +
nanocomposites O +
suggests O +
searching O +
for O +
more O +
general O +
biomimetic O +
compositions O +
involving O +
several O +
deformation O +
mechanisms O +
for O +
improved O +
mechanical O +
properties O -
. O +

Paths O +
to O +
selection O +
on O +
life O +
history O +
loci O +
in O +
different O +
natural O +
environments O +
across O +
the O +
native O +
range O +
of O +
Arabidopsis O +
thaliana O -
. O +

Selection O +
on O +
quantitative O +
trait O +
loci O +
( O -
QTL O -
) O +
may O +
vary O +
among O +
natural O +
environments O +
due O +
to O +
differences O +
in O +
the O +
genetic O +
architecture O +
of O +
traits O -
, O +
environment O -
- O -
specific O +
allelic O +
effects O +
or O +
changes O +
in O +
the O +
direction O +
and O +
magnitude O +
of O +
selection O +
on O +
specific O +
traits O -
. O +

To O +
dissect O +
the O +
environmental O +
differences O +
in O +
selection O +
on O +
life O +
history O +
QTL O +
across O +
climatic O +
regions O -
, O +
we O +
grew O +
a O +
panel O +
of O +
interconnected O +
recombinant O +
inbred O +
lines O +
( O -
RILs O -
) O +
of O +
Arabidopsis O +
thaliana O +
in O +
four O +
field O +
sites O +
across O +
its O +
native O +
European O +
range O -
. O +

For O +
each O +
environment O -
, O +
we O +
mapped O +
QTL O +
for O +
growth O -
, O +
reproductive O +
timing O +
and O +
development O -
. O +

Several O +
QTL O +
were O +
pleiotropic O +
across O +
environments O -
, O +
three O +
colocalizing O +
with O +
known O +
functional O +
polymorphisms O +
in O +
flowering O +
time O +
genes O +
( O -
CRY2 O -
, O +
FRI O +
and O +
MAF2 O -
- O -
5 O -
) O -
, O +
but O +
major O +
QTL O +
differed O +
across O +
field O +
sites O -
, O +
showing O +
conditional O +
neutrality O -
. O +

We O +
used O +
structural O +
equation O +
models O +
to O +
trace O +
selection O +
paths O +
from O +
QTL O +
to O +
lifetime O +
fitness O +
in O +
each O +
environment O -
. O +

Only O +
three O +
QTL O +
directly O +
affected O +
fruit O +
number O -
, O +
measuring O +
fitness O -
. O +

Most O +
QTL O +
had O +
an O +
indirect O +
effect O +
on O +
fitness O +
through O +
their O +
effect O +
on O +
bolting O +
time O +
or O +
leaf O +
length O -
. O +

Influence O +
of O +
life O +
history O +
traits O +
on O +
fitness O +
differed O +
dramatically O +
across O +
sites O -
, O +
resulting O +
in O +
different O +
patterns O +
of O +
selection O +
on O +
reproductive O +
timing O +
and O +
underlying O +
QTL O -
. O +

In O +
two O +
oceanic O +
field O +
sites O +
with O +
high O +
prereproductive O +
mortality O -
, O +
QTL O +
alleles O +
contributing O +
to O +
early O +
reproduction O +
resulted O +
in O +
greater O +
fruit O +
production O -
, O +
conferring O +
selective O +
advantage O -
, O +
whereas O +
alleles O +
contributing O +
to O +
later O +
reproduction O +
resulted O +
in O +
larger O +
size O +
and O +
higher O +
fitness O +
in O +
a O +
continental O +
site O -
. O +

This O +
demonstrates O +
how O +
environmental O +
variation O +
leads O +
to O +
change O +
in O +
both O +
QTL O +
effect O +
sizes O +
and O +
direction O +
of O +
selection O +
on O +
traits O -
, O +
justifying O +
the O +
persistence O +
of O +
allelic O +
polymorphism O +
at O +
life O +
history O +
QTL O +
across O +
the O +
species O +
range O -
. O +

Binding O +
Specificity O +
and O +
Thermodynamics O +
of O +
Cellulose O -
- O -
Binding O +
Modules O +
from O +
Trichoderma O +
reesei O +
Cel7A O +
and O +
Cel6A O -
. O +

In O +
this O +
work O -
, O +
Family O +
1 O +
cellulose O +
binding O +
modules O +
CBMCel7A O +
and O +
CBMCel6A O +
were O +
heterologously O +
expressed O +
and O +
purified O +
from O +
Escherichia O +
coli O +
, O +
and O +
the O +
binding O +
properties O +
between O +
these O +
CBMs O +
and O +
cellulose O +
substrates O +
were O +
studied O -
. O +

Cellulose O +
nanowhiskers O +
( O -
CNWs O -
, O +
the O +
crystalline O +
portion O +
of O +
cellulose O -
) O -
, O +
microcrystalline O +
cellulose O +
Avicel O +
PH101 O +
( O -
partially O +
crystalline O +
cellulose O -
) O -
, O +
and O +
phosphoric B-Chemical +
acid I-Chemical +
swollen O +
cellulose O +
( O -
PASC O -
, O +
amorphous O +
cellulose O -
) O +
were O +
used O +
as O +
representative O +
models O +
for O +
cellulose O +
to O +
better O +
understand O +
the O +
binding O +
interactions O +
between O +
the O +
CBMs O +
and O +
different O +
regions O +
of O +
native O +
cellulose O -
. O +

Isothermal O +
titration O +
calorimetry O +
( O -
ITC O -
) O +
was O +
combined O +
with O +
adsorption O -
- O -
isotherm O +
experiment O +
to O +
analyze O +
the O +
thermodynamics O +
of O +
CBM O +
binding O +
to O +
various O +
cellulose O +
substrates O -
. O +

N2 B-Chemical +
adsorption O +
and O +
static O +
light O +
scattering O +
( O -
SLS O -
) O +
data O +
were O +
used O +
to O +
estimate O +
the O +
accessible O +
surface O +
area O +
of O +
cellulose O +
which O +
was O +
then O +
used O +
for O +
ITC O +
data O +
analysis O -
. O +

A O +
new O +
method O +
of O +
determining O +
the O +
cellulose O +
molarity O +
based O +
on O +
the O +
available O +
surface O +
area O +
for O +
CBM O +
binding O +
was O +
developed O -
, O +
which O +
allows O +
different O +
cellulose O +
substrates O +
to O +
be O +
compared O +
for O +
binding O +
experiments O -
. O +

The O +
ITC O +
results O +
showed O +
that O +
the O +
binding O +
constant O +
( O -
Ka O -
) O +
to O +
crystalline O +
CNWs O +
was O +
∼10 O -
( O -
5 O -
) O +
M O -
( O -
-1 O -
) O +
for O +
CBMCel7A O -
, O +
while O +
∼10 O -
( O -
6 O -
) O +
M O -
( O -
-1 O -
) O +
for O +
CBMCel6A O -
, O +
suggesting O +
a O +
higher O +
binding O +
affinity O +
of O +
CBMCel6A O +
to O +
CNWs O -
. O +

For O +
Avicel O -
, O +
lower O +
binding O +
constants O +
for O +
both O +
CBMs O +
were O +
observed O -
, O +
and O +
weak O +
bindings O +
to O +
PASC O +
were O +
characterized O -
, O +
suggesting O +
that O +
the O +
binding O +
between O +
CBMCel7A O -
, O -
Cel6A O +
and O +
cellulose O +
to O +
some O +
extent O +
relates O +
to O +
the O +
crystallinity O +
of O +
cellulose O -
. O +

Additionally O -
, O +
the O +
binding O +
reactions O +
were O +
driven O +
by O +
a O +
favorable O +
enthalpy O +
change O -
, O +
offset O +
partially O +
by O +
an O +
unfavorable O +
entropy O +
change O -
. O +

It O +
is O +
suggested O +
that O +
CBMCel6A O +
preferentially O +
binds O +
to O +
the O +
reducing O +
end O +
of O +
cellulose O +
chain O -
, O +
while O +
CBMCel7A O +
does O +
not O +
show O +
such O +
end O +
binding O +
specificities O -
. O +

Cello O -
- O -
oligosaccharides O +
less O +
than O +
two O +
glucose B-Chemical +
units O +
did O +
not O +
bind O +
with O +
CBMs O -
, O +
and O +
improved O +
binding O +
affinities O +
were O +
observed O +
for O +
cello O -
- O -
oligosaccharides O +
with O +
longer O +
glucose B-Chemical +
units O -
. O +

LC O -
- O -
MS O -
/ O -
MS O +
Determination O +
of O +
Isoprostanes B-Chemical +
in O +
Plasma O +
Samples O +
Collected O +
from O +
Mice O +
Exposed O +
to O +
Doxorubicin B-Chemical +
or O +
Tert B-Chemical -
- I-Chemical -
Butyl I-Chemical +
Hydroperoxide I-Chemical -
. O +

Isoprostanes B-Chemical +
are O +
stable O +
products O +
of O +
arachidonic B-Chemical +
acid I-Chemical +
peroxidation O +
and O +
are O +
regarded O +
as O +
the O +
most O +
reliable O +
markers O +
of O +
oxidative O +
stress O +
in O +
vivo O -
. O +

Here O +
we O +
describe O +
the O +
LC O -
- O -
MS O -
/ O -
MS O +
procedure O +
enabling O +
simultaneous O +
determination O +
of O +
four O +
regioisomers O +
( O -
8-iso B-Chemical +
prostaglandin I-Chemical +
F2α I-Chemical -
, O +
8-iso-15 B-Chemical -
( I-Chemical -
R I-Chemical -
) I-Chemical -
-prostaglandin I-Chemical +
F2α I-Chemical -
, O +
11β B-Chemical -
- I-Chemical -
prostaglandin I-Chemical +
F2α I-Chemical -
, O +
15 B-Chemical -
( I-Chemical -
R I-Chemical -
) I-Chemical -
-prostaglandin I-Chemical +
F2α I-Chemical -
) O +
in O +
plasma O +
samples O +
collected O +
from O +
mice O -
. O +

The O +
four O +
plasma O +
isoprostanes B-Chemical +
are O +
determined O +
by O +
LC O -
- O -
ESI O -
- O -
MS O -
/ O -
MS O +
with O +
deuterated O +
8-iso B-Chemical -
- I-Chemical -
PGF2α I-Chemical -
- I-Chemical -
d4 I-Chemical +
as O +
an O +
internal O +
standard O +
( O -
I.S. O -
) O -
. O +

For O +
plasma O +
samples O +
spiked O +
with O +
the O +
isoprostanes B-Chemical +
at O +
a O +
level O +
of O +
200 O +
pg O -
/ O -
mL O +
each O -
, O +
the O +
method O +
imprecision O +
has O +
been O +
below O +
7.1 O -
% O +
and O +
mean O +
inaccuracy O +
equaled O +
8.7 O -
% O -
. O +

The O +
applicability O +
of O +
the O +
proposed O +
approach O +
has O +
been O +
verified O +
by O +
the O +
assessment O +
of O +
changes O +
in O +
isoprostane B-Chemical +
levels O +
in O +
plasma O +
samples O +
derived O +
from O +
mice O +
exposed O +
to O +
tert B-Chemical -
- I-Chemical -
butyl I-Chemical +
hydroperoxide I-Chemical +
( O -
TBHP B-Chemical -
) O -
, O +
a O +
model O +
inducer O +
of O +
oxidative O +
stress O -
, O +
or O +
to O +
antitumor O +
drug O +
doxorubicin B-Chemical +
( O -
DOX B-Chemical -
) O +
known O +
for O +
potent O +
stimulation O +
of O +
redox O +
cycling O -
. O +

Compared O +
to O +
the O +
control O +
group O +
of O +
mice O -
, O +
both O +
oxidative O +
stress O +
inducers O +
tested O +
increased O +
the O +
levels O +
of O +
three O +
out O +
of O +
four O +
isoprostanes O +
in O +
exposed O +
animals O -
; O +
11β B-Chemical -
- I-Chemical -
prostaglandin I-Chemical +
F2α I-Chemical +
being O +
the O +
exception O -
. O +

The O +
greatest O +
rise O +
was O +
observed O +
in O +
the O +
case O +
of O +
15 B-Chemical -
( I-Chemical -
R I-Chemical -
) I-Chemical -
-prostaglandin I-Chemical +
F2α I-Chemical -
, O +
by O +
about O +
50 O -
% O +
and O +
70 O -
% O +
in O +
plasma O +
samples O +
derived O +
from O +
mice O +
exposed O +
to O +
DOX B-Chemical +
and O +
TBHP B-Chemical -
, O +
respectively O -
. O +

Droplet O -
- O -
based O +
microfluidic O +
platform O +
for O +
heterogeneous O +
enzymatic O +
assays O -
. O +

Heterogeneous O +
enzymatic O +
reactions O +
are O +
used O +
in O +
many O +
industrial O +
processes O +
including O +
pulp O +
and O +
paper O -
, O +
food O -
, O +
and O +
biofuel O +
production O -
. O +

Industrially O -
- O -
relevant O +
optimization O +
of O +
the O +
enzymes O +
used O +
in O +
these O +
processes O +
requires O +
assaying O +
them O +
with O +
insoluble O +
substrates O -
. O +

However O -
, O +
platforms O +
for O +
high O +
throughput O +
heterogeneous O +
assays O +
do O +
not O +
exist O +
thereby O +
severely O +
increasing O +
the O +
cost O +
and O +
time O +
of O +
enzyme O +
optimization O -
, O +
or O +
leading O +
to O +
the O +
use O +
of O +
assays O +
with O +
soluble O +
substrates O +
for O +
convenient O -
, O +
but O +
non O -
- O -
ideal O -
, O +
optimization O -
. O +

We O +
present O +
an O +
innovative O +
approach O +
to O +
perform O +
heterogeneous O +
reactions O +
in O +
a O +
high O +
throughput O +
fashion O +
using O +
droplet O +
microfluidics O -
. O +

Droplets O +
provide O +
a O +
facile O +
platform O +
for O +
heterogeneous O +
reactions O +
as O +
internal O +
recirculation O +
allows O +
rapid O +
mixing O +
of O +
insoluble O +
substrates O +
with O +
soluble O +
enzymes O -
. O +

Moreover O -
, O +
it O +
is O +
easy O +
to O +
generate O +
hundreds O +
or O +
thousands O +
of O +
picoliter O +
droplets O +
in O +
a O +
small O +
footprint O +
chip O +
allowing O +
many O +
parallel O +
reactions O -
. O +

We O +
validate O +
our O +
approach O +
by O +
screening O +
combinations O +
of O +
cellulases O +
with O +
real O -
- O -
world O +
insoluble O +
substrates O -
, O +
and O +
demonstrate O +
that O +
the O +
chip O -
- O -
based O +
screening O +
is O +
in O +
excellent O +
agreement O +
with O +
the O +
conventional O +
screening O +
methods O -
, O +
while O +
offering O +
advantages O +
of O +
throughput O -
, O +
speed O +
and O +
lower O +
reagent O +
consumption O -
. O +

We O +
believe O +
that O +
our O +
approach O -
, O +
while O +
demonstrated O +
for O +
a O +
biofuel O +
application O -
, O +
provides O +
a O +
generic O +
platform O +
for O +
high O +
throughput O +
monitoring O +
of O +
heterogeneous O +
reactions O -
. O +

Lysophosphatidic B-Chemical +
acid I-Chemical +
impairs O +
glucose B-Chemical +
homeostasis O +
and O +
inhibits O +
insulin O +
secretion O +
in O +
high O -
- O -
fat O +
diet O +
obese O +
mice O -
. O +

AIMS O -
/ O -
HYPOTHESIS O -
: O +
Lysophosphatidic B-Chemical +
acid I-Chemical +
( O -
LPA B-Chemical -
) O +
is O +
a O +
lipid O +
mediator O +
produced O +
by O +
adipocytes O +
that O +
acts O +
via O +
specific O +
G O -
- O -
protein O -
- O -
coupled O +
receptors O -
; O +
its O +
synthesis O +
is O +
modulated O +
in O +
obesity O -
. O +

We O +
previously O +
reported O +
that O +
reducing O +
adipocyte O +
LPA B-Chemical +
production O +
in O +
high O -
- O -
fat O +
diet O +
( O -
HFD O -
) O -
-fed O +
obese O +
mice O +
is O +
associated O +
with O +
improved O +
glucose B-Chemical +
tolerance O -
, O +
suggesting O +
a O +
negative O +
impact O +
of O +
LPA B-Chemical +
on O +
glucose B-Chemical +
homeostasis O -
. O +

Here O -
, O +
our O +
aim O +
was O +
to O +
test O +
this O +
hypothesis O -
. O +

METHODS O -
: O +
First O -
, O +
glucose B-Chemical +
tolerance O +
and O +
plasma O +
insulin O +
were O +
assessed O +
after O +
acute O +
( O -
30 O +
min O -
) O +
injection O +
of O +
LPA B-Chemical +
( O -
50 O +
mg O -
/ O -
kg O -
) O +
or O +
of O +
the O +
LPA1 O -
/ O -
LPA3 O +
receptor O +
antagonist O +
Ki16425 O +
( O -
5 O +
mg O +
kg O -
( O -
-1 O -
) O +
day O -
( O -
-1 O -
) O -
, O +
i.p O -
. O -
) O +
in O +
non O -
- O -
obese O +
mice O +
fed O +
a O +
normal O +
diet O +
( O -
ND O -
) O +
and O +
in O +
obese O -
/ O -
prediabetic O +
( O -
defined O +
as O +
glucose B-Chemical -
- O -
intolerant O -
) O +
HFD O +
mice O -
. O +

Glucose B-Chemical +
and O +
insulin O +
tolerance O -
, O +
pancreas O +
morphology O -
, O +
glycogen O +
storage O -
, O +
glucose B-Chemical +
oxidation O +
and O +
glucose B-Chemical +
transport O +
were O +
then O +
studied O +
after O +
chronic O +
treatment O +
( O -
3 O +
weeks O -
) O +
of O +
HFD O +
mice O +
with O +
Ki16425 O -
. O +

RESULTS O -
: O +
In O +
ND O +
and O +
HFD O +
mice O -
, O +
LPA B-Chemical +
acutely O +
impaired O +
glucose B-Chemical +
tolerance O +
by O +
inhibiting O +
glucose B-Chemical -
- O -
induced O +
insulin O +
secretion O -
. O +

These O +
effects O +
were O +
blocked O +
by O +
pre O -
- O -
injection O +
of O +
Ki16425 O +
( O -
5 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O -
. O +

Inhibition O +
of O +
glucose B-Chemical -
- O -
induced O +
insulin O +
secretion O +
by O +
LPA B-Chemical +
also O +
occurred O +
in O +
isolated O +
mouse O +
islets O -
. O +

Plasma O +
LPA B-Chemical +
was O +
higher O +
in O +
HFD O +
mice O +
than O +
in O +
ND O +
mice O +
and O +
Ki16425 O +
transiently O +
improved O +
glucose B-Chemical +
tolerance O -
. O +

The O +
beneficial O +
effect O +
of O +
Ki16425 O +
became O +
permanent O +
after O +
chronic O +
treatment O +
and O +
was O +
associated O +
with O +
increased O +
pancreatic O +
islet O +
mass O +
and O +
higher O +
fasting O +
insulinaemia O -
. O +

Chronic O +
treatment O +
with O +
Ki16425 O +
also O +
improved O +
insulin O +
tolerance O +
and O +
increased O +
liver O +
glycogen O +
storage O +
and O +
basal O +
glucose B-Chemical +
use O +
in O +
skeletal O +
muscle O -
. O +

CONCLUSIONS O -
/ O -
INTERPRETATION O -
: O +
Exogenous O +
and O +
endogenous O +
LPA B-Chemical +
exerts O +
a O +
deleterious O +
effect O +
on O +
glucose B-Chemical +
disposal O +
through O +
a O +
reduction O +
of O +
plasma O +
insulin O -
; O +
pharmacological O +
blockade O +
of O +
LPA B-Chemical +
receptors O +
improves O +
glucose B-Chemical +
homeostasis O +
in O +
obese O -
/ O -
prediabetic O +
mice O -
. O +

Carbonic O +
anhydrase O +
inhibitors O -
: O +
Inhibition O +
of O +
the O +
β O -
- O -
class O +
enzyme O +
from O +
the O +
pathogenic O +
yeast O +
Candida O +
glabrata O +
with O +
sulfonamides B-Chemical -
, O +
sulfamates B-Chemical +
and O +
sulfamides B-Chemical -
. O +

The O +
fungal O +
pathogen O +
Candida O +
glabrata O +
encodes O +
for O +
a O +
β O -
- O -
carbonic O +
anhydrase O +
( O -
CA O -
, O +
EC O +
4.2.1.1 O -
) O -
, O +
CgNce103 O -
, O +
recently O +
discovered O -
. O +

Only O +
anions O +
have O +
been O +
investigated O +
as O +
CgNce103 O +
inhibitors O +
up O +
until O +
now O -
. O +

Here O +
we O +
report O +
the O +
first O +
sulfonamides B-Chemical +
inhibition O +
study O +
of O +
this O +
enzyme O -
. O +

Simple O +
sulfonamides B-Chemical +
showed O +
weak O +
or O +
moderate O +
CgNce103 O +
inhibitory O +
properties O -
, O +
whereas O +
acetazolamide B-Chemical -
, O +
and O +
a O +
series O +
of O +
4-substituted B-Chemical +
ureido I-Chemical -
- I-Chemical -
benzene I-Chemical -
- I-Chemical -
sulfonamides I-Chemical -
, O +
sulfamates B-Chemical +
and O +
sulfamides B-Chemical +
showed O +
effective O +
CgNce103 O +
inhibitory O +
properties O -
, O +
with O +
KIs O +
in O +
the O +
range O +
of O +
4.1 O -
- O -
115nM O -
, O +
being O +
also O +
ineffective O +
as O +
human O +
CA O +
II O +
inhibitors O -
. O +

As O +
there O +
is O +
significant O +
resistance O +
of O +
C. O +
glabrata O +
clinical O +
isolates O +
to O +
many O +
classical O +
antifungal O +
agents O -
, O +
inhibition O +
of O +
the O +
β O -
- O -
CA O +
from O +
this O +
organism O +
may O +
allow O +
an O +
interesting O +
means O +
of O +
controlling O +
the O +
pathogen O +
growth O -
, O +
eventually O +
leading O +
to O +
antifungals O +
with O +
a O +
novel O +
mechanism O +
of O +
action O -
. O +

A O +
copper B-Chemical +
hyperaccumulation O +
phenotype O +
correlates O +
with O +
pathogenesis O +
in O +
Cryptococcus O +
neoformans O -
. O +

Cryptococcus O +
neoformans O +
is O +
a O +
major O +
human O +
pathogen O +
and O +
a O +
cause O +
of O +
meningoencephalitis O +
in O +
immunocompromised O +
patients O -
. O +

Many O +
factors O +
contribute O +
to O +
the O +
extraordinary O +
survivability O +
and O +
pathogenicity O +
of O +
this O +
fungus O +
in O +
humans O -
, O +
including O +
copper B-Chemical +
homeostasis O +
pathways O -
. O +

Previous O +
work O +
has O +
shown O +
that O +
deletion O +
of O +
the O +
copper B-Chemical -
- O -
dependent O +
regulator O +
Cuf1 O +
results O +
in O +
decreased O +
virulence O +
and O +
dissemination O +
in O +
brain O +
infection O -
, O +
suggesting O +
that O +
copper B-Chemical +
acquisition O +
is O +
important O +
to O +
the O +
persistence O +
of O +
this O +
pathogen O -
. O +

Here O -
, O +
we O +
show O +
that O +
the O +
minimal O +
copper B-Chemical +
quota O +
of O +
C. O +
neoformans O +
is O +
maintained O +
at O +
a O +
high O +
level O +
even O +
when O +
grown O +
under O +
conditions O +
of O +
stringent O +
copper B-Chemical +
limitation O -
. O +

Intriguingly O -
, O +
when O +
this O +
fungal O +
pathogen O +
is O +
grown O +
in O +
standard O +
and O +
copper B-Chemical -
- O -
enriched O +
media O -
, O +
it O +
sequesters O +
even O +
higher O +
levels O +
of O +
this O +
essential O +
metal O -
, O +
achieving O +
levels O +
that O +
are O +
far O +
higher O +
than O +
non O -
- O -
pathogenic O +
S. O +
cerevisiae O -
. O +

The O +
hypothesis O +
that O +
copper B-Chemical +
acquisition O +
plays O +
an O +
essential O +
role O +
in O +
virulence O +
is O +
further O +
corroborated O +
by O +
the O +
findings O +
that O +
a O +
hypovirulent O +
CUF1-deletant O +
strain O +
of O +
C. O +
neoformans O +
retrieved O +
from O +
infected O +
mice O +
contains O +
almost O +
a O +
6-fold O +
lower O +
concentration O +
of O +
intracellular O +
copper B-Chemical +
than O +
the O +
pathogenic O +
wild O -
- O -
type O +
strain O -
. O +

The O +
concentration O +
difference O +
arises O +
in O +
part O +
from O +
larger O -
- O -
sized O +
cuf1Δ O +
cell O -
. O +

Under O +
in O +
vitro O +
growth O +
conditions O -
, O +
the O +
size O +
of O +
the O +
cuf1Δ O +
cells O +
is O +
normal O +
and O +
the O +
hypertrophy O +
phenotype O +
is O +
readily O +
induced O +
in O +
vitro O +
under O +
conditions O +
of O +
copper B-Chemical +
starvation O -
. O +

Taken O +
together O -
, O +
these O +
data O +
suggest O +
that O +
acquisition O +
of O +
extraordinary O +
levels O +
of O +
copper B-Chemical +
is O +
an O +
important O +
factor O +
in O +
the O +
survivability O +
of O +
the O +
pathogen O +
in O +
the O +
copper B-Chemical -
- O -
deplete O +
environment O +
of O +
infection O -
, O +
and O +
effective O +
copper B-Chemical +
concentration O +
may O +
play O +
an O +
important O +
role O +
in O +
the O +
pathogenesis O +
of O +
C. O +
neoformans O -
. O +

Is O +
Artemisinin B-Chemical +
the O +
Only O +
Antiplasmodial O +
Compound O +
in O +
the O +
Artemisia O +
annua O +
Tea O +
Infusion O -
? O +

An O +
in O +
Vitro O +
Study O -
. O +

In O +
our O +
ongoing O +
investigation O +
into O +
Artemisia O +
annua O +
for O +
the O +
treatment O +
of O +
malaria O -
, O +
we O +
decided O +
to O +
study O +
the O +
possibility O +
that O +
synergism O +
might O +
enhance O +
the O +
efficacy O +
of O +
artemisinin B-Chemical -
. O +

Our O +
main O +
objective O +
was O +
to O +
test O +
tea O +
infusions O +
and O +
nonpolar O +
extracts O +
prepared O +
from O +
different O +
A. O +
annua O +
varieties O +
against O +
Plasmodium O +
falciparum O +
in O +
vitro O +
in O +
order O +
to O +
determine O +
if O +
synergism O +
will O +
increase O +
the O +
effectiveness O +
of O +
artemisinin B-Chemical +
in O +
the O +
samples O +
as O +
compared O +
to O +
pure O +
artemisinin B-Chemical -
. O +

We O +
found O +
that O +
the O +
IC50 O +
of O +
artemisinin B-Chemical +
in O +
the O +
tea O +
and O +
nonpolar O +
extracts O +
was O +
not O +
significantly O +
different O +
to O +
the O +
IC50 O +
of O +
pure O +
artemisinin B-Chemical -
. O +

We O +
could O +
show O +
that O +
the O +
year O +
and O +
country O +
of O +
harvest O +
or O +
storage O +
conditions O +
did O +
not O +
have O +
any O +
influence O +
on O +
the O +
activity O +
and O +
that O +
it O +
narrowly O +
followed O +
the O +
concentration O +
of O +
artemisinin B-Chemical +
in O +
all O +
the O +
extracts O -
. O +

In O +
conclusion O -
, O +
based O +
on O +
these O +
in O +
vitro O +
results O -
, O +
artemisinin B-Chemical +
seems O +
to O +
be O +
the O +
only O +
active O +
antiplasmodial O +
compound O +
in O +
A. O +
annua O -
. O +

Hop O +
Extracts O +
and O +
Hop O +
Substances O +
in O +
Treatment O +
of O +
Menopausal O +
Complaints O -
. O +

Hop O +
extract O +
is O +
a O +
long O +
used O +
medicinal O +
product O +
and O -
, O +
regarding O +
hormonal O +
activities O -
, O +
in O +
1999 O +
a O +
number O +
of O +
prenylflavanones B-Chemical +
have O +
been O +
identified O +
as O +
its O +
major O +
constituents O +
with O +
8-prenylnaringenin B-Chemical +
( O -
8-PN B-Chemical -
) O +
being O +
the O +
main O +
active O +
estrogenic O +
compound O -
. O +

There O +
have O +
been O +
several O +
in O +
vivo O +
studies O +
performed O +
that O +
demonstrate O +
the O +
potential O +
of O +
hop O +
extract O +
and O +
the O +
single O +
compound O +
8-PN B-Chemical +
to O +
alleviate O +
climacteric O +
symptoms O +
like O +
osteoporosis O -
, O +
vasomotoric O +
complaints O -
, O +
and O +
sexual O +
motivation O -
. O +

On O +
the O +
other O +
hand O -
, O +
only O +
a O +
few O +
clinical O +
studies O +
have O +
been O +
performed O +
so O +
far O -
, O +
and O +
these O +
mainly O +
focused O +
on O +
menopausal O +
discomforts O -
, O +
especially O +
hot O +
flushes O -
, O +
yielding O +
rather O +
inconclusive O +
results O -
. O +

Despite O +
preferentially O +
activating O +
estrogen B-Chemical +
receptor O +
α O -
, O +
8-PN B-Chemical +
is O +
only O +
slightly O +
uterotrophic O -
, O +
but O +
it O +
also O +
elucidates O +
estrogenic O +
effects O +
on O +
the O +
mammary O +
gland O -
. O +

In O +
conclusion O -
, O +
although O +
hop O +
extract O +
and O +
especially O +
8-PN B-Chemical +
are O +
promising O +
candidates O +
as O +
a O +
relief O +
for O +
climacteric O +
symptoms O -
, O +
data O +
on O +
the O +
safety O +
and O +
efficacy O +
is O +
still O +
scarce O -
. O +

Cardamonin B-Chemical +
Ameliorates O +
Insulin O +
Resistance O +
Induced O +
by O +
High O +
Insulin O +
and O +
High O +
Glucose B-Chemical +
through O +
the O +
mTOR O +
and O +
Signal O +
Pathway O -
. O +

The O +
mammalian O +
target O +
of O +
rapamycin B-Chemical +
is O +
crucial O +
in O +
the O +
regulation O +
of O +
cell O +
growth O +
and O +
metabolism O -
. O +

Recent O +
studies O +
suggest O +
that O +
the O +
mammalian O +
target O +
of O +
rapamycin B-Chemical +
and O +
its O +
downstream O +
70-kDa O +
ribosomal O +
S6 O +
kinase O +
1 O +
negatively O +
modulate O +
the O +
insulin O -
- O -
signaling O +
pathway O -
, O +
which O +
is O +
considered O +
the O +
main O +
cause O +
of O +
insulin O +
resistance O -
. O +

The O +
aim O +
of O +
this O +
study O +
is O +
to O +
investigate O +
the O +
effects O +
of O +
cardamonin B-Chemical -
, O +
a O +
potential O +
inhibitor O +
of O +
the O +
mammalian O +
target O +
of O +
the O +
rapamycin B-Chemical -
, O +
on O +
insulin O -
- O -
resistant O +
vascular O +
smooth O +
muscle O +
cells O +
and O +
the O +
molecular O +
mechanisms O +
involved O -
. O +

Vascular O +
smooth O +
muscle O +
cells O +
were O +
cultured O +
with O +
high O +
glucose B-Chemical +
and O +
high O +
insulin O +
to O +
induce O +
insulin O +
resistance O -
. O +

The O +
mammalian O +
target O +
of O +
rapamycin B-Chemical +
was O +
overstimulated O +
in O +
cells O +
that O +
were O +
incubated O +
with O +
high O +
glucose B-Chemical +
and O +
high O +
insulin O -
, O +
as O +
reflected O +
by O +
the O +
excessive O +
activation O +
of O +
S6 O +
kinase O +
1 O -
. O +

Insulin O -
- O -
resistant O +
vascular O +
smooth O +
muscle O +
cells O +
displayed O +
hyperphosphorylation O +
of O +
insulin O +
receptor O +
substrate-1 O +
at O +
Ser B-Chemical +
residues O +
636 O -
/ O -
639 O -
, O +
which O +
decreased O +
the O +
activity O +
of O +
insulin O +
receptor O +
substrate-1 O -
. O +

Also O -
, O +
the O +
activation O +
of O +
protein O +
kinase O +
B O +
and O +
phosphorylation O +
of O +
glycogen O +
synthesis O +
kinase-3β O +
were O +
inhibited O -
. O +

Cardamonin B-Chemical +
increased O +
the O +
2-deoxyglucose B-Chemical +
uptake O +
and O +
glycogen O +
concentration O -
, O +
which O +
was O +
reduced O +
by O +
insulin O +
resistance O -
. O +

As O +
with O +
rapamycin B-Chemical -
, O +
cardamonin B-Chemical +
inhibited O +
the O +
activity O +
of O +
the O +
mammalian O +
target O +
of O +
rapamycin B-Chemical +
and O +
S6 O +
kinase O +
1 O -
, O +
decreased O +
the O +
Ser B-Chemical +
636 O -
/ O -
639 O +
phosphorylation O +
of O +
insulin O +
receptor O +
substrate-1 O +
and O +
increased O +
the O +
activation O +
of O +
protein O +
kinase O +
B. O +
Both O +
of O +
them O +
increased O +
the O +
Ser9 B-Chemical +
phosphorylation O +
of O +
glycogen O +
synthesis O +
kinase-3β O +
and O +
decreased O +
the O +
expression O +
of O +
glycogen O +
synthesis O +
kinase-3β O -
. O +

However O -
, O +
neither O +
cardamonin B-Chemical +
nor O +
rapamycin B-Chemical +
increased O +
the O +
expression O +
of O +
glucose B-Chemical +
transport O +
4 O +
which O +
decreased O +
in O +
insulin O -
- O -
resistant O +
vascular O +
smooth O +
muscle O +
cells O -
. O +

This O +
study O +
suggests O +
that O +
cardamonin B-Chemical +
inhibited O +
the O +
activity O +
of O +
the O +
mammalian O +
target O +
of O +
rapamycin B-Chemical +
and O +
eliminated O +
the O +
negative O +
feedback O +
of O +
the O +
mammalian O +
target O +
of O +
rapamycin B-Chemical +
and O +
S6 O +
kinase O +
1 O +
on O +
the O +
insulin O -
- O -
signaling O +
pathway O -
. O +

Cognitive O +
impairment O +
and O +
dietary O +
habits O +
among O +
elders O -
: O +
the O +
velestino O +
study O -
. O +

Abstract O +
To O +
investigate O +
the O +
association O +
of O +
dietary O +
habits O +
with O +
cognitive O +
function O +
among O +
elders O +
( O -
> O -
65 O +
years O -
) O -
. O +

Complete O +
sociodemographic O -
, O +
dietary O +
information O -
, O +
serum O +
measurements O -
, O +
and O +
Mini O -
- O -
Mental O +
State O +
Examination O +
( O -
MMSE O -
) O +
assessments O +
were O +
available O +
for O +
237 O +
elderly O +
men O +
and O +
320 O +
women O +
residing O +
in O +
Velestino O -
, O +
Greece O +
( O -
a O +
rural O +
Greek O +
town O -
) O -
. O +

All O +
models O +
were O +
adjusted O +
for O +
age O -
, O +
education O -
, O +
social O +
activity O -
, O +
smoking O -
, O +
depression O +
symptomatology O +
( O -
using O +
the O +
Geriatric O +
Depression O +
Scale O -
) O -
, O +
MedDietScore O +
( O -
range O +
0 O -
- O -
55 O -
) O -
, O +
and O +
metabolic O +
syndrome O -
. O +

About O +
49.8 O -
% O +
men O +
and O +
66.6 O -
% O +
women O +
had O +
MMSE O +
scores O +
< O -
24 O -
, O +
with O +
a O +
mean O +
MMSE O +
score O +
of O +
22.7±4.43 O +
and O +
21.1±4.73 O -
, O +
respectively O -
. O +

Adherence O +
to O +
the O +
Mediterranean O +
diet O +
was O +
moderate O +
( O -
mean O +
MedDietScore O +
of O +
34.1±3.25 O +
in O +
men O +
and O +
35.1±2.48 O +
in O +
women O -
) O -
. O +

Indicative O +
cognitive O +
impairment O +
( O -
MMSE O +
score O +
< O -
24 O -
) O +
was O +
positively O +
associated O +
with O +
age O +
and O +
low O +
education O +
in O +
women O +
and O +
with O +
depressive O +
symptoms O -
, O +
low O +
education O +
status O -
, O +
and O +
low O +
social O +
activity O +
in O +
men O -
. O +

Adherence O +
to O +
the O +
Mediterranean O +
diet O +
was O +
positively O +
associated O +
with O +
MMSE O +
score O +
in O +
men O +
( O -
P=.02 O -
) O -
, O +
but O +
inversely O +
associated O +
in O +
women O +
( O -
P=.04 O -
) O -
. O +

Concerning O +
the O +
food O +
groups O +
studied O -
, O +
intake O +
of O +
pulses O -
, O +
nuts O -
, O +
and O +
seeds O +
was O +
associated O +
with O +
lower O +
likelihood O +
of O +
having O +
MMSE O +
score<24 O +
in O +
men O +
( O -
P=.04 O -
) O -
. O +

Only O +
the O +
Mediterranean O +
dietary O +
pattern O +
showed O +
a O +
significant O +
association O +
with O +
MMSE O +
score O +
positive O +
for O +
cognitive O +
impairment O +
( O -
i.e. O -
, O +
protective O +
in O +
men O -
, O +
but O +
not O +
in O +
women O -
) O -
, O +
while O +
individual O +
food O +
groups O +
or O +
nutrients O +
did O +
not O +
achieve O +
significance O -
. O +

The O +
latter O +
findings O +
support O +
the O +
role O +
of O +
whole O +
diet O +
in O +
the O +
prevention O +
of O +
mental O +
disorders O -
, O +
and O +
state O +
a O +
research O +
hypothesis O +
for O +
a O +
sex O -
- O -
diet O +
interaction O +
on O +
cognitive O +
function O +
among O +
elders O -
. O +

Oxidative O +
and O +
Photoxidative O +
Polymerization O +
of O +
Humic O +
Suprastructures O +
by O +
Heterogeneous O +
Biomimetic O +
Catalysis O -
. O +

The O +
meso B-Chemical -
- I-Chemical -
tetra I-Chemical -
( I-Chemical -
2,6-dichloro-3-sulfonatophenyl I-Chemical -
) I-Chemical -
porphyrinate I-Chemical +
of O +
manganese B-Chemical -
( I-Chemical -
III I-Chemical -
) I-Chemical +
chloride I-Chemical +
[ B-Chemical -
Mn- I-Chemical -
( I-Chemical -
TDCPPS I-Chemical -
) I-Chemical -
Cl I-Chemical -
] I-Chemical +
biomimetic O +
catalyst O +
immobilized O +
on O +
spacer O -
- O -
functionalized O +
kaolinite B-Chemical +
clay O +
mineral O +
was O +
employed O +
in O +
the O +
oxidative O +
coupling O +
reaction O +
of O +
a O +
dissolved O +
humic O +
acid O +
( O -
HA O -
) O +
suprastructure O +
with O +
either O +
chemical O +
( O -
H2O2 B-Chemical -
) O +
or O +
UV O -
- O -
light O +
oxidation O -
. O +

The O +
changes O +
in O +
molecular O +
size O +
of O +
humic O +
matter O +
subjected O +
to O +
catalyzed O +
oxidative O +
reaction O +
were O +
followed O +
by O +
high O -
- O -
performance O +
size O +
exclusion O +
chromatography O +
( O -
HPSEC O -
) O +
with O +
UV O -
- O -
vis O +
and O +
refractive O +
index O +
( O -
RI O -
) O +
detectors O +
in O +
series O -
, O +
and O +
by O +
thermogravimetric O +
( O -
TGA O -
) O +
analysis O -
. O +

Both O +
the O +
enhanced O +
molecular O +
size O +
shown O +
by O +
differences O +
between O +
HPSEC O +
chromatograms O +
of O +
humic O +
reaction O +
mixtures O +
at O +
either O +
pH O +
6 O +
or O +
3.5 O +
and O +
the O +
increase O +
of O +
thermogravimetric O +
stability O +
suggest O +
that O +
the O +
heterogeneous O +
biomimetic O +
catalysis O +
promoted O +
the O +
stabilization O +
of O +
humic O +
conformations O +
by O +
new O +
intermolecular O +
covalent O +
bonds O +
during O +
oxidative O +
coupling O -
. O +

The O +
similarity O +
between O +
chemical O +
and O +
light O -
- O -
induced O +
oxidation O +
results O +
suggests O +
potential O +
multiple O +
applications O +
of O +
the O +
kaolinite B-Chemical -
- O -
supported O +
heterogeneous O +
catalyst O +
in O +
controlling O +
the O +
reactivity O +
of O +
natural O +
organic O +
matter O +
within O +
biogeochemical O +
cycles O +
and O +
environmental O +
reactions O -
. O +

Biological O +
activity O +
of O +
Pd B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical +
complexes O +
with O +
mono- B-Chemical +
and I-Chemical +
disubstituted I-Chemical +
pyridines I-Chemical -
- O -
Experimental O +
and O +
theoretical O +
studies O -
. O +

Due O +
to O +
the O +
similarity O +
between O +
Pd B-Chemical +
and O +
Pt B-Chemical -
, O +
the O +
complexes O +
of O +
palladium B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical +
can O +
be O +
considered O +
as O +
potential O +
anticancer O +
agents O -
. O +

Activity O +
of O +
six O +
PdCl2 B-Chemical -
( I-Chemical -
X2Py I-Chemical -
) I-Chemical -
2 I-Chemical +
complexes O +
( O -
Py B-Chemical -
= O -
pyridine B-Chemical -
, O +
and O +
X O -
= O -
CH3 B-Chemical +
or O +
Cl B-Chemical -
) O +
was O +
measured O +
by O +
MTT B-Chemical +
test O +
using O +
MCF7 O -
, O +
CCRF O -
- O -
SB O -
, O +
PC3 O +
and O +
human O +
B O -
- O -
lymphoblastoid O +
cell O +
lines O -
. O +

We O +
found O +
that O +
the O +
effect O +
of O +
PdCl2 B-Chemical -
( I-Chemical -
XnPy I-Chemical -
) I-Chemical -
2 I-Chemical +
was O +
cell O -
- O -
specific O +
and O +
time O -
- O -
dependent O -
. O +

Obtained O +
results O +
were O +
discussed O +
and O +
compared O +
with O +
the O +
activation O +
parameters O +
calculated O +
for O +
the O +
hydrolysis O +
of O +
PdCl2 B-Chemical -
( I-Chemical -
XnPy I-Chemical -
) I-Chemical -
2 I-Chemical -
, O +
indicating O +
a O +
correlation O +
between O +
viability O +
of O +
MCF7 O +
and O +
CCRF O -
- O -
SB O +
cells O +
and O +
rates O +
of O +
hydrolysis O +
of O +
the O +
Pd B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical +
complexes O -
. O +

Pathogenesis O +
of O +
preeclampsia O -
: O +
Implications O +
of O +
apoptotic O +
markers O +
and O +
oxidative O +
stress O -
. O +

This O +
study O +
aimed O +
to O +
investigate O +
the O +
implication O +
of O +
some O +
apoptotic O +
and O +
lipid O +
peroxidation O +
markers O +
in O +
preeclampsia O +
( O -
PE O -
) O -
. O +

A O +
total O +
of O +
25 O +
women O +
with O +
PE O +
and O +
25 O +
age- O +
and O +
parity O -
- O -
matched O +
normal O +
pregnant O +
women O +
were O +
enrolled O +
in O +
this O +
study O -
. O +

The O +
malondialdehyde B-Chemical +
( O -
MDA B-Chemical -
) O +
level O -
, O +
caspase-9 O +
activity O +
and O +
the O +
percentage O +
of O +
DNA O +
fragmentation O +
were O +
significantly O +
higher O +
in O +
placental O +
tissue O +
of O +
PE O +
than O +
in O +
control O +
women O -
. O +

The O +
serum O +
level O +
of O +
MDA B-Chemical +
was O +
significantly O +
elevated O +
in O +
women O +
with O +
PE O +
having O +
delivery O +
by O +
cesarean O +
section O +
( O -
CS O -
) O +
than O +
in O +
women O +
with O +
PE O +
having O +
vaginal O +
delivery O -
. O +

In O +
vitro O +
study O +
demonstrated O +
that O +
the O +
addition O +
of O +
0.5 O +
mM O +
Fe B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
and O +
0.1 O +
mM O +
ascorbate B-Chemical +
caused O +
increase O +
in O +
the O +
production O +
of O +
MDA B-Chemical +
level O +
in O +
placental O +
tissue O +
with O +
PE O +
than O +
normal O +
placentas O -
, O +
and O +
vitamin B-Chemical +
E I-Chemical +
( O -
100 O +
µM O -
) O +
caused O +
lower O +
inhibition O +
of O +
in O +
vitro O +
lipid O +
peroxidation O +
in O +
placental O +
tissue O +
with O +
PE O +
when O +
compared O +
with O +
normal O +
tissue O -
. O +

The O +
activity O +
of O +
caspase-9 O +
and O +
percentage O +
of O +
DNA O +
fragmentation O +
were O +
associated O +
with O +
the O +
severity O +
of O +
the O +
PE O +
and O +
both O +
could O +
differentiate O +
between O +
PE O +
and O +
control O +
women O +
with O +
88 O -
% O +
and O +
100 O -
% O +
sensitivity O +
and O +
96 O -
% O +
and O +
100 O -
% O +
specificity O -
, O +
respectively O -
. O +

The O +
activities O +
of O +
caspase-8 O +
and/or O +
-9 O +
were O +
positively O +
correlated O +
with O +
the O +
maternal O +
age O +
but O +
only O +
caspase-8 O +
was O +
negatively O +
correlated O +
with O +
neonatal O +
birth O +
weight O +
and O +
placental O +
weight O -
. O +

In O +
conclusion O -
, O +
the O +
elevations O +
of O +
MDA B-Chemical -
, O +
caspase-9 O +
activity O +
and O +
the O +
percentage O +
of O +
DNA O +
fragmentation O +
in O +
the O +
placentas O +
of O +
women O +
with O +
PE O +
implicate O +
the O +
involvement O +
of O +
lipid O +
peroxidation O +
and O +
apoptosis O +
in O +
PE O -
. O +

The O +
placenta O +
represents O +
a O +
considerable O +
source O +
of O +
the O +
elevated O +
circulating O +
MDA B-Chemical +
in O +
PE O -
. O +

Decreased O +
expression O +
of O +
hepatic O +
low O -
- O -
density O +
lipoprotein O +
related O +
protein O +
1 O +
in O +
hypothyroidism O -
: O +
a O +
novel O +
mechanism O +
of O +
atherogenic O +
dyslipidemia O +
in O +
hypothyroidism O -
. O +

Background O -
: O +
The O +
atherogenic O +
effects O +
of O +
hypothyroidism O +
on O +
lipid O +
metabolism O +
could O +
result O -
, O +
in O +
part O -
, O +
from O +
the O +
reduced O +
clearance O +
of O +
remnant O +
lipoproteins O -
. O +

In O +
this O +
study O -
, O +
we O +
investigated O +
the O +
expression O +
of O +
hepatic O +
low O -
- O -
density O +
lipoprotein O +
receptor O -
- O -
related O +
protein O +
1 O +
( O -
LRP1 O -
) O -
, O +
a O +
receptor O +
for O +
remnant O +
lipoproteins O -
, O +
in O +
hypothyroidism O +
and O +
the O +
effect O +
of O +
triiodothyronine B-Chemical +
( O -
T3 O -
) O +
treatment O +
on O +
hepatic O +
LRP1 O +
expression O -
. O +

Methods O -
: O +
C57BL O -
/ O -
6 O +
mice O +
were O +
fed O +
a O +
normal O +
diet O +
( O -
control O +
group O -
) O +
or O +
a O +
low O +
iodine B-Chemical +
diet O +
supplemented O +
with O +
0.15 O +
% O +
propylthiouracil B-Chemical +
( O -
PTU B-Chemical -
/ O -
LI O +
group O -
) O +
for O +
4 O +
weeks O -
. O +

Mice O +
in O +
PTU B-Chemical -
/ O -
LI O +
group O +
were O +
injected O +
intraperitoneally O +
with O +
T3 O +
( O -
0 O -
, O +
30 O -
, O +
and O +
150 O +
μg O -
/ O -
kg O +
of O +
body O +
weight O -
) O +
for O +
7 O +
days O -
. O +

HepG2 O +
cells O +
were O +
incubated O +
in O +
fetal O +
bovine O +
serum O +
( O -
FBS O -
) O +
or O +
charcoal O -
- O -
stripped O +
FBS O +
( O -
CSS O -
) O +
with O +
various O +
concentrations O +
of O +
T3 O -
. O +

The O +
expression O +
and O +
function O +
of O +
LRP1 O +
in O +
liver O +
samples O +
and O +
cells O +
were O +
analyzed O -
. O +

Results O -
: O +
Hypothyroidism O +
was O +
successfully O +
induced O +
in O +
PTU B-Chemical -
/ O -
LI O +
group O +
mice O -
. O +

Hepatic O +
LRP1 O +
protein O +
expression O +
was O +
lower O +
in O +
the O +
PTU B-Chemical -
/ O -
LI O +
group O +
than O +
the O +
control O +
group O -
. O +

T3 O +
treatment O +
up O -
- O -
regulated O +
hepatic O +
LRP1 O +
protein O +
expression O +
in O +
PTU B-Chemical -
/ O -
LI O +
group O +
mice O -
. O +

LRP1 O +
expression O +
in O +
HepG2 O +
cells O +
was O +
reduced O +
after O +
incubation O +
in O +
media O +
containing O +
CSS O -
, O +
which O +
mimics O +
hypothyroidism O +
in O +
vitro O -
, O +
and O +
was O +
recovered O +
by O +
T3 O +
treatment O -
. O +

The O +
protein O +
expression O +
of O +
LRP1 O +
in O +
HepG2 O +
cells O +
was O +
increased O +
by O +
T3 O +
treatment O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
up O +
to O +
2.0 O +
nM O +
T3 O -
. O +

However O -
, O +
LRP1 O +
mRNA O +
transcription O +
was O +
not O +
affected O +
by O +
hypothyroidism O +
conditions O +
or O +
T3 O +
treatment O -
, O +
either O +
in O +
liver O +
samples O +
or O +
HepG2 O +
cells O -
. O +

T3 O +
treatment O +
on O +
HepG2 O +
cells O +
increased O +
cellular O +
uptake O +
of O +
lipid O -
- O -
conjugated O +
apolipoprotein O +
E O +
through O +
LRP1 O -
. O +

Conclusions O -
: O +
Our O +
data O +
demonstrate O +
that O +
hepatic O +
LRP1 O +
expression O +
and O +
function O +
decrease O +
in O +
hypothyroidism O +
and O +
are O +
regulated O +
by O +
thyroid B-Chemical +
hormone I-Chemical -
. O +

These O +
results O +
suggest O +
that O +
in O +
hypothyroidism O -
, O +
decreased O +
expression O +
of O +
hepatic O +
LRP1 O +
may O +
be O +
associated O +
with O +
reduced O +
clearance O +
of O +
circulating O +
remnant O +
lipoproteins O -
. O +

Chemical O +
characterization O +
of O +
domestic O +
oral O +
tobacco O +
products O -
: O +
Total O +
nicotine B-Chemical -
, O +
pH O -
, O +
unprotonated O +
nicotine B-Chemical +
and O +
tobacco O -
- O -
specific O +
N B-Chemical -
- I-Chemical -
nitrosamines I-Chemical -
. O +

In O +
the O +
United O +
States O -
, O +
moist O +
snuff O +
has O +
been O +
studied O +
more O +
widely O +
than O +
other O +
distinct O +
categories O +
of O +
oral O +
tobacco O -
. O +

In O +
this O +
study O -
, O +
we O +
measured O +
pH O -
, O +
moisture O -
, O +
nicotine B-Chemical +
( O -
total O +
and O +
unprotonated O -
) O -
, O +
and O +
tobacco O -
- O -
specific O +
N B-Chemical -
- I-Chemical -
nitrosamines I-Chemical +
( O -
TSNAs O -
) O +
for O +
other O +
established O +
( O -
twist O -
, O +
loose O +
leaf O -
, O +
plug O -
, O +
and O +
dry O +
snuff O +
without O +
pouch O -
) O +
and O +
emerging O +
oral O +
tobacco O +
products O +
( O -
dry O +
snuff O +
pouch O -
, O +
US O -
- O -
made O +
snus O -
, O +
and O +
dissolvable O +
tobacco O -
) O -
. O +

Among O +
the O +
seven O +
product O +
categories O -
, O +
product O +
pH O +
ranged O +
from O +
4.7 O +
to O +
7.9 O -
, O +
and O +
total O +
nicotine B-Chemical +
concentration O +
spanned O +
from O +
3.9 O +
to O +
40.1mg O -
/ O -
g O -
. O +

The O +
most O +
readily O +
absorbable O +
form O +
of O +
nicotine B-Chemical +
( O -
unprotonated O +
nicotine B-Chemical -
) O +
varied O +
more O +
than O +
350-fold O -
, O +
ranging O +
from O +
0.01 O +
to O +
3.7mg O -
/ O -
g O -
. O +

While O +
the O +
highest O +
total O +
nicotine B-Chemical +
concentrations O +
were O +
observed O +
in O +
twist O +
products O -
, O +
snus O +
and O +
dissolvable O +
tobacco O +
had O +
the O +
highest O +
unprotonated O +
nicotine B-Chemical +
levels O -
. O +

Among O +
all O +
products O -
, O +
total O +
TSNA O +
concentrations O +
ranged O +
from O +
313 O +
to O +
76,500ng O -
/ O -
g O +
with O +
dry O +
snuff O +
having O +
the O +
highest O +
total O +
TSNA O +
concentrations O -
. O +

This O +
study O +
demonstrates O +
the O +
diversity O +
among O +
oral O +
tobacco O +
products O +
and O +
highlights O +
the O +
potential O +
of O +
these O +
products O +
to O +
deliver O +
a O +
wide O +
range O +
of O +
nicotine B-Chemical +
and O +
carcinogenic O +
TSNAs O -
. O +

Characterizing O +
the O +
chemical O +
content O +
of O +
these O +
products O +
may O +
be O +
helpful O +
in O +
further O +
understanding O +
the O +
risk O +
of O +
marketing O +
these O +
products O +
to O +
oral O +
tobacco O +
users O +
and O +
smokers O +
as O +
an O +
alternative O +
and O +
discrete O +
form O +
of O +
tobacco O -
. O +

SMC6 O +
is O +
an O +
essential O +
gene O +
in O +
mice O -
, O +
but O +
a O +
hypomorphic O +
mutant O +
in O +
the O +
ATPase O +
domain O +
has O +
a O +
mild O +
phenotype O +
with O +
a O +
range O +
of O +
subtle O +
abnormalities O -
. O +

Smc5 O -
- O -
6 O +
is O +
a O +
highly O +
conserved O +
protein O +
complex O +
related O +
to O +
cohesin O +
and O +
condensin O +
involved O +
in O +
the O +
structural O +
maintenance O +
of O +
chromosomes O -
. O +

In O +
yeasts O +
the O +
Smc5 O -
- O -
6 O +
complex O +
is O +
essential O +
for O +
proliferation O +
and O +
is O +
involved O +
in O +
DNA O +
repair O +
and O +
homologous O +
recombination O -
. O +

siRNA O +
depletion O +
of O +
genes O +
involved O +
in O +
the O +
Smc5 O -
- O -
6 O +
complex O +
in O +
cultured O +
mammalian O +
cells O +
results O +
in O +
sensitivity O +
to O +
some O +
DNA O +
damaging O +
agents O -
. O +

In O +
order O +
to O +
gain O +
further O +
insight O +
into O +
its O +
role O +
in O +
mammals O +
we O +
have O +
generated O +
mice O +
mutated O +
in O +
the O +
Smc6 O +
gene O -
. O +

A O +
complete O +
knockout O +
resulted O +
in O +
early O +
embryonic O +
lethality O -
, O +
demonstrating O +
that O +
this O +
gene O +
is O +
essential O +
in O +
mammals O -
. O +

However O -
, O +
mutation O +
of O +
the O +
highly O +
conserved O +
serine-994 B-Chemical +
to O +
alanine B-Chemical +
in O +
the O +
ATP B-Chemical +
hydrolysis O +
motif O +
in O +
the O +
SMC6 O +
C O -
- O -
terminal O +
domain O -
, O +
resulted O +
in O +
mice O +
with O +
a O +
surprisingly O +
mild O +
phenotype O -
. O +

With O +
the O +
neo O +
gene O +
selection O +
marker O +
in O +
the O +
intron O +
following O +
the O +
mutation O -
, O +
resulting O +
in O +
reduced O +
expression O +
of O +
the O +
SMC6 O +
gene O -
, O +
the O +
mice O +
were O +
reduced O +
in O +
size O -
, O +
but O +
fertile O +
and O +
had O +
normal O +
lifespans O -
. O +

When O +
the O +
neo O +
gene O +
was O +
removed O -
, O +
the O +
mice O +
had O +
normal O +
size O -
, O +
but O +
detailed O +
phenotypic O +
analysis O +
revealed O +
minor O +
abnormalities O +
in O +
glucose B-Chemical +
tolerance O -
, O +
haematopoiesis O -
, O +
nociception O +
and O +
global O +
gene O +
expression O +
patterns O -
. O +

Embryonic O +
fibroblasts O +
derived O +
from O +
the O +
ser994 B-Chemical +
mutant O +
mice O +
were O +
not O +
sensitive O +
to O +
killing O +
by O +
a O +
range O +
of O +
DNA O +
damaging O +
agents O -
, O +
but O +
they O +
were O +
sensitive O +
to O +
the O +
induction O +
of O +
sister O +
chromatid O +
exchanges O +
induced O +
by O +
ultraviolet O +
light O +
or O +
mitomycin B-Chemical +
C. I-Chemical +
They O +
also O +
accumulated O +
more O +
oxidative O +
damage O +
than O +
wild O -
- O -
type O +
cells O -
. O +

A O +
Redox O +
Responsive O -
, O +
Fluorescent O +
Supramolecular O +
Metallohydrogel O +
Consists O +
of O +
Nanofibers O +
with O +
Single O -
- O -
Molecule O +
Width O -
. O +

The O +
integration O +
of O +
a O +
tripeptide B-Chemical +
derivative O -
, O +
which O +
is O +
a O +
versatile O +
self O -
- O -
assembly O +
motif O -
, O +
with O +
a O +
ruthenium B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical -
tris I-Chemical -
( I-Chemical -
bipyridine I-Chemical -
) I-Chemical +
complex O +
affords O +
the O +
first O +
supramolecular O +
metallo O -
- O -
hydrogelator O +
that O +
not O +
only O +
self O +
assembles O +
in O +
water O +
to O +
form O +
a O +
hydrogel O +
but O +
also O +
exhibits O +
gel O -
- O -
sol O +
transition O +
upon O +
oxidation O +
of O +
the O +
metal O +
center O -
. O +

Surprisingly O -
, O +
the O +
incorporation O +
of O +
the O +
metal O +
complex O +
in O +
the O +
hydrogelator O +
results O +
in O +
the O +
nanofibers O -
, O +
formed O +
by O +
the O +
self O -
- O -
assembly O +
of O +
the O +
hydrogelator O +
in O +
water O -
, O +
to O +
have O +
the O +
width O +
of O +
a O +
single O +
molecule O +
of O +
the O +
hydrogelator O -
. O +

These O +
results O +
illustrate O +
that O +
metal O +
complexes O -
, O +
besides O +
being O +
able O +
to O +
impart O +
rich O +
optical O -
, O +
electronic O -
, O +
redox O -
, O +
or O +
magnetic O +
properties O +
to O +
supramolecular O +
hydrogels O -
, O +
also O +
offer O +
a O +
unique O +
geometrical O +
control O +
to O +
prearrange O +
the O +
self O -
- O -
assembly O +
motif O +
prior O +
to O +
self O -
- O -
assembling O -
. O +

The O +
use O +
of O +
metal O +
complexes O +
to O +
modulate O +
the O +
dimensionality O +
of O +
intermolecular O +
interactions O +
may O +
also O +
help O +
elucidate O +
the O +
interactions O +
of O +
the O +
molecular O +
nanofibers O +
with O +
other O +
molecules O -
, O +
thus O +
facilitating O +
the O +
development O +
of O +
supramolecular O +
hydrogel O +
materials O +
for O +
a O +
wide O +
range O +
of O +
applications O -
. O +

Avermectin B-Chemical +
induces O +
P O -
- O -
glycoprotein O +
expression O +
in O +
S2 O +
cells O +
via O +
the O +
calcium B-Chemical -
/ O -
calmodulin O -
/ O -
NF O -
- O -
κB O +
pathway O -
. O +

Avermectin B-Chemical +
( O -
AVM B-Chemical -
) O +
is O +
a O +
macrocyclic O +
lactone B-Chemical +
agent O +
widely O +
used O +
as O +
a O +
nematicide O -
, O +
acaricide O +
and O +
insecticide O +
in O +
veterinary O +
medicine O +
and O +
plant O +
protection O -
. O +

P O -
- O -
glycoprotein O +
( O -
P O -
- O -
gp O -
) O +
is O +
an O +
ATP B-Chemical -
- O -
dependent O +
drug O +
efflux O +
pump O +
for O +
xenobiotic O +
compounds O -
, O +
and O +
is O +
involved O +
in O +
multidrug O +
resistance O -
. O +

To O +
understand O +
the O +
development O +
of O +
AVM B-Chemical +
resistance O +
in O +
invertebrates O -
, O +
we O +
investigated O +
the O +
mechanisms O +
by O +
which O +
AVM B-Chemical +
affected O +
P O -
- O -
gp O +
expression O +
in O +
Drosophila O +
S2 O +
cells O -
. O +

We O +
found O +
that O +
AVM B-Chemical +
induced O +
upregulation O +
of O +
P O -
- O -
gp O +
protein O +
expression O -
, O +
increased O +
P O -
- O -
gp O +
ATPase O +
activity O +
and O +
enhanced O +
cellular O +
efflux O +
of O +
the O +
P O -
- O -
gp O +
substrate O +
rhodamine B-Chemical +
123 I-Chemical +
from O +
cells O -
. O +

Furthermore O -
, O +
we O +
observed O +
that O +
AVM B-Chemical -
- O -
induced O +
expression O +
of O +
P O -
- O -
gp O +
was O +
due O +
to O +
elevation O +
of O +
intracellular O +
calcium B-Chemical +
concentration O +
( O -
[ O -
Ca B-Chemical -
( I-Chemical -
2+ I-Chemical -
) I-Chemical -
] O -
i O -
) O -
. O +

This O +
occurred O +
both O +
directly O -
, O +
by O +
activating O +
calcium B-Chemical +
ion O +
channels O -
, O +
and O +
indirectly O -
, O +
by O +
activating O +
chloride B-Chemical +
ion O +
channels O -
. O +

These O +
results O +
are O +
supported O +
by O +
our O +
observations O +
that O +
verapamil B-Chemical -
, O +
a O +
Ca B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
channel O +
blocker O -
, O +
and O +
niflumic B-Chemical +
acid I-Chemical -
, O +
a O +
chloride B-Chemical +
channel O +
antagonist O -
, O +
significantly O +
attenuated O +
AVM B-Chemical -
- O -
induced O +
[ O -
Ca B-Chemical -
( I-Chemical -
2+ I-Chemical -
) I-Chemical -
] O -
i O +
elevation O -
, O +
thereby O +
reducing O +
P O -
- O -
gp O +
expression O -
. O +

Inhibition O +
of O +
P O -
- O -
gp O +
with O +
anti O -
- O -
P O -
- O -
gp O +
antibody O +
or O +
cyclosporine B-Chemical +
A I-Chemical +
( O -
a O +
P O -
- O -
gp O +
inhibitor O -
) O +
reduced O +
the O +
AVM B-Chemical -
- O -
induced O +
elevation O +
of O +
[ O -
Ca B-Chemical -
( I-Chemical -
2+ I-Chemical -
) I-Chemical -
] O -
i O -
, O +
implying O +
that O +
P O -
- O -
gp O +
and O +
[ O -
Ca B-Chemical -
( I-Chemical -
2+ I-Chemical -
) I-Chemical -
] O -
i O +
regulate O +
each O +
other O -
. O +

Finally O -
, O +
we O +
found O +
that O +
trifluoperazine B-Chemical -
, O +
a O +
calmodulin O +
inhibitor O -
, O +
and O +
pyrrolidine B-Chemical +
dithiocarbamic I-Chemical +
acid I-Chemical -
, O +
an O +
NF O -
- O -
κB O +
inhibitor O -
, O +
attenuated O +
the O +
AVM B-Chemical -
- O -
induced O +
expression O +
of O +
P O -
- O -
gp O -
, O +
suggesting O +
that O +
AVM B-Chemical +
induces O +
P O -
- O -
gp O +
protein O +
expression O +
via O +
the O +
calmodulin O -
/ O -
Relish O +
( O -
NF O -
- O -
κB O -
) O +
signaling O +
pathway O -
. O +

Evidence O +
of O +
securin O -
- O -
mediated O +
resistance O +
to O +
gefitinib B-Chemical -
- O -
induced O +
apoptosis O +
in O +
human O +
cancer O +
cells O -
. O +

Gefitinib B-Chemical -
, O +
a O +
tyrosine B-Chemical +
kinase O +
inhibitor O +
of O +
the O +
epidermal O +
growth O +
factor O +
receptor O +
( O -
EGFR O -
) O -
, O +
has O +
been O +
used O +
to O +
treat O +
numerous O +
cancers O -
; O +
however O -
, O +
evidence O +
has O +
shown O +
that O +
cancer O +
cells O +
can O +
become O +
resistant O +
to O +
gefitinib B-Chemical +
during O +
therapy O -
. O +

Here O -
, O +
we O +
report O +
a O +
human O +
proto O -
- O -
oncogene O -
, O +
securin O -
, O +
which O +
displays O +
resistance O +
to O +
death O +
in O +
cancer O +
cells O -
. O +

Gefitinib B-Chemical +
treatment O +
decreases O +
securin O +
levels O +
at O +
the O +
protein O +
level O +
by O +
inducing O +
protein O +
instability O +
but O +
did O +
not O +
affect O +
on O +
the O +
securin O +
gene O +
expression O -
. O +

Treatment O +
with O +
gefitinib B-Chemical +
induced O +
cytotoxicity O +
in O +
various O +
human O +
cancer O +
cell O +
types O -
, O +
including O +
RKO O +
( O -
colon O +
cancer O -
) O -
, O +
A549 O +
( O -
lung O +
cancer O -
) O -
, O +
BFTC905 O +
( O -
bladder O +
cancer O -
) O -
, O +
MCF7 O +
( O -
breast O +
cancer O -
) O +
and O +
A375 O +
( O -
skin O +
cancer O -
) O -
. O +

BFTC905 O +
and O +
A549 O +
cells O +
expressed O +
relatively O +
high O +
levels O +
of O +
the O +
phosphorylated O +
and O +
total O +
EGFR O +
proteins O -
; O +
however O -
, O +
A375 O -
, O +
MCF7 O +
and O +
RKO O +
cells O +
did O +
not O +
markedly O +
express O +
these O +
proteins O -
. O +

Moreover O -
, O +
following O +
treatment O +
with O +
gefitinib B-Chemical -
, O +
the O +
securin O -
- O -
wild O +
type O +
cancer O +
cells O +
were O +
more O +
resistant O +
to O +
apoptotic O +
induction O +
than O +
the O +
securin O -
- O -
null O +
cancer O +
cells O -
. O +

Surprisingly O -
, O +
both O +
the O +
securin O -
- O -
wild O +
type O +
and O +
securin O -
- O -
null O +
cancer O +
cells O +
expressed O +
the O +
EGFR O +
protein O +
at O +
similar O +
levels O -
. O +

Treatment O +
with O +
gefitinib B-Chemical +
induced O +
mitochondrial O +
dysfunction O -
, O +
cytochrome O +
c O +
release O -
, O +
caspase-3 O +
activation O +
and O +
poly B-Chemical +
( I-Chemical -
ADP I-Chemical -
- I-Chemical -
ribose I-Chemical -
) I-Chemical +
polymerase O +
protein O +
cleavage O -
, O +
indicating O +
that O +
apoptosis O +
occurred O +
in O +
these O +
cancer O +
cells O -
. O +

The O +
transfection O +
of O +
a O +
GPF O -
- O -
securin O +
expression O +
vector O +
increased O +
both O +
the O +
proliferation O +
rates O +
and O +
resistance O +
to O +
gefitinib B-Chemical -
- O -
induced O +
death O +
in O +
these O +
cancer O +
cells O -
. O +

Taken O +
together O -
, O +
these O +
findings O +
demonstrate O +
that O +
the O +
presence O +
of O +
securin O +
promotes O +
resistance O +
to O +
gefitinib B-Chemical -
- O -
induced O +
apoptosis O +
via O +
an O +
EGFR O -
- O -
independent O +
pathway O +
in O +
human O +
cancer O +
cells O -
. O +

Copper B-Chemical +
induces O +
apoptotic O +
cell O +
death O +
through O +
reactive O +
oxygen B-Chemical +
species O -
- O -
triggered O +
oxidative O +
stress O +
in O +
the O +
intertidal O +
copepod O +
Tigriopus O +
japonicus O -
. O +

The O +
copepod O -
, O +
Tigriopus O +
japonicus O +
is O +
an O +
important O +
model O +
for O +
toxicity O +
testing O -
. O +

However O -
, O +
no O +
attempt O +
has O +
been O +
made O +
in O +
analyzing O +
the O +
effect O +
of O +
toxicants O +
at O +
the O +
level O +
of O +
the O +
ROS O -
- O -
mediated O +
signal O +
transduction O +
pathway O -
. O +

To O +
understand O +
copper B-Chemical -
- O -
induced O +
cytotoxicity O +
at O +
the O +
molecular O +
level O -
, O +
we O +
employed O +
several O +
cellular O +
and O +
biochemical O +
assays O +
after O +
exposure O +
to O +
copper B-Chemical -
, O +
and O +
found O +
a O +
significant O +
induction O +
of O +
enzyme O +
activities O +
of O +
antioxidant O +
proteins O +
with O +
increased O +
intracellular O +
reactive O +
oxygen B-Chemical +
species O +
( O -
ROS O -
) O +
as O +
well O +
as O +
an O +
increase O +
of O +
TUNEL O -
- O -
positive O +
cells O -
, O +
but O +
a O +
decrease O +
of O +
BrdU B-Chemical -
- O -
positive O +
cells O -
. O +

In O +
addition O -
, O +
several O +
important O +
genes O +
such O +
as O +
p38 O +
MAPK O -
, O +
antioxidant O -
- O -
related O +
genes O -
, O +
Hsps O -
, O +
and O +
apoptosis O -
- O -
related O +
genes O +
were O +
significantly O +
modulated O +
by O +
copper B-Chemical +
exposure O -
. O +

Taken O +
together O -
, O +
we O +
suggest O +
that O +
copper B-Chemical -
- O -
induced O +
cytotoxicity O +
is O +
mediated O +
by O +
the O +
formation O +
of O +
intracellular O +
ROS O +
and O +
oxidative O +
stress O +
in O +
T. O +
japonicus O -
. O +

Whole O +
body O +
biochemical O +
assays O +
such O +
as O +
TUNEL- O +
and O +
BrdU B-Chemical -
- O -
assay O +
will O +
provide O +
a O +
better O +
understanding O +
of O +
cellular O +
responses O +
such O +
as O +
apoptosis O +
and O +
cell O +
death O +
upon O +
cytotoxic O +
exposure O +
of O +
copper B-Chemical +
in O +
T. O +
japonicus O -
. O +

Effect O +
of O +
quercetin B-Chemical -
- O -
rich O +
onion O +
peel O +
extracts O +
on O +
arterial O +
thrombosis O +
in O +
rats O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
examine O +
whether O +
oral O +
supplementation O +
of O +
quercetin B-Chemical -
- O -
rich O +
onion O +
peel O +
extract O +
( O -
OPE O -
) O +
influences O +
blood O +
coagulation O +
and O +
arterial O +
thrombosis O +
in O +
Sprague O -
- O -
Dawley O +
( O -
SD O -
) O +
rats O -
. O +

24 O +
male O +
rats O -
, O +
5weeks O +
old O -
, O +
were O +
divided O +
into O +
three O +
groups O +
with O +
different O +
diets O +
( O -
C O -
: O +
control O -
, O +
2 O -
mg O +
OPE O -
: O +
chow O +
diet O +
with O +
2 O -
mg O +
OPE O +
supplementation O -
, O +
10 O -
mg O +
OPE O -
: O +
chow O +
diet O +
with O +
10 O -
mg O +
OPE O +
supplementation O -
) O +
for O +
6weeks O -
. O +

Blood O +
coagulation O +
parameters O +
including O +
prothrombin O +
time O +
( O -
PT O -
) O -
, O +
activated O +
partial O +
thromboplastin O +
time O +
( O -
aPTT O -
) O +
and O +
platelet O +
aggregation O +
were O +
examined O -
. O +

The O +
OPE O +
did O +
not O +
affect O +
blood O +
cholesterol B-Chemical +
levels O +
but O +
significantly O +
decreased O +
blood O +
triglyceride B-Chemical +
and O +
glucose B-Chemical +
levels O -
. O +

PT O -
, O +
aPTT O +
and O +
platelet O +
aggregation O +
were O +
not O +
significantly O +
different O +
among O +
all O +
tested O +
groups O -
. O +

However O -
, O +
in O +
vivo O +
arterial O +
thrombosis O +
was O +
significantly O +
delayed O +
in O +
groups O +
that O +
were O +
fed O +
2 O -
mg O +
and O +
10 O -
mg O +
OPE O +
diets O +
compared O +
to O +
the O +
control O +
group O -
. O +

In O +
addition O -
, O +
the O +
OPE O +
greatly O +
diminished O +
thrombin O -
- O -
induced O +
expression O +
of O +
tissue O +
factor O +
in O +
human O +
umbilical O +
vein O +
endothelial O +
cells O +
( O -
HUVECs O -
) O -
, O +
a O +
coagulation O +
initiator O -
. O +

In O +
addition O -
, O +
extracellular O +
signal O -
- O -
regulated O +
kinase O +
( O -
ERK O -
) O +
and O +
c O -
- O -
Jun O +
N O -
- O -
terminal O +
kinase O +
( O -
JNK O -
) O +
signaling O +
pathways O +
activated O +
by O +
thrombin O +
treatment O +
were O +
prevented O +
by O +
the O +
OPE O +
pre O -
- O -
treatment O -
. O +

These O +
results O +
indicate O +
that O +
OPE O +
may O +
have O +
anti O -
- O -
thrombotic O +
effects O +
through O +
restricting O +
the O +
induced O +
expression O +
of O +
tissue O +
factor O +
via O +
down O -
- O -
regulating O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O -
MAPK O -
) O +
activation O +
upon O +
coagulation O +
stimulus O -
, O +
leading O +
to O +
the O +
prolongation O +
of O +
time O +
for O +
arterial O +
thrombosis O -
. O +

Modelling O +
the O +
surface O +
free O +
energy O +
parameters O +
of O +
polyurethane B-Chemical +
coats O -
- O -
part O +
1 O -
. O +

Solvent O -
- O -
based O +
coats O +
obtained O +
from O +
linear O +
polyurethane B-Chemical +
elastomers O -
. O +

Polyurethane B-Chemical +
elastomers O +
coating O +
were O +
synthesised O +
by O +
using O +
typical O +
diisocyanates B-Chemical -
, O +
polyether B-Chemical +
and O +
polyester B-Chemical +
polyols I-Chemical +
and O +
HO B-Chemical -
- O -
tertiary B-Chemical +
amines I-Chemical +
or O +
diols B-Chemical +
as O +
a O +
chain O +
extenders O -
. O +

Mole O +
fractions O +
of O +
structural O +
fragments O +
( O -
κ O +
exp O -
) O +
responsible O +
for O +
the O +
polar O +
interactions O +
within O +
polyurethane B-Chemical +
chains O +
were O +
calculated O +
by O +
( B-Chemical -
1 I-Chemical -
) I-Chemical -
H I-Chemical +
NMR O +
method O -
. O +

Obtained O +
results O +
were O +
confronted O +
with O +
the O +
analogous O +
parameter O +
values O +
( O -
κ O +
theor O -
) O +
calculated O +
on O +
the O +
basis O +
of O +
process O +
stoichiometry O -
, O +
considering O +
the O +
stage O +
of O +
the O +
production O +
of O +
isocyanate B-Chemical +
prepolymers O +
and O +
reaction O +
of O +
their O +
extension O +
for O +
polyurethanes B-Chemical -
. O +

Trials O +
of O +
linear O +
correlation O +
between O +
the O +
κ O +
exp O +
parameters O +
and O +
surface O +
free O +
energy O +
( O -
SFE O -
) O +
values O +
of O +
investigated O +
coatings O +
were O +
presented O -
. O +

SFE O +
values O +
were O +
determined O +
by O +
Owens O -
- O -
Wendt O +
method O -
, O +
using O +
contact O +
angles O +
measured O +
with O +
the O +
goniometric O +
method O -
. O +

Based O +
on O +
achieved O +
results O -
, O +
another O +
empirical O +
models O -
, O +
allowing O +
for O +
prediction O +
the O +
influence O +
of O +
the O +
kind O +
of O +
polyurethane B-Chemical +
raw O +
materials O +
on O +
SFE O +
values O +
of O +
received O +
coatings O +
were O +
determined O -
. O +

It O +
was O +
found O +
that O +
it O +
is O +
possible O +
to O +
regulate O +
the O +
SFE O +
in O +
the O +
range O +
millijoules O +
per O +
cubic O +
metre O +
by O +
the O +
selection O +
of O +
appropriate O +
substrates O -
. O +

It O +
has O +
been O +
found O +
that O +
use O +
of O +
2,2,3,3-tetrafluoro-1,4-butanediol B-Chemical +
as O +
a O +
fluorinated O +
extender O +
of O +
prepolymer O +
chains O +
is O +
essential O +
to O +
obtain O +
coatings O +
with O +
increased O +
hydrophobicity O -
, O +
applied O +
among O +
others O +
as O +
biomaterials O -
- O -
next O +
to O +
diphenylmethane B-Chemical +
diisocyanate I-Chemical +
and O +
polyoxyethylene B-Chemical +
glycol I-Chemical -
. O +

Biocomposites O +
of O +
pHEMA B-Chemical +
with O +
HA O -
/ O -
β B-Chemical +
-TCP I-Chemical +
( O -
60 O -
/ O -
40 O -
) O +
for O +
bone O +
tissue O +
engineering O -
: O +
Swelling O -
, O +
hydrolytic O +
degradation O -
, O +
and O +
in O +
vitro O +
behavior O -
. O +

The O +
field O +
of O +
bone O +
and O +
cartilage O +
tissue O +
engineering O +
has O +
a O +
pressing O +
need O +
for O +
novel O -
, O +
biocompatible O -
, O +
biodegradable O +
biocomposites O +
comprising O +
polymers O +
with O +
bioceramics O +
or O +
bioglasses O +
to O +
meet O +
numerous O +
requirements O +
for O +
these O +
applications O -
. O +

We O +
created O +
hydrolytically O +
degradable O +
hydrogel O -
/ O -
bioceramic O +
biocomposites O -
, O +
comprising O +
poly B-Chemical -
( I-Chemical -
2-hydroxyethyl I-Chemical +
methacrylate I-Chemical -
) I-Chemical +
( O -
pHEMA B-Chemical -
) O +
hydrogels O +
and O +
50 O +
wt% O +
biphasic O +
hydroxyapatite B-Chemical -
/ O -
β B-Chemical -
- I-Chemical -
tricalcium I-Chemical +
phosphate I-Chemical +
( O -
60 O -
/ O -
40 O -
) O +
through O +
in O +
situ O +
polymerization O -
. O +

The O +
hydrolytic O +
degradation O +
starts O +
with O +
hydrolysis O +
of O +
the O +
cross O -
- O -
linker O -
, O +
N B-Chemical -
, I-Chemical +
O I-Chemical -
- I-Chemical -
dimethacryloyl I-Chemical +
hydroxylamine I-Chemical -
, O +
which O +
was O +
synthesized O +
in O +
house O -
. O +

Swelling O +
and O +
degradation O +
were O +
examined O +
in O +
details O +
at O +
a O +
phosphate B-Chemical +
buffered O +
saline O +
solution O +
at O +
37 O +
° O -
C O +
over O +
a O +
12-week O +
period O +
of O +
time O -
. O +

To O +
vary O +
degradability O -
, O +
a O +
co O -
- O -
monomer O -
, O +
acrylic B-Chemical +
acid I-Chemical +
( O -
AA O -
) O +
or O +
2-hydroxypropyl B-Chemical +
methacrylamide I-Chemical +
( O -
HPMA B-Chemical -
) O -
, O +
was O +
introduced O -
, O +
coupled O +
with O +
altering O +
the O +
concentration O +
of O +
the O +
cross O -
- O -
linker O +
and O +
of O +
the O +
bioceramic O -
. O +

The O +
co O -
- O -
monomer O +
HPMA B-Chemical +
was O +
found O +
to O +
be O +
more O +
effective O +
than O +
AA O +
in O +
enhancing O +
degradation O -
, O +
though O +
AA O +
led O +
to O +
greater O +
swelling O +
ratios O -
. O +

33 O -
% O +
of O +
weight O +
loss O +
was O +
achieved O +
in O +
some O +
of O +
the O +
biocomposites O +
containing O +
HPMA B-Chemical -
. O +

Porous O +
structures O +
were O +
developed O +
during O +
swelling O +
and O +
degradation O +
in O +
biocomposites O +
with O +
AA O +
but O +
not O +
in O +
those O +
containing O +
HPMA B-Chemical -
, O +
suggesting O +
different O +
degradation O +
mechanisms O -
: O +
bulk O +
erosion O +
vs. O +
bulk O +
degradation O -
. O +

Good O +
biocompatibility O -
, O +
as O +
evidenced O +
by O +
attachment O +
and O +
proliferation O +
of O +
mouse O -
- O -
derived O +
osteoblast O +
precursor O +
cells O +
from O +
the O +
MC3T3-E1 O +
lineage O -
, O +
was O +
observed O +
on O +
these O +
biomaterials O -
, O +
regardless O +
of O +
the O +
type O +
of O +
the O +
co O -
- O -
monomer O -
. O +

The O +
rationale O +
and O +
approaches O +
employed O +
here O +
open O +
up O +
new O +
opportunities O +
for O +
creating O +
novel O -
, O +
complex O +
organic O -
- O -
inorganic O +
biomaterials O +
in O +
orthopedic O +
tissue O +
engineering O -
. O +

The O +
pre O -
- O -
clinical O +
absorption O -
, O +
distribution O -
, O +
metabolism O +
and O +
excretion O +
properties O +
of O +
IPI-926 B-Chemical -
, O +
an O +
orally O +
bioavailable O +
antagonist O +
of O +
the O +
hedgehog O +
signal O +
transduction O +
pathway O -
. O +

Abstract O +
1 O -
. O +

IPI-926 B-Chemical +
is O +
a O +
novel O +
semisynthetic O +
cyclopamine B-Chemical +
derivative O +
that O +
is O +
a O +
potent O +
and O +
selective O +
Smoothened O +
inhibitor O +
that O +
blocks O +
the O +
hedgehog O +
signal O +
transduction O +
pathway O -
. O +

2 O -
. O +

The O +
in O +
vivo O +
clearance O +
of O +
IPI-926 B-Chemical +
is O +
low O +
in O +
mouse O +
and O +
dog O +
and O +
moderate O +
in O +
monkey O -
. O +

The O +
volume O +
of O +
distribution O +
is O +
high O +
across O +
species O -
. O +

Oral O +
bioavailability O +
ranges O +
from O +
moderate O +
in O +
monkey O +
to O +
high O +
in O +
mouse O +
and O +
dog O -
. O +

Predicted O +
human O +
clearance O +
using O +
simple O +
allometry O +
is O +
low O +
( O -
24 O +
L O +
h O -
( O -
-1 O -
) O -
) O -
, O +
predicted O +
volume O +
of O +
distribution O +
is O +
high O +
( O -
469 O +
L O -
) O +
and O +
predicted O +
half O -
- O -
life O +
is O +
long O +
( O -
20 O +
h O -
) O -
. O +

3 O -
. O +
IPI-926 B-Chemical +
is O +
highly O +
bound O +
to O +
plasma O +
proteins O +
and O +
has O +
minimal O +
interaction O +
with O +
human O +
α-1-acid O +
glycoprotein O -
. O +

4 O -
. O +

In O +
vitro O +
metabolic O +
stability O +
ranges O +
from O +
stable O +
to O +
moderately O +
stable O -
. O +

Twelve O +
oxidative O +
metabolites O +
were O +
detected O +
in O +
mouse O -
, O +
rat O -
, O +
dog O -
, O +
monkey O +
and O +
human O +
liver O +
microsome O +
incubations O +
and O +
none O +
were O +
unique O +
to O +
human O -
. O +

5 O -
. O +

IPI-926 B-Chemical +
is O +
not O +
a O +
potent O +
reversible O +
inhibitor O +
of O +
CYP1A2 O -
, O +
2C8 O -
, O +
2C9 O +
or O +
3A4 O +
( O -
testosterone B-Chemical -
) O -
. O +

IPI-926 B-Chemical +
is O +
a O +
moderate O +
inhibitor O +
of O +
CYP2C19 O -
, O +
2D6 O +
and O +
3A4 O +
( O -
midazolam B-Chemical -
) O +
with O +
KI O +
values O +
of O +
19 O -
, O +
16 O +
and O +
4.5 O +
µM O -
, O +
respectively O -
. O +

IPI-926 B-Chemical +
is O +
both O +
a O +
substrate O +
and O +
inhibitor O +
( O -
IC50 O +
= O +
1.9 O +
µM O -
) O +
of O +
P O -
- O -
glycoprotein O -
. O +

6 O -
. O +

In O +
summary O -
, O +
IPI-926 B-Chemical +
has O +
desirable O +
pre O -
- O -
clinical O +
absorption O -
, O +
distribution O -
, O +
metabolism O +
and O +
excretion O +
properties O -
. O +

A O +
multiple O +
perspectives O +
on O +
atypical O +
polypoid O +
adenomyoma O +
of O +
uterus O -
. O +

Abstract O +
Atypical O +
polypoid O +
adenomyoma O +
( O -
APA O -
) O +
is O +
a O +
rare O +
benign O +
uterine O +
tumor O -
, O +
with O +
less O +
than O +
200 O +
cases O +
have O +
been O +
reported O +
in O +
English O +
literature O -
. O +

Although O -
, O +
it O +
is O +
considered O +
as O +
a O +
benign O +
lesion O +
and O +
treated O +
conservatively O +
previously O -
, O +
more O +
and O +
more O +
cases O +
show O +
that O +
APA O +
has O +
a O +
high O +
rate O +
of O +
recurrence O +
or O +
residual O -
, O +
and O +
is O +
found O +
to O +
precede O +
the O +
development O +
of O +
carcinoma O -
. O +

Given O +
the O +
data O +
from O +
present O +
research O +
on O +
APA O -
, O +
the O +
therapy O +
of O +
APA O +
becomes O +
more O +
complex O +
and O +
must O +
be O +
cautious O -
, O +
especially O +
for O +
the O +
nulliparous O +
and O +
premenopausal O +
patients O -
. O +

In O +
addition O -
, O +
because O +
of O +
the O +
low O +
incidence O -
, O +
studies O +
on O +
this O +
disease O +
are O +
less O -
, O +
and O +
the O +
etiology O +
and O +
pathogenesis O +
of O +
APA O +
is O +
still O +
unclear O -
. O +

In O +
this O +
review O -
, O +
we O +
aim O +
to O +
summarize O +
recent O +
researches O +
concerning O +
APA O +
from O +
multiple O +
perspectives O -
, O +
including O +
clinical O +
presentation O -
, O +
histogenesis O -
, O +
immunohistochemistry O +
and O +
molecular O +
features O -
, O +
diagnosis O +
and O +
differential O +
diagnosis O -
, O +
treatment O +
opinion O +
and O +
prognosis O -
, O +
which O +
may O +
provide O +
theory O +
and O +
clinical O +
basis O +
for O +
the O +
future O +
clinical O +
treatment O +
and O +
research O +
of O +
this O +
rare O +
disease O -
. O +

Path O -
- O -
Branching O +
Representation O +
for O +
Nonadiabatic O +
Electron O +
Dynamics O +
in O +
Conical O +
Intersection O -
. O +

Path O -
- O -
branching O +
representation O +
( O -
or O +
phase O -
- O -
space O +
averaging O +
and O +
natural O +
branching O +
method O +
( O -
PSANB O -
) O +
as O +
its O +
approximation O -
) O +
of O +
nonadiabatic O +
electron O +
wavepacket O +
dynamics O +
is O +
now O +
known O +
to O +
work O +
well O +
for O +
avoided O +
crossings O +
in O +
many O +
dimensional O +
nonadiabatic O +
transitions O +
[ O +
Yonehara O +
, O +
T. O +
; O +
Hanasaki O +
, O +
K. O +
; O +
Takatsuka O +
, O +
K. O +
Chem O -
. O +

Rev. O +
2012 O +
, O +
112 O +
, O +
499 O +
] O -
. O +

In O +
this O +
paper O +
we O +
examine O +
feasibility O +
of O +
the O +
path O -
- O -
branching O +
representation O +
in O +
the O +
theoretical O +
studies O +
of O +
conical O +
intersection O +
( O -
CI O -
) O -
. O +

The O +
most O +
characteristic O +
feature O +
of O +
CI O +
is O +
the O +
Herzberg O -
- O -
Longuet O -
- O -
Higgins O +
phase O +
( O -
or O +
the O +
Berry O +
phase O -
) O +
arising O +
from O +
the O +
electronic O +
part O +
of O +
the O +
total O +
wave O +
function O -
, O +
and O +
accordingly O +
quantum O +
phases O +
of O +
both O +
electronic O +
and O +
nuclear O +
dynamics O +
should O +
be O +
taken O +
into O +
account O +
in O +
a O +
balanced O +
manner O -
. O +

We O +
first O +
show O +
the O +
PSANB O +
can O +
well O +
capture O +
the O +
essential O +
feature O +
of O +
the O +
phase O +
dynamics O +
of O +
CI O -
. O +

However O -
, O +
the O +
nuclear O +
phases O -
, O +
the O +
wavelength O +
of O +
which O +
is O +
far O +
shorter O +
than O +
that O +
of O +
the O +
electronic O +
phases O -
, O +
make O +
the O +
computation O +
of O +
nonadiabatic O +
transition O +
extremely O +
oscillatory O -
, O +
resulting O +
in O +
very O +
slow O +
convergence O +
with O +
respect O +
to O +
the O +
number O +
of O +
sampling O +
paths O -
. O +

A O +
similar O +
difficulty O +
quite O +
often O +
takes O +
place O +
in O +
theoretical O +
chemical O +
dynamics O -
. O +

To O +
cope O +
with O +
this O +
situation O -
, O +
we O +
devise O +
a O +
simple O +
and O +
tractable O +
approximation O +
in O +
the O +
application O +
of O +
PSANB O +
resting O +
on O +
the O +
fact O +
that O +
a O +
small O +
number O +
of O +
PSANB O +
paths O +
already O +
reproduce O +
accurate O +
nonadiabatic O +
transition O +
probability O -
. O +

Complement O +
activation O +
by O +
PEGylated O +
liposomes O +
containing O +
prednisolone B-Chemical -
. O +

Infusion O +
of O +
PEGylated O +
liposomes O +
can O +
give O +
rise O +
to O +
hypersensitivity O +
reactions O +
( O -
HSRs O -
) O +
in O +
a O +
relatively O +
large O +
number O +
of O +
patients O -
. O +

Previously O +
it O +
has O +
been O +
shown O +
that O +
these O +
reactions O +
can O +
be O +
caused O +
by O +
activation O +
of O +
the O +
complement O +
( O -
C O -
) O +
system O +
by O +
a O +
negative O +
charge O +
on O +
the O +
anchor O +
molecule O +
of O +
PEG B-Chemical +
at O +
the O +
liposomal O +
surface O -
. O +

In O +
this O +
study O +
it O +
is O +
tested O +
whether O +
the O +
activation O +
of O +
the O +
C O +
system O +
by O +
PEG B-Chemical -
- O -
liposomes O +
could O +
be O +
significantly O +
reduced O +
to O +
values O +
comparable O +
to O +
nonreactive O +
liposomal O +
formulations O -
, O +
by O +
changing O +
the O +
PEGylation O -
- O -
profile O +
on O +
the O +
liposomal O +
surface O -
. O +

Therefore O -
, O +
the O +
formation O +
of O +
C O +
activation O +
markers O +
SC5b-9 O -
, O +
C3a O -
, O +
C4d O +
and O +
Bb O +
in O +
normal O +
human O +
serum O +
by O +
both O +
prednisolone B-Chemical +
loaded O +
and O +
empty O +
liposomes O +
with O +
a O +
variation O +
of O +
PEG B-Chemical +
chain O +
length O -
, O +
PEG B-Chemical +
surface O +
concentration O -
, O +
PEG B-Chemical +
anchor O +
molecule O +
and O +
liposomal O +
size O +
was O +
determined O +
using O +
in O +
vitro O +
assays O -
. O +

The O +
tested O +
liposomes O +
caused O +
no O +
or O +
only O +
mild O +
( O -
30 O -
% O -
) O +
activation O +
of O +
C O +
except O +
for O +
one O +
formulation O +
wherein O +
the O +
PEG2000 B-Chemical +
was O +
anchored O +
to O +
cholesterol B-Chemical +
( O -
CHOL B-Chemical -
- I-Chemical -
PEG2000 I-Chemical -
) O -
. O +

The O +
latter O +
liposomes O +
caused O +
paralleling O +
rises O +
in O +
SC5b-9 O +
and O +
Bb O +
levels O -
, O +
suggesting O +
excess O +
activation O +
of O +
the O +
alternative O +
pathway O -
. O +

While O +
the O +
relative O +
safety O +
of O +
weak O +
C O +
activator O +
liposomes O +
remains O +
to O +
be O +
confirmed O +
in O +
vivo O -
, O +
the O +
unique O -
, O +
non O -
- O -
charge O +
and O +
non O -
- O -
antibody O -
- O -
mediated O +
direct O +
conversion O +
of O +
C3 O +
by O +
CHOL B-Chemical -
- I-Chemical -
PEG2000 I-Chemical +
liposomes O +
( O -
although O +
argues O +
against O +
the O +
clinical O +
development O +
of O +
these O +
vesicles O -
) O +
opens O +
new O +
opportunities O +
to O +
understand O +
liposomal O +
C O +
activation O +
at O +
the O +
molecular O +
level O -
. O +

Technological O +
and O +
biopharmaceutical O +
optimization O +
of O +
nystatin B-Chemical +
release O +
from O +
a O +
multiparticulate O +
based O +
bioadhesive O +
drug O +
delivery O +
system O -
. O +

Formulation O +
considerations O +
of O +
a O +
new O +
drug O +
delivery O +
system O +
include O +
controlling O +
the O +
site O +
of O +
release O +
of O +
the O +
active O +
ingredient O -
, O +
maintaining O +
drug O +
level O +
for O +
a O +
suitable O +
time O +
and O +
decreasing O +
dosage O +
frequency O -
. O +

In O +
research O +
and O +
development O +
practice O -
, O +
these O +
therapeutic O +
benefits O +
can O +
be O +
attained O +
by O +
selecting O +
suitable O +
active O +
ingredients O +
and O +
optimizing O +
procedure O +
parameters O -
, O +
determining O +
the O +
composition O +
of O +
the O +
medicine O -
, O +
and O +
dissolution O +
properties O -
. O +

The O +
aim O +
of O +
our O +
study O +
was O +
to O +
design O +
a O +
pharmaceutical O +
preparation O +
with O +
increased O +
local O +
therapeutic O +
effect O +
in O +
the O +
therapy O +
of O +
gastrointestinal O +
candidiasis O -
. O +

The O +
polyene B-Chemical +
antibiotic O +
nystatin B-Chemical +
may O +
be O +
an O +
optimal O +
choice O +
for O +
active O +
agent O -
, O +
incorporated O +
in O +
a O +
bioadhesive O +
multiparticulate O +
system O -
. O +

Choosing O +
the O +
proper O +
excipients O +
in O +
the O +
proper O +
dosage O +
form O +
and O +
ensuring O +
prolonged O +
residence O +
time O +
may O +
further O +
improve O +
the O +
optimal O +
treatment O -
. O +

Using O +
an O +
experimental O +
design O -
, O +
the O +
micropellets O +
were O +
prepared O +
with O +
5 O -
% O +
nystatin B-Chemical +
content O -
, O +
taking O +
the O +
factors O +
average O +
pellet O +
size O +
( O -
∼200 O +
to O +
∼800μm O -
) O +
and O +
the O +
amount O +
of O +
applied O +
carbomer O +
and O +
hydroxyethylcellulose O +
( O -
0 O -
- O -
5 O -
% O -
) O +
into O +
consideration O -
. O +

Dissolution O +
of O +
the O +
active O +
ingredient O +
was O +
detected O +
by O +
UV O +
spectrophotometric O +
and O +
microbiological O +
assay O -
. O +

The O +
bioadhesive O +
character O +
of O +
the O +
multiparticulate O +
dosage O +
form O +
was O +
examined O +
by O +
ex O +
vivo O +
wash O -
- O -
off O +
test O -
. O +

The O +
only O +
factor O +
which O +
significantly O +
influenced O +
the O +
examined O +
parameters O +
was O +
average O +
pellet O +
size O -
. O +

The O +
proportion O +
of O +
applied O +
bioadhesive O +
excipients O +
had O +
significance O +
mostly O +
in O +
interactions O +
with O +
average O +
pellet O +
size O -
. O +

Eventually O -
, O +
optimized O +
drug O +
release O +
( O -
5 O -
- O -
10min O +
mean O +
dissolution O +
time O -
, O +
50 O -
- O -
55 O -
% O +
bioadhesion O +
retention O -
) O +
could O +
be O +
achieved O +
with O +
550μm O +
pellet O +
size O -
, O +
containing O +
carbomer O +
and O +
hydroxyethylcellulose O +
in O +
85:15 O +
ratio O -
. O +

The O +
molecular O +
fingerprint O +
of O +
high O +
grade O +
serous O +
ovarian O +
cancer O +
reflects O +
its O +
fallopian O +
tube O +
origin O -
. O +

High O +
grade O +
serous O +
ovarian O +
cancer O +
( O -
HGSC O -
) O -
, O +
the O +
most O +
lethal O +
and O +
frequent O +
type O +
of O +
epithelial O +
ovarian O +
cancer O +
( O -
EOC O -
) O -
, O +
has O +
poor O +
long O +
term O +
prognosis O +
due O +
to O +
a O +
combination O +
of O +
factors O -
: O +
late O +
detection O -
, O +
great O +
metastatic O +
potential O +
and O +
the O +
capacity O +
to O +
develop O +
resistance O +
to O +
available O +
therapeutic O +
drugs O -
. O +

Furthermore O -
, O +
there O +
has O +
been O +
considerable O +
controversy O +
concerning O +
the O +
etiology O +
of O +
this O +
malignancy O -
. O +

New O +
studies O -
, O +
both O +
clinical O +
and O +
molecular O -
, O +
strongly O +
suggest O +
that O +
HGSC O +
originates O +
not O +
from O +
the O +
surface O +
of O +
the O +
ovary O -
, O +
but O +
from O +
the O +
epithelial O +
layer O +
of O +
the O +
neighboring O +
fallopian O +
tube O +
fimbriae O -
. O +

In O +
this O +
paper O +
we O +
summarize O +
data O +
supporting O +
the O +
central O +
role O +
of O +
fallopian O +
tube O +
epithelium O +
in O +
the O +
development O +
of O +
HGSC O -
. O +

Specifically O -
, O +
we O +
address O +
cellular O +
pathways O +
and O +
regulatory O +
mechanisms O +
which O +
are O +
modulated O +
in O +
the O +
process O +
of O +
transformation O -
, O +
but O +
also O +
genetic O +
changes O +
which O +
accumulate O +
during O +
disease O +
progression O -
. O +

Similarities O +
between O +
fallopian O +
tube O +
mucosa O +
and O +
the O +
malignant O +
tissue O +
of O +
HGSC O +
warrant O +
a O +
closer O +
analysis O +
of O +
homeostatic O +
mechanisms O +
in O +
healthy O +
epithelium O +
in O +
order O +
to O +
elucidate O +
key O +
steps O +
in O +
disease O +
development O -
. O +

Finally O -
, O +
we O +
highlight O +
the O +
importance O +
of O +
the O +
cancer O +
stem O +
cell O +
( O -
CSC O -
) O +
identification O +
and O +
understanding O +
of O +
its O +
niche O +
regulation O +
for O +
improvement O +
of O +
therapeutic O +
strategies O -
. O +

Broadband O +
Light O -
- O -
Trapping O +
Enhancement O +
in O +
an O +
Ultrathin O +
Film O +
a O -
- O -
Si B-Chemical +
Absorber O +
Using O +
Whispering O +
Gallery O +
Modes O +
and O +
Guided O +
Wave O +
Modes O +
with O +
Dielectric O +
Surface O -
- O -
Textured O +
Structures O -
. O +

An O +
embedded O +
nanosphere O +
dielectric O +
structure O +
on O +
an O +
a O -
- O -
Si B-Chemical +
ultrathin O +
film O +
improves O +
weighted O +
absorption O +
from O +
23.8 O -
% O +
to O +
39.9 O -
% O -
. O +

The O +
PMMA B-Chemical +
embedding O +
layer O +
offers O +
a O +
guided O +
wave O +
mode O +
as O +
well O +
as O +
mechanical O +
robustness O -
, O +
in O +
addition O +
to O +
the O +
resonant O +
whispering O +
gallery O +
modes O +
coupling O -
. O +

Broadband O +
light O -
- O -
trapping O +
enhancements O +
are O +
observed O +
by O +
dielectric O +
surface O +
textured O +
structures O +
of O +
hemispheres O -
, O +
nanocones O -
, O +
nanospheres O -
, O +
or O +
embedded O +
nanospheres O -
. O +

The O +
Protective O +
Effects O +
of O +
α B-Chemical -
- I-Chemical -
Lipoic I-Chemical +
Acid I-Chemical +
on O +
Kidneys O +
in O +
Type O +
2 O +
Diabetic O +
Goto O -
- O -
Kakisaki O +
Rats O +
via O +
Reducing O +
Oxidative O +
Stress O -
. O +

To O +
evaluate O +
the O +
protective O +
effects O +
of O +
α B-Chemical -
- I-Chemical -
lipoic I-Chemical +
acid I-Chemical +
on O +
the O +
kidneys O +
of O +
Goto O -
- O -
Kakisaki O +
( O -
GK O -
) O +
diabetic O +
rats O -
, O +
ten O +
GK O +
diabetic O +
rats O +
were O +
randomly O +
divided O +
into O +
a O +
diabetic O +
control O +
group O +
and O +
a O +
lipoic B-Chemical +
acid I-Chemical -
- O -
treated O +
diabetic O +
group O +
with O +
α B-Chemical -
- I-Chemical -
lipoic I-Chemical +
acid I-Chemical +
35 O +
mg·Kg-1 O +
intraperitoneal O +
injections O -
. O +

Four O +
healthy O +
Wistar O +
rats O +
served O +
as O +
normal O +
controls O -
. O +

Malonaldehyde B-Chemical +
( O -
MDA B-Chemical -
) O -
, O +
ascorbic B-Chemical +
acid I-Chemical +
( O -
vitamin B-Chemical +
C I-Chemical -
) O -
, O +
vitamin B-Chemical +
E I-Chemical -
, O +
glutathione B-Chemical +
( O -
GSH B-Chemical -
) O +
and O +
superoxide B-Chemical +
dismutase O +
( O -
SOD O -
) O +
levels O +
in O +
renal O +
homogenate O -
, O +
and O +
urine O +
protein O +
excretion O +
were O +
measured O -
. O +

The O +
expression O +
of O +
mRNA O +
for O +
NF O -
- O -
κB O -
, O +
NADPH B-Chemical +
oxidase O +
subunits O +
p22phox O +
and O +
p47phox O +
in O +
renal O +
tissue O +
was O +
examined O +
by O +
realtime O +
PCR O -
. O +

Pathological O +
changes O +
in O +
renal O +
tissue O +
were O +
evaluated O +
by O +
light O +
and O +
electron O +
microscopy O -
. O +

There O +
were O +
significant O +
increases O +
in O +
urine O +
protein O +
excretion O -
, O +
MDA B-Chemical +
levels O +
and O +
the O +
expression O +
of O +
mRNA O +
of O +
NF O -
- O -
κB O -
, O +
p22phox O +
and O +
p47phox O -
, O +
and O +
significant O +
decreases O +
in O +
GSH B-Chemical -
, O +
SOD O -
, O +
vitamin B-Chemical +
C I-Chemical +
and O +
vitamin B-Chemical +
E I-Chemical +
levels O +
in O +
the O +
diabetic O +
control O +
group O +
compared O +
with O +
the O +
normal O +
control O +
group O -
. O +

Pathological O +
changes O +
of O +
renal O +
tissue O +
were O +
more O +
progressive O +
in O +
the O +
diabetic O +
control O +
group O +
than O +
in O +
the O +
normal O +
control O +
group O -
. O +

All O +
the O +
parameters O +
above O +
were O +
improved O +
in O +
the O +
α B-Chemical -
- I-Chemical -
lipoic I-Chemical +
acid I-Chemical -
- O -
treated O +
diabetic O +
group O -
. O +

Oxidative O +
stress O +
is O +
increased O +
in O +
the O +
kidney O +
of O +
type O +
2 O +
diabetic O +
GK O +
rats O -
. O +

It O +
is O +
associated O +
with O +
the O +
progression O +
of O +
diabetic O +
nephropathy O -
. O +

α B-Chemical -
- I-Chemical -
lipoic I-Chemical +
acid I-Chemical +
can O +
protect O +
renal O +
function O +
in O +
diabetic O +
rats O +
via O +
its O +
antioxidant O +
activity O -
. O +

Effect O +
of O +
oxygen B-Chemical +
concentration O +
and O +
selected O +
protocol O +
factors O +
on O +
viability O +
and O +
gene O +
expression O +
of O +
mouse O +
liver O +
slices O -
. O +

Precision O +
cut O +
liver O +
slices O +
( O -
PCLSs O -
) O +
are O +
widely O +
used O +
as O +
a O +
model O +
to O +
study O +
hepatotoxicity O -
. O +

For O +
culturing O +
of O +
PCLS O +
diverse O +
protocols O +
are O +
used O +
which O +
could O +
affect O +
slices O +
viability O +
and O +
results O -
. O +

We O +
aimed O +
to O +
identify O +
the O +
most O +
optimal O +
culture O +
protocol O +
for O +
mouse O +
PCLS O -
. O +

Slices O +
were O +
cultured O +
for O +
24h O +
under O +
different O +
concentrations O +
of O +
serum O -
, O +
glucose B-Chemical -
, O +
insulin O -
, O +
and O +
oxygen B-Chemical -
. O +

Thereafter O -
, O +
slices O +
viability O +
was O +
assessed O +
by O +
biochemical O +
methods O -
. O +

Transcriptome O +
analysis O +
was O +
performed O +
to O +
identify O +
changes O +
introduced O +
by O +
culture O +
at O +
different O +
oxygen B-Chemical +
concentrations O +
( O -
20 O -
% O -
, O +
40 O -
% O -
, O +
60 O -
% O -
, O +
and O +
80 O -
% O +
of O +
oxygen B-Chemical -
) O -
. O +

Medium O +
composition O +
did O +
not O +
affect O +
the O +
slices O +
viability O -
. O +

Although O +
metabolic O +
competence O +
was O +
unaffected O +
by O +
oxygen B-Chemical +
concentrations O -
, O +
culturing O +
at O +
80 O -
% O +
of O +
oxygen B-Chemical +
yielded O +
slices O +
with O +
the O +
best O +
biochemical O +
characteristics O -
. O +

The O +
comparison O +
of O +
uncultured O +
vs. O +
cultured O +
slices O +
revealed O +
2524 O +
genes O +
to O +
be O +
differentially O +
expressed O -
. O +

Genes O +
involved O +
in O +
drug O +
metabolism O -
, O +
peroxisomal O +
and O +
mitochondrial O +
functions O +
were O +
down O -
- O -
regulated O +
while O +
several O +
adaptive O -
/ O -
stress O +
response O +
processes O +
were O +
up O -
- O -
regulated O -
. O +

Moreover O -
, O +
80 O -
% O +
of O +
oxygen B-Chemical +
was O +
the O +
most O +
favorable O +
condition O +
with O +
respect O +
to O +
maintenance O +
of O +
expression O +
of O +
genes O +
involved O +
in O +
drug O +
and O +
energy O +
metabolism O -
. O +

The O +
outcome O +
of O +
this O +
study O +
indicates O +
that O +
mouse O +
PCLS O +
are O +
a O +
valuable O +
tool O +
in O +
research O +
on O +
hepatic O +
functions O +
and O +
toxicity O -
, O +
particularly O +
if O +
they O +
are O +
cultured O +
under O +
a O +
controlled O +
oxygen B-Chemical +
concentration O +
of O +
80 O -
% O -
. O +

The O +
noncellular O +
reduction O +
of O +
MTT B-Chemical +
tetrazolium I-Chemical +
salt I-Chemical +
by O +
TiO2 B-Chemical +
nanoparticles O +
and O +
its O +
implications O +
for O +
cytotoxicity O +
assays O -
. O +

We O +
report O +
results O +
of O +
noncellular O +
tests O -
, O +
revealing O +
the O +
occurrence O +
of O +
photocatalytic O +
interactions O +
between O +
titanium B-Chemical +
dioxide I-Chemical +
( O -
TiO2 B-Chemical -
, O +
titania B-Chemical -
) O +
nanoparticles O +
and O +
the O +
MTT B-Chemical +
[ O -
3- B-Chemical -
( I-Chemical -
4,5-Dimethylthiazol-2-yl I-Chemical -
) I-Chemical -
-2,5-diphenyltetrazolium I-Chemical -
- I-Chemical -
bromide I-Chemical -
] O +
cytotoxicity O +
indicator O -
. O +

These O +
interactions O +
induce O +
the O +
reduction O +
of O +
MTT B-Chemical +
and O +
formation O +
of O +
purple O +
formazan O +
under O +
biologically O +
relevant O +
conditions O -
. O +

Classical O +
MTT B-Chemical +
assays O +
have O +
been O +
performed O +
to O +
evaluate O +
the O +
production O +
of O +
formazan B-Chemical +
in O +
DMEM O -
- O -
F12 O +
and O +
RPMI-1640 O +
cell O +
culture O +
media O +
( O -
containing O +
10 O -
% O +
fetal O +
bovine O +
serum O -
- O -
FBS O -
) O +
treated O +
with O +
Degussa O -
- O -
P25 B-Chemical +
TiO2 I-Chemical +
nanoparticles O -
, O +
in O +
the O +
absence O +
of O +
cells O -
. O +

The O +
colorimetric O +
determinations O +
revealed O +
the O +
noncellular O +
MTT B-Chemical +
to O +
formazan B-Chemical +
transformation O +
induced O +
by O +
TiO2 B-Chemical +
nanoparticles O -
, O +
under O +
conditions O +
commonly O +
used O +
for O +
in O +
vitro O +
cytotoxicity O +
testing O +
of O +
nanomaterials O -
. O +

The O +
formazan B-Chemical +
precipitation O +
was O +
found O +
to O +
be O +
proportional O +
to O +
the O +
TiO2 B-Chemical +
concentration O -
, O +
being O +
enhanced O +
under O +
laboratory O +
daylight O +
exposure O -
. O +

The O +
photocatalytic O +
nature O +
of O +
the O +
studied O +
effect O +
was O +
assessed O +
under O +
UV O +
irradiation O +
at O +
365 O -
nm O -
. O +

The O +
biological O +
significance O +
of O +
the O +
reported O +
reaction O +
was O +
established O +
with O +
respect O +
to O +
cellular O +
reference O +
experiments O +
performed O +
on O +
V79 O -
- O -
4 O -
, O +
HeLa O +
and O +
B16 O +
cell O +
lines O -
. O +

The O +
results O +
show O +
false O +
viability O +
increases O +
with O +
up O +
to O +
14 O -
% O +
( O -
for O +
TiO2 B-Chemical +
concentrations O +
generally O +
higher O +
than O +
50μg O -
/ O -
ml O -
) O -
, O +
induced O +
by O +
the O +
TiO2-MTT B-Chemical +
reaction O -
. O +

This O +
type O +
of O +
artifacts O +
may O +
lead O +
to O +
underestimated O +
toxicity O +
or O +
false O +
proliferation O +
results O -
. O +

Streptococcal O +
collagen O -
- O -
like O +
protein O +
A O +
and O +
general O +
stress O +
protein O +
24 O +
are O +
immunomodulating O +
virulence O +
factors O +
of O +
group O +
A O +
Streptococcus O -
. O +

In O +
Western O +
countries O -
, O +
invasive O +
infections O +
caused O +
by O +
M1T1 O +
serotype O +
group O +
A O +
Streptococcus O +
( O -
GAS O -
) O +
are O +
epidemiologically O +
linked O +
to O +
mutations O +
in O +
the O +
control O +
of O +
virulence O +
regulatory O +
2-component O +
operon O +
( O -
covRS O -
) O -
. O +

In O +
indigenous O +
communities O +
and O +
developing O +
countries O -
, O +
severe O +
GAS O +
disease O +
is O +
associated O +
with O +
genetically O +
diverse O +
non O -
- O -
M1T1 O +
GAS O +
serotypes O -
. O +

Hypervirulent O +
M1T1 O +
covRS O +
mutant O +
strains O +
arise O +
through O +
selection O +
by O +
human O +
polymorphonuclear O +
cells O +
for O +
increased O +
expression O +
of O +
GAS O +
virulence O +
factors O +
such O +
as O +
the O +
DNase O +
Sda1 O -
, O +
which O +
promotes O +
neutrophil O +
resistance O -
. O +

The O +
GAS O +
bacteremia O +
isolate O +
NS88.2 O +
( O -
emm O +
98.1 O -
) O +
is O +
a O +
covS O +
mutant O +
that O +
exhibits O +
a O +
hypervirulent O +
phenotype O +
and O +
neutrophil O +
resistance O +
yet O +
lacks O +
the O +
phage O -
- O -
encoded O +
Sda1 O -
. O +

Here O -
, O +
we O +
have O +
employed O +
a O +
comprehensive O +
systems O +
biology O +
( O -
genomic O -
, O +
transcriptomic O -
, O +
and O +
proteomic O -
) O +
approach O +
to O +
identify O +
NS88.2 O +
virulence O +
determinants O +
that O +
enhance O +
neutrophil O +
resistance O +
in O +
the O +
non O -
- O -
M1T1 O +
GAS O +
genetic O +
background O -
. O +

Using O +
this O +
approach O -
, O +
we O +
have O +
identified O +
streptococcal O +
collagen O -
- O -
like O +
protein O +
A O +
and O +
general O +
stress O +
protein O +
24 O +
proteins O +
as O +
NS88.2 O +
determinants O +
that O +
contribute O +
to O +
survival O +
in O +
whole O +
blood O +
and O +
neutrophil O +
resistance O +
in O +
non O -
- O -
M1T1 O +
GAS O -
. O +

This O +
study O +
has O +
revealed O +
new O +
factors O +
that O +
contribute O +
to O +
GAS O +
pathogenicity O +
that O +
may O +
play O +
important O +
roles O +
in O +
resisting O +
innate O +
immune O +
defenses O +
and O +
the O +
development O +
of O +
human O +
invasive O +
infections O -
- O -
Tsatsaronis O -
, O +
J. O +
A. O -
, O +
Hollands O -
, O +
A. O -
, O +
Cole O -
, O +
J. O +
N. O -
, O +
Maamary O -
, O +
P. O +
G. O -
, O +
Gillen O -
, O +
C. O +
M. O -
, O +
Ben O +
Zakour O -
, O +
N. O +
L. O -
, O +
Kotb O -
, O +
M. O -
, O +
Nizet O -
, O +
V. O -
, O +
Beatson O -
, O +
S. O +
A. O +
Walker O -
, O +
M. O +
J. O -
, O +
Sanderson O -
- O -
Smith O -
, O +
M. O +
L. O +
Streptococcal O +
collagen O -
- O -
like O +
protein O +
A O +
and O +
general O +
stress O +
protein O +
24 O +
are O +
immunomodulating O +
virulence O +
factors O +
of O +
group O +
A O +
Streptococcus O -
. O +

Analysis O +
of O +
visible O -
- O -
light O -
- O -
active O +
Sn B-Chemical -
( I-Chemical -
ii I-Chemical -
) I-Chemical -
-TiO2 O +
photocatalysts O -
. O +

The O +
influence O +
of O +
Sn B-Chemical -
( I-Chemical -
ii I-Chemical -
) I-Chemical +
species O +
on O +
TiO2 B-Chemical +
is O +
investigated O -
. O +

The O +
absorption O +
spectra O +
of O +
these O +
materials O +
are O +
red O -
- O -
shifted O +
by O +
115 O +
nm O +
to O +
the O +
visible O +
region O +
of O +
the O +
solar O +
spectrum O +
compared O +
with O +
P25 B-Chemical +
TiO2 I-Chemical -
. O +

This O +
prominent O +
red O -
- O -
shift O +
is O +
attributed O +
to O +
the O +
interaction O +
of O +
Sn B-Chemical -
( I-Chemical -
ii I-Chemical -
) I-Chemical +
5s O +
orbitals O +
with O +
the O +
TiO2 B-Chemical +
decreasing O +
the O +
band O +
gap O +
of O +
TiO2 B-Chemical +
by O +
raising O +
its O +
valence O +
band O -
. O +

The O +
tin B-Chemical +
oxidation O +
state O +
and O +
the O +
materials O +
electronic O +
structure O +
are O +
evaluated O +
using O +
Mössbauer O +
spectroscopy O +
and O +
valence O +
band O +
X O -
- O -
ray O +
photoelectron O +
spectroscopy O +
respectively O -
. O +

These O +
materials O +
are O +
active O +
for O +
sacrificial O +
photo O -
- O -
generation O +
of O +
hydrogen B-Chemical +
in O +
visible O +
light O -
. O +

A O +
pyrrolidinium B-Chemical +
nitrate I-Chemical +
protic O +
ionic O +
liquid O -
- O -
based O +
electrolyte O +
for O +
very O +
low O -
- O -
temperature O +
electrical O +
double O -
- O -
layer O +
capacitors O -
. O +

This O +
study O +
describes O +
the O +
use O +
of O +
the O +
pyrrolidinium B-Chemical +
nitrate I-Chemical +
( O -
[ B-Chemical -
Pyrr I-Chemical -
] I-Chemical -
[ I-Chemical -
NO3 I-Chemical -
] I-Chemical -
) O +
protic O +
ionic O +
liquid O +
( O -
PIL O -
) O +
in O +
a O +
mixture O +
with O +
gamma B-Chemical +
butyrolactone I-Chemical +
( O -
γ B-Chemical -
- I-Chemical -
BL I-Chemical -
) O +
as O +
an O +
electrolyte O +
for O +
carbon B-Chemical -
- O -
based O +
supercapacitors O +
with O +
an O +
operating O +
voltage O +
of O +
2.0 O +
V O +
and O +
at O +
very O +
low O +
temperature O -
. O +

Thermal O +
and O +
transport O +
properties O +
of O +
this O +
electrolyte O +
were O +
firstly O +
evaluated O +
from O +
-40 O +
° O -
C O +
to O +
80 O +
° O -
C O -
. O +

The O +
evolution O +
of O +
conductivity O +
with O +
the O +
addition O +
of O +
γ B-Chemical -
- I-Chemical -
BL I-Chemical +
rendered O +
it O +
possible O +
to O +
determine O +
the O +
optimal O +
composition O +
for O +
electrochemical O +
application O -
, O +
with O +
a O +
molar O +
fraction O +
of O +
γ B-Chemical -
- I-Chemical -
BL I-Chemical +
of O +
0.6 O -
. O +

This O +
mixture O +
shows O +
a O +
Newtonian O +
behavior O +
with O +
a O +
low O +
viscosity O +
value O +
of O +
5 O +
mPa O +
s O +
at O +
25 O +
° O -
C O -
, O +
and O +
exhibits O +
high O +
conductivity O +
values O +
of O +
up O +
to O +
65 O +
mS O +
cm O -
( O -
-1 O -
) O +
at O +
80 O +
° O -
C O -
. O +

At O +
the O +
same O +
time O -
, O +
exceptional O +
residual O +
conductivity O +
was O +
measured O +
for O +
this O +
composition O +
at O +
-40 O +
° O -
C O +
( O -
9 O +
mS O +
cm O -
( O -
-1 O -
) O -
) O -
, O +
thanks O +
to O +
the O +
superionic O +
character O +
of O +
pyrrolidinium B-Chemical +
nitrate I-Chemical +
PIL O -
. O +

Electrochemical O +
characterization O +
of O +
this O +
electrolyte O +
demonstrated O -
, O +
at O +
first O -
, O +
a O +
passivation O +
on O +
the O +
aluminum B-Chemical +
collector O -
, O +
secondly O +
good O +
cycling O +
performances O +
with O +
an O +
activated O +
carbon B-Chemical +
electrode O +
from O +
50 O +
° O -
C O +
to O +
-40 O +
° O -
C O +
with O +
capacitance O +
up O +
to O +
132 O +
F O +
g O -
( O -
-1 O -
) O +
at O +
room O +
temperature O +
and O +
a O +
wide O +
voltage O +
window O +
( O -
2.0 O +
V O -
) O -
. O +

Finally O +
at O +
very O +
low O +
temperature O +
( O -
-40 O +
° O -
C O -
) O -
, O +
this O +
system O +
demonstrates O +
an O +
unprecedented O +
combination O +
of O +
high O +
specific O +
capacitance O +
( O -
up O +
to O +
117 O +
F O +
g O -
( O -
-1 O -
) O -
) O -
, O +
and O +
rapid O +
charging O -
- O -
discharging O +
even O +
at O +
high O +
current O +
density O -
, O +
which O +
is O +
very O +
promising O +
for O +
the O +
progress O +
of O +
energy O +
storage O +
systems O +
with O +
environmentally O +
friendly O +
electrolytes O +
at O +
such O +
very O +
low O +
temperatures O -
. O +

Tryptophan B-Chemical +
residue O +
at O +
active O -
- O -
site O +
tunnel O +
entrance O +
of O +
Trichoderma O +
reesei O +
cellobiohydrolase O +
Cel7A O +
is O +
important O +
to O +
initiate O +
degradation O +
of O +
crystalline O +
cellulose O -
. O +

Glycoside O +
hydrolase O +
family-7 O +
cellobiohydrolase O +
from O +
Trichoderma O +
reesei O +
( O -
TrCel7A O -
) O +
is O +
one O +
of O +
the O +
best O -
- O -
studied O +
cellulases O +
with O +
the O +
ability O +
to O +
degrade O +
highly O +
crystalline O +
cellulose O +
( O -
HCC O -
) O -
. O +

The O +
catalytic O +
domain O +
( O -
cat O -
) O +
and O +
cellulose O -
- O -
binding O +
domain O +
( O -
CBD O -
) O +
are O +
both O +
necessary O +
for O +
full O +
activity O +
on O +
crystalline O +
substrates O -
. O +

Our O +
previous O +
high O -
- O -
speed O +
AFM O +
studies O +
showed O +
that O +
mutation O +
of O +
tryptophan B-Chemical +
residue O +
( O -
Trp40 B-Chemical -
; O +
W40 O -
) O +
at O +
the O +
entrance O +
of O +
the O +
catalytic O +
tunnel O +
drastically O +
decreases O +
the O +
ability O +
to O +
degrade O +
crystalline O +
cellulose O -
. O +

Here O -
, O +
we O +
examined O +
the O +
activities O +
of O +
the O +
wild O -
- O -
type O +
( O -
WT O -
) O +
enzyme O +
and O +
tryptophan B-Chemical +
to O +
alanine B-Chemical +
mutant O +
( O -
W40A O -
) O +
enzyme O -
, O +
with O +
and O +
without O +
the O +
CBD O -
, O +
towards O +
various O +
substrates O -
. O +

Evaluation O +
and O +
comparison O +
of O +
the O +
specific O +
activities O +
of O +
the O +
enzymes O +
( O -
WT O -
, O +
WTcat O -
, O +
W40A O -
, O +
and O +
W40Acat O -
) O +
adsorbed O +
on O +
crystalline O +
cellulose O +
indicated O +
that O +
Trp40 B-Chemical +
is O +
involved O +
in O +
recruiting O +
individual O +
substrate O +
chains O +
into O +
the O +
active O +
site O +
tunnel O +
to O +
initiate O +
processive O +
hydrolysis O -
. O +

This O +
idea O +
was O +
supported O +
by O +
molecular O +
dynamics O +
simulation O +
study O -
, O +
i.e. O -
, O +
the O +
reducing O -
- O -
end O +
glucose B-Chemical +
unit O +
was O +
effectively O +
loaded O +
into O +
the O +
active O +
site O +
of O +
WTcat O -
, O +
but O +
not O +
into O +
that O +
of O +
W40Acat O -
. O +

when O +
the O +
simulation O +
was O +
started O +
from O +
subsite O +
-7 O -
. O +

However O -
, O +
when O +
the O +
similar O +
simulations O +
were O +
carried O +
out O +
starting O +
from O +
subsite O +
-5 O -
, O +
both O +
enzymes O +
hold O +
the O +
substrate O +
in O +
50 O +
ns O -
, O +
indicating O +
that O +
the O +
major O +
difference O +
between O +
WTcat O +
and O +
W40Acat O +
is O +
the O +
length O +
of O +
free O +
chain O -
- O -
end O +
of O +
the O +
substrate O +
required O +
to O +
allow O +
initiation O +
of O +
processive O +
movements O -
; O +
this O +
also O +
reflects O +
the O +
difference O +
between O +
crystalline O +
and O +
amorphous O +
celluloses O -
. O +

The O +
CBD O +
is O +
important O +
for O +
enhancing O +
the O +
enzyme O +
population O +
on O +
crystalline O +
substrate O -
, O +
but O +
it O +
also O +
decreases O +
the O +
specific O +
activity O +
of O +
the O +
adsorbed O +
enzyme O -
, O +
possibly O +
by O +
attaching O +
the O +
enzyme O +
to O +
non O -
- O -
optimal O +
places O +
on O +
cellulose O +
surface O +
and/or O +
hindering O +
processive O +
hydrolysis O -
. O +

A O +
Novel O +
Automethylation O +
Reaction O +
in O +
the O +
Aspergillus O +
nidulans O +
LaeA O +
Protein O +
Generates O +
S B-Chemical -
- I-Chemical -
Methylmethionine I-Chemical -
. O +

The O +
filamentous O +
fungi O +
in O +
the O +
genus O +
Aspergillus O +
are O +
opportunistic O +
plant O +
and O +
animal O +
pathogens O +
that O +
can O +
adapt O +
to O +
their O +
environment O +
by O +
producing O +
various O +
secondary O +
metabolites O +
including O +
lovastatin B-Chemical -
, O +
penicillin B-Chemical -
, O +
and O +
aflatoxin B-Chemical -
. O +

The O +
synthesis O +
of O +
these O +
small O +
molecules O +
is O +
dependent O +
on O +
gene O +
clusters O +
that O +
are O +
globally O +
regulated O +
by O +
the O +
LaeA O +
protein O -
. O +

Null O +
mutants O +
of O +
LaeA O +
in O +
all O +
pathogenic O +
fungi O +
examined O +
to O +
date O +
show O +
decreased O +
virulence O +
coupled O +
with O +
reduced O +
secondary O +
metabolism O -
. O +

Although O +
the O +
amino B-Chemical +
acid I-Chemical +
sequence O +
of O +
LaeA O +
contains O +
the O +
motifs O +
characteristic O +
of O +
seven O -
- O -
beta O -
- O -
strand O +
methyltransferases O -
, O +
a O +
methyl B-Chemical -
- O -
accepting O +
substrate O +
of O +
LaeA O +
has O +
not O +
been O +
identified O -
. O +

In O +
this O +
work O -
, O +
we O +
did O +
not O +
find O +
a O +
methyl B-Chemical -
- O -
accepting O +
substrate O +
in O +
A. O +
nidulans O +
with O +
various O +
assays O +
including O +
in O +
vivo O +
S B-Chemical -
- I-Chemical -
adenosyl- I-Chemical -
[ I-Chemical -
methyl- I-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
H I-Chemical -
] I-Chemical -
methionine I-Chemical +
labeling O -
, O +
targeted O +
in O +
vitro O +
methylation O +
experiments O +
using O +
putative O +
protein O +
substrates O -
, O +
or O +
in O +
vitro O +
methylation O +
assays O +
using O +
whole O +
cell O +
extracts O +
grown O +
under O +
different O +
conditions O -
. O +

However O -
, O +
in O +
each O +
experiment O +
LaeA O +
was O +
shown O +
to O +
self O -
- O -
methylate O -
. O +

Amino B-Chemical +
acid I-Chemical +
hydrolysis O +
of O +
radioactively O -
- O -
labeled O +
LaeA O +
followed O +
by O +
cation O +
exchange O +
and O +
reverse O +
phase O +
chromatography O +
identified O +
methionine B-Chemical +
as O +
the O +
modified O +
residue O -
. O +

Point O +
mutations O +
show O +
that O +
the O +
major O +
site O +
of O +
modification O +
of O +
LaeA O +
is O +
on O +
methionine-207 B-Chemical -
. O +

However O -
, O +
in O +
vivo O +
complementation O +
showed O +
that O +
methionine-207 B-Chemical +
is O +
not O +
required O +
for O +
the O +
biological O +
function O +
of O +
LaeA. O +
LaeA O +
is O +
the O +
first O +
protein O +
to O +
exhibit O +
automethylation O +
at O +
a O +
methionine B-Chemical +
residue O -
. O +

These O +
findings O +
not O +
only O +
indicate O +
LaeA O +
may O +
perform O +
novel O +
chemistry O +
with O +
S B-Chemical -
- I-Chemical -
adenosylmethionine I-Chemical -
, O +
but O +
also O +
provide O +
new O +
insights O +
into O +
the O +
physiological O +
function O +
of O +
LaeA. O +

Synthesis O +
and O +
in O +
Vitro O +
Characterisation O +
of O +
Ifenprodil B-Chemical -
- O -
Based O +
Fluorescein B-Chemical +
Conjugates O +
as O +
GluN1 O -
/ O -
GluN2B O +
N B-Chemical -
- I-Chemical -
Methyl I-Chemical -
- I-Chemical -
D I-Chemical -
- I-Chemical -
aspartate I-Chemical +
Receptor O +
Antagonists O -
. O +

GluN2B O -
- O -
containing O +
NMDA B-Chemical +
receptors O +
are O +
involved O +
in O +
many O +
important O +
physiological O +
functions O +
and O +
play O +
a O +
pivotal O +
role O +
in O +
mediating O +
pain O +
as O +
well O +
as O +
in O +
several O +
neurodegenerative O +
disorders O -
. O +

We O +
aimed O +
to O +
develop O +
fluorescent O +
probes O +
to O +
target O +
the O +
GluN2B O +
subunit O +
selectively O +
in O +
order O +
to O +
allow O +
better O +
understanding O +
of O +
the O +
relationships O +
between O +
receptor O +
localisation O +
and O +
physiological O +
importance O -
. O +

Ifenprodil B-Chemical -
, O +
known O +
as O +
the O +
GluNR2B O +
antagonist O +
of O +
reference O -
, O +
was O +
chosen O +
as O +
the O +
template O +
for O +
the O +
elaboration O +
of O +
probes O -
. O +

We O +
had O +
previously O +
reported O +
a O +
fluorescein B-Chemical +
conjugate O +
that O +
was O +
shown O +
( O -
by O +
confocal O +
microscopy O +
imaging O +
of O +
DS O -
- O -
red O -
- O -
labelled O +
cortical O +
neurons O -
) O +
to O +
bind O +
specifically O +
to O +
GluN2B O -
. O +

To O +
elaborate O +
this O +
probe O -
, O +
we O +
explored O +
the O +
influence O +
of O +
both O +
the O +
nature O +
and O +
the O +
attachment O +
point O +
of O +
the O +
spacer O +
between O +
the O +
fluorophore O +
and O +
the O +
parent O +
compound O -
, O +
ifenprodil B-Chemical -
. O +

We O +
performed O +
chemical O +
modifications O +
of O +
ifenprodil B-Chemical +
at O +
the O +
benzylic B-Chemical +
position O +
and O +
on O +
the O +
phenol B-Chemical +
ring O +
by O +
introducing O +
secondary B-Chemical +
amine I-Chemical +
or I-Chemical +
amide I-Chemical +
functions O +
and O +
evaluated O +
alkyl O +
chains O +
from O +
two O +
to O +
20 O +
bonds O +
either O +
including O +
or O +
not O +
including O +
secondary B-Chemical +
amide I-Chemical +
functions O +
as O +
spacers O -
. O +

The O +
previously O +
developed O +
probe O +
was O +
found O +
to O +
display O +
the O +
greatest O +
activity O +
in O +
the O +
inhibition O +
of O +
NMDA B-Chemical -
- O -
induced O +
Ca B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
influx O +
by O +
calcium B-Chemical +
imaging O +
experiments O +
on O +
HEK293 O +
cells O +
transfected O +
with O +
the O +
cDNA O +
encoding O +
for O +
GluN1 O -
- O -
1A O +
and O +
GluN2B O -
. O +

Further O +
investigations O +
revealed O +
that O +
this O +
probe O +
had O +
a O +
neuroprotective O +
effect O +
equivalent O +
to O +
that O +
of O +
ifenprodil B-Chemical +
in O +
a O +
standard O +
test O +
for O +
neurotoxicity O -
. O +

Despite O +
effects O +
of O +
lesser O +
amplitude O +
with O +
these O +
probes O +
relative O +
to O +
ifenprodil B-Chemical -
, O +
we O +
demonstrated O +
that O +
they O +
displaced O +
[ B-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical +
H I-Chemical -
] I-Chemical -
ifenprodil I-Chemical +
in O +
mouse O +
brain O +
slices O +
in O +
a O +
similar O +
manner O -
. O +

Pickering O -
- O -
Emulsion O -
- O -
Polymerized O +
Polystyrene B-Chemical -
/ O -
Fe2O3 B-Chemical +
Composite O +
Particles O +
and O +
Their O +
Magnetoresponsive O +
Characteristics O -
. O +

Core O -
- O -
shell O -
- O -
structured O +
magnetic O +
polystyrene B-Chemical +
( O -
PS O -
) O -
/ O -
inorganic O +
particles O +
were O +
fabricated O +
by O +
Pickering O +
emulsion O +
polymerization O +
using O +
nanosized O +
Fe2O3 B-Chemical +
particles O +
as O +
a O +
solid O +
stabilizer O -
. O +

Scanning O +
electron O +
microscopy O +
and O +
transmission O +
electron O +
microscopy O +
confirmed O +
the O +
synthesized O +
PS O -
/ O -
Fe2O3 B-Chemical +
particles O +
to O +
be O +
comprised O +
of O +
a O +
PS O +
surface O +
coated O +
with O +
Fe2O3 B-Chemical +
nanoparticles O -
. O +

The O +
chemical O +
structure O +
of O +
the O +
composite O +
nanospheres O +
was O +
characterized O +
by O +
Fourier O +
transform O +
infrared O +
spectroscopy O +
and O +
X O -
- O -
ray O +
diffraction O -
. O +

The O +
thermal O +
properties O +
of O +
composite O +
nanospheres O +
and O +
corresponding O +
pure O +
polymer O +
were O +
examined O +
by O +
thermogravimetric O +
analysis O -
. O +

The O +
rheological O +
properties O +
of O +
the O +
core O -
- O -
shell O -
- O -
structured O +
magnetic O +
PS O -
/ O -
inorganic O +
particles O +
dispersed O +
in O +
silicone O +
oil O +
were O +
investigated O +
under O +
an O +
external O +
magnetic O +
field O +
strength O +
using O +
a O +
rotational O +
rheometer O -
. O +

The O +
particles O +
with O +
extremely O +
lower O +
density O +
than O +
common O +
magnetic O +
particles O +
exhibited O +
solid O -
- O -
like O +
magnetorheological O +
phase O +
characteristics O -
, O +
and O +
the O +
flow O +
curves O +
were O +
fitted O +
to O +
the O +
Cho O -
- O -
Choi O -
- O -
Jhon O +
model O +
of O +
the O +
rheological O +
equation O +
of O +
state O -
. O +

Engineering O +
the O +
Microstructure O +
of O +
Electrospun O +
Fibrous O +
Scaffolds O +
by O +
Microtopography O -
. O +

Controlling O +
the O +
structure O +
and O +
organization O +
of O +
electrospun O +
fibers O +
is O +
desirable O +
for O +
fabricating O +
scaffolds O +
and O +
materials O +
with O +
defined O +
microstructures O -
. O +

However O -
, O +
the O +
effects O +
of O +
microtopography O +
on O +
the O +
deposition O +
and O -
, O +
in O +
turn O -
, O +
the O +
organization O +
of O +
the O +
electrospun O +
fibers O +
are O +
not O +
well O +
understood O -
. O +

In O +
this O +
study O -
, O +
conductive O +
polydimethylsiloxane B-Chemical +
( O -
PDMS B-Chemical -
) O +
templates O +
with O +
different O +
micropatterns O +
were O +
fabricated O +
by O +
combining O +
photolithography O -
, O +
silicon B-Chemical +
wet O +
etching O -
, O +
and O +
PDMS B-Chemical +
molding O +
techniques O -
. O +

The O +
fiber O +
organization O +
was O +
varied O +
by O +
fine O -
- O -
tuning O +
the O +
microtopography O +
of O +
the O +
electrospinning O +
collector O -
. O +

Fiber O +
conformity O +
and O +
alignment O +
were O +
influenced O +
by O +
the O +
depth O +
and O +
the O +
slope O +
of O +
microtopography O +
features O -
, O +
resulting O +
in O +
scaffolds O +
comprising O +
either O +
an O +
array O +
of O +
microdomains O +
with O +
different O +
porosity O +
and O +
fiber O +
alignment O +
or O +
an O +
array O +
of O +
microwells O -
. O +

Microtopography O +
affected O +
the O +
fiber O +
organization O +
for O +
hundreds O +
of O +
micrometers O +
below O +
the O +
scaffold O +
surface O -
, O +
resulting O +
in O +
scaffolds O +
with O +
distinct O +
surface O +
properties O +
on O +
each O +
side O -
. O +

In O +
addition O -
, O +
the O +
fiber O +
diameter O +
was O +
also O +
affected O +
by O +
the O +
fiber O +
conformity O -
. O +

The O +
effects O +
of O +
the O +
fiber O +
arrangement O +
in O +
the O +
scaffolds O +
on O +
the O +
morphology O -
, O +
migration O -
, O +
and O +
infiltration O +
of O +
cells O +
were O +
examined O +
by O +
in O +
vitro O +
and O +
in O +
vivo O +
experiments O -
. O +

Cell O +
morphology O +
and O +
organization O +
were O +
guided O +
by O +
the O +
fibers O +
in O +
the O +
microdomains O -
, O +
and O +
cell O +
migration O +
was O +
enhanced O +
by O +
the O +
aligned O +
fibers O +
and O +
the O +
three O -
- O -
dimensional O +
scaffold O +
structure O -
. O +

Cell O +
infiltration O +
was O +
correlated O +
with O +
the O +
microdomain O +
porosity O -
. O +

Microscale O +
control O +
of O +
the O +
fiber O +
organization O +
and O +
the O +
porosity O +
at O +
the O +
surface O +
and O +
through O +
the O +
thickness O +
of O +
the O +
fibrous O +
scaffolds O -
, O +
as O +
demonstrated O +
by O +
the O +
results O +
of O +
this O +
study O -
, O +
provides O +
a O +
powerful O +
means O +
of O +
engineering O +
the O +
three O -
- O -
dimensional O +
structure O +
of O +
electrospun O +
fibrous O +
scaffolds O +
for O +
cell O +
and O +
tissue O +
engineering O -
. O +

Directing O +
Chondrogenesis O +
of O +
Stem O +
Cells O +
with O +
Specific O +
Blends O +
of O +
Cellulose O +
and O +
Silk O -
. O +

Biomaterials O +
that O +
can O +
stimulate O +
stem O +
cell O +
differentiation O +
without O +
growth O +
factor O +
supplementation O +
provide O +
potent O +
and O +
cost O -
- O -
effective O +
scaffolds O +
for O +
regenerative O +
medicine O -
. O +

We O +
hypothesize O +
that O +
a O +
scaffold O +
prepared O +
from O +
cellulose O +
and O +
silk O +
blends O +
can O +
direct O +
stem O +
cell O +
chondrogenic O +
fate O -
. O +

We O +
systematically O +
prepared O +
cellulose O +
blends O +
with O +
silk O +
at O +
different O +
compositions O +
using O +
an O +
environmentally O +
benign O +
processing O +
method O +
based O +
on O +
ionic O +
liquids O +
as O +
a O +
common O +
solvent O -
. O +

We O +
tested O +
the O +
effect O +
of O +
blend O +
compositions O +
on O +
the O +
physical O +
properties O +
of O +
the O +
materials O +
as O +
well O +
as O +
on O +
their O +
ability O +
to O +
support O +
mesenchymal O +
stem O +
cell O +
( O -
MSC O -
) O +
growth O +
and O +
chondrogenic O +
differentiation O -
. O +

The O +
stiffness O +
and O +
tensile O +
strength O +
of O +
cellulose O +
was O +
significantly O +
reduced O +
by O +
blending O +
with O +
silk O -
. O +

The O +
characterized O +
materials O +
were O +
tested O +
using O +
MSCs O +
derived O +
from O +
four O +
different O +
patients O -
. O +

Growing O +
MSCs O +
on O +
a O +
specific O +
blend O +
combination O +
of O +
cellulose O +
and O +
silk O +
in O +
a O +
75:25 O +
ratio O +
significantly O +
upregulated O +
the O +
chondrogenic O +
marker O +
genes O +
SOX9 O -
, O +
aggrecan O -
, O +
and O +
type O +
II O +
collagen O +
in O +
the O +
absence O +
of O +
specific O +
growth O +
factors O -
. O +

This O +
chondrogenic O +
effect O +
was O +
neither O +
found O +
with O +
neat O +
cellulose O +
nor O +
the O +
cellulose O -
/ O -
silk O +
50:50 O +
blend O +
composition O -
. O +

No O +
adipogenic O +
or O +
osteogenic O +
differentiation O +
was O +
detected O +
on O +
the O +
blends O -
, O +
suggesting O +
that O +
the O +
cellulose O -
/ O -
silk O +
75:25 O +
blend O +
induced O +
specific O +
stem O +
cell O +
differentiation O +
into O +
the O +
chondrogenic O +
lineage O +
without O +
addition O +
of O +
the O +
soluble O +
growth O +
factor O +
TGF O -
- O -
β O -
. O +

The O +
cellulose O -
/ O -
silk O +
blend O +
we O +
identified O +
can O +
be O +
used O +
both O +
for O +
in O +
vitro O +
tissue O +
engineering O +
and O +
as O +
an O +
implantable O +
device O +
for O +
stimulating O +
endogenous O +
stem O +
cells O +
to O +
initiate O +
cartilage O +
repair O -
. O +

Recent O +
developments O +
in O +
design O +
and O +
synthesis O +
of O +
bicyclic B-Chemical +
azasugars I-Chemical -
, O +
carbasugars B-Chemical +
and O +
related O +
molecules O +
as O +
glycosidase O +
inhibitors O -
. O +

The O +
importance O +
of O +
glycosidase O +
inhibitors O +
and O +
especially O +
the O +
bicyclic O +
molecules O +
has O +
led O +
to O +
design O +
and O +
assessment O +
of O +
many O +
analogs O +
of O +
naturally O +
occurring O +
molecules O -
. O +

This O +
review O +
focuses O +
on O +
the O +
synthesis O +
and O +
enzyme O +
inhibitions O +
of O +
a O +
few O +
selected O +
( O -
synthetic O +
or O +
non O -
- O -
naturally O +
occurring O -
) O +
molecules O +
that O +
have O +
been O +
reported O +
in O +
the O +
last O +
decade O -
, O +
which O +
allow O +
one O +
to O +
draw O +
some O +
connection O +
between O +
varying O +
the O +
structural O +
features O +
and O +
their O +
effect O +
on O +
glycosidase O +
inhibitions O -
. O +

It O +
is O +
expected O +
that O +
further O +
improvements O +
based O +
on O +
these O +
features O +
could O +
lead O +
to O +
improved O +
inhibitors O -
. O +

Neuroprotective O +
Effects O +
of O +
Cilostazol B-Chemical +
on O +
Retinal O +
Ganglion O +
Cell O +
damage O +
in O +
Diabetic O +
Rats O -
. O +

Neurodegeneration O +
is O +
an O +
important O +
component O +
of O +
diabetic O +
retinopathy O +
with O +
increasing O +
evidence O +
that O +
retinal O +
ganglion O +
cell O +
( O -
RGC O -
) O +
death O +
occurs O +
early O +
in O +
diabetes O -
. O +

We O +
investigated O +
the O +
effects O +
of O +
cilostazol B-Chemical -
, O +
which O +
has O +
been O +
widely O +
used O +
to O +
manage O +
diabetic O +
complications O -
, O +
on O +
retinal O +
ganglion O +
cell O +
death O +
in O +
diabetic O +
retina O -
. O +

Four O -
- O -
week O -
- O -
old O +
Otsuka O +
Long O -
- O -
Evans O +
Tokushima O +
Fatty O +
( O -
OLETF O -
) O +
rats O +
and O +
Long O -
- O -
Evans O +
Tokushima O +
Otsuka O +
( O -
LETO O -
) O +
rats O +
as O +
matched O +
nondiabetic O +
controls O +
were O +
treated O +
with O +
daily O +
oral O +
cilostazol B-Chemical +
at O +
30mg O -
/ O -
kg O +
or O +
0.9 O +
% O +
saline O +
solution O -
. O +

In O +
OLETF O +
rats O +
at O +
the O +
age O +
of O +
40 O +
weeks O -
, O +
glial O +
fibrillary O +
acidic O +
protein O +
( O -
GFAP O -
) O +
immunofluorescence O +
staining O +
was O +
upregulated O +
in O +
vertical O +
sections O +
and O +
showed O +
a O +
more O +
ramified O +
pattern O +
in O +
whole O -
- O -
mount O +
retinas O +
compared O +
with O +
that O +
in O +
LETO O +
rats O -
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
expression O +
was O +
limited O +
to O +
the O +
ganglion O +
cell O +
layer O +
in O +
LETO O +
rats O -
, O +
but O +
extended O +
into O +
the O +
outer O +
plexiform O +
layer O +
in O +
OLETF O +
rats O -
. O +

Immunofluorescence O +
staining O +
and O +
western O +
blotting O +
demonstrated O +
that O +
cilostazol B-Chemical +
treatment O +
reduced O +
GFAP O +
and O +
VEGF O +
expression O +
in O +
the O +
retinas O +
of O +
OLETF O +
rats O -
. O +

Terminal O +
deoxynucleotidyl O +
transferase O -
- O -
mediated O +
dUTP B-Chemical +
nick O -
- O -
end O +
labeling O +
( O -
TUNLEL O -
) O +
staining O +
revealed O +
an O +
increase O +
in O +
the O +
RGC O +
layer O +
in O +
OLETF O +
compared O +
with O +
LETO O +
rats O +
( O -
P<0.05 O -
) O -
, O +
and O +
cilostazol B-Chemical +
treatment O +
reduced O +
the O +
number O +
of O +
TUNEL O -
- O -
positive O +
cells O +
in O +
OLETF O +
rats O +
( O -
P<0.05 O -
) O -
. O +

Relieving O +
retinal O +
ischemia O +
by O +
systemic O +
cilostazol B-Chemical +
treatment O +
had O +
a O +
noticeable O +
protective O +
effect O +
on O +
RGCs O +
in O +
diabetic O +
rats O -
. O +

Cilostazol B-Chemical +
treatment O +
may O +
be O +
useful O +
for O +
the O +
management O +
of O +
diabetic O +
retinal O +
vascular O +
dysfunction O +
and O +
neuronal O +
degeneration O -
. O +

Chrysin B-Chemical +
Ameliorates O +
Chemically O +
Induced O +
Colitis O +
in O +
the O +
Mouse O +
Through O +
Modulation O +
of O +
a O +
PXR O -
/ O -
NF O -
- O -
κB O +
Signaling O +
Pathway O -
. O +

Targeted O +
activation O +
of O +
pregnane O +
X O +
receptor O +
( O -
PXR O -
) O +
in O +
recent O +
years O +
has O +
become O +
a O +
therapeutic O +
strategy O +
for O +
inflammatory O +
bowel O +
disease O +
( O -
IBD O -
) O -
. O +

Chrysin B-Chemical +
is O +
a O +
naturally O +
occurring O +
flavonoid B-Chemical +
with O +
anti O -
- O -
inflammation O +
activity O -
. O +

The O +
current O +
study O +
investigated O +
the O +
role O +
of O +
chrysin B-Chemical +
as O +
a O +
putative O +
mouse O +
PXR O +
agonist O +
in O +
preventing O +
experimental O +
colitis O -
. O +

Pre O -
- O -
administration O +
of O +
chrysin B-Chemical +
ameliorated O +
inflammatory O +
symptoms O +
in O +
mouse O +
models O +
of O +
colitis O +
( O -
DSS- O +
and O +
TNBS O -
- O -
induced O -
) O +
and O +
resulted O +
in O +
down O -
- O -
regulation O +
of O +
NF O -
- O -
κB O +
target O +
genes O +
( O -
iNOS O -
, O +
ICAM-1 O -
, O +
MCP-1 O -
, O +
Cox2 O -
, O +
TNF O -
- O -
α O +
and O +
IL-6 O -
) O +
in O +
the O +
colon O +
mucosa O -
. O +

Chrysin B-Chemical +
inhibited O +
the O +
phosphorylation O -
/ O -
degradation O +
of O +
IκBα O -
, O +
which O +
correlated O +
with O +
the O +
decline O +
in O +
the O +
activity O +
of O +
myeloperoxidase O +
( O -
MPO O -
) O +
and O +
the O +
levels O +
of O +
TNF O -
- O -
α O +
and O +
IL-6 O +
in O +
the O +
colon O -
. O +

Consistent O +
with O +
the O +
in O +
vivo O +
results O -
, O +
chrysin B-Chemical +
blocked O +
LPS O -
- O -
stimulated O +
nuclear O +
translocation O +
of O +
NF O -
- O -
κB O +
p65 O +
in O +
mouse O +
macrophage O +
RAW264.7 O -
. O +

Furthermore O -
, O +
chrysin B-Chemical +
dose O -
- O -
dependently O +
activated O +
human O -
/ O -
mouse O +
PXR O +
in O +
reporter O +
gene O +
assays O +
and O +
up O -
- O -
regulated O +
xenobiotic O +
detoxification O +
genes O +
in O +
the O +
colon O +
mucosa O -
, O +
but O +
not O +
in O +
the O +
liver O -
. O +

Silencing O +
of O +
PXR O +
by O +
RNAi O +
demonstrated O +
necessity O +
of O +
PXR O +
in O +
mediating O +
chrysin B-Chemical -
's O +
ability O +
to O +
induce O +
xenobiotic O +
detoxification O +
genes O +
and O +
NF O -
- O -
κB O +
inactivation O -
. O +

The O +
repression O +
of O +
NF O -
- O -
κB O +
transcription O +
activity O +
by O +
chrysin B-Chemical +
was O +
confirmed O +
by O +
in O +
vitro O +
PXR O +
transduction O -
. O +

These O +
findings O +
suggest O +
the O +
effect O +
of O +
chrysin B-Chemical +
in O +
preventing O +
chemically O +
induced O +
colitis O +
is O +
mediated O +
in O +
large O +
part O +
by O +
a O +
PXR O -
/ O -
NF O -
- O -
κB O +
pathway O -
. O +

The O +
data O +
also O +
suggest O +
that O +
chrysin B-Chemical +
or O +
chrysin B-Chemical -
- O -
like O +
flavonoids B-Chemical +
could O +
be O +
further O +
developed O +
as O +
intestine O -
- O -
specific O +
PXR O +
activators O -
. O +

An O +
ultra O -
- O -
low O +
dose O +
of O +
tetrahydrocannabinol B-Chemical +
provides O +
cardioprotection O -
. O +

Tetrahydrocannabinol B-Chemical +
( O -
THC B-Chemical -
) O -
, O +
the O +
major O +
psychoactive O +
component O +
of O +
marijuana O -
, O +
is O +
a O +
cannabinoid O +
agonist O +
that O +
exerts O +
its O +
effects O +
by O +
activating O +
at O +
least O +
two O +
specific O +
receptors O +
( O -
CB1 O +
and O +
CB2 O -
) O +
that O +
belong O +
to O +
the O +
seven O +
transmembrane O +
G O -
- O -
protein O +
coupled O +
receptor O +
( O -
GPCR O -
) O +
family O -
. O +

Both O +
CB1 O +
and O +
CB2 O +
mRNA O +
and O +
proteins O +
are O +
present O +
in O +
the O +
heart O -
. O +

THC B-Chemical +
treatment O +
was O +
beneficial O +
against O +
hypoxia O +
in O +
neonatal O +
cardiomyocytes O +
in O +
vitro O -
. O +

We O +
also O +
observed O +
a O +
neuroprotective O +
effect O +
of O +
an O +
ultra O +
low O +
dose O +
of O +
THC B-Chemical +
when O +
applied O +
to O +
mice O +
before O +
brain O +
insults O -
. O +

The O +
present O +
study O +
was O +
aimed O +
to O +
test O +
and O +
characterize O +
the O +
cardioprotective O +
effects O +
of O +
a O +
very O +
low O +
dose O +
( O -
0.002mg O -
/ O -
kg O -
) O +
of O +
THC B-Chemical +
which O +
is O +
3 O -
- O -
4 O +
orders O +
of O +
magnitude O +
lower O +
than O +
the O +
conventional O +
doses O -
, O +
administered O +
before O +
myocardial O +
infarction O +
in O +
mice O +
in O +
vivo O -
. O +

Three O +
regimens O +
of O +
THC B-Chemical +
administration O +
were O +
tested O -
: O +
single O +
THC B-Chemical +
application O +
2h O +
or O +
48h O +
before O +
the O +
induction O +
of O +
infarct O -
, O +
or O +
3 O +
weeks O +
continuous O +
treatment O +
before O +
MI O -
. O +

All O +
protocols O +
of O +
THC B-Chemical +
administration O +
were O +
found O +
to O +
be O +
beneficial O -
. O +

In O +
the O +
case O +
of O +
THC B-Chemical +
treatment O +
2h O +
before O +
MI O -
, O +
fractional O +
shortening O +
was O +
elevated O +
( O -
37±4 O -
% O +
vs. O +
42±1 O -
% O -
, O +
p<0.04 O -
) O -
, O +
troponin O +
T O +
leakage O +
to O +
the O +
blood O +
was O +
reduced O +
( O -
14±3ng O -
/ O -
ml O +
vs. O +
10±4ng O -
/ O -
ml O -
, O +
p<0.008 O -
) O -
, O +
infarct O +
size O +
decreased O +
( O -
29±4 O -
% O +
vs. O +
23±4 O -
% O -
, O +
p<0.02 O -
) O -
, O +
and O +
the O +
accumulation O +
of O +
neutrophils O +
to O +
the O +
infarct O +
area O +
declined O +
( O -
36±10cells O -
/ O -
field O +
vs. O +
19±4cells O -
/ O -
field O -
, O +
p<0.007 O -
) O +
in O +
THC- B-Chemical +
compared O +
to O +
vehicle O -
- O -
pretreated O +
mice O -
, O +
24h O +
after O +
MI O -
. O +

ERK1 O -
/ O -
2 O +
phosphorylation O +
following O +
infarct O +
was O +
also O +
inhibited O +
by O +
pre O -
- O -
treatment O +
with O +
THC B-Chemical +
( O -
p<0.01 O -
) O -
. O +

CONCLUSION O -
: O +
A O +
single O +
ultra O +
low O +
dose O +
of O +
THC B-Chemical +
before O +
ischemia O +
is O +
a O +
safe O +
and O +
effective O +
treatment O +
that O +
reduces O +
myocardial O +
ischemic O +
damage O -
. O +

Systematic O +
evaluation O +
of O +
640 O +
FDA O +
drugs O +
for O +
their O +
effect O +
on O +
CD4 O -
( O -
+ O -
) O -
Foxp3 O -
( O -
+ O -
) O +
regulatory O +
T O +
cells O +
using O +
a O +
novel O +
cell O -
- O -
based O +
high O +
throughput O +
screening O +
assay O -
. O +

Regulatory O +
T O +
cells O +
( O -
Treg O -
) O -
, O +
which O +
play O +
a O +
pivotal O +
role O +
in O +
maintaining O +
immune O +
homeostasis O +
by O +
suppressing O +
the O +
proliferation O +
of O +
effector O +
T O +
cells O -
, O +
have O +
great O +
therapeutic O +
potential O +
for O +
autoimmune O +
diseases O +
and O +
transplantation O -
. O +

However O -
, O +
progress O +
on O +
their O +
clinical O +
application O +
has O +
been O +
hampered O +
by O +
the O +
lack O +
of O +
high O +
throughput O +
screening O +
( O -
HTS O -
) O +
strategies O +
for O +
the O +
systematic O +
and O +
rapid O +
evaluation O +
of O +
existing O +
drugs O +
and O +
the O +
identification O +
of O +
novel O +
drug O +
candidates O -
. O +

In O +
this O +
report O -
, O +
we O +
present O +
an O +
innovative O +
in O +
vitro O +
HTS O +
assay O +
using O +
CD4 O -
( O -
+ O -
) O +
T O +
cells O +
from O +
Foxp3-GFP O +
transgenic O +
mice O +
that O +
specifically O +
express O +
the O +
GFP O +
signal O +
in O +
Foxp3 O -
( O -
+ O -
) O +

Treg O +
cells O +
detectable O +
by O +
FACS O +
analysis O +
in O +
a O +
high O +
throughput O +
manner O -
. O +

Systematic O +
evaluation O +
of O +
640 O +
FDA O -
- O -
approved O +
drugs O +
revealed O +
that O +
70 O +
drugs O +
increased O +
the O +
number O +
of O +
Treg O +
cells O +
with O +
suppression O +
function O +
only O +
in O +
the O +
presence O +
of O +
TGFβ O -
, O +
75 O +
drugs O +
increased O +
Treg O +
numbers O +
even O +
in O +
the O +
absence O +
of O +
TGFβ O -
, O +
and O +
32 O +
drugs O +
increased O +
Treg O +
numbers O +
synergistically O +
with O +
TGFβ O -
. O +

The O +
identified O +
Treg O -
- O -
promoting O +
drugs O +
include O +
those O +
previously O +
known O +
to O +
induce O +
Treg O +
( O -
rapamycin B-Chemical +
and O +
retinoic B-Chemical +
acid I-Chemical -
) I-Chemical -
, O +
statins O -
, O +
glucocorticoids O +
and O +
drugs O +
in O +
many O +
other O +
categories O -
. O +

Furthermore O -
, O +
Treg O +
cells O +
cultured O +
with O +
the O +
identified O +
drugs O +
possess O +
surface O +
and O +
intracellular O +
markers O +
characteristic O +
of O +
natural O +
Treg O +
cells O +
and O +
possess O +
suppressive O +
function O -
. O +

These O +
results O +
suggest O +
that O +
this O +
Treg O +
HTS O +
assay O +
can O +
be O +
used O +
to O +
screen O +
compound O +
libraries O +
to O +
identify O +
novel O +
chemical O +
entities O +
for O +
Treg O -
- O -
based O +
immune O +
therapies O -
. O +

The O +
effect O +
of O +
a O +
Cimicifuga O +
racemosa O +
extracts O +
Ze B-Chemical +
450 I-Chemical +
in O +
the O +
treatment O +
of O +
climacteric O +
complaints O +
- O +
an O +
observational O +
study O -
. O +

BACKGROUND O -
: O +
Root O +
extracts O +
of O +
Cimicifuga O +
racemosa O +
( O -
L. O -
) O +
Nutt O -
. O +
have O +
been O +
successfully O +
used O +
in O +
the O +
treatment O +
of O +
climacteric O +
complaints O -
. O +

METHOD O -
: O +
In O +
this O +
observational O +
study O -
, O +
Cimicifuga O +
racemosa O +
( O -
CR O -
) O +
extract O +
Ze B-Chemical +
450 I-Chemical +
was O +
studied O +
in O +
442 O +
unselected O +
ambulatory O +
female O +
outpatients O +
with O +
menopausal O +
complaints O +
under O +
daily O +
practice O +
conditions O -
. O +

Physicians O +
were O +
suggested O +
to O +
treat O +
patients O +
for O +
the O +
first O +
3 O +
months O +
with O +
13mg O -
/ O -
d O +
CR O +
( O -
high O +
dose O -
, O +
HD O -
) O +
and O +
to O +
continue O +
over O +
additional O +
6 O +
months O +
either O +
with O +
this O +
treatment O +
or O +
to O +
switch O +
to O +
6.5mg O -
/ O -
d O +
CR O +
( O -
low O +
dose O -
, O +
LD O -
) O -
. O +

The O +
choice O +
of O +
treatment O +
and O +
its O +
dose O -
, O +
however O -
, O +
was O +
fully O +
at O +
the O +
discretion O +
of O +
the O +
physician O -
. O +

RESULTS O -
: O +
After O +
3-months O +
treatment O +
with O +
HD O -
, O +
symptom O +
severity O +
( O -
Kupperman O +
Menopause O +
Index O -
, O +
KMI O -
) O +
decreased O +
significantly O +
( O -
p<0.001 O -
) O +
from O +
baseline O +
values O -
. O +

Continuation O +
of O +
treatment O +
with O +
HD O +
or O +
LD O +
decreased O +
total O +
KMI O +
and O +
its O +
sub O -
- O -
item O +
scores O +
further O +
( O -
HD O -
, O +
LD O -
: O +
p<0.001 O -
) O -
. O +

However O -
, O +
more O +
patients O +
( O -
84.9 O -
% O -
) O +
responded O +
to O +
HD O +
than O +
to O +
LD O +
( O -
78.4 O -
% O -
) O +
and O +
showed O +
an O +
improvement O +
of O +
symptoms O +
( O -
p=0.011 O -
) O -
. O +

CONCLUSION O -
: O +
This O +
observational O +
study O +
demonstrated O +
that O +
treatment O +
with O +
CR O +
in O +
unselected O +
patients O +
with O +
climacteric O +
complaints O +
under O +
the O +
conditions O +
of O +
daily O +
practice O +
resulted O +
in O +
a O +
significant O +
improvement O +
of O +
menopausal O +
symptoms O +
assessed O +
by O +
the O +
total O +
KMI O +
score O +
and O +
its O +
sub O -
- O -
item O +
scores O +
with O +
an O +
effect O +
size O +
similar O +
to O +
that O +
in O +
a O +
previous O +
randomized O -
, O +
controlled O +
clinical O +
trial O -
. O +

Combination O +
of O +
essential O +
oils O +
and O +
antibiotics O +
reduce O +
antibiotic O +
resistance O +
in O +
plasmid O -
- O -
conferred O +
multidrug O +
resistant O +
bacteria O -
. O +

In O +
this O +
study O +
we O +
investigated O +
the O +
relationship O +
between O +
several O +
selected O +
commercially O +
available O +
essential O +
oils O +
and O +
beta B-Chemical -
- I-Chemical -
lactam I-Chemical +
antibiotics O +
on O +
their O +
antibacterial O +
effect O +
against O +
multidrug O +
resistant O +
bacteria O -
. O +

The O +
antibacterial O +
activity O +
of O +
essential O +
oils O +
and O +
antibiotics O +
was O +
assessed O +
using O +
broth O +
microdilution O -
. O +

The O +
combined O +
effects O +
between O +
essential O +
oils O +
of O +
cinnamon O +
bark O -
, O +
lavender O -
, O +
marjoram O -
, O +
tea O +
tree O -
, O +
peppermint O +
and O +
ampicillin B-Chemical -
, O +
piperacillin B-Chemical -
, O +
cefazolin B-Chemical -
, O +
cefuroxime B-Chemical -
, O +
carbenicillin B-Chemical -
, O +
ceftazidime B-Chemical -
, O +
meropenem B-Chemical -
, O +
were O +
evaluated O +
by O +
means O +
of O +
the O +
checkerboard O +
method O +
against O +
beta O -
- O -
lactamase O -
- O -
producing O +
Escherichia O +
coli O -
. O +

In O +
the O +
latter O +
assays O -
, O +
fractional O +
inhibitory O +
concentration O +
( O -
FIC O -
) O +
values O +
were O +
calculated O +
to O +
characterize O +
interaction O +
between O +
the O +
combinations O -
. O +

Substantial O +
susceptibility O +
of O +
the O +
bacteria O +
toward O +
natural O +
antibiotics O +
and O +
a O +
considerable O +
reduction O +
in O +
the O +
minimum O +
inhibitory O +
concentrations O +
( O -
MIC O -
) O +
of O +
the O +
antibiotics O +
were O +
noted O +
in O +
some O +
paired O +
combinations O +
of O +
antibiotics O +
and O +
essential O +
oils O -
. O +

Out O +
of O +
35 O +
antibiotic O -
- O -
essential O +
oil O +
pairs O +
tested O -
, O +
four O +
of O +
them O +
showed O +
synergistic O +
effect O +
( O -
FIC≤0.5 O -
) O +
and O +
31 O +
pairs O +
showed O +
no O +
interaction O +
( O -
FIC>0.5 O -
- O -
4.0 O -
) O -
. O +

The O +
preliminary O +
results O +
obtained O +
highlighted O +
the O +
occurrence O +
of O +
a O +
pronounced O +
synergistic O +
relationship O +
between O +
piperacillin B-Chemical -
/ O -
cinnamon O +
bark O +
oil O -
, O +
piperacillin B-Chemical -
/ O -
lavender O +
oil O -
, O +
piperacillin B-Chemical -
/ O -
peppermint O +
oil O +
as O +
well O +
as O +
meropenem B-Chemical -
/ O -
peppermint O +
oil O +
against O +
two O +
of O +
the O +
three O +
bacteria O +
under O +
study O +
with O +
a O +
FIC O +
index O +
in O +
the O +
range O +
0.26 O -
- O -
0.5 O -
. O +

The O +
finding O +
highlighted O +
the O +
potential O +
of O +
peppermint O -
, O +
cinnamon O +
bark O +
and O +
lavender O +
essential O +
oils O +
being O +
as O +
antibiotic O +
resistance O +
modifying O +
agent O -
. O +

Reduced O +
usage O +
of O +
antibiotics O +
could O +
be O +
employed O +
as O +
a O +
treatment O +
strategy O +
to O +
decrease O +
the O +
adverse O +
effects O +
and O +
possibly O +
to O +
reverse O +
the O +
beta B-Chemical -
- I-Chemical -
lactam I-Chemical +
antibiotic O +
resistance O -
. O +

The O +
conjugation O +
of O +
microcystin B-Chemical -
- I-Chemical -
RR I-Chemical +
by O +
human O +
recombinant O +
GSTs O +
and O +
hepatic O +
cytosol O -
. O +

Many O +
cyanobacterial O +
species O +
can O +
produce O +
cyanotoxins O -
, O +
among O +
which O +
mycrocistins B-Chemical +
( O -
MC O -
) O +
are O +
a O +
group O +
of O +
≈100 O +
congeners O +
of O +
hepatotoxic O +
cyclic B-Chemical +
heptapeptides I-Chemical -
. O +

MC B-Chemical -
- I-Chemical -
RR I-Chemical +
differs O +
from O +
MC B-Chemical -
- I-Chemical -
LR I-Chemical -
, O +
the O +
most O +
studied O +
congener O +
only O +
for O +
one O +
residue O +
( O -
arginine B-Chemical +
vs O +
leucine B-Chemical -
) O -
, O +
resulting O +
in O +
a O +
ten O -
- O -
fold O +
difference O +
in O +
the O +
acute O +
toxicity O +
in O +
mice O -
. O +

Although O +
humans O +
may O +
be O +
exposed O +
to O +
MC O +
through O +
several O +
routes O +
and O +
kinetics O +
appeared O +
to O +
be O +
the O +
major O +
factor O +
affecting O +
congener O -
- O -
specific O +
toxicity O -
, O +
little O +
is O +
known O +
on O +
MC O +
metabolism O -
. O +

The O +
accepted O +
pathway O +
for O +
MC O +
detoxication O +
is O +
GSH B-Chemical +
conjugation O -
: O +
here O +
the O +
MC B-Chemical -
- I-Chemical -
RR I-Chemical +
conjugation O +
with O +
GSH B-Chemical +
catalyzed O +
by O +
5 O +
recombinant O +
human O +
GSTs O +
and O +
human O +
liver O +
cytosol O +
( O -
HLC O -
) O +
has O +
been O +
characterized O +
and O +
appeared O +
to O +
be O +
more O +
efficient O +
than O +
MC B-Chemical -
- I-Chemical -
LR I-Chemical +
conjugation O -
. O +

The O +
catalytic O +
efficiency O +
score O +
is O +
T1 O -
- O -
1 O -
> O -
A1 O -
- O -
1≈P1 O -
- O -
1 O -
> O -
M1 O -
- O -
1 O -
> O -
A3 O -
- O -
3 O +
( O -
0.161 O -
- O -
0.056pmol O +
GSMC O -
- O -
RR O +
( O -
μgproteinminμM O -
) O -
( O -
-1 O -
) O -
) O -
. O +

In O +
HLC O +
the O +
spontaneous O +
reaction O +
is O +
favored O +
vs O +
the O +
enzymatic O +
one O +
( O -
ratio O +
3:1 O -
) O +
at O +
physiological O +
GSH B-Chemical +
content O -
. O +

However O -
, O +
at O +
low O +
MC B-Chemical -
- I-Chemical -
RR I-Chemical +
concentrations O -
, O +
representative O +
of O +
repeated O +
oral O +
exposure O -
, O +
and O +
low O +
GSH B-Chemical +
content O +
( O -
down O +
to O +
0.05mM O -
) O -
, O +
possibly O +
associated O +
to O +
exposure O +
to O +
drugs O +
or O +
in O +
patients O +
affected O +
by O +
several O +
pathologies O -
, O +
the O +
relevance O +
of O +
the O +
enzymatic O +
reaction O +
progressively O +
increases O -
, O +
providing O +
the O +
predominant O +
contribution O +
to O +
MC B-Chemical -
- I-Chemical -
RR I-Chemical +
detoxication O -
. O +

Activating O +
glucocorticoid O +
receptor O -
- O -
ERK O +
signaling O +
pathway O +
contributes O +
to O +
ginsenoside B-Chemical +
Rg1 I-Chemical +
protection O +
against O +
β O -
- O -
amyloid O +
peptide O -
- O -
induced O +
human O +
endothelial O +
cells O +
apoptosis O -
. O +

The O +
deposition O +
of O +
β O -
- O -
amyloid O +
( O -
Aβ O -
) O +
in O +
neurons O +
and O +
vascular O +
cells O +
of O +
the O +
brain O +
has O +
been O +
characterized O +
in O +
Alzheimer O -
's O +
disease O -
. O +

Ginsenoside B-Chemical +
Rg1 I-Chemical +
( O -
Rg1 B-Chemical -
) O +
is O +
an O +
active O +
components O +
in O +
Panax O +
ginseng O -
, O +
a O +
famous O +
traditional O +
Chinese O +
medicines O +
recorded O +
in O +
Compendium O +
of O +
Materia O +
Medica O -
. O +

Present O +
study O +
attempted O +
to O +
evaluate O +
the O +
potential O +
mechanisms O +
of O +
Aβ O -
- O -
mediated O +
insult O +
and O +
the O +
protective O +
effects O +
of O +
Rg1 B-Chemical +
on O +
human O +
endothelial O +
cells O -
. O +

Rg1 B-Chemical +
attenuated O +
the O +
Aβ25 O -
- O -
35-associated O +
mitochondrial O +
apoptotic O +
events O -
, O +
accompanied O +
by O +
inhibiting O +
HIF-1α O +
expression O +
followed O +
by O +
intracellular O +
reactive O +
nitrogen B-Chemical +
species O +
generation O -
, O +
and O +
protein O +
nitrotyrosination O -
. O +

These O +
protective O +
effects O +
were O +
abolished O +
by O +
glucocorticoid O +
receptor O +
( O -
GR O -
) O +
antagonist O +
RU486 B-Chemical +
or O +
p O -
- O -
ERK O +
inhibitor O +
U0126 B-Chemical +
rather O +
than O +
estrogen B-Chemical +
receptor O +
α O +
antagonist O +
ICI B-Chemical +
82,780 I-Chemical -
. O +

Taken O +
together O -
, O +
our O +
results O +
suggested O +
that O +
Rg1 B-Chemical +
protected O +
against O +
Aβ25 O -
- O -
35-induced O +
apoptosis O +
at O +
least O +
in O +
part O +
by O +
two O +
complementary O +
GR O -
- O -
dependent O +
ERK O +
phosphorylation O +
pathways O -
: O +
( O -
1 O -
) O +
down O -
- O -
regulating O +
HIF-1α O +
initiated O +
protein O +
nitrotyrosination O -
, O +
and O +
( O -
2 O -
) O +
inhibiting O +
mitochondrial O +
apoptotic O +
cascades O -
. O +

These O +
data O +
provided O +
a O +
novel O +
insight O +
to O +
the O +
mechanisms O +
of O +
Rg1protective B-Chemical +
effects O +
on O +
Aβ25 O -
- O -
35-induced O +
endothelial O +
cells O +
apoptosis O -
, O +
suggesting O +
that O +
GR O -
- O -
ERK O +
signaling O +
pathway O +
might O +
play O +
an O +
important O +
role O +
in O +
it O -
. O +

Cadmium B-Chemical +
Tolerance O +
and O +
Removal O +
from O +
Cunninghamella O +
elegans O +
Related O +
to O +
the O +
Polyphosphate O +
Metabolism O -
. O +

The O +
aim O +
of O +
the O +
present O +
work O +
was O +
to O +
study O +
the O +
cadmium B-Chemical +
effects O +
on O +
growth O -
, O +
ultrastructure O +
and O +
polyphosphate O +
metabolism O -
, O +
as O +
well O +
as O +
to O +
evaluate O +
the O +
metal O +
removal O +
and O +
accumulation O +
by O +
Cunninghamella O +
elegans O +
( O -
IFM O +
46109 O -
) O +
growing O +
in O +
culture O +
medium O -
. O +

The O +
presence O +
of O +
cadmium B-Chemical +
reduced O +
growth O -
, O +
and O +
a O +
longer O +
lag O +
phase O +
was O +
observed O -
. O +

However O -
, O +
the O +
phosphate B-Chemical +
uptake O +
from O +
the O +
culture O +
medium O +
increased O +
15 O -
% O +
when O +
compared O +
to O +
the O +
control O -
. O +

Moreover O -
, O +
C. O +
elegans O +
removed O +
70%-81 O -
% O +
of O +
the O +
cadmium B-Chemical +
added O +
to O +
the O +
culture O +
medium O +
during O +
its O +
growth O -
. O +

The O +
C. O +
elegans O +
mycelia O +
showed O +
a O +
removal O +
efficiency O +
of O +
280 O +
mg O -
/ O -
g O +
at O +
a O +
cadmium B-Chemical +
concentration O +
of O +
22.10 O +
mg O -
/ O -
L O -
, O +
and O +
the O +
removal O +
velocity O +
of O +
cadmium B-Chemical +
was O +
0.107 O +
mg O -
/ O -
h O -
. O +

Additionally O -
, O +
it O +
was O +
observed O +
that O +
cadmium B-Chemical +
induced O +
vacuolization O -
, O +
the O +
presence O +
of O +
electron O +
dense O +
deposits O +
in O +
vacuoles O -
, O +
cytoplasm O +
and O +
cell O +
membranes O -
, O +
as O +
well O +
as O +
the O +
distinct O +
behavior O +
of O +
polyphosphate O +
fractions O -
. O +

The O +
results O +
obtained O +
with O +
C. O +
elegans O +
suggest O +
that O +
precipitation O -
, O +
vacuolization O +
and O +
polyphosphate O +
fractions O +
were O +
associated O +
to O +
cadmium B-Chemical +
tolerance O -
, O +
and O +
this O +
species O +
demonstrated O +
a O +
higher O +
potential O +
for O +
bioremediation O +
of O +
heavy O +
metals O -
. O +

Inhibitors O +
of O +
bacterial O +
tubulin O +
target O +
bacterial O +
membranes O +
in O +
vivo O -
. O +

FtsZ O +
is O +
a O +
homolog O +
of O +
eukaryotic O +
tubulin O +
that O +
is O +
widely O +
conserved O +
among O +
bacteria O +
and O +
coordinates O +
the O +
assembly O +
of O +
the O +
cell O +
division O +
machinery O -
. O +

FtsZ O +
plays O +
a O +
central O +
role O +
in O +
cell O +
replication O +
and O +
is O +
a O +
target O +
of O +
interest O +
for O +
antibiotic O +
development O -
. O +

Several O +
FtsZ O +
inhibitors O +
have O +
been O +
reported O -
. O +

We O +
characterized O +
the O +
mechanism O +
of O +
these O +
compounds O +
in O +
bacteria O +
and O +
found O +
that O +
many O +
of O +
them O +
disrupt O +
the O +
localization O +
of O +
membrane O -
- O -
associated O +
proteins O -
, O +
including O +
FtsZ O -
, O +
by O +
reducing O +
the O +
transmembrane O +
potential O +
or O +
perturbing O +
membrane O +
permeability O -
. O +

We O +
tested O +
whether O +
the O +
reported O +
phenotypes O +
of O +
a O +
broad O +
collection O +
of O +
FtsZ O +
inhibitors O +
disrupt O +
the O +
transmembrane O +
potential O +
in O +
Bacillus O +
subtilis O +
strain O +
168 O -
. O +

Using O +
a O +
combination O +
of O +
flow O +
cytometry O +
and O +
microscopy O -
, O +
we O +
found O +
that O +
zantrin B-Chemical +
Z1 I-Chemical -
, O +
cinnamaldehyde B-Chemical -
, O +
totarol B-Chemical -
, O +
sanguinarine B-Chemical -
, O +
and O +
viriditoxin B-Chemical +
decreased O +
the O +
B. O +
subtilis O +
transmembrane O +
potential O +
or O +
perturbed O +
membrane O +
permeability O -
, O +
and O +
influenced O +
the O +
localization O +
of O +
the O +
membrane O -
- O -
associated O -
, O +
division O +
protein O +
MinD. O +
These O +
studies O +
demonstrate O +
that O +
small O +
molecules O +
that O +
disrupt O +
membrane O +
function O +
in O +
bacterial O +
cells O +
produce O +
phenotypes O +
that O +
are O +
similar O +
to O +
the O +
inhibition O +
of O +
proteins O +
associated O +
with O +
membranes O +
in O +
vivo O -
, O +
including O +
bacterial O +
cytoskeleton O +
homologs O -
, O +
such O +
as O +
FtsZ. O +
The O +
results O +
provide O +
a O +
new O +
dimension O +
for O +
consideration O +
in O +
the O +
design O +
and O +
testing O +
of O +
inhibitors O +
of O +
bacterial O +
targets O +
that O +
are O +
membrane O -
- O -
associated O +
and O +
provide O +
additional O +
insight O +
into O +
the O +
structural O +
characteristics O +
of O +
antibiotics O +
that O +
disrupt O +
the O +
membrane O -
. O +

Transfer O +
of O +
lipids O +
to O +
high O -
- O -
density O +
lipoprotein O +
( O -
HDL O -
) O +
is O +
altered O +
in O +
patients O +
with O +
familial O +
hypercholesterolemia O -
. O +

OBJECTIVE O -
: O +
In O +
familial O +
hypercholesterolemia O +
( O -
FH O -
) O -
, O +
the O +
metabolism O +
and O +
anti O -
- O -
atherogenic O +
functions O +
of O +
HDL O +
can O +
be O +
affected O +
by O +
the O +
continuous O +
interactions O +
with O +
excess O +
LDL O +
amounts O -
. O +

Here O -
, O +
lipid O +
transfers O +
to O +
HDL O -
, O +
an O +
important O +
step O +
for O +
HDL O +
intravascular O +
metabolism O +
and O +
for O +
HDL O +
role O +
in O +
reverse O +
cholesterol B-Chemical +
transport O +
( O -
RCT O -
) O +
were O +
investigated O +
in O +
FH O +
patients O -
. O +

METHODS O -
: O +
Seventy O -
- O -
one O +
FH O +
patients O +
( O -
39±15years O -
, O +
LDL O -
- O -
cholesterol=274±101 B-Chemical -
; O +
HDL O -
- O -
cholesterol=50±14mg B-Chemical -
/ O -
dl O -
) O +
and O +
66 O +
normolipidemic O +
subjects O +
( O -
NL O -
) O +
( O -
38±11years O -
, O +
LDL O -
- O -
cholesterol=105±27 B-Chemical -
; O +
HDL O -
- O -
cholesterol=52±12mg B-Chemical -
/ O -
dl O -
) O +
were O +
studied O -
. O +

In O +
vitro O -
, O +
lipid O +
transfers O +
were O +
evaluated O +
by O +
incubation O +
of O +
plasma O +
samples O +
( O -
37 O -
° O -
C O -
, O +
1h O -
) O +
with O +
a O +
donor O +
lipid O +
nanoemulsion O +
labeled O +
with O +
3H B-Chemical -
- I-Chemical -
triglycerides I-Chemical +
( O -
TG O -
) O +
and O +
14C B-Chemical -
- O -
unesterified O +
cholesterol B-Chemical +
( O -
UC O -
) O +
or O +
with O +
3H B-Chemical -
- I-Chemical -
cholesteryl I-Chemical +
ester I-Chemical +
( O -
EC O -
) O +
and O +
14C B-Chemical -
- O -
phospholipids O +
( O -
PL O -
) O -
. O +

Radioactivity O +
was O +
counted O +
at O +
the O +
HDL O +
fraction O +
after O +
chemical O +
precipitation O +
of O +
apolipoprotein O +
( O -
apo O -
) O +
B O -
- O -
containing O +
lipoproteins O +
and O +
the O +
nanoemulsion O -
. O +

Data O +
are O +
% O +
of O +
total O +
radioactivity O +
measured O +
in O +
the O +
HDL O +
fraction O -
. O +

RESULTS O -
: O +
Transfer O +
of O +
UC O +
to O +
HDL O +
was O +
lower O +
in O +
FH O +
than O +
in O +
NL O +
( O -
5.6±2.1 O +
vs O +
6.7±2.0 O -
% O -
, O +
p=0.0005 O -
) O +
whereas O +
TG O +
( O -
5.5±3.1 O +
vs O +
3.7±0.9 O -
% O -
, O +
p=0.018 O -
) O +
and O +
PL O +
( O -
20.9±4.6 O +
vs O +
18.2±3.7 O +
% O -
, O +
p=0.023 O -
) O +
transfers O +
were O +
higher O +
in O +
FH O -
. O +

EC O +
transfer O +
was O +
equal O -
. O +

By O +
multivariate O +
analysis O -
, O +
transfers O +
of O +
all O +
four O +
lipids O +
correlated O +
with O +
HDL O -
- O -
cholesterol B-Chemical +
and O +
with O +
apo O +
A O -
- O -
I. O +
CONCLUSION O -
: O +
FH O +
elicited O +
marked O +
changes O +
in O +
three O +
of O +
the O +
four O +
tested O +
lipid O +
transfers O +
to O +
HDL O -
. O +

The O +
entry O +
of O +
UC O +
into O +
HDL O +
for O +
subsequent O +
esterification O +
is O +
an O +
important O +
driving O +
force O +
for O +
RCT O +
and O +
reduction O +
of O +
UC O +
transfer O +
to O +
HDL O +
was O +
previously O +
associated O +
to O +
precocious O +
coronary O +
heart O +
disease O -
. O +

Therefore O -
, O +
in O +
FH O -
, O +
HDL O +
functions O +
can O +
be O +
lessened O -
, O +
which O +
can O +
also O +
contribute O +
to O +
atherogenesis O -
. O +

Synthesis O +
and O +
biological O +
evaluation O +
of O +
Foscan B-Chemical -
( O -
® O -
) O +
bile B-Chemical +
acid I-Chemical +
conjugates O +
to O +
target O +
esophageal O +
cancer O +
cells O -
. O +

Porphyrins B-Chemical +
and O +
chlorins B-Chemical +
such O +
as O +
Foscan B-Chemical -
® O +
have O +
a O +
natural O +
proclivity O +
to O +
accumulate O +
in O +
cancer O +
cells O -
. O +

This O +
trait O +
has O +
made O +
them O +
good O +
candidates O +
for O +
photosensitizers O +
and O +
as O +
imaging O +
agents O +
in O +
phototherapy O -
. O +

In O +
order O +
to O +
improve O +
on O +
cellular O +
selectivity O +
to O +
lower O +
post O -
- O -
treatment O +
photosensitivity O +
bile B-Chemical +
acid I-Chemical +
porphyrin I-Chemical +
bioconjugates O +
have O +
been O +
prepared O +
and O +
investigated O +
in O +
esophageal O +
cancer O +
cells O -
. O +

Bile B-Chemical +
acids I-Chemical +
which O +
are O +
known O +
to O +
selectively O +
bind O +
to O -
, O +
or O +
be O +
readily O +
taken O +
up O +
by O +
cancer O +
cells O +
were O +
chosen O +
as O +
targeting O +
moieties O -
. O +

Synthesis O +
of O +
the O +
conjugates O +
was O +
achieved O +
via O +
selective O +
nucleophilic O +
monofunctionalization O +
of O +
5,10,15,20-tetrahydroxyphenylporphyrins B-Chemical +
with O +
propargyl B-Chemical +
bromide I-Chemical +
followed O +
by O +
Cu B-Chemical -
( I-Chemical -
I I-Chemical -
) I-Chemical +
mediated O +
cycloaddition O +
with O +
bile B-Chemical +
acid I-Chemical +
azides I-Chemical +
in O +
good O +
yields O -
. O +

The O +
compounds O +
were O +
readily O +
taken O +
up O +
by O +
esophageal O +
cancer O +
cells O +
but O +
showed O +
no O +
PDT O +
activity O -
. O +

A O +
diazen-1-ium-1,2-diolate B-Chemical +
analog O +
of O +
7-azabenzobicyclo B-Chemical -
[ I-Chemical -
2.2.1 I-Chemical -
] I-Chemical -
heptane I-Chemical -
: O +
Synthesis O -
, O +
nitric B-Chemical +
oxide I-Chemical +
and O +
nitroxyl B-Chemical +
release O -
, O +
in O +
vitro O +
hemodynamic O -
, O +
and O +
anti O -
- O -
hypertensive O +
studies O -
. O +

1- B-Chemical -
( I-Chemical -
7-Azabenzobicyclo I-Chemical -
[ I-Chemical -
2.2.1 I-Chemical -
] I-Chemical -
heptane I-Chemical -
) I-Chemical -
diazen-1-ium-1,2-diolate I-Chemical +
( O -
16 O -
) O +
was O +
designed O +
with O +
the O +
expectation O +
that O +
it O +
would O +
act O +
as O +
a O +
dual O +
nitric B-Chemical +
oxide I-Chemical +
( O -
NO B-Chemical -
) O +
and O +
nitroxyl B-Chemical +
( O -
HNO B-Chemical -
) O +
donor O +
that O +
is O +
not O +
carcinogenic O +
or O +
genotoxic O -
. O +

Compound O +
16 O -
, O +
with O +
a O +
suitable O +
half O -
- O -
life O +
( O -
17.8min O -
) O +
in O +
PBS O +
at O +
pH O +
7 O -
, O +
released O +
NO B-Chemical +
( O -
19 O -
% O -
) O +
and O +
HNO B-Chemical +
( O -
22 O -
% O -
) O +
during O +
a O +
2h O +
incubation O +
in O +
PBS O +
at O +
pH O +
7 O -
. O +

In O +
addition O -
, O +
compound O +
16 O +
exhibited O +
a O +
significant O +
in O +
vitro O +
positive O +
inotropic O +
effect O -
, O +
increased O +
the O +
rates O +
of O +
contraction O +
and O +
relaxation O -
, O +
and O +
increased O +
coronary O +
flow O +
rate O -
, O +
but O +
did O +
not O +
induce O +
a O +
chronotropic O +
effect O -
. O +

Furthermore O -
, O +
compound O +
16 O +
( O -
13.7mgkg O -
( O -
-1 O -
) O -
, O +
po O +
dose O -
) O +
provided O +
a O +
significant O +
reduction O +
in O +
the O +
blood O +
pressure O +
of O +
mice O +
up O +
to O +
3h O +
post O -
- O -
drug O +
administration O -
. O +

All O +
these O +
data O +
suggest O +
that O +
compound O +
16 O +
constitutes O +
an O +
attractive O +
' O -
lead O -
- O -
compound O -
' O +
that O +
could O +
have O +
potential O +
applications O +
to O +
treat O +
cardiovascular O +
disease O -
( O -
s O -
) O +
such O +
as O +
congestive O +
heart O +
failure O -
. O +

Synthetic O +
oligoureas O +
of O +
metaphenylenediamine B-Chemical +
mimic O +
host O +
defence O +
peptides O +
in O +
their O +
antimicrobial O +
behaviour O -
. O +

Oligomeric O +
ureas B-Chemical +
of O +
m B-Chemical -
- I-Chemical -
phenylenediamine I-Chemical +
target O +
anionic O +
DMPG B-Chemical +
( O -
dimyristoylphosphatidylglycerol B-Chemical -
) O +
and O +
possess O +
promise O +
as O +
antimicrobial O +
agents O -
. O +

Their O +
similar O +
size O -
, O +
shape O +
and O +
hydrophobicity O +
to O +
helical O +
antimicrobial O +
peptides O +
( O -
AMPs O -
) O +
may O +
be O +
important O +
for O +
activity O +
to O +
exist O +
and O +
the O +
ability O +
of O +
these O +
compounds O +
to O +
insert O +
into O +
a O +
well O +
ordered O +
lipid O +
environment O -
. O +

PEG B-Chemical +
mediated O +
synthesis O +
and O +
pharmacological O +
evaluation O +
of O +
some O +
fluoro B-Chemical +
substituted I-Chemical +
pyrazoline I-Chemical +
derivatives O +
as O +
antiinflammatory O +
and O +
analgesic O +
agents O -
. O +

A O +
new O +
series O +
of O +
fluoro B-Chemical +
substituted I-Chemical +
pyrazoline I-Chemical +
derivatives O +
5a O -
- O -
g O +
and O +
6a O -
- O -
g O +
were O +
synthesized O +
in O +
good O +
to O +
excellent O +
yield O +
from O +
the O +
corresponding O +
pyrazole B-Chemical +
chalcones I-Chemical -
, O +
4a O -
- O -
g O -
, O +
by O +
using O +
polyethylene B-Chemical +
glycol-400 I-Chemical +
( O -
PEG-400 B-Chemical -
) O +
as O +
an O +
alternative O +
reaction O +
medium O -
. O +

The O +
newly O +
synthesized O +
compounds O +
were O +
characterized O +
and O +
screened O +
for O +
their O +
in O +
vivo O +
antiinflammatory O +
and O +
analgesic O +
activity O -
. O +

Compounds O +
5 O -
g O +
and O +
6 O -
g O +
were O +
found O +
to O +
be O +
more O +
potent O +
than O +
standard O +
drug O +
Diclofenac B-Chemical +
and O +
six O +
other O +
compounds O +
5b O -
, O +
5c O -
, O +
5f O -
, O +
6b O -
, O +
6c O +
and O +
6f O +
showed O +
significant O +
antiinflammatory O +
activity O +
as O +
compared O +
to O +
standard O +
drug O -
. O +

Compounds O +
5c O -
, O +
5d O -
, O +
5e O -
, O +
5f O -
, O +
6c O -
, O +
6d O -
, O +
6e O +
and O +
6f O +
showed O +
significant O +
analgesic O +
activity O +
as O +
compared O +
to O +
standard O +
drug O +
Aspirin O -
. O +

Identification O +
of O +
metal O +
ion O +
binding O +
peptides O +
containing O +
unnatural O +
amino B-Chemical +
acids I-Chemical +
by O +
phage O +
display O -
. O +

The O +
bidentate O +
metal O +
binding O +
amino B-Chemical +
acid I-Chemical +
bipyridylalanine B-Chemical +
( O -
BpyAla B-Chemical -
) O +
was O +
incorporated O +
into O +
a O +
disulfide B-Chemical +
linked O +
cyclic O +
peptide O +
phage O +
displayed O +
library O +
to O +
identify O +
metal O +
ion O +
binding O +
peptides O -
. O +

Selection O +
against O +
Ni B-Chemical -
( I-Chemical -
2+ I-Chemical -
) I-Chemical -
-nitrilotriacetic O +
acid B-Chemical +
( O -
NTA B-Chemical -
) O +
enriched O +
for O +
sequences O +
containing O +
histidine B-Chemical +
and O +
BpyAla B-Chemical -
. O +

BpyAla B-Chemical +
predominated O +
when O +
selections O +
were O +
carried O +
out O +
at O +
lower O +
pH O -
, O +
consistent O +
with O +
the O +
differential O +
pKa O -
's O +
of O +
histidine B-Chemical +
and O +
BpyAla B-Chemical -
. O +

Two O +
peptides O +
containing O +
BpyAla B-Chemical +
were O +
synthesized O +
and O +
found O +
to O +
bind O +
Ni B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
with O +
low O +
micromolar O +
dissociation O +
constants O -
. O +

Incorporation O +
of O +
BpyAla B-Chemical +
and O +
other O +
metal O +
binding O +
amino B-Chemical +
acids I-Chemical +
into O +
peptide O +
and O +
protein O +
libraries O +
should O +
enable O +
the O +
evolution O +
of O +
novel O +
binding O +
and O +
catalytic O +
activities O -
. O +

Tuning O +
into O +
diversity O +
of O +
homeostatic O +
synaptic O +
plasticity O -
. O +

Neurons O +
are O +
endowed O +
with O +
the O +
remarkable O +
ability O +
to O +
integrate O +
activity O +
levels O +
over O +
time O +
and O +
tune O +
their O +
excitability O +
such O +
that O +
action O +
potential O +
firing O +
is O +
maintained O +
within O +
a O +
computationally O +
optimal O +
range O -
. O +

These O +
feedback O +
mechanisms O -
, O +
collectively O +
referred O +
to O +
as O +
" O -
homeostatic O +
plasticity O -
" O -
, O +
enable O +
neurons O +
to O +
respond O +
and O +
adapt O +
to O +
prolonged O +
alterations O +
in O +
neuronal O +
activity O +
by O +
regulating O +
several O +
determinants O +
of O +
cellular O +
excitability O -
. O +

Perhaps O +
the O +
best O -
- O -
characterized O +
of O +
these O +
homeostatic O +
responses O +
involves O +
the O +
regulation O +
of O +
excitatory O +
glutamatergic O +
transmission O -
. O +

This O +
homeostatic O +
synaptic O +
plasticity O +
( O -
HSP O -
) O +
operates O +
bidirectionally O -
, O +
thus O +
providing O +
a O +
means O +
for O +
neurons O +
to O +
tune O +
cellular O +
excitability O +
in O +
response O +
to O +
either O +
elevations O +
or O +
reductions O +
in O +
net O +
activity O -
. O +

The O +
last O +
decade O +
has O +
seen O +
rapid O +
growth O +
in O +
interest O +
and O +
efforts O +
to O +
understand O +
the O +
mechanistic O +
underpinnings O +
of O +
HSP O +
in O +
part O +
because O +
of O +
the O +
theoretical O +
stabilization O +
that O +
HSP O +
confers O +
to O +
neural O +
network O +
function O -
. O +

Since O +
the O +
initial O +
reports O +
describing O +
HSP O +
in O +
central O +
neurons O -
, O +
innovations O +
in O +
experimental O +
approaches O +
have O +
permitted O +
the O +
mechanistic O +
dissection O +
of O +
this O +
cellular O +
adaptive O +
response O +
and O -
, O +
as O +
a O +
result O -
, O +
key O +
advances O +
have O +
been O +
made O +
in O +
our O +
understanding O +
of O +
the O +
cellular O +
and O +
molecular O +
basis O +
of O +
HSP O -
. O +

Here O -
, O +
we O +
review O +
recent O +
evidence O +
that O +
outline O +
the O +
presence O +
of O +
distinct O +
forms O +
of O +
HSP O +
at O +
excitatory O +
glutamatergic O +
synapses O +
which O +
operate O +
at O +
different O +
sub O -
- O -
cellular O +
levels O -
. O +

We O +
further O +
present O +
theoretical O +
considerations O +
on O +
the O +
potential O +
computational O +
roles O +
afforded O +
by O +
local O -
, O +
synapse O -
- O -
specific O +
homeostatic O +
regulation O -
. O +

This O +
article O +
is O +
part O +
of O +
a O +
Special O +
Issue O +
entitled O +
' O -
Homeostatic O +
Plasticity O -
' O -
. O +

Antagonists O +
reversibly O +
reverse O +
chemical O +
LTD O +
induced O +
by O +
group O +
I O -
, O +
group O +
II O +
and O +
group O +
III O +
metabotropic O +
glutamate B-Chemical +
receptors O -
. O +

Metabotropic O +
glutamate B-Chemical +
( O -
mGlu O -
) O +
receptors O +
are O +
implicated O +
in O +
many O +
neurological O +
and O +
psychiatric O +
diseases O +
and O +
are O +
the O +
targets O +
of O +
therapeutic O +
agents O +
currently O +
in O +
clinical O +
development O -
. O +

Their O +
activation O +
has O +
diverse O +
effects O +
in O +
the O +
central O +
nervous O +
system O +
( O -
CNS O -
) O +
that O +
includes O +
an O +
involvement O +
in O +
synaptic O +
plasticity O -
. O +

We O +
previously O +
reported O +
that O +
the O +
brief O +
exposure O +
of O +
hippocampal O +
slices O +
to O +
dihydroxyphenylglycine B-Chemical +
( O -
DHPG B-Chemical -
) O +
can O +
result O +
in O +
a O +
long O -
- O -
term O +
depression O +
( O -
LTD O -
) O +
of O +
excitatory O +
synaptic O +
transmission O -
. O +

Surprisingly O -
, O +
this O +
LTD O +
could O +
be O +
fully O +
reversed O +
by O +
mGlu O +
receptor O +
antagonists O +
in O +
a O +
manner O +
that O +
was O +
itself O +
fully O +
reversible O +
upon O +
washout O +
of O +
the O +
antagonist O -
. O +

Here O -
, O +
15 O +
years O +
after O +
the O +
discovery O +
of O +
DHPG B-Chemical -
- O -
LTD O +
and O +
its O +
reversible O +
reversibility O -
, O +
we O +
summarise O +
these O +
initial O +
findings O -
. O +

We O +
then O +
present O +
new O +
data O +
on O +
DHPG B-Chemical -
- O -
LTD O -
, O +
which O +
demonstrates O +
that O +
evoked O +
epileptiform O +
activity O +
triggered O +
by O +
activation O +
of O +
group O +
I O +
mGlu O +
receptors O +
can O +
also O +
be O +
reversibly O +
reversed O +
by O +
mGlu O +
receptor O +
antagonists O -
. O +

Furthermore O -
, O +
we O +
show O +
that O +
the O +
phenomenon O +
of O +
reversible O +
reversibility O +
is O +
not O +
specific O +
to O +
group O +
I O +
mGlu O +
receptors O -
. O +

We O +
report O +
that O +
activation O +
of O +
group O +
II O +
mGlu O +
receptors O +
in O +
the O +
temporo O -
- O -
ammonic O +
pathway O +
( O -
TAP O -
) O +
and O +
mossy O +
fibre O +
pathway O +
within O +
the O +
hippocampus O +
and O +
in O +
the O +
cortical O +
input O +
to O +
neurons O +
of O +
the O +
lateral O +
amygdala O +
induces O +
an O +
LTD O +
that O +
is O +
reversed O +
by O +
LY341495 B-Chemical -
, O +
a O +
group O +
II O +
mGlu O +
receptor O +
antagonist O -
. O +

We O +
also O +
show O +
that O +
activation O +
of O +
group O +
III O +
mGlu8 O +
receptors O +
induces O +
an O +
LTD O +
at O +
lateral O +
perforant O +
path O +
inputs O +
to O +
the O +
dentate O +
gyrus O +
and O +
that O +
this O +
LTD O +
is O +
reversed O +
by O +
MDCPG O -
, O +
an O +
mGlu8 O +
receptor O +
antagonist O -
. O +

In O +
conclusion O -
, O +
we O +
have O +
shown O +
that O +
activation O +
of O +
representative O +
members O +
of O +
each O +
of O +
the O +
three O +
groups O +
of O +
mGlu O +
receptors O +
can O +
induce O +
forms O +
of O +
LTD O +
than O +
can O +
be O +
reversed O +
by O +
antagonists O -
, O +
and O +
that O +
in O +
each O +
case O +
washout O +
of O +
the O +
antagonist O +
is O +
associated O +
with O +
the O +
re O -
- O -
establishment O +
of O +
the O +
LTD O -
. O +

This O +
article O +
is O +
part O +
of O +
a O +
Special O +
Issue O +
entitled O +
' O -
GluR O -
- O -
dep O +
synaptic O +
plasticity O -
' O -
. O +

Arsenic B-Chemical +
trioxide I-Chemical +
depletes O +
cancer O +
stem O -
- O -
like O +
cells O +
and O +
inhibits O +
repopulation O +
of O +
neurosphere O +
derived O +
from O +
glioblastoma O +
by O +
downregulation O +
of O +
Notch O +
pathway O -
. O +

Notch O +
signaling O +
has O +
been O +
demonstrated O +
to O +
have O +
a O +
central O +
role O +
in O +
cancer O +
stem O -
- O -
like O +
cells O +
( O -
CSLCs O -
) O +
in O +
glioblastoma O +
multiforme O +
( O -
GBM O -
) O -
. O +

We O +
have O +
recently O +
demonstrated O +
the O +
inhibitory O +
effect O +
of O +
arsenic B-Chemical +
trioxide I-Chemical +
( O -
ATO B-Chemical -
) O +
on O +
CSLCs O +
in O +
glioblastoma O +
cell O +
lines O -
. O +

In O +
this O +
study O +
we O +
used O +
neurosphere O +
recovery O +
assay O +
that O +
measured O +
neurosphere O +
formation O +
at O +
three O +
time O +
points O +
to O +
assess O +
the O +
capacity O +
of O +
the O +
culture O +
to O +
repopulate O +
after O +
ATO B-Chemical +
treatment O -
. O +

Our O +
results O +
provided O +
strong O +
evidence O +
that O +
ATO B-Chemical +
depleted O +
CSLCs O +
in O +
GBM O -
, O +
and O +
inhibited O +
neurosphere O +
recovery O +
and O +
secondary O +
neurosphere O +
formation O -
. O +

ATO B-Chemical +
inhibited O +
the O +
phosphorylation O +
and O +
activation O +
of O +
AKT O +
and O +
STAT3 O +
through O +
Notch O +
signaling O +
blockade O -
. O +

These O +
data O +
show O +
that O +
the O +
ATO B-Chemical +
is O +
a O +
promising O +
new O +
approach O +
to O +
decrease O +
glioblastoma O +
proliferation O +
and O +
recurrence O +
by O +
downregulation O +
of O +
Notch O +
pathway O -
. O +

Structure O -
- O -
activity O +
relationship O +
of O +
5-chloro-2-methyl-3- B-Chemical -
( I-Chemical -
1,2,3,6-tetrahydropyridin-4-yl I-Chemical -
) I-Chemical -
-1H I-Chemical -
- I-Chemical -
indole I-Chemical +
analogues O +
as O +
5-HT6 O +
receptor O +
agonists O -
. O +

To O +
further O +
investigate O +
the O +
structure O -
- O -
activity O +
relationship O +
( O -
SAR O -
) O +
of O +
the O +
5-hydroxytryptamine B-Chemical +
type O +
6 O +
( O -
5-HT6 O -
) O +
receptor O +
agonist O +
5-chloro-2-methyl-3- B-Chemical -
( I-Chemical -
1,2,3,6-tetrahydropyridin-4-yl I-Chemical -
) I-Chemical -
-1H I-Chemical -
- I-Chemical -
indole I-Chemical +
( O -
EMD386088 B-Chemical -
, O +
6 O -
) O -
, O +
a O +
series O +
of O +
2-methyl-3- B-Chemical -
( I-Chemical -
1,2,3,6-tetrahydropyridin-4-yl I-Chemical -
) I-Chemical -
-1H I-Chemical -
- I-Chemical -
indoles I-Chemical +
were O +
synthesized O -
, O +
and O +
in O +
vitro O +
affinity O +
to O -
, O +
and O +
functional O +
activity O +
at O +
5-HT6 O +
receptors O +
was O +
tested O -
. O +

We O +
focused O +
on O +
substituents O +
made O +
at O +
the O +
indole B-Chemical +
N O -
( O -
1 O -
) O -
- O -
, O +
2- O +
and O +
5-positions O +
and O +
these O +
were O +
found O +
to O +
not O +
only O +
influence O +
the O +
affinity O +
at O +
5-HT6 O +
receptors O +
but O +
also O +
the O +
intrinsic O +
activity O +
leading O +
to O +
antagonists O -
, O +
partial O +
agonists O +
and O +
full O +
agonists O -
. O +

In O +
order O +
for O +
a O +
compound O +
to O +
demonstrate O +
potent O +
5-HT6 O +
receptor O +
agonist O +
properties O -
, O +
the O +
indole B-Chemical +
N O -
( O -
1 O -
) O +
should O +
be O +
unsubstituted O -
, O +
an O +
alkyl B-Chemical +
group O +
such O +
as O +
2-methyl B-Chemical +
is O +
needed O +
and O +
finally O +
halogen B-Chemical +
substituents O +
in O +
the O +
indole B-Chemical +
5-position O +
( O -
fluoro B-Chemical -
, O +
chloro B-Chemical +
or O -
, O +
bromo B-Chemical -
) O +
were O +
essential O +
requirements O -
. O +

However O -
, O +
the O +
introduction O +
of O +
a O +
benzenesulfonyl B-Chemical +
group O +
at O +
N O -
( O -
1 O -
) O -
-position O +
switched O +
the O +
full O +
agonist O +
6 O +
to O +
be O +
a O +
5-HT6 O +
receptor O +
antagonist O +
( O -
30 O -
) O -
. O +

A O +
few O +
compounds O +
within O +
the O +
2-methyl-3- B-Chemical -
( I-Chemical -
1,2,3,6-tetrahydropyridin-4-yl I-Chemical -
) I-Chemical -
-1H I-Chemical -
- I-Chemical -
indoles I-Chemical +
were O +
also O +
screened O +
for O +
off O -
- O -
targets O +
and O +
generally O +
they O +
displayed O +
low O +
affinity O +
for O +
other O +
5-HT B-Chemical +
subtypes O +
and O +
serotonin B-Chemical +
transporter O +
protein O +
( O -
SERT O -
) O -
. O +

Induction O +
of O +
G2 O -
/ O -
M O +
arrest O -
, O +
caspase O +
activation O +
and O +
apoptosis O +
by O +
α B-Chemical -
- I-Chemical -
santonin I-Chemical +
derivatives O +
in O +
HL-60 O +
cells O -
. O +

Sesquiterpene B-Chemical +
lactones I-Chemical +
( O -
SLs B-Chemical -
) O +
are O +
natural O +
products O +
with O +
a O +
variety O +
of O +
biological O +
activities O -
. O +

Previously O -
, O +
we O +
demonstrated O +
the O +
cytotoxic O +
effects O +
of O +
three O +
new O +
α B-Chemical -
- I-Chemical -
santonin I-Chemical +
derivatives O +
on O +
different O +
tumor O +
cell O +
lines O +
with O +
low O +
toxic O +
effects O +
upon O +
peripheral O +
human O +
leukocytes O -
. O +

Here O -
, O +
we O +
evaluated O +
the O +
mechanism O +
of O +
action O +
triggered O +
by O +
these O +
derivatives O -
. O +

HL-60 O +
cell O +
cycle O +
determined O +
after O +
24h O +
treatment O +
revealed O +
a O +
significant O +
inhibition O +
on O +
cell O -
- O -
cycle O +
progression O +
and O +
leading O +
to O +
an O +
increasing O +
of O +
cells O +
in O +
G2 O -
/ O -
M O +
[ O -
7.6 O -
% O +
and O +
9.0 O -
% O +
for O +
compound O +
3 O -
% O +
and O +
9.0 O -
% O +
and O +
8.6 O -
% O +
for O +
compound O +
4 O +
( O -
1 O +
and O +
2μM O -
, O +
respectively O -
) O -
] O -
. O +

However O -
, O +
after O +
48h O +
exposure O -
, O +
all O +
compounds O +
caused O +
G2 O -
/ O -
M O +
reduction O +
and O +
a O +
significant O +
DNA O +
fragmentation O -
. O +

Compounds O +
2 O -
, O +
3 O +
and O +
4 O +
were O +
able O +
to O +
induce O +
apoptosis O +
on O +
leukemia O +
cells O -
, O +
which O +
was O +
corroborated O +
by O +
phosphatidyserine O +
externalization O +
and O +
activation O +
of O +
caspases-3 O +
and O +
-7 O +
after O +
24h O +
exposure O -
. O +

None O +
of O +
the O +
derivatives O +
analyzed O +
caused O +
depolarization O +
of O +
mitochondrial O +
membrane O +
within O +
24h O +
of O +
incubation O -
, O +
suggesting O +
the O +
involvement O +
of O +
the O +
extrinsic O +
apoptotic O +
pathway O +
in O +
the O +
death O +
process O -
. O +

The O +
antiproliferative O +
action O +
of O +
these O +
compounds O +
is O +
related O +
to O +
the O +
DNA O +
synthesis O +
inhibition O +
and O +
cell O +
cycle O +
arrest O -
, O +
which O +
probably O +
lead O +
to O +
apoptosis O +
activation O -
. O +

Therefore O -
, O +
these O +
santonin B-Chemical +
derivatives O +
are O +
promising O +
lead O +
candidates O +
for O +
development O +
of O +
new O +
cytotoxic O +
agents O -
. O +

Systematic O +
review O +
of O +
the O +
effects O +
of O +
maternal O +
hypertension O +
in O +
pregnancy O +
and O +
antihypertensive O +
therapies O +
on O +
child O +
neurocognitive O +
development O -
. O +

As O +
many O +
as O +
15 O -
% O +
of O +
women O +
experience O +
hypertension O +
during O +
pregnancy O -
. O +

Large O +
proportions O +
of O +
them O +
are O +
receiving O +
antihypertensive O +
medications O -
. O +

This O +
review O +
investigated O +
whether O +
hypertension O +
itself O -
, O +
or O +
the O +
antihypertensive O +
medications O -
, O +
adversely O +
affect O +
long O +
term O +
child O +
neurocognitive O +
development O -
. O +

The O +
existing O +
evidence O +
suggests O +
that O +
methyldopa B-Chemical +
and O +
labetalol B-Chemical +
probably O +
do O +
not O +
adversely O +
affect O +
neurobehavioral O +
development O -
. O +

Although O +
an O +
increasing O +
body O +
of O +
evidence O +
suggests O +
adverse O +
neurocognitive O +
effects O +
of O +
the O +
hypertension O +
itself O -
, O +
none O +
of O +
the O +
existing O +
studies O +
examined O +
simultaneously O +
the O +
effects O +
of O +
both O +
hypertension O +
and O +
the O +
drugs O +
used O +
therapeutically O -
. O +

The O +
confounding O +
effects O +
by O +
indication O +
must O +
be O +
addressed O +
in O +
future O +
studies O -
. O +

Comparison O +
of O +
the O +
Therapeutic O +
Effectiveness O +
of O +
Sustained O +
Low O -
- O -
Efficiency O +
Dialysis O +
( O -
SLED O -
) O +
with O +
Continuous O +
Blood O +
Purification O +
( O -
CBP O -
) O +
in O +
Critically O +
Ill O +
Patients O -
. O +

The O +
differences O +
in O +
therapeutic O +
effectiveness O +
between O +
sustained O +
low O -
- O -
efficiency O +
dialysis O +
( O -
SLED O -
) O +
and O +
continuous O +
blood O +
purification O +
( O -
CBP O -
) O +
were O +
investigated O -
. O +

In O +
order O +
to O +
assess O +
the O +
different O +
treatment O +
methods O -
, O +
56 O +
critically O +
ill O +
patients O +
were O +
divided O +
into O +
two O +
groups O -
, O +
the O +
CBP O +
group O +
and O +
the O +
SLED O +
group O -
. O +

A O +
comparison O +
was O +
made O +
between O +
all O +
the O +
biochemical O +
indicators O -
, O +
in O -
- O -
hospital O +
duration O -
, O +
hemodynamic O +
parameters O -
, O +
acute O +
physiology O +
and O +
chronic O +
health O +
evaluation O +
( O -
APACHE O -
- O -
II O -
) O -
, O +
the O +
survival O -
, O +
and O +
the O +
mortality O +
rates O -
. O +

After O +
treatment O -
, O +
the O +
levels O +
of O +
serum O +
creatine B-Chemical +
kinase O +
isozyme O +
MB O +
( O -
CK O -
- O -
MB O -
) O -
, O +
creatine B-Chemical +
kinase O -
, O +
creatinine B-Chemical -
, O +
glutamate B-Chemical -
- O -
oxalacetate B-Chemical +
transaminase O +
( O -
AST O -
) O -
, O +
glutamate B-Chemical -
- O -
pyruvate B-Chemical +
transaminase O +
( O -
ALT O -
) O -
, O +
APACHE O +
II O +
score O +
on O +
the O +
1st O -
, O +
2nd O -
, O +
and O +
7th O +
day O +
in O +
both O +
the O +
treatment O +
groups O +
were O +
lower O +
than O +
that O +
before O +
the O +
treatment O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

There O +
are O +
no O +
statistical O +
differences O +
in O +
in O -
- O -
hospital O +
duration O -
, O +
biochemical O +
indicators O -
, O +
APACHE O +
II O +
score O -
, O +
hemodynamic O +
parameters O -
, O +
the O +
survival O +
rate O +
and O +
the O +
mortality O +
rate O +
between O +
the O +
two O +
groups O +
( O -
P O +
> O +
0.05 O -
) O -
. O +

It O +
was O +
concluded O +
that O +
SLED O +
has O +
similar O +
hemodynamic O +
stability O +
with O +
CBP O +
and O +
the O +
two O +
methods O +
have O +
similar O +
treatment O +
effects O +
in O +
critically O +
ill O +
patients O -
. O +

However O -
, O +
we O +
noticed O +
that O +
SLED O +
can O +
be O +
relatively O +
economical O +
and O +
convenient O +
for O +
critically O +
ill O +
patients O +
in O +
clinical O +
practice O -
. O +

Virtual O +
medicinal O +
chemistry O -
: O +
In O +
silico O +
pre O -
- O -
docking O +
functional O +
group O +
transformation O +
for O +
discovery O +
of O +
novel O +
inhibitors O +
of O +
botulinum O +
toxin O +
serotype O +
A O +
light O +
chain O -
. O +

A O +
novel O +
method O +
for O +
applying O +
high O -
- O -
throughput O +
docking O +
to O +
challenging O +
metalloenzyme O +
targets O +
is O +
described O -
. O +

The O +
method O +
utilizes O +
information O -
- O -
based O +
virtual O +
transformation O +
of O +
library O +
carboxylates B-Chemical +
to O +
hydroxamic B-Chemical +
acids I-Chemical +
prior O +
to O +
docking O -
, O +
followed O +
by O +
compound O +
acquisition O -
, O +
one O -
- O -
pot O +
( O -
two O +
steps O -
) O +
chemical O +
synthesis O +
and O +
in O +
vitro O +
screening O -
. O +

In O +
two O +
experiments O +
targeting O +
the O +
botulinum O +
neurotoxin O +
serotype O +
A O +
metalloprotease O +
light O +
chain O -
, O +
hit O +
rates O +
of O +
32 O -
% O +
and O +
18 O -
% O +
were O +
observed O -
. O +

Excess O +
androgens B-Chemical +
in O +
utero O +
alters O +
fetal O +
testis O +
development O -
. O +

Prenatal O +
androgenization O +
induces O +
a O +
polycystic O +
ovary O +
syndrome O -
- O -
like O +
phenotype O +
in O +
adult O +
female O +
offspring O -
, O +
which O +
is O +
associated O +
with O +
alterations O +
that O +
can O +
be O +
detected O +
in O +
the O +
fetal O +
ovary O -
, O +
suggesting O +
gestational O +
origins O +
of O +
this O +
condition O -
. O +

We O +
therefore O +
investigated O +
whether O +
increased O +
prenatal O +
androgen B-Chemical +
exposure O +
also O +
altered O +
testicular O +
development O +
using O +
ovine O +
animal O +
models O -
. O +

Biweekly O +
maternal O +
testosterone B-Chemical +
propionate I-Chemical +
( O -
TP O -
; O +
100 O +
mg O -
) O +
from O +
day O +
62 O +
to O +
day O +
70 O -
/ O -
day O +
90 O +
of O +
gestation O +
altered O +
male O +
developmental O +
trajectory O -
. O +

In O +
male O +
fetuses O +
serum O +
LH O +
was O +
decreased O +
( O -
P O +
< O +
.01 O -
) O -
, O +
and O +
testicular O +
STAR O -
, O +
CYP11 O -
, O +
and O +
CYP17 O +
abundance O +
were O +
reduced O -
. O +

Coincident O +
with O +
this O -
, O +
basal O +
testicular O +
T O +
synthesis O +
was O +
decreased O +
in O +
vitro O +
( O -
P O +
< O +
.001 O -
) O -
. O +

Leydig O +
cell O +
distribution O +
was O +
severely O +
perturbed O +
in O +
all O +
testes O +
prenatally O +
exposed O +
to O +
TP O +
( O -
P O +
< O +
.001 O -
) O -
. O +

To O +
examine O +
the O +
contribution O +
of O +
estrogens B-Chemical -
, O +
fetuses O +
were O +
injected O +
with O +
TP O +
( O -
20 O +
mg O -
) O -
, O +
the O +
potent O +
estrogen B-Chemical +
agonist O -
, O +
diethylstilbestrol B-Chemical +
( O -
DES B-Chemical -
; O +
20 O +
mg O -
) O -
, O +
or O +
vehicle O +
control O +
at O +
day O +
62 O +
and O +
day O +
82 O +
and O +
assessed O +
at O +
day O +
90 O -
. O +

The O +
effects O +
of O +
fetal O +
( O -
direct O -
) O +
TP O +
treatment O -
, O +
but O +
not O +
DES B-Chemical -
, O +
paralleled O +
maternal O +
( O -
indirect O -
) O +
TP O +
exposure O -
, O +
supporting O +
a O +
direct O +
androgen B-Chemical +
effect O -
. O +

Cessation O +
of O +
maternal O +
androgenization O +
at O +
day O +
102 O +
returned O +
Leydig O +
cell O +
distribution O +
to O +
normal O +
but O +
increased O +
basal O +
T O +
output O -
, O +
at O +
day O +
112 O -
, O +
demonstrating O +
Leydig O +
cell O +
developmental O +
plasticity O -
. O +

Earlier O +
maternal O +
androgen B-Chemical +
exposure O +
from O +
day O +
30 O +
similarly O +
influenced O +
Leydig O +
cell O +
development O +
at O +
day O +
90 O +
but O +
additionally O +
affected O +
the O +
expression O +
of O +
Sertoli O +
and O +
germ O +
cell O +
markers O -
. O +

We O +
show O +
in O +
this O +
study O +
that O +
increased O +
prenatal O +
androgen O +
exposure O +
alters O +
development O +
and O +
function O +
of O +
Leydig O +
cells O +
at O +
a O +
time O +
when O +
androgen B-Chemical +
production O +
is O +
paramount O +
for O +
male O +
development O -
. O +

This O +
supports O +
the O +
concept O +
that O +
gestational O +
antecedents O +
associated O +
with O +
polycystic O +
ovary O +
syndrome O +
may O +
have O +
effects O +
on O +
the O +
male O +
fetus O -
. O +

Budesonide B-Chemical -
/ O -
cyclodextrin O +
complex O -
- O -
loaded O +
lyophilized O +
microparticles O +
for O +
intranasal O +
application O -
. O +

Abstract O +
Objective O -
: O +
Lyophilized O +
microparticles O +
composed O +
of O +
budesonide B-Chemical +
( O -
BDS B-Chemical -
) O -
, O +
hydroxypropyl B-Chemical -
- I-Chemical -
β I-Chemical -
- I-Chemical -
cyclodextrin I-Chemical +
( O -
HP B-Chemical -
- I-Chemical -
β I-Chemical -
- I-Chemical -
CD I-Chemical -
) O -
, O +
and O +
hydroxypropylmethylcellulose O +
( O -
HPMC O -
) O +
or O +
sodium B-Chemical +
carboxymethylcellulose O +
( O -
CMC O -
- O -
Na B-Chemical -
) O +
were O +
developed O +
for O +
intranasal O +
delivery O +
and O +
their O +
characteristics O +
were O +
evaluated O -
. O +

Materials O +
and O +
methods O -
: O +
The O +
particle O +
size O +
and O +
morphology O +
were O +
assessed O +
by O +
mean O +
diameter O +
measurement O +
and O +
scanning O +
electron O +
microscopy O +
( O -
SEM O -
) O +
image O -
, O +
respectively O -
. O +

The O +
solid O -
- O -
state O +
of O +
products O +
was O +
tested O +
by O +
X O -
- O -
ray O +
powder O +
diffraction O +
( O -
XRPD O -
) O -
, O +
Fourier O +
transform O +
infrared O +
spectroscopy O +
( O -
FT O -
- O -
IR O -
) O +
and O +
differential O +
scanning O +
calorimetry O +
( O -
DSC O -
) O -
. O +

In O +
vitro O +
drug O +
release O +
and O +
cytotoxicity O +
to O +
the O +
primary O +
human O +
nasal O +
epithelial O +
( O -
HNE O -
) O +
cells O +
were O +
also O +
evaluated O -
. O +

Results O +
and O +
discussion O -
: O +
Lyophilized O +
microparticles O +
exhibited O +
vanishment O +
of O +
crystallinity O +
of O +
drug O +
in O +
XRPD O +
analysis O -
, O +
the O +
enfeeblement O +
of O +
carbonyl B-Chemical +
( O -
C B-Chemical -
= I-Chemical -
O I-Chemical -
) O +
stretching O +
bands O +
of O +
carboxyl B-Chemical +
group O +
in O +
BDS B-Chemical +
in O +
FT O -
- O -
IR O +
spectra O +
and O +
the O +
disappearance O +
of O +
endothermic O +
peak O +
of O +
drug O +
in O +
the O +
results O +
of O +
DSC O +
study O -
. O +

Based O +
on O +
the O +
results O +
of O +
solid O -
- O -
state O +
studies O -
, O +
BDS B-Chemical +
was O +
existed O +
as O +
an O +
amorphous O +
form O +
in O +
the O +
lyophilized O +
microparticles O -
. O +

CD O +
complexation O +
enhanced O +
drug O +
solubility O +
and O +
release O +
rate O -
, O +
and O +
HPMC O +
or O +
CMC O -
- O -
Na B-Chemical +
also O +
improved O +
drug O +
dissolution O +
rates O -
. O +

Cytotoxicity O +
of O +
developed O +
microparticles O +
to O +
the O +
HNE O +
cells O +
was O +
measured O +
and O +
their O +
safety O +
to O +
HNE O +
cell O +
was O +
identified O -
. O +

Conclusion O -
: O +
Developed O +
microparticles O +
can O +
efficiently O +
deliver O +
insoluble O +
drug O -
, O +
such O +
as O +
BDS B-Chemical -
, O +
to O +
the O +
nasal O +
epithelium O +
and O +
thus O +
it O +
may O +
improve O +
therapeutic O +
efficacy O +
in O +
the O +
respiratory O +
tract O -
. O +

Serotonin B-Chemical +
( O -
5-HT B-Chemical -
) O +
in O +
the O +
Regulation O +
of O +
Depression O -
- O -
Related O +
Emotionality O -
: O +
Insight O +
from O +
5-HT B-Chemical +
Transporter O +
and O +
Tryptophan B-Chemical +
Hydroxylase-2 O +
Knockout O +
Mouse O +
Models O -
. O +

Disorders O +
of O +
emotion O +
regulation O +
such O +
as O +
anxiety O +
disorders O +
and O +
depression O +
are O +
common O +
and O +
yet O +
debilitating O -
. O +

Accumulating O +
evidence O +
suggests O +
involvement O +
of O +
serotonin B-Chemical +
( O -
5-HT B-Chemical -
) O +
in O +
the O +
regulation O +
of O +
emotion O -
. O +

Mice O +
with O +
targeted O +
deletion O +
of O +
genes O +
encoding O +
mediators O +
of O +
the O +
serotonergic O +
transmission O +
have O +
proven O +
to O +
be O +
a O +
powerful O +
tool O +
for O +
understanding O +
contributions O +
of O +
such O +
mediators O +
of O +
emotion O +
regulation O -
. O +

Over O +
the O +
last O +
decade O -
, O +
research O +
on O +
mice O +
with O +
a O +
targeted O +
inactivation O +
of O +
the O +
5-HT B-Chemical +
transporter O +
( O -
5-Htt O -
, O +
Sert O -
, O +
Slc6a4 O -
) O +
has O +
considerably O +
advanced O +
our O +
knowledge O +
about O +
functions O +
that O +
the O +
5-HTT O +
plays O +
in O +
the O +
context O +
of O +
emotion O +
related O +
to O +
depression O -
. O +

Moreover O -
, O +
the O +
recent O +
advent O +
of O +
knockout O +
( O -
KO O -
) O +
mice O +
for O +
tryptophan B-Chemical +
hydroxylase O +
2 O +
( O -
Tph2 O +
KO O -
) O -
, O +
which O +
lacks O +
the O +
rate O -
- O -
limiting O +
enzyme O +
for O +
5-HT B-Chemical +
synthesis O +
in O +
the O +
brain O -
, O +
has O +
further O +
provided O +
insight O +
to O +
the O +
brain O +
serotonergic O +
system O +
and O +
its O +
role O +
in O +
emotion O +
dysregulation O -
. O +

Here O -
, O +
we O +
first O +
highlight O +
basic O +
characteristics O +
of O +
the O +
serotonergic O +
system O +
including O +
the O +
biosynthesis O +
of O +
5-HT B-Chemical +
as O +
well O +
as O +
the O +
anatomy O +
and O +
firing O +
activity O +
of O +
serotonergic O +
neurons O -
. O +

Furthermore O -
, O +
characteristics O +
of O +
5-Htt O +
and O +
Tph2 O +
KO O +
mice O +
are O +
covered O +
together O +
with O +
association O +
studies O +
on O +
human O +
variants O +
of O +
5-HTT O +
and O +
TPH2 O +
in O +
emotional O +
regulation O -
. O +

Among O +
various O +
targets O +
of O +
serotonergic O +
projections O -
, O +
which O +
originate O +
from O +
the O +
raphe O +
nuclei O +
in O +
the O +
brain O +
stem O -
, O +
particular O +
focus O +
is O +
placed O +
on O +
the O +
hippocampus O +
due O +
to O +
its O +
unique O +
dual O +
role O +
in O +
memory O +
and O +
emotion O -
. O +

Finally O -
, O +
effects O +
of O +
therapeutic O +
drugs O +
and O +
psychoactive O +
drugs O +
on O +
KO O +
mouse O +
models O +
as O +
well O +
as O +
on O +
synaptic O +
plasticity O +
will O +
be O +
discussed O -
. O +

Controllable O +
Hydrogen B-Chemical +
Sulfide I-Chemical +
Donors O +
and O +
Their O +
Activity O +
against O +
Myocardial O +
Ischemia O -
- O -
Reperfusion O +
Injury O -
. O +

Hydrogen B-Chemical +
sulfide I-Chemical +
( O -
H2S B-Chemical -
) O -
, O +
known O +
as O +
an O +
important O +
cellular O +
signaling O +
molecule O -
, O +
plays O +
critical O +
roles O +
in O +
many O +
physiological O +
and/or O +
pathological O +
processes O -
. O +

Modulation O +
of O +
H2S B-Chemical +
levels O +
could O +
have O +
tremendous O +
therapeutic O +
value O -
. O +

However O -
, O +
the O +
study O +
on O +
H2S B-Chemical +
has O +
been O +
hindered O +
due O +
to O +
the O +
lack O +
of O +
controllable O +
H2S B-Chemical +
releasing O +
agents O +
that O +
could O +
mimic O +
the O +
slow O +
and O +
moderate O +
H2S B-Chemical +
release O +
in O +
vivo O -
. O +

In O +
this O +
work O +
we O +
report O +
the O +
design O -
, O +
synthesis O -
, O +
and O +
biological O +
evaluation O +
of O +
a O +
new O +
class O +
of O +
controllable O +
H2S B-Chemical +
donors O -
. O +

Twenty O -
- O -
five O +
donors O +
were O +
prepared O +
and O +
tested O -
. O +

Their O +
structures O +
were O +
based O +
on O +
a O +
perthiol B-Chemical +
template O -
, O +
which O +
was O +
suggested O +
to O +
be O +
involved O +
in O +
H2S B-Chemical +
biosynthesis O -
. O +

H2S B-Chemical +
release O +
mechanism O +
from O +
these O +
donors O +
was O +
studied O +
and O +
proved O +
to O +
be O +
thiol B-Chemical -
- O -
dependent O -
. O +

We O +
also O +
developed O +
a O +
series O +
of O +
cell O -
- O -
based O +
assays O +
to O +
access O +
their O +
H2S B-Chemical -
- O -
related O +
activities O -
. O +

H9c2 O +
cardiac O +
myocytes O +
were O +
used O +
in O +
these O +
experiments O -
. O +

We O +
tested O +
lead O +
donors O -
' O +
cytotoxicity O +
and O +
confirmed O +
their O +
H2S B-Chemical +
production O +
in O +
cells O -
. O +

Finally O +
we O +
demonstrated O +
that O +
selected O +
donors O +
showed O +
potent O +
protective O +
effects O +
in O +
an O +
in O +
vivo O +
murine O +
model O +
of O +
myocardial O +
ischemia O -
- O -
reperfusion O +
injury O -
, O +
through O +
a O +
H2S B-Chemical -
- O -
related O +
mechanism O -
. O +

Interfacial O +
Nanoarchitectonics O -
: O +
Lateral O +
and O +
Vertical O -
, O +
Static O +
and O +
Dynamic O -
. O +

The O +
exploration O +
of O +
nanostructures O +
and O +
nanomaterials O +
is O +
essential O +
to O +
the O +
development O +
of O +
advanced O +
functions O -
. O +

For O +
such O +
innovations O -
, O +
nanoarchitectonics O +
has O +
been O +
proposed O +
as O +
a O +
novel O +
paradigm O +
of O +
nanotechnology O +
aimed O +
at O +
assembling O +
nanoscale O +
structural O +
units O +
into O +
predesigned O +
configurations O +
or O +
arrangements O -
. O +

In O +
this O +
Feature O +
Article O -
, O +
we O +
provide O +
an O +
overview O +
of O +
several O +
recent O +
research O +
works O +
from O +
the O +
viewpoint O +
of O +
interfacial O +
nanoarchitectonics O +
with O +
features O +
developed O +
in O +
lateral O +
directions O +
or O +
grown O +
in O +
vertical O +
directions O +
with O +
construction O +
on O +
solid O -
, O +
static O -
, O +
or O +
flexible O +
dynamic O +
surfaces O -
. O +

Lateral O +
nanoarchitectonics O +
at O +
a O +
static O +
interface O +
provides O +
molecular O +
organization O +
by O +
bottom O -
- O -
up O +
nanoarchitectonics O +
and O +
can O +
also O +
be O +
used O +
to O +
realize O +
device O +
integration O +
by O +
top O -
- O -
down O +
nanoarchitectonics O -
. O +

In O +
particular O -
, O +
in O +
the O +
latter O +
case O -
, O +
the O +
fabrication O +
of O +
novel O +
devices O -
, O +
so O -
- O -
called O +
atomic O +
switches O -
, O +
are O +
introduced O +
as O +
a O +
demonstration O +
of O +
atomic O -
- O -
level O +
electronics O -
. O +

Lateral O +
nanoarchitectonics O +
at O +
dynamic O +
interfaces O +
is O +
exemplified O +
by O +
2D O +
molecular O +
patterning O +
and O +
molecular O +
machine O +
operation O +
induced O +
by O +
macroscopic O +
motion O -
. O +

The O +
dynamic O +
nature O +
of O +
interfaces O +
enables O +
us O +
to O +
operate O +
molecular O -
- O -
sized O +
machines O +
by O +
macroscopic O +
mechanical O +
stimuli O +
such O +
as O +
our O +
hand O +
motion O -
, O +
which O +
we O +
refer O +
to O +
as O +
hand O -
- O -
operated O +
nanotechnology O -
. O +

Vertical O +
nanoarchitectonics O +
is O +
mainly O +
discussed O +
in O +
relation O +
to O +
layer O -
- O -
by O -
- O -
layer O +
( O -
LbL O -
) O +
assembly O -
. O +

By O +
using O +
this O +
technique O -
, O +
we O +
can O +
assemble O +
a O +
variety O +
of O +
functional O +
materials O +
in O +
ultrathin O +
film O +
structures O +
of O +
defined O +
thickness O +
and O +
layer O +
sequence O -
. O +

The O +
organization O +
of O +
biomolecules O +
( O -
or O +
even O +
living O +
cells O -
) O +
within O +
thin O +
films O +
and O +
their O +
integration O +
with O +
device O +
structures O +
is O +
exemplified O -
. O +

Finally O -
, O +
the O +
anticipated O +
research O +
directions O +
of O +
interfacial O +
nanoarchitectonics O +
are O +
described O -
. O +

Polycyclic O +
Hybrid O +
Isoprenoids B-Chemical +
from O +
a O +
Reed O +
Rhizosphere O +
Soil O +
Derived O +
Streptomyces O +
sp. O +
CHQ-64 O -
. O +

Two O +
new O +
hybrid O +
isoprenoids B-Chemical -
, O +
named O +
indotertine B-Chemical +
B I-Chemical +
( O -
2 O -
) O +
and O +
drimentine B-Chemical +
H I-Chemical +
( O -
3 O -
) O -
, O +
along O +
with O +
the O +
known O +
analogue O +
drimentine B-Chemical +
C I-Chemical +
( O -
4 O -
) O -
, O +
were O +
isolated O +
from O +
the O +
reed O +
rhizosphere O +
soil O +
derived O +
actinomycete O +
Streptomyces O +
sp. O +
CHQ-64 O -
. O +

The O +
structures O +
of O +
these O +
compounds O -
, O +
including O +
absolute O +
configurations O -
, O +
were O +
elucidated O +
by O +
extensive O +
NMR O -
, O +
MS O -
, O +
and O +
CD O +
analyses O -
. O +

Indotertine B-Chemical +
B I-Chemical +
( O -
2 O -
) O +
exists O +
as O +
a O +
pair O +
of O +
rotamers O +
about O +
the O +
N B-Chemical -
- I-Chemical -
C I-Chemical -
( I-Chemical -
O I-Chemical -
) I-Chemical +
bond O +
with O +
a O +
2:1 O +
ratio O +
and O +
displays O +
activities O +
against O +
HCT-8 O +
and O +
A549 O +
tumor O +
cell O +
lines O +
with O +
IC50 O +
values O +
of O +
6.96 O +
and O +
4.88 O +
μM O -
, O +
respectively O -
. O +

A O +
mass O -
- O -
tagging O +
approach O +
for O +
enhanced O +
sensitivity O +
of O +
dynamic O +
cytokine O +
detection O +
using O +
a O +
label O -
- O -
free O +
biosensor O -
. O +

Monitoring O +
cytokine O +
release O +
by O +
cells O +
allows O +
the O +
investigation O +
of O +
cellular O +
response O +
to O +
specific O +
external O +
stimuli O -
, O +
such O +
as O +
pathogens O +
or O +
candidate O +
drugs O -
. O +

Unlike O +
conventional O +
colorimetric O +
techniques O -
, O +
label O -
- O -
free O +
detection O +
of O +
cytokines O +
enables O +
studying O +
cellular O +
secretions O +
in O +
real O +
time O +
by O +
eliminating O +
additional O +
wash O +
and O +
labeling O +
steps O +
after O +
the O +
binding O +
step O -
. O +

However O -
, O +
label O -
- O -
free O +
techniques O +
that O +
are O +
based O +
on O +
measuring O +
mass O +
accumulation O +
on O +
a O +
sensor O +
surface O +
are O +
challenging O +
for O +
measuring O +
small O +
cytokines O +
binding O +
to O +
much O +
larger O +
capture O +
agents O +
( O -
usually O +
antibodies O -
) O +
because O +
the O +
relative O +
signal O +
change O +
is O +
small O -
. O +

This O +
problem O +
is O +
exacerbated O +
when O +
the O +
capturing O +
antibodies O +
desorb O +
from O +
the O +
surface O -
, O +
a O +
phenomenon O +
that O +
almost O +
inevitably O +
occurs O +
in O +
immunoassays O +
but O +
is O +
rarely O +
accounted O +
for O -
. O +

Here O -
, O +
we O +
demonstrate O +
a O +
quantitative O +
dynamic O +
detection O +
of O +
interleukine-6 O +
( O -
IL-6 O -
) O -
, O +
a O +
pro O -
- O -
inflammatory O +
cytokine O -
, O +
using O +
an O +
interferometric O +
reflectance O +
imaging O +
sensor O +
( O -
IRIS O -
) O -
. O +

We O +
improved O +
the O +
accuracy O +
of O +
the O +
quantitative O +
analysis O +
of O +
this O +
relatively O +
small O +
protein O +
( O -
21 O +
kDa O -
) O +
by O +
characterizing O +
the O +
antibody O +
desorption O +
rate O +
and O +
compensating O +
for O +
the O +
antibody O +
loss O +
during O +
the O +
binding O +
experiment O -
. O +

By O +
correcting O +
for O +
protein O +
desorption O -
, O +
we O +
achieved O +
an O +
analytical O +
limit O +
of O +
detection O +
at O +
19 O +
ng O -
/ O -
mL O +
IL-6 O +
concentration O -
. O +

We O +
enhanced O +
the O +
sensitivity O +
by O +
7-fold O +
by O +
using O +
detection O +
antibodies O +
that O +
recognize O +
a O +
different O +
epitope O +
of O +
the O +
cytokine O -
. O +

We O +
demonstrate O +
that O +
these O +
detection O +
antibodies O -
, O +
which O +
we O +
call O +
" O -
mass O +
tags O -
" O -
, O +
can O +
be O +
used O +
concurrently O +
with O +
the O +
target O +
analyte O +
to O +
eliminate O +
an O +
additional O +
wash O +
and O +
binding O +
step O -
. O +

Finally O -
, O +
we O +
report O +
successful O +
label O -
- O -
free O +
detection O +
of O +
IL-6 O +
in O +
cell O +
culture O +
medium O +
( O -
with O +
10 O -
% O +
serum O -
) O +
with O +
comparable O +
signal O +
to O +
that O +
obtained O +
in O +
PBS O -
. O +

This O +
work O +
is O +
the O +
first O +
to O +
report O +
quantitative O +
dynamic O +
label O -
- O -
free O +
detection O +
of O +
small O +
protein O +
in O +
a O +
complex O +
biological O +
fluid O +
using O +
IRIS O -
. O +

Cytokines O +
as O +
biomarkers O +
of O +
nanoparticle O +
immunotoxicity O -
. O +

Nanoscale O +
objects O -
, O +
whether O +
of O +
biologic O +
origin O +
or O +
synthetically O +
created O -
, O +
are O +
being O +
developed O +
into O +
devices O +
for O +
a O +
variety O +
of O +
bionanotechnology O +
diagnostic O +
and O +
pharmaceutical O +
applications O -
. O +

However O -
, O +
the O +
potential O +
immunotoxicity O +
of O +
these O +
nanomaterials O +
and O +
mechanisms O +
by O +
which O +
they O +
may O +
induce O +
adverse O +
reactions O +
have O +
not O +
received O +
sufficient O +
attention O -
. O +

Nanomaterials O -
, O +
depending O +
on O +
their O +
characteristics O +
and O +
compositions O -
, O +
can O +
interact O +
with O +
the O +
immune O +
system O +
in O +
several O +
ways O +
and O +
either O +
enhance O +
or O +
suppress O +
immune O +
system O +
function O -
. O +

Cytokines O +
perform O +
pleiotropic O +
functions O +
to O +
mediate O +
and O +
regulate O +
the O +
immune O +
response O +
and O +
are O +
generally O +
recognized O +
as O +
biomarkers O +
of O +
immunotoxicity O -
. O +

While O +
the O +
specificity O +
and O +
validity O +
of O +
certain O +
cytokines O +
as O +
markers O +
of O +
adverse O +
immune O +
response O +
has O +
been O +
established O +
for O +
chemicals O -
, O +
small O +
and O +
macromolecular O +
drugs O -
, O +
research O +
on O +
their O +
applicability O +
for O +
predicting O +
and O +
monitoring O +
the O +
immunotoxicity O +
of O +
engineered O +
nanomaterials O +
is O +
still O +
ongoing O -
. O +

The O +
goal O +
of O +
this O +
review O +
is O +
to O +
provide O +
guidelines O +
as O +
to O +
important O +
cytokines O +
that O +
can O +
be O +
utilized O +
for O +
evaluating O +
the O +
immunotoxicity O +
of O +
nanomaterials O +
and O +
to O +
highlight O +
the O +
role O +
of O +
those O +
cytokines O +
in O +
mediating O +
adverse O +
reactions O -
, O +
which O +
is O +
of O +
particular O +
importance O +
for O +
the O +
clinical O +
development O +
of O +
nanopharmaceuticals O +
and O +
other O +
nanotechnology O -
- O -
based O +
products O -
. O +

Importantly O -
, O +
the O +
rational O +
design O +
of O +
nanomaterials O +
of O +
low O +
immunotoxicity O +
will O +
be O +
discussed O -
, O +
focusing O +
on O +
synthetic O +
nanodevices O -
, O +
with O +
emphasis O +
on O +
both O +
the O +
nanoparticle O -
- O -
forming O +
materials O +
and O +
the O +
embedded O +
cargoes O -
. O +

A O +
high O +
throughput O +
assay O +
for O +
the O +
glucuronidation O +
of O +
7-hydroxy-4-trifluoromethylcoumarin B-Chemical +
by O +
recombinant O +
human O +
UDP B-Chemical -
- O -
glucuronosyltransferases O +
and O +
liver O +
microsomes O -
. O +

Abstract O +
1 O -
. O +

UDP B-Chemical -
- O -
glucuronosyltransferases O +
( O -
UGTs O -
) O +
are O +
versatile O +
and O +
important O +
conjugation O +
enzymes O +
in O +
the O +
metabolism O +
of O +
drugs O +
and O +
other O +
xenobiotics O -
. O +

2 O -
. O +

We O +
have O +
developed O +
a O +
convenient O +
quantitative O +
multi O -
- O -
well O +
plate O +
assay O +
to O +
measure O +
the O +
glucuronidation O +
rate O +
of O +
7-hydroxy-4-trifluoromethylcoumarin B-Chemical +
( O -
HFC B-Chemical -
) O +
for O +
several O +
UGTs O -
. O +

3 O -
. O +
We O +
have O +
used O +
this O +
method O +
to O +
screen O +
11 O +
recombinant O +
human O +
UGTs O +
for O +
HFC B-Chemical +
glucuronidation O +
activity O +
and O +
studied O +
the O +
reaction O +
kinetics O +
with O +
the O +
most O +
active O +
enzymes O -
. O +

We O +
have O +
also O +
examined O +
the O +
HFC B-Chemical +
glucuronidation O +
activity O +
of O +
liver O +
microsomes O +
from O +
human O -
, O +
pig O -
, O +
rabbit O +
and O +
rat O -
. O +

4 O -
. O +

At O +
a O +
substrate O +
concentration O +
of O +
20 O +
µM O -
, O +
the O +
most O +
active O +
HFC B-Chemical +
glucuronidation O +
catalysts O +
were O +
UGT1A10 O +
followed O +
by O +
UGT1A6 O +
> O -
UGT1A7 O +
> O -
UGT2A1 O -
, O +
whereas O +
at O +
300 O +
µM O +
UGT1A6 O +
was O +
about O +
10 O +
times O +
better O +
catalyst O +
than O +
the O +
other O +
recombinant O +
UGTs O -
. O +

The O +
activities O +
of O +
UGTs O +
1A3 O -
, O +
1A8 O -
, O +
1A9 O -
, O +
2B4 O +
and O +
2B7 O +
were O +
low O -
, O +
whereas O +
UGT1A1 O +
and O +
UGT2B17 O +
exhibited O +
no O +
HFC B-Chemical +
glucuronidation O +
activity O -
. O +

UGT1A6 O +
exhibited O +
a O +
significantly O +
higher O +
Vmax O +
and O +
Km O +
values O +
toward O +
both O +
HFC B-Chemical +
and O +
UDP B-Chemical -
- O -
glucuronic B-Chemical +
acid I-Chemical +
than O +
the O +
other O +
UGTs O -
. O +

5 O -
. O +
Human O -
, O +
pig O +
and O +
rabbit O -
, O +
but O +
not O +
rat O +
liver O +
microsomes O -
, O +
catalyzed O +
HFC B-Chemical +
glucuronidation O +
at O +
high O +
rates O -
. O +

6 O -
. O +

This O +
new O +
method O +
is O +
particularly O +
suitable O +
for O +
fast O +
activity O +
screenings O +
of O +
UGTs O +
1A6 O -
, O +
1A7 O -
, O +
1A10 O +
and O +
2A1 O +
and O +
HFC B-Chemical +
glucuronidation O +
activity O +
determination O +
from O +
various O +
samples O -
. O +

Package O -
- O -
Free O +
Flexible O +
Organic O +
Solar O +
Cells O +
with O +
Graphene B-Chemical +
top O +
Electrodes O -
. O +

Package O -
- O -
free O +
flexible O +
organic O +
solar O +
cells O +
were O +
fabricated O +
with O +
multilayer O +
graphene B-Chemical +
as O +
top O +
transparent O +
electrodes O -
, O +
which O +
show O +
the O +
highest O +
power O +
conversion O +
efficiency O +
of O +
about O +
3.2 O -
% O +
and O +
excellent O +
flexibility O +
and O +
bending O +
stability O -
. O +

The O +
devices O +
also O +
show O +
good O +
air O +
stability O -
, O +
indicating O +
that O +
multilayer O +
graphene B-Chemical +
is O +
a O +
promising O +
environmental O +
barrier O +
that O +
can O +
protect O +
the O +
organic O +
solar O +
cells O +
from O +
air O +
contamination O -
. O +

High O +
Mobility O +
Field O -
- O -
Effect O +
Transistors O +
with O +
Versatile O +
Processing O +
from O +
a O +
Small O -
- O -
Molecule O +
Organic O +
Semiconductor O -
. O +

Trialkylgermyl B-Chemical +
functionalization O +
allows O +
development O +
of O +
high O -
- O -
performance O +
soluble O +
small O -
- O -
molecule O +
organic O +
semiconductors O +
with O +
mobilities O +
greater O +
than O +
5 O +
cm O -
( O -
2 O -
) O +
V O -
( O -
-1 O -
) O +
s O -
( O -
-1 O -
) O +
. O +

Spray O -
- O -
deposited O +
organic O +
thin O -
- O -
film O +
transistors O +
show O +
a O +
record O +
mobility O +
of O +
2.2 O +
cm O -
( O -
2 O -
) O +
V O -
( O -
-1 O -
) O +
s O -
( O -
-1 O -
) O +
and O +
demonstrate O +
the O +
potential O +
for O +
incorporation O +
in O +
large O -
- O -
area O -
, O +
low O -
- O -
cost O +
electronic O +
applications O -
. O +

Bone O +
remodeling O +
is O +
regulated O +
by O +
inner O +
ear O +
vestibular O +
signals O -
. O +

Bone O +
remodeling O +
allows O +
the O +
conservation O +
of O +
normal O +
bone O +
mass O +
despite O +
constant O +
changes O +
in O +
internal O +
and O +
external O +
environments O -
. O +

The O +
adaptation O +
of O +
the O +
skeleton O +
to O +
these O +
various O +
stimuli O +
led O +
credence O +
to O +
the O +
notion O +
that O +
bone O +
remodeling O +
is O +
a O +
true O +
homeostatic O +
function O -
, O +
and O +
as O +
such O +
is O +
under O +
the O +
control O +
of O +
specific O +
centers O +
in O +
the O +
central O +
nervous O +
system O +
( O -
CNS O -
) O -
. O +

Hypothalamic O +
and O +
brainstem O +
centers O -
, O +
as O +
well O +
as O +
the O +
sympathetic O +
nervous O +
system O +
( O -
SNS O -
) O -
, O +
have O +
been O +
identified O +
as O +
regulators O +
of O +
bone O +
remodeling O -
. O +

However O -
, O +
the O +
nature O +
of O +
the O +
afferent O +
CNS O +
stimuli O +
that O +
may O +
modulate O +
CNS O +
centers O +
involved O +
in O +
the O +
control O +
of O +
bone O +
remodeling O -
, O +
with O +
the O +
exception O +
of O +
leptin O -
, O +
remains O +
unclear O -
. O +

Based O +
on O +
the O +
partial O +
efficacy O +
of O +
exercise O +
and O +
mechanical O +
stimulation O +
regimens O +
to O +
prevent O +
microgravity O -
- O -
induced O +
bone O +
loss O +
and O +
the O +
known O +
alterations O +
in O +
vestibular O +
functions O +
associated O +
with O +
space O +
flights O -
, O +
we O +
hypothesized O +
that O +
inner O +
ear O +
vestibular O +
signals O +
may O +
contribute O +
to O +
the O +
regulation O +
of O +
bone O +
remodeling O -
. O +

Using O +
an O +
established O +
model O +
of O +
bilateral O +
vestibular O +
lesions O +
and O +
microtomographic O +
and O +
histomorphometric O +
bone O +
analyses O -
, O +
we O +
show O +
here O +
that O +
induction O +
of O +
bilateral O +
vestibular O +
lesion O +
in O +
rats O +
generates O +
significant O +
bone O +
loss O -
, O +
which O +
is O +
restricted O +
to O +
weight O -
- O -
bearing O +
bones O +
and O +
associated O +
with O +
a O +
significant O +
reduction O +
in O +
bone O +
formation O -
, O +
as O +
observed O +
in O +
rats O +
under O +
microgravity O +
conditions O -
. O +

Importantly O -
, O +
this O +
bone O +
loss O +
was O +
not O +
associated O +
with O +
reduced O +
locomotor O +
activity O +
or O +
metabolic O +
abnormalities O -
, O +
was O +
accompanied O +
with O +
molecular O +
signs O +
of O +
increased O +
sympathetic O +
outflow O -
, O +
and O +
could O +
be O +
prevented O +
by O +
the O +
β O -
- O -
blocker O +
propranolol B-Chemical -
. O +

Collectively O -
, O +
these O +
data O +
suggest O +
that O +
the O +
homeostatic O +
process O +
of O +
bone O +
remodeling O +
has O +
a O +
vestibulo O -
- O -
sympathetic O +
regulatory O +
component O +
and O +
that O +
vestibular O +
system O +
pathologies O +
might O +
be O +
accompanied O +
by O +
bone O +
fragility O -
. O +

© O +
2013 O +
American O +
Society O +
for O +
Bone O +
and O +
Mineral O +
Research O -
. O +

Determination O +
of O +
Specific O +
Binding O +
Interactions O +
at O +
l B-Chemical -
- I-Chemical -
Cystine I-Chemical +
Crystal O +
Surfaces O +
with O +
Chemical O +
Force O +
Microscopy O -
. O +

The O +
pathogenesis O +
of O +
l B-Chemical -
- I-Chemical -
cystine I-Chemical +
kidney O +
stones O +
involves O +
four O +
critical O +
steps O -
: O +
nucleation O -
, O +
crystal O +
growth O -
, O +
crystal O +
aggregation O -
, O +
and O +
crystal O +
adhesion O +
to O +
cells O -
. O +

Although O +
inhibition O +
of O +
crystal O +
growth O +
by O +
l B-Chemical -
- I-Chemical -
cystine I-Chemical +
" O -
imposters O -
" O +
at O +
l B-Chemical -
- I-Chemical -
cystine I-Chemical +
crystal O +
surfaces O +
has O +
been O +
suggested O +
as O +
a O +
plausible O +
route O +
for O +
the O +
suppression O +
of O +
stones O -
, O +
understanding O +
the O +
factors O +
that O +
govern O +
crystal O -
- O -
crystal O +
aggregation O +
and O +
adhesion O +
of O +
crystals O +
to O +
epithelial O +
cells O +
also O +
is O +
essential O +
for O +
devising O +
strategies O +
to O +
mitigate O +
l B-Chemical -
- I-Chemical -
cystine I-Chemical +
stone O +
formation O -
. O +

Chemical O +
force O +
microscopy O +
performed O +
with O +
atomic O +
force O +
microscope O +
tips O +
decorated O +
with O +
functional O +
groups O +
commonly O +
found O +
in O +
urinary O +
constituents O +
that O +
likely O +
mediate O +
aggregation O +
and O +
attachment O +
( O -
e.g. O -
, O +
COOH B-Chemical -
, O +
NH2 B-Chemical -
, O +
SH B-Chemical -
, O +
CH3 B-Chemical -
, O +
OH B-Chemical -
) O +
revealed O +
signatures O +
that O +
reflect O +
differences O +
in O +
the O +
chemical O +
affinity O +
of O +
these O +
groups O +
for O +
the O +
( O -
001 O -
) O +
and O +
{ O -
100 O -
} O +
faces O +
of O +
the O +
naturally O +
occurring O +
hexagonal O +
form O +
of O +
l B-Chemical -
- I-Chemical -
cystine I-Chemical +
single O +
crystals O +
and O +
the O +
{ O -
110 O -
} O +
faces O +
of O +
the O +
non O -
- O -
native O +
tetragonal O +
form O -
. O +

These O +
signatures O +
can O +
be O +
explained O +
by O +
the O +
different O +
chemical O +
compositions O +
of O +
the O +
crystal O +
faces O -
, O +
and O +
they O +
reveal O +
a O +
remarkable O +
binding O +
specificity O +
of O +
the O +
thiol O +
group O +
for O +
the O +
sulfur B-Chemical -
- O -
rich O +
{ O -
100 O -
} O +
and O +
{ O -
110 O -
} O +
faces O +
of O +
the O +
hexagonal O +
and O +
tetragonal O +
forms O -
, O +
respectively O -
. O +

Collectively O -
, O +
these O +
observations O +
suggest O +
that O +
alterations O +
of O +
the O +
crystal O +
habit O +
and O +
polymorph O +
by O +
crystal O +
growth O +
inhibitors O +
may O +
not O +
affect O +
crystal O +
aggregation O +
or O +
adhesion O +
to O +
cells O +
significantly O -
. O +

Association O +
of O +
serum O +
adiponectin O +
and O +
IGF O -
- O -
I O +
levels O +
with O +
parameters O +
of O +
cardiac O +
remodeling O +
in O +
severely O +
obese O +
patients O -
. O +

Background O -
. O +

Obesity O +
is O +
associated O +
with O +
various O +
changes O +
in O +
cardiac O +
geometry O +
and O +
this O +
process O +
involves O +
both O +
hemodynamic O +
and O +
non O -
- O -
hemodynamic O +
factors O -
, O +
among O +
which O +
adipocitokines O +
and O +
growth O +
factors O +
may O +
play O +
an O +
important O +
role O +
The O +
aim O +
of O +
this O +
study O +
was O +
to O +
identify O +
the O +
extent O +
and O +
pattern O +
of O +
cardiac O +
remodeling O +
in O +
a O +
group O +
of O +
severely O +
obese O +
patients O +
and O +
analyze O +
the O +
relationship O +
between O +
adiponectin O -
, O +
IGF O -
- O -
I O +
and O +
cardiac O +
parameters O +
reflecting O +
obesity O +
associated O +
structural O +
changes O -
. O +

Subjects O +
and O +
methods O -
. O +

Our O +
study O +
included O +
344 O +
patients O +
( O -
104 O +
men O -
) O +
with O +
severe O +
obesity O +
( O -
mean O +
body O +
mass O +
index O +
( O -
BMI O -
) O -
= O +
45.7±8.5 O +
kg O -
/ O -
m2 O -
) O -
, O +
extensively O +
evaluated O +
clinically O +
and O +
biologically O +
( O -
complete O +
metabolic O +
tests O -
, O +
serum O +
adiponectin O +
and O +
IGF O -
- O -
I O +
measurements O -
) O -
. O +

Left O +
ventricular O +
mass O +
index O +
( O -
LVMI O -
) O -
, O +
left O +
atrium O +
( O -
LA O -
) O +
size O +
and O +
LV O +
geometry O +
were O +
determined O +
by O +
means O +
of O +
cardiac O +
ultrasound O -
. O +

Results O -
. O +

The O +
most O +
prevalent O +
pattern O +
of O +
LV O +
geometry O +
was O +
eccentric O +
hypertrophy O +
( O -
28.7 O -
% O +
of O +
patients O -
) O -
. O +

In O +
a O +
gender O -
, O +
age O -
, O +
BMI O -
, O +
diabetes O +
and O +
hypertension O +
adjusted O +
general O +
linear O +
model O -
, O +
patients O +
with O +
concentric O +
or O +
eccentric O +
hypertrophy O +
had O +
significantly O +
lower O +
values O +
of O +
adiponectin O +
than O +
those O +
with O +
normal O +
geometry O +
( O -
6.75±0.41 O -
, O +
6.96±0.53 O -
, O +
versus O +
9.04±0.42 O +
mg O -
/ O -
l O -
, O +
p<0.05 O -
) O -
. O +

In O +
multivariate O +
analysis O -
, O +
independent O +
determinants O +
for O +
LVMI O +
were O +
BMI O +
( O -
B=0.364 O -
, O +
p<0.001 O -
) O -
, O +
systolic O +
blood O +
pressure O +
( O -
BP O -
) O +
( O -
β=0.187 O -
, O +
p=0.004 O -
) O -
, O +
age O +
( O -
β=0.246 O -
, O +
p<0.001 O -
) O -
, O +
adiponectin O +
( O -
β=-0.151 O -
, O +
p=0.012 O -
) O +
and O +
IGF O -
- O -
I O +
z O -
- O -
score O +
( O -
β=0.134 O -
, O +
p=0.025 O -
) O +
while O +
factors O +
independently O +
related O +
to O +
LA O +
size O +
were O +
systolic O +
BP O +
( O -
β=0.218 O -
, O +
p<0.001 O -
) O -
, O +
BMI O +
( O -
β=0.194 O -
, O +
p<0.001 O -
) O -
, O +
age O +
( O -
β=0.273 O -
, O +
p<0.001 O -
) O -
, O +
gender O +
( O -
β=-0.195 O -
, O +
p<0.001 O -
) O +
and O +
adiponectin O +
( O -
β=-0.180 O -
, O +
p=0.005 O -
) O -
. O +

Conclusions O -
: O +
In O +
patients O +
with O +
severe O +
obesity O -
, O +
IGF O -
- O -
I O +
z O +
score O +
and O +
adiponectin O +
correlate O +
with O +
parameters O +
of O +
cardiac O +
remodeling O +
independently O +
of O +
anthropometric O -
, O +
hemodynamic O +
or O +
metabolic O +
factors O -
. O +

Straight O +
talk O +
with O -
... O +

Miyoung O +
Chun O -
. O +

It O +
was O +
a O +
single O +
tweet O -
. O +

In O +
February O -
, O +
after O +
US O +
President O +
Barack O +
Obama O +
made O +
a O +
subtle O +
nod O +
to O +
a O +
new O +
neuroscience O +
project O +
in O +
his O +
annual O +
State O +
of O +
the O +
Union O +
address O -
, O +
Francis O +
Collins O -
, O +
director O +
of O +
the O +
country O -
's O +
National O +
Institutes O +
of O +
Health O +
( O -
NIH O -
) O -
, O +
posted O +
on O +
the O +
@NIHDirector O +
Twitter O +
feed O -
: O +
" O -
Obama O +
mentions O +
the O +
# O -
NIH O +
Brain O +
Activity O +
Map O +
in O +
# O -
SOTU O -
. O -
" O +

Instantly O -
, O +
scientists O +
were O +
buzzing O +
with O +
rumors O +
that O +
the O +
Brain O +
Activity O +
Map O +
could O +
be O +
the O +
next O +
moon O +
shot O -
, O +
with O +
a O +
budget O +
and O +
timeline O +
similar O +
to O +
the O +
Human O +
Genome O +
Project O -
. O +

The O +
brain O +
map O +
began O +
as O +
a O +
brief O +
white O +
paper O +
and O +
has O +
grown O +
into O +
a O +
large O -
- O -
and O +
still O +
largely O +
undefined O -
- O -
collaboration O +
of O +
several O +
government O +
agencies O -
, O +
nonprofit O +
foundations O +
and O +
private O +
companies O -
. O +

As O +
the O +
stakeholders O +
describe O +
in O +
a O +
commentary O +
published O +
last O +
month O +
( O +
339 O -
, O +
1284 O -
- O -
1285 O -
, O +
2013 O +
10.1126 O -
/ O -
science.1236939 O -
) O -
, O +
the O +
goal O +
of O +
the O +
initiative O +
is O +
to O +
understand O +
how O +
thousands O +
of O +
neurons O +
work O +
in O +
concert O +
to O +
control O +
behavior O +
and O +
trigger O +
disease O -
. O +

Miyoung O +
Chun O -
, O +
vice O +
president O +
for O +
science O +
programs O +
at O +
The O +
Kavli O +
Foundation O +
in O +
Oxnard O -
, O +
California O -
, O +
has O +
been O +
developing O +
the O +
project O +
since O +
the O +
beginning O +
and O +
is O +
the O +
self O -
- O -
described O +
" O -
glue O -
" O +
between O +
its O +
many O +
diverse O +
stakeholders O -
. O +

Chun O +
spoke O +
with O +
Virginia O +
Hughes O +
about O +
the O +
evolution O +
of O +
the O +
project O +
and O +
what O +
it O +
might O +
mean O +
for O +
biomedicine O -
. O +

Drosophila O +
homologues O +
of O +
Adenomatous O +
polyposis O +
coli O +
( O -
APC O -
) O +
and O +
the O +
formin O +
Diaphanous O +
collaborate O +
by O +
a O +
conserved O +
mechanism O +
to O +
stimulate O +
actin O +
filament O +
assembly O -
. O +

Adenomatous O +
polyposis O +
coli O +
( O -
APC O -
) O +
is O +
a O +
large O +
multi O -
- O -
domain O +
protein O +
that O +
regulates O +
the O +
cytoskeleton O -
. O +

Recently O -
, O +
it O +
was O +
shown O +
that O +
vertebrate O +
APC O +
through O +
its O +
Basic O +
domain O +
directly O +
collaborates O +
with O +
the O +
formin O +
mDia1 O +
to O +
stimulate O +
actin O +
filament O +
assembly O +
in O +
the O +
presence O +
of O +
nucleation O +
barriers O -
. O +

However O -
, O +
it O +
has O +
been O +
unclear O +
whether O +
these O +
activities O +
extend O +
to O +
homologues O +
of O +
APC O +
and O +
Dia O +
in O +
other O +
organisms O -
. O +

Drosophila O +
APC O +
and O +
Dia O +
are O +
each O +
required O +
to O +
promote O +
actin O +
furrow O +
formation O +
in O +
the O +
syncytial O +
embryo O -
, O +
suggesting O +
a O +
potential O +
collaboration O +
in O +
actin O +
assembly O -
, O +
but O +
low O +
sequence O +
homology O +
between O +
the O +
Basic O +
domains O +
of O +
Drosophila O +
and O +
vertebrate O +
APC O +
has O +
left O +
their O +
functional O +
and O +
mechanistic O +
parallels O +
uncertain O -
. O +

To O +
address O +
this O +
question O -
, O +
we O +
purified O +
Drosophila O +
APC1 O +
and O +
Dia O +
and O +
determined O +
their O +
individual O +
and O +
combined O +
effects O +
on O +
actin O +
assembly O +
using O +
both O +
bulk O +
fluorescence O +
assays O +
and O +
total O +
internal O +
reflection O +
fluorescence O +
( O -
TIRF O -
) O +
microscopy O -
. O +

Our O +
data O +
show O +
that O +
APC1 O -
, O +
similar O +
to O +
its O +
vertebrate O +
homologue O -
, O +
bound O +
to O +
actin O +
monomers O +
and O +
nucleated O +
and O +
bundled O +
filaments O -
. O +

Further O -
, O +
Drosophila O +
Dia O +
nucleated O +
actin O +
assembly O -
, O +
and O +
protected O +
growing O +
filament O +
barbed O +
ends O +
from O +
capping O +
protein O -
. O +

Drosophila O +
APC1 O +
and O +
Dia O +
directly O +
interacted O +
and O +
collaborated O +
to O +
promote O +
actin O +
assembly O +
in O +
the O +
combined O +
presence O +
of O +
profilin O +
and O +
capping O +
protein O -
. O +

Thus O -
, O +
despite O +
limited O +
sequence O +
homology O -
, O +
Drosophila O +
and O +
vertebrate O +
APCs O +
exhibit O +
highly O +
related O +
activities O +
and O +
mechanisms O -
, O +
and O +
directly O +
collaborate O +
with O +
formins O -
. O +

These O +
results O +
suggest O +
that O +
APC O -
- O -
Dia O +
interactions O +
in O +
actin O +
assembly O +
are O +
conserved O +
and O +
may O +
underlie O +
important O +
in O +
vivo O +
functions O +
in O +
a O +
broad O +
range O +
of O +
animal O +
phyla O -
. O +

Synergistic O +
Interactions O +
between O +
Grafted O +
Hyaluronic O +
Acid O +
and O +
Lubricin O +
Provide O +

Enhanced O +
Wear O +
Protection O +
and O +
Lubrication O -
. O +

Normal O +
( O -
e.g. O -
, O +
adhesion O -
) O +
and O +
lateral O +
( O -
friction O -
) O +
forces O +
were O +
measured O +
between O +
physisorbed O +
and O +
chemically O +
grafted O +
layers O +
of O +
hyaluronic O +
acid O +
( O -
HA O -
) O -
, O +
an O +
anionic O +
polyelectrolyte O +
in O +
the O +
presence O +
of O +
lubricin O +
( O -
Lub O -
) O -
, O +
a O +
mucinous O +
glycoprotein O -
, O +
on O +
mica O +
surfaces O +
using O +
a O +
surface O +
forces O +
apparatus O +
( O -
SFA O -
) O -
. O +

This O +
work O +
demonstrates O +
that O +
high O +
friction O +
coefficients O +
between O +
the O +
surfaces O +
do O +
not O +
necessarily O +
correlate O +
with O +
surface O +
damage O +
and O +
that O +
chemically O +
grafted O +
HA O +
acts O +
synergistically O +
with O +
Lub O +
to O +
provide O +
friction O +
reduction O +
and O +
enhanced O +
wear O +
protection O +
to O +
the O +
surfaces O -
. O +

Surface O +
immobilization O +
of O +
HA O +
by O +
grafting O +
is O +
necessary O +
for O +
such O +
wear O +
protection O -
. O +

Increasing O +
the O +
concentration O +
of O +
Lub O +
enhances O +
the O +
threshold O +
load O +
that O +
a O +
chemically O +
grafted O +
HA O +
surface O +
can O +
be O +
subjected O +
to O +
before O +
the O +
onset O +
of O +
wear O -
. O +

Addition O +
of O +
Lub O +
does O +
not O +
have O +
any O +
beneficial O +
effect O +
if O +
HA O +
is O +
physisorbed O +
to O +
the O +
mica O +
surfaces O -
. O +

Damage O +
occurs O +
at O +
loads O +
less O +
than O +
1 O +
mN O +
regardless O +
of O +
the O +
amount O +
of O +
Lub O -
, O +
indicating O +
that O +
the O +
molecules O +
in O +
the O +
bulk O +
play O +
little O +
or O +
no O +
role O +
in O +
protecting O +
the O +
surfaces O +
from O +
damage O -
. O +

Lub O +
penetrates O +
into O +
the O +
chemically O +
bound O +
HA O +
to O +
form O +
a O +
visco O -
- O -
elastic O +
gel O +
that O +
reduces O +
the O +
coefficient O +
of O +
friction O +
as O +
well O +
as O +
boosts O +
the O +
strength O +
of O +
the O +
surface O +
against O +
abrasive O +
wear O +
( O -
damage O -
) O -
. O +

LC O -
- O -
ESI O -
- O -
TOF O -
- O -
MS O +
identification O +
of O +
bioactive O +
secondary O +
metabolites O +
involved O +
in O +
the O +
antioxidant O -
, O +
anti O -
- O -
inflammatory O +
and O +
anticancer O +
activities O +
of O +
the O +
edible O +
halophyte O +
Zygophyllum O +
album O +
Desf O -
. O +

In O +
this O +
work O -
, O +
liquid O +
chromatography O +
coupled O +
to O +
electrospray O +
time O -
- O -
of O -
- O -
flight O +
mass O +
spectrometry O +
( O -
LC O -
- O -
ESI O -
- O -
TOF O -
- O -
MS O -
) O +
has O +
been O +
applied O +
to O +
screen O +
bioactive O +
metabolites O +
in O +
shoot O +
extract O +
of O +
the O +
medicinal O +
halophyte O +
Zygophyllum O +
album O -
. O +

Among O +
10 O +
compounds O +
identified O +
( O -
saponins B-Chemical -
, O +
flavonoids B-Chemical +
and O +
sterols B-Chemical -
) O +
five O +
were O +
reported O +
for O +
the O +
first O +
time O +
in O +
Z. O +
album O -
. O +

Furthermore O -
, O +
novel O +
biological O +
activities O +
of O +
hexane B-Chemical -
, O +
dichloromethane B-Chemical +
and O +
methanolic O +
extracts O +
were O +
assessed O -
. O +

Results O +
showed O +
that O +
methanolic O +
extract O +
exhibit O +
the O +
highest O +
antioxidant O +
activity O +
using O +
in O +
vitro O +
ORAC O +
test O +
and O +
anti O -
- O -
inflammatory O +
activity O -
, O +
inhibiting O +
by O +
84.8 O -
% O +
NO B-Chemical +
release O +
in O +
RAW264.7 O +
macrophages O -
. O +

However O -
, O +
dichloromethane B-Chemical +
extract O +
proved O +
the O +
utmost O +
antioxidant O +
activity O +
in O +
cell O +
( O -
WS1 O -
) O +
based O -
- O -
assay O +
( O -
IC50=57μg O -
/ O -
ml O -
) O +
and O +
interesting O +
anticancer O +
capacity O +
against O +
human O +
lung O +
carcinoma O +
( O -
A-549 O -
) O +
and O +
colon O +
adenocarcinoma O +
( O -
DLD-1 O -
) O +
cells O +
( O -
IC50=37 O +
and O +
48μg O -
/ O -
ml O -
, O +
respectively O -
) O -
. O +

These O +
findings O +
can O +
be O +
attributed O +
to O +
the O +
presence O +
of O +
triterpenes B-Chemical -
, O +
flavonoids B-Chemical +
and O +
sterols B-Chemical +
in O +
Z. O +
album O -
, O +
which O +
are O +
widely O +
known O +
as O +
powerful O +
antioxidants O +
and O +
used O +
in O +
various O +
industrial O +
fields O -
. O +

Degradation O +
of O +
complex O +
carbohydrate B-Chemical -
: O +
Immobilization O +
of O +
pectinase O +
from O +
Bacillus O +
licheniformis O +
KIBGE O -
- O -
IB21 O +
using O +
calcium B-Chemical +
alginate O +
as O +
a O +
support O -
. O +

Pectinases O +
are O +
heterogeneous O +
group O +
of O +
enzymes O +
that O +
catalyse O +
the O +
hydrolysis O +
of O +
pectin O +
substances O +
which O +
is O +
responsible O +
for O +
the O +
turbidity O +
and O +
undesirable O +
cloudiness O +
in O +
fruits O +
juices O -
. O +

In O +
current O +
study O -
, O +
partially O +
purified O +
pectinase O +
from O +
Bacillus O +
licheniformis O +
KIBGE O -
- O -
IB21 O +
was O +
immobilized O +
in O +
calcium B-Chemical +
alginate O +
beads O -
. O +

The O +
effect O +
of O +
sodium B-Chemical +
alginate O +
and O +
calcium B-Chemical +
chloride I-Chemical +
concentration O +
on O +
immobilization O +
was O +
studied O +
and O +
it O +
was O +
found O +
that O +
the O +
optimal O +
sodium B-Chemical +
alginate O +
and O +
calcium B-Chemical +
chloride I-Chemical +
concentration O +
was O +
3.0 O -
% O +
and O +
0.2 O -
M O -
, O +
respectively O -
. O +

It O +
was O +
found O +
that O +
immobilization O +
increases O +
the O +
optimal O +
reaction O +
time O +
for O +
pectin O +
degradation O +
from O +
5 O +
to O +
10min O +
and O +
temperature O +
from O +
45 O +
to O +
55 O -
° O -
C O -
, O +
whereas O -
, O +
the O +
optimal O +
pH O +
remained O +
same O +
with O +
reference O +
to O +
free O +
enzyme O -
. O +

Thermal O +
stability O +
of O +
enzyme O +
increased O +
after O +
immobilization O +
and O +
immobilized O +
pectinase O +
retained O +
more O +
than O +
80 O -
% O +
of O +
its O +
initial O +
activity O +
after O +
5days O +
at O +
30 O -
° O -
C O +
as O +
compared O +
with O +
free O +
enzyme O +
which O +
showed O +
only O +
30 O -
% O +
of O +
residual O +
activity O -
. O +

The O +
immobilized O +
enzyme O +
also O +
exhibited O +
good O +
operational O +
stability O +
and O +
65 O -
% O +
of O +
its O +
initial O +
activity O +
was O +
observed O +
during O +
third O +
cycle O -
. O +

In O +
term O +
of O +
pectinase O +
immobilization O +
efficiency O +
and O +
stability O -
, O +
this O +
calcium B-Chemical +
alginate O +
beads O +
approach O +
seemed O +
to O +
permit O +
good O +
results O +
and O +
can O +
be O +
used O +
to O +
make O +
a O +
bioreactor O +
for O +
various O +
applications O +
in O +
food O +
industries O -
. O +

Influence O +
of O +
pH O -
, O +
metal O +
chelator O -
, O +
free O +
radical O +
scavenger O +
and O +
interfacial O +
characteristics O +
on O +
the O +
oxidative O +
stability O +
of O +
β B-Chemical -
- I-Chemical -
carotene I-Chemical +
in O +
conjugated O +
whey O +
protein O -
- O -
pectin O +
stabilised O +
emulsion O -
. O +

The O +
influence O +
of O +
whey O +
protein O +
isolate O +
( O -
WPI O -
) O -
-beet O +
pectin O +
conjugates O +
formed O +
by O +
dry O -
- O -
heating O +
on O +
the O +
oxidative O +
stability O +
of O +
β B-Chemical -
- I-Chemical -
carotene I-Chemical +
in O +
O O -
/ O -
W O +
emulsions O +
was O +
studied O -
. O +

It O +
was O +
mainly O +
focused O +
on O +
the O +
influence O +
of O +
pH O -
, O +
metal O +
chelator O -
, O +
free O +
radical O +
scavenger O +
and O +
interfacial O +
characteristics O +
on O +
the O +
degradation O +
of O +
β B-Chemical -
- I-Chemical -
carotene I-Chemical +
in O +
the O +
emulsion O +
stabilised O +
by O +
conjugate O -
. O +

The O +
conjugate O +
increased O +
the O +
oxidative O +
stability O +
of O +
β B-Chemical -
- I-Chemical -
carotene I-Chemical +
in O +
the O +
emulsion O +
as O +
compared O +
to O +
their O +
unconjugated O +
mixture O +
at O +
pH O +
7.0 O -
. O +

The O +
desferoxamine B-Chemical +
retarded O +
β B-Chemical -
- I-Chemical -
carotene I-Chemical +
degradation O +
at O +
pH O +
4.0 O +
more O +
effectively O +
than O +
pH O +
7.0 O +
and O +
more O +
effectively O +
in O +
the O +
emulsion O +
with O +
the O +
conjugate O +
than O +
the O +
unconjugated O +
mixture O +
( O -
p<0.05 O -
) O -
. O +

The O +
addition O +
of O +
200mg O -
/ O -
kg O +
α B-Chemical -
- I-Chemical -
tocopherol I-Chemical +
significantly O +
improved O +
the O +
stability O +
of O +
β B-Chemical -
- I-Chemical -
carotene I-Chemical +
in O +
the O +
conjugate O +
stabilised O +
emulsion O -
. O +

The O +
emulsions O +
were O +
washed O +
to O +
remove O +
conjugate O +
not O +
absorbed O +
to O +
the O +
emulsion O +
droplet O +
interface O -
, O +
indicating O +
that O +
unabsorbed O +
emulsifiers O +
could O +
protect O +
β B-Chemical -
- I-Chemical -
carotene I-Chemical -
. O +

It O +
suggested O +
that O +
WPI O -
- O -
pectin O +
conjugate O +
could O +
be O +
used O +
to O +
protect O +
bioactive O +
lipids O +
in O +
emulsions O -
. O +

Beneficial O +
effects O +
of O +
asiaticoside B-Chemical +
on O +
cognitive O +
deficits O +
in O +
senescence O -
- O -
accelerated O +
mice O -
. O +

The O +
effect O +
of O +
asiaticoside B-Chemical +
isolated O +
from O +
Hydrocotyle O +
sibthorpioides O +
( O -
AHS O -
) O +
on O +
the O +
promotion O +
of O +
cognition O +
in O +
senescence O -
- O -
accelerated O +
mice O +
( O -
SAMP O -
) O +
was O +
evaluated O -
. O +

Six O -
- O -
month O +
old O +
male O +
SAMP8 O +
mice O +
were O +
orally O +
administered O +
20 O -
, O +
40 O +
or O +
80mg O -
/ O -
kg O +
AHS O +
daily O +
for O +
three O +
months O -
. O +

SAMR1 O +
mice O +
were O +
used O +
as O +
a O +
" O -
normal O +
aging O -
" O +
control O -
. O +

The O +
results O +
showed O +
that O +
treatment O +
with O +
AHS O +
significantly O +
improved O +
learning O +
and O +
memory O +
abilities O +
in O +
behavioral O +
tests O -
. O +

AHS O -
- O -
treated O +
mice O +
showed O +
higher O +
antioxidant O +
enzyme O +
activity O +
and O +
lower O +
lipid O +
oxidation O +
in O +
serum O +
compared O +
with O +
untreated O +
SAMP8 O +
mice O -
. O +

Mechanistically O -
, O +
studies O +
showed O +
that O +
AHS O +
markedly O +
reduced O +
the O +
content O +
and O +
deposition O +
of O +
β O -
- O -
amyloid O +
peptide O +
( O -
Aβ O -
) O +
by O +
inhibiting O +
the O +
expression O +
of O +
mRNA O +
for O +
amyloid O +
protein O +
precursor O -
, O +
β O -
- O -
site O +
amyloid O +
cleaving O +
enzyme-1 O +
and O +
cathepsin O +
B O +
and O +
promoting O +
the O +
expression O +
of O +
mRNA O +
for O +
neprilysin O +
and O +
insulin O +
degrading O +
enzyme O -
. O +

In O +
addition O -
, O +
AHS O +
significantly O +
increased O +
the O +
expression O +
of O +
plasticity O -
- O -
related O +
proteins O +
including O +
postsynaptic O +
density-95 O -
, O +
phosphor O -
- O -
N B-Chemical -
- I-Chemical -
methyl I-Chemical -
- I-Chemical -
d I-Chemical -
- I-Chemical -
aspartate I-Chemical +
receptor O +
1 O -
, O +
phospho B-Chemical -
- O -
calcium B-Chemical -
- O -
calmodulin O +
dependent O +
kinase O +
II O -
, O +
phospho B-Chemical -
- O -
protein O +
kinase O +
A O +
Catalyticβ O +
subunit O -
, O +
protein O +
kinase O +
Cγ O +
subunit O -
, O +
phospho B-Chemical -
- O -
CREB O +
and O +
brain O +
derived O +
neurotrophic O +
factor O -
. O +

Furthermore O -
, O +
AHS O +
increased O +
the O +
levels O +
of O +
acetylcholine B-Chemical +
( O -
Ach B-Chemical -
) O -
, O +
but O +
decreased O +
cholinesterase O +
( O -
AchE O -
) O +
activity O -
. O +

These O +
results O +
demonstrated O +
that O +
AHS O +
administration O +
may O +
prevent O +
spatial O +
learning O +
and O +
memory O +
decline O +
by O +
scavenging O +
free O +
radicals O -
, O +
up O -
- O -
regulating O +
the O +
activity O +
of O +
antioxidant O +
enzymes O -
, O +
decreasing O +
the O +
level O +
of O +
Aβ O -
, O +
ameliorating O +
dysfunction O +
in O +
synaptic O +
plasticity O -
, O +
and O +
reversing O +
abnormal O +
changes O +
in O +
Ach B-Chemical +
level O +
and O +
AchE O +
activity O -
. O +

Thus O -
, O +
AHS O +
should O +
be O +
developed O +
as O +
a O +
new O +
drug O +
to O +
prevent O +
age O -
- O -
related O +
cognitive O +
deficits O -
. O +

Bioreducible O +
alginate O -
- O -
poly B-Chemical -
( I-Chemical -
ethylenimine I-Chemical -
) I-Chemical +
nanogels O +
as O +
an O +
antigen O -
- O -
delivery O +
system O +
robustly O +
enhance O +
vaccine O -
- O -
elicited O +
humoral O +
and O +
cellular O +
immune O +
responses O -
. O +

Although O +
polysaccharide O +
nanogels O +
have O +
emerged O +
as O +
a O +
novel O +
antigen O +
delivery O +
system O +
for O +
vaccine O +
development O -
, O +
whether O +
modulating O +
the O +
redox O +
sensitivity O +
of O +
nanogels O +
could O +
improve O +
vaccine O +
efficacy O +
remains O +
unclear O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
generated O +
bioreducible O +
cationic O +
alginate O -
- O -
polyethylenimine B-Chemical +
( O -
PEI B-Chemical -
) O +
nanogels O +
as O +
a O +
novel O +
vaccine O +
delivery O +
system O -
. O +

Briefly O -
, O +
nanogels O +
were O +
prepared O +
by O +
the O +
electrostatic O +
interaction O +
of O +
negatively O +
charged O +
alginate O +
sodium B-Chemical +
with O +
branched O +
PEI2k O -
, O +
followed O +
by O +
disulfide B-Chemical +
cross O -
- O -
linking O +
to O +
generate O +
bioreducible O +
nanogels O +
( O -
AP O -
- O -
SS O -
) O -
. O +

The O +
AP O -
- O -
SS O +
nanogels O +
demonstrated O +
great O +
antigen O -
- O -
loading O +
capacity O +
and O +
minimal O +
cytotoxicity O -
. O +

The O +
in O +
vitro O +
study O +
showed O +
that O +
reducible O +
AP O -
- O -
SS O +
nanogels O +
not O +
only O +
facilitated O +
antigen O +
uptake O +
by O +
mouse O +
bone O +
marrow O +
dendritic O +
cells O +
( O -
BMDCs O -
) O -
, O +
but O +
also O +
promoted O +
intracellular O +
antigen O +
degradation O +
and O +
cytosolic O +
release O -
. O +

Moreover O -
, O +
AP O -
- O -
SS O +
nanogels O +
significantly O +
enhanced O +
both O +
MHC O +
class O +
I O +
and O +
II O +
antigen O +
presentation O +
by O +
BMDCs O -
. O +

Compared O +
with O +
the O +
non O -
- O -
reducible O +
nanogels O -
, O +
AP O -
- O -
SS O +
nanogels O +
more O +
potently O +
enhanced O +
vaccine O -
- O -
induced O +
antibody O +
production O +
and O +
CD8 O -
( O -
+ O -
) O +
T O +
cell O -
- O -
mediated O +
tumor O +
cell O +
lysis O -
. O +

Hence O -
, O +
the O +
bioreducible O +
alginate O -
- O -
PEI O +
nanogels O +
could O +
serve O +
as O +
a O +
potent O +
adjuvant O +
to O +
improve O +
vaccine O -
- O -
elicited O +
humoral O +
and O +
cellular O +
immune O +
responses O -
. O +

A O +
protocol O +
for O +
the O +
classification O +
of O +
wet O +
mass O +
in O +
extrusion O -
- O -
spheronization O -
. O +

In O +
this O +
study O -
, O +
a O +
structured O +
protocol O +
for O +
the O +
classification O +
of O +
wet O +
mass O +
in O +
extrusion O -
- O -
spheronization O +
was O +
developed O +
to O +
predict O +
formation O +
and O +
pellet O +
quality O -
. O +

The O +
wet O +
masses O +
of O +
120 O +
formulae O +
were O +
prepared O +
taking O +
microcrystalline O +
celluloses O +
as O +
pelletization O +
aid O +
and O +
lactose B-Chemical -
, O +
hydroxypropyl B-Chemical +
methylcellulose O +
grades O -
, O +
herbal O +
medicines O +
as O +
model O +
drugs O -
. O +

Physical O +
properties O +
of O +
the O +
wet O +
masses O +
such O +
as O +
hardness O -
, O +
adhesiveness O -
, O +
springiness O -
, O +
cohesiveness O -
, O +
chewiness O -
, O +
and O +
resilience O +
were O +
tested O -
, O +
respectively O -
, O +
using O +
a O +
texture O +
analyzer O -
. O +

Particles O +
were O +
produced O +
by O +
spheronization O +
process O -
, O +
and O +
the O +
quality O +
of O +
spherical O +
pellets O +
was O +
also O +
evaluated O -
. O +

Data O +
were O +
analyzed O +
by O +
principal O +
component O +
analysis O -
, O +
factor O +
analysis O -
, O +
and O +
classification O +
analysis O -
. O +

The O +
wet O +
masses O +
could O +
be O +
classified O +
into O +
five O +
groups O +
taking O +
the O +
ratio O +
of O +
hardness O +
to O +
springiness O +
( O -
Ha O -
/ O -
Sp O -
) O +
as O +
the O +
first O +
classification O +
index O +
and O +
chewiness O -
, O +
resilience O +
as O +
the O +
second O +
and O +
the O +
third O +
classification O +
index O -
. O +

The O +
wet O +
masses O +
of O +
different O +
classification O +
could O +
correspondingly O +
form O +
the O +
different O +
shapes O -
. O +

So O -
, O +
a O +
new O +
protocol O +
could O +
be O +
devised O -
, O +
for O +
example O -
, O +
if O +
the O +
range O +
of O +
Ha O -
/ O -
Sp O +
of O +
the O +
wet O +
masses O +
was O +
30,992 O -
- O -
47,689 O -
g O -
, O +
at O +
the O +
same O +
time O -
, O +
the O +
value O +
of O +
chewiness O +
was O +
less O +
than O +
4842 O -
, O +
and O +
the O +
value O +
of O +
resilience O +
was O +
no O +
more O +
than O +
0.139 O -
; O +
it O +
would O +
form O +
spherical O +
pellets O +
under O +
the O +
experimental O +
condition O -
. O +

These O +
results O +
demonstrate O +
that O +
the O +
proposed O +
protocol O +
could O +
be O +
a O +
valuable O +
asset O +
in O +
a O +
formulation O +
development O +
project O +
to O +
assess O +
the O +
physical O +
properties O +
of O +
wet O +
masses O +
and O +
to O +
predict O +
formation O +
and O +
pellet O +
quality O -
. O +

So O -
, O +
the O +
tedious O +
and O +
expensive O +
pre O -
- O -
production O +
( O -
pre O -
- O -
formulation O +
and O +
optimization O -
) O +
work O +
could O +
be O +
considerably O +
reduced O -
. O +

Assessing O +
triclosan B-Chemical -
- O -
induced O +
ecological O +
and O +
trans O -
- O -
generational O +
effects O +
in O +
natural O +
phytoplankton O +
communities O -
: O +
a O +
trait O -
- O -
based O +
field O +
method O -
. O +

We O +
exposed O +
replicated O +
phytoplankton O +
communities O +
confined O +
in O +
semi O -
- O -
permeable O +
membrane O -
- O -
based O +
mesocosms O +
to O +
0 O -
, O +
0.1 O -
, O +
1 O +
and O +
10 O +
μg O +
L O -
( O -
-1 O -
) O +
triclosan B-Chemical +
( O -
TCS B-Chemical -
) O +
and O +
placed O +
them O +
back O +
in O +
their O +
original O +
environment O +
to O +
investigate O +
the O +
occurrence O +
of O +
trans O -
- O -
generational O +
responses O +
at O +
individual O -
, O +
population O +
and O +
community O +
levels O -
. O +

TCS B-Chemical +
diffused O +
out O +
of O +
mesocosms O +
with O +
a O +
half O -
- O -
life O +
of O +
less O +
than O +
8 O +
h O -
, O +
so O +
that O +
only O +
the O +
parental O +
generation O +
was O +
directly O +
stressed O -
. O +

At O +
the O +
beginning O +
of O +
the O +
experiment O +
and O +
after O +
7 O +
days O +
( O -
approximately O +
2 O +
generations O -
) O +
we O +
analysed O +
responses O +
in O +
the O +
phytoplankton O +
using O +
scanning O +
flow O -
- O -
cytometry O -
. O +

We O +
acquired O +
information O +
on O +
several O +
individually O +
expressed O +
phenotypic O +
traits O -
, O +
such O +
as O +
size O -
, O +
biovolume O -
, O +
pigment O +
fluorescence O +
and O +
packaging O -
, O +
for O +
thousands O +
of O +
individuals O +
per O +
replicated O +
population O +
and O +
derived O +
population O +
and O +
community O +
aggregated O +
traits O -
. O +

We O +
found O +
significant O +
changes O +
in O +
community O +
functioning O +
( O -
increased O +
productivity O +
in O +
terms O +
of O +
biovolume O +
and O +
total O +
fluorescence O -
) O -
, O +
with O +
maximal O +
effects O +
at O +
1 O +
μg O +
L O -
( O -
-1 O -
) O +
TCS B-Chemical -
. O +

We O +
detected O +
significant O +
and O +
dose O -
- O -
dependent O +
responses O +
on O +
population O +
traits O -
, O +
such O +
as O +
changes O +
in O +
abundance O +
for O +
several O +
populations O -
, O +
increased O +
average O +
size O +
and O +
fluorescence O +
of O +
cells O -
, O +
and O +
strong O +
changes O +
in O +
within O -
- O -
population O +
trait O +
mean O +
and O +
variance O +
( O -
suggesting O +
micro O -
- O -
evolutionary O +
effects O -
) O -
. O +

We O +
applied O +
the O +
Price O +
equation O +
approach O +
to O +
partition O +
community O +
effects O +
( O -
changes O +
in O +
biovolume O +
or O +
fluorescence O -
) O +
in O +
their O +
physiological O +
and O +
ecological O +
components O -
, O +
and O +
quantified O +
the O +
residual O +
component O +
( O -
including O +
also O +
evolutionary O +
responses O -
) O -
. O +

Our O +
results O +
suggested O +
that O +
evolutionary O +
or O +
inheritable O +
phenotypic O +
plasticity O +
responses O +
may O +
represent O +
a O +
significant O +
component O +
of O +
the O +
total O +
observed O +
change O +
following O +
exposure O +
and O +
over O +
relatively O +
small O +
temporal O +
scales O -
. O +

Human O +
Precision O -
- O -
Cut O +
Liver O +
Slices O +
as O +
an O +
ex O +
Vivo O +
Model O +
to O +
Study O +
Idiosyncratic O +
Drug O -
- O -
Induced O +
Liver O +
Injury O -
. O +

Idiosyncratic O +
drug O -
- O -
induced O +
liver O +
injury O +
( O -
IDILI O -
) O +
is O +
a O +
major O +
problem O +
during O +
drug O +
development O +
and O +
has O +
caused O +
drug O +
withdrawal O +
and O +
black O -
- O -
box O +
warnings O -
. O +

Because O +
of O +
the O +
low O +
concordance O +
of O +
the O +
hepatotoxicity O +
of O +
drugs O +
in O +
animals O +
and O +
humans O -
, O +
robust O +
screening O +
methods O +
using O +
human O +
tissue O +
are O +
needed O +
to O +
predict O +
IDILI O +
in O +
humans O -
. O +

According O +
to O +
the O +
inflammatory O +
stress O +
hypothesis O -
, O +
the O +
effects O +
of O +
inflammation O +
interact O +
with O +
the O +
effects O +
of O +
a O +
drug O +
or O +
its O +
reactive O +
metabolite O -
, O +
precipitating O +
toxic O +
reactions O +
in O +
the O +
liver O -
. O +

As O +
a O +
follow O -
- O -
up O +
to O +
our O +
recently O +
published O +
mouse O +
precision O -
- O -
cut O +
liver O +
slices O +
model O -
, O +
an O +
ex O +
vivo O +
model O +
involving O +
human O +
precision O -
- O -
cut O +
liver O +
slices O +
( O -
hPCLS O -
) O -
, O +
co O -
- O -
incubated O +
for O +
24 O +
h O +
with O +
IDILI O -
- O -
related O +
drugs O +
and O +
lipopolysaccharide O +
( O -
LPS O -
) O -
, O +
was O +
developed O +
to O +
study O +
IDILI O +
mechanisms O +
related O +
to O +
inflammatory O +
stress O +
in O +
humans O +
and O +
to O +
detect O +
potential O +
biomarkers O -
. O +

LPS O +
exacerbated O +
the O +
effects O +
of O +
ketoconazole B-Chemical +
and O +
clozapine B-Chemical +
toxicity O +
but O +
not O +
those O +
of O +
their O +
non O -
- O -
IDILI O -
- O -
related O +
comparators O -
, O +
voriconazole B-Chemical +
and O +
olanzapine B-Chemical -
. O +

However O -
, O +
the O +
IDILI O -
- O -
related O +
drugs O +
diclofenac B-Chemical -
, O +
carbamazepine B-Chemical -
, O +
and O +
troglitazone B-Chemical +
did O +
not O +
show O +
synergistic O +
toxicity O +
with O +
LPS O +
after O +
incubation O +
for O +
24 O +
h. O +
Co O -
- O -
incubation O +
of O +
ketoconazole B-Chemical +
and O +
clozapine B-Chemical +
with O +
LPS O +
decreased O +
the O +
levels O +
of O +
glutathione B-Chemical +
in O +
hPCLS O -
, O +
but O +
this O +
was O +
not O +
seen O +
for O +
the O +
other O +
drugs O -
. O +

All O +
drugs O +
affected O +
LPS O -
- O -
induced O +
cytokine O +
release O -
, O +
but O +
interestingly O -
, O +
only O +
ketoconazole B-Chemical +
and O +
clozapine B-Chemical +
increased O +
the O +
level O +
of O +
LPS O -
- O -
induced O +
TNF O +
release O -
. O +

Decreased O +
levels O +
of O +
glutathione B-Chemical +
and O +
cysteine B-Chemical +
conjugates O +
of O +
clozapine B-Chemical +
were O +
detected O +
in O +
IDILI O -
- O -
responding O +
livers O +
following O +
cotreatment O +
with O +
LPS O -
. O +

In O +
conclusion O -
, O +
we O +
identified O +
ketoconazole B-Chemical +
and O +
clozapine B-Chemical +
as O +
drugs O +
that O +
exhibited O +
synergistic O +
toxicity O +
with O +
LPS O -
, O +
while O +
glutathione B-Chemical +
and O +
TNF O +
were O +
found O +
to O +
be O +
potential O +
biomarkers O +
for O +
IDILI O -
- O -
inducing O +
drugs O +
mediated O +
by O +
inflammatory O +
stress O -
. O +

hPCLS O +
appear O +
to O +
be O +
suitable O +
for O +
further O +
unraveling O +
the O +
mechanisms O +
of O +
inflammatory O +
stress O -
- O -
associated O +
IDILI O -
. O +

Controlling O +
the O +
Effective O +
Surface O +
Area O +
and O +
Pore O +
Size O +
Distribution O +
of O +
sp O -
( O -
2 O -
) O +
Carbon B-Chemical +
Materials O +
and O +
Their O +
Impact O +
on O +
the O +
Capacitance O +
Performance O +
of O +
These O +
Materials O -
. O +

A O +
series O +
of O +
sp O -
( O -
2 O -
) O +
carbon B-Chemical +
materials O +
with O +
different O +
specific O +
surface O +
area O +
( O -
SSA O -
) O +
and O +
controlled O +
pore O +
size O +
distribution O +
( O -
PSD O -
) O +
were O +
synthesized O +
at O +
large O +
scale O +
through O +
a O +
facile O +
and O +
low O -
- O -
cost O +
method O -
. O +

The O +
SSA O +
and O +
PSD O +
of O +
these O +
carbon B-Chemical +
materials O +
were O +
controlled O +
by O +
using O +
different O +
carbon B-Chemical +
sources O +
and O +
preparation O +
methods O -
. O +

With O +
different O +
total O +
and O +
effective O +
SSA O +
( O -
E O -
- O -
SSA O -
) O +
and O +
PSD O -
, O +
the O +
impacts O +
on O +
their O +
capacitance O +
performance O +
were O +
investigated O +
thoroughly O -
, O +
which O +
demonstrated O +
that O +
both O +
E O -
- O -
SSA O +
and O +
PSD O +
played O +
the O +
most O +
important O +
roles O +
in O +
their O +
capacitance O +
performance O -
. O +

Furthermore O -
, O +
theoretical O +
modeling O +
was O +
performed O -
, O +
and O +
the O +
results O +
are O +
in O +
agreement O +
with O +
the O +
experimental O +
results O +
for O +
the O +
influence O +
of O +
E O -
- O -
SSA O +
and O +
PSD O +
on O +
their O +
capacitance O +
performance O -
. O +

Based O +
on O +
these O -
, O +
a O +
general O +
model O +
using O +
the O +
slit O -
/ O -
cylindrical O +
NL O -
- O -
DFT O +
approach O +
is O +
proposed O +
for O +
the O +
estimation O +
of O +
the O +
specific O +
capacitance O +
of O +
sp O -
( O -
2 O -
) O +
carbon B-Chemical +
materials O -
, O +
which O +
offers O +
a O +
simple O +
but O +
reliable O +
method O +
to O +
predict O +
the O +
capacitance O +
performance O +
of O +
these O +
materials O -
, O +
thus O +
speeding O +
up O +
the O +
design O +
and O +
screening O +
of O +
the O +
materials O +
for O +
high O -
- O -
performance O +
supercapacitor O +
and O +
other O +
surface O +
area O +
related O +
devices O -
. O +

Approach O +
to O +
dark O +
spin O +
cooling O +
in O +
a O +
diamond B-Chemical +
nanocrystal O -
. O +

Using O +
a O +
Hartman O -
- O -
Hahn O +
protocol O -
, O +
we O +
demonstrate O +
spin O +
polarization O +
transfer O +
from O +
a O +
single O -
, O +
optically O +
polarized O +
nitrogen B-Chemical -
- O -
vacancy O +
( O -
NV O -
) O +
center O +
to O +
the O +
ensemble O +
of O +
paramagnetic O +
defects O +
hosted O +
by O +
an O +
individual O +
diamond B-Chemical +
nanocrystal O -
. O +

Owing O +
to O +
the O +
strong O +
NV O -
- O -
bath O +
coupling O -
, O +
the O +
transfer O +
takes O +
place O +
on O +
a O +
short O -
, O +
microsecond O +
time O +
scale O -
. O +

Upon O +
fast O +
repetition O +
of O +
the O +
pulse O +
sequence O -
, O +
we O +
observe O +
strong O +
polarization O +
transfer O +
blockade O -
, O +
which O +
we O +
interpret O +
as O +
an O +
indication O +
of O +
spin O +
bath O +
cooling O -
. O +

Numerical O +
simulations O +
indicate O +
that O +
the O +
spin O +
bath O +
polarization O +
is O +
nonuniform O +
throughout O +
the O +
nanoparticle O -
, O +
averaging O +
approximately O +
5 O -
% O +
over O +
the O +
crystal O +
volume O -
, O +
but O +
reaching O +
up O +
to O +
25 O -
% O +
in O +
the O +
immediate O +
vicinity O +
of O +
the O +
NV O -
. O +

These O +
observations O +
may O +
prove O +
relevant O +
to O +
the O +
planning O +
of O +
future O +
bath O -
- O -
assisted O +
magnetometry O +
tests O -
. O +

The O +
role O +
of O +
intracrine O +
androgen B-Chemical +
metabolism O -
, O +
androgen B-Chemical +
receptor O +
and O +
apoptosis O +
in O +
the O +
survival O +
and O +
recurrence O +
of O +
prostate O +
cancer O +
during O +
androgen B-Chemical +
deprivation O +
therapy O -
. O +

Prostate O +
cancer O +
( O -
CaP O -
) O +
is O +
the O +
most O +
frequently O +
diagnosed O +
cancer O +
and O +
leading O +
cause O +
of O +
cancer O +
death O +
in O +
American O +
men O -
. O +

Almost O +
all O +
men O +
present O +
with O +
advanced O +
CaP O +
and O +
some O +
men O +
who O +
fail O +
potentially O +
curative O +
therapy O +
are O +
treated O +
with O +
androgen B-Chemical +
deprivation O +
therapy O +
( O -
ADT O -
) O -
. O +

ADT O +
is O +
not O +
curative O +
and O +
CaP O +
recurs O +
as O +
the O +
lethal O +
phenotype O -
. O +

The O +
goal O +
of O +
this O +
review O +
is O +
to O +
apply O +
our O +
current O +
understanding O +
of O +
CaP O +
and O +
castration O -
- O -
recurrent O +
CaP O +
( O -
CR O -
- O -
CaP O -
) O +
to O +
earlier O +
studies O +
that O +
characterized O +
ADT O +
and O +
the O +
molecular O +
mechanisms O +
that O +
facilitate O +
the O +
transition O +
from O +
androgen B-Chemical -
- O -
stimulated O +
CaP O +
to O +
CR O -
- O -
CaP. O +
Reexamination O +
of O +
earlier O +
studies O +
also O +
may O +
provide O +
a O +
better O +
understanding O +
of O +
how O +
more O +
newly O +
recognized O +
mechanisms O -
, O +
such O +
as O +
intracrine O +
metabolism O -
, O +
may O +
be O +
involved O +
with O +
the O +
early O +
events O +
that O +
allow O +
CaP O +
survival O +
after O +
initiation O +
of O +
ADT O +
and O +
subsequent O +
development O +
of O +
CR O -
- O -
CaP. O +

Real O -
- O -
time O +
evaluation O +
of O +
binding O +
mechanisms O +
in O +
multivalent O +
interactions O -
: O +
a O +
surface O +
plasmon O +
resonance O +
kinetic O +
approach O -
. O +

Multivalency O +
is O +
a O +
key O -
, O +
ubiquitous O +
phenomenon O +
in O +
nature O +
characterized O +
by O +
a O +
complex O +
combination O +
of O +
binding O +
mechanisms O -
, O +
with O +
special O +
relevance O +
in O +
carbohydrate B-Chemical -
- O -
lectin O +
recognition O -
. O +

Herein O +
we O +
introduce O +
an O +
original O +
surface O +
plasmon O +
resonance O +
kinetic O +
approach O +
to O +
analyze O +
multivalent O +
interactions O +
that O +
has O +
been O +
validated O +
with O +
dendrimers O +
as O +
monodisperse O +
multivalent O +
analytes O +
binding O +
to O +
lectin O +
clusters O -
. O +

The O +
method O -
, O +
based O +
on O +
the O +
analysis O +
of O +
early O +
association O +
and O +
late O +
dissociation O +
phases O +
of O +
the O +
sensorgrams O +
provides O +
robust O +
information O +
of O +
the O +
glycoconjugate O +
binding O +
efficiency O +
and O +
real O -
- O -
time O +
structural O +
data O +
of O +
the O +
binding O +
events O +
under O +
the O +
complex O +
scenario O +
of O +
the O +
glyco O -
- O -
cluster O +
effect O -
. O +

Notably O -
, O +
it O +
reveals O +
the O +
dynamic O +
nature O +
of O +
the O +
interaction O +
and O +
offers O +
experimental O +
evidence O +
on O +
the O +
contribution O +
of O +
binding O +
mechanisms O -
. O +

Enhancing O +
Catalytic O +
Performance O +
of O +
Palladium B-Chemical +
in O +
Gold O +
and O +
Palladium B-Chemical +
Alloy O +
Nanoparticles O +
for O +
Organic O +
Synthesis O +
Reactions O +
through O +
Visible O +
Light O +
Irradiation O +
at O +
Ambient O +
Temperatures O -
. O +

The O +
intrinsic O +
catalytic O +
activity O +
of O +
palladium B-Chemical +
( O -
Pd B-Chemical -
) O +
is O +
significantly O +
enhanced O +
in O +
gold O +
( O -
Au B-Chemical -
) O -
-Pd O +
alloy O +
nanoparticles O +
( O -
NPs O -
) O +
under O +
visible O +
light O +
irradiation O +
at O +
ambient O +
temperatures O -
. O +

The O +
alloy O +
NPs O +
strongly O +
absorb O +
light O +
and O +
efficiently O +
enhance O +
the O +
conversion O +
of O +
several O +
reactions O -
, O +
including O +
Suzuki O -
- O -
Miyaura O +
cross O +
coupling O -
, O +
oxidative O +
addition O +
of O +
benzylamine B-Chemical -
, O +
selective O +
oxidation O +
of O +
aromatic B-Chemical +
alcohols I-Chemical +
to O +
corresponding O +
aldehydes B-Chemical +
and O +
ketones B-Chemical -
, O +
and O +
phenol B-Chemical +
oxidation O -
. O +

The O +
Au B-Chemical -
/ O -
Pd B-Chemical +
molar O +
ratio O +
of O +
the O +
alloy O +
NPs O +
has O +
an O +
important O +
impact O +
on O +
performance O +
of O +
the O +
catalysts O +
since O +
it O +
determines O +
both O +
the O +
electronic O +
heterogeneity O +
and O +
the O +
distribution O +
of O +
Pd B-Chemical +
sites O +
at O +
the O +
NP O +
surface O -
, O +
with O +
these O +
two O +
factors O +
playing O +
key O +
roles O +
in O +
the O +
catalytic O +
activity O -
. O +

Irradiating O +
with O +
light O +
produces O +
an O +
even O +
more O +
profound O +
enhancement O +
in O +
the O +
catalytic O +
performance O +
of O +
the O +
NPs O -
. O +

For O +
example O -
, O +
the O +
best O +
conversion O +
rate O +
achieved O +
thermally O +
at O +
30 O +
° O -
C O +
for O +
Suzuki O -
- O -
Miyaura O +
cross O +
coupling O +
was O +
37 O -
% O +
at O +
a O +
Au B-Chemical -
/ O -
Pd B-Chemical +
ratio O +
of O +
1:1.86 O -
, O +
while O +
under O +
light O +
illumination O +
the O +
yield O +
increased O +
to O +
96 O -
% O +
under O +
the O +
same O +
conditions O -
. O +

The O +
catalytic O +
activity O +
of O +
the O +
alloy O +
NPs O +
depends O +
on O +
the O +
intensity O +
and O +
wavelength O +
of O +
incident O +
light O -
. O +

Light O +
absorption O +
due O +
to O +
the O +
Localized O +
Surface O +
Plasmon O +
Resonance O +
of O +
gold O +
nanocrystals O +
plays O +
an O +
important O +
role O +
in O +
enhancing O +
catalyst O +
performance O -
. O +

We O +
believe O +
that O +
the O +
conduction O +
electrons O +
of O +
the O +
NPs O +
gain O +
the O +
light O +
absorbed O +
energy O +
producing O +
energetic O +
electrons O +
at O +
the O +
surface O +
Pd B-Chemical +
sites O -
, O +
which O +
enhances O +
the O +
sites O -
' O +
intrinsic O +
catalytic O +
ability O -
. O +

These O +
findings O +
provide O +
useful O +
guidelines O +
for O +
designing O +
efficient O +
catalysts O +
composed O +
of O +
alloys O +
of O +
a O +
plasmonic O +
metal O +
and O +
a O +
catalytically O +
active O +
transition B-Chemical +
metal I-Chemical +
for O +
various O +
organic O +
syntheses O +
driven O +
by O +
sunlight O -
. O +

Effects O +
of O +
Curcumin B-Chemical +
on O +
Apoptosis O +
and O +
Oxidoinflammatory O +
Regulation O +
in O +
a O +
Rat O +
Model O +
of O +
Acetic B-Chemical +
Acid I-Chemical -
- O -
Induced O +
Colitis O -
: O +
The O +
Roles O +
of O +
c O -
- O -
Jun O +
N B-Chemical -
- O -
Terminal O +
Kinase O +
and O +
p38 O +
Mitogen O -
- O -
Activated O +
Protein O +
Kinase O -
. O +

Abstract O +
The O +
present O +
study O +
evaluated O +
the O +
effects O +
of O +
curcumin B-Chemical +
on O +
epithelial O +
cell O +
apoptosis O -
, O +
the O +
immunoreactivity O +
of O +
the O +
phospho O -
- O -
c O -
- O -
Jun O +
N O -
- O -
terminal O +
kinase O +
( O -
JNK O -
) O +
and O +
phospho O -
- O -
p38 O +
mitogen O -
- O -
activated O +
protein O +
kinases O +
( O -
MAPKs O -
) O +
in O +
inflamed O +
colon O +
mucosa O -
, O +
and O +
oxidative O +
stress O +
in O +
a O +
rat O +
model O +
of O +
ulcerative O +
colitis O +
induced O +
by O +
acetic B-Chemical +
acid I-Chemical -
. O +

Rats O +
were O +
randomly O +
divided O +
into O +
three O +
groups O -
: O +
control O -
, O +
acetic B-Chemical +
acid I-Chemical -
, O +
and O +
acetic B-Chemical +
acid+curcumin I-Chemical -
. O +

Curcumin B-Chemical +
( O -
100 O +
mg O -
/ O -
kg O +
per O +
day O -
, O +
intragastrically O -
) O +
was O +
administered O +
10 O +
days O +
before O +
the O +
induction O +
of O +
colitis O +
and O +
was O +
continued O +
for O +
two O +
additional O +
days O -
. O +

Acetic B-Chemical +
acid I-Chemical -
- O -
induced O +
colitis O +
caused O +
a O +
significant O +
increase O +
in O +
the O +
macroscopic O +
and O +
microscopic O +
tissue O +
ranking O +
scores O +
as O +
well O +
as O +
an O +
elevation O +
in O +
colonic O +
myeloperoxidase O +
( O -
MPO O -
) O +
activity O -
, O +
malondialdehyde B-Chemical +
( O -
MDA B-Chemical -
) O +
levels O -
, O +
and O +
the O +
number O +
of O +
apoptotic O +
epithelial O +
cells O +
in O +
colon O +
tissue O +
compared O +
to O +
controls O -
. O +

In O +
the O +
rat O +
colon O -
, O +
immunoreactivity O +
of O +
phospho O -
- O -
p38 O +
MAPK O +
was O +
increased O -
, O +
whereas O +
the O +
phospho O -
- O -
JNK O +
activity O +
was O +
decreased O +
following O +
the O +
induction O +
of O +
colitis O -
. O +

Curcumin B-Chemical +
treatment O +
was O +
associated O +
with O +
amelioration O +
of O +
macroscopic O +
and O +
microscopic O +
colitis O +
sores O -
, O +
decreased O +
MPO O +
activity O -
, O +
and O +
decreased O +
MDA B-Chemical +
levels O +
in O +
acetic B-Chemical +
acid I-Chemical -
- O -
induced O +
colitis O -
. O +

Furthermore O -
, O +
oral O +
curcumin B-Chemical +
supplementation O +
clearly O +
prevented O +
programmed O +
cell O +
death O +
and O +
restored O +
immunreactivity O +
of O +
MAPKs O +
in O +
the O +
colons O +
of O +
colitic O +
rats O -
. O +

The O +
results O +
of O +
this O +
study O +
suggest O +
that O +
oral O +
curcumin B-Chemical +
treatment O +
decreases O +
colon O +
injury O +
and O +
is O +
associated O +
with O +
decreased O +
inflammatory O +
reactions O -
, O +
lipid O +
peroxidation O -
, O +
apoptotic O +
cell O +
death O -
, O +
and O +
modulating O +
p38- O +
and O +
JNK O -
- O -
MAPK O +
pathways O -
. O +

Oligonol O +
supplementation O +
attenuates O +
body O +
temperature O +
and O +
the O +
circulating O +
levels O +
of O +
prostaglandin B-Chemical +
e2 I-Chemical +
and O +
cyclooxygenase-2 O +
after O +
heat O +
stress O +
in O +
humans O -
. O +

Abstract O +
Oligonol O -
, O +
a O +
phenolic B-Chemical +
production O +
from O +
lychee O -
, O +
has O +
been O +
reported O +
to O +
exhibit O +
anti O -
- O -
oxidative O +
and O +
anti O -
- O -
inflammatory O +
effects O -
. O +

This O +
study O +
investigated O +
the O +
effect O +
of O +
Oligonol O +
supplementation O +
on O +
circulating O +
levels O +
of O +
prostaglandin B-Chemical +
E2 I-Chemical +
( O -
PGE2 B-Chemical -
) O +
and O +
cyclooxygenase O +
( O -
COX O -
) O -
-2 O -
, O +
as O +
well O +
as O +
body O +
temperature O -
, O +
after O +
heat O +
stress O +
in O +
17 O +
healthy O +
human O +
male O +
volunteers O +
( O -
age O -
, O +
21.6±2.1 O +
years O -
) O -
. O +

All O +
experiments O +
were O +
performed O +
in O +
an O +
automated O +
climate O +
chamber O +
( O -
26.0 O -
° O -
C±0.5 O -
° O -
C O -
, O +
relative O +
humidity O +
60%±3.0 O -
% O -
, O +
air O +
velocity O +
less O +
than O +
1 O +
m O -
/ O -
sec O -
) O +
between O +
2 O +
and O +
5 O +
p.m. O +
Subjects O +
ingested O +
an O +
Oligonol O +
( O -
100 O +
mg O -
) O -
-containing O +
beverage O +
or O +
placebo O +
beverage O +
before O +
half O -
- O -
body O +
immersion O +
into O +
hot O +
water O +
( O -
42 O -
° O -
C±0.5 O -
° O -
C O +
for O +
30 O +
min O -
) O -
. O +

Tympanic O +
and O +
skin O +
temperatures O +
were O +
measured O +
and O +
mean O +
body O +
temperatures O +
were O +
calculated O -
. O +

Serum O +
concentrations O +
of O +
PGE2 B-Chemical +
and O +
COX-2 O +
were O +
analyzed O +
before O -
, O +
immediately O +
after O -
, O +
and O +
60 O +
min O +
after O +
immersion O -
. O +

Oligonol O +
intake O +
significantly O +
prevented O +
elevation O +
of O +
tympanic O +
( O -
temperature O +
difference O -
: O +
0.17 O -
° O -
C O +
at O +
Post O -
, O +
P<.05 O -
; O +
0.17 O -
° O -
C O +
at O +
Re-60 O -
, O +
P<.05 O -
) O +
and O +
mean O +
body O +
temperatures O +
( O -
temperature O +
difference O -
: O +
0.18 O -
° O -
C O +
at O +
Post O -
, O +
P<.05 O -
; O +
0.15 O -
° O -
C O +
at O +
Re-60 O -
, O +
P<.05 O -
) O -
, O +
and O +
lowered O +
concentrations O +
of O +
serum O +
PGE2 B-Chemical +
( O -
increased O +
by O +
13.3 O -
% O +
vs. O +
29.6 O -
% O +
at O +
Post O -
, O +
P<.05 O -
) O +
and O +
COX-2 O +
( O -
increased O +
by O +
15.6 O -
% O +
vs. O +
21.8 O -
% O +
at O +
Post O -
, O +
P<.05 O -
) O -
, O +
compared O +
to O +
placebo O +
beverage O -
. O +

Our O +
result O +
suggests O +
that O +
Oligonol O +
has O +
the O +
potential O +
to O +
suppress O +
increases O +
in O +
body O +
temperature O +
under O +
heat O +
stress O -
, O +
and O +
this O +
is O +
associated O +
with O +
decreases O +
in O +
serum O +
levels O +
of O +
PGE2 B-Chemical +
and O +
COX-2 O -
. O +

Flaxseed O -
- O -
derived O +
enterolactone B-Chemical +
is O +
inversely O +
associated O +
with O +
tumor O +
cell O +
proliferation O +
in O +
men O +
with O +
localized O +
prostate O +
cancer O -
. O +

Abstract O +
Enterolactone B-Chemical +
and O +
enterodiol B-Chemical -
, O +
mammalian O +
lignans B-Chemical +
derived O +
from O +
dietary O +
sources O +
such O +
as O +
flaxseed O -
, O +
sesame O +
seeds O -
, O +
kale O -
, O +
broccoli O -
, O +
and O +
apricots O -
, O +
may O +
impede O +
tumor O +
proliferation O +
by O +
inhibiting O +
activation O +
of O +
nuclear O +
factor O +
kappa O +
B O +
( O -
NFκB O -
) O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
. O +

We O +
examined O +
the O +
associations O +
between O +
urinary O +
enterolactone B-Chemical +
and O +
enterodiol B-Chemical +
with O +
prostatic O +
tumor O +
expression O +
of O +
NFκB O -
, O +
VEGF O -
, O +
and O +
Ki67 O +
among O +
147 O +
patients O +
with O +
prostate O +
cancer O +
who O +
participated O +
in O +
a O +
presurgical O +
trial O +
of O +
flaxseed O +
supplementation O +
( O -
30 O +
g O -
/ O -
day O -
) O +
for O +
∼30 O +
days O -
. O +

Urinary O +
enterolignans B-Chemical +
and O +
tissue O +
biomarkers O +
were O +
determined O +
by O +
high O -
- O -
performance O +
liquid O +
chromatography O +
and O +
immunohistochemistry O -
, O +
respectively O -
. O +

After O +
supplementation O -
, O +
we O +
observed O +
significant O +
correlations O +
between O +
intakes O +
of O +
plant O +
lignan B-Chemical +
and O +
urinary O +
concentrations O +
of O +
total O +
enterolignans B-Chemical +
( O -
ρ=0.677 O -
, O +
P<.0001 O -
) O -
, O +
enterolactone B-Chemical +
( O -
ρ=0.676 O -
, O +
P<.0001 O -
) O -
, O +
and O +
enterodiol B-Chemical +
( O -
ρ=0.628 O -
, O +
P<.0001 O -
) O -
. O +

Importantly O -
, O +
we O +
observed O +
that O +
total O +
urinary O +
enterolignans B-Chemical +
and O +
enterolactone B-Chemical +
were O +
significantly O +
and O +
inversely O +
correlated O +
with O +
Ki67 O +
in O +
the O +
tumor O +
tissue O +
( O -
ρ=-0.217 O -
, O +
P=.011 O -
, O +
and O +
ρ=-0.230 O -
, O +
P=.007 O -
, O +
respectively O -
) O -
, O +
and O +
a O +
near O -
- O -
significant O +
inverse O +
association O +
was O +
observed O +
for O +
enterodiol B-Chemical +
( O -
ρ=-0.159 O -
, O +
P=.064 O -
) O -
. O +

An O +
inverse O +
association O +
was O +
observed O +
between O +
enterolactone B-Chemical +
and O +
VEGF O +
( O -
ρ=-0.143 O -
, O +
P=.141 O -
) O -
, O +
although O +
this O +
did O +
not O +
reach O +
statistical O +
significance O -
. O +

We O +
did O +
not O +
observe O +
an O +
association O +
between O +
enterolignans B-Chemical +
and O +
NFκB. O +
In O +
conclusion O -
, O +
flaxseed O -
- O -
derived O +
enterolignans B-Chemical +
may O +
hinder O +
cancer O +
cell O +
proliferation O +
via O +
VEGF O -
- O -
associated O +
pathways O -
. O +

Lyophilization O +
of O +
a O +
triply O +
unsaturated O +
phospholipid O -
: O +
Effects O +
of O +
trace O +
metal O +
contaminants O -
. O +

As O +
liquid O +
liposomal O +
formulations O +
are O +
prone O +
to O +
chemical O +
degradation O +
and O +
aggregation O -
, O +
these O +
formulations O +
often O +
require O +
freeze O +
drying O +
( O -
e.g. O -
, O +
lyophilization O -
) O +
to O +
achieve O +
sufficient O +
shelf O -
- O -
life O -
. O +

However O -
, O +
liposomal O +
formulations O +
may O +
undergo O +
oxidation O +
during O +
lyophilization O +
and/or O +
during O +
prolonged O +
storage O -
. O +

The O +
goal O +
of O +
the O +
current O +
study O +
was O +
to O +
characterize O +
the O +
degradation O +
of O +
1,2-dilinolenoyl B-Chemical -
- I-Chemical -
sn I-Chemical -
- I-Chemical -
glycero-3-phosphocholine I-Chemical +
( O -
DLPC B-Chemical -
) O +
during O +
lyophilization O +
and O +
to O +
also O +
probe O +
the O +
influence O +
of O +
metal O +
contaminants O +
in O +
promoting O +
the O +
observed O +
degradation O -
. O +

Aqueous O +
sugar B-Chemical +
formulations O +
containing O +
DLPC B-Chemical +
( O -
0.01mg O -
/ O -
ml O -
) O +
were O +
lyophilized O -
, O +
and O +
DLPC B-Chemical +
degradation O +
was O +
monitored O +
using O +
HPLC O -
/ O -
UV O +
and O +
GC O -
/ O -
MS O +
methods O -
. O +

The O +
effect O +
of O +
ferrous B-Chemical +
ion O +
and O +
sucrose B-Chemical +
concentration O -
, O +
as O +
well O +
as O +
lyophilization O +
stage O +
promoting O +
lipid O +
degradation O -
, O +
was O +
investigated O -
. O +

DLPC B-Chemical +
degradation O +
increased O +
with O +
higher O +
levels O +
of O +
ferrous B-Chemical +
ion O -
. O +

After O +
lyophilization O -
, O +
103.1±1.1 O -
% O -
, O +
66.9±0.8 O -
% O -
, O +
and O +
28.7±0.7 O -
% O +
DLPC B-Chemical +
remained O +
in O +
the O +
sucrose B-Chemical +
samples O +
spiked O +
with O +
0.0ppm O -
, O +
0.2ppm O -
, O +
and O +
1.0ppm O +
ferrous B-Chemical +
ion O -
, O +
respectively O -
. O +

Lipid O +
degradation O +
predominantly O +
occurs O +
during O +
the O +
freezing O +
stage O +
of O +
lyophilization O -
. O +

Sugar B-Chemical +
concentration O +
and O +
buffer O +
ionic O +
strength O +
also O +
influence O +
the O +
extent O +
of O +
lipid O +
degradation O -
, O +
and O +
DLPC B-Chemical +
loss O +
correlated O +
with O +
degradation O +
product O +
formation O -
. O +

We O +
conclude O +
that O +
DLPC B-Chemical +
oxidation O +
during O +
the O +
freezing O +
stage O +
of O +
lyophilization O +
dramatically O +
compromises O +
the O +
stability O +
of O +
lipid O -
- O -
based O +
formulations O -
. O +

In O +
addition O -
, O +
we O +
demonstrate O +
that O +
metal O +
contaminants O +
in O +
sugars B-Chemical +
can O +
become O +
highly O +
active O +
when O +
lyophilized O +
in O +
the O +
presence O +
of O +
a O +
reducing O +
agent O -
. O +

The O +
cyclin O +
D1 O +
( O -
CCND1 O -
) O +
rs9344 O +
G O -
> O -
A O +
polymorphism O +
predicts O +
clinical O +
outcome O +
in O +
colon O +
cancer O +
patients O +
treated O +
with O +
adjuvant O +
5-FU B-Chemical -
- O -
based O +
chemotherapy O -
. O +

Recent O +
evidence O +
indicates O +
a O +
potential O +
prognostic O +
and O +
predictive O +
value O +
for O +
germline O +
polymorphisms O +
in O +
genes O +
involved O +
in O +
cell O +
cycle O +
control O -
. O +

We O +
investigated O +
the O +
effect O +
of O +
cyclin O +
D1 O +
( O -
CCND1 O -
) O +
rs9344 O +
G O -
> O -
A O +
in O +
stage O +
II O -
/ O -
III O +
colon O +
cancer O +
patients O +
and O +
validated O +
the O +
findings O +
in O +
an O +
independent O +
study O +
cohort O -
. O +

For O +
evaluation O +
and O +
validation O +
set O -
, O +
a O +
total O +
of O +
264 O +
and O +
234 O +
patients O +
were O +
included O -
. O +

Patients O +
treated O +
with O +
5-fluorouracil B-Chemical -
- O -
based O +
chemotherapy O -
, O +
carrying O +
the O +
CCND1 O +
rs9344 O +
A O -
/ O -
A O +
genotype O +
had O +
significantly O +
decreased O +
time O -
- O -
to O -
- O -
tumor O +
recurrence O +
( O -
TTR O -
) O +
in O +
univariate O +
analysis O +
and O +
multivariate O +
analysis O +
( O -
hazard O +
ratio O +
( O -
HR O -
) O +
2.47 O -
; O +
95 O -
% O +
confidence O +
interval O +
( O -
CI O -
) O +
1.16 O -
- O -
5.29 O -
; O +
P=0.019 O -
) O -
. O +

There O +
was O +
no O +
significant O +
association O +
between O +
CCND1 O +
rs9344 O +
G O -
> O -
A O +
and O +
TTR O +
in O +
patients O +
with O +
curative O +
surgery O +
alone O -
. O +

In O +
the O +
validation O +
set O -
, O +
the O +
A O +
allele O +
of O +
CCND1 O +
rs9344 O +
G O -
> O -
A O +
remained O +
significantly O +
associated O +
with O +
decreased O +
TTR O +
in O +
univariate O +
and O +
multivariate O +
analyses O +
( O -
HR O +
1.94 O -
; O +
95 O -
% O +
CI O +
1.05 O -
- O -
3.58 O -
; O +
P=0.035 O -
) O -
. O +

CCND1 O +
rs9344 O +
G O -
> O -
A O +
may O +
be O +
a O +
predictive O +
and/or O +
prognostic O +
biomarker O +
in O +
stage O +
II O -
/ O -
III O +
colon O +
cancer O +
patients O -
, O +
however O -
, O +
prospective O +
trials O +
are O +
warranted O +
to O +
confirm O +
our O +
findings O -
. O +

The O +
Pharmacogenomics O +
Journal O +
advance O +
online O +
publication O -
, O +
9 O +
April O +
2013 O -
; O +
doi:10.1038 O -
/ O -
tpj.2013.15 O -
. O +

Signaling O +
mechanism O +
of O +
tumor O +
cell O -
- O -
induced O +
up O -
- O -
regulation O +
of O +
E3 O +
ubiquitin O +
ligase O +
UBR2 O -
. O +

The O +
N O -
- O -
end O +
rule O +
pathway O +
contributes O +
significantly O +
to O +
accelerated O +
muscle O +
proteolysis O +
mediated O +
by O +
the O +
ubiquitin O -
- O -
proteasome O +
pathway O +
in O +
various O +
catabolic O +
conditions O -
. O +

UBR2 O +
( O -
aka O +
E3α O -
- O -
II O -
) O +
is O +
the O +
only O +
known O +
E3 O +
ubiquitin O +
ligase O +
of O +
the O +
N O -
- O -
end O +
rule O +
pathway O +
that O +
is O +
up O -
- O -
regulated O +
by O +
cachectic O +
stimuli O +
including O +
proinflammatory O +
cytokines O +
and O +
tumors O -
. O +

However O -
, O +
the O +
signaling O +
mechanism O +
through O +
which O +
UBR2 O +
is O +
up O -
- O -
regulated O +
remains O +
undetermined O -
. O +

Here O +
we O +
identify O +
a O +
signaling O +
pathway O +
that O +
mediates O +
tumor O +
cell O -
- O -
induced O +
up O -
- O -
regulation O +
of O +
UBR2 O -
. O +

UBR2 O +
expression O +
in O +
C2C12 O +
myotubes O +
was O +
up O -
- O -
regulated O +
by O +
conditioned O +
medium O +
from O +
Lewis O +
lung O +
carcinoma O +
cells O +
or O +
C26 O +
colon O +
adenocarcinoma O +
cells O -
, O +
which O +
was O +
blocked O +
by O +
a O +
pharmacological O +
inhibitor O +
of O +
p38α O -
/ O -
β O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O -
MAPK O -
) O -
, O +
SB202190 B-Chemical -
. O +

Similarly O -
, O +
SB202190 B-Chemical +
administration O +
( O -
i.p O -
. O -
) O +
abolished O +
UBR2 O +
up O -
- O -
regulation O +
in O +
the O +
tibialis O +
anterior O +
of O +
LLC O +
tumor O -
- O -
bearing O +
mice O -
. O +

Genetic O +
gain O +
and O +
loss O +
of O +
function O +
assays O +
in O +
C2C12 O +
myotubes O +
indicated O +
that O +
tumor O -
- O -
induced O +
activation O +
of O +
the O +
p38β O +
isoform O +
is O +
sufficient O +
and O +
necessary O +
for O +
UBR2 O +
up O -
- O -
regulation O -
. O +

In O +
addition O -
, O +
UBR2 O +
up O -
- O -
regulation O +
required O +
p38β O -
- O -
mediated O +
phosphorylation O +
of O +
CCAAT O -
/ O -
enhancer O +
binding O +
protein O +
( O -
C O -
/ O -
EBP O -
) O -
-β O +
Thr-188 B-Chemical -
, O +
which O +
was O +
critical O +
to O +
C O -
/ O -
EBPβ O +
binding O +
to O +
the O +
UBR2 O +
promoter O -
. O +

Furthermore O -
, O +
luciferase O +
reporter O +
assay O +
revealed O +
that O +
the O +
C O -
/ O -
EBPβ O +
binding O +
motif O +
in O +
the O +
UBR2 O +
promoter O +
is O +
a O +
functional O +
C O -
/ O -
EBPβ O -
- O -
responsive O +
cis O -
- O -
element O +
that O +
enhances O +
the O +
promoter O +
activity O +
on O +
activation O +
by O +
p38β O -
. O +

Finally O -
, O +
genetic O +
ablation O +
of O +
C O -
/ O -
EBPβ O +
blocked O +
UBR2 O +
up O -
- O -
regulation O +
in O +
LLC O +
tumor O -
- O -
bearing O +
mice O -
. O +

These O +
results O +
suggest O +
that O +
UBR2 O +
up O -
- O -
regulation O +
in O +
cachectic O +
muscle O +
is O +
mediated O +
by O +
the O +
p38β O -
- O -
C O -
/ O -
EBPβ O +
signaling O +
pathway O +
responsible O +
for O +
the O +
bulk O +
of O +
tumor O -
- O -
induced O +
muscle O +
proteolysis O -
.- O -
Zhang O -
, O +
G. O -
, O +
Lin O -
, O +
R O -
.- O -
K. O -
, O +
Kwon O -
, O +
Y. O +
T. O -
, O +
Li O -
, O +
Y O -
.- O -
P. O +
Signaling O +
mechanism O +
of O +
tumor O +
cell O -
- O -
induced O +
up O -
- O -
regulation O +
of O +
E3 O +
ubiquitin O +
ligase O +
UBR2 O -
. O +

Structural O +
and O +
functional O +
characterization O +
of O +
a O +
phosphatase O +
domain O +
within O +
yeast O +
general O +
transcription O +
factor O +
TFIIIC O -
. O +

Saccharomyces O +
cerevisiae O +
τ55 O -
, O +
a O +
subunit O +
of O +
the O +
RNA O +
polymerase O +
III O -
- O -
specific O +
general O +
transcription O +
factor O +
TFIIIC O -
, O +
comprises O +
an O +
N O -
- O -
terminal O +
histidine B-Chemical +
phosphatase O +
domain O +
( O -
τ55-HPD O -
) O +
whose O +
catalytic O +
activity O +
and O +
cellular O +
function O +
is O +
poorly O +
understood O -
. O +

We O +
solved O +
the O +
crystal O +
structures O +
of O +
τ55-HPD O +
and O +
its O +
closely O +
related O +
paralogue O +
Huf O +
and O +
used O +
in O +
silico O +
docking O +
methods O +
to O +
identify O +
phospho B-Chemical -
- I-Chemical -
serine I-Chemical +
and O +
phospho B-Chemical -
- I-Chemical -
tyrosine I-Chemical +
containing O +
peptides O +
as O +
possible O +
substrates O +
that O +
were O +
subsequently O +
validated O +
using O +
in O +
vitro O +
phosphatase O +
assays O -
. O +

A O +
comparative O +
phospho B-Chemical -
- O -
proteomic O +
study O +
identified O +
additional O +
phosphopeptides O +
as O +
possible O +
targets O -
, O +
which O +
show O +
the O +
involvement O +
of O +
these O +
two O +
phosphatases O +
in O +
the O +
regulation O +
of O +
a O +
variety O +
of O +
cellular O +
functions O -
. O +

Our O +
results O +
identify O +
τ55-HPD O +
and O +
Huf O +
as O +
bona O +
fide O +
protein O +
phosphatases O -
, O +
characterize O +
their O +
substrate O +
specificities O +
and O +
provide O +
a O +
small O +
set O +
of O +
regulated O +
phosphosite O +
targets O +
in O +
vivo O -
. O +

Adenine B-Chemical -
- O -
DNA O +
Adducts O +
Derived O +
from O +
the O +
Highly O +
Tumorigenic O +
Dibenzo B-Chemical -
[ I-Chemical -
a I-Chemical -
, I-Chemical -
l I-Chemical -
] I-Chemical -
pyrene I-Chemical +
Are O +
Resistant O +
to O +
Nucleotide B-Chemical +
Excision O +
Repair O +
while O +
Guanine B-Chemical +
Adducts O +
Are O +
Not O -
. O +

The O +
structural O +
origins O +
of O +
differences O +
in O +
susceptibilities O +
of O +
various O +
DNA O +
lesions O +
to O +
nucleotide B-Chemical +
excision O +
repair O +
( O -
NER O -
) O +
are O +
poorly O +
understood O -
. O +

Here O +
we O +
compared O -
, O +
in O +
the O +
same O +
sequence O +
context O -
, O +
the O +
relative O +
NER O +
dual O +
incision O +
efficiencies O +
elicited O +
by O +
two O +
stereochemically O +
distinct O +
pairs O +
of O +
guanine B-Chemical +
( O -
N O -
( O -
2 O -
) O -
-dG O -
) O +
and O +
adenine B-Chemical +
( O -
N O -
( O -
6 O -
) O -
-dA O -
) O +
DNA O +
lesions O -
, O +
derived O +
from O +
enantiomeric O +
genotoxic O +
diol B-Chemical +
epoxides I-Chemical +
of O +
the O +
highly O +
tumorigenic O +
fjord O +
region O +
polycyclic O +
aromatic O +
hydrocarbon O +
dibenzo B-Chemical -
[ I-Chemical -
a I-Chemical -
, I-Chemical -
l I-Chemical -
] I-Chemical -
pyrene I-Chemical +
( O -
DB B-Chemical -
[ I-Chemical -
a I-Chemical -
, I-Chemical -
l I-Chemical -
] I-Chemical -
P I-Chemical -
) O -
. O +

Remarkably O -
, O +
in O +
cell O -
- O -
free O +
HeLa O +
cell O +
extracts O -
, O +
the O +
guanine B-Chemical +
adduct O +
with O +
R O +
absolute O +
chemistry O +
at O +
the O +
N O -
( O -
2 O -
) O -
-dG O +
linkage O +
site O +
is O +
∼35 O +
times O +
more O +
susceptible O +
to O +
NER O +
dual O +
incisions O +
than O +
the O +
stereochemically O +
identical O +
N O -
( O -
6 O -
) O -
-dA O +
adduct O -
. O +

For O +
the O +
guanine B-Chemical +
and O +
adenine B-Chemical +
adducts O +
with O +
S O +
stereochemistry O -
, O +
a O +
similar O +
but O +
somewhat O +
smaller O +
effect O +
( O -
factor O +
of O +
∼15 O -
) O +
is O +
observed O -
. O +

The O +
striking O +
resistance O +
of O +
the O +
bulky O +
N O -
( O -
6 O -
) O -
-dA O +
in O +
contrast O +
to O +
the O +
modest O +
to O +
good O +
susceptibilities O +
of O +
the O +
N O -
( O -
2 O -
) O -
-dG O +
adducts O +
to O +
NER O +
is O +
interpreted O +
in O +
terms O +
of O +
the O +
balance O +
between O +
lesion O -
- O -
induced O +
DNA O +
distorting O +
and O +
DNA O +
stabilizing O +
van O +
der O +
Waals O +
interactions O +
in O +
their O +
structures O -
, O +
that O +
are O +
partly O +
reflected O +
in O +
the O +
overall O +
thermal O +
stabilities O +
of O +
the O +
modified O +
duplexes O -
. O +

Our O +
results O +
are O +
consistent O +
with O +
the O +
hypothesis O +
that O +
the O +
high O +
genotoxic O +
activity O +
of O +
DB B-Chemical -
[ I-Chemical -
a I-Chemical -
, I-Chemical -
l I-Chemical -
] I-Chemical -
P I-Chemical +
is O +
related O +
to O +
the O +
formation O +
of O +
NER O -
- O -
resistant O +
and O +
persistent O +
DB B-Chemical -
[ I-Chemical -
a I-Chemical -
, I-Chemical -
l I-Chemical -
] I-Chemical -
P I-Chemical -
- O -
derived O +
adenine B-Chemical +
adducts O +
in O +
cellular O +
DNA O -
. O +

Reactions O +
of O +
Hydrocarbon B-Chemical +
Radicals I-Chemical +
and I-Chemical +
Biradicals I-Chemical -
. O +

Experimental O +
measurements O +
of O +
the O +
rate O +
coefficients O +
for O +
several O +
types O +
of O +
gas O +
phase O +
radical O +
reactions O +
are O +
reviewed O -
. O +

They O +
include O +
radical O +
isomerization O +
and O +
dissociation O -
, O +
radical O +
+ O +
radical O +
association O -
, O +
and O +
unimolecular O +
reactions O +
of O +
peroxy B-Chemical +
radicals O -
. O +

Some O +
reactions O +
of O +
methylene B-Chemical +
in O +
its O +
lowest O +
singlet O +
state O +
are O +
also O +
considered O -
. O +

The O +
links O +
to O +
theories O +
of O +
chemical O +
reaction O +
rates O +
and O +
especially O +
of O +
capture O +
rates O +
for O +
radical O +
+ O +
radical O +
reactions O +
are O +
examined O -
. O +

Many O +
of O +
the O +
reactions O +
involve O +
formation O +
of O +
adducts O -
, O +
which O +
can O +
isomerize O +
and O +
dissociate O -
. O +

Such O +
reactions O +
frequently O +
involve O +
energy O +
distributions O +
of O +
the O +
adducts O +
that O +
are O +
far O +
from O +
Boltzmann O -
, O +
and O +
the O +
interpretation O +
of O +
measurements O +
requires O +
the O +
use O +
of O +
master O +
equation O +
techniques O -
. O +

The O +
basis O +
of O +
these O +
methods O +
and O +
the O +
use O +
of O +
matrix O +
diagonalization O +
and O +
eigenvector O -
/ O -
eigenvalue O +
analysis O +
to O +
extract O +
phenomenological O +
rate O +
coefficients O +
are O +
discussed O -
. O +

The O +
relevance O +
of O +
the O +
measurements O +
to O +
applications O +
in O +
atmospheric O +
chemistry O +
and O -
, O +
especially O -
, O +
in O +
combustion O +
is O +
briefly O +
considered O -
. O +

Ion O +
impacts O +
on O +
graphene B-Chemical -
/ O -
ir B-Chemical -
( I-Chemical -
111 I-Chemical -
) I-Chemical -
: O +
interface O +
channeling O -
, O +
vacancy O +
funnels O -
, O +
and O +
a O +
nanomesh O -
. O +

By O +
combining O +
ion O +
beam O +
experiments O +
and O +
atomistic O +
simulations O +
we O +
study O +
the O +
production O +
of O +
defects O +
in O +
graphene B-Chemical +
on O +
Ir B-Chemical -
( I-Chemical -
111 I-Chemical -
) I-Chemical +
under O +
grazing O +
incidence O +
of O +
low O +
energy O +
Xe B-Chemical +
ions O -
. O +

We O +
demonstrate O +
that O +
the O +
ions O +
are O +
channeled O +
in O +
between O +
graphene B-Chemical +
and O +
the O +
substrate O -
, O +
giving O +
rise O +
to O +
chains O +
of O +
vacancy O +
clusters O +
with O +
their O +
edges O +
bending O +
down O +
toward O +
the O +
substrate O -
. O +

These O +
clusters O +
self O -
- O -
organize O +
to O +
a O +
graphene B-Chemical +
nanomesh O +
via O +
thermally O +
activated O +
diffusion O +
as O +
their O +
formation O +
energy O +
varies O +
within O +
the O +
graphene B-Chemical +
moiré O +
supercell O -
. O +

A O +
facile O +
strategy O +
to O +
design O +
zeolite B-Chemical +
L I-Chemical +
crystals O +
with O +
tunable O +
morphology O +
and O +
surface O +
architecture O -
. O +

Tailoring O +
the O +
anisotropic O +
growth O +
rates O +
of O +
materials O +
to O +
achieve O +
desired O +
structural O +
outcomes O +
is O +
a O +
pervasive O +
challenge O +
in O +
synthetic O +
crystallization O -
. O +

Here O +
we O +
discuss O +
a O +
method O +
to O +
selectively O +
control O +
the O +
growth O +
of O +
zeolite B-Chemical +
crystals O -
, O +
which O +
are O +
used O +
extensively O +
in O +
a O +
wide O +
range O +
of O +
industrial O +
applications O -
. O +

This O +
facile O +
method O +
cooperatively O +
tunes O +
crystal O +
properties O -
, O +
such O +
as O +
morphology O +
and O +
surface O +
architecture O -
, O +
through O +
the O +
use O +
of O +
inexpensive O -
, O +
commercially O +
available O +
chemicals O +
with O +
specificity O +
for O +
binding O +
to O +
crystallographic O +
surfaces O +
and O +
mediating O +
anisotropic O +
growth O -
. O +

We O +
examined O +
over O +
30 O +
molecules O +
as O +
potential O +
zeolite B-Chemical +
growth O +
modifiers O +
( O -
ZGMs O -
) O +
of O +
zeolite B-Chemical +
L I-Chemical +
( O -
LTL O +
type O -
) O +
crystallization O -
. O +

ZGM O +
efficacy O +
was O +
quantified O +
through O +
a O +
combination O +
of O +
macroscopic O +
( O -
bulk O -
) O +
and O +
microscopic O +
( O -
surface O -
) O +
investigations O +
that O +
identified O +
modifiers O +
capable O +
of O +
dramatically O +
altering O +
the O +
cylindrical O +
morphology O +
of O +
LTL O +
crystals O -
. O +

We O +
demonstrate O +
an O +
ability O +
to O +
tailor O +
properties O +
critical O +
to O +
zeolite B-Chemical +
performance O -
, O +
such O +
as O +
external O +
porous O +
surface O +
area O -
, O +
crystal O +
shape O -
, O +
and O +
pore O +
length O -
, O +
which O +
can O +
enhance O +
sorbate B-Chemical +
accessibility O +
to O +
LTL O +
pores O -
, O +
tune O +
the O +
supramolecular O +
organization O +
of O +
guest O -
- O -
host O +
composites O -
, O +
and O +
minimize O +
the O +
diffusion O +
path O +
length O -
, O +
respectively O -
. O +

We O +
report O +
that O +
a O +
synergistic O +
combination O +
of O +
ZGMs O +
and O +
the O +
judicious O +
adjustment O +
of O +
synthesis O +
parameters O +
produce O +
LTL O +
crystals O +
with O +
unique O +
surface O +
features O -
, O +
and O +
a O +
range O +
of O +
length O -
- O -
to O -
- O -
diameter O +
aspect O +
ratios O +
spanning O +
3 O +
orders O +
of O +
magnitude O -
. O +

A O +
systematic O +
examination O +
of O +
different O +
ZGM O +
structures O +
and O +
molecular O +
compositions O +
( O -
i.e. O -
, O +
hydrophobicity O +
and O +
binding O +
moieties O -
) O +
reveal O +
interesting O +
physicochemical O +
properties O +
governing O +
their O +
efficacy O +
and O +
specificity O -
. O +

Results O +
of O +
this O +
study O +
suggest O +
this O +
versatile O +
strategy O +
may O +
prove O +
applicable O +
for O +
a O +
host O +
of O +
framework O +
types O +
to O +
produce O +
unrivaled O +
materials O +
that O +
have O +
eluded O +
more O +
conventional O +
techniques O -
. O +

Silver B-Chemical +
Nanoparticles O +
Induced O +
RNA O +
Polymerase O -
- O -
Silver B-Chemical +
Binding O +
and O +
RNA O +
Transcription O +
Inhibition O +
in O +
Erythroid O +
Progenitor O +
Cells O -
. O +

Due O +
to O +
its O +
antimicrobial O +
activity O -
, O +
nanosilver O +
( O -
nAg O -
) O +
has O +
become O +
the O +
most O +
widely O +
used O +
nanomaterial O -
. O +

Thus O +
far O -
, O +
the O +
mechanisms O +
responsible O +
for O +
nAg O -
- O -
induced O +
antimicrobial O +
properties O +
and O +
nAg O -
- O -
mediated O +
toxicity O +
to O +
organisms O +
have O +
not O +
been O +
clearly O +
recognized O -
. O +

Silver B-Chemical +
( O -
Ag B-Chemical -
) O +
ions O +
certainly O +
play O +
a O +
crucial O +
role O -
, O +
and O +
the O +
form O +
of O +
nanoparticles O +
can O +
change O +
the O +
dissolution O +
rate O -
, O +
bioavailability O -
, O +
biodistribution O -
, O +
and O +
cellular O +
uptake O +
of O +
Ag B-Chemical -
. O +

However O -
, O +
whether O +
nAg O +
exerts O +
direct O +
" O -
particle O -
- O -
specific O -
" O +
effects O +
has O +
been O +
under O +
debate O -
. O +

Here O +
we O +
demonstrated O +
that O +
nAg O +
exhibited O +
a O +
robust O +
inhibition O +
on O +
RNA O +
polymerase O +
activity O +
and O +
overall O +
RNA O +
transcription O +
through O +
direct O +
Ag B-Chemical +
binding O +
to O +
RNA O +
polymerase O -
, O +
which O +
is O +
separated O +
from O +
the O +
cytotoxicity O +
pathway O +
induced O +
by O +
Ag B-Chemical +
ions O -
. O +

nAg O +
treatment O +
in O +
vitro O +
resulted O +
in O +
reduced O +
hemoglobin O +
concentration O +
in O +
erythroid O +
cells O -
; O +
in O +
vivo O +
administration O +
of O +
nAg O +
in O +
mice O +
caused O +
profound O +
reduction O +
of O +
hemoglobin O +
content O +
in O +
embryonic O +
erythrocytes O -
, O +
associated O +
with O +
anemia O +
in O +
the O +
embryos O -
. O +

Embryonic O +
anemia O +
and O +
general O +
proliferation O +
deficit O +
due O +
to O +
the O +
significant O +
inhibition O +
on O +
RNA O +
synthesis O -
, O +
at O +
least O +
partially O -
, O +
accounted O +
for O +
embryonic O +
developmental O +
retardation O +
upon O +
nAg O +
administration O -
. O +

To O +
date O -
, O +
there O +
is O +
no O +
conclusive O +
answer O +
to O +
the O +
sources O +
of O +
nAg O -
- O -
mediated O +
toxicity O -
: O +
Ag B-Chemical +
ions O +
or O +
" O -
particle O -
- O -
specific O -
" O +
effects O -
, O +
or O +
both O -
. O +

We O +
here O +
demonstrated O +
that O +
both O +
Ag B-Chemical +
ions O +
and O +
nAg O +
particles O +
simultaneously O +
existed O +
inside O +
cells O -
, O +
demonstrating O +
the O +
" O -
Trojan O +
horse O -
" O +
effects O +
of O +
nAg O +
particles O +
in O +
posing O +
biological O +
impacts O +
on O +
erythroid O +
cells O -
. O +

Moreover O -
, O +
our O +
results O +
suggested O +
that O +
" O -
particle O -
- O -
specific O -
" O +
effects O +
could O +
be O +
the O +
predominant O +
mediator O +
in O +
eliciting O +
biological O +
influences O +
on O +
erythroid O +
cells O +
under O +
relatively O +
low O +
concentrations O +
of O +
nAg O +
exposure O -
. O +

The O +
combined O +
data O +
highlighted O +
the O +
inhibitory O +
effect O +
of O +
nAg O +
on O +
RNA O +
polymerase O +
activity O +
through O +
a O +
direct O +
reciprocal O +
interaction O -
. O +

Pyranocycloartobiloxanthone B-Chemical +
A I-Chemical -
, O +
a O +
novel O +
gastroprotective O +
compound O +
from O +
Artocarpus O +
obtusus O +
Jarret O -
, O +
against O +
ethanol B-Chemical -
- O -
induced O +
acute O +
gastric O +
ulcer O +
in O +
vivo O -
. O +

Pyranocycloartobiloxanthone B-Chemical +
A I-Chemical +
( O -
PA O -
) O -
, O +
a O +
xanthone B-Chemical +
derived O +
from O +
the O +
Artocarpus O +
obtusus O +
Jarret O -
, O +
belongs O +
to O +
the O +
Moraceae O +
family O +
which O +
is O +
native O +
to O +
the O +
tropical O +
forest O +
of O +
Malaysia O -
. O +

In O +
this O +
study O -
, O +
the O +
efficacy O +
of O +
PA O +
as O +
a O +
gastroprotective O +
compound O +
was O +
examined O +
against O +
ethanol B-Chemical -
- O -
induced O +
ulcer O +
model O +
in O +
rats O -
. O +

The O +
rats O +
were O +
pretreated O +
with O +
PA O +
and O +
subsequently O +
exposed O +
to O +
acute O +
gastric O +
lesions O +
induced O +
by O +
absolute O +
ethanol B-Chemical -
. O +

The O +
ulcer O +
index O -
, O +
gastric O +
juice O +
acidity O -
, O +
mucus O +
content O -
, O +
histological O +
analysis O -
, O +
glutathione B-Chemical +
( O -
GSH B-Chemical -
) O +
levels O -
, O +
malondialdehyde B-Chemical +
level O +
( O -
MDA B-Chemical -
) O -
, O +
nitric B-Chemical +
oxide I-Chemical +
( O -
NO B-Chemical -
) O +
and O +
non O -
- O -
protein O +
sulfhydryl B-Chemical +
group O +
( O -
NP O -
- O -
SH B-Chemical -
) O +
contents O +
were O +
evaluated O +
in O +
vivo O -
. O +

The O +
activities O +
of O +
PA O +
as O +
anti O -
- O -
Helicobacter O +
pylori O -
, O +
cyclooxygenase-2 O +
( O -
COX-2 O -
) O +
inhibitor O +
and O +
free O +
radical O +
scavenger O +
were O +
also O +
investigated O +
in O +
vitro O -
. O +

The O +
results O +
showed O +
that O +
the O +
oral O +
administration O +
of O +
PA O +
protects O +
gastric O +
mucosa O +
from O +
ethanol B-Chemical -
- O -
induced O +
gastric O +
lesions O -
. O +

PA O +
pretreatment O +
significantly O +
( O -
p<0.05 O -
) O +
restored O +
the O +
depleted O +
GSH B-Chemical -
, O +
NP O -
- O -
SH B-Chemical +
and O +
NO B-Chemical +
levels O +
in O +
the O +
gastric O +
homogenate O -
. O +

Moreover O -
, O +
PA O +
significantly O +
( O -
p<0.05 O -
) O +
reduced O +
the O +
elevated O +
MDA B-Chemical +
level O +
due O +
to O +
ethanol B-Chemical +
administration O -
. O +

The O +
gastroprotective O +
effect O +
of O +
PA O +
was O +
associated O +
with O +
an O +
over O +
expression O +
of O +
HSP70 O +
and O +
suppression O +
of O +
Bax O +
proteins O +
in O +
the O +
ulcerated O +
tissue O -
. O +

In O +
addition O -
, O +
PA O +
exhibited O +
a O +
potent O +
FRAP O +
value O +
and O +
significant O +
COX-2 O +
inhibition O -
. O +

It O +
also O +
showed O +
a O +
significant O +
minimum O +
inhibitory O +
concentration O +
( O -
MIC O -
) O +
against O +
H. O +
pylori O +
bacterium O -
. O +

The O +
efficacy O +
of O +
PA O +
was O +
accomplished O +
safely O +
without O +
the O +
presence O +
of O +
any O +
toxicological O +
parameters O -
. O +

The O +
results O +
of O +
the O +
present O +
study O +
indicate O +
that O +
the O +
gastroprotective O +
effect O +
of O +
PA O +
might O +
contribute O +
to O +
the O +
antioxidant O +
and O +
anti O -
- O -
inflammatory O +
properties O +
as O +
well O +
as O +
the O +
anti O -
- O -
apoptotic O +
mechanism O +
and O +
antibacterial O +
action O +
against O +
Helicobacter O +
pylori O -
. O +

Bioinspired O +
design O +
and O +
macroscopic O +
assembly O +
of O +
poly B-Chemical -
( I-Chemical -
vinyl I-Chemical +
alcohol I-Chemical -
) I-Chemical -
-coated O +
graphene B-Chemical +
into O +
kilometers O -
- O -
long O +
fibers O -
. O +

Nacre O +
is O +
characterized O +
by O +
its O +
excellent O +
mechanical O +
performance O +
due O +
to O +
the O +
well O -
- O -
recognized O +
" O -
brick O +
and O +
mortar O -
" O +
structure O -
. O +

Many O +
efforts O +
have O +
been O +
applied O +
to O +
make O +
nacre O -
- O -
mimicking O +
materials O -
, O +
but O +
it O +
is O +
still O +
a O +
big O +
challenge O +
to O +
realize O +
their O +
continuous O +
production O -
. O +

Here O -
, O +
we O +
prepared O +
sandwich O -
- O -
like O +
building O +
blocks O +
of O +
poly B-Chemical -
( I-Chemical -
vinyl I-Chemical +
alcohol I-Chemical -
) I-Chemical +
( O -
PVA B-Chemical -
) O -
-coated O +
graphene B-Chemical -
, O +
and O +
achieved O +
high O -
- O -
nanofiller O -
- O -
content O +
kilometers O -
- O -
long O +
fibers O +
by O +
continuous O +
wet O -
- O -
spinning O +
assembly O +
technology O -
. O +

The O +
fibers O +
have O +
a O +
strict O +
" O -
brick O +
and O +
mortar O -
" O +
layered O +
structure O -
, O +
with O +
graphene B-Chemical +
sheet O +
as O +
rigid O +
brick O +
and O +
PVA B-Chemical +
as O +
soft O +
mortar O -
. O +

The O +
mortar O +
thickness O +
can O +
be O +
precisely O +
tuned O +
from O +
2.01 O +
to O +
3.31 O +
nm O +
by O +
the O +
weight O +
feed O +
ratio O +
of O +
PVA O +
to O +
graphene B-Chemical -
, O +
as O +
demonstrated O +
by O +
both O +
atomic O +
force O +
microscopy O +
and O +
X O -
- O -
ray O +
diffraction O +
measurements O -
. O +

The O +
mechanical O +
strength O +
of O +
the O +
nacre O -
- O -
mimicking O +
fibers O +
increases O +
with O +
increasing O +
the O +
content O +
of O +
PVA B-Chemical -
, O +
and O +
it O +
rises O +
gradually O +
from O +
81 O +
MPa O +
for O +
the O +
fiber O +
with O +
53.1 O +
wt% O +
PVA B-Chemical +
to O +
161 O +
MPa O +
for O +
the O +
fiber O +
with O +
65.8 O +
wt% O +
PVA B-Chemical -
. O +

The O +
mechanical O +
performance O +
of O +
our O +
fibers O +
was O +
independent O +
of O +
the O +
molecular O +
weight O +
( O -
MW O -
) O +
of O +
PVA B-Chemical +
in O +
the O +
wide O +
range O +
of O +
2 O -
- O -
100 O +
kDa O -
, O +
indicating O +
that O +
low O +
MW O +
polymers O +
can O +
also O +
be O +
used O +
to O +
make O +
strong O +
nanocomposites O -
. O +

The O +
tensile O +
stress O +
of O +
fibers O +
immersed O +
in O +
PVA B-Chemical +
5 O +
wt% O +
solution O +
reached O +
ca O -
. O +

200 O +
MPa O -
, O +
surpassing O +
the O +
values O +
of O +
nacre O +
and O +
most O +
of O +
other O +
nacre O -
- O -
mimicking O +
materials O -
. O +

The O +
nacre O -
- O -
mimicking O +
fibers O +
are O +
highly O +
electrically O +
conductive O +
( O -
∼350 O +
S O +
m O -
( O -
-1 O -
) O -
) O +
after O +
immersing O +
in O +
hydroiodic B-Chemical +
acid I-Chemical -
, O +
enabling O +
them O +
to O +
connect O +
a O +
circuit O +
to O +
illuminate O +
an O +
LED O +
lamp O -
. O +

Proposed O +
diagnostic O +
criteria O +
for O +
subclinical O +
Cushing O -
's O +
syndrome O +
associated O +
with O +
adrenal O +
incidentaloma O -
. O +

Subclinical O +
Cushing O -
's O +
syndrome O +
( O -
SCS O -
) O +
associated O +
with O +
adrenal O +
incidentaloma O +
is O +
usually O +
characterized O +
by O +
autonomous O +
cortisol B-Chemical +
secretion O +
without O +
overt O +
symptoms O +
of O +
Cushing O -
's O +
syndrome O +
( O -
CS O -
) O -
. O +

Although O +
the O +
diagnostic O +
criteria O +
for O +
SCS O +
differ O +
among O +
countries O -
, O +
the O +
1 O +
mg O +
dexamethasone B-Chemical +
suppression O +
test O +
( O -
DST O -
) O +
is O +
essential O +
to O +
confirm O +
the O +
presence O +
and O +
the O +
extent O +
of O +
cortisol B-Chemical +
overproduction O -
. O +

Since O +
1995 O -
, O +
SCS O +
has O +
been O +
diagnosed O +
in O +
Japan O +
based O +
on O +
serum O +
cortisol B-Chemical +
levels O +
≥3 O +
μg O -
/ O -
dl O +
( O -
measured O +
by O +
radioimmunoassay O +
[ O -
RIA O -
] O -
) O +
after O +
a O +
1 O +
mg O +
DST O -
. O +

However O -
, O +
the O +
increasing O +
use O +
of O +
enzyme O +
immunoassays O +
( O -
EIA O -
) O +
instead O +
of O +
RIA O +
has O +
hindered O +
the O +
diagnosis O +
of O +
SCS O +
because O +
of O +
the O +
differing O +
sensitivities O +
of O +
commercially O +
available O +
assays O -
, O +
particularly O +
for O +
serum O +
cortisol B-Chemical +
levels O +
of O +
around O +
3 O +
μg O -
/ O -
dl O -
. O +

One O +
way O +
to O +
overcome O +
this O +
problem O +
is O +
to O +
lower O +
the O +
cortisol B-Chemical +
threshold O +
level O +
after O +
a O +
1 O +
mg O +
DST O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
examined O +
the O +
clinical O +
applicability O +
of O +
lowering O +
the O +
cortisol B-Chemical +
threshold O +
to O +
1.8 O +
μg O -
/ O -
dl O -
, O +
similar O +
to O +
the O +
American O +
Endocrine O +
Society O -
's O +
guidelines O +
for O +
CS O -
, O +
by O +
reanalyzing O +
119 O +
patients O +
with O +
adrenal O +
incidentaloma O -
. O +

Our O +
findings O +
indicate O +
that O +
serum O +
cortisol B-Chemical +
levels O +
≥1.8 O +
μg O -
/ O -
dl O +
after O +
1 O +
mg O +
DST O +
are O +
useful O +
to O +
confirm O +
the O +
diagnosis O +
of O +
SCS O +
if O +
both O +
of O +
the O +
following O +
criteria O +
are O +
met O -
: O +
( O -
1 O -
) O +
basal O +
ACTH O +
level O +
< O -
10 O +
pg O -
/ O -
ml O +
( O -
or O +
poor O +
plasma O +
ACTH O +
response O +
to O +
corticotrophin O -
- O -
releasing O +
hormone O -
) O +
and O +
( O -
2 O -
) O +
serum O +
cortisol B-Chemical +
≥5 O +
μg O -
/ O -
dl O +
at O +
21:00 O +
to O +
23:00 O +
h. O +
If O +
only O +
one O +
of O +
( O -
1 O -
) O +
and O +
( O -
2 O -
) O +
are O +
met O -
, O +
we O +
recommend O +
that O +
other O +
clinical O +
features O +
are O +
considered O +
in O +
the O +
diagnosis O +
of O +
SCS O -
, O +
including O +
serum O +
dehydroepiandrosterone B-Chemical +
sulfate I-Chemical +
levels O -
, O +
urine O +
free O +
cortisol B-Chemical +
levels O -
, O +
adrenal O +
scintigraphy O -
, O +
and O +
clinical O +
manifestation O -
. O +

Boron B-Chemical +
Enhances O +
Odontogenic O +
and O +
Osteogenic O +
Differentiation O +
of O +
Human O +
Tooth O +
Germ O +
Stem O +
Cells O +
( O -
hTGSCs O -
) O +
In O +
Vitro O -
. O +

Stem O +
cell O +
technology O +
has O +
been O +
a O +
great O +
hope O +
for O +
the O +
treatment O +
of O +
many O +
common O +
problems O +
such O +
as O +
Parkinson O -
's O +
disease O -
, O +
Alzheimer O -
's O +
disease O -
, O +
diabetes O -
, O +
cancer O -
, O +
and O +
tissue O +
regeneration O -
. O +

Therefore O -
, O +
the O +
main O +
challenge O +
in O +
hard O +
tissue O +
engineering O +
is O +
to O +
make O +
a O +
successful O +
combination O +
of O +
stem O +
cells O +
and O +
efficient O +
inductors O +
in O +
the O +
concept O +
of O +
stem O +
cell O +
differentiation O +
into O +
odontogenic O +
and O +
osteogenic O +
cell O +
types O -
. O +

Although O +
some O +
boron B-Chemical +
derivatives O +
have O +
been O +
reported O +
to O +
promote O +
bone O +
and O +
teeth O +
growth O +
in O +
vivo O -
, O +
the O +
molecular O +
mechanism O +
of O +
bone O +
formation O +
has O +
not O +
been O +
elucidated O +
yet O -
. O +

Different O +
concentrations O +
of O +
sodium B-Chemical +
pentaborate I-Chemical +
pentahydrate I-Chemical +
( O -
NaB B-Chemical -
) O +
were O +
prepared O +
for O +
the O +
analysis O +
of O +
cell O +
toxicity O +
and O +
differentiation O +
evaluations O -
. O +

The O +
odontogenic O -
, O +
osteogenic O +
differentiation O +
and O +
biomineralization O +
of O +
human O +
tooth O +
germ O +
stem O +
cells O +
( O -
hTGSCs O -
) O +
were O +
evaluated O +
by O +
analyzing O +
the O +
mRNA O +
expression O +
levels O -
, O +
odontogenic O +
and O +
osteogenic O +
protein O +
expressions O -
, O +
alkaline O +
phosphatase O +
( O -
ALP O -
) O +
activity O -
, O +
mineralization O -
, O +
and O +
calcium B-Chemical +
deposits O -
. O +

The O +
NaB B-Chemical -
- O -
treated O +
group O +
displayed O +
the O +
highest O +
ALP O +
activity O +
and O +
expression O +
of O +
osteo- O +
and O +
odontogenic O -
- O -
related O +
genes O +
and O +
proteins O +
compared O +
to O +
the O +
other O +
groups O +
and O +
baseline O -
. O +

In O +
the O +
current O +
study O -
, O +
increased O +
in O +
vitro O +
odontogenic O +
and O +
osteogenic O +
differentiation O +
capacity O +
of O +
hTGSCs O +
by O +
NaB B-Chemical +
application O +
has O +
been O +
shown O +
for O +
the O +
first O +
time O -
. O +

The O +
study O +
offers O +
considerable O +
promise O +
for O +
the O +
development O +
of O +
new O +
scaffold O +
systems O +
combined O +
with O +
NaB B-Chemical +
in O +
both O +
functional O +
bone O +
and O +
tooth O +
tissue O +
engineering O -
. O +

Cryptococcal O +
infections O -
: O +
changing O +
epidemiology O +
and O +
implications O +
for O +
therapy O -
. O +

Although O +
the O +
incidence O +
of O +
HIV O -
- O -
associated O +
cryptococcosis O +
has O +
decreased O +
in O +
developed O +
countries O +
since O +
the O +
introduction O +
of O +
antiretroviral O +
therapy O -
, O +
this O +
disease O +
continues O +
to O +
cause O +
significant O +
morbidity O +
and O +
mortality O +
in O +
sub O -
- O -
Saharan O +
Africa O +
among O +
patients O +
with O +
AIDS O -
. O +

Important O +
strides O +
have O +
been O +
made O +
in O +
an O +
attempt O +
to O +
decrease O +
the O +
burden O +
of O +
disease O -
, O +
particularly O +
the O +
development O +
of O +
the O +
lateral O +
flow O +
assay O +
cryptococcal O +
antigen O +
( O -
LFA O +
CrAg O -
) O +
as O +
a O +
diagnostic O +
tool O +
in O +
resource O -
- O -
limited O +
settings O -
, O +
coupled O +
with O +
the O +
introduction O +
of O +
pre O -
- O -
emptive O +
treatment O +
with O +
fluconazole B-Chemical +
for O +
HIV O -
- O -
positive O +
patients O +
at O +
risk O +
for O +
cryptococcosis O +
with O +
a O +
positive O +
LFA O +
CrAg O -
. O +

Among O +
solid O +
organ O +
transplant O +
recipients O -
, O +
recent O +
prospective O +
studies O +
have O +
identified O +
cryptococcosis O +
as O +
the O +
third O +
most O +
common O +
invasive O +
fungal O +
infection O -
, O +
and O +
progress O +
is O +
being O +
made O +
toward O +
earlier O +
diagnosis O +
and O +
more O +
effective O +
therapy O -
. O +

Finally O -
, O +
the O +
Cryptococcus O +
gattii O +
outbreak O +
in O +
British O +
Columbia O -
, O +
Canada O +
and O +
the O +
US O +
Pacific O +
Northwest O +
is O +
providing O +
important O +
new O +
insights O +
into O +
the O +
emergence O +
of O +
this O +
pathogen O +
in O +
geographic O +
areas O +
previously O +
considered O +
low O +
risk O +
for O +
acquisition O +
of O +
infection O -
. O +

Understanding O +
the O +
similarities O +
and O +
differences O +
among O +
C. O +
gattii O +
and O +
C. O +
neoformans O +
infections O +
will O +
provide O +
critical O +
insights O +
into O +
the O +
behavior O +
of O +
these O +
organisms O +
in O +
the O +
human O +
host O -
. O +

Both O +
pathogens O +
affect O +
immunocompetent O +
and O +
immunosuppressed O +
hosts O -
, O +
causing O +
pulmonary O -
, O +
central O +
nervous O +
system O +
and O +
widely O +
disseminated O +
infections O -
. O +

Treatment O +
recommendations O +
in O +
the O +
future O +
will O +
necessarily O +
take O +
into O +
account O +
the O +
site O +
of O +
infection O -
, O +
clinical O +
severity O +
of O +
the O +
infection O -
, O +
Cryptococcus O +
species O -
, O +
host O +
immune O +
status O +
and O +
economic O +
resources O -
. O +

Congruence O +
of O +
Phytochemical O +
and O +
Morphological O +
Profiles O +
along O +
an O +
Altitudinal O +
Gradient O +
in O +
Origanum O +
vulgare O +
ssp O -
. O +

vulgare O +
from O +
Venetian O +
Region O +
( O -
NE O +
Italy O -
) O -
. O +

Plants O +
of O +
Origanum O +
vulgare O +
L. O +
ssp O -
. O +

vulgare O +
from O +
the O +
Veneto O +
region O +
( O -
NE O +
Italy O -
) O +
were O +
selected O +
to O +
study O +
the O +
variability O +
of O +
the O +
essential O -
- O -
oil O +
composition O +
from O +
leaves O +
and O +
inflorescences O +
throughout O +
an O +
elevation O +
gradient O -
. O +

We O +
investigated O +
also O +
the O +
morphology O +
of O +
non O -
- O -
glandular O +
and O +
glandular O +
trichomes O -
, O +
their O +
distribution O +
on O +
the O +
vegetative O +
and O +
reproductive O +
organs O -
, O +
as O +
well O +
as O +
the O +
histochemistry O +
of O +
the O +
secreted O +
products O -
, O +
with O +
special O +
focus O +
on O +
the O +
terpenoidic O +
fraction O -
. O +

Since O +
glandular O +
trichomes O +
are O +
prerequisite O +
for O +
the O +
essential O -
- O -
oil O +
synthesis O -
, O +
the O +
second O +
objective O +
was O +
to O +
establish O +
whether O +
its O +
production O +
is O +
related O +
to O +
glandular O +
hair O +
number O -
, O +
and O +
density O -
. O +

Essential O -
- O -
oil O +
contents O +
decline O +
with O +
increasing O +
altitude O -
, O +
and O +
the O +
micromorphological O +
observations O +
revealed O +
a O +
decrease O +
in O +
trichome O +
density O +
along O +
the O +
same O +
direction O -
. O +

Moreover O -
, O +
GC O -
/ O -
MS O +
analysis O +
together O +
with O +
principal O +
component O +
analysis O +
( O -
PCA O -
) O +
showed O +
that O +
the O +
three O +
investigated O +
populations O +
were O +
significantly O +
different O +
in O +
chemical O +
composition O -
. O +

Therefore O -
, O +
an O +
important O +
interpopulation O +
variability O +
for O +
low- O -
, O +
mid- O -
, O +
and O +
high O -
- O -
altitude O +
sites O +
was O +
established O -
, O +
suggesting O +
the O +
likely O +
occurrence O +
of O +
different O +
biotypes O +
associated O +
with O +
altitudinal O +
levels O -
. O +

Hence O -
, O +
the O +
involvement O +
of O +
abiotic O +
factors O +
such O +
as O +
temperature O +
and O +
drought O +
in O +
the O +
chemical O +
polymorphism O +
of O +
O. O +
vulgare O +
associated O +
with O +
elevation O +
is O +
briefly O +
discussed O -
. O +

Configurational O +
Assignment O +
of O +
Secondary O +
Hydroxyl B-Chemical +
Groups O +
and O +
Methyl B-Chemical +
Branches O +
in O +
Polyketide O +
Natural O +
Products O +
through O +
Bioinformatic O +
Analysis O +
of O +
the O +
Ketoreductase O +
Domain O -
. O +

Profile O +
hidden O +
Markov O +
models O +
( O -
HMMs O -
) O +
were O +
used O +
to O +
predict O +
the O +
configuration O +
of O +
secondary B-Chemical +
alcohols I-Chemical +
and O +
α B-Chemical -
- I-Chemical -
methyl I-Chemical +
branches O +
of O +
modular O +
polyketides O -
. O +

Based O +
on O +
the O +
configurations O +
of O +
two O +
chiral O +
centers O +
in O +
these O +
polyketides O -
, O +
78 O +
ketoreductases O +
were O +
classified O +
into O +
four O +
different O +
types O +
of O +
polyketide O +
producers O -
. O +

The O +
identification O +
of O +
positions O +
that O +
discriminate O +
between O +
these O +
protein O +
families O +
was O +
followed O +
by O +
fitting O +
six O +
profile O +
HMMs O +
to O +
the O +
data O +
set O +
and O +
the O +
corresponding O +
subsets O -
, O +
to O +
model O +
the O +
conserved O +
regions O +
of O +
the O +
protein O +
types O -
. O +

Ultimately O -
, O +
the O +
profile O +
HMMs O +
described O +
herein O +
predict O +
protein O +
subtypes O +
based O +
on O +
the O +
complete O +
information O -
- O -
rich O +
region O -
; O +
consequently O -
, O +
slight O +
changes O +
in O +
a O +
multiple O +
sequence O +
alignment O +
do O +
not O +
significantly O +
alter O +
the O +
outcome O +
of O +
this O +
classification O +
method O -
. O +

Additionally O -
, O +
Viterbi O +
scores O +
can O +
be O +
used O +
to O +
assess O +
the O +
reliability O +
of O +
the O +
classification O -
. O +

Probing O +
the O +
Mechanism O +
of O +
TBAF B-Chemical -
- O -
Catalyzed O +
Deacylation O +
of O +
Cellulose O +
Esters B-Chemical -
. O +

The O +
mechanism O +
of O +
the O +
recently O +
discovered O -
, O +
unusual O +
tetrabutylammonium B-Chemical +
fluoride I-Chemical +
( O -
TBAF B-Chemical -
) O +
deacylation O +
of O +
cellulose O +
esters O +
has O +
been O +
investigated O +
by O +
methods O +
including O +
kinetic O +
isotope O +
effect O +
( O -
KIE O -
) O +
studies O -
. O +

The O +
secondary O +
KIE O +
( O -
kH O -
/ O -
kD O +
= O +
1.26 O +
± O +
0.04 O -
) O +
measured O +
for O +
deacylation O +
at O +
C-2 O -
/ O -
3 O +
suggests O +
a O +
mechanism O +
involving O +
a O +
ketene O +
intermediate O +
for O +
those O +
positions O -
. O +

An O +
inverse O +
KIE O +
( O -
kH O -
/ O -
kD O +
= O +
0.87 O +
± O +
0.03 O -
) O +
for O +
the O +
deacylation O +
at O +
C-6 O +
indicates O +
the O +
involvement O +
of O +
a O +
tetrahedral O +
intermediate O +
in O +
the O +
mechanism O -
. O +

Additional O +
studies O +
suggest O +
the O +
possibility O +
that O +
TBAF B-Chemical +
chelation O +
by O +
neighboring O +
acyl B-Chemical +
groups O +
may O +
account O +
for O +
the O +
unexpected O +
regioselectivity O +
at O +
the O +
secondary B-Chemical +
alcohol I-Chemical +
esters I-Chemical +
that O +
is O +
observed O +
in O +
the O +
TBAF B-Chemical +
deacylation O +
of O +
cellulose O +
esters B-Chemical -
. O +

Liquid O -
/ O -
Gas O +
and O +
Liquid O -
/ O -
Liquid O +
Phase O +
Equilibria O +
of O +
the O +
System O +
Water O -
/ O -
Bovine O +
Serum O +
Albumin O -
. O +

The O +
thermodynamic O +
behavior O +
of O +
the O +
system O +
H2O B-Chemical -
/ O -
BSA O +
was O +
studied O +
at O +
25 O +
° O -
C O +
within O +
the O +
entire O +
composition O +
range O -
: O +
vapor O +
pressure O +
measurements O +
via O +
head O +
space O +
sampling O +
gas O +
chromatography O +
demonstrate O +
that O +
the O +
attainment O +
of O +
equilibria O +
takes O +
more O +
than O +
one O +
week O -
. O +

A O +
miscibility O +
gap O +
was O +
detected O +
via O +
turbidity O +
and O +
the O +
coexisting O +
phases O +
were O +
analyzed O -
. O +

At O +
6 O +
° O -
C O +
the O +
two O +
phase O +
region O +
extends O +
from O +
ca O -
. O +

34 O +
to O +
40 O +
wt O +
% O +
BSA O +

; O +
it O +
shrinks O +
upon O +
heating O -
. O +

The O +
polymer O +
rich O +
phase O +
is O +
locally O +
ordered O -
, O +
as O +
can O +
be O +
seen O +
under O +
the O +
optical O +
microscope O +
using O +
crossed O +
polarizers O -
. O +

The O +
Flory O -
- O -
Huggins O +
theory O +
turns O +
out O +
to O +
be O +
inappropriate O +
for O +
the O +
modeling O +
of O +
experimental O +
results O -
. O +

A O +
phenomenological O +
expression O +
is O +
employed O +
which O +
uses O +
three O +
adjustable O +
parameters O +
and O +
describes O +
the O +
vapor O +
pressures O +
quantitatively O -
; O +
it O +
also O +
forecasts O +
the O +
existence O +
of O +
a O +
miscibility O +
gap O -
. O +

Monitoring O +
Controlled O +
Release O +
of O +
Payload O +
from O +
Gold O +
Nanocages O +
Using O +
Surface O +
Enhanced O +
Raman O +
Scattering O -
. O +

Novel O +
organic O +
and O +
inorganic O +
nanostructures O +
for O +
localized O +
and O +
externally O +
triggered O +
delivery O +
of O +
therapeutic O +
agents O +
at O +
a O +
target O +
site O +
have O +
received O +
immense O +
attention O +
over O +
the O +
past O +
decade O +
owing O +
to O +
their O +
enormous O +
potential O +
in O +
treating O +
complex O +
diseases O +
such O +
as O +
cancer O -
. O +

Gold O +
nanocages O -
, O +
a O +
novel O +
class O +
of O +
hollow O +
plasmonic O +
nanostructures O -
, O +
have O +
been O +
recently O +
demonstrated O +
to O +
serve O +
as O +
carriers O +
for O +
the O +
delivery O +
of O +
payload O +
with O +
external O +
trigger O +
such O +
as O +
light O +
or O +
ultrasound O -
. O +

In O +
this O +
article O -
, O +
we O +
demonstrate O +
that O +
surface O +
enhanced O +
Raman O +
spectroscopy O +
( O -
SERS O -
) O +
can O +
be O +
employed O +
to O +
noninvasively O +
monitor O +
the O +
release O +
of O +
payload O +
from O +
these O +
hollow O +
plasmonic O +
nanostructures O -
. O +

The O +
large O +
enhancement O +
of O +
electromagnetic O +
( O -
EM O -
) O +
field O +
at O +
the O +
interior O +
surface O +
of O +
these O +
nanostructures O +
enables O +
us O +
to O +
monitor O +
the O +
controlled O +
release O +
of O +
Raman O -
- O -
active O +
cargo O +
from O +
nanocages O -
. O +

Considering O +
that O +
SERS O +
can O +
be O +
excited O +
and O +
collected O +
in O +
near O -
- O -
infrared O +
( O -
NIR O -
) O +
therapeutic O +
window O -
, O +
this O +
technique O +
can O +
serve O +
as O +
a O +
powerful O +
tool O +
to O +
monitor O +
the O +
drug O +
release O +
in O +
vivo O -
, O +
providing O +
additional O +
control O +
over O +
externally O +
triggered O +
drug O +
administration O -
. O +

Carcinogenicity O +
Prediction O +
of O +
Noncongeneric O +
Chemicals O +
by O +
a O +
Support O +
Vector O +
Machine O -
. O +

The O +
ability O +
to O +
identify O +
carcinogenic O +
compounds O +
is O +
of O +
fundamental O +
importance O +
to O +
the O +
safe O +
application O +
of O +
chemicals O -
. O +

In O +
this O +
study O -
, O +
we O +
generated O +
an O +
array O +
of O +
in O +
silico O +
models O +
allowing O +
the O +
classification O +
of O +
compounds O +
into O +
carcinogenic O +
and O +
noncarcinogenic O +
agents O +
based O +
on O +
a O +
data O +
set O +
of O +
852 O +
noncongeneric O +
chemicals O +
collected O +
from O +
the O +
Carcinogenic O +
Potency O +
Database O +
( O -
CPDBAS O -
) O -
. O +

Twenty O -
- O -
four O +
molecular O +
descriptors O +
were O +
selected O +
by O +
Pearson O +
correlation O -
, O +
F O -
- O -
score O -
, O +
and O +
stepwise O +
regression O +
analysis O -
. O +

These O +
descriptors O +
cover O +
a O +
range O +
of O +
physicochemical O +
properties O -
, O +
including O +
electrophilicity O -
, O +
geometry O -
, O +
molecular O +
weight O -
, O +
size O -
, O +
and O +
solubility O -
. O +

The O +
descriptor O +
mutagenic O +
showed O +
the O +
highest O +
correlation O +
coefficient O +
with O +
carcinogenicity O -
. O +

On O +
the O +
basis O +
of O +
these O +
descriptors O -
, O +
a O +
support O +
vector O +
machine O -
- O -
based O +
( O -
SVM O -
) O +
classification O +
model O +
was O +
developed O +
and O +
fine O -
- O -
tuned O +
by O +
a O +
10-fold O +
cross O -
- O -
validation O +
approach O -
. O +

Both O +
the O +
SVM O +
model O +
( O -
Model O +
A1 O -
) O +
and O +
the O +
best O +
model O +
from O +
the O +
10-fold O +
cross O -
- O -
validation O +
( O -
Model O +
B3 O -
) O +
runs O +
gave O +
good O +
results O +
on O +
the O +
test O +
set O +
with O +
prediction O +
accuracy O +
over O +
80 O -
% O -
, O +
sensitivity O +
over O +
76 O -
% O -
, O +
and O +
specificity O +
over O +
82 O -
% O -
. O +

In O +
addition O -
, O +
extended O +
connectivity O +
fingerprints O +
( O -
ECFPs O -
) O +
and O +
the O +
Toxtree O +
software O +
were O +
used O +
to O +
analyze O +
the O +
functional O +
groups O +
and O +
substructures O +
linked O +
to O +
carcinogenicity O -
. O +

It O +
was O +
found O +
that O +
the O +
results O +
of O +
both O +
methods O +
are O +
in O +
good O +
agreement O -
. O +

Monoacylglycerol B-Chemical +
lipase O +
inhibition O -
- O -
induced O +
changes O +
in O +
plasma O +
corticosterone B-Chemical +
levels O -
, O +
anxiety O +
and O +
locomotor O +
activity O +
in O +
male O +
CD1 O +
mice O -
. O +

The O +
hypothalamus O -
- O -
pituitary O -
- O -
adrenal O -
- O -
axis O +
is O +
strongly O +
controlled O +
by O +
the O +
endocannabinoid O +
system O -
. O +

The O +
specific O +
impact O +
of O +
enhanced O +
2-arachidonoylglycerol B-Chemical +
signaling O +
on O +
corticosterone B-Chemical +
plasma O +
levels O -
, O +
however O -
, O +
was O +
not O +
investigated O +
so O +
far O -
. O +

Here O +
we O +
studied O +
the O +
effects O +
of O +
the O +
recently O +
developed O +
monoacylglycerol B-Chemical +
lipase O +
inhibitor O +
JZL184 B-Chemical +
on O +
basal O +
and O +
stress O -
- O -
induced O +
corticosterone B-Chemical +
levels O +
in O +
male O +
CD1 O +
mice O -
, O +
and O +
found O +
that O +
this O +
compound O +
dramatically O +
increased O +
basal O +
levels O +
without O +
affecting O +
stress O +
responses O -
. O +

Since O +
acute O +
changes O +
in O +
corticosterone B-Chemical +
levels O +
can O +
affect O +
behavior O -
, O +
JZL184 B-Chemical +
was O +
administered O +
concurrently O +
with O +
the O +
corticosterone B-Chemical +
synthesis O +
inhibitor O +
metyrapone B-Chemical -
, O +
to O +
investigate O +
whether O +
the O +
previously O +
shown O +
behavioral O +
effects O +
of O +
JZL184 B-Chemical +
are O +
dependent O +
on O +
corticosterone B-Chemical -
. O +

We O +
found O +
that O +
in O +
the O +
elevated O +
plus O -
- O -
maze O -
, O +
the O +
effects O +
of O +
JZL184 B-Chemical +
on O +
" O -
classical O -
" O +
anxiety O -
- O -
related O +
measures O +
were O +
abolished O +
by O +
corticosterone B-Chemical +
synthesis O +
blockade O -
. O +

By O +
contrast O -
, O +
effects O +
on O +
the O +
" O -
ethological O -
" O +
measures O +
of O +
anxiety O +
( O -
i.e. O +
risk O +
assessment O -
) O +
were O +
not O +
affected O +
by O +
metyrapone B-Chemical -
. O +

In O +
the O +
open O -
- O -
field O -
, O +
the O +
locomotion O -
- O -
enhancing O +
effects O +
of O +
the O +
compound O +
were O +
not O +
changed O +
either O -
. O +

These O +
findings O +
show O +
that O +
monoacylglycerol B-Chemical +
lipase O +
inhibition O +
dramatically O +
increases O +
basal O +
levels O +
of O +
corticosterone B-Chemical -
. O +

This O +
endocrine O +
effect O +
partly O +
affects O +
the O +
anxiolytic O -
, O +
but O +
not O +
the O +
locomotion O -
- O -
enhancing O +
effects O +
of O +
monoacylglycerol B-Chemical +
lipase O +
blockade O -
. O +

Effect O +
of O +
N B-Chemical -
- I-Chemical -
acetyl I-Chemical +
cysteine I-Chemical +
( O -
NAC B-Chemical -
) O -
, O +
an O +
organosulfur B-Chemical +
compound O +
from O +
Allium O +
plants O -
, O +
on O +
experimentally O +
induced O +
hepatic O +
prefibrogenic O +
events O +
in O +
wistar O +
rat O -
. O +

Aim O +
of O +
present O +
study O +
was O +
to O +
investigate O +
the O +
effect O +
of O +
NAC B-Chemical +
on O +
experimental O +
chronic O +
hepatotoxicity O +
models O +
induced O +
by O +
carbon B-Chemical +
tetrachloride I-Chemical +
( O -
CCl4 B-Chemical -
) O +
and O +
thioacetamide B-Chemical +
( O -
TAA B-Chemical -
) O -
. O +

CCl4 O +
toxicity O +
was O +
induced O +
by O +
administering O +
200μl O +
CCl4 B-Chemical +
( O -
diluted O +
2:3 O +
in O +
coconut O +
oil O -
) O -
/ O -
100 O -
g O +
body O +
weight O -
, O +
p.o O -
. O -
, O +
twice O +
weekly O +
for O +
8 O +
weeks O -
. O +

TAA B-Chemical +
toxicity O +
was O +
induced O +
by O +
administering O +
150mg O -
/ O -
kg O +
b. O +
wt O -
. O +
of O +
TAA B-Chemical +
i.p O -
. O -
, O +
twice O +
weekly O +
for O +
8 O +
weeks O -
. O +

NAC B-Chemical +
treatment O +
was O +
started O +
along O +
with O +
toxicants O +
( O -
CCl4 B-Chemical +
and O +
TAA B-Chemical -
) O +
for O +
8 O +
weeks O +
and O +
continued O +
for O +
further O +
4 O +
weeks O -
. O +

Self O +
reversal O +
group O +
was O +
kept O +
without O +
any O +
treatment O +
for O +
4 O +
weeks O +
after O +
completion O +
of O +
toxicant O +
treatments O -
. O +

Alanine B-Chemical +
aminotransferase O +
( O -
ALT O -
) O -
, O +
Aspartate B-Chemical +
aminotransferase O +
( O -
AST O -
) O -
, O +
Alkaline O +
phosphatase O +
( O -
ALP O -
) O -
, O +
Bilirubin B-Chemical +
were O +
measured O +
in O +
serum O -
. O +

Hydroxyproline B-Chemical +
( O -
HP O -
) O -
, O +
lipid O +
peroxidation O +
( O -
LPO O -
) O -
, O +
catalase O +
( O -
CAT O -
) O -
, O +
Glutathione B-Chemical +
peroxidase O +
( O -
GPx O -
) O +
and O +
Glutathione B-Chemical +
( O -
GSH B-Chemical -
) O +
were O +
determined O +
in O +
liver O +
samples O +
by O +
colorimetric O +
methods O -
. O +

Cytochrome O +
P450 O +
2E1 O +
( O -
CYP O +
450 O +
2E1 O -
) O -
, O +
activity O +
was O +
determined O +
as O +
hydroxylation O +
of O +
aniline B-Chemical +
in O +
liver O +
microsomes O -
. O +

General O +
examination O +
and O +
histological O +
analysis O +
were O +
also O +
performed O -
. O +

Serum O +
markers O +
of O +
liver O +
damage O +
( O -
AST O -
, O +
ALT O -
, O +
ALP O +
and O +
Bilirubin B-Chemical -
) O +
were O +
increased O +
by O +
CCl4 B-Chemical +
and O +
TAA B-Chemical +
intoxication O +
( O -
p<0.001 O -
) O -
, O +
whereas O +
co O -
- O -
treatment O +
with O +
NAC B-Chemical +
reversed O +
such O +
changes O +
( O -
p<0.001 O -
) O -
. O +

HP O +
was O +
enhanced O +
in O +
toxicant O +
groups O +
( O -
p<0.001 O +
in O +
CCl4 B-Chemical +
and O +
TAA B-Chemical -
) O -
, O +
but O +
inhibited O +
by O +
NAC B-Chemical +
( O -
p<0.001 O -
) O -
. O +

LPO O +
was O +
increased O +
while O +
as O +
GSH B-Chemical -
, O +
CAT O +
and O +
GPx O +
decreased O +
by O +
the O +
administration O +
of O +
CCl4 O +
and O +
TAA O +
( O -
p<0.001 O -
) O -
; O +
co O -
- O -
administration O +
of O +
NAC B-Chemical +
restored O +
these O +
liver O +
markers O +
to O +
normal O +
levels O +
( O -
p<0.001 O -
) O -
. O +

Biochemical O +
determinations O +
were O +
corroborated O +
by O +
general O +
and O +
histological O +
findings O -
. O +

Keeping O +
in O +
view O +
the O +
biochemical O +
and O +
histopathological O +
studies O -
, O +
it O +
was O +
concluded O +
that O +
CCl4 B-Chemical +
and O +
TAA B-Chemical +
are O +
strong O +
hepatotoxic O +
agents O +
that O +
produce O +
liver O +
fibrosis O +
with O +
close O +
proximity O +
to O +
human O +
etiology O +
( O -
micronodular O +
cirrhosis O -
) O +
and O +
NAC B-Chemical +
has O +
a O +
significant O +
protective O +
activity O +
against O +
CCl4 B-Chemical +
and O +
TAA B-Chemical -
. O +

NAC B-Chemical +
has O +
also O +
been O +
validated O +
as O +
a O +
model O +
against O +
oxidative O +
burden O +
in O +
chronic O +
liver O +
pathology O -
. O +

Pancreatic O +
beta O -
- O -
cell O +
response O +
to O +
increased O +
metabolic O +
demand O +
and O +
to O +
pharmacologic O +
secretagogues O +
requires O +
EPAC2A O -
. O +

Incretin O +
hormone O +
action O +
on O +
ß O -
- O -
cells O +
stimulates O +
in O +
parallel O +
two O +
different O +
intracellular O +
cyclic B-Chemical +
AMP I-Chemical -
- O -
dependent O +
signaling O +
branches O +
mediated O +
by O +
PKA O +
and O +
EPAC2A O -
. O +

Both O +
pathways O +
contribute O +
towards O +
potentiation O +
of O +
glucose B-Chemical -
- O -
stimulated O +
insulin O +
secretion O +
( O -
GSIS O -
) O -
. O +

However O -
, O +
the O +
overall O +
functional O +
role O +
of O +
EPAC2A O +
in O +
ß O -
- O -
cells O +
as O +
it O +
relates O +
to O +
in O +
vivo O +
glucose B-Chemical +
homeostasis O +
remains O +
incompletely O +
understood O -
. O +

Therefore O -
, O +
we O +
have O +
examined O +
in O +
vivo O +
GSIS O +
in O +
global O +
EPAC2A O +
knockout O +
mice O -
. O +

Additionally O -
, O +
we O +
have O +
conducted O +
in O +
vitro O +
studies O +
of O +
GSIS O +
and O +
calcium B-Chemical +
dynamics O +
in O +
isolated O +
EPAC2A O -
- O -
deficient O +
islets O -
. O +

EPAC2A O +
deficiency O +
does O +
not O +
impact O +
glucose B-Chemical -
- O -
stimulated O +
insulin O +
secretion O +
in O +
mice O +
under O +
basal O +
conditions O -
. O +

However O -
, O +
when O +
mice O +
are O +
exposed O +
to O +
diet O -
- O -
induced O +
insulin O +
resistance O -
, O +
pharmacologic O +
secretagogue O +
stimulation O +
of O +
ß O -
- O -
cells O +
with O +
an O +
incretin O +
hormone O +
glucagon O -
- O -
like O +
peptide-1 O +
analogue O +
or O +
with O +
a O +
Fatty B-Chemical +
Acid I-Chemical +
Receptor O +
1 O -
/ O -
GPR40 O +
selective O +
activator O -
, O +
EPAC2A O +
is O +
required O +
for O +
the O +
increased O +
ß O -
- O -
cell O +
response O +
to O +
secretory O +
demand O -
. O +

Under O +
these O +
circumstances O -
, O +
EPAC2A O +
is O +
required O +
for O +
potentiating O +
the O +
early O +
dynamic O +
increase O +
in O +
islet O +
calcium B-Chemical +
levels O +
after O +
glucose B-Chemical +
stimulation O -
, O +
which O +
is O +
reflected O +
in O +
potentiated O +
first O +
phase O +
insulin O +
secretion O -
. O +

These O +
studies O +
broaden O +
our O +
understanding O +
of O +
EPAC2A O +
function O +
and O +
highlight O +
its O +
significance O +
during O +
increased O +
secretory O +
demand O +
or O +
drive O +
on O +
ß O -
- O -
cells O -
. O +

Our O +
findings O +
advance O +
the O +
rationale O +
for O +
developing O +
EPAC2A O +
selective O +
pharmacologic O +
activators O +
for O +
ß O -
- O -
cell O +
targeted O +
pharmacotherapy O +
in O +
type O +
2 O +
diabetes O +
mellitus O -
. O +

Salicylic B-Chemical +
acid I-Chemical +
alleviates O +
copper B-Chemical +
toxicity O +
in O +
rice O +
( O -
Oryza O +
sativa O +
L. O -
) O +
seedlings O +
by O +
up O -
- O -
regulating O +
antioxidative O +
and O +
glyoxalase O +
systems O -
. O +

The O +
present O +
study O +
investigated O +
the O +
effect O +
of O +
salicylic B-Chemical +
acid I-Chemical +
( O -
SA O -
) O +
on O +
toxic O +
symptoms O -
, O +
lipid O +
peroxidation O -
, O +
reactive O +
oxygen B-Chemical +
species O +
generation O +
and O +
responses O +
of O +
antioxidative O +
and O +
glyoxalase O +
systems O +
in O +
rice O +
seedlings O +
grown O +
hydroponically O +
under O +
copper B-Chemical +
( O -
Cu B-Chemical -
) O +
stress O +
for O +
48 O +
h. O +
Exposures O +
of O +
75 O +
and O +
150 O +
μM O +
Cu B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
caused O +
toxicity O +
symptoms O +
( O -
chlorosis O -
, O +
necrosis O +
and O +
rolling O +
in O +
leaves O -
) O -
, O +
sharp O +
increases O +
in O +
malondialdehyde B-Chemical +
( O -
MDA B-Chemical -
) O -
, O +
hydrogen B-Chemical +
peroxide I-Chemical +
( O -
H2O2 B-Chemical -
) O +
contents O +
and O +
lipoxygenase O +
( O -
LOX O -
) O +
activity O +
with O +
concomitant O +
reductions O +
of O +
chlorophyll O +
( O -
Chl O -
) O +
and O +
relative O +
water O +
content O +
( O -
RWC O -
) O -
. O +

Both O +
levels O +
of O +
Cu B-Chemical +
decreased O +
ascorbic B-Chemical +
acid I-Chemical +
( O -
AsA B-Chemical -
) O -
, O +
glutathione B-Chemical +
( O -
GSH B-Chemical -
) O -
, O +
non O -
- O -
protein O +
thiol B-Chemical +
( O -
NPT O -
) O +
and O +
proline B-Chemical +
contents O +
in O +
roots O +
but O +
rather O +
increased O +
in O +
leaves O +
except O +
that O +
AsA B-Chemical +
decreased O +
in O +
leaves O +
too O -
. O +

These O +
results O +
together O +
with O +
overaccumulation O +
of O +
superoxide B-Chemical +
( O -
O B-Chemical +
2 I-Chemical +
( I-Chemical -
•- I-Chemical -
) I-Chemical +
) O +
and O +
H2O2 B-Chemical +
in O +
leaves O +
revealed O +
that O +
Cu B-Chemical +
exposures O +
induced O +
oxidative O +
stress O -
. O +

Contrary O -
, O +
SA O -
- O -
pretreatment O +
( O -
100 O +
μM O +
for O +
24 O +
h O -
) O +
reduced O +
toxicity O +
symptoms O +
and O +
diminished O +
Cu B-Chemical -
- O -
induced O +
increases O +
in O +
LOX O +
activity O -
, O +
H2O2 B-Chemical -
, O +
MDA B-Chemical +
and O +
proline B-Chemical +
contents O +
while O +
the O +
levels O +
of O +
RWC O -
, O +
Chl O -
, O +
AsA B-Chemical +
and O +
redox O +
ratios O +
were O +
elevated O -
. O +

Higher O +
levels O +
of O +
GSH B-Chemical +
and O +
NPT O +
were O +
also O +
observed O +
in O +
roots O +
of O +
SA O -
- O -
pretreated O +
Cu B-Chemical -
- O -
exposed O +
seedlings O -
. O +

SA O -
- O -
pretreatment O +
also O +
exerted O +
its O +
beneficial O +
role O +
by O +
inhibiting O +
the O +
Cu B-Chemical +
upward O +
process O -
. O +

Studies O +
on O +
antioxidant O +
enzymes O +
showed O +
that O +
SA O +
further O +
enhanced O +
the O +
activities O +
of O +
superoxide B-Chemical +
dismutase O -
, O +
ascorbate B-Chemical +
peroxidase O -
, O +
glutathione B-Chemical +
reductase O +
and O +
glutathione B-Chemical +
peroxidase O -
, O +
and O +
also O +
elevated O +
the O +
depressed O +
activities O +
of O +
catalase O -
, O +
dehydroascorbate B-Chemical +
reductase O +
and O +
glutathione B-Chemical +
S O -
- O -
transferase O +
particularly O +
at O +
150 O +
μM O +
Cu B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
stress O -
. O +

In O +
addition O -
, O +
the O +
activity O +
of O +
glyoxalase O +
system O +
( O -
glyoxalase O +
I O +
and O +
II O -
) O +
was O +
further O +
elevated O +
by O +
SA O +
pretreatment O +
in O +
the O +
Cu B-Chemical -
- O -
exposed O +
seedlings O -
. O +

These O +
results O +
concluded O +
that O +
SA O -
- O -
mediated O +
retention O +
of O +
Cu B-Chemical +
in O +
roots O +
and O +
enhanced O +
capacity O +
of O +
both O +
antioxidative O +
and O +
glyoxalase O +
systems O +
might O +
be O +
associated O +
with O +
the O +
alleviation O +
of O +
Cu B-Chemical -
- O -
toxicity O +
in O +
rice O +
seedlings O -
. O +

Endowing O +
carbon B-Chemical +
nanotubes O +
with O +
superparamagnetic O +
properties O -
: O +
applications O +
for O +
cell O +
labeling O -
, O +
MRI O +
cell O +
tracking O +
and O +
magnetic O +
manipulations O -
. O +

Coating O +
of O +
carbon B-Chemical +
nanotubes O +
( O -
CNTs O -
) O +
with O +
magnetic O +
nanoparticles O +
( O -
NPs O -
) O +
imparts O +
novel O +
magnetic O -
, O +
optical O -
, O +
and O +
thermal O +
properties O +
with O +
potential O +
applications O +
in O +
the O +
biomedical O +
domain O -
. O +

Multi O -
- O -
walled O +
CNTs O +
have O +
been O +
decorated O +
with O +
iron B-Chemical +
oxide I-Chemical +
superparamagnetic O +
NPs O -
. O +

Two O +
different O +
approaches O +
have O +
been O +
investigated O +
based O +
on O +
ligand O +
exchange O +
or O +
" O -
click O +
chemistry O -
" O -
. O +

The O +
presence O +
of O +
the O +
NPs O +
on O +
the O +
nanotube O +
surface O +
allows O +
conferring O +
magnetic O +
properties O +
to O +
CNTs O -
. O +

We O +
have O +
evaluated O +
the O +
potential O +
of O +
the O +
NP O -
/ O -
CNT O +
hybrids O +
as O +
a O +
contrast O +
agent O +
for O +
magnetic O +
resonance O +
imaging O +
( O -
MRI O -
) O +
and O +
their O +
interactions O +
with O +
cells O -
. O +

The O +
capacity O +
of O +
the O +
hybrids O +
to O +
magnetically O +
monitor O +
and O +
manipulate O +
cells O +
has O +
also O +
been O +
investigated O -
. O +

The O +
NP O -
/ O -
CNTs O +
can O +
be O +
manipulated O +
by O +
a O +
remote O +
magnetic O +
field O +
with O +
enhanced O +
contrast O +
in O +
MRI O -
. O +

They O +
are O +
internalized O +
into O +
tumor O +
cells O +
without O +
showing O +
cytotoxicity O -
. O +

The O +
labeled O +
cells O +
can O +
be O +
magnetically O +
manipulated O +
as O +
they O +
display O +
magnetic O +
mobility O +
and O +
are O +
detected O +
at O +
a O +
single O +
cell O +
level O +
through O +
high O +
resolution O +
MRI O -
. O +

The O +
lack O +
of O +
association O +
between O +
components O +
of O +
metabolic O +
syndrome O +
and O +
treatment O +
resistance O +
in O +
depression O -
. O +

RATIONALE O -
: O +
Although O +
a O +
number O +
of O +
studies O +
investigated O +
the O +
link O +
between O +
major O +
depressive O +
disorder O +
( O -
MDD O -
) O +
and O +
metabolic O +
syndrome O +
( O -
MetS O -
) O -
, O +
the O +
association O +
between O +
MetS O +
and O +
treatment O -
- O -
resistant O +
depression O +
( O -
TRD O -
) O +
is O +
still O +
not O +
clear O -
. O +

OBJECTIVES O -
: O +
The O +
aim O +
of O +
the O +
study O +
was O +
to O +
investigate O +
the O +
relationship O +
between O +
TRD O +
and O +
MetS O +
and/or O +
components O +
of O +
MetS O +
and O +
cardiovascular O +
risk O +
factors O -
. O +

Given O +
the O +
high O +
prevalence O +
of O +
both O +
conditions O -
, O +
the O +
hypothesis O +
was O +
that O +
TRD O +
would O +
be O +
significantly O +
associated O +
with O +
MetS. O +
METHODS O -
: O +
This O +
cross O -
- O -
sectional O +
study O +
included O +
203 O +
inpatients O +
with O +
MDD O -
, O +
assessed O +
for O +
the O +
treatment O +
resistance O -
, O +
MetS O +
and O +
its O +
components O -
, O +
and O +
severity O +
of O +
MDD O -
. O +

Diagnoses O +
and O +
evaluations O +
were O +
made O +
with O +
SCID O +
based O +
on O +
DSM O -
- O -
IV O -
, O +
National O +
Cholesterol B-Chemical +
Education O +
Program O +
Adult O +
Treatment O +
Panel O +
III O +
criteria O -
, O +
and O +
the O +
Hamilton O +
Depression O +
Rating O +
Scale O -
. O +

RESULTS O -
: O +
TRD O +
prior O +
to O +
study O +
entry O +
was O +
found O +
in O +
26.1 O +
% O +
of O +
patients O -
, O +
while O +
MetS O +
was O +
observed O +
in O +
33.5 O +
% O +
of O +
patients O -
. O +

The O +
prevalence O +
of O +
MetS O +
did O +
not O +
differ O +
significantly O +
between O +
TRD O +
and O +
non O -
- O -
TRD O +
patients O -
. O +

In O +
addition O -
, O +
the O +
frequency O +
of O +
the O +
altered O +
values O +
of O +
particular O +
components O +
of O +
the O +
MetS O +
or O +
cardiovascular O +
risk O +
factors O +
was O +
not O +
associated O +
with O +
treatment O +
resistance O +
in O +
depressed O +
patients O -
. O +

Patients O +
with O +
TRD O +
were O +
older O -
, O +
had O +
a O +
higher O +
number O +
of O +
lifetime O +
episodes O +
of O +
depression O +
and O +
suicide O +
attempts O -
, O +
and O +
longer O +
duration O +
of O +
MDD O +
compared O +
to O +
non O -
- O -
TRD O +
patients O -
. O +

CONCLUSIONS O -
: O +
The O +
occurrence O +
of O +
either O +
MetS O +
or O +
the O +
particular O +
components O +
of O +
the O +
MetS O +
and O +
other O +
cardiovascular O +
risk O +
factors O +
was O +
similar O +
between O +
TRD O +
and O +
non O -
- O -
TRD O +
patients O -
. O +

Although O +
there O +
is O +
a O +
bidirectional O +
relationship O +
between O +
depression O +
and O +
MetS O -
, O +
neither O +
MetS O +
nor O +
its O +
components O +
appear O +
to O +
influence O +
treatment O +
resistance O +
to O +
antidepressants O -
. O +

Application O +
of O +
Ultra O -
- O -
Performance O +
Liquid O +
Chromatography O -
/ O -
Mass O +
Spectrometry O -
- O -
Based O +
Metabonomic O +
Techniques O +
to O +
Analyze O +
the O +
Joint O +
Toxic O +
Action O +
of O +
Long O -
- O -
Term O +
Low O -
- O -
Level O +
Exposure O +
to O +
a O +
Mixture O +
of O +
Organophosphate B-Chemical +
Pesticides O +
on O +
Rat O +
Urine O +
Profile O -
. O +

In O +
previously O +
published O +
articles O -
, O +
we O +
evaluated O +
the O +
toxicity O +
of O +
four O +
organophosphate B-Chemical +
( O -
OP O -
) O +
pesticides O +
( O -
dichlorvos B-Chemical -
, O +
dimethoate B-Chemical -
, O +
acephate B-Chemical +
and O +
phorate B-Chemical -
) O +
to O +
rats O +
using O +
metabonomic O +
technology O +
at O +
their O +
corresponding O +
no O +
observed O +
adverse O +
effect O +
level O +
( O -
NOAEL O -
) O -
. O +

Results O +
show O +
that O +
a O +
single O +
pesticide O +
elicits O +
no O +
toxic O +
response O -
. O +

The O +
present O +
study O +
aimed O +
to O +
determine O +
whether O +
chronic O +
exposure O +
to O +
a O +
mixture O +
of O +
the O +
above O +
four O +
pesticides O +
( O -
at O +
their O +
corresponding O +
NOAEL O -
) O +
can O +
lead O +
to O +
joint O +
toxic O +
action O +
in O +
rats O +
using O +
the O +
same O +
technology O -
. O +

Pesticides O +
were O +
administered O +
daily O +
to O +
rats O +
through O +
drinking O +
water O +
for O +
24 O +
weeks O -
. O +

The O +
above O +
mixture O +
of O +
the O +
four O +
pesticides O +
showed O +
joint O +
toxic O +
action O +
at O +
the O +
NOAEL O +
of O +
each O +
pesticide O -
. O +

The O +
metabonomic O +
profiles O +
of O +
rats O +
urine O +
were O +
analyzed O +
by O +
ultra O -
- O -
performance O +
liquid O +
chromatography O -
/ O -
mass O +
spectrometry O -
. O +

The O +
16 O +
metabolites O +
statistically O +
significantly O +
changed O +
in O +
all O +
treated O +
groups O +
compared O +
with O +
the O +
control O +
group O -
. O +

Dimethylphosphate B-Chemical +
and O +
dimethyldithiophosphate B-Chemical +
exclusively O +
detected O +
in O +
all O +
treated O +
groups O +
can O +
be O +
used O +
as O +
early O -
, O +
sensitive O +
biomarkers O +
for O +
exposure O +
to O +
a O +
mixture O +
of O +
the O +
OP O +
pesticides O -
. O +

Moreover O -
, O +
exposure O +
to O +
the O +
OP O +
pesticides O +
resulted O +
in O +
increased O +
7-methylguanine B-Chemical -
, O +
ribothymidine B-Chemical -
, O +
cholic B-Chemical +
acid I-Chemical -
, O +
4-pyridoxic B-Chemical +
acid I-Chemical -
, O +
kynurenine B-Chemical +
and O +
indoxyl B-Chemical +
sulfate I-Chemical +
levels O -
, O +
as O +
well O +
as O +
decreased O +
hippuric B-Chemical +
acid I-Chemical -
, O +
creatinine B-Chemical -
, O +
uric B-Chemical +
acid I-Chemical -
, O +
gentisic B-Chemical +
acid I-Chemical -
, O +
C18-dihydrosphingosine B-Chemical -
, O +
phytosphingosine B-Chemical -
, O +
suberic B-Chemical +
acid I-Chemical +
and O +
citric B-Chemical +
acid I-Chemical -
. O +

The O +
results O +
indicated O +
that O +
a O +
mixture O +
of O +
OP O +
pesticides O +
induced O +
DNA O +
damage O -
, O +
oxidative O +
stress O -
, O +
disturbed O +
the O +
metabolism O +
of O +
lipids O +
as O +
well O +
as O +
interfered O +
with O +
the O +
tricarboxylic B-Chemical +
acid I-Chemical +
cycle O -
. O +

Ensuring O +
food O +
safety O +
requires O +
not O +
only O +
the O +
toxicology O +
test O +
data O +
of O +
each O +
pesticide O +
for O +
the O +
calculation O +
of O +
the O +
acceptable O +
daily O +
intake O -
, O +
but O +
also O +
the O +
joint O +
toxic O +
action O -
. O +

Anti O -
- O -
Ulcerative O +
Colitis O +
Activity O +
of O +
Compounds O +
from O +
Euphorbia O +
granuleta O +
Forssk O -
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
evaluate O +
the O +
anti O -
- O -
ulcerative O +
colitis O +
( O -
UC O -
) O +
activity O +
of O +
the O +
total O +
alcohol B-Chemical +
extracts O +
of O +
Euphorbia O +
granuleta O +
Forssk O -
. O +

( O -
Euphorpiaceae O -
) O -
, O +
isolate O +
and O +
identify O +
the O +
active O +
compounds O +
that O +
could O +
be O +
responsible O +
for O +
the O +
activity O -
, O +
in O +
addition O +
to O +
determination O +
of O +
the O +
possible O +
mechanism O +
of O +
action O -
. O +

Six O +
compounds O +
were O +
isolated O +
and O +
identified O +
from O +
this O +
plant O -
: O +
three O +
phenolic B-Chemical +
compounds O +
( O -
kampferol B-Chemical -
, O +
kampferol-3-glucoside B-Chemical +
and O +
kampferol-3-galactoside B-Chemical -
) O +
in O +
addition O +
to O +
three O +
steroidal O +
compounds O +
( O -
1-ethoxypentacosane B-Chemical -
, O +
heptacosan-1-ol B-Chemical +
and O +
β B-Chemical -
- I-Chemical -
sitosterol I-Chemical -
) O -
. O +

Three O +
compounds O +
( O -
heptacosan-1-ol B-Chemical -
, O +
β B-Chemical -
- I-Chemical -
sitosterol I-Chemical +
and O +
kampferol-3-galactoside B-Chemical -
) O +
were O +
found O +
to O +
be O +
responsible O +
for O +
the O +
anti O -
- O -
UC O +
activity O +
of O +
E. O +
granuleta O +
extract O -
. O +

The O +
anti O -
- O -
UC O +
activity O +
of O +
these O +
compounds O +
may O +
be O +
explained O +
by O +
reducing O +
the O +
pro O -
- O -
inflammatory O +
cytokine O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O -
TNF O -
- O -
α O -
) O -
, O +
in O +
addition O +
to O +
reduction O +
of O +
colonic O +
malondialdehyde B-Chemical +
( O -
MDA B-Chemical -
) O +
contents O -
. O +

No O +
side O +
effects O +
were O +
reported O +
on O +
liver O +
and O +
kidney O +
functions O -
. O +

The O +
active O +
compounds O +
reduced O +
both O +
serum O +
TNF O -
- O -
α O +
and O +
mucosal O +
MDA B-Chemical +
levels O -
. O +

Copyright O +
© O +
2013 O +
John O +
Wiley O +
& O +
Sons O -
, O +
Ltd. O +

Decursin B-Chemical +
Exerts O +
Anti O -
- O -
cancer O +
Activity O +
in O +
MDA O -
- O -
MB-231 O +
Breast O +
Cancer O +
Cells O +
Via O +
Inhibition O +
of O +
the O +
Pin1 O +
Activity O +
and O +
Enhancement O +
of O +
the O +
Pin1 O -
/ O -
p53 O +
Association O -
. O +

The O +
peptidyl O -
- O -
prolyl B-Chemical +
cis O -
/ O -
trans O +
isomerase O +
Pin1 O +
is O +
overexpressed O +
in O +
a O +
wide O +
variety O +
of O +
cancer O +
cells O +
and O +
thus O +
considered O +
as O +
an O +
important O +
target O +
molecule O +
for O +
cancer O +
therapy O -
. O +

This O +
study O +
demonstrates O +
that O +
decursin B-Chemical -
, O +
a O +
bioactive O +
compound O +
from O +
Angelica O +
gigas O -
, O +
exert O +
the O +
anti O -
- O -
cancer O +
effect O +
against O +
breast O +
cancer O +
cells O +
via O +
regulation O +
of O +
Pin1 O +
and O +
its O +
related O +
signaling O +
molecules O -
. O +

We O +
observed O +
that O +
decursin B-Chemical +
induced O +
G1 O +
arrest O +
with O +
decrease O +
in O +
cyclin O +
D1 O +
level O +
in O +
Pin1-expressing O +
breast O +
cancer O +
cells O +
MDA O -
- O -
MB-231 O -
, O +
but O +
not O +
Pin1-non O -
- O -
expressing O +
breast O +
cancer O +
cells O +
MDA O -
- O -
MB-157 O -
. O +

In O +
addition O -
, O +
decursin B-Chemical +
significantly O +
reduced O +
protein O +
expression O +
and O +
enzymatic O +
activity O +
of O +
Pin1 O +
in O +
MDA O -
- O -
MB-231 O +
cells O -
. O +

Further O -
, O +
we O +
found O +
that O +
decursin B-Chemical +
treatment O +
enhanced O +
the O +
p53 O +
expression O +
level O +
and O +
failed O +
to O +
down O -
- O -
regulate O +
Pin1 O +
in O +
the O +
cells O +
transfected O +
with O +
p53 O +
siRNA O -
, O +
indicating O +
the O +
importance O +
of O +
p53 O +
in O +
the O +
decursin B-Chemical -
- O -
mediated O +
Pin1 O +
inhibition O +
in O +
MDA O -
- O -
MB-231 O +
cells O -
. O +

Decursin B-Chemical +
stimulated O +
association O +
between O +
Pin1 O +
to O +
p53 O -
. O +

Moreover O -
, O +
decursin B-Chemical +
facilitated O +
p53 O +
transcription O +
in O +
MDA O -
- O -
MB-231 O +
cells O -
. O +

Overall O -
, O +
our O +
current O +
study O +
suggests O +
the O +
potential O +
of O +
decursin B-Chemical +
as O +
an O +
attractive O +
cancer O +
therapeutic O +
agent O +
for O +
breast O +
cancer O +
by O +
targeting O +
Pin1 O +
protein O -
. O +

Copyright O +
© O +
2013 O +
John O +
Wiley O +
& O +
Sons O -
, O +
Ltd. O +

Pharmacological O +
Inhibition O +
of O +
Platelet O -
- O -
tumor O +
Cell O +
Cross O -
- O -
talk O +
Prevents O +
Platelet O -
- O -
induced O +
Overexpression O +
of O +
Cyclooxygenase-2 O +
in O +
HT29 O +
Human O +
Colon O +
Carcinoma O +
Cells O -
. O +

Cyclooxygenase O -
( O -
COX O -
) O -
-2-derived O +
prostanoids B-Chemical +
can O +
influence O +
several O +
processes O +
that O +
are O +
linked O +
to O +
carcinogenesis O -
. O +

We O +
aimed O +
to O +
address O +
the O +
hypothesis O +
that O +
platelets O +
contribute O +
to O +
aberrant O +
COX-2 O +
expression O +
in O +
HT29 O +
colon O +
carcinoma O +
cells O +
and O +
to O +
reveal O +
the O +
role O +
of O +
platelet O -
- O -
induced O +
COX-2 O +
on O +
the O +
expression O +
of O +
proteins O +
involved O +
in O +
malignancy O +
and O +
marker O +
genes O +
of O +
epithelial O -
- O -
mesenchymal O +
transition O -
( O -
EMT O -
) O -
. O +

Human O +
platelets O +
co O -
- O -
cultured O +
with O +
HT29 O +
cells O +
rapidly O +
adhered O +
to O +
cancer O +
cells O +
and O +
induced O +
COX-2 O +
mRNA O +
expression O -
, O +
but O +
not O +
protein O +
synthesis O +
which O +
required O +
the O +
late O +
release O +
of O +
platelet O +
PDGF O +
and O +
COX-2 O +
mRNA O +
stabilization O -
. O +

Platelet O -
- O -
induced O +
COX-2-dependent O +
PGE2 B-Chemical +
synthesis O +
in O +
HT29 O +
cells O +
was O +
involved O +
in O +
downregulation O +
of O +
p21 O -
( O -
WAF1 O -
/ O -
CIP1 O -
) O +
and O +
upregulation O +
of O +
cyclinB1 O -
, O +
since O +
these O +
effects O +
were O +
prevented O +
by O +
rofecoxib B-Chemical -
( O -
a O +
selective O +
COX-2 O +
inhibitor O -
) O +
and O +
rescued O +
by O +
exogenous O +
PGE2 B-Chemical -
. O +

Galectin-3 O -
, O +
highly O +
expressed O +
in O +
HT29 O +
cells O -
, O +
is O +
unique O +
among O +
galectins O +
because O +
it O +
contains O +
a O +
collagen O -
- O -
like O +
domain O -
. O +

Thus O -
, O +
we O +
studied O +
the O +
role O +
of O +
galectin-3 O +
and O +
platelet O +
collagen O +
receptors O +
in O +
platelet O -
- O -
induced O +
COX-2 O +
overexpression O -
. O +

Inhibitors O +
of O +
galectin-3 O +
function O -
( O -
β B-Chemical -
- I-Chemical -
lactose I-Chemical -
, O +
a O +
dominant O -
- O -
negative O +
form O +
of O +
galectin-3,Gal-3C O -
, O +
and O +
anti O -
- O -
galectin-3 O +
antibody O +
M3 O -
/ O -
38 O -
) O +
or O +
collagen O +
receptor O -
- O -
mediated O +
platelet O +
adhesion O -
( O -
revacept O -
, O +
a O +
dimeric O +
collagen O +
receptor O +
GPVI O -
- O -
Fc O -
) O +
prevented O +
aberrant O +
COX-2 O +
expression O -
. O +

Inhibition O +
of O +
platelet O -
- O -
cancer O +
cell O +
interaction O +
by O +
revacept O +
was O +
more O +
effective O +
than O +
rofecoxib B-Chemical +
in O +
preventing O +
platelet O -
- O -
induced O +
mRNA O +
changes O +
of O +
EMT O +
markers O +
suggesting O +
that O +
direct O +
cell O -
- O -
cell O +
contact O +
and O +
aberrant O +
COX-2 O +
expression O +
synergistically O +
induced O +
gene O +
expression O +
modifications O +
associated O +
with O +
EMT O -
. O +

In O +
conclusion O -
, O +
our O +
findings O +
provide O +
the O +
rationale O +
for O +
testing O +
blockers O +
of O +
collagen O +
binding O +
sites O -
, O +
such O +
as O +
revacept O -
, O +
and O +
galectin-3 O +
inhibitors O +
in O +
the O +
prevention O +
of O +
colon O +
cancer O +
metastasis O +
in O +
animal O +
models O +
followed O +
by O +
studies O +
in O +
patients O -
. O +

The O +
absence O +
of O +
ERβ O +
results O +
in O +
altered O +
gene O +
expression O +
in O +
ovarian O +
granulosa O +
cells O +
isolated O +
from O +
in O +
vivo O +
preovulatory O +
follicles O -
. O +

Determining O +
the O +
spatial O +
and O +
temporal O +
expression O +
of O +
genes O +
involved O +
in O +
the O +
ovulatory O +
pathway O +
is O +
critical O +
for O +
the O +
understanding O +
of O +
the O +
role O +
of O +
each O +
estrogen B-Chemical +
receptor O +
in O +
the O +
modulation O +
of O +
folliculogenesis O +
and O +
ovulation O -
. O +

Estrogen B-Chemical +
receptor O +
( O -
ER O -
) O +
β O +
is O +
highly O +
expressed O +
in O +
ovarian O +
granulosa O +
cells O +
and O +
mice O +
lacking O +
ERβ O +
( O -
βERKO O -
) O +
are O +
subfertile O +
due O +
to O +
inefficient O +
ovulation O -
. O +

Previous O +
work O +
has O +
focused O +
on O +
isolated O +
granulosa O +
cells O +
or O +
cultured O +
follicles O +
and O +
while O +
informative O -
, O +
provides O +
confounding O +
results O +
due O +
to O +
the O +
heterogeneous O +
cell O +
types O +
present O +
including O +
granulosa O -
, O +
theca O +
and O +
oocytes O +
and O +
exposure O +
to O +
in O +
vitro O +
conditions O -
. O +

Herein O -
, O +
we O +
isolated O +
preovulatory O +
granulosa O +
cells O +
from O +
WT O +
and O +
ERβ O -
- O -
null O +
mice O +
using O +
laser O +
capture O +
microdissection O +
to O +
examine O +
the O +
genomic O +
transcriptional O +
response O +
downstream O +
of O +
PMSG O +
( O -
mimicking O +
FSH O -
) O +
and O +
PMSG O -
/ O -
hCG O +
( O -
mimicking O +
LH O -
) O +
stimulation O -
. O +

This O +
allows O +
for O +
a O +
direct O +
comparison O +
of O +
in O +
vivo O +
granulosa O +
cells O +
at O +
the O +
same O +
stage O +
of O +
development O +
from O +
both O +
WT O +
and O +
ERβ O -
- O -
null O +
ovaries O -
. O +

ERβ O -
- O -
null O +
granulosa O +
cells O +
showed O +
altered O +
expression O +
of O +
genes O +
known O +
to O +
be O +
regulated O +
by O +
FSH O +
( O -
Akap12 O +
and O +
Runx2 O -
) O +
as O +
well O +
as O +
not O +
previously O +
reported O +
( O -
Arnt2 O +
and O +
Pou5f1 O -
) O +
in O +
WT O +
granulosa O +
cells O -
. O +

Our O +
analysis O +
also O +
identified O +
304 O +
genes O +
not O +
previously O +
associated O +
with O +
ERβ O +
in O +
granulosa O +
cells O -
. O +

LH O +
responsive O +
genes O +
including O +
Abcb1b O +
and O +
Fam110c O +
show O +
reduced O +
expression O +
in O +
ERβ O -
- O -
null O +
granulosa O +
cells O -
; O +
however O +
novel O +
genes O +
including O +
Rassf2 O +
and O +
Megf10 O +
were O +
also O +
identified O +
as O +
being O +
downstream O +
of O +
LH O +
signaling O +
in O +
granulosa O +
cells O -
. O +

Collectively O -
, O +
our O +
data O +
suggests O +
that O +
granulosa O +
cells O +
from O +
ERβ O -
- O -
null O +
ovaries O +
may O +
not O +
be O +
appropriately O +
differentiated O +
and O +
are O +
unable O +
to O +
respond O +
properly O +
to O +
gonadotropin O +
stimulation O -
. O +

A O +
Butterfly O -
- O -
Shaped O +
Pyrene B-Chemical +
Derivative O +
of O +
Cholesterol B-Chemical +
and O +
Its O +
Uses O +
as O +
a O +
Fluorescent O +
Probe O -
. O +

A O +
butterfly O -
- O -
shaped O +
pyrene O +
derivative O +
of O +
cholesterol B-Chemical -
, O +
namely O -
, O +
N B-Chemical -
, I-Chemical -
N'- I-Chemical -
( I-Chemical -
ethane-1,2-diyl I-Chemical -
) I-Chemical -
-bis I-Chemical -
( I-Chemical -
N- I-Chemical -
( I-Chemical -
2- I-Chemical -
( I-Chemical -
chol I-Chemical -
- I-Chemical -
amino I-Chemical -
) I-Chemical -
ethyl I-Chemical -
) I-Chemical -
pyrene-1-sulfonamide I-Chemical -
) I-Chemical +
( O -
ECPS B-Chemical -
) O -
, O +
has O +
been O +
designed O +
and O +
synthesized O -
. O +

Solvent O +
effect O +
studies O +
revealed O +
that O +
in O +
good O +
solvents O +
such O +
as O +
n B-Chemical -
- I-Chemical -
hexane I-Chemical -
, O +
benzene B-Chemical -
, O +
and O +
1,4-dioxane B-Chemical -
, O +
the O +
profile O +
of O +
the O +
fluorescence O +
emission O +
of O +
the O +
compound O +
is O +
characterized O +
by O +
pyrene B-Chemical +
monomer O +
emission O -
, O +
but O +
in O +
poor O +
solvent O +
such O +
as O +
water O -
, O +
the O +
emission O +
is O +
dominated O +
by O +
pyrene O +
excimer O +
emission O -
. O +

Quantitatively O +
speaking O -
, O +
the O +
ratio O +
of O +
the O +
excimer O +
emission O +
to O +
monomer O +
emission O +
changes O +
from O +
50 O +
to O +
0 O +
when O +
ECPS O +
is O +
dissolved O +
in O +
water O +
and O +
n B-Chemical -
- I-Chemical -
hexane I-Chemical -
, O +
respectively O -
. O +

In O +
contrast O -
, O +
for O +
a O +
commonly O +
used O +
polarity O +
probe O +
pyrene B-Chemical -
, O +
the O +
ratio O +
of O +
I3 O -
/ O -
I1 O +
varies O +
only O +
from O +
∼0.6 O +
to O +
∼1.7 O -
, O +
where O +
I3 O +
and O +
I1 O +
stand O +
for O +
the O +
intensities O +
of O +
the O +
fluorescence O +
emission O +
at O +
peak O +
3 O +
and O +
peak O +
1 O -
, O +
respectively O -
. O +

This O +
value O +
suggests O +
that O +
a O +
more O +
powerful O +
discriminating O +
ability O +
of O +
the O +
new O +
compound O +
in O +
polarity O +
sensing O -
. O +

Furthermore O -
, O +
unlike O +
the O +
main O +
components O +
of O +
the O +
compound O -
, O +
pyrene B-Chemical +
and O +
cholesterol B-Chemical -
, O +
its O +
main O +
chain O +
is O +
composed O +
of O +
multiple O +
hydrophilic O +
structures O -
, O +
and O +
it O +
is O +
this O +
structure O +
that O +
makes O +
the O +
emission O +
of O +
the O +
compound O +
in O +
organic O +
solvents O +
sensitive O +
to O +
the O +
presence O +
of O +
water O -
. O +

Accordingly O -
, O +
the O +
applicability O +
of O +
the O +
compound O +
in O +
determination O +
of O +
the O +
trace O +
amount O +
of O +
water O +
in O +
some O +
organic O +
solvents O +
was O +
evaluated O -
. O +

As O +
expected O -
, O +
the O +
detection O +
limit O +
of O +
the O +
compound O +
toward O +
water O +
in O +
acetonitrile B-Chemical +
reaches O +
7 O +
ppm O -
, O +
a O +
result O +
never O +
reached O +
before O -
. O +

Furthermore O -
, O +
the O +
fluorescence O +
emission O +
of O +
the O +
compound O +
is O +
also O +
sensitive O +
to O +
viscosity O +
variation O -
. O +

Therefore O -
, O +
it O +
is O +
assumed O +
that O +
ECPS B-Chemical +
may O +
be O +
used O +
both O +
as O +
a O +
polarity O +
probe O +
and O +
a O +
viscosity O +
probe O -
. O +

On O +
the O +
bases O +
of O +
a O +
series O +
of O +
steady O -
- O -
state O +
and O +
time O -
- O -
resolved O +
fluorescence O -
, O +
as O +
well O +
as O +
dynamic O +
light O +
scattering O +
studies O -
, O +
a O +
structural O +
model O +
was O +
proposed O +
to O +
rationalize O +
the O +
fluorescence O +
behavior O +
of O +
the O +
compound O +
in O +
different O +
solvents O +
and O +
its O +
polarity O +
and O +
viscosity O +
probing O +
performances O -
. O +

Condensation O +
of O +
DNA O -
- O -
A O +
putative O +
obstruction O +
for O +
repair O +
process O +
in O +
abasic O +
clustered O +
DNA O +
damage O -
. O +

Clustered O +
DNA O +
damages O +
are O +
defined O +
as O +
two O +
or O +
more O +
closely O +
located O +
DNA O +
damage O +
lesions O +
that O +
may O +
be O +
present O +
within O +
a O +
few O +
helical O +
turns O +
of O +
the O +
DNA O +
double O +
strand O -
. O +

These O +
damages O +
are O +
potential O +
signatures O +
of O +
ionizing O +
radiation O +
and O +
are O +
often O +
found O +
to O +
be O +
repair O +
resistant O -
. O +

Types O +
of O +
damaged O +
lesions O +
frequently O +
found O +
inside O +
clustered O +
DNA O +
damage O +
sites O +
include O +
oxidized O +
bases O -
, O +
abasic O +
sites O -
, O +
nucleotide B-Chemical +
dimers I-Chemical -
, O +
strand O +
breaks O +
or O +
their O +
complex O +
combinations O -
. O +

In O +
this O +
study O -
, O +
we O +
used O +
a O +
bistranded O +
two O -
- O -
lesion O +
abasic O +
cluster O +
DNA O +
damage O +
model O +
to O +
access O +
the O +
repair O +
process O +
of O +
DNA O +
in O +
condensate O +
form O -
. O +

Oligomer O +
DNA O +
duplexes O +
( O -
47bp O -
) O +
were O +
designed O +
to O +
have O +
two O +
deoxyuridine B-Chemical +
in O +
the O +
middle O +
of O +
the O +
sequences O -
, O +
three O +
bases O +
apart O +
in O +
opposite O +
strands O -
. O +

The O +
deoxyuridine B-Chemical +
residues O +
were O +
converted O +
into O +
abasic O +
sites O +
by O +
treatment O +
with O +
UDG O +
enzyme O +
creating O +
an O +
abasic O +
clustered O +
damage O +
site O +
in O +
a O +
precise O +
position O +
in O +
each O +
of O +
the O +
single O +
strand O +
of O +
the O +
DNA O +
duplex O -
. O +

This O +
oligomer O +
duplex O +
having O +
compatible O +
cohesive O +
ends O +
was O +
ligated O +
to O +
pUC19 O +
plasmid O -
, O +
linearized O +
with O +
HindIII O +
restriction O +
endonuclease O -
. O +

The O +
plasmid O -
- O -
oligomer O +
conjugate O +
was O +
transformed O +
into O +
condensates O +
by O +
treating O +
them O +
with O +
spermidine B-Chemical -
. O +

The O +
efficiency O +
of O +
strand O +
cleavage O +
action O +
of O +
ApeI O +
enzyme O +
on O +
the O +
abasic O +
sites O +
was O +
determined O +
by O +
denaturing O +
PAGE O +
after O +
timed O +
incubation O +
of O +
the O +
oligomer O +
duplex O +
and O +
the O +
oligomer O -
- O -
plasmid O +
conjugate O +
in O +
presence O +
and O +
absence O +
of O +
spermidine B-Chemical -
. O +

The O +
efficiency O +
of O +
double O +
strand O +
breaks O +
was O +
determined O +
similarly O +
by O +
native O +
PAGE O -
. O +

Quantitative O +
gel O +
analysis O +
revealed O +
that O +
rate O +
of O +
abasic O +
site O +
cleavage O +
is O +
reduced O +
in O +
the O +
DNA O +
condensates O +
as O +
compared O +
to O +
the O +
oligomer O +
DNA O +
duplex O +
or O +
the O +
linear O +
ligated O +
oligomer O -
- O -
plasmid O +
conjugates O -
. O +

Generation O +
of O +
double O +
strand O +
break O +
is O +
significantly O +
reduced O +
also O -
, O +
suggesting O +
that O +
their O +
creation O +
is O +
not O +
proportionate O +
to O +
the O +
number O +
of O +
abasic O +
sites O +
cleaved O +
in O +
the O +
condensate O +
model O -
. O +

All O +
these O +
suggest O +
that O +
the O +
ApeI O +
enzyme O +
have O +
difficulty O +
to O +
access O +
the O +
abasic O +
sites O +
located O +
deep O +
into O +
the O +
condensates O +
leading O +
to O +
repair O +
refractivity O +
of O +
the O +
damages O -
. O +

In O +
addition O -
, O +
we O +
found O +
that O +
presence O +
of O +
a O +
polyamine B-Chemical +
such O +
as O +
spermidine B-Chemical +
has O +
no O +
notable O +
effect O +
in O +
the O +
incision O +
activity O +
of O +
ApeI O +
enzyme O +
in O +
linear O +
oligomer O +
DNA O +
duplexes O +
in O +
our O +
experimental O +
concentration O -
. O +

Synthesis O +
and O +
antitumor O +
activity O +
of O +
1,3,4-oxadiazole B-Chemical +
possessing O +
1,4-benzodioxan B-Chemical +
moiety O +
as O +
a O +
novel O +
class O +
of O +
potent O +
methionine B-Chemical +
aminopeptidase O +
type O +
II O +
inhibitors O -
. O +

A O +
series O +
of O +
1,3,4-oxadiazole B-Chemical +
derivatives O +
containing O +
1,4-benzodioxan B-Chemical +
moiety O +
( O -
7a-7q O -
) O +
have O +
been O +
designed O -
, O +
synthesized O +
and O +
evaluated O +
for O +
their O +
antitumor O +
activity O -
. O +

Most O +
of O +
the O +
synthesized O +
compounds O +
were O +
proved O +
to O +
have O +
potent O +
antitumor O +
activity O +
and O +
low O +
toxicity O -
. O +

Among O +
them O -
, O +
compound O +
7a O +
showed O +
the O +
most O +
potent O +
biological O +
activity O +
against O +
Human O +
Umbilical O +
Vein O +
Endothelial O +
cells O -
, O +
which O +
was O +
comparable O +
to O +
the O +
positive O +
control O -
. O +

The O +
results O +
of O +
apoptosis O +
and O +
flow O +
cytometry O +
( O -
FCM O -
) O +
demonstrated O +
that O +
compound O +
7a O +
induce O +
cell O +
apoptosis O +
by O +
the O +
inhibition O +
of O +
MetAP2 B-Chemical +
pathway O -
. O +

Molecular O +
docking O +
was O +
performed O +
to O +
position O +
compound O +
7a O +
into O +
MetAP2 B-Chemical +
binding O +
site O +
in O +
order O +
to O +
explore O +
the O +
potential O +
target O -
. O +

Nr4a1-Dependent O +
Ly6C O -
( O -
low O -
) O +

Monocytes O +
Monitor O +
Endothelial O +
Cells O +
and O +
Orchestrate O +
Their O +
Disposal O -
. O +

The O +
functions O +
of O +
Nr4a1-dependent O +
Ly6C O -
( O -
low O -
) O +
monocytes O +
remain O +
enigmatic O -
. O +

We O +
show O +
that O +
they O +
are O +
enriched O +
within O +
capillaries O +
and O +
scavenge O +
microparticles O +
from O +
their O +
lumenal O +
side O +
in O +
a O +
steady O +
state O -
. O +

In O +
the O +
kidney O +
cortex O -
, O +
perturbation O +
of O +
homeostasis O +
by O +
a O +
TLR7-dependent O +
nucleic O +
acid O +
" O -
danger O -
" O +
signal O -
, O +
which O +
may O +
signify O +
viral O +
infection O +
or O +
local O +
cell O +
death O -
, O +
triggers O +
Gαi O -
- O -
dependent O +
intravascular O +
retention O +
of O +
Ly6C O -
( O -
low O -
) O +
monocytes O +
by O +
the O +
endothelium O -
. O +

Then O -
, O +
monocytes O +
recruit O +
neutrophils O +
in O +
a O +
TLR7-dependent O +
manner O +
to O +
mediate O +
focal O +
necrosis O +
of O +
endothelial O +
cells O -
, O +
whereas O +
the O +
monocytes O +
remove O +
cellular O +
debris O -
. O +

Prevention O +
of O +
Ly6C O -
( O -
low O -
) O +
monocyte O +
development O -
, O +
crawling O -
, O +
or O +
retention O +
in O +
Nr4a1 O -
( O -
- O -
/ O -
- O -
) O -
, O +
Itgal O -
( O -
- O -
/ O -
- O -
) O -
, O +
and O +
Tlr7 O -
( O -
host- O -
/ O -
-BM+ O -
/ O -
+ O -
) O +
and O +
Cx3cr1 O -
( O -
- O -
/ O -
- O -
) O +
mice O -
, O +
respectively O -
, O +
abolished O +
neutrophil O +
recruitment O +
and O +
endothelial O +
killing O -
. O +

Prevention O +
of O +
neutrophil O +
recruitment O +
in O +
Tlr7 O -
( O -
host+ O -
/ O -
+BM- O -
/ O -
- O -
) O +
mice O +
or O +
by O +
neutrophil O +
depletion O +
also O +
abolished O +
endothelial O +
cell O +
necrosis O -
. O +

Therefore O -
, O +
Ly6C O -
( O -
low O -
) O +
monocytes O +
are O +
intravascular O +
housekeepers O +
that O +
orchestrate O +
the O +
necrosis O +
by O +
neutrophils O +
of O +
endothelial O +
cells O +
that O +
signal O +
a O +
local O +
threat O +
sensed O +
via O +
TLR7 O +
followed O +
by O +
the O +
in O +
situ O +
phagocytosis O +
of O +
cellular O +
debris O -
. O +

Thermal O +
stability O +
of O +
oligodeoxynucleotide O +
duplexes O +
containing O +
l B-Chemical -
- I-Chemical -
deoxynucleotide I-Chemical +
at O +
termini O -
. O +

The O +
effects O +
of O +
substituting O +
l B-Chemical -
- I-Chemical -
deoxynucleotide I-Chemical +
for O +
d B-Chemical -
- I-Chemical -
deoxynucleotide I-Chemical +
at O +
duplex O +
termini O +
were O +
evaluated O +
and O +
the O +
terminal O +
substitutions O +
were O +
found O +
to O +
show O +
much O +
less O +
effects O +
on O +
duplex O +
destabilization O +
and O +
to O +
show O +
a O +
similar O +
tendency O +
in O +
base O +
pairing O +
selectivity O -
, O +
compared O +
with O +
internal O +
chiral O +
substitutions O -
. O +

Agonistic O +
activity O +
of O +
ICI B-Chemical +
182 I-Chemical +
780 I-Chemical +
on O +
activation O +
of O +
GSK O +
3β O -
/ O -
AKT O +
pathway O +
in O +
the O +
rat O +
uterus O +
during O +
the O +
estrous O +
cycle O -
. O +

We O +
examined O +
the O +
ability O +
of O +
ICI B-Chemical +
182,780 I-Chemical +
( O -
ICI B-Chemical -
) O +
to O +
block O +
uterine O +
cell O +
proliferation O +
via O +
protein O +
kinase O +
b O -
/ O -
AKT O +
pathway O +
in O +
the O +
uterus O +
of O +
the O +
rat O +
during O +
the O +
estrous O +
cycle O -
. O +

Intact O +
rats O -
, O +
with O +
regular O +
estrous O +
cycles O -
, O +
received O +
a O +
subcutaneous O +
( O -
s.c O -
. O -
) O +
injection O +
of O +
either O +
vehicle O +
or O +
ICI B-Chemical +
at O +
08:00h O +
on O +
the O +
day O +
of O +
proestrus O +
or O +
at O +
00:00h O +
on O +
the O +
day O +
of O +
estrus O +
and O +
sacrificed O +
at O +
13:00h O +
of O +
metaestrus O -
. O +

Estradiol B-Chemical +
( O -
E2 O -
) O +
and O +
progesterone B-Chemical +
( O -
P4 O -
) O +
plasma O +
levels O +
were O +
measured O +
by O +
radioimmunoassay O -
. O +

Both O +
ICI B-Chemical +
treatments O -
, O +
induced O +
a O +
significant O +
decrease O +
( O -
p<0.01 O -
) O +
in O +
uterine O +
estrogen B-Chemical +
receptor O +
alpha O +
( O -
ERα O -
) O +
content O -
, O +
had O +
no O +
effect O +
on O +
uterine O +
progesterone B-Chemical +
receptor O +
( O -
PR O -
) O +
protein O +
expression O +
and O +
caused O +
marked O +
nuclear O +
localization O +
of O +
cyclin O +
D1 O -
, O +
in O +
both O +
luminal O +
and O +
glandular O +
uterine O +
epithelium O -
, O +
as O +
compared O +
to O +
vehicle O -
- O -
treated O +
animals O -
. O +

Furthermore O -
, O +
we O +
detected O +
that O +
ICI B-Chemical +
treatment O +
induced O +
glycogen O +
synthase O +
kinase O +
( O -
Gsk3-β O -
) O +
Ser O +
9 O +
phosphorylation O -
, O +
which O +
correlates O +
with O +
cyclin O +
D1 O +
nuclear O +
localization O -
. O +

However O -
, O +
some O +
differences O +
were O +
observed O +
between O +
the O +
two O +
different O +
time O +
schedules O +
of O +
administration O -
. O +

We O +
observed O +
that O +
the O +
administration O +
of O +
ICI B-Chemical +
at O +
08:00h O +
on O +
proestrus O +
day O +
produced O +
a O +
15 O -
% O +
inhibition O +
of O +
luminal O +
epithelial O +
cell O +
proliferation O -
, O +
reduced O +
uterine O +
wet O +
weight O +
by O +
21 O -
% O +
and O +
caused O +
reduction O +
of O +
Akt O +
phosphorylation O +
at O +
Ser B-Chemical +
473 O +
as O +
compared O +
to O +
vehicle O -
- O -
treated O +
animals O -
, O +
whereas O +
ICI B-Chemical +
treatment O +
at O +
00:00h O +
on O +
estrus O +
day O +
had O +
no O +
effect O +
on O +
these O +
parameters O -
. O +

The O +
overall O +
results O +
indicate O +
that O +
ICI B-Chemical +
may O +
exert O +
agonistic O +
and O +
antagonistic O +
effects O +
on O +
uterine O +
cell O +
proliferation O +
through O +
differential O +
activation O +
of O +
the O +
Akt O +
pathway O +
depending O +
on O +
the O +
administration O +
period O +
during O +
the O +
estrous O +
cycle O -
, O +
and O +
indicates O +
that O +
the O +
mechanism O +
of O +
cell O +
proliferation O +
during O +
the O +
physiological O +
conditions O +
of O +
the O +
estrous O +
cycle O -
, O +
is O +
under O +
a O +
different O +
and O +
more O +
complex O +
regulation O +
than O +
in O +
the O +
ovariectomized O +
+ O -
E2 O +
animal O +
model O -
. O +

Chronic O +
Administration O +
of O +
Small O +
Non O -
- O -
Erythropoietic O +
Peptide O +
Sequence O +
of O +
Erythropoietin O +
Effectively O +
Ameliorates O +
the O +
Progression O +
of O +
Post O +
Myocardial O +
Infarction O +
Dilated O +
Cardiomyopathy O -
. O +

The O +
cardioprotective O +
properties O +
of O +
erythropoietin O +
( O -
EPO O -
) O +
in O +
pre O -
- O -
clinical O +
studies O +
are O +
well O +
documented O -
, O +
but O +
erythropoietic O +
and O +
prothrombotic O +
properties O +
of O +
EPO O +
preclude O +
its O +
use O +
in O +
chronic O +
heart O +
failure O +
( O -
CHF O -
) O -
. O +

We O +
tested O +
the O +
effect O +
of O +
long O -
- O -
term O +
treatment O +
with O +
a O +
small O +
peptide O +
sequence O +
within O +
the O +
EPO O +
molecule O -
, O +
Helix O +
B O +
surface O +
peptide O +
( O -
HBSP O -
) O -
, O +
that O +
possess O +
tissue O -
- O -
protective O -
, O +
but O +
not O +
erythropoietic O +
properties O +
of O +
EPO O -
, O +
on O +
mortality O +
and O +
cardiac O +
remodeling O +
in O +
post O -
- O -
myocardial O +
infarction O +
dilated O +
cardiomyopaty O +
in O +
rats O -
. O +

Starting O +
two O +
weeks O +
after O +
permanent O +
left O +
coronary O +
artery O +
ligation O -
, O +
rats O +
received O +
i.p O -
. O +

injections O +
of O +
HBSP O +
( O -
60µg O -
/ O -
kg O -
) O +
or O +
saline O +
2 O +
times O -
/ O -
week O +
for O +
10 O +
months O -
. O +

Treatment O +
did O +
not O +
elicit O +
an O +
immune O +
response O -
, O +
and O +
did O +
not O +
affect O +
the O +
hematocrit O -
. O +

Compared O +
to O +
untreated O +
rats O -
, O +
HBSP O +
treatment O +
reduced O +
mortality O +
by O +
50 O -
% O +
( O -
p<0.05 O -
) O -
. O +

Repeated O +
echocardiography O +
demonstrated O +
remarkable O +
attenuation O +
of O +
left O +
ventricular O +
dilatation O +
( O -
EDV O -
: O +
41 O -
% O +
vs. O +
86 O -
% O -
; O +
ESV O -
: O +
44 O -
% O +
vs. O +
135 O -
% O -
; O +
p<0.05 O -
) O -
, O +
LV O +
functional O +
deterioration O +
( O -
EF O -
: O +
-4 O -
% O +
vs. O +
-63 O -
% O -
; O +
p<0.05 O -
) O +
and O +
MI O +
expansion O +
( O -
3 O -
% O +
vs. O +
38 O -
% O -
; O +
p<0.05 O -
) O -
. O +

A O +
hemodynamic O +
assessment O +
at O +
study O +
termination O +
demonstrated O +
normal O +
preload O +
independent O +
stroke O +
work O +
( O -
63±5 O +
vs. O +
40±4 O -
; O +
p<0.05 O -
) O +
and O +
arterio O -
- O -
ventricular O +
coupling O +
( O -
1.2±0.2 O +
vs. O +
2.7±0.7 O -
; O +
p<0.05 O -
) O -
. O +

Histological O +
analysis O +
revealed O +
reduced O +
apoptosis O +
( O -
p<0.05 O -
) O +
and O +
fibrosis O +
( O -
p<0.05 O -
) O -
, O +
increased O +
cardiomyocyte O +
density O +
( O -
p<0.05 O -
) O -
, O +
and O +
increased O +
number O +
of O +
cardiomyocytes O +
in O +
myocardium O +
among O +
HBSP O -
- O -
treated O +
rats O -
. O +

The O +
results O +
indicate O +
that O +
HBSP O +
effectively O +
reduces O +
mortality O -
, O +
ameliorates O +
the O +
MI O +
expansion O +
and O +
CHF O +
progression O -
, O +
and O +
preserves O +
systolic O +
reserve O +
in O +
the O +
rat O +
post O +
MI O +
model O -
. O +

There O +
is O +
also O +
a O +
suggestion O +
that O +
HBSP O +
promoted O +
the O +
increase O +
of O +
the O +
myocytes O +
number O +
in O +
the O +
myocardial O +
wall O +
remote O +
from O +
the O +
infarct O -
. O +

Thus O +
HBSP O +
peptide O +
merits O +
consideration O +
for O +
clinical O +
testing O -
. O +

Diamond B-Chemical -
- O -
Lipid O +
Hybrids O +
Enhance O +
Chemotherapeutic O +
Tolerance O +
and O +
Mediate O +
Tumor O +
Regression O -
. O +

Self O -
- O -
assembled O +
nanodiamond O -
- O -
lipid O +
hybrid O +
particles O +
( O -
NDLPs O -
) O +
harness O +
the O +
potent O +
interaction O +
between O +
the O +
nanodiamond O +
( O -
ND O -
) O -
-surface O +
and O +
small O +
molecules O -
, O +
while O +
providing O +
a O +
mechanism O +
for O +
cell O -
- O -
targeted O +
imaging O +
and O +
therapy O +
of O +
triple O +
negative O +
breast O +
cancers O -
. O +

Epidermal O +
growth O +
factor O +
receptor O -
- O -
targeted O +
NDLPs O +
are O +
highly O +
biocompatible O +
particles O +
that O +
provide O +
cell O -
- O -
specific O +
imaging O -
, O +
promote O +
tumor O +
retention O +
of O +
ND O -
- O -
complexes O -
, O +
prevent O +
epirubicin B-Chemical +
toxicities O +
and O +
mediate O +
regression O +
of O +
triple O +
negative O +
breast O +
cancers O -
. O +

Alkane B-Chemical +
Oxidation O +
by O +
an O +
Immobilized O +
Nickel B-Chemical +
Complex O +
Catalyst O -
: O +
Structural O +
and O +
Reactivity O +
Differences O +
Induced O +
by O +
Surface O -
- O -
Ligand O +
Density O +
on O +
Mesoporous O +
Silica B-Chemical -
. O +

Immobilized O +
nickel B-Chemical +
catalysts O +
SBA*-L O -
- O -
x O -
/ O -
Ni B-Chemical +
( O -
L O -
= O -
bis B-Chemical -
( I-Chemical -
2-pyridylmethyl I-Chemical -
) I-Chemical -
( I-Chemical -
1H-1,2,3-triazol-4-ylmethyl I-Chemical -
) I-Chemical -
amine I-Chemical -
) O +
with O +
various O +
ligand O +
densities O +
( O -
L O +
content O +
( O -
x O -
) O -
=0.5 O -
, O +
1 O -
, O +
2 O -
, O +
4 O +
mol O +
% O +
Si B-Chemical -
) O +
have O +
been O +
prepared O +
from O +
azidopropyl B-Chemical -
- O -
functionalized O +
mesoporous O +
silicas B-Chemical +
SBA O -
- O -
N3 O +
-x O -
. O +

Related O +
homogeneous O +
ligand O +
L B-Chemical -
( I-Chemical -
t I-Chemical -
) I-Chemical +
( I-Chemical -
Bu I-Chemical -
) I-Chemical +
and O +
its O +
Ni B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical +
complexes O -
, O +
[ B-Chemical -
Ni I-Chemical -
( I-Chemical -
L I-Chemical -
( I-Chemical -
t I-Chemical -
) I-Chemical +
( I-Chemical -
Bu I-Chemical -
) I-Chemical +
) I-Chemical -
( I-Chemical -
OAc I-Chemical -
) I-Chemical -
2 I-Chemical +
( I-Chemical -
H2 I-Chemical +
O I-Chemical -
) I-Chemical -
] I-Chemical +
( I-Chemical -
L I-Chemical -
( I-Chemical -
t I-Chemical -
) I-Chemical +
( I-Chemical -
Bu I-Chemical -
) I-Chemical +
/Ni I-Chemical -
) I-Chemical +
and O +
[ B-Chemical -
Ni I-Chemical -
( I-Chemical -
L I-Chemical -
( I-Chemical -
t I-Chemical -
) I-Chemical +
( I-Chemical -
Bu I-Chemical -
) I-Chemical +
) I-Chemical -
2 I-Chemical +
] I-Chemical -
BF4 I-Chemical +
( I-Chemical -
2 I-Chemical +
L I-Chemical -
( I-Chemical -
t I-Chemical -
) I-Chemical +
( I-Chemical -
Bu I-Chemical -
) I-Chemical +
/Ni I-Chemical -
) I-Chemical -
, O +
have O +
been O +
synthesized O -
. O +

The O +
L O -
/ O -
Ni B-Chemical +
ratio O +
( O -
0.9 O -
- O -
1.7:1 O -
) O +
in O +
SBA*-L O -
- O -
x O -
/ O -
Ni B-Chemical +
suggests O +
the O +
formation O +
of O +
an O +
inert O +
[ O -
NiL2 B-Chemical +
] O +
site O +
on O +
the O +
surface O +
at O +
higher O +
ligand O +
loadings O -
. O +

SBA*-L O -
- O -
x O -
/ O -
Ni B-Chemical +
has O +
been O +
applied O +
to O +
the O +
catalytic O +
oxidation O +
of O +
cyclohexane B-Chemical +
with O +
m B-Chemical -
- I-Chemical -
chloroperbenzoic I-Chemical +
acid I-Chemical +
( O -
mCPBA B-Chemical -
) O -
. O +

The O +
catalyst O +
with O +
the O +
lowest O +
loading O +
shows O +
high O +
activity O +
in O +
its O +
initial O +
use O +
as O +
the O +
homogeneous O +
L B-Chemical -
( I-Chemical -
t I-Chemical -
) I-Chemical +
( I-Chemical -
Bu I-Chemical -
) I-Chemical +
/Ni O +
catalyst O -
, O +
with O +
some O +
metal O +
leaching O -
. O +

As O +
the O +
ligand O +
loading O +
increases O -
, O +
the O +
activity O +
and O +
Ni B-Chemical +
leaching O +
are O +
suppressed O -
. O +

The O +
importance O +
of O +
site O -
- O -
density O +
control O +
for O +
the O +
development O +
of O +
immobilized O +
catalysts O +
has O +
been O +
demonstrated O -
. O +

Simulating O +
Lifetime O +
Outcomes O +
Associated O +
with O +
Complications O +
for O +
People O +
with O +
Type O +
1 O +
Diabetes O -
. O +

OBJECTIVES O -
: O +
The O +
aim O +
of O +
this O +
study O +
was O +
to O +
develop O +
a O +
discrete O -
- O -
time O +
simulation O +
model O +
for O +
people O +
with O +
type O +
1 O +
diabetes O +
mellitus O -
, O +
to O +
estimate O +
and O +
compare O +
mean O +
life O +
expectancy O +
and O +
quality O -
- O -
adjusted O +
life O -
- O -
years O +
( O -
QALYs O -
) O +
over O +
a O +
lifetime O +
between O +
intensive O +
and O +
conventional O +
blood O +
glucose B-Chemical +
treatment O +
groups O -
. O +

METHODS O -
: O +
We O +
synthesized O +
evidence O +
on O +
type O +
1 O +
diabetes O +
patients O +
using O +
several O +
published O +
sources O -
. O +

The O +
simulation O +
model O +
was O +
based O +
on O +
13 O +
equations O +
to O +
estimate O +
risks O +
of O +
events O +
and O +
mortality O -
. O +

Cardiovascular O +
disease O +
( O -
CVD O -
) O +
risk O +
was O +
obtained O +
from O +
results O +
of O +
the O +
DCCT O +
( O -
diabetes O +
control O +
and O +
complications O +
trial O -
) O -
. O +

Mortality O +
post O -
- O -
CVD O +
event O +
was O +
based O +
on O +
a O +
study O +
using O +
linked O +
administrative O +
data O +
on O +
people O +
with O +
diabetes O +
from O +
Western O +
Australia O -
. O +

Information O +
on O +
incidence O +
of O +
renal O +
disease O +
and O +
the O +
progression O +
to O +
CVD O +
was O +
obtained O +
from O +
studies O +
in O +
Finland O +
and O +
Italy O -
. O +

Lower O -
- O -
extremity O +
amputation O +
( O -
LEA O -
) O +
risk O +
was O +
based O +
on O +
the O +
type O +
1 O +
diabetes O +
Swedish O +
inpatient O +
registry O -
, O +
and O +
the O +
risk O +
of O +
blindness O +
was O +
obtained O +
from O +
results O +
of O +
a O +
German O -
- O -
based O +
study O -
. O +

Where O +
diabetes O -
- O -
specific O +
data O +
were O +
unavailable O -
, O +
information O +
from O +
other O +
populations O +
was O +
used O -
. O +

We O +
examine O +
the O +
degree O +
and O +
source O +
of O +
parameter O +
uncertainty O +
and O +
illustrate O +
an O +
application O +
of O +
the O +
model O +
in O +
estimating O +
lifetime O +
outcomes O +
of O +
using O +
intensive O +
and O +
conventional O +
treatments O +
for O +
blood O +
glucose B-Chemical +
control O -
. O +

RESULTS O -
: O +
From O +
15 O +
years O +
of O +
age O -
, O +
male O +
and O +
female O +
patients O +
had O +
an O +
estimated O +
life O +
expectancy O +
of O +
47.2 O +
( O -
95 O +
% O +
CI O +
35.2 O -
- O -
59.2 O -
) O +
and O +
52.7 O +
( O -
95 O +
% O +
CI O +
41.7 O -
- O -
63.6 O -
) O +
years O +
in O +
the O +
intensive O +
treatment O +
group O -
. O +

The O +
model O +
produced O +
estimates O +
of O +
the O +
lifetime O +
benefits O +
of O +
intensive O +
treatment O +
for O +
blood O +
glucose B-Chemical +
from O +
the O +
DCCT O +
of O +
4.0 O +
( O -
95 O +
% O +
CI O +
1.2 O -
- O -
6.8 O -
) O +
QALYs O +
for O +
women O +
and O +
4.6 O +
( O -
95 O +
% O +
CI O +
2.7 O -
- O -
6.9 O -
) O +
QALYs O +
for O +
men O -
. O +

Absolute O +
risk O +
per O +
1,000 O +
person O -
- O -
years O +
for O +
fatal O +
CVD O +
events O +
was O +
simulated O +
to O +
be O +
1.37 O +
and O +
2.51 O +
in O +
intensive O +
and O +
conventional O +
treatment O +
groups O -
, O +
respectively O -
. O +

CONCLUSIONS O -
: O +
The O +
model O +
incorporates O +
diabetic O +
complications O +
risk O +
data O +
from O +
a O +
type O +
1 O +
diabetes O +
population O +
and O +
synthesizes O +
other O +
type O +
1-specific O +
data O +
to O +
estimate O +
long O -
- O -
term O +
outcomes O +
of O +
CVD O -
, O +
end O -
- O -
stage O +
renal O +
disease O -
, O +
LEA O +
and O +
risk O +
of O +
blindness O -
, O +
along O +
with O +
life O +
expectancy O +
and O +
QALYs O -
. O +

External O +
validation O +
was O +
carried O +
out O +
using O +
life O +
expectancy O +
and O +
absolute O +
risk O +
for O +
fatal O +
CVD O +
events O -
. O +

Because O +
of O +
the O +
flexible O +
and O +
transparent O +
nature O +
of O +
the O +
model O -
, O +
it O +
has O +
many O +
potential O +
future O +
applications O -
. O +

tert B-Chemical -
- I-Chemical -
Butylhydroquinone I-Chemical +
reduces O +
lipid O +
accumulation O +
in O +
C57BL O -
/ O -
6 O +
mice O +
with O +
lower O +
body O +
weight O +
gain O -
. O +

tert B-Chemical -
- I-Chemical -
Butylhydroquinone I-Chemical +
( O -
tBHQ B-Chemical -
) O +
is O +
a O +
commonly O +
used O +
antioxidant O +
additive O +
that O +
is O +
approved O +
for O +
human O +
use O +
by O +
both O +
the O +
Food O +
and O +
Agriculture O +
Organization O +
and O +
the O +
World O +
Health O +
Organization O +
( O -
FAO O -
/ O -
WHO O -
) O -
. O +

In O +
this O +
study O -
, O +
we O +
examined O +
the O +
effect O +
of O +
tBHQ B-Chemical +
on O +
body O +
weight O +
gain O +
and O +
found O +
that O +
food O +
supplementation O +
with O +
0.001 O +
% O +
( O -
w O -
/ O -
w O -
) O +
tBHQ B-Chemical +
inhibited O +
61.4 O +
% O +
( O -
P O +
< O +
0.01 O -
) O +
of O +
body O +
weight O +
gain O +
in O +
high O -
- O -
fat O +
diet O +
( O -
HFD O -
) O -
-induced O +
C57BL O -
/ O -
6 O +
mice O -
, O +
and O +
the O +
oral O +
administration O +
of O +
tBHQ B-Chemical +
( O -
1.5 O +
mg O -
/ O -
kg O -
) O +
reduced O +
47.5 O +
% O +
( O -
P O +
< O +
0.05 O -
) O +
of O +
body O +
weight O +
gain O +
in O +
normal O +
diet O +
fed O +
db O -
/ O -
db O +
mice O -
. O +

The O +
HFD O +
increased O +
lipid O +
deposit O +
in O +
adipocytes O -
, O +
but O +
these O +
were O +
reduced O +
significantly O +
by O +
tBHQ B-Chemical +
treatment O +
in O +
C57BL O -
/ O -
6 O +
mice O -
. O +

tBHQ B-Chemical +
supplementation O +
significantly O +
lowered O +
the O +
plasma O +
triglyceride B-Chemical +
and O +
total O +
cholesterol B-Chemical -
, O +
with O +
reduced O +
size O +
of O +
accumulated O +
fat O +
mass O -
. O +

The O +
rate O +
limiting O +
enzyme O +
of O +
beta O -
- O -
oxidation O +
( O -
ACOX1 O -
) O +
was O +
significantly O +
over O -
- O -
expressed O +
in O +
the O +
liver O +
with O +
tBHQ B-Chemical +
treatment O -
. O +

These O +
results O +
indicate O +
that O +
tBHQ B-Chemical +
suppresses O +
body O +
weight O +
gain O +
in O +
mice O -
, O +
possibly O +
at O +
least O +
related O +
to O +
the O +
up O -
- O -
regulation O +
of O +
ACOX1 O +
gene O +
expression O -
. O +

Tandem O +
Assays O +
of O +
Protein O +
and O +
Glucose B-Chemical +
with O +
Functionalized O +
Core O -
/ O -
Shell O +
Particles O +
Based O +
on O +
Magnetic O +
Separation O +
and O +
Surface O -
- O -
Enhanced O +
Raman O +
Scattering O -
. O +

Tandem O +
assays O +
of O +
protein O +
and O +
glucose B-Chemical +
in O +
combination O +
with O +
mannose B-Chemical -
- O -
functionalized O +
Fe3 B-Chemical +
O4 I-Chemical +
@SiO2 O +
and O +
Ag@SiO2 B-Chemical +
tag O +
particles O +
have O +
promising O +
potential O +
in O +
effective O +
magnetic O +
separation O +
and O +
highly O +
sensitive O +
and O +
selective O +
SERS O +
assays O +
of O +
biomaterials O -
. O +

It O +
is O +
for O +
the O +
first O +
time O +
that O +
tandem O +
assay O +
of O +
glucose B-Chemical +
is O +
developed O +
using O +
SERS O +
based O +
on O +
the O +
Con O +
A O -
- O -
sandwiched O +
microstructures O +
between O +
the O +
functionalized O +
magnetic O +
and O +
tag O +
particles O -
. O +

Ligand O +
Based O +
Approach O +
to O +
L O -
- O -
Type O +
Calcium B-Chemical +
Channel O +
by O +
Imidazo B-Chemical -
[ I-Chemical -
2,1-b I-Chemical -
] I-Chemical -
thiazole-1,4-Dihydropyridines I-Chemical -
: O +
from O +
Heart O +
Activity O +
to O +
Brain O +
Affinity O -
. O +

The O +
synthesis O -
, O +
characterization O -
, O +
and O +
functional O +
in O +
vitro O +
assay O +
in O +
cardiac O +
and O +
smooth O +
muscle O +
( O -
vascular O +
and O +
nonvascular O -
) O +
of O +
a O +
series O +
of O +
4-imidazo B-Chemical -
[ I-Chemical -
2,1-b I-Chemical -
] I-Chemical -
thiazole-1,4-dihydropyridines I-Chemical +
are O +
reported O -
. O +

To O +
define O +
the O +
calcium B-Chemical +
blocker O +
nature O +
of O +
the O +
imidazo B-Chemical -
[ I-Chemical -
2,1-b I-Chemical -
] I-Chemical -
thiazole-1,4-DHPs I-Chemical +
and O +
their O +
selectivity O +
on O +
Cav1.2 O +
and O +
Cav1.3 O +
isoforms O +
we O +
performed O +
binding O +
studies O +
on O +
guinea O +
pig O +
atrial O +
and O +
ventricular O +
membranes O -
, O +
on O +
intact O +
cells O +
expressing O +
the O +
cloned O +
Cav1.2a O +
subunit O +
and O +
on O +
rat O +
brain O +
cortex O -
. O +

To O +
get O +
major O +
insights O +
into O +
the O +
reasons O +
for O +
the O +
affinity O +
for O +
Cav1.2 O +
and/or O +
Cav1.3 O +
molecular O +
modelling O +
studies O +
were O +
also O +
undertaken O -
. O +

Some O +
physicochemical O +
and O +
pharmacokinetic O +
properties O +
of O +
selected O +
compounds O +
were O +
calculated O +
and O +
compared O -
. O +

All O +
the O +
biological O +
data O +
collected O +
and O +
reported O +
herein O +
allowed O +
us O +
to O +
rationalize O +
the O +
structure O -
- O -
activity O +
relationship O +
of O +
the O +
4-imidazo B-Chemical -
[ I-Chemical -
2,1-b I-Chemical -
] I-Chemical -
thiazole-1,4-DHPs I-Chemical +
and O +
to O +
identify O +
which O +
of O +
these O +
enhanced O +
the O +
activity O +
at O +
the O +
central O +
level O -
. O +

Synthesis O +
of O +
chemicals O +
using O +
solar O +
energy O +
with O +
stable O +
photoelectrochemically O +
active O +
heterostructures O -
. O +

Efficient O +
and O +
cost O -
- O -
effective O +
conversion O +
of O +
solar O +
energy O +
to O +
useful O +
chemicals O +
and O +
fuels O +
could O +
lead O +
to O +
a O +
significant O +
reduction O +
in O +
fossil O +
hydrocarbon B-Chemical +
use O -
. O +

Artificial O +
systems O +
that O +
use O +
solar O +
energy O +
to O +
produce O +
chemicals O +
have O +
been O +
reported O +
for O +
more O +
than O +
a O +
century O -
. O +

However O +
the O +
most O +
efficient O +
devices O +
demonstrated O -
, O +
based O +
on O +
traditionally O +
fabricated O +
compound O +
semiconductors O -
, O +
have O +
extremely O +
short O +
working O +
lifetimes O +
due O +
to O +
photocorrosion O +
by O +
the O +
electrolyte O -
. O +

Here O +
we O +
report O +
a O +
stable O -
, O +
scalable O +
design O +
and O +
molecular O +
level O +
fabrication O +
strategy O +
to O +
create O +
photoelectrochemically O +
active O +
heterostructure O +
( O -
PAH O -
) O +
units O +
consisting O +
of O +
an O +
efficient O +
semiconductor O +
light O +
absorber O +
in O +
contact O +
with O +
oxidation O +
and O +
reduction O +
electrocatalysts O +
and O +
otherwise O +
protected O +
by O +
alumina B-Chemical -
. O +

The O +
functional O +
heterostructures O +
are O +
fabricated O +
by O +
layer O -
- O -
by O -
- O -
layer O -
, O +
template O -
- O -
directed O -
, O +
electrochemical O +
synthesis O +
in O +
porous O +
anodic O +
aluminum B-Chemical +
oxide I-Chemical +
membranes O +
to O +
produce O +
high O +
density O +
arrays O +
of O +
electronically O +
autonomous O -
, O +
nanostructured O -
, O +
corrosion O +
resistant O -
, O +
photoactive O +
units O +
( O -
∼10 O -
( O -
9 O -
) O -
-10 O -
( O -
10 O -
) O +
PAHs O +
per O +
cm O -
( O -
2 O -
) O -
) O -
. O +

Each O +
PAH O +
unit O +
is O +
isolated O +
from O +
its O +
neighbor O +
by O +
the O +
transparent O +
electrically O +
insulating O +
oxide B-Chemical +
cellular O +
enclosure O +
that O +
makes O +
the O +
overall O +
assembly O +
fault O +
tolerant O -
. O +

When O +
illuminated O +
with O +
visible O +
light O -
, O +
the O +
free O +
floating O +
devices O +
have O +
been O +
demonstrated O +
to O +
produce O +
hydrogen B-Chemical +
at O +
a O +
stable O +
rate O +
for O +
over O +
24 O +
h O +
in O +
corrosive O +
hydroiodic B-Chemical +
acid I-Chemical +
electrolyte O +
with O +
light O +
as O +
the O +
only O +
input O -
. O +

The O +
quantum O +
efficiency O +
( O -
averaged O +
over O +
the O +
solar O +
spectrum O -
) O +
for O +
absorbed O +
photons O -
- O -
to O -
- O -
hydrogen B-Chemical +
conversion O +
was O +
7.4 O -
% O +
and O +
solar O -
- O -
to O -
- O -
hydrogen B-Chemical +
energy O +
efficiency O +
of O +
incident O +
light O +
was O +
0.9 O -
% O -
. O +

The O +
fabrication O +
approach O +
is O +
scalable O +
for O +
commercial O +
manufacturing O +
and O +
readily O +
adaptable O +
to O +
a O +
variety O +
of O +
earth O +
abundant O +
semiconductors O +
which O +
might O +
otherwise O +
be O +
unstable O +
as O +
photoelectrocatalysts O -
. O +

The O +
role O +
of O +
external O +
defects O +
in O +
chemical O +
sensing O +
of O +
graphene B-Chemical +
field O -
- O -
effect O +
transistors O -
. O +

A O +
fundamental O +
understanding O +
of O +
chemical O +
sensing O +
mechanisms O +
in O +
graphene B-Chemical -
- O -
based O +
chemical O +
field O -
- O -
effect O +
transistors O +
( O -
chemFETs O -
) O +
is O +
essential O +
for O +
the O +
development O +
of O +
next O +
generation O +
chemical O +
sensors O -
. O +

Here O +
we O +
explore O +
the O +
hidden O +
sensing O +
modalities O +
responsible O +
for O +
tailoring O +
the O +
gas O +
detection O +
ability O +
of O +
pristine B-Chemical +
graphene I-Chemical +
sensors O +
by O +
exposing O +
graphene B-Chemical +
chemFETs O +
to O +
electron O +
donor O +
and O +
acceptor O +
trace O +
gas O +
vapors O -
. O +

We O +
uncover O +
that O +
the O +
sensitivity O +
( O -
in O +
terms O +
of O +
modulation O +
in O +
electrical O +
conductivity O -
) O +
of O +
pristine B-Chemical +
graphene I-Chemical +
chemFETs O +
is O +
not O +
necessarily O +
intrinsic O +
to O +
graphene B-Chemical -
, O +
but O +
rather O +
it O +
is O +
facilitated O +
by O +
external O +
defects O +
in O +
the O +
insulating O +
substrate O -
, O +
which O +
can O +
modulate O +
the O +
electronic O +
properties O +
of O +
graphene B-Chemical -
. O +

We O +
disclose O +
a O +
mixing O +
effect O +
caused O +
by O +
partial O +
overlap O +
of O +
the O +
highest O +
occupied O +
molecular O +
orbital O +
( O -
HOMO O -
) O +
and O +
lowest O +
unoccupied O +
molecular O +
orbital O +
( O -
LUMO O -
) O +
of O +
adsorbed O +
gas O +
molecules O +
to O +
explain O +
graphene B-Chemical -
's O +
ability O +
to O +
detect O +
adsorbed O +
molecules O -
. O +

Our O +
results O +
open O +
a O +
new O +
design O +
space O -
, O +
suggesting O +
that O +
control O +
of O +
external O +
defects O +
in O +
supporting O +
substrates O +
can O +
lead O +
to O +
tunable O +
graphene O +
chemical O +
sensors O -
, O +
which O +
could O +
be O +
developed O +
without O +
compromising O +
the O +
intrinsic O +
electrical O +
and O +
structural O +
properties O +
of O +
graphene B-Chemical -
. O +

Study O +
of O +
the O +
microcharacter O +
of O +
ultrastable O +
aqueous O +
foam O +
stabilized O +
by O +
a O +
kind O +
of O +
flexible O +
connecting O +
bipolar O -
- O -
headed O +
surfactant O +
with O +
existence O +
of O +
magnesium B-Chemical +
ion O -
. O +

In O +
this O +
paper O -
, O +
ultrastable O +
aqueous O +
foam O +
stabilized O +
by O +
a O +
kind O +
of O +
flexible O +
connecting O +
bipolar O -
- O -
headed O +
surfactant O +
alkyl B-Chemical +
polyoxyethylene I-Chemical +
sulfate I-Chemical +
( O -
AE3S B-Chemical -
) O +
with O +
coexisting O +
Mg B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
was O +
reported O -
. O +

Detailed O +
molecular O +
behaviors O +
of O +
AE3S B-Chemical +
in O +
foam O +
film O +
with O +
coexisting O +
divalent O +
cationic O +
Ca B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
or O +
Mg B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
were O +
investigated O +
by O +
molecular O +
dynamic O +
simulation O -
, O +
comparing O +
with O +
the O +
traditional O +
surfactant O +
sodium B-Chemical +
dodecyl I-Chemical +
sulfate I-Chemical +
( O -
SDS B-Chemical -
) O -
, O +
to O +
find O +
out O +
how O +
the O +
microcharacter O +
and O +
array O +
behavior O +
of O +
molecules O +
in O +
the O +
foam O +
film O +
determined O +
by O +
molecular O +
interaction O +
effect O +
the O +
foam O +
stability O -
. O +

It O +
was O +
found O +
that O +
the O +
ultrastable O +
foam O +
film O +
obtained O +
by O +
the O +
cooperation O +
of O +
magnesium B-Chemical +
ions O +
and O +
AE3S B-Chemical +
was O +
driven O +
from O +
two O +
aspects O -
: O +
one O +
is O +
the O +
favorable O +
arrangement O +
of O +
surfactant O +
molecules O -
, O +
and O +
the O +
other O +
is O +
the O +
increase O +
of O +
capacity O +
of O +
foam O +
films O +
for O +
resolutely O +
holding O +
water O +
molecules O +
deduced O +
by O +
a O +
dipolar O +
pair O +
formed O +
by O +
the O +
flexible O +
connecting O +
head O +
groups O +
of O +
AE3S B-Chemical +
and O +
hydrated B-Chemical +
Mg I-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
via O +
intermolecular O +
coactions O -
, O +
both O +
related O +
to O +
the O +
presence O +
of O +
magnesium B-Chemical +
ions O -
. O +

Foam O +
lamella O +
stability O +
measurement O +
and O +
foam O +
decay O +
method O +
were O +
both O +
used O +
to O +
evaluate O +
the O +
stability O +
of O +
foam O -
. O +

Fourier O +
transform O +
infrared O +
( O -
FT O -
- O -
IR O -
) O +
was O +
used O +
to O +
detect O +
the O +
composition O +
variation O +
of O +
foam O +
film O +
in O +
the O +
drainage O +
process O -
; O +
the O +
vibration O +
peak O +
of O +
OH B-Chemical +
for O +
water O +
molecule O +
shifted O +
from O +
the O +
3390 O +
cm O -
( O -
-1 O -
) O +
( O -
being O +
assigned O +
to O +
the O +
bulk O +
water O +
integrated O +
by O +
hydrogen B-Chemical +
bonds O -
) O +
to O +
3685 O +
cm O -
( O -
-1 O -
) O +
( O -
being O +
assigned O +
to O +
the O +
vibration O +
of O +
isolated O +
water O +
molecules O -
) O +
for O +
the O +
ultrastable O +
foam O +
film O +
after O +
complete O +
drainage O -
, O +
which O +
agreed O +
very O +
well O +
with O +
the O +
molecular O +
simulation O +
results O -
. O +

Quinoline B-Chemical +
Drug O -
- O -
Heme B-Chemical +
Interactions O +
and O +
Implications O +
for O +
Antimalarial O +
Cytostatic O +
versus O +
Cytocidal O +
Activities O -
. O +

Historically O -
, O +
the O +
most O +
successful O +
molecular O +
target O +
for O +
antimalarial O +
drugs O +
has O +
been O +
heme O +
biomineralization O +
within O +
the O +
malarial O +
parasite O +
digestive O +
vacuole O -
. O +

Heme B-Chemical +
released O +
from O +
catabolized O +
host O +
red O +
blood O +
cell O +
hemoglobin O +
is O +
toxic O -
, O +
so O +
malarial O +
parasites O +
crystallize O +
heme B-Chemical +
to O +
nontoxic O +
hemozoin O -
. O +

For O +
years O +
it O +
has O +
been O +
accepted O +
that O +
a O +
number O +
of O +
effective O +
quinoline B-Chemical +
antimalarial O +
drugs O +
( O -
e.g. O -
, O +
chloroquine B-Chemical -
, O +
quinine B-Chemical -
, O +
amodiaquine B-Chemical -
) O +
function O +
by O +
preventing O +
hemozoin O +
crystallization O -
. O +

However O -
, O +
recent O +
studies O +
over O +
the O +
past O +
decade O +
have O +
revealed O +
a O +
surprising O +
molecular O +
diversity O +
in O +
quinoline B-Chemical -
- O -
heme B-Chemical +
molecular O +
interactions O -
. O +

This O +
diversity O +
shows O +
that O +
even O +
closely O +
related O +
quinoline B-Chemical +
drugs O +
may O +
have O +
quite O +
different O +
molecular O +
pharmacology O -
. O +

This O +
paper O +
reviews O +
the O +
molecular O +
diversity O +
and O +
highlights O +
important O +
implications O +
for O +
understanding O +
quinoline B-Chemical +
antimalarial O +
drug O +
resistance O +
and O +
for O +
future O +
drug O +
design O -
. O +

Why O +
Clinical O +
Inhibition O +
of O +
Efflux O +
Transport O +
at O +
the O +
Blood O -
- O -
Brain O +
Barrier O +
is O +
Unlikely O -
: O +

The O +
ITC O +
Evidence O -
- O -
Based O +
Position O -
. O +

Drug O +
interactions O +
due O +
to O +
efflux O +
transporter O +
inhibition O +
at O +
the O +
blood O -
- O -
brain O +
barrier O +
have O +
been O +
receiving O +
increasing O +
scrutiny O +
due O +
to O +
the O +
theoretical O +
possibility O +
of O +
adverse O +
CNS O +
effects O +
based O +
on O +
findings O +
from O +
preclinical O +
studies O -
. O +

In O +
this O +
commentary O -
, O +
evidence O +
from O +
pharmacokinetic O -
, O +
pharmacodynamic O -
, O +
imaging O -
, O +
pharmacogenetic O -
, O +
and O +
pharmacovigilance O +
studies O -
, O +
along O +
with O +
drug O +
safety O +
reports O -
, O +
is O +
presented O +
supporting O +
a O +
low O +
probability O +
of O +
inhibiting O +
efflux O +
transporters O +
at O +
the O +
human O +
blood O -
- O -
brain O +
barrier O +
by O +
currently O +
marketed O +
drugs O -
. O +

Clinical O +
Pharmacology O +
& O +
Therapeutics O +
( O -
2013 O -
) O -
; O +
accepted O +
article O +
preview O +
14 O +
February O +
2013 O +
doi:10.1038 O -
/ O -
clpt.2013.34 O -
. O +

A O +
Physiologically O -
- O -
Based O +
Pharmacokinetic O +
Modelling O +
Approach O +
to O +
Predict O +
Disease O -
- O -
Drug O +
Interactions O -
: O +
Suppression O +
of O +
CYP3A O +
by O +
IL-6 O -
. O +

Elevated O +
cytokine O +
levels O +
can O +
down O -
- O -
regulate O +
expression O +
of O +
cytochrome O +
P450 O +
enzymes O +
( O -
CYPs O -
) O +
and O +
suppress O +
their O +
activity O -
. O +

Treatment O +
of O +
inflammation O +
or O +
infection O +
with O +
cytokine O -
- O -
modulating O +
therapeutic O +
proteins O +
( O -
TP O -
) O +
could O +
reverse O +
suppression O +
manifesting O +
as O +
therapeutic O +
protein O -
- O -
drug O +
drug O +
interactions O +
( O -
TP O -
- O -
DDI O -
) O -
. O +

A O +
physiologically O -
- O -
based O +
pharmacokinetic O +
model O +
was O +
used O +
to O +
quantitatively O +
predict O +
the O +
impact O +
of O +
IL-6 O +
on O +
sensitive O +
CYP3A4 O +
substrates O -
. O +

Elevated O +
simvastatin B-Chemical +
AUC O +
in O +
virtual O +
rheumatoid O +
arthritis O +
patients O -
, O +
following O +
100 O +
pg O -
/ O -
mL O +
of O +
IL-6 O +
was O +
comparable O +
to O +
observed O +
clinical O +
data O +
( O -
59 O -
% O +
versus O +
58 O -
% O -
) O -
. O +

In O +
virtual O +
bone O +
marrow O +
transplant O +
( O -
BMT O -
) O +
patients O -
, O +
500 O +
pg O -
/ O -
ml O +
of O +
IL-6 O +
resulted O +
in O +
increase O +
in O +
cyclosporine B-Chemical +
AUC O +
that O +
was O +
in O +
good O +
agreement O +
with O +
the O +
observed O +
data O +
( O -
45 O -
% O +
versus O +
39 O -
% O -
) O -
. O +

In O +
a O +
different O +
group O +
of O +
BMT O +
patients O +
treated O +
with O +
cyclosporine B-Chemical -
, O +
the O +
magnitude O +
of O +
interaction O +
with O +
IL-6 O +
was O +
under O +
predicted O +
~3-fold O -
. O +

The O +
complexity O +
of O +
TP O -
- O -
DDI O +
highlights O +
underlying O +
pathophysiological O +
factors O +
to O +
be O +
considered O +
but O +
these O +
simulations O +
provide O +
valuable O +
first O +
steps O +
towards O +
predictions O +
of O +
TP O -
- O -
DDI O +
risk O -
. O +

Clinical O +
Pharmacology O +
& O +
Therapeutics O +
( O -
2013 O -
) O -
; O +
accepted O +
article O +
preview O +
online O +
10 O +
April O +
2013 O +
doi:10.1038 O -
/ O -
clpt.2013.79 O -
. O +

Model O -
- O -
Based O +
Drug O +
Development O -
: O +

A O +
Rational O +
Approach O +
to O +
Efficiently O +
Accelerate O +
Drug O +
Development O -
. O +

The O +
pharmaceutical O +
industry O +
continues O +
to O +
face O +
significant O +
challenges O -
. O +

Very O +
few O +
compounds O +
that O +
enter O +
development O +
reach O +
the O +
marketplace O -
, O +
and O +
the O +
investment O +
required O +
for O +
each O +
success O +
can O +
surpass O +
$ O -
1.8 O +
billion O -
. O +

Despite O +
attempts O +
to O +
improve O +
efficiency O +
and O +
increase O +
productivity O -
, O +
total O +
investment O +
continues O +
to O +
rise O +
whereas O +
the O +
output O +
of O +
new O +
medicines O +
declines O -
. O +

With O +
costs O +
increasing O +
exponentially O +
through O +
each O +
development O +
phase O -
, O +
it O +
is O +
failure O +
in O +
phase O +
II O +
and O +
phase O +
III O +
that O +
is O +
most O +
wasteful O -
. O +

In O +
today O -
's O +
development O +
paradigm O -
, O +
late O -
- O -
stage O +
failure O +
is O +
principally O +
a O +
result O +
of O +
insufficient O +
efficacy O -
. O +

This O +
is O +
manifested O +
as O +
either O +
a O +
failure O +
to O +
differentiate O +
sufficiently O +
from O +
placebo O +
( O -
shown O +
for O +
both O +
novel O +
and O +
precedented O +
mechanisms O -
) O +
or O +
a O +
failure O +
to O +
demonstrate O +
sufficient O +
differentiation O +
from O +
existing O +
compounds O -
. O +

Set O +
in O +
this O +
context O -
, O +
this O +
article O +
will O +
discuss O +
the O +
role O +
model O -
- O -
based O +
drug O +
development O +
( O -
MBDD O -
) O +
approaches O +
can O +
and O +
do O +
play O +
in O +
accelerating O +
and O +
optimizing O +
compound O +
development O +
strategies O +
through O +
a O +
series O +
of O +
illustrative O +
examples O -
. O +

Clinical O +
Pharmacology O +
& O +
Therapeutics O +
( O -
2013 O -
) O -
; O +
advance O +
online O +
publication O +
1 O +
May O +
2013 O -
. O +

doi:10.1038 O -
/ O -
clpt.2013.54 O -
. O +

pH O -
- O -
Responsive O +
Nanoparticle O +
Vaccines O +
for O +
Dual O -
- O -
Delivery O +
of O +
Antigens O +
and O +
Immunostimulatory O +
Oligonucleotides O -
. O +

Protein O +
subunit O +
vaccines O +
offer O +
important O +
potential O +
advantages O +
over O +
live O +
vaccine O +
vectors O +
but O +
generally O +
elicit O +
weaker O +
and O +
shorter O -
- O -
lived O +
cellular O +
immune O +
responses O -
. O +

Here O +
we O +
investigate O +
the O +
use O +
of O +
pH O -
- O -
responsive O -
, O +
endosomolytic O +
polymer O +
nanoparticles O +
that O +
were O +
originally O +
developed O +
for O +
RNA O +
delivery O +
as O +
vaccine O +
delivery O +
vehicles O +
for O +
enhancing O +
cellular O +
and O +
humoral O +
immune O +
responses O -
. O +

Micellar O +
nanoparticles O +
were O +
assembled O +
from O +
amphiphilic O +
diblock O +
copolymers O +
composed O +
of O +
an O +
ampholytic O +
core O -
- O -
forming O +
block O +
and O +
a O +
redesigned O +
polycationic O +
corona O +
block O +
doped O +
with O +
thiol B-Chemical -
- O -
reactive O +
pyridyl B-Chemical +
disulfide I-Chemical +
groups O +
to O +
enable O +
dual O -
- O -
delivery O +
of O +
antigens O +
and O +
immunostimulatory O +
CpG B-Chemical +
oligodeoxynucleotide O +
( O -
CpG B-Chemical +
ODN O -
) O +
adjuvants O -
. O +

Polymers O +
assembled O +
into O +
23 O +
nm O +
particles O +
with O +
simultaneous O +
packaging O +
of O +
CpG B-Chemical +
ODN O +
and O +
a O +
thiolated O +
protein O +
antigen O -
, O +
ovalbumin O +
( O -
ova O -
) O -
. O +

Conjugation O +
of O +
ova O +
to O +
nanoparticles O +
significantly O +
enhanced O +
antigen O +
cross O -
- O -
presentation O +
in O +
vitro O +
relative O +
to O +
free O +
ova O +
or O +
an O +
unconjugated O -
, O +
physical O +
mixture O +
of O +
the O +
parent O +
compounds O -
. O +

Subcutaneous O +
vaccination O +
of O +
mice O +
with O +
ova O -
- O -
nanoparticle O +
conjugates O +
elicited O +
a O +
significantly O +
higher O +
CD8 O -
( O -
+ O -
) O +
T O +
cell O +
response O +
( O -
0.5 O -
% O +
IFN O -
- O -
γ O -
( O -
+ O -
) O +
of O +
CD8 O -
( O -
+ O -
) O -
) O +
compared O +
to O +
mice O +
vaccinated O +
with O +
free O +
ova O +
or O +
a O +
physical O +
mixture O +
of O +
the O +
two O +
components O -
. O +

Significantly O -
, O +
immunization O +
with O +
ova O -
- O -
nanoparticle O +
conjugates O +
electrostatically O +
complexed O +
with O +
CpG B-Chemical +
ODN O +
( O -
dual O -
- O -
delivery O -
) O +
enhanced O +
CD8 O -
( O -
+ O -
) O +
T O +
cell O +
responses O +
( O -
3.4 O -
% O +
IFN O -
- O -
γ O -
( O -
+ O -
) O +
of O +
CD8 O -
( O -
+ O -
) O -
) O +
7- O -
, O +
18- O -
, O +
and O +
8-fold O +
relative O +
to O +
immunization O +
with O +
conjugates O -
, O +
ova O +
administered O +
with O +
free O +
CpG B-Chemical -
, O +
or O +
a O +
formulation O +
containing O +
free O +
ova O +
and O +
CpG B-Chemical +
complexed O +
to O +
micelles O -
, O +
respectively O -
. O +

Similarly O -
, O +
dual O -
- O -
delivery O +
carriers O +
significantly O +
increased O +
CD4 O -
( O -
+ O -
) O -
IFN O -
- O -
γ O -
( O -
+ O -
) O +
( O -
Th1 O -
) O +
responses O +
and O +
elicited O +
a O +
balanced O +
IgG1 O -
/ O -
IgG2c O +
antibody O +
response O -
. O +

Intradermal O +
administration O +
further O +
augmented O +
cellular O +
immune O +
responses O -
, O +
with O +
dual O -
- O -
delivery O +
carriers O +
inducing O +
∼7 O -
% O +
antigen O -
- O -
specific O +
CD8 O -
( O -
+ O -
) O +
T O +
cells O -
. O +

This O +
work O +
demonstrates O +
the O +
ability O +
of O +
pH O -
- O -
responsive O -
, O +
endosomolytic O +
nanoparticles O +
to O +
actively O +
promote O +
antigen O +
cross O -
- O -
presentation O +
and O +
augment O +
cellular O +
and O +
humoral O +
immune O +
responses O +
via O +
dual O -
- O -
delivery O +
of O +
protein O +
antigens O +
and O +
CpG B-Chemical +
ODN O -
. O +

Hence O -
, O +
pH O -
- O -
responsive O +
polymeric O +
nanoparticles O +
offer O +
promise O +
as O +
a O +
delivery O +
platform O +
for O +
protein O +
subunit O +
vaccines O -
. O +

Improved O +
Carrier O +
Mobility O +
in O +
Few O -
- O -
Layer O +
MoS2 B-Chemical +
Field O -
- O -
Effect O +
Transistors O +
with O +
Ionic O -
- O -
Liquid O +
Gating O -
. O +

We O +
report O +
the O +
fabrication O +
of O +
ionic O +
liquid O +
( O -
IL O -
) O -
-gated O +
field O -
- O -
effect O +
transistors O +
( O -
FETs O -
) O +
consisting O +
of O +
bilayer O +
and O +
few O -
- O -
layer O +
MoS2 B-Chemical -
. O +

Our O +
transport O +
measurements O +
indicate O +
that O +
the O +
electron O +
mobility O +
μ O +
≈ O +
60 O +
cm O -
( O -
2 O -
) O +
V O -
( O -
-1 O -
) O +
s O -
( O -
-1 O -
) O +
at O +
250 O +
K O +
in O +
IL O -
- O -
gated O +
devices O +
exceeds O +
significantly O +
that O +
of O +
comparable O +
back O -
- O -
gated O +
devices O -
. O +

IL O -
- O -
FETs O +
display O +
a O +
mobility O +
increase O +
from O +
≈100 O +
cm O -
( O -
2 O -
) O +
V O -
( O -
-1 O -
) O +
s O -
( O -
-1 O -
) O +
at O +
180 O +
K O +
to O +
≈220 O +
cm O -
( O -
2 O -
) O +
V O -
( O -
-1 O -
) O +
s O -
( O -
-1 O -
) O +
at O +
77 O +
K O +
in O +
good O +
agreement O +
with O +
the O +
true O +
channel O +
mobility O +
determined O +
from O +
four O -
- O -
terminal O +
measurements O -
, O +
ambipolar O +
behavior O +
with O +
a O +
high O +
ON O -
/ O -
OFF O +
ratio O +
> O -
10 O -
( O -
7 O -
) O +
( O -
10 O -
( O -
4 O -
) O -
) O +
for O +
electrons O +
( O -
holes O -
) O -
, O +
and O +
a O +
near O +
ideal O +
subthreshold O +
swing O +
of O +
≈50 O +
mV O -
/ O -
dec O +
at O +
250 O +
K. O +
We O +
attribute O +
the O +
observed O +
performance O +
enhancement O -
, O +
specifically O +
the O +
increased O +
carrier O +
mobility O +
that O +
is O +
limited O +
by O +
phonons O -
, O +
to O +
the O +
reduction O +
of O +
the O +
Schottky O +
barrier O +
at O +
the O +
source O +
and O +
drain O +
electrode O +
by O +
band O +
bending O +
caused O +
by O +
the O +
ultrathin O +
IL O +
dielectric O +
layer O -
. O +

pH O -
- O -
Responsive O +
Aggregation O +
States O +
of O +
Chiral O +
Polymerizable O +
Amphiphiles O +
from O +
l B-Chemical -
- I-Chemical -
Tyrosine I-Chemical +
and O +
l B-Chemical -
- I-Chemical -
Phenyl I-Chemical +
Alanine I-Chemical +
in O +
Water O -
. O +

Sodium B-Chemical +
salts O +
of O +
maleamic B-Chemical +
acid I-Chemical +
derivatives O +
of O +
lauryl B-Chemical +
ester I-Chemical +
of O +
tyrosine B-Chemical +
( O -
MTNa O -
) O +
and O +
phenyl B-Chemical +
alanine I-Chemical +
( O -
MPNa O -
) O +
in O +
water O +
exhibited O +
strong O +
pH O -
- O -
responsive O +
behaviors O +
of O +
viscosity O +
and O +
specific O +
conductivity O +
that O +
originate O +
from O +
the O +
concentration O +
and O +
pH O +
dependence O +
of O +
their O +
aggregation O +
states O -
. O +

The O +
aggregates O +
were O +
characterized O +
by O +
a O +
novel O +
spin O -
- O -
probe O -
- O -
partitioning O +
electron O +
paramagnetic O +
resonance O +
( O -
SPPEPR O -
) O +
method O +
and O +
dynamic O +
light O +
scattering O +
( O -
DLS O -
) O -
. O +

Results O +
of O +
high O -
- O -
precision O +
fitting O +
of O +
the O +
second O -
- O -
harmonic O +
EPR O +
spectra O +
of O +
the O +
small O +
spin O +
probe O +
di B-Chemical -
- I-Chemical -
tert I-Chemical -
- I-Chemical -
butyl I-Chemical +
nitroxide I-Chemical +
( O -
DTBN B-Chemical -
) O +
in O +
these O +
aggregates O +
together O +
with O +
viscosity O -
, O +
conductivity O -
, O +
and O +
DLS O +
showed O +
that O -
, O +
at O +
pH O +
∼ O +
7.54 O -
, O +
MTNa O +
formed O +
micelles O +
and O +
MPNa O +
vesicles O +
and O +
MTNa O +
exhibited O +
a O +
pH O -
- O -
induced O +
micelle O +
to O +
vesicle O +
transition O +
as O +
pH O +
was O +
lowered O +
toward O +
6 O -
. O +

MTNa O -
, O +
at O +
pH O +
∼ O +
7.54 O -
, O +
formed O +
small O +
micelles O +
at O +
low O +
concentrations O +
that O +
transformed O +
to O +
long O +
worm O -
- O -
like O +
micelles O +
for O +
concentrations O +
≥ O +
0.05 O +
M O -
, O +
accompanied O +
by O +
a O +
30-fold O +
increase O +
in O +
solution O +
viscosity O -
. O +

The O +
hydrodynamic O +
radii O +
from O +
DLS O +
confirmed O +
the O +
presence O +
of O +
small O +
micellar O +
aggregates O +
of O +
radius O +
∼ O +
2 O +
nm O +
in O +
MTNa O +
at O +
pH O +
∼ O +
7.54 O +
at O +
the O +
lower O +
concentrations O -
, O +
with O +
coexisting O +
micelles O +
( O -
∼2 O +
nm O -
) O +
and O +
vesicles O +
( O -
∼50 O +
nm O -
) O +
at O +
pH O +
near O +
6.5 O -
, O +
vesicles O +
( O -
radii O +
∼ O +
70 O +
nm O -
) O +
at O +
pH O +
near O +
6 O -
, O +
and O +
large O +
vesicles O +
( O -
85 O +
nm O -
) O +
in O +
MPNa O +
at O +
pH O +
∼ O +
7.60 O -
. O +

Both O +
MTNa O +
and O +
MPNa O +
precipitated O +
upon O +
reduction O +
of O +
pH O +
below O +
6 O +
and O +
below O +
7 O -
, O +
respectively O -
. O +

The O +
rate O +
of O +
transfer O +
of O +
DTBN B-Chemical +
between O +
the O +
aqueous O +
phase O +
and O +
the O +
aggregate O +
was O +
calculated O +
from O +
the O +
high O -
- O -
field O +
Lorentzian O +
linewidths O +
of O +
the O +
electron O +
paramagnetic O +
resonance O +
( O -
EPR O -
) O +
spectra O -
. O +

The O +
activation O +
energy O +
for O +
the O +
transfer O +
determined O +
from O +
the O +
temperature O +
dependence O +
of O +
the O +
rate O +
of O +
transfer O +
is O +
12.7 O +
kJ O -
/ O -
mol O +
for O +
MTNa O +
vesicles O +
( O -
pH O +
∼ O +
6 O -
) O +
and O +
20.6 O +
± O +
1.3 O +
kJ O -
/ O -
mol O +
for O +
MPNa O +
( O -
pH O +
∼ O +
7.60 O -
) O -
. O +

The O +
pH O -
- O -
induced O +
transformations O +
were O +
reversible O -
. O +

Discovery O +
of O +
aryl B-Chemical +
ureas I-Chemical +
and O +
aryl B-Chemical +
amides I-Chemical +
as O +
potent O +
and O +
selective O +
histamine B-Chemical +
H3 O +
receptor O +
antagonists O +
for O +
the O +
treatment O +
of O +
obesity O +
( O -
Part O +
I O -
) O -
. O +

A O +
series O +
of O +
structurally O +
novel O +
aryl B-Chemical +
ureas I-Chemical +
was O +
derived O +
from O +
optimization O +
of O +
the O +
HTS O +
lead O +
as O +
selective O +
histamine B-Chemical +
H3 O +
receptor O +
( O -
H3R O -
) O +
antagonists O -
. O +

The O +
SAR O +
was O +
explored O +
and O +
the O +
data O +
obtained O +
set O +
up O +
the O +
starting O +
point O +
and O +
foundation O +
for O +
further O +
optimization O -
. O +

The O +
most O +
potent O +
tool O +
compounds O -
, O +
as O +
exemplified O +
by O +
compounds O +
2l O -
, O +
5b O -
, O +
5d O -
, O +
and O +
5e O -
, O +
displayed O +
antagonism O +
potencies O +
in O +
the O +
subnanomolar O +
range O +
in O +
in O +
vitro O +
human O -
- O -
H3R O +
FLIPR O +
assays O +
and O +
rhesus O +
monkey O +
H3R O +
binding O +
assays O -
. O +

Phenanthroimidazole B-Chemical -
- O -
based O +
thiobenzamide B-Chemical +
as O +
an O +
effective O +
sensor O +
for O +
highly O +
selective O +
detection O +
of O +
mercury B-Chemical -
( I-Chemical -
II I-Chemical -
) I-Chemical -
. O +

Based O +
on O +
highly O +
selective O +
and O +
irreversible O +
Hg B-Chemical -
( I-Chemical -
2+ I-Chemical -
) I-Chemical -
-promoted O +
desulfurization O +
reaction O -
, O +
a O +
new O +
and O +
simple O +
phenanthroimidazole B-Chemical -
- O -
type O +
sensor O +
was O +
prepared O +
and O +
exhibited O +
high O +
selectivity O +
towards O +
Hg B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
ion O +
over O +
other O +
metal O +
ions O -
, O +
accompanied O +
by O +
transformation O +
of O +
a O +
weakly O +
fluorescent O +
thioamide B-Chemical +
moiety O +
( O -
colorless O -
) O +
to O +
a O +
highly O +
fluorescent O +
amide B-Chemical +
one O +
( O -
blue O -
) O -
, O +
with O +
a O +
136-fold O +
increase O +
in O +
fluorescent O +
intensity O +
in O +
aqueous O +
solution O +
with O +
a O +
pH O +
span O +
2.57 O -
- O -
9.12 O -
. O +

Cerebral O +
ischemia O -
- O -
induced O +
difference O +
in O +
sensitivity O +
to O +
depression O +
and O +
potential O +
therapeutics O +
in O +
rats O -
. O +

The O +
' O -
vascular O +
depression O -
' O +
hypothesis O +
has O +
recently O +
attracted O +
significant O +
research O +
attention O -
, O +
although O +
the O +
causal O +
relationship O +
between O +
vascular O -
- O -
related O +
injuries O +
and O +
depression O +
has O +
not O +
been O +
established O -
. O +

Here O -
, O +
we O +
show O +
that O +
one O +
episode O +
of O +
cerebral O +
ischemia O +
was O +
sufficient O +
to O +
greatly O +
increase O +
the O +
sensitivity O +
of O +
rats O +
to O +
potentially O +
depressogenic O +
events O -
, O +
evaluated O +
at O +
below O -
- O -
threshold O +
intensities O +
in O +
the O +
open O +
space O +
swim O +
test O -
. O +

The O +
induced O +
' O -
ischemic O +
depression O -
' O +
was O +
lasting O +
and O +
sensitive O +
to O +
an O +
acute O +
administration O +
of O +
brain O -
- O -
derived O +
neurotrophic O +
factor O +
or O +
bryostatin-1 B-Chemical -
, O +
a O +
relatively O +
selective O +
activator O +
of O +
protein O +
kinase O +
Cε O -
, O +
during O +
the O +
induction O +
phase O -
. O +

Chronic O +
treatment O +
with O +
bryostatin-1 B-Chemical +
( O -
5 O +
weeks O -
) O +
after O +
the O +
induction O +
of O +
depressive O +
behavior O +
reversed O +
the O +
depressive O +
immobility O +
and O +
produced O +
a O +
lasting O +
therapeutic O +
effect O -
, O +
which O +
remained O +
effective O +
3 O +
weeks O +
after O +
discontinuation O +
of O +
the O +
treatment O -
. O +

Similar O +
treatment O +
with O +
alaproclate B-Chemical -
, O +
a O +
selective O +
serotonin B-Chemical +
reuptake O +
inhibitor O -
, O +
in O +
contrast O -
, O +
produced O +
temporary O +
relief O +
from O +
the O +
depressive O +
symptoms O -
, O +
with O +
the O +
therapeutic O +
effect O +
disappearing O +
soon O +
after O +
the O +
end O +
of O +
the O +
treatment O -
. O +

The O +
results O +
strongly O +
suggest O +
that O +
cerebral O +
ischemia O +
has O +
a O +
direct O +
role O +
in O +
shaping O +
the O +
sensitivity O +
of O +
an O +
individual O +
to O +
depressogenic O +
events O +
and O +
that O +
bryostatin-1-like B-Chemical +
agents O +
may O +
be O +
developed O +
as O +
therapeutics O +
for O +
treating O +
ischemic O +
depression O +
in O +
humans O -
. O +

Current O +
status O +
of O +
liposomal O +
porphyrinoid B-Chemical +
photosensitizers O -
. O +

The O +
complete O +
eradication O +
of O +
various O +
targets O -
, O +
such O +
as O +
infectious O +
agents O +
or O +
cancer O +
cells O -
, O +
while O +
leaving O +
healthy O +
host O +
cells O +
untouched O -
, O +
is O +
still O +
a O +
great O +
challenge O +
faced O +
in O +
the O +
field O +
of O +
medicine O -
. O +

Photodynamic O +
therapy O +
( O -
PDT O -
) O +
seems O +
to O +
be O +
a O +
promising O +
approach O +
for O +
anticancer O +
treatment O -
, O +
as O +
well O +
as O +
to O +
combat O +
various O +
dermatologic O +
and O +
ophthalmic O +
diseases O +
and O +
microbial O +
infections O -
. O +

The O +
application O +
of O +
liposomes O +
as O +
delivery O +
systems O +
for O +
porphyrinoids B-Chemical +
has O +
helped O +
overcome O +
many O +
drawbacks O +
of O +
conventional O +
photosensitizers O +
and O +
facilitated O +
the O +
development O +
of O +
novel O +
effective O +
photosensitizers O +
that O +
can O +
be O +
encapsulated O +
in O +
liposomes O -
. O +

The O +
development O -
, O +
preclinical O +
studies O +
and O +
future O +
directions O +
for O +
liposomal O +
delivery O +
of O +
conventional O +
and O +
novel O +
photosensitizers O +
are O +
reviewed O -
. O +

Effects O +
of O +
Selenium B-Chemical +
Intervention O +
on O +
Chronic O +
Fluorosis O -
- O -
Induced O +
Renal O +
Cell O +
Apoptosis O +
in O +
Rats O -
. O +

This O +
study O +
aims O +
to O +
explore O +
the O +
effect O +
of O +
selenium B-Chemical +
in O +
fluoride B-Chemical -
- O -
induced O +
renal O +
cell O +
apoptosis O +
in O +
rats O +
and O +
determine O +
the O +
optimal O +
level O +
of O +
selenium B-Chemical +
in O +
drinking O +
water O +
to O +
prevent O +
fluorosis O -
. O +

Experimental O +
animals O +
were O +
divided O +
into O +
a O +
control O +
group O -
, O +
a O +
sodium B-Chemical +
fluoride I-Chemical -
- O -
treated O +
group O +
( O -
NaF B-Chemical -
, O +
50 O +
mg O -
/ O -
L O -
) O -
, O +
three O +
sodium B-Chemical +
selenite I-Chemical -
- O -
treated O +
groups O +
( O -
Na2SeO3 B-Chemical -
, O +
0.375 O -
, O +
0.75 O -
, O +
and O +
1.5 O +
mg O -
/ O -
L O -
) O -
, O +
and O +
three O +
selenium B-Chemical +
+ O +
NaF B-Chemical -
- O -
treated O +
groups O +
( O -
Na2SeO3 B-Chemical -
, O +
0.375 O -
, O +
0.75 O -
, O +
and O +
1.5 O +
mg O -
/ O -
L O -
; O +
NaF B-Chemical -
, O +
50 O +
mg O -
/ O -
L O -
) O -
. O +

Ultrastructural O +
changes O +
in O +
the O +
kidney O +
tissues O +
of O +
each O +
group O +
were O +
observed O +
by O +
transmission O +
electron O +
microscopy O -
. O +

Apoptosis O +
was O +
detected O +
by O +
terminal O +
deoxynucleotidyl O +
transferase O -
- O -
mediated O +
dUTP B-Chemical +
nick O -
- O -
end O +
labeling O +
assay O +
and O +
the O +
expressions O +
of O +
Bcl-2 O +
and O +
Bax O +
proteins O +
were O +
detected O +
by O +
immunohistochemical O +
methods O -
. O +

The O +
expressions O +
of O +
Bcl-2 O +
and O +
Bax O +
mRNA O +
were O +
detected O +
by O +
reverse O +
transcription O -
- O -
polymerase O +
chain O +
reaction O -
. O +

The O +
results O +
showed O +
that O +
Bcl-2 O -
, O +
Bax O -
, O +
and O +
Bax O -
/ O -
Bcl-2 O +
protein O +
expressions O +
in O +
the O +
fluoride B-Chemical +
and O +
high O +
selenium B-Chemical +
groups O +
were O +
highly O +
elevated O +
compared O +
with O +
the O +
control O +
group O +
( O -
P O +
< O +
0.01 O -
) O -
. O +

Bax O +
expression O +
in O +
the O +
low O +
selenium B-Chemical +
group O +
and O +
Bcl-2 O -
, O +
Bax O -
, O +
and O +
Bax O -
/ O -
Bcl-2 O +
protein O +
expressions O +
in O +
the O +
moderate O +
selenium B-Chemical +
groups O +
were O +
observably O +
elevated O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

Bax O +
and O +
Bax O -
/ O -
Bcl-2 O +
expressions O +
in O +
the O +
fluoride B-Chemical +
group O +
and O +
Bax O +
mRNA O +
expression O +
in O +
the O +
high O +
selenium B-Chemical +
group O +
were O +
highly O +
elevated O +
( O -
P O +
< O +
0.01 O -
) O -
. O +

Bax O -
/ O -
Bcl-2 O +
mRNA O +
expression O +
in O +
the O +
high O +
selenium B-Chemical +
group O +
was O +
also O +
highly O +
elevated O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

Compared O +
with O +
the O +
fluoride B-Chemical +
group O -
, O +
the O +
group O +
treated O +
with O +
low O +
selenium B-Chemical +
has O +
Bax O +
protein O +
expression O +
that O +
was O +
observably O +
reduced O +
( O -
P O +
< O +
0.05 O -
) O -
; O +
the O +
group O +
treated O +
with O +
moderate O +
selenium B-Chemical +
has O +
Bcl-2 O +
protein O +
expression O +
that O +
was O +
observably O +
elevated O +
( O -
P O +
< O +
0.05 O -
) O -
, O +
Bax O +
protein O +
expression O +
that O +
was O +
highly O +
reduced O +
( O -
P O +
< O +
0.01 O -
) O -
, O +
and O +
Bax O -
/ O -
Bcl-2 O +
protein O +
expression O +
that O +
was O +
observably O +
reduced O +
( O -
P O +
< O +
0.05 O -
) O -
; O +
the O +
group O +
treated O +
with O +
high O +
selenium B-Chemical +
has O +
Bcl-2 O +
protein O +
expression O +
that O +
was O +
highly O +
elevated O +
( O -
P O +
< O +
0.01 O -
) O -
, O +
Bax O +
protein O +
expression O +
that O +
was O +
highly O +
elevated O +
( O -
P O +
< O +
0.01 O -
) O -
, O +
and O +
Bax O -
/ O -
Bcl-2 O +
protein O +
expression O +
that O +
was O +
highly O +
reduced O +
( O -
P O +
< O +
0.01 O -
) O -
; O +
the O +
groups O +
treated O +
with O +
moderate O +
selenium B-Chemical +
and O +
high O +
selenium B-Chemical +
have O +
Bax O +
mRNA O +
expression O +
that O +
was O +
highly O +
reduced O +
( O -
P O +
< O +
0.01 O -
) O -
, O +
and O +
the O +
groups O +
treated O +
with O +
high O +
selenium B-Chemical +
have O +
Bax O -
/ O -
Bcl-2 O +
mRNA O +
expression O +
that O +
was O +
observably O +
reduced O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

Selenium B-Chemical +
may O +
inhibit O +
the O +
apoptosis O +
of O +
renal O +
cells O +
in O +
fluorosis O +
rats O +
by O +
regulating O +
the O +
expressions O +
of O +
Bcl-2 O +
and O +
Bax O -
. O +

The O +
optimal O +
dose O +
of O +
Na2SeO3 B-Chemical +
to O +
protect O +
against O +
fluoride B-Chemical -
- O -
induced O +
renal O +
cell O +
apoptosis O +
was O +
determined O +
to O +
be O +
1.5 O +
mg O -
/ O -
L. O +

Melatonin B-Chemical +
and O +
its O +
analogue O +
5-MCA B-Chemical -
- I-Chemical -
NAT I-Chemical +
potentiate O +
adrenergic O +
receptor O -
- O -
mediated O +
ocular O +
hypotensive O +
effects O +
in O +
rabbits O -
: O +
Significance O +
for O +
combination O +
therapy O +
in O +
glaucoma O -
. O +

Melatonin B-Chemical +
is O +
currently O +
considered O +
as O +
a O +
promising O +
drug O +
for O +
glaucoma O +
treatment O +
due O +
to O +
its O +
ocular O +
hypotensive O +
and O +
neuroprotective O +
effects O -
. O +

We O +
have O +
investigated O +
the O +
effect O +
of O +
melatonin B-Chemical +
and O +
its O +
analogue O +
5-methoxycarbonylamino B-Chemical -
- I-Chemical -
N I-Chemical -
- I-Chemical -
acetyltryptamine I-Chemical -
, O +
5-MCA B-Chemical -
- I-Chemical -
NAT I-Chemical -
, O +
on O +
β2 O -
/ O -
α2A O -
- O -
adrenergic O +
receptor O +
mRNA O +
as O +
well O +
as O +
protein O +
expression O +
in O +
cultured O +
rabbit O +
non O -
- O -
pigmented O +
ciliary O +
epithelial O +
cells O -
. O +

Quantitative O +
PCR O +
and O +
immunocytochemical O +
assays O +
revealed O +
a O +
significant O +
β2-adrenergic O +
receptor O +
down O -
- O -
regulation O +
as O +
well O +
as O +
α2A O -
- O -
adrenergic O +
receptor O +
up O -
- O -
regulation O +
of O +
treated O +
cells O +
( O -
p<0.001 O -
, O +
maximal O +
significant O +
effect O -
) O -
. O +

In O +
addition O -
, O +
we O +
have O +
studied O +
the O +
effect O +
of O +
these O +
drugs O +
upon O +
the O +
ocular O +
hypotensive O +
action O +
of O +
a O +
non O -
- O -
selective O +
β O -
- O -
adrenergic O +
receptor O +
( O -
timolol B-Chemical -
) O +
and O +
a O +
selective O +
α2-adrenergic O +
receptor O +
agonist O +
( O -
brimonidine B-Chemical -
) O +
in O +
normotensive O +
rabbits O -
. O +

IOP O +
experiments O +
showed O +
that O +
the O +
administration O +
of O +
timolol B-Chemical +
in O +
rabbits O +
pre O -
- O -
treated O +
with O +
melatonin B-Chemical +
or O +
5-MCA B-Chemical -
- I-Chemical -
NAT I-Chemical +
evoked O +
an O +
additional O +
IOP O +
reduction O +
of O +
14.02 O +
± O +
5.8 O +
% O +
or O +
16.75 O +
± O +
5.48 O +
% O +
( O -
p<0.01 O -
) O +
in O +
comparison O +
with O +
rabbits O +
treated O +
with O +
timolol B-Chemical +
alone O +
for O +
24 O +
hours O -
. O +

Concerning O +
brimonidine B-Chemical +
hypotensive O +
action O -
, O +
an O +
additional O +
IOP O +
reduction O +
of O +
29.26 O +
± O +
5.21 O +
% O +
or O +
39.07 O +
± O +
5.81 O +
% O +
( O -
p<0.001 O -
) O +
was O +
observed O +
in O +
rabbits O +
pretreated O +
with O +
melatonin B-Chemical +
or O +
5-MCA B-Chemical -
- I-Chemical -
NAT I-Chemical +
when O +
compared O +
with O +
animals O +
treated O +
with O +
brimonidine B-Chemical +
alone O +
for O +
24 O +
hours O -
. O +

Additionally O -
, O +
a O +
sustained O +
potentiating O +
effect O +
of O +
a O +
single O +
dose O +
of O +
5-MCA B-Chemical -
- I-Chemical -
NAT I-Chemical +
was O +
seen O +
in O +
rabbits O +
treated O +
with O +
brimonidine B-Chemical +
once O +
daily O +
for O +
up O +
four O +
days O +
( O -
extra O +
IOP O +
decrease O +
of O +
15.57 O +
± O +
5.15 O -
% O -
, O +
p<0.05 O -
, O +
compared O +
to O +
brimonidine B-Chemical +
alone O -
) O -
. O +

These O +
data O +
confirm O +
the O +
indirect O +
action O +
of O +
melatoninergic O +
compounds O +
on O +
adrenergic O +
receptors O +
and O +
their O +
remarkable O +
effect O +
upon O +
the O +
ocular O +
hypotensive O +
action O +
mainly O +
of O +
α2-adrenergic O +
receptor O +
agonists O +
but O +
also O +
of O +
β O -
- O -
adrenergic O +
antagonists O -
. O +

Focal O +
adhesion O +
kinase O +
regulates O +
collagen O +
I O -
- O -
induced O +
airway O +
smooth O +
muscle O +
phenotype O +
switching O -
. O +

Increased O +
extracellular O +
matrix O +
( O -
ECM O -
) O +
deposition O +
and O +
airway O +
smooth O +
muscle O +
( O -
ASM O -
) O +
mass O +
are O +
major O +
contributors O +
to O +
airway O +
remodeling O +
in O +
asthma O -
. O +

Recently O -
, O +
we O +
have O +
demonstrated O +
that O +
the O +
ECM O +
protein O +
collagen O +
I O -
, O +
which O +
is O +
increased O +
surrounding O +
asthmatic O +
ASM O -
, O +
induces O +
a O +
proliferative O -
, O +
hypocontractile O +
ASM O +
phenotype O -
. O +

Little O +
is O +
known O -
, O +
however O -
, O +
on O +
the O +
signaling O +
pathways O +
involved O -
. O +

Using O +
bovine O +
tracheal O +
smooth O +
muscle O -
, O +
we O +
investigated O +
the O +
role O +
of O +
focal O +
adhesion O +
kinase O +
( O -
FAK O -
) O +
and O +
downstream O +
signaling O +
pathways O +
in O +
collagen O +
I O -
- O -
induced O +
ASM O +
phenotype O +
modulation O -
. O +

Phosphorylation O +
of O +
FAK O +
was O +
increased O +
during O +
adhesion O +
to O +
both O +
uncoated O +
and O +
collagen O +
I O -
- O -
coated O +
culture O +
dishes O -
, O +
without O +
differences O +
between O +
these O +
matrices O -
. O +

No O +
differences O +
in O +
cellular O +
adhesion O +
were O +
found O +
either O -
. O +

Inhibition O +
of O +
FAK O +
activity O +
by O +
overexpression O +
of O +
the O +
FAK O +
deletion O +
mutants O +
FAT O +
( O -
focal O +
adhesion O +
targeting O +
domain O -
) O +
and O +
FRNK O +
( O -
FAK O -
- O -
related O +
non O -
- O -
kinase O -
) O +
attenuated O +
adhesion O -
. O +

After O +
attachment O -
, O +
FAK O +
phosphorylation O +
was O +
time O -
- O -
dependently O +
increased O +
in O +
cells O +
cultured O +
on O +
collagen O +
I O -
, O +
whereas O +
no O +
activation O +
was O +
found O +
on O +
an O +
uncoated O +
plastic O +
matrix O -
. O +

In O +
addition O -
, O +
collagen O +
I O +
time- O +
and O +
concentration O -
- O -
dependently O +
increased O +
cell O +
proliferation O -
, O +
which O +
was O +
fully O +
inhibited O +
by O +
FAT O +
and O +
FRNK O -
. O +

Similarly O -
, O +
the O +
specific O +
pharmacological O +
FAK O +
inhibitor O +
PF-573,228 B-Chemical +
as O +
well O +
as O +
specific O +
inhibitors O +
of O +
p38 O +
MAPK O +
and O +
Src O +
also O +
fully O +
inhibited O +
collagen O +
I O -
- O -
induced O +
proliferation O -
, O +
whereas O +
partial O +
inhibition O +
was O +
observed O +
by O +
inhibition O +
of O +
PI3-kinase O +
and O +
MEK O -
. O +

The O +
inhibition O +
of O +
cell O +
proliferation O +
by O +
these O +
inhibitors O +
was O +
associated O +
with O +
attenuation O +
of O +
the O +
collagen O +
I O -
- O -
induced O +
hypocontractility O -
. O +

Collectively O -
, O +
the O +
results O +
indicate O +
that O +
induction O +
of O +
a O +
proliferative O -
, O +
hypocontractile O +
ASM O +
phenotype O +
by O +
collagen O +
I O +
is O +
mediated O +
by O +
FAK O +
and O +
downstream O +
signaling O +
pathways O -
. O +

Selective O +
Smad4 O +
Knockout O +
in O +
Ovarian O +
Preovulatory O +
Follicles O +
Results O +
in O +
Multiple O +
Defects O +
in O +
Ovulation O -
. O +

The O +
TGF O -
- O -
β O +
signaling O +
pathway O +
is O +
involved O +
with O +
multiple O +
processes O +
in O +
the O +
mammalian O +
ovary O -
, O +
including O +
primordial O +
follicle O +
formation O -
, O +
granulosa O +
cell O +
( O -
GC O -
) O +
proliferation O -
, O +
follicle O +
atresia O -
, O +
ovulation O -
, O +
and O +
feedback O +
regulation O +
between O +
the O +
pituitary O +
and O +
ovary O -
. O +

The O +
transcriptional O +
factor O +
SMAD4 O +
is O +
the O +
central O +
component O +
of O +
the O +
canonical O +
TGF O -
- O -
β O +
signaling O +
pathway O -
. O +

Smad4 O +
knockout O +
using O +
Amhr2-Cre O -
, O +
which O +
is O +
expressed O +
in O +
GCs O +
of O +
immature O +
developing O +
follicles O -
, O +
causes O +
premature O +
luteinization O -
. O +

In O +
this O +
study O -
, O +
we O +
specifically O +
depleted O +
Smad4 O +
in O +
GCs O +
of O +
preovulatory O +
follicles O +
using O +
Cyp19-Cre O +
mice O -
. O +

As O +
different O +
from O +
results O +
with O +
Smad4 O -
( O -
fl O -
/ O -
fl O -
) O -
;Amhr2-Cre O +
mice O -
, O +
Smad4 O +
depletion O +
in O +
preovulatory O +
follicles O +
did O +
not O +
cause O +
premature O +
luteinization O +
or O +
suppress O +
GC O +
proliferation O -
; O +
rather O -
, O +
it O +
increased O +
follicle O +
atresia O -
. O +

In O +
addition O -
, O +
Nppc O +
and O +
Npr2 O +
expressions O +
were O +
reduced O +
by O +
Smad4 O +
depletion O -
; O +
thus O -
, O +
their O +
effect O +
of O +
maintaining O +
oocyte O +
meiotic O +
arrest O +
was O +
weakened O +
in O +
Smad4 O +
conditional O +
knockout O +
mice O -
. O +

Smad4 O -
( O -
fl O -
/ O -
fl O -
) O -
;Cyp19-Cre O +
female O +
mice O +
were O +
subfertile O +
and O +
had O +
irregular O +
estrous O +
cycles O +
and O +
ovulation O +
defects O -
. O +

Smad4 O +
knockout O +
also O +
blocked O +
luteinizing O +
hormone O +
( O -
LH O -
) O -
-induced O +
cumulus O +
expansion O +
and O +
follicle O +
rupture O -
, O +
but O +
not O +
oocyte O +
meiotic O +
resumption O -
. O +

Our O +
results O +
also O +
indicated O +
that O +
SMAD4 O +
was O +
required O +
for O +
LH O -
- O -
stimulated O +
activation O +
of O +
ERK1 O -
/ O -
2 O +
and O +
the O +
expressions O +
of O +
ovulation O -
- O -
related O +
genes O -
. O +

The O +
defects O +
arising O +
from O +
SMAD4 O +
depletion O +
could O +
not O +
be O +
rescued O +
by O +
intra O -
- O -
ovarian O +
mediators O +
of O +
LH O +
actions O -
, O +
such O +
as O +
EGF O -
- O -
like O +
factors O +
and O +
prostaglandin B-Chemical +
E2 I-Chemical -
. O +

Furthermore O -
, O +
corpus O +
lutea O +
did O +
not O +
form O +
in O +
Smad4 O -
( O -
fl O -
/ O -
fl O -
) O -
;Cyp19-Cre O +
female O +
mice O -
, O +
indicating O +
that O +
SMAD4 O +
was O +
crucial O +
for O +
GCs O +
terminal O +
differentiation O -
. O +

Thus O -
, O +
by O +
characterizing O +
the O +
ovarian O +
phenotypes O +
of O +
preovulatory O +
follicle O -
- O -
specific O +
Smad4 O +
knockout O +
mice O -
, O +
we O +
identified O +
the O +
developmental O +
stage O -
- O -
specific O +
functions O +
of O +
the O +
canonical O +
TGF O -
- O -
β O +
signaling O +
pathway O +
in O +
ovulation O +
and O +
luteinization O -
. O +

Charge O -
- O -
Transfer O +
Interaction O +
between O +
Few O -
- O -
Layer O +
MoS2 B-Chemical +
and O +
Tetrathiafulvalene B-Chemical -
. O +

Graphene B-Chemical +
look O -
- O -
alike O -
: O +
MoS2 B-Chemical +
has O +
a O +
layered O +
structure O +
similar O +
to O +
graphene B-Chemical -
. O +

Tetrathiafulvalene B-Chemical +
( O -
TTF B-Chemical -
) O +
interacts O +
with O +
thin O -
, O +
few O -
- O -
layer O +
MoS2 B-Chemical +
material O +
by O +
donating O +
an O +
electron O -
, O +
resulting O +
in O +
the O +
formation O +
of O +
TTF B-Chemical +
radical O +
cation O +
and O +
n O -
- O -
type O +
doping O +
of O +
MoS2 B-Chemical +
. O +

Electron O -
- O -
withdrawing O +
tetracyanoethylene B-Chemical -
, O +
in O +
contrast O -
, O +
does O +
not O +
cause O +
p O -
- O -
type O +
doping O +
in O +
MoS2 B-Chemical +
. O +

Matrix O +
Isolation O +
Spectroscopy O +
and O +
Nuclear O +
Spin O +
Conversion O +
of O +
NH3 B-Chemical +
and O +
ND3 B-Chemical +
in O +
Solid O +
Parahydrogen B-Chemical -
. O +

We O +
present O +
matrix O +
isolation O +
infrared O +
absorption O +
spectra O +
of O +
NH3 B-Chemical +
and O +
ND3 B-Chemical +
trapped O +
in O +
solid O +
parahydrogen B-Chemical +
( O -
pH2 B-Chemical -
) O +
at O +
temperatures O +
around O +
1.8 O +
K. O +
We O +
used O +
the O +
relatively O +
slow O +
nuclear O +
spin O +
conversion O +
( O -
NSC O -
) O +
of O +
NH3 B-Chemical +
and O +
ND3 B-Chemical +
in O +
freshly O +
deposited O +
pH2 B-Chemical +
samples O +
as O +
a O +
tool O +
to O +
assign O +
the O +
sparse O +
vibration O -
- O -
inversion O -
- O -
rotation O +
( O -
VIR O -
) O +
spectra O +
of O +
NH3 B-Chemical +
in O +
the O +
regions O +
of O +
the O +
ν2 O -
, O +
ν4 O -
, O +
2ν4 O -
, O +
ν1 O -
, O +
and O +
ν3 O +
bands O +
and O +
ND3 B-Chemical +
in O +
the O +
regions O +
of O +
the O +
ν2 O -
, O +
ν4 O -
, O +
ν1 O -
, O +
and O +
ν3 O +
fundamentals O -
. O +

Partial O +
assignments O +
are O +
also O +
presented O +
for O +
various O +
combination O +
bands O +
of O +
NH3 B-Chemical -
. O +

Detailed O +
analysis O +
of O +
the O +
ν2 O +
bands O +
of O +
NH3 B-Chemical +
and O +
ND3 B-Chemical +
indicates O +
that O +
both O +
isotopomers O +
are O +
nearly O +
free O +
rotors O -
; O +
that O +
the O +
vibrational O +
energy O +
is O +
blue O -
- O -
shifted O +
by O +
1 O -
- O -
2 O -
% O -
; O +
and O +
that O +
the O +
rotational O +
constants O +
and O +
inversion O +
tunneling O +
splitting O +
are O +
91 O -
- O -
94 O -
% O +
and O +
67 O -
- O -
75 O -
% O -
, O +
respectively O -
, O +
of O +
the O +
gas O -
- O -
phase O +
values O -
. O +

The O +
line O +
shapes O +
of O +
the O +
VIR O +
absorptions O +
are O +
narrow O +
( O -
0.2 O -
- O -
0.4 O +
cm O -
( O -
-1 O -
) O -
) O +
for O +
upper O +
states O +
that O +
can O -
not O +
rotationally O +
relax O +
and O +
broad O +
( O -
> O -
1 O +
cm O -
( O -
-1 O -
) O -
) O +
for O +
upper O +
states O +
that O +
can O +
rotationally O +
relax O -
. O +

We O +
report O +
and O +
assign O +
a O +
number O +
of O +
NH3-induced B-Chemical +
infrared O +
absorption O +
features O +
of O +
the O +
pH2 B-Chemical +
host O +
near O +
4150 O +
cm O -
( O -
-1 O -
) O -
, O +
along O +
with O +
a O +
cooperative O +
transition O +
that O +
involves O +
simultaneous O +
vibrational O +
excitation O +
of O +
a O +
pH2 B-Chemical +
molecule O +
and O +
rotation O -
- O -
inversion O +
excitation O +
of O +
NH3 B-Chemical -
. O +

The O +
NSCs O +
of O +
NH3 B-Chemical +
and O +
ND3 B-Chemical +
were O +
found O +
to O +
follow O +
first O -
- O -
order O +
kinetics O +
with O +
rate O +
constants O +
at O +
1.8 O +
K O +
of O +
k O +
= O +
1.88 O -
( O -
16 O -
) O +
× O +
10 O -
( O -
-3 O -
) O +
s O -
( O -
-1 O -
) O +
and O +
k O +
= O +
1.08 O -
( O -
8 O -
) O +
× O +
10 O -
( O -
-3 O -
) O +
s O -
( O -
-1 O -
) O -
, O +
respectively O -
. O +

These O +
measured O +
rate O +
constants O +
are O +
compared O +
to O +
previous O +
measurements O +
for O +
NH3 B-Chemical +
in O +
an O +
Ar O +
matrix O +
and O +
with O +
the O +
rate O +
constants O +
measured O +
for O +
other O +
dopant O +
molecules O +
isolated O +
in O +
solid O +
pH2 B-Chemical -
. O +

Development O +
and O +
validation O +
of O +
NIR O -
- O -
chemometric O +
methods O +
for O +
chemical O +
and O +
pharmaceutical O +
characterization O +
of O +
meloxicam B-Chemical +
tablets O -
. O +

Abstract O +
Context O -
: O +
Near O -
- O -
Infrared O +
( O -
NIR O -
) O +
spectroscopy O +
is O +
an O +
important O +
component O +
of O +
a O +
Process O +
Analytical O +
Technology O +
( O -
PAT O -
) O +
toolbox O +
and O +
is O +
a O +
key O +
technology O +
for O +
enabling O +
the O +
rapid O +
analysis O +
of O +
pharmaceutical O +
tablets O -
. O +

Objective O -
: O +

The O +
aim O +
of O +
this O +
research O +
work O +
was O +
to O +
develop O +
and O +
validate O +
NIR O -
- O -
chemometric O +
methods O +
not O +
only O +
for O +
the O +
determination O +
of O +
active O +
pharmaceutical O +
ingredients O +
content O +
but O +
also O +
pharmaceutical O +
properties O +
( O -
crushing O +
strength O -
, O +
disintegration O +
time O -
) O +
of O +
meloxicam B-Chemical +
tablets O -
. O +

Materials O +
and O +
methods O -
: O +
The O +
development O +
of O +
the O +
method O +
for O +
active O +
content O +
assay O +
was O +
performed O +
on O +
samples O +
corresponding O +
to O +
80 O -
% O -
, O +
90 O -
% O -
, O +
100 O -
% O -
, O +
110 O -
% O +
and O +
120 O -
% O +
of O +
meloxicam B-Chemical +
content O +
and O +
the O +
development O +
of O +
the O +
methods O +
for O +
pharmaceutical O +
characterization O +
was O +
performed O +
on O +
samples O +
prepared O +
at O +
seven O +
different O +
compression O +
forces O +
( O -
ranging O +
from O +
7 O +
to O +
45 O +
kN O -
) O +
using O +
NIR O +
transmission O +
spectra O +
of O +
intact O +
tablets O +
and O +
PLS O +
as O +
a O +
regression O +
method O -
. O +

Results O -
: O +
The O +
results O +
show O +
that O +
the O +
developed O +
methods O +
have O +
good O +
trueness O -
, O +
precision O +
and O +
accuracy O +
and O +
are O +
appropriate O +
for O +
direct O +
active O +
content O +
assay O +
in O +
tablets O +
( O -
ranging O +
from O +
12 O +
to O +
18 O +
mg O -
/ O -
tablet O -
) O +
and O +
also O +
for O +
predicting O +
crushing O +
strength O +
and O +
disintegration O +
time O +
of O +
intact O +
meloxicam B-Chemical +
tablets O -
. O +

Discussion O -
: O +
The O +
comparative O +
data O +
show O +
that O +
the O +
proposed O +
methods O +
are O +
in O +
good O +
agreement O +
with O +
the O +
reference O +
methods O +
currently O +
used O +
for O +
the O +
characterization O +
of O +
meloxicam B-Chemical +
tablets O +
( O -
HPLC O -
- O -
UV O +
methods O +
for O +
the O +
assay O +
and O +
European O +
Pharmacopeia O +
methods O +
for O +
determining O +
the O +
crushing O +
strength O +
and O +
disintegration O +
time O -
) O -
. O +

Conclusion O -
: O +
The O +
results O +
show O +
the O +
possibility O +
to O +
predict O +
both O +
chemical O +
properties O +
( O -
active O +
content O -
) O +
and O +
physical O -
/ O -
pharmaceutical O +
properties O +
( O -
crushing O +
strength O +
and O +
disintegration O +
time O -
) O +
directly O -
, O +
without O +
any O +
sample O +
preparation O -
, O +
from O +
the O +
same O +
NIR O +
transmission O +
spectrum O +
of O +
meloxicam B-Chemical +
tablets O -
. O +

Physicochemical O +
characterization O +
of O +
phyllanthin B-Chemical +
from O +
Phyllanthus O +
amarus O +
Schum O -
. O +

et O +
Thonn O -
. O +

Abstract O +
Phyllanthin B-Chemical +
is O +
a O +
major O +
bioactive O +
lignan B-Chemical +
component O +
of O +
Phyllanthus O +
amarus O -
, O +
with O +
several O +
known O +
biological O +
activities O -
. O +

This O +
study O +
dealt O +
with O +
the O +
isolation O +
and O +
physicochemical O +
characterization O +
of O +
phyllanthin B-Chemical -
. O +

Phyllanthin B-Chemical +
was O +
isolated O +
from O +
P. O +
amarus O +
leaves O +
by O +
column O +
chromatography O +
and O +
purified O +
by O +
recrystallization O +
to O +
obtain O +
phyllanthin B-Chemical +
crystals O +
with O +
a O +
purity O +
of O +
more O +
than O +
98 O -
% O -
. O +

UV O -
, O +
IR O -
, O +
MS O -
, O +
( B-Chemical -
1 I-Chemical -
) I-Chemical -
H I-Chemical +
NMR O +
and O +
( B-Chemical -
13 I-Chemical -
) I-Chemical -
C I-Chemical +
NMR O +
spectra O +
were O +
employed O +
to O +
identify O +
phyllanthin B-Chemical -
. O +

The O +
physicochemical O +
properties O +
of O +
phyllanthin B-Chemical +
were O +
characterized O +
using O +
differential O +
scanning O +
calorimetry O -
, O +
thermogravimetric O +
analysis O -
, O +
X O -
- O -
ray O +
diffraction O -
, O +
pH O -
- O -
solubility O -
, O +
ionization O +
property O +
and O +
lipophilicity O -
. O +

The O +
results O +
indicated O +
that O +
phyllanthin B-Chemical +
crystals O +
had O +
the O +
melting O +
point O +
and O +
melting O +
enthalpy O +
range O +
of O +
96.67 O -
- O -
97.03 O +
° O -
C O +
and O +
109.61 O -
- O -
116.34 O +
J O -
/ O -
g O -
, O +
respectively O -
. O +

Three O +
kinds O +
of O +
phyllanthin B-Chemical +
crystals O -
, O +
recrystallized O +
by O +
petroleum B-Chemical +
ether I-Chemical -
, O +
absolute O +
ethanol B-Chemical +
and O +
25 O -
% O +
ethanol B-Chemical +
solution O -
, O +
showed O +
only O +
one O +
polymorph O +
and O +
no O +
polymorphic O +
impurity O -
. O +

Phyllanthin B-Chemical +
in O +
a O +
solid O +
state O +
was O +
found O +
to O +
undergo O +
significant O +
thermal O +
decomposition O +
above O +
200 O +
° O -
C O -
. O +

The O +
compound O +
demonstrated O +
good O +
stability O +
in O +
aqueous O +
solution O +
over O +
a O +
pH O +
range O +
of O +
1.07 O -
- O -
10.02 O +
for O +
at O +
least O +
4 O +
h. O +
The O +
solubility O +
of O +
phyllanthin B-Chemical +
appeared O +
to O +
be O +
pH O -
- O -
independent O +
of O +
pH O +
range O +
from O +
1.07 O +
to O +
10.26 O -
. O +

Ionization O +
property O +
studied O +
by O +
absorbance O +
spectroscopy O +
method O +
was O +
in O +
agreement O +
with O +
the O +
result O +
of O +
pH O -
- O -
solubility O +
study O -
, O +
showing O +
that O +
phyllanthin B-Chemical +
has O +
no O +
pKa O +
over O +
a O +
pH O +
range O +
of O +
1.12 O -
- O -
10.02 O -
. O +

The O +
log O +
Pow O +
value O +
of O +
phyllanthin B-Chemical +
was O +
found O +
to O +
be O +
3.30 O +
± O +
0.05 O +
at O +
pH O +
7.48 O -
, O +
suggesting O +
that O +
phyllanthin B-Chemical +
may O +
have O +
good O +
permeability O +
through O +
biological O +
membranes O -
. O +

The O +
findings O +
could O +
be O +
useful O +
tools O +
for O +
the O +
development O +
of O +
stable O +
and O +
bioavailable O +
oral O +
dosage O +
forms O +
of O +
phyllanthin B-Chemical -
. O +

Genistein O -
- O -
Modified O +
Poly B-Chemical -
( I-Chemical -
ethylene I-Chemical +
oxide I-Chemical -
) I-Chemical -
/ O -
Poly B-Chemical -
( I-Chemical -
d I-Chemical -
, I-Chemical -
l I-Chemical -
- I-Chemical -
lactic I-Chemical +
acid I-Chemical -
) I-Chemical +
Electrospun O +
Mats O +
with O +
Improved O +
Antioxidant O +
and O +
Anti O -
- O -
inflammatory O +
Properties O -
. O +

Genistein B-Chemical +
is O +
a O +
phytochemical O +
with O +
a O +
broad O +
range O +
of O +
desirable O +
biological O +
activity O +
for O +
wound O +
healing O -
. O +

However O -
, O +
its O +
poor O +
bioavailability O +
requires O +
developing O +
a O +
new O +
method O +
for O +
fabricating O +
an O +
appropriate O +
carrier O +
vehicle O +
to O +
deliver O +
genistein B-Chemical +
in O +
a O +
sustained O +
manner O -
. O +

Based O +
on O +
the O +
guidance O +
afforded O +
by O +
the O +
ternary O +
phase O +
diagram O +
of O +
poly B-Chemical -
( I-Chemical -
d I-Chemical -
, I-Chemical -
l I-Chemical -
- I-Chemical -
lactic I-Chemical +
acid I-Chemical -
) I-Chemical +
( O -
PDLLA B-Chemical -
) O -
, O +
poly B-Chemical -
( I-Chemical -
ethylene I-Chemical +
oxide I-Chemical -
) I-Chemical +
( O -
PEO B-Chemical -
) O -
, O +
and O +
genistein B-Chemical +
blends O -
, O +
certain O +
selective O +
compositions O +
were O +
electrospun O -
. O +

We O +
obtained O +
a O +
uniformly O +
smooth O +
surface O +
morphology O +
in O +
unmodified O +
and O +
genistein B-Chemical -
- O -
modified O +
PEO B-Chemical -
/ O -
PDLLA B-Chemical +
fibers O -
, O +
documented O +
by O +
scanning O +
electron O +
microscopy O -
. O +

Moreover O -
, O +
wide O -
- O -
angle O +
X O -
- O -
ray O +
diffraction O +
and O +
( B-Chemical -
1 I-Chemical -
) I-Chemical -
H I-Chemical +
NMR O +
studies O +
revealed O +
that O +
the O +
genistein B-Chemical +
molecules O -
, O +
successfully O +
incorporated O +
in O +
the O +
blends O -
, O +
remained O +
chemically O +
stable O +
after O +
electrospinning O -
. O +

Besides O +
surface O +
wettability O +
and O +
dimensional O +
stability O +
of O +
the O +
electrospun O +
mats O -
, O +
the O +
released O +
genistein B-Chemical +
amount O +
has O +
been O +
evaluated O +
as O +
a O +
function O +
of O +
PEO B-Chemical +
concentration O -
. O +

Our O +
biocompatibility O +
investigations O +
suggest O +
that O +
genistein B-Chemical -
- O -
modified O +
PEO B-Chemical -
/ O -
PDLLA B-Chemical +
electrospun O +
mats O +
exhibit O +
strong O +
antioxidant O +
and O +
anti O -
- O -
inflammatory O +
activities O +
which O +
indicate O +
they O +
have O +
potential O +
applications O +
for O +
wound O +
dressings O -
. O +

Cannabis O +
intoxication O +
inhibits O +
avoidance O +
action O +
tendencies O -
: O +
a O +
field O +
study O +
in O +
the O +
Amsterdam O +
coffee O +
shops O -
. O +

RATIONALE O -
: O +
Experimental O +
laboratory O +
studies O +
suggest O +
that O +
the O +
approach O +
bias O +
( O -
relatively O +
fast O +
approach O +
responses O -
) O +
toward O +
substance O -
- O -
related O +
materials O +
plays O +
an O +
important O +
role O +
in O +
problematic O +
substance O +
use O -
. O +

How O +
this O +
bias O +
is O +
moderated O +
by O +
intention O +
to O +
use O +
versus O +
recent O +
use O +
remains O +
unknown O -
. O +

Moreover O -
, O +
the O +
relationship O +
between O +
approach O +
bias O +
and O +
other O +
motivational O +
processes O +
( O -
satiation O +
and O +
craving O -
) O +
and O +
executive O +
functioning O +
remains O +
unclear O -
. O +

OBJECTIVES O -
: O +
The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
cannabis O +
approach O +
bias O +
before O +
and O +
after O +
cannabis O +
use O +
in O +
real O -
- O -
life O +
setting O +
( O -
Amsterdam O +
coffee O +
shops O -
) O +
and O +
to O +
assess O +
the O +
relationship O +
between O +
approach O +
bias O -
, O +
craving O -
, O +
satiation O -
, O +
cannabis O +
use O -
, O +
and O +
response O +
inhibition O -
. O +

METHODS O -
: O +
Cannabis O -
, O +
tobacco O -
, O +
and O +
neutral O +
approach O +
and O +
avoidance O +
action O +
tendencies O +
were O +
measured O +
with O +
the O +
Approach O +
Avoidance O +
Task O +
and O +
compared O +
between O +
42 O +
heavy O +
cannabis O +
users O +
with O +
the O +
intention O +
to O +
use O +
and O +
45 O +
heavy O +
cannabis O +
users O +
shortly O +
after O +
cannabis O +
use O -
. O +

The O +
classical O +
Stroop O +
was O +
used O +
to O +
measure O +
response O +
inhibition O -
. O +

Multiple O +
regression O +
analyses O +
were O +
conducted O +
to O +
investigate O +
relationships O +
between O +
approach O +
bias O -
, O +
satiation O -
, O +
craving O -
, O +
cannabis O +
use O -
, O +
and O +
response O +
inhibition O -
. O +

RESULTS O -
: O +
In O +
contrast O +
to O +
the O +
hypotheses O -
, O +
heavy O +
cannabis O +
users O +
with O +
the O +
intention O +
to O +
use O +
did O +
not O +
show O +
a O +
cannabis O +
approach O +
bias O -
, O +
whereas O +
intoxicated O +
cannabis O +
users O +
did O +
show O +
an O +
approach O +
bias O +
regardless O +
of O +
image O +
category O -
. O +

This O +
could O +
be O +
attributed O +
to O +
a O +
general O +
slowing O +
of O +
avoidance O +
action O +
tendencies O -
. O +

Moreover O -
, O +
craving O +
was O +
negatively O +
associated O +
with O +
the O +
approach O +
bias O -
, O +
and O +
no O +
relationships O +
were O +
observed O +
between O +
the O +
cannabis O +
approach O +
bias O -
, O +
satiation O -
, O +
prior O +
cannabis O +
use O -
, O +
and O +
response O +
inhibition O -
. O +

CONCLUSION O -
: O +
Cannabis O +
intoxication O +
in O +
a O +
real O -
- O -
life O +
setting O +
inhibited O +
general O +
avoidance O -
. O +

Expression O +
of O +
the O +
cannabis O +
approach O +
bias O +
appeared O +
not O +
to O +
be O +
modulated O +
by O +
satiation O +
or O +
response O +
inhibition O -
. O +

Metabolism O +
and O +
pathways O +
for O +
denitration O +
of O +
organic O +
nitrates B-Chemical +
in O +
the O +
human O +
liver O -
. O +

Liver O +
first O -
- O -
pass O +
metabolism O +
differs O +
considerably O +
among O +
organic O +
nitrates B-Chemical +
but O +
little O +
information O +
exists O +
on O +
the O +
mechanism O +
of O +
denitration O +
of O +
these O +
compounds O +
in O +
hepatic O +
tissue O -
. O +

The O +
metabolism O +
of O +
nitrooxybutyl B-Chemical -
- I-Chemical -
esters I-Chemical +
of O +
flurbiprofen B-Chemical +
and O +
ferulic B-Chemical -
- I-Chemical -
acid I-Chemical -
, O +
a O +
class O +
of O +
organic O +
nitrates B-Chemical +
with O +
potential O +
therapeutic O +
implication O +
in O +
variety O +
of O +
different O +
conditions O -
, O +
was O +
investigated O +
in O +
comparison O +
with O +
glyceryl B-Chemical +
trinitrate I-Chemical +
( O -
GTN B-Chemical -
) O +
in O +
human O +
liver O +
by O +
a O +
multiple O +
approach O -
, O +
using O +
a O +
spontaneous O +
metabolism O -
- O -
independent O +
NO B-Chemical +
donor O +
( O -
NOC-5 B-Chemical -
) O +
as O +
a O +
reference O +
tool O -
. O +

Nitrooxybutyl B-Chemical -
- I-Chemical -
esters I-Chemical +
were O +
rapidly O +
and O +
quantitatively O +
metabolized O +
to O +
their O +
respective O +
parent O +
compounds O +
and O +
the O +
organic O +
nitrate B-Chemical +
moiety O +
nitrooxybutyl B-Chemical -
- I-Chemical -
alcohol I-Chemical +
( O -
NOBA B-Chemical -
) O -
. O +

Differently O +
from O +
GTN B-Chemical +
which O +
was O +
rapidly O +
and O +
completely O +
metabolized O +
to O +
nitrite B-Chemical -
, O +
NOBA B-Chemical +
was O +
slowly O +
metabolized O +
to O +
nitrate B-Chemical -
. O +

In O +
contrast O +
to O +
the O +
spontaneous O +
NO B-Chemical +
donor O +
NOC-5 B-Chemical -
, O +
NOBA B-Chemical +
and O +
GTN B-Chemical +
did O +
not O +
generate O +
detectable O +
NO B-Chemical +
and O +
failed O +
to O +
suppress O +
the O +
activity O +
of O +
cytochromeP450 O -
; O +
an O +
enzyme O +
known O +
to O +
be O +
inhibited O +
by O +
NO B-Chemical -
. O +

The O +
direct O +
identification O +
of O +
NOBA B-Chemical +
following O +
liver O +
metabolism O +
targets O +
this O +
compound O +
as O +
the O +
functional O +
organic O +
nitrate B-Chemical +
metabolite O +
of O +
nitrooxybutyl B-Chemical -
- I-Chemical -
esters I-Chemical -
. O +

Moreover O +
the O +
investigation O +
of O +
the O +
pathways O +
for O +
denitration O +
of O +
NOBA B-Chemical +
and O +
GTN B-Chemical +
suggests O +
that O +
organic O +
nitrates B-Chemical +
are O +
not O +
primarily O +
metabolized O +
to O +
NO B-Chemical +
in O +
the O +
liver O +
but O +
to O +
different O +
extents O +
of O +
nitrite B-Chemical +
or O +
nitrate B-Chemical +
depending O +
from O +
their O +
different O +
chemical O +
structure O -
. O +

It O +
follows O +
that O +
cytochromeP450-dependent O +
metabolism O +
of O +
concomitant O +
drugs O +
is O +
not O +
likely O +
to O +
be O +
affected O +
by O +
oral O +
co O -
- O -
administration O +
of O +
organic O +
nitrates B-Chemical -
. O +

However O +
the O +
first O -
- O -
pass O +
may O +
differently O +
affect O +
the O +
pharmacological O +
profile O +
of O +
organic O +
nitrates B-Chemical +
in O +
connection O +
with O +
the O +
different O +
extent O +
of O +
denitration O +
and O +
the O +
distinct O +
bioactive O +
species O +
generated O +
and O +
exported O +
from O +
the O +
liver O +
( O -
nitrate B-Chemical +
or O +
nitrite B-Chemical -
) O -
. O +

Determining O +
osmotic O +
pressure O +
of O +
drug O +
solutions O +
by O +
air O +
humidity O +
in O +
equilibrium O +
method O -
. O +

Abstract O +
Objective O -
: O +
To O +
establish O +
a O +
new O +
osmotic O +
pressure O +
measuring O +
method O +
with O +
a O +
wide O +
measuring O +
range O -
. O +

Method O -
: O +
The O +
osmotic O +
pressure O +
of O +
drug O +
solutions O +
is O +
determined O +
by O +
measuring O +
the O +
relative O +
air O +
humidity O +
in O +
equilibrium O +
with O +
the O +
solution O -
. O +

The O +
freezing O +
point O +
osmometry O +
is O +
used O +
as O +
a O +
control O -
. O +

Results O -
: O +
The O +
data O +
obtained O +
by O +
the O +
proposed O +
method O +
are O +
comparable O +
to O +
those O +
by O +
the O +
control O +
method O -
, O +
and O +
the O +
measuring O +
range O +
of O +
the O +
proposed O +
method O +
is O +
significantly O +
wider O +
than O +
that O +
of O +
the O +
control O +
method O -
. O +

Conclusion O -
: O +
The O +
proposed O +
method O +
is O +
performed O +
in O +
an O +
isothermal O +
and O +
equilibrium O +
state O -
, O +
so O +
it O +
overcomes O +
the O +
defects O +
of O +
the O +
freezing O +
point O +
and O +
dew O +
point O +
osmometries O +
which O +
result O +
from O +
the O +
heterothermal O +
process O +
in O +
the O +
measurement O -
, O +
and O +
therefore O +
is O +
not O +
limited O +
to O +
diluted O +
solutions O -
. O +

Enantioselective O +
thiourea B-Chemical -
- O -
catalyzed O +
intramolecular O +
cope O -
- O -
type O +
hydroamination O -
. O +

Catalysis O +
of O +
Cope O -
- O -
type O +
rearrangements O +
of O +
bis B-Chemical -
- I-Chemical -
homoallylic I-Chemical +
hydroxylamines I-Chemical +
is O +
demonstrated O +
using O +
chiral O +
thiourea O +
derivatives O -
. O +

This O +
formal O +
intramolecular O +
hydroamination O +
reaction O +
provides O +
access O +
to O +
highly O +
enantioenriched O +
α O -
- O -
substituted O +
pyrrolidine B-Chemical +
products O +
and O +
represents O +
a O +
complementary O +
approach O +
to O +
metal O -
- O -
catalyzed O +
methods O -
. O +

Flavone B-Chemical +
C I-Chemical -
- I-Chemical -
glycosides I-Chemical +
from O +
the O +
flowers O +
of O +
Trollius O +
chinensis O +
and O +
their O +
anti O -
- O -
complementary O +
activity O -
. O +

Phytochemical O +
investigation O +
of O +
ethanol B-Chemical +
extract O +
from O +
the O +
flowers O +
of O +
Trollius O +
chinensis O +
Bunge O +
resulted O +
in O +
the O +
isolation O +
of O +
two O +
new O +
flavone B-Chemical +
C I-Chemical -
- I-Chemical -
glycosides I-Chemical +
( O -
1 O -
- O -
2 O -
) O -
, O +
along O +
with O +
10 O +
known O +
compounds O +
( O -
3 O -
- O -
12 O -
) O -
. O +

The O +
structures O +
of O +
the O +
new O +
compounds O +
were O +
established O +
as O +
6‴- B-Chemical -
( I-Chemical -
3-hydroxy-3-methylglutaroyl I-Chemical -
) I-Chemical -
-2″-O I-Chemical -
- I-Chemical -
β I-Chemical -
- I-Chemical -
d I-Chemical -
- I-Chemical -
galactopyranosyl I-Chemical +
orientin I-Chemical +
( O -
1 O -
) O +
and O +
6‴- B-Chemical -
( I-Chemical -
3-hydroxy-3-methylglutaroyl I-Chemical -
) I-Chemical -
-2″-O I-Chemical -
- I-Chemical -
β I-Chemical -
- I-Chemical -
d I-Chemical -
- I-Chemical -
galactopyranosyl I-Chemical +
vitexin I-Chemical +
( O -
2 O -
) O +
on O +
the O +
basis O +
of O +
various O +
spectroscopic O +
analysis O +
( O -
including O +
different O +
1D O +
and O +
2D O +
NMR O +
spectroscopies O -
, O +
high O -
- O -
resolution O +
electrospray O +
ionization O +
mass O +
spectrometry O -
) O +
and O +
chemical O +
evidences O -
. O +

Bioassay O +
showed O +
that O +
eight O +
flavonoids B-Chemical +
inhibited O +
complement O +
activation O +
on O +
the O +
classic O +
pathway O +
in O +
vitro O -
, O +
with O +
their O +
IC50 O +
values O +
ranging O +
from O +
0.88 O +
to O +
4.02 O +
mM O -
, O +
which O +
may O +
contribute O +
to O +
the O +
applications O +
of O +
the O +
herb O +
in O +
treatment O +
of O +
acute O +
respiratory O +
distress O +
syndrome O -
, O +
etc O -
. O +

In O +
Vitro O +
Reconstitution O +
of O +
Complexes O +
between O +
proMatrix O +
Metalloproteinase-9 O +
and O +
the O +
Proteoglycans O +
Serglycin O +
and O +
Versican O -
. O +

Previously O +
we O +
have O +
shown O +
that O +
a O +
fraction O +
of O +
the O +
matrix O +
metalloproteinase-9 O +
( O -
MMP-9 O -
) O +
synthesized O +
by O +
the O +
macrophage O +
cell O +
line O +
THP-1 O +
was O +
bound O +
to O +
a O +
chondroitin O +
sulphate O +
proteoglycan O +
( O -
CSPG O -
) O +
core O +
protein O +
as O +
a O +
reduction O +
sensitive O +
heteromer O -
. O +

It O +
was O +
also O +
shown O +
that O +
the O +
hemopexin O -
- O -
like O +
( O -
PEX O -
) O +
domain O +
and O +
the O +
fibronectin O -
- O -
like O +
( O -
FnII O -
) O +
module O +
in O +
the O +
enzyme O +
are O +
involved O +
in O +
the O +
heteromer O +
formation O -
. O +

In O +
the O +
present O +
work O +
we O +
show O +
that O +
reduction O +
sensitive O +
and O +
SDS B-Chemical -
- O -
stable O +
heteromers O +
can O +
be O +
reconstituted O +
in O +
vitro O +
by O +
mixing O +
proMMP-9 O +
with O +
either O +
serglycin O -
, O +
versican O +
or O +
CSPGs O +
isolated O +
from O +
various O +
monocytic O +
cell O +
lines O -
. O +

In O +
addition O -
, O +
a O +
strong O +
but O +
SDS B-Chemical -
- O -
soluble O +
proMMP-9·CSPG O +
heteromer O +
was O +
formed O -
. O +

The O +
two O +
macromolecules O +
in O +
the O +
SDS B-Chemical -
- O -
stable O +
reduction O +
sensitive O +
heteromers O +
were O +
not O +
linked O +
together O +
by O +
disulphide B-Chemical +
bonds O -
. O +

As O +
for O +
the O +
heteromer O +
isolated O +
from O +
THP-1 O +
cells O -
, O +
the O +
in O +
vitro O +
reconstituted O +
SDS B-Chemical -
- O -
stable O +
and O +
SDS B-Chemical -
- O -
soluble O +
heteromers O +
had O +
a O +
weaker O +
binding O +
to O +
gelatin O +
than O +
the O +
proMMP-9 O +
monomer O -
. O +

Furthermore O -
, O +
gelatin O +
inhibited O +
the O +
in O +
vitro O +
reconstitution O +
of O +
the O +
heteromers O -
, O +
showing O +
that O +
the O +
FnII O +
module O +
is O +
involved O +
in O +
the O +
complex O +
formation O -
. O +

TIMP-1 O +
could O +
not O +
be O +
detected O +
in O +
the O +
formed O +
proMMP-9·CSPG O +
complexes O -
. O +

However O -
, O +
the O +
presence O +
of O +
TIMP-1 O +
inhibited O +
the O +
formation O +
of O +
the O +
SDS B-Chemical -
- O -
soluble O +
heteromer O -
, O +
but O +
not O +
the O +
SDS B-Chemical -
- O -
stable O +
reduction O +
sensitive O +
heteromer O -
. O +

This O +
indicates O +
that O +
different O +
regions O +
in O +
the O +
PEX O +
domain O +
are O +
involved O +
the O +
formation O +
of O +
these O +
heteromers O -
. O +

This O +
article O +
is O +
protected O +
by O +
copyright O -
. O +

All O +
rights O +
reserved O -
. O +

Synthesis O +
and O +
biological O +
evaluation O +
of O +
phosphorylated B-Chemical +
flavonoids I-Chemical +
as O +
potent O +
and O +
selective O +
inhibitors O +
of O +
cholesterol B-Chemical +
esterase O -
. O +

A O +
series O +
of O +
phosphorylated B-Chemical +
flavonoids I-Chemical +
were O +
synthesized O +
and O +
investigated O +
in O +
vitro O +
as O +
inhibitors O +
of O +
pancreatic O +
cholesterol B-Chemical +
esterase O +
( O -
CEase O -
) O +
and O +
acetylcholinesterase O +
( O -
AChE O -
) O -
. O +

The O +
results O +
showed O +
that O +
most O +
of O +
the O +
synthesized O +
compounds O +
exhibited O +
nanomolar O +
potency O +
against O +
CEase O -
, O +
much O +
better O +
than O +
the O +
parent O +
flavonoids B-Chemical -
. O +

Furthermore O -
, O +
these O +
phosphorylated B-Chemical +
flavonoids I-Chemical +
demonstrated O +
good O +
to O +
high O +
selectivity O +
for O +
CEase O +
over O +
AChE O -
, O +
which O +
only O +
showed O +
micromolar O +
potency O +
inhibition O +
of O +
AChE. O +
The O +
most O +
selective O +
and O +
potent O +
inhibitor O +
of O +
CEase O +
( O -
3e O -
) O +
had O +
IC50 O +
value O +
of O +
0.72 O +
nM O +
and O +
11800-fold O +
selectivity O +
for O +
CEase O +
over O +
AChE. O +
The O +
structure O -
- O -
activity O +
relationships O +
revealed O +
that O +
the O +
free O +
hydroxyl B-Chemical +
group O +
at O +
position O +
5 O +
and O +
phosphate B-Chemical +
group O +
at O +
position O +
7 O +
of O +
the O +
phosphorylated B-Chemical +
flavonoids I-Chemical +
are O +
favorable O +
to O +
the O +
inhibition O +
of O +
CEase O -
. O +

The O +
inhibition O +
mechanism O +
and O +
kinetic O +
characterization O +
studies O +
indicated O +
that O +
they O +
are O +
irreversible O +
competitive O +
inhibitors O +
of O +
CEase O -
. O +

Flies O +
Cope O +
with O +
Uncontrollable O +
Stress O +
by O +
Learned O +
Helplessness O -
. O +

In O +
a O +
wide O +
range O +
of O +
animals O -
, O +
uncontrollable O +
stressful O +
events O +
can O +
induce O +
a O +
condition O +
called O +
" O -
learned O +
helplessness O -
. O -
" O +

In O +
mammals O +
it O +
is O +
associated O +
with O +
low O +
general O +
activity O -
, O +
poor O +
learning O -
, O +
disorders O +
of O +
sleep O +
and O +
feeding O -
, O +
ulcers O -
, O +
and O +
reduced O +
immune O +
status O -
, O +
as O +
well O +
as O +
with O +
increased O +
serotonin B-Chemical +
in O +
parts O +
of O +
the O +
brain O -
. O +

It O +
is O +
considered O +
an O +
animal O +
model O +
of O +
depression O +
in O +
humans O +
[ O -
1 O -
- O -
4 O -
] O -
. O +

Here O +
we O +
investigate O +
learned O +
helplessness O +
in O +
Drosophila O -
, O +
showing O +
that O +
this O +
behavioral O +
state O +
consists O +
of O +
a O +
cognitive O +
and O +
a O +
modulatory O -
, O +
possibly O +
mood O -
- O -
like O -
, O +
component O -
. O +

A O +
fly O -
, O +
getting O +
heated O +
as O +
soon O +
as O +
it O +
stops O +
walking O -
, O +
reliably O +
resumes O +
walking O +
to O +
escape O +
the O +
heat O -
. O +

If O -
, O +
in O +
contrast O -
, O +
the O +
fly O +
is O +
not O +
in O +
control O +
of O +
the O +
heat O -
, O +
it O +
learns O +
that O +
its O +
behavior O +
has O +
no O +
effect O +
and O +
quits O +
responding O -
. O +

In O +
this O +
state O -
, O +
the O +
fly O +
walks O +
slowly O +
and O +
takes O +
longer O +
and O +
more O +
frequent O +
rests O -
, O +
as O +
if O +
it O +
were O +
" O -
depressed O -
. O -
" O +

This O +
downregulation O +
of O +
walking O +
behavior O +
is O +
more O +
pronounced O +
in O +
females O +
than O +
in O +
males O -
. O +

Learned O +
helplessness O +
in O +
Drosophila O +
is O +
an O +
example O +
of O +
how O -
, O +
in O +
a O +
certain O +
situation O -
, O +
behavior O +
is O +
organized O +
according O +
to O +
its O +
expected O +
consequences O -
. O +

Multiple O +
treatments O +
with O +
liposomal O +
doxorubicin B-Chemical +
and O +
ultrasound O -
- O -
induced O +
disruption O +
of O +
blood O -
- O -
tumor O +
and O +
blood O -
- O -
brain O +
barriers O +
improve O +
outcomes O +
in O +
a O +
rat O +
glioma O +
model O -
. O +

The O +
blood O -
- O -
brain O -
- O -
barrier O +
( O -
BBB O -
) O +
prevents O +
the O +
transport O +
of O +
most O +
anticancer O +
agents O +
to O +
the O +
central O +
nervous O +
system O +
and O +
restricts O +
delivery O +
to O +
infiltrating O +
brain O +
tumors O -
. O +

The O +
heterogeneous O +
vascular O +
permeability O +
in O +
tumor O +
vessels O -
, O +
along O +
with O +
several O +
other O +
factors O -
, O +
creates O +
additional O +
barriers O +
for O +
drug O +
treatment O +
of O +
brain O +
tumors O -
. O +

Focused O +
ultrasound O +
( O -
FUS O -
) O -
, O +
when O +
combined O +
with O +
circulating O +
microbubbles O -
, O +
is O +
an O +
emerging O +
noninvasive O +
method O +
to O +
temporarily O +
permeabilize O +
the O +
BBB O +
and O +
the O +
" O -
blood O -
- O -
tumor O +
barrier O -
" O -
. O +

Here O -
, O +
we O +
tested O +
the O +
impact O +
of O +
three O +
weekly O +
sessions O +
of O +
FUS O +
and O +
liposomal O +
doxorubicin B-Chemical +
( O -
DOX B-Chemical -
) O +
in O +
9L O +
rat O +
glioma O +
tumors O -
. O +

Animals O +
that O +
received O +
FUS+DOX O +
( O -
N=8 O -
) O +
had O +
a O +
median O +
survival O +
time O +
that O +
was O +
increased O +
significantly O +
( O -
P<0.001 O -
) O +
compared O +
to O +
animals O +
who O +
received O +
DOX B-Chemical +
only O +
( O -
N=6 O -
) O -
, O +
FUS O +
only O +
( O -
N=8 O -
) O -
, O +
or O +
no O +
treatment O +
( O -
N=7 O -
) O -
. O +

Median O +
survival O +
for O +
animals O +
that O +
received O +
FUS+DOX O +
was O +
increased O +
by O +
100 O -
% O +
relative O +
to O +
untreated O +
controls O -
, O +
whereas O +
animals O +
who O +
received O +
DOX B-Chemical +
alone O +
had O +
only O +
a O +
16 O -
% O +
improvement O -
. O +

Animals O +
who O +
received O +
only O +
FUS O +
showed O +
no O +
improvement O -
. O +

No O +
tumor O +
cells O +
were O +
found O +
in O +
histology O +
in O +
4 O -
/ O -
8 O +
animals O +
in O +
the O +
FUS+DOX O +
group O -
, O +
and O +
in O +
two O +
animals O -
, O +
only O +
a O +
few O +
tumor O +
cells O +
were O +
detected O -
. O +

Adverse O +
events O +
in O +
the O +
treatment O +
group O +
included O +
skin O +
toxicity O -
, O +
impaired O +
activity O -
, O +
damage O +
to O +
surrounding O +
brain O +
tissue O -
, O +
and O +
tissue O +
loss O +
at O +
the O +
tumor O +
site O -
. O +

In O +
one O +
animal O -
, O +
intratumoral O +
hemorrhage O +
was O +
observed O -
. O +

These O +
events O +
are O +
largely O +
consistent O +
with O +
known O +
side O +
effects O +
of O +
doxorubicin B-Chemical +
and O +
with O +
an O +
extensive O +
tumor O +
burden O -
. O +

Overall O +
this O +
work O +
demonstrates O +
that O +
multiple O +
sessions O +
using O +
this O +
FUS O +
technique O +
to O +
enhance O +
the O +
delivery O +
of O +
liposomal O +
doxorubicin B-Chemical +
have O +
a O +
pronounced O +
therapeutic O +
effect O +
in O +
this O +
rat O +
glioma O +
model O -
. O +

Global O +
analytical O +
strategy O +
to O +
measure O +
drug O -
- O -
plasma O +
protein O +
interactions O -
: O +
from O +
high O -
- O -
throughput O +
to O +
in O -
- O -
depth O +
analysis O -
. O +

The O +
selection O +
of O +
drug O +
candidates O +
with O +
improved O +
pharmacokinetics O +
is O +
essential O +
to O +
reduce O +
the O +
attrition O +
rates O +
during O +
drug O +
development O +
and O +
represents O +
one O +
of O +
the O +
big O +
challenges O +
faced O +
by O +
the O +
pharmaceutical O +
industry O -
. O +

Plasma O +
protein O +
binding O +
( O -
PPB O -
) O +
is O +
an O +
important O +
parameter O +
with O +
significant O +
implications O +
for O +
in O +
vivo O +
drug O +
performance O -
. O +

Today O -
, O +
the O +
most O +
widely O +
used O +
techniques O +
for O +
PPB O +
measurement O +
in O +
the O +
pharmaceutical O +
community O +
are O +
equilibrium O +
dialysis O +
( O -
ED O -
) O +
and O +
ultrafiltration O +
( O -
UF O -
) O -
. O +

However O -
, O +
these O +
techniques O +
have O +
some O +
limitations O -
. O +

Thus O -
, O +
we O +
emphasize O +
an O +
alternative O +
strategy O -
, O +
based O +
on O +
a O +
global O -
, O +
new O +
and O +
easy O -
- O -
to O -
- O -
follow O +
methodology O -
, O +
to O +
screen O +
and O +
perform O +
determination O +
of O +
PPB O -
, O +
using O +
orthogonal O +
techniques O +
( O -
i.e. O +
liquid O +
chromatography O -
, O +
capillary O +
electrophoresis O +
( O -
CE O -
) O -
, O +
surface O +
plasmon O +
resonance O +
( O -
SPR O -
) O +
based O +
biosensor O -
) O -
. O +

We O +
anticipate O +
that O +
the O +
increased O +
knowledge O +
gained O +
through O +
this O +
strategy O +
will O +
lead O +
to O +
improved O +
drug O +
candidates O -
. O +

BID O -
- O -
induced O +
structural O +
changes O +
in O +
BAK O +
promote O +
apoptosis O -
. O +

The O +
BCL-2-family O +
protein O +
BAK O +
is O +
responsible O +
for O +
mitochondrial O +
outer O -
- O -
membrane O +
permeabilization O +
( O -
MOMP O -
) O -
, O +
which O +
leads O +
to O +
apoptosis O -
. O +

The O +
BCL-2 O +
homology O +
3 O +
( O -
BH3 O -
) O -
-only O +
protein O +
BID O +
activates O +
BAK O +
to O +
perform O +
this O +
function O -
. O +

We O +
report O +
the O +
NMR O +
solution O +
structure O +
of O +
the O +
human O +
BID O +
BH3-BAK O +
complex O -
, O +
which O +
identified O +
the O +
activation O +
site O +
at O +
the O +
canonical O +
BH3-binding O +
groove O +
of O +
BAK O -
. O +

Mutating O +
the O +
BAK O +
BH1 O +
in O +
the O +
groove O +
prevented O +
activation O +
and O +
MOMP O +
but O +
not O +
the O +
binding O +
of O +
BID O -
. O +

BAK O +
BH3 O +
mutations O +
allowed O +
BID O +
binding O +
and O +
activation O +
but O +
blunted O +
function O +
by O +
blocking O +
BAK O +
oligomerization O -
. O +

BAK O +
activation O +
follows O +
a O +
' O -
hit O -
- O -
and O -
- O -
run O -
' O +
mechanism O +
whereby O +
BID O +
dissociates O +
from O +
the O +
trigger O +
site O -
, O +
which O +
allows O +
BAK O +
oligomerization O +
at O +
an O +
overlapping O +
interface O -
. O +

In O +
contrast O -
, O +
the O +
BH3-only O +
proteins O +
NOXA O +
and O +
BAD O +
are O +
predicted O +
to O +
clash O +
with O +
the O +
trigger O +
site O +
and O +
are O +
not O +
activators O +
of O +
BAK O -
. O +

These O +
findings O +
provide O +
insights O +
into O +
the O +
early O +
stages O +
of O +
BAK O +
activation O -
. O +

Facile O +
Preparation O +
of O +
Ordered O +
Porous O +
Graphene B-Chemical -
- O -
Metal B-Chemical +
Oxide@C I-Chemical +
Binder O -
- O -
Free O +
Electrodes O +
with O +
High O +
Li B-Chemical +
Storage O +
Performance O -
. O +

A O +
facile O +
and O +
general O +
method O +
is O +
reported O +
to O +
prepare O +
ordered O +
porous O +
graphene B-Chemical -
- O -
based O +
binder O -
- O -
free O +
electrodes O +
on O +
a O +
large O +
scale O -
. O +

This O +
preparation O +
process O +
allows O +
the O +
easy O +
adjustment O +
of O +
the O +
selected O +
components O -
, O +
weight O +
ratio O +
of O +
componets O -
, O +
and O +
the O +
thickness O +
of O +
the O +
electrodes O -
. O +

Such O +
ordered O +
porous O +
electrodes O +
demonstrate O +
superior O +
Li B-Chemical +
storage O +
properties O -
; O +
for O +
example O -
, O +
graphene B-Chemical -
- O -
Fe3 B-Chemical +
O4 I-Chemical +
@C O +
depicts O +
high O +
capacities O +
of O +
1123.8 O +
and O +
505 O +
mAh O +
g O -
( O -
-1 O -
) O +
at O +
current O +
densities O +
of O +
0.5 O +
and O +
10 O +
A O +
g O -
( O -
-1 O -
) O +
, O +
respectively O -
. O +

On O +
the O +
association O +
between O +
Hashimoto O -
's O +
thyroiditis O +
and O +
papillary O +
thyroid O +
carcinoma O -
. O +

Looking O +
100 O +
years O +
back O +
and O -
, O +
hopefully O -
, O +
fewer O +
years O +
ahead O +
to O +
sort O +
out O +
this O +
association O -
. O +

NOT O +
required O +
for O +
a O +
LETTER O +
TO O +
THE O +
EDITOR O -
. O +

Designing O +
degradable O +
hydrogels O +
for O +
orthogonal O +
control O +
of O +
cell O +
microenvironments O -
. O +

Degradable O +
and O +
cell O -
- O -
compatible O +
hydrogels O +
can O +
be O +
designed O +
to O +
mimic O +
the O +
physical O +
and O +
biochemical O +
characteristics O +
of O +
native O +
extracellular O +
matrices O +
and O +
provide O +
tunability O +
of O +
degradation O +
rates O +
and O +
related O +
properties O +
under O +
physiological O +
conditions O -
. O +

Hence O -
, O +
such O +
hydrogels O +
are O +
finding O +
widespread O +
application O +
in O +
many O +
bioengineering O +
fields O -
, O +
including O +
controlled O +
bioactive O +
molecule O +
delivery O -
, O +
cell O +
encapsulation O +
for O +
controlled O +
three O -
- O -
dimensional O +
culture O -
, O +
and O +
tissue O +
engineering O -
. O +

Cellular O +
processes O -
, O +
such O +
as O +
adhesion O -
, O +
proliferation O -
, O +
spreading O -
, O +
migration O -
, O +
and O +
differentiation O -
, O +
can O +
be O +
controlled O +
within O +
degradable O -
, O +
cell O -
- O -
compatible O +
hydrogels O +
with O +
temporal O +
tuning O +
of O +
biochemical O +
or O +
biophysical O +
cues O -
, O +
such O +
as O +
growth O +
factor O +
presentation O +
or O +
hydrogel O +
stiffness O -
. O +

However O -
, O +
thoughtful O +
selection O +
of O +
hydrogel O +
base O +
materials O -
, O +
formation O +
chemistries O -
, O +
and O +
degradable O +
moieties O +
is O +
necessary O +
to O +
achieve O +
the O +
appropriate O +
level O +
of O +
property O +
control O +
and O +
desired O +
cellular O +
response O -
. O +

In O +
this O +
review O -
, O +
hydrogel O +
design O +
considerations O +
and O +
materials O +
for O +
hydrogel O +
preparation O -
, O +
ranging O +
from O +
natural O +
polymers O +
to O +
synthetic O +
polymers O -
, O +
are O +
overviewed O -
. O +

Recent O +
advances O +
in O +
chemical O +
and O +
physical O +
methods O +
to O +
crosslink O +
hydrogels O +
are O +
highlighted O -
, O +
as O +
well O +
as O +
recent O +
developments O +
in O +
controlling O +
hydrogel O +
degradation O +
rates O +
and O +
modes O +
of O +
degradation O -
. O +

Special O +
attention O +
is O +
given O +
to O +
spatial O +
or O +
temporal O +
presentation O +
of O +
various O +
biochemical O +
and O +
biophysical O +
cues O +
to O +
modulate O +
cell O +
response O +
in O +
static O +
( O -
i.e. O -
, O +
non O -
- O -
degradable O -
) O +
or O +
dynamic O +
( O -
i.e. O -
, O +
degradable O -
) O +
microenvironments O -
. O +

This O +
review O +
provides O +
insight O +
into O +
the O +
design O +
of O +
new O +
cell O -
- O -
compatible O -
, O +
degradable O +
hydrogels O +
to O +
understand O +
and O +
modulate O +
cellular O +
processes O +
for O +
various O +
biomedical O +
applications O -
. O +

The O +
Beneficial O +
Effect O +
of O +
Total O +
Glucosides O +
of O +
Paeony O +
on O +
Psoriatic O +
Arthritis O +
Links O +
to O +
Circulating O +
Tregs O +
and O +
Th1 O +
Cell O +
Function O -
. O +

Total O +
glycosides O +
of O +
peony O +
( O -
TGP O -
) O +
is O +
a O +
natural O +
immuno O -
- O -
modulatory O +
drug O +
extracted O +
from O +
traditional O +
Chinese O +
herb O +
peony O -
. O +

It O +
has O +
been O +
approved O +
by O +
State O +
Food O +
and O +
Drug O +
Administration O +
for O +
the O +
treatment O +
of O +
rheumatoid O +
arthritis O -
. O +

However O -
, O +
data O +
of O +
TGP O +
effect O +
on O +
psoriatic O +
arthritis O +
( O -
PsA O -
) O +
is O +
still O +
scarce O -
. O +

In O +
this O +
study O -
, O +
19 O +
patients O +
with O +
PsA O +
received O +
12-week O +
treatment O +
of O +
TGP O -
, O +
and O +
clinical O +
efficacy O +
in O +
joint O +
manifestations O +
was O +
evaluated O +
by O +
DAS28 O +
at O +
weeks O +
0 O -
, O +
4 O -
, O +
8 O +
and O +
12 O -
. O +

Peripheral O +
percentages O +
of O +
Tregs O -
, O +
Th1 O -
, O +
Th2 O +
and O +
NK O +
cells O +
were O +
analyzed O -
, O +
and O +
serum O +
Th1-type O +
cytokines O +
( O -
IL-12 O -
, O +
IFN O -
- O -
γ O +
and O +
TNF O -
- O -
α O -
) O -
, O +
Th2-type O +
cytokines O +
( O -
IL-4 O -
, O +
IL-5 O +
and O +
IL-10 O -
) O +
as O +
well O +
as O +
pro O -
- O -
inflammatory O +
factors O +
( O -
IL-2 O -
, O +
IL-6 O +
and O +
IL-8 O -
) O +
were O +
concomitantly O +
examined O -
. O +

Six O +
patients O +
( O -
32 O -
% O -
) O +
exhibited O +
≥25 O -
% O +
decrease O +
of O +
DAS28 O +
( O -
responders O -
) O -
. O +

Interestingly O -
, O +
all O +
responders O +
displayed O +
a O +
continuous O +
decrease O +
in O +
Treg O +
and O +
Th1 O +
numbers O +
during O +
TGP O +
treatment O -
, O +
concomitant O +
with O +
significant O +
decreases O +
in O +
Th1-type O +
cytokine O +
levels O -
. O +

Serum O +
IL-6 O +
also O +
showed O +
a O +
significant O +
decline O +
in O +
responders O -
. O +

Non O -
- O -
responders O +
lacked O +
these O +
sequential O +
alterations O -
. O +

Thus O -
, O +
TGP O +
merits O +
further O +
consideration O +
as O +
a O +
promising O +
therapeutic O +
option O +
for O +
PsA. O +
The O +
result O +
indicated O +
that O +
recovery O +
of O +
Tregs O +
and O +
Th1 O +
may O +
serve O +
as O +
prognostic O +
markers O +
to O +
assess O +
responsiveness O +
to O +
TGP O +
treatment O +
in O +
PsA. O +
Copyright O +
© O +
2013 O +
John O +
Wiley O +
& O +
Sons O -
, O +
Ltd. O +

Amphiphilic O +
Polypeptides O +
as O +
a O +
Bifunctional O +
Template O +
in O +
the O +
Mineralization O +
of O +
Calcium B-Chemical +
Carbonate I-Chemical +
at O +
the O +
Air O -
/ O -
Water O +
Interface O -
. O +

A O +
well O -
- O -
defined O +
amphiphilic O +
polypeptide O -
, O +
poly B-Chemical -
( I-Chemical -
glutamic I-Chemical +
acid I-Chemical -
) I-Chemical -
22 I-Chemical +
-block I-Chemical -
- I-Chemical -
poly I-Chemical -
( I-Chemical -
alanine I-Chemical -
) I-Chemical -
8 I-Chemical +
( O -
PGlu22 B-Chemical +
-b I-Chemical -
- I-Chemical -
PAla8 I-Chemical +
) O -
, O +
which O +
plays O +
the O +
roles O +
of O +
both O +
soluble O +
( O -
functional O -
) O +
additive O +
and O +
insoluble O +
( O -
structural O -
) O +
matrix O -
, O +
is O +
employed O +
to O +
mediate O +
the O +
mineralization O +
of O +
CaCO3 B-Chemical +
at O +
the O +
air O -
/ O -
water O +
interface O -
. O +

X O -
- O -
ray O +
diffraction O +
( O -
XRD O -
) O +
and O +
Raman O +
spectroscopy O -
, O +
for O +
example O -
, O +
show O +
that O +
the O +
polymorph O +
of O +
CaCO3 B-Chemical +
particles O +
obtained O +
is O +
calcite B-Chemical -
. O +

The O +
observations O +
from O +
SEM O +
and O +
TEM O +
suggest O +
that O +
PGlu22 B-Chemical +
-b I-Chemical -
- I-Chemical -
PAla8 I-Chemical +
initiates O +
the O +
amorphous O +
precursor O +
phase O +
and O +
heterogeneous O +
nucleation O +
of O +
CaCO3 B-Chemical +
at O +
the O +
air O -
/ O -
water O +
interface O -
, O +
while O +
temporarily O +
stabilizes O +
the O +
gelatinous O +
precursors O +
as O +
a O +
process O -
- O -
directing O +
agent O -
; O +
nevertheless O -
, O +
the O +
initial O +
concentration O +
of O +
Ca B-Chemical -
( I-Chemical -
2 I-Chemical -
+ I-Chemical -
) I-Chemical +
controls O +
the O +
procedure O +
of O +
crystallization O +
and O +
the O +
final O +
morphology O +
of O +
CaCO3 B-Chemical +
particles O -
. O +

Such O +
" O -
bifunctional O -
" O +
amphiphilic O -
- O -
polypeptide O -
- O -
regulated O +
mineralization O +
at O +
the O +
air O -
/ O -
water O +
interface O +
may O +
be O +
applied O +
to O +
the O +
synthesis O +
of O +
many O +
kinds O +
of O +
symmetrical O +
inorganic O -
/ O -
organic O +
hybrids O -
. O +

Very O +
Low O +
Calorie O +
Diet O +
Mimics O +
the O +
Early O +
Beneficial O +
Effect O +
of O +
Roux O -
- O -
en O -
- O -
Y O +
Gastric O +
Bypass O +
on O +
Insulin O +
Sensitivity O +
and O +
Beta O -
- O -
Cell O +
Function O +
in O +
Type O +
2 O +
Diabetic O +
Patients O -
. O +

Marked O +
improvement O +
in O +
glycemic O +
control O +
occurs O +
in O +
patients O +
with O +
type O +
2 O +
diabetes O +
( O -
T2DM O -
) O +
shortly O +
after O +
Roux O -
- O -
en O -
- O -
Y O +
gastric O +
bypass O +
surgery O +
( O -
RYGB O -
) O +
and O +
before O +
there O +
is O +
major O +
weight O +
loss O -
. O +

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
determine O +
if O +
the O +
magnitude O +
of O +
this O +
change O +
is O +
primarily O +
due O +
to O +
caloric O +
restriction O +
or O +
is O +
unique O +
to O +
the O +
surgical O +
procedure O -
. O +

We O +
studied O +
eleven O +
subjects O +
who O +
underwent O +
RYGB O +
and O +
fourteen O +
subjects O +
mean O -
- O -
matched O +
for O +
BMI O -
, O +
HbA1c O +
and O +
diabetes O +
duration O +
who O +
were O +
admitted O +
to O +
our O +
inpatient O +
research O +
unit O +
and O +
given O +
a O +
very O +
low O +
calorie O +
diet O +
( O -
VLCD O -
) O +
of O +
500 O +
kcal O -
/ O -
day O +
with O +
a O +
macronutrient O +
content O +
similar O +
to O +
that O +
consumed O +
by O +
patients O +
after O +
RYGB O -
. O +

Frequently O +
sampled O +
intravenous O +
glucose B-Chemical +
tolerance O +
tests O +
were O +
performed O +
before O +
and O +
after O +
interventions O -
. O +

Both O +
groups O +
lost O +
an O +
equivalent O +
amount O +
of O +
weight O +
over O +
a O +
mean O +
study O +
period O +
of O +
21 O +
days O -
. O +

Insulin O +
sensitivity O -
, O +
acute O +
insulin O +
secretion O +
after O +
intravenous O +
glucose B-Chemical +
administration O +
and O +
beta O -
- O -
cell O +
function O +
as O +
determined O +
by O +
disposition O +
index O +
improved O +
to O +
a O +
similar O +
extent O +
in O +
both O +
groups O -
. O +

Likewise O -
, O +
changes O +
in O +
fasting O +
glucose B-Chemical +
and O +
fructosamine B-Chemical +
levels O +
were O +
similar O -
. O +

Based O +
on O +
these O +
data O -
, O +
VLCD O +
improves O +
insulin O +
sensitivity O +
and O +
beta O -
- O -
cell O +
function O +
just O +
as O +
well O +
as O +
RYGB O +
in O +
the O +
short O +
term O -
. O +

This O +
study O +
was O +
registered O +
in O +
ClinicalTrials.gov O +
NCT00627484 O -
. O +

Central O +
Pulse O +
Pressure O +
and O +
Its O +
Hemodynamic O +
Determinants O +
in O +
Middle O -
- O -
Aged O +
Adults O +
With O +
Impaired O +
Fasting O +
Glucose B-Chemical +
and O +
Diabetes O -
: O +

The O +
Asklepios O +
study O -
. O +

OBJECTIVEPulse O +
pressure O +
( O -
PP O -
) O -
, O +
a O +
strong O +
predictor O +
of O +
cardiovascular O +
events O +
in O +
type O +
2 O +
diabetes O -
, O +
is O +
a O +
composite O +
measure O +
affected O +
by O +
several O +
hemodynamic O +
factors O -
. O +

Little O +
is O +
known O +
about O +
the O +
hemodynamic O +
determinants O +
of O +
central O +
PP O +
in O +
type O +
2 O +
diabetes O +
or O +
whether O +
abnormalities O +
in O +
central O +
pulsatile O +
hemodynamics O +
are O +
already O +
present O +
in O +
individuals O +
with O +
impaired O +
fasting O +
glucose B-Chemical +
( O -
IFG O -
) O -
. O +

In O +
a O +
population O -
- O -
based O +
study O -
, O +
we O +
aimed O +
to O +
compare O +
central O +
PP O +
and O +
its O +
hemodynamic O +
determinants O +
among O +
adults O +
with O +
normal O +
fasting O +
glucose B-Chemical +
( O -
n O +
= O +
1654 O -
) O -
, O +
IFG O +
( O -
n O +
= O +
240 O -
) O -
, O +
and O +
type O +
2 O +
diabetes O +
( O -
n O +
= O +
33 O -
) O -
.RESEARCH O +
DESIGN O +
AND O +
METHODSWe O +
measured O +
carotid O +
pressure O -
, O +
left O +
ventricular O +
outflow O -
, O +
aortic O +
root O +
diameter O -
, O +
carotid O +
artery O +
flow O -
, O +
and O +
distension O +
in O +
order O +
to O +
measure O +
various O +
structural O +
and O +
hemodynamic O +
arterial O +
parameters O -
. O +

RESULTSIFG O +
was O +
associated O +
with O +
a O +
greater O +
mean O +
arterial O +
pressure O +
( O -
MAP O -
) O +
but O +
was O +
not O +
associated O +
with O +
intrinsic O +
aortic O +
stiffening O +
or O +
abnormal O +
aortic O +
pulsatile O +
indices O +
after O +
adjustment O +
for O +
MAP O -
. O +

After O +
adjustment O +
for O +
age O -
, O +
sex O -
, O +
and O +
MAP O -
, O +
type O +
2 O +
diabetes O +
was O +
associated O +
with O +
a O +
higher O +
aortic O +
root O +
characteristic O +
impedance O +
( O -
Zc O -
) O -
, O +
aortic O +
root O +
elastance O -
- O -
thickness O +
product O +
( O -
Eh O -
) O -
, O +
and O +
aortic O +
root O +
pulse O +
wave O +
velocity O +
( O -
but O +
not O +
aortic O +
root O +
diameter O -
) O -
, O +
a O +
greater O +
carotid O -
- O -
femoral O +
pulse O +
wave O +
velocity O -
, O +
and O +
lower O +
total O +
arterial O +
compliance O +
and O +
wave O +
reflection O +
magnitude O -
. O +

Carotid O +
size O -
, O +
Zc O -
, O +
distensibility O -
, O +
or O +
Eh O +
did O +
not O +
significantly O +
differ O +
between O +
the O +
groups O -
. O +

CONCLUSIONSType O +
2 O +
diabetes O -
, O +
but O +
not O +
IFG O -
, O +
is O +
associated O +
with O +
greater O +
large O +
artery O +
stiffness O -
, O +
without O +
abnormalities O +
in O +
aortic O +
root O +
diameter O +
or O +
carotid O +
stiffness O -
. O +

Subjects O +
with O +
type O +
2 O +
diabetes O +
demonstrate O +
a O +
decreased O +
reflection O +
magnitude O -
, O +
which O +
may O +
indicate O +
an O +
increased O +
penetration O +
of O +
pulsatile O +
energy O +
to O +
distal O +
vascular O +
beds O -
. O +

Structure O +
of O +
hydrated O +
cobalt B-Chemical +
ions O +
confined O +
in O +
the O +
nanospace O +
of O +
single O -
- O -
walled O +
carbon B-Chemical +
nanotubes O -
. O +

The O +
structure O +
of O +
hydrated O +
Co B-Chemical +
ions O +
confined O +
in O +
the O +
nanospace O +
of O +
single O -
- O -
walled O +
carbon B-Chemical +
nanotubes O +
( O -
SWNTs O -
) O +
has O +
been O +
studied O +
using O +
the O +
X O -
- O -
ray O +
absorption O +
fine O +
structure O +
( O -
XAFS O -
) O +
technique O -
. O +

Water O +
adsorption O +
isotherms O +
on O +
Co B-Chemical -
- O -
impregnated O +
SWNTs O +
indicate O +
a O +
high O +
affinity O +
of O +
Co B-Chemical +
ions O +
to O +
water O +
molecules O -
. O +

The O +
results O +
of O +
XAFS O +
analysis O +
provided O +
the O +
information O +
on O +
the O +
proportion O +
of O +
dissolved O +
species O +
in O +
nanospaces O +
against O +
the O +
total O +
amount O +
of O +
cobalt B-Chemical +
ions O +
adsorbed O +
on O +
the O +
open O -
- O -
pored O +
SWNT O -
. O +

The O +
structural O +
information O +
of O +
the O +
first O +
shell O +
around O +
a O +
Co B-Chemical +
ion O +
was O +
expressed O +
in O +
terms O +
of O +
the O +
hydration O +
number O -
, O +
Co B-Chemical -
- I-Chemical -
O I-Chemical +
distance O +
and O +
Debye O -
- O -
Waller O +
factor O -
. O +

The O +
actual O +
coordination O +
number O +
and O +
the O +
interatomic O +
distance O +
of O +
Co B-Chemical -
- I-Chemical -
O I-Chemical +
for O +
the O +
dissolved O +
species O +
were O +
remarkably O +
reduced O +
compared O +
to O +
the O +
bulk O +
aqueous O +
solution O +
indicating O +
the O +
dehydration O +
of O +
water O +
molecules O +
from O +
Co B-Chemical +
ions O +
and O +
a O +
compact O +
hydrated O +
structure O +
in O +
the O +
micropore O +
of O +
SWNTs O -
. O +

One O -
- O -
Pot O +
in O +
Situ O +
Mixed O +
Film O +
Formation O +
by O +
Azo B-Chemical +
Coupling O +
and O +
Diazonium B-Chemical +
Salt I-Chemical +
Electrografting O -
. O +

So O +
simple O -
: O +
The O +
in O +
situ O +
synthesis O +
of O +
an O +
aryldiazonium B-Chemical +
salt I-Chemical +
and O +
an O +
azo B-Chemical -
- I-Chemical -
aryldiazonium I-Chemical +
salt I-Chemical +
by O +
azo B-Chemical +
coupling O +
from O +
sulfanilic B-Chemical +
acid I-Chemical +
and O +
aniline B-Chemical +
is O +
reported O -
. O +

Formation O +
of O +
a O +
mixed O +
organic O +
layer O +
is O +
monitored O +
by O +
cyclic O +
voltammetry O +
and O +
atomic O +
force O +
microscopy O -
. O +

A O +
compact O +
mixed O +
layer O +
is O +
obtained O +
with O +
a O +
global O +
roughness O +
of O +
0.4 O +
nm O +
and O +
10 O -
- O -
15 O +
% O +
vertical O +
extension O +
in O +
the O +
range O +
1.5 O -
- O -
6 O +
nm O -
. O +

Grb10-mediated O +
Negative O +
Regulation O +
of O +
IGF1R O -
- O -
Activated O +
Signalling O +
Pathway O +
Results O +
in O +
Cognitive O +
Disorder O +
in O +
Diabetic O +
Rats O -
. O +

Growth O +
factor O +
receptor O -
- O -
bound O +
protein O +
10 O -
( O -
Grb10 O -
) O -
is O +
a O +
Src O +
homology O +
2 O +
( O -
SH2 O -
) O +
domain O -
- O -
containing O +
protein O +
and O +
one O +
of O +
the O +
binding O +
partners O +
for O +
several O +
trans O -
- O -
membrane O +
tyrosine B-Chemical -
- O -
kinase O +
receptors O -
, O +
including O +
insulin O +
receptor O +
( O -
IR O -
) O +
and O +
insulin O -
- O -
like O +
growth O +
factor-1 O +
receptor O +
( O -
IGF1-R O -
) O -
. O +

The O +
hippocampus O -
, O +
which O +
is O +
critical O +
for O +
cognitive O +
functions O -
, O +
is O +
one O +
of O +
the O +
main O +
distribution O +
areas O +
of O +
Grb10 O +
in O +
the O +
central O +
nervous O +
system O -
. O +

In O +
recent O +
years O -
, O +
diabetic O +
encephalopathy O +
has O +
been O +
defined O +
as O +
a O +
third O +
type O +
of O +
diabetes O +
and O +
the O +
IGF1-IR O +
pathway O +
has O +
been O +
shown O +
to O +
be O +
critical O +
for O +
the O +
neuropathogenic O +
process O +
of O +
cognitive O +
disorder O +
in O +
diabetes O -
. O +

However O -
, O +
the O +
role O +
of O +
endogenous O +
Grb10 O +
in O +
regulating O +
the O +
IGF1-IR O +
pathway O +
and O +
neurobehavioral O +
changes O +
is O +
not O +
explicit O -
. O +

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
determine O +
the O +
in O +
vivo O +
function O +
of O +
endogenous O +
Grb10 O +
in O +
diabetic O +
encephalopathy O +
and O +
the O +
underlying O +
mechanisms O -
. O +

Using O +
stereotaxic O +
surgical O +
techniques O +
and O +
lentiviral O +
vectors O +
expressing O +
specific O +
short O +
hairpin O +
RNA O +
( O -
shRNA O -
) O -
, O +
we O +
could O +
steadily O +
knock O +
down O +
Grb10 O +
expression O +
in O +
the O +
hippocampus O -
. O +

More O +
importantly O -
, O +
we O +
demonstrated O +
that O +
hippocampus O -
- O -
specific O +
modulation O +
of O +
Grb10 O +
protein O +
levels O +
led O +
to O +
a O +
prominent O +
remission O +
of O +
cognitive O +
disorder O -
, O +
including O +
improvements O +
in O +
both O +
ultrastructural O +
pathology O +
and O +
abnormal O +
neurobehavioural O +
changes O -
. O +

Our O +
findings O +
indicate O +
that O +
endogenous O +
overexpression O +
of O +
Grb10 O +
functions O +
as O +
a O +
suppressor O +
of O +
the O +
IGF1-IR O +
pathway O -
, O +
which O +
may O +
represent O +
an O +
important O +
mechanism O +
that O +
regulates O +
cognitive O +
disorder O +
in O +
diabetes O -
. O +

This O +
article O +
is O +
protected O +
by O +
copyright O -
. O +

All O +
rights O +
reserved O -
. O +

A O +
new O +
ent B-Chemical -
- I-Chemical -
kaurane I-Chemical +
diterpenoid B-Chemical +
glycoside I-Chemical +
from O +
Isodon O +
japonica O +
var O -
. O +

glaucocalyx O -
. O +

A O +
new O +
ent B-Chemical -
- I-Chemical -
kaurane I-Chemical +
diterpenoid B-Chemical +
glycoside I-Chemical +
( O -
1 O -
) O -
, O +
named O +
glaucocalyxin B-Chemical +
G I-Chemical -
, O +
has O +
been O +
isolated O +
from O +
the O +
n B-Chemical -
- I-Chemical -
butanol I-Chemical -
- O -
soluble O +
fraction O +
of O +
the O +
dried O +
whole O +
plants O +
of O +
Isodon O +
japonica O +
var O -
. O +

glaucocalyx O +
along O +
with O +
two O +
known O +
compounds O -
, O +
namely O +
arjunglucoside B-Chemical +
( O -
2 O -
) O +
and O +
kaempferol-3-O B-Chemical -
- I-Chemical -
rutinoside I-Chemical +
( O -
3 O -
) O -
. O +

The O +
structures O +
of O +
the O +
isolated O +
compounds O +
were O +
assigned O +
on O +
the O +
basis O +
of O +
their O +
( B-Chemical -
1 I-Chemical -
) I-Chemical -
H I-Chemical +
and O +
( B-Chemical -
13 I-Chemical -
) I-Chemical -
C I-Chemical +
NMR O +
spectra O +
including O +
two O -
- O -
dimensional O +
NMR O +
techniques O +
such O +
as O +
HMQC O -
, O +
HMBC O -
, O +
and O +
NOESY O +
experiments O +
and O +
comparison O +
with O +
the O +
literature O +
data O -
. O +

Assessment O +
of O +
genotoxic O +
effects O +
of O +
flumorph B-Chemical +
by O +
the O +
comet O +
assay O +
in O +
mice O +
organs O -
. O +

The O +
present O +
study O +
investigated O +
the O +
genotoxic O +
effects O +
of O +
flumorph B-Chemical +
in O +
various O +
organs O +
( O -
brain O -
, O +
liver O -
, O +
spleen O -
, O +
kidney O +
and O +
sperm O -
) O +
of O +
mice O -
. O +

The O +
DNA O +
damage O -
, O +
measured O +
as O +
comet O +
tail O +
length O +
( O -
µm O -
) O -
, O +
was O +
determined O +
using O +
the O +
alkaline O +
comet O +
assay O -
. O +

The O +
comet O +
assay O +
is O +
a O +
sensitive O +
assay O +
for O +
the O +
detection O +
of O +
genotoxicity O +
caused O +
by O +
flumorph B-Chemical +
using O +
mice O +
as O +
a O +
model O -
. O +

Statistically O +
significant O +
increases O +
in O +
comet O +
assay O +
for O +
both O +
dose O -
- O -
dependent O +
and O +
duration O -
- O -
dependent O +
DNA O +
damage O +
were O +
observed O +
in O +
all O +
the O +
organs O +
assessed O -
. O +

The O +
organs O +
exhibited O +
the O +
maximum O +
DNA O +
damage O +
in O +
96 O +
h O +
at O +
54 O +
mg O -
/ O -
kg O +
body O +
weight O -
. O +

Brain O +
showed O +
maximum O +
DNA O +
damage O +
followed O +
by O +
spleen O +
> O +
kidney O +
> O +
liver O +
> O +
sperm O -
. O +

Our O +
data O +
demonstrated O +
that O +
flumorph B-Chemical +
had O +
induced O +
systemic O +
genotoxicity O +
in O +
mammals O +
as O +
it O +
caused O +
DNA O +
damage O +
in O +
all O +
tested O +
vital O +
organs O -
, O +
especially O +
in O +
brain O +
and O +
spleen O -
. O +

In O +
Vitro O +
Activity O +
of O +
Paclitaxel B-Chemical -
- O -
Loaded O +
Polymeric O +
Expansile O +
Nanoparticles O +
in O +
Breast O +
Cancer O +
Cells O -
. O +

Through O +
a O +
series O +
of O +
in O +
vitro O +
studies O -
, O +
the O +
essential O +
steps O +
for O +
intracellular O +
drug O +
delivery O +
of O +
paclitaxel B-Chemical +
using O +
a O +
pH O -
- O -
responsive O +
nanoparticle O +
system O +
have O +
been O +
investigated O +
in O +
breast O +
cancer O +
cells O -
. O +

We O +
successfully O +
encapsulated O +
paclitaxel B-Chemical +
within O +
polymeric O +
expansile O +
nanoparticles O +
( O -
Pax B-Chemical -
- O -
eNPs O -
) O +
at O +
5 O -
% O +
loading O +
via O +
a O +
miniemulsion O +
polymerization O +
procedure O -
. O +

Fluorescently O +
tagged O +
eNPs O +
were O +
readily O +
taken O +
up O +
by O +
MDA O -
- O -
MB-231 O +
breast O +
cancer O +
cells O +
grown O +
in O +
culture O +
as O +
confirmed O +
by O +
confocal O +
microscopy O +
and O +
flow O +
cytometry O -
. O +

The O +
ability O +
of O +
the O +
encapsulated O +
paclitaxel B-Chemical +
to O +
reach O +
the O +
cytoplasm O +
was O +
also O +
observed O +
using O +
confocal O +
microscopy O +
and O +
fluorescently O +
labeled O +
paclitaxel B-Chemical -
. O +

Pax B-Chemical -
- O -
eNPs O +
were O +
shown O +
to O +
be O +
efficacious O +
against O +
three O +
in O +
vitro O +
human O +
breast O +
adenocarcinoma O +
cell O +
lines O +
( O -
MDA O -
- O -
MB-231 O -
, O +
MCF-7 O +
and O +
SK O -
- O -
BR-3 O -
) O +
as O +
well O +
as O +
cells O +
isolated O +
from O +
the O +
pleural O +
effusions O +
of O +
two O +
different O +
breast O +
cancer O +
patients O -
. O +

Lastly O -
, O +
macropinocytosis O +
was O +
identified O +
as O +
the O +
major O +
cellular O +
pathway O +
responsible O +
for O +
eNP O +
uptake O -
, O +
as O +
confirmed O +
using O +
temperature O -
- O -
sensitive O +
metabolic O +
reduction O -
, O +
pharmacologic O +
inhibitors O -
, O +
and O +
fluid O -
- O -
phase O +
marker O +
co O -
- O -
localization O -
. O +

LiGen O -
: O +
a O +
High O +
Performance O +
workflow O +
for O +
chemistry O +
driven O +
de O +
novo O +
design O -
. O +

Tools O +
for O +
molecular O +
de O +
novo O +
design O +
are O +
actively O +
sought O +
incorporating O +
sets O +
of O +
chemical O +
rules O +
for O +
fast O +
and O +
efficient O +
identification O +
of O +
structurally O +
new O +
chemotypes O +
endowed O +
with O +
a O +
desired O +
set O +
of O +
biological O +
properties O -
. O +

In O +
this O +
paper O -
, O +
we O +
present O +
LiGen O -
, O +
a O +
suite O +
of O +
programs O +
which O +
can O +
be O +
used O +
sequentially O +
or O +
as O +
stand O -
- O -
alone O +
tools O +
for O +
specific O +
purposes O -
. O +

In O +
its O +
standard O +
application O -
, O +
LiGen O +
modules O +
are O +
used O +
to O +
define O +
input O +
constraints O -
, O +
either O +
structure O -
- O -
based O -
, O +
through O +
active O +
site O +
identification O -
, O +
or O +
ligand O -
- O -
based O -
, O +
through O +
pharmacophore O +
definition O -
, O +
to O +
docking O +
and O +
to O +
de O +
novo O +
generation O -
. O +

Alternatively O -
, O +
individual O +
modules O +
can O +
be O +
combined O +
in O +
a O +
user O -
- O -
defined O +
manner O +
to O +
generate O +
project O -
- O -
centric O +
workflows O -
. O +

Specific O +
features O +
of O +
LiGen O +
are O +
the O +
use O +
of O +
a O +
pharmacophore O -
- O -
based O +
docking O +
procedure O +
which O +
allows O +
Flexible O +
docking O +
without O +
conformer O +
enumeration O +
and O +
accurate O +
and O +
flexible O +
reactant O +
mapping O +
coupled O +
with O +
reactant O +
tagging O +
through O +
substructure O +
searching O -
. O +

The O +
full O +
description O +
of O +
LiGen O +
functionalities O +
is O +
herein O +
presented O -
. O +

Structures O -
, O +
Dynamics O -
, O +
and O +
Stabilities O +
of O +
Fully O +
Modified O +
Locked O +
Nucleic O +
Acid O +
( O -
β O -
- O -
d O -
- O -
LNA O +
and O +
α O -
- O -
l O -
- O -
LNA O -
) O +
Duplexes O +
in O +
Comparison O +
to O +
Pure O +
DNA O +
and O +
RNA O +
Duplexes O -
. O +

Locked O +
nucleic O +
acid O +
( O -
LNA O -
) O +
is O +
a O +
chemical O +
modification O +
which O +
introduces O +
a O +
-O O -
- B-Chemical -
CH2- I-Chemical +
linkage O +
in O +
the O +
furanose B-Chemical +
sugar I-Chemical +
of O +
nucleic O +
acids O +
and O +
blocks O +
its O +
conformation O +
in O +
a O +
particular O +
state O -
. O +

Two O +
types O +
of O +
modifications O -
, O +
namely O -
, O +
2'-O,4'-C B-Chemical -
- I-Chemical -
methylene I-Chemical -
- I-Chemical -
β I-Chemical -
- I-Chemical -
d I-Chemical -
- I-Chemical -
ribofuranose I-Chemical +
( O -
β O -
- O -
d O -
- O -
LNA O -
) O +
and O +
2'-O,4'-C B-Chemical -
- I-Chemical -
methylene I-Chemical -
- I-Chemical -
α I-Chemical -
- I-Chemical -
l I-Chemical -
- I-Chemical -
ribofuranose I-Chemical +
( O -
α O -
- O -
l O -
- O -
LNA O -
) O -
, O +
have O +
been O +
shown O +
to O +
yield O +
RNA O +
and O +
DNA O +
duplex O -
- O -
like O +
structures O -
, O +
respectively O -
. O +

LNA O +
modifications O +
lead O +
to O +
increased O +
melting O +
temperatures O +
of O +
DNA O +
and O +
RNA O +
duplexes O -
, O +
and O +
have O +
been O +
suggested O +
as O +
potential O +
therapeutic O +
agents O +
in O +
antisense O +
therapy O -
. O +

In O +
this O +
study O -
, O +
molecular O +
dynamics O +
( O -
MD O -
) O +
simulations O +
were O +
performed O +
on O +
fully O +
modified O +
LNA O +
duplexes O +
and O +
pure O +
DNA O +
and O +
RNA O +
duplexes O +
sharing O +
a O +
similar O +
sequence O +
to O +
investigate O +
their O +
structure O -
, O +
stabilities O -
, O +
and O +
solvation O +
properties O -
. O +

Both O +
LNA O +
duplexes O +
undergo O +
unwinding O +
of O +
the O +
helical O +
structure O +
compared O +
to O +
the O +
pure O +
DNA O +
and O +
RNA O +
duplexes O -
. O +

Though O +
the O +
α O -
- O -
LNA O +
substituent O +
has O +
been O +
proposed O +
to O +
mimic O +
deoxyribose B-Chemical +
sugar B-Chemical +
in O +
its O +
conformational O +
properties O -
, O +
the O +
fully O +
modified O +
duplex O +
was O +
found O +
to O +
exhibit O +
unique O +
structural O +
and O +
dynamic O +
properties O +
with O +
respect O +
to O +
the O +
other O +
three O +
nucleic O +
acid O +
structures O -
. O +

Free O +
energy O +
calculations O +
accurately O +
capture O +
the O +
enhanced O +
stabilization O +
of O +
the O +
LNA O +
duplex O +
structures O +
compared O +
to O +
DNA O +
and O +
RNA O +
molecules O +
as O +
observed O +
in O +
experiments O -
. O +

π O -
- O -
stacking O +
interaction O +
between O +
bases O +
from O +
complementary O +
strands O +
is O +
shown O +
to O +
be O +
one O +
of O +
the O +
contributors O +
to O +
enhanced O +
stabilization O +
upon O +
LNA O +
substitution O -
. O +

A O +
combination O +
of O +
two O +
factors O -
, O +
namely O -
, O +
nature O +
of O +
the O +
-O O -
- B-Chemical -
CH2- I-Chemical +
linkage O +
in O +
the O +
LNAs O +
vs O +
their O +
absence O +
in O +
the O +
pure O +
duplexes O +
and O +
similar O +
conformations O +
of O +
the O +
sugar O +
rings O +
in O +
DNA O +
and O +
α O -
- O -
LNA O +
vs O +
the O +
other O +
two O -
, O +
is O +
suggested O +
to O +
contribute O +
to O +
the O +
stark O +
differences O +
among O +
the O +
four O +
duplexes O +
studied O +
here O +
in O +
terms O +
of O +
their O +
structural O -
, O +
dynamic O -
, O +
and O +
energetic O +
properties O -
. O +

Interview O +
with O +
m O +
frederick O +
hawthorne O -
. O +

M O +
Frederick O +
Hawthorne O +
is O +
a O +
world O -
- O -
renowned O +
scientist O +
in O +
the O +
field O +
of O +
molecular O +
medicine O +
and O +
a O +
pioneer O +
in O +
boron B-Chemical +
chemistry O -
. O +

He O +
currently O +
serves O +
as O +
the O +
founding O +
Director O +
of O +
the O +
University O +
of O +
Missouri O +
International O +
Institute O +
of O +
Nano O +
and O +
Molecular O +
Medicine O +
( O -
MO O -
, O +
USA O -
) O -
. O +

Prof. O +
Hawthorne O +
is O +
a O +
University O +
of O +
Missouri O +
Curators O -
' O +
Distinguished O +
Professor O +
and O +
University O +
Professor O +
of O +
Chemistry O +
Emeritus O +
of O +
the O +
University O +
of O +
California O -
, O +
Los O +
Angeles O +
( O -
CA O -
, O +
USA O -
) O -
. O +

He O +
is O +
a O +
member O +
of O +
the O +
US O +
National O +
Academy O +
of O +
Sciences O +
and O +
the O +
recipient O +
of O +
many O +
national O +
and O +
international O +
honors O -
, O +
including O +
the O +
2003 O +
King O +
Faisal O +
Prize O +
in O +
Science O -
, O +
the O +
American O +
Chemical O +
Society O -
's O +
2009 O +
Priestley O +
Medal O +
and O +
the O +
2011 O +
National O +
Medal O +
of O +
Science O -
. O +

Prof. O +
Hawthorne O +
has O +
authored O +
or O +
co O -
- O -
authored O +
more O +
than O +
540 O +
research O +
articles O -
, O +
30 O +
patents O -
, O +
ten O +
book O +
chapters O +
and O +
two O +
books O -
. O +

Prof. O +
Hawthorne O +
spoke O +
to O +
Future O +
Medicinal O +
Chemistry O +
on O +
how O +
he O +
became O +
involved O +
in O +
the O +
field O -
, O +
the O +
future O +
of O +
boron B-Chemical +
neutron O +
capture O +
therapy O -
, O +
and O +
provides O +
his O +
advice O +
for O +
the O +
next O +
generation O +
of O +
boron B-Chemical +
scientists O -
. O +

Interview O +
conducted O +
by O +
Isaac O +
Bruce O -
, O +
Managing O +
Commissioning O +
Editor O -
. O +

Boron B-Chemical +
chemicals O +
in O +
diagnosis O +
and O +
therapeutics O -
. O +

Advances O +
in O +
the O +
field O +
of O +
boron B-Chemical +
chemistry O +
have O +
expanded O +
the O +
application O +
of O +
boron B-Chemical +
from O +
material O +
use O +
to O +
medicine O -
. O +

Boron B-Chemical -
- O -
based O +
drugs O +
represent O +
a O +
new O +
class O +
of O +
molecules O +
that O +
possess O +
several O +
biomedical O +
applications O +
including O +
use O +
as O +
imaging O +
agents O +
for O +
both O +
optical O +
and O +
nuclear O +
imaging O +
as O +
well O +
as O +
therapeutic O +
agents O +
with O +
anticancer O -
, O +
antiviral O -
, O +
antibacterial O -
, O +
antifungal O +
and O +
other O +
disease O -
- O -
specific O +
activities O -
. O +

For O +
example O -
, O +
bortezomib B-Chemical +
( O -
Velcade B-Chemical -
( O -
® O -
) O -
) O -
, O +
the O +
only O +
drug O +
in O +
clinical O +
use O +
with O +
boron B-Chemical +
as O +
an O +
active O +
element O -
, O +
was O +
approved O +
in O +
2003 O +
as O +
a O +
proteasome O +
inhibitor O +
for O +
the O +
treatment O +
of O +
multiple O +
myeloma O +
and O +
non O -
- O -
Hodgkin O -
's O +
lymphoma O -
. O +

Several O +
other O +
boron B-Chemical -
- O -
based O +
compounds O +
are O +
in O +
various O +
phases O +
of O +
clinical O +
trials O -
, O +
which O +
illustrates O +
the O +
promise O +
of O +
this O +
approach O +
for O +
medicinal O +
chemists O +
working O +
in O +
the O +
area O +
of O +
boron B-Chemical +
chemistry O -
. O +

It O +
is O +
expected O +
that O +
in O +
the O +
near O +
future O -
, O +
several O +
boron B-Chemical -
- O -
containing O +
drugs O +
should O +
become O +
available O +
in O +
the O +
market O +
with O +
better O +
efficacy O +
and O +
potency O +
than O +
existing O +
drugs O -
. O +

This O +
article O +
discusses O +
the O +
current O +
status O +
of O +
the O +
development O +
of O +
boron B-Chemical -
- O -
based O +
compounds O +
as O +
diagnostic O +
and O +
therapeutic O +
agents O +
in O +
humans O -
. O +

Boronated B-Chemical +
carbohydrate I-Chemical +
derivatives O +
as O +
potential O +
boron B-Chemical +
neutron O +
capture O +
therapy O +
reagents O -
. O +

The O +
treatment O +
of O +
cancer O +
remains O +
one O +
of O +
the O +
most O +
challenging O +
problems O +
for O +
humanity O -
. O +

Boron B-Chemical +
neutron O +
capture O +
therapy O +
is O +
a O +
binary O +
approach O +
for O +
cancer O +
treatment O +
that O +
is O +
particularly O +
attractive O +
in O +
treating O +
high O -
- O -
grade O +
gliomas O +
and O +
metastatic O +
brain O +
tumors O -
. O +

Among O +
the O +
types O +
of O +
boron B-Chemical -
- O -
containing O +
molecules O +
used O +
as O +
boron B-Chemical +
neutron O +
capture O +
therapy O +
agents O -
, O +
boronated B-Chemical +
carbohydrate I-Chemical +
derivatives O +
have O +
received O +
significant O +
attention O +
because O +
of O +
their O +
preferential O +
uptake O +
by O +
growing O +
tumor O +
cells O -
. O +

This O +
review O +
provides O +
a O +
summary O +
of O +
the O +
recent O +
developments O +
in O +
the O +
chemistry O +
of O +
carborane B-Chemical -
- O -
containing O +
carbohydrates B-Chemical -
. O +

Characterization O +
of O +
the O +
nucleation O +
process O +
of O +
lysozyme O +
at O +
physiological O +
pH O -
: O +
Primary O +
but O +
not O +
sole O +
process O -
. O +

We O +
report O +
on O +
a O +
kinetic O +
study O +
of O +
the O +
heat O -
- O -
induced O +
aggregation O +
process O +
of O +
lysozyme O +
at O +
physiological O +
pH. O +
The O +
time O +
evolution O +
of O +
the O +
aggregation O +
extent O +
and O +
the O +
conformational O +
changes O +
of O +
the O +
protein O +
were O +
followed O +
by O +
dynamic O +
light O +
scattering O +
( O -
DLS O -
) O +
and O +
FTIR O +
spectroscopy O -
, O +
respectively O -
, O +
whereas O +
the O +
morphology O +
of O +
the O +
aggregates O +
was O +
observed O +
by O +
Atomic O +
Force O +
Microscopy O +
( O -
AFM O -
) O -
. O +

The O +
conformational O +
changes O +
of O +
the O +
secondary O +
and O +
tertiary O +
structures O +
were O +
simultaneous O +
and O +
distinct O +
in O +
time O +
with O +
respect O +
to O +
the O +
formation O +
of O +
aggregates O -
. O +

Oligomer O +
formation O +
occurred O +
through O +
at O +
least O +
two O +
different O +
aggregation O +
processes O -
: O +
a O +
nucleation O +
process O +
and O +
a O +
homogeneous O +
non O -
- O -
nucleative O +
diffusion O -
- O -
controlled O +
process O -
. O +

FTIR O +
measurements O +
showed O +
that O +
supramolecular O +
aggregation O +
proceeded O +
without O +
the O +
formation O +
of O +
β O -
- O -
aggregated O +
structures O +
and O +
AFM O +
images O +
revealed O +
the O +
presence O +
of O +
oligomers O +
and O +
amorphous O +
aggregates O -
; O +
no O +
fibrillar O +
structures O +
were O +
observed O -
. O +

Tandutinib B-Chemical +
( O -
MLN518 B-Chemical -
/ O -
CT53518 B-Chemical -
) O +
targeted O +
to O +
stem O -
- O -
like O +
cells O +
by O +
inhibiting O +
the O +
function O +
of O +
ATP B-Chemical -
- O -
binding O +
cassette O +
subfamily O +
G O +
member O +
2 O -
. O +

Tandutinib B-Chemical +
is O +
a O +
novel O +
inhibitor O +
of O +
tyrosine B-Chemical +
kinases O +
FLT3 O -
, O +
PDGFR O +
and O +
KIT O -
. O +

Our O +
study O +
was O +
to O +
explore O +
the O +
capability O +
of O +
tandutinib B-Chemical +
to O +
reverse O +
ABC O +
transporter O -
- O -
mediated O +
multidrug O +
resistance O -
. O +

Tandutinib B-Chemical +
reversed O +
ABCG2-mediated O +
drug O +
resistance O +
in O +
ABCG2 O -
- O -
482-R2 O -
, O +
ABCG2 O -
- O -
482-G2 O -
, O +
ABCG2 O -
- O -
482-T7 O +
and O +
S1-M1 O -
- O -
80 O +
cells O +
and O +
increased O +
the O +
accumulation O +
of O +
doxorubicin B-Chemical -
, O +
rhodamine B-Chemical +
123 I-Chemical +
and O +
[ B-Chemical -
H I-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
] I-Chemical +
mitoxantrone I-Chemical +
in O +
ABCG2-overexpressing O +
cells O -
. O +

Importantly O -
, O +
tandutinib B-Chemical +
selectively O +
sensitized O +
side O +
population O +
cells O +
to O +
mitoxantrone B-Chemical -
. O +

Taken O +
together O -
, O +
our O +
results O +
advocate O +
the O +
potency O +
of O +
tandutinib B-Chemical +
as O +
an O +
ABCG2 O +
modulator O +
and O +
stem O -
- O -
like O +
cells O +
targeted O +
agent O +
to O +
increase O +
efficiency O +
of O +
anticancer O +
drugs O -
. O +

How O +
do O +
polymeric O +
micelles O +
cross O +
epithelial O +
barriers O -
? O +

Non O -
- O -
parenteral O +
delivery O +
of O +
drugs O +
using O +
nanotechnology O -
- O -
based O +
delivery O +
systems O +
is O +
a O +
promising O +
non O -
- O -
invasive O +
way O +
to O +
achieve O +
effective O +
local O +
or O +
systemic O +
drug O +
delivery O -
. O +

The O +
efficacy O +
of O +
drugs O +
administered O +
non O -
- O -
parenterally O +
is O +
limited O +
by O +
their O +
ability O +
to O +
cross O +
biological O +
barriers O -
, O +
and O +
epithelial O +
tissues O +
particularly O +
present O +
challenges O -
. O +

Polymeric O +
micelles O +
can O +
achieve O +
transepithelial O +
drug O +
delivery O +
because O +
of O +
their O +
ability O +
to O +
be O +
internalized O +
into O +
cells O +
and/or O +
cross O +
epithelial O +
barriers O -
, O +
thereby O +
delivering O +
drugs O +
either O +
locally O +
or O +
systematically O +
following O +
non O -
- O -
parenteral O +
administration O -
. O +

This O +
review O +
discusses O +
the O +
particular O +
characteristics O +
of O +
various O +
epithelial O +
barriers O +
and O +
assesses O +
their O +
potential O +
as O +
non O -
- O -
parenteral O +
routes O +
of O +
delivery O -
. O +

The O +
material O +
characteristics O +
of O +
polymeric O +
micelles O +
( O -
e.g. O -
, O +
size O -
, O +
surface O +
charge O -
, O +
and O +
surface O +
decoration O -
) O +
and O +
of O +
unimers O +
dissociated O +
from O +
polymeric O +
micelles O +
determine O +
their O +
interactions O +
( O -
non O -
- O -
specific O +
and/or O +
specific O -
) O +
with O +
mucus O +
and O +
epithelial O +
cells O +
as O +
well O +
as O +
their O +
intracellular O +
fate O -
. O +

This O +
paper O +
outlines O +
the O +
mechanisms O +
governing O +
the O +
major O +
modes O +
of O +
internalization O +
of O +
polymeric O +
micelles O +
into O +
epithelial O +
cells O -
, O +
with O +
an O +
emphasis O +
on O +
specific O +
recent O +
examples O +
of O +
the O +
transport O +
of O +
drug O -
- O -
loaded O +
polymeric O +
micelles O +
across O +
epithelial O +
barriers O -
. O +

Polymorphism O +
in O +
porphyrin B-Chemical +
monolayers O -
: O +
the O +
relation O +
between O +
adsorption O +
configuration O +
and O +
molecular O +
conformation O -
. O +

Self O -
- O -
assembled O +
monolayers O +
of O +
meso-5,10,15,20-tetrakis B-Chemical -
( I-Chemical -
undecyl I-Chemical -
) I-Chemical -
porphyrin I-Chemical +
copper I-Chemical -
( I-Chemical -
ii I-Chemical -
) I-Chemical +
on O +
a O +
graphite B-Chemical -
/ O -
1-octanoic B-Chemical +
acid I-Chemical +
interface O +
have O +
been O +
studied O +
by O +
Scanning O +
Tunnelling O +
Microscopy O -
. O +

Four O +
distinct O +
polymorphs O +
were O +
observed O -
, O +
varying O +
in O +
their O +
unit O +
cell O +
size O -
. O +

Arrays O +
of O +
unit O +
cells O +
of O +
the O +
various O +
polymorphs O +
seamlessly O +
connect O +
to O +
each O +
other O +
via O +
shared O +
unit O +
cell O +
vectors O -
. O +

The O +
monolayers O +
are O +
not O +
commensurate O -
, O +
but O +
coincident O +
with O +
the O +
underlying O +
graphite B-Chemical +
substrate O -
. O +

The O +
seamless O +
transition O +
between O +
the O +
polymorphs O +
is O +
proposed O +
to O +
be O +
the O +
result O +
of O +
an O +
adaptation O +
of O +
the O +
molecular O +
conformations O +
in O +
the O +
polymorphs O +
and O +
at O +
the O +
boundaries O -
, O +
which O +
is O +
enabled O +
by O +
the O +
conformational O +
freedom O +
of O +
the O +
alkyl B-Chemical +
tails O +
of O +
these O +
molecules O -
. O +

Random O +
Regret O -
- O -
Based O +
Discrete O -
- O -
Choice O +
Modelling O -
: O +

An O +
Application O +
to O +
Healthcare O -
. O +

BACKGROUND O -
: O +
A O +
new O +
modelling O +
approach O +
for O +
analysing O +
data O +
from O +
discrete O -
- O -
choice O +
experiments O +
( O -
DCEs O -
) O +
has O +
been O +
recently O +
developed O +
in O +
transport O +
economics O +
based O +
on O +
the O +
notion O +
of O +
regret O +
minimization O -
- O -
driven O +
choice O +
behaviour O -
. O +

This O +
so O -
- O -
called O +
Random O +
Regret O +
Minimization O +
( O -
RRM O -
) O +
approach O +
forms O +
an O +
alternative O +
to O +
the O +
dominant O +
Random O +
Utility O +
Maximization O +
( O -
RUM O -
) O +
approach O -
. O +

The O +
RRM O +
approach O +
is O +
able O +
to O +
model O +
semi O -
- O -
compensatory O +
choice O +
behaviour O +
and O +
compromise O +
effects O -
, O +
while O +
being O +
as O +
parsimonious O +
and O +
formally O +
tractable O +
as O +
the O +
RUM O +
approach O -
. O +

OBJECTIVES O -
: O +
Our O +
objectives O +
were O +
to O +
introduce O +
the O +
RRM O +
modelling O +
approach O +
to O +
healthcare O -
- O -
related O +
decisions O -
, O +
and O +
to O +
investigate O +
its O +
usefulness O +
in O +
this O +
domain O -
. O +

METHODS O -
: O +
Using O +
data O +
from O +
DCEs O +
aimed O +
at O +
determining O +
valuations O +
of O +
attributes O +
of O +
osteoporosis O +
drug O +
treatments O +
and O +
human O +
papillomavirus O +
( O -
HPV O -
) O +
vaccinations O -
, O +
we O +
empirically O +
compared O +
RRM O +
models O -
, O +
RUM O +
models O +
and O +
Hybrid O +
RUM O -
- O -
RRM O +
models O +
in O +
terms O +
of O +
goodness O +
of O +
fit O -
, O +
parameter O +
ratios O +
and O +
predicted O +
choice O +
probabilities O -
. O +

RESULTS O -
: O +
In O +
terms O +
of O +
model O +
fit O -
, O +
the O +
RRM O +
model O +
did O +
not O +
outperform O +
the O +
RUM O +
model O +
significantly O +
in O +
the O +
case O +
of O +
the O +
osteoporosis O +
DCE O +
data O +
( O -
p O +
= O +
0.21 O -
) O -
, O +
whereas O +
in O +
the O +
case O +
of O +
the O +
HPV O +
DCE O +
data O -
, O +
the O +
Hybrid O +
RUM O -
- O -
RRM O +
model O +
outperformed O +
the O +
RUM O +
model O +
( O -
p O +
< O +
0.05 O -
) O -
. O +

Differences O +
in O +
predicted O +
choice O +
probabilities O +
between O +
RUM O +
models O +
and O +
( O -
Hybrid O +
RUM- O -
) O +
RRM O +
models O +
were O +
small O -
. O +

Derived O +
parameter O +
ratios O +
did O +
not O +
differ O +
significantly O +
between O +
model O +
types O -
, O +
but O +
trade O -
- O -
offs O +
between O +
attributes O +
implied O +
by O +
the O +
two O +
models O +
can O +
vary O +
substantially O -
. O +

CONCLUSION O -
: O +
Differences O +
in O +
model O +
fit O +
between O +
RUM O -
, O +
RRM O +
and O +
Hybrid O +
RUM O -
- O -
RRM O +
were O +
found O +
to O +
be O +
small O -
. O +

Although O +
our O +
study O +
did O +
not O +
show O +
significant O +
differences O +
in O +
parameter O +
ratios O -
, O +
the O +
RRM O +
and O +
Hybrid O +
RUM O -
- O -
RRM O +
models O +
did O +
feature O +
considerable O +
differences O +
in O +
terms O +
of O +
the O +
trade O -
- O -
offs O +
implied O +
by O +
these O +
ratios O -
. O +

In O +
combination O -
, O +
our O +
results O +
suggest O +
that O +
RRM O +
and O +
Hybrid O +
RUM O -
- O -
RRM O +
modelling O +
approach O +
hold O +
the O +
potential O +
of O +
offering O +
new O +
and O +
policy O -
- O -
relevant O +
insights O +
for O +
health O +
researchers O +
and O +
policy O +
makers O -
. O +

Genetic O +
Variants O +
in O +
2q31 O +
and O +
5p15 O +
Are O +
Associated O +
With O +
Aggressive O +
Benign O +
Prostatic O +
Hyperplasia O +
in O +
a O +
Chinese O +
Population O -
. O +

BACKGROUND O -
: O +
Benign O +
prostatic O +
hyperplasia O +
( O -
BPH O -
) O +
is O +
a O +
common O +
disease O +
prevalent O +
in O +
elderly O +
men O -
. O +

However O -
, O +
the O +
genetic O +
determinants O +
of O +
BPH O +
remain O +
unclear O -
. O +

Because O +
BPH O +
and O +
prostate O +
cancer O +
( O -
PCa O -
) O +
share O +
some O +
common O +
pathological O +
characteristics O -
, O +
we O +
investigated O +
whether O +
susceptibility O +
loci O +
for O +
PCa O +
contributed O +
to O +
BPH O +
risk O +
and O +
BPH O +
aggressiveness O +
in O +
Chinese O +
men O -
. O +

METHODS O -
: O +
Fourteen O +
SNPs O +
associated O +
with O +
PCa O +
risk O +
in O +
a O +
Chinese O +
population O +
were O +
genotyped O +
in O +
426 O +
BPH O +
cases O +
( O -
184 O +
aggressive O +
and O +
242 O +
non O -
- O -
aggressive O +
BPH O +
cases O -
) O +
and O +
1,008 O +
controls O -
. O +

The O +
association O +
between O +
the O +
SNPs O +
and O +
BPH O +
risk O -
/ O -
aggressiveness O +
was O +
estimated O +
using O +
logistic O +
regression O +
analysis O -
. O +

In O +
addition O -
, O +
effects O +
of O +
the O +
14 O +
SNPs O +
on O +
BPH O +
related O +
clinical O +
traits O -
, O +
including O +
International O +
Prostate O +
Symptom O +
Score O +
( O -
IPSS O -
) O -
, O +
prostate O +
volume O -
, O +
total O +
PSA O -
, O +
and O +
free O +
PSA O +
were O +
evaluated O +
using O +
linear O +
regression O +
analysis O -
. O +

RESULTS O -
: O +
Two O +
SNPs O -
, O +
rs12621278 O +
in O +
ITGA6 O +
at O +
2q31 O +
( O -
OR O +
= O +
0.82 O -
, O +
P O +
= O +
0.05 O -
) O +
and O +
rs339331 O +
in O +
RFX6 O +
at O +
6q22 O +
( O -
OR O +
= O +
1.22 O -
, O +
P O +
= O +
0.04 O -
) O +
were O +
significantly O +
associated O +
with O +
BPH O -
. O +

In O +
addition O -
, O +
rs12621278 O +
( O -
OR O +
= O +
0.73 O -
, O +
P O +
= O +
0.05 O -
) O +
and O +
rs12653946 O -
, O +
13 O +
kb O +
upstream O +
of O +
IRX4 O +
at O +
5p15 O +
( O -
OR O +
= O +
1.40 O -
, O +
0.03 O -
) O -
, O +
were O +
significantly O +
associated O +
with O +
aggressive O +
BPH O -
. O +

Moreover O -
, O +
the O +
risk O +
allele O +
of O +
rs12621278 O +
( O -
G O -
) O +
and O +
rs12653946 O +
( O -
T O -
) O +
for O +
aggressive O +
BPH O +
were O +
significantly O +
associated O +
with O +
elevated O +
IPSS O +
after O +
treatment O +
( O -
P O +
= O +
0.01 O -
) O -
. O +

CONCLUSIONS O -
: O +
This O +
is O +
the O +
first O +
systematic O +
investigation O +
on O +
the O +
contributions O +
of O +
PCa O +
susceptibility O +
loci O +
to O +
risk O +
and O +
aggressiveness O +
of O +
BPH O -
. O +

Our O +
findings O +
advance O +
our O +
understanding O +
of O +
the O +
genetic O +
basis O +
of O +
BPH O -
, O +
especially O +
aggressive O +
BPH O -
. O +

In O +
addition O -
, O +
our O +
results O +
provide O +
new O +
insights O +
into O +
the O +
genetic O +
determinants O +
shared O +
between O +
BPH O +
and O +
PCa O -
. O +

Prostate O +
9999 O -
: O -
XX O -
- O -
XX O -
. O +

© O +
2013 O +

Wiley O +
Periodicals O -
, O +
Inc. O +

Microbial O +
degradation O +
of O +
microcystins B-Chemical -
. O +

Hepatotoxic O +
microcystins B-Chemical +
that O +
are O +
produced O +
by O +
freshwater O +
cyanobacteria O +
pose O +
a O +
risk O +
to O +
public O +
health O -
. O +

These O +
compounds O +
may O +
be O +
eliminated O +
by O +
enzymatic O +
degradation O -
. O +

Here O -
, O +
we O +
review O +
the O +
enzymatic O +
pathways O +
for O +
the O +
degradation O +
of O +
these O +
hepatotoxins O -
, O +
some O +
of O +
which O +
are O +
newly O +
discovered O +
processes O -
. O +

The O +
efficiencies O +
of O +
microcystin B-Chemical +
biodegradation O +
pathways O +
are O +
documented O +
in O +
several O +
papers O +
and O +
are O +
compared O +
here O -
. O +

Additionally O -
, O +
a O +
comprehensive O +
description O +
of O +
the O +
microcystin B-Chemical +
enzymatic O +
degradation O +
scheme O +
has O +
been O +
supplemented O +
with O +
a O +
proposal O +
for O +
a O +
new O +
biodegradation O +
pathway O -
. O +

Critical O +
comments O +
on O +
less O +
documented O +
hypotheses O +
are O +
also O +
included O +
in O +
this O +
review O -
. O +

The O +
genetic O +
aspects O +
of O +
biodegradation O +
activity O +
are O +
discussed O +
in O +
detail O -
. O +

We O +
also O +
describe O +
some O +
methods O +
that O +
are O +
useful O +
for O +
studying O +
the O +
biological O +
decomposition O +
of O +
microcystins B-Chemical -
, O +
including O +
screening O +
for O +
microcystin B-Chemical +
degraders O +
and O +
detecting O +
microcystin B-Chemical +
degradation O +
products O -
, O +
with O +
an O +
emphasis O +
on O +
mass O +
spectrometric O +
methodology O -
. O +

Insertion O +
of O +
CO2 B-Chemical +
and O +
COS B-Chemical +
into O +
Bi B-Chemical -
- I-Chemical -
C I-Chemical +
Bonds O -
: O +
Reactivity O +
of O +
a O +
Bismuth B-Chemical +
NCN I-Chemical +
Pincer O +
Complex O +
of O +
an O +
Oxyaryl B-Chemical +
Dianionic O +
Ligand O -
, O +
[ B-Chemical -
2,6- I-Chemical -
( I-Chemical -
Me2NCH2 I-Chemical -
) I-Chemical -
2C6H3 I-Chemical -
] I-Chemical -
Bi I-Chemical -
( I-Chemical -
C6H2tBu2O I-Chemical -
) I-Chemical -
. O +

The O +
reactivity O +
of O +
the O +
unusual O +
oxyaryl B-Chemical +
dianionic O +
ligand O -
, O +
( B-Chemical -
C6H2tBu2 I-Chemical -
- I-Chemical -
3,5-O-4 I-Chemical -
) I-Chemical -
2- I-Chemical -
, O +
in O +
the O +
Bi3 B-Chemical -
+ I-Chemical +
NCN I-Chemical +
pincer O +
complex O +
Ar'Bi B-Chemical -
( I-Chemical -
C6H2tBu2 I-Chemical -
- I-Chemical -
3,5-O-4 I-Chemical -
) I-Chemical -
, O +
1 O -
, O +
[ O -
Ar O -
' O +
= O +
2,6- B-Chemical -
( I-Chemical -
Me2NCH2 I-Chemical -
) I-Chemical -
2C6H3 I-Chemical -
] O +
has O +
been O +
explored O +
with O +
small O +
molecule O +
substrates O +
and O +
electrophiles O -
. O +

The O +
first O +
insertion O +
reactions O +
of O +
CO2 B-Chemical +
and O +
COS B-Chemical +
into O +
Bi B-Chemical -
- I-Chemical -
C I-Chemical +
bonds O +
are O +
observed O +
with O +
this O +
oxyaryl B-Chemical +
dianionic O +
ligand O +
complex O -
. O +

These O +
reactions O +
generate O +
new O +
dianions O +
that O +
have O +
quinoidal O +
character O +
similar O +
to O +
the O +
oxyaryl B-Chemical +
dianionic O +
ligand O +
in O +
1 O -
. O +

The O +
oxyarylcarboxy B-Chemical +
and O +
oxyarylthiocarboxy B-Chemical +
dianionic O +
ligands O +
were O +
identified O +
by O +
X O -
- O -
ray O +
crystallography O +
in O +
Ar'Bi B-Chemical -
[ I-Chemical -
O2C I-Chemical -
( I-Chemical -
C6H2tBu2 I-Chemical -
- I-Chemical -
3 I-Chemical -
- I-Chemical -
5-O-4 I-Chemical -
) I-Chemical -
-κ2O I-Chemical -
, I-Chemical -
O I-Chemical -
' I-Chemical -
] I-Chemical -
, O +
2 O +
and O +
Ar'Bi B-Chemical -
[ I-Chemical -
OSC I-Chemical -
( I-Chemical -
C6H2tBu2 I-Chemical -
- I-Chemical -
3 I-Chemical -
- I-Chemical -
5-O-4 I-Chemical -
) I-Chemical -
-κ2O I-Chemical -
, I-Chemical -
S I-Chemical -
] I-Chemical -
, O +
3 O -
, O +
respectively O -
. O +

Silyl B-Chemical +
halides I-Chemical +
and O +
pseudohalides B-Chemical -
, O +
R3SiX B-Chemical +
( O -
X O +
= O +
Cl B-Chemical -
, O +
CN B-Chemical -
, O +
N3 B-Chemical -
; O +
R O +
= O +
Me B-Chemical -
, O +
Ph B-Chemical -
) O -
, O +
react O +
with O +
1 O +
by O +
attaching O +
X O +
to O +
bismuth B-Chemical +
and O +
R3Si B-Chemical +
to O +
the O +
oxyaryl B-Chemical +
oxygen B-Chemical +
to O +
form O +
Ar'Bi B-Chemical -
( I-Chemical -
X I-Chemical -
) I-Chemical -
( I-Chemical -
C6H2tBu2 I-Chemical -
- I-Chemical -
3,5-OSiR3 I-Chemical -
- I-Chemical -
4 I-Chemical -
) I-Chemical +
complexes O -
, O +
a O +
formal O +
addition O +
across O +
five O +
bonds O -
. O +

These O +
react O +
with O +
additional O +
R3SiX B-Chemical +
to O +
generate O +
Ar'BiX2 B-Chemical +
complexes O +
and O +
R3SiOC6H3tBu2 B-Chemical -
- I-Chemical -
2,6 I-Chemical -
. O +

The O +
reaction O +
of O +
1 O +
with O +
I2 B-Chemical +
forms O +
Ar'BiI2 B-Chemical +
and O +
the O +
coupled O +
quinone B-Chemical -
, O +
3,3',5,5'-tetra B-Chemical -
- I-Chemical -
tert I-Chemical -
- I-Chemical -
butyl-4,4'-diphenoquinone I-Chemical -
, O +
by O +
oxidative O +
coupling O -
. O +

High O -
- O -
Accuracy O +
Estimates O +
for O +
the O +
Vinylidene B-Chemical -
- O -
Acetylene B-Chemical +
Isomerization O +
Energy O +
and O +
the O +
Ground O +
State O +
Rotational O +
Constants O +
of O +
: B-Chemical -
C I-Chemical -
= I-Chemical -
CH2 I-Chemical -
. O +

Highly O +
accurate O +
calculations O +
are O +
reported O +
for O +
properties O +
of O +
vinylidene B-Chemical +
( O -
H2C B-Chemical -
= I-Chemical -
C I-Chemical -
: I-Chemical -
) O -
, O +
specically O +
the O +
position O +
of O +
its O +
zero O -
- O -
point O +
vibrational O +
level O +
relative O +
to O +
that O +
of O +
acetylene B-Chemical +
and O +
its O +
equilibrium O +
structure O +
and O +
ground O +
state O +
rotational O +
constants O -
. O +

The O +
isomerization O +
energy O +
of O +
vinylidene B-Chemical +
calculated O +
at O +
the O +
HEAT-456QP O +
level O +
of O +
theory O +
is O +
45.530.15 O +
kcal O +
mol1 O -
, O +
in O +
agreement O +
with O +
the O +
previous O +
best O +
estimate O -
, O +
but O +
associated O +
with O +
a O +
much O +
smaller O +
uncertainty O -
. O +

In O +
addition O -
, O +
the O +
thermochemical O +
calculations O +
presented O +
here O +
also O +
allow O +
a O +
determination O +
of O +
the O +
: B-Chemical -
C I-Chemical -
= I-Chemical -
CH2 I-Chemical +
bond O +
energy O +
of O +
the O +
vinyl B-Chemical +
radical O +
at O +
the O +
HEAT-345 O -
( O -
Q O -
) O +
level O +
of O +
theory O -
, O +
which O +
is O +
77.70.3 O +
kcal O +
mol1 O -
. O +

The O +
equilibrium O +
structure O +
of O +
vinylidene B-Chemical -
, O +
estimated O +
with O +
an O +
additivity O +
scheme O +
that O +
includes O +
treatment O +
of O +
correlation O +
eects O +
beyond O +
CCSD O -
( O -
T O -
) O +
as O +
well O +
as O +
relativistic O +
and O +
adiabatic O +
( O -
diagonal O +
Born O -
- O -
Oppenheimer O +
correction O -
) O +
contributions O +
is O +
rCC=1.29820.0003 O +
A O -
; O +
rCH=1.08440.0003 O +
A O -
; O +
and O +
CCH=120.050.05o B-Chemical -
, O +
with O +
zero O -
- O -
point O +
rotational O +
constants O +
( O -
including O +
vibrational O +
contributions O +
and O +
electronic O +
contributions O +
to O +
the O +
moment O +
of O +
inertia O -
) O +
estimated O +
to O +
be O +
A0 O +
= O +
9.49250.0150 O +
cm1 O -
; O +
B0 O +
= O +
1.32170.0017 O +
cm1 O +
and O +
C0 O +
= O +
1.16020.0016 O +
cm1 O -
. O +

INTRODUCTION O -
. O +

An O +
archaeal O +
RadA O +
paralog O +
influences O +
presynaptic O +
filament O +
formation O -
. O +

Recombinases O +
of O +
the O +
RecA O +
family O +
play O +
vital O +
roles O +
in O +
homologous O +
recombination O -
, O +
a O +
high O -
- O -
fidelity O +
mechanism O +
to O +
repair O +
DNA O +
double O -
- O -
stranded O +
breaks O -
. O +

These O +
proteins O +
catalyze O +
strand O +
invasion O +
and O +
exchange O +
after O +
forming O +
dynamic O +
nucleoprotein O +
filaments O +
on O +
ssDNA O -
. O +

Increasing O +
evidence O +
suggests O +
that O +
stabilization O +
of O +
these O +
dynamic O +
filaments O +
is O +
a O +
highly O +
conserved O +
function O +
across O +
diverse O +
species O -
. O +

Here O -
, O +
we O +
analyze O +
the O +
presynaptic O +
filament O +
formation O +
and O +
DNA O +
binding O +
characteristics O +
of O +
the O +
Sulfolobus O +
solfataricus O +
recombinase O +
SsoRadA O +
in O +
conjunction O +
with O +
the O +
SsoRadA O +
paralog O +
SsoRal1 O -
. O +

In O +
addition O +
to O +
constraining O +
SsoRadA O +
ssDNA O -
- O -
dependent O +
ATPase O +
activity O -
, O +
the O +
paralog O +
also O +
enhances O +
SsoRadA O +
ssDNA O +
binding O -
, O +
effectively O +
influencing O +
activities O +
necessary O +
for O +
presynaptic O +
filament O +
formation O -
. O +

These O +
activities O +
result O +
in O +
enhanced O +
SsoRadA O -
- O -
mediated O +
strand O +
invasion O +
in O +
the O +
presence O +
of O +
SsoRal1 O +
and O +
suggest O +
a O +
filament O +
stabilization O +
function O +
for O +
the O +
SsoRal1 O +
protein O -
. O +

Developmental O +
immunotoxicity O +
in O +
male O +
rats O +
after O +
juvenile O +
exposure O +
to O +
ethanol B-Chemical -
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
determine O +
the O +
sensitivity O +
of O +
the O +
developing O +
immune O +
system O +
to O +
ethanol B-Chemical +
( O -
EtOH B-Chemical -
) O +
after O +
exposure O +
from O +
postnatal O +
day O +
( O -
PND O -
) O +
10 O +
onward O -
. O +

Adult O +
Wistar O +
dams O +
and O +
litters O +
were O +
exposed O +
to O +
EtOH B-Chemical +
via O +
drinking O +
water O +
( O -
0 O -
, O +
0.25 O -
, O +
1.5 O -
, O +
2.75 O -
, O +
4 O -
, O +
5.25 O -
, O +
or O +
6.5 O -
% O +
( O -
w O -
/ O -
v O -
) O +
EtOH B-Chemical +
ad O +
libitum O -
) O +
and O +
drinking O +
water O +
exposure O +
of O +
the O +
F1 O +
was O +
continued O +
from O +
weaning O +
until O +
sacrifice O -
. O +

Immune O +
assessments O +
were O +
performed O +
at O +
postnatal O +
days O +
( O -
PNDs O -
) O +
21 O -
, O +
42 O -
, O +
and O +
70 O -
. O +

Furthermore O -
, O +
Keyhole O +
Limpet O +
Hemocyanin O +
( O -
KLH O -
) O +
specific O +
immune O +
responses O +
were O +
evaluated O +
following O +
subcutaneous O +
immunizations O +
on O +
PNDs O +
21 O +
and O +
35 O -
. O +

EtOH B-Chemical +
exposure O +
affected O +
innate O +
immune O +
responses O -
, O +
such O +
as O +
LPS O -
- O -
induced O +
NO B-Chemical -
- O -
production O +
by O +
adherent O +
splenocytes O -
, O +
as O +
well O +
as O +
adaptive O +
immune O +
responses O +
as O +
represented O +
by O +
KLH O -
- O -
specific O +
parameters O -
. O +

The O +
most O +
sensitive O +
developmental O +
parameters O +
included O +
effects O +
on O +
maternal O +
and O +
pup O +
bodyweight O +
with O +
calculated O +
BMDs O +
of O +
4.0 O -
% O +
and O +
4.3 O -
% O +
EtOH B-Chemical -
, O +
respectively O -
. O +

The O +
most O +
sensitive O +
immune O +
parameters O +
were O +
affected O +
at O +
dose O +
levels O +
lower O +
than O +
those O +
affecting O +
developmental O +
parameters O +
and O +
included O +
KLH O -
- O -
specific O +
immune O +
responses O -
, O +
LPS O -
- O -
induced O +
NO B-Chemical +
production O +
by O +
adherent O +
splenocytes O -
, O +
and O +
IL-10 O +
production O +
by O +
ConA O +
stimulated O +
splenocytes O -
. O +

Calculated O +
BMDs O +
for O +
these O +
parameters O +
were O +
between O +
0.01 O -
% O +
and O +
0.1 O -
% O +
EtOH B-Chemical -
. O +

A O +
comparison O +
of O +
the O +
results O +
of O +
this O +
juvenile O +
study O +
with O +
an O +
extended O +
one O -
- O -
generation O +
reproductive O +
toxicity O +
study O +
revealed O +
that O +
the O +
juvenile O +
study O +
design O +
may O +
result O +
in O +
a O +
higher O +
sensitivity O +
related O +
to O +
differences O +
in O +
the O +
exposure O +
design O -
. O +

These O +
findings O +
demonstrate O +
the O +
relative O +
sensitivity O +
of O +
the O +
developing O +
immune O +
system O +
for O +
EtOH B-Chemical +
exposure O -
, O +
the O +
additional O +
value O +
of O +
assessing O +
functional O +
immune O +
parameters O -
, O +
and O +
the O +
importance O +
of O +
the O +
juvenile O +
window O +
in O +
developmental O +
immunotoxicity O +
testing O -
. O +

Growth O +
and O +
potential O +
damage O +
of O +
human O +
bone O -
- O -
derived O +
cells O +
on O +
fresh O +
and O +
aged O +
fullerene B-Chemical +
c60 B-Chemical +
films O -
. O +

Fullerenes B-Chemical +
are O +
nanoparticles O +
composed O +
of O +
carbon B-Chemical +
atoms O +
arranged O +
in O +
a O +
spherical O +
hollow O +
cage O -
- O -
like O +
structure O -
. O +

Numerous O +
studies O +
have O +
evaluated O +
the O +
therapeutic O +
potential O +
of O +
fullerene B-Chemical +
derivates O +
against O +
oxidative O +
stress O -
- O -
associated O +
conditions O -
, O +
including O +
the O +
prevention O +
or O +
treatment O +
of O +
arthritis O -
. O +

On O +
the O +
other O +
hand O -
, O +
fullerenes B-Chemical +
are O +
not O +
only O +
able O +
to O +
quench O -
, O +
but O +
also O +
to O +
generate O +
harmful O +
reactive O +
oxygen B-Chemical +
species O -
. O +

The O +
reactivity O +
of O +
fullerenes B-Chemical +
may O +
change O +
in O +
time O +
due O +
to O +
the O +
oxidation O +
and O +
polymerization O +
of O +
fullerenes B-Chemical +
in O +
an O +
air O +
atmosphere O -
. O +

In O +
this O +
study O -
, O +
we O +
therefore O +
tested O +
the O +
dependence O +
between O +
the O +
age O +
of O +
fullerene B-Chemical +
films O +
( O -
from O +
one O +
week O +
to O +
one O +
year O -
) O +
and O +
the O +
proliferation O -
, O +
viability O +
and O +
metabolic O +
activity O +
of O +
human O +
osteosarcoma O +
cells O +
( O -
lines O +
MG-63 O +
and O +
U-2 O +
OS O -
) O -
. O +

We O +
also O +
monitored O +
potential O +
membrane O +
and O +
DNA O +
damage O +
and O +
morphological O +
changes O +
of O +
the O +
cells O -
. O +

After O +
seven O +
days O +
of O +
cultivation O -
, O +
we O +
did O +
not O +
observe O +
any O +
cytotoxic O +
morphological O +
changes O -
, O +
such O +
as O +
enlarged O +
cells O +
or O +
cytosolic O +
vacuole O +
formation O -
. O +

Furthermore O -
, O +
there O +
was O +
no O +
increased O +
level O +
of O +
DNA O +
damage O -
. O +

The O +
increasing O +
age O +
of O +
the O +
fullerene B-Chemical +
films O +
did O +
not O +
cause O +
enhancement O +
of O +
cytotoxicity O -
. O +

On O +
the O +
contrary O -
, O +
it O +
resulted O +
in O +
an O +
improvement O +
in O +
the O +
properties O +
of O +
these O +
materials O -
, O +
which O +
are O +
more O +
suitable O +
for O +
cell O +
cultivation O -
. O +

Therefore O -
, O +
fullerene B-Chemical +
films O +
could O +
be O +
considered O +
as O +
a O +
promising O +
material O +
with O +
potential O +
use O +
as O +
a O +
bioactive O +
coating O +
of O +
cell O +
carriers O +
for O +
bone O +
tissue O +
engineering O -
. O +

Excitation O +
and O +
Adaptation O +
in O +
Bacteria O -
- O -
a O +
Model O +
Signal O +
Transduction O +
System O +
that O +
Controls O +
Taxis O +
and O +
Spatial O +
Pattern O +
Formation O -
. O +

The O +
machinery O +
for O +
transduction O +
of O +
chemotactic O +
stimuli O +
in O +
the O +
bacterium O +
E. O +
coli O +
is O +
one O +
of O +
the O +
most O +
completely O +
characterized O +
signal O +
transduction O +
systems O -
, O +
and O +
because O +
of O +
its O +
relative O +
simplicity O -
, O +
quantitative O +
analysis O +
of O +
this O +
system O +
is O +
possible O -
. O +

Here O +
we O +
discuss O +
models O +
which O +
reproduce O +
many O +
of O +
the O +
important O +
behaviors O +
of O +
the O +
system O -
. O +

The O +
important O +
characteristics O +
of O +
the O +
signal O +
transduction O +
system O +
are O +
excitation O +
and O +
adaptation O -
, O +
and O +
the O +
latter O +
implies O +
that O +
the O +
transduction O +
system O +
can O +
function O +
as O +
a O +
" O -
derivative O +
sensor O -
" O +
with O +
respect O +
to O +
the O +
ligand O +
concentration O +
in O +
that O +
the O +
DC O +
component O +
of O +
a O +
signal O +
is O +
ultimately O +
ignored O +
if O +
it O +
is O +
not O +
too O +
large O -
. O +

This O +
temporal O +
sensing O +
mechanism O +
provides O +
the O +
bacterium O +
with O +
a O +
memory O +
of O +
its O +
passage O +
through O +
spatially- O +
or O +
temporally O -
- O -
varying O +
signal O +
fields O -
, O +
and O +
adaptation O +
is O +
essential O +
for O +
successful O +
chemotaxis O -
. O +

We O +
also O +
discuss O +
some O +
of O +
the O +
spatial O +
patterns O +
observed O +
in O +
populations O +
and O +
indicate O +
how O +
cell O -
- O -
level O +
behavior O +
can O +
be O +
embedded O +
in O +
population O -
- O -
level O +
descriptions O -
. O +

Mechanistic O +
Aspects O +
of O +
hSOD1 O +
Maturation O +
from O +
the O +
Solution O +
Structure O +
of O +
Cu B-Chemical -
( I-Chemical -
I I-Chemical -
) I-Chemical +
-Loaded O +
hCCS O +
Domain O +
1 O +
and O +
Analysis O +
of O +
Disulfide B-Chemical -
- O -
Free O +
hSOD1 O +
Mutants O -
. O +

Superoxide B-Chemical +
dismutase O +
1 O +
( O -
SOD1 O -
) O +
maturation O +
within O +
the O +
cell O +
is O +
mainly O +
accomplished O +
with O +
the O +
SOD1-specific O +
chaperone O -
, O +
CCS O -
, O +
a O +
dimeric O +
protein O +
with O +
three O +
distinct O +
domains O +
in O +
each O +
monomer O -
. O +

We O +
recently O +
showed O +
that O +
the O +
first O +
domain O +
of O +
human O +
CCS O +
( O -
hCCSD1 O -
) O +
is O +
responsible O +
for O +
copper B-Chemical +
transfer O +
to O +
its O +
protein O +
partner O -
, O +
human O +
SOD1 O +
( O -
hSOD1 O -
) O -
. O +

The O +
NMR O +
solution O +
structure O +
of O +
the O +
copper B-Chemical -
( I-Chemical -
I I-Chemical -
) I-Chemical -
-loaded O +
form O +
of O +
hCCSD1 O +
reported O +
here O +
contributes O +
further O +
to O +
characterization O +
of O +
the O +
copper O -
- O -
transfer O +
mechanism O +
to O +
hSOD1 O -
. O +

NMR O +
spectroscopy O +
was O +
also O +
used O +
to O +
examine O +
the O +
hSOD1 O +
mutants O +
C57A O -
, O +
C146A O -
, O +
and O +
C57A O -
/ O -
C146A O -
, O +
which O +
are O +
unable O +
to O +
form O +
the O +
structurally O +
conserved O +
disulfide B-Chemical +
bond O +
in O +
SOD1 O -
, O +
in O +
order O +
to O +
investigate O +
the O +
role O +
of O +
these O +
cysteines B-Chemical +
during O +
hSOD1 O +
copper O +
acquisition O -
. O +

Together O -
, O +
the O +
information O +
on O +
both O +
hCCS O +
and O +
hSOD1 O -
, O +
along O +
with O +
a O +
sequence O +
analysis O +
of O +
eukaryotic O +
CCSD1 O -
, O +
allows O +
us O +
to O +
propose O +
important O +
mechanistic O +
aspects O +
regarding O +
the O +
copper B-Chemical -
- O -
transfer O +
process O +
from O +
hCCS O +
to O +
hSOD1 O -
. O +

Metoprolol B-Chemical +
and O +
diltiazem B-Chemical +
ameliorate O +
ziprasidone B-Chemical -
- O -
induced O +
prolonged O +
corrected O +
QT O +
interval O +
in O +
rats O -
. O +

Ziprasidone B-Chemical -
, O +
an O +
atypical O +
antipsychotic O +
agent O -
, O +
has O +
been O +
shown O +
to O +
increase O +
the O +
corrected O +
QT O +
( O -
QTc O -
) O +
interval O +
in O +
some O +
patients O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
reveal O +
the O +
effects O +
of O +
metoprolol B-Chemical +
and O +
diltiazem B-Chemical +
on O +
ziprasidone B-Chemical +
drug O -
- O -
induced O +
prolonged O +
QTc O +
interval O -
. O +

A O +
total O +
of O +
24 O +
rats O +
were O +
equally O +
divided O +
into O +
the O +
following O +
four O +
groups O -
: O +
the O +
first O +
group O +
was O +
used O +
as O +
the O +
control O +
and O +
received O +
1 O +
mL O -
/ O -
kg O +
saline O -
; O +
3 O +
mg O -
/ O -
kg O +
ziprasidone B-Chemical +
and O +
saline O +
were O +
administered O +
to O +
the O +
second O +
group O -
; O +
3 O +
mg O -
/ O -
kg O +
ziprasidone B-Chemical +
and O +
1 O +
mg O -
/ O -
kg O +
metoprolol B-Chemical +
were O +
administered O +
to O +
the O +
third O +
group O +
and O +
3 O +
mg O -
/ O -
kg O +
ziprasidone B-Chemical +
and O +
2 O +
mg O -
/ O -
kg O +
diltiazem B-Chemical +
were O +
administered O +
to O +
the O +
fourth O +
group O -
. O +

Two O +
hours O +
following O +
application O +
of O +
the O +
drugs O -
, O +
the O +
QTc O +
was O +
calculated O +
by O +
performing O +
electrocardiography O +
in O +
derivation O +
( O -
D O -
) O -
I. O +
The O +
duration O +
of O +
QTc O +
interval O +
was O +
compared O +
among O +
the O +
four O +
groups O -
. O +

The O +
mean O +
QTc O +
intervals O +
were O +
significantly O +
increased O +
in O +
the O +
third O +
and O +
fourth O +
groups O +
compared O +
with O +
the O +
second O +
group O +
( O -
p O +
< O +
0.0005 O +
and O +
p O +
< O +
0.0001 O -
, O +
respectively O -
) O -
. O +

The O +
study O +
demonstrated O +
the O +
effectiveness O +
of O +
metoprolol B-Chemical +
and O +
diltiazem B-Chemical +
in O +
the O +
prevention O +
of O +
ziprasidone B-Chemical -
- O -
induced O +
elongation O +
in O +
the O +
QTc O +
interval O -
. O +

Both O +
metoprolol B-Chemical +
and O +
diltiazem B-Chemical +
may O +
be O +
considered O +
in O +
the O +
prophylactic O +
therapy O +
of O +
high O -
- O -
risk O +
patients O +
who O +
are O +
using O +
ziprasidone B-Chemical -
. O +

Store O -
- O -
operated O +
Ca2 B-Chemical -
+ I-Chemical +
Entry O +
( O -
SOCE O -
) O +
Induced O +
by O +
Protease O -
- O -
activated O +
Receptor-1 O +
mediates O +
STIM1 O +
Phosphorylation O +
to O +
inhibit O +
SOCE O +
in O +
Endothelial O +
Cells O +
through O +
AMP B-Chemical -
- O -
activated O +
Protein O +
Kinase O +
and O +
p38beta O +
Mitogen O -
- O -
activated O +
Protein O +
Kinase O -
. O +

The O +
Ca2 B-Chemical -
+ I-Chemical +
sensor O +
STIM1 O +
is O +
crucial O +
for O +
activation O +
of O +
store O -
- O -
operated O +
Ca2 B-Chemical -
+ I-Chemical +
entry O +
( O -
SOCE O -
) O +
through O +
TRPC O +
and O +
Orai O +
channels O -
. O +

STIM1 O +
phosphorylation O +
serves O +
as O +
an O +
off O -
- O -
switch O +
for O +
SOCE O -
. O +

However O -
, O +
the O +
signaling O +
pathway O +
for O +
STIM1 O +
phosphorylation O +
is O +
unknown O -
. O +

Here O +
we O +
show O +
that O +
SOCE O +
activates O +
AMP B-Chemical -
- O -
activated O +
protein O +
kinase O +
( O -
AMPK O -
) O -
; O +
its O +
effector O +
p38β O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O -
p38β O +
MAPK O -
) O +
phosphorylates O +
STIM1 O -
, O +
thus O +
inhibiting O +
SOCE O +
in O +
human O +
lung O +
microvascular O +
endothelial O +
cells O +
( O -
ECs O -
) O -
. O +

Activation O +
of O +
AMPK O +
using O +
AICAR B-Chemical +
resulted O +
in O +
STIM1 O +
phosphorylation O +
on O +
serine B-Chemical +
residues O +
and O +
prevented O +
PAR-1-induced O +
Ca2 B-Chemical -
+ I-Chemical +
entry O -
. O +

Further O -
, O +
AICAR B-Chemical +
pretreatment O +
blocked O +
PAR-1-induced O +
increase O +
in O +
permeability O +
of O +
mouse O -
- O -
lung O +
microvessels O -
. O +

Activation O +
of O +
SOCE O +
with O +
thrombin O +
caused O +
phosphorylation O +
of O +
isoform O +
α1 O -
, O +
but O +
not O +
α2 O +
of O +
the O +
AMPK O +
catalytic O +
subunit O -
. O +

Moreover O -
, O +
knockdown O +
of O +
AMPKα1 O +
augmented O +
SOCE O +
induced O +
by O +
thrombin O -
. O +

Interestingly O -
, O +
SB203580 B-Chemical -
, O +
a O +
selective O +
inhibitor O +
of O +
p38 O +
MAPK O -
, O +
blocked O +
STIM1 O +
phosphorylation O +
and O +
led O +
to O +
sustained O +
STIM1-puncta O +
formation O +
and O +
Ca2 B-Chemical -
+ I-Chemical +
entry O -
. O +

Of O +
the O +
three O +
p38 O +
MAPK O +
isoforms O +
expressed O +
in O +
ECs O -
, O +
p38β O +
knockdown O +
prevented O +
PAR-1-mediated O +
STIM1 O +
phosphorylation O +
and O +
potentiated O +
SOCE O -
. O +

In O +
addition O -
, O +
inhibition O +
of O +
the O +
SOCE O +
downstream O +
target O +
CaMKKβ O +
or O +
knockdown O +
of O +
AMPKα1 O +
suppressed O +
PAR-1-mediated O +
phosphorylation O +
of O +
p38β O +
and O +
hence O +
STIM1 O -
. O +

Thus O -
, O +
our O +
findings O +
demonstrate O +
that O +
SOCE O +
activates O +
CaMKKβ O -
- O -
AMPKα1-p38β O +
MAPK O +
signaling O +
to O +
phosphorylate O +
STIM1 O -
, O +
thereby O +
suppressing O +
endothelial O +
SOCE O +
and O +
permeability O +
responses O -
. O +

Novel O +
pentablock O +
copolymer O +
( O -
PLA B-Chemical -
- O -
PCL B-Chemical -
- O -
PEG B-Chemical -
- O -
PCL B-Chemical -
- O -
PLA B-Chemical -
) O +
based O +
nanoparticles O +
for O +
controlled O +
drug O +
delivery O -
: O +
Effect O +
of O +
copolymer O +
compositions O +
on O +
the O +
crystallinity O +
of O +
copolymers O +
and O +
in O +
vitro O +
drug O +
release O +
profile O +
from O +
nanoparticles O -
. O +

The O +
purpose O +
of O +
this O +
investigation O +
was O +
to O +
design O +
novel O +
pentablock O +
copolymers O +
( O -
polylatide B-Chemical -
- O -
polycaprolactone B-Chemical -
- O -
polyethylene B-Chemical +
glycol- I-Chemical +
polycaprolactone B-Chemical -
- O -
polylatide B-Chemical -
) O +
( O -
PLA B-Chemical -
- O -
PCL B-Chemical -
- O -
PEG B-Chemical -
- O -
PCL B-Chemical -
- O -
PLA B-Chemical -
) O +
to O +
prepare O +
nanoparticle O +
formulations O +
which O +
provide O +
continuous O +
delivery O +
of O +
steroids B-Chemical +
over O +
a O +
longer O +
duration O +
with O +
minimal O +
burst O +
effect O -
. O +

Another O +
purpose O +
was O +
to O +
evaluate O +
the O +
effect O +
of O +
poly B-Chemical +
( I-Chemical -
L I-Chemical -
- I-Chemical -
lactide I-Chemical -
) I-Chemical +
( O -
PLLA B-Chemical -
) O +
or O +
poly B-Chemical +
( I-Chemical -
D I-Chemical -
, I-Chemical +
L I-Chemical -
- I-Chemical -
lactide I-Chemical -
) I-Chemical +
( O -
PDLLA B-Chemical -
) O +
incorporation O +
on O +
crystallinity O +
of O +
pentablock O +
copolymers O +
and O +
in O +
vitro O +
release O +
profile O +
of O +
triamcinolone B-Chemical +
acetonide I-Chemical +
( O -
selected O +
as O +
model O +
drug O -
) O +
from O +
nanoparticles O -
. O +

PLA B-Chemical -
- O -
PCL B-Chemical -
- O -
PEG B-Chemical -
- O -
PCL B-Chemical -
- O -
PLA B-Chemical +
copolymers O +
with O +
different O +
block O +
ratio O +
of O +
PCL B-Chemical -
/ O -
PLA B-Chemical +
segment O +
were O +
synthesized O -
. O +

Release O +
of O +
triamcinolone B-Chemical +
acetonide I-Chemical +
from O +
nanoparticles O +
was O +
significantly O +
affected O +
by O +
crystallinity O +
of O +
the O +
copolymers O -
. O +

Burst O +
release O +
of O +
triamcinolone B-Chemical +
acetonide I-Chemical +
from O +
nanoparticles O +
was O +
significantly O +
minimized O +
with O +
incorporation O +
of O +
proper O +
ratio O +
of O +
PDLLA B-Chemical +
in O +
the O +
existing O +
triblock O +
( O -
PCL B-Chemical -
- O -
PEG B-Chemical -
- O -
PCL B-Chemical -
) O +
copolymer O -
. O +

Moreover O -
, O +
pentablock O +
copolymer O +
based O +
nanoparticles O +
exhibited O +
continuous O +
release O +
of O +
triamcinolone B-Chemical +
acetonide I-Chemical -
. O +

Pentablock O +
copolymer O +
based O +
nanoparticles O +
can O +
be O +
utilized O +
to O +
achieve O +
continuous O +
near O +
zero O -
- O -
order O +
delivery O +
of O +
corticosteroids O +
from O +
nanoparticles O +
without O +
any O +
burst O +
effect O -
. O +

Broad O -
- O -
Range O +
Modulation O +
of O +
Light O +
Emission O +
in O +
Two O -
- O -
Dimensional O +
Semiconductors O +
by O +
Molecular O +
Physisorption O +
Gating O -
. O +

In O +
the O +
monolayer O +
limit O -
, O +
transition B-Chemical +
metal I-Chemical +
dichalcogenides I-Chemical +
become O +
direct O -
- O -
bandgap O -
, O +
light O -
- O -
emitting O +
semiconductors O -
. O +

The O +
quantum O +
yield O +
of O +
light O +
emission O +
is O +
low O +
and O +
extremely O +
sensitive O +
to O +
the O +
substrate O +
used O -
, O +
while O +
the O +
underlying O +
physics O +
remains O +
elusive O -
. O +

In O +
this O +
work O -
, O +
we O +
report O +
over O +
100 O +
times O +
modulation O +
of O +
light O +
emission O +
efficiency O +
of O +
these O +
two O -
- O -
dimensional O +
semiconductors O +
by O +
physical O +
adsorption O +
of O +
O2 B-Chemical +
and/or O +
H2O B-Chemical +
molecules O -
, O +
while O +
inert O +
gases O +
do O +
not O +
cause O +
such O +
effect O -
. O +

The O +
O2 B-Chemical +
and/or O +
H2O B-Chemical +
pressure O +
acts O +
quantitatively O +
as O +
an O +
instantaneously O +
reversible O +
" O -
molecular O +
gating O -
" O +
force O -
, O +
providing O +
orders O +
of O +
magnitude O +
broader O +
control O +
of O +
carrier O +
density O +
and O +
light O +
emission O +
than O +
conventional O +
electric O +
field O +
gating O -
. O +

Physi O -
- O -
sorbed O +
O2 B-Chemical +
and/or O +
H2O B-Chemical +
molecules O +
electronically O +
deplete O +
n O -
- O -
type O +
materials O +
such O +
as O +
MoS2 B-Chemical +
and O +
MoSe2 B-Chemical -
, O +
which O +
weakens O +
electrostatic O +
screening O +
that O +
would O +
otherwise O +
destabilize O +
excitons O -
, O +
leading O +
to O +
the O +
drastic O +
enhancement O +
in O +
photoluminescence O -
. O +

In O +
p O -
- O -
type O +
materials O +
such O +
as O +
WSe2 B-Chemical -
, O +
the O +
molecular O +
physisorption O +
results O +
in O +
the O +
opposite O +
effect O -
. O +

Unique O +
and O +
universal O +
in O +
two O -
- O -
dimensional O +
semiconductors O -
, O +
the O +
effect O +
offers O +
a O +
new O +
mechanism O +
for O +
modulating O +
electronic O +
interactions O +
and O +
implementing O +
optical O +
devices O -
. O +

Combinatorial O +
Growth O +
and O +
Anisotropy O +
Control O +
of O +
Self O -
- O -
Assembled O +
Epitaxial O +
Ultrathin O +
Alloy O +
Nanowires O -
. O +

Self O -
- O -
assembled O +
vertical O +
epitaxial O +
nanostructures O +
form O +
a O +
new O +
class O +
of O +
heterostructured O +
materials O +
that O +
has O +
emerged O +
in O +
recent O +
years O -
. O +

Interestingly O -
, O +
such O +
kind O +
of O +
architectures O +
can O +
be O +
grown O +
using O +
combinatorial O +
processes O -
, O +
implying O +
sequential O +
deposition O +
of O +
distinct O +
materials O -
. O +

Although O +
opening O +
many O +
perspectives O -
, O +
this O +
combinatorial O +
nature O +
has O +
not O +
been O +
fully O +
exploited O +
yet O -
. O +

This O +
work O +
demonstrates O +
that O +
the O +
combinatorial O +
character O +
of O +
the O +
growth O +
can O +
be O +
further O +
exploited O +
in O +
order O +
to O +
obtain O +
alloy O +
nanowires O +
coherently O +
embedded O +
in O +
a O +
matrix O -
. O +

This O +
issue O +
is O +
illustrated O +
in O +
the O +
case O +
of O +
a O +
fully O +
epitaxial O +
system O -
: O +
CoxNi1-x B-Chemical +
nanowires O +
in O +
CeO2 B-Chemical -
/ O -
SrTiO3 B-Chemical -
( O -
001 O -
) O -
. O +

The O +
advantage O +
brought O +
by O +
the O +
ability O +
to O +
grow O +
alloys O +
is O +
illustrated O +
by O +
the O +
control O +
of O +
the O +
magnetic O +
anisotropy O +
of O +
the O +
nanowires O +
when O +
passing O +
from O +
pure O +
Ni B-Chemical +
wires O +
to O +
CoxNi1-x B-Chemical +
alloys O -
. O +

Further O +
exploitation O +
of O +
this O +
combinatorial O +
approach O +
may O +
pave O +
the O +
way O +
toward O +
full O +
three O -
- O -
dimensional O +
heteroepitaxial O +
architectures O +
through O +
axial O +
structuring O +
of O +
the O +
wires O -
. O +

Conformational O +
determinants O +
of O +
the O +
activity O +
of O +
Antiproliferative O +
factor O +
glycopeptide O -
. O +

The O +
antiproliferative O +
factor O +
( O -
APF O -
) O +
involved O +
in O +
interstitial O +
cystitis O +
is O +
a O +
glycosylated O +
nonapeptide B-Chemical +
( O -
TVPAAVVVA O -
) O +
containing O +
a O +
sialylated O +
core O +
α B-Chemical -
- I-Chemical -
O I-Chemical -
- I-Chemical -
disaccharide I-Chemical +
linked O +
to O +
the O +
N O -
- O -
terminal O +
threonine B-Chemical -
. O +

The O +
chemical O +
structure O +
of O +
APF O +
was O +
deduced O +
using O +
spectroscopic O +
techniques O +
and O +
confirmed O +
using O +
total O +
syn O -
- O -
thesis O -
. O +

The O +
synthetic O +
APF O +
provided O +
a O +
platform O +
to O +
study O +
amino B-Chemical +
acid I-Chemical +
modifications O +
and O +
their O +
effect O +
on O +
APF O +
activity O -
, O +
based O +
on O +
which O +
a O +
structure O -
- O -
activity O +
relationship O +
( O -
SAR O -
) O +
for O +
APF O +
activity O +
was O +
previously O +
proposed O -
. O +

However O -
, O +
this O +
SAR O +
model O +
could O +
not O +
explain O +
the O +
change O +
in O +
activity O +
associated O +
with O +
minor O +
al O -
- O -
terations O +
in O +
the O +
peptide O +
sequence O -
. O +

Presented O +
is O +
computational O +
analysis O +
of O +
14 O +
APF O +
derivatives O +
to O +
identify O +
structural O +
trends O +
from O +
which O +
a O +
more O +
detailed O +
SAR O +
is O +
obtained O -
. O +

The O +
APF O +
activity O +
is O +
found O +
to O +
be O +
dictated O +
by O +
the O +
close O +
interplay O +
between O +
carbohydrate B-Chemical -
- O -
peptide O +
and O +
peptide O -
- O -
peptide O +
interactions O -
. O +

The O +
former O +
in O -
- O -
volves O +
hydrogen B-Chemical +
bond O +
and O +
hydrophobic O +
interactions O +
and O +
the O +
latter O +
is O +
dominated O +
by O +
hydrophobic O +
interac O -
- O -
tions O -
. O +

The O +
highly O +
flexible O +
hydrophobic O +
peptide O +
adopts O +
collapsed O +
conformations O +
separated O +
by O +
low O +
energy O +
barriers O -
. O +

APF O +
activity O +
correlates O +
with O +
hydrophobic O +
clustering O +
associated O +
with O +
amino B-Chemical +
acids I-Chemical +
4A O -
, O +
6V O +
and O +
8V O -
. O +

Peptide O +
conformations O +
are O +
highly O +
sensitive O +
to O +
single O +
point O +
mutations O -
, O +
which O +
explain O +
the O +
experi O -
- O -
mental O +
trends O -
. O +

The O +
presented O +
SAR O +
will O +
act O +
as O +
a O +
guide O +
for O +
lead O +
optimization O +
of O +
more O +
potent O +
APF O +
ana O -
- O -
logues O +
of O +
potential O +
therapeutic O +
utility O -
. O +

Active O +
Layer O -
- O -
Incorporated O -
, O +
Spectrally O -
- O -
Tuned O +
Au B-Chemical -
/ O -
SiO2 B-Chemical +
Core O -
/ O -
Shell O +
Nanorod O -
- O -
Based O +
Light O +
Trapping O +
for O +
Organic O +
Photovoltaics O -
. O +

We O +
demonstrated O +
that O +
incorporation O +
of O +
octadecyltrimethoxysilane B-Chemical +
( O -
OTMS B-Chemical -
) O +
functionalized O -
, O +
spectrally O +
tuned O -
, O +
gold O -
/ O -
silica B-Chemical +
( O -
Au B-Chemical -
/ O -
SiO2 B-Chemical -
) O +
core O -
/ O -
shell O +
nanospheres O +
and O +
nanorods O +
into O +
the O +
active O +
layer O +
of O +
an O +
organic O +
photovoltaic O +
( O -
OPV O -
) O +
device O +
led O +
to O +
an O +
in O +
increase O +
photo O +
conversion O +
efficiency O +
( O -
PCE O -
) O -
. O +

A O +
silica B-Chemical +
shell O +
layer O +
was O +
added O +
onto O +
Au B-Chemical +
core O +
nanospheres O +
and O +
nanorods O +
in O +
order O +
to O +
provide O +
an O +
electrically O +
insulating O +
surface O +
that O +
does O +
not O +
interfere O +
with O +
carrier O +
generation O +
and O +
transport O +
inside O +
the O +
active O +
layer O -
. O +

Functionalization O +
of O +
the O +
Au B-Chemical -
/ O -
SiO2 B-Chemical +
core O -
/ O -
shell O +
nanoparticles O +
with O +
the O +
OTMS B-Chemical +
organic O +
ligand O +
was O +
then O +
necessary O +
in O +
order O +
to O +
transfer O +
the O +
Au B-Chemical -
/ O -
SiO2 B-Chemical +
core O -
/ O -
shell O +
nanoparticles O +
from O +
an O +
ethanol B-Chemical +
solution O +
into O +
an O +
OPV O +
polymer O -
- O -
compatible O +
solvent O -
, O +
such O +
as O +
dichlorobenzene B-Chemical +
( O -
DCB B-Chemical -
) O -
. O +

The O +
OTMS B-Chemical -
- O -
functionalized O +
Au B-Chemical -
/ O -
SiO2 B-Chemical +
core O -
/ O -
shell O +
nanorods O +
and O +
nanospheres O +
were O +
then O +
incorporated O +
into O +
the O +
active O +
layers O +
of O +
two O +
OPV O +
polymer O +
systems O -
: O +
a O +
poly B-Chemical -
( I-Chemical -
3-hexylthiophene I-Chemical -
) I-Chemical -
: O -
[ B-Chemical -
6,6 I-Chemical -
] I-Chemical -
-phenyl I-Chemical -
- I-Chemical -
C61-butyric I-Chemical +
acid I-Chemical +
methyl I-Chemical +
ester I-Chemical +
( O -
P3HT B-Chemical -
: O -
PCB60 B-Chemical -
M I-Chemical -
) O +
OPV O +
device O +
and O +
a O +
poly B-Chemical -
[ I-Chemical -
2,6 I-Chemical -
- I-Chemical -
4,8-di I-Chemical -
( I-Chemical -
5-ethylhexylthienyl I-Chemical -
) I-Chemical -
benzo I-Chemical -
[ I-Chemical -
1,2-b;3,4-b I-Chemical -
] I-Chemical -
dithiophene I-Chemical -
- I-Chemical -
alt-5-dibutyloctyl-3,6-bis I-Chemical -
( I-Chemical -
5-bromothiophen-2-yl I-Chemical -
) I-Chemical +
pyrrolo I-Chemical -
[ I-Chemical -
3,4-c I-Chemical -
] I-Chemical -
pyrrole-1,4-dione I-Chemical -
] I-Chemical +
( O -
PBDTT B-Chemical -
- I-Chemical -
DPP I-Chemical -
: O -
PC60BM B-Chemical -
) O +
OPV O +
device O -
. O +

For O +
the O +
P3HT B-Chemical -
: O -
PC60BM B-Chemical +
polymer O +
with O +
a O +
band O +
edge O +
of O +
~700 O +
nm O -
, O +
the O +
addition O +
of O +
the O +
core O -
/ O -
shell O +
nanorods O +
with O +
an O +
aspect O +
ratio O +
( O -
AR O -
) O +
of O +
~2.5 O +
( O -
extinction O +
peak O +
~670 O +
nm O -
) O +
resulted O +
in O +
a O +
7.1 O -
% O +
improvement O +
in O +
PCE O -
, O +
while O +
for O +
the O +
PBDTT B-Chemical -
- I-Chemical -
DPP I-Chemical -
: O -
PC60BM B-Chemical +
polymer O +
with O +
a O +
band O +
edge O +
~860 O +
nm O -
, O +
the O +
addition O +
of O +
core O -
/ O -
shell O +
nanorods O +
with O +
an O +
AR O +
of O +
~4 O +
( O -
extinction O +
peak O +
~830 O +
nm O -
) O +
resulted O +
in O +
a O +
14.4 O -
% O +
improvement O +
in O +
PCE O -
. O +

The O +
addition O +
of O +
Au B-Chemical -
/ O -
SiO2 B-Chemical +
core O -
/ O -
shell O +
nanospheres O +
to O +
the O +
P3HT B-Chemical -
: O -
PC60BM B-Chemical -
- O -
polymer O +
resulted O +
in O +
a O +
2.7 O -
% O +
improvement O +
in O +
PCE O -
, O +
while O +
their O +
addition O +
to O +
a O +
PBDTT B-Chemical -
- I-Chemical -
DPP I-Chemical -
: O -
PC60BM B-Chemical +
polymer O +
resulted O +
in O +
a O +
9.1 O -
% O +
improvement O -
. O +

The O +
PCE O +
and O +
Jsc O +
enhancements O +
were O +
consistent O +
with O +
external O +
quantum O +
efficiency O +
( O -
EQE O -
) O +
measurements O +
and O +
the O +
EQE O +
enhancements O +
spectrally O +
matched O +
the O +
extinction O +
spectra O +
of O +
Au B-Chemical -
/ O -
SiO2 B-Chemical +
nanospheres O +
and O +
nanorods O +
in O +
both O +
OPV O +
polymer O +
systems O -
. O +

Interactions O +
between O +
solid O +
surfaces O +
with O +
pre O -
- O -
adsorbed O +
poly B-Chemical -
( I-Chemical -
ethylenimine I-Chemical -
) I-Chemical +
( O -
PEI B-Chemical -
) O +
layers O -
: O +
effect O +
of O +
unadsorbed O +
free O +
PEI B-Chemical +
chains O -
. O +

Poly B-Chemical -
( I-Chemical -
ethylenimine I-Chemical -
) I-Chemical +
( O -
PEI B-Chemical -
) O +
polyelectrolytes O +
have O +
been O +
widely O +
used O +
to O +
tune O +
the O +
stability O -
, O +
rheology O -
, O +
or O +
adhesion O +
properties O +
of O +
colloidal O +
suspensions O +
due O +
to O +
their O +
strong O +
tendency O +
to O +
adsorb O +
to O +
solid O +
surfaces O -
. O +

They O +
have O +
also O +
gained O +
importance O +
as O +
gene O +
carriers O +
in O +
biomedical O +
applications O -
, O +
in O +
which O +
the O +
anionic O +
DNA O +
chains O +
are O +
complexed O +
and O +
condensed O +
to O +
form O +
PEI B-Chemical -
/ O -
DNA O +
polyplexes O -
. O +

Some O +
reported O +
literatures O +
have O +
recently O +
shown O +
that O +
the O +
overdosed O +
PEI B-Chemical +
chains O -
, O +
which O +
are O +
free O +
in O +
the O +
solution O +
mixture O -
, O +
also O +
play O +
a O +
vital O +
role O +
in O +
promoting O +
the O +
gene O +
transfection O -
, O +
but O +
the O +
reason O +
is O +
unclear O -
. O +

In O +
this O +
work O -
, O +
we O +
present O +
the O +
results O +
of O +
using O +
total O +
internal O +
reflection O +
microscopy O +
( O -
TIRM O -
) O +
to O +
measure O +
the O +
interaction O +
forces O +
between O +
a O +
Brownian O +
colloidal O +
sphere O +
and O +
a O +
flat O +
glass O +
plate O +
in O +
the O +
presence O +
of O +
overdosed O +
free O +
PEI B-Chemical +
cationic O +
chains O -
, O +
when O +
both O +
surfaces O +
were O +
saturated O +
adsorbed O +
with O +
the O +
PEI B-Chemical +
chains O -
. O +

The O +
colloidal O +
sphere O +
pre O -
- O -
adsorbed O +
with O +
PEI B-Chemical +
chains O +
was O +
chosen O +
to O +
mimic O +
the O +
PEI B-Chemical -
/ O -
DNA O +
polyplex O -
. O +

Results O +
for O +
the O +
potential O +
energy O +
of O +
interaction O +
measured O +
for O +
model O +
polyplex O +
( O -
e.g. O -
, O +
PEI B-Chemical -
- O -
coated O +
sphere O -
) O +
interacting O +
with O +
a O +
PEI B-Chemical -
- O -
coated O +
glass O +
surface O +
in O +
the O +
presence O +
of O +
overdosed O +
free O +
PEI B-Chemical +
chains O +
at O +
various O +
pH O +
values O +
and O +
salt O +
concentrations O +
were O +
presented O -
. O +

As O +
can O +
be O +
shown O +
by O +
direct O +
force O +
measurements O -
, O +
the O +
interaction O +
potentials O +
in O +
NaCl B-Chemical +
salt O +
solution O +
are O +
dominated O +
by O +
repulsive O +
forces O +
originating O +
from O +
diffuse O +
layer O +
overlap O +
and O +
gravitational O +
attraction O -
. O +

However O -
, O +
the O +
presence O +
of O +
free O +
PEI B-Chemical +
chains O +
in O +
the O +
solution O +
mixture O +
produces O +
a O +
long O -
- O -
ranged O +
( O -
> O +
60 O +
nm O -
) O +
attractive O +
force O +
between O +
two O +
PEI B-Chemical -
- O -
coated O +
surfaces O +
with O +
the O +
range O +
and O +
magnitude O +
tunable O +
by O +
pH O +
value O -
, O +
PEI B-Chemical +
and O +
salt O +
concentrations O -
. O +

The O +
possible O +
mechanisms O +
of O +
this O +
long O -
- O -
ranged O +
attractive O +
force O +
are O +
discussed O -
. O +

A O +
better O +
understanding O +
of O +
this O +
free O +
PEI B-Chemical -
- O -
induced O +
attractive O +
force O +
will O +
be O +
useful O +
in O +
the O +
development O +
of O +
improved O +
PEI B-Chemical -
/ O -
DNA O +
polyplexes O +
systems O +
for O +
biomedical O +
applications O -
. O +

Strong O +
Parent O -
- O -
of O -
- O -
Origin O +
Effects O +
in O +
the O +
Association O +
of O +
KCNQ1 O +
Variants O +
with O +
Type O +
2 O +
Diabetes O +
Mellitus O +
in O +
American O +
Indians O -
. O +

Parent O -
- O -
of O -
- O -
origin O +
effects O +
were O +
observed O +
in O +
an O +
Icelandic O +
population O +
for O +
several O +
genetic O +
variants O +
associated O +
with O +
type O +
2 O +
diabetes O -
, O +
including O +
those O +
in O +
KLF14 O +
( O -
rs4731702 O -
) O -
, O +
MOB2 O +
( O -
rs2334499 O -
) O +
and O +
KCNQ1 O +
( O -
rs2237892 O -
, O +
rs231362 O -
) O -
. O +

We O +
analyzed O +
parent O -
- O -
of O -
- O -
origin O +
effects O +
for O +
these O +
variants O -
, O +
along O +
with O +
two O +
others O +
in O +
KCNQ1 O +
identified O +
in O +
previous O +
genome O -
- O -
wide O +
association O +
studies O +
( O -
rs2237895 O -
, O +
rs2299620 O -
) O -
, O +
in O +
7351 O +
Pima O +
Indians O +
from O +
4549 O +
nuclear O +
families O -
; O +
34 O -
% O +
of O +
participants O +
had O +
diabetes O -
. O +

In O +
a O +
subset O +
of O +
287 O +
normoglycemic O +
individuals O -
, O +
acute O +
insulin O +
secretion O +
was O +
measured O +
by O +
an O +
intravenous O +
glucose B-Chemical +
tolerance O +
test O -
. O +

Statistically O +
significant O +
( O -
P<0.05 O -
) O +
parent O -
- O -
of O -
- O -
origin O +
effects O +
were O +
seen O +
for O +
association O +
with O +
type O +
2 O +
diabetes O +
for O +
all O +
variants O -
. O +

The O +
strongest O +
effect O +
was O +
seen O +
at O +
rs2299620 O +
in O +
KCNQ1 O -
: O +
the O +
C O +
allele O +
was O +
associated O +
with O +
increased O +
diabetes O +
when O +
maternally O -
- O -
derived O +
( O -
odds O +
ratio=1.92 O -
, O +
P=4.1x10 O -
( O -
-12 O -
) O -
) O -
, O +
but O +
not O +
when O +
paternally O -
- O -
derived O +
( O -
odds O +
ratio=0.93 O -
, O +
P=0.47 O -
; O +
P=9.9x10 O -
( O -
-6 O -
) O +
for O +
difference O +
in O +
maternal O +
and O +
paternal O +
effects O -
) O -
. O +

A O +
maternally O -
- O -
derived O +
C O +
allele O +
was O +
also O +
associated O +
with O +
a O +
28 O -
% O +
decrease O +
in O +
insulin O +
secretion O +
( O -
P=0.002 O -
) O -
. O +

This O +
study O +
confirms O +
parent O -
- O -
of O -
- O -
origin O +
effects O +
in O +
the O +
association O +
with O +
type O +
2 O +
diabetes O +
for O +
variants O +
in O +
KLF14 O -
, O +
MOB2 O +
and O +
KCNQ1 O -
. O +

In O +
Pima O +
Indians O +
the O +
effect O +
of O +
maternally O -
- O -
derived O +
KCNQ1 O +
variants O +
appears O +
to O +
be O +
mediated O +
through O +
decreased O +
insulin O +
secretion O -
, O +
and O +
is O +
particularly O +
strong O -
, O +
accounting O +
for O +
4 O -
% O +
of O +
the O +
variance O +
in O +
liability O +
to O +
diabetes O -
. O +

Designed O +
amphiphilic O +
β O -
- O -
sheet O +
peptides O +
as O +
templates O +
for O +
paraoxon B-Chemical +
adsorption O +
and O +
detection O -
. O +

Amphiphilic O +
peptides O +
were O +
designed O +
to O +
fold O +
into O +
a O +
β O -
- O -
sheet O +
monolayer O +
structure O +
while O +
presenting O +
the O +
catalytic O +
triad O +
residues O +
of O +
the O +
enzyme O -
, O +
acetylcholinesterase O +
( O -
Glu B-Chemical -
, O +
His B-Chemical +
and O +
Ser B-Chemical -
) O -
, O +
to O +
a O +
solution O +
containing O +
the O +
organophosphate B-Chemical -
, O +
paraoxon B-Chemical -
. O +

Three O +
peptides O -
, O +
in O +
which O +
the O +
catalytic O +
triad O +
residues O +
were O +
arranged O +
in O +
different O +
orders O +
along O +
the O +
strand O -
, O +
were O +
generated O +
to O +
reveal O +
potential O +
differences O +
in O +
interactions O +
with O +
paraoxon B-Chemical +
as O +
a O +
function O +
of O +
the O +
order O +
of O +
these O +
amino B-Chemical +
acids I-Chemical -
. O +

One O +
additional O +
peptide O +
with O +
amino B-Chemical +
acids I-Chemical +
introduced O +
in O +
random O +
order O +
was O +
studied O +
to O +
highlight O +
the O +
contribution O +
of O +
the O +
β O -
- O -
sheet O +
secondary O +
structure O +
to O +
any O +
interactions O +
with O +
paraoxon B-Chemical -
. O +

Langmuir O +
isotherms O -
, O +
Brewster O +
angle O +
microscope O +
at O +
interfaces O +
and O +
circular O +
dichroism O +
measurements O +
in O +
bulk O +
showed O +
that O +
both O +
the O +
β O -
- O -
sheet O +
conformation O +
and O +
the O +
order O +
of O +
the O +
amino B-Chemical +
acids I-Chemical +
along O +
the O +
strand O +
influenced O +
the O +
interactions O +
of O +
paraoxon B-Chemical +
with O +
the O +
peptides O -
. O +

Compression O +
isotherm O +
curves O -
, O +
as O +
well O +
as O +
Brewster O -
- O -
angle O +
microscopy O +
images O -
, O +
provided O +
evidence O +
for O +
enhanced O +
adsorption O +
of O +
the O +
paraoxon B-Chemical +
to O +
the O +
monolayers O +
of O +
peptides O +
which O +
present O +
neighboring O +
Glu B-Chemical +
and O +
Ser B-Chemical +
residues O +
along O +
the O +
hydrophilic O +
face O +
of O +
the O +
β O -
- O -
strand O -
. O +

Circular O +
dichroism O +
revealed O +
that O +
the O +
peptide O +
most O +
sensitive O +
to O +
interactions O +
with O +
paraoxon B-Chemical +
was O +
that O +
with O +
the O +
triad O +
residues O +
in O +
the O +
order O +
Glu B-Chemical -
, O +
Ser B-Chemical +
and O +
His B-Chemical -
, O +
which O +
appears O +
to O +
be O +
appropriate O +
for O +
supporting O +
a O +
catalytic O +
mechanism O +
similar O +
to O +
that O +
in O +
acetylcholinesterase O +
enzyme O -
. O +

These O +
rationally O +
designed O +
peptides O +
may O +
be O +
further O +
utilized O +
for O +
the O +
development O +
of O +
technologies O +
for O +
organophosphate B-Chemical +
adsorption O +
and O +
detection O -
. O +

Evaluation O +
of O +
intratympanic O +
formulations O +
for O +
inner O +
ear O +
delivery O -
: O +
methodology O +
and O +
sustained O +
release O +
formulation O +
testing O -
. O +

Abstract O +
A O +
convenient O +
and O +
efficient O +
in O +
vitro O +
diffusion O +
cell O +
method O +
to O +
evaluate O +
formulations O +
for O +
inner O +
ear O +
delivery O +
via O +
the O +
intratympanic O +
route O +
is O +
currently O +
not O +
available O -
. O +

The O +
existing O +
in O +
vitro O +
diffusion O +
cell O +
systems O +
commonly O +
used O +
to O +
evaluate O +
drug O +
formulations O +
do O +
not O +
resemble O +
the O +
physical O +
dimensions O +
of O +
the O +
middle O +
ear O +
and O +
round O +
window O +
membrane O -
. O +

The O +
objectives O +
of O +
this O +
study O +
were O +
to O +
examine O +
a O +
modified O +
in O +
vitro O +
diffusion O +
cell O +
system O +
of O +
a O +
small O +
diffusion O +
area O +
for O +
studying O +
sustained O +
release O +
formulations O +
in O +
inner O +
ear O +
drug O +
delivery O +
and O +
to O +
identify O +
a O +
formulation O +
for O +
sustained O +
drug O +
delivery O +
to O +
the O +
inner O +
ear O -
. O +

Four O +
formulations O +
and O +
a O +
control O +
were O +
examined O +
in O +
this O +
study O +
using O +
cidofovir B-Chemical +
as O +
the O +
model O +
drug O -
. O +

Drug O +
release O +
from O +
the O +
formulations O +
in O +
the O +
modified O +
diffusion O +
cell O +
system O +
was O +
slower O +
than O +
that O +
in O +
the O +
conventional O +
diffusion O +
cell O +
system O +
due O +
to O +
the O +
decrease O +
in O +
the O +
diffusion O +
surface O +
area O +
of O +
the O +
modified O +
diffusion O +
cell O +
system O -
. O +

The O +
modified O +
diffusion O +
cell O +
system O +
was O +
able O +
to O +
show O +
different O +
drug O +
release O +
behaviors O +
among O +
the O +
formulations O +
and O +
allowed O +
formulation O +
evaluation O +
better O +
than O +
the O +
conventional O +
diffusion O +
cell O +
system O -
. O +

Among O +
the O +
formulations O +
investigated O -
, O +
poly B-Chemical -
( I-Chemical -
lactic I-Chemical -
- I-Chemical -
co I-Chemical -
- I-Chemical -
glycolic I-Chemical +
acid I-Chemical -
) I-Chemical -
-poly O -
( B-Chemical -
ethylene I-Chemical +
glycol I-Chemical -
) I-Chemical -
-poly O -
( B-Chemical -
lactic I-Chemical -
- I-Chemical -
co I-Chemical -
- I-Chemical -
glycolic I-Chemical +
acid I-Chemical -
) I-Chemical +
triblock O +
copolymer O +
systems O +
provided O +
the O +
longest O +
sustained O +
drug O +
delivery O -
, O +
probably O +
due O +
to O +
their O +
rigid O +
gel O +
structures O +
and/or O +
polymer O -
- O -
to O -
- O -
cidofovir B-Chemical +
interactions O -
. O +

Membrane O +
fusion O -
- O -
competent O +
virus O -
- O -
like O +
proteoliposomes O +
and O +
proteinaceous O +
supported O +
bilayers O +
made O +
directly O +
from O +
cell O +
plasma O +
membranes O -
. O +

Virus O -
- O -
like O +
particles O +
are O +
useful O +
materials O +
for O +
studying O +
virus O -
- O -
host O +
interactions O +
in O +
a O +
safe O +
manner O -
. O +

However O -
, O +
the O +
standard O +
production O +
of O +
pseudovirus O +
based O +
on O +
the O +
Vesicular O +
Stomatitis O +
Virus O +
( O -
VSV O -
) O +
backbone O +
is O +
an O +
intricate O +
procedure O +
that O +
requires O +
trained O +
laboratory O +
personnel O -
. O +

In O +
this O +
work O -
, O +
a O +
new O +
strategy O +
for O +
creating O +
virus O -
- O -
like O +
proteoliposomes O +
( O -
VLPLs O -
) O +
and O +
virus O -
- O -
like O +
supported O +
bilayers O +
( O -
VLSBs O -
) O +
is O +
presented O -
. O +

This O +
strategy O +
uses O +
a O +
cell O +
blebbing O +
technique O +
to O +
induce O +
the O +
formation O +
of O +
nanoscale O +
vesicles O +
from O +
the O +
plasma O +
membrane O +
of O +
BHK O +
cells O +
expressing O +
the O +
hemagglutinin O +
( O -
HA O -
) O +
fusion O +
protein O +
of O +
influenza O +
X-31 O -
. O +

These O +
vesicles O +
and O +
supported O +
bilayers O +
contain O +
HA O +
and O +
are O +
used O +
to O +
carry O +
out O +
single O +
particle O +
membrane O +
fusion O +
events O -
, O +
monitored O +
using O +
total O +
internal O +
reflection O +
fluorescence O +
microscopy O -
. O +

The O +
results O +
of O +
these O +
studies O +
show O +
that O +
the O +
VLPLs O +
and O +
VLSBs O +
contain O +
HA O +
proteins O +
that O +
are O +
fully O +
competent O +
to O +
carry O +
out O +
membrane O +
fusion O -
, O +
including O +
the O +
formation O +
of O +
a O +
fusion O +
pore O +
and O +
the O +
release O +
of O +
fluorophores O +
loaded O +
into O +
vesicles O -
. O +

This O +
new O +
strategy O +
for O +
creating O +
spherical O +
and O +
planar O +
geometry O +
virus O -
- O -
like O +
membranes O +
has O +
many O +
potential O +
applications O -
. O +

VLPLs O +
could O +
be O +
used O +
to O +
study O +
fusion O +
proteins O +
of O +
virulent O +
viruses O +
in O +
a O +
safe O +
manner O -
, O +
or O +
they O +
could O +
be O +
used O +
as O +
therapeutic O +
delivery O +
particles O +
to O +
transport O +
beneficial O +
proteins O +
co O -
- O -
expressed O +
in O +
the O +
cells O +
to O +
a O +
target O +
cell O -
. O +

VLSBs O +
could O +
facilitate O +
high O +
throughput O +
screening O +
of O +
antiviral O +
drugs O +
or O +
pathogen O -
- O -
host O +
cell O +
interactions O -
. O +

Synthesis O +
of O +
Amylose O -
- O -
Polystyrene B-Chemical +
Inclusion O +
Complexes O +
by O +
a O +
Facile O +
Preparation O +
Route O -
. O +

The O +
formation O +
of O +
amylose O -
- O -
polystyrene B-Chemical +
inclusion O +
complexes O +
via O +
a O +
novel O +
two O -
- O -
step O +
approach O +
is O +
described O -
. O +

In O +
the O +
first O -
- O -
step O -
, O +
styrene O +
was O +
inserted O +
inside O +
the O +
amylose O +
helical O +
cavity O -
, O +
followed O +
by O +
free O +
radical O +
polymerization O +
in O +
the O +
second O +
step O -
. O +

The O +
inclusion O +
complexes O +
were O +
characterized O +
by O +
Attenuated O +
Total O +
Reflection O +
Fourier O +
Transform O +
Infrared O +
Spectroscopy O +
( O -
ATR O -
- O -
FTIR O -
) O -
, O +
Ultraviolet O +
Spectroscopy O +
( O -
UV O -
) O -
, O +
X O -
- O -
ray O +
Diffraction O +
( O -
XRD O -
) O -
, O +
Atomic O +
Force O +
Microscopy O +
( O -
AFM O -
) O -
, O +
and O +
Differential O +
Scanning O +
Calorimetry O +
( O -
DSC O -
) O -
. O +

The O +
formation O +
of O +
polystyrene B-Chemical +
was O +
confirmed O +
by O +
gel O +
Permeation O +
Chromatography O +
( O -
GPC O -
) O -
. O +

The O +
molecular O +
weight O +
of O +
polystyrene B-Chemical +
can O +
be O +
varied O +
by O +
using O +
amylose O +
bearing O +
different O +
molar O +
masses O -
. O +

The O +
approach O +
described O +
here O +
is O +
general O +
and O +
could O +
be O +
used O +
to O +
synthesis O +
other O +
host O -
- O -
polymer O +
inclusion O +
complexes O +
for O +
which O +
long O +
chains O +
of O +
polymeric O +
guests O +
are O +
difficult O +
to O +
insert O +
into O +
the O +
host O +
cavity O -
. O +

Synthesis O +
of O +
Silver B-Chemical +
Octahedra O +
with O +
Controlled O +
Sizes O +
and O +
Optical O +
Properties O +
via O +
Seed O -
- O -
Mediated O +
Growth O -
. O +

Silver B-Chemical +
octahedra O +
with O +
edge O +
lengths O +
controlled O +
in O +
the O +
range O +
of O +
20 O -
- O -
72 O +
nm O +
were O +
synthesized O +
via O +
seed O -
- O -
mediated O +
growth O -
. O +

The O +
key O +
to O +
the O +
success O +
of O +
this O +
synthesis O +
is O +
the O +
use O +
of O +
single O -
- O -
crystal O +
Ag B-Chemical +
seeds O +
with O +
uniform O +
and O +
precisely O +
controlled O +
sizes O +
to O +
direct O +
the O +
growth O +
and O +
the O +
use O +
of O +
citrate B-Chemical +
as O +
a O +
selective O +
capping O +
agent O +
for O +
the O +
{ O -
111 O -
} O +
facets O -
. O +

Our O +
mechanistic O +
studies O +
demonstrated O +
that O +
Ag B-Chemical +
seeds O +
with O +
both O +
cubic O +
and O +
quasi O -
- O -
spherical O +
shapes O +
could O +
evolve O +
into O +
octahedra O -
. O +

For O +
the O +
first O +
time O -
, O +
we O +
were O +
able O +
to O +
precisely O +
control O +
the O +
edge O +
lengths O +
of O +
Ag B-Chemical +
octahedra O +
below O +
100 O +
nm O -
, O +
and O +
the O +
lower O +
limit O +
of O +
size O +
could O +
even O +
be O +
pushed O +
down O +
to O +
20 O +
nm O -
. O +

Using O +
the O +
as O -
- O -
obtained O +
Ag B-Chemical +
octahedra O +
as O +
sacrificial O +
templates O -
, O +
Au B-Chemical +
nanocages O +
with O +
an O +
octahedral O +
shape O +
and O +
precisely O +
tunable O +
optical O +
properties O +
were O +
synthesized O +
through O +
a O +
galvanic O +
replacement O +
reaction O -
. O +

Such O +
hollow O +
nanostructures O +
are O +
promising O +
candidates O +
for O +
a O +
broad O +
range O +
of O +
applications O +
related O +
to O +
optics O -
, O +
catalysis O -
, O +
and O +
biomedicine O -
. O +

Highly O +
Enantioselective O +
Zirconium B-Chemical -
- O -
Catalyzed O +
Cyclization O +
of O +
Aminoalkenes B-Chemical -
. O +

Aminoalkenes B-Chemical +
are O +
catalytically O +
cyclized O +
in O +
the O +
presence O +
of O +
cyclopentadienylbis B-Chemical -
( I-Chemical -
oxazolinyl I-Chemical -
) I-Chemical -
borato I-Chemical +
group O +
4 O +
complexes O +
{ B-Chemical -
PhB I-Chemical -
( I-Chemical -
C5H4 I-Chemical -
) I-Chemical -
( I-Chemical -
Ox I-Chemical -
( I-Chemical -
R I-Chemical -
) I-Chemical -
) I-Chemical -
2 I-Chemical -
} I-Chemical -
M I-Chemical -
( I-Chemical -
NMe2 I-Chemical -
) I-Chemical -
2 I-Chemical +
( O -
M O +
= O +
Ti B-Chemical -
, O +
Zr B-Chemical -
, O +
Hf B-Chemical -
; O +
Ox B-Chemical -
( I-Chemical -
R I-Chemical -
) I-Chemical +
= O +
4,4-dimethyl-2-oxazoline B-Chemical -
, O +
4S B-Chemical -
- I-Chemical -
isopropyl-5,5-dimethyl-2-oxazoline I-Chemical -
, O +
4S B-Chemical -
- I-Chemical -
tert I-Chemical -
- I-Chemical -
butyl-2-oxazoline I-Chemical -
) O +
at O +
room O +
temperature O +
and O +
below O -
, O +
affording O +
five- O -
, O +
six- O -
, O +
and O +
seven O -
- O -
membered O +
N B-Chemical -
- I-Chemical -
heterocyclic I-Chemical +
amines I-Chemical +
with O +
enantiomeric O +
excesses O +
of O +
> O -
90 O -
% O +
in O +
many O +
cases O +
and O +
up O +
to O +
99 O -
% O -
. O +

Mechanistic O +
investigations O +
of O +
this O +
highly O +
selective O +
system O +
employed O +
synthetic O +
tests O -
, O +
kinetics O -
, O +
and O +
stereochemistry O -
. O +

Secondary B-Chemical +
aminopentene I-Chemical +
cyclizations O +
require O +
a O +
primary B-Chemical +
amine I-Chemical +
( O -
1 O -
- O -
2 O +
equiv O +
vs O +
catalyst O -
) O -
. O +

Aminoalkenes B-Chemical +
are O +
unchanged O +
in O +
the O +
presence O +
of O +
a O +
zirconium B-Chemical +
monoamido I-Chemical +
complex O +
{ B-Chemical -
PhB I-Chemical -
( I-Chemical -
C5H4 I-Chemical -
) I-Chemical -
( I-Chemical -
Ox I-Chemical -
( I-Chemical -
4S I-Chemical -
- I-Chemical -
iPr I-Chemical -
, I-Chemical -
Me2 I-Chemical -
) I-Chemical -
) I-Chemical -
2 I-Chemical -
} I-Chemical -
Zr I-Chemical -
( I-Chemical -
NMe2 I-Chemical -
) I-Chemical -
Cl I-Chemical +
or O +
a O +
cyclopentadienylmono B-Chemical -
( I-Chemical -
oxazolinyl I-Chemical -
) I-Chemical -
borato I-Chemical +
zirconium I-Chemical +
diamide I-Chemical +
{ B-Chemical -
Ph2B I-Chemical -
( I-Chemical -
C5H4 I-Chemical -
) I-Chemical -
( I-Chemical -
Ox I-Chemical -
( I-Chemical -
4S I-Chemical -
- I-Chemical -
iPr I-Chemical -
, I-Chemical -
Me2 I-Chemical -
) I-Chemical -
) I-Chemical -
} I-Chemical -
Zr I-Chemical -
( I-Chemical -
NMe2 I-Chemical -
) I-Chemical -
2 I-Chemical -
. O +

Plots O +
of O +
initial O +
rate O +
versus O +
[ O -
substrate O -
] O +
show O +
a O +
rate O +
dependence O +
that O +
evolves O +
from O +
first O -
- O -
order O +
at O +
low O +
concentration O +
to O +
zero O -
- O -
order O +
at O +
high O +
concentration O -
, O +
and O +
this O +
is O +
consistent O +
with O +
a O +
reversible O +
substrate O -
- O -
catalyst O +
interaction O +
preceding O +
an O +
irreversible O +
step O -
. O +

Primary O +
kinetic O +
isotope O +
effects O +
from O +
substrate O +
conversion O +
measurements O +
( O -
k'obs O -
( O -
( O -
H O -
) O -
) O -
/ O -
k'obs O -
( O -
( O -
D O -
) O -
) O +
= O +
3.3 O +
± O +
0.3 O -
) O +
and O +
from O +
initial O +
rate O +
analysis O +
( O -
k2 O -
( O -
( O -
H O -
) O -
) O -
/ O -
k2 O -
( O -
( O -
D O -
) O -
) O +
= O +
2.3 O +
± O +
0.4 O -
) O +
indicate O +
that O +
a O +
N B-Chemical -
- I-Chemical -
H I-Chemical +
bond O +
is O +
broken O +
in O +
the O +
turnover O -
- O -
limiting O +
and O +
irreversible O +
step O +
of O +
the O +
catalytic O +
cycle O -
. O +

Asymmetric O +
hydroamination O -
/ O -
cyclization O +
of O +
N B-Chemical -
- I-Chemical -
deutero I-Chemical -
- I-Chemical -
aminoalkenes I-Chemical +
provides O +
products O +
with O +
higher O +
optical O +
purities O +
than O +
obtained O +
with O +
N B-Chemical -
- I-Chemical -
proteo I-Chemical -
- I-Chemical -
aminoalkenes I-Chemical -
. O +

Transition O +
state O +
theory O -
, O +
applied O +
to O +
the O +
rate O +
constant O +
k2 O +
that O +
characterizes O +
the O +
irreversible O +
step O -
, O +
provides O +
activation O +
parameters O +
consistent O +
with O +
a O +
highly O +
organized O +
transition O +
state O +
( O -
ΔS O -
( O -
⧧ O -
) O +
= O +
-43 O -
( O -
7 O -
) O +
cal·mol O -
( O -
-1 O -
) O +
K O -
( O -
-1 O -
) O -
) O +
and O +
a O +
remarkably O +
low O +
enthalpic O +
barrier O +
( O -
ΔH O -
( O -
⧧ O -
) O +
= O +
6.7 O -
( O -
2 O -
) O +
kcal·mol O -
( O -
-1 O -
) O -
) O -
. O +

A O +
six O -
- O -
centered O -
, O +
concerted O +
transition O +
state O +
for O +
C B-Chemical -
- I-Chemical -
N I-Chemical +
and O +
C B-Chemical -
- I-Chemical -
H I-Chemical +
bond O +
formation O +
and O +
N B-Chemical -
- I-Chemical -
H I-Chemical +
bond O +
cleavage O +
involving O +
two O +
amidoalkene B-Chemical +
ligands O +
is O +
proposed O +
as O +
most O +
consistent O +
with O +
the O +
current O +
data O -
. O +

Elucidation O +
of O +
the O +
biochemical O +
basis O +
for O +
a O +
clinical O +
drug O -
- O -
drug O +
interaction O +
between O +
atorvastatin B-Chemical +
and O +
5- B-Chemical -
( I-Chemical -
N- I-Chemical -
( I-Chemical -
4- I-Chemical -
( I-Chemical -
( I-Chemical -
4-ethylbenzyl I-Chemical -
) I-Chemical -
thio I-Chemical -
) I-Chemical -
phenyl I-Chemical -
) I-Chemical -
sulfamoyl I-Chemical -
) I-Chemical -
-2-methyl I-Chemical +
benzoic I-Chemical +
acid I-Chemical +
( O -
CP-778 B-Chemical +
875 I-Chemical -
) O -
, O +
a O +
subtype O +
selective O +
agonist O +
of O +
the O +
peroxisome O +
proliferator O -
- O -
activated O +
receptor O +
alpha O -
. O +

Abstract O +
1 O -
. O +
5- B-Chemical -
( I-Chemical -
N- I-Chemical -
( I-Chemical -
4- I-Chemical -
( I-Chemical -
( I-Chemical -
4-ethylbenzyl I-Chemical -
) I-Chemical -
thio I-Chemical -
) I-Chemical -
phenyl I-Chemical -
) I-Chemical -
sulfamoyl I-Chemical -
) I-Chemical -
-2-methyl I-Chemical +
benzoic I-Chemical +
acid I-Chemical +
( O -
CP-778 B-Chemical +
875 I-Chemical -
) O -
, O +
an O +
agonist O +
of O +
the O +
peroxisome O +
proliferator O -
- O -
activated O +
receptor O +
alpha O -
, O +
has O +
been O +
evaluated O +
in O +
the O +
clinic O +
to O +
treat O +
dyslipidemia O +
and O +
type O +
2 O +
diabetes O +
mellitus O -
. O +

Herein O -
, O +
we O +
investigate O +
the O +
effect O +
of O +
CP-778 B-Chemical +
875 I-Chemical +
on O +
the O +
pharmacokinetics O +
of O +
atorvastatin B-Chemical +
acid I-Chemical +
and O +
its O +
metabolites O +
in O +
humans O -
. O +

2 O -
. O +

The O +
study O +
incorporated O +
a O +
fixed O -
- O -
sequence O +
design O +
conducted O +
in O +
two O +
groups O -
. O +

Group O +
A O +
was O +
designed O +
to O +
estimate O +
the O +
effects O +
of O +
multiple O +
doses O +
of O +
CP-778 B-Chemical +
875 I-Chemical +
on O +
the O +
single O +
dose O +
pharmacokinetics O +
of O +
atorvastatin B-Chemical -
. O +

Subjects O +
in O +
group O +
A O +
( O -
n O +
= O +
26 O -
) O +
received O +
atorvastatin B-Chemical +
( O -
40 O +
mg O -
) O +
on O +
days O +
1 O +
and O +
9 O +
and O +
CP-778 B-Chemical +
875 I-Chemical +
( O -
1.0 O +
mg O +
QD O -
) O +
on O +
days O +
5 O -
- O -
12 O -
. O +

Group O +
B O +
was O +
designed O +
to O +
examine O +
the O +
effects O +
of O +
multiple O +
doses O +
of O +
atorvastatin B-Chemical +
on O +
the O +
single O +
dose O +
pharmacokinetics O +
of O +
CP-778 B-Chemical +
875 I-Chemical -
. O +

Subjects O +
in O +
group O +
B O +
( O -
n O +
= O +
29 O -
) O +
received O +
CP-778 B-Chemical +
875 I-Chemical +
( O -
0.3 O +
mg O -
) O +
on O +
days O +
1 O +
and O +
9 O +
and O +
atorvastatin B-Chemical +
( O -
40 O +
mg O +
QD O -
) O +
on O +
days O +
5 O -
- O -
12 O -
. O +

3 O -
. O +
Mean O +
maximum O +
serum O +
concentration O +
( O -
Cmax O -
) O +
and O +
area O +
under O +
the O +
curve O +
of O +
atorvastatin B-Chemical +
were O +
increased O +
by O +
45 O -
% O +
and O +
20 O -
% O -
, O +
respectively O -
, O +
upon O +
co O -
- O -
administration O +
with O +
CP-778 B-Chemical +
875 I-Chemical -
. O +

Statistically O +
significant O +
increases O +
in O +
the O +
systemic O +
exposure O +
of O +
ortho- B-Chemical +
and I-Chemical +
para I-Chemical -
- I-Chemical -
hydroxyatorvastatin I-Chemical +
were O +
also O +
observed O +
upon O +
concomitant O +
dosing O +
with O +
CP-778 B-Chemical +
875 I-Chemical -
. O +

CP-778 B-Chemical +
875 I-Chemical +
pharmacokinetics O -
, O +
however O -
, O +
were O +
not O +
impacted O +
upon O +
concomitant O +
dosing O +
with O +
atorvastatin B-Chemical -
. O +

4 O -
. O +
Inhibition O +
of O +
organic O +
anion O +
transporting O +
polypeptide O +
1B1 O +
by O +
CP-778 B-Chemical +
875 I-Chemical +
( O -
IC50 O +
= O +
2.14 O +
±0.40 O +
μM O -
) O +
could O +
be O +
the O +
dominant O +
cause O +
of O +
the O +
pharmacokinetic O +
interaction O +
as O +
CP-778 B-Chemical +
875 I-Chemical +
did O +
not O +
exhibit O +
significant O +
inhibition O +
of O +
cytochrome O +
P450 O +
3A4 O -
/ O -
3A5 O -
, O +
multidrug O +
resistant O +
protein O +
1 O +
or O +
breast O +
cancer O +
resistant O +
protein O -
, O +
which O +
are O +
also O +
involved O +
in O +
the O +
hepatobiliary O +
disposition O +
of O +
atorvastatin B-Chemical -
. O +

Simultaneous O +
determination O +
by O +
LC O -
- O -
MS O -
/ O -
MS O +
of O +
25-methoxydammarane-3β,12β,20-triol B-Chemical +
epimers O +
and O +
active O +
metabolites O +
in O +
rat O +
plasma O +
after O +
intravenous O +
administration O -
. O +

Abstract O +
1 O -
. O +

The O +
pharmacokinetics O +
of O +
the O +
25-OCH3-PPD B-Chemical +
epimers O +
and O +
active O +
metabolites O +
in O +
rat O +
plasma O +
after O +
a O +
single O +
intravenous O +
( O -
i.v O -
. O -
) O +
administration O +
were O +
studied O +
by O +
a O +
rapid O -
, O +
selective O +
and O +
sensitive O +
UPLC O -
- O -
MS O -
/ O -
MS O +
method O -
. O +

2 O -
. O +

Chromatographic O +
separation O +
was O +
performed O +
on O +
an O +
Acquity O +
UPLC O +
with O +
Agela O +
C18 O +
column O -
, O +
and O +
the O +
solvents O +
of O +
5 O +
mM O +
ammonium B-Chemical +
acetate I-Chemical +
( O -
pH O +
7.8 O -
) O +
- O +
acetonitrile B-Chemical +
( O -
65 O -
: O +
35 O -
, O +
v O -
/ O -
v O -
) O +
were O +
used O +
as O +
mobile O +
phase O +
for O +
elution O -
. O +

The O +
quantification O +
was O +
performed O +
with O +
the O +
transitions O +
of O +
m O -
/ O -
z O +
493.5 O +
→ O +
475.5 O +
for O +
20 B-Chemical -
( I-Chemical -
R I-Chemical -
, I-Chemical -
S I-Chemical -
) I-Chemical -
-25-OCH3-PPD I-Chemical -
, O +
m O -
/ O -
z O +
479.5 O +
→ O +
461.5 O +
for O +
20 B-Chemical -
( I-Chemical -
R I-Chemical -
, I-Chemical -
S I-Chemical -
) I-Chemical -
-25-OH I-Chemical -
- I-Chemical -
PPD I-Chemical -
. O +

The O +
Lower O +
Limit O +
Of O +
Quantitation O +
( O -
LLOQ O -
) O +
was O +
20.0 O +
ng O +
mL O -
( O -
-1 O -
) O +
for O +
20 B-Chemical -
( I-Chemical -
R I-Chemical -
, I-Chemical -
S I-Chemical -
) I-Chemical -
-25-OCH3-PPD I-Chemical -
, O +
2.0 O +
ng O +
mL O -
( O -
-1 O -
) O +
for O +
20 B-Chemical -
( I-Chemical -
R I-Chemical -
, I-Chemical -
S I-Chemical -
) I-Chemical -
-25-OH I-Chemical -
- I-Chemical -
PPD I-Chemical +
in O +
the O +
plasma O +
samples O +
assay O -
. O +

3 O -
. O +

The O +
pharmacokinetic O +
parameters O +
of O +
AUC O -
, O +
t1 O -
/ O -
2 O +
and O +
MRT O +
had O +
no O +
difference O +
between O +
20 B-Chemical -
( I-Chemical -
R I-Chemical -
) I-Chemical -
- I-Chemical +
and I-Chemical +
( I-Chemical -
S I-Chemical -
) I-Chemical -
-25-OCH3-PPD I-Chemical -
, O +
but O +
S O -
- O -
epimer O +
has O +
a O +
lower O +
plasma O +
clearance O +
compared O +
to O +
the O +
R O -
- O -
isomer O -
. O +

The O +
active O +
metabolite O +
20 B-Chemical -
( I-Chemical -
S I-Chemical -
) I-Chemical -
-25-OH I-Chemical -
- I-Chemical -
PPD I-Chemical +
showed O +
significantly O +
higher O +
AUC O -
, O +
MRT O +
and O +
a O +
longer O +
half O -
- O -
life O +
than O +
that O +
of O +
20 B-Chemical -
( I-Chemical -
R I-Chemical -
) I-Chemical -
-25-OH I-Chemical -
- I-Chemical -
PPD I-Chemical -
. O +

These O +
assay O +
results O +
are O +
necessary O +
for O +
the O +
evaluation O +
of O +
the O +
pharmacokinetic O +
behavior O +
of O +
25-methoxydammarane-3β,12β,20-triol B-Chemical +
in O +
vivo O -
. O +

Single O +
Ion O +
Channel O +
Recordings O +
with O +
CMOS O -
- O -
Anchored O +
Lipid O +
Membranes O -
. O +

We O +
present O +
single O -
- O -
ion O -
- O -
channel O +
recordings O +
performed O +
with O +
biomimetic O +
lipid O +
membranes O +
which O +
are O +
directly O +
attached O +
to O +
the O +
surface O +
of O +
a O +
complementary O +
metal B-Chemical -
- I-Chemical -
oxide I-Chemical -
- O -
semiconductor O +
( O -
CMOS O -
) O +
preamplifier O +
chip O -
. O +

With O +
this O +
system O +
we O +
resolve O +
single O -
- O -
channel O +
currents O +
from O +
several O +
types O +
of O +
bacterial O +
ion O +
channels O -
, O +
including O +
fluctuations O +
of O +
a O +
single O +
alamethicin O +
channel O +
at O +
a O +
bandwidth O +
of O +
1 O +
MHz O +
which O +
represent O +
the O +
fastest O +
single O -
- O -
ion O -
- O -
channel O +
recordings O +
reported O +
to O +
date O -
. O +

The O +
platform O +
is O +
also O +
used O +
for O +
high O -
- O -
resolution O +
α O -
- O -
hemolysin O +
nanopore O +
recordings O -
. O +

These O +
results O +
illustrate O +
the O +
high O +
signal O +
fidelity O -
, O +
fine O +
temporal O +
resolution O -
, O +
small O +
geometry O -
, O +
and O +
multiplexed O +
integration O +
which O +
can O +
be O +
achieved O +
by O +
leveraging O +
integrated O +
semiconductor O +
platforms O +
for O +
advanced O +
ion O +
channel O +
interfaces O -
. O +

Indazole B-Chemical -
- O -
based O +
Potent O +
and O +
Cell O -
- O -
Active O +
Mps1 O +
Kinase O +
Inhibitors O -
: O +
Rational O +
Design O +
from O +
Pan O -
- O -
Kinase O +
Inhibitor O +
Anthrapyrazolone B-Chemical +
( O -
SP600125 B-Chemical -
) O -
. O +

Monopolar O +
spindle O +
1 O +
( O -
Mps1 O -
) O +
is O +
essential O +
for O +
centrosome O +
duplication O -
, O +
the O +
spindle O +
assembly O +
check O +
point O -
, O +
and O +
the O +
maintenance O +
of O +
chromosomal O +
instability O -
. O +

Mps1 O +
is O +
highly O +
expressed O +
in O +
cancer O +
cells O -
, O +
and O +
its O +
expression O +
levels O +
correlate O +
with O +
the O +
histological O +
grades O +
of O +
cancers O -
. O +

Thus O -
, O +
selective O +
Mps1 O +
inhibitors O +
offer O +
an O +
attractive O +
opportunity O +
for O +
the O +
development O +
of O +
novel O +
cancer O +
therapies O -
. O +

To O +
design O +
novel O +
Mps1 O +
inhibitors O -
, O +
we O +
utilized O +
the O +
pan O -
- O -
kinase O +
inhibitor O +
anthrapyrazolone B-Chemical +
( O -
4 O -
, O +
SP600125 B-Chemical -
) O +
and O +
its O +
crystal O +
structure O +
bound O +
to O +
JNK1 O -
. O +

Our O +
design O +
efforts O +
led O +
to O +
the O +
identification O +
of O +
indazole B-Chemical -
- O -
based O +
lead O +
6 O +
with O +
an O +
Mps1 O +
IC50 O +
value O +
of O +
498 O +
nM. O +
Optimization O +
of O +
the O +
3- O +
and O +
6-positions O +
on O +
the O +
indazole B-Chemical +
core O +
of O +
6 O +
resulted O +
in O +
23c O +
with O +
improved O +
Mps1 O +
activity O +
( O -
IC50 O +
= O +
3.06 O +
nM O -
) O -
. O +

Finally O -
, O +
application O +
of O +
structure O -
- O -
based O +
design O +
using O +
the O +
X O -
- O -
ray O +
structure O +
of O +
23d O +
bound O +
to O +
Mps1 O +
culminated O +
in O +
the O +
discovery O +
of O +
32a O +
and O +
32b O +
with O +
improved O +
potency O +
for O +
cellular O +
Mps1 O +
and O +
A549 O +
lung O +
cancer O +
cells O -
. O +

Moreover O -
, O +
32a O +
and O +
32b O +
exhibited O +
reasonable O +
selectivities O +
over O +
120 O +
and O +
166 O +
kinases O -
, O +
respectively O -
. O +

Enhanced O +
beta O +
cell O +
function O +
and O +
anti O -
- O -
inflammatory O +
effect O +
after O +
chronic O +
treatment O +
with O +
the O +
dipeptidyl O +
peptidase-4 O +
inhibitor O +
vildagliptin B-Chemical +
in O +
an O +
advanced O -
- O -
aged O +
diet O -
- O -
induced O +
obesity O +
mouse O +
model O -
. O +

AIMS O -
/ O -
HYPOTHESIS O -
: O +
Studies O +
have O +
shown O +
that O +
dipeptidyl O +
peptidase-4 O +
( O -
DPP4 O -
) O +
inhibitors O +
stimulate O +
insulin O +
secretion O +
and O +
increase O +
beta O +
cell O +
mass O +
in O +
rodents O -
. O +

However O -
, O +
in O +
these O +
models O +
hyperglycaemia O +
has O +
been O +
induced O +
early O +
on O +
in O +
life O +
and O +
the O +
treatment O +
periods O +
have O +
been O +
short O -
. O +

To O +
explore O +
the O +
long O -
- O -
term O +
effects O +
of O +
DPP4 O +
inhibition O +
on O +
insulin O +
secretion O +
and O +
beta O +
cell O +
mass O -
, O +
we O +
have O +
generated O +
a O +
high O -
- O -
fat O +
diet O +
( O -
HFD O -
) O -
-induced O -
- O -
obesity O +
model O +
in O +
mice O +
of O +
advanced O +
age O +
( O -
10 O +
months O +
old O -
) O -
. O +

METHODS O -
: O +
After O +
1 O +
month O +
of O +
HFD O +
alone O -
, O +
the O +
mice O +
were O +
given O +
the O +
DPP4 O +
inhibitor O +
vildagliptin B-Chemical +
for O +
a O +
further O +
11 O +
months O -
. O +

At O +
multiple O +
time O +
points O +
throughout O +
the O +
study O -
, O +
OGTTs O +
were O +
performed O +
and O +
beta O +
cell O +
area O +
and O +
long O -
- O -
term O +
survival O +
were O +
evaluated O -
. O +

RESULTS O -
: O +
Beta O +
cell O +
function O +
and O +
glucose B-Chemical +
tolerance O +
were O +
significantly O +
improved O +
by O +
vildagliptin B-Chemical +
with O +
both O +
diets O -
. O +

In O +
contrast O -
, O +
in O +
spite O +
of O +
the O +
long O +
treatment O +
period O -
, O +
beta O +
cell O +
area O +
was O +
not O +
significantly O +
different O +
between O +
vildagliptin B-Chemical -
- O -
treated O +
mice O +
and O +
controls O -
. O +

Mice O +
of O +
advanced O +
age O +
chronically O +
fed O +
an O +
HFD O +
displayed O +
clear O +
and O +
extensive O +
pancreatic O +
inflammation O +
and O +
peri O -
- O -
insulitis O -
, O +
mainly O +
formed O +
by O +
CD3-positive O +
T O +
cells O -
, O +
which O +
were O +
completely O +
prevented O +
by O +
vildagliptin B-Chemical +
treatment O -
. O +

Chronic O +
vildagliptin B-Chemical +
treatment O +
also O +
improved O +
survival O +
rates O +
for O +
HFD O -
- O -
fed O +
mice O -
. O +

CONCLUSIONS O -
/ O -
INTERPRETATION O -
: O +
In O +
a O +
unique O +
advanced O -
- O -
aged O +
HFD O -
- O -
induced O -
- O -
obesity O +
mouse O +
model O -
, O +
insulin O +
secretion O +
was O +
improved O +
and O +
the O +
extensive O +
peri O -
- O -
insulitis O +
prevented O +
by O +
chronic O +
DPP4 O +
inhibition O -
. O +

The O +
improved O +
survival O +
rates O +
for O +
obese O +
mice O +
chronically O +
treated O +
with O +
vildagliptin B-Chemical +
suggest O +
that O +
chronic O +
DPP4 O +
inhibition O +
potentially O +
results O +
in O +
additional O +
quality O -
- O -
adjusted O +
life O -
- O -
years O +
for O +
individuals O +
with O +
type O +
2 O +
diabetes O -
, O +
which O +
is O +
the O +
primary O +
goal O +
of O +
any O +
diabetes O +
therapy O -
. O +

PT O -
- O -
ACRAMTU O -
, O +
A O +
Platinum B-Chemical -
- O -
Acridine B-Chemical +
Anticancer O +
Agent O -
, O +
Lengthens O +
and O +
Aggregates O -
, O +
but O +
does O +
not O +
Stiffen O +
or O +
Soften O +
DNA O -
. O +

We O +
used O +
atomic O +
force O +
microscopy O +
( O -
AFM O -
) O +
to O +
study O +
the O +
dose O -
- O -
dependent O +
change O +
in O +
conformational O +
and O +
mechanical O +
properties O +
of O +
DNA O +
treated O +
with O +
PT B-Chemical -
- I-Chemical -
ACRAMTU I-Chemical +
( B-Chemical -
[ I-Chemical -
PtCl I-Chemical -
( I-Chemical -
en I-Chemical -
) I-Chemical -
( I-Chemical -
ACRAMTU I-Chemical -
- I-Chemical -
S I-Chemical -
) I-Chemical -
] I-Chemical -
( I-Chemical -
NO3 I-Chemical -
) I-Chemical -
2 I-Chemical -
, O +
( O -
en O +
= O +
ethane-1,2-diamine B-Chemical -
, O +
ACRAMTU B-Chemical +
= O +
1- B-Chemical -
[ I-Chemical -
2- I-Chemical -
( I-Chemical -
acridin-9-ylamino I-Chemical -
) I-Chemical -
ethyl I-Chemical -
] I-Chemical -
-1,3-dimethylthiourea I-Chemical -
. O +

PT B-Chemical -
- I-Chemical -
ACRAMTU I-Chemical +
is O +
the O +
parent O +
drug O +
of O +
a O +
family O +
of O +
non O -
- O -
classical O +
platinum B-Chemical -
- O -
based O +
agents O +
that O +
show O +
potent O +
activity O +
in O +
non O -
- O -
small O +
cell O +
lung O +
cancer O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

Its O +
acridine B-Chemical +
moiety O +
intercalates O +
between O +
DNA O +
bases O -
, O +
while O +
the O +
platinum B-Chemical +
group O +
forms O +
mono O -
- O -
adducts O +
with O +
DNA O +
bases O -
. O +

AFM O +
images O +
show O +
that O +
PT B-Chemical -
- I-Chemical -
ACRAMTU I-Chemical +
causes O +
some O +
DNA O +
looping O +
and O +
aggregation O +
at O +
drug O -
- O -
to O -
- O -
base O +
pair O +
ratio O +
( O -
r O +
b O -
) O +
of O +
0.1 O +
and O +
higher O -
. O +

Very O +
significant O +
lengthening O +
of O +
the O +
DNA O +
was O +
observed O +
with O +
increasing O +
doses O +
of O +
PT B-Chemical -
- I-Chemical -
ACRAMTU I-Chemical -
, O +
and O +
reached O +
saturation O +
at O +
an O +
r O +
b O +
of O +
0.15 O -
. O +

At O +
r O +
b O +
of O +
0.1 O -
, O +
lengthening O +
was O +
0.6 O +
nm O +
per O +
drug O +
molecule O -
, O +
which O +
is O +
more O +
than O +
one O +
fully O +
stretched O +
base O +
pair O +
stack O +
can O +
accommodate O -
, O +
indicating O +
that O +
ACRAMTU B-Chemical +
also O +
disturbs O +
the O +
stacking O +
of O +
neighboring O +
base O +
pair O +
stacks O -
. O +

Analysis O +
of O +
the O +
AFM O +
images O +
based O +
on O +
the O +
worm O -
- O -
like O +
chain O +
( O -
WLC O -
) O +
model O +
showed O +
that O +
PT B-Chemical -
- I-Chemical -
ACRAMTU I-Chemical +
did O +
not O +
change O +
the O +
flexibility O +
of O +
( O -
non O -
- O -
aggregated O -
) O +
DNA O -
, O +
despite O +
the O +
extreme O +
lengthening O -
. O +

The O +
persistence O +
length O +
of O +
untreated O +
DNA O +
and O +
DNA O +
treated O +
with O +
PT B-Chemical -
- I-Chemical -
ACRAMTU I-Chemical +
was O +
in O +
the O +
range O +
of O +
49 O -
- O -
65 O +
nm O -
. O +

Potential O +
consequences O +
of O +
the O +
perturbations O +
caused O +
by O +
this O +
agent O +
for O +
the O +
recognition O +
and O +
processing O +
of O +
the O +
DNA O +
adducts O +
it O +
forms O +
are O +
discussed O -
. O +

A O +
dihydrochalcone B-Chemical +
and O +
several O +
homoisoflavonoids B-Chemical +
from O +
Polygonatum O +
odoratum O +
are O +
activators O +
of O +
adenosine B-Chemical +
monophosphate I-Chemical -
- O -
activated O +
protein O +
kinase O -
. O +

Adenosine B-Chemical +
monophosphate I-Chemical +
( O -
AMP B-Chemical -
) O -
-activated O +
protein O +
kinase O +
( O -
AMPK O -
) O +
is O +
a O +
major O +
cellular O +
energy O +
sensor O +
and O +
master O +
regulator O +
of O +
metabolic O +
homeostasis O -
; O +
thus O -
, O +
AMPK O +
plays O +
a O +
central O +
role O +
in O +
studies O +
on O +
diabetes O +
and O +
related O +
metabolic O +
diseases O -
. O +

From O +
the O +
rhizomes O +
of O +
Polygonatum O +
odoratum O +
( O -
Mill O -
. O -
) O +

Druce O -
, O +
six O +
homoisoflavonoids B-Chemical +
( O -
1 O -
- O -
6 O -
) O +
and O +
one O +
dihydrochalcone B-Chemical +
( O -
7 O -
) O +
were O +
isolated O -
, O +
and O +
the O +
structures O +
of O +
polygonatones B-Chemical +
A I-Chemical -
- I-Chemical -
D I-Chemical +
( O -
4 O -
- O -
7 O -
) O +
were O +
elucidated O +
by O +
various O +
spectroscopic O +
analyses O -
. O +

Compounds O +
1 O -
- O -
7 O +
were O +
evaluated O +
for O +
their O +
effect O +
on O +
AMPK O +
activation O -
. O +

The O +
amount O +
of O +
active O +
phosphorylated O +
AMPK O +
and O +
acetyl B-Chemical -
- I-Chemical -
CoA I-Chemical +
carboxylase O +
in O +
rat O +
liver O +
epithelial O +
IAR-20 O +
cells O +
increased O +
when O +
the O +
cells O +
were O +
incubated O +
with O +
the O +
aforementioned O +
compounds O -
. O +

Specifically O -
, O +
( B-Chemical -
3R I-Chemical -
) I-Chemical -
-5,7-dihydroxyl-6-methyl-8-methoxyl-3- I-Chemical -
( I-Chemical -
4'-hydroxylbenzyl I-Chemical -
) I-Chemical -
-chroman-4-one I-Chemical +
( O -
1 O -
) O -
, O +
( B-Chemical -
3R I-Chemical -
) I-Chemical -
-5,7-dihydroxyl-6,8-dimethyl-3- I-Chemical -
( I-Chemical -
4'-hydroxylbenzyl I-Chemical -
) I-Chemical -
-chroman-4-one I-Chemical +
( O -
2 O -
) O -
, O +
( B-Chemical -
3R I-Chemical -
) I-Chemical -
-5,7-dihydroxyl-6-methyl-3- I-Chemical -
( I-Chemical -
4'-hydroxylbenzyl I-Chemical -
) I-Chemical -
-chroman-4-one I-Chemical +
( O -
3 O -
) O -
, O +
and O +
polygonatone B-Chemical +
D I-Chemical +
( O -
7 O -
) O +
exhibited O +
significant O +
activation O +
effects O -
. O +

Synthesis O +
and O +
structure O -
- O -
activity O +
relationships O +
of O +
a O +
novel O +
and O +
selective O +
bone O +
morphogenetic O +
protein O +
receptor O +
( O -
BMP O -
) O +
inhibitor O +
derived O +
from O +
the O +
pyrazolo B-Chemical -
[ I-Chemical -
1.5-a I-Chemical -
] I-Chemical -
pyrimidine I-Chemical +
scaffold O +
of O +
Dorsomorphin O -
: O +
The O +
discovery O +
of O +
ML347 B-Chemical +
as O +
an O +
ALK2 O +
versus O +
ALK3 O +
selective O +
MLPCN O +
probe O -
. O +

A O +
structure O -
- O -
activity O +
relationship O +
of O +
the O +
3- O +
and O +
6-positions O +
of O +
the O +
pyrazolo B-Chemical -
[ I-Chemical -
1,5-a I-Chemical -
] I-Chemical -
pyrimidine I-Chemical +
scaffold O +
of O +
the O +
known O +
BMP O +
inhibitors O +
dorsomorphin B-Chemical -
, O +
1 O -
, O +
LDN-193189 B-Chemical -
, O +
2 O -
, O +
and O +
DMH1 B-Chemical -
, O +
3 O -
, O +
led O +
to O +
the O +
identification O +
of O +
a O +
potent O +
and O +
selective O +
compound O +
for O +
ALK2 O +
versus O +
ALK3 O -
. O +

The O +
potency O +
contributions O +
of O +
several O +
3-position O +
substituents O +
were O +
evaluated O +
with O +
subtle O +
structural O +
changes O +
leading O +
to O +
significant O +
changes O +
in O +
potency O -
. O +

From O +
these O +
studies O -
, O +
a O +
novel O +
5-quinoline B-Chemical +
molecule O +
was O +
identified O +
and O +
designated O +
an O +
MLPCN O +
probe O +
molecule O -
, O +
ML347 B-Chemical -
, O +
which O +
shows O +
> O -
300-fold O +
selectivity O +
for O +
ALK2 O +
and O +
presents O +
the O +
community O +
with O +
a O +
selective O +
molecular O +
probe O +
for O +
further O +
biological O +
evaluation O -
. O +

Synthesis O +
and O +
in O +
vitro O +
evaluation O +
of O +
a O +
PDT O +
active O +
BODIPY O -
- O -
NLS O +
conjugate O -
. O +

Two O +
new O +
photosensitizers O +
based O +
on O +
the O +
BODIPY B-Chemical +
scaffold O +
have O +
been O +
synthesized O -
, O +
of O +
which O +
one O +
bears O +
an O +
NLS O +
peptide O -
, O +
which O +
is O +
linked O +
to O +
the O +
BODIPY O -
's O +
core O +
using O +
the O +
copper B-Chemical +
catalysed O +
azide B-Chemical -
- O -
alkyne B-Chemical +
click O +
reaction O -
. O +

The O +
phototoxicities O +
of O +
these O +
BODIPY B-Chemical +
based O +
photosensitizers O +
have O +
been O +
determined O -
, O +
as O +
well O +
as O +
their O +
dark O +
toxicities O -
. O +

Although O +
the O +
conjugation O +
of O +
a O +
single O +
NLS O +
peptide O +
to O +
the O +
BODIPY B-Chemical +
did O +
not O +
lead O +
to O +
any O +
observable O +
nuclear O +
localization O -
, O +
the O +
photosensitizer O +
did O +
exhibit O +
a O +
superior O +
photoxicity O -
. O +

Cellular O +
co O -
- O -
localization O +
experiments O +
revealed O +
a O +
localization O +
of O +
both O +
dyes O +
in O +
the O +
lysosomes O -
, O +
as O +
well O +
as O +
a O +
partial O +
localization O +
within O +
the O +
ER O +
( O -
for O +
the O +
peptide O -
- O -
bearing O +
BODIPY B-Chemical -
) O -
. O +

Barnacle O +
Cement O +
as O +
Surface O +
Anchor O +
for O +
' O -
Clicking O -
' O +
of O +
Antifouling O +
and O +
Antimicrobial O +
Polymer O +
Brushes O +
on O +
Stainless O +
Steel O -
. O +

Barnacle O +
cement O +
( O -
BC O -
) O +
was O +
utilized O +
' O -
beneficially O -
' O +
as O +
a O +
surface O +
anchor O +
on O +
stainless O +
steel O +
( O -
SS O -
) O +
for O +
coupling O +
of O +
functional O +
polymer O +
brushes O +
via O +
' O -
click O -
' O +
reactions O +
in O +
both O +
" O -
grafting O -
- O -
to O -
" O +
and O +
" O -
grafting O -
- O -
from O -
" O +
processes O -
. O +

Ethylene B-Chemical +
sulfide I-Chemical +
( O -
ES O -
) O -
, O +
propargyl B-Chemical +
carbonylimidazole I-Chemical +
( O -
PPC B-Chemical -
) O +
and O +
azidoethyl B-Chemical +
carbonylimidazole I-Chemical +
( O -
AEC B-Chemical -
) O +
reacted O +
with O +
amine B-Chemical +
and/or O +
hydroxyl B-Chemical +
groups O +
in O +
BC O +
to O +
introduce O +
the O +
corresponding O +
thiol B-Chemical -
, O +
alkyne B-Chemical +
and O +
azide B-Chemical +
groups O +
on O +
SS O +
surfaces O +
( O -
SS O -
- O -
thiol B-Chemical -
, O +
SS O -
- O -
alkyne B-Chemical +
and O +
SS O -
- O -
azide B-Chemical -
, O +
respectively O -
) O -
. O +

Antifouling O +
zwitterionic O +
SS O -
- O -
PMPC O +
surface O +
was O +
prepared O +
by O +
thiol B-Chemical -
- O -
ene O +
photopolymerization O +
of O +
2-methacryloyloxyethyl B-Chemical +
phosphorylcholine I-Chemical +
( O -
MPC B-Chemical -
) O +
from O +
the O +
SS O -
- O -
thiol B-Chemical +
surface O -
. O +

Protein O -
- O -
resistant O +
SS O -
- O -
PPEGMA B-Chemical +
and O +
protein O -
- O -
adsorbing O +
SS O -
- O -
PPFS B-Chemical +
surfaces O +
were O +
prepared O +
by O +
coupling O +
of O +
the O +
respective O +
azide B-Chemical -
- O -
functionalized O +
poly B-Chemical -
( I-Chemical -
poly I-Chemical -
( I-Chemical -
ethylene I-Chemical +
glycol I-Chemical -
) I-Chemical -
methyl I-Chemical +
ether I-Chemical +
methacrylate I-Chemical -
) I-Chemical +
( O -
azido B-Chemical -
- I-Chemical -
PPEGMA I-Chemical -
) O +
and O +
poly B-Chemical -
( I-Chemical -
2,3,4,5,6-pentafluorostyrene I-Chemical -
) I-Chemical +
( O -
azido B-Chemical -
- I-Chemical -
PPFS I-Chemical -
) O +
polymer O +
brushes O +
in O +
azide B-Chemical -
- O -
alkyne B-Chemical +
' O -
click O -
' O +
reaction O -
. O +

Antifouling O +
alkyne B-Chemical -
- O -
functionalized O +
poly B-Chemical -
( I-Chemical -
N I-Chemical -
- I-Chemical -
hydroxyethyl I-Chemical +
acrylamide I-Chemical -
) I-Chemical +
( O -
alkynyl B-Chemical -
- I-Chemical -
PHEAA I-Chemical -
) O +
and O +
antibacterial O +
alkyne B-Chemical -
- O -
functionalized O +
poly B-Chemical -
( I-Chemical -
2- I-Chemical -
( I-Chemical -
methacryloyloxy I-Chemical -
) I-Chemical -
ethyl I-Chemical +
trimethylammonium I-Chemical +
chloride I-Chemical -
) I-Chemical +
( O -
alkynyl B-Chemical -
- I-Chemical -
PMETA I-Chemical -
) O +
polymer O +
brushes O +
were O +
clicked O +
on O +
the O +
SS O -
- O -
azide B-Chemical +
surface O -
. O +

Adsorption O +
of O +
bovine O +
serum O +
albumin O +
and O +
bacteria O +
fouling O +
of O +
Gram O -
- O -
negative O +
Escherichia O +
coli O +
( O -
E. O +
coli O -
) O +
and O +
Gram O -
- O -
positive O +
Staphylococcus O +
epidermidis O +
( O -
S. O +
epidermidis O -
) O +
were O +
investigated O +
on O +
the O +
polymer O -
- O -
functionalized O +
SS O +
surfaces O -
. O +

The O +
versatile O +
bio O -
- O -
anchor O +
and O +
functional O +
polymer O +
brush O +
coatings O +
are O +
stable O +
in O +
abiotic O +
aqueous O +
environment O +
for O +
over O +
a O +
month O -
. O +

Vibrational O +
Perturbations O +
of O +
W B-Chemical -
( I-Chemical -
CO I-Chemical -
) I-Chemical -
6 I-Chemical +
Trapped O +
in O +
a O +
Molecular O +
Lattice O +
Probed O +
by O +
Linear O +
and O +
Non O +
Linear O +
Spectroscopy O -
. O +

Vibrational O +
dynamics O +
of O +
the O +
T1u O +
CO B-Chemical +
stretching O +
mode O +
of O +
tungsten B-Chemical +
hexacarbonyl I-Chemical +
is O +
explored O +
when O +
the O +
molecule O +
is O +
embedded O +
in O +
a O +
nitrogen B-Chemical +
matrix O +
at O +
low O +
temperature O -
. O +

Experiments O +
combined O +
IR O +
absorption O +
spectroscopy O +
and O +
IR O +
stimulated O +
photon O +
echoes O +
at O +
the O +
femtosecond O +
timescale O -
. O +

W B-Chemical -
( I-Chemical -
CO I-Chemical -
) I-Chemical -
6 I-Chemical +
is O +
found O +
to O +
be O +
trapped O +
in O +
two O +
main O +
families O +
of O +
sites O +
differing O +
by O +
their O +
symmetries O +
( O -
called O +
hereafter O +
Oh O +
and O +
D2h O +
) O -
. O +

In O +
Oh O +
sites O -
, O +
the O +
vibrational O +
coherence O +
is O +
strongly O +
temperature O +
dependent O -
, O +
exhibiting O +
a O +
coupling O +
with O +
librational O +
phonons O +
of O +
the O +
nitrogen B-Chemical +
lattice O -
. O +

Perturbation O +
in O +
D2h O +
sites O +
results O +
in O +
the O +
splitting O +
of O +
the O +
T1u O +
band O +
in O +
three O +
components O -
. O +

Each O +
component O +
is O +
inhomogeneously O +
broadened O -
, O +
with O +
dephasing O +
times O +
in O +
the O +
tens O +
of O +
picoseconds O -
, O +
weakly O +
coupled O +
to O +
the O +
lattice O +
phonons O -
. O +

Experiments O +
in O +
solid O +
krypton B-Chemical +
are O +
performed O +
to O +
compare O +
the O +
effect O +
of O +
atomic O +
and O +
diatomic O +
host O +
lattices O -
. O +

Dephasing O +
time O +
in O +
Kr B-Chemical +
does O +
not O +
depend O +
on O +
temperature O +
and O +
remains O +
in O +
the O +
hundreds O +
of O +
picosecond O -
, O +
highlighting O +
the O +
molecular O +
origin O +
of O +
dephasing O +
process O +
in O +
N2 B-Chemical +
. O +

Additionally O -
, O +
non O +
linear O +
signals O +
show O +
oscillations O +
due O +
to O +
quantum O +
beats O +
and O +
polarization O +
interferences O +
between O +
different O +
frequency O +
components O +
of O +
the O +
induced O +
third O +
order O +
polarization O -
, O +
giving O +
information O -
, O +
in O +
particular O -
, O +
on O +
the O +
overtone O +
vibrational O +
transition O -
. O +

Melamine B-Chemical +
activates O +
NFκB O -
/ O -
COX-2 O -
/ O -
PGE2 O +
pathway O +
and O +
increases O +
NADPH B-Chemical +
oxidase O -
- O -
dependent O +
ROS O +
production O +
in O +
macrophages O +
and O +
human O +
embryonic O +
kidney O +
cells O -
. O +

Melamine B-Chemical +
is O +
a O +
wildly O +
used O +
compound O +
in O +
manufactures O +
of O +
plastics O +
and O +
resins O -
. O +

A O +
variety O +
of O +
toxic O +
effects O +
from O +
melamine B-Chemical -
, O +
including O +
nephrolithiasis O -
, O +
chronic O +
kidney O +
inflammation O -
, O +
and O +
bladder O +
carcinoma O -
, O +
have O +
been O +
mentioned O -
. O +

Oxidative O +
stress O +
is O +
considered O +
to O +
be O +
an O +
important O +
pathogenic O +
mechanism O +
of O +
kidney O +
disease O +
which O +
may O +
develop O +
from O +
an O +
increasing O +
free O +
radical O +
production O +
through O +
inflammation O -
. O +

The O +
aim O +
of O +
this O +
study O +
is O +
to O +
investigate O +
melamine B-Chemical -
- O -
induced O +
oxidative O +
stress O +
and O +
inflammation O +
in O +
macrophage O -
- O -
like O +
cell O +
line O +
RAW O +
264.7 O +
and O +
human O +
embryonic O +
kidney O +
cell O +
line O +
HEK293 O -
. O +

Results O +
indicated O +
melamine B-Chemical +
activated O +
nuclear O +
factor O +
( O -
NF O -
) O -
-κB O +
through O +
increasing O +
IκB O -
- O -
α O +
degradation O +
and O +
NF O -
- O -
κB O +
p65 O -
/ O -
p50 O +
DNA O -
- O -
binding O +
activity O -
. O +

In O +
addition O -
, O +
melamine B-Chemical +
significantly O +
increased O +
COX-2 O +
expression O +
and O +
prostaglandin B-Chemical +
E2 I-Chemical +
( O -
PGE2 B-Chemical -
) O +
production O -
. O +

Moreover O -
, O +
melamine B-Chemical +
activated O +
NADPH B-Chemical +
oxidase O +
( O -
NOX O -
) O -
, O +
including O +
NOX1 O -
, O +
2 O +
and O +
4 O -
, O +
accompanied O +
with O +
an O +
increase O +
in O +
reactive O +
oxygen B-Chemical +
species O +
( O -
ROS O -
) O +
production O -
. O +

Furthermore O -
, O +
melamine B-Chemical -
- O -
induced O +
ROS O +
production O +
could O +
be O +
attenuated O +
by O +
apocynin B-Chemical -
, O +
a O +
NOX O +
inhibitor O -
. O +

In O +
conclusion O -
, O +
our O +
findings O +
suggest O +
melamine B-Chemical +
increased O +
inflammation O +
and O +
oxidative O +
stress O +
via O +
activation O +
of O +
NF O -
- O -
κB O -
/ O -
COX-2 O +
and O +
NOX O -
/ O -
ROS O +
pathway O -
, O +
and O +
first O +
revealed O +
the O +
critical O +
role O +
of O +
NOX O +
in O +
melamine B-Chemical -
- O -
induced O +
ROS O +
production O -
, O +
suggesting O +
the O +
potential O +
of O +
NOX O +
inhibitor O +
against O +
melamine B-Chemical +
toxicity O -
. O +

Genetic O +
Polymorphism O +
at O +
Val B-Chemical -
( O -
80 O -
) O +
( O -
rs700518 O -
) O +
of O +
the O +
CYP19A1 O +
Gene O +
is O +
Associated O +
with O +
Aromatase O +
Inhibitor O +
Associated O +
Bone O +
Loss O +
in O +
Women O +
with O +
ER O +
( O -
+ O -
) O +
Breast O +
Cancer O -
. O +

PURPOSE O -
: O +
Polymorphisms O +
in O +
the O +
CYP19A1 O +
( O -
aromatase O -
) O +
gene O +
have O +
been O +
reported O +
to O +
influence O +
disease O -
- O -
free O +
survival O +
and O +
the O +
incidence O +
of O +
musculoskeletal O +
complaints O +
in O +
patients O +
taking O +
aromatase O +
inhibitors O +
( O -
AIs O -
) O +
for O +
estrogen B-Chemical +
receptor O +
positive O +
( O -
ER+ O -
) O +
breast O +
cancer O -
. O +

Bone O +
loss O +
and O +
fractures O +
are O +
well O -
- O -
recognized O +
complications O +
from O +
AI O +
therapy O -
. O +

The O +
objective O +
of O +
this O +
study O +
is O +
to O +
determine O +
the O +
influence O +
of O +
polymorphisms O +
in O +
the O +
CYP19A1 O +
gene O +
on O +
bone O +
loss O +
among O +
patients O +
taking O +
aromatase O +
inhibitors O +
for O +
ER+ O +
breast O +
cancer O -
. O +

PATIENTS O +
AND O +
METHODS O -
: O +
The O +
subjects O +
consisted O +
of O +
97 O +
postmenopausal O +
women O +
with O +
ER+ O +
breast O +
cancer O +
who O +
were O +
initiated O +
on O +
third O -
- O -
generation O +
AIs O -
. O +

Bone O +
mineral O +
density O +
( O -
BMD O -
) O +
was O +
measured O +
by O +
dual O +
energy O +
x O -
- O -
ray O +
absorptiometry O +
at O +
baseline O +
and O +
at O +
6 O +
and O +
12 O +
months O -
. O +

Twenty O -
- O -
four O +
hour O +
urine O +
N O -
- O -
telopeptide O +
( O -
NTX O -
) O +
was O +
measured O +
by O +
Elisa O +
and O +
serum O +
estradiol B-Chemical +
was O +
measured O +
by O +
ultrasensitive O +
radioimmunoassay O +
at O +
baseline O -
, O +
and O +
at O +
6 O +
months O -
. O +

Genotyping O +
was O +
done O +
by O +
Taqman O +
SNP O +
allelic O +
discrimination O +
assay O -
. O +

RESULTS O -
: O +
Women O +
with O +
the O +
AA O +
genotype O +
for O +
the O +
rs700518 O +
( O -
G O -
/ O -
A O +
at O +
Val B-Chemical -
( O -
80 O -
) O -
) O +
developed O +
significant O +
bone O +
loss O +
at O +
the O +
lumbar O +
spine O +
and O +
the O +
total O +
hip O +
at O +
12 O +
months O +
relative O +
to O +
patients O +
carrying O +
the O +
G O +
allele O +
( O -
GA O -
/ O -
GG O -
) O -
; O +
both O +
p=0.03 O -
. O +

There O +
was O +
a O +
borderline O +
greater O +
increase O +
in O +
urinary O +
NTX O +
in O +
those O +
with O +
the O +
AA O +
genotype O +
compared O +
to O +
patients O +
with O +
the O +
G O +
allele O -
, O +
p=0.05 O -
; O +
but O +
no O +
significant O +
difference O +
in O +
changes O +
in O +
estradiol B-Chemical +
levels O +
among O +
the O +
genotypes O -
. O +

CONCLUSION O -
: O +
Patients O +
with O +
the O +
AA O +
genotype O +
for O +
the O +
rs700518 O +
polymorphism O +
in O +
the O +
CYP19A1 O +
gene O +
are O +
at O +
risk O +
for O +
AI O -
- O -
associated O +
bone O +
loss O +
and O +
deserve O +
close O +
follow O -
- O -
up O +
during O +
long O -
- O -
term O +
AI O +
therapy O -
. O +

Epigenetic O +
Mechanisms O +
of O +
Drug O +
Addiction O -
. O +

Drug O +
addiction O +
involves O +
potentially O +
life O -
- O -
long O +
behavioral O +
abnormalities O +
that O +
are O +
caused O +
in O +
vulnerable O +
individuals O +
by O +
repeated O +
exposure O +
to O +
a O +
drug O +
of O +
abuse O -
. O +

The O +
persistence O +
of O +
these O +
behavioral O +
changes O +
suggests O +
that O +
long O -
- O -
lasting O +
changes O +
in O +
gene O +
expression O -
, O +
within O +
particular O +
regions O +
of O +
the O +
brain O -
, O +
may O +
contribute O +
importantly O +
to O +
the O +
addiction O +
phenotype O -
. O +

Work O +
over O +
the O +
past O +
decade O +
has O +
demonstrated O +
a O +
crucial O +
role O +
for O +
epigenetic O +
mechanisms O +
in O +
driving O +
lasting O +
changes O +
in O +
gene O +
expression O +
in O +
diverse O +
tissues O -
, O +
including O +
brain O -
. O +

This O +
has O +
prompted O +
recent O +
research O +
aimed O +
at O +
characterizing O +
the O +
influence O +
of O +
epigenetic O +
regulatory O +
events O +
in O +
mediating O +
the O +
lasting O +
effects O +
of O +
drugs O +
of O +
abuse O +
on O +
the O +
brain O +
in O +
animal O +
models O +
of O +
drug O +
addiction O -
. O +

This O +
review O +
provides O +
a O +
progress O +
report O +
of O +
this O +
still O +
early O +
work O +
in O +
the O +
field O -
. O +

As O +
will O +
be O +
seen O -
, O +
there O +
is O +
robust O +
evidence O +
that O +
repeated O +
exposure O +
to O +
drugs O +
of O +
abuse O +
induces O +
changes O +
within O +
the O +
brain O -
's O +
reward O +
regions O +
in O +
three O +
major O +
modes O +
of O +
epigenetic O +
regulation O -
- O -
histone O +
modifications O +
such O +
as O +
acetylation O +
and O +
methylation O -
, O +
DNA O +
methylation O -
, O +
and O +
non O -
- O -
coding O +
RNAs O -
. O +

In O +
several O +
instances O -
, O +
it O +
has O +
been O +
possible O +
to O +
demonstrate O +
directly O +
the O +
contribution O +
of O +
such O +
epigenetic O +
changes O +
to O +
addiction O -
- O -
related O +
behavioral O +
abnormalities O -
. O +

Studies O +
of O +
epigenetic O +
mechanisms O +
of O +
addiction O +
are O +
also O +
providing O +
an O +
unprecedented O +
view O +
of O +
the O +
range O +
of O +
genes O +
and O +
non O -
- O -
genic O +
regions O +
that O +
are O +
affected O +
by O +
repeated O +
drug O +
exposure O +
and O +
the O +
precise O +
molecular O +
basis O +
of O +
that O +
regulation O -
. O +

Work O +
is O +
now O +
needed O +
to O +
validate O +
key O +
aspects O +
of O +
this O +
work O +
in O +
human O +
addiction O +
and O +
evaluate O +
the O +
possibility O +
of O +
mining O +
this O +
information O +
to O +
develop O +
new O +
diagnostic O +
tests O +
and O +
more O +
effective O +
treatments O +
for O +
addiction O +
syndromes O -
. O +

A O +
new O +
perspective O +
on O +
muscarinic O +
receptor O +
antagonism O +
in O +
obstructive O +
airways O +
diseases O -
. O +

Acetylcholine B-Chemical +
has O +
traditionally O +
only O +
been O +
regarded O +
as O +
a O +
neurotransmitter O +
of O +
the O +
parasympathetic O +
nervous O +
system O -
, O +
causing O +
bronchoconstriction O +
and O +
mucus O +
secretion O +
in O +
asthma O +
and O +
COPD O +
by O +
muscarinic O +
receptor O +
activation O +
on O +
airway O +
smooth O +
muscle O +
and O +
mucus O -
- O -
producing O +
cells O -
. O +

Recent O +
studies O +
in O +
experimental O +
models O +
indicate O +
that O +
muscarinic O +
receptor O +
stimulation O +
in O +
the O +
airways O +
also O +
induces O +
pro O -
- O -
inflammatory O -
, O +
pro O -
- O -
proliferative O +
and O +
pro O -
- O -
fibrotic O +
effects O -
, O +
which O +
may O +
involve O +
activation O +
of O +
airway O +
structural O +
and O +
inflammatory O +
cells O +
by O +
neuronal O +
as O +
well O +
as O +
non O -
- O -
neuronal O +
acetylcholine B-Chemical -
. O +

In O +
addition O -
, O +
mechanical O +
changes O +
caused O +
by O +
muscarinic O +
agonist O -
- O -
induced O +
bronchoconstriction O +
may O +
be O +
involved O +
in O +
airway O +
remodeling O -
. O +

Crosstalk O +
between O +
muscarinic O +
receptors O +
and O +
β2-adrenoceptors O +
on O +
airway O +
smooth O +
muscle O +
causes O +
a O +
reduced O +
bronchodilator O +
response O +
to O +
β2-agonists O -
, O +
and O +
a O +
similar O +
mechanism O +
could O +
possibly O +
apply O +
to O +
the O +
poor O +
inhibition O +
of O +
inflammatory O +
and O +
remodeling O +
processes O +
by O +
these O +
drugs O -
. O +

Collectively O -
, O +
these O +
findings O +
provide O +
novel O +
perspectives O +
for O +
muscarinic O +
receptor O +
antagonists O +
in O +
asthma O +
and O +
COPD O -
, O +
since O +
these O +
drugs O +
may O +
not O +
only O +
acutely O +
affect O +
cholinergic O +
airways O +
obstruction O -
, O +
but O +
also O +
have O +
important O +
beneficial O +
effects O +
on O +
β2-agonist O +
responsiveness O -
, O +
airway O +
inflammation O +
and O +
remodeling O -
. O +

The O +
clinical O +
relevance O +
of O +
these O +
findings O +
is O +
presently O +
under O +
investigation O +
and O +
starting O +
to O +
emerge O -
. O +

Enhanced O +
excitability O +
in O +
the O +
infralimbic O +
cortex O +
produces O +
anxiety O -
- O -
like O +
behaviors O -
. O +

The O +
medial O +
prefrontal O +
cortex O +
( O -
mPFC O -
) O +
has O +
been O +
implicated O +
in O +
modulating O +
anxiety O -
. O +

However O -
, O +
it O +
is O +
unknown O +
whether O +
excitatory O +
or O +
inhibitory O +
neurotransmission O +
in O +
the O +
infralimbic O +
( O -
IL O -
) O +
subregion O +
of O +
the O +
mPFC O +
underlies O +
the O +
pathology O +
of O +
anxiety O -
- O -
related O +
behavior O -
. O +

To O +
address O +
this O +
issue O -
, O +
we O +
infused O +
the O +
GABAA O +
receptor O +
( O -
GABAAR O -
) O +
antagonist O +
bicuculline B-Chemical +
to O +
temporarily O +
activate O +
the O +
IL O +
cortex O -
. O +

IL O +
cortex O +
activation O +
decreased O +
the O +
time O +
spent O +
in O +
the O +
center O +
area O +
in O +
the O +
open O +
field O +
test O -
, O +
decreased O +
exploration O +
of O +
the O +
open O -
- O -
arms O +
in O +
the O +
elevated O +
plus O +
maze O +
test O -
, O +
and O +
increased O +
the O +
latency O +
to O +
bite O +
food O +
in O +
the O +
novelty O -
- O -
suppressed O +
feeding O +
test O -
. O +

These O +
findings O +
substantiate O +
the O +
GABAergic B-Chemical +
system O -
's O +
role O +
in O +
anxiety O -
- O -
related O +
behaviors O -
. O +

IL O +
cortex O +
inactivation O +
with O +
the O +
AMPA B-Chemical +
receptor O +
( O -
AMPAR O -
) O +
antagonist O +
CNQX O +
produced O +
opposite O -
, O +
anxiolytic O +
effects O -
. O +

However O -
, O +
infusion O +
of O +
the O +
NMDA B-Chemical +
receptor O +
( O -
NMDAR O -
) O +
antagonist O +
AP5 O +
into O +
the O +
IL O +
cortex O +
had O +
no O +
significant O +
effect O -
. O +

Additionally O -
, O +
we O +
did O +
not O +
observe O +
motor O +
activity O +
deficits O +
or O +
appetite O +
deficits O +
following O +
inhibition O +
of O +
GABAergic B-Chemical +
or O +
glutamatergic O +
neurotransmission O -
. O +

Interestingly O -
, O +
we O +
found O +
parallel O +
and O +
corresponding O +
electrophysiological O +
changes O +
in O +
anxious O +
mice O -
; O +
compared O +
to O +
mice O +
with O +
relatively O +
low O +
anxiety O -
, O +
the O +
relatively O +
high O +
anxiety O +
mice O +
exhibited O +
smaller O +
evoked O +
inhibitory O +
postsynaptic O +
currents O +
( O -
eIPSCs O -
) O +
and O +
larger O +
AMPA B-Chemical -
- O -
mediated O +
evoked O +
excitatory O +
postsynaptic O +
currents O +
( O -
eEPSCs O -
) O +
in O +
pyramidal O +
neurons O +
in O +
the O +
IL O +
cortex O -
. O +

The O +
changes O +
of O +
eIPSCs O +
and O +
eEPSCs O +
were O +
due O +
to O +
presynaptic O +
mechanisms O -
. O +

Our O +
results O +
suggest O +
that O +
imbalances O +
of O +
neurotransmission O +
in O +
the O +
IL O +
cortex O +
may O +
cause O +
a O +
net O +
increase O +
in O +
excitatory O +
inputs O +
onto O +
pyramidal O +
neurons O -
, O +
which O +
may O +
underlie O +
the O +
pathogenic O +
mechanism O +
of O +
anxiety O +
disorders O -
. O +

Haloperidol B-Chemical +
promotes O +
mTORC1-dependent O +
phosphorylation O +
of O +
ribosomal O +
protein O +
S6 O +
via O +
dopamine- B-Chemical +
and O +
cAMP B-Chemical -
- O -
regulated O +
phosphoprotein O +
of O +
32 O +
kDa O +
and O +
inhibition O +
of O +
protein O +
phosphatase-1 O -
. O +

The O +
ribosomal O +
protein O +
S6 O +
( O -
rpS6 O -
) O +
is O +
a O +
component O +
of O +
the O +
small O +
40S O +
ribosomal O +
subunit O -
, O +
involved O +
in O +
multiple O +
physiological O +
functions O -
. O +

Here O -
, O +
we O +
examined O +
the O +
effects O +
produced O +
by O +
haloperidol B-Chemical -
, O +
a O +
typical O +
antipsychotic O +
drug O -
, O +
on O +
the O +
phosphorylation O +
of O +
rpS6 O +
at O +
Ser240 B-Chemical -
/ O -
244 O +
in O +
the O +
striatum O -
, O +
a O +
brain O +
region O +
involved O +
in O +
neurodegenerative O +
and O +
neuropsychiatric O +
disorders O -
. O +

Administration O +
of O +
haloperidol B-Chemical +
increased O +
Ser240 B-Chemical -
/ O -
244 O +
phosphorylation O +
in O +
a O +
subpopulation O +
of O +
GABA B-Chemical -
- O -
ergic O +
medium O +
spiny O +
neurons O +
( O -
MSNs O -
) O -
, O +
which O +
express O +
dopamine B-Chemical +
D2 O +
receptors O +
( O -
D2Rs O -
) O -
. O +

This O +
effect O +
was O +
prevented O +
by O +
rapamycin B-Chemical -
, O +
an O +
inhibitor O +
of O +
the O +
mammalian O +
target O +
of O +
rapamycin B-Chemical +
complex O +
1 O +
( O -
mTORC1 O -
) O -
, O +
or O +
by O +
PF470867 B-Chemical -
, O +
a O +
selective O +
inhibitor O +
of O +
the O +
p70 O +
ribosomal O +
S6 O +
kinase O +
1 O +
( O -
S6K1 O -
) O -
. O +

We O +
also O +
found O +
that O +
the O +
effect O +
of O +
haloperidol B-Chemical +
on O +
Ser240 B-Chemical -
/ O -
244 O +
phosphorylation O +
was O +
prevented O +
by O +
functional O +
inactivation O +
of O +
dopamine- B-Chemical +
and O +
cAMP B-Chemical -
- O -
regulated O +
phosphoprotein O +
of O +
32 O +
kDa O +
( O -
DARPP-32 O -
) O -
, O +
an O +
endogenous O +
inhibitor O +
of O +
protein O +
phosphatase-1 O +
( O -
PP-1 O -
) O -
. O +

In O +
line O +
with O +
this O +
observation O -
, O +
incubation O +
of O +
striatal O +
slices O +
with O +
okadaic B-Chemical +
acid I-Chemical +
and O +
calyculin B-Chemical +
A I-Chemical -
, O +
two O +
inhibitors O +
of O +
PP-1 O -
, O +
increased O +
Ser240 B-Chemical -
/ O -
244 O +
phosphorylation O -
. O +

These O +
results O +
show O +
that O +
haloperidol B-Chemical +
promotes O +
mTORC1- O +
and O +
S6K1-dependent O +
phosphorylation O +
of O +
rpS6 O +
at O +
Ser240 B-Chemical -
/ O -
244 O -
, O +
in O +
a O +
subpopulation O +
of O +
striatal O +
MSNs O +
expressing O +
D2Rs O -
. O +

They O +
also O +
indicate O +
that O +
this O +
effect O +
is O +
exerted O +
by O +
suppressing O +
dephosphorylation O +
at O +
Ser240 B-Chemical -
/ O -
244 O -
, O +
through O +
PKA O -
- O -
dependent O +
activation O +
of O +
DARPP-32 O +
and O +
inhibition O +
of O +
PP-1 O -
. O +

Arylpiperazine B-Chemical -
- O -
mediated O +
activation O +
of O +
Akt O +
protects O +
SH O -
- O -
SY5Y O +
neuroblastoma O +
cells O +
from O +
6-hydroxydopamine B-Chemical -
- O -
induced O +
apoptotic O +
and O +
autophagic O +
death O -
. O +

We O +
investigated O +
the O +
ability O +
of O +
19 O +
recently O +
synthesized O +
arylpiperazine B-Chemical +
compounds O +
to O +
protect O +
human O +
SH O -
- O -
SY5Y O +
neuroblastoma O +
cells O +
from O +
the O +
neurotoxin O +
6-hydroxydopamine B-Chemical +
( O -
6-OHDA B-Chemical -
) O -
. O +

The O +
compound O +
with O +
the O +
most O +
potent O +
neuroprotective O +
action O +
was O +
N- B-Chemical -
{ I-Chemical -
3- I-Chemical -
[ I-Chemical -
2- I-Chemical -
( I-Chemical -
4-phenyl I-Chemical -
- I-Chemical -
piperazin-1-yl I-Chemical -
) I-Chemical -
-ethyl I-Chemical -
] I-Chemical -
-phenyl I-Chemical -
} I-Chemical -
-picolinamide I-Chemical +
( O -
6b O -
) O -
, O +
which O +
reduced O +
6-OHDA B-Chemical -
- O -
induced O +
apoptotic O +
death O +
through O +
stabilization O +
of O +
mitochondrial O +
membrane O +
and O +
subsequent O +
prevention O +
of O +
superoxide B-Chemical +
production O -
, O +
caspase O +
activation O +
and O +
DNA O +
fragmentation O -
. O +

6-OHDA B-Chemical -
- O -
triggered O +
autophagic O +
response O +
was O +
also O +
reduced O +
by O +
6b O -
, O +
which O +
prevented O +
inactivation O +
of O +
the O +
main O +
autophagy O +
repressor O +
mTOR O -
, O +
upregulation O +
of O +
pro O -
- O -
autophagic O +
beclin-1 O -
, O +
conversion O +
of O +
microtubule O -
- O -
associated O +
protein O +
1 O +
light O +
chain O +
3 O +
( O -
LC3 O -
) O -
-I O +
to O +
autophagosome O -
- O -
associated O +
LC3-II O -
, O +
as O +
well O +
as O +
intracytoplasmic O +
acidification O +
induced O +
by O +
6-OHDA B-Chemical -
. O +

The O +
inhibition O +
of O +
autophagy O +
using O +
LC3β O +
gene O +
silencing O +
or O +
pharmacological O +
autophagy O +
blockers O +
3-methyladenine B-Chemical +
or O +
bafilomycin B-Chemical +
A1 I-Chemical -
, O +
mimicked O +
the O +
cytoprotective O +
effect O +
of O +
6b O -
. O +

While O +
the O +
treatment O +
with O +
6b O +
had O +
no O +
effect O +
on O +
the O +
phosphorylation O +
of O +
proapoptotic O +
MAP O +
kinases O +
ERK O +
and O +
JNK O -
, O +
it O +
markedly O +
increased O +
the O +
phosphorylation O +
of O +
the O +
prosurvival O +
kinase O +
Akt O +
in O +
6-OHDA B-Chemical -
- O -
treated O +
cells O -
. O +

Akt O +
inhibitor O +
DEBC O +
or O +
RNA O +
interference O -
- O -
mediated O +
Akt O +
silencing O +
reduced O +
the O +
ability O +
of O +
6b O +
to O +
block O +
6-OHDA B-Chemical -
- O -
triggered O +
apoptotic O +
and O +
autophagic O +
responses O -
, O +
thus O +
confirming O +
their O +
dependency O +
on O +
Akt O +
activation O -
. O +

The O +
cytoprotective O +
effect O +
of O +
6b O +
was O +
also O +
observed O +
in O +
6-OHDA B-Chemical -
- O -
treated O +
neuronal O +
PC12 O +
cells O -
, O +
but O +
not O +
in O +
SH O -
- O -
SY5Y O +
or O +
PC12 O +
cells O +
exposed O +
to O +
1-methyl-4-phenylpyridinium B-Chemical -
, O +
indicating O +
that O +
the O +
observed O +
neuroprotection O +
was O +
dependent O +
on O +
the O +
cytotoxic O +
stimulus O -
. O +

Because O +
of O +
the O +
ability O +
to O +
prevent O +
6-OHDA B-Chemical +
induced O +
apoptotic O -
/ O -
autophagic O +
cell O +
death O +
through O +
activation O +
of O +
Akt O -
, O +
the O +
investigated O +
arylpiperazines B-Chemical +
could O +
be O +
potential O +
candidates O +
for O +
treatment O +
of O +
neurodegenerative O +
diseases O -
. O +

The O +
fatty B-Chemical +
acid I-Chemical +
amide I-Chemical +
hydrolase O +
inhibitor O -
, O +
URB597 B-Chemical -
, O +
promotes O +
retinal B-Chemical +
ganglion O +
cell O +
neuroprotection O +
in O +
a O +
rat O +
model O +
of O +
optic O +
nerve O +
axotomy O -
. O +

The O +
endocannabinoid O -
, O +
N B-Chemical -
- I-Chemical -
arachidonoylethanolamine I-Chemical +
( O -
AEA B-Chemical -
) O -
, O +
is O +
degraded O +
by O +
the O +
enzyme O +
fatty B-Chemical +
acid I-Chemical +
amide I-Chemical +
hydrolase O +
( O -
FAAH O -
) O -
. O +

This O +
study O +
examined O +
whether O +
the O +
FAAH O +
inhibitor O -
, O +
URB597 O -
, O +
increases O +
retinal B-Chemical +
ganglion O +
cell O +
( O -
RGC O -
) O +
survival O +
following O +
optic O +
nerve O +
axotomy O +
in O +
young O +
and O +
aged O +
animals O -
. O +

URB597 B-Chemical +
alone O -
, O +
or O +
together O +
with O +
either O +
a O +
CB1 O +
or O +
CB2 O +
receptor O +
antagonist O -
, O +
was O +
administered O +
daily O +
for O +
1 O +
or O +
2 O +
weeks O +
post O -
- O -
axotomy O -
. O +

Histological O +
assessment O +
of O +
retinas O +
indicated O +
that O +
URB597 B-Chemical +
increased O +
RGC O +
survival O +
in O +
young O +
retina O +
at O +
1 O +
and O +
2 O +
weeks O +
post O -
- O -
axotomy O -
. O +

The O +
increase O +
in O +
RGC O +
survival O +
at O +
2 O +
weeks O +
was O +
accompanied O +
by O +
a O +
reduction O +
in O +
phagocytic O +
microglia O -
. O +

The O +
CB1 O +
antagonist O -
, O +
AM281 B-Chemical -
, O +
but O +
not O +
the O +
CB2 O +
antagonist O -
, O +
AM630 B-Chemical -
, O +
ablated O +
URB597-mediated B-Chemical +
RGC O +
neuroprotection O -
. O +

CB1 O +
or O +
CB2 O +
antagonism O +
increased O +
phagocytic O +
microglia O +
in O +
URB597 B-Chemical +
and O +
vehicle O -
- O -
treated O +
animals O -
. O +

In O +
aged O +
animals O -
, O +
URB597 B-Chemical +
increased O +
RGC O +
survival O +
at O +
1 O +
week O -
, O +
but O +
not O +
at O +
2 O +
weeks O +
post O -
- O -
axotomy O +
and O +
had O +
no O +
effect O +
on O +
microglia O -
. O +

Retinal B-Chemical +
Iba-1 O +
positive O +
microglia O +
were O +
also O +
decreased O +
in O +
URB597-treated B-Chemical +
axotomized O +
young O +
animals O +
and O +
this O +
decrease O +
was O +
mitigated O +
by O +
CB1 O +
but O +
not O +
CB2 O +
antagonism O -
. O +

As O +
seen O +
with O +
phagocytotic O +
microglia O -
, O +
the O +
CB2 O +
antagonist O -
, O +
AM630 B-Chemical -
, O +
increased O +
Iba-1 O +
positive O +
microglia O +
in O +
the O +
absence O +
of O +
URB597 B-Chemical +
treatment O -
. O +

Measurement O +
of O +
retinal B-Chemical +
endocannabinoid O +
levels O +
in O +
URB597-treated B-Chemical +
animals O +
at O +
2 O +
weeks O +
post O -
- O -
axotomy O +
revealed O +
a O +
significant O +
increase O +
in O +
AEA B-Chemical +
levels O -
, O +
accompanied O +
by O +
a O +
decrease O +
by O +
a O +
decrease O +
in O +
the O +
AEA B-Chemical +
metabolite O -
, O +
N B-Chemical -
- I-Chemical -
arachidonoylglycine I-Chemical -
, O +
in O +
young O +
animals O +
but O +
not O +
aged O +
animals O -
. O +

2-arachidonoylglycerol B-Chemical +
levels O +
were O +
similar O +
across O +
all O +
experimental O +
groups O -
. O +

These O +
data O +
demonstrate O +
that O +
URB597-mediated B-Chemical +
retinal B-Chemical +
neuroprotective O +
effects O +
are O +
mediated O +
primarily O +
through O +
CB1 O +
receptors O +
and O +
that O +
URB597 B-Chemical +
neuroprotective O +
efficacy O +
declines O +
with O +
age O -
. O +

Differential O +
Effects O +
of O +
Cholinergic O +
and O +
Noradrenergic O +
Neuromodulation O +
on O +
Spontaneous O +
Cortical O +
Network O +
Dynamics O -
. O +

Cholinergic O +
and O +
noradrenergic O +
neuromodulation O +
play O +
a O +
key O +
role O +
in O +
determining O +
overall O +
behavioral O +
state O +
by O +
shaping O +
the O +
underlying O +
cortical O +
network O +
dynamics O -
. O +

The O +
effects O +
of O +
these O +
systems O +
on O +
synaptic O +
and O +
intrinsic O +
cellular O +
targets O +
are O +
quite O +
diverse O +
and O +
a O +
comprehensive O +
understanding O +
of O +
how O +
these O +
neuromodulators O +
regulate O +
( O -
spontaneous O -
) O +
cortical O +
network O +
activity O +
has O +
remained O +
elusive O -
. O +

Here O -
, O +
we O +
used O +
multielectrode O +
electrophysiology O +
in O +
vitro O +
to O +
investigate O +
the O +
effect O +
of O +
these O +
neuromodulators O +
on O +
spontaneous O +
network O +
dynamics O +
in O +
acute O +
slices O +
of O +
mouse O +
visual O +
cortex O -
. O +

We O +
found O +
that O +
application O +
of O +
Carbachol B-Chemical +
( O -
CCh B-Chemical -
) O +
and O +
Norepinephrine B-Chemical +
( O -
NE O -
) O +
both O +
enhanced O +
the O +
spontaneous O +
network O +
dynamics O +
by O +
increasing O +
( O -
1 O -
) O +
the O +
activity O +
levels O -
, O +
( O -
2 O -
) O +
the O +
temporal O +
complexity O +
of O +
the O +
network O +
activity O -
, O +
and O +
( O -
3 O -
) O +
the O +
spatial O +
complexity O +
by O +
decorrelating O +
the O +
network O +
activity O +
over O +
a O +
wide O +
range O +
of O +
neuromodulator O +
concentrations O +
( O -
1μM O -
, O +
10μM O -
, O +
50μM O -
, O +
and O +
100μM O -
) O -
. O +

Interestingly O -
, O +
we O +
found O +
that O +
cholinergic O +
neuromodulation O +
was O +
limited O +
to O +
the O +
presence O +
of O +
CCh B-Chemical +
in O +
the O +
bath O +
whereas O +
the O +
effects O +
of O +
NE O -
, O +
in O +
particular O +
for O +
higher O +
concentrations O -
, O +
induced O +
plasticity O +
that O +
caused O +
outlasting O +
effects O +
most O +
prominently O +
in O +
the O +
deep O +
cortical O +
layers O -
. O +

Together O -
, O +
these O +
results O +
provide O +
a O +
comprehensive O +
network O -
- O -
level O +
understanding O +
of O +
the O +
similarities O +
and O +
differences O +
of O +
cholinergic O +
and O +
noradrenergic O +
modulation O +
of O +
spontaneous O +
network O +
dynamics O -
. O +

Assessment O +
of O +
subjective O +
cognitive O +
and O +
emotional O +
effects O +
of O +
antipsychotic O +
drugs O -
. O +

Effect O +
by O +
defect O -
? O +

Antipsychotic O +
medication O +
represents O +
the O +
first O -
- O -
line O +
treatment O +
of O +
schizophrenia O -
. O +

While O +
it O +
is O +
undisputed O +
that O +
antipsychotics O +
ameliorate O +
positive O +
symptoms O -
, O +
the O +
exact O +
cognitive O +
and O +
emotional O +
pathways O +
through O +
which O +
its O +
effect O +
is O +
exerted O +
has O +
remained O +
unclear O -
. O +

The O +
present O +
study O +
investigated O +
the O +
subjective O +
effects O +
of O +
antipsychotics O +
across O +
various O +
domains O +
of O +
cognition O +
and O +
emotion O +
in O +
both O +
patients O +
with O +
psychotic O +
symptoms O +
and O +
patients O +
with O +
other O +
psychiatric O +
diagnoses O -
. O +

A O +
total O +
of O +
69 O +
patients O +
with O +
a O +
probable O +
history O +
of O +
psychosis O +
or O +
psychotic O +
symptoms O +
and O +
26 O +
patients O +
with O +
psychiatric O +
diagnoses O +
other O +
than O +
psychosis O +
participated O +
in O +
a O +
survey O +
conducted O +
over O +
the O +
Internet O -
. O +

Multiple O +
control O +
measures O +
aimed O +
to O +
secure O +
response O +
validity O -
. O +

All O +
patients O +
were O +
currently O +
or O +
had O +
previously O +
been O +
treated O +
with O +
antipsychotic O +
agents O -
. O +

A O +
questionnaire O +
comprising O +
49 O +
items O +
and O +
measuring O +
possible O +
effects O +
of O +
antipsychotics O +
on O +
cognition O +
and O +
emotion O +
was O +
administered O -
. O +

For O +
30 O +
out O +
of O +
49 O +
items O +
a O +
clear O +
response O +
pattern O +
emerged O -
, O +
which O +
was O +
similar O +
for O +
patients O +
with O +
psychotic O +
disorders O +
and O +
patients O +
with O +
other O +
diagnoses O -
. O +

Factor O +
analysis O +
of O +
these O +
items O +
revealed O +
three O +
main O +
effects O +
of O +
antipsychotic O +
medication O +
related O +
to O +
doubt O +
and O +
self O -
- O -
doubt O -
, O +
cognitive O +
and O +
emotional O +
numbing O -
, O +
and O +
social O +
withdrawal O -
. O +

Antipsychotic O +
treatment O +
appears O +
to O +
be O +
connected O +
to O +
a O +
number O +
of O +
negative O +
subjective O +
effects O +
on O +
cognition O +
and O +
emotion O -
. O +

Further O +
studies O +
are O +
warranted O +
to O +
assess O +
how O +
these O +
effects O +
impact O +
on O +
the O +
patients O -
' O +
subjective O +
well O -
- O -
being O +
and O +
quality O +
of O +
life O -
, O +
as O +
well O +
as O +
their O +
association O +
with O +
antipsychotic O +
efficacy O +
on O +
the O +
one O +
hand O -
, O +
and O +
adherence O +
rates O +
on O +
the O +
other O -
. O +

The O +
induction O +
of O +
doubt O +
and O +
the O +
dampening O +
of O +
emotion O +
may O +
be O +
one O +
reason O +
why O +
antipsychotics O +
work O +
and O +
at O +
the O +
same O +
time O +
offer O +
an O +
explanation O +
why O +
they O +
are O +
experienced O +
as O +
rather O +
unpleasant O +
and O +
are O +
eventually O +
discontinued O +
by O +
many O +
patients O -
. O +

Controlling O +
the O +
Physical O +
form O +
of O +
Mannitol B-Chemical +
in O +
Freeze O -
- O -
Dried O +
Systems O -
. O +

A O +
potential O +
drawback O +
with O +
the O +
use O +
of O +
mannitol B-Chemical +
as O +
a O +
bulking O +
agent O +
is O +
its O +
existence O +
as O +
mannitol B-Chemical +
hemihydrate I-Chemical +
( O -
MHH B-Chemical -
; O +
C6H14O6 B-Chemical -
( I-Chemical -
. I-Chemical -
) I-Chemical -
0.5H2O I-Chemical -
) O +
in O +
the O +
lyophile O -
. O +

Once O +
formed O +
during O +
freeze O -
- O -
drying O -
, O +
MHH B-Chemical +
dehydration O +
may O +
require O +
secondary O +
drying O +
under O +
aggressive O +
conditions O +
which O +
can O +
be O +
detrimental O +
to O +
the O +
stability O +
of O +
thermolabile O +
components O -
. O +

If O +
MHH B-Chemical +
is O +
retained O +
in O +
the O +
lyophile O -
, O +
the O +
water O +
released O +
by O +
MHH B-Chemical +
dehydration O +
during O +
storage O +
has O +
the O +
potential O +
to O +
cause O +
product O +
instability O -
. O +

We O +
systematically O +
identified O +
the O +
conditions O +
under O +
which O +
anhydrous O +
mannitol B-Chemical +
and O +
MHH B-Chemical +
crystallized O +
in O +
frozen O +
systems O +
with O +
the O +
goal O +
of O +
preventing O +
MHH B-Chemical +
formation O +
during O +
freeze O -
- O -
drying O -
. O +

When O +
mannitol B-Chemical +
solutions O +
were O +
cooled O -
, O +
the O +
temperature O +
of O +
solute O +
crystallization O +
was O +
the O +
determinant O +
of O +
the O +
physical O +
form O +
of O +
mannitol B-Chemical -
. O +

Based O +
on O +
low O +
temperature O +
X O -
- O -
ray O +
diffractometry O +
( O -
using O +
both O +
laboratory O +
and O +
synchrotron O +
sources O -
) O -
, O +
MHH B-Chemical +
formation O +
was O +
observed O +
when O +
solute O +
crystallization O +
occurred O +
at O +
temperatures O +
⩽ O +
-20 O +
° O -
C O +
while O +
anhydrous O +
mannitol B-Chemical +
crystallized O +
at O +
temperatures O +
⩾ O +
-10 O +
° O -
C O -
. O +

The O +
transition O +
temperature O +
( O -
anhydrate O +
- O +
MHH B-Chemical -
) O +
appears O +
to O +
be O +
∼ O +
-15 O +
° O -
C O -
. O +

The O +
use O +
of O +
a O +
freeze O -
- O -
dryer O +
with O +
controlled O +
ice O +
nucleation O +
technology O +
enabled O +
anhydrous O +
mannitol B-Chemical +
crystallization O +
at O +
∼ O +
-5 O +
° O -
C O -
. O +

Thus O -
, O +
ice O +
crystallization O +
followed O +
by O +
annealing O +
at O +
temperatures O +
⩾ O +
-10 O +
° O -
C O +
can O +
be O +
an O +
effective O +
strategy O +
to O +
prevent O +
MHH B-Chemical +
formation O -
. O +

Investigation O +
on O +
the O +
interaction O +
of O +
the O +
toxicant O -
, O +
gentian B-Chemical +
violet I-Chemical -
, O +
with O +
bovine O +
hemoglobin O -
. O +

Gentian B-Chemical +
violet I-Chemical +
( O -
GV O -
) O +
is O +
a O +
well O -
- O -
known O +
triarylmethane B-Chemical +
dye O +
that O +
is O +
used O +
in O +
aquacultural O -
, O +
industrial O +
and O +
medicinal O +
fields O -
. O +

But O +
concerns O +
in O +
growing O +
number O +
have O +
been O +
paid O +
to O +
its O +
potential O +
health O +
problems O +
to O +
human O +
beings O +
and O +
its O +
hazardous O +
effects O +
to O +
environment O -
. O +

Herein O -
, O +
the O +
toxic O +
interaction O +
of O +
GV O +
with O +
bovine O +
hemoglobin O +
( O -
BHb O -
) O +
was O +
investigated O +
by O +
a O +
series O +
of O +
spectroscopic O +
methods O +
and O +
molecular O +
modeling O +
method O -
. O +

The O +
fluorescence O +
emission O +
profile O +
exhibited O +
a O +
remarkable O +
quenching O +
upon O +
addition O +
of O +
GV O +
to O +
the O +
buffered O +
aqueous O +
solution O +
of O +
BHb O +
and O +
the O +
analysis O +
of O +
results O +
revealed O +
the O +
dominant O +
role O +
of O +
static O +
quenching O +
mechanism O +
in O +
GV O -
- O -
BHb O +
interaction O -
. O +

The O +
negative O +
ΔH O +
and O +
positive O +
ΔS O +
values O +
demonstrated O +
that O +
the O +
electrostatic O +
interactions O +
mainly O +
stabilized O +
this O +
toxicant O -
- O -
protein O +
complex O -
. O +

Synchronous O +
fluorescence O -
, O +
UV O -
- O -
vis O +
absorption O +
and O +
CD O +
spectroscopic O +
studies O +
proved O +
that O +
the O +
conformational O +
change O +
of O +
BHb O +
was O +
induced O +
by O +
GV O -
's O +
combination O -
. O +

Molecular O +
modeling O +
studies O +
exhibited O +
the O +
binding O +
mode O +
of O +
GV O -
- O -
BHb O +
complex O +
and O +
the O +
detailed O +
information O +
of O +
related O +
driving O +
forces O -
. O +

During O +
the O +
1H B-Chemical +
nuclear O +
magnetic O +
resonance O +
spectra O +
( O -
1H B-Chemical +
NMR O -
) O +
study O -
, O +
the O +
chemical O +
shift O +
perturbation O +
and O +
spin O -
- O -
lattice O +
relaxation O +
times O +
of O +
different O +
protons O +
were O +
further O +
used O +
to O +
investigate O +
the O +
interaction O +
of O +
GV O +
with O +
BHb O +
and O +
the O +
results O +
indicated O +
that O +
GV O +
bound O +
orientationally O +
to O +
BHb O -
. O +

Design O -
, O +
synthesis O +
and O +
antiproliferative O +
activity O +
studies O +
of O +
novel O +
1,2,3-triazole B-Chemical -
- I-Chemical -
dithiocarbamate I-Chemical -
- I-Chemical -
urea I-Chemical +
hybrids O -
. O +

A O +
series O +
of O +
novel O +
1,2,3-triazole B-Chemical -
- I-Chemical -
dithiocarbamate I-Chemical -
- I-Chemical -
urea I-Chemical +
hybrids O +
were O +
designed O -
, O +
synthesized O +
and O +
their O +
antiproliferative O +
activities O +
against O +
four O +
selected O +
human O +
cancer O +
cell O +
lines O +
were O +
evaluated O -
. O +

The O +
results O +
showed O +
that O +
a O +
number O +
of O +
the O +
hybrids O +
exhibited O +
potent O +
activity O +
in O +
selected O +
human O +
cancer O +
cell O +
lines O -
. O +

Among O +
them O -
, O +
compounds O +
27 O +
and O +
34 O +
showed O +
broad O +
spectrum O +
anticancer O +
activity O +
with O +
IC50 O +
values O +
ranging O +
from O +
1.62 O +
to O +
20.84 O +
μM O +
and O +
0.76 O +
to O +
13.55 O +
μM O -
, O +
respectively O -
. O +

Interestingly O -
, O +
compounds O +
27 O +
and O +
34 O -
, O +
being O +
very O +
potent O +
against O +
MGC-803 O +
cells O -
, O +
exhibited O +
no O +
significant O +
cytotoxicity O +
against O +
normal O +
human O +
embryonic O +
kidney O +
cells O +
at O +
up O +
to O +
55 O +
μM O +
and O +
70 O +
μM O -
, O +
respectively O -
. O +

Evidences O +
of O +
cell O +
cycle O +
arrest O +
and O +
apoptosis O +
induction O +
were O +
obtained O +
for O +
the O +
most O +
effective O +
compounds O +
27 O +
and O +
34 O +
by O +
means O +
of O +
flow O +
cytometry O +
and O +
microscopic O +
techniques O -
. O +

Elucidation O +
of O +
the O +
pharmacophore O +
of O +
echinocystic B-Chemical +
acid I-Chemical -
, O +
a O +
new O +
lead O +
for O +
blocking O +
HCV O +
entry O -
. O +

To O +
elucidate O +
the O +
pharmacophore O +
of O +
echinocystic B-Chemical +
acid I-Chemical +
( O -
EA O -
) O -
, O +
an O +
oleanane B-Chemical -
- O -
type O +
triterpene B-Chemical +
displaying O +
substantial O +
inhibitory O +
activity O +
on O +
HCV O +
entry O -
, O +
two O +
microbial O +
strains O -
, O +
Rhizopus O +
chinensis O +
CICC O +
3043 O +
and O +
Alternaria O +
alternata O +
AS O +
3.4578 O -
, O +
were O +
utilized O +
to O +
modify O +
the O +
chemical O +
structure O +
of O +
EA O -
. O +

Eight O +
new O +
metabolites O +
with O +
regio- O +
and O +
stereo O -
- O -
selective O +
introduction O +
of O +
hydroxyl B-Chemical +
and O +
lactone B-Chemical +
groups O +
at O +
various O +
inert O +
carbon B-Chemical +
positions O +
were O +
obtained O -
. O +

The O +
anti O -
- O -
HCV O +
entry O +
activity O +
of O +
the O +
metabolites O +
2 O -
- O -
13 O -
, O +
along O +
with O +
their O +
parental O +
compound O +
EA O +
and O +
other O +
analogs O +
14 O -
- O -
15 O -
, O +
were O +
evaluated O -
. O +

Most O +
of O +
the O +
metabolites O +
showed O +
no O +
improvement O +
but O +
detrimental O +
effect O +
on O +
potency O +
except O +
compound O +
5 O +
and O +
6 O -
, O +
which O +
showed O +
similar O +
and O +
even O +
a O +
litter O +
higher O +
anti O -
- O -
HCV O +
entry O +
activity O +
than O +
that O +
of O +
EA O -
. O +

The O +
results O +
demonstrated O +
that O +
ring O +
A O -
, O +
B O -
, O +
C O +
and O +
the O +
left O +
side O +
of O +
ring O +
E O +
of O +
EA O +
are O +
highly O +
conserved O -
, O +
while O +
ring O +
D O +
and O +
the O +
right O +
side O +
of O +
ring O +
E O +
of O +
EA O +
are O +
flexible O -
. O +

Introduction O +
of O +
a O +
hydroxyl B-Chemical +
group O +
at O +
C-16 O +
enhanced O +
the O +
triterpene B-Chemical +
potency O -
. O +

Further O +
analysis O +
indicated O +
that O +
the O +
hemolytic O +
effect O +
of O +
EA O +
disappeared O +
upon O +
such O +
modifications O -
. O +

Ligand O -
- O -
based O +
design O -
, O +
synthesis O -
, O +
and O +
experimental O +
evaluation O +
of O +
novel O +
benzofuroxan B-Chemical +
derivatives O +
as O +
anti O -
- O -
Trypanosoma O +
cruzi O +
agents O -
. O +

A O +
set O +
of O +
substituted- O -
[ O -
N'- B-Chemical -
( I-Chemical -
benzofuroxan-5-yl I-Chemical -
) I-Chemical -
methylene I-Chemical -
] I-Chemical -
benzohydrazides I-Chemical +
( O -
4a O -
- O -
t O -
) O -
, O +
previously O +
designed O +
and O +
synthesized O -
, O +
was O +
experimentally O +
assayed O +
against O +
Trypanosoma O +
cruzi O -
, O +
the O +
etiological O +
agent O +
of O +
Chagas O -
' O +
disease O -
, O +
one O +
of O +
the O +
most O +
neglected O +
tropical O +
diseases O -
. O +

Exploratory O +
data O +
analysis O -
, O +
Hansch O +
approach O +
and O +
VolSurf O +
formalism O +
were O +
applied O +
to O +
aid O +
the O +
ligand O -
- O -
based O +
design O +
of O +
novel O +
anti O -
- O -
T. O +
cruzi O +
agents O -
. O +

The O +
best O +
2D O -
- O -
QSAR O +
model O +
showed O +
suitable O +
statistical O +
measures O +
[ O -
n O +
= O +
18 O -
; O +
s O +
= O +
0.11 O -
; O +
F O +
= O +
42.19 O -
; O +
R O -
( O -
2 O -
) O +
= O +
0.90 O +
and O +
Q O -
( O -
2 O -
) O +
= O +
0.77 O +
( O -
SDEP O +
= O +
0.15 O -
) O -
] O -
, O +
and O +
according O +
to O +
the O +
optimum O +
3D O -
- O -
QSAR O +
model O +
[ O -
R O -
( O -
2 O -
) O +
= O +
0.98 O -
, O +
Q O -
( O -
2 O -
) O +
= O +
0.93 O +
( O -
SDEP O +
= O +
0.08 O -
) O -
] O -
, O +
three O +
latent O +
variables O +
explained O +
62 O -
% O +
of O +
the O +
total O +
variance O +
from O +
original O +
data O -
. O +

Steric O +
and O +
hydrophobic O +
properties O +
were O +
pointed O +
out O +
as O +
the O +
key O +
for O +
biological O +
activity O -
. O +

Based O +
upon O +
the O +
findings O -
, O +
six O +
novel O +
benzofuroxan B-Chemical +
derivatives O +
( O -
4u O -
- O -
z O -
) O +
were O +
designed O -
, O +
synthesized O -
, O +
and O +
in O +
vitro O +
assayed O +
to O +
perform O +
the O +
QSAR O +
external O +
prediction O -
. O +

Then O -
, O +
the O +
predictability O +
for O +
the O +
both O +
models O -
, O +
2D O -
- O -
QSAR O +
( O -
Rpred O -
( O -
2 O -
) O +
= O +
0.91 O -
) O +
and O +
3D O -
- O -
QSAR O +
( O -
Rpred O -
( O -
2 O -
) O +
= O +
0.77 O -
) O -
, O +
was O +
experimentally O +
validated O -
, O +
and O +
compound O +
4u O +
was O +
identified O +
as O +
the O +
most O +
active O +
anti O -
- O -
T. O +
cruzi O +
hit O +
( O -
IC50 O +
= O +
3.04 O +
μM O -
) O -
. O +

N B-Chemical -
- I-Chemical -
Alkylated I-Chemical +
2,3,3-trimethylindolenines I-Chemical +
and O +
2-methylbenzothiazoles B-Chemical -
. O +

Potential O +
lead O +
compounds O +
in O +
the O +
fight O +
against O +
Saccharomyces O +
cerevisiae O +
infections O -
. O +

The O +
synthesis O +
of O +
a O +
variety O +
of O +
N B-Chemical -
- I-Chemical -
alkylated I-Chemical +
2,3,3-trimethylindolenines I-Chemical +
and O +
2-methylbenzothiazoles B-Chemical +
is O +
reported O +
herein O -
. O +

Their O +
potential O +
as O +
antifungal O +
agents O +
is O +
evaluated O +
by O +
preliminary O +
screening O +
against O +
Saccharomyces O +
cerevisiae O +
( O -
S. O +
cerevisiae O -
) O -
, O +
Schizosaccharomyces O +
pombe O +
( O -
S. O +
pombe O -
) O -
, O +
and O +
Candida O +
albicans O +
( O -
C. O +
albicans O -
) O -
. O +

Statistical O +
analyses O +
illustrate O +
a O +
strong O +
relationship O +
between O +
chain O +
length O +
and O +
growth O +
inhibition O +
for O +
S. O +
cerevisiae O +
and O +
S. O +
pombe O +
( O -
p O +
< O +
0.0001 O +
in O +
every O +
case O -
) O -
. O +

Of O +
particular O +
interest O +
is O +
the O +
activity O +
of O +
both O +
sets O +
of O +
compounds O +
against O +
S. O +
cerevisiae O -
, O +
as O +
this O +
is O +
emerging O +
as O +
an O +
opportunistic O +
pathogen O -
, O +
especially O +
in O +
immunosuppressed O +
and O +
immunocompromised O +
patients O -
. O +

Bioassays O +
were O +
set O +
up O +
to O +
compare O +
the O +
efficacy O +
of O +
our O +
range O +
of O +
N O -
- O -
alkylated O +
compounds O +
against O +
classic O +
antifungal O +
agents O -
; O +
Amphotericin B-Chemical +
B I-Chemical +
and O +
Thiabendazole B-Chemical -
. O +

Synthesis O +
and O +
biological O +
characterization O +
of O +
spiro B-Chemical -
[ I-Chemical -
2H- I-Chemical -
( I-Chemical -
1,3 I-Chemical -
) I-Chemical -
-benzoxazine-2,4'-piperidine I-Chemical -
] I-Chemical +
based O +
histone O +
deacetylase O +
inhibitors O -
. O +

Histone O +
Deacetylases O +
( O -
HDACs O -
) O +
have O +
become O +
important O +
targets O +
for O +
the O +
treatment O +
of O +
cancer O +
and O +
other O +
diseases O -
. O +

In O +
previous O +
studies O +
we O +
described O +
the O +
development O +
of O +
novel O +
spirocyclic O +
HDAC O +
inhibitors O +
based O +
on O +
the O +
combination O +
of O +
privileged O +
structures O +
with O +
hydroxamic B-Chemical +
acid I-Chemical +
moieties O +
as O +
zinc B-Chemical +
binding O +
group O -
. O +

Herein O -
, O +
we O +
report O +
further O +
explorations O -
, O +
which O +
resulted O +
in O +
the O +
discovery O +
of O +
a O +
new O +
class O +
of O +
spiro B-Chemical -
[ I-Chemical -
2H- I-Chemical -
( I-Chemical -
1,3 I-Chemical -
) I-Chemical -
-benzoxazine-2,4'-piperidine I-Chemical -
] I-Chemical +
derivatives O -
. O +

Several O +
compounds O +
showed O +
good O +
potency O +
of O +
around O +
100 O +
nM O +
and O +
less O +
in O +
the O +
HDAC O +
inhibition O +
assays O -
, O +
submicromolar O +
IC50 O +
values O +
when O +
tested O +
against O +
tumour O +
cell O +
lines O +
and O +
a O +
remarkable O +
stability O +
in O +
human O +
and O +
mouse O +
microsomes O -
. O +

Two O +
representative O +
examples O +
exhibited O +
a O +
good O +
pharmacokinetic O +
profile O +
with O +
an O +
oral O +
bioavailability O +
equal O +
or O +
higher O +
than O +
35 O -
% O +
and O +
one O +
of O +
them O +
studied O +
in O +
an O +
HCT116 O +
murine O +
xenograft O +
model O +
showing O +
a O +
robust O +
tumour O +
growth O +
inhibition O -
. O +

In O +
addition O -
, O +
the O +
two O +
benzoxazines B-Chemical +
were O +
found O +
to O +
have O +
a O +
minor O +
affinity O +
for O +
the O +
hERG O +
potassium B-Chemical +
channel O +
compared O +
to O +
their O +
corresponding O +
ketone B-Chemical +
analogues O -
. O +

Synthesis O +
and O +
in O +
vitro O +
anticancer O +
studies O +
of O +
novel O +
C-2 O +
arylidene O +
congeners O +
of O +
lantadenes B-Chemical -
. O +

The O +
antitumor O +
pentacyclic O +
triterpenoids O -
, O +
Lantadene B-Chemical +
A I-Chemical +
( I-Chemical -
1 I-Chemical -
) I-Chemical +
and I-Chemical +
B I-Chemical +
( O -
2 O -
) O +
were O +
isolated O +
from O +
the O +
leaves O +
of O +
weed O +
Lantana O +
camara O +
L. O +
( O -
Verbenaceae O -
) O +
and O +
were O +
structurally O +
transformed O +
to O +
bioactive O +
intermediates O +
3 O -
- O -
6 O -
. O +

The O +
Claisen O -
- O -
Schmidt O +
reaction O +
of O +
22β B-Chemical -
- I-Chemical -
hydroxy-3-oxoolean-12-en-28-oic I-Chemical +
acid I-Chemical +
( O -
5 O -
) O +
with O +
requisite O +
aldehydes B-Chemical +
afforded O +
2-arylidene-22β B-Chemical -
- I-Chemical -
hydroxy-3-oxoolean-12-en-28-oic I-Chemical +
acids I-Chemical +
( O -
7 O -
- O -
16 O -
) O -
. O +

The O +
compounds O +
were O +
evaluated O +
for O +
their O +
in O -
- O -
vitro O +
anticancer O +
activity O +
by O +
National O +
Cancer O +
Institute O +
( O -
NCI O -
) O -
, O +
USA O +
and O +
some O +
of O +
these O +
compounds O +
showed O +
marked O +
cytotoxicity O +
in O +
micromolar O +
range O -
. O +

The O +
mean O +
graph O +
midpoint O +
( O -
MG_MID O -
) O +
value O +
of O +
compound O +
3 O +
( O -
MG_MID O +
-5.69 O -
) O +
was O +
higher O +
than O +
standard O +
drug O +
cisplatin B-Chemical +
( O -
MG_MID O +
-5.66 O -
) O +
while O +
comparable O +
in O +
case O +
of O +
compound O +
12 O +
( O -
MG_MID O +
-5.52 O -
) O -
. O +

The O +
NCI O -
's O +
COMPARE O +
molecular O +
mechanistic O +
analysis O +
showed O +
that O +
these O +
compounds O +
were O +
in O +
significant O +
correlations O +
with O +
activity O +
patterns O +
of O +
mechanistic O +
set O +
of O +
compounds O +
( O -
PCC O +
≥ O +
0.60 O -
) O -
. O +

Low O +
molecular O +
weight O +
dual O +
inhibitors O +
of O +
factor O +
Xa O +
and O +
fibrinogen O +
binding O +
to O +
GPIIb O -
/ O -
IIIa O +
with O +
highly O +
overlapped O +
pharmacophores O -
. O +

Dual O +
antithrombotic O +
agents O +
acting O +
as O +
anticoagulants O +
and O +
aggregation O +
inhibitors O +
could O +
have O +
substantial O +
advantages O +
over O +
currently O +
prescribed O +
combinations O +
of O +
antithrombotic O +
drugs O -
. O +

Herein O -
, O +
we O +
report O +
compounds O +
with O +
moderate O +
inhibitory O +
activity O +
for O +
factor O +
Xa O +
and O +
fibrinogen O +
GPIIb O -
/ O -
IIIa O +
binding O +
( O -
both O +
in O +
the O +
micromolar O +
range O -
) O -
. O +

These O +
compounds O +
resulted O +
from O +
our O +
efforts O +
to O +
merge O +
the O +
pharmacophores O +
of O +
selective O +
factor O +
Xa O +
inhibitor O +
rivaroxaban B-Chemical +
with O +
a O +
mimic O +
of O +
the O +
Arg B-Chemical -
- I-Chemical -
Gly I-Chemical -
- I-Chemical -
Asp I-Chemical +
( O -
RGD O -
) O +
sequence O +
of O +
fibrinogen O +
to O +
obtain O +
designed O +
multiple O +
ligands O +
with O +
potential O +
antithrombotic O +
activity O -
. O +

Resulting O +
from O +
this O +
study O -
, O +
a O +
structurally O +
novel O +
class O +
of O +
submicromolar O +
fibrinogen O +
GPIIb O -
/ O -
IIIa O +
binding O +
inhibitor O +
bearing O +
1,2,4-oxadiazol-5 B-Chemical -
( I-Chemical -
4H I-Chemical -
) I-Chemical -
-one I-Chemical +
moiety O +
is O +
also O +
described O -
. O +

Synthesis O +
and O +
biological O +
evaluation O +
of O +
N- B-Chemical -
( I-Chemical -
4-hydroxy-3-mercaptonaphthalen-1-yl I-Chemical -
) I-Chemical -
amides I-Chemical +
as O +
inhibitors O +
of O +
angiogenesis O +
and O +
tumor O +
growth O -
. O +

A O +
series O +
of O +
N- B-Chemical -
( I-Chemical -
4-hydroxy-3-mercaptonaphthalen-1-yl I-Chemical -
) I-Chemical -
amides I-Chemical +
were O +
synthesized O +
and O +
investigated O +
for O +
their O +
in O +
vitro O +
antiangiogenic O +
activity O -
. O +

Among O +
these O +
compounds O -
, O +
6d O -
, O +
which O +
possesses O +
an O +
ortho B-Chemical -
- I-Chemical -
nitro I-Chemical +
group O +
at O +
the O +
benzene B-Chemical +
ring O -
, O +
exhibited O +
potent O +
inhibitory O +
effect O +
on O +
the O +
proliferation O +
of O +
HUVECs O -
, O +
A549 O -
, O +
K562 O -
, O +
PC-3 O -
, O +
HCT116 O -
, O +
MDA O -
- O -
MB-231 O +
and O +
MCF-7 O +
cells O +
( O -
IC50 O +
= O +
5.34 O -
, O +
40.53 O -
, O +
10.81 O -
, O +
52.52 O -
, O +
10.19 O -
, O +
21.37 O +
and O +
2.81 O +
μM O -
, O +
respectively O -
) O -
. O +

Meanwhile O -
, O +
compound O +
6d O +
inhibited O +
in O +
vitro O +
angiogenesis O +
markedly O +
in O +
both O +
HUVECs O +
tube O +
formation O +
assay O +
and O +
the O +
rat O +
thoracic O +
aorta O +
rings O +
test O -
. O +

Further O +
kinase O +
assay O +
study O +
showed O +
that O +
compound O +
6d O +
had O +
good O +
VEGFR2 O -
, O +
ALK O -
, O +
AKT1 O +
and O +
ABL O +
inhibitory O +
activities O +
and O +
moderate O +
EGFR O +
and O +
PDGFR O -
- O -
β O +
inhibitory O +
activities O -
. O +

The O +
data O +
supports O +
the O +
further O +
investigation O +
of O +
this O +
class O +
of O +
compounds O +
as O +
potential O +
antiangiogenic O +
and O +
anticancer O +
agents O -
. O +

Correction O -
: O +
Wiedmann O -
, O +
M. O -
, O +
et O +
al. O +
Exploration O +
of O +
the O +
Role O +
of O +
the O +
Non O -
- O -
Coding O +
RNA O +
SbrE O +
in O +
L. O +
monocytogenes O +
Stress O +
Response O -
. O +

Int O -
. O +

J. O +
Mol O -
. O +

Sci O -
. O +
2013 O -
, O +
14 O -
, O +
378 O -
- O -
393 O -
. O +

The O +
original O +
version O +
of O +
the O +
paper O +
in O +
Section O +
3.8 O +
reports O +
that O +
" O -
The O +
peptide O +
mass O +
tolerance O +
and O +
fragment O +
mass O +
tolerance O +
values O +
were O +
10 O +
ppm O +
and O +
30 O +
mDa O -
, O +
respectively O -
" O +
[ O -
1 O -
] O +
( O -
p. O +
387 O -
) O -
. O +

To O +
help O +
others O +
who O +
may O +
want O +
to O +
use O +
the O +
same O +
methods O +
in O +
the O +
future O -
, O +
the O +
authors O +
would O +
like O +
to O +
correct O +
the O +
wording O +
to O -
: O +
" O -
The O +
peptide O +
mass O +
tolerance O +
and O +
fragment O +
mass O +
tolerance O +
values O +
were O +
30 O +
ppm O +
and O +
0.15 O +
Da O -
, O +
respectively O -
. O +

In O +
order O +
to O +
decrease O +
the O +
probability O +
of O +
false O +
peptide O +
identification O -
, O +
only O +
peptides O +
with O +
significance O +
scores O +
above O +
the O +
identity O +
threshold O +
( O -
at O +
the O +
95 O -
% O +
confidence O +
interval O -
) O -
, O +
defined O +
by O +
Mascot O +
probability O +
analysis O +
( O -
www.matrixscience.com/help/scoring_help.html#PBM O -
) O -
, O +
were O +
considered O +
to O +
be O +
confidently O +
identified O +
and O +
used O +
for O +
protein O +
identification O -
. O +

Furthermore O -
, O +
only O +
proteins O +
identified O +
in O +
all O +
four O +
iTRAQ O +
samples O +
through O +
at O +
least O +
two O +
peptides O +
with O +
a O +
p O -
- O -
value O +
of O +
< O -
0.05 O +
( O -
expectation O +
value O -
) O +
were O +
further O +
analyzed O -
" O -
. O +

The O +
authors O +
would O +
like O +
to O +
apologize O +
for O +
any O +
inconvenience O +
this O +
may O +
have O +
caused O +
to O +
the O +
readers O +
of O +
this O +
journal O -
. O +

Cortical O +
excitability O +
in O +
smoking O +
and O +
not O +
smoking O +
individuals O +
with O +
and O +
without O +
nicotine B-Chemical -
. O +

RATIONAL O -
: O +
Activation O +
of O +
nicotinic O +
acetylcholine B-Chemical +
receptors O +
has O +
a O +
major O +
neuromodulatory O +
impact O +
on O +
central O +
nervous O +
system O +
function O -
. O +

Beyond O +
acute O +
activation O -
, O +
chronic O +
nicotine B-Chemical +
intake O +
has O +
long O -
- O -
lasting O +
effects O +
on O +
cortical O +
excitability O +
in O +
animal O +
experiments O -
, O +
caused O +
by O +
receptor O +
up- O +
or O +
down O -
- O -
regulation O -
. O +

Knowledge O +
about O +
the O +
impact O +
of O +
nicotine B-Chemical +
on O +
cortical O +
excitability O +
in O +
humans O -
, O +
however O -
, O +
is O +
limited O -
. O +

OBJECTIVES O -
: O +
We O +
therefore O +
aimed O +
to O +
explore O +
the O +
effect O +
of O +
nicotine B-Chemical +
intake O +
on O +
cortical O +
excitability O +
in O +
healthy O +
human O +
smokers O +
and O +
non O -
- O -
smokers O -
. O +

METHODS O -
: O +
The O +
primary O +
motor O +
cortex O +
served O +
as O +
model O -
, O +
and O +
cortical O +
excitability O +
was O +
monitored O +
via O +
transcranial O +
magnetic O +
stimulation O +
( O -
TMS O -
) O -
. O +

Corticospinal O +
excitability O +
and O +
intracortical O +
excitability O +
were O +
recorded O +
before O +
and O +
after O +
application O +
of O +
nicotine B-Chemical +
patch O +
in O +
both O +
groups O -
. O +

Corticospinal O +
excitability O +
was O +
explored O +
by O +
motor O +
threshold O +
and O +
input O -
/ O -
output O +
curve O +
( O -
I O -
/ O -
O O +
curve O -
) O -
, O +
and O +
intracortical O +
excitability O +
was O +
explored O +
by O +
means O +
of O +
paired O -
- O -
pulse O +
TMS O +
techniques O +
( O -
intracortical O +
facilitation O +
( O -
ICF O -
) O -
, O +
short O -
- O -
latency O +
intracortical O +
inhibition O +
( O -
SICI O -
) O -
, O +
I O -
- O -
wave O +
facilitation O +
and O +
short O -
- O -
latency O +
afferent O +
inhibition O +
( O -
SAI O -
) O -
) O -
. O +

RESULTS O -
: O +
The O +
results O +
show O +
that O +
smokers O +
during O +
nicotine B-Chemical +
withdrawal O +
display O +
increased O +
corticospinal O +
excitability O +
with O +
regard O +
to O +
the O +
I O -
/ O -
O O +
curve O +
( O -
TMS O +
intensity O +
150 O +
% O +
of O +
resting O +
motor O +
threshold O -
) O +
compared O +
to O +
non O -
- O -
smokers O +
and O +
furthermore O +
enhanced O +
SAI O +
and O +
diminished O +
ICF O +
at O +
the O +
intracortical O +
circuit O +
level O -
. O +

After O +
administration O +
of O +
nicotine B-Chemical -
, O +
intracortical O +
facilitation O +
in O +
smokers O +
increased O -
, O +
while O +
in O +
non O -
- O -
smokers O -
, O +
inhibition O +
( O -
SICI O -
, O +
SAI O -
) O +
was O +
enhanced O -
. O +

CONCLUSION O -
: O +
Our O +
results O +
show O +
that O +
chronic O +
nicotine B-Chemical +
consumption O +
in O +
smokers O +
alters O +
cortical O +
excitability O +
independent O +
from O +
acute O +
nicotine B-Chemical +
consumption O +
and O +
that O +
acute O +
nicotine B-Chemical +
has O +
different O +
effects O +
on O +
motor O +
cortical O +
excitability O +
in O +
both O +
groups O -
. O +

Neuritogenic O +
and O +
Neuroprotective O +
Effects O +
of O +
Polar O +
Steroids B-Chemical +
from O +
the O +
Far O +
East O +
Starfishes O +
Patiria O +
pectinifera O +
and O +
Distolasterias O +
nipon O -
. O +

The O +
neuritogenic O +
and O +
neuroprotective O +
activities O +
of O +
six O +
starfish O +
polar O +
steroids B-Chemical -
, O +
asterosaponin B-Chemical +
Р1 I-Chemical -
, O +
( B-Chemical -
25S I-Chemical -
) I-Chemical -
-5α I-Chemical -
- I-Chemical -
cholestane-3β,4β,6α,7α,8,15α,16β,26-octaol I-Chemical -
, O +
and O +
( B-Chemical -
25S I-Chemical -
) I-Chemical -
-5α I-Chemical -
- I-Chemical -
cholestane-3β,6α,7α,8,15α,16β,26-heptaol I-Chemical +
( O -
1 O -
- O -
3 O -
) O +
from O +
the O +
starfish O +
Patiria O +
pectinifera O +
and O +
distolasterosides B-Chemical +
D1-D3 I-Chemical +
( O -
4 O -
- O -
6 O -
) O +
from O +
the O +
starfish O +
Distolasterias O +
nipon O +
were O +
analyzed O +
using O +
the O +
mouse O +
neuroblastoma O +
( O -
NB O -
) O +
C-1300 O +
cell O +
line O +
and O +
an O +
organotypic O +
rat O +
hippocampal O +
slice O +
culture O +
( O -
OHSC O -
) O -
. O +

All O +
of O +
these O +
compounds O +
enhanced O +
neurite O +
outgrowth O +
in O +
NB O +
cells O -
. O +

Dose O -
- O -
dependent O +
responses O +
to O +
compounds O +
1 O -
- O -
3 O +
were O +
observed O +
within O +
the O +
concentration O +
range O +
of O +
10 O -
- O -
100 O +
nM O -
, O +
and O +
dose O -
- O -
dependent O +
responses O +
to O +
glycosides O +
4 O -
- O -
6 O +
were O +
observed O +
at O +
concentrations O +
of O +
1 O -
- O -
50 O +
nM. O +
All O +
the O +
tested O +
substances O +
exhibited O +
notable O +
synergistic O +
effects O +
with O +
trace O +
amounts O +
of O +
nerve O +
growth O +
factor O +
( O -
NGF O -
, O +
1 O +
ng O -
/ O -
mL O -
) O +
or O +
brain O -
- O -
derived O +
neurotrophic O +
factor O +
( O -
BDNF O -
, O +
0.1 O +
ng O -
/ O -
mL O -
) O -
. O +

Using O +
NB O +
cells O +
and O +
OHSCs O -
, O +
it O +
was O +
shown O +
for O +
the O +
first O +
time O +
that O +
starfish O +
steroids B-Chemical +
1 O -
- O -
6 O +
act O +
as O +
neuroprotectors O +
against O +
oxygen B-Chemical -
- O -
glucose B-Chemical +
deprivation O +
( O -
OGD O -
) O +
by O +
increasing O +
the O +
number O +
of O +
surviving O +
cells O -
. O +

Altogether O -
, O +
these O +
results O +
suggest O +
that O +
neurotrophin O -
- O -
like O +
neuritogenic O +
and O +
neuroprotective O +
activities O +
are O +
most O +
likely O +
common O +
properties O +
of O +
starfish O +
polyhydroxysteroids B-Chemical +
and O +
the O +
related O +
glycosides O -
, O +
although O +
the O +
magnitude O +
of O +
the O +
effect O +
depended O +
on O +
the O +
particular O +
compound O +
structure O -
. O +

Self O -
- O -
assembling O +
doxorubicin B-Chemical +
silk O +
hydrogels O +
for O +
the O +
focal O +
treatment O +
of O +
primary O +
breast O +
cancer O -
. O +

Standard O +
care O +
for O +
early O +
stage O +
breast O +
cancer O +
includes O +
tumor O +
resection O +
and O +
local O +
radiotherapy O +
to O +
achieve O +
long O -
- O -
term O +
remission O -
. O +

Systemic O +
chemotherapy O +
provides O +
only O +
low O +
locoregional O +
control O +
of O +
the O +
disease O -
; O +
therefore O -
, O +
we O +
describe O +
self O -
- O -
assembling O +
silk O +
hydrogels O +
that O +
can O +
retain O +
and O +
then O +
deliver O +
doxorubicin B-Chemical +
locally O -
. O +

Self O -
- O -
assembling O +
silk O +
hydrogels O +
show O +
no O +
swelling O -
, O +
are O +
readily O +
loaded O +
with O +
doxorubicin B-Chemical +
under O +
aqueous O +
conditions O +
and O +
release O +
drug O +
over O +
4 O +
weeks O +
in O +
amounts O +
that O +
can O +
be O +
fine O -
- O -
tuned O +
by O +
varying O +
the O +
silk O +
content O -
. O +

Following O +
successful O +
in O +
vitro O +
studies O -
, O +
locally O +
injected O +
silk O +
hydrogels O +
loaded O +
with O +
doxorubicin B-Chemical +
show O +
excellent O +
antitumor O +
response O +
in O +
mice O -
, O +
outperforming O +
the O +
equivalent O +
amount O +
of O +
doxorubicin B-Chemical +
delivered O +
intravenously O -
. O +

In O +
addition O +
to O +
reducing O +
primary O +
tumor O +
growth O -
, O +
doxorubicin B-Chemical -
- O -
loaded O +
silk O +
hydrogels O +
reduce O +
metastatic O +
spread O +
and O +
are O +
well O +
tolerated O +
in O +
vivo O -
. O +

Thus O -
, O +
silk O +
hydrogels O +
are O +
well O +
suited O +
for O +
the O +
local O +
delivery O +
of O +
chemotherapy O +
and O +
provide O +
a O +
promising O +
approach O +
to O +
improve O +
locoregional O +
control O +
of O +
breast O +
cancer O -
. O +

